{"PMID":10076535,"re_id":4,"annotated sentence":"Binding of <e1>hydroxyflutamide<\\e1> to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of <e2>PSA<\\e2> expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"hydroxyflutamide","object":"PSA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Binding of <e1>CHEMICAL<\\e1> to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of <e2>GENE-Y<\\e2> expression, suggesting that CHEMICAL acted as an agonist of the m-AR","sentence":"Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR"}
{"PMID":10076535,"re_id":5,"annotated sentence":"Down-regulation of <e2>prostate-specific antigen<\\e2> (PSA) expression, an AR-target gene, by <e1>estramustine<\\e1> and bicalutamide was accompanied by the blockade of the mutated androgen receptor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"estramustine","object":"prostate-specific antigen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Down-regulation of <e2>GENE-Y<\\e2> (PSA) expression, an AR-target gene, by <e1>CHEMICAL<\\e1> and bicalutamide was accompanied by the blockade of the mutated androgen receptor","sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated androgen receptor"}
{"PMID":10076535,"re_id":6,"annotated sentence":"Down-regulation of prostate-specific antigen (<e2>PSA<\\e2>  expression, an AR-target gene, by <e1>estramustine<\\e1> and bicalutamide was accompanied by the blockade of the mutated androgen receptor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"estramustine","object":"PSA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Down-regulation of prostate-specific antigen (<e2>GENE-Y<\\e2>  expression, an AR-target gene, by <e1>CHEMICAL<\\e1> and bicalutamide was accompanied by the blockade of the mutated androgen receptor","sentence":"Down-regulation of prostate-specific antigen (PSA  expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated androgen receptor"}
{"PMID":10076535,"re_id":7,"annotated sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an <e2>AR<\\e2> target gene, by <e1>estramustine<\\e1> and bicalutamide was accompanied by the blockade of the mutated androgen receptor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"estramustine","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an <e2>GENE-Y<\\e2> target gene, by <e1>CHEMICAL<\\e1> and bicalutamide was accompanied by the blockade of the mutated androgen receptor","sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an AR target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated androgen receptor"}
{"PMID":10076535,"re_id":8,"annotated sentence":"Down-regulation of <e2>prostate-specific antigen<\\e2> (PSA) expression, an AR-target gene, by estramustine and <e1>bicalutamide<\\e1> was accompanied by the blockade of the mutated androgen receptor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"bicalutamide","object":"prostate-specific antigen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Down-regulation of <e2>GENE-Y<\\e2> (PSA) expression, an AR-target gene, by estramustine and <e1>CHEMICAL<\\e1> was accompanied by the blockade of the mutated androgen receptor","sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated androgen receptor"}
{"PMID":10076535,"re_id":9,"annotated sentence":"Down-regulation of prostate-specific antigen (<e2>PSA<\\e2>  expression, an AR-target gene, by estramustine and <e1>bicalutamide<\\e1> was accompanied by the blockade of the mutated androgen receptor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"bicalutamide","object":"PSA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Down-regulation of prostate-specific antigen (<e2>GENE-Y<\\e2>  expression, an AR-target gene, by estramustine and <e1>CHEMICAL<\\e1> was accompanied by the blockade of the mutated androgen receptor","sentence":"Down-regulation of prostate-specific antigen (PSA  expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated androgen receptor"}
{"PMID":10076535,"re_id":10,"annotated sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an <e2>AR<\\e2> target gene, by estramustine and <e1>bicalutamide<\\e1> was accompanied by the blockade of the mutated androgen receptor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"bicalutamide","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an <e2>GENE-Y<\\e2> target gene, by estramustine and <e1>CHEMICAL<\\e1> was accompanied by the blockade of the mutated androgen receptor","sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an AR target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated androgen receptor"}
{"PMID":10076535,"re_id":11,"annotated sentence":"The levels of <e2>PSA<\\e2> mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of <e1>estramustine<\\e1>  respectively (IC50 = 10.97 +\/- 1.68 microM)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"estramustine","object":"PSA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The levels of <e2>GENE-Y<\\e2> mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of <e1>CHEMICAL<\\e1>  respectively (IC50 = 10.97 +\/- 1.68 microM)","sentence":"The levels of PSA mRNA decreased 56 and 90% when LNCaP cells were treated with 5 and 10 microM of estramustine  respectively (IC50 = 10.97 +\/- 1.68 microM)"}
{"PMID":10076535,"re_id":12,"annotated sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by <e1>estramustine<\\e1> and bicalutamide was accompanied by the blockade of the mutated <e2>androgen receptor<\\e2>  Exposure of LNCaP cells to estramustine for 24 hr caused transcriptional inhibition of PSA in a concentration-dependent manner","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"estramustine","object":"androgen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by <e1>CHEMICAL<\\e1> and bicalutamide was accompanied by the blockade of the mutated <e2>GENE-Y<\\e2>  Exposure of LNCaP cells to CHEMICAL for 24 hr caused transcriptional inhibition of PSA in a concentration-dependent manner","sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated androgen receptor  Exposure of LNCaP cells to estramustine for 24 hr caused transcriptional inhibition of PSA in a concentration-dependent manner"}
{"PMID":10076535,"re_id":13,"annotated sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and <e1>bicalutamide<\\e1> was accompanied by the blockade of the mutated <e2>androgen receptor<\\e2>  Exposure of LNCaP cells to estramustine for 24 hr caused transcriptional inhibition of PSA in a concentration-dependent manner","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bicalutamide","object":"androgen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and <e1>CHEMICAL<\\e1> was accompanied by the blockade of the mutated <e2>GENE-Y<\\e2>  Exposure of LNCaP cells to estramustine for 24 hr caused transcriptional inhibition of PSA in a concentration-dependent manner","sentence":"Down-regulation of prostate-specific antigen (PSA) expression, an AR-target gene, by estramustine and bicalutamide was accompanied by the blockade of the mutated androgen receptor  Exposure of LNCaP cells to estramustine for 24 hr caused transcriptional inhibition of PSA in a concentration-dependent manner"}
{"PMID":10076535,"re_id":14,"annotated sentence":"Exposure of LNCaP cells to <e1>estramustine<\\e1> for 24 hr caused transcriptional inhibition of <e2>PSA<\\e2> in a concentration-dependent manner","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"estramustine","object":"PSA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exposure of LNCaP cells to <e1>CHEMICAL<\\e1> for 24 hr caused transcriptional inhibition of <e2>GENE-Y<\\e2> in a concentration-dependent manner","sentence":"Exposure of LNCaP cells to estramustine for 24 hr caused transcriptional inhibition of PSA in a concentration-dependent manner"}
{"PMID":10076535,"re_id":15,"annotated sentence":"Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that <e1>hydroxyflutamide<\\e1> acted as an agonist of the m-<e2>AR<\\e2>  Our data indicate that estramustine phosphate metabolites perform as androgen antagonists of AR, an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"hydroxyflutamide","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Binding of CHEMICAL to m-GENE-Y in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that <e1>CHEMICAL<\\e1> acted as an agonist of the m-<e2>GENE-Y<\\e2>  Our data indicate that estramustine phosphate metabolites perform as androgen antagonists of GENE-Y, an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.","sentence":"Binding of hydroxyflutamide to m-AR in LNCaP cells resulted in a concentration-dependent stimulation of PSA expression, suggesting that hydroxyflutamide acted as an agonist of the m-AR  Our data indicate that estramustine phosphate metabolites perform as androgen antagonists of AR, an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer."}
{"PMID":10076535,"re_id":16,"annotated sentence":"Our data indicate that <e1>estramustine phosphate<\\e1> metabolites perform as androgen antagonists of <e2>AR<\\e2>  an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"estramustine phosphate","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our data indicate that <e1>CHEMICAL<\\e1> metabolites perform as androgen antagonists of <e2>GENE-Y<\\e2>  an additional mechanism involved in the therapeutic effect of CHEMICAL in patients with prostate cancer.","sentence":"Our data indicate that estramustine phosphate metabolites perform as androgen antagonists of AR  an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer."}
{"PMID":10076535,"re_id":17,"annotated sentence":"Our data indicate that estramustine phosphate metabolites perform as <e1>androgen<\\e1> antagonists of <e2>AR<\\e2>  an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"androgen","object":"AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our data indicate that estramustine phosphate metabolites perform as <e1>CHEMICAL<\\e1> antagonists of <e2>GENE-Y<\\e2>  an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer.","sentence":"Our data indicate that estramustine phosphate metabolites perform as androgen antagonists of AR  an additional mechanism involved in the therapeutic effect of estramustine phosphate in patients with prostate cancer."}
{"PMID":10076535,"re_id":18,"annotated sentence":"<e1>Androgen<\\e1> antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated <e2>androgen receptor<\\e2>  Estramustine phosphate is used frequently, alone or in combination with other antitumor agents, for the treatment of hormone-refractory prostate cancer","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Androgen","object":"androgen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated <e2>GENE-Y<\\e2>  Estramustine phosphate is used frequently, alone or in combination with other antitumor agents, for the treatment of hormone-refractory prostate cancer","sentence":"Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor  Estramustine phosphate is used frequently, alone or in combination with other antitumor agents, for the treatment of hormone-refractory prostate cancer"}
{"PMID":10076535,"re_id":19,"annotated sentence":"Androgen antagonistic effect of <e1>estramustine phosphate<\\e1> (EMP) metabolites on wild-type and mutated <e2>androgen receptor<\\e2>  Estramustine phosphate is used frequently, alone or in combination with other antitumor agents, for the treatment of hormone-refractory prostate cancer","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"estramustine phosphate","object":"androgen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Androgen antagonistic effect of <e1>CHEMICAL<\\e1> (EMP) metabolites on wild-type and mutated <e2>GENE-Y<\\e2>  Estramustine phosphate is used frequently, alone or in combination with other antitumor agents, for the treatment of hormone-refractory prostate cancer","sentence":"Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor  Estramustine phosphate is used frequently, alone or in combination with other antitumor agents, for the treatment of hormone-refractory prostate cancer"}
{"PMID":10076535,"re_id":20,"annotated sentence":"Androgen antagonistic effect of estramustine phosphate (<e1>EMP<\\e1>  metabolites on wild-type and mutated <e2>androgen receptor<\\e2>  Estramustine phosphate is used frequently, alone or in combination with other antitumor agents, for the treatment of hormone-refractory prostate cancer","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"EMP","object":"androgen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Androgen antagonistic effect of estramustine phosphate (<e1>CHEMICAL<\\e1>  metabolites on wild-type and mutated <e2>GENE-Y<\\e2>  Estramustine phosphate is used frequently, alone or in combination with other antitumor agents, for the treatment of hormone-refractory prostate cancer","sentence":"Androgen antagonistic effect of estramustine phosphate (EMP  metabolites on wild-type and mutated androgen receptor  Estramustine phosphate is used frequently, alone or in combination with other antitumor agents, for the treatment of hormone-refractory prostate cancer"}
{"PMID":10089512,"re_id":0,"annotated sentence":"In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of <e2>Torpedo californica AChE<\\e2> soaked with the reversible inhibitor <e1>edrophonium<\\e1>  using a total X-ray exposure time of 24 ms","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"edrophonium","object":"Torpedo californica AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of <e2>GENE-Y<\\e2> soaked with the reversible inhibitor <e1>CHEMICAL<\\e1>  using a total X-ray exposure time of 24 ms","sentence":"In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of Torpedo californica AChE soaked with the reversible inhibitor edrophonium  using a total X-ray exposure time of 24 ms"}
{"PMID":10220509,"re_id":0,"annotated sentence":"The current study evaluates the effects of a selective <e2>COX-2<\\e2> inhibitor (<e1>SC-236<\\e1>  on renal function in cirrhotic rats with ascites","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SC-236","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The current study evaluates the effects of a selective <e2>GENE-Y<\\e2> inhibitor (<e1>CHEMICAL<\\e1>  on renal function in cirrhotic rats with ascites","sentence":"The current study evaluates the effects of a selective COX-2 inhibitor (SC-236  on renal function in cirrhotic rats with ascites"}
{"PMID":10220509,"re_id":1,"annotated sentence":"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective <e2>COX-1<\\e2> COX-2 inhibitor, <e1>ketorolac<\\e1>  resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ketorolac","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective <e2>GENE-Y<\\e2> COX-2 inhibitor, <e1>CHEMICAL<\\e1>  resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism","sentence":"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1 COX-2 inhibitor, ketorolac  resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism"}
{"PMID":10220509,"re_id":2,"annotated sentence":"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1\/<e2>COX-2<\\e2> inhibitor, <e1>ketorolac<\\e1>  resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ketorolac","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1\/<e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism","sentence":"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1\/COX-2 inhibitor, ketorolac  resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism"}
{"PMID":10220509,"re_id":3,"annotated sentence":"Selective inhibition of <e2>cyclooxygenase 2<\\e2> spares renal function and <e1>prostaglandin<\\e1> synthesis in cirrhotic rats with ascites","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin","object":"cyclooxygenase 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective inhibition of <e2>GENE-Y<\\e2> spares renal function and <e1>CHEMICAL<\\e1> synthesis in cirrhotic rats with ascites","sentence":"Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites"}
{"PMID":10220509,"re_id":4,"annotated sentence":"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective <e2>COX-1<\\e2> COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of <e1>prostaglandins<\\e1>  and glomerular filtration rate and in a significant impairment in renal water metabolism","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandins","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective <e2>GENE-Y<\\e2> COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of <e1>CHEMICAL<\\e1>  and glomerular filtration rate and in a significant impairment in renal water metabolism","sentence":"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1 COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of prostaglandins  and glomerular filtration rate and in a significant impairment in renal water metabolism"}
{"PMID":10220509,"re_id":5,"annotated sentence":"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1\/<e2>COX-2<\\e2> inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of <e1>prostaglandins<\\e1>  and glomerular filtration rate and in a significant impairment in renal water metabolism","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandins","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1\/<e2>GENE-Y<\\e2> inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of <e1>CHEMICAL<\\e1>  and glomerular filtration rate and in a significant impairment in renal water metabolism","sentence":"RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1\/COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of prostaglandins  and glomerular filtration rate and in a significant impairment in renal water metabolism"}
{"PMID":10351938,"re_id":13,"annotated sentence":"Inhibition of LTC4 synthesis precedes the global cytotoxic effects of <e1>FP<\\e1> as indicated by the simultaneous upregulation of <e2>annexin-1<\\e2> expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"FP","object":"annexin-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of LTC4 synthesis precedes the global cytotoxic effects of <e1>CHEMICAL<\\e1> as indicated by the simultaneous upregulation of <e2>GENE-Y<\\e2> expression","sentence":"Inhibition of LTC4 synthesis precedes the global cytotoxic effects of FP as indicated by the simultaneous upregulation of annexin-1 expression"}
{"PMID":10351938,"re_id":14,"annotated sentence":"FMLP\/CB-stimulated translocation of <e2>cPLA2<\\e2> to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by <e1>FP<\\e1>  By contrast, membrane expression of annexin-1, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M FP, and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"FP","object":"cPLA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"FMLP\/CB-stimulated translocation of <e2>GENE-Y<\\e2> to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by <e1>CHEMICAL<\\e1>  By contrast, membrane expression of annexin-1, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M CHEMICAL, and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA)","sentence":"FMLP\/CB-stimulated translocation of cPLA2 to the nuclear envelope assessed by specific immunohistochemical staining also was blocked by FP  By contrast, membrane expression of annexin-1, which was not minimal at 30 min, was substantial at 48 h for eosinophils treated with > 10(-)10 M FP, and inhibition of LTC4 synthesis was reversed by exogenous arachidonic acid (AA)"}
{"PMID":10351938,"re_id":15,"annotated sentence":"Inhibition of <e2>cPLA2<\\e2> translocation and leukotriene C4 secretion by <e1>fluticasone propionate<\\e1> in exogenously activated human eosinophils","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"fluticasone propionate","object":"cPLA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> translocation and leukotriene C4 secretion by <e1>CHEMICAL<\\e1> in exogenously activated human eosinophils","sentence":"Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils"}
{"PMID":10351938,"re_id":16,"annotated sentence":"We find that <e1>FP<\\e1> causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by <e2>phospholipase A2<\\e2> (PLA2)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"FP","object":"phospholipase A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We find that <e1>CHEMICAL<\\e1> causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by <e2>GENE-Y<\\e2> (PLA2)","sentence":"We find that FP causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by phospholipase A2 (PLA2)"}
{"PMID":10351938,"re_id":17,"annotated sentence":"We find that FP causes a decrease in stimulated eosinophil secretion of <e1>LTC4<\\e1> that is regulated by <e2>phospholipase A2<\\e2> (PLA2)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"LTC4","object":"phospholipase A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We find that FP causes a decrease in stimulated eosinophil secretion of <e1>CHEMICAL<\\e1> that is regulated by <e2>GENE-Y<\\e2> (PLA2)","sentence":"We find that FP causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by phospholipase A2 (PLA2)"}
{"PMID":10351938,"re_id":18,"annotated sentence":"We find that FP causes a decrease in stimulated eosinophil secretion of <e1>LTC4<\\e1> that is regulated by phospholipase A2 (<e2>PLA2<\\e2> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"LTC4","object":"PLA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We find that FP causes a decrease in stimulated eosinophil secretion of <e1>CHEMICAL<\\e1> that is regulated by phospholipase A2 (<e2>GENE-Y<\\e2> ","sentence":"We find that FP causes a decrease in stimulated eosinophil secretion of LTC4 that is regulated by phospholipase A2 (PLA2 "}
{"PMID":10424850,"re_id":1,"annotated sentence":"We conclude that decreased NET synthesis may contribute to the chronic, but not acute, effect of <e1>desipramine<\\e1> to downregulate the <e2>NET<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"desipramine","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that decreased GENE-Y synthesis may contribute to the chronic, but not acute, effect of <e1>CHEMICAL<\\e1> to downregulate the <e2>GENE-Y<\\e2> ","sentence":"We conclude that decreased NET synthesis may contribute to the chronic, but not acute, effect of desipramine to downregulate the NET "}
{"PMID":10424850,"re_id":2,"annotated sentence":"The antidepressant <e1>desipramine<\\e1> has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter (<e2>NET<\\e2>  in vivo and in vitro, on both an acute and a chronic basis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"desipramine","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The antidepressant <e1>CHEMICAL<\\e1> has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter (<e2>GENE-Y<\\e2>  in vivo and in vitro, on both an acute and a chronic basis","sentence":"The antidepressant desipramine has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter (NET  in vivo and in vitro, on both an acute and a chronic basis"}
{"PMID":10424850,"re_id":3,"annotated sentence":"The antidepressant <e1>desipramine<\\e1> has been shown to decrease synaptic membrane concentrations of the <e2>norepinephrine re-uptake transporter<\\e2> (NET) in vivo and in vitro, on both an acute and a chronic basis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"desipramine","object":"norepinephrine re-uptake transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The antidepressant <e1>CHEMICAL<\\e1> has been shown to decrease synaptic membrane concentrations of the <e2>GENE-Y<\\e2> (NET) in vivo and in vitro, on both an acute and a chronic basis","sentence":"The antidepressant desipramine has been shown to decrease synaptic membrane concentrations of the norepinephrine re-uptake transporter (NET) in vivo and in vitro, on both an acute and a chronic basis"}
{"PMID":10424850,"re_id":4,"annotated sentence":"<e1>Desipramine<\\e1> treatment decreases 3H-nisoxetine binding and <e2>norepinephrine transporter<\\e2> mRNA in SK-N-SHSY5Y cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Desipramine","object":"norepinephrine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment decreases 3H-nisoxetine binding and <e2>GENE-Y<\\e2> mRNA in SK-N-SHSY5Y cells","sentence":"Desipramine treatment decreases 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells"}
{"PMID":10510456,"re_id":1,"annotated sentence":"Inhibition of the <e2>human ether-a-go-go-related gene (HERG) potassium channel<\\e2> by <e1>cisapride<\\e1>  affinity for open and inactivated states","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cisapride","object":"human ether-a-go-go-related gene (HERG) potassium channel","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of the <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1>  affinity for open and inactivated states","sentence":"Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride  affinity for open and inactivated states"}
{"PMID":10510456,"re_id":2,"annotated sentence":"6 In conclusion, <e2>HERG<\\e2> channel inhibition by <e1>cisapride<\\e1> exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cisapride","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"6 In conclusion, <e2>GENE-Y<\\e2> channel inhibition by <e1>CHEMICAL<\\e1> exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration","sentence":"6 In conclusion, HERG channel inhibition by cisapride exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concentration"}
{"PMID":10510456,"re_id":3,"annotated sentence":"2 In a chronic transfection model using CHO-K1 cells, <e1>cisapride<\\e1> inhibited <e2>HERG<\\e2> tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cisapride","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"2 In a chronic transfection model using CHO-K1 cells, <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16","sentence":"2 In a chronic transfection model using CHO-K1 cells, cisapride inhibited HERG tail currents after a step to +25 mV with similar potency at room and physiological temperatures (IC50 16"}
{"PMID":10516958,"re_id":11,"annotated sentence":"These profiles suggest a mechanism of action for each agent, <e2>5-HT1A<\\e2> agonism for <e1>ziprasidone<\\e1> and alpha 1 antagonism for clozapine and olanzapine","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"ziprasidone","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These profiles suggest a mechanism of action for each agent, <e2>GENE-Y<\\e2> agonism for <e1>CHEMICAL<\\e1> and alpha 1 antagonism for clozapine and olanzapine","sentence":"These profiles suggest a mechanism of action for each agent, 5-HT1A agonism for ziprasidone and alpha 1 antagonism for clozapine and olanzapine"}
{"PMID":10516958,"re_id":12,"annotated sentence":"The <e2>5-HT1A<\\e2> agonist activity reported here clearly distinguishes <e1>ziprasidone<\\e1> from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"ziprasidone","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> agonist activity reported here clearly distinguishes <e1>CHEMICAL<\\e1> from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.","sentence":"The 5-HT1A agonist activity reported here clearly distinguishes ziprasidone from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions."}
{"PMID":10516958,"re_id":13,"annotated sentence":"While it is an antagonist at these latter receptors, <e1>ziprasidone<\\e1> behaves as a <e2>5-HT1A<\\e2> agonist in vitro in adenylate cyclase measurements","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"ziprasidone","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While it is an antagonist at these latter receptors, <e1>CHEMICAL<\\e1> behaves as a <e2>GENE-Y<\\e2> agonist in vitro in adenylate cyclase measurements","sentence":"While it is an antagonist at these latter receptors, ziprasidone behaves as a 5-HT1A agonist in vitro in adenylate cyclase measurements"}
{"PMID":10516958,"re_id":14,"annotated sentence":"Pretreatment with the <e2>5-HT1A<\\e2> antagonist <e1>WAY-100,635<\\e1> (10 micrograms\/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"WAY-100,635","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> (10 micrograms\/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of CHEMICAL had little effect on the inhibition produced by clozapine and olanzapine","sentence":"Pretreatment with the 5-HT1A antagonist WAY-100,635 (10 micrograms\/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine"}
{"PMID":10516958,"re_id":15,"annotated sentence":"Pretreatment with the <e2>5-HT1A<\\e2> antagonist WAY-100,635 (10 micrograms\/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of <e1>WAY-100,635<\\e1> had little effect on the inhibition produced by clozapine and olanzapine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"WAY-100,635","object":"5-HT1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with the <e2>GENE-Y<\\e2> antagonist CHEMICAL (10 micrograms\/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of <e1>CHEMICAL<\\e1> had little effect on the inhibition produced by clozapine and olanzapine","sentence":"Pretreatment with the 5-HT1A antagonist WAY-100,635 (10 micrograms\/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine"}
{"PMID":10548268,"re_id":0,"annotated sentence":"The nonselective and irreversible <e2>MAO<\\e2> inhibitors, <e1>phenelzine<\\e1> (3-10 mg\/kg), tranylcypromine (1-3 mg\/kg), and nialamide (30 mg\/kg), decreased rates of responding maintained by ethanol reinforcement","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"phenelzine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The nonselective and irreversible <e2>GENE-N<\\e2> inhibitors, <e1>CHEMICAL<\\e1> (3-10 mg\/kg), tranylcypromine (1-3 mg\/kg), and nialamide (30 mg\/kg), decreased rates of responding maintained by ethanol reinforcement","sentence":"The nonselective and irreversible MAO inhibitors, phenelzine (3-10 mg\/kg), tranylcypromine (1-3 mg\/kg), and nialamide (30 mg\/kg), decreased rates of responding maintained by ethanol reinforcement"}
{"PMID":10548268,"re_id":1,"annotated sentence":"The nonselective and irreversible <e2>MAO<\\e2> inhibitors, phenelzine (3-10 mg\/kg), <e1>tranylcypromine<\\e1> (1-3 mg\/kg), and nialamide (30 mg\/kg), decreased rates of responding maintained by ethanol reinforcement","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"tranylcypromine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The nonselective and irreversible <e2>GENE-N<\\e2> inhibitors, phenelzine (3-10 mg\/kg), <e1>CHEMICAL<\\e1> (1-3 mg\/kg), and nialamide (30 mg\/kg), decreased rates of responding maintained by ethanol reinforcement","sentence":"The nonselective and irreversible MAO inhibitors, phenelzine (3-10 mg\/kg), tranylcypromine (1-3 mg\/kg), and nialamide (30 mg\/kg), decreased rates of responding maintained by ethanol reinforcement"}
{"PMID":10548268,"re_id":2,"annotated sentence":"The nonselective and irreversible <e2>MAO<\\e2> inhibitors, phenelzine (3-10 mg\/kg), tranylcypromine (1-3 mg\/kg), and <e1>nialamide<\\e1> (30 mg\/kg), decreased rates of responding maintained by ethanol reinforcement","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nialamide","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The nonselective and irreversible <e2>GENE-N<\\e2> inhibitors, phenelzine (3-10 mg\/kg), tranylcypromine (1-3 mg\/kg), and <e1>CHEMICAL<\\e1> (30 mg\/kg), decreased rates of responding maintained by ethanol reinforcement","sentence":"The nonselective and irreversible MAO inhibitors, phenelzine (3-10 mg\/kg), tranylcypromine (1-3 mg\/kg), and nialamide (30 mg\/kg), decreased rates of responding maintained by ethanol reinforcement"}
{"PMID":10548268,"re_id":3,"annotated sentence":"The irreversible <e2>MAO-B<\\e2> inhibitors, <e1>pargyline<\\e1> (30 mg\/kg) and l-deprenyl (3-10 mg\/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"pargyline","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The irreversible <e2>GENE-Y<\\e2> inhibitors, <e1>CHEMICAL<\\e1> (30 mg\/kg) and l-deprenyl (3-10 mg\/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice","sentence":"The irreversible MAO-B inhibitors, pargyline (30 mg\/kg) and l-deprenyl (3-10 mg\/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice"}
{"PMID":10548268,"re_id":4,"annotated sentence":"The reversible <e2>MAO-A<\\e2> inhibitor, <e1>befloxatone<\\e1> (0.3-3 mg\/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg\/kg), also reduced ethanol self-administration","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"befloxatone","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The reversible <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1> (0.3-3 mg\/kg), and the irreversible GENE-Y inhibitor, clorgyline (10-30 mg\/kg), also reduced ethanol self-administration","sentence":"The reversible MAO-A inhibitor, befloxatone (0.3-3 mg\/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg\/kg), also reduced ethanol self-administration"}
{"PMID":10548268,"re_id":5,"annotated sentence":"The reversible MAO-A inhibitor, befloxatone (0.3-3 mg\/kg), and the irreversible <e2>MAO-A<\\e2> inhibitor, <e1>clorgyline<\\e1> (10-30 mg\/kg), also reduced ethanol self-administration","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"clorgyline","object":"MAO-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The reversible GENE-Y inhibitor, befloxatone (0.3-3 mg\/kg), and the irreversible <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1> (10-30 mg\/kg), also reduced ethanol self-administration","sentence":"The reversible MAO-A inhibitor, befloxatone (0.3-3 mg\/kg), and the irreversible MAO-A inhibitor, clorgyline (10-30 mg\/kg), also reduced ethanol self-administration"}
{"PMID":10548268,"re_id":6,"annotated sentence":"The irreversible <e2>MAO-B<\\e2> inhibitors, pargyline (30 mg\/kg) and <e1>l-deprenyl<\\e1> (3-10 mg\/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"l-deprenyl","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The irreversible <e2>GENE-Y<\\e2> inhibitors, pargyline (30 mg\/kg) and <e1>CHEMICAL<\\e1> (3-10 mg\/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice","sentence":"The irreversible MAO-B inhibitors, pargyline (30 mg\/kg) and l-deprenyl (3-10 mg\/kg) also decreased responding maintained by ethanol reinforcement; these results are consistent with previous findings that both drugs decreased ethanol intake in mice"}
{"PMID":10561120,"re_id":0,"annotated sentence":"<e1>Dicumarol<\\e1>  a potent inhibitor of <e2>quinone oxidoreductase<\\e2>  at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Dicumarol","object":"quinone oxidoreductase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a potent inhibitor of <e2>GENE-N<\\e2>  at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin","sentence":"Dicumarol  a potent inhibitor of quinone oxidoreductase  at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin"}
{"PMID":10577279,"re_id":5,"annotated sentence":"Activity of the mutant <e2>delta-aminolevulinate synthase<\\e2> protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of <e1>pyridoxal 5'-phosphate<\\e1>  consistent with the clinical response of the patient to pyridoxine treatment","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"pyridoxal 5'-phosphate","object":"delta-aminolevulinate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activity of the mutant <e2>GENE-Y<\\e2> protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of <e1>CHEMICAL<\\e1>  consistent with the clinical response of the patient to pyridoxine treatment","sentence":"Activity of the mutant delta-aminolevulinate synthase protein expressed in vitro was 15.1% compared with the normal control, but was increased up to 34.5% by the addition of pyridoxal 5'-phosphate  consistent with the clinical response of the patient to pyridoxine treatment"}
{"PMID":10587286,"re_id":0,"annotated sentence":"Preferential cerebrospinal fluid <e2>acetylcholinesterase<\\e2> inhibition by <e1>rivastigmine<\\e1> in humans","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivastigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preferential cerebrospinal fluid <e2>GENE-Y<\\e2> inhibition by <e1>CHEMICAL<\\e1> in humans","sentence":"Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans"}
{"PMID":10587286,"re_id":1,"annotated sentence":"Inhibition of <e2>AChE<\\e2> in the CSF after <e1>rivastigmine<\\e1> administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivastigmine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> in the CSF after <e1>CHEMICAL<\\e1> administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours","sentence":"Inhibition of AChE in the CSF after rivastigmine administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours"}
{"PMID":10587286,"re_id":2,"annotated sentence":"Plasma <e2>BuChE<\\e2> activity was significantly lower after <e1>rivastigmine<\\e1> than after placebo, but this was not clinically relevant","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivastigmine","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Plasma <e2>GENE-Y<\\e2> activity was significantly lower after <e1>CHEMICAL<\\e1> than after placebo, but this was not clinically relevant","sentence":"Plasma BuChE activity was significantly lower after rivastigmine than after placebo, but this was not clinically relevant"}
{"PMID":10587286,"re_id":3,"annotated sentence":"<e2>BuChE<\\e2> activity in CSF was significantly lower after <e1>rivastigmine<\\e1> than after placebo for up to 3.6 hours after dosing, but this difference was not sustained","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivastigmine","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> activity in CSF was significantly lower after <e1>CHEMICAL<\\e1> than after placebo for up to 3.6 hours after dosing, but this difference was not sustained","sentence":"BuChE activity in CSF was significantly lower after rivastigmine than after placebo for up to 3.6 hours after dosing, but this difference was not sustained"}
{"PMID":10587286,"re_id":4,"annotated sentence":"This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that <e1>rivastigmine<\\e1> markedly inhibits CSF <e2>AChE<\\e2> after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivastigmine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study confirms the feasibility of using continuous measurement of GENE-Y activity in CSF over prolonged periods, that <e1>CHEMICAL<\\e1> markedly inhibits CSF <e2>GENE-Y<\\e2> after a single oral dose of 3 mg, and that the inhibition of central GENE-Y is substantially greater than that of peripheral GENE-Y or BuChE.","sentence":"This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that rivastigmine markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE."}
{"PMID":10587286,"re_id":5,"annotated sentence":"This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that <e1>rivastigmine<\\e1> markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central <e2>AChE<\\e2> is substantially greater than that of peripheral AChE or BuChE.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivastigmine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study confirms the feasibility of using continuous measurement of GENE-Y activity in CSF over prolonged periods, that <e1>CHEMICAL<\\e1> markedly inhibits CSF GENE-Y after a single oral dose of 3 mg, and that the inhibition of central <e2>GENE-Y<\\e2> is substantially greater than that of peripheral GENE-Y or BuChE.","sentence":"This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that rivastigmine markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE."}
{"PMID":10587286,"re_id":6,"annotated sentence":"This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that <e1>rivastigmine<\\e1> markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral <e2>AChE<\\e2> or BuChE.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivastigmine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study confirms the feasibility of using continuous measurement of GENE-Y activity in CSF over prolonged periods, that <e1>CHEMICAL<\\e1> markedly inhibits CSF GENE-Y after a single oral dose of 3 mg, and that the inhibition of central GENE-Y is substantially greater than that of peripheral <e2>GENE-Y<\\e2> or BuChE.","sentence":"This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that rivastigmine markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE."}
{"PMID":10587286,"re_id":7,"annotated sentence":"This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that <e1>rivastigmine<\\e1> markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or <e2>BuChE<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivastigmine","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that <e1>CHEMICAL<\\e1> markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or <e2>GENE-Y<\\e2> ","sentence":"This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that rivastigmine markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE "}
{"PMID":10611634,"re_id":12,"annotated sentence":"However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the <e2>5-HT(1A)<\\e2> agonist actions of <e1>yohimbine<\\e1> suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"yohimbine","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the <e2>GENE-Y<\\e2> agonist actions of <e1>CHEMICAL<\\e1> suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.","sentence":"However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan, the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels."}
{"PMID":10611634,"re_id":13,"annotated sentence":"In [(35)S]GTPgammaS binding protocols, <e1>yohimbine<\\e1> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at <e2>h5-HT(1A)<\\e2> sites","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"yohimbine","object":"h5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In [(35)S]GTPgammaS binding protocols, <e1>CHEMICAL<\\e1> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at <e2>GENE-Y<\\e2> sites","sentence":"In [(35)S]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites"}
{"PMID":10611634,"re_id":14,"annotated sentence":"In vivo, agonist actions of <e1>yohimbine<\\e1> at <e2>5-HT(1A)<\\e2> sites are revealed by WAY100,635-reversible induction of hypothermia in the rat","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"yohimbine","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vivo, agonist actions of <e1>CHEMICAL<\\e1> at <e2>GENE-Y<\\e2> sites are revealed by WAY100,635-reversible induction of hypothermia in the rat","sentence":"In vivo, agonist actions of yohimbine at 5-HT(1A) sites are revealed by WAY100,635-reversible induction of hypothermia in the rat"}
{"PMID":10611634,"re_id":15,"annotated sentence":"In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the <e2>5-HT(1B)<\\e2> agonist, <e1>GR46,611<\\e1>  In distinction to yohimbine, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at halpha(2)-ARs","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"GR46,611","object":"5-HT(1B)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In guinea pigs, antagonist actions of yohimbine at GENE-Y receptors are revealed by blockade of hypothermia evoked by the <e2>GENE-Y<\\e2> agonist, <e1>CHEMICAL<\\e1>  In distinction to yohimbine, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at halpha(2)-ARs","sentence":"In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611  In distinction to yohimbine, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at halpha(2)-ARs"}
{"PMID":10611634,"re_id":16,"annotated sentence":"In distinction to <e1>yohimbine<\\e1>  fluparoxan shows only modest partial agonist actions at <e2>h5-HT(1A)<\\e2> sites versus marked antagonist actions at halpha(2)-ARs","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"yohimbine","object":"h5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In distinction to <e1>CHEMICAL<\\e1>  fluparoxan shows only modest partial agonist actions at <e2>GENE-Y<\\e2> sites versus marked antagonist actions at halpha(2)-ARs","sentence":"In distinction to yohimbine  fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at halpha(2)-ARs"}
{"PMID":10611634,"re_id":17,"annotated sentence":"In distinction to yohimbine, <e1>fluparoxan<\\e1> shows only modest partial agonist actions at <e2>h5-HT(1A)<\\e2> sites versus marked antagonist actions at halpha(2)-ARs","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"fluparoxan","object":"h5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In distinction to yohimbine, <e1>CHEMICAL<\\e1> shows only modest partial agonist actions at <e2>GENE-Y<\\e2> sites versus marked antagonist actions at halpha(2)-ARs","sentence":"In distinction to yohimbine, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at halpha(2)-ARs"}
{"PMID":10611634,"re_id":18,"annotated sentence":"Agonist and antagonist actions of <e1>yohimbine<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors <e2>(AR)s<\\e2>  serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"yohimbine","object":"(AR)s","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Agonist and antagonist actions of <e1>CHEMICAL<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors <e2>GENE-N<\\e2>  serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s  serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10611634,"re_id":19,"annotated sentence":"Agonist and antagonist actions of <e1>yohimbine<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin <e2>(5-HT)(1A)<\\e2>  5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"yohimbine","object":"(5-HT)(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agonist and antagonist actions of <e1>CHEMICAL<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin <e2>GENE-Y<\\e2>  5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A)  5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10611634,"re_id":20,"annotated sentence":"Agonist and antagonist actions of <e1>yohimbine<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), <e2>5-HT(1B)<\\e2>  5-HT(1D) and dopamine D(2) and D(3) receptors","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"yohimbine","object":"5-HT(1B)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agonist and antagonist actions of <e1>CHEMICAL<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), <e2>GENE-Y<\\e2>  5-HT(1D) and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B)  5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10611634,"re_id":21,"annotated sentence":"Agonist and antagonist actions of <e1>yohimbine<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), <e2>5-HT(1D)<\\e2> and dopamine D(2) and D(3) receptors","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"yohimbine","object":"5-HT(1D)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agonist and antagonist actions of <e1>CHEMICAL<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), <e2>GENE-Y<\\e2> and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10611634,"re_id":22,"annotated sentence":"Agonist and antagonist actions of <e1>yohimbine<\\e1> as compared to fluparoxan at <e2>alpha(2)-adrenergic receptors<\\e2> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"yohimbine","object":"alpha(2)-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Agonist and antagonist actions of <e1>CHEMICAL<\\e1> as compared to fluparoxan at <e2>GENE-N<\\e2> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10611634,"re_id":23,"annotated sentence":"Agonist and antagonist actions of yohimbine as compared to <e1>fluparoxan<\\e1> at alpha(2)-adrenergic receptors <e2>(AR)s<\\e2>  serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"fluparoxan","object":"(AR)s","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Agonist and antagonist actions of yohimbine as compared to <e1>CHEMICAL<\\e1> at alpha(2)-adrenergic receptors <e2>GENE-N<\\e2>  serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s  serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10611634,"re_id":24,"annotated sentence":"Agonist and antagonist actions of yohimbine as compared to <e1>fluparoxan<\\e1> at <e2>alpha(2)-adrenergic receptors<\\e2> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"fluparoxan","object":"alpha(2)-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Agonist and antagonist actions of yohimbine as compared to <e1>CHEMICAL<\\e1> at <e2>GENE-N<\\e2> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10611634,"re_id":25,"annotated sentence":"In conclusion, the <e2>alpha(2)-AR<\\e2> antagonist properties of <e1>yohimbine<\\e1> increase DA and NAD levels both alone and in association with fluoxetine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"alpha(2)-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, the <e2>GENE-N<\\e2> antagonist properties of <e1>CHEMICAL<\\e1> increase DA and NAD levels both alone and in association with fluoxetine","sentence":"In conclusion, the alpha(2)-AR antagonist properties of yohimbine increase DA and NAD levels both alone and in association with fluoxetine"}
{"PMID":10611634,"re_id":26,"annotated sentence":"However, in contrast to the selective <e2>alpha(2)-AR<\\e2> antagonist, <e1>fluparoxan<\\e1>  the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"fluparoxan","object":"alpha(2)-AR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, in contrast to the selective <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1>  the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels.","sentence":"However, in contrast to the selective alpha(2)-AR antagonist, fluparoxan  the 5-HT(1A) agonist actions of yohimbine suppress 5-HT levels alone and underlie its inability to augment the influence of fluoxetine upon 5-HT levels."}
{"PMID":10611634,"re_id":27,"annotated sentence":"In [(35)S]GTPgammaS binding protocols, <e1>yohimbine<\\e1> exerts antagonist actions at <e2>halpha(2A)-AR<\\e2>  h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"halpha(2A)-AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In [(35)S]GTPgammaS binding protocols, <e1>CHEMICAL<\\e1> exerts antagonist actions at <e2>GENE-Y<\\e2>  h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites","sentence":"In [(35)S]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR  h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites"}
{"PMID":10611634,"re_id":28,"annotated sentence":"In [(35)S]GTPgammaS binding protocols, <e1>yohimbine<\\e1> exerts antagonist actions at halpha(2A)-AR, <e2>h5-HT(1B)<\\e2>  h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"h5-HT(1B)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In [(35)S]GTPgammaS binding protocols, <e1>CHEMICAL<\\e1> exerts antagonist actions at halpha(2A)-AR, <e2>GENE-Y<\\e2>  h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites","sentence":"In [(35)S]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B)  h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites"}
{"PMID":10611634,"re_id":29,"annotated sentence":"In [(35)S]GTPgammaS binding protocols, <e1>yohimbine<\\e1> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), <e2>h5-HT(1D)<\\e2>  and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"h5-HT(1D)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In [(35)S]GTPgammaS binding protocols, <e1>CHEMICAL<\\e1> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), <e2>GENE-Y<\\e2>  and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites","sentence":"In [(35)S]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D)  and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites"}
{"PMID":10611634,"re_id":30,"annotated sentence":"In [(35)S]GTPgammaS binding protocols, <e1>yohimbine<\\e1> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and <e2>hD(2)<\\e2> sites, yet partial agonist actions at h5-HT(1A) sites","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"hD(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In [(35)S]GTPgammaS binding protocols, <e1>CHEMICAL<\\e1> exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and <e2>GENE-Y<\\e2> sites, yet partial agonist actions at h5-HT(1A) sites","sentence":"In [(35)S]GTPgammaS binding protocols, yohimbine exerts antagonist actions at halpha(2A)-AR, h5-HT(1B), h5-HT(1D), and hD(2) sites, yet partial agonist actions at h5-HT(1A) sites"}
{"PMID":10611634,"re_id":31,"annotated sentence":"Herein, we evaluate the interaction of the <e2>alpha(2)-AR antagonist<\\e2>  <e1>yohimbine<\\e1>  as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"alpha(2)-AR antagonist","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein, we evaluate the interaction of the <e2>GENE-N<\\e2>  <e1>CHEMICAL<\\e1>  as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats","sentence":"Herein, we evaluate the interaction of the alpha(2)-AR antagonist  yohimbine  as compared to fluparoxan, at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats"}
{"PMID":10611634,"re_id":32,"annotated sentence":"In vivo, agonist actions of yohimbine at <e2>5-HT(1A)<\\e2> sites are revealed by <e1>WAY100,635<\\e1> reversible induction of hypothermia in the rat","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"WAY100,635","object":"5-HT(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vivo, agonist actions of yohimbine at <e2>GENE-Y<\\e2> sites are revealed by <e1>CHEMICAL<\\e1> reversible induction of hypothermia in the rat","sentence":"In vivo, agonist actions of yohimbine at 5-HT(1A) sites are revealed by WAY100,635 reversible induction of hypothermia in the rat"}
{"PMID":10611634,"re_id":33,"annotated sentence":"In guinea pigs, antagonist actions of <e1>yohimbine<\\e1> at <e2>5-HT(1B)<\\e2> receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"5-HT(1B)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In guinea pigs, antagonist actions of <e1>CHEMICAL<\\e1> at <e2>GENE-Y<\\e2> receptors are revealed by blockade of hypothermia evoked by the GENE-Y agonist, GR46,611","sentence":"In guinea pigs, antagonist actions of yohimbine at 5-HT(1B) receptors are revealed by blockade of hypothermia evoked by the 5-HT(1B) agonist, GR46,611"}
{"PMID":10611634,"re_id":34,"annotated sentence":"Herein, we evaluate the interaction of the <e2>alpha(2)-AR antagonist<\\e2>  yohimbine, as compared to <e1>fluparoxan<\\e1>  at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"fluparoxan","object":"alpha(2)-AR antagonist","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein, we evaluate the interaction of the <e2>GENE-N<\\e2>  yohimbine, as compared to <e1>CHEMICAL<\\e1>  at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats","sentence":"Herein, we evaluate the interaction of the alpha(2)-AR antagonist  yohimbine, as compared to fluparoxan  at multiple monoaminergic receptors and examine their roles in the modulation of adrenergic, dopaminergic and serotonergic transmission in freely-moving rats"}
{"PMID":10611634,"re_id":35,"annotated sentence":"In distinction to <e1>yohimbine<\\e1>  fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at <e2>halpha(2)-ARs<\\e2>  While fluparoxan selectively enhances hippocampal noradrenaline (NAD) turnover, yohimbine also enhances striatal dopamine (DA) turnover and suppresses striatal turnover of 5-HT","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"halpha(2)-ARs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In distinction to <e1>CHEMICAL<\\e1>  fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at <e2>GENE-N<\\e2>  While fluparoxan selectively enhances hippocampal noradrenaline (NAD) turnover, CHEMICAL also enhances striatal dopamine (DA) turnover and suppresses striatal turnover of 5-HT","sentence":"In distinction to yohimbine  fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at halpha(2)-ARs  While fluparoxan selectively enhances hippocampal noradrenaline (NAD) turnover, yohimbine also enhances striatal dopamine (DA) turnover and suppresses striatal turnover of 5-HT"}
{"PMID":10611634,"re_id":36,"annotated sentence":"In distinction to yohimbine, <e1>fluparoxan<\\e1> shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at <e2>halpha(2)-ARs<\\e2>  While fluparoxan selectively enhances hippocampal noradrenaline (NAD) turnover, yohimbine also enhances striatal dopamine (DA) turnover and suppresses striatal turnover of 5-HT","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"fluparoxan","object":"halpha(2)-ARs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In distinction to yohimbine, <e1>CHEMICAL<\\e1> shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at <e2>GENE-N<\\e2>  While CHEMICAL selectively enhances hippocampal noradrenaline (NAD) turnover, yohimbine also enhances striatal dopamine (DA) turnover and suppresses striatal turnover of 5-HT","sentence":"In distinction to yohimbine, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at halpha(2)-ARs  While fluparoxan selectively enhances hippocampal noradrenaline (NAD) turnover, yohimbine also enhances striatal dopamine (DA) turnover and suppresses striatal turnover of 5-HT"}
{"PMID":10611634,"re_id":37,"annotated sentence":"Agonist and antagonist actions of <e1>yohimbine<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors <e2>(AR)s<\\e2>  serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"(AR)s","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Agonist and antagonist actions of <e1>CHEMICAL<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors <e2>GENE-N<\\e2>  serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s  serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10611634,"re_id":38,"annotated sentence":"Agonist and antagonist actions of <e1>yohimbine<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin <e2>(5-HT)(1A)<\\e2>  5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"(5-HT)(1A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agonist and antagonist actions of <e1>CHEMICAL<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin <e2>GENE-Y<\\e2>  5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A)  5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10611634,"re_id":39,"annotated sentence":"Agonist and antagonist actions of <e1>yohimbine<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), <e2>5-HT(1B)<\\e2>  5-HT(1D) and dopamine D(2) and D(3) receptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"5-HT(1B)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agonist and antagonist actions of <e1>CHEMICAL<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), <e2>GENE-Y<\\e2>  5-HT(1D) and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B)  5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10611634,"re_id":40,"annotated sentence":"Agonist and antagonist actions of <e1>yohimbine<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), <e2>5-HT(1D)<\\e2> and dopamine D(2) and D(3) receptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"5-HT(1D)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agonist and antagonist actions of <e1>CHEMICAL<\\e1> as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), <e2>GENE-Y<\\e2> and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10611634,"re_id":41,"annotated sentence":"Agonist and antagonist actions of <e1>yohimbine<\\e1> as compared to fluparoxan at <e2>alpha(2)-adrenergic receptors<\\e2> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"alpha(2)-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Agonist and antagonist actions of <e1>CHEMICAL<\\e1> as compared to fluparoxan at <e2>GENE-N<\\e2> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10611634,"re_id":42,"annotated sentence":"Agonist and antagonist actions of yohimbine as compared to <e1>fluparoxan<\\e1> at alpha(2)-adrenergic receptors <e2>(AR)s<\\e2>  serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"fluparoxan","object":"(AR)s","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Agonist and antagonist actions of yohimbine as compared to <e1>CHEMICAL<\\e1> at alpha(2)-adrenergic receptors <e2>GENE-N<\\e2>  serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s  serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10611634,"re_id":43,"annotated sentence":"Agonist and antagonist actions of yohimbine as compared to <e1>fluparoxan<\\e1> at <e2>alpha(2)-adrenergic receptors<\\e2> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"fluparoxan","object":"alpha(2)-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Agonist and antagonist actions of yohimbine as compared to <e1>CHEMICAL<\\e1> at <e2>GENE-N<\\e2> (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors","sentence":"Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors"}
{"PMID":10640321,"re_id":0,"annotated sentence":"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and <e2>kappa-opioid receptor<\\e2> (<e1>BRL 52974<\\e1>  produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg\/kg, respectively","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"BRL 52974","object":"kappa-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and <e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1>  produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg\/kg, respectively","sentence":"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974  produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg\/kg, respectively"}
{"PMID":10640321,"re_id":1,"annotated sentence":"The nonselective <e2>opioid receptor<\\e2> antagonist, naloxone (3 mg\/kg, i.m.), attenuated the antitussive effects of <e1>codeine<\\e1> or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"codeine","object":"opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The nonselective <e2>GENE-N<\\e2> antagonist, naloxone (3 mg\/kg, i.m.), attenuated the antitussive effects of <e1>CHEMICAL<\\e1> or SB 227122, indicating that the antitussive activity of both compounds is GENE-N-mediated","sentence":"The nonselective opioid receptor antagonist, naloxone (3 mg\/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated"}
{"PMID":10640321,"re_id":2,"annotated sentence":"The nonselective opioid receptor antagonist, naloxone (3 mg\/kg, i.m.), attenuated the antitussive effects of <e1>codeine<\\e1> or SB 227122, indicating that the antitussive activity of both compounds is <e2>opioid receptor<\\e2> mediated","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"codeine","object":"opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The nonselective GENE-N antagonist, naloxone (3 mg\/kg, i.m.), attenuated the antitussive effects of <e1>CHEMICAL<\\e1> or SB 227122, indicating that the antitussive activity of both compounds is <e2>GENE-N<\\e2> mediated","sentence":"The nonselective opioid receptor antagonist, naloxone (3 mg\/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor mediated"}
{"PMID":10640321,"re_id":3,"annotated sentence":"The nonselective <e2>opioid receptor<\\e2> antagonist, naloxone (3 mg\/kg, i.m.), attenuated the antitussive effects of codeine or <e1>SB 227122<\\e1>  indicating that the antitussive activity of both compounds is opioid receptor-mediated","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"SB 227122","object":"opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The nonselective <e2>GENE-N<\\e2> antagonist, naloxone (3 mg\/kg, i.m.), attenuated the antitussive effects of codeine or <e1>CHEMICAL<\\e1>  indicating that the antitussive activity of both compounds is GENE-N-mediated","sentence":"The nonselective opioid receptor antagonist, naloxone (3 mg\/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122  indicating that the antitussive activity of both compounds is opioid receptor-mediated"}
{"PMID":10640321,"re_id":4,"annotated sentence":"The nonselective opioid receptor antagonist, naloxone (3 mg\/kg, i.m.), attenuated the antitussive effects of codeine or <e1>SB 227122<\\e1>  indicating that the antitussive activity of both compounds is <e2>opioid receptor<\\e2> mediated","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"SB 227122","object":"opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The nonselective GENE-N antagonist, naloxone (3 mg\/kg, i.m.), attenuated the antitussive effects of codeine or <e1>CHEMICAL<\\e1>  indicating that the antitussive activity of both compounds is <e2>GENE-N<\\e2> mediated","sentence":"The nonselective opioid receptor antagonist, naloxone (3 mg\/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122  indicating that the antitussive activity of both compounds is opioid receptor mediated"}
{"PMID":10640321,"re_id":5,"annotated sentence":"The <e2>delta-receptor<\\e2> antagonist, SB 244525 (10 mg\/kg, i.p.), inhibited the antitussive effect of <e1>SB 227122<\\e1> (20 mg\/kg, i.p.)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"SB 227122","object":"delta-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> antagonist, SB 244525 (10 mg\/kg, i.p.), inhibited the antitussive effect of <e1>CHEMICAL<\\e1> (20 mg\/kg, i.p.)","sentence":"The delta-receptor antagonist, SB 244525 (10 mg\/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg\/kg, i.p.)"}
{"PMID":10640321,"re_id":6,"annotated sentence":"In this study, the activity of the <e2>delta-opioid receptor<\\e2> subtype-selective agonist, <e1>SB 227122<\\e1>  was investigated in a guinea pig model of citric acid-induced cough","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"SB 227122","object":"delta-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, the activity of the <e2>GENE-Y<\\e2> subtype-selective agonist, <e1>CHEMICAL<\\e1>  was investigated in a guinea pig model of citric acid-induced cough","sentence":"In this study, the activity of the delta-opioid receptor subtype-selective agonist, SB 227122  was investigated in a guinea pig model of citric acid-induced cough"}
{"PMID":10640321,"re_id":7,"annotated sentence":"The <e2>sigma-receptor<\\e2> antagonist rimcazole (3 mg\/kg, i.p.) inhibited the antitussive effect of <e1>dextromethorphan<\\e1> (30 mg\/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"dextromethorphan","object":"sigma-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> antagonist rimcazole (3 mg\/kg, i.p.) inhibited the antitussive effect of <e1>CHEMICAL<\\e1> (30 mg\/kg, i.p.), a GENE-N agonist, but not that of SB 227122","sentence":"The sigma-receptor antagonist rimcazole (3 mg\/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg\/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122"}
{"PMID":10640321,"re_id":8,"annotated sentence":"These studies provide compelling evidence that the antitussive effects of <e1>SB 227122<\\e1> in this guinea pig cough model are mediated by agonist activity at the <e2>delta-opioid receptor<\\e2> ","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"SB 227122","object":"delta-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These studies provide compelling evidence that the antitussive effects of <e1>CHEMICAL<\\e1> in this guinea pig cough model are mediated by agonist activity at the <e2>GENE-Y<\\e2> ","sentence":"These studies provide compelling evidence that the antitussive effects of SB 227122 in this guinea pig cough model are mediated by agonist activity at the delta-opioid receptor "}
{"PMID":10640321,"re_id":9,"annotated sentence":"Parenteral administration of selective agonists of the <e2>delta-opioid receptor<\\e2> (<e1>SB 227122<\\e1> , mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg\/kg, respectively","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"SB 227122","object":"delta-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Parenteral administration of selective agonists of the <e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1> , mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg\/kg, respectively","sentence":"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122 , mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg\/kg, respectively"}
{"PMID":10640321,"re_id":10,"annotated sentence":"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), <e2>mu-opioid receptor<\\e2> (<e1>codeine<\\e1> and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg\/kg, respectively","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"codeine","object":"mu-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), <e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1> and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg\/kg, respectively","sentence":"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone), and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg\/kg, respectively"}
{"PMID":10640321,"re_id":11,"annotated sentence":"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), <e2>mu-opioid receptor<\\e2> (codeine and <e1>hydrocodone<\\e1> , and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg\/kg, respectively","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"hydrocodone","object":"mu-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), <e2>GENE-Y<\\e2> (codeine and <e1>CHEMICAL<\\e1> , and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg\/kg, respectively","sentence":"Parenteral administration of selective agonists of the delta-opioid receptor (SB 227122), mu-opioid receptor (codeine and hydrocodone , and kappa-opioid receptor (BRL 52974) produced dose-related inhibition of citric acid-induced cough with ED(50) values of 7.3, 5.2, 5.1, and 5.3 mg\/kg, respectively"}
{"PMID":10640321,"re_id":12,"annotated sentence":"The nonselective <e2>opioid receptor<\\e2> antagonist, <e1>naloxone<\\e1> (3 mg\/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"naloxone","object":"opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The nonselective <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1> (3 mg\/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is GENE-N-mediated","sentence":"The nonselective opioid receptor antagonist, naloxone (3 mg\/kg, i.m.), attenuated the antitussive effects of codeine or SB 227122, indicating that the antitussive activity of both compounds is opioid receptor-mediated"}
{"PMID":10640321,"re_id":13,"annotated sentence":"The <e2>delta-receptor<\\e2> antagonist, <e1>SB 244525<\\e1> (10 mg\/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg\/kg, i.p.)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"SB 244525","object":"delta-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1> (10 mg\/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg\/kg, i.p.)","sentence":"The delta-receptor antagonist, SB 244525 (10 mg\/kg, i.p.), inhibited the antitussive effect of SB 227122 (20 mg\/kg, i.p.)"}
{"PMID":10640321,"re_id":14,"annotated sentence":"In contrast, combined pretreatment with <e1>beta-funaltrexamine<\\e1> (<e2>mu-receptor<\\e2> antagonist; 20 mg\/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg\/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg\/kg, i.p.)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"beta-funaltrexamine","object":"mu-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, combined pretreatment with <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> antagonist; 20 mg\/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg\/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg\/kg, i.p.)","sentence":"In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg\/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg\/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg\/kg, i.p.)"}
{"PMID":10640321,"re_id":15,"annotated sentence":"In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg\/kg, s.c.) and <e1>norbinaltorphimine<\\e1> (<e2>kappa-receptor<\\e2> antagonist; 20 mg\/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg\/kg, i.p.)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"norbinaltorphimine","object":"kappa-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg\/kg, s.c.) and <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> antagonist; 20 mg\/kg, s.c.), at doses that inhibited the antitussive activity of mu- and GENE-Y agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg\/kg, i.p.)","sentence":"In contrast, combined pretreatment with beta-funaltrexamine (mu-receptor antagonist; 20 mg\/kg, s.c.) and norbinaltorphimine (kappa-receptor antagonist; 20 mg\/kg, s.c.), at doses that inhibited the antitussive activity of mu- and kappa-receptor agonists, respectively, was without effect on the antitussive response of SB 227122 (20 mg\/kg, i.p.)"}
{"PMID":10640321,"re_id":16,"annotated sentence":"The <e2>sigma-receptor<\\e2> antagonist <e1>rimcazole<\\e1> (3 mg\/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg\/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"rimcazole","object":"sigma-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> (3 mg\/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg\/kg, i.p.), a GENE-N agonist, but not that of SB 227122","sentence":"The sigma-receptor antagonist rimcazole (3 mg\/kg, i.p.) inhibited the antitussive effect of dextromethorphan (30 mg\/kg, i.p.), a sigma-receptor agonist, but not that of SB 227122"}
{"PMID":10643177,"re_id":0,"annotated sentence":"New modes of therapy have recently been introduced, and data on the <e2>cyclooxygenase-2<\\e2> (COX-2)-specific inhibitors <e1>celecoxib<\\e1> and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"celecoxib","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"New modes of therapy have recently been introduced, and data on the <e2>GENE-Y<\\e2> (COX-2)-specific inhibitors <e1>CHEMICAL<\\e1> and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.","sentence":"New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (COX-2)-specific inhibitors celecoxib and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs."}
{"PMID":10643177,"re_id":1,"annotated sentence":"New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (<e2>COX-2<\\e2> -specific inhibitors <e1>celecoxib<\\e1> and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"celecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (<e2>GENE-Y<\\e2> -specific inhibitors <e1>CHEMICAL<\\e1> and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.","sentence":"New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (COX-2 -specific inhibitors celecoxib and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs."}
{"PMID":10643177,"re_id":2,"annotated sentence":"New modes of therapy have recently been introduced, and data on the <e2>cyclooxygenase-2<\\e2> (COX-2)-specific inhibitors celecoxib and <e1>rofecoxib<\\e1> suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rofecoxib","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"New modes of therapy have recently been introduced, and data on the <e2>GENE-Y<\\e2> (COX-2)-specific inhibitors celecoxib and <e1>CHEMICAL<\\e1> suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.","sentence":"New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (COX-2)-specific inhibitors celecoxib and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs."}
{"PMID":10643177,"re_id":3,"annotated sentence":"New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (<e2>COX-2<\\e2> -specific inhibitors celecoxib and <e1>rofecoxib<\\e1> suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (<e2>GENE-Y<\\e2> -specific inhibitors celecoxib and <e1>CHEMICAL<\\e1> suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.","sentence":"New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (COX-2 -specific inhibitors celecoxib and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs."}
{"PMID":10658902,"re_id":0,"annotated sentence":"<e1>Dichloroally]-lawsone<\\e1> was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for <e2>mammalian dihydroorotate dehydrogenases<\\e2>  Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Dichloroally]-lawsone","object":"mammalian dihydroorotate dehydrogenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for <e2>GENE-N<\\e2>  Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W","sentence":"Dichloroally]-lawsone was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for mammalian dihydroorotate dehydrogenases  Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W"}
{"PMID":10658902,"re_id":1,"annotated sentence":"Another inhibitor, <e1>brequinar<\\e1> was previously reported to be a slow-binding inhibitor of the <e2>human dihydroorotate dehydrogenase<\\e2> [W","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"brequinar","object":"human dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Another inhibitor, <e1>CHEMICAL<\\e1> was previously reported to be a slow-binding inhibitor of the <e2>GENE-Y<\\e2> [W","sentence":"Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W"}
{"PMID":10658902,"re_id":2,"annotated sentence":"Loffler, Species-related inhibition of <e2>human and rat dihyroorotate dehydrogenase<\\e2> by immunosuppressive <e1>isoxazol<\\e1> and cinchoninic acid derivatives, Biochem","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"isoxazol","object":"human and rat dihyroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Loffler, Species-related inhibition of <e2>GENE-N<\\e2> by immunosuppressive <e1>CHEMICAL<\\e1> and cinchoninic acid derivatives, Biochem","sentence":"Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem"}
{"PMID":10658902,"re_id":3,"annotated sentence":"Loffler, Species-related inhibition of <e2>human and rat dihyroorotate dehydrogenase<\\e2> by immunosuppressive isoxazol and <e1>cinchoninic acid<\\e1> derivatives, Biochem","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cinchoninic acid","object":"human and rat dihyroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Loffler, Species-related inhibition of <e2>GENE-N<\\e2> by immunosuppressive isoxazol and <e1>CHEMICAL<\\e1> derivatives, Biochem","sentence":"Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem"}
{"PMID":10658902,"re_id":4,"annotated sentence":"With respect to the substrate <e1>dihydroorotate<\\e1>  atovaquone was an uncompetitive inhibitor of <e2>human dihydroorotate dehydrogenase<\\e2> (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905\/ Kic = 1,012 nM)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dihydroorotate","object":"human dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"With respect to the substrate <e1>CHEMICAL<\\e1>  atovaquone was an uncompetitive inhibitor of <e2>human CHEMICAL dehydrogenase<\\e2> (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905\/ Kic = 1,012 nM)","sentence":"With respect to the substrate dihydroorotate  atovaquone was an uncompetitive inhibitor of human dihydroorotate dehydrogenase (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905\/ Kic = 1,012 nM)"}
{"PMID":10658902,"re_id":5,"annotated sentence":"With respect to the substrate dihydroorotate, <e1>atovaquone<\\e1> was an uncompetitive inhibitor of <e2>human dihydroorotate dehydrogenase<\\e2> (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905\/ Kic = 1,012 nM)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"atovaquone","object":"human dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"With respect to the substrate dihydroorotate, <e1>CHEMICAL<\\e1> was an uncompetitive inhibitor of <e2>GENE-Y<\\e2> (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905\/ Kic = 1,012 nM)","sentence":"With respect to the substrate dihydroorotate, atovaquone was an uncompetitive inhibitor of human dihydroorotate dehydrogenase (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905\/ Kic = 1,012 nM)"}
{"PMID":10658902,"re_id":6,"annotated sentence":"Kinetics of inhibition of <e2>human and rat dihydroorotate dehydrogenase<\\e2> by atovaquone, lawsone derivatives, <e1>brequinar sodium<\\e1> and polyporic acid","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"brequinar sodium","object":"human and rat dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Kinetics of inhibition of <e2>GENE-N<\\e2> by atovaquone, lawsone derivatives, <e1>CHEMICAL<\\e1> and polyporic acid","sentence":"Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid"}
{"PMID":10658902,"re_id":7,"annotated sentence":"Kinetics of inhibition of <e2>human and rat dihydroorotate dehydrogenase<\\e2> by atovaquone, lawsone derivatives, brequinar sodium and <e1>polyporic acid<\\e1>  Mitochondrially-bound dihydroorotate dehydrogenase (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of uridine monophosphate","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"polyporic acid","object":"human and rat dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Kinetics of inhibition of <e2>GENE-N<\\e2> by atovaquone, lawsone derivatives, brequinar sodium and <e1>CHEMICAL<\\e1>  Mitochondrially-bound dihydroorotate dehydrogenase (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of uridine monophosphate","sentence":"Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid  Mitochondrially-bound dihydroorotate dehydrogenase (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of uridine monophosphate"}
{"PMID":10658902,"re_id":8,"annotated sentence":"Kinetics of inhibition of <e2>human and rat dihydroorotate dehydrogenase<\\e2> by <e1>atovaquone<\\e1>  lawsone derivatives, brequinar sodium and polyporic acid","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"atovaquone","object":"human and rat dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Kinetics of inhibition of <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1>  lawsone derivatives, brequinar sodium and polyporic acid","sentence":"Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone  lawsone derivatives, brequinar sodium and polyporic acid"}
{"PMID":10658902,"re_id":9,"annotated sentence":"Kinetics of inhibition of <e2>human and rat dihydroorotate dehydrogenase<\\e2> by atovaquone, <e1>lawsone<\\e1> derivatives, brequinar sodium and polyporic acid","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lawsone","object":"human and rat dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Kinetics of inhibition of <e2>GENE-N<\\e2> by atovaquone, <e1>CHEMICAL<\\e1> derivatives, brequinar sodium and polyporic acid","sentence":"Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid"}
{"PMID":10658902,"re_id":10,"annotated sentence":"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, <e1>atovaquone<\\e1> (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of <e2>human dihydroorotate dehydrogenase<\\e2>  Atovaquone (Kic = 60 nM) was also acompetitive inhibitor of the rat enzyme","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"atovaquone","object":"human dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, <e1>CHEMICAL<\\e1> (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of <e2>GENE-Y<\\e2>  Atovaquone (Kic = 60 nM) was also acompetitive inhibitor of the rat enzyme","sentence":"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase  Atovaquone (Kic = 60 nM) was also acompetitive inhibitor of the rat enzyme"}
{"PMID":10658902,"re_id":11,"annotated sentence":"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and <e1>dichloroally-lawsone<\\e1> (Kic = 9.8 nM) were shown to be competitive inhibitors of <e2>human dihydroorotate dehydrogenase<\\e2>  Atovaquone (Kic = 60 nM) was also acompetitive inhibitor of the rat enzyme","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dichloroally-lawsone","object":"human dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and <e1>CHEMICAL<\\e1> (Kic = 9.8 nM) were shown to be competitive inhibitors of <e2>GENE-Y<\\e2>  Atovaquone (Kic = 60 nM) was also acompetitive inhibitor of the rat enzyme","sentence":"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase  Atovaquone (Kic = 60 nM) was also acompetitive inhibitor of the rat enzyme"}
{"PMID":10658902,"re_id":12,"annotated sentence":"Mitochondrially-bound <e2>dihydroorotate dehydrogenase<\\e2> (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of <e1>uridine monophosphate<\\e1>  The enzyme has been identified as or surmised to be the pharmacological target for isoxazol, triazine, cinchoninic acid and (naphtho)quinone derivatives, which exerted antiproliferative, immunosuppressive, and antiparasitic effects","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"uridine monophosphate","object":"dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mitochondrially-bound <e2>GENE-Y<\\e2> (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of <e1>CHEMICAL<\\e1>  The enzyme has been identified as or surmised to be the pharmacological target for isoxazol, triazine, cinchoninic acid and (naphtho)quinone derivatives, which exerted antiproliferative, immunosuppressive, and antiparasitic effects","sentence":"Mitochondrially-bound dihydroorotate dehydrogenase (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of uridine monophosphate  The enzyme has been identified as or surmised to be the pharmacological target for isoxazol, triazine, cinchoninic acid and (naphtho)quinone derivatives, which exerted antiproliferative, immunosuppressive, and antiparasitic effects"}
{"PMID":10658902,"re_id":13,"annotated sentence":"Mitochondrially-bound dihydroorotate dehydrogenase (<e2>EC 1.3.99.11<\\e2>  catalyzes the fourth sequential step in the de novo synthesis of <e1>uridine monophosphate<\\e1>  The enzyme has been identified as or surmised to be the pharmacological target for isoxazol, triazine, cinchoninic acid and (naphtho)quinone derivatives, which exerted antiproliferative, immunosuppressive, and antiparasitic effects","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"uridine monophosphate","object":"EC 1.3.99.11","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mitochondrially-bound dihydroorotate dehydrogenase (<e2>GENE-Y<\\e2>  catalyzes the fourth sequential step in the de novo synthesis of <e1>CHEMICAL<\\e1>  The enzyme has been identified as or surmised to be the pharmacological target for isoxazol, triazine, cinchoninic acid and (naphtho)quinone derivatives, which exerted antiproliferative, immunosuppressive, and antiparasitic effects","sentence":"Mitochondrially-bound dihydroorotate dehydrogenase (EC 1.3.99.11  catalyzes the fourth sequential step in the de novo synthesis of uridine monophosphate  The enzyme has been identified as or surmised to be the pharmacological target for isoxazol, triazine, cinchoninic acid and (naphtho)quinone derivatives, which exerted antiproliferative, immunosuppressive, and antiparasitic effects"}
{"PMID":10658902,"re_id":14,"annotated sentence":"With respect to the <e1>quinone<\\e1> co-substrate of the <e2>dihydroorotate dehydrogenase<\\e2>  atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"quinone","object":"dihydroorotate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"With respect to the <e1>CHEMICAL<\\e1> co-substrate of the <e2>GENE-Y<\\e2>  atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human GENE-Y","sentence":"With respect to the quinone co-substrate of the dihydroorotate dehydrogenase  atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase"}
{"PMID":10665814,"re_id":2,"annotated sentence":"<e1>Mibefradil<\\e1> blocked alpha1A and alpha1E with a Kd comparable to that reported for <e2>T-type channels<\\e2>  but had a lower affinity (approximately 30-fold) for alpha1C","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Mibefradil","object":"T-type channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> blocked alpha1A and alpha1E with a Kd comparable to that reported for <e2>GENE-N<\\e2>  but had a lower affinity (approximately 30-fold) for alpha1C","sentence":"Mibefradil blocked alpha1A and alpha1E with a Kd comparable to that reported for T-type channels  but had a lower affinity (approximately 30-fold) for alpha1C"}
{"PMID":10665814,"re_id":3,"annotated sentence":"<e1>Mibefradil<\\e1> (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block <e2>T-type Ca2+ channels<\\e2>  However, this molecule has also been shown to inhibit other Ca2+ channel subtypes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Mibefradil","object":"T-type Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block <e2>GENE-N<\\e2>  However, this molecule has also been shown to inhibit other Ca2+ channel subtypes","sentence":"Mibefradil (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block T-type Ca2+ channels  However, this molecule has also been shown to inhibit other Ca2+ channel subtypes"}
{"PMID":10665814,"re_id":4,"annotated sentence":"Determinants of voltage-dependent inactivation affect <e1>Mibefradil<\\e1> block of <e2>calcium channels<\\e2>  The voltage gated calcium channel family is a major target for a range of therapeutic drugs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Mibefradil","object":"calcium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Determinants of voltage-dependent inactivation affect <e1>CHEMICAL<\\e1> block of <e2>GENE-N<\\e2>  The voltage gated calcium channel family is a major target for a range of therapeutic drugs","sentence":"Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels  The voltage gated calcium channel family is a major target for a range of therapeutic drugs"}
{"PMID":10665814,"re_id":5,"annotated sentence":"Mibefradil (<e1>Ro 40-5967<\\e1>  belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block <e2>T-type Ca2+ channels<\\e2>  However, this molecule has also been shown to inhibit other Ca2+ channel subtypes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Ro 40-5967","object":"T-type Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Mibefradil (<e1>CHEMICAL<\\e1>  belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block <e2>GENE-N<\\e2>  However, this molecule has also been shown to inhibit other Ca2+ channel subtypes","sentence":"Mibefradil (Ro 40-5967  belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block T-type Ca2+ channels  However, this molecule has also been shown to inhibit other Ca2+ channel subtypes"}
{"PMID":10673876,"re_id":0,"annotated sentence":"Postoperative concentrations of <e2>plasminogen<\\e2> were decreased significantly in the <e1>tranexamic acid<\\e1> group (P < 0.001)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"tranexamic acid","object":"plasminogen","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Postoperative concentrations of <e2>GENE-Y<\\e2> were decreased significantly in the <e1>CHEMICAL<\\e1> group (P < 0.001)","sentence":"Postoperative concentrations of plasminogen were decreased significantly in the tranexamic acid group (P < 0.001)"}
{"PMID":10682715,"re_id":0,"annotated sentence":"Iontophoresis of <e1>+\/- propranolol<\\e1>  whose serotonergic actions include antagonism and partial agonism at <e2>5-HT1<\\e2> receptors, also increased serotonin and decreased firing (n=4)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"+\/- propranolol","object":"5-HT1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Iontophoresis of <e1>CHEMICAL<\\e1>  whose serotonergic actions include antagonism and partial agonism at <e2>GENE-N<\\e2> receptors, also increased serotonin and decreased firing (n=4)","sentence":"Iontophoresis of +\/- propranolol  whose serotonergic actions include antagonism and partial agonism at 5-HT1 receptors, also increased serotonin and decreased firing (n=4)"}
{"PMID":10682715,"re_id":1,"annotated sentence":"<e1>Methiothepin<\\e1> (intravenous, 1 mg\/kg), whose serotonergic actions include <e2>5-HT1<\\e2> and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Methiothepin","object":"5-HT1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (intravenous, 1 mg\/kg), whose serotonergic actions include <e2>GENE-N<\\e2> and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)","sentence":"Methiothepin (intravenous, 1 mg\/kg), whose serotonergic actions include 5-HT1 and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)"}
{"PMID":10682715,"re_id":2,"annotated sentence":"<e1>Methiothepin<\\e1> (intravenous, 1 mg\/kg), whose serotonergic actions include 5-HT1 and <e2>5-HT2<\\e2> antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Methiothepin","object":"5-HT2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (intravenous, 1 mg\/kg), whose serotonergic actions include 5-HT1 and <e2>GENE-N<\\e2> antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)","sentence":"Methiothepin (intravenous, 1 mg\/kg), whose serotonergic actions include 5-HT1 and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3)"}
{"PMID":10682715,"re_id":3,"annotated sentence":"Iontophoresis of <e1>+\/- propranolol<\\e1>  whose serotonergic actions include antagonism and partial agonism at <e2>5-HT1<\\e2> receptors, also increased serotonin and decreased firing (n=4)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"+\/- propranolol","object":"5-HT1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Iontophoresis of <e1>CHEMICAL<\\e1>  whose serotonergic actions include antagonism and partial agonism at <e2>GENE-N<\\e2> receptors, also increased serotonin and decreased firing (n=4)","sentence":"Iontophoresis of +\/- propranolol  whose serotonergic actions include antagonism and partial agonism at 5-HT1 receptors, also increased serotonin and decreased firing (n=4)"}
{"PMID":10701840,"re_id":1,"annotated sentence":"In this study, we demonstrate that <e1>geldanamycin<\\e1> treatment blocks <e2>interleukin (IL)-2<\\e2> secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"geldanamycin","object":"interleukin (IL)-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study, we demonstrate that <e1>CHEMICAL<\\e1> treatment blocks <e2>GENE-Y<\\e2> secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes","sentence":"In this study, we demonstrate that geldanamycin treatment blocks interleukin (IL)-2 secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes"}
{"PMID":10701840,"re_id":2,"annotated sentence":"In this study, we demonstrate that <e1>geldanamycin<\\e1> treatment blocks interleukin (IL)-2 secretion, <e2>IL-2 receptor<\\e2> expression, and proliferation of stimulated T-lymphocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"geldanamycin","object":"IL-2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this study, we demonstrate that <e1>CHEMICAL<\\e1> treatment blocks interleukin (IL)-2 secretion, <e2>GENE-N<\\e2> expression, and proliferation of stimulated T-lymphocytes","sentence":"In this study, we demonstrate that geldanamycin treatment blocks interleukin (IL)-2 secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes"}
{"PMID":10701840,"re_id":3,"annotated sentence":"Moreover, <e1>geldanamycin<\\e1> decreases the amount and phosphorylation of <e2>Lck<\\e2> and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"geldanamycin","object":"Lck","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> decreases the amount and phosphorylation of <e2>GENE-Y<\\e2> and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase","sentence":"Moreover, geldanamycin decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase"}
{"PMID":10701840,"re_id":4,"annotated sentence":"Moreover, <e1>geldanamycin<\\e1> decreases the amount and phosphorylation of Lck and <e2>Raf-1<\\e2> kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"geldanamycin","object":"Raf-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> decreases the amount and phosphorylation of Lck and <e2>GENE-Y<\\e2> kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase","sentence":"Moreover, geldanamycin decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase"}
{"PMID":10701840,"re_id":5,"annotated sentence":"Moreover, <e1>geldanamycin<\\e1> decreases the amount and phosphorylation of Lck and Raf-1 <e2>kinases<\\e2> and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"geldanamycin","object":"kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> decreases the amount and phosphorylation of Lck and Raf-1 <e2>GENE-N<\\e2> and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase","sentence":"Moreover, geldanamycin decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase"}
{"PMID":10701840,"re_id":6,"annotated sentence":"Through demonstrating the selective inhibition of <e2>kinase<\\e2> related T-lymphocyte responses by <e1>geldanamycin<\\e1>  our results emphasize the substantial role of Hsp90-kinase complexes in T-cell activation.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"geldanamycin","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Through demonstrating the selective inhibition of <e2>GENE-N<\\e2> related T-lymphocyte responses by <e1>CHEMICAL<\\e1>  our results emphasize the substantial role of Hsp90-GENE-N complexes in T-cell activation.","sentence":"Through demonstrating the selective inhibition of kinase related T-lymphocyte responses by geldanamycin  our results emphasize the substantial role of Hsp90-kinase complexes in T-cell activation."}
{"PMID":10701840,"re_id":7,"annotated sentence":"Improper function of these proteins can be induced by selective disruption of their complexes with <e2>Hsp90<\\e2> using the <e1>benzoquinonoid ansamycin<\\e1> geldanamycin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"benzoquinonoid ansamycin","object":"Hsp90","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Improper function of these proteins can be induced by selective disruption of their complexes with <e2>GENE-N<\\e2> using the <e1>CHEMICAL<\\e1> geldanamycin","sentence":"Improper function of these proteins can be induced by selective disruption of their complexes with Hsp90 using the benzoquinonoid ansamycin geldanamycin"}
{"PMID":10701840,"re_id":8,"annotated sentence":"Improper function of these proteins can be induced by selective disruption of their complexes with <e2>Hsp90<\\e2> using the benzoquinonoid ansamycin <e1>geldanamycin<\\e1>  In this study, we demonstrate that geldanamycin treatment blocks interleukin (IL)-2 secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"geldanamycin","object":"Hsp90","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Improper function of these proteins can be induced by selective disruption of their complexes with <e2>GENE-N<\\e2> using the benzoquinonoid ansamycin <e1>CHEMICAL<\\e1>  In this study, we demonstrate that CHEMICAL treatment blocks interleukin (IL)-2 secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes","sentence":"Improper function of these proteins can be induced by selective disruption of their complexes with Hsp90 using the benzoquinonoid ansamycin geldanamycin  In this study, we demonstrate that geldanamycin treatment blocks interleukin (IL)-2 secretion, IL-2 receptor expression, and proliferation of stimulated T-lymphocytes"}
{"PMID":10701840,"re_id":9,"annotated sentence":"Moreover, <e1>geldanamycin<\\e1> decreases the amount and phosphorylation of <e2>Lck<\\e2> and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"geldanamycin","object":"Lck","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> decreases the amount and phosphorylation of <e2>GENE-Y<\\e2> and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase","sentence":"Moreover, geldanamycin decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase"}
{"PMID":10701840,"re_id":10,"annotated sentence":"Moreover, <e1>geldanamycin<\\e1> decreases the amount and phosphorylation of Lck and <e2>Raf-1<\\e2> kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"geldanamycin","object":"Raf-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> decreases the amount and phosphorylation of Lck and <e2>GENE-Y<\\e2> kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase","sentence":"Moreover, geldanamycin decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase"}
{"PMID":10701840,"re_id":11,"annotated sentence":"Moreover, <e1>geldanamycin<\\e1> decreases the amount and phosphorylation of Lck and Raf-1 <e2>kinases<\\e2> and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"geldanamycin","object":"kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> decreases the amount and phosphorylation of Lck and Raf-1 <e2>GENE-N<\\e2> and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase","sentence":"Moreover, geldanamycin decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase"}
{"PMID":10701840,"re_id":12,"annotated sentence":"Moreover, <e1>geldanamycin<\\e1> decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the <e2>extracellular signal regulated kinase (ERK)-2<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"geldanamycin","object":"extracellular signal regulated kinase (ERK)-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the <e2>GENE-Y<\\e2> kinase","sentence":"Moreover, geldanamycin decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase"}
{"PMID":10701840,"re_id":13,"annotated sentence":"Moreover, <e1>geldanamycin<\\e1> decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 <e2>kinase<\\e2>  Geldanamycin also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (NF-AT)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"geldanamycin","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> decreases the amount and phosphorylation of Lck and Raf-1 GENE-Ns and prevents activation of the extracellular signal regulated GENE-N (ERK)-2 <e2>GENE-N<\\e2>  Geldanamycin also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (NF-AT)","sentence":"Moreover, geldanamycin decreases the amount and phosphorylation of Lck and Raf-1 kinases and prevents activation of the extracellular signal regulated kinase (ERK)-2 kinase  Geldanamycin also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (NF-AT)"}
{"PMID":10701840,"re_id":14,"annotated sentence":"<e1>Geldanamycin<\\e1> also disrupts the <e2>T-cell receptor<\\e2> mediated activation of nuclear factor of activated T-cells (NF-AT)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Geldanamycin","object":"T-cell receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also disrupts the <e2>GENE-N<\\e2> mediated activation of nuclear factor of activated T-cells (NF-AT)","sentence":"Geldanamycin also disrupts the T-cell receptor mediated activation of nuclear factor of activated T-cells (NF-AT)"}
{"PMID":10701840,"re_id":15,"annotated sentence":"<e1>Geldanamycin<\\e1> also disrupts the T-cell receptor-mediated activation of <e2>nuclear factor of activated T-cells<\\e2> (NF-AT)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Geldanamycin","object":"nuclear factor of activated T-cells","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also disrupts the T-cell receptor-mediated activation of <e2>GENE-N<\\e2> (NF-AT)","sentence":"Geldanamycin also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (NF-AT)"}
{"PMID":10701840,"re_id":16,"annotated sentence":"<e1>Geldanamycin<\\e1> also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (<e2>NF-AT<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Geldanamycin","object":"NF-AT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (<e2>GENE-N<\\e2> ","sentence":"Geldanamycin also disrupts the T-cell receptor-mediated activation of nuclear factor of activated T-cells (NF-AT "}
{"PMID":10701840,"re_id":17,"annotated sentence":"The <e2>Hsp90<\\e2> specific inhibitor <e1>geldanamycin<\\e1> selectively disrupts kinase-mediated signaling events of T-lymphocyte activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"geldanamycin","object":"Hsp90","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> specific inhibitor <e1>CHEMICAL<\\e1> selectively disrupts kinase-mediated signaling events of T-lymphocyte activation","sentence":"The Hsp90 specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation"}
{"PMID":10701840,"re_id":18,"annotated sentence":"The Hsp90-specific inhibitor <e1>geldanamycin<\\e1> selectively disrupts <e2>kinase<\\e2> mediated signaling events of T-lymphocyte activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"geldanamycin","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The Hsp90-specific inhibitor <e1>CHEMICAL<\\e1> selectively disrupts <e2>GENE-N<\\e2> mediated signaling events of T-lymphocyte activation","sentence":"The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase mediated signaling events of T-lymphocyte activation"}
{"PMID":10709635,"re_id":4,"annotated sentence":"<e2>gamma-Butyrobetaine hydroxylase<\\e2> catalyse the last step in <e1>carnitine<\\e1> biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"carnitine","object":"gamma-Butyrobetaine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> catalyse the last step in <e1>CHEMICAL<\\e1> biosynthesis, the formation of L-CHEMICAL from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen","sentence":"gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen"}
{"PMID":10709635,"re_id":5,"annotated sentence":"<e2>gamma-Butyrobetaine hydroxylase<\\e2> catalyse the last step in carnitine biosynthesis, the formation of <e1>L-carnitine<\\e1> from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"L-carnitine","object":"gamma-Butyrobetaine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> catalyse the last step in carnitine biosynthesis, the formation of <e1>CHEMICAL<\\e1> from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen","sentence":"gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine, a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen"}
{"PMID":10709635,"re_id":6,"annotated sentence":"<e2>gamma-Butyrobetaine hydroxylase<\\e2> catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from <e1>gamma-butyrobetaine<\\e1>  a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"gamma-butyrobetaine","object":"gamma-Butyrobetaine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from <e1>CHEMICAL<\\e1>  a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen","sentence":"gamma-Butyrobetaine hydroxylase catalyse the last step in carnitine biosynthesis, the formation of L-carnitine from gamma-butyrobetaine  a reaction dependent on Fe2+, alpha-ketoglutarate, ascorbate and oxygen"}
{"PMID":10727528,"re_id":20,"annotated sentence":"Inhibition of the actions of <e2>ET-1<\\e2> by <e1>salicylates<\\e1> is apparently competitive","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"salicylates","object":"ET-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of the actions of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> is apparently competitive","sentence":"Inhibition of the actions of ET-1 by salicylates is apparently competitive"}
{"PMID":10755406,"re_id":1,"annotated sentence":"Among the various enzymes, <e1>dicoumarol<\\e1> inhibitable cytosolic <e2>NAD(P)H:quinone oxidoreductase1<\\e2> (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dicoumarol","object":"NAD(P)H:quinone oxidoreductase1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Among the various enzymes, <e1>CHEMICAL<\\e1> inhibitable cytosolic <e2>GENE-N<\\e2> (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity","sentence":"Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity"}
{"PMID":10755406,"re_id":2,"annotated sentence":"Among the various enzymes, <e1>dicoumarol<\\e1> inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (<e2>NQO1<\\e2>  was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dicoumarol","object":"NQO1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Among the various enzymes, <e1>CHEMICAL<\\e1> inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (<e2>GENE-N<\\e2>  was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity","sentence":"Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1  was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity"}
{"PMID":10755406,"re_id":3,"annotated sentence":"This activity, like <e2>NQO1<\\e2>  was inhibited by <e1>dicoumarol<\\e1> and immunologically related to NQO1.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dicoumarol","object":"NQO1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This activity, like <e2>GENE-N<\\e2>  was inhibited by <e1>CHEMICAL<\\e1> and immunologically related to GENE-N.","sentence":"This activity, like NQO1  was inhibited by dicoumarol and immunologically related to NQO1."}
{"PMID":10755406,"re_id":4,"annotated sentence":"Among the various enzymes, dicoumarol inhibitable cytosolic <e2>NAD(P)H:quinone oxidoreductase1<\\e2> (NQO1) was shown to catalyse bioreductive activation of <e1>MMC<\\e1> leading to cross-linking of the DNA and cytotoxicity","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"MMC","object":"NAD(P)H:quinone oxidoreductase1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Among the various enzymes, dicoumarol inhibitable cytosolic <e2>GENE-N<\\e2> (NQO1) was shown to catalyse bioreductive activation of <e1>CHEMICAL<\\e1> leading to cross-linking of the DNA and cytotoxicity","sentence":"Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity"}
{"PMID":10755406,"re_id":5,"annotated sentence":"Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (<e2>NQO1<\\e2>  was shown to catalyse bioreductive activation of <e1>MMC<\\e1> leading to cross-linking of the DNA and cytotoxicity","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"MMC","object":"NQO1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (<e2>GENE-N<\\e2>  was shown to catalyse bioreductive activation of <e1>CHEMICAL<\\e1> leading to cross-linking of the DNA and cytotoxicity","sentence":"Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1  was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity"}
{"PMID":10755406,"re_id":6,"annotated sentence":"However, the role of <e2>NQO1<\\e2> in metabolic activation of <e1>MMC<\\e1> has been disputed","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"MMC","object":"NQO1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, the role of <e2>GENE-N<\\e2> in metabolic activation of <e1>CHEMICAL<\\e1> has been disputed","sentence":"However, the role of NQO1 in metabolic activation of MMC has been disputed"}
{"PMID":10755406,"re_id":7,"annotated sentence":"In this report, we present cellular and animal models to demonstrate that <e2>NQO1<\\e2> may play only a minor role in metabolic activation of <e1>MMC<\\e1>  We further demonstrate that bioreductive activation of MMC is catalysed by a unique cytosolic activity which is related but distinct from NQO1","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"MMC","object":"NQO1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this report, we present cellular and animal models to demonstrate that <e2>GENE-N<\\e2> may play only a minor role in metabolic activation of <e1>CHEMICAL<\\e1>  We further demonstrate that bioreductive activation of CHEMICAL is catalysed by a unique cytosolic activity which is related but distinct from GENE-N","sentence":"In this report, we present cellular and animal models to demonstrate that NQO1 may play only a minor role in metabolic activation of MMC  We further demonstrate that bioreductive activation of MMC is catalysed by a unique cytosolic activity which is related but distinct from NQO1"}
{"PMID":10755406,"re_id":8,"annotated sentence":"A unique cytosolic activity related but distinct from <e2>NQO1<\\e2> catalyses metabolic activation of <e1>mitomycin C<\\e1>  Mitomycin C (MMC) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"mitomycin C","object":"NQO1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A unique cytosolic activity related but distinct from <e2>GENE-N<\\e2> catalyses metabolic activation of <e1>CHEMICAL<\\e1>  Mitomycin C (MMC) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer","sentence":"A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C  Mitomycin C (MMC) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer"}
{"PMID":10768100,"re_id":2,"annotated sentence":"In cultures from severely obese subjects, <e1>troglitazone<\\e1> induced a decrease of <e2>PAI-1<\\e2> antigen secretion from newly differentiated omental adipocytes by 49 +\/- 8% (p < 0.01) and from subcutaneous adipocytes by 30 +\/- 7% (p < 0.05)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"troglitazone","object":"PAI-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In cultures from severely obese subjects, <e1>CHEMICAL<\\e1> induced a decrease of <e2>GENE-Y<\\e2> antigen secretion from newly differentiated omental adipocytes by 49 +\/- 8% (p < 0.01) and from subcutaneous adipocytes by 30 +\/- 7% (p < 0.05)","sentence":"In cultures from severely obese subjects, troglitazone induced a decrease of PAI-1 antigen secretion from newly differentiated omental adipocytes by 49 +\/- 8% (p < 0.01) and from subcutaneous adipocytes by 30 +\/- 7% (p < 0.05)"}
{"PMID":10768100,"re_id":3,"annotated sentence":"Exposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to <e1>troglitazone<\\e1> induced a similar reduction of <e2>PAI-1<\\e2> concentration in the culture medium (by 35 +\/- 11%, p < 0.05, and 33 +\/- 8%, p < 0.05 compared with control, respectively)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"troglitazone","object":"PAI-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to <e1>CHEMICAL<\\e1> induced a similar reduction of <e2>GENE-Y<\\e2> concentration in the culture medium (by 35 +\/- 11%, p < 0.05, and 33 +\/- 8%, p < 0.05 compared with control, respectively)","sentence":"Exposure of freshly isolated subcutaneous and omental adipocytes in suspension culture to troglitazone induced a similar reduction of PAI-1 concentration in the culture medium (by 35 +\/- 11%, p < 0.05, and 33 +\/- 8%, p < 0.05 compared with control, respectively)"}
{"PMID":10768100,"re_id":4,"annotated sentence":"CONCLUSION\/INTERPRETATION: This study provides evidence that <e1>troglitazone<\\e1> reduces <e2>PAI-1<\\e2> production in human adipocytes, probably at the transcriptional level","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"troglitazone","object":"PAI-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION\/INTERPRETATION: This study provides evidence that <e1>CHEMICAL<\\e1> reduces <e2>GENE-Y<\\e2> production in human adipocytes, probably at the transcriptional level","sentence":"CONCLUSION\/INTERPRETATION: This study provides evidence that troglitazone reduces PAI-1 production in human adipocytes, probably at the transcriptional level"}
{"PMID":10768100,"re_id":5,"annotated sentence":"RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram\/ml <e1>troglitazone<\\e1> for 72 h caused a reduction of both <e2>PAI-1<\\e2> secretion (by 29 +\/- 5%; p < 0.01) and PAI-1 mRNA expression (by 26 +\/- 3%; p < 0.05)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"troglitazone","object":"PAI-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram\/ml <e1>CHEMICAL<\\e1> for 72 h caused a reduction of both <e2>GENE-Y<\\e2> secretion (by 29 +\/- 5%; p < 0.01) and GENE-Y mRNA expression (by 26 +\/- 3%; p < 0.05)","sentence":"RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram\/ml troglitazone for 72 h caused a reduction of both PAI-1 secretion (by 29 +\/- 5%; p < 0.01) and PAI-1 mRNA expression (by 26 +\/- 3%; p < 0.05)"}
{"PMID":10768100,"re_id":6,"annotated sentence":"RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram\/ml <e1>troglitazone<\\e1> for 72 h caused a reduction of both PAI-1 secretion (by 29 +\/- 5%; p < 0.01) and <e2>PAI-1<\\e2> mRNA expression (by 26 +\/- 3%; p < 0.05)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"troglitazone","object":"PAI-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram\/ml <e1>CHEMICAL<\\e1> for 72 h caused a reduction of both GENE-Y secretion (by 29 +\/- 5%; p < 0.01) and <e2>GENE-Y<\\e2> mRNA expression (by 26 +\/- 3%; p < 0.05)","sentence":"RESULTS: Exposure of in vitro differentiated subcutaneous adipocytes from young normal-weight females to 1 microgram\/ml troglitazone for 72 h caused a reduction of both PAI-1 secretion (by 29 +\/- 5%; p < 0.01) and PAI-1 mRNA expression (by 26 +\/- 3%; p < 0.05)"}
{"PMID":10768100,"re_id":7,"annotated sentence":"<e1>Troglitazone<\\e1> reduces <e2>plasminogen activator inhibitor-1<\\e2> expression and secretion in cultured human adipocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Troglitazone","object":"plasminogen activator inhibitor-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduces <e2>GENE-Y<\\e2> expression and secretion in cultured human adipocytes","sentence":"Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes"}
{"PMID":10771044,"re_id":0,"annotated sentence":"In these tissues, <e1>JTH-601<\\e1>  prazosin (a non-selective <e2>alpha(1)-adrenoceptor<\\e2> antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"JTH-601","object":"alpha(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In these tissues, <e1>CHEMICAL<\\e1>  prazosin (a non-selective <e2>GENE-N<\\e2> antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner","sentence":"In these tissues, JTH-601  prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner"}
{"PMID":10771044,"re_id":1,"annotated sentence":"In these tissues, JTH-601, <e1>prazosin<\\e1> (a non-selective <e2>alpha(1)-adrenoceptor<\\e2> antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"prazosin","object":"alpha(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In these tissues, JTH-601, <e1>CHEMICAL<\\e1> (a non-selective <e2>GENE-N<\\e2> antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner","sentence":"In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner"}
{"PMID":10771044,"re_id":2,"annotated sentence":"In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and <e1>tamsulosin<\\e1> (an <e2>alpha(1A)-adrenoceptor<\\e2> antagonist) competitively antagonized contraction in a concentration-dependent manner","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"tamsulosin","object":"alpha(1A)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and <e1>CHEMICAL<\\e1> (an <e2>GENE-Y<\\e2> antagonist) competitively antagonized contraction in a concentration-dependent manner","sentence":"In these tissues, JTH-601, prazosin (a non-selective alpha(1)-adrenoceptor antagonist), and tamsulosin (an alpha(1A)-adrenoceptor antagonist) competitively antagonized contraction in a concentration-dependent manner"}
{"PMID":10771044,"re_id":3,"annotated sentence":"We examined the effect of JTH-601 (3- inverted question mark<e1>N-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom<\\e1> ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new <e2>alpha(1L)-adrenoceptor<\\e2> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"N-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom","object":"alpha(1L)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We examined the effect of JTH-601 (3- inverted question mark<e1>CHEMICAL<\\e1> ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new <e2>GENE-N<\\e2> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs","sentence":"We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new alpha(1L)-adrenoceptor antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs"}
{"PMID":10771044,"re_id":4,"annotated sentence":"We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom <e1>ethyl<\\e1> inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new <e2>alpha(1L)-adrenoceptor<\\e2> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"ethyl","object":"alpha(1L)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-mCHEMICALphenoxy)CHEMICAL]-N-mCHEMICALaminom <e1>CHEMICAL<\\e1> inverted question mark-4-methoxy-2,5,6-trimCHEMICALphenol hemifumarate), a new <e2>GENE-N<\\e2> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs","sentence":"We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new alpha(1L)-adrenoceptor antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs"}
{"PMID":10771044,"re_id":5,"annotated sentence":"<e1>JTH-601<\\e1> is expected to be an effective <e2>alpha(1)-adrenoceptor<\\e2> antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"JTH-601","object":"alpha(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is expected to be an effective <e2>GENE-N<\\e2> antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system.","sentence":"JTH-601 is expected to be an effective alpha(1)-adrenoceptor antagonist for the treatment of urinary outlet obstruction by benign prostatic hypertrophy with a minimum effect on the cardiovascular system."}
{"PMID":10771044,"re_id":6,"annotated sentence":"We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-<e1>4-methoxy-2,5,6-trimethylphenol hemifumarate<\\e1> , a new <e2>alpha(1L)-adrenoceptor<\\e2> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"4-methoxy-2,5,6-trimethylphenol hemifumarate","object":"alpha(1L)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-<e1>CHEMICAL<\\e1> , a new <e2>GENE-N<\\e2> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs","sentence":"We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate , a new alpha(1L)-adrenoceptor antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs"}
{"PMID":10771044,"re_id":7,"annotated sentence":"We examined the effect of <e1>JTH-601<\\e1> (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new <e2>alpha(1L)-adrenoceptor<\\e2> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"JTH-601","object":"alpha(1L)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We examined the effect of <e1>CHEMICAL<\\e1> (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new <e2>GENE-N<\\e2> antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs","sentence":"We examined the effect of JTH-601 (3- inverted question markN-[2-(4-hydroxy-2-isopropyl-5-methylphenoxy)ethyl]-N-methylaminom ethyl inverted question mark-4-methoxy-2,5,6-trimethylphenol hemifumarate), a new alpha(1L)-adrenoceptor antagonist, on prostatic function in isolated canine prostate and in anesthetized dogs"}
{"PMID":10831596,"re_id":0,"annotated sentence":"These data directly demonstrate that <e2>NKCC1<\\e2> is the major <e1>Cl(-)<\\e1> uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Cl(-)","object":"NKCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data directly demonstrate that <e2>GENE-Y<\\e2> is the major <e1>CHEMICAL<\\e1> uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.","sentence":"These data directly demonstrate that NKCC1 is the major Cl(-) uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo."}
{"PMID":10831596,"re_id":1,"annotated sentence":"The salivary fluid secretory mechanism is thought to require <e2>Na(+)\/K(+)\/2Cl(-) cotransporter<\\e2> mediated <e1>Cl(-)<\\e1> uptake","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Cl(-)","object":"Na(+)\/K(+)\/2Cl(-) cotransporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The salivary fluid secretory mechanism is thought to require <e2>Na(+)\/K(+)\/2CHEMICAL cotransporter<\\e2> mediated <e1>CHEMICAL<\\e1> uptake","sentence":"The salivary fluid secretory mechanism is thought to require Na(+)\/K(+)\/2Cl(-) cotransporter mediated Cl(-) uptake"}
{"PMID":10907719,"re_id":10,"annotated sentence":"UNLABELLED: Apparent <e2>muscarinic acetylcholine (mAch) receptor<\\e2> occupancy in mouse cerebral cortex, hippocampus, and striatum by <e1>scopolamine<\\e1>  an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"scopolamine","object":"muscarinic acetylcholine (mAch) receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"UNLABELLED: Apparent <e2>GENE-N<\\e2> occupancy in mouse cerebral cortex, hippocampus, and striatum by <e1>CHEMICAL<\\e1>  an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)","sentence":"UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine  an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)"}
{"PMID":10907719,"re_id":11,"annotated sentence":"UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and <e1>biperiden<\\e1>  a relatively selective <e2>M1<\\e2> antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"biperiden","object":"M1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and <e1>CHEMICAL<\\e1>  a relatively selective <e2>GENE-Y<\\e2> antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)","sentence":"UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden  a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB)"}
{"PMID":10909982,"re_id":11,"annotated sentence":"Treatment of lactating mice with a single injection of <e1>bezafibrate<\\e1>  an activator of the <e2>peroxisome proliferator-activated receptor<\\e2> (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"bezafibrate","object":"peroxisome proliferator-activated receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment of lactating mice with a single injection of <e1>CHEMICAL<\\e1>  an activator of the <e2>GENE-N<\\e2> (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice","sentence":"Treatment of lactating mice with a single injection of bezafibrate  an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice"}
{"PMID":10909982,"re_id":12,"annotated sentence":"Treatment of lactating mice with a single injection of <e1>bezafibrate<\\e1>  an activator of the peroxisome proliferator-activated receptor (<e2>PPAR<\\e2> , raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"bezafibrate","object":"PPAR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment of lactating mice with a single injection of <e1>CHEMICAL<\\e1>  an activator of the peroxisome proliferator-activated receptor (<e2>GENE-N<\\e2> , raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice","sentence":"Treatment of lactating mice with a single injection of bezafibrate  an activator of the peroxisome proliferator-activated receptor (PPAR , raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice"}
{"PMID":10909982,"re_id":13,"annotated sentence":"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas <e1>troglitazone<\\e1>  a specific activator of <e2>PPAR-gamma<\\e2>  also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"troglitazone","object":"PPAR-gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas <e1>CHEMICAL<\\e1>  a specific activator of <e2>GENE-Y<\\e2>  also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice","sentence":"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone  a specific activator of PPAR-gamma  also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice"}
{"PMID":10909982,"re_id":14,"annotated sentence":"It is proposed that the UCP-3 gene is regulated in skeletal muscle during lactation in response to changes in circulating free <e1>fatty acids<\\e1> by mechanisms involving activation of <e2>PPARs<\\e2>  The impaired expression of the UCP-3 gene is consistent with the involvement of UCP-3 gene regulation in the reduction of the use of fatty acids as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"fatty acids","object":"PPARs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It is proposed that the UCP-3 gene is regulated in skeletal muscle during lactation in response to changes in circulating free <e1>CHEMICAL<\\e1> by mechanisms involving activation of <e2>GENE-N<\\e2>  The impaired expression of the UCP-3 gene is consistent with the involvement of UCP-3 gene regulation in the reduction of the use of CHEMICAL as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation.","sentence":"It is proposed that the UCP-3 gene is regulated in skeletal muscle during lactation in response to changes in circulating free fatty acids by mechanisms involving activation of PPARs  The impaired expression of the UCP-3 gene is consistent with the involvement of UCP-3 gene regulation in the reduction of the use of fatty acids as fuel by the skeletal muscle and in impaired adaptative thermogenesis, both of which are major metabolic adaptations that occur during lactation."}
{"PMID":10909982,"re_id":15,"annotated sentence":"Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and <e1>troglitazone<\\e1> reverse lactation-induced downregulation of the <e2>uncoupling protein-3<\\e2> gene","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"troglitazone","object":"uncoupling protein-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Impaired expression of the GENE-Y gene in skeletal muscle during lactation: fibrates and <e1>CHEMICAL<\\e1> reverse lactation-induced downregulation of the <e2>GENE-Y<\\e2> gene","sentence":"Impaired expression of the uncoupling protein-3 gene in skeletal muscle during lactation: fibrates and troglitazone reverse lactation-induced downregulation of the uncoupling protein-3 gene"}
{"PMID":10909982,"re_id":16,"annotated sentence":"Treatment of lactating mice with a single injection of <e1>bezafibrate<\\e1>  an activator of the peroxisome proliferator-activated receptor (PPAR), raises <e2>UCP-3<\\e2> mRNA in skeletal muscle to levels similar to those in virgin mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"bezafibrate","object":"UCP-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment of lactating mice with a single injection of <e1>CHEMICAL<\\e1>  an activator of the peroxisome proliferator-activated receptor (PPAR), raises <e2>GENE-Y<\\e2> mRNA in skeletal muscle to levels similar to those in virgin mice","sentence":"Treatment of lactating mice with a single injection of bezafibrate  an activator of the peroxisome proliferator-activated receptor (PPAR), raises UCP-3 mRNA in skeletal muscle to levels similar to those in virgin mice"}
{"PMID":10909982,"re_id":17,"annotated sentence":"<e1>4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid<\\e1> (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in <e2>UCP-3<\\e2> mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid","object":"UCP-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in <e2>GENE-Y<\\e2> mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases GENE-Y mRNA abundance in skeletal muscle of lactating mice","sentence":"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice"}
{"PMID":10909982,"re_id":18,"annotated sentence":"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (<e1>WY-14,643<\\e1> , a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in <e2>UCP-3<\\e2> mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"WY-14,643","object":"UCP-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (<e1>CHEMICAL<\\e1> , a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in <e2>GENE-Y<\\e2> mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases GENE-Y mRNA abundance in skeletal muscle of lactating mice","sentence":"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643 , a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone, a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice"}
{"PMID":10909982,"re_id":19,"annotated sentence":"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas <e1>troglitazone<\\e1>  a specific activator of PPAR-gamma, also significantly increases <e2>UCP-3<\\e2> mRNA abundance in skeletal muscle of lactating mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"troglitazone","object":"UCP-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in GENE-Y mRNA, whereas <e1>CHEMICAL<\\e1>  a specific activator of PPAR-gamma, also significantly increases <e2>GENE-Y<\\e2> mRNA abundance in skeletal muscle of lactating mice","sentence":"4-chloro-6-[(2,3-xylidine)-pirimidinylthio] acetic acid (WY-14,643), a specific ligand of the PPAR-alpha subtype, causes the most dramatic increase in UCP-3 mRNA, whereas troglitazone  a specific activator of PPAR-gamma, also significantly increases UCP-3 mRNA abundance in skeletal muscle of lactating mice"}
{"PMID":10953053,"re_id":0,"annotated sentence":"<e1>Retigabine<\\e1>  a novel anti-convulsant, enhances activation of KCNQ2\/Q3 <e2>potassium channels<\\e2>  Retigabine [N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid; D-23129] is a novel anticonvulsant, unrelated to currently available antiepileptic agents, with activity in a broad range of seizure models","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Retigabine","object":"potassium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a novel anti-convulsant, enhances activation of KCNQ2\/Q3 <e2>GENE-N<\\e2>  CHEMICAL [N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid; D-23129] is a novel anticonvulsant, unrelated to currently available antiepileptic agents, with activity in a broad range of seizure models","sentence":"Retigabine  a novel anti-convulsant, enhances activation of KCNQ2\/Q3 potassium channels  Retigabine [N-(2-amino-4-[fluorobenzylamino]-phenyl) carbamic acid; D-23129] is a novel anticonvulsant, unrelated to currently available antiepileptic agents, with activity in a broad range of seizure models"}
{"PMID":11054378,"re_id":6,"annotated sentence":"RESULTS: <e2>NF-kappaB<\\e2> Rel activity induced by tumor necrosis factor alpha, <e1>12-O-tetradecanoylphorbol-13-acetate<\\e1>  or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"12-O-tetradecanoylphorbol-13-acetate","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: <e2>GENE-N<\\e2> Rel activity induced by tumor necrosis factor alpha, <e1>CHEMICAL<\\e1>  or overexpression of GENE-N-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine","sentence":"RESULTS: NF-kappaB Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate  or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine"}
{"PMID":11054378,"re_id":7,"annotated sentence":"RESULTS: NF-kappaB\/<e2>Rel<\\e2> activity induced by tumor necrosis factor alpha, <e1>12-O-tetradecanoylphorbol-13-acetate<\\e1>  or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"12-O-tetradecanoylphorbol-13-acetate","object":"Rel","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: NF-kappaB\/<e2>GENE-Y<\\e2> activity induced by tumor necrosis factor alpha, <e1>CHEMICAL<\\e1>  or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine","sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate  or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine"}
{"PMID":11054378,"re_id":8,"annotated sentence":"The suppression of <e2>NF-kappaB<\\e2> activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of <e1>sulfasalazine<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfasalazine","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The suppression of <e2>GENE-N<\\e2> activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of <e1>CHEMICAL<\\e1> ","sentence":"The suppression of NF-kappaB activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of sulfasalazine "}
{"PMID":11054378,"re_id":9,"annotated sentence":"The suppression of NF-kappaB activation by inhibition of the <e2>IKKs<\\e2> contributes to the well-known anti-inflammatory and immunosuppressive effects of <e1>sulfasalazine<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfasalazine","object":"IKKs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The suppression of NF-kappaB activation by inhibition of the <e2>GENE-N<\\e2> contributes to the well-known anti-inflammatory and immunosuppressive effects of <e1>CHEMICAL<\\e1> ","sentence":"The suppression of NF-kappaB activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of sulfasalazine "}
{"PMID":11054378,"re_id":10,"annotated sentence":"The aim of this study was to define the molecular mechanism by which <e1>sulfasalazine<\\e1> inhibits <e2>NF-kappaB<\\e2> activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfasalazine","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was to define the molecular mechanism by which <e1>CHEMICAL<\\e1> inhibits <e2>GENE-N<\\e2> activation","sentence":"The aim of this study was to define the molecular mechanism by which sulfasalazine inhibits NF-kappaB activation"}
{"PMID":11054378,"re_id":11,"annotated sentence":"RESULTS: <e2>NF-kappaB<\\e2> Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by <e1>sulfasalazine<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfasalazine","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: <e2>GENE-N<\\e2> Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of GENE-N-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by <e1>CHEMICAL<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro","sentence":"RESULTS: NF-kappaB Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro"}
{"PMID":11054378,"re_id":12,"annotated sentence":"RESULTS: NF-kappaB\/<e2>Rel<\\e2> activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by <e1>sulfasalazine<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfasalazine","object":"Rel","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: NF-kappaB\/<e2>GENE-Y<\\e2> activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by <e1>CHEMICAL<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro","sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro"}
{"PMID":11054378,"re_id":13,"annotated sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of <e2>NF-kappaB-inducing kinase<\\e2>  IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by <e1>sulfasalazine<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfasalazine","object":"NF-kappaB-inducing kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of <e2>GENE-Y<\\e2>  IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by <e1>CHEMICAL<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro","sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase  IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro"}
{"PMID":11054378,"re_id":14,"annotated sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, <e2>IKK-alpha<\\e2>  IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by <e1>sulfasalazine<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfasalazine","object":"IKK-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, <e2>GENE-Y<\\e2>  IKK-beta, or constitutively active GENE-Y and IKK-beta mutants was inhibited dose dependently by <e1>CHEMICAL<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified GENE-Y and IKK-beta in vitro","sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha  IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro"}
{"PMID":11054378,"re_id":15,"annotated sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, <e2>IKK-beta<\\e2>  or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by <e1>sulfasalazine<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfasalazine","object":"IKK-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, <e2>GENE-Y<\\e2>  or constitutively active IKK-alpha and GENE-Y mutants was inhibited dose dependently by <e1>CHEMICAL<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and GENE-Y in vitro","sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta  or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro"}
{"PMID":11054378,"re_id":16,"annotated sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active <e2>IKK-alpha<\\e2> and IKK-beta mutants was inhibited dose dependently by <e1>sulfasalazine<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfasalazine","object":"IKK-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, GENE-Y, IKK-beta, or constitutively active <e2>GENE-Y<\\e2> and IKK-beta mutants was inhibited dose dependently by <e1>CHEMICAL<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified GENE-Y and IKK-beta in vitro","sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro"}
{"PMID":11054378,"re_id":17,"annotated sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and <e2>IKK-beta<\\e2> mutants was inhibited dose dependently by <e1>sulfasalazine<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfasalazine","object":"IKK-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, GENE-Y, or constitutively active IKK-alpha and <e2>GENE-Y<\\e2> mutants was inhibited dose dependently by <e1>CHEMICAL<\\e1>  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and GENE-Y in vitro","sentence":"RESULTS: NF-kappaB\/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine  Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro"}
{"PMID":11054378,"re_id":18,"annotated sentence":"<e1>Sulfasalazine<\\e1> inhibited <e2>tumor necrosis factor alpha<\\e2> induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sulfasalazine","object":"tumor necrosis factor alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro","sentence":"Sulfasalazine inhibited tumor necrosis factor alpha induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro"}
{"PMID":11054378,"re_id":19,"annotated sentence":"<e1>Sulfasalazine<\\e1> inhibited tumor necrosis factor alpha-induced activation of endogenous <e2>IKK<\\e2> in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sulfasalazine","object":"IKK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited tumor necrosis factor alpha-induced activation of endogenous <e2>GENE-N<\\e2> in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified GENE-N-alpha and GENE-N-beta in vitro","sentence":"Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro"}
{"PMID":11054378,"re_id":20,"annotated sentence":"<e1>Sulfasalazine<\\e1> inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified <e2>IKK-alpha<\\e2> and IKK-beta in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sulfasalazine","object":"IKK-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified <e2>GENE-Y<\\e2> and IKK-beta in vitro","sentence":"Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro"}
{"PMID":11054378,"re_id":21,"annotated sentence":"<e1>Sulfasalazine<\\e1> inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and <e2>IKK-beta<\\e2> in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sulfasalazine","object":"IKK-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and <e2>GENE-Y<\\e2> in vitro","sentence":"Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro"}
{"PMID":11054378,"re_id":22,"annotated sentence":"Suppression of <e2>NF-kappaB<\\e2> activity by <e1>sulfasalazine<\\e1> is mediated by direct inhibition of IkappaB kinases alpha and beta","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfasalazine","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Suppression of <e2>GENE-N<\\e2> activity by <e1>CHEMICAL<\\e1> is mediated by direct inhibition of IkappaB kinases alpha and beta","sentence":"Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta"}
{"PMID":11054378,"re_id":23,"annotated sentence":"The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of <e2>IKKs<\\e2> and can be antagonized by excess <e1>adenosine triphosphate<\\e1>  CONCLUSIONS: These data identify sulfasalazine as a direct inhibitor of IKK-alpha and -beta by antagonizing adenosine triphosphate binding","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"adenosine triphosphate","object":"IKKs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of <e2>GENE-N<\\e2> and can be antagonized by excess <e1>CHEMICAL<\\e1>  CONCLUSIONS: These data identify sulfasalazine as a direct inhibitor of IKK-alpha and -beta by antagonizing CHEMICAL binding","sentence":"The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of IKKs and can be antagonized by excess adenosine triphosphate  CONCLUSIONS: These data identify sulfasalazine as a direct inhibitor of IKK-alpha and -beta by antagonizing adenosine triphosphate binding"}
{"PMID":11078056,"re_id":6,"annotated sentence":"This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of <e2>Bcl-2<\\e2>  as has been demonstrated for some nonselective NSAIDs, for instance, <e1>flurbiprofen<\\e1>  COX-2 mRNA and COX-2 protein is constitutively expressed in the kidney, brain, spinal cord, and ductus deferens, and in the uterus during implantation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"flurbiprofen","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of <e2>GENE-Y<\\e2>  as has been demonstrated for some nonselective NSAIDs, for instance, <e1>CHEMICAL<\\e1>  COX-2 mRNA and COX-2 protein is constitutively expressed in the kidney, brain, spinal cord, and ductus deferens, and in the uterus during implantation","sentence":"This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of Bcl-2  as has been demonstrated for some nonselective NSAIDs, for instance, flurbiprofen  COX-2 mRNA and COX-2 protein is constitutively expressed in the kidney, brain, spinal cord, and ductus deferens, and in the uterus during implantation"}
{"PMID":11078056,"re_id":7,"annotated sentence":"In contrast, aspirin-like nonselective NSAIDs such as sulindac and <e1>indomethacin<\\e1> inhibit not only the enzymatic action of the highly inducible, proinflammatory <e2>COX-2<\\e2> but the constitutively expressed, cytoprotective COX-1 as well","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"indomethacin","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, aspirin-like nonselective NSAIDs such as sulindac and <e1>CHEMICAL<\\e1> inhibit not only the enzymatic action of the highly inducible, proinflammatory <e2>GENE-Y<\\e2> but the constitutively expressed, cytoprotective COX-1 as well","sentence":"In contrast, aspirin-like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective COX-1 as well"}
{"PMID":11078056,"re_id":8,"annotated sentence":"In contrast, aspirin-like nonselective NSAIDs such as sulindac and <e1>indomethacin<\\e1> inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective <e2>COX-1<\\e2> as well","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"indomethacin","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, aspirin-like nonselective NSAIDs such as sulindac and <e1>CHEMICAL<\\e1> inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective <e2>GENE-Y<\\e2> as well","sentence":"In contrast, aspirin-like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective COX-1 as well"}
{"PMID":11078056,"re_id":9,"annotated sentence":"Selective COX-2 inhibitors, such as <e1>meloxicam<\\e1>  celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit <e2>COX-2<\\e2> but not COX-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"meloxicam","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective GENE-Y inhibitors, such as <e1>CHEMICAL<\\e1>  celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit <e2>GENE-Y<\\e2> but not COX-1","sentence":"Selective COX-2 inhibitors, such as meloxicam  celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1"}
{"PMID":11078056,"re_id":10,"annotated sentence":"Selective <e2>COX-2<\\e2> inhibitors, such as <e1>meloxicam<\\e1>  celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"meloxicam","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective <e2>GENE-Y<\\e2> inhibitors, such as <e1>CHEMICAL<\\e1>  celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit GENE-Y but not COX-1","sentence":"Selective COX-2 inhibitors, such as meloxicam  celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1"}
{"PMID":11078056,"re_id":11,"annotated sentence":"Selective COX-2 inhibitors, such as meloxicam, <e1>celecoxib<\\e1> (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit <e2>COX-2<\\e2> but not COX-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"celecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective GENE-Y inhibitors, such as meloxicam, <e1>CHEMICAL<\\e1> (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit <e2>GENE-Y<\\e2> but not COX-1","sentence":"Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1"}
{"PMID":11078056,"re_id":12,"annotated sentence":"Selective <e2>COX-2<\\e2> inhibitors, such as meloxicam, <e1>celecoxib<\\e1> (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"celecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective <e2>GENE-Y<\\e2> inhibitors, such as meloxicam, <e1>CHEMICAL<\\e1> (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit GENE-Y but not COX-1","sentence":"Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1"}
{"PMID":11078056,"re_id":13,"annotated sentence":"Selective COX-2 inhibitors, such as meloxicam, celecoxib (<e1>SC-58635<\\e1> , and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit <e2>COX-2<\\e2> but not COX-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SC-58635","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective GENE-Y inhibitors, such as meloxicam, celecoxib (<e1>CHEMICAL<\\e1> , and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit <e2>GENE-Y<\\e2> but not COX-1","sentence":"Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635 , and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1"}
{"PMID":11078056,"re_id":14,"annotated sentence":"Selective <e2>COX-2<\\e2> inhibitors, such as meloxicam, celecoxib (<e1>SC-58635<\\e1> , and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SC-58635","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective <e2>GENE-Y<\\e2> inhibitors, such as meloxicam, celecoxib (<e1>CHEMICAL<\\e1> , and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit GENE-Y but not COX-1","sentence":"Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635 , and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1"}
{"PMID":11078056,"re_id":15,"annotated sentence":"Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and <e1>rofecoxib<\\e1> (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit <e2>COX-2<\\e2> but not COX-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective GENE-Y inhibitors, such as meloxicam, celecoxib (SC-58635), and <e1>CHEMICAL<\\e1> (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit <e2>GENE-Y<\\e2> but not COX-1","sentence":"Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1"}
{"PMID":11078056,"re_id":16,"annotated sentence":"Selective <e2>COX-2<\\e2> inhibitors, such as meloxicam, celecoxib (SC-58635), and <e1>rofecoxib<\\e1> (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective <e2>GENE-Y<\\e2> inhibitors, such as meloxicam, celecoxib (SC-58635), and <e1>CHEMICAL<\\e1> (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit GENE-Y but not COX-1","sentence":"Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1"}
{"PMID":11078056,"re_id":17,"annotated sentence":"Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (<e1>MK-0966<\\e1> , are NSAIDs that have been modified chemically to preferentially inhibit <e2>COX-2<\\e2> but not COX-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"MK-0966","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective GENE-Y inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (<e1>CHEMICAL<\\e1> , are NSAIDs that have been modified chemically to preferentially inhibit <e2>GENE-Y<\\e2> but not COX-1","sentence":"Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966 , are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1"}
{"PMID":11078056,"re_id":18,"annotated sentence":"Selective <e2>COX-2<\\e2> inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (<e1>MK-0966<\\e1> , are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"MK-0966","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective <e2>GENE-Y<\\e2> inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (<e1>CHEMICAL<\\e1> , are NSAIDs that have been modified chemically to preferentially inhibit GENE-Y but not COX-1","sentence":"Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966 , are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1"}
{"PMID":11078056,"re_id":19,"annotated sentence":"For instance, <e1>meloxicam<\\e1> inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express <e2>COX-2<\\e2> but has no effect on HCT-116 tumor cells that do not express COX-2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"meloxicam","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"For instance, <e1>CHEMICAL<\\e1> inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express <e2>GENE-Y<\\e2> but has no effect on HCT-116 tumor cells that do not express GENE-Y","sentence":"For instance, meloxicam inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express COX-2 but has no effect on HCT-116 tumor cells that do not express COX-2"}
{"PMID":11078056,"re_id":20,"annotated sentence":"In contrast, <e1>aspirin<\\e1> like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory <e2>COX-2<\\e2> but the constitutively expressed, cytoprotective COX-1 as well","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"aspirin","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, <e1>CHEMICAL<\\e1> like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory <e2>GENE-Y<\\e2> but the constitutively expressed, cytoprotective COX-1 as well","sentence":"In contrast, aspirin like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective COX-1 as well"}
{"PMID":11078056,"re_id":21,"annotated sentence":"In contrast, <e1>aspirin<\\e1> like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective <e2>COX-1<\\e2> as well","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"aspirin","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, <e1>CHEMICAL<\\e1> like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective <e2>GENE-Y<\\e2> as well","sentence":"In contrast, aspirin like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective COX-1 as well"}
{"PMID":11078056,"re_id":22,"annotated sentence":"In contrast, aspirin-like nonselective NSAIDs such as <e1>sulindac<\\e1> and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory <e2>COX-2<\\e2> but the constitutively expressed, cytoprotective COX-1 as well","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulindac","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, aspirin-like nonselective NSAIDs such as <e1>CHEMICAL<\\e1> and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory <e2>GENE-Y<\\e2> but the constitutively expressed, cytoprotective COX-1 as well","sentence":"In contrast, aspirin-like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective COX-1 as well"}
{"PMID":11078056,"re_id":23,"annotated sentence":"In contrast, aspirin-like nonselective NSAIDs such as <e1>sulindac<\\e1> and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective <e2>COX-1<\\e2> as well","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulindac","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, aspirin-like nonselective NSAIDs such as <e1>CHEMICAL<\\e1> and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective <e2>GENE-Y<\\e2> as well","sentence":"In contrast, aspirin-like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective COX-1 as well"}
{"PMID":11078056,"re_id":24,"annotated sentence":"<e2>COX-2<\\e2> produces <e1>prostaglandins<\\e1> that inhibit apoptosis and stimulate angiogenesis and invasiveness","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandins","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> produces <e1>CHEMICAL<\\e1> that inhibit apoptosis and stimulate angiogenesis and invasiveness","sentence":"COX-2 produces prostaglandins that inhibit apoptosis and stimulate angiogenesis and invasiveness"}
{"PMID":11106255,"re_id":1,"annotated sentence":"To assess the feasibility of targeting these high AAAD levels for chemotherapy, <e2>AAAD<\\e2> inhibitors <e1>carbidopa<\\e1> (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carbidopa","object":"AAAD","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To assess the feasibility of targeting these high GENE-Y levels for chemotherapy, <e2>GENE-Y<\\e2> inhibitors <e1>CHEMICAL<\\e1> (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells","sentence":"To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells"}
{"PMID":11106255,"re_id":2,"annotated sentence":"To assess the feasibility of targeting these high AAAD levels for chemotherapy, <e2>AAAD<\\e2> inhibitors carbidopa (<e1>alpha-methyl-dopahydrazine<\\e1> , alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"alpha-methyl-dopahydrazine","object":"AAAD","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To assess the feasibility of targeting these high GENE-Y levels for chemotherapy, <e2>GENE-Y<\\e2> inhibitors carbidopa (<e1>CHEMICAL<\\e1> , alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells","sentence":"To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine , alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells"}
{"PMID":11106255,"re_id":3,"annotated sentence":"To assess the feasibility of targeting these high AAAD levels for chemotherapy, <e2>AAAD<\\e2> inhibitors carbidopa (alpha-methyl-dopahydrazine), <e1>alpha-monofluoromethyldopa<\\e1> (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"alpha-monofluoromethyldopa","object":"AAAD","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To assess the feasibility of targeting these high GENE-Y levels for chemotherapy, <e2>GENE-Y<\\e2> inhibitors carbidopa (alpha-methyl-dopahydrazine), <e1>CHEMICAL<\\e1> (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells","sentence":"To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells"}
{"PMID":11106255,"re_id":4,"annotated sentence":"To assess the feasibility of targeting these high AAAD levels for chemotherapy, <e2>AAAD<\\e2> inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (<e1>MFMD<\\e1> , and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"MFMD","object":"AAAD","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To assess the feasibility of targeting these high GENE-Y levels for chemotherapy, <e2>GENE-Y<\\e2> inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (<e1>CHEMICAL<\\e1> , and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells","sentence":"To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD , and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells"}
{"PMID":11106255,"re_id":5,"annotated sentence":"To assess the feasibility of targeting these high AAAD levels for chemotherapy, <e2>AAAD<\\e2> inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and <e1>3-hydroxybenzylhydrazine<\\e1> (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-hydroxybenzylhydrazine","object":"AAAD","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To assess the feasibility of targeting these high GENE-Y levels for chemotherapy, <e2>GENE-Y<\\e2> inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and <e1>CHEMICAL<\\e1> (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells","sentence":"To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells"}
{"PMID":11106255,"re_id":6,"annotated sentence":"To assess the feasibility of targeting these high AAAD levels for chemotherapy, <e2>AAAD<\\e2> inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (<e1>NSD-1015<\\e1>  were incubated (72 h) with NCI-H727 human lung carcinoid cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NSD-1015","object":"AAAD","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To assess the feasibility of targeting these high GENE-Y levels for chemotherapy, <e2>GENE-Y<\\e2> inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (<e1>CHEMICAL<\\e1>  were incubated (72 h) with NCI-H727 human lung carcinoid cells","sentence":"To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015  were incubated (72 h) with NCI-H727 human lung carcinoid cells"}
{"PMID":11141093,"re_id":3,"annotated sentence":"<e1>Hexahydrochromeno[4,3-b]pyrrole<\\e1> derivatives as <e2>acetylcholinesterase<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Hexahydrochromeno[4,3-b]pyrrole","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> derivatives as <e2>GENE-Y<\\e2> inhibitors","sentence":"Hexahydrochromeno[4,3-b]pyrrole derivatives as acetylcholinesterase inhibitors"}
{"PMID":11141093,"re_id":4,"annotated sentence":"Since this compound retains good <e2>AChE<\\e2> inhibitory activity and its <e1>hexahydrochromeno[4,3-b]pyrrole<\\e1> moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"hexahydrochromeno[4,3-b]pyrrole","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Since this compound retains good <e2>GENE-Y<\\e2> inhibitory activity and its <e1>CHEMICAL<\\e1> moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human GENE-Y and BChE","sentence":"Since this compound retains good AChE inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE"}
{"PMID":11141093,"re_id":5,"annotated sentence":"Since this compound retains good <e2>AChE<\\e2> inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the <e1>hexahydropyrrolo[2,3-b]indole of physostigmine<\\e1> (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"hexahydropyrrolo[2,3-b]indole of physostigmine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Since this compound retains good <e2>GENE-Y<\\e2> inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the <e1>CHEMICAL<\\e1> (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human GENE-Y and BChE","sentence":"Since this compound retains good AChE inhibitory activity and its hexahydrochromeno[4,3-b]pyrrole moiety is reminiscent of the hexahydropyrrolo[2,3-b]indole of physostigmine (3), we have designed and synthesized carbamates 4-6, and their biological evaluation has been assessed in vitro against human AChE and BChE"}
{"PMID":11161433,"re_id":1,"annotated sentence":"When the anti-corticosterone drug <e1>aminoglutethimide<\\e1> (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and <e2>CYP11A1<\\e2> mRNA expression were decreased at 14 days after tumor inoculation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"aminoglutethimide","object":"CYP11A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When the anti-corticosterone drug <e1>CHEMICAL<\\e1> (GENE-Y inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and <e2>GENE-Y<\\e2> mRNA expression were decreased at 14 days after tumor inoculation","sentence":"When the anti-corticosterone drug aminoglutethimide (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation"}
{"PMID":11161433,"re_id":2,"annotated sentence":"When the anti-corticosterone drug <e1>aminoglutethimide<\\e1> (<e2>CYP11A1<\\e2> inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"aminoglutethimide","object":"CYP11A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When the anti-corticosterone drug <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and GENE-Y mRNA expression were decreased at 14 days after tumor inoculation","sentence":"When the anti-corticosterone drug aminoglutethimide (CYP11A1 inhibitor) was administered to B16F10 mice, corticosterone levels in splenic tissue or serum and CYP11A1 mRNA expression were decreased at 14 days after tumor inoculation"}
{"PMID":11212269,"re_id":2,"annotated sentence":"Furthermore, h[<e1>Gly2<\\e1> -GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited <e2>poly(ADP-ribose) polymerase<\\e2> cleavage in heterologous cells transfected with the GLP-2 receptor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gly2","object":"poly(ADP-ribose) polymerase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, h[<e1>CHEMICAL<\\e1> -GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited <e2>GENE-N<\\e2> cleavage in heterologous cells transfected with the GLP-2 receptor","sentence":"Furthermore, h[Gly2 -GLP-2 reduced chemotherapy-induced apoptosis, decreased activation of caspase-8 and -3, and inhibited poly(ADP-ribose) polymerase cleavage in heterologous cells transfected with the GLP-2 receptor"}
{"PMID":11212269,"re_id":3,"annotated sentence":"We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of <e2>topoisomerase I<\\e2> inhibitor <e1>irinotecan hydrochloride<\\e1> or the antimetabolite 5-fluorouracil","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"irinotecan hydrochloride","object":"topoisomerase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> or the antimetabolite 5-fluorouracil","sentence":"We report here that a human degradation-resistant GLP-2 analogue, h[Gly2]-GLP-2 significantly improves survival, reduces bacteremia, attenuates epithelial injury, and inhibits crypt apoptosis in the murine gastrointestinal tract after administration of topoisomerase I inhibitor irinotecan hydrochloride or the antimetabolite 5-fluorouracil"}
{"PMID":11255924,"re_id":0,"annotated sentence":"OBJECTIVES: The hypothesis of the present study was that differences among <e2>dopamine transporter<\\e2> (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as <e1>DA<\\e1> uptake inhibitors","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"DA","object":"dopamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"OBJECTIVES: The hypothesis of the present study was that differences among <e2>GENE-N<\\e2> (CHEMICALT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as <e1>CHEMICAL<\\e1> uptake inhibitors","sentence":"OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter (DAT) ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as DA uptake inhibitors"}
{"PMID":11255924,"re_id":1,"annotated sentence":"OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter (<e2>DAT<\\e2>  ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as <e1>DA<\\e1> uptake inhibitors","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"DA","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter (<e2>CHEMICALT<\\e2>  ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as <e1>CHEMICAL<\\e1> uptake inhibitors","sentence":"OBJECTIVES: The hypothesis of the present study was that differences among dopamine transporter (DAT  ligands in potency and effectiveness as a positive reinforcers were related to potency and effectiveness as DA uptake inhibitors"}
{"PMID":11255924,"re_id":2,"annotated sentence":"Accordingly, self-administration of a group of local anesthetics that are <e2>DAT<\\e2> ligands was compared to their effects as <e1>DA<\\e1> uptake blockers in vitro in brain tissue","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"DA","object":"DAT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Accordingly, self-administration of a group of local anesthetics that are <e2>CHEMICALT<\\e2> ligands was compared to their effects as <e1>CHEMICAL<\\e1> uptake blockers in vitro in brain tissue","sentence":"Accordingly, self-administration of a group of local anesthetics that are DAT ligands was compared to their effects as DA uptake blockers in vitro in brain tissue"}
{"PMID":11292635,"re_id":1,"annotated sentence":"Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of <e2>NKCC1<\\e2> mediated <e1>Cl-<\\e1> transport","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Cl-","object":"NKCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Bumetanide-sensitive CHEMICAL secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> transport","sentence":"Bumetanide-sensitive Cl- secretion was dependent on extracellular Na+ and either K+ or NH, consistent with the ion dependency of NKCC1 mediated Cl- transport"}
{"PMID":11292635,"re_id":2,"annotated sentence":"Contribution of the <e2>Na+-K+-2Cl- cotransporter<\\e2> NKCC1 to <e1>Cl-<\\e1> secretion in rat OMCD","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Cl-","object":"Na+-K+-2Cl- cotransporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Contribution of the <e2>Na+-K+-2CHEMICAL cotransporter<\\e2> NKCC1 to <e1>CHEMICAL<\\e1> secretion in rat OMCD","sentence":"Contribution of the Na+-K+-2Cl- cotransporter NKCC1 to Cl- secretion in rat OMCD"}
{"PMID":11292635,"re_id":3,"annotated sentence":"Contribution of the Na+-K+-2Cl- cotransporter <e2>NKCC1<\\e2> to <e1>Cl-<\\e1> secretion in rat OMCD","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Cl-","object":"NKCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Contribution of the Na+-K+-2CHEMICAL cotransporter <e2>GENE-Y<\\e2> to <e1>CHEMICAL<\\e1> secretion in rat OMCD","sentence":"Contribution of the Na+-K+-2Cl- cotransporter NKCC1 to Cl- secretion in rat OMCD"}
{"PMID":11292635,"re_id":4,"annotated sentence":"In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete <e1>Cl-<\\e1> into the luminal fluid through <e2>NKCC1<\\e2> mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Cl-","object":"NKCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete <e1>CHEMICAL<\\e1> into the luminal fluid through <e2>GENE-Y<\\e2> mediated CHEMICAL uptake across the basolateral membrane in series with CHEMICAL efflux across the apical membrane","sentence":"In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through NKCC1 mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane"}
{"PMID":11292635,"re_id":5,"annotated sentence":"In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through <e2>NKCC1<\\e2> mediated <e1>Cl-<\\e1> uptake across the basolateral membrane in series with Cl- efflux across the apical membrane","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Cl-","object":"NKCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete CHEMICAL into the luminal fluid through <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> uptake across the basolateral membrane in series with CHEMICAL efflux across the apical membrane","sentence":"In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through NKCC1 mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane"}
{"PMID":11292635,"re_id":6,"annotated sentence":"In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through <e2>NKCC1<\\e2> mediated Cl- uptake across the basolateral membrane in series with <e1>Cl-<\\e1> efflux across the apical membrane","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Cl-","object":"NKCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete CHEMICAL into the luminal fluid through <e2>GENE-Y<\\e2> mediated CHEMICAL uptake across the basolateral membrane in series with <e1>CHEMICAL<\\e1> efflux across the apical membrane","sentence":"In conclusion, OMCD tubules from deoxycorticosterone pivalate-treated rats secrete Cl- into the luminal fluid through NKCC1 mediated Cl- uptake across the basolateral membrane in series with Cl- efflux across the apical membrane"}
{"PMID":11292635,"re_id":7,"annotated sentence":"The physiological role of <e2>NKCC1<\\e2> mediated <e1>Cl-<\\e1> uptake remains to be determined","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Cl-","object":"NKCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The physiological role of <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> uptake remains to be determined","sentence":"The physiological role of NKCC1 mediated Cl- uptake remains to be determined"}
{"PMID":11292635,"re_id":8,"annotated sentence":"The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through <e1>Cl-<\\e1> uptake across the basolateral membrane mediated by <e2>NKCC1<\\e2> in series with Cl- efflux across the apical membrane","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Cl-","object":"NKCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes CHEMICAL and whether transepithelial CHEMICAL transport occurs, in part, through <e1>CHEMICAL<\\e1> uptake across the basolateral membrane mediated by <e2>GENE-Y<\\e2> in series with CHEMICAL efflux across the apical membrane","sentence":"The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through Cl- uptake across the basolateral membrane mediated by NKCC1 in series with Cl- efflux across the apical membrane"}
{"PMID":11292635,"re_id":9,"annotated sentence":"The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through Cl- uptake across the basolateral membrane mediated by <e2>NKCC1<\\e2> in series with <e1>Cl-<\\e1> efflux across the apical membrane","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Cl-","object":"NKCC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes CHEMICAL and whether transepithelial CHEMICAL transport occurs, in part, through CHEMICAL uptake across the basolateral membrane mediated by <e2>GENE-Y<\\e2> in series with <e1>CHEMICAL<\\e1> efflux across the apical membrane","sentence":"The purpose of this study was to determine whether rat outer medullary collecting duct (OMCD) secretes Cl- and whether transepithelial Cl- transport occurs, in part, through Cl- uptake across the basolateral membrane mediated by NKCC1 in series with Cl- efflux across the apical membrane"}
{"PMID":11350861,"re_id":5,"annotated sentence":"In mice, <e1>AS-8112<\\e1> (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the <e2>dopamine D3 receptor<\\e2> agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AS-8112","object":"dopamine D3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In mice, <e1>CHEMICAL<\\e1> (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the <e2>GENE-Y<\\e2> agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)","sentence":"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the dopamine D3 receptor agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)"}
{"PMID":11350861,"re_id":6,"annotated sentence":"In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of <e1>2-methyl-5HT<\\e1>  a <e2>5-HT3 receptor<\\e2> agonist (pA2 value of 7.04)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"2-methyl-5HT","object":"5-HT3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of <e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> agonist (pA2 value of 7.04)","sentence":"In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of 2-methyl-5HT  a 5-HT3 receptor agonist (pA2 value of 7.04)"}
{"PMID":11350861,"re_id":7,"annotated sentence":"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the <e2>dopamine D3 receptor<\\e2> agonist; <e1>R(+)-7-OH-DPAT<\\e1> (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"R(+)-7-OH-DPAT","object":"dopamine D3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the <e2>GENE-Y<\\e2> agonist; <e1>CHEMICAL<\\e1> (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)","sentence":"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the dopamine D3 receptor agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)"}
{"PMID":11350861,"re_id":8,"annotated sentence":"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the <e2>dopamine D3 receptor<\\e2> agonist; R(+)-7-OH-DPAT (<e1>R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline<\\e1>  (0.3 mg kg(-1) s.c.)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline","object":"dopamine D3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the <e2>GENE-Y<\\e2> agonist; R(+)-7-OH-DPAT (<e1>CHEMICAL<\\e1>  (0.3 mg kg(-1) s.c.)","sentence":"In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the dopamine D3 receptor agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline  (0.3 mg kg(-1) s.c.)"}
{"PMID":11350861,"re_id":9,"annotated sentence":"In guinea-pig isolated colon, <e1>AS-8112<\\e1> produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a <e2>5-HT3 receptor<\\e2> agonist (pA2 value of 7.04)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"AS-8112","object":"5-HT3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In guinea-pig isolated colon, <e1>CHEMICAL<\\e1> produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a <e2>GENE-Y<\\e2> agonist (pA2 value of 7.04)","sentence":"In guinea-pig isolated colon, AS-8112 produced a rightward shift of the concentration-response curves of 2-methyl-5HT, a 5-HT3 receptor agonist (pA2 value of 7.04)"}
{"PMID":11350861,"re_id":10,"annotated sentence":"Other <e2>5-HT3 receptor<\\e2> antagonists also produced such a shift in the following antagonistic-potency order: <e1>granisetron<\\e1>  ondansetron=AS-8112>>metoclopramide","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"granisetron","object":"5-HT3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Other <e2>GENE-Y<\\e2> antagonists also produced such a shift in the following antagonistic-potency order: <e1>CHEMICAL<\\e1>  ondansetron=AS-8112>>metoclopramide","sentence":"Other 5-HT3 receptor antagonists also produced such a shift in the following antagonistic-potency order: granisetron  ondansetron=AS-8112>>metoclopramide"}
{"PMID":11350861,"re_id":11,"annotated sentence":"Other <e2>5-HT3 receptor<\\e2> antagonists also produced such a shift in the following antagonistic-potency order: granisetron> <e1>ondansetron<\\e1> AS-8112>>metoclopramide","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"ondansetron","object":"5-HT3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Other <e2>GENE-Y<\\e2> antagonists also produced such a shift in the following antagonistic-potency order: granisetron> <e1>CHEMICAL<\\e1> AS-8112>>metoclopramide","sentence":"Other 5-HT3 receptor antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron AS-8112>>metoclopramide"}
{"PMID":11350861,"re_id":12,"annotated sentence":"Other <e2>5-HT3 receptor<\\e2> antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=<e1>AS-8112<\\e1> >metoclopramide","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"AS-8112","object":"5-HT3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Other <e2>GENE-Y<\\e2> antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=<e1>CHEMICAL<\\e1> >metoclopramide","sentence":"Other 5-HT3 receptor antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=AS-8112 >metoclopramide"}
{"PMID":11350861,"re_id":13,"annotated sentence":"Other <e2>5-HT3 receptor<\\e2> antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=AS-8112>><e1>metoclopramide<\\e1>  In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the dopamine D3 receptor agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"metoclopramide","object":"5-HT3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Other <e2>GENE-Y<\\e2> antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=AS-8112>><e1>CHEMICAL<\\e1>  In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the dopamine D3 receptor agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)","sentence":"Other 5-HT3 receptor antagonists also produced such a shift in the following antagonistic-potency order: granisetron> ondansetron=AS-8112>>metoclopramide  In mice, AS-8112 (1.0 - 3.0 mg kg(-1) s.c.) potently inhibited hypothermia induced by the dopamine D3 receptor agonist; R(+)-7-OH-DPAT (R(+)-7-hydroxy-2-(N,N-di-n-propylamino)tetraline) (0.3 mg kg(-1) s.c.)"}
{"PMID":11350861,"re_id":14,"annotated sentence":"The broad-spectrum anti-emetic activity of <e1>AS-8112<\\e1>  a novel dopamine D2, D3 and <e2>5-HT3 receptors<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"AS-8112","object":"5-HT3 receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The broad-spectrum anti-emetic activity of <e1>CHEMICAL<\\e1>  a novel dopamine D2, D3 and <e2>GENE-Y<\\e2> antagonist","sentence":"The broad-spectrum anti-emetic activity of AS-8112  a novel dopamine D2, D3 and 5-HT3 receptors antagonist"}
{"PMID":11350861,"re_id":15,"annotated sentence":"In conclusion, <e1>AS-8112<\\e1> is a potent dopamine D2, D3 and <e2>5-HT3 receptors<\\e2> antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"AS-8112","object":"5-HT3 receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> is a potent dopamine D2, D3 and <e2>GENE-Y<\\e2> antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity","sentence":"In conclusion, AS-8112 is a potent dopamine D2, D3 and 5-HT3 receptors antagonist, and a novel anti-emetic agent with a broad-spectrum of anti-emetic activity"}
{"PMID":11398914,"re_id":5,"annotated sentence":"<e1>Rofecoxib<\\e1> is a selective <e2>cyclo-oxygenase (COX)-2<\\e2> inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg\/day","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Rofecoxib","object":"cyclo-oxygenase (COX)-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a selective <e2>GENE-Y<\\e2> inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg\/day","sentence":"Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg\/day"}
{"PMID":11398914,"re_id":6,"annotated sentence":"<e1>Rofecoxib<\\e1> has greater selectivity for <e2>COX-2<\\e2> than celecoxib, meloxicam, diclofenac and indomethacin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has greater selectivity for <e2>GENE-Y<\\e2> than celecoxib, meloxicam, diclofenac and indomethacin","sentence":"Rofecoxib has greater selectivity for COX-2 than celecoxib, meloxicam, diclofenac and indomethacin"}
{"PMID":11474486,"re_id":4,"annotated sentence":"<e1>Fenofibrate<\\e1> and GW2331 induced expression of <e2>acyl-coenzyme A (CoA) oxidase<\\e2> and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Fenofibrate","object":"acyl-coenzyme A (CoA) oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and GW2331 induced expression of <e2>GENE-N<\\e2> and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs","sentence":"Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs"}
{"PMID":11474486,"re_id":5,"annotated sentence":"<e1>Fenofibrate<\\e1> and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and <e2>enoyl-CoA hydratase<\\e2> and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Fenofibrate","object":"enoyl-CoA hydratase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and <e2>GENE-Y<\\e2> and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs","sentence":"Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs"}
{"PMID":11474486,"re_id":6,"annotated sentence":"Fenofibrate and <e1>GW2331<\\e1> induced expression of <e2>acyl-coenzyme A (CoA) oxidase<\\e2> and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GW2331","object":"acyl-coenzyme A (CoA) oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Fenofibrate and <e1>CHEMICAL<\\e1> induced expression of <e2>GENE-N<\\e2> and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs","sentence":"Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs"}
{"PMID":11474486,"re_id":7,"annotated sentence":"Fenofibrate and <e1>GW2331<\\e1> induced expression of acyl-coenzyme A (CoA) oxidase and <e2>enoyl-CoA hydratase<\\e2> and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GW2331","object":"enoyl-CoA hydratase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Fenofibrate and <e1>CHEMICAL<\\e1> induced expression of acyl-coenzyme A (CoA) oxidase and <e2>GENE-Y<\\e2> and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs","sentence":"Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs"}
{"PMID":11474486,"re_id":8,"annotated sentence":"<e1>Rosiglitazone<\\e1> modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of <e2>glucose transporter 4<\\e2> and phosphoenolpyruvate carboxykinase in adipose tissue","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Rosiglitazone","object":"glucose transporter 4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of <e2>GENE-Y<\\e2> and phosphoenolpyruvate carboxykinase in adipose tissue","sentence":"Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue"}
{"PMID":11474486,"re_id":9,"annotated sentence":"<e1>Rosiglitazone<\\e1> modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and <e2>phosphoenolpyruvate carboxykinase<\\e2> in adipose tissue","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Rosiglitazone","object":"phosphoenolpyruvate carboxykinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and <e2>GENE-N<\\e2> in adipose tissue","sentence":"Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue"}
{"PMID":11474486,"re_id":10,"annotated sentence":"<e1>Rosiglitazone<\\e1> modestly increased <e2>apolipoprotein C-III<\\e2> mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Rosiglitazone","object":"apolipoprotein C-III","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> modestly increased <e2>GENE-Y<\\e2> mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue","sentence":"Rosiglitazone modestly increased apolipoprotein C-III mRNA and had no effect on expression of the other 2 genes in the liver but increased the expression of glucose transporter 4 and phosphoenolpyruvate carboxykinase in adipose tissue"}
{"PMID":11474486,"re_id":11,"annotated sentence":"<e1>Fenofibrate<\\e1> and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced <e2>apolipoprotein C-III<\\e2> and phosphoenolpyruvate carboxykinase mRNAs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Fenofibrate","object":"apolipoprotein C-III","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced <e2>GENE-Y<\\e2> and phosphoenolpyruvate carboxykinase mRNAs","sentence":"Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs"}
{"PMID":11474486,"re_id":12,"annotated sentence":"<e1>Fenofibrate<\\e1> and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and <e2>phosphoenolpyruvate carboxykinase<\\e2> mRNAs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Fenofibrate","object":"phosphoenolpyruvate carboxykinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and <e2>GENE-N<\\e2> mRNAs","sentence":"Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs"}
{"PMID":11474486,"re_id":13,"annotated sentence":"Fenofibrate and <e1>GW2331<\\e1> induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced <e2>apolipoprotein C-III<\\e2> and phosphoenolpyruvate carboxykinase mRNAs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"GW2331","object":"apolipoprotein C-III","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Fenofibrate and <e1>CHEMICAL<\\e1> induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced <e2>GENE-Y<\\e2> and phosphoenolpyruvate carboxykinase mRNAs","sentence":"Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs"}
{"PMID":11474486,"re_id":14,"annotated sentence":"Fenofibrate and <e1>GW2331<\\e1> induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and <e2>phosphoenolpyruvate carboxykinase<\\e2> mRNAs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"GW2331","object":"phosphoenolpyruvate carboxykinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Fenofibrate and <e1>CHEMICAL<\\e1> induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and <e2>GENE-N<\\e2> mRNAs","sentence":"Fenofibrate and GW2331 induced expression of acyl-coenzyme A (CoA) oxidase and enoyl-CoA hydratase and reduced apolipoprotein C-III and phosphoenolpyruvate carboxykinase mRNAs"}
{"PMID":11551210,"re_id":3,"annotated sentence":"<e1>Long-chain alkanols<\\e1> are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral <e2>nicotinic acetylcholine receptor<\\e2> (AChR) by binding to one or more specific sites on the AChR","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Long-chain alkanols","object":"nicotinic acetylcholine receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral <e2>GENE-N<\\e2> (AChR) by binding to one or more specific sites on the AChR","sentence":"Long-chain alkanols are general anesthetics which can also act as uncharged noncompetitive inhibitors of the peripheral nicotinic acetylcholine receptor (AChR) by binding to one or more specific sites on the AChR"}
{"PMID":11551210,"re_id":4,"annotated sentence":"<e1>Cembranoids<\\e1> are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal <e2>AChRs<\\e2>  which have no demonstrable general anesthetic activity in vivo","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Cembranoids","object":"AChRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal <e2>GENE-N<\\e2>  which have no demonstrable general anesthetic activity in vivo","sentence":"Cembranoids are naturally occurring, uncharged noncompetitive inhibitors of peripheral and neuronal AChRs  which have no demonstrable general anesthetic activity in vivo"}
{"PMID":11587223,"re_id":1,"annotated sentence":"<e1>Sulfasalazine<\\e1> was fortuitously found to be a novel, potent inhibitor of the <e2>x(c)- transporter<\\e2>  It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c)--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sulfasalazine","object":"x(c)- transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> was fortuitously found to be a novel, potent inhibitor of the <e2>GENE-Y<\\e2>  It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c)--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid","sentence":"Sulfasalazine was fortuitously found to be a novel, potent inhibitor of the x(c)- transporter  It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c)--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid"}
{"PMID":11587223,"re_id":2,"annotated sentence":"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of <e2>x(c)<\\e2> -mediated cystine uptake, in contrast to its colonic metabolites, <e1>sulfapyridine<\\e1> and 5-aminosalicylic acid","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfapyridine","object":"x(c)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of <e2>GENE-Y<\\e2> -mediated cystine uptake, in contrast to its colonic metabolites, <e1>CHEMICAL<\\e1> and 5-aminosalicylic acid","sentence":"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c) -mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid"}
{"PMID":11587223,"re_id":3,"annotated sentence":"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of <e2>x(c)<\\e2> -mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and <e1>5-aminosalicylic acid<\\e1>  Sulfasalazine was even more effective against human non-Hodgkin's lymphoma (DoHH2) cultures","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"5-aminosalicylic acid","object":"x(c)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of <e2>GENE-Y<\\e2> -mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and <e1>CHEMICAL<\\e1>  Sulfasalazine was even more effective against human non-Hodgkin's lymphoma (DoHH2) cultures","sentence":"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c) -mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid  Sulfasalazine was even more effective against human non-Hodgkin's lymphoma (DoHH2) cultures"}
{"PMID":11587223,"re_id":4,"annotated sentence":"<e1>Sulfasalazine<\\e1>  a potent suppressor of lymphoma growth by inhibition of the <e2>x(c)- cystine transporter<\\e2>  a new action for an old drug","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sulfasalazine","object":"x(c)- cystine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a potent suppressor of lymphoma growth by inhibition of the <e2>GENE-Y<\\e2>  a new action for an old drug","sentence":"Sulfasalazine  a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter  a new action for an old drug"}
{"PMID":11587223,"re_id":5,"annotated sentence":"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of <e2>x(c)<\\e2> -mediated <e1>cystine<\\e1> uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cystine","object":"x(c)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of <e2>GENE-Y<\\e2> -mediated <e1>CHEMICAL<\\e1> uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid","sentence":"It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c) -mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid"}
{"PMID":11587223,"re_id":6,"annotated sentence":"The <e2>x(c)- cystine transporter<\\e2> represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular <e1>cyst(e)ine<\\e1> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cyst(e)ine","object":"x(c)- cystine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular <e1>CHEMICAL<\\e1> ","sentence":"The x(c)- cystine transporter represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine "}
{"PMID":11588409,"re_id":0,"annotated sentence":"Like conventional ACE inhibitors, <e1>omapatrilat<\\e1> causes extracellular volume reduction and vasodilatation; moreover, it increases levels of <e2>atrial and brain natriuretic peptides<\\e2> and bradykinin","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"omapatrilat","object":"atrial and brain natriuretic peptides","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Like conventional ACE inhibitors, <e1>CHEMICAL<\\e1> causes extracellular volume reduction and vasodilatation; moreover, it increases levels of <e2>GENE-N<\\e2> and bradykinin","sentence":"Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin"}
{"PMID":11588409,"re_id":1,"annotated sentence":"Like conventional ACE inhibitors, <e1>omapatrilat<\\e1> causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and <e2>bradykinin<\\e2>  Effective blood pressure control, especially in the high-risk patient, usually necessitates combination therapy","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"omapatrilat","object":"bradykinin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Like conventional ACE inhibitors, <e1>CHEMICAL<\\e1> causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and <e2>GENE-Y<\\e2>  Effective blood pressure control, especially in the high-risk patient, usually necessitates combination therapy","sentence":"Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin  Effective blood pressure control, especially in the high-risk patient, usually necessitates combination therapy"}
{"PMID":11588409,"re_id":2,"annotated sentence":"Like conventional <e2>ACE<\\e2> inhibitors, <e1>omapatrilat<\\e1> causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"omapatrilat","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Like conventional <e2>GENE-Y<\\e2> inhibitors, <e1>CHEMICAL<\\e1> causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin","sentence":"Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin"}
{"PMID":11588409,"re_id":3,"annotated sentence":"Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with <e1>omapatrilat<\\e1>  a <e2>vasopeptidase<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"omapatrilat","object":"vasopeptidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> inhibitor","sentence":"Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with omapatrilat  a vasopeptidase inhibitor"}
{"PMID":11588409,"re_id":4,"annotated sentence":"<e1>Omapatrilat<\\e1>  the prototypical <e2>vasopeptidase<\\e2> inhibitor, inhibits not only ACE but also neutral endopeptidase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Omapatrilat","object":"vasopeptidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  the prototypical <e2>GENE-N<\\e2> inhibitor, inhibits not only ACE but also neutral endopeptidase","sentence":"Omapatrilat  the prototypical vasopeptidase inhibitor, inhibits not only ACE but also neutral endopeptidase"}
{"PMID":11588409,"re_id":5,"annotated sentence":"<e1>Omapatrilat<\\e1>  the prototypical vasopeptidase inhibitor, inhibits not only <e2>ACE<\\e2> but also neutral endopeptidase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Omapatrilat","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  the prototypical vasopeptidase inhibitor, inhibits not only <e2>GENE-Y<\\e2> but also neutral endopeptidase","sentence":"Omapatrilat  the prototypical vasopeptidase inhibitor, inhibits not only ACE but also neutral endopeptidase"}
{"PMID":11588409,"re_id":6,"annotated sentence":"<e1>Omapatrilat<\\e1>  the prototypical vasopeptidase inhibitor, inhibits not only ACE but also <e2>neutral endopeptidase<\\e2>  Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Omapatrilat","object":"neutral endopeptidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  the prototypical vasopeptidase inhibitor, inhibits not only ACE but also <e2>GENE-Y<\\e2>  Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin","sentence":"Omapatrilat  the prototypical vasopeptidase inhibitor, inhibits not only ACE but also neutral endopeptidase  Like conventional ACE inhibitors, omapatrilat causes extracellular volume reduction and vasodilatation; moreover, it increases levels of atrial and brain natriuretic peptides and bradykinin"}
{"PMID":11688549,"re_id":0,"annotated sentence":"The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to <e1>Na+<\\e1> H+ exchange (<e2>NHE1<\\e2> isoform)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Na+","object":"NHE1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to <e1>CHEMICAL<\\e1> H+ exchange (<e2>GENE-Y<\\e2> isoform)","sentence":"The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+ H+ exchange (NHE1 isoform)"}
{"PMID":11688549,"re_id":1,"annotated sentence":"The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-<e1>H+<\\e1> exchange (<e2>NHE1<\\e2> isoform)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"H+","object":"NHE1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-<e1>CHEMICAL<\\e1> exchange (<e2>GENE-Y<\\e2> isoform)","sentence":"The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-H+ exchange (NHE1 isoform)"}
{"PMID":11689471,"re_id":6,"annotated sentence":"<e1>Salicylates<\\e1> inhibited <e2>ATPase<\\e2> activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Salicylates","object":"ATPase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibited <e2>GENE-N<\\e2> activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression","sentence":"Salicylates inhibited ATPase activity stimulated by this specific heptapeptide but did not block ATP binding or induce BiP expression"}
{"PMID":11689471,"re_id":7,"annotated sentence":"<e1>Aspirin<\\e1> and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its <e2>ATPase<\\e2> activity in human fibroblasts","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Aspirin","object":"ATPase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its <e2>GENE-N<\\e2> activity in human fibroblasts","sentence":"Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its ATPase activity in human fibroblasts"}
{"PMID":11689471,"re_id":8,"annotated sentence":"Aspirin and <e1>salicylate<\\e1> bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its <e2>ATPase<\\e2> activity in human fibroblasts","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"salicylate","object":"ATPase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Aspirin and <e1>CHEMICAL<\\e1> bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its <e2>GENE-N<\\e2> activity in human fibroblasts","sentence":"Aspirin and salicylate bind to immunoglobulin heavy chain binding protein (BiP) and inhibit its ATPase activity in human fibroblasts"}
{"PMID":11691635,"re_id":0,"annotated sentence":"The specific activity of only <e2>ornithine aminotransferase<\\e2> (OAT), the rate-limiting enzyme in the conversion of ornithine to <e1>proline<\\e1>  increased in 2 weeks of hypertrophy","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"proline","object":"ornithine aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The specific activity of only <e2>GENE-Y<\\e2> (OAT), the rate-limiting enzyme in the conversion of ornithine to <e1>CHEMICAL<\\e1>  increased in 2 weeks of hypertrophy","sentence":"The specific activity of only ornithine aminotransferase (OAT), the rate-limiting enzyme in the conversion of ornithine to proline  increased in 2 weeks of hypertrophy"}
{"PMID":11691635,"re_id":1,"annotated sentence":"The specific activity of only ornithine aminotransferase (<e2>OAT<\\e2> , the rate-limiting enzyme in the conversion of ornithine to <e1>proline<\\e1>  increased in 2 weeks of hypertrophy","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"proline","object":"OAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The specific activity of only ornithine aminotransferase (<e2>GENE-Y<\\e2> , the rate-limiting enzyme in the conversion of ornithine to <e1>CHEMICAL<\\e1>  increased in 2 weeks of hypertrophy","sentence":"The specific activity of only ornithine aminotransferase (OAT , the rate-limiting enzyme in the conversion of ornithine to proline  increased in 2 weeks of hypertrophy"}
{"PMID":11691635,"re_id":2,"annotated sentence":"The specific activity of only <e2>ornithine aminotransferase<\\e2> (OAT), the rate-limiting enzyme in the conversion of <e1>ornithine<\\e1> to proline, increased in 2 weeks of hypertrophy","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ornithine","object":"ornithine aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The specific activity of only <e2>CHEMICAL aminotransferase<\\e2> (OAT), the rate-limiting enzyme in the conversion of <e1>CHEMICAL<\\e1> to proline, increased in 2 weeks of hypertrophy","sentence":"The specific activity of only ornithine aminotransferase (OAT), the rate-limiting enzyme in the conversion of ornithine to proline, increased in 2 weeks of hypertrophy"}
{"PMID":11691635,"re_id":3,"annotated sentence":"The specific activity of only ornithine aminotransferase (<e2>OAT<\\e2> , the rate-limiting enzyme in the conversion of <e1>ornithine<\\e1> to proline, increased in 2 weeks of hypertrophy","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ornithine","object":"OAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The specific activity of only CHEMICAL aminotransferase (<e2>GENE-Y<\\e2> , the rate-limiting enzyme in the conversion of <e1>CHEMICAL<\\e1> to proline, increased in 2 weeks of hypertrophy","sentence":"The specific activity of only ornithine aminotransferase (OAT , the rate-limiting enzyme in the conversion of ornithine to proline, increased in 2 weeks of hypertrophy"}
{"PMID":11695255,"re_id":2,"annotated sentence":"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective <e2>cyclooxygenase (COX)-2<\\e2> inhibitor (<e1>celecoxib<\\e1>  in comparison to a dual COX-1\/COX-2 inhibitor (ketorolac)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"celecoxib","object":"cyclooxygenase (COX)-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective <e2>GENE-Y<\\e2> inhibitor (<e1>CHEMICAL<\\e1>  in comparison to a dual COX-1\/COX-2 inhibitor (ketorolac)","sentence":"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib  in comparison to a dual COX-1\/COX-2 inhibitor (ketorolac)"}
{"PMID":11695255,"re_id":3,"annotated sentence":"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual <e2>COX-1<\\e2> COX-2 inhibitor (<e1>ketorolac<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ketorolac","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual <e2>GENE-Y<\\e2> COX-2 inhibitor (<e1>CHEMICAL<\\e1> ","sentence":"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1 COX-2 inhibitor (ketorolac "}
{"PMID":11695255,"re_id":4,"annotated sentence":"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1\/<e2>COX-2<\\e2> inhibitor (<e1>ketorolac<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ketorolac","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1\/<e2>GENE-Y<\\e2> inhibitor (<e1>CHEMICAL<\\e1> ","sentence":"A series of studies is reviewed that assesses the relationship between cytokines released at the site of tissue injury and NSAID analgesia, and the in vivo selectivity of a selective cyclooxygenase (COX)-2 inhibitor (celecoxib) in comparison to a dual COX-1\/COX-2 inhibitor (ketorolac "}
{"PMID":11695255,"re_id":5,"annotated sentence":"<e1>Celecoxib<\\e1> selectively suppressed PGE2 but not TxB2 at time points consistent with <e2>COX-2<\\e2> activity, while producing analgesia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Celecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> selectively suppressed PGE2 but not TxB2 at time points consistent with <e2>GENE-Y<\\e2> activity, while producing analgesia","sentence":"Celecoxib selectively suppressed PGE2 but not TxB2 at time points consistent with COX-2 activity, while producing analgesia"}
{"PMID":11695255,"re_id":6,"annotated sentence":"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of <e1>prostaglandin E2<\\e1> (PGE2; a product of both <e2>COX-1<\\e2> and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin E2","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of <e1>CHEMICAL<\\e1> (PGE2; a product of both <e2>GENE-Y<\\e2> and COX-2) and thromboxane B2 (as a biomarker for GENE-Y activity) with parallel assessments of pain","sentence":"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2; a product of both COX-1 and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain"}
{"PMID":11695255,"re_id":7,"annotated sentence":"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of <e1>prostaglandin E2<\\e1> (PGE2; a product of both COX-1 and <e2>COX-2<\\e2>  and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin E2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of <e1>CHEMICAL<\\e1> (PGE2; a product of both COX-1 and <e2>GENE-Y<\\e2>  and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain","sentence":"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2; a product of both COX-1 and COX-2  and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain"}
{"PMID":11695255,"re_id":8,"annotated sentence":"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (<e1>PGE2<\\e1>  a product of both <e2>COX-1<\\e2> and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PGE2","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (<e1>CHEMICAL<\\e1>  a product of both <e2>GENE-Y<\\e2> and COX-2) and thromboxane B2 (as a biomarker for GENE-Y activity) with parallel assessments of pain","sentence":"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2  a product of both COX-1 and COX-2) and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain"}
{"PMID":11695255,"re_id":9,"annotated sentence":"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (<e1>PGE2<\\e1>  a product of both COX-1 and <e2>COX-2<\\e2>  and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PGE2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (<e1>CHEMICAL<\\e1>  a product of both COX-1 and <e2>GENE-Y<\\e2>  and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain","sentence":"Three replicate studies in the oral surgery model of acute pain used submucosal microdialysis sample collection for the measurement of prostaglandin E2 (PGE2  a product of both COX-1 and COX-2  and thromboxane B2 (as a biomarker for COX-1 activity) with parallel assessments of pain"}
{"PMID":11695255,"re_id":10,"annotated sentence":"The time course of <e1>PGE2<\\e1> production was consistent with early release due to <e2>COX-1<\\e2> activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PGE2","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The time course of <e1>CHEMICAL<\\e1> production was consistent with early release due to <e2>GENE-Y<\\e2> activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression","sentence":"The time course of PGE2 production was consistent with early release due to COX-1 activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression"}
{"PMID":11695255,"re_id":11,"annotated sentence":"The time course of <e1>PGE2<\\e1> production was consistent with early release due to COX-1 activity followed by increased production 2-3 hours after surgery, consistent with <e2>COX-2<\\e2> expression","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PGE2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The time course of <e1>CHEMICAL<\\e1> production was consistent with early release due to COX-1 activity followed by increased production 2-3 hours after surgery, consistent with <e2>GENE-Y<\\e2> expression","sentence":"The time course of PGE2 production was consistent with early release due to COX-1 activity followed by increased production 2-3 hours after surgery, consistent with COX-2 expression"}
{"PMID":11695255,"re_id":12,"annotated sentence":"Celecoxib selectively suppressed <e1>PGE2<\\e1> but not TxB2 at time points consistent with <e2>COX-2<\\e2> activity, while producing analgesia","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PGE2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Celecoxib selectively suppressed <e1>CHEMICAL<\\e1> but not TxB2 at time points consistent with <e2>GENE-Y<\\e2> activity, while producing analgesia","sentence":"Celecoxib selectively suppressed PGE2 but not TxB2 at time points consistent with COX-2 activity, while producing analgesia"}
{"PMID":11695255,"re_id":13,"annotated sentence":"These studies demonstrate the ability to assess the time course and selective effects of COX-2 inhibitors in vivo and suggest that suppression of <e2>COX-2<\\e2> mediated <e1>PGE2<\\e1> is temporally related to NSAID analgesia.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PGE2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These studies demonstrate the ability to assess the time course and selective effects of GENE-Y inhibitors in vivo and suggest that suppression of <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> is temporally related to NSAID analgesia.","sentence":"These studies demonstrate the ability to assess the time course and selective effects of COX-2 inhibitors in vivo and suggest that suppression of COX-2 mediated PGE2 is temporally related to NSAID analgesia."}
{"PMID":11775064,"re_id":0,"annotated sentence":"Acute and chronic <e1>PLZ<\\e1> administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, <e2>GABA transaminase<\\e2> (GABA-T)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PLZ","object":"GABA transaminase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acute and chronic <e1>CHEMICAL<\\e1> administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, <e2>GENE-Y<\\e2> (GABA-T)","sentence":"Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (GABA-T)"}
{"PMID":11775064,"re_id":1,"annotated sentence":"Acute and chronic <e1>PLZ<\\e1> administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (<e2>GABA-T<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PLZ","object":"GABA-T","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acute and chronic <e1>CHEMICAL<\\e1> administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (<e2>GENE-Y<\\e2> ","sentence":"Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (GABA-T "}
{"PMID":11775064,"re_id":2,"annotated sentence":"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of <e1>PLZ<\\e1> on <e2>alanine transaminase<\\e2> (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PLZ","object":"alanine transaminase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-N<\\e2> (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced","sentence":"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced"}
{"PMID":11775064,"re_id":3,"annotated sentence":"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of <e1>PLZ<\\e1> on alanine transaminase (<e2>ALA-T<\\e2> , although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PLZ","object":"ALA-T","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of <e1>CHEMICAL<\\e1> on alanine transaminase (<e2>GENE-N<\\e2> , although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced","sentence":"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (ALA-T , although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced"}
{"PMID":11775064,"re_id":4,"annotated sentence":"In addition, we also showed that the elevation in alanine levels and the inhibition of <e2>alanine transaminase<\\e2> in the brain are retained after 14 days of <e1>PLZ<\\e1> treatment, and that PLZ produces a marked increase in extracellular levels of alanine","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PLZ","object":"alanine transaminase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, we also showed that the elevation in alanine levels and the inhibition of <e2>GENE-N<\\e2> in the brain are retained after 14 days of <e1>CHEMICAL<\\e1> treatment, and that CHEMICAL produces a marked increase in extracellular levels of alanine","sentence":"In addition, we also showed that the elevation in alanine levels and the inhibition of alanine transaminase in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine"}
{"PMID":11775064,"re_id":5,"annotated sentence":"As with GABA, the metabolism of <e1>alanine<\\e1> involves a <e2>pyridoxal phosphate-dependent transaminase<\\e2>  3","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"alanine","object":"pyridoxal phosphate-dependent transaminase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"As with GABA, the metabolism of <e1>CHEMICAL<\\e1> involves a <e2>GENE-N<\\e2>  3","sentence":"As with GABA, the metabolism of alanine involves a pyridoxal phosphate-dependent transaminase  3"}
{"PMID":11775064,"re_id":6,"annotated sentence":"In the study reported here, the effects of acute PLZ treatment on the levels of various <e1>amino acids<\\e1>  some of which are also metabolized by <e2>pyridoxal phosphate-dependent transaminases<\\e2> were compared in rat whole brain","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"amino acids","object":"pyridoxal phosphate-dependent transaminases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the study reported here, the effects of acute PLZ treatment on the levels of various <e1>CHEMICAL<\\e1>  some of which are also metabolized by <e2>GENE-N<\\e2> were compared in rat whole brain","sentence":"In the study reported here, the effects of acute PLZ treatment on the levels of various amino acids  some of which are also metabolized by pyridoxal phosphate-dependent transaminases were compared in rat whole brain"}
{"PMID":11775064,"re_id":7,"annotated sentence":"In addition, we also showed that the elevation in <e1>alanine<\\e1> levels and the inhibition of <e2>alanine transaminase<\\e2> in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"alanine","object":"alanine transaminase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, we also showed that the elevation in <e1>CHEMICAL<\\e1> levels and the inhibition of <e2>CHEMICAL transaminase<\\e2> in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of CHEMICAL","sentence":"In addition, we also showed that the elevation in alanine levels and the inhibition of alanine transaminase in the brain are retained after 14 days of PLZ treatment, and that PLZ produces a marked increase in extracellular levels of alanine"}
{"PMID":11775064,"re_id":8,"annotated sentence":"The elevation in brain <e1>alanine<\\e1> levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on <e2>alanine transaminase<\\e2> (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"alanine","object":"alanine transaminase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The elevation in brain <e1>CHEMICAL<\\e1> levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on <e2>CHEMICAL transaminase<\\e2> (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced","sentence":"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (ALA-T), although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced"}
{"PMID":11775064,"re_id":9,"annotated sentence":"The elevation in brain <e1>alanine<\\e1> levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (<e2>ALA-T<\\e2> , although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"alanine","object":"ALA-T","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The elevation in brain <e1>CHEMICAL<\\e1> levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on CHEMICAL transaminase (<e2>GENE-N<\\e2> , although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced","sentence":"The elevation in brain alanine levels could be explained, at least in part, by a time- and dose-dependent inhibitory effect of PLZ on alanine transaminase (ALA-T , although as with GABA the increases are higher than expected from the degree of enzyme inhibition produced"}
{"PMID":11775064,"re_id":10,"annotated sentence":"Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the <e1>GABA<\\e1> metabolizing enzyme, <e2>GABA transaminase<\\e2> (GABA-T)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"GABA","object":"GABA transaminase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acute and chronic PLZ administration increase brain CHEMICAL levels, an effect due, at least in part, to an inhibition of the activity of the <e1>CHEMICAL<\\e1> metabolizing enzyme, <e2>CHEMICAL transaminase<\\e2> (CHEMICAL-T)","sentence":"Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (GABA-T)"}
{"PMID":11775064,"re_id":11,"annotated sentence":"Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the <e1>GABA<\\e1> metabolizing enzyme, GABA transaminase (<e2>GABA-T<\\e2> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"GABA","object":"GABA-T","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acute and chronic PLZ administration increase brain CHEMICAL levels, an effect due, at least in part, to an inhibition of the activity of the <e1>CHEMICAL<\\e1> metabolizing enzyme, CHEMICAL transaminase (<e2>CHEMICAL-T<\\e2> ","sentence":"Acute and chronic PLZ administration increase brain GABA levels, an effect due, at least in part, to an inhibition of the activity of the GABA metabolizing enzyme, GABA transaminase (GABA-T "}
{"PMID":11811354,"re_id":0,"annotated sentence":"<e2>Cyclooxygenase-1<\\e2> (COX-1) inhibitors (<e1>flurbiprofen<\\e1>  ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flurbiprofen","object":"Cyclooxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (COX-1) inhibitors (<e1>CHEMICAL<\\e1>  ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction","sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen  ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction"}
{"PMID":11811354,"re_id":1,"annotated sentence":"Cyclooxygenase-1 (<e2>COX-1<\\e2>  inhibitors (<e1>flurbiprofen<\\e1>  ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flurbiprofen","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cyclooxygenase-1 (<e2>GENE-Y<\\e2>  inhibitors (<e1>CHEMICAL<\\e1>  ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction","sentence":"Cyclooxygenase-1 (COX-1  inhibitors (flurbiprofen  ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction"}
{"PMID":11811354,"re_id":2,"annotated sentence":"<e2>Cyclooxygenase-1<\\e2> (COX-1) inhibitors (flurbiprofen, <e1>ketoprofen<\\e1> and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ketoprofen","object":"Cyclooxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (COX-1) inhibitors (flurbiprofen, <e1>CHEMICAL<\\e1> and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction","sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction"}
{"PMID":11811354,"re_id":3,"annotated sentence":"Cyclooxygenase-1 (<e2>COX-1<\\e2>  inhibitors (flurbiprofen, <e1>ketoprofen<\\e1> and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ketoprofen","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cyclooxygenase-1 (<e2>GENE-Y<\\e2>  inhibitors (flurbiprofen, <e1>CHEMICAL<\\e1> and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction","sentence":"Cyclooxygenase-1 (COX-1  inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction"}
{"PMID":11811354,"re_id":4,"annotated sentence":"<e2>Cyclooxygenase-1<\\e2> (COX-1) inhibitors (flurbiprofen, ketoprofen and <e1>ketrolack<\\e1>  attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ketrolack","object":"Cyclooxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (COX-1) inhibitors (flurbiprofen, ketoprofen and <e1>CHEMICAL<\\e1>  attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction","sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack  attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction"}
{"PMID":11811354,"re_id":5,"annotated sentence":"Cyclooxygenase-1 (<e2>COX-1<\\e2>  inhibitors (flurbiprofen, ketoprofen and <e1>ketrolack<\\e1>  attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ketrolack","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cyclooxygenase-1 (<e2>GENE-Y<\\e2>  inhibitors (flurbiprofen, ketoprofen and <e1>CHEMICAL<\\e1>  attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction","sentence":"Cyclooxygenase-1 (COX-1  inhibitors (flurbiprofen, ketoprofen and ketrolack  attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction"}
{"PMID":11811354,"re_id":6,"annotated sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and <e2>cyclooxygenase-2<\\e2> (COX-2) inhibitors at high concentrations (<e1>nimesulide<\\e1> and NS-389) slightly attenuated the contraction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nimesulide","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and <e2>GENE-Y<\\e2> (COX-2) inhibitors at high concentrations (<e1>CHEMICAL<\\e1> and NS-389) slightly attenuated the contraction","sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction"}
{"PMID":11811354,"re_id":7,"annotated sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (<e2>COX-2<\\e2>  inhibitors at high concentrations (<e1>nimesulide<\\e1> and NS-389) slightly attenuated the contraction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nimesulide","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (<e2>GENE-Y<\\e2>  inhibitors at high concentrations (<e1>CHEMICAL<\\e1> and NS-389) slightly attenuated the contraction","sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2  inhibitors at high concentrations (nimesulide and NS-389) slightly attenuated the contraction"}
{"PMID":11811354,"re_id":8,"annotated sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and <e2>cyclooxygenase-2<\\e2> (COX-2) inhibitors at high concentrations (nimesulide and <e1>NS-389<\\e1>  slightly attenuated the contraction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NS-389","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and <e2>GENE-Y<\\e2> (COX-2) inhibitors at high concentrations (nimesulide and <e1>CHEMICAL<\\e1>  slightly attenuated the contraction","sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2) inhibitors at high concentrations (nimesulide and NS-389  slightly attenuated the contraction"}
{"PMID":11811354,"re_id":9,"annotated sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (<e2>COX-2<\\e2>  inhibitors at high concentrations (nimesulide and <e1>NS-389<\\e1>  slightly attenuated the contraction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NS-389","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (<e2>GENE-Y<\\e2>  inhibitors at high concentrations (nimesulide and <e1>CHEMICAL<\\e1>  slightly attenuated the contraction","sentence":"Cyclooxygenase-1 (COX-1) inhibitors (flurbiprofen, ketoprofen and ketrolack) attenuated the nicotine-induced contraction in a concentration-dependent manner, and cyclooxygenase-2 (COX-2  inhibitors at high concentrations (nimesulide and NS-389  slightly attenuated the contraction"}
{"PMID":11811354,"re_id":10,"annotated sentence":"A <e2>TXA2 synthetase<\\e2> inhibitor (<e1>OKY-046<\\e1>  attenuated the contraction to a small extent only at high concentrations","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"OKY-046","object":"TXA2 synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A <e2>GENE-Y<\\e2> inhibitor (<e1>CHEMICAL<\\e1>  attenuated the contraction to a small extent only at high concentrations","sentence":"A TXA2 synthetase inhibitor (OKY-046  attenuated the contraction to a small extent only at high concentrations"}
{"PMID":11811354,"re_id":11,"annotated sentence":"A <e2>TXA2 receptor<\\e2> antagonist (<e1>S-1452<\\e1>  attenuated the contraction in a concentration-dependent manner","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"S-1452","object":"TXA2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A <e2>GENE-Y<\\e2> antagonist (<e1>CHEMICAL<\\e1>  attenuated the contraction in a concentration-dependent manner","sentence":"A TXA2 receptor antagonist (S-1452  attenuated the contraction in a concentration-dependent manner"}
{"PMID":11811354,"re_id":12,"annotated sentence":"A <e2>nicotinic receptor<\\e2> antagonist (<e1>hexamethonium<\\e1>  attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"hexamethonium","object":"nicotinic receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A <e2>GENE-N<\\e2> antagonist (<e1>CHEMICAL<\\e1>  attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction","sentence":"A nicotinic receptor antagonist (hexamethonium  attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin) nearly abolished the contraction"}
{"PMID":11811354,"re_id":13,"annotated sentence":"A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an <e2>alpha-adrenoceptor<\\e2> antagonist (<e1>prazosin<\\e1>  nearly abolished the contraction","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"prazosin","object":"alpha-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an <e2>GENE-N<\\e2> antagonist (<e1>CHEMICAL<\\e1>  nearly abolished the contraction","sentence":"A nicotinic receptor antagonist (hexamethonium) attenuated the contraction in part and an alpha-adrenoceptor antagonist (prazosin  nearly abolished the contraction"}
{"PMID":11885959,"re_id":8,"annotated sentence":"Accordingly, docking of different <e2>COX<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, <e1>zomepirac<\\e1>  indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"zomepirac","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Accordingly, docking of different <e2>GENE-N<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, <e1>CHEMICAL<\\e1>  indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program","sentence":"Accordingly, docking of different COX inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac  indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program"}
{"PMID":11885959,"re_id":9,"annotated sentence":"Accordingly, docking of different <e2>COX<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, <e1>indomethacin<\\e1>  diclofenac and meclofenamic acid were undertaken using the AMBER program","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"indomethacin","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Accordingly, docking of different <e2>GENE-N<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, <e1>CHEMICAL<\\e1>  diclofenac and meclofenamic acid were undertaken using the AMBER program","sentence":"Accordingly, docking of different COX inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin  diclofenac and meclofenamic acid were undertaken using the AMBER program"}
{"PMID":11885959,"re_id":10,"annotated sentence":"Accordingly, docking of different <e2>COX<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, <e1>diclofenac<\\e1> and meclofenamic acid were undertaken using the AMBER program","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diclofenac","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Accordingly, docking of different <e2>GENE-N<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, <e1>CHEMICAL<\\e1> and meclofenamic acid were undertaken using the AMBER program","sentence":"Accordingly, docking of different COX inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program"}
{"PMID":11885959,"re_id":11,"annotated sentence":"Accordingly, docking of different <e2>COX<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and <e1>meclofenamic acid<\\e1> were undertaken using the AMBER program","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"meclofenamic acid","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Accordingly, docking of different <e2>GENE-N<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and <e1>CHEMICAL<\\e1> were undertaken using the AMBER program","sentence":"Accordingly, docking of different COX inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program"}
{"PMID":11885959,"re_id":12,"annotated sentence":"Non-<e1>steroidal<\\e1> anti-inflammatory drugs (NSAIDs) are competitive inhibitors of <e2>cyclooxygenase<\\e2> (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"steroidal","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Non-<e1>CHEMICAL<\\e1> anti-inflammatory drugs (NSAIDs) are competitive inhibitors of <e2>GENE-N<\\e2> (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid","sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid"}
{"PMID":11885959,"re_id":13,"annotated sentence":"Non-<e1>steroidal<\\e1> anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (<e2>COX<\\e2> , the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"steroidal","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Non-<e1>CHEMICAL<\\e1> anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (<e2>GENE-N<\\e2> , the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid","sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX , the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid"}
{"PMID":11885959,"re_id":14,"annotated sentence":"Accordingly, docking of different <e2>COX<\\e2> inhibitors, including selective and non-selective ligands: <e1>rofecoxib<\\e1>  ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rofecoxib","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Accordingly, docking of different <e2>GENE-N<\\e2> inhibitors, including selective and non-selective ligands: <e1>CHEMICAL<\\e1>  ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program","sentence":"Accordingly, docking of different COX inhibitors, including selective and non-selective ligands: rofecoxib  ketoprofen, suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program"}
{"PMID":11885959,"re_id":15,"annotated sentence":"Accordingly, docking of different <e2>COX<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, <e1>ketoprofen<\\e1>  suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ketoprofen","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Accordingly, docking of different <e2>GENE-N<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, <e1>CHEMICAL<\\e1>  suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program","sentence":"Accordingly, docking of different COX inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen  suprofen, carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program"}
{"PMID":11885959,"re_id":16,"annotated sentence":"Accordingly, docking of different <e2>COX<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, <e1>suprofen<\\e1>  carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"suprofen","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Accordingly, docking of different <e2>GENE-N<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, <e1>CHEMICAL<\\e1>  carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program","sentence":"Accordingly, docking of different COX inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen  carprofen, zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program"}
{"PMID":11885959,"re_id":17,"annotated sentence":"Accordingly, docking of different <e2>COX<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, <e1>carprofen<\\e1>  zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carprofen","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Accordingly, docking of different <e2>GENE-N<\\e2> inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, <e1>CHEMICAL<\\e1>  zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program","sentence":"Accordingly, docking of different COX inhibitors, including selective and non-selective ligands: rofecoxib, ketoprofen, suprofen, carprofen  zomepirac, indomethacin, diclofenac and meclofenamic acid were undertaken using the AMBER program"}
{"PMID":11885959,"re_id":18,"annotated sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of <e2>cyclooxygenase<\\e2> (COX), the enzyme that mediates biosynthesis of <e1>prostaglandins<\\e1> and thromboxanes from arachidonic acid","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandins","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of <e2>GENE-N<\\e2> (COX), the enzyme that mediates biosynthesis of <e1>CHEMICAL<\\e1> and thromboxanes from arachidonic acid","sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid"}
{"PMID":11885959,"re_id":19,"annotated sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (<e2>COX<\\e2> , the enzyme that mediates biosynthesis of <e1>prostaglandins<\\e1> and thromboxanes from arachidonic acid","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandins","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (<e2>GENE-N<\\e2> , the enzyme that mediates biosynthesis of <e1>CHEMICAL<\\e1> and thromboxanes from arachidonic acid","sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX , the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid"}
{"PMID":11885959,"re_id":20,"annotated sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of <e2>cyclooxygenase<\\e2> (COX), the enzyme that mediates biosynthesis of prostaglandins and <e1>thromboxanes<\\e1> from arachidonic acid","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"thromboxanes","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of <e2>GENE-N<\\e2> (COX), the enzyme that mediates biosynthesis of prostaglandins and <e1>CHEMICAL<\\e1> from arachidonic acid","sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid"}
{"PMID":11885959,"re_id":21,"annotated sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (<e2>COX<\\e2> , the enzyme that mediates biosynthesis of prostaglandins and <e1>thromboxanes<\\e1> from arachidonic acid","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"thromboxanes","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (<e2>GENE-N<\\e2> , the enzyme that mediates biosynthesis of prostaglandins and <e1>CHEMICAL<\\e1> from arachidonic acid","sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX , the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid"}
{"PMID":11885959,"re_id":22,"annotated sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of <e2>cyclooxygenase<\\e2> (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from <e1>arachidonic acid<\\e1>  There are at least two different isoforms of the enzyme known as COX-1 and -2","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"arachidonic acid","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of <e2>GENE-N<\\e2> (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from <e1>CHEMICAL<\\e1>  There are at least two different isoforms of the enzyme known as COX-1 and -2","sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX), the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid  There are at least two different isoforms of the enzyme known as COX-1 and -2"}
{"PMID":11885959,"re_id":23,"annotated sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (<e2>COX<\\e2> , the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from <e1>arachidonic acid<\\e1>  There are at least two different isoforms of the enzyme known as COX-1 and -2","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"arachidonic acid","object":"COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (<e2>GENE-N<\\e2> , the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from <e1>CHEMICAL<\\e1>  There are at least two different isoforms of the enzyme known as GENE-N-1 and -2","sentence":"Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of cyclooxygenase (COX , the enzyme that mediates biosynthesis of prostaglandins and thromboxanes from arachidonic acid  There are at least two different isoforms of the enzyme known as COX-1 and -2"}
{"PMID":12046981,"re_id":1,"annotated sentence":"Olopatadine hydrochloride (<e1>olopatadine<\\e1>  11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic\/<e2>histamine H1-receptor<\\e2> antagonistic drug that was synthesized and evaluated in our laboratories","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"olopatadine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Olopatadine hydrochloride (<e1>CHEMICAL<\\e1>  11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic\/<e2>GENE-Y<\\e2> antagonistic drug that was synthesized and evaluated in our laboratories","sentence":"Olopatadine hydrochloride (olopatadine  11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic\/histamine H1-receptor antagonistic drug that was synthesized and evaluated in our laboratories"}
{"PMID":12046981,"re_id":2,"annotated sentence":"Olopatadine hydrochloride (olopatadine, <e1>11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride<\\e1>  is a novel antiallergic\/<e2>histamine H1-receptor<\\e2> antagonistic drug that was synthesized and evaluated in our laboratories","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Olopatadine hydrochloride (olopatadine, <e1>CHEMICAL<\\e1>  is a novel antiallergic\/<e2>GENE-Y<\\e2> antagonistic drug that was synthesized and evaluated in our laboratories","sentence":"Olopatadine hydrochloride (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride  is a novel antiallergic\/histamine H1-receptor antagonistic drug that was synthesized and evaluated in our laboratories"}
{"PMID":12046981,"re_id":3,"annotated sentence":"<e1>Olopatadine<\\e1> is a selective <e2>histamine H1-receptor<\\e2> antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Olopatadine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a selective <e2>GENE-Y<\\e2> antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils","sentence":"Olopatadine is a selective histamine H1-receptor antagonist possessing inhibitory effects on the release of inflammatory lipid mediators such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils"}
{"PMID":12046981,"re_id":4,"annotated sentence":"<e1>Olopatadine hydrochloride<\\e1> (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic\/<e2>histamine H1-receptor<\\e2> antagonistic drug that was synthesized and evaluated in our laboratories","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Olopatadine hydrochloride","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic\/<e2>GENE-Y<\\e2> antagonistic drug that was synthesized and evaluated in our laboratories","sentence":"Olopatadine hydrochloride (olopatadine, 11-[(Z)-3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid monohydrochloride) is a novel antiallergic\/histamine H1-receptor antagonistic drug that was synthesized and evaluated in our laboratories"}
{"PMID":12070353,"re_id":4,"annotated sentence":"A molecular mechanism of action of <e1>theophylline<\\e1>  Induction of <e2>histone deacetylase<\\e2> activity to decrease inflammatory gene expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"theophylline","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A molecular mechanism of action of <e1>CHEMICAL<\\e1>  Induction of <e2>GENE-N<\\e2> activity to decrease inflammatory gene expression","sentence":"A molecular mechanism of action of theophylline  Induction of histone deacetylase activity to decrease inflammatory gene expression"}
{"PMID":12070353,"re_id":5,"annotated sentence":"Thus we have shown that low-dose <e1>theophylline<\\e1> exerts an anti-asthma effect through increasing activation of <e2>HDAC<\\e2> which is subsequently recruited by corticosteroids to suppress inflammatory genes.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"theophylline","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thus we have shown that low-dose <e1>CHEMICAL<\\e1> exerts an anti-asthma effect through increasing activation of <e2>GENE-N<\\e2> which is subsequently recruited by corticosteroids to suppress inflammatory genes.","sentence":"Thus we have shown that low-dose theophylline exerts an anti-asthma effect through increasing activation of HDAC which is subsequently recruited by corticosteroids to suppress inflammatory genes."}
{"PMID":12070353,"re_id":6,"annotated sentence":"We show both in vitro and in vivo that low-dose <e1>theophylline<\\e1> enhances <e2>HDAC<\\e2> activity in epithelial cells and macrophages","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"theophylline","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We show both in vitro and in vivo that low-dose <e1>CHEMICAL<\\e1> enhances <e2>GENE-N<\\e2> activity in epithelial cells and macrophages","sentence":"We show both in vitro and in vivo that low-dose theophylline enhances HDAC activity in epithelial cells and macrophages"}
{"PMID":12085361,"re_id":2,"annotated sentence":"Inhibition of <e2>human liver OATPs<\\e2> can explain the previously observed effects of <e1>rifamycin SV<\\e1> and rifampicin on hepatic organic anion elimination.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"human liver OATPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of <e2>GENE-N<\\e2> can explain the previously observed effects of <e1>CHEMICAL<\\e1> and rifampicin on hepatic organic anion elimination.","sentence":"Inhibition of human liver OATPs can explain the previously observed effects of rifamycin SV and rifampicin on hepatic organic anion elimination."}
{"PMID":12085361,"re_id":3,"annotated sentence":"Inhibition of <e2>human liver OATPs<\\e2> can explain the previously observed effects of rifamycin SV and <e1>rifampicin<\\e1> on hepatic organic anion elimination.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifampicin","object":"human liver OATPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of <e2>GENE-N<\\e2> can explain the previously observed effects of rifamycin SV and <e1>CHEMICAL<\\e1> on hepatic organic anion elimination.","sentence":"Inhibition of human liver OATPs can explain the previously observed effects of rifamycin SV and rifampicin on hepatic organic anion elimination."}
{"PMID":12085361,"re_id":4,"annotated sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV<\\e1> (10 micromol\/L) cis-inhibited <e2>human organic anion transporting polypeptide C<\\e2> (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"human organic anion transporting polypeptide C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>CHEMICAL<\\e1> (10 micromol\/L) cis-inhibited <e2>GENE-Y<\\e2> (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes"}
{"PMID":12085361,"re_id":5,"annotated sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (<e2>SLC21A6<\\e2>  (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"SLC21A6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>CHEMICAL<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (<e2>GENE-Y<\\e2>  (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6  (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes"}
{"PMID":12085361,"re_id":6,"annotated sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (<e2>OATP-C<\\e2> , human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"OATP-C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>CHEMICAL<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (<e2>GENE-Y<\\e2> , human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C , human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes"}
{"PMID":12085361,"re_id":7,"annotated sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), <e2>human organic anion transporting polypeptide 8<\\e2> (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"human organic anion transporting polypeptide 8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>CHEMICAL<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), <e2>GENE-Y<\\e2> (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes"}
{"PMID":12085361,"re_id":8,"annotated sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (<e2>SLC21A8<\\e2>  (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"SLC21A8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>CHEMICAL<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (<e2>GENE-Y<\\e2>  (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8  (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes"}
{"PMID":12085361,"re_id":9,"annotated sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (<e2>OATP8<\\e2> , human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"OATP8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>CHEMICAL<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (<e2>GENE-Y<\\e2> , human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8 , human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes"}
{"PMID":12085361,"re_id":10,"annotated sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), <e2>human organic anion transporting polypeptide B<\\e2> (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"human organic anion transporting polypeptide B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>CHEMICAL<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), <e2>GENE-Y<\\e2> (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes"}
{"PMID":12085361,"re_id":11,"annotated sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (<e2>SLC21A9<\\e2>  (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"SLC21A9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>CHEMICAL<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (<e2>GENE-Y<\\e2>  (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9  (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes"}
{"PMID":12085361,"re_id":12,"annotated sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (<e2>OATP-B<\\e2> , and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"OATP-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>CHEMICAL<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (<e2>GENE-Y<\\e2> , and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B , and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes"}
{"PMID":12085361,"re_id":13,"annotated sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and <e2>human organic anion transporting polypeptide A<\\e2> (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"human organic anion transporting polypeptide A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>CHEMICAL<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and <e2>GENE-Y<\\e2> (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes"}
{"PMID":12085361,"re_id":14,"annotated sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (<e2>SLC21A3<\\e2>  (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"SLC21A3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>CHEMICAL<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (<e2>GENE-Y<\\e2>  (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3  (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes"}
{"PMID":12085361,"re_id":15,"annotated sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>rifamycin SV<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (<e2>OATP-A<\\e2>  mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"OATP-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, <e1>CHEMICAL<\\e1> (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (<e2>GENE-Y<\\e2>  mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes","sentence":"In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol\/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A  mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes"}
{"PMID":12085361,"re_id":16,"annotated sentence":"<e1>Rifampicin<\\e1> (10 micromol\/L) inhibited <e2>OATP8<\\e2> mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Rifampicin","object":"OATP8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (10 micromol\/L) inhibited <e2>GENE-Y<\\e2> mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%","sentence":"Rifampicin (10 micromol\/L) inhibited OATP8 mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%"}
{"PMID":12085361,"re_id":17,"annotated sentence":"<e1>Rifampicin<\\e1> (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of <e2>OATP-C<\\e2> , OATP-B-, and OATP-A-mediated BSP transport was below 15%","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Rifampicin","object":"OATP-C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of <e2>GENE-Y<\\e2> , OATP-B-, and OATP-A-mediated BSP transport was below 15%","sentence":"Rifampicin (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C , OATP-B-, and OATP-A-mediated BSP transport was below 15%"}
{"PMID":12085361,"re_id":18,"annotated sentence":"<e1>Rifampicin<\\e1> (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, <e2>OATP-B<\\e2> , and OATP-A-mediated BSP transport was below 15%","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Rifampicin","object":"OATP-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, <e2>GENE-Y<\\e2> , and OATP-A-mediated BSP transport was below 15%","sentence":"Rifampicin (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B , and OATP-A-mediated BSP transport was below 15%"}
{"PMID":12085361,"re_id":19,"annotated sentence":"<e1>Rifampicin<\\e1> (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and <e2>OATP-A<\\e2> mediated BSP transport was below 15%","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Rifampicin","object":"OATP-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and <e2>GENE-Y<\\e2> mediated BSP transport was below 15%","sentence":"Rifampicin (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A mediated BSP transport was below 15%"}
{"PMID":12085361,"re_id":20,"annotated sentence":"In rats, <e1>rifamycin SV<\\e1> and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the <e2>organic anion transporting polypeptides<\\e2> Oatp1 and Oatp2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"organic anion transporting polypeptides","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In rats, <e1>CHEMICAL<\\e1> and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the <e2>GENE-N<\\e2> Oatp1 and Oatp2","sentence":"In rats, rifamycin SV and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and Oatp2"}
{"PMID":12085361,"re_id":21,"annotated sentence":"In rats, <e1>rifamycin SV<\\e1> and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides <e2>Oatp1<\\e2> and Oatp2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"Oatp1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In rats, <e1>CHEMICAL<\\e1> and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides <e2>GENE-Y<\\e2> and Oatp2","sentence":"In rats, rifamycin SV and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and Oatp2"}
{"PMID":12085361,"re_id":22,"annotated sentence":"In rats, <e1>rifamycin SV<\\e1> and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and <e2>Oatp2<\\e2>  Therefore, we investigated the effects of rifamycin SV and rifampicin on the OATPs of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifamycin SV","object":"Oatp2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In rats, <e1>CHEMICAL<\\e1> and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and <e2>GENE-Y<\\e2>  Therefore, we investigated the effects of CHEMICAL and rifampicin on the OATPs of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers","sentence":"In rats, rifamycin SV and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and Oatp2  Therefore, we investigated the effects of rifamycin SV and rifampicin on the OATPs of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers"}
{"PMID":12085361,"re_id":23,"annotated sentence":"100 micromol\/L <e1>rifampicin<\\e1> inhibited <e2>OATP-C<\\e2>  and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifampicin","object":"OATP-C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"100 micromol\/L <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2>  and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively","sentence":"100 micromol\/L rifampicin inhibited OATP-C  and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively"}
{"PMID":12085361,"re_id":24,"annotated sentence":"100 micromol\/L <e1>rifampicin<\\e1> inhibited OATP-C- and <e2>OATP8<\\e2> , OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifampicin","object":"OATP8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"100 micromol\/L <e1>CHEMICAL<\\e1> inhibited OATP-C- and <e2>GENE-Y<\\e2> , OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively","sentence":"100 micromol\/L rifampicin inhibited OATP-C- and OATP8 , OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively"}
{"PMID":12085361,"re_id":25,"annotated sentence":"100 micromol\/L <e1>rifampicin<\\e1> inhibited OATP-C- and OATP8-, <e2>OATP-B<\\e2>  and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifampicin","object":"OATP-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"100 micromol\/L <e1>CHEMICAL<\\e1> inhibited OATP-C- and OATP8-, <e2>GENE-Y<\\e2>  and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively","sentence":"100 micromol\/L rifampicin inhibited OATP-C- and OATP8-, OATP-B  and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively"}
{"PMID":12085361,"re_id":26,"annotated sentence":"100 micromol\/L <e1>rifampicin<\\e1> inhibited OATP-C- and OATP8-, OATP-B- and <e2>OATP-A<\\e2> mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifampicin","object":"OATP-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"100 micromol\/L <e1>CHEMICAL<\\e1> inhibited OATP-C- and OATP8-, OATP-B- and <e2>GENE-Y<\\e2> mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively","sentence":"100 micromol\/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively"}
{"PMID":12085361,"re_id":27,"annotated sentence":"In rats, rifamycin SV and <e1>rifampicin<\\e1> were shown to interfere with hepatic organic anion uptake by inhibition of the <e2>organic anion transporting polypeptides<\\e2> Oatp1 and Oatp2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifampicin","object":"organic anion transporting polypeptides","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In rats, rifamycin SV and <e1>CHEMICAL<\\e1> were shown to interfere with hepatic organic anion uptake by inhibition of the <e2>GENE-N<\\e2> Oatp1 and Oatp2","sentence":"In rats, rifamycin SV and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and Oatp2"}
{"PMID":12085361,"re_id":28,"annotated sentence":"In rats, rifamycin SV and <e1>rifampicin<\\e1> were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides <e2>Oatp1<\\e2> and Oatp2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifampicin","object":"Oatp1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In rats, rifamycin SV and <e1>CHEMICAL<\\e1> were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides <e2>GENE-Y<\\e2> and Oatp2","sentence":"In rats, rifamycin SV and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and Oatp2"}
{"PMID":12085361,"re_id":29,"annotated sentence":"In rats, rifamycin SV and <e1>rifampicin<\\e1> were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and <e2>Oatp2<\\e2>  Therefore, we investigated the effects of rifamycin SV and rifampicin on the OATPs of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rifampicin","object":"Oatp2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In rats, rifamycin SV and <e1>CHEMICAL<\\e1> were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and <e2>GENE-Y<\\e2>  Therefore, we investigated the effects of rifamycin SV and CHEMICAL on the OATPs of human liver and determined whether CHEMICAL is a substrate of 1 or several of these carriers","sentence":"In rats, rifamycin SV and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and Oatp2  Therefore, we investigated the effects of rifamycin SV and rifampicin on the OATPs of human liver and determined whether rifampicin is a substrate of 1 or several of these carriers"}
{"PMID":12085361,"re_id":30,"annotated sentence":"Rifampicin (10 micromol\/L) inhibited <e2>OATP8<\\e2> mediated <e1>BSP<\\e1> uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"BSP","object":"OATP8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rifampicin (10 micromol\/L) inhibited <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated CHEMICAL transport was below 15%","sentence":"Rifampicin (10 micromol\/L) inhibited OATP8 mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%"}
{"PMID":12085361,"re_id":31,"annotated sentence":"Rifampicin (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of <e2>OATP-C<\\e2> , OATP-B-, and OATP-A-mediated <e1>BSP<\\e1> transport was below 15%","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"BSP","object":"OATP-C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rifampicin (10 micromol\/L) inhibited OATP8-mediated CHEMICAL uptake by 50%, whereas inhibition of <e2>GENE-Y<\\e2> , OATP-B-, and OATP-A-mediated <e1>CHEMICAL<\\e1> transport was below 15%","sentence":"Rifampicin (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C , OATP-B-, and OATP-A-mediated BSP transport was below 15%"}
{"PMID":12085361,"re_id":32,"annotated sentence":"Rifampicin (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, <e2>OATP-B<\\e2> , and OATP-A-mediated <e1>BSP<\\e1> transport was below 15%","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"BSP","object":"OATP-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rifampicin (10 micromol\/L) inhibited OATP8-mediated CHEMICAL uptake by 50%, whereas inhibition of OATP-C-, <e2>GENE-Y<\\e2> , and OATP-A-mediated <e1>CHEMICAL<\\e1> transport was below 15%","sentence":"Rifampicin (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B , and OATP-A-mediated BSP transport was below 15%"}
{"PMID":12085361,"re_id":33,"annotated sentence":"Rifampicin (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and <e2>OATP-A<\\e2> mediated <e1>BSP<\\e1> transport was below 15%","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"BSP","object":"OATP-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rifampicin (10 micromol\/L) inhibited OATP8-mediated CHEMICAL uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> transport was below 15%","sentence":"Rifampicin (10 micromol\/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A mediated BSP transport was below 15%"}
{"PMID":12085361,"re_id":34,"annotated sentence":"100 micromol\/L rifampicin inhibited <e2>OATP-C<\\e2>  and OATP8-, OATP-B- and OATP-A-mediated <e1>BSP<\\e1> uptake by 66%, 96%, 25%, and 49%, respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"BSP","object":"OATP-C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"100 micromol\/L rifampicin inhibited <e2>GENE-Y<\\e2>  and OATP8-, OATP-B- and OATP-A-mediated <e1>CHEMICAL<\\e1> uptake by 66%, 96%, 25%, and 49%, respectively","sentence":"100 micromol\/L rifampicin inhibited OATP-C  and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively"}
{"PMID":12085361,"re_id":35,"annotated sentence":"100 micromol\/L rifampicin inhibited OATP-C- and <e2>OATP8<\\e2> , OATP-B- and OATP-A-mediated <e1>BSP<\\e1> uptake by 66%, 96%, 25%, and 49%, respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"BSP","object":"OATP8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"100 micromol\/L rifampicin inhibited OATP-C- and <e2>GENE-Y<\\e2> , OATP-B- and OATP-A-mediated <e1>CHEMICAL<\\e1> uptake by 66%, 96%, 25%, and 49%, respectively","sentence":"100 micromol\/L rifampicin inhibited OATP-C- and OATP8 , OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively"}
{"PMID":12085361,"re_id":36,"annotated sentence":"100 micromol\/L rifampicin inhibited OATP-C- and OATP8-, <e2>OATP-B<\\e2>  and OATP-A-mediated <e1>BSP<\\e1> uptake by 66%, 96%, 25%, and 49%, respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"BSP","object":"OATP-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"100 micromol\/L rifampicin inhibited OATP-C- and OATP8-, <e2>GENE-Y<\\e2>  and OATP-A-mediated <e1>CHEMICAL<\\e1> uptake by 66%, 96%, 25%, and 49%, respectively","sentence":"100 micromol\/L rifampicin inhibited OATP-C- and OATP8-, OATP-B  and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively"}
{"PMID":12085361,"re_id":37,"annotated sentence":"100 micromol\/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and <e2>OATP-A<\\e2> mediated <e1>BSP<\\e1> uptake by 66%, 96%, 25%, and 49%, respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"BSP","object":"OATP-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"100 micromol\/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> uptake by 66%, 96%, 25%, and 49%, respectively","sentence":"100 micromol\/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively"}
{"PMID":12085361,"re_id":38,"annotated sentence":"Direct transport of <e1>rifampicin<\\e1> could be shown for <e2>OATP-C<\\e2> (apparent K(m) value 13 micromol\/L) and OATP8 (2.3 micromol\/L)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"rifampicin","object":"OATP-C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Direct transport of <e1>CHEMICAL<\\e1> could be shown for <e2>GENE-Y<\\e2> (apparent K(m) value 13 micromol\/L) and OATP8 (2.3 micromol\/L)","sentence":"Direct transport of rifampicin could be shown for OATP-C (apparent K(m) value 13 micromol\/L) and OATP8 (2.3 micromol\/L)"}
{"PMID":12085361,"re_id":39,"annotated sentence":"Direct transport of <e1>rifampicin<\\e1> could be shown for OATP-C (apparent K(m) value 13 micromol\/L) and <e2>OATP8<\\e2> (2.3 micromol\/L)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"rifampicin","object":"OATP8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Direct transport of <e1>CHEMICAL<\\e1> could be shown for OATP-C (apparent K(m) value 13 micromol\/L) and <e2>GENE-Y<\\e2> (2.3 micromol\/L)","sentence":"Direct transport of rifampicin could be shown for OATP-C (apparent K(m) value 13 micromol\/L) and OATP8 (2.3 micromol\/L)"}
{"PMID":12086935,"re_id":2,"annotated sentence":"We recently reported that <e2>AMPK<\\e2> is activated by <e1>metformin<\\e1> in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We recently reported that <e2>GENE-N<\\e2> is activated by <e1>CHEMICAL<\\e1> in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production","sentence":"We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production"}
{"PMID":12086935,"re_id":3,"annotated sentence":"In the present study, we evaluated whether therapeutic doses of <e1>metformin<\\e1> increase <e2>AMPK<\\e2> activity in vivo in subjects with type 2 diabetes","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, we evaluated whether therapeutic doses of <e1>CHEMICAL<\\e1> increase <e2>GENE-N<\\e2> activity in vivo in subjects with type 2 diabetes","sentence":"In the present study, we evaluated whether therapeutic doses of metformin increase AMPK activity in vivo in subjects with type 2 diabetes"}
{"PMID":12086935,"re_id":4,"annotated sentence":"<e1>Metformin<\\e1> treatment for 10 weeks significantly increased <e2>AMPK alpha2<\\e2> activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Metformin","object":"AMPK alpha2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment for 10 weeks significantly increased <e2>GENE-Y<\\e2> activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity","sentence":"Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity"}
{"PMID":12086935,"re_id":5,"annotated sentence":"<e1>Metformin<\\e1> treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of <e2>AMPK<\\e2> on Thr172 and decreased acetyl-CoA carboxylase-2 activity","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment for 10 weeks significantly increased GENE-N alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of <e2>GENE-N<\\e2> on Thr172 and decreased acetyl-CoA carboxylase-2 activity","sentence":"Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity"}
{"PMID":12086935,"re_id":6,"annotated sentence":"<e1>Metformin<\\e1> increases <e2>AMP-activated protein kinase<\\e2> activity in skeletal muscle of subjects with type 2 diabetes","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Metformin","object":"AMP-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> increases <e2>GENE-N<\\e2> activity in skeletal muscle of subjects with type 2 diabetes","sentence":"Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes"}
{"PMID":12086935,"re_id":7,"annotated sentence":"The increase in <e2>AMPK alpha2<\\e2> activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after <e1>metformin<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"metformin","object":"AMPK alpha2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The increase in <e2>GENE-Y<\\e2> activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after <e1>CHEMICAL<\\e1> treatment","sentence":"The increase in AMPK alpha2 activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after metformin treatment"}
{"PMID":12086935,"re_id":8,"annotated sentence":"<e1>Metformin<\\e1> induced increases in <e2>AMPK<\\e2> activity were associated with higher rates of glucose disposal and muscle glycogen concentrations","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induced increases in <e2>GENE-N<\\e2> activity were associated with higher rates of glucose disposal and muscle glycogen concentrations","sentence":"Metformin induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations"}
{"PMID":12086935,"re_id":9,"annotated sentence":"<e1>Metformin<\\e1> treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased <e2>acetyl-CoA carboxylase-2<\\e2> activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Metformin","object":"acetyl-CoA carboxylase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased <e2>GENE-Y<\\e2> activity","sentence":"Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity"}
{"PMID":12086935,"re_id":10,"annotated sentence":"<e2>AMP-activated protein kinase<\\e2> (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of <e1>glucose<\\e1> uptake into skeletal muscle and the inhibition of liver gluconeogenesis","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glucose","object":"AMP-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of <e1>CHEMICAL<\\e1> uptake into skeletal muscle and the inhibition of liver gluconeogenesis","sentence":"AMP-activated protein kinase (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis"}
{"PMID":12086935,"re_id":11,"annotated sentence":"AMP-activated protein kinase (<e2>AMPK<\\e2>  activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of <e1>glucose<\\e1> uptake into skeletal muscle and the inhibition of liver gluconeogenesis","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glucose","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"AMP-activated protein kinase (<e2>GENE-N<\\e2>  activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of <e1>CHEMICAL<\\e1> uptake into skeletal muscle and the inhibition of liver gluconeogenesis","sentence":"AMP-activated protein kinase (AMPK  activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis"}
{"PMID":12105857,"re_id":1,"annotated sentence":"CONCLUSIONS: These results collectively indicate that <e1>thalidomide<\\e1> prevents alcoholic liver injury through suppression of <e2>TNF-alpha<\\e2> production and abolishment of KC sensitization.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"thalidomide","object":"TNF-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: These results collectively indicate that <e1>CHEMICAL<\\e1> prevents alcoholic liver injury through suppression of <e2>GENE-Y<\\e2> production and abolishment of KC sensitization.","sentence":"CONCLUSIONS: These results collectively indicate that thalidomide prevents alcoholic liver injury through suppression of TNF-alpha production and abolishment of KC sensitization."}
{"PMID":12105857,"re_id":2,"annotated sentence":"<e1>Thalidomide<\\e1> has been shown to suppress <e2>TNF-alpha<\\e2> production from macrophages","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Thalidomide","object":"TNF-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has been shown to suppress <e2>GENE-Y<\\e2> production from macrophages","sentence":"Thalidomide has been shown to suppress TNF-alpha production from macrophages"}
{"PMID":12105857,"re_id":3,"annotated sentence":"<e1>Thalidomide<\\e1> prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and <e2>TNF-alpha<\\e2> production","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Thalidomide","object":"TNF-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and <e2>GENE-Y<\\e2> production","sentence":"Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production"}
{"PMID":12105857,"re_id":4,"annotated sentence":"Furthermore, <e1>thalidomide<\\e1> abolished the LPS-induced increase in <e2>CD14<\\e2> expression and [Ca2+]i elevation in KCs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"thalidomide","object":"CD14","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> abolished the LPS-induced increase in <e2>GENE-Y<\\e2> expression and [Ca2+]i elevation in KCs","sentence":"Furthermore, thalidomide abolished the LPS-induced increase in CD14 expression and [Ca2+]i elevation in KCs"}
{"PMID":12105857,"re_id":5,"annotated sentence":"Moreover, <e1>thalidomide<\\e1> reduced the LPS-induced <e2>TNF-alpha<\\e2> production by KCs by decreasing TNF-alpha messenger RNA","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"thalidomide","object":"TNF-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> reduced the LPS-induced <e2>GENE-Y<\\e2> production by KCs by decreasing GENE-Y messenger RNA","sentence":"Moreover, thalidomide reduced the LPS-induced TNF-alpha production by KCs by decreasing TNF-alpha messenger RNA"}
{"PMID":12105857,"re_id":6,"annotated sentence":"Moreover, <e1>thalidomide<\\e1> reduced the LPS-induced TNF-alpha production by KCs by decreasing <e2>TNF-alpha<\\e2> messenger RNA","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"thalidomide","object":"TNF-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> reduced the LPS-induced GENE-Y production by KCs by decreasing <e2>GENE-Y<\\e2> messenger RNA","sentence":"Moreover, thalidomide reduced the LPS-induced TNF-alpha production by KCs by decreasing TNF-alpha messenger RNA"}
{"PMID":12141946,"re_id":4,"annotated sentence":"The <e2>PAO<\\e2> inhibitor, <e1>MDL-72,527<\\e1>  only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"MDL-72,527","object":"PAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  only partially blocked oxidation of spermine while a previously reported GENE-Y substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction","sentence":"The PAO inhibitor, MDL-72,527  only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction"}
{"PMID":12141946,"re_id":5,"annotated sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by <e2>polyamine oxidase<\\e2> (PAO) to produce <e1>spermidine<\\e1> and putrescine, respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"spermidine","object":"polyamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During polyamine catabolism, spermine and CHEMICAL are first acetylated by CHEMICAL\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by <e2>GENE-Y<\\e2> (PAO) to produce <e1>CHEMICAL<\\e1> and putrescine, respectively","sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively"}
{"PMID":12141946,"re_id":6,"annotated sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (<e2>PAO<\\e2>  to produce <e1>spermidine<\\e1> and putrescine, respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"spermidine","object":"PAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During polyamine catabolism, spermine and CHEMICAL are first acetylated by CHEMICAL\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (<e2>GENE-Y<\\e2>  to produce <e1>CHEMICAL<\\e1> and putrescine, respectively","sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO  to produce spermidine and putrescine, respectively"}
{"PMID":12141946,"re_id":7,"annotated sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by <e2>polyamine oxidase<\\e2> (PAO) to produce spermidine and <e1>putrescine<\\e1>  respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"putrescine","object":"polyamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by <e2>GENE-Y<\\e2> (PAO) to produce spermidine and <e1>CHEMICAL<\\e1>  respectively","sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine  respectively"}
{"PMID":12141946,"re_id":8,"annotated sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (<e2>PAO<\\e2>  to produce spermidine and <e1>putrescine<\\e1>  respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"putrescine","object":"PAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (<e2>GENE-Y<\\e2>  to produce spermidine and <e1>CHEMICAL<\\e1>  respectively","sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO  to produce spermidine and putrescine  respectively"}
{"PMID":12141946,"re_id":9,"annotated sentence":"During polyamine catabolism, <e1>spermine<\\e1> and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (<e2>SSAT<\\e2>  and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"spermine","object":"SSAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During polyamine catabolism, <e1>CHEMICAL<\\e1> and spermidine are first acetylated by spermidine\/CHEMICAL N(1)-acetyltransferase (<e2>GENE-Y<\\e2>  and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively","sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT  and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively"}
{"PMID":12141946,"re_id":10,"annotated sentence":"During polyamine catabolism, <e1>spermine<\\e1> and spermidine are first acetylated by <e2>spermidine\/spermine N(1)-acetyltransferase<\\e2> (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"spermine","object":"spermidine\/spermine N(1)-acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During polyamine catabolism, <e1>CHEMICAL<\\e1> and spermidine are first acetylated by <e2>spermidine\/CHEMICAL N(1)-acetyltransferase<\\e2> (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively","sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively"}
{"PMID":12141946,"re_id":11,"annotated sentence":"In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves <e1>spermine<\\e1> in the absence of prior acetylation by <e2>SSAT<\\e2>  A BLAST search using maize PAO sequences identified homologous mammalian cDNAs derived from human hepatoma and mouse mammary carcinoma: the encoded proteins differed by 20 amino acids","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"spermine","object":"SSAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves <e1>CHEMICAL<\\e1> in the absence of prior acetylation by <e2>GENE-Y<\\e2>  A BLAST search using maize PAO sequences identified homologous mammalian cDNAs derived from human hepatoma and mouse mammary carcinoma: the encoded proteins differed by 20 amino acids","sentence":"In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves spermine in the absence of prior acetylation by SSAT  A BLAST search using maize PAO sequences identified homologous mammalian cDNAs derived from human hepatoma and mouse mammary carcinoma: the encoded proteins differed by 20 amino acids"}
{"PMID":12141946,"re_id":12,"annotated sentence":"During polyamine catabolism, spermine and <e1>spermidine<\\e1> are first acetylated by spermidine\/spermine N(1)-acetyltransferase (<e2>SSAT<\\e2>  and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"spermidine","object":"SSAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During polyamine catabolism, spermine and <e1>CHEMICAL<\\e1> are first acetylated by CHEMICAL\/spermine N(1)-acetyltransferase (<e2>GENE-Y<\\e2>  and subsequently oxidized by polyamine oxidase (PAO) to produce CHEMICAL and putrescine, respectively","sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT  and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively"}
{"PMID":12141946,"re_id":13,"annotated sentence":"During polyamine catabolism, spermine and <e1>spermidine<\\e1> are first acetylated by <e2>spermidine\/spermine N(1)-acetyltransferase<\\e2> (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"spermidine","object":"spermidine\/spermine N(1)-acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During polyamine catabolism, spermine and <e1>CHEMICAL<\\e1> are first acetylated by <e2>CHEMICAL\/spermine N(1)-acetyltransferase<\\e2> (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce CHEMICAL and putrescine, respectively","sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively"}
{"PMID":12141946,"re_id":14,"annotated sentence":"During <e1>polyamine<\\e1> catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (<e2>SSAT<\\e2>  and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"polyamine","object":"SSAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During <e1>CHEMICAL<\\e1> catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (<e2>GENE-Y<\\e2>  and subsequently oxidized by CHEMICAL oxidase (PAO) to produce spermidine and putrescine, respectively","sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT  and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively"}
{"PMID":12141946,"re_id":15,"annotated sentence":"During <e1>polyamine<\\e1> catabolism, spermine and spermidine are first acetylated by <e2>spermidine\/spermine N(1)-acetyltransferase<\\e2> (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"polyamine","object":"spermidine\/spermine N(1)-acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"During <e1>CHEMICAL<\\e1> catabolism, spermine and spermidine are first acetylated by <e2>GENE-Y<\\e2> (SSAT) and subsequently oxidized by CHEMICAL oxidase (PAO) to produce spermidine and putrescine, respectively","sentence":"During polyamine catabolism, spermine and spermidine are first acetylated by spermidine\/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively"}
{"PMID":12141946,"re_id":16,"annotated sentence":"Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified <e2>oxidase<\\e2> strongly favoured <e1>spermine<\\e1> over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"spermine","object":"oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Substrate specificity using lysates of GENE-N-transfected HEK-293 cells revealed that the newly identified <e2>GENE-N<\\e2> strongly favoured <e1>CHEMICAL<\\e1> over N (1)-acetylCHEMICAL and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylCHEMICAL","sentence":"Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine"}
{"PMID":12141946,"re_id":17,"annotated sentence":"Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified <e2>oxidase<\\e2> strongly favoured spermine over <e1>N (1)-acetylspermine<\\e1> and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"N (1)-acetylspermine","object":"oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Substrate specificity using lysates of GENE-N-transfected HEK-293 cells revealed that the newly identified <e2>GENE-N<\\e2> strongly favoured spermine over <e1>CHEMICAL<\\e1> and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine","sentence":"Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine"}
{"PMID":12141946,"re_id":18,"annotated sentence":"Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred <e2>PAO<\\e2> substrate, <e1>N (1), N (12)-diacetylspermine<\\e1>  The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"N (1), N (12)-diacetylspermine","object":"PAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred <e2>GENE-Y<\\e2> substrate, <e1>CHEMICAL<\\e1>  The GENE-Y inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported GENE-Y substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction","sentence":"Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine  The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction"}
{"PMID":12141946,"re_id":19,"annotated sentence":"The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported <e2>PAO<\\e2> substrate, <e1>N (1)-( n -octanesulphonyl)spermine<\\e1>  potently inhibited the reaction","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"N (1)-( n -octanesulphonyl)spermine","object":"PAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The GENE-Y inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported <e2>GENE-Y<\\e2> substrate, <e1>CHEMICAL<\\e1>  potently inhibited the reaction","sentence":"The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine  potently inhibited the reaction"}
{"PMID":12165285,"re_id":2,"annotated sentence":"In no other subject any activation of platelets by GP IIb\/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb\/IIIa inhibitors on basal or <e1>ADP<\\e1> stimulated <e2>CD62P<\\e2> expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ADP","object":"CD62P","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In no other subject any activation of platelets by GP IIb\/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb\/IIIa inhibitors on basal or <e1>CHEMICAL<\\e1> stimulated <e2>GENE-Y<\\e2> expression","sentence":"In no other subject any activation of platelets by GP IIb\/IIIa inhibitors was observed and there were no statistically significant differences between HPA-1 genotypes with respect to the effects of GP IIb\/IIIa inhibitors on basal or ADP stimulated CD62P expression"}
{"PMID":12165285,"re_id":3,"annotated sentence":"Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or <e1>ADP<\\e1> induced <e2>CD62P<\\e2> expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ADP","object":"CD62P","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> expression","sentence":"Although a significant platelet hyperreactivity was observed in the patients, the HPA-1 genotype did not influence basal or ADP induced CD62P expression"}
{"PMID":12167474,"re_id":2,"annotated sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases<\\e2> to <e1>pyruvate<\\e1>  ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyruvate","object":"beta-lyases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>GENE-N<\\e2> to <e1>CHEMICAL<\\e1>  ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate beta-lyases to pyruvate  ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins"}
{"PMID":12167474,"re_id":3,"annotated sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases<\\e2> to pyruvate, <e1>ammonia<\\e1>  and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"ammonia","object":"beta-lyases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>GENE-N<\\e2> to pyruvate, <e1>CHEMICAL<\\e1>  and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate beta-lyases to pyruvate, ammonia  and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins"}
{"PMID":12167474,"re_id":4,"annotated sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases<\\e2> to pyruvate, ammonia, and an <e1>alpha-chloroenethiolate<\\e1> (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"alpha-chloroenethiolate","object":"beta-lyases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>GENE-N<\\e2> to pyruvate, ammonia, and an <e1>CHEMICAL<\\e1> (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate beta-lyases to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins"}
{"PMID":12167474,"re_id":5,"annotated sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases<\\e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with <e1>DCVC<\\e1>  or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"DCVC","object":"beta-lyases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>GENE-N<\\e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with <e1>CHEMICAL<\\e1>  or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate beta-lyases to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC  or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins"}
{"PMID":12167474,"re_id":6,"annotated sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases<\\e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an <e1>alpha-difluoroalkylthiolate<\\e1> (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"alpha-difluoroalkylthiolate","object":"beta-lyases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>GENE-N<\\e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an <e1>CHEMICAL<\\e1> (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate beta-lyases to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins"}
{"PMID":12167474,"re_id":7,"annotated sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>beta-lyases<\\e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with <e1>TFEC<\\e1>  that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"TFEC","object":"beta-lyases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate <e2>GENE-N<\\e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with <e1>CHEMICAL<\\e1>  that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate beta-lyases to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC  that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins"}
{"PMID":12167474,"re_id":8,"annotated sentence":"Most halogenated <e1>cysteine S-conjugates<\\e1> are metabolized by cysteine S-conjugate <e2>beta-lyases<\\e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cysteine S-conjugates","object":"beta-lyases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Most halogenated <e1>CHEMICAL<\\e1> are metabolized by cysteine S-conjugate <e2>GENE-N<\\e2> to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins","sentence":"Most halogenated cysteine S-conjugates are metabolized by cysteine S-conjugate beta-lyases to pyruvate, ammonia, and an alpha-chloroenethiolate (with DCVC) or an alpha-difluoroalkylthiolate (with TFEC) that may eliminate halide to give a thioacyl halide, which reacts with epsilon-amino groups of lysine residues in proteins"}
{"PMID":12175785,"re_id":0,"annotated sentence":"The juvenile visceral steatosis (jvs) mouse, having a mutation in the <e1>carnitine<\\e1> transporter gene <e2>Octn2<\\e2>  is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"carnitine","object":"Octn2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The juvenile visceral steatosis (jvs) mouse, having a mutation in the <e1>CHEMICAL<\\e1> transporter gene <e2>GENE-Y<\\e2>  is a model of primary systemic CHEMICAL deficiency in humans (SCD, OMIM 212140)","sentence":"The juvenile visceral steatosis (jvs) mouse, having a mutation in the carnitine transporter gene Octn2  is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140)"}
{"PMID":12181285,"re_id":3,"annotated sentence":"The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the <e2>OCT3<\\e2> inhibitors cyanine 863, <e1>oestradiol<\\e1> and corticosterone","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"oestradiol","object":"OCT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the <e2>GENE-Y<\\e2> inhibitors cyanine 863, <e1>CHEMICAL<\\e1> and corticosterone","sentence":"The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the OCT3 inhibitors cyanine 863, oestradiol and corticosterone"}
{"PMID":12181285,"re_id":4,"annotated sentence":"The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the <e2>OCT3<\\e2> inhibitors cyanine 863, oestradiol and <e1>corticosterone<\\e1>  In contrast, cyanine 863 enhanced the radioactive outflow from cultures preloaded with [3H]-NA","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"corticosterone","object":"OCT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the <e2>GENE-Y<\\e2> inhibitors cyanine 863, oestradiol and <e1>CHEMICAL<\\e1>  In contrast, cyanine 863 enhanced the radioactive outflow from cultures preloaded with [3H]-NA","sentence":"The ensuing radioactive outflow from these cultures was enhanced by desipramine and reserpine, but reduced (in the presence of desipramine) by the OCT3 inhibitors cyanine 863, oestradiol and corticosterone  In contrast, cyanine 863 enhanced the radioactive outflow from cultures preloaded with [3H]-NA"}
{"PMID":12181285,"re_id":5,"annotated sentence":"However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of <e1>MPP+<\\e1>  indicating the <e2>NAT<\\e2> and not an OCT as their primary site of action","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"MPP+","object":"NAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of <e1>CHEMICAL<\\e1>  indicating the <e2>GENE-Y<\\e2> and not an OCT as their primary site of action","sentence":"However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+  indicating the NAT and not an OCT as their primary site of action"}
{"PMID":12181285,"re_id":6,"annotated sentence":"Our observations indicate an <e2>OCT<\\e2> mediated transmembrane transport of <e1>[3H]-MPP+<\\e1>  Amongst the three OCTs expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [3H]-MPP+ release.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"[3H]-MPP+","object":"OCT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our observations indicate an <e2>GENE-N<\\e2> mediated transmembrane transport of <e1>CHEMICAL<\\e1>  Amongst the three GENE-Ns expressed in the SCG, GENE-N3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of CHEMICAL release.","sentence":"Our observations indicate an OCT mediated transmembrane transport of [3H]-MPP+  Amongst the three OCTs expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [3H]-MPP+ release."}
{"PMID":12181285,"re_id":7,"annotated sentence":"Amongst the three <e2>OCTs<\\e2> expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of <e1>[3H]-MPP+<\\e1> release.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"[3H]-MPP+","object":"OCTs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Amongst the three <e2>GENE-N<\\e2> expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of <e1>CHEMICAL<\\e1> release.","sentence":"Amongst the three OCTs expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [3H]-MPP+ release."}
{"PMID":12181285,"re_id":8,"annotated sentence":"Amongst the three OCTs expressed in the SCG, <e2>OCT3<\\e2> best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of <e1>[3H]-MPP+<\\e1> release.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"[3H]-MPP+","object":"OCT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Amongst the three OCTs expressed in the SCG, <e2>GENE-Y<\\e2> best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of <e1>CHEMICAL<\\e1> release.","sentence":"Amongst the three OCTs expressed in the SCG, OCT3 best fits the profile of substrates and antagonists that cause trans-stimulation and trans-inhibition, respectively, of [3H]-MPP+ release."}
{"PMID":12181285,"re_id":9,"annotated sentence":"Reuptake of extracellular <e1>noradrenaline<\\e1> (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the <e2>noradrenaline transporter<\\e2> (NAT, uptake 1)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"noradrenaline","object":"noradrenaline transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reuptake of extracellular <e1>CHEMICAL<\\e1> (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the <e2>CHEMICAL transporter<\\e2> (NAT, uptake 1)","sentence":"Reuptake of extracellular noradrenaline (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (NAT, uptake 1)"}
{"PMID":12181285,"re_id":10,"annotated sentence":"Reuptake of extracellular <e1>noradrenaline<\\e1> (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (<e2>NAT<\\e2>  uptake 1)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"noradrenaline","object":"NAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reuptake of extracellular <e1>CHEMICAL<\\e1> (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the CHEMICAL transporter (<e2>GENE-Y<\\e2>  uptake 1)","sentence":"Reuptake of extracellular noradrenaline (NA) into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (NAT  uptake 1)"}
{"PMID":12181285,"re_id":11,"annotated sentence":"Reuptake of extracellular noradrenaline (<e1>NA<\\e1>  into superior cervical ganglion (SCG) neurones is mediated by means of the <e2>noradrenaline transporter<\\e2> (NAT, uptake 1)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":null,"object":"noradrenaline transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reuptake of extracellular noradrenaline (<e1>NA<\\e1>  into superior cervical ganglion (SCG) neurones is mediated by means of the <e2>GENE-Y<\\e2> (NAT, uptake 1)","sentence":"Reuptake of extracellular noradrenaline (NA  into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (NAT, uptake 1)"}
{"PMID":12181285,"re_id":12,"annotated sentence":"Reuptake of extracellular noradrenaline (<e1>NA<\\e1>  into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (<e2>NAT<\\e2>  uptake 1)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":null,"object":"NAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reuptake of extracellular noradrenaline (<e1>NA<\\e1>  into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (<e2>GENE-Y<\\e2>  uptake 1)","sentence":"Reuptake of extracellular noradrenaline (NA  into superior cervical ganglion (SCG) neurones is mediated by means of the noradrenaline transporter (NAT  uptake 1)"}
{"PMID":12181285,"re_id":13,"annotated sentence":"The outflow of <e1>[3H]-MPP+<\\e1> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for <e2>OCT<\\e2> related transmembrane transporters","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"[3H]-MPP+","object":"OCT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The outflow of <e1>CHEMICAL<\\e1> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for <e2>GENE-N<\\e2> related transmembrane transporters","sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT related transmembrane transporters"}
{"PMID":12181285,"re_id":14,"annotated sentence":"The outflow of <e1>[3H]-MPP+<\\e1> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related <e2>transmembrane transporters<\\e2>  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"[3H]-MPP+","object":"transmembrane transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The outflow of <e1>CHEMICAL<\\e1> was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related <e2>GENE-N<\\e2>  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action","sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related transmembrane transporters  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action"}
{"PMID":12181285,"re_id":15,"annotated sentence":"The outflow of [3H]-MPP+ was significantly enhanced by <e1>MPP+<\\e1>  guanidine, choline and amantadine as potential substrates for <e2>OCT<\\e2> related transmembrane transporters","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"MPP+","object":"OCT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The outflow of [3H]-CHEMICAL was significantly enhanced by <e1>CHEMICAL<\\e1>  guanidine, choline and amantadine as potential substrates for <e2>GENE-N<\\e2> related transmembrane transporters","sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+  guanidine, choline and amantadine as potential substrates for OCT related transmembrane transporters"}
{"PMID":12181285,"re_id":16,"annotated sentence":"The outflow of [3H]-MPP+ was significantly enhanced by <e1>MPP+<\\e1>  guanidine, choline and amantadine as potential substrates for OCT-related <e2>transmembrane transporters<\\e2>  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"MPP+","object":"transmembrane transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The outflow of [3H]-CHEMICAL was significantly enhanced by <e1>CHEMICAL<\\e1>  guanidine, choline and amantadine as potential substrates for OCT-related <e2>GENE-N<\\e2>  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of CHEMICAL, indicating the NAT and not an OCT as their primary site of action","sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+  guanidine, choline and amantadine as potential substrates for OCT-related transmembrane transporters  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action"}
{"PMID":12181285,"re_id":17,"annotated sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, <e1>guanidine<\\e1>  choline and amantadine as potential substrates for <e2>OCT<\\e2> related transmembrane transporters","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"guanidine","object":"OCT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, <e1>CHEMICAL<\\e1>  choline and amantadine as potential substrates for <e2>GENE-N<\\e2> related transmembrane transporters","sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine  choline and amantadine as potential substrates for OCT related transmembrane transporters"}
{"PMID":12181285,"re_id":18,"annotated sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, <e1>guanidine<\\e1>  choline and amantadine as potential substrates for OCT-related <e2>transmembrane transporters<\\e2>  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"guanidine","object":"transmembrane transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, <e1>CHEMICAL<\\e1>  choline and amantadine as potential substrates for OCT-related <e2>GENE-N<\\e2>  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action","sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine  choline and amantadine as potential substrates for OCT-related transmembrane transporters  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action"}
{"PMID":12181285,"re_id":19,"annotated sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, <e1>choline<\\e1> and amantadine as potential substrates for <e2>OCT<\\e2> related transmembrane transporters","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"choline","object":"OCT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, <e1>CHEMICAL<\\e1> and amantadine as potential substrates for <e2>GENE-N<\\e2> related transmembrane transporters","sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT related transmembrane transporters"}
{"PMID":12181285,"re_id":20,"annotated sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, <e1>choline<\\e1> and amantadine as potential substrates for OCT-related <e2>transmembrane transporters<\\e2>  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"choline","object":"transmembrane transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, <e1>CHEMICAL<\\e1> and amantadine as potential substrates for OCT-related <e2>GENE-N<\\e2>  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action","sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related transmembrane transporters  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action"}
{"PMID":12181285,"re_id":21,"annotated sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and <e1>amantadine<\\e1> as potential substrates for <e2>OCT<\\e2> related transmembrane transporters","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"amantadine","object":"OCT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and <e1>CHEMICAL<\\e1> as potential substrates for <e2>GENE-N<\\e2> related transmembrane transporters","sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT related transmembrane transporters"}
{"PMID":12181285,"re_id":22,"annotated sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and <e1>amantadine<\\e1> as potential substrates for OCT-related <e2>transmembrane transporters<\\e2>  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"amantadine","object":"transmembrane transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and <e1>CHEMICAL<\\e1> as potential substrates for OCT-related <e2>GENE-N<\\e2>  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action","sentence":"The outflow of [3H]-MPP+ was significantly enhanced by MPP+, guanidine, choline and amantadine as potential substrates for OCT-related transmembrane transporters  However, desipramine at a low concentration essentially blocked the radioactive outflow induced by all of these substances with the exception of MPP+, indicating the NAT and not an OCT as their primary site of action"}
{"PMID":12200198,"re_id":0,"annotated sentence":"Long-term administration of <e1>propargylamines<\\e1> to rats increased the activities of antioxidative enzymes <e2>superoxide dismutase<\\e2> (SOD) and catalase in the brain regions containing dopamine neurons","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"propargylamines","object":"superoxide dismutase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Long-term administration of <e1>CHEMICAL<\\e1> to rats increased the activities of antioxidative enzymes <e2>GENE-N<\\e2> (SOD) and catalase in the brain regions containing dopamine neurons","sentence":"Long-term administration of propargylamines to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and catalase in the brain regions containing dopamine neurons"}
{"PMID":12200198,"re_id":1,"annotated sentence":"Long-term administration of <e1>propargylamines<\\e1> to rats increased the activities of antioxidative enzymes superoxide dismutase (<e2>SOD<\\e2>  and catalase in the brain regions containing dopamine neurons","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"propargylamines","object":"SOD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Long-term administration of <e1>CHEMICAL<\\e1> to rats increased the activities of antioxidative enzymes superoxide dismutase (<e2>GENE-N<\\e2>  and catalase in the brain regions containing dopamine neurons","sentence":"Long-term administration of propargylamines to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD  and catalase in the brain regions containing dopamine neurons"}
{"PMID":12200198,"re_id":2,"annotated sentence":"Long-term administration of <e1>propargylamines<\\e1> to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and <e2>catalase<\\e2> in the brain regions containing dopamine neurons","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"propargylamines","object":"catalase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Long-term administration of <e1>CHEMICAL<\\e1> to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and <e2>GENE-Y<\\e2> in the brain regions containing dopamine neurons","sentence":"Long-term administration of propargylamines to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and catalase in the brain regions containing dopamine neurons"}
{"PMID":12200198,"re_id":3,"annotated sentence":"<e1>Rasagiline<\\e1> prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic <e2>Bcl-2<\\e2> and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Rasagiline","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic <e2>GENE-Y<\\e2> and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF)","sentence":"Rasagiline prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF)"}
{"PMID":12200198,"re_id":4,"annotated sentence":"<e1>Rasagiline<\\e1> prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a <e2>neurotrophic factor<\\e2>  glial cell line-derived neurotrophic factor (GDNF)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Rasagiline","object":"neurotrophic factor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a <e2>GENE-N<\\e2>  glial cell line-derived GENE-N (GDNF)","sentence":"Rasagiline prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor  glial cell line-derived neurotrophic factor (GDNF)"}
{"PMID":12200198,"re_id":5,"annotated sentence":"<e1>Rasagiline<\\e1> prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, <e2>glial cell line-derived neurotrophic factor<\\e2> (GDNF)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Rasagiline","object":"glial cell line-derived neurotrophic factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, <e2>GENE-Y<\\e2> (GDNF)","sentence":"Rasagiline prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF)"}
{"PMID":12200198,"re_id":6,"annotated sentence":"<e1>Rasagiline<\\e1> prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (<e2>GDNF<\\e2> ","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Rasagiline","object":"GDNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (<e2>GENE-Y<\\e2> ","sentence":"Rasagiline prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF "}
{"PMID":12200198,"re_id":7,"annotated sentence":"An inhibitor of <e2>type B monoamine oxidase<\\e2> (MAO-B), <e1>(-)deprenyl<\\e1> (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"(-)deprenyl","object":"type B monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"An inhibitor of <e2>GENE-Y<\\e2> (MAO-B), <e1>CHEMICAL<\\e1> (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it","sentence":"An inhibitor of type B monoamine oxidase (MAO-B), (-)deprenyl (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it"}
{"PMID":12200198,"re_id":8,"annotated sentence":"An inhibitor of type B monoamine oxidase (<e2>MAO-B<\\e2> , <e1>(-)deprenyl<\\e1> (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"(-)deprenyl","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"An inhibitor of type B monoamine oxidase (<e2>GENE-Y<\\e2> , <e1>CHEMICAL<\\e1> (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it","sentence":"An inhibitor of type B monoamine oxidase (MAO-B , (-)deprenyl (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it"}
{"PMID":12200198,"re_id":9,"annotated sentence":"An inhibitor of <e2>type B monoamine oxidase<\\e2> (MAO-B), (-)deprenyl (<e1>selegiline<\\e1> , was reported to have neuroprotective activity, but clinical trials failed to confirm it","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"selegiline","object":"type B monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"An inhibitor of <e2>GENE-Y<\\e2> (MAO-B), (-)deprenyl (<e1>CHEMICAL<\\e1> , was reported to have neuroprotective activity, but clinical trials failed to confirm it","sentence":"An inhibitor of type B monoamine oxidase (MAO-B), (-)deprenyl (selegiline , was reported to have neuroprotective activity, but clinical trials failed to confirm it"}
{"PMID":12200198,"re_id":10,"annotated sentence":"An inhibitor of type B monoamine oxidase (<e2>MAO-B<\\e2> , (-)deprenyl (<e1>selegiline<\\e1> , was reported to have neuroprotective activity, but clinical trials failed to confirm it","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"selegiline","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"An inhibitor of type B monoamine oxidase (<e2>GENE-Y<\\e2> , (-)deprenyl (<e1>CHEMICAL<\\e1> , was reported to have neuroprotective activity, but clinical trials failed to confirm it","sentence":"An inhibitor of type B monoamine oxidase (MAO-B , (-)deprenyl (selegiline , was reported to have neuroprotective activity, but clinical trials failed to confirm it"}
{"PMID":12227806,"re_id":0,"annotated sentence":"A streamlined and high-yielding synthesis of <e1>aprepitant<\\e1> (1), a potent <e2>substance P (SP) receptor<\\e2> antagonist, is described","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"aprepitant","object":"substance P (SP) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A streamlined and high-yielding synthesis of <e1>CHEMICAL<\\e1> (1), a potent <e2>GENE-Y<\\e2> antagonist, is described","sentence":"A streamlined and high-yielding synthesis of aprepitant (1), a potent substance P (SP) receptor antagonist, is described"}
{"PMID":12227806,"re_id":1,"annotated sentence":"Practical asymmetric synthesis of <e1>aprepitant<\\e1>  a potent human <e2>NK-1 receptor<\\e2> antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"aprepitant","object":"NK-1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Practical asymmetric synthesis of <e1>CHEMICAL<\\e1>  a potent human <e2>GENE-Y<\\e2> antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction","sentence":"Practical asymmetric synthesis of aprepitant  a potent human NK-1 receptor antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction"}
{"PMID":12375053,"re_id":1,"annotated sentence":"Pentosan polysulfate <e1>sodium<\\e1> (PPS) has been shown to exert antitumor activity by antagonizing the binding of <e2>bFGF<\\e2> to cell surface receptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"sodium","object":"bFGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pentosan polysulfate <e1>CHEMICAL<\\e1> (PPS) has been shown to exert antitumor activity by antagonizing the binding of <e2>GENE-Y<\\e2> to cell surface receptors","sentence":"Pentosan polysulfate sodium (PPS) has been shown to exert antitumor activity by antagonizing the binding of bFGF to cell surface receptors"}
{"PMID":12388412,"re_id":1,"annotated sentence":"These findings suggest that <e2>RhBG<\\e2> and RhCG may play important and cell-specific roles in <e1>ammonium<\\e1> transport and signaling in these regions of the kidney.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ammonium","object":"RhBG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings suggest that <e2>GENE-Y<\\e2> and RhCG may play important and cell-specific roles in <e1>CHEMICAL<\\e1> transport and signaling in these regions of the kidney.","sentence":"These findings suggest that RhBG and RhCG may play important and cell-specific roles in ammonium transport and signaling in these regions of the kidney."}
{"PMID":12388412,"re_id":2,"annotated sentence":"These findings suggest that RhBG and <e2>RhCG<\\e2> may play important and cell-specific roles in <e1>ammonium<\\e1> transport and signaling in these regions of the kidney.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ammonium","object":"RhCG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings suggest that RhBG and <e2>GENE-Y<\\e2> may play important and cell-specific roles in <e1>CHEMICAL<\\e1> transport and signaling in these regions of the kidney.","sentence":"These findings suggest that RhBG and RhCG may play important and cell-specific roles in ammonium transport and signaling in these regions of the kidney."}
{"PMID":12414329,"re_id":0,"annotated sentence":"This approach is validated by the clinical efficacy and safety of <e1>sildenafil<\\e1>  the pioneering drug for selective <e2>PDE5<\\e2> inhibitor therapy for ED","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sildenafil","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This approach is validated by the clinical efficacy and safety of <e1>CHEMICAL<\\e1>  the pioneering drug for selective <e2>GENE-Y<\\e2> inhibitor therapy for ED","sentence":"This approach is validated by the clinical efficacy and safety of sildenafil  the pioneering drug for selective PDE5 inhibitor therapy for ED"}
{"PMID":12414329,"re_id":1,"annotated sentence":"<e1>Sildenafil<\\e1> exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant <e2>PDE<\\e2> in the phototransduction cascade in rods","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sildenafil","object":"PDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> exhibits inhibitory potency against GENE-N5 and a 10-fold lower dose-related inhibitory potency against rod outer segment GENE-N6, the predominant <e2>GENE-N<\\e2> in the phototransduction cascade in rods","sentence":"Sildenafil exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods"}
{"PMID":12414329,"re_id":2,"annotated sentence":"<e1>Sildenafil<\\e1> exhibits inhibitory potency against <e2>PDE5<\\e2> and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sildenafil","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> exhibits inhibitory potency against <e2>GENE-Y<\\e2> and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods","sentence":"Sildenafil exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6, the predominant PDE in the phototransduction cascade in rods"}
{"PMID":12414329,"re_id":3,"annotated sentence":"<e1>Sildenafil<\\e1> exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment <e2>PDE6<\\e2>  the predominant PDE in the phototransduction cascade in rods","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sildenafil","object":"PDE6","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment <e2>GENE-N<\\e2>  the predominant PDE in the phototransduction cascade in rods","sentence":"Sildenafil exhibits inhibitory potency against PDE5 and a 10-fold lower dose-related inhibitory potency against rod outer segment PDE6  the predominant PDE in the phototransduction cascade in rods"}
{"PMID":12414329,"re_id":4,"annotated sentence":"As free <e1>sildenafil<\\e1> plasma concentrations approach concentrations sufficient to inhibit retinal <e2>PDE6<\\e2>  usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sildenafil","object":"PDE6","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"As free <e1>CHEMICAL<\\e1> plasma concentrations approach concentrations sufficient to inhibit retinal <e2>GENE-N<\\e2>  usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently","sentence":"As free sildenafil plasma concentrations approach concentrations sufficient to inhibit retinal PDE6  usually at higher therapeutic doses, transient, reversible visual adverse events can occur, albeit infrequently"}
{"PMID":12414329,"re_id":5,"annotated sentence":"Selective inhibition of <e2>PDE5<\\e2> is a rational therapeutic approach in ED, as proved by the clinical success of <e1>sildenafil<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sildenafil","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Selective inhibition of <e2>GENE-Y<\\e2> is a rational therapeutic approach in ED, as proved by the clinical success of <e1>CHEMICAL<\\e1> ","sentence":"Selective inhibition of PDE5 is a rational therapeutic approach in ED, as proved by the clinical success of sildenafil "}
{"PMID":12414329,"re_id":6,"annotated sentence":"Therefore, in men with ED, elevation of cGMP in corpus cavernosal tissue via selective inhibition of <e1>cGMP<\\e1> specific <e2>PDE5<\\e2> is a means of improving erectile function at minimal risk of adverse events","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cGMP","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Therefore, in men with ED, elevation of CHEMICAL in corpus cavernosal tissue via selective inhibition of <e1>CHEMICAL<\\e1> specific <e2>GENE-Y<\\e2> is a means of improving erectile function at minimal risk of adverse events","sentence":"Therefore, in men with ED, elevation of cGMP in corpus cavernosal tissue via selective inhibition of cGMP specific PDE5 is a means of improving erectile function at minimal risk of adverse events"}
{"PMID":12414329,"re_id":7,"annotated sentence":"<e2>PDE5<\\e2> is the predominant PDE in the corpus cavernosum, and <e1>cGMP<\\e1> is its primary substrate","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cGMP","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> is the predominant PDE in the corpus cavernosum, and <e1>CHEMICAL<\\e1> is its primary substrate","sentence":"PDE5 is the predominant PDE in the corpus cavernosum, and cGMP is its primary substrate"}
{"PMID":12414329,"re_id":8,"annotated sentence":"PDE5 is the predominant <e2>PDE<\\e2> in the corpus cavernosum, and <e1>cGMP<\\e1> is its primary substrate","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cGMP","object":"PDE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"GENE-N5 is the predominant <e2>GENE-N<\\e2> in the corpus cavernosum, and <e1>CHEMICAL<\\e1> is its primary substrate","sentence":"PDE5 is the predominant PDE in the corpus cavernosum, and cGMP is its primary substrate"}
{"PMID":12421359,"re_id":10,"annotated sentence":"However, when coapplied with 10 micro m GABA, <e1>ivermectin<\\e1> potentiated the GABA-evoked current of the <e2>GAB-1<\\e2> HG1A receptor, but attenuated the GABA response of the GAB-1\/HG1E receptor","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"ivermectin","object":"GAB-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, when coapplied with 10 micro m GABA, <e1>CHEMICAL<\\e1> potentiated the GABA-evoked current of the <e2>GENE-Y<\\e2> HG1A receptor, but attenuated the GABA response of the GENE-Y\/HG1E receptor","sentence":"However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1 HG1A receptor, but attenuated the GABA response of the GAB-1\/HG1E receptor"}
{"PMID":12421359,"re_id":11,"annotated sentence":"However, when coapplied with 10 micro m GABA, <e1>ivermectin<\\e1> potentiated the GABA-evoked current of the GAB-1\/<e2>HG1A<\\e2> receptor, but attenuated the GABA response of the GAB-1\/HG1E receptor","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"ivermectin","object":"HG1A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, when coapplied with 10 micro m GABA, <e1>CHEMICAL<\\e1> potentiated the GABA-evoked current of the GAB-1\/<e2>GENE-Y<\\e2> receptor, but attenuated the GABA response of the GAB-1\/HG1E receptor","sentence":"However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1\/HG1A receptor, but attenuated the GABA response of the GAB-1\/HG1E receptor"}
{"PMID":12421359,"re_id":12,"annotated sentence":"However, when coapplied with 10 micro m GABA, <e1>ivermectin<\\e1> potentiated the GABA-evoked current of the GAB-1\/HG1A receptor, but attenuated the GABA response of the <e2>GAB-1<\\e2> HG1E receptor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"ivermectin","object":"GAB-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, when coapplied with 10 micro m GABA, <e1>CHEMICAL<\\e1> potentiated the GABA-evoked current of the GENE-Y\/HG1A receptor, but attenuated the GABA response of the <e2>GENE-Y<\\e2> HG1E receptor","sentence":"However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1\/HG1A receptor, but attenuated the GABA response of the GAB-1 HG1E receptor"}
{"PMID":12421359,"re_id":13,"annotated sentence":"However, when coapplied with 10 micro m GABA, <e1>ivermectin<\\e1> potentiated the GABA-evoked current of the GAB-1\/HG1A receptor, but attenuated the GABA response of the GAB-1\/<e2>HG1E<\\e2> receptor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"ivermectin","object":"HG1E","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, when coapplied with 10 micro m GABA, <e1>CHEMICAL<\\e1> potentiated the GABA-evoked current of the GAB-1\/HG1A receptor, but attenuated the GABA response of the GAB-1\/<e2>GENE-Y<\\e2> receptor","sentence":"However, when coapplied with 10 micro m GABA, ivermectin potentiated the GABA-evoked current of the GAB-1\/HG1A receptor, but attenuated the GABA response of the GAB-1\/HG1E receptor"}
{"PMID":12438517,"re_id":5,"annotated sentence":"<e1>Yohimbine<\\e1> is a potent and selective <e2>alpha2- versus alpha1-adrenoceptor<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Yohimbine","object":"alpha2- versus alpha1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a potent and selective <e2>GENE-N<\\e2> antagonist","sentence":"Yohimbine is a potent and selective alpha2- versus alpha1-adrenoceptor antagonist"}
{"PMID":12470615,"re_id":6,"annotated sentence":"These results demonstrate that <e1>imidazoquinoline<\\e1> molecules directly induce pDC maturation as determined by <e2>cytokine<\\e2> induction, CCR7 and co-stimulatory marker expression and prolonging viability.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"imidazoquinoline","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results demonstrate that <e1>CHEMICAL<\\e1> molecules directly induce pDC maturation as determined by <e2>GENE-N<\\e2> induction, CCR7 and co-stimulatory marker expression and prolonging viability.","sentence":"These results demonstrate that imidazoquinoline molecules directly induce pDC maturation as determined by cytokine induction, CCR7 and co-stimulatory marker expression and prolonging viability."}
{"PMID":12470615,"re_id":7,"annotated sentence":"The immune response modifiers, <e1>imiquimod<\\e1> and resiquimod, are TLR7 agonists that induce <e2>type I interferon<\\e2> in numerous species, including humans","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"imiquimod","object":"type I interferon","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The immune response modifiers, <e1>CHEMICAL<\\e1> and resiquimod, are TLR7 agonists that induce <e2>GENE-N<\\e2> in numerous species, including humans","sentence":"The immune response modifiers, imiquimod and resiquimod, are TLR7 agonists that induce type I interferon in numerous species, including humans"}
{"PMID":12470615,"re_id":8,"annotated sentence":"Results indicate that <e1>imiquimod<\\e1> and resiquimod induce <e2>IFN-alpha<\\e2> and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"imiquimod","object":"IFN-alpha","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results indicate that <e1>CHEMICAL<\\e1> and resiquimod induce <e2>GENE-N<\\e2> and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood","sentence":"Results indicate that imiquimod and resiquimod induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood"}
{"PMID":12470615,"re_id":9,"annotated sentence":"Results indicate that <e1>imiquimod<\\e1> and resiquimod induce IFN-alpha and <e2>IFN-omega<\\e2> from purified pDC, and pDC are the principle IFN-producing cells in the blood","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"imiquimod","object":"IFN-omega","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results indicate that <e1>CHEMICAL<\\e1> and resiquimod induce IFN-alpha and <e2>GENE-N<\\e2> from purified pDC, and pDC are the principle IFN-producing cells in the blood","sentence":"Results indicate that imiquimod and resiquimod induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood"}
{"PMID":12470615,"re_id":10,"annotated sentence":"The immune response modifiers, imiquimod and <e1>resiquimod<\\e1>  are TLR7 agonists that induce <e2>type I interferon<\\e2> in numerous species, including humans","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"resiquimod","object":"type I interferon","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The immune response modifiers, imiquimod and <e1>CHEMICAL<\\e1>  are TLR7 agonists that induce <e2>GENE-N<\\e2> in numerous species, including humans","sentence":"The immune response modifiers, imiquimod and resiquimod  are TLR7 agonists that induce type I interferon in numerous species, including humans"}
{"PMID":12470615,"re_id":11,"annotated sentence":"<e1>Resiquimod<\\e1> stimulated pDC also produce a number of other <e2>cytokines<\\e2> including TNF-alpha and IP-10","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Resiquimod","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> stimulated pDC also produce a number of other <e2>GENE-N<\\e2> including TNF-alpha and IP-10","sentence":"Resiquimod stimulated pDC also produce a number of other cytokines including TNF-alpha and IP-10"}
{"PMID":12470615,"re_id":12,"annotated sentence":"<e1>Resiquimod<\\e1> stimulated pDC also produce a number of other cytokines including <e2>TNF-alpha<\\e2> and IP-10","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Resiquimod","object":"TNF-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> stimulated pDC also produce a number of other cytokines including <e2>GENE-Y<\\e2> and IP-10","sentence":"Resiquimod stimulated pDC also produce a number of other cytokines including TNF-alpha and IP-10"}
{"PMID":12470615,"re_id":13,"annotated sentence":"<e1>Resiquimod<\\e1> stimulated pDC also produce a number of other cytokines including TNF-alpha and <e2>IP-10<\\e2>  Resiquimod enhances co-stimulatory marker expression, CCR7 expression, and pDC viability","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Resiquimod","object":"IP-10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> stimulated pDC also produce a number of other cytokines including TNF-alpha and <e2>GENE-Y<\\e2>  CHEMICAL enhances co-stimulatory marker expression, CCR7 expression, and pDC viability","sentence":"Resiquimod stimulated pDC also produce a number of other cytokines including TNF-alpha and IP-10  Resiquimod enhances co-stimulatory marker expression, CCR7 expression, and pDC viability"}
{"PMID":12470615,"re_id":14,"annotated sentence":"<e1>Resiquimod<\\e1> enhances co-stimulatory marker expression, <e2>CCR7<\\e2> expression, and pDC viability","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Resiquimod","object":"CCR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> enhances co-stimulatory marker expression, <e2>GENE-Y<\\e2> expression, and pDC viability","sentence":"Resiquimod enhances co-stimulatory marker expression, CCR7 expression, and pDC viability"}
{"PMID":12470615,"re_id":15,"annotated sentence":"Plasmacytoid dendritic cells produce cytokines and mature in response to the <e2>TLR7<\\e2> agonists, imiquimod and <e1>resiquimod<\\e1>  The immune response modifiers, imiquimod and resiquimod, are TLR7 agonists that induce type I interferon in numerous species, including humans","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"resiquimod","object":"TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Plasmacytoid dendritic cells produce cytokines and mature in response to the <e2>GENE-Y<\\e2> agonists, imiquimod and <e1>CHEMICAL<\\e1>  The immune response modifiers, imiquimod and CHEMICAL, are GENE-Y agonists that induce type I interferon in numerous species, including humans","sentence":"Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod  The immune response modifiers, imiquimod and resiquimod, are TLR7 agonists that induce type I interferon in numerous species, including humans"}
{"PMID":12470615,"re_id":16,"annotated sentence":"Plasmacytoid dendritic cells produce cytokines and mature in response to the <e2>TLR7<\\e2> agonists, <e1>imiquimod<\\e1> and resiquimod","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"imiquimod","object":"TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Plasmacytoid dendritic cells produce cytokines and mature in response to the <e2>GENE-Y<\\e2> agonists, <e1>CHEMICAL<\\e1> and resiquimod","sentence":"Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod"}
{"PMID":12470615,"re_id":17,"annotated sentence":"The immune response modifiers, <e1>imiquimod<\\e1> and resiquimod, are <e2>TLR7<\\e2> agonists that induce type I interferon in numerous species, including humans","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"imiquimod","object":"TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The immune response modifiers, <e1>CHEMICAL<\\e1> and resiquimod, are <e2>GENE-Y<\\e2> agonists that induce type I interferon in numerous species, including humans","sentence":"The immune response modifiers, imiquimod and resiquimod, are TLR7 agonists that induce type I interferon in numerous species, including humans"}
{"PMID":12470615,"re_id":18,"annotated sentence":"Here, we characterize the activation of human pDC with the <e2>TLR7<\\e2> agonists <e1>imiquimod<\\e1> and resiquimod","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"imiquimod","object":"TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we characterize the activation of human pDC with the <e2>GENE-Y<\\e2> agonists <e1>CHEMICAL<\\e1> and resiquimod","sentence":"Here, we characterize the activation of human pDC with the TLR7 agonists imiquimod and resiquimod"}
{"PMID":12470615,"re_id":19,"annotated sentence":"Here, we characterize the activation of human pDC with the <e2>TLR7<\\e2> agonists imiquimod and <e1>resiquimod<\\e1>  Results indicate that imiquimod and resiquimod induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"resiquimod","object":"TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we characterize the activation of human pDC with the <e2>GENE-Y<\\e2> agonists imiquimod and <e1>CHEMICAL<\\e1>  Results indicate that imiquimod and CHEMICAL induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood","sentence":"Here, we characterize the activation of human pDC with the TLR7 agonists imiquimod and resiquimod  Results indicate that imiquimod and resiquimod induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood"}
{"PMID":12470615,"re_id":20,"annotated sentence":"The immune response modifiers, imiquimod and <e1>resiquimod<\\e1>  are <e2>TLR7<\\e2> agonists that induce type I interferon in numerous species, including humans","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"resiquimod","object":"TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The immune response modifiers, imiquimod and <e1>CHEMICAL<\\e1>  are <e2>GENE-Y<\\e2> agonists that induce type I interferon in numerous species, including humans","sentence":"The immune response modifiers, imiquimod and resiquimod  are TLR7 agonists that induce type I interferon in numerous species, including humans"}
{"PMID":12472888,"re_id":1,"annotated sentence":"none","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"H2O2","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":12472888,"re_id":2,"annotated sentence":"Pre-treatment with arsenite increased <e2>protein kinase B<\\e2> (Akt) and extracellular signal regulated kinase 1\/2 (ERK1\/2) phosphorylation after <e1>H2O2<\\e1>  However, while Akt phosphorylation was prevented by CHX, Erk1\/2 phosphorylation was further enhanced by CHX","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"H2O2","object":"protein kinase B","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pre-treatment with arsenite increased <e2>GENE-N<\\e2> (Akt) and extracellular signal regulated kinase 1\/2 (ERK1\/2) phosphorylation after <e1>CHEMICAL<\\e1>  However, while Akt phosphorylation was prevented by CHX, Erk1\/2 phosphorylation was further enhanced by CHX","sentence":"Pre-treatment with arsenite increased protein kinase B (Akt) and extracellular signal regulated kinase 1\/2 (ERK1\/2) phosphorylation after H2O2  However, while Akt phosphorylation was prevented by CHX, Erk1\/2 phosphorylation was further enhanced by CHX"}
{"PMID":12472888,"re_id":3,"annotated sentence":"Pre-treatment with arsenite increased protein kinase B (<e2>Akt<\\e2>  and extracellular signal regulated kinase 1\/2 (ERK1\/2) phosphorylation after <e1>H2O2<\\e1>  However, while Akt phosphorylation was prevented by CHX, Erk1\/2 phosphorylation was further enhanced by CHX","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"H2O2","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pre-treatment with arsenite increased protein kinase B (<e2>GENE-N<\\e2>  and extracellular signal regulated kinase 1\/2 (ERK1\/2) phosphorylation after <e1>CHEMICAL<\\e1>  However, while GENE-N phosphorylation was prevented by CHX, Erk1\/2 phosphorylation was further enhanced by CHX","sentence":"Pre-treatment with arsenite increased protein kinase B (Akt  and extracellular signal regulated kinase 1\/2 (ERK1\/2) phosphorylation after H2O2  However, while Akt phosphorylation was prevented by CHX, Erk1\/2 phosphorylation was further enhanced by CHX"}
{"PMID":12472888,"re_id":4,"annotated sentence":"The results show that transient <e1>arsenite<\\e1> pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of <e2>Akt<\\e2> following H2O2","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"arsenite","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results show that transient <e1>CHEMICAL<\\e1> pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of <e2>GENE-N<\\e2> following H2O2","sentence":"The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2"}
{"PMID":12472888,"re_id":5,"annotated sentence":"The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of <e2>Akt<\\e2> following <e1>H2O2<\\e1>  It is suggested that HSP expression at the time of H2O2 exposure protects astrocytes from oxidative injury and apoptotic cell death by means of pro-survival Akt.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"H2O2","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces CHEMICAL-induced astrocyte death; and it causes selective activation of <e2>GENE-N<\\e2> following <e1>CHEMICAL<\\e1>  It is suggested that HSP expression at the time of CHEMICAL exposure protects astrocytes from oxidative injury and apoptotic cell death by means of pro-survival GENE-N.","sentence":"The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2  It is suggested that HSP expression at the time of H2O2 exposure protects astrocytes from oxidative injury and apoptotic cell death by means of pro-survival Akt."}
{"PMID":12472888,"re_id":6,"annotated sentence":"Induction of <e2>heat shock proteins<\\e2> (HSPs) by <e1>sodium arsenite<\\e1> in cultured astrocytes and reduction of hydrogen peroxide-induced cell death","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"sodium arsenite","object":"heat shock proteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Induction of <e2>GENE-N<\\e2> (HSPs) by <e1>CHEMICAL<\\e1> in cultured astrocytes and reduction of hydrogen peroxide-induced cell death","sentence":"Induction of heat shock proteins (HSPs) by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death"}
{"PMID":12472888,"re_id":7,"annotated sentence":"Induction of heat shock proteins (<e2>HSPs<\\e2>  by <e1>sodium arsenite<\\e1> in cultured astrocytes and reduction of hydrogen peroxide-induced cell death","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"sodium arsenite","object":"HSPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Induction of heat shock proteins (<e2>GENE-N<\\e2>  by <e1>CHEMICAL<\\e1> in cultured astrocytes and reduction of hydrogen peroxide-induced cell death","sentence":"Induction of heat shock proteins (HSPs  by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death"}
{"PMID":12472888,"re_id":8,"annotated sentence":"The results show that transient <e1>arsenite<\\e1> pre-treatment induces <e2>Hsp72<\\e2>  HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"arsenite","object":"Hsp72","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results show that transient <e1>CHEMICAL<\\e1> pre-treatment induces <e2>GENE-Y<\\e2>  HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2","sentence":"The results show that transient arsenite pre-treatment induces Hsp72  HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2"}
{"PMID":12472888,"re_id":9,"annotated sentence":"The results show that transient <e1>arsenite<\\e1> pre-treatment induces Hsp72, <e2>HO-1<\\e2> and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"arsenite","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results show that transient <e1>CHEMICAL<\\e1> pre-treatment induces Hsp72, <e2>GENE-Y<\\e2> and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2","sentence":"The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2"}
{"PMID":12472888,"re_id":10,"annotated sentence":"The results show that transient <e1>arsenite<\\e1> pre-treatment induces Hsp72, HO-1 and, to a lesser extent, <e2>Hsp27<\\e2>  it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"arsenite","object":"Hsp27","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results show that transient <e1>CHEMICAL<\\e1> pre-treatment induces Hsp72, HO-1 and, to a lesser extent, <e2>GENE-Y<\\e2>  it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2","sentence":"The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27  it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2"}
{"PMID":12472888,"re_id":11,"annotated sentence":"<e1>Arsenite<\\e1> triggered strong induction of <e2>HSPs<\\e2>  which was prevented by 1 micro g\/mL cycloheximide (CXH)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"Arsenite","object":"HSPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> triggered strong induction of <e2>GENE-N<\\e2>  which was prevented by 1 micro g\/mL cycloheximide (CXH)","sentence":"Arsenite triggered strong induction of HSPs  which was prevented by 1 micro g\/mL cycloheximide (CXH)"}
{"PMID":12472888,"re_id":12,"annotated sentence":"Arsenite triggered strong induction of <e2>HSPs<\\e2>  which was prevented by 1 micro g\/mL <e1>cycloheximide<\\e1> (CXH)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"cycloheximide","object":"HSPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Arsenite triggered strong induction of <e2>GENE-N<\\e2>  which was prevented by 1 micro g\/mL <e1>CHEMICAL<\\e1> (CXH)","sentence":"Arsenite triggered strong induction of HSPs  which was prevented by 1 micro g\/mL cycloheximide (CXH)"}
{"PMID":12472888,"re_id":13,"annotated sentence":"Arsenite triggered strong induction of <e2>HSPs<\\e2>  which was prevented by 1 micro g\/mL cycloheximide (<e1>CXH<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"CXH","object":"HSPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Arsenite triggered strong induction of <e2>GENE-N<\\e2>  which was prevented by 1 micro g\/mL cycloheximide (<e1>CHEMICAL<\\e1> ","sentence":"Arsenite triggered strong induction of HSPs  which was prevented by 1 micro g\/mL cycloheximide (CXH "}
{"PMID":12472888,"re_id":14,"annotated sentence":"However, while <e2>Akt<\\e2> phosphorylation was prevented by CHX, Erk1\/2 phosphorylation was further enhanced by <e1>CHX<\\e1>  The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CHX","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, while <e2>GENE-N<\\e2> phosphorylation was prevented by CHEMICAL, Erk1\/2 phosphorylation was further enhanced by <e1>CHEMICAL<\\e1>  The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of GENE-N following H2O2","sentence":"However, while Akt phosphorylation was prevented by CHX, Erk1\/2 phosphorylation was further enhanced by CHX  The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2"}
{"PMID":12487427,"re_id":14,"annotated sentence":"<e1>GW660511X<\\e1> and omapatrilat increased the production of both <e2>BrBK1-8<\\e2> and Br-Phe5 but not that of BrBK4-8 and BrBK2-8","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GW660511X","object":"BrBK1-8","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and omapatrilat increased the production of both <e2>GENE-N<\\e2> and Br-Phe5 but not that of BrBK4-8 and BrBK2-8","sentence":"GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8"}
{"PMID":12487427,"re_id":15,"annotated sentence":"<e1>GW660511X<\\e1> and omapatrilat increased the production of both BrBK1-8 and <e2>Br-Phe5<\\e2> but not that of BrBK4-8 and BrBK2-8","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GW660511X","object":"Br-Phe5","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and omapatrilat increased the production of both BrBK1-8 and <e2>GENE-N<\\e2> but not that of BrBK4-8 and BrBK2-8","sentence":"GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8"}
{"PMID":12487427,"re_id":16,"annotated sentence":"GW660511X and <e1>omapatrilat<\\e1> increased the production of both <e2>BrBK1-8<\\e2> and Br-Phe5 but not that of BrBK4-8 and BrBK2-8","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"omapatrilat","object":"BrBK1-8","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"GW660511X and <e1>CHEMICAL<\\e1> increased the production of both <e2>GENE-N<\\e2> and Br-Phe5 but not that of BrBK4-8 and BrBK2-8","sentence":"GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8"}
{"PMID":12487427,"re_id":17,"annotated sentence":"GW660511X and <e1>omapatrilat<\\e1> increased the production of both BrBK1-8 and <e2>Br-Phe5<\\e2> but not that of BrBK4-8 and BrBK2-8","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"omapatrilat","object":"Br-Phe5","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"GW660511X and <e1>CHEMICAL<\\e1> increased the production of both BrBK1-8 and <e2>GENE-N<\\e2> but not that of BrBK4-8 and BrBK2-8","sentence":"GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8"}
{"PMID":12487427,"re_id":18,"annotated sentence":"In addition the production of <e2>BrBK1-8<\\e2> was enhanced in the presence of these inhibitors with a greater accumulation being observed with <e1>omapatrilat<\\e1>  The production of Br-Phe5 was reduced with GW660511X while no significant change was observed with omapatrilat after 4 h of incubation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"omapatrilat","object":"BrBK1-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition the production of <e2>GENE-Y<\\e2> was enhanced in the presence of these inhibitors with a greater accumulation being observed with <e1>CHEMICAL<\\e1>  The production of Br-Phe5 was reduced with GW660511X while no significant change was observed with CHEMICAL after 4 h of incubation","sentence":"In addition the production of BrBK1-8 was enhanced in the presence of these inhibitors with a greater accumulation being observed with omapatrilat  The production of Br-Phe5 was reduced with GW660511X while no significant change was observed with omapatrilat after 4 h of incubation"}
{"PMID":12487427,"re_id":19,"annotated sentence":"<e1>GW660511X<\\e1> and omapatrilat reduced the production of <e2>BrBK1-5<\\e2> and BrBK1-7 with more effect being observed with omapatrilat","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"GW660511X","object":"BrBK1-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and omapatrilat reduced the production of <e2>GENE-Y<\\e2> and BrBK1-7 with more effect being observed with omapatrilat","sentence":"GW660511X and omapatrilat reduced the production of BrBK1-5 and BrBK1-7 with more effect being observed with omapatrilat"}
{"PMID":12487427,"re_id":20,"annotated sentence":"<e1>GW660511X<\\e1> and omapatrilat reduced the production of BrBK1-5 and <e2>BrBK1-7<\\e2> with more effect being observed with omapatrilat","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"GW660511X","object":"BrBK1-7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and omapatrilat reduced the production of BrBK1-5 and <e2>GENE-Y<\\e2> with more effect being observed with omapatrilat","sentence":"GW660511X and omapatrilat reduced the production of BrBK1-5 and BrBK1-7 with more effect being observed with omapatrilat"}
{"PMID":12487427,"re_id":21,"annotated sentence":"GW660511X and <e1>omapatrilat<\\e1> reduced the production of <e2>BrBK1-5<\\e2> and BrBK1-7 with more effect being observed with omapatrilat","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"omapatrilat","object":"BrBK1-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GW660511X and <e1>CHEMICAL<\\e1> reduced the production of <e2>GENE-Y<\\e2> and BrBK1-7 with more effect being observed with CHEMICAL","sentence":"GW660511X and omapatrilat reduced the production of BrBK1-5 and BrBK1-7 with more effect being observed with omapatrilat"}
{"PMID":12487427,"re_id":22,"annotated sentence":"GW660511X and <e1>omapatrilat<\\e1> reduced the production of BrBK1-5 and <e2>BrBK1-7<\\e2> with more effect being observed with omapatrilat","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"omapatrilat","object":"BrBK1-7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GW660511X and <e1>CHEMICAL<\\e1> reduced the production of BrBK1-5 and <e2>GENE-Y<\\e2> with more effect being observed with CHEMICAL","sentence":"GW660511X and omapatrilat reduced the production of BrBK1-5 and BrBK1-7 with more effect being observed with omapatrilat"}
{"PMID":12487427,"re_id":23,"annotated sentence":"GW660511X and omapatrilat reduced the production of <e2>BrBK1-5<\\e2> and BrBK1-7 with more effect being observed with <e1>omapatrilat<\\e1>  GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"omapatrilat","object":"BrBK1-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GW660511X and CHEMICAL reduced the production of <e2>GENE-Y<\\e2> and BrBK1-7 with more effect being observed with <e1>CHEMICAL<\\e1>  GW660511X and CHEMICAL increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8","sentence":"GW660511X and omapatrilat reduced the production of BrBK1-5 and BrBK1-7 with more effect being observed with omapatrilat  GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8"}
{"PMID":12487427,"re_id":24,"annotated sentence":"GW660511X and omapatrilat reduced the production of BrBK1-5 and <e2>BrBK1-7<\\e2> with more effect being observed with <e1>omapatrilat<\\e1>  GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"omapatrilat","object":"BrBK1-7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GW660511X and CHEMICAL reduced the production of BrBK1-5 and <e2>GENE-Y<\\e2> with more effect being observed with <e1>CHEMICAL<\\e1>  GW660511X and CHEMICAL increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8","sentence":"GW660511X and omapatrilat reduced the production of BrBK1-5 and BrBK1-7 with more effect being observed with omapatrilat  GW660511X and omapatrilat increased the production of both BrBK1-8 and Br-Phe5 but not that of BrBK4-8 and BrBK2-8"}
{"PMID":12487427,"re_id":25,"annotated sentence":"Unlike GW660511X, <e1>omapatrilat<\\e1> abolished the production of <e2>BrBK1-5<\\e2> and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"omapatrilat","object":"BrBK1-5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Unlike GW660511X, <e1>CHEMICAL<\\e1> abolished the production of <e2>GENE-Y<\\e2> and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found","sentence":"Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found"}
{"PMID":12487427,"re_id":26,"annotated sentence":"Unlike GW660511X, <e1>omapatrilat<\\e1> abolished the production of BrBK1-5 and <e2>BrBK1-7<\\e2>  suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"omapatrilat","object":"BrBK1-7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Unlike GW660511X, <e1>CHEMICAL<\\e1> abolished the production of BrBK1-5 and <e2>GENE-Y<\\e2>  suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found","sentence":"Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7  suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found"}
{"PMID":12487427,"re_id":27,"annotated sentence":"The production of <e2>Br-Phe5<\\e2> was reduced with <e1>GW660511X<\\e1> while no significant change was observed with omapatrilat after 4 h of incubation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"GW660511X","object":"Br-Phe5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The production of <e2>GENE-Y<\\e2> was reduced with <e1>CHEMICAL<\\e1> while no significant change was observed with omapatrilat after 4 h of incubation","sentence":"The production of Br-Phe5 was reduced with GW660511X while no significant change was observed with omapatrilat after 4 h of incubation"}
{"PMID":12487427,"re_id":28,"annotated sentence":"This study shows that the potency of <e1>GW660511X<\\e1> in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of <e2>ACE<\\e2> NEP inhibition in relation to effects in humans.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW660511X","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study shows that the potency of <e1>CHEMICAL<\\e1> in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of <e2>GENE-Y<\\e2> NEP inhibition in relation to effects in humans.","sentence":"This study shows that the potency of GW660511X in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE NEP inhibition in relation to effects in humans."}
{"PMID":12487427,"re_id":29,"annotated sentence":"This study shows that the potency of <e1>GW660511X<\\e1> in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE\/<e2>NEP<\\e2> inhibition in relation to effects in humans.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW660511X","object":"NEP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study shows that the potency of <e1>CHEMICAL<\\e1> in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE\/<e2>GENE-Y<\\e2> inhibition in relation to effects in humans.","sentence":"This study shows that the potency of GW660511X in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE\/NEP inhibition in relation to effects in humans."}
{"PMID":12487427,"re_id":30,"annotated sentence":"This study shows that the potency of GW660511X in comparison with <e1>omapatrilat<\\e1> is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE\/<e2>NEP<\\e2> inhibition in relation to effects in humans.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"omapatrilat","object":"NEP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study shows that the potency of GW660511X in comparison with <e1>CHEMICAL<\\e1> is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE\/<e2>GENE-Y<\\e2> inhibition in relation to effects in humans.","sentence":"This study shows that the potency of GW660511X in comparison with omapatrilat is more than 100-fold lower in human, but less than 10-fold lower in rat plasma, suggesting that rat may not be a suitable in vivo model for the evaluation of ACE\/NEP inhibition in relation to effects in humans."}
{"PMID":12487427,"re_id":31,"annotated sentence":"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79\/81 Br-Phe5) BrBK in the presence of two new dual <e2>ACE<\\e2> NEP inhibitors (<e1>GW660511X<\\e1> and omapatrilat) currently under clinical trial","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW660511X","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79\/81 Br-Phe5) BrBK in the presence of two new dual <e2>GENE-N<\\e2> NEP inhibitors (<e1>CHEMICAL<\\e1> and omapatrilat) currently under clinical trial","sentence":"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79\/81 Br-Phe5) BrBK in the presence of two new dual ACE NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial"}
{"PMID":12487427,"re_id":32,"annotated sentence":"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79\/81 Br-Phe5) BrBK in the presence of two new dual ACE\/<e2>NEP<\\e2> inhibitors (<e1>GW660511X<\\e1> and omapatrilat) currently under clinical trial","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW660511X","object":"NEP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79\/81 Br-Phe5) BrBK in the presence of two new dual ACE\/<e2>GENE-N<\\e2> inhibitors (<e1>CHEMICAL<\\e1> and omapatrilat) currently under clinical trial","sentence":"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79\/81 Br-Phe5) BrBK in the presence of two new dual ACE\/NEP inhibitors (GW660511X and omapatrilat) currently under clinical trial"}
{"PMID":12487427,"re_id":33,"annotated sentence":"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79\/81 Br-Phe5) BrBK in the presence of two new dual <e2>ACE<\\e2> NEP inhibitors (GW660511X and <e1>omapatrilat<\\e1>  currently under clinical trial","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"omapatrilat","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79\/81 Br-Phe5) BrBK in the presence of two new dual <e2>GENE-N<\\e2> NEP inhibitors (GW660511X and <e1>CHEMICAL<\\e1>  currently under clinical trial","sentence":"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79\/81 Br-Phe5) BrBK in the presence of two new dual ACE NEP inhibitors (GW660511X and omapatrilat  currently under clinical trial"}
{"PMID":12487427,"re_id":34,"annotated sentence":"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79\/81 Br-Phe5) BrBK in the presence of two new dual ACE\/<e2>NEP<\\e2> inhibitors (GW660511X and <e1>omapatrilat<\\e1>  currently under clinical trial","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"omapatrilat","object":"NEP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79\/81 Br-Phe5) BrBK in the presence of two new dual ACE\/<e2>GENE-N<\\e2> inhibitors (GW660511X and <e1>CHEMICAL<\\e1>  currently under clinical trial","sentence":"In this work a novel approach combining HPLC-UV on-line with oaTOF-MS and ICPMS was applied to investigate in human and rat plasma the metabolism of labelled BK (79\/81 Br-Phe5) BrBK in the presence of two new dual ACE\/NEP inhibitors (GW660511X and omapatrilat  currently under clinical trial"}
{"PMID":12487427,"re_id":35,"annotated sentence":"Unlike GW660511X, <e1>omapatrilat<\\e1> abolished the production of BrBK1-5 and BrBK1-7, suggesting a better <e2>ACE<\\e2> inhibition effect over GW660511X as no NEP activity was found","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"omapatrilat","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Unlike GW660511X, <e1>CHEMICAL<\\e1> abolished the production of BrBK1-5 and BrBK1-7, suggesting a better <e2>GENE-Y<\\e2> inhibition effect over GW660511X as no NEP activity was found","sentence":"Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found"}
{"PMID":12487427,"re_id":36,"annotated sentence":"Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better <e2>ACE<\\e2> inhibition effect over <e1>GW660511X<\\e1> as no NEP activity was found","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW660511X","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Unlike CHEMICAL, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better <e2>GENE-Y<\\e2> inhibition effect over <e1>CHEMICAL<\\e1> as no NEP activity was found","sentence":"Unlike GW660511X, omapatrilat abolished the production of BrBK1-5 and BrBK1-7, suggesting a better ACE inhibition effect over GW660511X as no NEP activity was found"}
{"PMID":12487427,"re_id":37,"annotated sentence":"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual <e2>ACE<\\e2> NEP inhibitors <e1>GW660511X<\\e1> and omapatrilat","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW660511X","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual <e2>GENE-N<\\e2> NEP inhibitors <e1>CHEMICAL<\\e1> and omapatrilat","sentence":"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE NEP inhibitors GW660511X and omapatrilat"}
{"PMID":12487427,"re_id":38,"annotated sentence":"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE\/<e2>NEP<\\e2> inhibitors <e1>GW660511X<\\e1> and omapatrilat","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW660511X","object":"NEP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE\/<e2>GENE-N<\\e2> inhibitors <e1>CHEMICAL<\\e1> and omapatrilat","sentence":"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE\/NEP inhibitors GW660511X and omapatrilat"}
{"PMID":12487427,"re_id":39,"annotated sentence":"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual <e2>ACE<\\e2> NEP inhibitors GW660511X and <e1>omapatrilat<\\e1>  Several studies have suggested that the accumulation of bradykinin, or that of one its metabolites BK1-8, is involved in the occurrence of side effects such as AE associated with the use of various ACEi","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"omapatrilat","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual <e2>GENE-N<\\e2> NEP inhibitors GW660511X and <e1>CHEMICAL<\\e1>  Several studies have suggested that the accumulation of bradykinin, or that of one its metabolites BK1-8, is involved in the occurrence of side effects such as AE associated with the use of various GENE-Ni","sentence":"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE NEP inhibitors GW660511X and omapatrilat  Several studies have suggested that the accumulation of bradykinin, or that of one its metabolites BK1-8, is involved in the occurrence of side effects such as AE associated with the use of various ACEi"}
{"PMID":12487427,"re_id":40,"annotated sentence":"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE\/<e2>NEP<\\e2> inhibitors GW660511X and <e1>omapatrilat<\\e1>  Several studies have suggested that the accumulation of bradykinin, or that of one its metabolites BK1-8, is involved in the occurrence of side effects such as AE associated with the use of various ACEi","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"omapatrilat","object":"NEP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE\/<e2>GENE-N<\\e2> inhibitors GW660511X and <e1>CHEMICAL<\\e1>  Several studies have suggested that the accumulation of bradykinin, or that of one its metabolites BK1-8, is involved in the occurrence of side effects such as AE associated with the use of various ACEi","sentence":"Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE\/NEP inhibitors GW660511X and omapatrilat  Several studies have suggested that the accumulation of bradykinin, or that of one its metabolites BK1-8, is involved in the occurrence of side effects such as AE associated with the use of various ACEi"}
{"PMID":12636181,"re_id":2,"annotated sentence":"The development of specific <e2>BuChE<\\e2> inhibitors and further experience with the dual enzyme inhibitor <e1>rivastigmine<\\e1> will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivastigmine","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The development of specific <e2>GENE-Y<\\e2> inhibitors and further experience with the dual enzyme inhibitor <e1>CHEMICAL<\\e1> will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options.","sentence":"The development of specific BuChE inhibitors and further experience with the dual enzyme inhibitor rivastigmine will improve understanding of the aetiology of AD and should lead to a wider variety of potent treatment options."}
{"PMID":12636181,"re_id":3,"annotated sentence":"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both <e2>AChE<\\e2> and BuChE, <e1>rivastigmine<\\e1>  indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivastigmine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both <e2>GENE-Y<\\e2> and BuChE, <e1>CHEMICAL<\\e1>  indicates potential therapeutic benefits of inhibiting both GENE-Y and BuChE in AD and related dementias","sentence":"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine  indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias"}
{"PMID":12636181,"re_id":4,"annotated sentence":"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and <e2>BuChE<\\e2>  <e1>rivastigmine<\\e1>  indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivastigmine","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Experimental evidence from the use of agents with enhanced selectivity for GENE-Y (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and <e2>GENE-Y<\\e2>  <e1>CHEMICAL<\\e1>  indicates potential therapeutic benefits of inhibiting both AChE and GENE-Y in AD and related dementias","sentence":"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE  rivastigmine  indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias"}
{"PMID":12636181,"re_id":5,"annotated sentence":"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, <e1>rivastigmine<\\e1>  indicates potential therapeutic benefits of inhibiting both <e2>AChE<\\e2> and BuChE in AD and related dementias","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivastigmine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both GENE-Y and BuChE, <e1>CHEMICAL<\\e1>  indicates potential therapeutic benefits of inhibiting both <e2>GENE-Y<\\e2> and BuChE in AD and related dementias","sentence":"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine  indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias"}
{"PMID":12636181,"re_id":6,"annotated sentence":"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, <e1>rivastigmine<\\e1>  indicates potential therapeutic benefits of inhibiting both AChE and <e2>BuChE<\\e2> in AD and related dementias","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivastigmine","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Experimental evidence from the use of agents with enhanced selectivity for GENE-Y (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and GENE-Y, <e1>CHEMICAL<\\e1>  indicates potential therapeutic benefits of inhibiting both AChE and <e2>GENE-Y<\\e2> in AD and related dementias","sentence":"Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine  indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias"}
{"PMID":12636181,"re_id":7,"annotated sentence":"Acetylcholinesterase (<e2>AChE<\\e2>  predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain <e1>acetylcholine<\\e1> (ACh) levels","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"acetylcholine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acetylcholinesterase (<e2>GENE-Y<\\e2>  predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain <e1>CHEMICAL<\\e1> (ACh) levels","sentence":"Acetylcholinesterase (AChE  predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels"}
{"PMID":12636181,"re_id":8,"annotated sentence":"Acetylcholinesterase (AChE) predominates in the healthy brain, with <e2>butyrylcholinesterase<\\e2> (BuChE) considered to play a minor role in regulating brain <e1>acetylcholine<\\e1> (ACh) levels","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"acetylcholine","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acetylcholinesterase (AChE) predominates in the healthy brain, with <e2>GENE-Y<\\e2> (BuChE) considered to play a minor role in regulating brain <e1>CHEMICAL<\\e1> (ACh) levels","sentence":"Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels"}
{"PMID":12636181,"re_id":9,"annotated sentence":"Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (<e2>BuChE<\\e2>  considered to play a minor role in regulating brain <e1>acetylcholine<\\e1> (ACh) levels","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"acetylcholine","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (<e2>GENE-Y<\\e2>  considered to play a minor role in regulating brain <e1>CHEMICAL<\\e1> (ACh) levels","sentence":"Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE  considered to play a minor role in regulating brain acetylcholine (ACh) levels"}
{"PMID":12636181,"re_id":10,"annotated sentence":"<e2>Acetylcholinesterase<\\e2> (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain <e1>acetylcholine<\\e1> (ACh) levels","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"acetylcholine","object":"Acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain <e1>CHEMICAL<\\e1> (ACh) levels","sentence":"Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh) levels"}
{"PMID":12636181,"re_id":11,"annotated sentence":"Acetylcholinesterase (<e2>AChE<\\e2>  predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (<e1>ACh<\\e1>  levels","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ACh","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acetylcholinesterase (<e2>CHEMICALE<\\e2>  predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (<e1>CHEMICAL<\\e1>  levels","sentence":"Acetylcholinesterase (AChE  predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh  levels"}
{"PMID":12636181,"re_id":12,"annotated sentence":"Acetylcholinesterase (AChE) predominates in the healthy brain, with <e2>butyrylcholinesterase<\\e2> (BuChE) considered to play a minor role in regulating brain acetylcholine (<e1>ACh<\\e1>  levels","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ACh","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acetylcholinesterase (CHEMICALE) predominates in the healthy brain, with <e2>GENE-Y<\\e2> (BuChE) considered to play a minor role in regulating brain acetylcholine (<e1>CHEMICAL<\\e1>  levels","sentence":"Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh  levels"}
{"PMID":12636181,"re_id":13,"annotated sentence":"Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (<e2>BuChE<\\e2>  considered to play a minor role in regulating brain acetylcholine (<e1>ACh<\\e1>  levels","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ACh","object":"BuChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acetylcholinesterase (CHEMICALE) predominates in the healthy brain, with butyrylcholinesterase (<e2>GENE-Y<\\e2>  considered to play a minor role in regulating brain acetylcholine (<e1>CHEMICAL<\\e1>  levels","sentence":"Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE  considered to play a minor role in regulating brain acetylcholine (ACh  levels"}
{"PMID":12636181,"re_id":14,"annotated sentence":"<e2>Acetylcholinesterase<\\e2> (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (<e1>ACh<\\e1>  levels","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ACh","object":"Acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CHEMICALE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (<e1>CHEMICAL<\\e1>  levels","sentence":"Acetylcholinesterase (AChE) predominates in the healthy brain, with butyrylcholinesterase (BuChE) considered to play a minor role in regulating brain acetylcholine (ACh  levels"}
{"PMID":12710892,"re_id":1,"annotated sentence":"Agents which have recently been shown to block <e2>cyclin D1<\\e2> translation by regulating calcium levels are the <e1>unsaturated essential fatty acid<\\e1>  eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"unsaturated essential fatty acid","object":"cyclin D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agents which have recently been shown to block <e2>GENE-Y<\\e2> translation by regulating calcium levels are the <e1>CHEMICAL<\\e1>  eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole","sentence":"Agents which have recently been shown to block cyclin D1 translation by regulating calcium levels are the unsaturated essential fatty acid  eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole"}
{"PMID":12710892,"re_id":2,"annotated sentence":"Agents which have recently been shown to block <e2>cyclin D1<\\e2> translation by regulating calcium levels are the unsaturated essential fatty acid, <e1>eicosapentaenoic acid<\\e1> (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"eicosapentaenoic acid","object":"cyclin D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agents which have recently been shown to block <e2>GENE-Y<\\e2> translation by regulating calcium levels are the unsaturated essential fatty acid, <e1>CHEMICAL<\\e1> (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole","sentence":"Agents which have recently been shown to block cyclin D1 translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole"}
{"PMID":12710892,"re_id":3,"annotated sentence":"Agents which have recently been shown to block <e2>cyclin D1<\\e2> translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (<e1>EPA<\\e1> , the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"EPA","object":"cyclin D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agents which have recently been shown to block <e2>GENE-Y<\\e2> translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (<e1>CHEMICAL<\\e1> , the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole","sentence":"Agents which have recently been shown to block cyclin D1 translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA , the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole"}
{"PMID":12710892,"re_id":4,"annotated sentence":"Agents which have recently been shown to block <e2>cyclin D1<\\e2> translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic <e1>thiazolidinediones<\\e1>  and the antifungal agent, clotrimazole","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"thiazolidinediones","object":"cyclin D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agents which have recently been shown to block <e2>GENE-Y<\\e2> translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic <e1>CHEMICAL<\\e1>  and the antifungal agent, clotrimazole","sentence":"Agents which have recently been shown to block cyclin D1 translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones  and the antifungal agent, clotrimazole"}
{"PMID":12710892,"re_id":5,"annotated sentence":"Agents which have recently been shown to block <e2>cyclin D1<\\e2> translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, <e1>clotrimazole<\\e1>  Two types of agent which have been shown to inhibit angiogenesis are the teratogen, thalidomide, and the selective inhibitors of cyclo-oxygenase 2 (COX-2)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"clotrimazole","object":"cyclin D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agents which have recently been shown to block <e2>GENE-Y<\\e2> translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, <e1>CHEMICAL<\\e1>  Two types of agent which have been shown to inhibit angiogenesis are the teratogen, thalidomide, and the selective inhibitors of cyclo-oxygenase 2 (COX-2)","sentence":"Agents which have recently been shown to block cyclin D1 translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole  Two types of agent which have been shown to inhibit angiogenesis are the teratogen, thalidomide, and the selective inhibitors of cyclo-oxygenase 2 (COX-2)"}
{"PMID":12719755,"re_id":1,"annotated sentence":"We investigated the effect of <e2>AT1 receptor<\\e2> blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent <e1>pancuronium bromide<\\e1>  The characteristic increase in heart rate, blood pressure and phrenic nerve activity evoked by electrical stimulation of HDA is decreased by the microinjection of the AT1 receptor antagonist losartan into the NTS and the cardiovascular response to carotid body chemical stimulation is also reduced","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"pancuronium bromide","object":"AT1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We investigated the effect of <e2>GENE-Y<\\e2> blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent <e1>CHEMICAL<\\e1>  The characteristic increase in heart rate, blood pressure and phrenic nerve activity evoked by electrical stimulation of HDA is decreased by the microinjection of the GENE-Y antagonist losartan into the NTS and the cardiovascular response to carotid body chemical stimulation is also reduced","sentence":"We investigated the effect of AT1 receptor blockade in the NTS on the response to stimulation of HDA in anaesthetised rats treated with the neuromuscular blocking agent pancuronium bromide  The characteristic increase in heart rate, blood pressure and phrenic nerve activity evoked by electrical stimulation of HDA is decreased by the microinjection of the AT1 receptor antagonist losartan into the NTS and the cardiovascular response to carotid body chemical stimulation is also reduced"}
{"PMID":12719755,"re_id":2,"annotated sentence":"<e2>Angiotensin AT1 receptor<\\e2> antagonist <e1>losartan<\\e1> and the defence reaction in the anaesthetised rat","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"losartan","object":"Angiotensin AT1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> and the defence reaction in the anaesthetised rat","sentence":"Angiotensin AT1 receptor antagonist losartan and the defence reaction in the anaesthetised rat"}
{"PMID":12897749,"re_id":2,"annotated sentence":"RESULTS: Rolipram unmasked the inhibitory effect of <e2>beta(2)-adrenoceptor<\\e2> stimulation with <e1>salmeterol<\\e1> and significantly attenuated the stimulated release of AA and subsequent LTC(4)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"salmeterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: Rolipram unmasked the inhibitory effect of <e2>GENE-N<\\e2> stimulation with <e1>CHEMICAL<\\e1> and significantly attenuated the stimulated release of AA and subsequent LTC(4)","sentence":"RESULTS: Rolipram unmasked the inhibitory effect of beta(2)-adrenoceptor stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent LTC(4)"}
{"PMID":12897749,"re_id":3,"annotated sentence":"Inhibition corresponded to increased cAMP production caused by rolipram alone or <e1>rolipram<\\e1> plus salmeterol and blocked proportionately the phosphorylation and activation of <e2>gIV-PLA(2)<\\e2> in FMLP\/B-activated eosinophils","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rolipram","object":"gIV-PLA(2)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition corresponded to increased cAMP production caused by CHEMICAL alone or <e1>CHEMICAL<\\e1> plus salmeterol and blocked proportionately the phosphorylation and activation of <e2>GENE-N<\\e2> in FMLP\/B-activated eosinophils","sentence":"Inhibition corresponded to increased cAMP production caused by rolipram alone or rolipram plus salmeterol and blocked proportionately the phosphorylation and activation of gIV-PLA(2) in FMLP\/B-activated eosinophils"}
{"PMID":12897749,"re_id":4,"annotated sentence":"Inhibition corresponded to increased cAMP production caused by rolipram alone or rolipram plus <e1>salmeterol<\\e1> and blocked proportionately the phosphorylation and activation of <e2>gIV-PLA(2)<\\e2> in FMLP\/B-activated eosinophils","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"salmeterol","object":"gIV-PLA(2)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition corresponded to increased cAMP production caused by rolipram alone or rolipram plus <e1>CHEMICAL<\\e1> and blocked proportionately the phosphorylation and activation of <e2>GENE-N<\\e2> in FMLP\/B-activated eosinophils","sentence":"Inhibition corresponded to increased cAMP production caused by rolipram alone or rolipram plus salmeterol and blocked proportionately the phosphorylation and activation of gIV-PLA(2) in FMLP\/B-activated eosinophils"}
{"PMID":12897749,"re_id":5,"annotated sentence":"CONCLUSIONS: Inhibition of <e2>PDE4<\\e2> by <e1>rolipram<\\e1> unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP\/B.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rolipram","object":"PDE4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: Inhibition of <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1> unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP\/B.","sentence":"CONCLUSIONS: Inhibition of PDE4 by rolipram unmasks beta(2)-adrenergic blockade of LTC(4) synthesis caused by FMLP\/B."}
{"PMID":12897749,"re_id":6,"annotated sentence":"OBJECTIVE: To determine (a) whether <e2>PDE4<\\e2> inhibition alone with <e1>rolipram<\\e1> blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP\/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rolipram","object":"PDE4","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"OBJECTIVE: To determine (a) whether <e2>GENE-N<\\e2> inhibition alone with <e1>CHEMICAL<\\e1> blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP\/B), (b) to determine if GENE-N inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP","sentence":"OBJECTIVE: To determine (a) whether PDE4 inhibition alone with rolipram blocked secretions of arachidonic acid (AA) and leukotriene C(4) (LTC(4)) caused by activation of eosinophils with formyl-met-leu-phe plus cytochalasin B (FMLP\/B), (b) to determine if PDE4 inhibition plus beta(2)-adrenoceptor agonist act additively to augment endogenous cAMP concentration, and (c) to determine the mechanism by which additive inhibition of AA and LTC(4) synthesis is regulated by cAMP"}
{"PMID":12897749,"re_id":7,"annotated sentence":"Blockade of <e1>LTC4<\\e1> synthesis caused by additive inhibition of <e2>gIV-PLA2<\\e2> phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"LTC4","object":"gIV-PLA2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Blockade of <e1>CHEMICAL<\\e1> synthesis caused by additive inhibition of <e2>GENE-N<\\e2> phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils","sentence":"Blockade of LTC4 synthesis caused by additive inhibition of gIV-PLA2 phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils"}
{"PMID":1322047,"re_id":3,"annotated sentence":"Anabolic effects of <e1>clenbuterol<\\e1> on skeletal muscle are mediated by <e2>beta 2-adrenoceptor<\\e2> activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"clenbuterol","object":"beta 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Anabolic effects of <e1>CHEMICAL<\\e1> on skeletal muscle are mediated by <e2>GENE-Y<\\e2> activation","sentence":"Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation"}
{"PMID":1322047,"re_id":4,"annotated sentence":"These effects were not mimicked by oral administration of the <e2>beta 2-adrenoceptor<\\e2> agonist <e1>salbutamol<\\e1> even at high dose (52 mg\/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg\/kg diet)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"salbutamol","object":"beta 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These effects were not mimicked by oral administration of the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> even at high dose (52 mg\/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg\/kg diet)","sentence":"These effects were not mimicked by oral administration of the beta 2-adrenoceptor agonist salbutamol even at high dose (52 mg\/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg\/kg diet)"}
{"PMID":1322047,"re_id":5,"annotated sentence":"These effects were not mimicked by oral administration of the <e2>beta 2-adrenoceptor<\\e2> agonist salbutamol even at high dose (52 mg\/kg diet), and the effects of <e1>clenbuterol<\\e1> were not inhibited by addition of DL-propranolol (200 mg\/kg diet)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"clenbuterol","object":"beta 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These effects were not mimicked by oral administration of the <e2>GENE-Y<\\e2> agonist salbutamol even at high dose (52 mg\/kg diet), and the effects of <e1>CHEMICAL<\\e1> were not inhibited by addition of DL-propranolol (200 mg\/kg diet)","sentence":"These effects were not mimicked by oral administration of the beta 2-adrenoceptor agonist salbutamol even at high dose (52 mg\/kg diet), and the effects of clenbuterol were not inhibited by addition of DL-propranolol (200 mg\/kg diet)"}
{"PMID":1322047,"re_id":6,"annotated sentence":"The potent anabolic effects of the <e2>beta 2-adrenoceptor<\\e2> agonist <e1>clenbuterol<\\e1> on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"clenbuterol","object":"beta 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The potent anabolic effects of the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors","sentence":"The potent anabolic effects of the beta 2-adrenoceptor agonist clenbuterol on skeletal muscle have been reported to be independent of actions on beta-adrenoceptors"}
{"PMID":1356794,"re_id":0,"annotated sentence":"In the hot-plate test in mice, the antinociceptive action of the <e2>alpha 2-adrenoceptor<\\e2> agonist, <e1>UK 14,304<\\e1>  was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"UK 14,304","object":"alpha 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the hot-plate test in mice, the antinociceptive action of the <e2>GENE-N<\\e2> agonist, <e1>CHEMICAL<\\e1>  was abolished by the GENE-N antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408","sentence":"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304  was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408"}
{"PMID":1356794,"re_id":1,"annotated sentence":"The preferential <e2>alpha 2A-adrenoceptor<\\e2> partial agonist, <e1>guanfacine<\\e1>  partially inhibited UK 14,304-induced antinociception","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"guanfacine","object":"alpha 2A-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The preferential <e2>GENE-Y<\\e2> partial agonist, <e1>CHEMICAL<\\e1>  partially inhibited UK 14,304-induced antinociception","sentence":"The preferential alpha 2A-adrenoceptor partial agonist, guanfacine  partially inhibited UK 14,304-induced antinociception"}
{"PMID":1356794,"re_id":2,"annotated sentence":"The preferential <e2>alpha 2A-adrenoceptor<\\e2> partial agonist, guanfacine, partially inhibited <e1>UK 14,304<\\e1> induced antinociception","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"UK 14,304","object":"alpha 2A-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The preferential <e2>GENE-Y<\\e2> partial agonist, guanfacine, partially inhibited <e1>CHEMICAL<\\e1> induced antinociception","sentence":"The preferential alpha 2A-adrenoceptor partial agonist, guanfacine, partially inhibited UK 14,304 induced antinociception"}
{"PMID":1356794,"re_id":3,"annotated sentence":"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the <e2>alpha 2-adrenoceptor<\\e2> antagonist, <e1>idazoxan<\\e1>  the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"idazoxan","object":"alpha 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the hot-plate test in mice, the antinociceptive action of the GENE-N agonist, UK 14,304, was abolished by the <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1>  the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408","sentence":"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan  the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408"}
{"PMID":1356794,"re_id":4,"annotated sentence":"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent <e2>alpha 2A-adrenoceptor<\\e2> antagonist, <e1>RX 821002<\\e1> and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"RX 821002","object":"alpha 2A-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1> and the preferential GENE-Y antagonist, BRL 44408","sentence":"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408"}
{"PMID":1356794,"re_id":5,"annotated sentence":"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential <e2>alpha 2A-adrenoceptor<\\e2> antagonist, <e1>BRL 44408<\\e1>  In contrast, the preferential alpha 2B- (and alpha 2C)-adrenoceptor ligands ('antagonists'), ARC-239, BRL 41992 and prazosin were inactive","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"BRL 44408","object":"alpha 2A-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent GENE-Y antagonist, RX 821002 and the preferential <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1>  In contrast, the preferential alpha 2B- (and alpha 2C)-adrenoceptor ligands ('antagonists'), ARC-239, BRL 41992 and prazosin were inactive","sentence":"In the hot-plate test in mice, the antinociceptive action of the alpha 2-adrenoceptor agonist, UK 14,304, was abolished by the alpha 2-adrenoceptor antagonist, idazoxan, the potent alpha 2A-adrenoceptor antagonist, RX 821002 and the preferential alpha 2A-adrenoceptor antagonist, BRL 44408  In contrast, the preferential alpha 2B- (and alpha 2C)-adrenoceptor ligands ('antagonists'), ARC-239, BRL 41992 and prazosin were inactive"}
{"PMID":14596599,"re_id":18,"annotated sentence":"Formation of <e1>pyruvate<\\e1> by <e2>SDH<\\e2> is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyruvate","object":"SDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Formation of <e1>CHEMICAL<\\e1> by <e2>GENE-Y<\\e2> is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce CHEMICAL","sentence":"Formation of pyruvate by SDH is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate"}
{"PMID":14596599,"re_id":19,"annotated sentence":"Formation of pyruvate by <e2>SDH<\\e2> is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce <e1>pyruvate<\\e1>  The crystal structure of rat liver apo-SDH was determined by single isomorphous replacement at 2.8 A resolution","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyruvate","object":"SDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Formation of CHEMICAL by <e2>GENE-Y<\\e2> is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce <e1>CHEMICAL<\\e1>  The crystal structure of rat liver apo-GENE-Y was determined by single isomorphous replacement at 2.8 A resolution","sentence":"Formation of pyruvate by SDH is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate, and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate  The crystal structure of rat liver apo-SDH was determined by single isomorphous replacement at 2.8 A resolution"}
{"PMID":14596599,"re_id":20,"annotated sentence":"<e2>SDH<\\e2> (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield <e1>pyruvate<\\e1> and ammonia","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyruvate","object":"SDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield <e1>CHEMICAL<\\e1> and ammonia","sentence":"SDH (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia"}
{"PMID":14596599,"re_id":21,"annotated sentence":"SDH (L-serine dehydratase, <e2>EC 4.3.1.17<\\e2>  catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield <e1>pyruvate<\\e1> and ammonia","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyruvate","object":"EC 4.3.1.17","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SDH (L-serine dehydratase, <e2>GENE-Y<\\e2>  catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield <e1>CHEMICAL<\\e1> and ammonia","sentence":"SDH (L-serine dehydratase, EC 4.3.1.17  catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia"}
{"PMID":14596599,"re_id":22,"annotated sentence":"SDH <e2>(L-serine dehydratase<\\e2>  EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield <e1>pyruvate<\\e1> and ammonia","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyruvate","object":"(L-serine dehydratase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SDH <e2>GENE-Y<\\e2>  EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield <e1>CHEMICAL<\\e1> and ammonia","sentence":"SDH (L-serine dehydratase  EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia"}
{"PMID":14596599,"re_id":23,"annotated sentence":"<e2>SDH<\\e2> (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and <e1>ammonia<\\e1>  Liver SDH plays an important role in gluconeogenesis","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"ammonia","object":"SDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and <e1>CHEMICAL<\\e1>  Liver GENE-Y plays an important role in gluconeogenesis","sentence":"SDH (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia  Liver SDH plays an important role in gluconeogenesis"}
{"PMID":14596599,"re_id":24,"annotated sentence":"SDH (L-serine dehydratase, <e2>EC 4.3.1.17<\\e2>  catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and <e1>ammonia<\\e1>  Liver SDH plays an important role in gluconeogenesis","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"ammonia","object":"EC 4.3.1.17","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SDH (L-serine dehydratase, <e2>GENE-Y<\\e2>  catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and <e1>CHEMICAL<\\e1>  Liver SDH plays an important role in gluconeogenesis","sentence":"SDH (L-serine dehydratase, EC 4.3.1.17  catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia  Liver SDH plays an important role in gluconeogenesis"}
{"PMID":14596599,"re_id":25,"annotated sentence":"SDH <e2>(L-serine dehydratase<\\e2>  EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and <e1>ammonia<\\e1>  Liver SDH plays an important role in gluconeogenesis","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"ammonia","object":"(L-serine dehydratase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SDH <e2>GENE-Y<\\e2>  EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and <e1>CHEMICAL<\\e1>  Liver SDH plays an important role in gluconeogenesis","sentence":"SDH (L-serine dehydratase  EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia  Liver SDH plays an important role in gluconeogenesis"}
{"PMID":14596599,"re_id":26,"annotated sentence":"<e2>SDH<\\e2> (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of <e1>L-serine<\\e1> to yield pyruvate and ammonia","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-serine","object":"SDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (CHEMICAL dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of <e1>CHEMICAL<\\e1> to yield pyruvate and ammonia","sentence":"SDH (L-serine dehydratase, EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia"}
{"PMID":14596599,"re_id":27,"annotated sentence":"SDH (L-serine dehydratase, <e2>EC 4.3.1.17<\\e2>  catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of <e1>L-serine<\\e1> to yield pyruvate and ammonia","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-serine","object":"EC 4.3.1.17","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SDH (CHEMICAL dehydratase, <e2>GENE-Y<\\e2>  catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of <e1>CHEMICAL<\\e1> to yield pyruvate and ammonia","sentence":"SDH (L-serine dehydratase, EC 4.3.1.17  catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia"}
{"PMID":14596599,"re_id":28,"annotated sentence":"SDH <e2>(L-serine dehydratase<\\e2>  EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of <e1>L-serine<\\e1> to yield pyruvate and ammonia","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-serine","object":"(L-serine dehydratase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SDH <e2>(CHEMICAL dehydratase<\\e2>  EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of <e1>CHEMICAL<\\e1> to yield pyruvate and ammonia","sentence":"SDH (L-serine dehydratase  EC 4.3.1.17) catalyzes the pyridoxal 5'-phosphate (PLP)-dependent dehydration of L-serine to yield pyruvate and ammonia"}
{"PMID":14596599,"re_id":29,"annotated sentence":"Formation of pyruvate by <e2>SDH<\\e2> is a two-step reaction in which the hydroxyl group of serine is cleaved to produce <e1>aminoacrylate<\\e1>  and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"aminoacrylate","object":"SDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Formation of pyruvate by <e2>GENE-Y<\\e2> is a two-step reaction in which the hydroxyl group of serine is cleaved to produce <e1>CHEMICAL<\\e1>  and then the CHEMICAL is deaminated by nonenzymatic hydrolysis to produce pyruvate","sentence":"Formation of pyruvate by SDH is a two-step reaction in which the hydroxyl group of serine is cleaved to produce aminoacrylate  and then the aminoacrylate is deaminated by nonenzymatic hydrolysis to produce pyruvate"}
{"PMID":14633707,"re_id":0,"annotated sentence":"Blocking EGFR signaling with the EGFR\/HER-2 kinase inhibitor (KI) <e1>GW572016<\\e1> decreased the postradiation survival of irradiated <e2>Ras<\\e2> transformed cells and normal cells but had no effect on the survival of unirradiated cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"GW572016","object":"Ras","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Blocking EGFR signaling with the EGFR\/HER-2 kinase inhibitor (KI) <e1>CHEMICAL<\\e1> decreased the postradiation survival of irradiated <e2>GENE-N<\\e2> transformed cells and normal cells but had no effect on the survival of unirradiated cells","sentence":"Blocking EGFR signaling with the EGFR\/HER-2 kinase inhibitor (KI) GW572016 decreased the postradiation survival of irradiated Ras transformed cells and normal cells but had no effect on the survival of unirradiated cells"}
{"PMID":14633707,"re_id":1,"annotated sentence":"Blocking <e2>EGFR<\\e2> signaling with the EGFR\/HER-2 kinase inhibitor (KI) <e1>GW572016<\\e1> decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"GW572016","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Blocking <e2>GENE-Y<\\e2> signaling with the GENE-Y\/HER-2 kinase inhibitor (KI) <e1>CHEMICAL<\\e1> decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells","sentence":"Blocking EGFR signaling with the EGFR\/HER-2 kinase inhibitor (KI) GW572016 decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells"}
{"PMID":14633707,"re_id":2,"annotated sentence":"Thus, <e2>Ras<\\e2> utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI <e1>GW572016<\\e1> acts as a radiosensitizer","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"GW572016","object":"Ras","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thus, <e2>GENE-N<\\e2> utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI <e1>CHEMICAL<\\e1> acts as a radiosensitizer","sentence":"Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radiosensitizer"}
{"PMID":14633707,"re_id":3,"annotated sentence":"The observation that <e2>Ras<\\e2> transformed cells can be sensitized to killing by ionizing radiation with <e1>GW572016<\\e1> demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"GW572016","object":"Ras","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The observation that <e2>GENE-N<\\e2> transformed cells can be sensitized to killing by ionizing radiation with <e1>CHEMICAL<\\e1> demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on GENE-N-driven autocrine signaling through EGFR.","sentence":"The observation that Ras transformed cells can be sensitized to killing by ionizing radiation with GW572016 demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR."}
{"PMID":14633707,"re_id":4,"annotated sentence":"Blocking EGFR signaling with the <e2>EGFR<\\e2> HER-2 kinase inhibitor (KI) <e1>GW572016<\\e1> decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Blocking GENE-Y signaling with the <e2>GENE-Y<\\e2> HER-2 kinase inhibitor (KI) <e1>CHEMICAL<\\e1> decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells","sentence":"Blocking EGFR signaling with the EGFR HER-2 kinase inhibitor (KI) GW572016 decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells"}
{"PMID":14633707,"re_id":5,"annotated sentence":"Blocking EGFR signaling with the EGFR\/<e2>HER-2<\\e2> kinase inhibitor (KI) <e1>GW572016<\\e1> decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"HER-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Blocking EGFR signaling with the EGFR\/<e2>GENE-Y<\\e2> kinase inhibitor (KI) <e1>CHEMICAL<\\e1> decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells","sentence":"Blocking EGFR signaling with the EGFR\/HER-2 kinase inhibitor (KI) GW572016 decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells"}
{"PMID":14633707,"re_id":6,"annotated sentence":"Ras-CM and TGF-alpha also increase <e2>PI3-K<\\e2> activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by <e1>GW572016<\\e1>  Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radiosensitizer","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"PI3-K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Ras-CM and TGF-alpha also increase <e2>GENE-N<\\e2> activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by <e1>CHEMICAL<\\e1>  Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI CHEMICAL acts as a radiosensitizer","sentence":"Ras-CM and TGF-alpha also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by GW572016  Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radiosensitizer"}
{"PMID":14633707,"re_id":7,"annotated sentence":"Ras-CM and TGF-alpha also increase PI3-K activity downstream of the <e2>EGFR<\\e2> and increase postradiation survival, both of which are abrogated by <e1>GW572016<\\e1>  Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radiosensitizer","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ras-CM and TGF-alpha also increase PI3-K activity downstream of the <e2>GENE-Y<\\e2> and increase postradiation survival, both of which are abrogated by <e1>CHEMICAL<\\e1>  Thus, Ras utilizes autocrine signaling through GENE-Y to increase radioresistance, and the GENE-Y KI CHEMICAL acts as a radiosensitizer","sentence":"Ras-CM and TGF-alpha also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by GW572016  Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radiosensitizer"}
{"PMID":14633707,"re_id":8,"annotated sentence":"Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the <e2>EGFR<\\e2> KI <e1>GW572016<\\e1> acts as a radiosensitizer","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, Ras utilizes autocrine signaling through GENE-Y to increase radioresistance, and the <e2>GENE-Y<\\e2> KI <e1>CHEMICAL<\\e1> acts as a radiosensitizer","sentence":"Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radiosensitizer"}
{"PMID":14633707,"re_id":9,"annotated sentence":"The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with <e1>GW572016<\\e1> demonstrates that <e2>EGFR<\\e2> KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with <e1>CHEMICAL<\\e1> demonstrates that <e2>GENE-Y<\\e2> KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through GENE-Y.","sentence":"The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with GW572016 demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR."}
{"PMID":14660028,"re_id":0,"annotated sentence":"(-)-Isoprenaline and a nonconventional <e2>beta(3)-adrenoceptor<\\e2> agonist, <e1>(+\/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride<\\e1> ((+\/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"(+\/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride","object":"beta(3)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"(-)-Isoprenaline and a nonconventional <e2>GENE-Y<\\e2> agonist, <e1>CHEMICAL<\\e1> ((+\/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations","sentence":"(-)-Isoprenaline and a nonconventional beta(3)-adrenoceptor agonist, (+\/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+\/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations"}
{"PMID":14660028,"re_id":1,"annotated sentence":"(-)-Isoprenaline and a nonconventional <e2>beta(3)-adrenoceptor<\\e2> agonist, (+\/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride (<e1>(+\/-)-CGP12177A<\\e1> , induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"(+\/-)-CGP12177A","object":"beta(3)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"(-)-Isoprenaline and a nonconventional <e2>GENE-Y<\\e2> agonist, (+\/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride (<e1>CHEMICAL<\\e1> , induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations","sentence":"(-)-Isoprenaline and a nonconventional beta(3)-adrenoceptor agonist, (+\/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+\/-)-CGP12177A , induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations"}
{"PMID":14660028,"re_id":2,"annotated sentence":"Pretreatment with a combination of <e1>(+\/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate<\\e1> (CGP20712A, a selective <e2>beta(1)-adrenoceptor<\\e2> antagonist) and (+\/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+\/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"(+\/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate","object":"beta(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with a combination of <e1>CHEMICAL<\\e1> (CGP20712A, a selective <e2>GENE-Y<\\e2> antagonist) and (+\/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+\/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors","sentence":"Pretreatment with a combination of (+\/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+\/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+\/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors"}
{"PMID":14660028,"re_id":3,"annotated sentence":"Pretreatment with a combination of (+\/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (<e1>CGP20712A<\\e1>  a selective <e2>beta(1)-adrenoceptor<\\e2> antagonist) and (+\/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+\/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"CGP20712A","object":"beta(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with a combination of (+\/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (<e1>CHEMICAL<\\e1>  a selective <e2>GENE-Y<\\e2> antagonist) and (+\/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+\/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors","sentence":"Pretreatment with a combination of (+\/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A  a selective beta(1)-adrenoceptor antagonist) and (+\/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+\/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors"}
{"PMID":14660028,"re_id":4,"annotated sentence":"Pretreatment with a combination of (+\/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and <e1>(+\/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride<\\e1> (ICI-118,5511, a selective <e2>beta(2)-adrenoceptor<\\e2> antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+\/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"(+\/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with a combination of (+\/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and <e1>CHEMICAL<\\e1> (ICI-118,5511, a selective <e2>GENE-Y<\\e2> antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+\/-)-CGP12177A was unaffected by the blockade of beta(1)- and GENE-Ys","sentence":"Pretreatment with a combination of (+\/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+\/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+\/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors"}
{"PMID":14660028,"re_id":5,"annotated sentence":"Pretreatment with a combination of (+\/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+\/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (<e1>ICI-118,5511<\\e1>  a selective <e2>beta(2)-adrenoceptor<\\e2> antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+\/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"ICI-118,5511","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with a combination of (+\/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+\/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (<e1>CHEMICAL<\\e1>  a selective <e2>GENE-Y<\\e2> antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+\/-)-CGP12177A was unaffected by the blockade of beta(1)- and GENE-Ys","sentence":"Pretreatment with a combination of (+\/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+\/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511  a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+\/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors"}
{"PMID":14716684,"re_id":2,"annotated sentence":"The specificity of tracer uptake was determined by adding the <e2>NET<\\e2> inhibitor <e1>imipramine<\\e1>  Rat PC12 cells served as positive controls","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"imipramine","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The specificity of tracer uptake was determined by adding the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  Rat PC12 cells served as positive controls","sentence":"The specificity of tracer uptake was determined by adding the NET inhibitor imipramine  Rat PC12 cells served as positive controls"}
{"PMID":14716684,"re_id":3,"annotated sentence":"<e1>[(131)I]MIBG<\\e1> uptake in PC12 cells, which express the <e2>NET<\\e2> endogenously, was 20- to 28-fold lower than in transduced cells","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"[(131)I]MIBG","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> uptake in PC12 cells, which express the <e2>GENE-Y<\\e2> endogenously, was 20- to 28-fold lower than in transduced cells","sentence":"[(131)I]MIBG uptake in PC12 cells, which express the NET endogenously, was 20- to 28-fold lower than in transduced cells"}
{"PMID":14716684,"re_id":4,"annotated sentence":"In vivo, A431<e2>NET<\\e2> tumors demonstrated a 33-fold higher <e1>[(123)I]MIBG<\\e1> uptake than parental tumors","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"[(123)I]MIBG","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vivo, A431<e2>GENE-Y<\\e2> tumors demonstrated a 33-fold higher <e1>CHEMICAL<\\e1> uptake than parental tumors","sentence":"In vivo, A431NET tumors demonstrated a 33-fold higher [(123)I]MIBG uptake than parental tumors"}
{"PMID":14730417,"re_id":0,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, <e1>formoterol<\\e1>  broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"formoterol","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, <e1>CHEMICAL<\\e1>  broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol  broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":1,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, <e1>broxaterol<\\e1>  and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"broxaterol","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, <e1>CHEMICAL<\\e1>  and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol  and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":2,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (<e1>epinephrine<\\e1>  norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"epinephrine","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (<e1>CHEMICAL<\\e1>  norCHEMICAL, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine  norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":3,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, <e1>norepinephrine<\\e1>  isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"norepinephrine","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, <e1>CHEMICAL<\\e1>  isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine  isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":4,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, <e1>isoproterenol<\\e1>  fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"isoproterenol","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, <e1>CHEMICAL<\\e1>  fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol  fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":5,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, <e1>fenoterol<\\e1>  salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"fenoterol","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, <e1>CHEMICAL<\\e1>  salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol  salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":6,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, <e1>salbutamol<\\e1>  salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"salbutamol","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, <e1>CHEMICAL<\\e1>  salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol  salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":7,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, <e1>salmeterol<\\e1>  terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"salmeterol","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, <e1>CHEMICAL<\\e1>  terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol  terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":8,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, <e1>terbutalin<\\e1>  formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"terbutalin","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, <e1>CHEMICAL<\\e1>  formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin  formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":9,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (<e1>propranolol<\\e1>  alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"propranolol","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (<e1>CHEMICAL<\\e1>  alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol  alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":10,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, <e1>alprenolol<\\e1>  atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"alprenolol","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, <e1>CHEMICAL<\\e1>  atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol  atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":11,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, <e1>atenolol<\\e1>  metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"atenolol","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, <e1>CHEMICAL<\\e1>  metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol  metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":12,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, <e1>metoprolol<\\e1>  bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"metoprolol","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, <e1>CHEMICAL<\\e1>  bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol  bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":13,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, <e1>bisoprolol<\\e1>  carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"bisoprolol","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, <e1>CHEMICAL<\\e1>  carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol  carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":14,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, <e1>carvedilol<\\e1>  pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"carvedilol","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, <e1>CHEMICAL<\\e1>  pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol  pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":15,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, <e1>pindolol<\\e1>  BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"pindolol","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, <e1>CHEMICAL<\\e1>  BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol  BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":16,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, <e1>BRL 37344<\\e1>  CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"BRL 37344","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, <e1>CHEMICAL<\\e1>  CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344  CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":17,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, <e1>CGP 20712<\\e1>  SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"CGP 20712","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, <e1>CHEMICAL<\\e1>  SR 59230A, CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712  SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":18,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, <e1>SR 59230A<\\e1>  CGP 12177, ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"SR 59230A","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, <e1>CHEMICAL<\\e1>  CGP 12177, ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A  CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":19,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, <e1>CGP 12177<\\e1>  ICI 118551) at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"CGP 12177","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, <e1>CHEMICAL<\\e1>  ICI 118551) at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177  ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14730417,"re_id":20,"annotated sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, <e1>ICI 118551<\\e1>  at all three subtypes of <e2>human beta-adrenergic receptors<\\e2> in an identical cellular background","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"ICI 118551","object":"human beta-adrenergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, <e1>CHEMICAL<\\e1>  at all three subtypes of <e2>GENE-N<\\e2> in an identical cellular background","sentence":"The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551  at all three subtypes of human beta-adrenergic receptors in an identical cellular background"}
{"PMID":14741265,"re_id":2,"annotated sentence":"Manipulation of kinetic profiles in <e1>2-aryl propionic acid<\\e1> <e2>cyclooxygenase<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"2-aryl propionic acid","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Manipulation of kinetic profiles in <e1>CHEMICAL<\\e1> <e2>GENE-N<\\e2> inhibitors","sentence":"Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors"}
{"PMID":14751502,"re_id":8,"annotated sentence":"Effects of the <e2>EGFR<\\e2> HER2 kinase inhibitor <e1>GW572016<\\e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effects of the <e2>GENE-Y<\\e2> HER2 kinase inhibitor <e1>CHEMICAL<\\e1> on GENE-Y- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance","sentence":"Effects of the EGFR HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance"}
{"PMID":14751502,"re_id":9,"annotated sentence":"Effects of the EGFR\/<e2>HER2<\\e2> kinase inhibitor <e1>GW572016<\\e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"HER2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effects of the EGFR\/<e2>GENE-Y<\\e2> kinase inhibitor <e1>CHEMICAL<\\e1> on EGFR- and GENE-Y-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance","sentence":"Effects of the EGFR\/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance"}
{"PMID":14751502,"re_id":10,"annotated sentence":"Effects of the EGFR\/HER2 <e2>kinase<\\e2> inhibitor <e1>GW572016<\\e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Effects of the EGFR\/HER2 <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance","sentence":"Effects of the EGFR\/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance"}
{"PMID":14751502,"re_id":11,"annotated sentence":"Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of <e1>GW572016<\\e1> to inhibit downstream ERK and Akt activation, despite inhibition of <e2>HER2<\\e2> phosphorylation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"HER2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of <e1>CHEMICAL<\\e1> to inhibit downstream ERK and Akt activation, despite inhibition of <e2>GENE-Y<\\e2> phosphorylation","sentence":"Exploration of potential mechanisms of resistance in SUM185 cells revealed failure of GW572016 to inhibit downstream ERK and Akt activation, despite inhibition of HER2 phosphorylation"}
{"PMID":14751502,"re_id":12,"annotated sentence":"CONCLUSION: <e1>GW572016<\\e1> potently inhibits receptor phosphorylation in either <e2>EGFR<\\e2>  or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: <e1>CHEMICAL<\\e1> potently inhibits receptor phosphorylation in either <e2>GENE-Y<\\e2>  or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects","sentence":"CONCLUSION: GW572016 potently inhibits receptor phosphorylation in either EGFR  or HER2-overexpressing cell lines and has both antiproliferative and radiosensitizing effects"}
{"PMID":14751502,"re_id":13,"annotated sentence":"CONCLUSION: <e1>GW572016<\\e1> potently inhibits receptor phosphorylation in either EGFR- or <e2>HER2<\\e2> overexpressing cell lines and has both antiproliferative and radiosensitizing effects","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"HER2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: <e1>CHEMICAL<\\e1> potently inhibits receptor phosphorylation in either EGFR- or <e2>GENE-Y<\\e2> overexpressing cell lines and has both antiproliferative and radiosensitizing effects","sentence":"CONCLUSION: GW572016 potently inhibits receptor phosphorylation in either EGFR- or HER2 overexpressing cell lines and has both antiproliferative and radiosensitizing effects"}
{"PMID":14751502,"re_id":14,"annotated sentence":"To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual <e2>EGFR<\\e2> HER2 inhibitor, <e1>GW572016<\\e1>  on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To gauge the potential clinical utility of targeting both GENE-Y and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual <e2>GENE-Y<\\e2> HER2 inhibitor, <e1>CHEMICAL<\\e1>  on the proliferation and radiation response of either GENE-Y- or HER2-overexpressing human breast cancer cell lines","sentence":"To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR HER2 inhibitor, GW572016  on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines"}
{"PMID":14751502,"re_id":15,"annotated sentence":"To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR\/<e2>HER2<\\e2> inhibitor, <e1>GW572016<\\e1>  on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"HER2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To gauge the potential clinical utility of targeting both EGFR and GENE-Y to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR\/<e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  on the proliferation and radiation response of either EGFR- or GENE-Y-overexpressing human breast cancer cell lines","sentence":"To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR\/HER2 inhibitor, GW572016  on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines"}
{"PMID":14751502,"re_id":16,"annotated sentence":"RESULTS: <e1>GW572016<\\e1> inhibited constitutive and\/or ligand-induced <e2>EGFR<\\e2> or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> inhibited constitutive and\/or ligand-induced <e2>GENE-Y<\\e2> or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line","sentence":"RESULTS: GW572016 inhibited constitutive and\/or ligand-induced EGFR or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line"}
{"PMID":14751502,"re_id":17,"annotated sentence":"RESULTS: <e1>GW572016<\\e1> inhibited constitutive and\/or ligand-induced EGFR or <e2>HER2<\\e2> tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW572016","object":"HER2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> inhibited constitutive and\/or ligand-induced EGFR or <e2>GENE-Y<\\e2> tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line","sentence":"RESULTS: GW572016 inhibited constitutive and\/or ligand-induced EGFR or HER2 tyrosine phosphorylation of all five cell lines, which correlated with the antiproliferative response in all but one cell line"}
{"PMID":14871885,"re_id":3,"annotated sentence":"Incubation with <e1>metformin<\\e1> (0.2-1 mM) activated <e2>AMPK<\\e2> in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Incubation with <e1>CHEMICAL<\\e1> (0.2-1 mM) activated <e2>GENE-N<\\e2> in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells","sentence":"Incubation with metformin (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells"}
{"PMID":14871885,"re_id":4,"annotated sentence":"<e1>Metformin<\\e1>  a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of <e2>AMP-activated protein kinase<\\e2> (AMPK)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Metformin","object":"AMP-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of <e2>GENE-N<\\e2> (AMPK)","sentence":"Metformin  a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of AMP-activated protein kinase (AMPK)"}
{"PMID":14871885,"re_id":5,"annotated sentence":"<e1>Metformin<\\e1>  a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of AMP-activated protein kinase (<e2>AMPK<\\e2> ","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of AMP-activated protein kinase (<e2>GENE-N<\\e2> ","sentence":"Metformin  a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of AMP-activated protein kinase (AMPK "}
{"PMID":14871885,"re_id":6,"annotated sentence":"Whether <e1>metformin<\\e1> or the satiety factor leptin, which also stimulates <e2>AMPK<\\e2> in muscle, regulates this enzyme in pancreatic islets is unknown","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Whether <e1>CHEMICAL<\\e1> or the satiety factor leptin, which also stimulates <e2>GENE-N<\\e2> in muscle, regulates this enzyme in pancreatic islets is unknown","sentence":"Whether metformin or the satiety factor leptin, which also stimulates AMPK in muscle, regulates this enzyme in pancreatic islets is unknown"}
{"PMID":14871885,"re_id":7,"annotated sentence":"Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on <e1>glucose<\\e1> stimulated <e2>insulin<\\e2> secretion","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on <e1>CHEMICAL<\\e1> stimulated <e2>GENE-N<\\e2> secretion","sentence":"Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose stimulated insulin secretion"}
{"PMID":14871885,"re_id":8,"annotated sentence":"Incubation with <e1>metformin<\\e1> (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of <e2>insulin<\\e2> secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"metformin","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Incubation with <e1>CHEMICAL<\\e1> (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of <e2>GENE-N<\\e2> secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells","sentence":"Incubation with metformin (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells"}
{"PMID":14871885,"re_id":9,"annotated sentence":"The inhibitory effects of <e1>metformin<\\e1> on <e2>insulin<\\e2> secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"metformin","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibitory effects of <e1>CHEMICAL<\\e1> on <e2>GENE-N<\\e2> secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.","sentence":"The inhibitory effects of metformin on insulin secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes."}
{"PMID":14871885,"re_id":10,"annotated sentence":"Increases in <e1>glucose<\\e1> concentration from 0 to 3 and from 3 to 17 mM inhibited <e2>AMPK<\\e2> activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"glucose","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Increases in <e1>CHEMICAL<\\e1> concentration from 0 to 3 and from 3 to 17 mM inhibited <e2>GENE-N<\\e2> activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells","sentence":"Increases in glucose concentration from 0 to 3 and from 3 to 17 mM inhibited AMPK activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells"}
{"PMID":14993281,"re_id":15,"annotated sentence":"A 5'-flanking region capable of supporting <e1>RA<\\e1> induced <e2>blr1<\\e2> activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"RA","object":"blr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A 5'-flanking region capable of supporting <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by CHEMICAL","sentence":"A 5'-flanking region capable of supporting RA induced blr1 activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA"}
{"PMID":14993281,"re_id":16,"annotated sentence":"RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of <e2>blr1<\\e2> expression by <e1>RA<\\e1>  The RA-treated HL-60 cells used here expressed all RA receptor (RAR) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"RA","object":"blr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CHEMICAL is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels CHEMICAL-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of <e2>GENE-Y<\\e2> expression by <e1>CHEMICAL<\\e1>  The CHEMICAL-treated HL-60 cells used here expressed all CHEMICAL receptor (CHEMICALR) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma","sentence":"RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA  The RA-treated HL-60 cells used here expressed all RA receptor (RAR) and retinoid X receptor (RXR) subtypes (as detected by Northern analysis) except RXRgamma"}
{"PMID":14993281,"re_id":17,"annotated sentence":"A novel retinoic acid-responsive element regulates <e1>retinoic acid<\\e1> induced <e2>BLR1<\\e2> expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"retinoic acid","object":"BLR1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A novel CHEMICAL-responsive element regulates <e1>CHEMICAL<\\e1> induced <e2>GENE-N<\\e2> expression","sentence":"A novel retinoic acid-responsive element regulates retinoic acid induced BLR1 expression"}
{"PMID":14993281,"re_id":18,"annotated sentence":"<e1>RA<\\e1> is known to induce expression of the <e2>Burkitt's lymphoma receptor 1<\\e2> (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"RA","object":"Burkitt's lymphoma receptor 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is known to induce expression of the <e2>GENE-Y<\\e2> (BLR1) gene which propels CHEMICAL-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by CHEMICAL","sentence":"RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA"}
{"PMID":14993281,"re_id":19,"annotated sentence":"<e1>RA<\\e1> is known to induce expression of the Burkitt's lymphoma receptor 1 (<e2>BLR1<\\e2>  gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"RA","object":"BLR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is known to induce expression of the Burkitt's lymphoma receptor 1 (<e2>GENE-Y<\\e2>  gene which propels CHEMICAL-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by CHEMICAL","sentence":"RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1  gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA"}
{"PMID":14993281,"re_id":20,"annotated sentence":"In sum the results of the present study indicate that <e1>RA<\\e1> induced expression of <e2>blr1<\\e2> expression depends on a novel RA response element","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"RA","object":"blr1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In sum the results of the present study indicate that <e1>CHEMICAL<\\e1> induced expression of <e2>GENE-Y<\\e2> expression depends on a novel CHEMICAL response element","sentence":"In sum the results of the present study indicate that RA induced expression of blr1 expression depends on a novel RA response element"}
{"PMID":14993281,"re_id":21,"annotated sentence":"The ability of this cis-acting RAR-RXR binding element to activate transcription in response to <e1>RA<\\e1> also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a <e2>nuclear factor of activated T cells<\\e2> (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"RA","object":"nuclear factor of activated T cells","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ability of this cis-acting CHEMICALR-RXR binding element to activate transcription in response to <e1>CHEMICAL<\\e1> also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a <e2>GENE-Y<\\e2> (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary","sentence":"The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary"}
{"PMID":15002740,"re_id":6,"annotated sentence":"The persistent membrane retention of <e1>desipramine<\\e1> causes lasting inhibition of <e2>norepinephrine transporter<\\e2> function","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"desipramine","object":"norepinephrine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The persistent membrane retention of <e1>CHEMICAL<\\e1> causes lasting inhibition of <e2>GENE-Y<\\e2> function","sentence":"The persistent membrane retention of desipramine causes lasting inhibition of norepinephrine transporter function"}
{"PMID":15002740,"re_id":7,"annotated sentence":"[3H]DMI trapped in membranes was displaceable by the structurally unrelated <e2>NET<\\e2> inhibitor, <e1>nisoxetine<\\e1>  in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nisoxetine","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"[3H]DMI trapped in membranes was displaceable by the structurally unrelated <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  in a concentration-dependent manner, implying interaction of retained [3H]DMI with the GENE-Y","sentence":"[3H]DMI trapped in membranes was displaceable by the structurally unrelated NET inhibitor, nisoxetine  in a concentration-dependent manner, implying interaction of retained [3H]DMI with the NET"}
{"PMID":15030294,"re_id":1,"annotated sentence":"<e1>Irbesartan<\\e1> may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of <e2>angiotensin II<\\e2>  Irbesartan given alone or in combination with a diuretic therefore represents a rational approach to treat hypertensive patients.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Irbesartan","object":"angiotensin II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of <e2>GENE-Y<\\e2>  CHEMICAL given alone or in combination with a diuretic therefore represents a rational approach to treat hypertensive patients.","sentence":"Irbesartan may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1-blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II  Irbesartan given alone or in combination with a diuretic therefore represents a rational approach to treat hypertensive patients."}
{"PMID":15030294,"re_id":2,"annotated sentence":"<e1>Irbesartan<\\e1> may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this <e2>AT1<\\e2> blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Irbesartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this <e2>GENE-Y<\\e2> blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II","sentence":"Irbesartan may have antiatherosclerotic properties beyond those expected from blood pressure lowering per se: this AT1 blocker decreases the vascular oxidative stress and prevents the procoagulant as well as the pro-inflammatory effects of angiotensin II"}
{"PMID":15030294,"re_id":3,"annotated sentence":"AT1-receptor antagonism in hypertension: what has been learned with irbesartan? <e1>Irbesartan<\\e1> is a long-acting <e2>angiotensin II<\\e2> antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Irbesartan","object":"angiotensin II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"AT1-receptor antagonism in hypertension: what has been learned with irbesartan? <e1>CHEMICAL<\\e1> is a long-acting <e2>GENE-Y<\\e2> antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor)","sentence":"AT1-receptor antagonism in hypertension: what has been learned with irbesartan? Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1-receptor subtype (AT1-receptor)"}
{"PMID":15060759,"re_id":7,"annotated sentence":"To verify the hypothesis that the non-conventional partial agonist <e1>(-)-CGP12177<\\e1> binds at two beta(1)-adrenoceptor sites, <e2>human beta(1)-adrenoceptors<\\e2>  expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"(-)-CGP12177","object":"human beta(1)-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To verify the hypothesis that the non-conventional partial agonist <e1>CHEMICAL<\\e1> binds at two beta(1)-adrenoceptor sites, <e2>GENE-Y<\\e2>  expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177","sentence":"To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two beta(1)-adrenoceptor sites, human beta(1)-adrenoceptors  expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177"}
{"PMID":15060759,"re_id":8,"annotated sentence":"To verify the hypothesis that the non-conventional partial agonist <e1>(-)-CGP12177<\\e1> binds at two <e2>beta(1)-adrenoceptor<\\e2> sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"(-)-CGP12177","object":"beta(1)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To verify the hypothesis that the non-conventional partial agonist <e1>CHEMICAL<\\e1> binds at two <e2>GENE-Y<\\e2> sites, human GENE-Ys, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177","sentence":"To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two beta(1)-adrenoceptor sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177"}
{"PMID":15072849,"re_id":1,"annotated sentence":"<e1>Imiquimod<\\e1> (IMQ), an activator of <e2>Toll-like receptor-7<\\e2> (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Imiquimod","object":"Toll-like receptor-7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (IMQ), an activator of <e2>GENE-Y<\\e2> (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo","sentence":"Imiquimod (IMQ), an activator of Toll-like receptor-7 (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo"}
{"PMID":15072849,"re_id":2,"annotated sentence":"<e1>Imiquimod<\\e1> (IMQ), an activator of Toll-like receptor-7 (<e2>TLR-7<\\e2> , induces by several routes a profound anti-viral and anti-tumor effect in vivo","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Imiquimod","object":"TLR-7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (IMQ), an activator of Toll-like receptor-7 (<e2>GENE-Y<\\e2> , induces by several routes a profound anti-viral and anti-tumor effect in vivo","sentence":"Imiquimod (IMQ), an activator of Toll-like receptor-7 (TLR-7 , induces by several routes a profound anti-viral and anti-tumor effect in vivo"}
{"PMID":15072849,"re_id":3,"annotated sentence":"Imiquimod (<e1>IMQ<\\e1> , an activator of <e2>Toll-like receptor-7<\\e2> (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"IMQ","object":"Toll-like receptor-7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imiquimod (<e1>CHEMICAL<\\e1> , an activator of <e2>GENE-Y<\\e2> (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo","sentence":"Imiquimod (IMQ , an activator of Toll-like receptor-7 (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo"}
{"PMID":15072849,"re_id":4,"annotated sentence":"Imiquimod (<e1>IMQ<\\e1> , an activator of Toll-like receptor-7 (<e2>TLR-7<\\e2> , induces by several routes a profound anti-viral and anti-tumor effect in vivo","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"IMQ","object":"TLR-7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imiquimod (<e1>CHEMICAL<\\e1> , an activator of Toll-like receptor-7 (<e2>GENE-Y<\\e2> , induces by several routes a profound anti-viral and anti-tumor effect in vivo","sentence":"Imiquimod (IMQ , an activator of Toll-like receptor-7 (TLR-7 , induces by several routes a profound anti-viral and anti-tumor effect in vivo"}
{"PMID":15072849,"re_id":5,"annotated sentence":"Thus, the biological activity of <e1>IMQ<\\e1> appears to exceed its previously known functions, inasmuch as it boosts up significantly the <e2>perforin<\\e2> granule system.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"IMQ","object":"perforin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, the biological activity of <e1>CHEMICAL<\\e1> appears to exceed its previously known functions, inasmuch as it boosts up significantly the <e2>GENE-Y<\\e2> granule system.","sentence":"Thus, the biological activity of IMQ appears to exceed its previously known functions, inasmuch as it boosts up significantly the perforin granule system."}
{"PMID":15072849,"re_id":6,"annotated sentence":"In peripheral lymphocytes of healthy and diseased subjects, <e1>IMQ<\\e1> induced a significant increase of <e2>perforin<\\e2> +) CTLs within 12h in all experiments performed","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"IMQ","object":"perforin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In peripheral lymphocytes of healthy and diseased subjects, <e1>CHEMICAL<\\e1> induced a significant increase of <e2>GENE-Y<\\e2> +) CTLs within 12h in all experiments performed","sentence":"In peripheral lymphocytes of healthy and diseased subjects, IMQ induced a significant increase of perforin +) CTLs within 12h in all experiments performed"}
{"PMID":15072849,"re_id":7,"annotated sentence":"This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of <e2>perforin<\\e2> +) CTLs were induced by 2.5 microg\/ml [corrected] <e1>IMQ<\\e1>  Perforin release from peripheral blood CTLs after PMA\/ionomycin-stimulation was not influenced significantly by IMQ","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"IMQ","object":"perforin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal GENE-Y expression: as compared to GENE-Y(+) CTLs detected at time point zero (100%), up to 270% of <e2>GENE-Y<\\e2> +) CTLs were induced by 2.5 microg\/ml [corrected] <e1>CHEMICAL<\\e1>  Perforin release from peripheral blood CTLs after PMA\/ionomycin-stimulation was not influenced significantly by CHEMICAL","sentence":"This effect was most pronounced in CTLs of patients suffering from atopic dermatitis, a model disorder for subnormal perforin expression: as compared to perforin(+) CTLs detected at time point zero (100%), up to 270% of perforin +) CTLs were induced by 2.5 microg\/ml [corrected] IMQ  Perforin release from peripheral blood CTLs after PMA\/ionomycin-stimulation was not influenced significantly by IMQ"}
{"PMID":15072849,"re_id":8,"annotated sentence":"<e1>Imiquimod<\\e1>  a Toll-like receptor-7 agonist, induces <e2>perforin<\\e2> in cytotoxic T lymphocytes in vitro","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"Imiquimod","object":"perforin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a Toll-like receptor-7 agonist, induces <e2>GENE-Y<\\e2> in cytotoxic T lymphocytes in vitro","sentence":"Imiquimod  a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro"}
{"PMID":15072849,"re_id":9,"annotated sentence":"<e1>Imiquimod<\\e1>  a <e2>Toll-like receptor-7<\\e2> agonist, induces perforin in cytotoxic T lymphocytes in vitro","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"Imiquimod","object":"Toll-like receptor-7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> agonist, induces perforin in cytotoxic T lymphocytes in vitro","sentence":"Imiquimod  a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro"}
{"PMID":15133856,"re_id":0,"annotated sentence":"<e2>Ang II<\\e2> level in plasma and mesenteric arteries in imidapril group was significantly lower than that in <e1>irbesartan<\\e1> group (P<0.05)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"irbesartan","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> level in plasma and mesenteric arteries in imidapril group was significantly lower than that in <e1>CHEMICAL<\\e1> group (P<0.05)","sentence":"Ang II level in plasma and mesenteric arteries in imidapril group was significantly lower than that in irbesartan group (P<0.05)"}
{"PMID":15133856,"re_id":1,"annotated sentence":"The <e2>c-Jun<\\e2> absorbed light value\/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+\/-0.015, which was significantly higher than that in the WKY, <e1>imidapril<\\e1>  and irbesartan groups (0.582+\/-0.013, 0.743+\/-0.012, and 0.789+\/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"imidapril","object":"c-Jun","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> absorbed light value\/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+\/-0.015, which was significantly higher than that in the WKY, <e1>CHEMICAL<\\e1>  and irbesartan groups (0.582+\/-0.013, 0.743+\/-0.012, and 0.789+\/-0.013, respectively, P<0.01), and was significantly lower in CHEMICAL group than in irbesartan group (P<0.05)","sentence":"The c-Jun absorbed light value\/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+\/-0.015, which was significantly higher than that in the WKY, imidapril  and irbesartan groups (0.582+\/-0.013, 0.743+\/-0.012, and 0.789+\/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05)"}
{"PMID":15133856,"re_id":2,"annotated sentence":"The c-Jun absorbed light value\/<e2>GAPDH<\\e2> absorbed light value of mesenteric arteries in the SHR group was 0.850+\/-0.015, which was significantly higher than that in the WKY, <e1>imidapril<\\e1>  and irbesartan groups (0.582+\/-0.013, 0.743+\/-0.012, and 0.789+\/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"imidapril","object":"GAPDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The c-Jun absorbed light value\/<e2>GENE-Y<\\e2> absorbed light value of mesenteric arteries in the SHR group was 0.850+\/-0.015, which was significantly higher than that in the WKY, <e1>CHEMICAL<\\e1>  and irbesartan groups (0.582+\/-0.013, 0.743+\/-0.012, and 0.789+\/-0.013, respectively, P<0.01), and was significantly lower in CHEMICAL group than in irbesartan group (P<0.05)","sentence":"The c-Jun absorbed light value\/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+\/-0.015, which was significantly higher than that in the WKY, imidapril  and irbesartan groups (0.582+\/-0.013, 0.743+\/-0.012, and 0.789+\/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05)"}
{"PMID":15133856,"re_id":3,"annotated sentence":"The <e2>c-Jun<\\e2> absorbed light value\/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+\/-0.015, which was significantly higher than that in the WKY, imidapril, and <e1>irbesartan<\\e1> groups (0.582+\/-0.013, 0.743+\/-0.012, and 0.789+\/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"irbesartan","object":"c-Jun","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> absorbed light value\/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+\/-0.015, which was significantly higher than that in the WKY, imidapril, and <e1>CHEMICAL<\\e1> groups (0.582+\/-0.013, 0.743+\/-0.012, and 0.789+\/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in CHEMICAL group (P<0.05)","sentence":"The c-Jun absorbed light value\/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+\/-0.015, which was significantly higher than that in the WKY, imidapril, and irbesartan groups (0.582+\/-0.013, 0.743+\/-0.012, and 0.789+\/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05)"}
{"PMID":15133856,"re_id":4,"annotated sentence":"The c-Jun absorbed light value\/<e2>GAPDH<\\e2> absorbed light value of mesenteric arteries in the SHR group was 0.850+\/-0.015, which was significantly higher than that in the WKY, imidapril, and <e1>irbesartan<\\e1> groups (0.582+\/-0.013, 0.743+\/-0.012, and 0.789+\/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"irbesartan","object":"GAPDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The c-Jun absorbed light value\/<e2>GENE-Y<\\e2> absorbed light value of mesenteric arteries in the SHR group was 0.850+\/-0.015, which was significantly higher than that in the WKY, imidapril, and <e1>CHEMICAL<\\e1> groups (0.582+\/-0.013, 0.743+\/-0.012, and 0.789+\/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in CHEMICAL group (P<0.05)","sentence":"The c-Jun absorbed light value\/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+\/-0.015, which was significantly higher than that in the WKY, imidapril, and irbesartan groups (0.582+\/-0.013, 0.743+\/-0.012, and 0.789+\/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05)"}
{"PMID":15133856,"re_id":5,"annotated sentence":"<e2>Ang II<\\e2> level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in <e1>irbesartan<\\e1> group and lower in imidapril group","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"irbesartan","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in <e1>CHEMICAL<\\e1> group and lower in imidapril group","sentence":"Ang II level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in imidapril group"}
{"PMID":15133856,"re_id":6,"annotated sentence":"The ratio of <e2>TGF-beta1<\\e2> absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+\/-0.019, which was significantly higher than that in WKY group, <e1>imidapril<\\e1> group, and irbesartan group with the ratios of 0.780+\/-0.018, 0.803+\/-0.005, and 0.847+\/-0.017, respectively (P<0.01)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"imidapril","object":"TGF-beta1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ratio of <e2>GENE-Y<\\e2> absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+\/-0.019, which was significantly higher than that in WKY group, <e1>CHEMICAL<\\e1> group, and irbesartan group with the ratios of 0.780+\/-0.018, 0.803+\/-0.005, and 0.847+\/-0.017, respectively (P<0.01)","sentence":"The ratio of TGF-beta1 absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+\/-0.019, which was significantly higher than that in WKY group, imidapril group, and irbesartan group with the ratios of 0.780+\/-0.018, 0.803+\/-0.005, and 0.847+\/-0.017, respectively (P<0.01)"}
{"PMID":15133856,"re_id":7,"annotated sentence":"The ratio of TGF-beta1 absorbed light value to <e2>GAPDH<\\e2> absorbed light value in the SHR group was 0.887+\/-0.019, which was significantly higher than that in WKY group, <e1>imidapril<\\e1> group, and irbesartan group with the ratios of 0.780+\/-0.018, 0.803+\/-0.005, and 0.847+\/-0.017, respectively (P<0.01)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"imidapril","object":"GAPDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ratio of TGF-beta1 absorbed light value to <e2>GENE-Y<\\e2> absorbed light value in the SHR group was 0.887+\/-0.019, which was significantly higher than that in WKY group, <e1>CHEMICAL<\\e1> group, and irbesartan group with the ratios of 0.780+\/-0.018, 0.803+\/-0.005, and 0.847+\/-0.017, respectively (P<0.01)","sentence":"The ratio of TGF-beta1 absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+\/-0.019, which was significantly higher than that in WKY group, imidapril group, and irbesartan group with the ratios of 0.780+\/-0.018, 0.803+\/-0.005, and 0.847+\/-0.017, respectively (P<0.01)"}
{"PMID":15133856,"re_id":8,"annotated sentence":"The ratio of <e2>TGF-beta1<\\e2> absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+\/-0.019, which was significantly higher than that in WKY group, imidapril group, and <e1>irbesartan<\\e1> group with the ratios of 0.780+\/-0.018, 0.803+\/-0.005, and 0.847+\/-0.017, respectively (P<0.01)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"irbesartan","object":"TGF-beta1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ratio of <e2>GENE-Y<\\e2> absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+\/-0.019, which was significantly higher than that in WKY group, imidapril group, and <e1>CHEMICAL<\\e1> group with the ratios of 0.780+\/-0.018, 0.803+\/-0.005, and 0.847+\/-0.017, respectively (P<0.01)","sentence":"The ratio of TGF-beta1 absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+\/-0.019, which was significantly higher than that in WKY group, imidapril group, and irbesartan group with the ratios of 0.780+\/-0.018, 0.803+\/-0.005, and 0.847+\/-0.017, respectively (P<0.01)"}
{"PMID":15133856,"re_id":9,"annotated sentence":"The ratio of TGF-beta1 absorbed light value to <e2>GAPDH<\\e2> absorbed light value in the SHR group was 0.887+\/-0.019, which was significantly higher than that in WKY group, imidapril group, and <e1>irbesartan<\\e1> group with the ratios of 0.780+\/-0.018, 0.803+\/-0.005, and 0.847+\/-0.017, respectively (P<0.01)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"irbesartan","object":"GAPDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ratio of TGF-beta1 absorbed light value to <e2>GENE-Y<\\e2> absorbed light value in the SHR group was 0.887+\/-0.019, which was significantly higher than that in WKY group, imidapril group, and <e1>CHEMICAL<\\e1> group with the ratios of 0.780+\/-0.018, 0.803+\/-0.005, and 0.847+\/-0.017, respectively (P<0.01)","sentence":"The ratio of TGF-beta1 absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+\/-0.019, which was significantly higher than that in WKY group, imidapril group, and irbesartan group with the ratios of 0.780+\/-0.018, 0.803+\/-0.005, and 0.847+\/-0.017, respectively (P<0.01)"}
{"PMID":15133856,"re_id":10,"annotated sentence":"<e2>Ang II<\\e2> level in plasma and mesenteric arteries in <e1>imidapril<\\e1> group was significantly lower than that in irbesartan group (P<0.05)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"imidapril","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> level in plasma and mesenteric arteries in <e1>CHEMICAL<\\e1> group was significantly lower than that in irbesartan group (P<0.05)","sentence":"Ang II level in plasma and mesenteric arteries in imidapril group was significantly lower than that in irbesartan group (P<0.05)"}
{"PMID":15133856,"re_id":11,"annotated sentence":"CONCLUSION: <e1>Imidapril<\\e1> and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of <e2>TGF-beta1<\\e2>  c-Jun in SHR","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Imidapril","object":"TGF-beta1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: <e1>CHEMICAL<\\e1> and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of <e2>GENE-Y<\\e2>  c-Jun in SHR","sentence":"CONCLUSION: Imidapril and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1  c-Jun in SHR"}
{"PMID":15133856,"re_id":12,"annotated sentence":"CONCLUSION: <e1>Imidapril<\\e1> and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, <e2>c-Jun<\\e2> in SHR","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Imidapril","object":"c-Jun","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: <e1>CHEMICAL<\\e1> and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, <e2>GENE-Y<\\e2> in SHR","sentence":"CONCLUSION: Imidapril and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, c-Jun in SHR"}
{"PMID":15133856,"re_id":13,"annotated sentence":"CONCLUSION: Imidapril and <e1>irbesartan<\\e1> can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of <e2>TGF-beta1<\\e2>  c-Jun in SHR","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"irbesartan","object":"TGF-beta1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Imidapril and <e1>CHEMICAL<\\e1> can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of <e2>GENE-Y<\\e2>  c-Jun in SHR","sentence":"CONCLUSION: Imidapril and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1  c-Jun in SHR"}
{"PMID":15133856,"re_id":14,"annotated sentence":"CONCLUSION: Imidapril and <e1>irbesartan<\\e1> can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, <e2>c-Jun<\\e2> in SHR","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"irbesartan","object":"c-Jun","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Imidapril and <e1>CHEMICAL<\\e1> can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, <e2>GENE-Y<\\e2> in SHR","sentence":"CONCLUSION: Imidapril and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, c-Jun in SHR"}
{"PMID":15133856,"re_id":15,"annotated sentence":"<e2>Ang II<\\e2> level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in <e1>imidapril<\\e1> group","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"imidapril","object":"Ang II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in <e1>CHEMICAL<\\e1> group","sentence":"Ang II level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in imidapril group"}
{"PMID":15184278,"re_id":1,"annotated sentence":"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized <e2>NET<\\e2> by a range of doses of <e1>duloxetine<\\e1> [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"duloxetine","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (GENE-Y) function, we chronically antagonized <e2>GENE-Y<\\e2> by a range of doses of <e1>CHEMICAL<\\e1> [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process","sentence":"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process"}
{"PMID":15184278,"re_id":2,"annotated sentence":"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized <e2>NET<\\e2> by a range of doses of duloxetine [<e1>(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine<\\e1> , which blocks the NE reuptake process","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (GENE-Y) function, we chronically antagonized <e2>GENE-Y<\\e2> by a range of doses of duloxetine [<e1>CHEMICAL<\\e1> , which blocks the NE reuptake process","sentence":"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine , which blocks the NE reuptake process"}
{"PMID":15184278,"re_id":3,"annotated sentence":"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized <e2>NET<\\e2> by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the <e1>NE<\\e1> reuptake process","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"NE","object":"NET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (CHEMICAL) transporter (CHEMICALT) function, we chronically antagonized <e2>CHEMICALT<\\e2> by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the <e1>CHEMICAL<\\e1> reuptake process","sentence":"BACKGROUND: To assess the sensitivity of biochemical, physiological, and pharmacological markers of peripheral norepinephrine (NE) transporter (NET) function, we chronically antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophenepropanamine], which blocks the NE reuptake process"}
{"PMID":15191400,"re_id":0,"annotated sentence":"<e1>Auranofin<\\e1>  an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and <e2>glutathione peroxidase<\\e2>  These enzymes play an important role in protecting cardiac tissue from oxidative stress generated during ischaemia-reperfusion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Auranofin","object":"glutathione peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and <e2>GENE-N<\\e2>  These enzymes play an important role in protecting cardiac tissue from oxidative stress generated during ischaemia-reperfusion","sentence":"Auranofin  an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and glutathione peroxidase  These enzymes play an important role in protecting cardiac tissue from oxidative stress generated during ischaemia-reperfusion"}
{"PMID":15191400,"re_id":1,"annotated sentence":"<e1>Auranofin<\\e1>  an antirheumatic gold compound, is an inhibitor of <e2>selenocysteine enzymes<\\e2>  such as thioredoxin reductase and glutathione peroxidase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Auranofin","object":"selenocysteine enzymes","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  an antirheumatic gold compound, is an inhibitor of <e2>GENE-N<\\e2>  such as thioredoxin reductase and glutathione peroxidase","sentence":"Auranofin  an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes  such as thioredoxin reductase and glutathione peroxidase"}
{"PMID":15191400,"re_id":2,"annotated sentence":"<e1>Auranofin<\\e1>  an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as <e2>thioredoxin reductase<\\e2> and glutathione peroxidase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Auranofin","object":"thioredoxin reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as <e2>GENE-Y<\\e2> and glutathione peroxidase","sentence":"Auranofin  an antirheumatic gold compound, is an inhibitor of selenocysteine enzymes, such as thioredoxin reductase and glutathione peroxidase"}
{"PMID":15191400,"re_id":3,"annotated sentence":"There was significantly less <e2>thioredoxin reductase<\\e2> activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of <e1>auranofin<\\e1> used was able to selectively inhibit one of these enzyme systems","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"auranofin","object":"thioredoxin reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"There was significantly less <e2>GENE-Y<\\e2> activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of <e1>CHEMICAL<\\e1> used was able to selectively inhibit one of these enzyme systems","sentence":"There was significantly less thioredoxin reductase activity in rat liver extracts, whereas the level of glutathione activity remained unchanged, demonstrating that the dose of auranofin used was able to selectively inhibit one of these enzyme systems"}
{"PMID":15206110,"re_id":8,"annotated sentence":"Furthermore, <e1>gallium<\\e1> also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on <e2>vacuolar-type H(+)-ATPases<\\e2>  Apart from the consequences of iron deprivation, gallium exerts cytotoxic effects by direct interaction with the iron-dependent enzyme ribonucleotide reductase, resulting in reduced dNTP pools and inhibition of DNA synthesis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"gallium","object":"vacuolar-type H(+)-ATPases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on <e2>GENE-N<\\e2>  Apart from the consequences of iron deprivation, CHEMICAL exerts cytotoxic effects by direct interaction with the iron-dependent enzyme ribonucleotide reductase, resulting in reduced dNTP pools and inhibition of DNA synthesis","sentence":"Furthermore, gallium also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on vacuolar-type H(+)-ATPases  Apart from the consequences of iron deprivation, gallium exerts cytotoxic effects by direct interaction with the iron-dependent enzyme ribonucleotide reductase, resulting in reduced dNTP pools and inhibition of DNA synthesis"}
{"PMID":15206110,"re_id":9,"annotated sentence":"However, some experimental findings raise the question whether these effects resulting from the <e1>iron<\\e1> mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting <e2>tubulin<\\e2> polymerization","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"iron","object":"tubulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, some experimental findings raise the question whether these effects resulting from the <e1>CHEMICAL<\\e1> mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting <e2>GENE-N<\\e2> polymerization","sentence":"However, some experimental findings raise the question whether these effects resulting from the iron mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting tubulin polymerization"}
{"PMID":15206110,"re_id":10,"annotated sentence":"However, some experimental findings raise the question whether these effects resulting from the iron-mimicking properties of <e1>gallium<\\e1> are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting <e2>tubulin<\\e2> polymerization","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"gallium","object":"tubulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, some experimental findings raise the question whether these effects resulting from the iron-mimicking properties of <e1>CHEMICAL<\\e1> are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting <e2>GENE-N<\\e2> polymerization","sentence":"However, some experimental findings raise the question whether these effects resulting from the iron-mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting tubulin polymerization"}
{"PMID":15240758,"re_id":7,"annotated sentence":"GABA-evoked currents were completely and reversibly blocked by the competitive <e2>GABAA receptor<\\e2> antagonist <e1>bicuculline<\\e1> (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"bicuculline","object":"GABAA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"GABA-evoked currents were completely and reversibly blocked by the competitive <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors","sentence":"GABA-evoked currents were completely and reversibly blocked by the competitive GABAA receptor antagonist bicuculline (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors"}
{"PMID":15286093,"re_id":6,"annotated sentence":"<e2>Histamine H1-receptor<\\e2> (H1R) antagonists, or <e1>antihistamines<\\e1>  often induce sedative side effects when used for the treatment of allergic disorders","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"antihistamines","object":"Histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (H1R) antagonists, or <e1>CHEMICAL<\\e1>  often induce sedative side effects when used for the treatment of allergic disorders","sentence":"Histamine H1-receptor (H1R) antagonists, or antihistamines  often induce sedative side effects when used for the treatment of allergic disorders"}
{"PMID":15286093,"re_id":7,"annotated sentence":"Histamine H1-receptor (<e2>H1R<\\e2>  antagonists, or <e1>antihistamines<\\e1>  often induce sedative side effects when used for the treatment of allergic disorders","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"antihistamines","object":"H1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Histamine H1-receptor (<e2>GENE-Y<\\e2>  antagonists, or <e1>CHEMICAL<\\e1>  often induce sedative side effects when used for the treatment of allergic disorders","sentence":"Histamine H1-receptor (H1R  antagonists, or antihistamines  often induce sedative side effects when used for the treatment of allergic disorders"}
{"PMID":15352500,"re_id":0,"annotated sentence":"A novel membrane sensor for <e2>histamine H1-receptor<\\e2> antagonist \"<e1>fexofenadine<\\e1> ","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"fexofenadine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A novel membrane sensor for <e2>GENE-Y<\\e2> antagonist \"<e1>CHEMICAL<\\e1> ","sentence":"A novel membrane sensor for histamine H1-receptor antagonist \"fexofenadine "}
{"PMID":15353299,"re_id":16,"annotated sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates <e1>ZD1694<\\e1> (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent <e2>TS<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ZD1694","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates <e1>CHEMICAL<\\e1> (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent <e2>GENE-Y<\\e2> inhibitors","sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent TS inhibitors"}
{"PMID":15353299,"re_id":17,"annotated sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (<e1>raltitrexed<\\e1>  Tomudex) and AG337 (Thymitag) are more specific and potent <e2>TS<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"raltitrexed","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (<e1>CHEMICAL<\\e1>  Tomudex) and AG337 (Thymitag) are more specific and potent <e2>GENE-Y<\\e2> inhibitors","sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed  Tomudex) and AG337 (Thymitag) are more specific and potent TS inhibitors"}
{"PMID":15353299,"re_id":18,"annotated sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, <e1>Tomudex<\\e1>  and AG337 (Thymitag) are more specific and potent <e2>TS<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Tomudex","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, <e1>CHEMICAL<\\e1>  and AG337 (Thymitag) are more specific and potent <e2>GENE-Y<\\e2> inhibitors","sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex  and AG337 (Thymitag) are more specific and potent TS inhibitors"}
{"PMID":15353299,"re_id":19,"annotated sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and <e1>AG337<\\e1> (Thymitag) are more specific and potent <e2>TS<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AG337","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and <e1>CHEMICAL<\\e1> (Thymitag) are more specific and potent <e2>GENE-Y<\\e2> inhibitors","sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 (Thymitag) are more specific and potent TS inhibitors"}
{"PMID":15353299,"re_id":20,"annotated sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 (<e1>Thymitag<\\e1>  are more specific and potent <e2>TS<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Thymitag","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 (<e1>CHEMICAL<\\e1>  are more specific and potent <e2>GENE-Y<\\e2> inhibitors","sentence":"While fluoropyrimidine antimetabolites have other sites of action, antifolates ZD1694 (raltitrexed, Tomudex) and AG337 (Thymitag  are more specific and potent TS inhibitors"}
{"PMID":15353299,"re_id":21,"annotated sentence":"<e2>Thymidylate synthase<\\e2> (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT\/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of <e1>2-deoxythymidine-5-monophosphate<\\e1>  a precursor for DNA synthesis","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"2-deoxythymidine-5-monophosphate","object":"Thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT\/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of <e1>CHEMICAL<\\e1>  a precursor for DNA synthesis","sentence":"Thymidylate synthase (TS) continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT\/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate  a precursor for DNA synthesis"}
{"PMID":15353299,"re_id":22,"annotated sentence":"Thymidylate synthase (<e2>TS<\\e2>  continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT\/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of <e1>2-deoxythymidine-5-monophosphate<\\e1>  a precursor for DNA synthesis","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"2-deoxythymidine-5-monophosphate","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thymidylate synthase (<e2>GENE-Y<\\e2>  continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT\/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of <e1>CHEMICAL<\\e1>  a precursor for DNA synthesis","sentence":"Thymidylate synthase (TS  continues to be a critical target for 5-fluorouracil (5-FU) and its prodrugs, UFT\/LV (Orzel), capecitabine (Xeloda), and S-1, primarily because this enzyme is essential for the synthesis of 2-deoxythymidine-5-monophosphate  a precursor for DNA synthesis"}
{"PMID":15353299,"re_id":23,"annotated sentence":"The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that <e2>thymidine phosphorylase<\\e2>  the activating enzyme for <e1>5-FU<\\e1>  is expressed at a higher level in tumor tissue compared with normal tissue counterparts","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"5-FU","object":"thymidine phosphorylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The availability of the CHEMICAL prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that <e2>GENE-Y<\\e2>  the activating enzyme for <e1>CHEMICAL<\\e1>  is expressed at a higher level in tumor tissue compared with normal tissue counterparts","sentence":"The availability of the 5-FU prodrugs offers the possibility of greater therapeutic selectivity based on the demonstration that thymidine phosphorylase  the activating enzyme for 5-FU  is expressed at a higher level in tumor tissue compared with normal tissue counterparts"}
{"PMID":15382615,"re_id":0,"annotated sentence":"<e1>Orlistat<\\e1> is an inhibitor of <e2>pancreatic lipase<\\e2> which is able to block the absorption of 30% of ingested fat","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Orlistat","object":"pancreatic lipase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is an inhibitor of <e2>GENE-N<\\e2> which is able to block the absorption of 30% of ingested fat","sentence":"Orlistat is an inhibitor of pancreatic lipase which is able to block the absorption of 30% of ingested fat"}
{"PMID":15465654,"re_id":1,"annotated sentence":"<e1>Troglitazone<\\e1>  bosentan and glibenclamide inhibit the <e2>bile salt export pump<\\e2> (Bsep) which transports taurocholate into bile","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Troglitazone","object":"bile salt export pump","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  bosentan and glibenclamide inhibit the <e2>GENE-Y<\\e2> (Bsep) which transports taurocholate into bile","sentence":"Troglitazone  bosentan and glibenclamide inhibit the bile salt export pump (Bsep) which transports taurocholate into bile"}
{"PMID":15465654,"re_id":2,"annotated sentence":"<e1>Troglitazone<\\e1>  bosentan and glibenclamide inhibit the bile salt export pump (<e2>Bsep<\\e2>  which transports taurocholate into bile","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Troglitazone","object":"Bsep","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  bosentan and glibenclamide inhibit the bile salt export pump (<e2>GENE-Y<\\e2>  which transports taurocholate into bile","sentence":"Troglitazone  bosentan and glibenclamide inhibit the bile salt export pump (Bsep  which transports taurocholate into bile"}
{"PMID":15465654,"re_id":3,"annotated sentence":"Troglitazone, <e1>bosentan<\\e1> and glibenclamide inhibit the <e2>bile salt export pump<\\e2> (Bsep) which transports taurocholate into bile","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bosentan","object":"bile salt export pump","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Troglitazone, <e1>CHEMICAL<\\e1> and glibenclamide inhibit the <e2>GENE-Y<\\e2> (Bsep) which transports taurocholate into bile","sentence":"Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (Bsep) which transports taurocholate into bile"}
{"PMID":15465654,"re_id":4,"annotated sentence":"Troglitazone, <e1>bosentan<\\e1> and glibenclamide inhibit the bile salt export pump (<e2>Bsep<\\e2>  which transports taurocholate into bile","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bosentan","object":"Bsep","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Troglitazone, <e1>CHEMICAL<\\e1> and glibenclamide inhibit the bile salt export pump (<e2>GENE-Y<\\e2>  which transports taurocholate into bile","sentence":"Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (Bsep  which transports taurocholate into bile"}
{"PMID":15465654,"re_id":5,"annotated sentence":"Troglitazone, bosentan and <e1>glibenclamide<\\e1> inhibit the <e2>bile salt export pump<\\e2> (Bsep) which transports taurocholate into bile","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"glibenclamide","object":"bile salt export pump","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Troglitazone, bosentan and <e1>CHEMICAL<\\e1> inhibit the <e2>GENE-Y<\\e2> (Bsep) which transports taurocholate into bile","sentence":"Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (Bsep) which transports taurocholate into bile"}
{"PMID":15465654,"re_id":6,"annotated sentence":"Troglitazone, bosentan and <e1>glibenclamide<\\e1> inhibit the bile salt export pump (<e2>Bsep<\\e2>  which transports taurocholate into bile","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"glibenclamide","object":"Bsep","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Troglitazone, bosentan and <e1>CHEMICAL<\\e1> inhibit the bile salt export pump (<e2>GENE-Y<\\e2>  which transports taurocholate into bile","sentence":"Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (Bsep  which transports taurocholate into bile"}
{"PMID":15465654,"re_id":7,"annotated sentence":"Troglitazone, bosentan and glibenclamide inhibit the <e2>bile salt export pump<\\e2> (Bsep) which transports <e1>taurocholate<\\e1> into bile","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"taurocholate","object":"bile salt export pump","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Troglitazone, bosentan and glibenclamide inhibit the <e2>GENE-Y<\\e2> (Bsep) which transports <e1>CHEMICAL<\\e1> into bile","sentence":"Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (Bsep) which transports taurocholate into bile"}
{"PMID":15465654,"re_id":8,"annotated sentence":"Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (<e2>Bsep<\\e2>  which transports <e1>taurocholate<\\e1> into bile","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"taurocholate","object":"Bsep","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (<e2>GENE-Y<\\e2>  which transports <e1>CHEMICAL<\\e1> into bile","sentence":"Troglitazone, bosentan and glibenclamide inhibit the bile salt export pump (Bsep  which transports taurocholate into bile"}
{"PMID":15494548,"re_id":9,"annotated sentence":"Unique binding interactions of <e1>valdecoxib<\\e1> with COX-2 translate into a fast rate of inactivation of <e2>COX-2<\\e2> (110,000 M\/s compared with 7000 M\/s for rofecoxib and 80 M\/s for etoricoxib)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"valdecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Unique binding interactions of <e1>CHEMICAL<\\e1> with GENE-Y translate into a fast rate of inactivation of <e2>GENE-Y<\\e2> (110,000 M\/s compared with 7000 M\/s for rofecoxib and 80 M\/s for etoricoxib)","sentence":"Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M\/s compared with 7000 M\/s for rofecoxib and 80 M\/s for etoricoxib)"}
{"PMID":15494548,"re_id":10,"annotated sentence":"We report here the pharmacological properties of a third selective <e2>COX-2<\\e2> inhibitor, <e1>valdecoxib<\\e1>  which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"valdecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report here the pharmacological properties of a third selective <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  which is the most potent and in vitro selective of the marketed GENE-Y inhibitors that we have studied","sentence":"We report here the pharmacological properties of a third selective COX-2 inhibitor, valdecoxib  which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied"}
{"PMID":15494548,"re_id":11,"annotated sentence":"We report here the pharmacological properties of a third selective COX-2 inhibitor, <e1>valdecoxib<\\e1>  which is the most potent and in vitro selective of the marketed <e2>COX-2<\\e2> inhibitors that we have studied","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"valdecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report here the pharmacological properties of a third selective GENE-Y inhibitor, <e1>CHEMICAL<\\e1>  which is the most potent and in vitro selective of the marketed <e2>GENE-Y<\\e2> inhibitors that we have studied","sentence":"We report here the pharmacological properties of a third selective COX-2 inhibitor, valdecoxib  which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied"}
{"PMID":15494548,"re_id":12,"annotated sentence":"<e1>Valdecoxib<\\e1> potently inhibits recombinant <e2>COX-2<\\e2>  with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Valdecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> potently inhibits recombinant <e2>GENE-Y<\\e2>  with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib","sentence":"Valdecoxib potently inhibits recombinant COX-2  with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib"}
{"PMID":15494548,"re_id":13,"annotated sentence":"Valdecoxib potently inhibits recombinant <e2>COX-2<\\e2>  with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for <e1>celecoxib<\\e1>  0.5 microM for rofecoxib, and 5 microM for etoricoxib","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"celecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Valdecoxib potently inhibits recombinant <e2>GENE-Y<\\e2>  with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for <e1>CHEMICAL<\\e1>  0.5 microM for rofecoxib, and 5 microM for etoricoxib","sentence":"Valdecoxib potently inhibits recombinant COX-2  with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib  0.5 microM for rofecoxib, and 5 microM for etoricoxib"}
{"PMID":15494548,"re_id":14,"annotated sentence":"Valdecoxib potently inhibits recombinant <e2>COX-2<\\e2>  with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for <e1>rofecoxib<\\e1>  and 5 microM for etoricoxib","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Valdecoxib potently inhibits recombinant <e2>GENE-Y<\\e2>  with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for <e1>CHEMICAL<\\e1>  and 5 microM for etoricoxib","sentence":"Valdecoxib potently inhibits recombinant COX-2  with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib  and 5 microM for etoricoxib"}
{"PMID":15494548,"re_id":15,"annotated sentence":"Valdecoxib potently inhibits recombinant <e2>COX-2<\\e2>  with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for <e1>etoricoxib<\\e1>  Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M\/s compared with 7000 M\/s for rofecoxib and 80 M\/s for etoricoxib)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"etoricoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Valdecoxib potently inhibits recombinant <e2>GENE-Y<\\e2>  with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for <e1>CHEMICAL<\\e1>  Unique binding interactions of valdecoxib with GENE-Y translate into a fast rate of inactivation of GENE-Y (110,000 M\/s compared with 7000 M\/s for rofecoxib and 80 M\/s for CHEMICAL)","sentence":"Valdecoxib potently inhibits recombinant COX-2  with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib  Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M\/s compared with 7000 M\/s for rofecoxib and 80 M\/s for etoricoxib)"}
{"PMID":15494548,"re_id":16,"annotated sentence":"<e1>Valdecoxib<\\e1> inhibits <e2>COX-1<\\e2> in a competitive fashion only at very high concentrations (IC(50) = 150 microM)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Valdecoxib","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> in a competitive fashion only at very high concentrations (IC(50) = 150 microM)","sentence":"Valdecoxib inhibits COX-1 in a competitive fashion only at very high concentrations (IC(50) = 150 microM)"}
{"PMID":15494548,"re_id":17,"annotated sentence":"<e1>Valdecoxib<\\e1> showed similar activity in the <e2>human whole-blood COX<\\e2> assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Valdecoxib","object":"human whole-blood COX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> showed similar activity in the <e2>GENE-N<\\e2> assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM)","sentence":"Valdecoxib showed similar activity in the human whole-blood COX assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM)"}
{"PMID":15494548,"re_id":18,"annotated sentence":"<e1>Valdecoxib<\\e1> showed similar activity in the human whole-blood COX assay (<e2>COX-2<\\e2> IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Valdecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> showed similar activity in the human whole-blood COX assay (<e2>GENE-Y<\\e2> IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM)","sentence":"Valdecoxib showed similar activity in the human whole-blood COX assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM)"}
{"PMID":15494548,"re_id":19,"annotated sentence":"<e1>Valdecoxib<\\e1> showed similar activity in the human whole-blood COX assay (COX-2 IC(50) = 0.24 microM; <e2>COX-1<\\e2> IC(50) = 21.9 microM)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Valdecoxib","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> showed similar activity in the human whole-blood COX assay (COX-2 IC(50) = 0.24 microM; <e2>GENE-Y<\\e2> IC(50) = 21.9 microM)","sentence":"Valdecoxib showed similar activity in the human whole-blood COX assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM)"}
{"PMID":15494548,"re_id":20,"annotated sentence":"The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing <e1>prostaglandin<\\e1> formation from <e2>COX-1<\\e2>  Celecoxib and rofecoxib were among the molecules developed from these efforts","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing <e1>CHEMICAL<\\e1> formation from <e2>GENE-Y<\\e2>  Celecoxib and rofecoxib were among the molecules developed from these efforts","sentence":"The discovery of a second isoform of cyclooxygenase (COX) led to the search for compounds that could selectively inhibit COX-2 in humans while sparing prostaglandin formation from COX-1  Celecoxib and rofecoxib were among the molecules developed from these efforts"}
{"PMID":15498586,"re_id":0,"annotated sentence":"An angiotensin II AT1 receptor antagonist, <e1>telmisartan<\\e1> augments glucose uptake and <e2>GLUT4<\\e2> protein expression in 3T3-L1 adipocytes","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"telmisartan","object":"GLUT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"An angiotensin II AT1 receptor antagonist, <e1>CHEMICAL<\\e1> augments glucose uptake and <e2>GENE-Y<\\e2> protein expression in 3T3-L1 adipocytes","sentence":"An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes"}
{"PMID":15498586,"re_id":1,"annotated sentence":"Treatment of both differentiating adipocytes and fully differentiated adipocytes with <e1>telmisartan<\\e1> caused a dose-dependent increase in mRNA levels for <e2>PPARgamma<\\e2> target genes such as aP2 and adiponectin","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"telmisartan","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment of both differentiating adipocytes and fully differentiated adipocytes with <e1>CHEMICAL<\\e1> caused a dose-dependent increase in mRNA levels for <e2>GENE-Y<\\e2> target genes such as aP2 and adiponectin","sentence":"Treatment of both differentiating adipocytes and fully differentiated adipocytes with telmisartan caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and adiponectin"}
{"PMID":15498586,"re_id":2,"annotated sentence":"Treatment of both differentiating adipocytes and fully differentiated adipocytes with <e1>telmisartan<\\e1> caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as <e2>aP2<\\e2> and adiponectin","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"telmisartan","object":"aP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment of both differentiating adipocytes and fully differentiated adipocytes with <e1>CHEMICAL<\\e1> caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as <e2>GENE-Y<\\e2> and adiponectin","sentence":"Treatment of both differentiating adipocytes and fully differentiated adipocytes with telmisartan caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and adiponectin"}
{"PMID":15498586,"re_id":3,"annotated sentence":"Treatment of both differentiating adipocytes and fully differentiated adipocytes with <e1>telmisartan<\\e1> caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and <e2>adiponectin<\\e2>  By contrast, telmisartan attenuated 11beta-hydroxysteroid dehydrogenase type 1 mRNA level in differentiated adipocytes","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"telmisartan","object":"adiponectin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment of both differentiating adipocytes and fully differentiated adipocytes with <e1>CHEMICAL<\\e1> caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and <e2>GENE-Y<\\e2>  By contrast, CHEMICAL attenuated 11beta-hydroxysteroid dehydrogenase type 1 mRNA level in differentiated adipocytes","sentence":"Treatment of both differentiating adipocytes and fully differentiated adipocytes with telmisartan caused a dose-dependent increase in mRNA levels for PPARgamma target genes such as aP2 and adiponectin  By contrast, telmisartan attenuated 11beta-hydroxysteroid dehydrogenase type 1 mRNA level in differentiated adipocytes"}
{"PMID":15498586,"re_id":4,"annotated sentence":"By contrast, <e1>telmisartan<\\e1> attenuated <e2>11beta-hydroxysteroid dehydrogenase type 1<\\e2> mRNA level in differentiated adipocytes","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"telmisartan","object":"11beta-hydroxysteroid dehydrogenase type 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"By contrast, <e1>CHEMICAL<\\e1> attenuated <e2>GENE-Y<\\e2> mRNA level in differentiated adipocytes","sentence":"By contrast, telmisartan attenuated 11beta-hydroxysteroid dehydrogenase type 1 mRNA level in differentiated adipocytes"}
{"PMID":15498586,"re_id":5,"annotated sentence":"Of note, we demonstrated for the first time that <e1>telmisartan<\\e1> augmented <e2>GLUT4<\\e2> protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"telmisartan","object":"GLUT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of note, we demonstrated for the first time that <e1>CHEMICAL<\\e1> augmented <e2>GENE-Y<\\e2> protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.","sentence":"Of note, we demonstrated for the first time that telmisartan augmented GLUT4 protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability."}
{"PMID":15498586,"re_id":6,"annotated sentence":"An <e2>angiotensin II AT1 receptor<\\e2> antagonist, <e1>telmisartan<\\e1> augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"telmisartan","object":"angiotensin II AT1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"An <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1> augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes","sentence":"An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes"}
{"PMID":15498586,"re_id":7,"annotated sentence":"An angiotensin II AT1 receptor antagonist, telmisartan augments <e1>glucose<\\e1> uptake and <e2>GLUT4<\\e2> protein expression in 3T3-L1 adipocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glucose","object":"GLUT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"An angiotensin II AT1 receptor antagonist, telmisartan augments <e1>CHEMICAL<\\e1> uptake and <e2>GENE-Y<\\e2> protein expression in 3T3-L1 adipocytes","sentence":"An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes"}
{"PMID":15498586,"re_id":8,"annotated sentence":"Of note, we demonstrated for the first time that telmisartan augmented <e2>GLUT4<\\e2> protein expression and <e1>2-deoxy glucose<\\e1> uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2-deoxy glucose","object":"GLUT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of note, we demonstrated for the first time that telmisartan augmented <e2>GENE-Y<\\e2> protein expression and <e1>CHEMICAL<\\e1> uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability.","sentence":"Of note, we demonstrated for the first time that telmisartan augmented GLUT4 protein expression and 2-deoxy glucose uptake both in basal and insulin-stimulated state of adipocytes, which may contribute, at least partly, to its insulin-sensitizing ability."}
{"PMID":15577244,"re_id":0,"annotated sentence":"Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme <e2>tyrosinase<\\e2>  as compared to the standard tyrosinase inhibitors <e1>kojic acid<\\e1> (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"kojic acid","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme <e2>GENE-Y<\\e2>  as compared to the standard GENE-Y inhibitors <e1>CHEMICAL<\\e1> (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.","sentence":"Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme tyrosinase  as compared to the standard tyrosinase inhibitors kojic acid (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes."}
{"PMID":15577244,"re_id":1,"annotated sentence":"Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme <e2>tyrosinase<\\e2>  as compared to the standard tyrosinase inhibitors kojic acid (IC50=16.67 microM) and <e1>L-mimosine<\\e1> (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"L-mimosine","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme <e2>GENE-Y<\\e2>  as compared to the standard GENE-Y inhibitors kojic acid (IC50=16.67 microM) and <e1>CHEMICAL<\\e1> (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes.","sentence":"Especially, the compound 1 showed strong inhibition (IC50=1.33 microM) against the enzyme tyrosinase  as compared to the standard tyrosinase inhibitors kojic acid (IC50=16.67 microM) and L-mimosine (IC50=3.68 microM), indicating its potential used for the treatment of hyperpigmentation associated with the high production of melanocytes."}
{"PMID":15646817,"re_id":4,"annotated sentence":"In Experiment 2, <e1>TT-235<\\e1> induced a significant decrease (p<0.05) in <e2>oxytocin receptor<\\e2> number and binding affinity at both 0.5 and 4 hours compared with controls","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"TT-235","object":"oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In Experiment 2, <e1>CHEMICAL<\\e1> induced a significant decrease (p<0.05) in <e2>GENE-Y<\\e2> number and binding affinity at both 0.5 and 4 hours compared with controls","sentence":"In Experiment 2, TT-235 induced a significant decrease (p<0.05) in oxytocin receptor number and binding affinity at both 0.5 and 4 hours compared with controls"}
{"PMID":15646817,"re_id":5,"annotated sentence":"In conclusion, <e1>TT-235<\\e1> may inhibit the uterine response to oxytocin by decreasing <e2>oxytocin receptor<\\e2> numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"TT-235","object":"oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> may inhibit the uterine response to oxytocin by decreasing <e2>GENE-Y<\\e2> numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of CHEMICAL.","sentence":"In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235."}
{"PMID":15646817,"re_id":6,"annotated sentence":"In conclusion, <e1>TT-235<\\e1> may inhibit the uterine response to <e2>oxytocin<\\e2> by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TT-235","object":"oxytocin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> may inhibit the uterine response to <e2>GENE-Y<\\e2> by decreasing GENE-Y receptor numbers and GENE-Y binding affinity, which might explain the prolonged GENE-Y antagonist activity of CHEMICAL.","sentence":"In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235."}
{"PMID":15646817,"re_id":7,"annotated sentence":"The purpose of the present study was to confirm the duration of <e1>TT-235<\\e1> to block <e2>oxytocin<\\e2> induced uterine contractions in estrous rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TT-235","object":"oxytocin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The purpose of the present study was to confirm the duration of <e1>CHEMICAL<\\e1> to block <e2>GENE-Y<\\e2> induced uterine contractions in estrous rats","sentence":"The purpose of the present study was to confirm the duration of TT-235 to block oxytocin induced uterine contractions in estrous rats"}
{"PMID":15646817,"re_id":8,"annotated sentence":"Oxytocin antagonist (OTA), <e1>TT-235<\\e1>  was developed by our group and shown to inhibit either spontaneous or <e2>oxytocin<\\e2> induced uterine contractions in primates","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TT-235","object":"oxytocin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Oxytocin antagonist (OTA), <e1>CHEMICAL<\\e1>  was developed by our group and shown to inhibit either spontaneous or <e2>GENE-Y<\\e2> induced uterine contractions in primates","sentence":"Oxytocin antagonist (OTA), TT-235  was developed by our group and shown to inhibit either spontaneous or oxytocin induced uterine contractions in primates"}
{"PMID":15646817,"re_id":9,"annotated sentence":"In Experiment 1, <e1>Antag I<\\e1>  Antag II and TT-235 inhibited the integrated uterine response to <e2>oxytocin<\\e2> at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Antag I","object":"oxytocin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In Experiment 1, <e1>CHEMICAL<\\e1>  CHEMICALI and TT-235 inhibited the integrated uterine response to <e2>GENE-Y<\\e2> at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)","sentence":"In Experiment 1, Antag I  Antag II and TT-235 inhibited the integrated uterine response to oxytocin at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)"}
{"PMID":15646817,"re_id":10,"annotated sentence":"In Experiment 1, Antag I, <e1>Antag II<\\e1> and TT-235 inhibited the integrated uterine response to <e2>oxytocin<\\e2> at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Antag II","object":"oxytocin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In Experiment 1, Antag I, <e1>CHEMICAL<\\e1> and TT-235 inhibited the integrated uterine response to <e2>GENE-Y<\\e2> at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)","sentence":"In Experiment 1, Antag I, Antag II and TT-235 inhibited the integrated uterine response to oxytocin at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)"}
{"PMID":15646817,"re_id":11,"annotated sentence":"In Experiment 1, Antag I, Antag II and <e1>TT-235<\\e1> inhibited the integrated uterine response to <e2>oxytocin<\\e2> at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TT-235","object":"oxytocin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In Experiment 1, Antag I, Antag II and <e1>CHEMICAL<\\e1> inhibited the integrated uterine response to <e2>GENE-Y<\\e2> at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)","sentence":"In Experiment 1, Antag I, Antag II and TT-235 inhibited the integrated uterine response to oxytocin at 5 minutes by 76%, 77% and 80%, respectively, compared to controls (p<0.05)"}
{"PMID":15646817,"re_id":12,"annotated sentence":"In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged <e2>oxytocin<\\e2> antagonist activity of <e1>TT-235<\\e1> ","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"TT-235","object":"oxytocin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, CHEMICAL may inhibit the uterine response to GENE-Y by decreasing GENE-Y receptor numbers and GENE-Y binding affinity, which might explain the prolonged <e2>GENE-Y<\\e2> antagonist activity of <e1>CHEMICAL<\\e1> ","sentence":"In conclusion, TT-235 may inhibit the uterine response to oxytocin by decreasing oxytocin receptor numbers and oxytocin binding affinity, which might explain the prolonged oxytocin antagonist activity of TT-235 "}
{"PMID":15646817,"re_id":13,"annotated sentence":"<e2>Oxytocin<\\e2> antagonist (OTA), <e1>TT-235<\\e1>  was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"TT-235","object":"Oxytocin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> antagonist (OTA), <e1>CHEMICAL<\\e1>  was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates","sentence":"Oxytocin antagonist (OTA), TT-235  was developed by our group and shown to inhibit either spontaneous or oxytocin-induced uterine contractions in primates"}
{"PMID":15655513,"re_id":1,"annotated sentence":"This manuscript presents the preclinical profile of <e1>lumiracoxib<\\e1>  a novel <e2>cyclooxygenase-2<\\e2> (COX-2) selective inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lumiracoxib","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This manuscript presents the preclinical profile of <e1>CHEMICAL<\\e1>  a novel <e2>GENE-Y<\\e2> (COX-2) selective inhibitor","sentence":"This manuscript presents the preclinical profile of lumiracoxib  a novel cyclooxygenase-2 (COX-2) selective inhibitor"}
{"PMID":15655513,"re_id":2,"annotated sentence":"This manuscript presents the preclinical profile of <e1>lumiracoxib<\\e1>  a novel cyclooxygenase-2 (<e2>COX-2<\\e2>  selective inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lumiracoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This manuscript presents the preclinical profile of <e1>CHEMICAL<\\e1>  a novel cyclooxygenase-2 (<e2>GENE-Y<\\e2>  selective inhibitor","sentence":"This manuscript presents the preclinical profile of lumiracoxib  a novel cyclooxygenase-2 (COX-2  selective inhibitor"}
{"PMID":15655513,"re_id":3,"annotated sentence":"Ex vivo, <e1>lumiracoxib<\\e1> inhibited <e2>COX-1<\\e2> derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lumiracoxib","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ex vivo, <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)","sentence":"Ex vivo, lumiracoxib inhibited COX-1 derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)"}
{"PMID":15655513,"re_id":4,"annotated sentence":"Preclinical pharmacology of <e1>lumiracoxib<\\e1>  a novel selective inhibitor of <e2>cyclooxygenase-2<\\e2>  1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lumiracoxib","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preclinical pharmacology of <e1>CHEMICAL<\\e1>  a novel selective inhibitor of <e2>GENE-Y<\\e2>  1","sentence":"Preclinical pharmacology of lumiracoxib  a novel selective inhibitor of cyclooxygenase-2  1"}
{"PMID":15655513,"re_id":5,"annotated sentence":"However, consistent with its low <e2>COX-1<\\e2> inhibitory activity, <e1>lumiracoxib<\\e1> at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lumiracoxib","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, consistent with its low <e2>GENE-Y<\\e2> inhibitory activity, <e1>CHEMICAL<\\e1> at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05)","sentence":"However, consistent with its low COX-1 inhibitory activity, lumiracoxib at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05)"}
{"PMID":15655513,"re_id":6,"annotated sentence":"<e1>Lumiracoxib<\\e1> inhibited purified <e2>COX-1<\\e2> and COX-2 with K(i) values of 3 and 0.06 microM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Lumiracoxib","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited purified <e2>GENE-Y<\\e2> and COX-2 with K(i) values of 3 and 0.06 microM, respectively","sentence":"Lumiracoxib inhibited purified COX-1 and COX-2 with K(i) values of 3 and 0.06 microM, respectively"}
{"PMID":15655513,"re_id":7,"annotated sentence":"<e1>Lumiracoxib<\\e1> inhibited purified COX-1 and <e2>COX-2<\\e2> with K(i) values of 3 and 0.06 microM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Lumiracoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited purified COX-1 and <e2>GENE-Y<\\e2> with K(i) values of 3 and 0.06 microM, respectively","sentence":"Lumiracoxib inhibited purified COX-1 and COX-2 with K(i) values of 3 and 0.06 microM, respectively"}
{"PMID":15655513,"re_id":8,"annotated sentence":"However, consistent with its low <e2>COX-1<\\e2> inhibitory activity, lumiracoxib at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than <e1>diclofenac<\\e1> (P<0.05)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diclofenac","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, consistent with its low <e2>GENE-Y<\\e2> inhibitory activity, lumiracoxib at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than <e1>CHEMICAL<\\e1> (P<0.05)","sentence":"However, consistent with its low COX-1 inhibitory activity, lumiracoxib at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05)"}
{"PMID":15655513,"re_id":9,"annotated sentence":"<e1>Lumiracoxib<\\e1> is a highly selective <e2>COX-2<\\e2> inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Lumiracoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a highly selective <e2>GENE-Y<\\e2> inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.","sentence":"Lumiracoxib is a highly selective COX-2 inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety."}
{"PMID":15655513,"re_id":10,"annotated sentence":"Lumiracoxib is a highly selective <e2>COX-2<\\e2> inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with <e1>diclofenac<\\e1>  the reference NSAID, but with much improved gastrointestinal safety.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diclofenac","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Lumiracoxib is a highly selective <e2>GENE-Y<\\e2> inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with <e1>CHEMICAL<\\e1>  the reference NSAID, but with much improved gastrointestinal safety.","sentence":"Lumiracoxib is a highly selective COX-2 inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac  the reference NSAID, but with much improved gastrointestinal safety."}
{"PMID":15655513,"re_id":11,"annotated sentence":"In cellular assays, <e1>lumiracoxib<\\e1> had an IC(50) of 0.14 microM in <e2>COX-2<\\e2> expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lumiracoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In cellular assays, <e1>CHEMICAL<\\e1> had an IC(50) of 0.14 microM in <e2>GENE-Y<\\e2> expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1)","sentence":"In cellular assays, lumiracoxib had an IC(50) of 0.14 microM in COX-2 expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1)"}
{"PMID":15655513,"re_id":12,"annotated sentence":"In a human whole blood assay, IC(50) values for <e1>lumiracoxib<\\e1> were 0.13 microM for <e2>COX-2<\\e2> and 67 microM for COX-1 (COX-1\/COX-2 selectivity ratio 515)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lumiracoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In a human whole blood assay, IC(50) values for <e1>CHEMICAL<\\e1> were 0.13 microM for <e2>GENE-Y<\\e2> and 67 microM for COX-1 (COX-1\/GENE-Y selectivity ratio 515)","sentence":"In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1\/COX-2 selectivity ratio 515)"}
{"PMID":15655513,"re_id":13,"annotated sentence":"In a human whole blood assay, IC(50) values for <e1>lumiracoxib<\\e1> were 0.13 microM for COX-2 and 67 microM for <e2>COX-1<\\e2> (COX-1\/COX-2 selectivity ratio 515)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lumiracoxib","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In a human whole blood assay, IC(50) values for <e1>CHEMICAL<\\e1> were 0.13 microM for COX-2 and 67 microM for <e2>GENE-Y<\\e2> (GENE-Y\/COX-2 selectivity ratio 515)","sentence":"In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1\/COX-2 selectivity ratio 515)"}
{"PMID":15655513,"re_id":14,"annotated sentence":"In a human whole blood assay, IC(50) values for <e1>lumiracoxib<\\e1> were 0.13 microM for COX-2 and 67 microM for COX-1 (<e2>COX-1<\\e2> COX-2 selectivity ratio 515)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lumiracoxib","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In a human whole blood assay, IC(50) values for <e1>CHEMICAL<\\e1> were 0.13 microM for COX-2 and 67 microM for GENE-Y (<e2>GENE-Y<\\e2> COX-2 selectivity ratio 515)","sentence":"In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1 COX-2 selectivity ratio 515)"}
{"PMID":15655513,"re_id":15,"annotated sentence":"In a human whole blood assay, IC(50) values for <e1>lumiracoxib<\\e1> were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1\/<e2>COX-2<\\e2> selectivity ratio 515)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lumiracoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In a human whole blood assay, IC(50) values for <e1>CHEMICAL<\\e1> were 0.13 microM for GENE-Y and 67 microM for COX-1 (COX-1\/<e2>GENE-Y<\\e2> selectivity ratio 515)","sentence":"In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1\/COX-2 selectivity ratio 515)"}
{"PMID":15655513,"re_id":16,"annotated sentence":"Ex vivo, lumiracoxib inhibited <e2>COX-1<\\e2> derived <e1>thromboxane B(2)<\\e1> (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"thromboxane B(2)","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ex vivo, lumiracoxib inhibited <e2>GENE-Y<\\e2> derived <e1>CHEMICAL<\\e1> (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)","sentence":"Ex vivo, lumiracoxib inhibited COX-1 derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)"}
{"PMID":15655513,"re_id":17,"annotated sentence":"Ex vivo, lumiracoxib inhibited <e2>COX-1<\\e2> derived thromboxane B(2) (<e1>TxB(2)<\\e1>  generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"TxB(2)","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ex vivo, lumiracoxib inhibited <e2>GENE-Y<\\e2> derived thromboxane B(2) (<e1>CHEMICAL<\\e1>  generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)","sentence":"Ex vivo, lumiracoxib inhibited COX-1 derived thromboxane B(2) (TxB(2)  generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)"}
{"PMID":15655513,"re_id":18,"annotated sentence":"Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas <e2>COX-2<\\e2> derived production of <e1>prostaglandin E(2)<\\e1> (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin E(2)","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas <e2>GENE-Y<\\e2> derived production of <e1>CHEMICAL<\\e1> (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)","sentence":"Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2 derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)"}
{"PMID":15655513,"re_id":19,"annotated sentence":"Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas <e2>COX-2<\\e2> derived production of prostaglandin E(2) (<e1>PGE(2)<\\e1>  in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PGE(2)","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas <e2>GENE-Y<\\e2> derived production of prostaglandin E(2) (<e1>CHEMICAL<\\e1>  in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)","sentence":"Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2 derived production of prostaglandin E(2) (PGE(2)  in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1)"}
{"PMID":15664409,"re_id":0,"annotated sentence":"As <e1>thiamine<\\e1> metabolism deficiencies have been seen in placental infarcts previously, these indicate that <e2>PP20<\\e2> hTPK may have a role in placental diseases","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"thiamine","object":"PP20","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As <e1>CHEMICAL<\\e1> metabolism deficiencies have been seen in placental infarcts previously, these indicate that <e2>GENE-Y<\\e2> hTPK may have a role in placental diseases","sentence":"As thiamine metabolism deficiencies have been seen in placental infarcts previously, these indicate that PP20 hTPK may have a role in placental diseases"}
{"PMID":15664409,"re_id":1,"annotated sentence":"As <e1>thiamine<\\e1> metabolism deficiencies have been seen in placental infarcts previously, these indicate that PP20\/<e2>hTPK<\\e2> may have a role in placental diseases","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"thiamine","object":"hTPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As <e1>CHEMICAL<\\e1> metabolism deficiencies have been seen in placental infarcts previously, these indicate that PP20\/<e2>GENE-Y<\\e2> may have a role in placental diseases","sentence":"As thiamine metabolism deficiencies have been seen in placental infarcts previously, these indicate that PP20\/hTPK may have a role in placental diseases"}
{"PMID":15704203,"re_id":0,"annotated sentence":"<e1>Denufosol<\\e1> is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated <e2>P2Y(2)<\\e2> agonists","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"Denufosol","object":"P2Y(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated <e2>GENE-Y<\\e2> agonists","sentence":"Denufosol is metabolically more stable and better tolerated, and may enhance mucociliary clearance for a longer period of time than previously investigated P2Y(2) agonists"}
{"PMID":15704203,"re_id":1,"annotated sentence":"Safety and tolerability of <e1>denufosol tetrasodium<\\e1> inhalation solution, a novel <e2>P2Y2 receptor<\\e2> agonist: results of a phase 1\/phase 2 multicenter study in mild to moderate cystic fibrosis","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"denufosol tetrasodium","object":"P2Y2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Safety and tolerability of <e1>CHEMICAL<\\e1> inhalation solution, a novel <e2>GENE-Y<\\e2> agonist: results of a phase 1\/phase 2 multicenter study in mild to moderate cystic fibrosis","sentence":"Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1\/phase 2 multicenter study in mild to moderate cystic fibrosis"}
{"PMID":15704203,"re_id":2,"annotated sentence":"<e1>Denufosol tetrasodium<\\e1> (INS37217) is a selective <e2>P2Y(2)<\\e2> agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"Denufosol tetrasodium","object":"P2Y(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (INS37217) is a selective <e2>GENE-Y<\\e2> agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF","sentence":"Denufosol tetrasodium (INS37217) is a selective P2Y(2) agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF"}
{"PMID":15704203,"re_id":3,"annotated sentence":"Denufosol tetrasodium (<e1>INS37217<\\e1>  is a selective <e2>P2Y(2)<\\e2> agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"INS37217","object":"P2Y(2)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Denufosol tetrasodium (<e1>CHEMICAL<\\e1>  is a selective <e2>GENE-Y<\\e2> agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF","sentence":"Denufosol tetrasodium (INS37217  is a selective P2Y(2) agonist that stimulates ciliary beat frequency and Cl(-) secretion in normal and cystic fibrosis (CF) airway epithelia, and is being investigated as an inhaled treatment for CF"}
{"PMID":15704203,"re_id":4,"annotated sentence":"The <e1>Cl(-)<\\e1> secretory response is mediated via a non-<e2>CFTR<\\e2> pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Cl(-)","object":"CFTR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> secretory response is mediated via a non-<e2>GENE-Y<\\e2> pathway, and the driving force for CHEMICAL secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport","sentence":"The Cl(-) secretory response is mediated via a non-CFTR pathway, and the driving force for Cl(-) secretion is enhanced by the effect of P2Y(2) activation to also inhibit epithelial Na(+) transport"}
{"PMID":15723099,"re_id":7,"annotated sentence":"Dimemorfan pre-treatment also attenuated the <e1>KA<\\e1> induced increases in c-fos\/c-jun expression, <e2>activator protein (AP)-1<\\e2> DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"KA","object":"activator protein (AP)-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dimemorfan pre-treatment also attenuated the <e1>CHEMICAL<\\e1> induced increases in c-fos\/c-jun expression, <e2>GENE-Y<\\e2> DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus","sentence":"Dimemorfan pre-treatment also attenuated the KA induced increases in c-fos\/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus"}
{"PMID":15723099,"re_id":8,"annotated sentence":"The dextromethorphan analog <e1>dimemorfan<\\e1> attenuates kainate-induced seizures via <e2>sigma1 receptor<\\e2> activation: comparison with the effects of dextromethorphan","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"dimemorfan","object":"sigma1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The dextromethorphan analog <e1>CHEMICAL<\\e1> attenuates kainate-induced seizures via <e2>GENE-Y<\\e2> activation: comparison with the effects of dextromethorphan","sentence":"The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan"}
{"PMID":15723099,"re_id":9,"annotated sentence":"The <e1>dextromethorphan<\\e1> analog dimemorfan attenuates kainate-induced seizures via <e2>sigma1 receptor<\\e2> activation: comparison with the effects of dextromethorphan","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"dextromethorphan","object":"sigma1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> analog dimemorfan attenuates kainate-induced seizures via <e2>GENE-Y<\\e2> activation: comparison with the effects of CHEMICAL","sentence":"The dextromethorphan analog dimemorfan attenuates kainate-induced seizures via sigma1 receptor activation: comparison with the effects of dextromethorphan"}
{"PMID":15723099,"re_id":10,"annotated sentence":"Dimemorfan pre-treatment also attenuated the <e1>KA<\\e1> induced increases in <e2>c-fos<\\e2> c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"KA","object":"c-fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dimemorfan pre-treatment also attenuated the <e1>CHEMICAL<\\e1> induced increases in <e2>GENE-Y<\\e2> c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus","sentence":"Dimemorfan pre-treatment also attenuated the KA induced increases in c-fos c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus"}
{"PMID":15723099,"re_id":11,"annotated sentence":"Dimemorfan pre-treatment also attenuated the <e1>KA<\\e1> induced increases in c-fos\/<e2>c-jun<\\e2> expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"KA","object":"c-jun","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dimemorfan pre-treatment also attenuated the <e1>CHEMICAL<\\e1> induced increases in c-fos\/<e2>GENE-Y<\\e2> expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus","sentence":"Dimemorfan pre-treatment also attenuated the KA induced increases in c-fos\/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus"}
{"PMID":15723099,"re_id":12,"annotated sentence":"<e1>Dimemorfan<\\e1> pre-treatment also attenuated the KA-induced increases in <e2>c-fos<\\e2> c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Dimemorfan","object":"c-fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> pre-treatment also attenuated the KA-induced increases in <e2>GENE-Y<\\e2> c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus","sentence":"Dimemorfan pre-treatment also attenuated the KA-induced increases in c-fos c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus"}
{"PMID":15723099,"re_id":13,"annotated sentence":"<e1>Dimemorfan<\\e1> pre-treatment also attenuated the KA-induced increases in c-fos\/<e2>c-jun<\\e2> expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Dimemorfan","object":"c-jun","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> pre-treatment also attenuated the KA-induced increases in c-fos\/<e2>GENE-Y<\\e2> expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus","sentence":"Dimemorfan pre-treatment also attenuated the KA-induced increases in c-fos\/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus"}
{"PMID":15723099,"re_id":14,"annotated sentence":"<e1>Dimemorfan<\\e1> pre-treatment also attenuated the KA-induced increases in c-fos\/c-jun expression, <e2>activator protein (AP)-1<\\e2> DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Dimemorfan","object":"activator protein (AP)-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> pre-treatment also attenuated the KA-induced increases in c-fos\/c-jun expression, <e2>GENE-Y<\\e2> DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus","sentence":"Dimemorfan pre-treatment also attenuated the KA-induced increases in c-fos\/c-jun expression, activator protein (AP)-1 DNA-binding activity, and loss of cells in the CA1 and CA3 fields of the hippocampus"}
{"PMID":15723099,"re_id":15,"annotated sentence":"The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective <e2>sigma1 receptor<\\e2> antagonist <e1>BD 1047<\\e1>  suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"BD 1047","object":"sigma1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1>  suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to GENE-Y-activated modulation of AP-1 transcription factors","sentence":"The anticonvulsant action of dextromethorphan or dimemorfan was significantly counteracted by a selective sigma1 receptor antagonist BD 1047  suggesting that the anticonvulsant action of dextromethorphan or dimemorfan is, at least in part, related to sigma1 receptor-activated modulation of AP-1 transcription factors"}
{"PMID":15740719,"re_id":6,"annotated sentence":"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined <e2>vasopressin V1A\/oxytocin receptor<\\e2> antagonist atosiban and the agonists <e1>oxytocin<\\e1> and carbetocin","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"oxytocin","object":"vasopressin V1A\/oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have analyzed binding domains of the CHEMICAL receptor for barusiban, a highly selective CHEMICAL receptor antagonist, in comparison to the combined <e2>vasopressin V1A\/CHEMICAL receptor<\\e2> antagonist atosiban and the agonists <e1>CHEMICAL<\\e1> and carbetocin","sentence":"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A\/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin"}
{"PMID":15740719,"re_id":7,"annotated sentence":"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined <e2>vasopressin V1A\/oxytocin receptor<\\e2> antagonist atosiban and the agonists oxytocin and <e1>carbetocin<\\e1>  For this purpose, chimeric 'gain-in function' oxytocin\/vasopressin V2 receptors were expressed in COS-7 cells","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"carbetocin","object":"vasopressin V1A\/oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined <e2>GENE-N<\\e2> antagonist atosiban and the agonists oxytocin and <e1>CHEMICAL<\\e1>  For this purpose, chimeric 'gain-in function' oxytocin\/vasopressin V2 receptors were expressed in COS-7 cells","sentence":"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A\/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin  For this purpose, chimeric 'gain-in function' oxytocin\/vasopressin V2 receptors were expressed in COS-7 cells"}
{"PMID":15740719,"re_id":8,"annotated sentence":"Binding domains of the oxytocin receptor for the selective <e2>oxytocin receptor<\\e2> antagonist barusiban in comparison to the agonists <e1>oxytocin<\\e1> and carbetocin","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"oxytocin","object":"oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Binding domains of the CHEMICAL receptor for the selective <e2>CHEMICAL receptor<\\e2> antagonist barusiban in comparison to the agonists <e1>CHEMICAL<\\e1> and carbetocin","sentence":"Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin"}
{"PMID":15740719,"re_id":9,"annotated sentence":"Binding domains of the oxytocin receptor for the selective <e2>oxytocin receptor<\\e2> antagonist barusiban in comparison to the agonists oxytocin and <e1>carbetocin<\\e1>  We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A\/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"carbetocin","object":"oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Binding domains of the GENE-Y for the selective <e2>GENE-Y<\\e2> antagonist barusiban in comparison to the agonists oxytocin and <e1>CHEMICAL<\\e1>  We have analyzed binding domains of the GENE-Y for barusiban, a highly selective GENE-Y antagonist, in comparison to the combined vasopressin V1A\/GENE-Y antagonist atosiban and the agonists oxytocin and CHEMICAL","sentence":"Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin  We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A\/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin"}
{"PMID":15740719,"re_id":10,"annotated sentence":"The binding domain of barusiban differs from the binding domain of the agonists and the nonselective <e2>oxytocin receptor<\\e2> antagonist <e1>d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin<\\e1> that has been used in previous studies","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin","object":"oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The binding domain of barusiban differs from the binding domain of the agonists and the nonselective <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> that has been used in previous studies","sentence":"The binding domain of barusiban differs from the binding domain of the agonists and the nonselective oxytocin receptor antagonist d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin that has been used in previous studies"}
{"PMID":15740719,"re_id":11,"annotated sentence":"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined <e2>vasopressin V1A\/oxytocin receptor<\\e2> antagonist <e1>atosiban<\\e1> and the agonists oxytocin and carbetocin","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"atosiban","object":"vasopressin V1A\/oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> and the agonists oxytocin and carbetocin","sentence":"We have analyzed binding domains of the oxytocin receptor for barusiban, a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A\/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin"}
{"PMID":15740719,"re_id":12,"annotated sentence":"We have analyzed binding domains of the oxytocin receptor for <e1>barusiban<\\e1>  a highly selective <e2>oxytocin receptor<\\e2> antagonist, in comparison to the combined vasopressin V1A\/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"barusiban","object":"oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have analyzed binding domains of the GENE-Y for <e1>CHEMICAL<\\e1>  a highly selective <e2>GENE-Y<\\e2> antagonist, in comparison to the combined vasopressin V1A\/GENE-Y antagonist atosiban and the agonists oxytocin and carbetocin","sentence":"We have analyzed binding domains of the oxytocin receptor for barusiban  a highly selective oxytocin receptor antagonist, in comparison to the combined vasopressin V1A\/oxytocin receptor antagonist atosiban and the agonists oxytocin and carbetocin"}
{"PMID":15740719,"re_id":13,"annotated sentence":"Binding domains of the oxytocin receptor for the selective <e2>oxytocin receptor<\\e2> antagonist <e1>barusiban<\\e1> in comparison to the agonists oxytocin and carbetocin","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"barusiban","object":"oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Binding domains of the GENE-Y for the selective <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> in comparison to the agonists oxytocin and carbetocin","sentence":"Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin"}
{"PMID":15740719,"re_id":14,"annotated sentence":"For the <e2>vasopressin V1A\/oxytocin receptor<\\e2> antagonist <e1>atosiban<\\e1>  none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"atosiban","object":"vasopressin V1A\/oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"For the <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1>  none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor","sentence":"For the vasopressin V1A\/oxytocin receptor antagonist atosiban  none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor"}
{"PMID":15795105,"re_id":2,"annotated sentence":"However, the flowcytometric analysis revealed that <e1>AZC<\\e1> and PCA decreased intracellular contents of <e2>CD3-zeta chain<\\e2> in these cells in dose dependent manner","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"AZC","object":"CD3-zeta chain","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, the flowcytometric analysis revealed that <e1>CHEMICAL<\\e1> and PCA decreased intracellular contents of <e2>GENE-Y<\\e2> in these cells in dose dependent manner","sentence":"However, the flowcytometric analysis revealed that AZC and PCA decreased intracellular contents of CD3-zeta chain in these cells in dose dependent manner"}
{"PMID":15795105,"re_id":3,"annotated sentence":"However, the flowcytometric analysis revealed that AZC and <e1>PCA<\\e1> decreased intracellular contents of <e2>CD3-zeta chain<\\e2> in these cells in dose dependent manner","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"PCA","object":"CD3-zeta chain","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, the flowcytometric analysis revealed that AZC and <e1>CHEMICAL<\\e1> decreased intracellular contents of <e2>GENE-Y<\\e2> in these cells in dose dependent manner","sentence":"However, the flowcytometric analysis revealed that AZC and PCA decreased intracellular contents of CD3-zeta chain in these cells in dose dependent manner"}
{"PMID":15795105,"re_id":4,"annotated sentence":"The compounds <e1>5'-azacytidine<\\e1> (AZC) and procainamide (PCA) belong to inhibitors of <e2>DNMT1<\\e2>  whose low activity correlates with increase in transcription of various genes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"5'-azacytidine","object":"DNMT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The compounds <e1>CHEMICAL<\\e1> (AZC) and procainamide (PCA) belong to inhibitors of <e2>GENE-Y<\\e2>  whose low activity correlates with increase in transcription of various genes","sentence":"The compounds 5'-azacytidine (AZC) and procainamide (PCA) belong to inhibitors of DNMT1  whose low activity correlates with increase in transcription of various genes"}
{"PMID":15795105,"re_id":5,"annotated sentence":"The compounds 5'-azacytidine (<e1>AZC<\\e1>  and procainamide (PCA) belong to inhibitors of <e2>DNMT1<\\e2>  whose low activity correlates with increase in transcription of various genes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AZC","object":"DNMT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The compounds 5'-azacytidine (<e1>CHEMICAL<\\e1>  and procainamide (PCA) belong to inhibitors of <e2>GENE-Y<\\e2>  whose low activity correlates with increase in transcription of various genes","sentence":"The compounds 5'-azacytidine (AZC  and procainamide (PCA) belong to inhibitors of DNMT1  whose low activity correlates with increase in transcription of various genes"}
{"PMID":15795105,"re_id":6,"annotated sentence":"The compounds 5'-azacytidine (AZC) and <e1>procainamide<\\e1> (PCA) belong to inhibitors of <e2>DNMT1<\\e2>  whose low activity correlates with increase in transcription of various genes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"procainamide","object":"DNMT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The compounds 5'-azacytidine (AZC) and <e1>CHEMICAL<\\e1> (PCA) belong to inhibitors of <e2>GENE-Y<\\e2>  whose low activity correlates with increase in transcription of various genes","sentence":"The compounds 5'-azacytidine (AZC) and procainamide (PCA) belong to inhibitors of DNMT1  whose low activity correlates with increase in transcription of various genes"}
{"PMID":15795105,"re_id":7,"annotated sentence":"The compounds 5'-azacytidine (AZC) and procainamide (<e1>PCA<\\e1>  belong to inhibitors of <e2>DNMT1<\\e2>  whose low activity correlates with increase in transcription of various genes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PCA","object":"DNMT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The compounds 5'-azacytidine (AZC) and procainamide (<e1>CHEMICAL<\\e1>  belong to inhibitors of <e2>GENE-Y<\\e2>  whose low activity correlates with increase in transcription of various genes","sentence":"The compounds 5'-azacytidine (AZC) and procainamide (PCA  belong to inhibitors of DNMT1  whose low activity correlates with increase in transcription of various genes"}
{"PMID":15866500,"re_id":0,"annotated sentence":"These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to <e2>TS<\\e2> inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (<e1>FdUMP<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"FdUMP","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to <e2>GENE-Y<\\e2> inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (<e1>CHEMICAL<\\e1> ","sentence":"These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to TS inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (FdUMP "}
{"PMID":15866500,"re_id":1,"annotated sentence":"Clinical studies in cancer patients treated with the new <e1>fluoropyrimidine<\\e1> analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of <e2>thymidylate synthase<\\e2> (TS)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"fluoropyrimidine","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clinical studies in cancer patients treated with the new <e1>CHEMICAL<\\e1> analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of <e2>GENE-Y<\\e2> (TS)","sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS)"}
{"PMID":15866500,"re_id":2,"annotated sentence":"Clinical studies in cancer patients treated with the new <e1>fluoropyrimidine<\\e1> analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (<e2>TS<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"fluoropyrimidine","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clinical studies in cancer patients treated with the new <e1>CHEMICAL<\\e1> analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (<e2>GENE-Y<\\e2> ","sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS "}
{"PMID":15866500,"re_id":3,"annotated sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue <e1>capecitabine<\\e1> (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of <e2>thymidylate synthase<\\e2> (TS)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"capecitabine","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue <e1>CHEMICAL<\\e1> (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of <e2>GENE-Y<\\e2> (TS)","sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS)"}
{"PMID":15866500,"re_id":4,"annotated sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue <e1>capecitabine<\\e1> (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (<e2>TS<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"capecitabine","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue <e1>CHEMICAL<\\e1> (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (<e2>GENE-Y<\\e2> ","sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS "}
{"PMID":15866500,"re_id":5,"annotated sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (<e1>N4-pentoxycarbonyl-5'-5-fluorocytidine<\\e1>  have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of <e2>thymidylate synthase<\\e2> (TS)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"N4-pentoxycarbonyl-5'-5-fluorocytidine","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (<e1>CHEMICAL<\\e1>  have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of <e2>GENE-Y<\\e2> (TS)","sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine  have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS)"}
{"PMID":15866500,"re_id":6,"annotated sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (<e1>N4-pentoxycarbonyl-5'-5-fluorocytidine<\\e1>  have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (<e2>TS<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"N4-pentoxycarbonyl-5'-5-fluorocytidine","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (<e1>CHEMICAL<\\e1>  have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (<e2>GENE-Y<\\e2> ","sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine  have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS "}
{"PMID":15866500,"re_id":7,"annotated sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma <e1>2'-deoxyuridine<\\e1> was significantly elevated after 1 week of treatment, consistent with inhibition of <e2>thymidylate synthase<\\e2> (TS)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"2'-deoxyuridine","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma <e1>CHEMICAL<\\e1> was significantly elevated after 1 week of treatment, consistent with inhibition of <e2>GENE-Y<\\e2> (TS)","sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS)"}
{"PMID":15866500,"re_id":8,"annotated sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma <e1>2'-deoxyuridine<\\e1> was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (<e2>TS<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"2'-deoxyuridine","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma <e1>CHEMICAL<\\e1> was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (<e2>GENE-Y<\\e2> ","sentence":"Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS "}
{"PMID":15866500,"re_id":9,"annotated sentence":"These findings suggest that the mechanism of antiproliferative toxicity of <e1>capecitabine<\\e1> is at least partly due to <e2>TS<\\e2> inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (FdUMP)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"capecitabine","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings suggest that the mechanism of antiproliferative toxicity of <e1>CHEMICAL<\\e1> is at least partly due to <e2>GENE-Y<\\e2> inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (FdUMP)","sentence":"These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to TS inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (FdUMP)"}
{"PMID":15866500,"re_id":10,"annotated sentence":"These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to <e2>TS<\\e2> inhibitory activity of its active metabolite <e1>5-fluoro-2'-deoxyuridine monophosphate<\\e1> (FdUMP)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"5-fluoro-2'-deoxyuridine monophosphate","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to <e2>GENE-Y<\\e2> inhibitory activity of its active metabolite <e1>CHEMICAL<\\e1> (FdUMP)","sentence":"These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to TS inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (FdUMP)"}
{"PMID":15887238,"re_id":6,"annotated sentence":"<e1>Imatinib<\\e1> induced changes were blocked with the EGFR antagonist cetuximab, which suggested direct involvement of <e2>EGFR<\\e2> in this process","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Imatinib","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced changes were blocked with the GENE-Y antagonist cetuximab, which suggested direct involvement of <e2>GENE-Y<\\e2> in this process","sentence":"Imatinib induced changes were blocked with the EGFR antagonist cetuximab, which suggested direct involvement of EGFR in this process"}
{"PMID":15887238,"re_id":7,"annotated sentence":"Western blot analysis of cells incubated with <e1>imatinib<\\e1> demonstrated activation of <e2>EGFR<\\e2> and downstream signaling that was reduced by inhibition of mitogen-activated protein\/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2\/ErbB2","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imatinib","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Western blot analysis of cells incubated with <e1>CHEMICAL<\\e1> demonstrated activation of <e2>GENE-Y<\\e2> and downstream signaling that was reduced by inhibition of mitogen-activated protein\/extracellular signal-regulated kinase kinase 1 (MEK1) and GENE-Y, but not Her2\/ErbB2","sentence":"Western blot analysis of cells incubated with imatinib demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein\/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2\/ErbB2"}
{"PMID":15887238,"re_id":8,"annotated sentence":"Induction of heparin-binding EGF-like growth factor and activation of <e2>EGF receptor<\\e2> in <e1>imatinib mesylate<\\e1> treated squamous carcinoma cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imatinib mesylate","object":"EGF receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Induction of heparin-binding EGF-like growth factor and activation of <e2>GENE-Y<\\e2> in <e1>CHEMICAL<\\e1> treated squamous carcinoma cells","sentence":"Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate treated squamous carcinoma cells"}
{"PMID":15887238,"re_id":9,"annotated sentence":"Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced <e1>imatinib<\\e1> mediated <e2>mitogen activated protein kinase<\\e2> (MAPK) activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imatinib","object":"mitogen activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced <e1>CHEMICAL<\\e1> mediated <e2>GENE-N<\\e2> (MAPK) activation","sentence":"Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced imatinib mediated mitogen activated protein kinase (MAPK) activation"}
{"PMID":15887238,"re_id":10,"annotated sentence":"Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced <e1>imatinib<\\e1> mediated mitogen activated protein kinase (<e2>MAPK<\\e2>  activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imatinib","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced <e1>CHEMICAL<\\e1> mediated mitogen activated protein kinase (<e2>GENE-N<\\e2>  activation","sentence":"Inhibitors and neutralizing antibodies against heparin-binding epidermal growth factor-like growth factor (HB-EGF), and to a lesser extent transforming growth factor-alpha, reduced imatinib mediated mitogen activated protein kinase (MAPK  activation"}
{"PMID":15887238,"re_id":11,"annotated sentence":"<e1>Imatinib<\\e1> stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic <e2>MAPK<\\e2> activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Imatinib","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic <e2>GENE-N<\\e2> activation","sentence":"Imatinib stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic MAPK activation"}
{"PMID":15887238,"re_id":12,"annotated sentence":"Although, <e1>imatinib<\\e1> primarily inhibits tyrosine kinases, it also stimulates the activity of <e2>EGFR<\\e2> tyrosine kinase in head and neck squamous tumors","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imatinib","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although, <e1>CHEMICAL<\\e1> primarily inhibits tyrosine kinases, it also stimulates the activity of <e2>GENE-Y<\\e2> tyrosine kinase in head and neck squamous tumors","sentence":"Although, imatinib primarily inhibits tyrosine kinases, it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors"}
{"PMID":15887238,"re_id":13,"annotated sentence":"Although, <e1>imatinib<\\e1> primarily inhibits tyrosine kinases, it also stimulates the activity of EGFR <e2>tyrosine kinase<\\e2> in head and neck squamous tumors","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imatinib","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although, <e1>CHEMICAL<\\e1> primarily inhibits GENE-Ns, it also stimulates the activity of EGFR <e2>GENE-N<\\e2> in head and neck squamous tumors","sentence":"Although, imatinib primarily inhibits tyrosine kinases, it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors"}
{"PMID":15887238,"re_id":14,"annotated sentence":"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>imatinib<\\e1> induced changes in cell morphology and growth similar to changes associated with <e2>epidermal growth factor receptor<\\e2> (EGFR) activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imatinib","object":"epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>CHEMICAL<\\e1> induced changes in cell morphology and growth similar to changes associated with <e2>GENE-Y<\\e2> (EGFR) activation","sentence":"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of imatinib induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (EGFR) activation"}
{"PMID":15887238,"re_id":15,"annotated sentence":"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>imatinib<\\e1> induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (<e2>EGFR<\\e2>  activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imatinib","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of <e1>CHEMICAL<\\e1> induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (<e2>GENE-Y<\\e2>  activation","sentence":"Treatment of head and neck squamous carcinoma cells with clinically relevant concentrations of imatinib induced changes in cell morphology and growth similar to changes associated with epidermal growth factor receptor (EGFR  activation"}
{"PMID":15887238,"re_id":16,"annotated sentence":"Western blot analysis of cells incubated with <e1>imatinib<\\e1> demonstrated activation of <e2>EGFR<\\e2> and downstream signaling that was reduced by inhibition of mitogen-activated protein\/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2\/ErbB2","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"imatinib","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Western blot analysis of cells incubated with <e1>CHEMICAL<\\e1> demonstrated activation of <e2>GENE-Y<\\e2> and downstream signaling that was reduced by inhibition of mitogen-activated protein\/extracellular signal-regulated kinase kinase 1 (MEK1) and GENE-Y, but not Her2\/ErbB2","sentence":"Western blot analysis of cells incubated with imatinib demonstrated activation of EGFR and downstream signaling that was reduced by inhibition of mitogen-activated protein\/extracellular signal-regulated kinase kinase 1 (MEK1) and EGFR, but not Her2\/ErbB2"}
{"PMID":15887238,"re_id":17,"annotated sentence":"<e1>Imatinib<\\e1> stimulated the rapid release of soluble <e2>HB-EGF<\\e2> and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic MAPK activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Imatinib","object":"HB-EGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> stimulated the rapid release of soluble <e2>GENE-Y<\\e2> and the subsequent induction of membrane-bound GENE-Y, which correlated with biphasic MAPK activation","sentence":"Imatinib stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF, which correlated with biphasic MAPK activation"}
{"PMID":15887238,"re_id":18,"annotated sentence":"<e1>Imatinib<\\e1> stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound <e2>HB-EGF<\\e2>  which correlated with biphasic MAPK activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Imatinib","object":"HB-EGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> stimulated the rapid release of soluble GENE-Y and the subsequent induction of membrane-bound <e2>GENE-Y<\\e2>  which correlated with biphasic MAPK activation","sentence":"Imatinib stimulated the rapid release of soluble HB-EGF and the subsequent induction of membrane-bound HB-EGF  which correlated with biphasic MAPK activation"}
{"PMID":15887238,"re_id":19,"annotated sentence":"Together, these results suggested that <e1>imatinib<\\e1> affects EGFR activation and signaling pathways through rapid release and increased expression of endogenous <e2>EGFR<\\e2> activating ligands","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"imatinib","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Together, these results suggested that <e1>CHEMICAL<\\e1> affects GENE-Y activation and signaling pathways through rapid release and increased expression of endogenous <e2>GENE-Y<\\e2> activating ligands","sentence":"Together, these results suggested that imatinib affects EGFR activation and signaling pathways through rapid release and increased expression of endogenous EGFR activating ligands"}
{"PMID":15887238,"re_id":20,"annotated sentence":"<e1>Imatinib mesylate<\\e1> is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (<e2>PDGFR<\\e2> , and c-kit kinases","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib mesylate","object":"PDGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (<e2>GENE-Y<\\e2> , and c-kit kinases","sentence":"Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR , and c-kit kinases"}
{"PMID":15887238,"re_id":21,"annotated sentence":"<e1>Imatinib mesylate<\\e1> is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and <e2>c-kit<\\e2> kinases","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib mesylate","object":"c-kit","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and <e2>GENE-Y<\\e2> kinases","sentence":"Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases"}
{"PMID":15887238,"re_id":22,"annotated sentence":"<e1>Imatinib mesylate<\\e1> is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit <e2>kinases<\\e2>  Inhibition of BCR-ABL and c-kit accounts for its clinical activity in leukemia and sarcoma, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib mesylate","object":"kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit <e2>GENE-N<\\e2>  Inhibition of BCR-ABL and c-kit accounts for its clinical activity in leukemia and sarcoma, respectively","sentence":"Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases  Inhibition of BCR-ABL and c-kit accounts for its clinical activity in leukemia and sarcoma, respectively"}
{"PMID":15887238,"re_id":23,"annotated sentence":"<e1>Imatinib mesylate<\\e1> is a <e2>tyrosine kinase<\\e2> inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib mesylate","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a <e2>GENE-N<\\e2> inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases","sentence":"Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases"}
{"PMID":15887238,"re_id":24,"annotated sentence":"<e1>Imatinib mesylate<\\e1> is a tyrosine kinase inhibitor of the <e2>ABL<\\e2>  platelet-derived growth factor receptor (PDGFR), and c-kit kinases","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib mesylate","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a tyrosine kinase inhibitor of the <e2>GENE-Y<\\e2>  platelet-derived growth factor receptor (PDGFR), and c-kit kinases","sentence":"Imatinib mesylate is a tyrosine kinase inhibitor of the ABL  platelet-derived growth factor receptor (PDGFR), and c-kit kinases"}
{"PMID":15887238,"re_id":25,"annotated sentence":"<e1>Imatinib mesylate<\\e1> is a tyrosine kinase inhibitor of the ABL, <e2>platelet-derived growth factor receptor<\\e2> (PDGFR), and c-kit kinases","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib mesylate","object":"platelet-derived growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a tyrosine kinase inhibitor of the ABL, <e2>GENE-Y<\\e2> (PDGFR), and c-kit kinases","sentence":"Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases"}
{"PMID":15887238,"re_id":26,"annotated sentence":"Although, <e1>imatinib<\\e1> primarily inhibits <e2>tyrosine kinases<\\e2>  it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"imatinib","object":"tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Although, <e1>CHEMICAL<\\e1> primarily inhibits <e2>GENE-N<\\e2>  it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors","sentence":"Although, imatinib primarily inhibits tyrosine kinases  it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors"}
{"PMID":1590750,"re_id":0,"annotated sentence":"The identity of the lung <e2>beta-ADHs<\\e2> was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by <e1>4-methylpyrazole<\\e1> or 1,10-phenanthroline","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"4-methylpyrazole","object":"beta-ADHs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The identity of the lung <e2>GENE-N<\\e2> was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by <e1>CHEMICAL<\\e1> or 1,10-phenanthroline","sentence":"The identity of the lung beta-ADHs was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline"}
{"PMID":1590750,"re_id":1,"annotated sentence":"The identity of the lung <e2>beta-ADHs<\\e2> was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or <e1>1,10-phenanthroline<\\e1>  The beta 2 allele, coding for beta 2 polypeptide, was found to be predominant in the lung specimens studied","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"1,10-phenanthroline","object":"beta-ADHs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The identity of the lung <e2>GENE-N<\\e2> was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or <e1>CHEMICAL<\\e1>  The beta 2 allele, coding for beta 2 polypeptide, was found to be predominant in the lung specimens studied","sentence":"The identity of the lung beta-ADHs was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline  The beta 2 allele, coding for beta 2 polypeptide, was found to be predominant in the lung specimens studied"}
{"PMID":1590750,"re_id":2,"annotated sentence":"The results suggest that individuals with high Vmax <e2>beta 2-ADH<\\e2> and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with <e1>acetaldehyde<\\e1> accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"acetaldehyde","object":"beta 2-ADH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results suggest that individuals with high Vmax <e2>GENE-Y<\\e2> and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with <e1>CHEMICAL<\\e1> accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.","sentence":"The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite."}
{"PMID":1590750,"re_id":3,"annotated sentence":"The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial <e2>ALDH2<\\e2>  accounting for approximately 45% of the Chinese population, may end up with <e1>acetaldehyde<\\e1> accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"acetaldehyde","object":"ALDH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial <e2>GENE-Y<\\e2>  accounting for approximately 45% of the Chinese population, may end up with <e1>CHEMICAL<\\e1> accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.","sentence":"The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial ALDH2  accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite."}
{"PMID":1590750,"re_id":4,"annotated sentence":"These findings indicate that human pulmonary <e1>ethanol<\\e1> metabolizing activities differ significantly with respect to genetic polymorphism at both the <e2>ADH2<\\e2> and the ALDH2 loci","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ethanol","object":"ADH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings indicate that human pulmonary <e1>CHEMICAL<\\e1> metabolizing activities differ significantly with respect to genetic polymorphism at both the <e2>GENE-Y<\\e2> and the ALDH2 loci","sentence":"These findings indicate that human pulmonary ethanol metabolizing activities differ significantly with respect to genetic polymorphism at both the ADH2 and the ALDH2 loci"}
{"PMID":1590750,"re_id":5,"annotated sentence":"These findings indicate that human pulmonary <e1>ethanol<\\e1> metabolizing activities differ significantly with respect to genetic polymorphism at both the ADH2 and the <e2>ALDH2<\\e2> loci","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ethanol","object":"ALDH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings indicate that human pulmonary <e1>CHEMICAL<\\e1> metabolizing activities differ significantly with respect to genetic polymorphism at both the ADH2 and the <e2>GENE-Y<\\e2> loci","sentence":"These findings indicate that human pulmonary ethanol metabolizing activities differ significantly with respect to genetic polymorphism at both the ADH2 and the ALDH2 loci"}
{"PMID":1590750,"re_id":6,"annotated sentence":"The results suggest that individuals with high Vmax <e2>beta 2-ADH<\\e2> and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during <e1>alcohol<\\e1> consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"alcohol","object":"beta 2-ADH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results suggest that individuals with high Vmax <e2>GENE-Y<\\e2> and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during <e1>CHEMICAL<\\e1> consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.","sentence":"The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial ALDH2, accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite."}
{"PMID":1590750,"re_id":7,"annotated sentence":"The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial <e2>ALDH2<\\e2>  accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during <e1>alcohol<\\e1> consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"alcohol","object":"ALDH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial <e2>GENE-Y<\\e2>  accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during <e1>CHEMICAL<\\e1> consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite.","sentence":"The results suggest that individuals with high Vmax beta 2-ADH and deficient in low-Km mitochondrial ALDH2  accounting for approximately 45% of the Chinese population, may end up with acetaldehyde accumulation during alcohol consumption, rendering them vulnerable to tissue injury caused by this highly reactive and toxic metabolite."}
{"PMID":1590750,"re_id":8,"annotated sentence":"The identity of the lung <e2>beta-ADHs<\\e2> was further demonstrated by their characteristic pH-activity profiles for <e1>ethanol<\\e1> oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ethanol","object":"beta-ADHs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The identity of the lung <e2>GENE-N<\\e2> was further demonstrated by their characteristic pH-activity profiles for <e1>CHEMICAL<\\e1> oxidation, Km values for NAD and CHEMICAL, and inhibition by 4-methylpyrazole or 1,10-phenanthroline","sentence":"The identity of the lung beta-ADHs was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol, and inhibition by 4-methylpyrazole or 1,10-phenanthroline"}
{"PMID":1590750,"re_id":9,"annotated sentence":"The identity of the lung <e2>beta-ADHs<\\e2> was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and <e1>ethanol<\\e1>  and inhibition by 4-methylpyrazole or 1,10-phenanthroline","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ethanol","object":"beta-ADHs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The identity of the lung <e2>GENE-N<\\e2> was further demonstrated by their characteristic pH-activity profiles for CHEMICAL oxidation, Km values for NAD and <e1>CHEMICAL<\\e1>  and inhibition by 4-methylpyrazole or 1,10-phenanthroline","sentence":"The identity of the lung beta-ADHs was further demonstrated by their characteristic pH-activity profiles for ethanol oxidation, Km values for NAD and ethanol  and inhibition by 4-methylpyrazole or 1,10-phenanthroline"}
{"PMID":15936988,"re_id":2,"annotated sentence":"The IL-18 production is located upstream of the <e2>cytokine<\\e2> cascade activated by <e1>simvastatin<\\e1>  Moreover, simvastatin concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"simvastatin","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The IL-18 production is located upstream of the <e2>GENE-N<\\e2> cascade activated by <e1>CHEMICAL<\\e1>  Moreover, CHEMICAL concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes","sentence":"The IL-18 production is located upstream of the cytokine cascade activated by simvastatin  Moreover, simvastatin concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes"}
{"PMID":15936988,"re_id":3,"annotated sentence":"In the presence of IL-18, <e1>simvastatin<\\e1> suppressed the expression of ICAM-1 and CD40 as well as the production of <e2>IL-12<\\e2>  TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"simvastatin","object":"IL-12","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the presence of IL-18, <e1>CHEMICAL<\\e1> suppressed the expression of ICAM-1 and CD40 as well as the production of <e2>GENE-N<\\e2>  TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of CHEMICAL","sentence":"In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12  TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin"}
{"PMID":15936988,"re_id":4,"annotated sentence":"In the presence of IL-18, <e1>simvastatin<\\e1> suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, <e2>TNF-alpha<\\e2> and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"simvastatin","object":"TNF-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the presence of IL-18, <e1>CHEMICAL<\\e1> suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, <e2>GENE-Y<\\e2> and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of CHEMICAL","sentence":"In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin"}
{"PMID":15936988,"re_id":5,"annotated sentence":"In the presence of IL-18, <e1>simvastatin<\\e1> suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and <e2>IFN-gamma<\\e2> in PBMC, contributing to the anti-inflammatory effect of simvastatin","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"simvastatin","object":"IFN-gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the presence of IL-18, <e1>CHEMICAL<\\e1> suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and <e2>GENE-Y<\\e2> in PBMC, contributing to the anti-inflammatory effect of CHEMICAL","sentence":"In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin"}
{"PMID":15936988,"re_id":6,"annotated sentence":"<e1>Simvastatin<\\e1> induces <e2>interleukin-18<\\e2> production in human peripheral blood mononuclear cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Simvastatin","object":"interleukin-18","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induces <e2>GENE-Y<\\e2> production in human peripheral blood mononuclear cells","sentence":"Simvastatin induces interleukin-18 production in human peripheral blood mononuclear cells"}
{"PMID":15936988,"re_id":7,"annotated sentence":"<e1>Simvastatin<\\e1>  an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of <e2>interleukin (IL)-18<\\e2>  tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Simvastatin","object":"interleukin (IL)-18","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of <e2>GENE-Y<\\e2>  tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)","sentence":"Simvastatin  an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18  tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)"}
{"PMID":15936988,"re_id":8,"annotated sentence":"<e1>Simvastatin<\\e1>  an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, <e2>tumor necrosis factor (TNF)-alpha<\\e2> and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Simvastatin","object":"tumor necrosis factor (TNF)-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, <e2>GENE-Y<\\e2> and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)","sentence":"Simvastatin  an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)"}
{"PMID":15936988,"re_id":9,"annotated sentence":"<e1>Simvastatin<\\e1>  an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and <e2>interferon (IFN)-gamma<\\e2> in human peripheral blood mononuclear cells (PBMC)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Simvastatin","object":"interferon (IFN)-gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and <e2>GENE-Y<\\e2> in human peripheral blood mononuclear cells (PBMC)","sentence":"Simvastatin  an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)"}
{"PMID":15936988,"re_id":10,"annotated sentence":"The <e2>IL-18<\\e2> production is located upstream of the cytokine cascade activated by <e1>simvastatin<\\e1>  Moreover, simvastatin concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"simvastatin","object":"IL-18","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> production is located upstream of the cytokine cascade activated by <e1>CHEMICAL<\\e1>  Moreover, CHEMICAL concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes","sentence":"The IL-18 production is located upstream of the cytokine cascade activated by simvastatin  Moreover, simvastatin concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes"}
{"PMID":15936988,"re_id":11,"annotated sentence":"Moreover, <e1>simvastatin<\\e1> concentration-dependently inhibited the expression of ICAM-1 and induced the expression of <e2>CD40<\\e2> on monocytes","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"simvastatin","object":"CD40","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> concentration-dependently inhibited the expression of ICAM-1 and induced the expression of <e2>GENE-Y<\\e2> on monocytes","sentence":"Moreover, simvastatin concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes"}
{"PMID":15936988,"re_id":12,"annotated sentence":"In the presence of IL-18, <e1>simvastatin<\\e1> suppressed the expression of <e2>ICAM-1<\\e2> and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"simvastatin","object":"ICAM-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the presence of IL-18, <e1>CHEMICAL<\\e1> suppressed the expression of <e2>GENE-Y<\\e2> and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of CHEMICAL","sentence":"In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin"}
{"PMID":15936988,"re_id":13,"annotated sentence":"In the presence of IL-18, <e1>simvastatin<\\e1> suppressed the expression of ICAM-1 and <e2>CD40<\\e2> as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"simvastatin","object":"CD40","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the presence of IL-18, <e1>CHEMICAL<\\e1> suppressed the expression of ICAM-1 and <e2>GENE-Y<\\e2> as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of CHEMICAL","sentence":"In the presence of IL-18, simvastatin suppressed the expression of ICAM-1 and CD40 as well as the production of IL-12, TNF-alpha and IFN-gamma in PBMC, contributing to the anti-inflammatory effect of simvastatin"}
{"PMID":15936988,"re_id":14,"annotated sentence":"Moreover, <e1>simvastatin<\\e1> concentration-dependently inhibited the expression of <e2>ICAM-1<\\e2> and induced the expression of CD40 on monocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"simvastatin","object":"ICAM-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> concentration-dependently inhibited the expression of <e2>GENE-Y<\\e2> and induced the expression of CD40 on monocytes","sentence":"Moreover, simvastatin concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes"}
{"PMID":15936988,"re_id":15,"annotated sentence":"<e1>Simvastatin<\\e1>  an <e2>HMG-CoA reductase<\\e2> inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Simvastatin","object":"HMG-CoA reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an <e2>GENE-Y<\\e2> inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)","sentence":"Simvastatin  an HMG-CoA reductase inhibitor with mild inhibition of LFA-1, induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)"}
{"PMID":15936988,"re_id":16,"annotated sentence":"<e1>Simvastatin<\\e1>  an HMG-CoA reductase inhibitor with mild inhibition of <e2>LFA-1<\\e2>  induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Simvastatin","object":"LFA-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an HMG-CoA reductase inhibitor with mild inhibition of <e2>GENE-Y<\\e2>  induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)","sentence":"Simvastatin  an HMG-CoA reductase inhibitor with mild inhibition of LFA-1  induced the production of interleukin (IL)-18, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in human peripheral blood mononuclear cells (PBMC)"}
{"PMID":15936988,"re_id":17,"annotated sentence":"The effects of simvastatin were abolished by the addition of the product of the <e2>HMG-CoA reductase<\\e2>  <e1>mevalonate<\\e1>  indicating the involvement of HMG-CoA reductase in the action of simvastatin.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"mevalonate","object":"HMG-CoA reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of simvastatin were abolished by the addition of the product of the <e2>GENE-Y<\\e2>  <e1>CHEMICAL<\\e1>  indicating the involvement of GENE-Y in the action of simvastatin.","sentence":"The effects of simvastatin were abolished by the addition of the product of the HMG-CoA reductase  mevalonate  indicating the involvement of HMG-CoA reductase in the action of simvastatin."}
{"PMID":15939622,"re_id":0,"annotated sentence":"However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and <e1>carprofen<\\e1> (-12.9%) had lower <e2>COX-2<\\e2> selectivity than at IC50","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carprofen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater GENE-Y selectivity than at IC50, and meloxicam (-41.2%) and <e1>CHEMICAL<\\e1> (-12.9%) had lower <e2>GENE-Y<\\e2> selectivity than at IC50","sentence":"However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50"}
{"PMID":15939622,"re_id":1,"annotated sentence":"We report on the inhibitory activity of the NSAIDs meloxicam, <e1>carprofen<\\e1>  phenylbutazone and flunixin, on blood <e2>cyclooxygenases<\\e2> in the horse using in vitro enzyme-linked assays","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carprofen","object":"cyclooxygenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We report on the inhibitory activity of the NSAIDs meloxicam, <e1>CHEMICAL<\\e1>  phenylbutazone and flunixin, on blood <e2>GENE-N<\\e2> in the horse using in vitro enzyme-linked assays","sentence":"We report on the inhibitory activity of the NSAIDs meloxicam, carprofen  phenylbutazone and flunixin, on blood cyclooxygenases in the horse using in vitro enzyme-linked assays"}
{"PMID":15939622,"re_id":2,"annotated sentence":"We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, <e1>phenylbutazone<\\e1> and flunixin, on blood <e2>cyclooxygenases<\\e2> in the horse using in vitro enzyme-linked assays","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"phenylbutazone","object":"cyclooxygenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, <e1>CHEMICAL<\\e1> and flunixin, on blood <e2>GENE-N<\\e2> in the horse using in vitro enzyme-linked assays","sentence":"We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, phenylbutazone and flunixin, on blood cyclooxygenases in the horse using in vitro enzyme-linked assays"}
{"PMID":15939622,"re_id":3,"annotated sentence":"We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, phenylbutazone and <e1>flunixin<\\e1>  on blood <e2>cyclooxygenases<\\e2> in the horse using in vitro enzyme-linked assays","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flunixin","object":"cyclooxygenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, phenylbutazone and <e1>CHEMICAL<\\e1>  on blood <e2>GENE-N<\\e2> in the horse using in vitro enzyme-linked assays","sentence":"We report on the inhibitory activity of the NSAIDs meloxicam, carprofen, phenylbutazone and flunixin  on blood cyclooxygenases in the horse using in vitro enzyme-linked assays"}
{"PMID":15939622,"re_id":4,"annotated sentence":"<e2>COX-1<\\e2> and COX-2 inhibition in horse blood by <e1>phenylbutazone<\\e1>  flunixin, carprofen and meloxicam: an in vitro analysis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"phenylbutazone","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and COX-2 inhibition in horse blood by <e1>CHEMICAL<\\e1>  flunixin, carprofen and meloxicam: an in vitro analysis","sentence":"COX-1 and COX-2 inhibition in horse blood by phenylbutazone  flunixin, carprofen and meloxicam: an in vitro analysis"}
{"PMID":15939622,"re_id":5,"annotated sentence":"COX-1 and <e2>COX-2<\\e2> inhibition in horse blood by <e1>phenylbutazone<\\e1>  flunixin, carprofen and meloxicam: an in vitro analysis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"phenylbutazone","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"COX-1 and <e2>GENE-Y<\\e2> inhibition in horse blood by <e1>CHEMICAL<\\e1>  flunixin, carprofen and meloxicam: an in vitro analysis","sentence":"COX-1 and COX-2 inhibition in horse blood by phenylbutazone  flunixin, carprofen and meloxicam: an in vitro analysis"}
{"PMID":15939622,"re_id":6,"annotated sentence":"<e2>COX-1<\\e2> and COX-2 inhibition in horse blood by phenylbutazone, <e1>flunixin<\\e1>  carprofen and meloxicam: an in vitro analysis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flunixin","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and COX-2 inhibition in horse blood by phenylbutazone, <e1>CHEMICAL<\\e1>  carprofen and meloxicam: an in vitro analysis","sentence":"COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin  carprofen and meloxicam: an in vitro analysis"}
{"PMID":15939622,"re_id":7,"annotated sentence":"COX-1 and <e2>COX-2<\\e2> inhibition in horse blood by phenylbutazone, <e1>flunixin<\\e1>  carprofen and meloxicam: an in vitro analysis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flunixin","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"COX-1 and <e2>GENE-Y<\\e2> inhibition in horse blood by phenylbutazone, <e1>CHEMICAL<\\e1>  carprofen and meloxicam: an in vitro analysis","sentence":"COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin  carprofen and meloxicam: an in vitro analysis"}
{"PMID":15939622,"re_id":8,"annotated sentence":"<e2>COX-1<\\e2> and COX-2 inhibition in horse blood by phenylbutazone, flunixin, <e1>carprofen<\\e1> and meloxicam: an in vitro analysis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carprofen","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and COX-2 inhibition in horse blood by phenylbutazone, flunixin, <e1>CHEMICAL<\\e1> and meloxicam: an in vitro analysis","sentence":"COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis"}
{"PMID":15939622,"re_id":9,"annotated sentence":"COX-1 and <e2>COX-2<\\e2> inhibition in horse blood by phenylbutazone, flunixin, <e1>carprofen<\\e1> and meloxicam: an in vitro analysis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carprofen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"COX-1 and <e2>GENE-Y<\\e2> inhibition in horse blood by phenylbutazone, flunixin, <e1>CHEMICAL<\\e1> and meloxicam: an in vitro analysis","sentence":"COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis"}
{"PMID":15939622,"re_id":10,"annotated sentence":"<e2>COX-1<\\e2> and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and <e1>meloxicam<\\e1>  an in vitro analysis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"meloxicam","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and <e1>CHEMICAL<\\e1>  an in vitro analysis","sentence":"COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam  an in vitro analysis"}
{"PMID":15939622,"re_id":11,"annotated sentence":"COX-1 and <e2>COX-2<\\e2> inhibition in horse blood by phenylbutazone, flunixin, carprofen and <e1>meloxicam<\\e1>  an in vitro analysis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"meloxicam","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"COX-1 and <e2>GENE-Y<\\e2> inhibition in horse blood by phenylbutazone, flunixin, carprofen and <e1>CHEMICAL<\\e1>  an in vitro analysis","sentence":"COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam  an in vitro analysis"}
{"PMID":15939622,"re_id":12,"annotated sentence":"As expected, comparison of IC50 indicated that <e1>meloxicam<\\e1> and carprofen are more selective inhibitors of <e2>COX-2<\\e2> than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"meloxicam","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As expected, comparison of IC50 indicated that <e1>CHEMICAL<\\e1> and carprofen are more selective inhibitors of <e2>GENE-Y<\\e2> than phenylbutazone and flunixin; CHEMICAL was the most advantageous for horses of four NSAIDs examined","sentence":"As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of COX-2 than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined"}
{"PMID":15939622,"re_id":13,"annotated sentence":"As expected, comparison of IC50 indicated that meloxicam and <e1>carprofen<\\e1> are more selective inhibitors of <e2>COX-2<\\e2> than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carprofen","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As expected, comparison of IC50 indicated that meloxicam and <e1>CHEMICAL<\\e1> are more selective inhibitors of <e2>GENE-Y<\\e2> than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined","sentence":"As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of COX-2 than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined"}
{"PMID":15939622,"re_id":14,"annotated sentence":"As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of <e2>COX-2<\\e2> than <e1>phenylbutazone<\\e1> and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"phenylbutazone","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of <e2>GENE-Y<\\e2> than <e1>CHEMICAL<\\e1> and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined","sentence":"As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of COX-2 than phenylbutazone and flunixin; meloxicam was the most advantageous for horses of four NSAIDs examined"}
{"PMID":15939622,"re_id":15,"annotated sentence":"As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of <e2>COX-2<\\e2> than phenylbutazone and <e1>flunixin<\\e1>  meloxicam was the most advantageous for horses of four NSAIDs examined","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flunixin","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of <e2>GENE-Y<\\e2> than phenylbutazone and <e1>CHEMICAL<\\e1>  meloxicam was the most advantageous for horses of four NSAIDs examined","sentence":"As expected, comparison of IC50 indicated that meloxicam and carprofen are more selective inhibitors of COX-2 than phenylbutazone and flunixin  meloxicam was the most advantageous for horses of four NSAIDs examined"}
{"PMID":15939622,"re_id":16,"annotated sentence":"However at IC80, <e1>phenylbutazone<\\e1> (+134.4%) and flunixin (+29.7%) had greater <e2>COX-2<\\e2> selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"phenylbutazone","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However at IC80, <e1>CHEMICAL<\\e1> (+134.4%) and flunixin (+29.7%) had greater <e2>GENE-Y<\\e2> selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower GENE-Y selectivity than at IC50","sentence":"However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50"}
{"PMID":15939622,"re_id":17,"annotated sentence":"However at IC80, phenylbutazone (+134.4%) and <e1>flunixin<\\e1> (+29.7%) had greater <e2>COX-2<\\e2> selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flunixin","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However at IC80, phenylbutazone (+134.4%) and <e1>CHEMICAL<\\e1> (+29.7%) had greater <e2>GENE-Y<\\e2> selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower GENE-Y selectivity than at IC50","sentence":"However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50"}
{"PMID":15939622,"re_id":18,"annotated sentence":"However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and <e1>meloxicam<\\e1> (-41.2%) and carprofen (-12.9%) had lower <e2>COX-2<\\e2> selectivity than at IC50","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"meloxicam","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater GENE-Y selectivity than at IC50, and <e1>CHEMICAL<\\e1> (-41.2%) and carprofen (-12.9%) had lower <e2>GENE-Y<\\e2> selectivity than at IC50","sentence":"However at IC80, phenylbutazone (+134.4%) and flunixin (+29.7%) had greater COX-2 selectivity than at IC50, and meloxicam (-41.2%) and carprofen (-12.9%) had lower COX-2 selectivity than at IC50"}
{"PMID":15939622,"re_id":19,"annotated sentence":"We report on the inhibitory activity of the NSAIDs <e1>meloxicam<\\e1>  carprofen, phenylbutazone and flunixin, on blood <e2>cyclooxygenases<\\e2> in the horse using in vitro enzyme-linked assays","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"meloxicam","object":"cyclooxygenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We report on the inhibitory activity of the NSAIDs <e1>CHEMICAL<\\e1>  carprofen, phenylbutazone and flunixin, on blood <e2>GENE-N<\\e2> in the horse using in vitro enzyme-linked assays","sentence":"We report on the inhibitory activity of the NSAIDs meloxicam  carprofen, phenylbutazone and flunixin, on blood cyclooxygenases in the horse using in vitro enzyme-linked assays"}
{"PMID":15942707,"re_id":7,"annotated sentence":"Treatment with <e1>carvedilol<\\e1> reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and <e2>NGF-beta<\\e2> to the baseline values","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"carvedilol","object":"NGF-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and <e2>GENE-Y<\\e2> to the baseline values","sentence":"Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP, and NGF-beta to the baseline values"}
{"PMID":15942707,"re_id":8,"annotated sentence":"<e1>Carvedilol<\\e1> prevents cardiac hypertrophy and overexpression of <e2>hypoxia-inducible factor-1alpha<\\e2> and vascular endothelial growth factor in pressure-overloaded rat heart","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Carvedilol","object":"hypoxia-inducible factor-1alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> prevents cardiac hypertrophy and overexpression of <e2>GENE-Y<\\e2> and vascular endothelial growth factor in pressure-overloaded rat heart","sentence":"Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart"}
{"PMID":15942707,"re_id":9,"annotated sentence":"<e1>Carvedilol<\\e1> prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and <e2>vascular endothelial growth factor<\\e2> in pressure-overloaded rat heart","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Carvedilol","object":"vascular endothelial growth factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and <e2>GENE-Y<\\e2> in pressure-overloaded rat heart","sentence":"Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart"}
{"PMID":15942707,"re_id":10,"annotated sentence":"Treatment with <e1>carvedilol<\\e1> reversed both protein and mRNA of <e2>HIF-1alpha<\\e2>  VEGF, BNP, and NGF-beta to the baseline values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"carvedilol","object":"HIF-1alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> reversed both protein and mRNA of <e2>GENE-Y<\\e2>  VEGF, BNP, and NGF-beta to the baseline values","sentence":"Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha  VEGF, BNP, and NGF-beta to the baseline values"}
{"PMID":15942707,"re_id":11,"annotated sentence":"Treatment with <e1>carvedilol<\\e1> reversed both protein and mRNA of HIF-1alpha, <e2>VEGF<\\e2>  BNP, and NGF-beta to the baseline values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"carvedilol","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> reversed both protein and mRNA of HIF-1alpha, <e2>GENE-Y<\\e2>  BNP, and NGF-beta to the baseline values","sentence":"Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF  BNP, and NGF-beta to the baseline values"}
{"PMID":15942707,"re_id":12,"annotated sentence":"Treatment with <e1>carvedilol<\\e1> reversed both protein and mRNA of HIF-1alpha, VEGF, <e2>BNP<\\e2>  and NGF-beta to the baseline values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"carvedilol","object":"BNP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> reversed both protein and mRNA of HIF-1alpha, VEGF, <e2>GENE-Y<\\e2>  and NGF-beta to the baseline values","sentence":"Treatment with carvedilol reversed both protein and mRNA of HIF-1alpha, VEGF, BNP  and NGF-beta to the baseline values"}
{"PMID":15942707,"re_id":13,"annotated sentence":"Increased immunohistochemical labeling of <e2>HIF-1alpha<\\e2>  VEGF, and BNP in the ventricular myocardium was observed in the banding group and <e1>carvedilol<\\e1> again normalized the labeling","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"carvedilol","object":"HIF-1alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Increased immunohistochemical labeling of <e2>GENE-Y<\\e2>  VEGF, and BNP in the ventricular myocardium was observed in the banding group and <e1>CHEMICAL<\\e1> again normalized the labeling","sentence":"Increased immunohistochemical labeling of HIF-1alpha  VEGF, and BNP in the ventricular myocardium was observed in the banding group and carvedilol again normalized the labeling"}
{"PMID":15942707,"re_id":14,"annotated sentence":"Increased immunohistochemical labeling of HIF-1alpha, <e2>VEGF<\\e2>  and BNP in the ventricular myocardium was observed in the banding group and <e1>carvedilol<\\e1> again normalized the labeling","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"carvedilol","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Increased immunohistochemical labeling of HIF-1alpha, <e2>GENE-Y<\\e2>  and BNP in the ventricular myocardium was observed in the banding group and <e1>CHEMICAL<\\e1> again normalized the labeling","sentence":"Increased immunohistochemical labeling of HIF-1alpha, VEGF  and BNP in the ventricular myocardium was observed in the banding group and carvedilol again normalized the labeling"}
{"PMID":15942707,"re_id":15,"annotated sentence":"Increased immunohistochemical labeling of HIF-1alpha, VEGF, and <e2>BNP<\\e2> in the ventricular myocardium was observed in the banding group and <e1>carvedilol<\\e1> again normalized the labeling","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"carvedilol","object":"BNP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Increased immunohistochemical labeling of HIF-1alpha, VEGF, and <e2>GENE-Y<\\e2> in the ventricular myocardium was observed in the banding group and <e1>CHEMICAL<\\e1> again normalized the labeling","sentence":"Increased immunohistochemical labeling of HIF-1alpha, VEGF, and BNP in the ventricular myocardium was observed in the banding group and carvedilol again normalized the labeling"}
{"PMID":15942707,"re_id":16,"annotated sentence":"Treatment with <e1>carvedilol<\\e1> is associated with a reversal of abnormal regulation of <e2>HIF-1alpha<\\e2>  VEGF, BNP, and NGF-beta in the hypertrophic myocardium.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"carvedilol","object":"HIF-1alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> is associated with a reversal of abnormal regulation of <e2>GENE-Y<\\e2>  VEGF, BNP, and NGF-beta in the hypertrophic myocardium.","sentence":"Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1alpha  VEGF, BNP, and NGF-beta in the hypertrophic myocardium."}
{"PMID":15942707,"re_id":17,"annotated sentence":"Treatment with <e1>carvedilol<\\e1> is associated with a reversal of abnormal regulation of HIF-1alpha, <e2>VEGF<\\e2>  BNP, and NGF-beta in the hypertrophic myocardium.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"carvedilol","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> is associated with a reversal of abnormal regulation of HIF-1alpha, <e2>GENE-Y<\\e2>  BNP, and NGF-beta in the hypertrophic myocardium.","sentence":"Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF  BNP, and NGF-beta in the hypertrophic myocardium."}
{"PMID":15942707,"re_id":18,"annotated sentence":"Treatment with <e1>carvedilol<\\e1> is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF, <e2>BNP<\\e2>  and NGF-beta in the hypertrophic myocardium.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"carvedilol","object":"BNP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF, <e2>GENE-Y<\\e2>  and NGF-beta in the hypertrophic myocardium.","sentence":"Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1alpha, VEGF, BNP  and NGF-beta in the hypertrophic myocardium."}
{"PMID":15946589,"re_id":5,"annotated sentence":"<e1>Imatinib<\\e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of <e2>KIT<\\e2>  ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib","object":"KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of <e2>GENE-Y<\\e2>  ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT  ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":6,"annotated sentence":"<e1>Imatinib<\\e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>ABL<\\e2>  BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>GENE-Y<\\e2>  BCR-GENE-Y, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL  BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":7,"annotated sentence":"<e1>Imatinib<\\e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, <e2>BCR<\\e2> ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib","object":"BCR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, <e2>GENE-Y<\\e2> ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":8,"annotated sentence":"<e1>Imatinib<\\e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-<e2>ABL<\\e2>  PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, GENE-Y, BCR-<e2>GENE-Y<\\e2>  PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL  PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":9,"annotated sentence":"<e1>Imatinib<\\e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, <e2>PDGFRA<\\e2>  and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib","object":"PDGFRA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, <e2>GENE-Y<\\e2>  and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA  and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":10,"annotated sentence":"<e1>Imatinib<\\e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and <e2>PDGFRB,<\\e2> represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib","object":"PDGFRB,","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and <e2>GENE-Y<\\e2> represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":11,"annotated sentence":"Imatinib (<e1>STI571<\\e1>  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of <e2>KIT<\\e2>  ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"STI571","object":"KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (<e1>CHEMICAL<\\e1>  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of <e2>GENE-Y<\\e2>  ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT  ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":12,"annotated sentence":"Imatinib (<e1>STI571<\\e1>  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>ABL<\\e2>  BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"STI571","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (<e1>CHEMICAL<\\e1>  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>GENE-Y<\\e2>  BCR-GENE-Y, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL  BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":13,"annotated sentence":"Imatinib (<e1>STI571<\\e1>  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, <e2>BCR<\\e2> ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"STI571","object":"BCR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (<e1>CHEMICAL<\\e1>  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, <e2>GENE-Y<\\e2> ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":14,"annotated sentence":"Imatinib (<e1>STI571<\\e1>  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-<e2>ABL<\\e2>  PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"STI571","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (<e1>CHEMICAL<\\e1>  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, GENE-Y, BCR-<e2>GENE-Y<\\e2>  PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL  PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":15,"annotated sentence":"Imatinib (<e1>STI571<\\e1>  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, <e2>PDGFRA<\\e2>  and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"STI571","object":"PDGFRA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (<e1>CHEMICAL<\\e1>  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, <e2>GENE-Y<\\e2>  and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA  and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":16,"annotated sentence":"Imatinib (<e1>STI571<\\e1>  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and <e2>PDGFRB,<\\e2> represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"STI571","object":"PDGFRB,","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (<e1>CHEMICAL<\\e1>  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and <e2>GENE-Y<\\e2> represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571  Gleevec, Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":17,"annotated sentence":"Imatinib (STI571, <e1>Gleevec<\\e1>  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of <e2>KIT<\\e2>  ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gleevec","object":"KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (STI571, <e1>CHEMICAL<\\e1>  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of <e2>GENE-Y<\\e2>  ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT  ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":18,"annotated sentence":"Imatinib (STI571, <e1>Gleevec<\\e1>  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>ABL<\\e2>  BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gleevec","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (STI571, <e1>CHEMICAL<\\e1>  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>GENE-Y<\\e2>  BCR-GENE-Y, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL  BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":19,"annotated sentence":"Imatinib (STI571, <e1>Gleevec<\\e1>  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, <e2>BCR<\\e2> ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gleevec","object":"BCR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (STI571, <e1>CHEMICAL<\\e1>  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, <e2>GENE-Y<\\e2> ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":20,"annotated sentence":"Imatinib (STI571, <e1>Gleevec<\\e1>  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-<e2>ABL<\\e2>  PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gleevec","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (STI571, <e1>CHEMICAL<\\e1>  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, GENE-Y, BCR-<e2>GENE-Y<\\e2>  PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL  PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":21,"annotated sentence":"Imatinib (STI571, <e1>Gleevec<\\e1>  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, <e2>PDGFRA<\\e2>  and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gleevec","object":"PDGFRA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (STI571, <e1>CHEMICAL<\\e1>  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, <e2>GENE-Y<\\e2>  and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA  and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":22,"annotated sentence":"Imatinib (STI571, <e1>Gleevec<\\e1>  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and <e2>PDGFRB,<\\e2> represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gleevec","object":"PDGFRB,","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (STI571, <e1>CHEMICAL<\\e1>  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and <e2>GENE-Y<\\e2> represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec  Glivec; Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":23,"annotated sentence":"Imatinib (STI571, Gleevec, <e1>Glivec<\\e1>  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of <e2>KIT<\\e2>  ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Glivec","object":"KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (STI571, Gleevec, <e1>CHEMICAL<\\e1>  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of <e2>GENE-Y<\\e2>  ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec, Glivec  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT  ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":24,"annotated sentence":"Imatinib (STI571, Gleevec, <e1>Glivec<\\e1>  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>ABL<\\e2>  BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Glivec","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (STI571, Gleevec, <e1>CHEMICAL<\\e1>  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, <e2>GENE-Y<\\e2>  BCR-GENE-Y, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec, Glivec  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL  BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":25,"annotated sentence":"Imatinib (STI571, Gleevec, <e1>Glivec<\\e1>  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, <e2>BCR<\\e2> ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Glivec","object":"BCR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (STI571, Gleevec, <e1>CHEMICAL<\\e1>  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, <e2>GENE-Y<\\e2> ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec, Glivec  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":26,"annotated sentence":"Imatinib (STI571, Gleevec, <e1>Glivec<\\e1>  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-<e2>ABL<\\e2>  PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Glivec","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (STI571, Gleevec, <e1>CHEMICAL<\\e1>  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, GENE-Y, BCR-<e2>GENE-Y<\\e2>  PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec, Glivec  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL  PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":27,"annotated sentence":"Imatinib (STI571, Gleevec, <e1>Glivec<\\e1>  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, <e2>PDGFRA<\\e2>  and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Glivec","object":"PDGFRA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (STI571, Gleevec, <e1>CHEMICAL<\\e1>  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, <e2>GENE-Y<\\e2>  and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec, Glivec  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA  and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15946589,"re_id":28,"annotated sentence":"Imatinib (STI571, Gleevec, <e1>Glivec<\\e1>  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and <e2>PDGFRB,<\\e2> represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Glivec","object":"PDGFRB,","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Imatinib (STI571, Gleevec, <e1>CHEMICAL<\\e1>  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and <e2>GENE-Y<\\e2> represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs","sentence":"Imatinib (STI571, Gleevec, Glivec  Novartis Pharmaceuticals, East Hanover, NJ), a selective inhibitor of KIT, ABL, BCR-ABL, PDGFRA, and PDGFRB, represents a new paradigm of targeted cancer therapy and has revolutionized the treatment of patients with chronic myelogenous leukemia and GISTs"}
{"PMID":15947036,"re_id":7,"annotated sentence":"Moreover, <e1>4-methylhistamine<\\e1> potently activated the <e2>hH(4)R<\\e2> (pEC(50) = 7.4 +\/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"4-methylhistamine","object":"hH(4)R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> potently activated the <e2>GENE-Y<\\e2> (pEC(50) = 7.4 +\/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8)","sentence":"Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +\/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8)"}
{"PMID":15947036,"re_id":8,"annotated sentence":"Most of the tested H(2)R agonists and <e1>imidazole<\\e1> based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic <e2>hH(4)R<\\e2> activities, ranging from full agonists to inverse agonists","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-ACTIVATOR","subject":"imidazole","object":"hH(4)R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Most of the tested H(2)R agonists and <e1>CHEMICAL<\\e1> based H(3)R ligands show micromolar-to-nanomolar range GENE-Y affinity, and these ligands exert different intrinsic <e2>GENE-Y<\\e2> activities, ranging from full agonists to inverse agonists","sentence":"Most of the tested H(2)R agonists and imidazole based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists"}
{"PMID":15947036,"re_id":9,"annotated sentence":"Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of <e1>4-methylhistamine<\\e1> as the first potent and selective <e2>H4 receptor<\\e2> agonist","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"4-methylhistamine","object":"H4 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine GENE-Y: identification of <e1>CHEMICAL<\\e1> as the first potent and selective <e2>GENE-Y<\\e2> agonist","sentence":"Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist"}
{"PMID":15947036,"re_id":10,"annotated sentence":"The identification of <e1>4-methylhistamine<\\e1> as a potent <e2>H(4)R<\\e2> agonist is of major importance for future studies to unravel the physiological roles of the H(4)R.","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"4-methylhistamine","object":"H(4)R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The identification of <e1>CHEMICAL<\\e1> as a potent <e2>GENE-Y<\\e2> agonist is of major importance for future studies to unravel the physiological roles of the GENE-Y.","sentence":"The identification of 4-methylhistamine as a potent H(4)R agonist is of major importance for future studies to unravel the physiological roles of the H(4)R."}
{"PMID":15947036,"re_id":11,"annotated sentence":"Most of the tested H(2)R agonists and <e1>imidazole<\\e1> based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic <e2>hH(4)R<\\e2> activities, ranging from full agonists to inverse agonists","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-INHIBITOR","subject":"imidazole","object":"hH(4)R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Most of the tested H(2)R agonists and <e1>CHEMICAL<\\e1> based H(3)R ligands show micromolar-to-nanomolar range GENE-Y affinity, and these ligands exert different intrinsic <e2>GENE-Y<\\e2> activities, ranging from full agonists to inverse agonists","sentence":"Most of the tested H(2)R agonists and imidazole based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists"}
{"PMID":15947036,"re_id":12,"annotated sentence":"Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +\/- 0.1; alpha = 1), and this response was competitively antagonized by the selective <e2>H(4)R<\\e2> antagonist <e1>JNJ 7777120<\\e1> [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"JNJ 7777120","object":"H(4)R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, 4-methylhistamine potently activated the hGENE-Y (pEC(50) = 7.4 +\/- 0.1; alpha = 1), and this response was competitively antagonized by the selective <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8)","sentence":"Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +\/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8)"}
{"PMID":15947036,"re_id":13,"annotated sentence":"Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +\/- 0.1; alpha = 1), and this response was competitively antagonized by the selective <e2>H(4)R<\\e2> antagonist JNJ 7777120 [<e1>1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine<\\e1>  (pA(2) = 7.8)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine","object":"H(4)R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, 4-methylhistamine potently activated the hGENE-Y (pEC(50) = 7.4 +\/- 0.1; alpha = 1), and this response was competitively antagonized by the selective <e2>GENE-Y<\\e2> antagonist JNJ 7777120 [<e1>CHEMICAL<\\e1>  (pA(2) = 7.8)","sentence":"Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +\/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine  (pA(2) = 7.8)"}
{"PMID":15975002,"re_id":3,"annotated sentence":"Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of <e2>acetylcholinesterase<\\e2> activity, which can be eliminated by administration of <e1>atropine<\\e1>  Late-onset diarrhea appears to be associated with intestinal exposure to SN-38 (7-ethyl-10-hydroxycamptothecin), the major active metabolite of CPT-11, which may bind to Topo I and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"atropine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of <e2>GENE-Y<\\e2> activity, which can be eliminated by administration of <e1>CHEMICAL<\\e1>  Late-onset diarrhea appears to be associated with intestinal exposure to SN-38 (7-ethyl-10-hydroxycamptothecin), the major active metabolite of CPT-11, which may bind to Topo I and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa","sentence":"Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of acetylcholinesterase activity, which can be eliminated by administration of atropine  Late-onset diarrhea appears to be associated with intestinal exposure to SN-38 (7-ethyl-10-hydroxycamptothecin), the major active metabolite of CPT-11, which may bind to Topo I and induce apoptosis of intestinal epithelia, leading to the disturbance in the absorptive and secretory functions of mucosa"}
{"PMID":15975002,"re_id":4,"annotated sentence":"<e1>CPT-11<\\e1> and SN-38 may also stimulate the production of pro-inflammatory <e2>cytokines<\\e2> and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"CPT-11","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and SN-38 may also stimulate the production of pro-inflammatory <e2>GENE-N<\\e2> and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)","sentence":"CPT-11 and SN-38 may also stimulate the production of pro-inflammatory cytokines and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)"}
{"PMID":15975002,"re_id":5,"annotated sentence":"CPT-11 and <e1>SN-38<\\e1> may also stimulate the production of pro-inflammatory <e2>cytokines<\\e2> and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"SN-38","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CPT-11 and <e1>CHEMICAL<\\e1> may also stimulate the production of pro-inflammatory <e2>GENE-N<\\e2> and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)","sentence":"CPT-11 and SN-38 may also stimulate the production of pro-inflammatory cytokines and prostaglandins (PGs), thus inducing the secretion of Na(+) and Cl(-)"}
{"PMID":15975002,"re_id":6,"annotated sentence":"Irinotecan (CPT-11, <e1>7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin<\\e1>  has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting <e2>DNA topoisomerase I<\\e2> (Topo I)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin","object":"DNA topoisomerase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Irinotecan (CPT-11, <e1>CHEMICAL<\\e1>  has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting <e2>GENE-Y<\\e2> (Topo I)","sentence":"Irinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin  has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (Topo I)"}
{"PMID":15975002,"re_id":7,"annotated sentence":"Irinotecan (CPT-11, <e1>7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin<\\e1>  has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (<e2>Topo I<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin","object":"Topo I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Irinotecan (CPT-11, <e1>CHEMICAL<\\e1>  has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (<e2>GENE-Y<\\e2> ","sentence":"Irinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin  has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (Topo I "}
{"PMID":15975002,"re_id":8,"annotated sentence":"Early-onset diarrhea is observed immediately after <e1>CPT-11<\\e1> infusion and probably due to the inhibition of <e2>acetylcholinesterase<\\e2> activity, which can be eliminated by administration of atropine","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CPT-11","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Early-onset diarrhea is observed immediately after <e1>CHEMICAL<\\e1> infusion and probably due to the inhibition of <e2>GENE-Y<\\e2> activity, which can be eliminated by administration of atropine","sentence":"Early-onset diarrhea is observed immediately after CPT-11 infusion and probably due to the inhibition of acetylcholinesterase activity, which can be eliminated by administration of atropine"}
{"PMID":15975002,"re_id":9,"annotated sentence":"<e1>Irinotecan<\\e1> (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting <e2>DNA topoisomerase I<\\e2> (Topo I)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Irinotecan","object":"DNA topoisomerase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting <e2>GENE-Y<\\e2> (Topo I)","sentence":"Irinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (Topo I)"}
{"PMID":15975002,"re_id":10,"annotated sentence":"<e1>Irinotecan<\\e1> (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (<e2>Topo I<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Irinotecan","object":"Topo I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (<e2>GENE-Y<\\e2> ","sentence":"Irinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (Topo I "}
{"PMID":15975002,"re_id":11,"annotated sentence":"Irinotecan (<e1>CPT-11<\\e1>  7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting <e2>DNA topoisomerase I<\\e2> (Topo I)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CPT-11","object":"DNA topoisomerase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Irinotecan (<e1>CHEMICAL<\\e1>  7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting <e2>GENE-Y<\\e2> (Topo I)","sentence":"Irinotecan (CPT-11  7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (Topo I)"}
{"PMID":15975002,"re_id":12,"annotated sentence":"Irinotecan (<e1>CPT-11<\\e1>  7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (<e2>Topo I<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CPT-11","object":"Topo I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Irinotecan (<e1>CHEMICAL<\\e1>  7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (<e2>GENE-Y<\\e2> ","sentence":"Irinotecan (CPT-11  7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA topoisomerase I (Topo I "}
{"PMID":15985434,"re_id":19,"annotated sentence":"<e1>(R)-Roscovitine<\\e1> (CYC202, Seliciclib) is a relatively selective inhibitor of <e2>cyclin-dependent kinases<\\e2> (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"(R)-Roscovitine","object":"cyclin-dependent kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (CYC202, Seliciclib) is a relatively selective inhibitor of <e2>GENE-N<\\e2> (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections","sentence":"(R)-Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections"}
{"PMID":15985434,"re_id":20,"annotated sentence":"<e1>(R)-Roscovitine<\\e1> (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (<e2>CDKs<\\e2> , currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"(R)-Roscovitine","object":"CDKs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (<e2>GENE-N<\\e2> , currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections","sentence":"(R)-Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (CDKs , currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections"}
{"PMID":15985434,"re_id":21,"annotated sentence":"(R)-Roscovitine (<e1>CYC202<\\e1>  Seliciclib) is a relatively selective inhibitor of <e2>cyclin-dependent kinases<\\e2> (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CYC202","object":"cyclin-dependent kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"(R)-Roscovitine (<e1>CHEMICAL<\\e1>  Seliciclib) is a relatively selective inhibitor of <e2>GENE-N<\\e2> (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections","sentence":"(R)-Roscovitine (CYC202  Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections"}
{"PMID":15985434,"re_id":22,"annotated sentence":"(R)-Roscovitine (<e1>CYC202<\\e1>  Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (<e2>CDKs<\\e2> , currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CYC202","object":"CDKs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"(R)-Roscovitine (<e1>CHEMICAL<\\e1>  Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (<e2>GENE-N<\\e2> , currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections","sentence":"(R)-Roscovitine (CYC202  Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (CDKs , currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections"}
{"PMID":15985434,"re_id":23,"annotated sentence":"(R)-Roscovitine (CYC202, <e1>Seliciclib<\\e1>  is a relatively selective inhibitor of <e2>cyclin-dependent kinases<\\e2> (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Seliciclib","object":"cyclin-dependent kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"(R)-Roscovitine (CYC202, <e1>CHEMICAL<\\e1>  is a relatively selective inhibitor of <e2>GENE-N<\\e2> (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections","sentence":"(R)-Roscovitine (CYC202, Seliciclib  is a relatively selective inhibitor of cyclin-dependent kinases (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections"}
{"PMID":15985434,"re_id":24,"annotated sentence":"(R)-Roscovitine (CYC202, <e1>Seliciclib<\\e1>  is a relatively selective inhibitor of cyclin-dependent kinases (<e2>CDKs<\\e2> , currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Seliciclib","object":"CDKs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"(R)-Roscovitine (CYC202, <e1>CHEMICAL<\\e1>  is a relatively selective inhibitor of cyclin-dependent kinases (<e2>GENE-N<\\e2> , currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections","sentence":"(R)-Roscovitine (CYC202, Seliciclib  is a relatively selective inhibitor of cyclin-dependent kinases (CDKs , currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections"}
{"PMID":15985434,"re_id":25,"annotated sentence":"<e2>Pyridoxal kinase<\\e2> (PDXK) catalyzes the phosphorylation of <e1>pyridoxal<\\e1>  pyridoxamine, and pyridoxine in the presence of ATP and Zn2+","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"pyridoxal","object":"Pyridoxal kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (PDXK) catalyzes the phosphorylation of <e1>CHEMICAL<\\e1>  pyridoxamine, and pyridoxine in the presence of ATP and Zn2+","sentence":"Pyridoxal kinase (PDXK) catalyzes the phosphorylation of pyridoxal  pyridoxamine, and pyridoxine in the presence of ATP and Zn2+"}
{"PMID":15985434,"re_id":26,"annotated sentence":"Pyridoxal kinase (<e2>PDXK<\\e2>  catalyzes the phosphorylation of <e1>pyridoxal<\\e1>  pyridoxamine, and pyridoxine in the presence of ATP and Zn2+","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"pyridoxal","object":"PDXK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pyridoxal kinase (<e2>GENE-Y<\\e2>  catalyzes the phosphorylation of <e1>CHEMICAL<\\e1>  pyridoxamine, and pyridoxine in the presence of ATP and Zn2+","sentence":"Pyridoxal kinase (PDXK  catalyzes the phosphorylation of pyridoxal  pyridoxamine, and pyridoxine in the presence of ATP and Zn2+"}
{"PMID":15985434,"re_id":27,"annotated sentence":"<e2>Pyridoxal kinase<\\e2> (PDXK) catalyzes the phosphorylation of pyridoxal, <e1>pyridoxamine<\\e1>  and pyridoxine in the presence of ATP and Zn2+","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"pyridoxamine","object":"Pyridoxal kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (PDXK) catalyzes the phosphorylation of pyridoxal, <e1>CHEMICAL<\\e1>  and pyridoxine in the presence of ATP and Zn2+","sentence":"Pyridoxal kinase (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine  and pyridoxine in the presence of ATP and Zn2+"}
{"PMID":15985434,"re_id":28,"annotated sentence":"Pyridoxal kinase (<e2>PDXK<\\e2>  catalyzes the phosphorylation of pyridoxal, <e1>pyridoxamine<\\e1>  and pyridoxine in the presence of ATP and Zn2+","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"pyridoxamine","object":"PDXK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pyridoxal kinase (<e2>GENE-Y<\\e2>  catalyzes the phosphorylation of pyridoxal, <e1>CHEMICAL<\\e1>  and pyridoxine in the presence of ATP and Zn2+","sentence":"Pyridoxal kinase (PDXK  catalyzes the phosphorylation of pyridoxal, pyridoxamine  and pyridoxine in the presence of ATP and Zn2+"}
{"PMID":15985434,"re_id":29,"annotated sentence":"<e2>Pyridoxal kinase<\\e2> (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and <e1>pyridoxine<\\e1> in the presence of ATP and Zn2+","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"pyridoxine","object":"Pyridoxal kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and <e1>CHEMICAL<\\e1> in the presence of ATP and Zn2+","sentence":"Pyridoxal kinase (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+"}
{"PMID":15985434,"re_id":30,"annotated sentence":"Pyridoxal kinase (<e2>PDXK<\\e2>  catalyzes the phosphorylation of pyridoxal, pyridoxamine, and <e1>pyridoxine<\\e1> in the presence of ATP and Zn2+","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"pyridoxine","object":"PDXK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pyridoxal kinase (<e2>GENE-Y<\\e2>  catalyzes the phosphorylation of pyridoxal, pyridoxamine, and <e1>CHEMICAL<\\e1> in the presence of ATP and Zn2+","sentence":"Pyridoxal kinase (PDXK  catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+"}
{"PMID":15985706,"re_id":4,"annotated sentence":"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as <e2>adenylate cyclase<\\e2> activator, <e1>forskolin<\\e1>  The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"forskolin","object":"adenylate cyclase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as <e2>GENE-N<\\e2> activator, <e1>CHEMICAL<\\e1>  The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059","sentence":"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin  The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059"}
{"PMID":15985706,"re_id":5,"annotated sentence":"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by <e1>PP2<\\e1>  a selective inhibitor of tyrosine kinase Src responsible for ligand-independent <e2>EGFR<\\e2> autophosphorylation, but not by ERK inhibitor, PD98059","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"PP2","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by <e1>CHEMICAL<\\e1>  a selective inhibitor of tyrosine kinase Src responsible for ligand-independent <e2>GENE-Y<\\e2> autophosphorylation, but not by ERK inhibitor, PD98059","sentence":"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2  a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059"}
{"PMID":15985706,"re_id":6,"annotated sentence":"Both inhibitors, moreover, blunted the <e2>mucin<\\e2> secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, <e1>forskolin<\\e1>  The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"forskolin","object":"mucin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both inhibitors, moreover, blunted the <e2>GENE-N<\\e2> secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, <e1>CHEMICAL<\\e1>  The gastric GENE-N secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059","sentence":"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin  The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059"}
{"PMID":15985706,"re_id":7,"annotated sentence":"The <e2>gastric mucin<\\e2> secretory responses to isoproterenol, furthermore, were inhibited by <e1>PP2<\\e1>  a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"PP2","object":"gastric mucin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> secretory responses to isoproterenol, furthermore, were inhibited by <e1>CHEMICAL<\\e1>  a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059","sentence":"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2  a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059"}
{"PMID":15985706,"re_id":8,"annotated sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on <e2>mucin<\\e2> secretion was inhibited by EGFR kinase inhibitor, <e1>PD153035<\\e1>  as well as wortmannin, a specific inhibitor of PI3K","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"PD153035","object":"mucin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on <e2>GENE-N<\\e2> secretion was inhibited by EGFR kinase inhibitor, <e1>CHEMICAL<\\e1>  as well as wortmannin, a specific inhibitor of PI3K","sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035  as well as wortmannin, a specific inhibitor of PI3K"}
{"PMID":15985706,"re_id":9,"annotated sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on <e2>mucin<\\e2> secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as <e1>wortmannin<\\e1>  a specific inhibitor of PI3K","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"wortmannin","object":"mucin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on <e2>GENE-N<\\e2> secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as <e1>CHEMICAL<\\e1>  a specific inhibitor of PI3K","sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as wortmannin  a specific inhibitor of PI3K"}
{"PMID":15985706,"re_id":10,"annotated sentence":"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by <e1>PP2<\\e1>  a selective inhibitor of <e2>tyrosine kinase<\\e2> Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PP2","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by <e1>CHEMICAL<\\e1>  a selective inhibitor of <e2>GENE-N<\\e2> Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059","sentence":"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2  a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059"}
{"PMID":15985706,"re_id":11,"annotated sentence":"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by <e1>PP2<\\e1>  a selective inhibitor of tyrosine kinase <e2>Src<\\e2> responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PP2","object":"Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by <e1>CHEMICAL<\\e1>  a selective inhibitor of tyrosine kinase <e2>GENE-Y<\\e2> responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059","sentence":"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2  a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059"}
{"PMID":15985706,"re_id":12,"annotated sentence":"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by <e2>ERK<\\e2> inhibitor, <e1>PD98059<\\e1>  The inhibition of ERK, moreover, did not cause attenuation in mucin secretion in response to cAMP and forskolin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PD98059","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by <e2>GENE-N<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  The inhibition of GENE-N, moreover, did not cause attenuation in mucin secretion in response to cAMP and forskolin","sentence":"The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059  The inhibition of ERK, moreover, did not cause attenuation in mucin secretion in response to cAMP and forskolin"}
{"PMID":15985706,"re_id":13,"annotated sentence":"The inhibition of <e2>ERK<\\e2>  moreover, did not cause attenuation in mucin secretion in response to <e1>cAMP<\\e1> and forskolin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cAMP","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibition of <e2>GENE-N<\\e2>  moreover, did not cause attenuation in mucin secretion in response to <e1>CHEMICAL<\\e1> and forskolin","sentence":"The inhibition of ERK  moreover, did not cause attenuation in mucin secretion in response to cAMP and forskolin"}
{"PMID":15985706,"re_id":14,"annotated sentence":"The inhibition of <e2>ERK<\\e2>  moreover, did not cause attenuation in mucin secretion in response to cAMP and <e1>forskolin<\\e1>  The findings underline the role of EGFR as a convergence point in gastric mucin secretion triggered by beta-adrenergic GPCR activation, and demonstrate the requirement for Src kinase in EGFR transactivation.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"forskolin","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibition of <e2>GENE-N<\\e2>  moreover, did not cause attenuation in mucin secretion in response to cAMP and <e1>CHEMICAL<\\e1>  The findings underline the role of EGFR as a convergence point in gastric mucin secretion triggered by beta-adrenergic GPCR activation, and demonstrate the requirement for Src kinase in EGFR transactivation.","sentence":"The inhibition of ERK  moreover, did not cause attenuation in mucin secretion in response to cAMP and forskolin  The findings underline the role of EGFR as a convergence point in gastric mucin secretion triggered by beta-adrenergic GPCR activation, and demonstrate the requirement for Src kinase in EGFR transactivation."}
{"PMID":15985706,"re_id":15,"annotated sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by <e2>EGFR<\\e2> kinase inhibitor, <e1>PD153035<\\e1>  as well as wortmannin, a specific inhibitor of PI3K","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PD153035","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by <e2>GENE-Y<\\e2> kinase inhibitor, <e1>CHEMICAL<\\e1>  as well as wortmannin, a specific inhibitor of PI3K","sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035  as well as wortmannin, a specific inhibitor of PI3K"}
{"PMID":15985706,"re_id":16,"annotated sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR <e2>kinase<\\e2> inhibitor, <e1>PD153035<\\e1>  as well as wortmannin, a specific inhibitor of PI3K","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PD153035","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR <e2>GENE-N<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  as well as wortmannin, a specific inhibitor of PI3K","sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035  as well as wortmannin, a specific inhibitor of PI3K"}
{"PMID":15985706,"re_id":17,"annotated sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as <e1>wortmannin<\\e1>  a specific inhibitor of <e2>PI3K<\\e2>  Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"wortmannin","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as <e1>CHEMICAL<\\e1>  a specific inhibitor of <e2>GENE-N<\\e2>  Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin","sentence":"Using [(3)H]glucosamine-labeled gastric mucosal cells, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on mucin secretion was inhibited by EGFR kinase inhibitor, PD153035, as well as wortmannin  a specific inhibitor of PI3K  Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin"}
{"PMID":15985706,"re_id":18,"annotated sentence":"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, <e1>cAMP<\\e1> as well as <e2>adenylate cyclase<\\e2> activator, forskolin","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cAMP","object":"adenylate cyclase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, <e1>CHEMICAL<\\e1> as well as <e2>GENE-N<\\e2> activator, forskolin","sentence":"Both inhibitors, moreover, blunted the mucin secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenylate cyclase activator, forskolin"}
{"PMID":15991937,"re_id":2,"annotated sentence":"<e1>Losartan<\\e1> is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the <e2>AT(1) receptor<\\e2> (non-competitive inhibition)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Losartan","object":"AT(1) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the <e2>GENE-Y<\\e2> (non-competitive inhibition)","sentence":"Losartan is well-absorbed orally as an active drug and is rapidly converted via oxidation in the human liver to a more potent metabolite (designated E3174) with an affinity 20- to 30-times greater for the AT(1) receptor (non-competitive inhibition)"}
{"PMID":15991937,"re_id":3,"annotated sentence":"Clinical experience in heart failure is growing, and recent data suggest an improved survival with <e1>losartan<\\e1> versus captopril, a drug from the <e2>angiotensin-converting-enzyme<\\e2> inhibitor class with proven benefit in this population","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"losartan","object":"angiotensin-converting-enzyme","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clinical experience in heart failure is growing, and recent data suggest an improved survival with <e1>CHEMICAL<\\e1> versus captopril, a drug from the <e2>GENE-Y<\\e2> inhibitor class with proven benefit in this population","sentence":"Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus captopril, a drug from the angiotensin-converting-enzyme inhibitor class with proven benefit in this population"}
{"PMID":15991937,"re_id":4,"annotated sentence":"Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus <e1>captopril<\\e1>  a drug from the <e2>angiotensin-converting-enzyme<\\e2> inhibitor class with proven benefit in this population","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"captopril","object":"angiotensin-converting-enzyme","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus <e1>CHEMICAL<\\e1>  a drug from the <e2>GENE-Y<\\e2> inhibitor class with proven benefit in this population","sentence":"Clinical experience in heart failure is growing, and recent data suggest an improved survival with losartan versus captopril  a drug from the angiotensin-converting-enzyme inhibitor class with proven benefit in this population"}
{"PMID":15991937,"re_id":5,"annotated sentence":"The current comprehensive losartan clinical end-point programme (4 large scale morbidity\/mortality trials) should provide evidence regarding the efficacy of direct blockade of the <e2>AT(1) receptor<\\e2> with <e1>losartan<\\e1> compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"losartan","object":"AT(1) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The current comprehensive CHEMICAL clinical end-point programme (4 large scale morbidity\/mortality trials) should provide evidence regarding the efficacy of direct blockade of the <e2>GENE-Y<\\e2> with <e1>CHEMICAL<\\e1> compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL.","sentence":"The current comprehensive losartan clinical end-point programme (4 large scale morbidity\/mortality trials) should provide evidence regarding the efficacy of direct blockade of the AT(1) receptor with losartan compared to standard therapy: 1) The Losartan Heart Failure Survival Study - ELITE II, 2) The Losartan Post-Myocardial Infarction Survival Study - OPTIMAAL, 3) The Losartan Hypertension Survival Study - LIFE and 4) The Losartan Renal Protection Study - RENAAL."}
{"PMID":15991937,"re_id":6,"annotated sentence":"<e1>Losartan<\\e1>  a selective <e2>angiotensin II type 1 (AT1) receptor<\\e2> antagonist for the treatment of heart failure","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Losartan","object":"angiotensin II type 1 (AT1) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a selective <e2>GENE-Y<\\e2> antagonist for the treatment of heart failure","sentence":"Losartan  a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure"}
{"PMID":15991937,"re_id":7,"annotated sentence":"<e1>Losartan<\\e1> (COZAAR) is the prototype of a new class of potent and selective <e2>angiotensin II (AII) type 1 (AT(1)) receptor<\\e2> antagonists with the largest published preclinical and clinical data base","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Losartan","object":"angiotensin II (AII) type 1 (AT(1)) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (COZAAR) is the prototype of a new class of potent and selective <e2>GENE-Y<\\e2> antagonists with the largest published preclinical and clinical data base","sentence":"Losartan (COZAAR) is the prototype of a new class of potent and selective angiotensin II (AII) type 1 (AT(1)) receptor antagonists with the largest published preclinical and clinical data base"}
{"PMID":15991937,"re_id":8,"annotated sentence":"Losartan (<e1>COZAAR<\\e1>  is the prototype of a new class of potent and selective <e2>angiotensin II (AII) type 1 (AT(1)) receptor<\\e2> antagonists with the largest published preclinical and clinical data base","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"COZAAR","object":"angiotensin II (AII) type 1 (AT(1)) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Losartan (<e1>CHEMICAL<\\e1>  is the prototype of a new class of potent and selective <e2>GENE-Y<\\e2> antagonists with the largest published preclinical and clinical data base","sentence":"Losartan (COZAAR  is the prototype of a new class of potent and selective angiotensin II (AII) type 1 (AT(1)) receptor antagonists with the largest published preclinical and clinical data base"}
{"PMID":1611705,"re_id":0,"annotated sentence":"Abrupt removal of <e1>amrinone<\\e1> or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented <e2>TNF<\\e2> production","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"amrinone","object":"TNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Abrupt removal of <e1>CHEMICAL<\\e1> or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented <e2>GENE-Y<\\e2> production","sentence":"Abrupt removal of amrinone or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented TNF production"}
{"PMID":1611705,"re_id":1,"annotated sentence":"Abrupt removal of amrinone or <e1>pentoxifylline<\\e1> from the culture medium prior to LPS stimulation, however, caused significantly augmented <e2>TNF<\\e2> production","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"pentoxifylline","object":"TNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Abrupt removal of amrinone or <e1>CHEMICAL<\\e1> from the culture medium prior to LPS stimulation, however, caused significantly augmented <e2>GENE-Y<\\e2> production","sentence":"Abrupt removal of amrinone or pentoxifylline from the culture medium prior to LPS stimulation, however, caused significantly augmented TNF production"}
{"PMID":1611705,"re_id":2,"annotated sentence":"We now demonstrate that <e1>amrinone<\\e1>  a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced <e2>TNF<\\e2> production at concentrations readily achieved in vivo","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"amrinone","object":"TNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We now demonstrate that <e1>CHEMICAL<\\e1>  a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced <e2>GENE-Y<\\e2> production at concentrations readily achieved in vivo","sentence":"We now demonstrate that amrinone  a noncatechol inotrope, strongly inhibits lipopolysaccharide (LPS)-induced TNF production at concentrations readily achieved in vivo"}
{"PMID":1611705,"re_id":3,"annotated sentence":"Combined application of <e1>dexamethasone<\\e1> and amrinone caused additive inhibition of <e2>TNF<\\e2> biosynthesis in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dexamethasone","object":"TNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Combined application of <e1>CHEMICAL<\\e1> and amrinone caused additive inhibition of <e2>GENE-Y<\\e2> biosynthesis in vitro","sentence":"Combined application of dexamethasone and amrinone caused additive inhibition of TNF biosynthesis in vitro"}
{"PMID":1611705,"re_id":4,"annotated sentence":"Combined application of dexamethasone and <e1>amrinone<\\e1> caused additive inhibition of <e2>TNF<\\e2> biosynthesis in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"amrinone","object":"TNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Combined application of dexamethasone and <e1>CHEMICAL<\\e1> caused additive inhibition of <e2>GENE-Y<\\e2> biosynthesis in vitro","sentence":"Combined application of dexamethasone and amrinone caused additive inhibition of TNF biosynthesis in vitro"}
{"PMID":16207494,"re_id":0,"annotated sentence":"Therefore, decreases of <e2>PLK<\\e2> and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with <e1>gamma-aminobutyric acid<\\e1> (GABA) function.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"gamma-aminobutyric acid","object":"PLK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Therefore, decreases of <e2>GENE-N<\\e2> and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with <e1>CHEMICAL<\\e1> (GABA) function.","sentence":"Therefore, decreases of PLK and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid (GABA) function."}
{"PMID":16207494,"re_id":1,"annotated sentence":"Therefore, decreases of PLK and <e2>PNPO<\\e2> in the hippocampal CA1 region of aged brains may be involved in aging processes related with <e1>gamma-aminobutyric acid<\\e1> (GABA) function.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"gamma-aminobutyric acid","object":"PNPO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Therefore, decreases of PLK and <e2>GENE-N<\\e2> in the hippocampal CA1 region of aged brains may be involved in aging processes related with <e1>CHEMICAL<\\e1> (GABA) function.","sentence":"Therefore, decreases of PLK and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid (GABA) function."}
{"PMID":16207494,"re_id":2,"annotated sentence":"Therefore, decreases of <e2>PLK<\\e2> and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid (<e1>GABA<\\e1>  function.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"GABA","object":"PLK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Therefore, decreases of <e2>GENE-N<\\e2> and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid (<e1>CHEMICAL<\\e1>  function.","sentence":"Therefore, decreases of PLK and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid (GABA  function."}
{"PMID":16207494,"re_id":3,"annotated sentence":"Therefore, decreases of PLK and <e2>PNPO<\\e2> in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid (<e1>GABA<\\e1>  function.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"GABA","object":"PNPO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Therefore, decreases of PLK and <e2>GENE-N<\\e2> in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid (<e1>CHEMICAL<\\e1>  function.","sentence":"Therefore, decreases of PLK and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid (GABA  function."}
{"PMID":16207494,"re_id":4,"annotated sentence":"In the present study, age-related changes of <e1>pyridoxal 5'-phosphate<\\e1> (PLP) synthesizing enzymes, pyridoxal kinase (<e2>PLK<\\e2>  and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyridoxal 5'-phosphate","object":"PLK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, age-related changes of <e1>CHEMICAL<\\e1> (PLP) synthesizing enzymes, pyridoxal kinase (<e2>GENE-N<\\e2>  and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper","sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (PLK  and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper"}
{"PMID":16207494,"re_id":5,"annotated sentence":"In the present study, age-related changes of <e1>pyridoxal 5'-phosphate<\\e1> (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and <e2>pyridoxine 5'-phosphate oxidase<\\e2> (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyridoxal 5'-phosphate","object":"pyridoxine 5'-phosphate oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, age-related changes of <e1>CHEMICAL<\\e1> (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and <e2>GENE-N<\\e2> (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper","sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper"}
{"PMID":16207494,"re_id":6,"annotated sentence":"In the present study, age-related changes of <e1>pyridoxal 5'-phosphate<\\e1> (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (<e2>PNPO<\\e2> , their protein contents and activities were examined in the gerbil hippocampus proper","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyridoxal 5'-phosphate","object":"PNPO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, age-related changes of <e1>CHEMICAL<\\e1> (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (<e2>GENE-N<\\e2> , their protein contents and activities were examined in the gerbil hippocampus proper","sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (PNPO , their protein contents and activities were examined in the gerbil hippocampus proper"}
{"PMID":16207494,"re_id":7,"annotated sentence":"In the present study, age-related changes of <e1>pyridoxal 5'-phosphate<\\e1> (PLP) synthesizing enzymes, <e2>pyridoxal kinase<\\e2> (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyridoxal 5'-phosphate","object":"pyridoxal kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, age-related changes of <e1>CHEMICAL<\\e1> (PLP) synthesizing enzymes, <e2>GENE-N<\\e2> (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper","sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper"}
{"PMID":16207494,"re_id":8,"annotated sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (<e1>PLP<\\e1>  synthesizing enzymes, pyridoxal kinase (<e2>PLK<\\e2>  and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PLP","object":"PLK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (<e1>CHEMICAL<\\e1>  synthesizing enzymes, pyridoxal kinase (<e2>GENE-N<\\e2>  and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper","sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (PLP  synthesizing enzymes, pyridoxal kinase (PLK  and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper"}
{"PMID":16207494,"re_id":9,"annotated sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (<e1>PLP<\\e1>  synthesizing enzymes, pyridoxal kinase (PLK) and <e2>pyridoxine 5'-phosphate oxidase<\\e2> (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PLP","object":"pyridoxine 5'-phosphate oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (<e1>CHEMICAL<\\e1>  synthesizing enzymes, pyridoxal kinase (PLK) and <e2>GENE-N<\\e2> (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper","sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (PLP  synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper"}
{"PMID":16207494,"re_id":10,"annotated sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (<e1>PLP<\\e1>  synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (<e2>PNPO<\\e2> , their protein contents and activities were examined in the gerbil hippocampus proper","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PLP","object":"PNPO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (<e1>CHEMICAL<\\e1>  synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (<e2>GENE-N<\\e2> , their protein contents and activities were examined in the gerbil hippocampus proper","sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (PLP  synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (PNPO , their protein contents and activities were examined in the gerbil hippocampus proper"}
{"PMID":16207494,"re_id":11,"annotated sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (<e1>PLP<\\e1>  synthesizing enzymes, <e2>pyridoxal kinase<\\e2> (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PLP","object":"pyridoxal kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (<e1>CHEMICAL<\\e1>  synthesizing enzymes, <e2>GENE-N<\\e2> (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper","sentence":"In the present study, age-related changes of pyridoxal 5'-phosphate (PLP  synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper"}
{"PMID":16213084,"re_id":4,"annotated sentence":"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical <e2>monocarboxylate transporter<\\e2> (MCT) inhibitor, <e1>alpha-cyano-4-hydroxycinnamic acid<\\e1>  suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"alpha-cyano-4-hydroxycinnamic acid","object":"monocarboxylate transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical <e2>GENE-N<\\e2> (MCT) inhibitor, <e1>CHEMICAL<\\e1>  suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system","sentence":"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid  suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system"}
{"PMID":16213084,"re_id":5,"annotated sentence":"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (<e2>MCT<\\e2>  inhibitor, <e1>alpha-cyano-4-hydroxycinnamic acid<\\e1>  suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"alpha-cyano-4-hydroxycinnamic acid","object":"MCT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (<e2>GENE-N<\\e2>  inhibitor, <e1>CHEMICAL<\\e1>  suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system","sentence":"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT  inhibitor, alpha-cyano-4-hydroxycinnamic acid  suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system"}
{"PMID":16213084,"re_id":6,"annotated sentence":"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that <e1>nicotinate<\\e1> uptake by rat astrocytes is mediated by H(+)-coupled <e2>monocarboxylate transport system<\\e2>  [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"nicotinate","object":"monocarboxylate transport system","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that <e1>CHEMICAL<\\e1> uptake by rat astrocytes is mediated by H(+)-coupled <e2>GENE-N<\\e2>  [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)","sentence":"This process was reduced by a protonophore, carbonylcyanide p-trifluoromethoxyphenylhydrazone, and a typical monocarboxylate transporter (MCT) inhibitor, alpha-cyano-4-hydroxycinnamic acid, suggesting that nicotinate uptake by rat astrocytes is mediated by H(+)-coupled monocarboxylate transport system  [(3)H]Nicotinate transport in rat astrocytes was significantly inhibited by various monocarboxylic acids such as l-lactic acid and pyruvic acid with a relatively low affinity (K(i)>10 mM)"}
{"PMID":16213084,"re_id":7,"annotated sentence":"Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that <e1>nicotinate<\\e1> uptake in rat astrocytes is mediated by <e2>MCT1<\\e2> and\/or MCT2","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"nicotinate","object":"MCT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Because l-lactate reduced to 67% of the CHEMICAL uptake even at 10mM, it is unlikely that <e1>CHEMICAL<\\e1> uptake in rat astrocytes is mediated by <e2>GENE-Y<\\e2> and\/or MCT2","sentence":"Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and\/or MCT2"}
{"PMID":16213084,"re_id":8,"annotated sentence":"Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that <e1>nicotinate<\\e1> uptake in rat astrocytes is mediated by MCT1 and\/or <e2>MCT2<\\e2>  These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"nicotinate","object":"MCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Because l-lactate reduced to 67% of the CHEMICAL uptake even at 10mM, it is unlikely that <e1>CHEMICAL<\\e1> uptake in rat astrocytes is mediated by MCT1 and\/or <e2>GENE-Y<\\e2>  These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for CHEMICAL in rat cerebrocortical astrocytes.","sentence":"Because l-lactate reduced to 67% of the nicotinate uptake even at 10mM, it is unlikely that nicotinate uptake in rat astrocytes is mediated by MCT1 and\/or MCT2  These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes."}
{"PMID":16213084,"re_id":9,"annotated sentence":"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a <e2>low-affinity monocarboxylate transporter<\\e2> MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for <e1>nicotinate<\\e1> in rat cerebrocortical astrocytes.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"nicotinate","object":"low-affinity monocarboxylate transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a <e2>GENE-N<\\e2> MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for <e1>CHEMICAL<\\e1> in rat cerebrocortical astrocytes.","sentence":"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes."}
{"PMID":16213084,"re_id":10,"annotated sentence":"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter <e2>MCT4<\\e2> or other unknown H(+)-coupled monocarboxylate transport system, for <e1>nicotinate<\\e1> in rat cerebrocortical astrocytes.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"nicotinate","object":"MCT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter <e2>GENE-Y<\\e2> or other unknown H(+)-coupled monocarboxylate transport system, for <e1>CHEMICAL<\\e1> in rat cerebrocortical astrocytes.","sentence":"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown H(+)-coupled monocarboxylate transport system, for nicotinate in rat cerebrocortical astrocytes."}
{"PMID":16213084,"re_id":11,"annotated sentence":"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown <e2>H(+)-coupled monocarboxylate transport system<\\e2>  for <e1>nicotinate<\\e1> in rat cerebrocortical astrocytes.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"nicotinate","object":"H(+)-coupled monocarboxylate transport system","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown <e2>GENE-N<\\e2>  for <e1>CHEMICAL<\\e1> in rat cerebrocortical astrocytes.","sentence":"These results provide biochemical evidence of a H(+)-coupled and saturable transport system, presumed to be a low-affinity monocarboxylate transporter MCT4 or other unknown H(+)-coupled monocarboxylate transport system  for nicotinate in rat cerebrocortical astrocytes."}
{"PMID":16220064,"re_id":2,"annotated sentence":"A review of the structural and functional features of <e1>olmesartan medoxomil<\\e1>  an <e2>angiotensin receptor<\\e2> blocker","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"olmesartan medoxomil","object":"angiotensin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A review of the structural and functional features of <e1>CHEMICAL<\\e1>  an <e2>GENE-N<\\e2> blocker","sentence":"A review of the structural and functional features of olmesartan medoxomil  an angiotensin receptor blocker"}
{"PMID":16220064,"re_id":3,"annotated sentence":"The marked antihypertensive efficacy of <e1>olmesartan medoxomil<\\e1> may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of <e2>A-II<\\e2>  This review article characterizes the structural features of olmesartan that may be responsible for its clinical efficacy","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"olmesartan medoxomil","object":"A-II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The marked antihypertensive efficacy of <e1>CHEMICAL<\\e1> may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of <e2>GENE-Y<\\e2>  This review article characterizes the structural features of olmesartan that may be responsible for its clinical efficacy","sentence":"The marked antihypertensive efficacy of olmesartan medoxomil may result from a unique pharmacological interaction of the drug with the AT1 receptor, resulting in a potent, long-lasting, dose-dependent blockade of A-II  This review article characterizes the structural features of olmesartan that may be responsible for its clinical efficacy"}
{"PMID":16245075,"re_id":0,"annotated sentence":"We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific <e2>neutrophil elastase<\\e2> inhibitor (<e1>ONO-5046<\\e1>  on acid lung injury in rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ONO-5046","object":"neutrophil elastase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific <e2>GENE-Y<\\e2> inhibitor (<e1>CHEMICAL<\\e1>  on acid lung injury in rats","sentence":"We examined the effects of the high dose of granulocyte-colony stimulating factor (G-CSF), which is capable of increasing peripheral neutrophils, and a specific neutrophil elastase inhibitor (ONO-5046  on acid lung injury in rats"}
{"PMID":16245075,"re_id":1,"annotated sentence":"Effects of <e2>granulocyte colony-stimulating factor<\\e2> (G-CSF) and neutrophil elastase inhibitor (<e1>ONO-5046<\\e1>  on acid-induced lung injury in rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ONO-5046","object":"granulocyte colony-stimulating factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effects of <e2>GENE-Y<\\e2> (G-CSF) and neutrophil elastase inhibitor (<e1>CHEMICAL<\\e1>  on acid-induced lung injury in rats","sentence":"Effects of granulocyte colony-stimulating factor (G-CSF) and neutrophil elastase inhibitor (ONO-5046  on acid-induced lung injury in rats"}
{"PMID":16245075,"re_id":2,"annotated sentence":"Effects of granulocyte colony-stimulating factor (<e2>G-CSF<\\e2>  and neutrophil elastase inhibitor (<e1>ONO-5046<\\e1>  on acid-induced lung injury in rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ONO-5046","object":"G-CSF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effects of granulocyte colony-stimulating factor (<e2>GENE-Y<\\e2>  and neutrophil elastase inhibitor (<e1>CHEMICAL<\\e1>  on acid-induced lung injury in rats","sentence":"Effects of granulocyte colony-stimulating factor (G-CSF  and neutrophil elastase inhibitor (ONO-5046  on acid-induced lung injury in rats"}
{"PMID":16245075,"re_id":3,"annotated sentence":"Effects of granulocyte colony-stimulating factor (G-CSF) and <e2>neutrophil elastase<\\e2> inhibitor (<e1>ONO-5046<\\e1>  on acid-induced lung injury in rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ONO-5046","object":"neutrophil elastase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effects of granulocyte colony-stimulating factor (G-CSF) and <e2>GENE-Y<\\e2> inhibitor (<e1>CHEMICAL<\\e1>  on acid-induced lung injury in rats","sentence":"Effects of granulocyte colony-stimulating factor (G-CSF) and neutrophil elastase inhibitor (ONO-5046  on acid-induced lung injury in rats"}
{"PMID":16247743,"re_id":0,"annotated sentence":"<e1>Miglustat<\\e1>  an imino sugar that reversibly inhibits <e2>glucosylceramide synthase<\\e2> and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Miglustat","object":"glucosylceramide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  an imino sugar that reversibly inhibits <e2>GENE-Y<\\e2> and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option","sentence":"Miglustat  an imino sugar that reversibly inhibits glucosylceramide synthase and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option"}
{"PMID":16247743,"re_id":1,"annotated sentence":"Miglustat, an <e1>imino sugar<\\e1> that reversibly inhibits <e2>glucosylceramide synthase<\\e2> and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"imino sugar","object":"glucosylceramide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Miglustat, an <e1>CHEMICAL<\\e1> that reversibly inhibits <e2>GENE-Y<\\e2> and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option","sentence":"Miglustat, an imino sugar that reversibly inhibits glucosylceramide synthase and reduces intracellular substrate burden, is an oral treatment for patients with type 1 GD that was recently approved in the United States for symptomatic patients with mild to moderate clinical manifestations for whom ERT is not an option"}
{"PMID":16248990,"re_id":2,"annotated sentence":"This effect was reverted in the presence of <e1>atropine<\\e1> (ATR; 0.1 microM), which blocks the pre-synaptic <e2>muscarinic M2 receptor<\\e2>  After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a dopamine D2 antagonist","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"atropine","object":"muscarinic M2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This effect was reverted in the presence of <e1>CHEMICAL<\\e1> (ATR; 0.1 microM), which blocks the pre-synaptic <e2>GENE-Y<\\e2>  After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a dopamine D2 antagonist","sentence":"This effect was reverted in the presence of atropine (ATR; 0.1 microM), which blocks the pre-synaptic muscarinic M2 receptor  After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a dopamine D2 antagonist"}
{"PMID":16248990,"re_id":3,"annotated sentence":"This effect was reverted in the presence of atropine (<e1>ATR<\\e1>  0.1 microM), which blocks the pre-synaptic <e2>muscarinic M2 receptor<\\e2>  After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a dopamine D2 antagonist","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ATR","object":"muscarinic M2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This effect was reverted in the presence of atropine (<e1>CHEMICAL<\\e1>  0.1 microM), which blocks the pre-synaptic <e2>GENE-Y<\\e2>  After that, a wide range of concentrations of drugs, concomitantly with CHEMICAL (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a dopamine D2 antagonist","sentence":"This effect was reverted in the presence of atropine (ATR  0.1 microM), which blocks the pre-synaptic muscarinic M2 receptor  After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a dopamine D2 antagonist"}
{"PMID":16248990,"re_id":4,"annotated sentence":"Nicotinic-receptor potentiator drugs, huprine X and <e1>galantamine<\\e1>  increase ACh release by blocking <e2>AChE<\\e2> activity but not acting on nicotinic receptors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"galantamine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nicotinic-receptor potentiator drugs, huprine X and <e1>CHEMICAL<\\e1>  increase ACh release by blocking <e2>GENE-Y<\\e2> activity but not acting on nicotinic receptors","sentence":"Nicotinic-receptor potentiator drugs, huprine X and galantamine  increase ACh release by blocking AChE activity but not acting on nicotinic receptors"}
{"PMID":16248990,"re_id":5,"annotated sentence":"To test the role of <e2>nicotinic receptors<\\e2> in the drugs' effects on [3H]-ACh release, <e1>mecamylamine<\\e1> (MEC) 100 microM was used to block such receptors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"mecamylamine","object":"nicotinic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To test the role of <e2>GENE-N<\\e2> in the drugs' effects on [3H]-ACh release, <e1>CHEMICAL<\\e1> (MEC) 100 microM was used to block such receptors","sentence":"To test the role of nicotinic receptors in the drugs' effects on [3H]-ACh release, mecamylamine (MEC) 100 microM was used to block such receptors"}
{"PMID":16248990,"re_id":6,"annotated sentence":"To test the role of <e2>nicotinic receptors<\\e2> in the drugs' effects on [3H]-ACh release, mecamylamine (<e1>MEC<\\e1>  100 microM was used to block such receptors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"MEC","object":"nicotinic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To test the role of <e2>GENE-N<\\e2> in the drugs' effects on [3H]-ACh release, mecamylamine (<e1>CHEMICAL<\\e1>  100 microM was used to block such receptors","sentence":"To test the role of nicotinic receptors in the drugs' effects on [3H]-ACh release, mecamylamine (MEC  100 microM was used to block such receptors"}
{"PMID":16248990,"re_id":7,"annotated sentence":"After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of <e1>haloperidol<\\e1> (HAL; 0.01 microM), a <e2>dopamine D2<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"haloperidol","object":"dopamine D2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of <e1>CHEMICAL<\\e1> (HAL; 0.01 microM), a <e2>GENE-Y<\\e2> antagonist","sentence":"After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (HAL; 0.01 microM), a dopamine D2 antagonist"}
{"PMID":16248990,"re_id":8,"annotated sentence":"After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (<e1>HAL<\\e1>  0.01 microM), a <e2>dopamine D2<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"HAL","object":"dopamine D2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (<e1>CHEMICAL<\\e1>  0.01 microM), a <e2>GENE-Y<\\e2> antagonist","sentence":"After that, a wide range of concentrations of drugs, concomitantly with ATR (0.1 microM), was studied in the presence of haloperidol (HAL  0.01 microM), a dopamine D2 antagonist"}
{"PMID":16253547,"re_id":4,"annotated sentence":"mRNA levels for <e2>RAR-alpha<\\e2>  RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with <e1>retinoid<\\e1> supplementation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"retinoid","object":"RAR-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"mRNA levels for <e2>GENE-Y<\\e2>  RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with <e1>CHEMICAL<\\e1> supplementation","sentence":"mRNA levels for RAR-alpha  RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation"}
{"PMID":16253547,"re_id":5,"annotated sentence":"mRNA levels for RAR-alpha, <e2>RAR-beta<\\e2> and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with <e1>retinoid<\\e1> supplementation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"retinoid","object":"RAR-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"mRNA levels for RAR-alpha, <e2>GENE-Y<\\e2> and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with <e1>CHEMICAL<\\e1> supplementation","sentence":"mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation"}
{"PMID":16253547,"re_id":6,"annotated sentence":"mRNA levels for RAR-alpha, RAR-beta and <e2>RAR-gamma<\\e2>  the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with <e1>retinoid<\\e1> supplementation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"retinoid","object":"RAR-gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"mRNA levels for RAR-alpha, RAR-beta and <e2>GENE-Y<\\e2>  the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with <e1>CHEMICAL<\\e1> supplementation","sentence":"mRNA levels for RAR-alpha, RAR-beta and RAR-gamma  the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation"}
{"PMID":16253547,"re_id":7,"annotated sentence":"mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the <e2>nuclear receptors<\\e2> for retinoic acid, decreased during activation of freshly isolated HSC even with <e1>retinoid<\\e1> supplementation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"retinoid","object":"nuclear receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the <e2>GENE-N<\\e2> for retinoic acid, decreased during activation of freshly isolated HSC even with <e1>CHEMICAL<\\e1> supplementation","sentence":"mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation"}
{"PMID":16324695,"re_id":1,"annotated sentence":"Preincubation with 1 microM of the <e2>protein kinase C<\\e2> (PKC) activator phorbol 12-myristate 13-acetate (<e1>PMA<\\e1>  caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"PMA","object":"protein kinase C","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Preincubation with 1 microM of the <e2>GENE-N<\\e2> (PKC) activator phorbol 12-myristate 13-acetate (<e1>CHEMICAL<\\e1>  caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization","sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA  caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization"}
{"PMID":16324695,"re_id":2,"annotated sentence":"Preincubation with 1 microM of the protein kinase C (<e2>PKC<\\e2>  activator phorbol 12-myristate 13-acetate (<e1>PMA<\\e1>  caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"PMA","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Preincubation with 1 microM of the protein kinase C (<e2>GENE-N<\\e2>  activator phorbol 12-myristate 13-acetate (<e1>CHEMICAL<\\e1>  caused a small but significant decrease in isoprenaline-induced E(max), indicating activated GENE-N-mediated heterologous beta(2)-adrenoceptor desensitization","sentence":"Preincubation with 1 microM of the protein kinase C (PKC  activator phorbol 12-myristate 13-acetate (PMA  caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization"}
{"PMID":16324695,"re_id":3,"annotated sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (<e1>PMA<\\e1>  caused a small but significant decrease in isoprenaline-induced E(max), indicating activated <e2>PKC<\\e2> mediated heterologous beta(2)-adrenoceptor desensitization","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"PMA","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Preincubation with 1 microM of the protein kinase C (GENE-N) activator phorbol 12-myristate 13-acetate (<e1>CHEMICAL<\\e1>  caused a small but significant decrease in isoprenaline-induced E(max), indicating activated <e2>GENE-N<\\e2> mediated heterologous beta(2)-adrenoceptor desensitization","sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA  caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC mediated heterologous beta(2)-adrenoceptor desensitization"}
{"PMID":16324695,"re_id":4,"annotated sentence":"Preincubation with 1 microM of the <e2>protein kinase C<\\e2> (PKC) activator <e1>phorbol 12-myristate 13-acetate<\\e1> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"phorbol 12-myristate 13-acetate","object":"protein kinase C","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Preincubation with 1 microM of the <e2>GENE-N<\\e2> (PKC) activator <e1>CHEMICAL<\\e1> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization","sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization"}
{"PMID":16324695,"re_id":5,"annotated sentence":"Preincubation with 1 microM of the protein kinase C (<e2>PKC<\\e2>  activator <e1>phorbol 12-myristate 13-acetate<\\e1> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"phorbol 12-myristate 13-acetate","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Preincubation with 1 microM of the protein kinase C (<e2>GENE-N<\\e2>  activator <e1>CHEMICAL<\\e1> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated GENE-N-mediated heterologous beta(2)-adrenoceptor desensitization","sentence":"Preincubation with 1 microM of the protein kinase C (PKC  activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization"}
{"PMID":16324695,"re_id":6,"annotated sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator <e1>phorbol 12-myristate 13-acetate<\\e1> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated <e2>PKC<\\e2> mediated heterologous beta(2)-adrenoceptor desensitization","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"phorbol 12-myristate 13-acetate","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Preincubation with 1 microM of the protein kinase C (GENE-N) activator <e1>CHEMICAL<\\e1> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated <e2>GENE-N<\\e2> mediated heterologous beta(2)-adrenoceptor desensitization","sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC mediated heterologous beta(2)-adrenoceptor desensitization"}
{"PMID":16324695,"re_id":7,"annotated sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (<e1>PMA<\\e1>  caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous <e2>beta(2)-adrenoceptor<\\e2> desensitization","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"PMA","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (<e1>CHEMICAL<\\e1>  caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous <e2>GENE-Y<\\e2> desensitization","sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA  caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization"}
{"PMID":16324695,"re_id":8,"annotated sentence":"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of <e1>fenoterol<\\e1> decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the <e2>beta(2)-adrenoceptor<\\e2>  Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"fenoterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of <e1>CHEMICAL<\\e1> decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the <e2>GENE-Y<\\e2>  Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous GENE-Y desensitization","sentence":"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased isoprenaline-induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the beta(2)-adrenoceptor  Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization"}
{"PMID":16324695,"re_id":9,"annotated sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator <e1>phorbol 12-myristate 13-acetate<\\e1> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous <e2>beta(2)-adrenoceptor<\\e2> desensitization","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"phorbol 12-myristate 13-acetate","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator <e1>CHEMICAL<\\e1> (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous <e2>GENE-Y<\\e2> desensitization","sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization"}
{"PMID":16324695,"re_id":10,"annotated sentence":"Moreover, the specific <e2>PKC<\\e2> inhibitor <e1>2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide<\\e1> (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, the specific <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented","sentence":"Moreover, the specific PKC inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X) markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented"}
{"PMID":16324695,"re_id":11,"annotated sentence":"Moreover, the specific <e2>PKC<\\e2> inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (<e1>GF 109203X<\\e1>  markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GF 109203X","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, the specific <e2>GENE-N<\\e2> inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (<e1>CHEMICAL<\\e1>  markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented","sentence":"Moreover, the specific PKC inhibitor 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF 109203X  markedly increased the potency and E(max) of isoprenaline for all conditions used, including control conditions, and the synergistic effects of PMA and fenoterol were completely prevented"}
{"PMID":16324695,"re_id":12,"annotated sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in <e1>isoprenaline<\\e1> induced E(max), indicating activated PKC-mediated heterologous <e2>beta(2)-adrenoceptor<\\e2> desensitization","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"isoprenaline","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in <e1>CHEMICAL<\\e1> induced E(max), indicating activated PKC-mediated heterologous <e2>GENE-Y<\\e2> desensitization","sentence":"Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization"}
{"PMID":16324695,"re_id":13,"annotated sentence":"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased <e1>isoprenaline<\\e1> induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the <e2>beta(2)-adrenoceptor<\\e2>  Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"isoprenaline","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased <e1>CHEMICAL<\\e1> induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the <e2>GENE-Y<\\e2>  Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in CHEMICAL-induced E(max), indicating activated PKC-mediated heterologous GENE-Y desensitization","sentence":"Preincubation (30 min) of bovine tracheal smooth muscle with various concentrations (0.1, 1 and 10 microM) of fenoterol decreased isoprenaline induced maximal relaxation (E(max)) of methacholine-contracted preparations in a concentration dependent fashion, indicating desensitization of the beta(2)-adrenoceptor  Preincubation with 1 microM of the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) caused a small but significant decrease in isoprenaline-induced E(max), indicating activated PKC-mediated heterologous beta(2)-adrenoceptor desensitization"}
{"PMID":16336752,"re_id":0,"annotated sentence":"Tyrosine kinase inhibitors are <e1>quinazoline<\\e1> derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of <e2>EGFR<\\e2> signaling","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"quinazoline","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Tyrosine kinase inhibitors are <e1>CHEMICAL<\\e1> derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including GENE-Y, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of <e2>GENE-Y<\\e2> signaling","sentence":"Tyrosine kinase inhibitors are quinazoline derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling"}
{"PMID":16336752,"re_id":1,"annotated sentence":"<e2>Tyrosine kinase<\\e2> inhibitors are <e1>quinazoline<\\e1> derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"quinazoline","object":"Tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> inhibitors are <e1>CHEMICAL<\\e1> derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling","sentence":"Tyrosine kinase inhibitors are quinazoline derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling"}
{"PMID":16336752,"re_id":2,"annotated sentence":"Tyrosine kinase inhibitors are <e1>quinazoline<\\e1> derived, low molecular weight synthetic molecules that can block the intracellular <e2>tyrosine kinase domain<\\e2> of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"quinazoline","object":"tyrosine kinase domain","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Tyrosine kinase inhibitors are <e1>CHEMICAL<\\e1> derived, low molecular weight synthetic molecules that can block the intracellular <e2>GENE-N<\\e2> of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling","sentence":"Tyrosine kinase inhibitors are quinazoline derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling"}
{"PMID":16336752,"re_id":3,"annotated sentence":"Tyrosine kinase inhibitors are <e1>quinazoline<\\e1> derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including <e2>EGFR<\\e2>  Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"quinazoline","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Tyrosine kinase inhibitors are <e1>CHEMICAL<\\e1> derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including <e2>GENE-Y<\\e2>  Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of GENE-Y signaling","sentence":"Tyrosine kinase inhibitors are quinazoline derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR  Erb2, and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling"}
{"PMID":16336752,"re_id":4,"annotated sentence":"Tyrosine kinase inhibitors are <e1>quinazoline<\\e1> derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, <e2>Erb2<\\e2>  and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"quinazoline","object":"Erb2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Tyrosine kinase inhibitors are <e1>CHEMICAL<\\e1> derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, <e2>GENE-Y<\\e2>  and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling","sentence":"Tyrosine kinase inhibitors are quinazoline derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2  and vascular endothelial growth factor receptor, and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling"}
{"PMID":16336752,"re_id":5,"annotated sentence":"Tyrosine kinase inhibitors are <e1>quinazoline<\\e1> derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and <e2>vascular endothelial growth factor receptor<\\e2>  and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"quinazoline","object":"vascular endothelial growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Tyrosine kinase inhibitors are <e1>CHEMICAL<\\e1> derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and <e2>GENE-N<\\e2>  and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling","sentence":"Tyrosine kinase inhibitors are quinazoline derived, low molecular weight synthetic molecules that can block the intracellular tyrosine kinase domain of several receptors, including EGFR, Erb2, and vascular endothelial growth factor receptor  and thereby inhibit ligand-induced receptor phosphorylation and abrogate the biologic effect of EGFR signaling"}
{"PMID":16373326,"re_id":2,"annotated sentence":"When expressed heterologously in a mammalian cell line, <e2>rabbit PAT1<\\e2> mediates pH-dependent, Na(+)-independent uptake of <e1>proline<\\e1>  glycine, l-alanine and alpha-(methylamino)isobutyric acid","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"proline","object":"rabbit PAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When expressed heterologously in a mammalian cell line, <e2>GENE-Y<\\e2> mediates pH-dependent, Na(+)-independent uptake of <e1>CHEMICAL<\\e1>  glycine, l-alanine and alpha-(methylamino)isobutyric acid","sentence":"When expressed heterologously in a mammalian cell line, rabbit PAT1 mediates pH-dependent, Na(+)-independent uptake of proline  glycine, l-alanine and alpha-(methylamino)isobutyric acid"}
{"PMID":16373326,"re_id":3,"annotated sentence":"When expressed heterologously in a mammalian cell line, <e2>rabbit PAT1<\\e2> mediates pH-dependent, Na(+)-independent uptake of proline, <e1>glycine<\\e1>  l-alanine and alpha-(methylamino)isobutyric acid","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glycine","object":"rabbit PAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When expressed heterologously in a mammalian cell line, <e2>GENE-Y<\\e2> mediates pH-dependent, Na(+)-independent uptake of proline, <e1>CHEMICAL<\\e1>  l-alanine and alpha-(methylamino)isobutyric acid","sentence":"When expressed heterologously in a mammalian cell line, rabbit PAT1 mediates pH-dependent, Na(+)-independent uptake of proline, glycine  l-alanine and alpha-(methylamino)isobutyric acid"}
{"PMID":16373326,"re_id":4,"annotated sentence":"When expressed heterologously in a mammalian cell line, <e2>rabbit PAT1<\\e2> mediates pH-dependent, Na(+)-independent uptake of proline, glycine, <e1>l-alanine<\\e1> and alpha-(methylamino)isobutyric acid","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"l-alanine","object":"rabbit PAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When expressed heterologously in a mammalian cell line, <e2>GENE-Y<\\e2> mediates pH-dependent, Na(+)-independent uptake of proline, glycine, <e1>CHEMICAL<\\e1> and alpha-(methylamino)isobutyric acid","sentence":"When expressed heterologously in a mammalian cell line, rabbit PAT1 mediates pH-dependent, Na(+)-independent uptake of proline, glycine, l-alanine and alpha-(methylamino)isobutyric acid"}
{"PMID":16373326,"re_id":5,"annotated sentence":"When expressed heterologously in a mammalian cell line, <e2>rabbit PAT1<\\e2> mediates pH-dependent, Na(+)-independent uptake of proline, glycine, l-alanine and <e1>alpha-(methylamino)isobutyric acid<\\e1>  Proline uptake was maximal at pH 5.0 (K(m) 2.2+\/-0.7 mM)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"alpha-(methylamino)isobutyric acid","object":"rabbit PAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When expressed heterologously in a mammalian cell line, <e2>GENE-Y<\\e2> mediates pH-dependent, Na(+)-independent uptake of proline, glycine, l-alanine and <e1>CHEMICAL<\\e1>  Proline uptake was maximal at pH 5.0 (K(m) 2.2+\/-0.7 mM)","sentence":"When expressed heterologously in a mammalian cell line, rabbit PAT1 mediates pH-dependent, Na(+)-independent uptake of proline, glycine, l-alanine and alpha-(methylamino)isobutyric acid  Proline uptake was maximal at pH 5.0 (K(m) 2.2+\/-0.7 mM)"}
{"PMID":16373326,"re_id":6,"annotated sentence":"In the presence of Na+ and under conditions in which <e2>PAT1<\\e2> transport function was suppressed, a second <e1>proline<\\e1> uptake system was detected that exhibited functional characteristics similar to those of the IMINO system","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"proline","object":"PAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the presence of Na+ and under conditions in which <e2>GENE-Y<\\e2> transport function was suppressed, a second <e1>CHEMICAL<\\e1> uptake system was detected that exhibited functional characteristics similar to those of the IMINO system","sentence":"In the presence of Na+ and under conditions in which PAT1 transport function was suppressed, a second proline uptake system was detected that exhibited functional characteristics similar to those of the IMINO system"}
{"PMID":16373326,"re_id":7,"annotated sentence":"The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that <e2>PAT1<\\e2> is the low-affinity transporter of <e1>proline<\\e1>  glycine and hydroxyproline believed to be defective in patients with iminoglycinuria.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"proline","object":"PAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The functional characteristics of rabbit GENE-Y in either mammalian cells or renal BBMV suggest that <e2>GENE-Y<\\e2> is the low-affinity transporter of <e1>CHEMICAL<\\e1>  glycine and hydroxyCHEMICAL believed to be defective in patients with iminoglycinuria.","sentence":"The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that PAT1 is the low-affinity transporter of proline  glycine and hydroxyproline believed to be defective in patients with iminoglycinuria."}
{"PMID":16373326,"re_id":8,"annotated sentence":"The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that <e2>PAT1<\\e2> is the low-affinity transporter of proline, <e1>glycine<\\e1> and hydroxyproline believed to be defective in patients with iminoglycinuria.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glycine","object":"PAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The functional characteristics of rabbit GENE-Y in either mammalian cells or renal BBMV suggest that <e2>GENE-Y<\\e2> is the low-affinity transporter of proline, <e1>CHEMICAL<\\e1> and hydroxyproline believed to be defective in patients with iminoglycinuria.","sentence":"The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that PAT1 is the low-affinity transporter of proline, glycine and hydroxyproline believed to be defective in patients with iminoglycinuria."}
{"PMID":16373326,"re_id":9,"annotated sentence":"The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that <e2>PAT1<\\e2> is the low-affinity transporter of proline, glycine and <e1>hydroxyproline<\\e1> believed to be defective in patients with iminoglycinuria.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"hydroxyproline","object":"PAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The functional characteristics of rabbit GENE-Y in either mammalian cells or renal BBMV suggest that <e2>GENE-Y<\\e2> is the low-affinity transporter of proline, glycine and <e1>CHEMICAL<\\e1> believed to be defective in patients with iminoglycinuria.","sentence":"The functional characteristics of rabbit PAT1 in either mammalian cells or renal BBMV suggest that PAT1 is the low-affinity transporter of proline, glycine and hydroxyproline believed to be defective in patients with iminoglycinuria."}
{"PMID":16388933,"re_id":6,"annotated sentence":"The fact that <e1>trimipramine<\\e1> also suppressed <e2>IFN-gamma<\\e2> production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"trimipramine","object":"IFN-gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The fact that <e1>CHEMICAL<\\e1> also suppressed <e2>GENE-Y<\\e2> production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake","sentence":"The fact that trimipramine also suppressed IFN-gamma production and T-cell proliferation indicates that these immunomodulatory actions of antidepressants are most likely unrelated to inhibition of monoamine reuptake"}
{"PMID":16418149,"re_id":5,"annotated sentence":"The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean <e2>leptin<\\e2> level after 1 week of treatment with <e1>cyproheptadine<\\e1> (3.14 ng\/mL) was 14.2% higher than that at baseline (2.75 ng\/mL; P < .05)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"cyproheptadine","object":"leptin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean <e2>GENE-Y<\\e2> level after 1 week of treatment with <e1>CHEMICAL<\\e1> (3.14 ng\/mL) was 14.2% higher than that at baseline (2.75 ng\/mL; P < .05)","sentence":"The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean leptin level after 1 week of treatment with cyproheptadine (3.14 ng\/mL) was 14.2% higher than that at baseline (2.75 ng\/mL; P < .05)"}
{"PMID":16424790,"re_id":8,"annotated sentence":"Given the treatment with three doses of <e1>Captopril<\\e1> (15 approximately 45 mg\/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of <e2>PON1<\\e2> and SOD in serum by single intragastric gavaged L-methionine","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Captopril","object":"PON1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given the treatment with three doses of <e1>CHEMICAL<\\e1> (15 approximately 45 mg\/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of <e2>GENE-Y<\\e2> and SOD in serum by single intragastric gavaged L-methionine","sentence":"Given the treatment with three doses of Captopril (15 approximately 45 mg\/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and SOD in serum by single intragastric gavaged L-methionine"}
{"PMID":16424790,"re_id":9,"annotated sentence":"Given the treatment with three doses of <e1>Captopril<\\e1> (15 approximately 45 mg\/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and <e2>SOD<\\e2> in serum by single intragastric gavaged L-methionine","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Captopril","object":"SOD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Given the treatment with three doses of <e1>CHEMICAL<\\e1> (15 approximately 45 mg\/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and <e2>GENE-N<\\e2> in serum by single intragastric gavaged L-methionine","sentence":"Given the treatment with three doses of Captopril (15 approximately 45 mg\/kg) markedly attenuated inhibition of vasodilator responses to ACh, and eliminated the increased level of malondialdehyde, the decreased level of NO, activity of PON1 and SOD in serum by single intragastric gavaged L-methionine"}
{"PMID":16424790,"re_id":10,"annotated sentence":"These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of <e1>Captopril<\\e1> may be related to attenuating the decrease in <e2>PON1<\\e2> activity and NO levels","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Captopril","object":"PON1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggested that CHEMICAL can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of <e1>CHEMICAL<\\e1> may be related to attenuating the decrease in <e2>GENE-Y<\\e2> activity and NO levels","sentence":"These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in PON1 activity and NO levels"}
{"PMID":16424790,"re_id":11,"annotated sentence":"These results suggested that Captopril can protect the vascular endothelium against the damages induced by <e1>L-methionine<\\e1> in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in <e2>PON1<\\e2> activity and NO levels","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"L-methionine","object":"PON1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggested that Captopril can protect the vascular endothelium against the damages induced by <e1>CHEMICAL<\\e1> in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in <e2>GENE-Y<\\e2> activity and NO levels","sentence":"These results suggested that Captopril can protect the vascular endothelium against the damages induced by L-methionine in rats, and the beneficial effects of Captopril may be related to attenuating the decrease in PON1 activity and NO levels"}
{"PMID":16424790,"re_id":12,"annotated sentence":"We compared the effects of <e1>Captopril<\\e1> (an <e2>ACE<\\e2> inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Captopril","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We compared the effects of <e1>CHEMICAL<\\e1> (an <e2>GENE-Y<\\e2> inhibitor with -SH group), enalapril (an GENE-Y-inhibitor without -SH group), N-acetylcysteine (only -SH group not GENE-Y inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats","sentence":"We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats"}
{"PMID":16424790,"re_id":13,"annotated sentence":"We compared the effects of Captopril (an <e2>ACE<\\e2> inhibitor with -<e1>SH<\\e1> group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SH","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We compared the effects of Captopril (an <e2>GENE-Y<\\e2> inhibitor with -<e1>CHEMICAL<\\e1> group), enalapril (an GENE-Y-inhibitor without -CHEMICAL group), N-acetylcysteine (only -CHEMICAL group not GENE-Y inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats","sentence":"We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE-inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats"}
{"PMID":16424790,"re_id":14,"annotated sentence":"We compared the effects of Captopril (an ACE inhibitor with -SH group), <e1>enalapril<\\e1> (an <e2>ACE<\\e2> inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"enalapril","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We compared the effects of Captopril (an GENE-Y inhibitor with -SH group), <e1>CHEMICAL<\\e1> (an <e2>GENE-Y<\\e2> inhibitor without -SH group), N-acetylcysteine (only -SH group not GENE-Y inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats","sentence":"We compared the effects of Captopril (an ACE inhibitor with -SH group), enalapril (an ACE inhibitor without -SH group), N-acetylcysteine (only -SH group not ACE inhibitor) on endothelial dysfunction injured by methionine-induced hyperhomocysteinemia (HHcy) in rats"}
{"PMID":16424790,"re_id":15,"annotated sentence":"Comparison of <e1>captopril<\\e1> and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with <e2>ACE<\\e2> inhibitors in high dieted methionine mice","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"captopril","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Comparison of <e1>CHEMICAL<\\e1> and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with <e2>GENE-Y<\\e2> inhibitors in high dieted methionine mice","sentence":"Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice"}
{"PMID":16424790,"re_id":16,"annotated sentence":"Comparison of captopril and <e1>enalapril<\\e1> to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with <e2>ACE<\\e2> inhibitors in high dieted methionine mice","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"enalapril","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Comparison of captopril and <e1>CHEMICAL<\\e1> to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with <e2>GENE-Y<\\e2> inhibitors in high dieted methionine mice","sentence":"Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice"}
{"PMID":16424790,"re_id":17,"annotated sentence":"Comparison of captopril and enalapril to study the role of the <e1>sulfhydryl<\\e1> group in improvement of endothelial dysfunction with <e2>ACE<\\e2> inhibitors in high dieted methionine mice","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfhydryl","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Comparison of captopril and enalapril to study the role of the <e1>CHEMICAL<\\e1> group in improvement of endothelial dysfunction with <e2>GENE-Y<\\e2> inhibitors in high dieted methionine mice","sentence":"Comparison of captopril and enalapril to study the role of the sulfhydryl group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice"}
{"PMID":16424790,"re_id":18,"annotated sentence":"It was found that a single intragastric gavage by <e1>L-methionine<\\e1> resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of <e2>PON1<\\e2> and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"L-methionine","object":"PON1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It was found that a single intragastric gavage by <e1>CHEMICAL<\\e1> resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of <e2>GENE-Y<\\e2> and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group","sentence":"It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD, similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group"}
{"PMID":16424790,"re_id":19,"annotated sentence":"It was found that a single intragastric gavage by <e1>L-methionine<\\e1> resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and <e2>SOD<\\e2>  similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"L-methionine","object":"SOD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It was found that a single intragastric gavage by <e1>CHEMICAL<\\e1> resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and <e2>GENE-N<\\e2>  similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group","sentence":"It was found that a single intragastric gavage by L-methionine resulted in inhibition of endothelium-dependent relaxation, markedly increased the serum level of malondialdehyde and decreased the activity of PON1 and SOD  similarly decreased the level of NO in the serum; but had no effects on endothelium-independent relaxation and angiotensin-converting enzyme activity compared with the control group"}
{"PMID":16474853,"re_id":0,"annotated sentence":"In addition, <e1>sorafenib<\\e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, <e2>VEGFR-3<\\e2>  platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"sorafenib","object":"VEGFR-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, <e2>GENE-Y<\\e2>  platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT","sentence":"In addition, sorafenib demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3  platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT"}
{"PMID":16474853,"re_id":1,"annotated sentence":"In addition, <e1>sorafenib<\\e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, <e2>platelet-derived growth factor (PDGFR)-beta<\\e2> Flt-3, and c-KIT","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"sorafenib","object":"platelet-derived growth factor (PDGFR)-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, <e2>GENE-Y<\\e2> Flt-3, and c-KIT","sentence":"In addition, sorafenib demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT"}
{"PMID":16474853,"re_id":2,"annotated sentence":"In addition, <e1>sorafenib<\\e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta <e2>Flt-3<\\e2>  and c-KIT","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"sorafenib","object":"Flt-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta <e2>GENE-Y<\\e2>  and c-KIT","sentence":"In addition, sorafenib demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3  and c-KIT"}
{"PMID":16474853,"re_id":3,"annotated sentence":"In addition, <e1>sorafenib<\\e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and <e2>c-KIT<\\e2>  Preclinically, sorafenib showed broad-spectrum antitumor activity in colon, breast and non-small-cell lung cancer xenograft models","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"sorafenib","object":"c-KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and <e2>GENE-Y<\\e2>  Preclinically, CHEMICAL showed broad-spectrum antitumor activity in colon, breast and non-small-cell lung cancer xenograft models","sentence":"In addition, sorafenib demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT  Preclinically, sorafenib showed broad-spectrum antitumor activity in colon, breast and non-small-cell lung cancer xenograft models"}
{"PMID":16474853,"re_id":4,"annotated sentence":"In addition, <e1>sorafenib<\\e1> demonstrated significant activity against several <e2>receptor tyrosine kinases<\\e2> involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"sorafenib","object":"receptor tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> demonstrated significant activity against several <e2>GENE-N<\\e2> involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT","sentence":"In addition, sorafenib demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2, VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT"}
{"PMID":16474853,"re_id":5,"annotated sentence":"In addition, <e1>sorafenib<\\e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including <e2>vascular-endothelial growth factor (VEGFR)-2<\\e2>  VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"sorafenib","object":"vascular-endothelial growth factor (VEGFR)-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including <e2>GENE-Y<\\e2>  VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT","sentence":"In addition, sorafenib demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular-endothelial growth factor (VEGFR)-2  VEGFR-3, platelet-derived growth factor (PDGFR)-beta Flt-3, and c-KIT"}
{"PMID":16474853,"re_id":6,"annotated sentence":"Further characterization showed that <e1>sorafenib<\\e1> suppresses both wild-type and <e2>V599E<\\e2> mutant B-Raf activity in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"V599E","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Further characterization showed that <e1>CHEMICAL<\\e1> suppresses both wild-type and <e2>GENE-N<\\e2> mutant B-Raf activity in vitro","sentence":"Further characterization showed that sorafenib suppresses both wild-type and V599E mutant B-Raf activity in vitro"}
{"PMID":16474853,"re_id":7,"annotated sentence":"Further characterization showed that <e1>sorafenib<\\e1> suppresses both wild-type and V599E mutant <e2>B-Raf<\\e2> activity in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"B-Raf","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Further characterization showed that <e1>CHEMICAL<\\e1> suppresses both wild-type and V599E mutant <e2>GENE-Y<\\e2> activity in vitro","sentence":"Further characterization showed that sorafenib suppresses both wild-type and V599E mutant B-Raf activity in vitro"}
{"PMID":16474853,"re_id":8,"annotated sentence":"<e1>Sorafenib<\\e1>  which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of <e2>Raf-1<\\e2> and its favorable kinase selectivity profile","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sorafenib","object":"Raf-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of <e2>GENE-Y<\\e2> and its favorable kinase selectivity profile","sentence":"Sorafenib  which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable kinase selectivity profile"}
{"PMID":16474853,"re_id":9,"annotated sentence":"<e1>Sorafenib<\\e1>  which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable <e2>kinase<\\e2> selectivity profile","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sorafenib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable <e2>GENE-N<\\e2> selectivity profile","sentence":"Sorafenib  which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable kinase selectivity profile"}
{"PMID":16474853,"re_id":10,"annotated sentence":"Sorafenib, which belongs chemically to a class that can be described as <e1>bis-aryl ureas<\\e1>  was selected for further pharmacologic characterization based on potent inhibition of <e2>Raf-1<\\e2> and its favorable kinase selectivity profile","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bis-aryl ureas","object":"Raf-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sorafenib, which belongs chemically to a class that can be described as <e1>CHEMICAL<\\e1>  was selected for further pharmacologic characterization based on potent inhibition of <e2>GENE-Y<\\e2> and its favorable kinase selectivity profile","sentence":"Sorafenib, which belongs chemically to a class that can be described as bis-aryl ureas  was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable kinase selectivity profile"}
{"PMID":16474853,"re_id":11,"annotated sentence":"Sorafenib, which belongs chemically to a class that can be described as <e1>bis-aryl ureas<\\e1>  was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable <e2>kinase<\\e2> selectivity profile","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bis-aryl ureas","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib, which belongs chemically to a class that can be described as <e1>CHEMICAL<\\e1>  was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable <e2>GENE-N<\\e2> selectivity profile","sentence":"Sorafenib, which belongs chemically to a class that can be described as bis-aryl ureas  was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable kinase selectivity profile"}
{"PMID":16495926,"re_id":3,"annotated sentence":"The ability of <e1>bexarotene<\\e1> to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner <e2>peroxisome proliferator-activated receptor gamma<\\e2>  Collectively, our results suggest a role of bexarotene in treatment of angiogenesis and metastasis in solid tumours.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"bexarotene","object":"peroxisome proliferator-activated receptor gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ability of <e1>CHEMICAL<\\e1> to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner <e2>GENE-Y<\\e2>  Collectively, our results suggest a role of CHEMICAL in treatment of angiogenesis and metastasis in solid tumours.","sentence":"The ability of bexarotene to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner peroxisome proliferator-activated receptor gamma  Collectively, our results suggest a role of bexarotene in treatment of angiogenesis and metastasis in solid tumours."}
{"PMID":16495926,"re_id":4,"annotated sentence":"Analysis of tumour-conditioned medium indicated that <e1>bexarotene<\\e1> decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of <e2>matrix metalloproteinases<\\e2>  The ability of bexarotene to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner peroxisome proliferator-activated receptor gamma","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"bexarotene","object":"matrix metalloproteinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Analysis of tumour-conditioned medium indicated that <e1>CHEMICAL<\\e1> decreased the secretion of angiogenic factors and GENE-N and increased the tissue inhibitor of <e2>GENE-N<\\e2>  The ability of CHEMICAL to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner peroxisome proliferator-activated receptor gamma","sentence":"Analysis of tumour-conditioned medium indicated that bexarotene decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of matrix metalloproteinases  The ability of bexarotene to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner peroxisome proliferator-activated receptor gamma"}
{"PMID":16495926,"re_id":5,"annotated sentence":"Analysis of tumour-conditioned medium indicated that <e1>bexarotene<\\e1> decreased the secretion of angiogenic factors and <e2>matrix metalloproteinases<\\e2> and increased the tissue inhibitor of matrix metalloproteinases","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"bexarotene","object":"matrix metalloproteinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Analysis of tumour-conditioned medium indicated that <e1>CHEMICAL<\\e1> decreased the secretion of angiogenic factors and <e2>GENE-N<\\e2> and increased the tissue inhibitor of GENE-N","sentence":"Analysis of tumour-conditioned medium indicated that bexarotene decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of matrix metalloproteinases"}
{"PMID":16495926,"re_id":6,"annotated sentence":"A selective <e2>retinoid X receptor<\\e2> agonist <e1>bexarotene<\\e1> (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"bexarotene","object":"retinoid X receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A selective <e2>GENE-N<\\e2> agonist <e1>CHEMICAL<\\e1> (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours","sentence":"A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours"}
{"PMID":16495926,"re_id":7,"annotated sentence":"A selective <e2>retinoid X receptor<\\e2> agonist bexarotene (<e1>LGD1069<\\e1>  targretin) inhibits angiogenesis and metastasis in solid tumours","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"LGD1069","object":"retinoid X receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A selective <e2>GENE-N<\\e2> agonist bexarotene (<e1>CHEMICAL<\\e1>  targretin) inhibits angiogenesis and metastasis in solid tumours","sentence":"A selective retinoid X receptor agonist bexarotene (LGD1069  targretin) inhibits angiogenesis and metastasis in solid tumours"}
{"PMID":16495926,"re_id":8,"annotated sentence":"A selective <e2>retinoid X receptor<\\e2> agonist bexarotene (LGD1069, <e1>targretin<\\e1>  inhibits angiogenesis and metastasis in solid tumours","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"targretin","object":"retinoid X receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A selective <e2>GENE-N<\\e2> agonist bexarotene (LGD1069, <e1>CHEMICAL<\\e1>  inhibits angiogenesis and metastasis in solid tumours","sentence":"A selective retinoid X receptor agonist bexarotene (LGD1069, targretin  inhibits angiogenesis and metastasis in solid tumours"}
{"PMID":16495926,"re_id":9,"annotated sentence":"The present study determined the influence of a <e2>retinoid X receptor<\\e2> agonist <e1>bexarotene<\\e1> on angiogenesis and metastasis in solid tumours","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"bexarotene","object":"retinoid X receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present study determined the influence of a <e2>GENE-N<\\e2> agonist <e1>CHEMICAL<\\e1> on angiogenesis and metastasis in solid tumours","sentence":"The present study determined the influence of a retinoid X receptor agonist bexarotene on angiogenesis and metastasis in solid tumours"}
{"PMID":16532916,"re_id":1,"annotated sentence":"In subjects with dysmenorrhea the increase in pain following the administration of <e2>vasopressin<\\e2> was significantly lower during <e1>atosiban<\\e1> than during placebo infusion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"atosiban","object":"vasopressin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In subjects with dysmenorrhea the increase in pain following the administration of <e2>GENE-Y<\\e2> was significantly lower during <e1>CHEMICAL<\\e1> than during placebo infusion","sentence":"In subjects with dysmenorrhea the increase in pain following the administration of vasopressin was significantly lower during atosiban than during placebo infusion"}
{"PMID":16532916,"re_id":2,"annotated sentence":"CONCLUSIONS: <e1>Atosiban<\\e1> reduces <e2>vasopressin<\\e2> induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Atosiban","object":"vasopressin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: <e1>CHEMICAL<\\e1> reduces <e2>GENE-Y<\\e2> induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea","sentence":"CONCLUSIONS: Atosiban reduces vasopressin induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea"}
{"PMID":16599255,"re_id":0,"annotated sentence":"Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the <e2>acetylcholinesterase<\\e2> inhibitor <e1>tacrine<\\e1>  H3 receptor antagonism, inhibition of metabolisation of neuronal histamine as well as inhibition of hydrolysis of acetylcholine are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"tacrine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  H3 receptor antagonism, inhibition of metabolisation of neuronal histamine as well as inhibition of hydrolysis of acetylcholine are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease","sentence":"Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase, chemically show structural elements of the acetylcholinesterase inhibitor tacrine  H3 receptor antagonism, inhibition of metabolisation of neuronal histamine as well as inhibition of hydrolysis of acetylcholine are each one believed to improve reduced cognitive functions, which is useful for symptomatic treatment of Alzheimer's disease"}
{"PMID":16599255,"re_id":1,"annotated sentence":"Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of <e2>acetylcholinesterase<\\e2> and of butyrylcholinesterase which is another catalytic enzyme hydrolysing <e1>acetylcholine<\\e1>  Some compounds with (sub)nanomolar activities on the histamine-related targets are also active in the nanomolar concentration range on both cholinesterase targets being 5- to 40-times more potent than tacrine","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"acetylcholine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of <e2>CHEMICALsterase<\\e2> and of butyrylcholinesterase which is another catalytic enzyme hydrolysing <e1>CHEMICAL<\\e1>  Some compounds with (sub)nanomolar activities on the histamine-related targets are also active in the nanomolar concentration range on both cholinesterase targets being 5- to 40-times more potent than tacrine","sentence":"Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of acetylcholinesterase and of butyrylcholinesterase which is another catalytic enzyme hydrolysing acetylcholine  Some compounds with (sub)nanomolar activities on the histamine-related targets are also active in the nanomolar concentration range on both cholinesterase targets being 5- to 40-times more potent than tacrine"}
{"PMID":16599255,"re_id":2,"annotated sentence":"Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of acetylcholinesterase and of <e2>butyrylcholinesterase<\\e2> which is another catalytic enzyme hydrolysing <e1>acetylcholine<\\e1>  Some compounds with (sub)nanomolar activities on the histamine-related targets are also active in the nanomolar concentration range on both cholinesterase targets being 5- to 40-times more potent than tacrine","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"acetylcholine","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of CHEMICALsterase and of <e2>GENE-Y<\\e2> which is another catalytic enzyme hydrolysing <e1>CHEMICAL<\\e1>  Some compounds with (sub)nanomolar activities on the histamine-related targets are also active in the nanomolar concentration range on both cholinesterase targets being 5- to 40-times more potent than tacrine","sentence":"Some of the new compounds proved in a slightly modified colorimetric Ellmann's assay to be potent inhibitors of acetylcholinesterase and of butyrylcholinesterase which is another catalytic enzyme hydrolysing acetylcholine  Some compounds with (sub)nanomolar activities on the histamine-related targets are also active in the nanomolar concentration range on both cholinesterase targets being 5- to 40-times more potent than tacrine"}
{"PMID":16599255,"re_id":3,"annotated sentence":"Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main <e1>histamine<\\e1> metabolizing enzyme in the brain, <e2>N-methyltransferase<\\e2>  chemically show structural elements of the acetylcholinesterase inhibitor tacrine","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"histamine","object":"N-methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Novel highly affine CHEMICAL H3 receptor ligands with additional inhibitory effects on the main <e1>CHEMICAL<\\e1> metabolizing enzyme in the brain, <e2>GENE-N<\\e2>  chemically show structural elements of the acetylcholinesterase inhibitor tacrine","sentence":"Novel highly affine histamine H3 receptor ligands with additional inhibitory effects on the main histamine metabolizing enzyme in the brain, N-methyltransferase  chemically show structural elements of the acetylcholinesterase inhibitor tacrine"}
{"PMID":16609060,"re_id":0,"annotated sentence":"For some, pharmacologic inhibitors are available, including <e1>sorafenib<\\e1> for <e2>BRAF<\\e2>  farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"BRAF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"For some, pharmacologic inhibitors are available, including <e1>CHEMICAL<\\e1> for <e2>GENE-Y<\\e2>  farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors","sentence":"For some, pharmacologic inhibitors are available, including sorafenib for BRAF  farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors"}
{"PMID":16609060,"re_id":1,"annotated sentence":"For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, <e1>PD-0325901<\\e1> for <e2>mitogen-activated protein kinase<\\e2> extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PD-0325901","object":"mitogen-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, <e1>CHEMICAL<\\e1> for <e2>GENE-N<\\e2> extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors","sentence":"For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors"}
{"PMID":16609060,"re_id":2,"annotated sentence":"For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, <e1>PD-0325901<\\e1> for mitogen-activated protein kinase\/<e2>extracellular signal-regulated kinase kinase<\\e2>  rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PD-0325901","object":"extracellular signal-regulated kinase kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, <e1>CHEMICAL<\\e1> for mitogen-activated protein kinase\/<e2>GENE-N<\\e2>  rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors","sentence":"For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase  rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors"}
{"PMID":16609060,"re_id":3,"annotated sentence":"For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase, <e1>rapamycin<\\e1> analogues for <e2>mammalian target of rapamycin<\\e2>  and agents that inhibit either vascular endothelial growth factor or its receptors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rapamycin","object":"mammalian target of rapamycin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase, <e1>CHEMICAL<\\e1> analogues for <e2>mammalian target of CHEMICAL<\\e2>  and agents that inhibit either vascular endothelial growth factor or its receptors","sentence":"For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin  and agents that inhibit either vascular endothelial growth factor or its receptors"}
{"PMID":16618126,"re_id":13,"annotated sentence":"Similar to the <e2>plasma membrane PS transporter<\\e2>  Atp8a1 is activated only by the naturally occurring <e1>sn-1,2-glycerol<\\e1> isomer of PS and not the sn-2,3-glycerol stereoisomer","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"sn-1,2-glycerol","object":"plasma membrane PS transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Similar to the <e2>GENE-N<\\e2>  Atp8a1 is activated only by the naturally occurring <e1>CHEMICAL<\\e1> isomer of PS and not the sn-2,3-glycerol stereoisomer","sentence":"Similar to the plasma membrane PS transporter  Atp8a1 is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the sn-2,3-glycerol stereoisomer"}
{"PMID":16618126,"re_id":14,"annotated sentence":"Similar to the plasma membrane PS transporter, <e2>Atp8a1<\\e2> is activated only by the naturally occurring <e1>sn-1,2-glycerol<\\e1> isomer of PS and not the sn-2,3-glycerol stereoisomer","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"sn-1,2-glycerol","object":"Atp8a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to the plasma membrane PS transporter, <e2>GENE-Y<\\e2> is activated only by the naturally occurring <e1>CHEMICAL<\\e1> isomer of PS and not the sn-2,3-glycerol stereoisomer","sentence":"Similar to the plasma membrane PS transporter, Atp8a1 is activated only by the naturally occurring sn-1,2-glycerol isomer of PS and not the sn-2,3-glycerol stereoisomer"}
{"PMID":16618126,"re_id":15,"annotated sentence":"Weakly translocated lipids (<e1>PE<\\e1>  phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak <e2>Atp8a1<\\e2> activators","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"PE","object":"Atp8a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Weakly translocated lipids (<e1>CHEMICAL<\\e1>  phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak <e2>GENE-Y<\\e2> activators","sentence":"Weakly translocated lipids (PE  phosphatidylhydroxypropionate, and phosphatidylhomoserine) are also weak Atp8a1 activators"}
{"PMID":16618126,"re_id":16,"annotated sentence":"Weakly translocated lipids (PE, <e1>phosphatidylhydroxypropionate<\\e1>  and phosphatidylhomoserine) are also weak <e2>Atp8a1<\\e2> activators","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"phosphatidylhydroxypropionate","object":"Atp8a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Weakly translocated lipids (PE, <e1>CHEMICAL<\\e1>  and phosphatidylhomoserine) are also weak <e2>GENE-Y<\\e2> activators","sentence":"Weakly translocated lipids (PE, phosphatidylhydroxypropionate  and phosphatidylhomoserine) are also weak Atp8a1 activators"}
{"PMID":16618126,"re_id":17,"annotated sentence":"Weakly translocated lipids (PE, phosphatidylhydroxypropionate, and <e1>phosphatidylhomoserine<\\e1>  are also weak <e2>Atp8a1<\\e2> activators","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"phosphatidylhomoserine","object":"Atp8a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Weakly translocated lipids (PE, phosphatidylhydroxypropionate, and <e1>CHEMICAL<\\e1>  are also weak <e2>GENE-Y<\\e2> activators","sentence":"Weakly translocated lipids (PE, phosphatidylhydroxypropionate, and phosphatidylhomoserine  are also weak Atp8a1 activators"}
{"PMID":16618126,"re_id":18,"annotated sentence":"These results indicate that the <e2>ATPase<\\e2> activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties (<e1>PS<\\e1> selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"PS","object":"ATPase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results indicate that the <e2>GENE-N<\\e2> activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties (<e1>CHEMICAL<\\e1> selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.","sentence":"These results indicate that the ATPase activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties (PS selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase."}
{"PMID":16618126,"re_id":19,"annotated sentence":"These results indicate that the ATPase activity of the secretory granule <e2>Atp8a1<\\e2> is activated by phospholipids binding to a specific site whose properties (<e1>PS<\\e1> selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"PS","object":"Atp8a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that the ATPase activity of the secretory granule <e2>GENE-Y<\\e2> is activated by phospholipids binding to a specific site whose properties (<e1>CHEMICAL<\\e1> selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase.","sentence":"These results indicate that the ATPase activity of the secretory granule Atp8a1 is activated by phospholipids binding to a specific site whose properties (PS selectivity, dependence upon glycerol but not serine, stereochemistry, and vanadate sensitivity) are similar to, but distinct from, the properties of the substrate binding site of the plasma membrane flippase."}
{"PMID":16618126,"re_id":20,"annotated sentence":"The purified <e2>Atp8a1<\\e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by <e1>phosphatidylglycerol<\\e1> or phosphatidylethanolamine (PE), and is maximally activated by PS","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"phosphatidylglycerol","object":"Atp8a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The purified <e2>GENE-Y<\\e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by <e1>CHEMICAL<\\e1> or phosphatidylethanolamine (PE), and is maximally activated by PS","sentence":"The purified Atp8a1 is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS"}
{"PMID":16618126,"re_id":21,"annotated sentence":"The purified <e2>Atp8a1<\\e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or <e1>phosphatidylethanolamine<\\e1> (PE), and is maximally activated by PS","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"phosphatidylethanolamine","object":"Atp8a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The purified <e2>GENE-Y<\\e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or <e1>CHEMICAL<\\e1> (PE), and is maximally activated by PS","sentence":"The purified Atp8a1 is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS"}
{"PMID":16618126,"re_id":22,"annotated sentence":"The purified <e2>Atp8a1<\\e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (<e1>PE<\\e1> , and is maximally activated by PS","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"PE","object":"Atp8a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The purified <e2>GENE-Y<\\e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (<e1>CHEMICAL<\\e1> , and is maximally activated by PS","sentence":"The purified Atp8a1 is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE , and is maximally activated by PS"}
{"PMID":16618126,"re_id":23,"annotated sentence":"The purified <e2>Atp8a1<\\e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by <e1>PS<\\e1>  The selectivity for PS is dependent upon multiple elements of the lipid structure","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"PS","object":"Atp8a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The purified <e2>GENE-Y<\\e2> is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by <e1>CHEMICAL<\\e1>  The selectivity for CHEMICAL is dependent upon multiple elements of the lipid structure","sentence":"The purified Atp8a1 is inactive in detergent micelles or in micelles containing phosphatidylcholine, phosphatidic acid, or phosphatidylinositol, is minimally activated by phosphatidylglycerol or phosphatidylethanolamine (PE), and is maximally activated by PS  The selectivity for PS is dependent upon multiple elements of the lipid structure"}
{"PMID":16618126,"re_id":24,"annotated sentence":"Activation of <e2>Atp8a1<\\e2> is also reduced by these modifications; <e1>phosphatidylserine-O-methyl ester<\\e1>  lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"phosphatidylserine-O-methyl ester","object":"Atp8a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of <e2>GENE-Y<\\e2> is also reduced by these modifications; <e1>CHEMICAL<\\e1>  lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate GENE-Y","sentence":"Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester  lysophosphatidylserine, glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1"}
{"PMID":16618126,"re_id":25,"annotated sentence":"Activation of <e2>Atp8a1<\\e2> is also reduced by these modifications; phosphatidylserine-O-methyl ester, <e1>lysophosphatidylserine<\\e1>  glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"lysophosphatidylserine","object":"Atp8a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of <e2>GENE-Y<\\e2> is also reduced by these modifications; phosphatidylserine-O-methyl ester, <e1>CHEMICAL<\\e1>  glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate GENE-Y","sentence":"Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine  glycerophosphoserine, and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1"}
{"PMID":16618126,"re_id":26,"annotated sentence":"Activation of <e2>Atp8a1<\\e2> is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, <e1>glycerophosphoserine<\\e1>  and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"glycerophosphoserine","object":"Atp8a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of <e2>GENE-Y<\\e2> is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, <e1>CHEMICAL<\\e1>  and phosphoserine, which are not transported by the plasma membrane flippase, do not activate GENE-Y","sentence":"Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycerophosphoserine  and phosphoserine, which are not transported by the plasma membrane flippase, do not activate Atp8a1"}
{"PMID":16618126,"re_id":27,"annotated sentence":"Activation of <e2>Atp8a1<\\e2> is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycerophosphoserine, and <e1>phosphoserine<\\e1>  which are not transported by the plasma membrane flippase, do not activate Atp8a1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"phosphoserine","object":"Atp8a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of <e2>GENE-Y<\\e2> is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glyceroCHEMICAL, and <e1>CHEMICAL<\\e1>  which are not transported by the plasma membrane flippase, do not activate GENE-Y","sentence":"Activation of Atp8a1 is also reduced by these modifications; phosphatidylserine-O-methyl ester, lysophosphatidylserine, glycerophosphoserine, and phosphoserine  which are not transported by the plasma membrane flippase, do not activate Atp8a1"}
{"PMID":16618126,"re_id":28,"annotated sentence":"However, <e1>N-methyl-phosphatidylserine<\\e1>  which is transported by the plasma membrane <e2>flippase<\\e2> at a rate equivalent to PS, is incapable of activating Atp8a1 activity","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"N-methyl-phosphatidylserine","object":"flippase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, <e1>CHEMICAL<\\e1>  which is transported by the plasma membrane <e2>GENE-N<\\e2> at a rate equivalent to PS, is incapable of activating Atp8a1 activity","sentence":"However, N-methyl-phosphatidylserine  which is transported by the plasma membrane flippase at a rate equivalent to PS, is incapable of activating Atp8a1 activity"}
{"PMID":16618126,"re_id":29,"annotated sentence":"This aminophospholipid \"<e2>flippase<\\e2>  selectively transports <e1>PS<\\e1> to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"PS","object":"flippase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This aminophospholipid \"<e2>GENE-N<\\e2>  selectively transports <e1>CHEMICAL<\\e1> to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents","sentence":"This aminophospholipid \"flippase  selectively transports PS to the cytosolic leaflet of the bilayer and is sensitive to vanadate, Ca(2+), and modification by sulfhydryl reagents"}
{"PMID":16729906,"re_id":0,"annotated sentence":"<e1>Sorafenib<\\e1> (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of <e2>tyrosine kinases<\\e2> that are known to be involved in tumor cell proliferation and tumor angiogenesis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sorafenib","object":"tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of <e2>GENE-N<\\e2> that are known to be involved in tumor cell proliferation and tumor angiogenesis","sentence":"Sorafenib (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of tyrosine kinases that are known to be involved in tumor cell proliferation and tumor angiogenesis"}
{"PMID":16729906,"re_id":1,"annotated sentence":"Sorafenib (<e1>BAY 43-9006<\\e1>  is a small-molecule inhibitor that has been shown to target members of multiple classes of <e2>tyrosine kinases<\\e2> that are known to be involved in tumor cell proliferation and tumor angiogenesis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"BAY 43-9006","object":"tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sorafenib (<e1>CHEMICAL<\\e1>  is a small-molecule inhibitor that has been shown to target members of multiple classes of <e2>GENE-N<\\e2> that are known to be involved in tumor cell proliferation and tumor angiogenesis","sentence":"Sorafenib (BAY 43-9006  is a small-molecule inhibitor that has been shown to target members of multiple classes of tyrosine kinases that are known to be involved in tumor cell proliferation and tumor angiogenesis"}
{"PMID":16781459,"re_id":5,"annotated sentence":"Both <e1>H(2)S<\\e1> solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the <e2>extracellular signal-regulated kinase<\\e2> (ERK)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"H(2)S","object":"extracellular signal-regulated kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both <e1>CHEMICAL<\\e1> solution prepared by bubbling pure CHEMICAL gas and NaSH, a CHEMICAL donor, dose dependently induced HO-1 expression through the activation of the <e2>GENE-N<\\e2> (ERK)","sentence":"Both H(2)S solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase (ERK)"}
{"PMID":16781459,"re_id":6,"annotated sentence":"Both <e1>H(2)S<\\e1> solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase (<e2>ERK<\\e2> ","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"H(2)S","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both <e1>CHEMICAL<\\e1> solution prepared by bubbling pure CHEMICAL gas and NaSH, a CHEMICAL donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase (<e2>GENE-N<\\e2> ","sentence":"Both H(2)S solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase (ERK "}
{"PMID":16781459,"re_id":7,"annotated sentence":"Both <e1>H(2)S<\\e1> solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced <e2>HO-1<\\e2> expression through the activation of the extracellular signal-regulated kinase (ERK)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"H(2)S","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both <e1>CHEMICAL<\\e1> solution prepared by bubbling pure CHEMICAL gas and NaSH, a CHEMICAL donor, dose dependently induced <e2>GENE-Y<\\e2> expression through the activation of the extracellular signal-regulated kinase (ERK)","sentence":"Both H(2)S solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase (ERK)"}
{"PMID":16781459,"re_id":8,"annotated sentence":"<e1>CO<\\e1> treatment also inhibited LPS-induced NO production and <e2>iNOS<\\e2> expression via its inactivation of NF-kappaB","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"CO","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment also inhibited LPS-induced NO production and <e2>GENE-Y<\\e2> expression via its inactivation of NF-kappaB","sentence":"CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB"}
{"PMID":16781459,"re_id":9,"annotated sentence":"Here, we show that at noncytotoxic concentrations, <e1>H(2)S<\\e1> was able to inhibit NO production and <e2>inducible NO synthase<\\e2> (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"H(2)S","object":"inducible NO synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we show that at noncytotoxic concentrations, <e1>CHEMICAL<\\e1> was able to inhibit NO production and <e2>GENE-Y<\\e2> (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)","sentence":"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)"}
{"PMID":16781459,"re_id":10,"annotated sentence":"Here, we show that at noncytotoxic concentrations, <e1>H(2)S<\\e1> was able to inhibit NO production and inducible NO synthase (<e2>iNOS<\\e2>  expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"H(2)S","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we show that at noncytotoxic concentrations, <e1>CHEMICAL<\\e1> was able to inhibit NO production and inducible NO synthase (<e2>GENE-Y<\\e2>  expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)","sentence":"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible NO synthase (iNOS  expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)"}
{"PMID":16781459,"re_id":11,"annotated sentence":"Pretreatment with <e1>H(2)S<\\e1> or NaHS significantly inhibited LPS-induced <e2>iNOS<\\e2> expression and NO production","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"H(2)S","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with <e1>CHEMICAL<\\e1> or NaHS significantly inhibited LPS-induced <e2>GENE-Y<\\e2> expression and NO production","sentence":"Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced iNOS expression and NO production"}
{"PMID":16781459,"re_id":12,"annotated sentence":"Pretreatment with H(2)S or <e1>NaHS<\\e1> significantly inhibited LPS-induced <e2>iNOS<\\e2> expression and NO production","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"NaHS","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with H(2)S or <e1>CHEMICAL<\\e1> significantly inhibited LPS-induced <e2>GENE-Y<\\e2> expression and NO production","sentence":"Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced iNOS expression and NO production"}
{"PMID":16781459,"re_id":13,"annotated sentence":"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of <e1>H(2)S<\\e1> on <e2>iNOS<\\e2> expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"H(2)S","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of <e1>CHEMICAL<\\e1> on <e2>GENE-Y<\\e2> expression and NO production, HO-1 overexpression produced the same inhibitory effects of CHEMICAL","sentence":"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S"}
{"PMID":16781459,"re_id":14,"annotated sentence":"<e1>CO<\\e1> treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of <e2>NF-kappaB<\\e2>  Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1\/CO.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CO","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of <e2>GENE-N<\\e2>  Collectively, our results suggest that H(2)S can inhibit NO production and GENE-N activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1\/CHEMICAL.","sentence":"CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB  Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1\/CO."}
{"PMID":16781459,"re_id":15,"annotated sentence":"Collectively, our results suggest that <e1>H(2)S<\\e1> can inhibit NO production and <e2>NF-kappaB<\\e2> activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1\/CO.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"H(2)S","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Collectively, our results suggest that <e1>CHEMICAL<\\e1> can inhibit NO production and <e2>GENE-N<\\e2> activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1\/CO.","sentence":"Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1\/CO."}
{"PMID":16781459,"re_id":16,"annotated sentence":"Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective <e2>CSE<\\e2> inhibitor <e1>beta-cyano-L-alanine<\\e1> but not by the CBS inhibitor aminooxyacetic acid","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"beta-cyano-L-alanine","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, NO production in LPS-stimulated macrophages that are expressing GENE-Y mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> but not by the CBS inhibitor aminooxyacetic acid","sentence":"Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid"}
{"PMID":16781459,"re_id":17,"annotated sentence":"<e1>Hydrogen sulfide<\\e1> inhibits nitric oxide production and <e2>nuclear factor-kappaB<\\e2> via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Hydrogen sulfide","object":"nuclear factor-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits nitric oxide production and <e2>GENE-N<\\e2> via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide","sentence":"Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide"}
{"PMID":16781459,"re_id":18,"annotated sentence":"Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the <e2>CBS<\\e2> inhibitor <e1>aminooxyacetic acid<\\e1>  While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"aminooxyacetic acid","object":"CBS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S","sentence":"Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid  While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S"}
{"PMID":16781459,"re_id":19,"annotated sentence":"In addition, LPS-induced nuclear factor <e2>(NF)-kappaB<\\e2> activation was diminished in RAW264.7 macrophages preincubated with <e1>H(2)S<\\e1>  Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"H(2)S","object":"(NF)-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, LPS-induced nuclear factor <e2>GENE-N<\\e2> activation was diminished in RAW264.7 macrophages preincubated with <e1>CHEMICAL<\\e1>  Interestingly, the inhibitory effect of CHEMICAL on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1","sentence":"In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S  Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1"}
{"PMID":16781459,"re_id":20,"annotated sentence":"Interestingly, the inhibitory effect of <e1>H(2)S<\\e1> on <e2>NF-kappaB<\\e2> activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"H(2)S","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, the inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-N<\\e2> activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1","sentence":"Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1"}
{"PMID":16781459,"re_id":21,"annotated sentence":"Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with <e1>carbon monoxide<\\e1> (CO), an end product of <e2>HO-1<\\e2>  CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"carbon monoxide","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with GENE-Y siRNA, but was mimicked by either GENE-Y gene transfection or treatment with <e1>CHEMICAL<\\e1> (CO), an end product of <e2>GENE-Y<\\e2>  CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB","sentence":"Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1  CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB"}
{"PMID":16781459,"re_id":22,"annotated sentence":"Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (<e1>CO<\\e1> , an end product of <e2>HO-1<\\e2>  CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"CO","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with GENE-Y siRNA, but was mimicked by either GENE-Y gene transfection or treatment with carbon monoxide (<e1>CHEMICAL<\\e1> , an end product of <e2>GENE-Y<\\e2>  CHEMICAL treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB","sentence":"Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO , an end product of HO-1  CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB"}
{"PMID":16781459,"re_id":23,"annotated sentence":"CO treatment also inhibited LPS-induced <e1>NO<\\e1> production and <e2>iNOS<\\e2> expression via its inactivation of NF-kappaB","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"NO","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CO treatment also inhibited LPS-induced <e1>CHEMICAL<\\e1> production and <e2>iCHEMICALS<\\e2> expression via its inactivation of NF-kappaB","sentence":"CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB"}
{"PMID":16781459,"re_id":24,"annotated sentence":"Hydrogen sulfide (<e1>H(2)S<\\e1> , a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<e2>CSE<\\e2>  and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"H(2)S","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulfide (<e1>CHEMICAL<\\e1> , a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<e2>GENE-Y<\\e2>  and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S , a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE  and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":25,"annotated sentence":"Hydrogen sulfide (<e1>H(2)S<\\e1> , a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or <e2>cystathionine beta-synthase<\\e2> (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"H(2)S","object":"cystathionine beta-synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulfide (<e1>CHEMICAL<\\e1> , a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or <e2>GENE-Y<\\e2> (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S , a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":26,"annotated sentence":"Hydrogen sulfide (<e1>H(2)S<\\e1> , a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (<e2>CBS<\\e2>  from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"H(2)S","object":"CBS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulfide (<e1>CHEMICAL<\\e1> , a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (<e2>GENE-Y<\\e2>  from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S , a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (CBS  from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":27,"annotated sentence":"Hydrogen sulfide (<e1>H(2)S<\\e1> , a regulatory gaseous molecule that is endogenously synthesized by <e2>cystathionine gamma-lyase<\\e2> (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"H(2)S","object":"cystathionine gamma-lyase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulfide (<e1>CHEMICAL<\\e1> , a regulatory gaseous molecule that is endogenously synthesized by <e2>GENE-Y<\\e2> (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S , a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":28,"annotated sentence":"Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of <e2>HO-1<\\e2> <e1>CO<\\e1> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"CO","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of <e2>GENE-Y<\\e2> <e1>CHEMICAL<\\e1> ","sentence":"Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1 CO "}
{"PMID":16781459,"re_id":29,"annotated sentence":"<e1>Hydrogen sulfide<\\e1> (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<e2>CSE<\\e2>  and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"Hydrogen sulfide","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<e2>GENE-Y<\\e2>  and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE  and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":30,"annotated sentence":"<e1>Hydrogen sulfide<\\e1> (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or <e2>cystathionine beta-synthase<\\e2> (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"Hydrogen sulfide","object":"cystathionine beta-synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or <e2>GENE-Y<\\e2> (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":31,"annotated sentence":"<e1>Hydrogen sulfide<\\e1> (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (<e2>CBS<\\e2>  from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"Hydrogen sulfide","object":"CBS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (<e2>GENE-Y<\\e2>  from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (CBS  from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":32,"annotated sentence":"<e1>Hydrogen sulfide<\\e1> (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by <e2>cystathionine gamma-lyase<\\e2> (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"Hydrogen sulfide","object":"cystathionine gamma-lyase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by <e2>GENE-Y<\\e2> (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":33,"annotated sentence":"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit <e1>NO<\\e1> production and <e2>inducible NO synthase<\\e2> (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"NO","object":"inducible NO synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit <e1>CHEMICAL<\\e1> production and <e2>inducible CHEMICAL synthase<\\e2> (iCHEMICALS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)","sentence":"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)"}
{"PMID":16781459,"re_id":34,"annotated sentence":"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit <e1>NO<\\e1> production and inducible NO synthase (<e2>iNOS<\\e2>  expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"NO","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit <e1>CHEMICAL<\\e1> production and inducible CHEMICAL synthase (<e2>iCHEMICALS<\\e2>  expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)","sentence":"Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible NO synthase (iNOS  expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS)"}
{"PMID":16781459,"re_id":35,"annotated sentence":"Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced <e2>iNOS<\\e2> expression and <e1>NO<\\e1> production","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"NO","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced <e2>iCHEMICALS<\\e2> expression and <e1>CHEMICAL<\\e1> production","sentence":"Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced iNOS expression and NO production"}
{"PMID":16781459,"re_id":36,"annotated sentence":"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on <e2>iNOS<\\e2> expression and <e1>NO<\\e1> production, HO-1 overexpression produced the same inhibitory effects of H(2)S","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"NO","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on <e2>iCHEMICALS<\\e2> expression and <e1>CHEMICAL<\\e1> production, HO-1 overexpression produced the same inhibitory effects of H(2)S","sentence":"While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S"}
{"PMID":16781459,"re_id":37,"annotated sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<e2>CSE<\\e2>  and\/or cystathionine beta-synthase (CBS) from <e1>L-cysteine<\\e1> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-cysteine","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<e2>GENE-Y<\\e2>  and\/or cystathionine beta-synthase (CBS) from <e1>CHEMICAL<\\e1> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE  and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":38,"annotated sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or <e2>cystathionine beta-synthase<\\e2> (CBS) from <e1>L-cysteine<\\e1> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-cysteine","object":"cystathionine beta-synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or <e2>GENE-Y<\\e2> (CBS) from <e1>CHEMICAL<\\e1> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":39,"annotated sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (<e2>CBS<\\e2>  from <e1>L-cysteine<\\e1> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-cysteine","object":"CBS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (<e2>GENE-Y<\\e2>  from <e1>CHEMICAL<\\e1> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (CBS  from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":40,"annotated sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by <e2>cystathionine gamma-lyase<\\e2> (CSE) and\/or cystathionine beta-synthase (CBS) from <e1>L-cysteine<\\e1> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-cysteine","object":"cystathionine gamma-lyase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by <e2>GENE-Y<\\e2> (CSE) and\/or cystathionine beta-synthase (CBS) from <e1>CHEMICAL<\\e1> (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":41,"annotated sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<e2>CSE<\\e2>  and\/or cystathionine beta-synthase (CBS) from L-cysteine (<e1>L-Cys<\\e1>  metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-Cys","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (<e2>GENE-Y<\\e2>  and\/or cystathionine beta-synthase (CBS) from L-cysteine (<e1>CHEMICAL<\\e1>  metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE  and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys  metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":42,"annotated sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or <e2>cystathionine beta-synthase<\\e2> (CBS) from L-cysteine (<e1>L-Cys<\\e1>  metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-Cys","object":"cystathionine beta-synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or <e2>GENE-Y<\\e2> (CBS) from L-cysteine (<e1>CHEMICAL<\\e1>  metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys  metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":43,"annotated sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (<e2>CBS<\\e2>  from L-cysteine (<e1>L-Cys<\\e1>  metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-Cys","object":"CBS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (<e2>GENE-Y<\\e2>  from L-cysteine (<e1>CHEMICAL<\\e1>  metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (CBS  from L-cysteine (L-Cys  metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":44,"annotated sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by <e2>cystathionine gamma-lyase<\\e2> (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (<e1>L-Cys<\\e1>  metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-Cys","object":"cystathionine gamma-lyase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by <e2>GENE-Y<\\e2> (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (<e1>CHEMICAL<\\e1>  metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored","sentence":"Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and\/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys  metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored"}
{"PMID":16781459,"re_id":45,"annotated sentence":"Moreover, NO production in LPS-stimulated macrophages that are expressing <e2>CSE<\\e2> mRNA was significantly reduced by the addition of <e1>L-Cys<\\e1>  a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-Cys","object":"CSE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, NO production in LPS-stimulated macrophages that are expressing <e2>GENE-Y<\\e2> mRNA was significantly reduced by the addition of <e1>CHEMICAL<\\e1>  a substrate for H(2)S, but enhanced by the selective GENE-Y inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid","sentence":"Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys  a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid"}
{"PMID":16809898,"re_id":0,"annotated sentence":"However, in vitro experiments simulating a uremic milieu revealed a marked concentration-dependent inhibition of <e2>arginase<\\e2> activity by <e1>urea<\\e1> in the tissue lysates","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"urea","object":"arginase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, in vitro experiments simulating a uremic milieu revealed a marked concentration-dependent inhibition of <e2>GENE-N<\\e2> activity by <e1>CHEMICAL<\\e1> in the tissue lysates","sentence":"However, in vitro experiments simulating a uremic milieu revealed a marked concentration-dependent inhibition of arginase activity by urea in the tissue lysates"}
{"PMID":16809898,"re_id":1,"annotated sentence":"CONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of <e2>arginase<\\e2>  the inherent rise in <e1>urea<\\e1> concentration inhibits its enzymatic activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"urea","object":"arginase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of <e2>GENE-N<\\e2>  the inherent rise in <e1>CHEMICAL<\\e1> concentration inhibits its enzymatic activity","sentence":"CONCLUSIONS: Although CRF does not change the abundance or intrinsic properties of arginase  the inherent rise in urea concentration inhibits its enzymatic activity"}
{"PMID":16809898,"re_id":2,"annotated sentence":"L-arg is converted to <e1>urea<\\e1> by <e2>arginase I<\\e2> in the liver and arginase II in the kidney","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"urea","object":"arginase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"L-arg is converted to <e1>CHEMICAL<\\e1> by <e2>GENE-Y<\\e2> in the liver and GENE-YI in the kidney","sentence":"L-arg is converted to urea by arginase I in the liver and arginase II in the kidney"}
{"PMID":16809898,"re_id":3,"annotated sentence":"L-arg is converted to <e1>urea<\\e1> by arginase I in the liver and <e2>arginase II<\\e2> in the kidney","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"urea","object":"arginase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"L-arg is converted to <e1>CHEMICAL<\\e1> by arginase I in the liver and <e2>GENE-Y<\\e2> in the kidney","sentence":"L-arg is converted to urea by arginase I in the liver and arginase II in the kidney"}
{"PMID":16809898,"re_id":4,"annotated sentence":"Sources of <e1>L-arg<\\e1> include dietary proteins and endogenous synthesis by <e2>argininosuccinate synthetase<\\e2> and argininosuccinate lyase","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"L-arg","object":"argininosuccinate synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sources of <e1>CHEMICAL<\\e1> include dietary proteins and endogenous synthesis by <e2>GENE-Y<\\e2> and argininosuccinate lyase","sentence":"Sources of L-arg include dietary proteins and endogenous synthesis by argininosuccinate synthetase and argininosuccinate lyase"}
{"PMID":16809898,"re_id":5,"annotated sentence":"Sources of <e1>L-arg<\\e1> include dietary proteins and endogenous synthesis by argininosuccinate synthetase and <e2>argininosuccinate lyase<\\e2>  L-arg is converted to urea by arginase I in the liver and arginase II in the kidney","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"L-arg","object":"argininosuccinate lyase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sources of <e1>CHEMICAL<\\e1> include dietary proteins and endogenous synthesis by argininosuccinate synthetase and <e2>GENE-Y<\\e2>  CHEMICAL is converted to urea by arginase I in the liver and arginase II in the kidney","sentence":"Sources of L-arg include dietary proteins and endogenous synthesis by argininosuccinate synthetase and argininosuccinate lyase  L-arg is converted to urea by arginase I in the liver and arginase II in the kidney"}
{"PMID":16809898,"re_id":6,"annotated sentence":"<e1>L-arg<\\e1> is converted to urea by <e2>arginase I<\\e2> in the liver and arginase II in the kidney","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-arg","object":"arginase I","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is converted to urea by <e2>GENE-Y<\\e2> in the liver and GENE-YI in the kidney","sentence":"L-arg is converted to urea by arginase I in the liver and arginase II in the kidney"}
{"PMID":16809898,"re_id":7,"annotated sentence":"<e1>L-arg<\\e1> is converted to urea by arginase I in the liver and <e2>arginase II<\\e2> in the kidney","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-arg","object":"arginase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is converted to urea by arginase I in the liver and <e2>GENE-Y<\\e2> in the kidney","sentence":"L-arg is converted to urea by arginase I in the liver and arginase II in the kidney"}
{"PMID":16809898,"re_id":8,"annotated sentence":"We hypothesized that preservation of plasma <e1>L-arg<\\e1> in CRF may be, partly, due to downregulation\/inhibition of <e2>arginase<\\e2>  METHODS: Argininosuccinate synthetase, arginase I and II protein abundance and activity were measured in the liver and kidneys of rats 6 weeks after 5\/6 nephrectomy or sham operation","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-arg","object":"arginase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We hypothesized that preservation of plasma <e1>CHEMICAL<\\e1> in CRF may be, partly, due to downregulation\/inhibition of <e2>GENE-N<\\e2>  METHODS: Argininosuccinate synthetase, GENE-N I and II protein abundance and activity were measured in the liver and kidneys of rats 6 weeks after 5\/6 nephrectomy or sham operation","sentence":"We hypothesized that preservation of plasma L-arg in CRF may be, partly, due to downregulation\/inhibition of arginase  METHODS: Argininosuccinate synthetase, arginase I and II protein abundance and activity were measured in the liver and kidneys of rats 6 weeks after 5\/6 nephrectomy or sham operation"}
{"PMID":16843091,"re_id":0,"annotated sentence":"However, several promising nonpeptide, <e2>vasopressin receptor<\\e2> antagonists have been described; these agents are <e1>VPA-985<\\e1> (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"VPA-985","object":"vasopressin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, several promising nonpeptide, <e2>GENE-N<\\e2> antagonists have been described; these agents are <e1>CHEMICAL<\\e1> (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463","sentence":"However, several promising nonpeptide, vasopressin receptor antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463"}
{"PMID":16843091,"re_id":1,"annotated sentence":"However, several promising nonpeptide, <e2>vasopressin receptor<\\e2> antagonists have been described; these agents are VPA-985 (<e1>lixivaptan<\\e1> , YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"lixivaptan","object":"vasopressin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, several promising nonpeptide, <e2>GENE-N<\\e2> antagonists have been described; these agents are VPA-985 (<e1>CHEMICAL<\\e1> , YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463","sentence":"However, several promising nonpeptide, vasopressin receptor antagonists have been described; these agents are VPA-985 (lixivaptan , YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463"}
{"PMID":16843091,"re_id":2,"annotated sentence":"However, several promising nonpeptide, <e2>vasopressin receptor<\\e2> antagonists have been described; these agents are VPA-985 (lixivaptan), <e1>YM-087<\\e1> (conivaptan), OPC-41061 (tolvaptan), and SR-121463","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"YM-087","object":"vasopressin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, several promising nonpeptide, <e2>GENE-N<\\e2> antagonists have been described; these agents are VPA-985 (lixivaptan), <e1>CHEMICAL<\\e1> (conivaptan), OPC-41061 (tolvaptan), and SR-121463","sentence":"However, several promising nonpeptide, vasopressin receptor antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463"}
{"PMID":16843091,"re_id":3,"annotated sentence":"However, several promising nonpeptide, <e2>vasopressin receptor<\\e2> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (<e1>conivaptan<\\e1> , OPC-41061 (tolvaptan), and SR-121463","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"conivaptan","object":"vasopressin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, several promising nonpeptide, <e2>GENE-N<\\e2> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (<e1>CHEMICAL<\\e1> , OPC-41061 (tolvaptan), and SR-121463","sentence":"However, several promising nonpeptide, vasopressin receptor antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan , OPC-41061 (tolvaptan), and SR-121463"}
{"PMID":16843091,"re_id":4,"annotated sentence":"However, several promising nonpeptide, <e2>vasopressin receptor<\\e2> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), <e1>OPC-41061<\\e1> (tolvaptan), and SR-121463","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"OPC-41061","object":"vasopressin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, several promising nonpeptide, <e2>GENE-N<\\e2> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), <e1>CHEMICAL<\\e1> (tolvaptan), and SR-121463","sentence":"However, several promising nonpeptide, vasopressin receptor antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463"}
{"PMID":16843091,"re_id":5,"annotated sentence":"However, several promising nonpeptide, <e2>vasopressin receptor<\\e2> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (<e1>tolvaptan<\\e1> , and SR-121463","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"tolvaptan","object":"vasopressin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, several promising nonpeptide, <e2>GENE-N<\\e2> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (<e1>CHEMICAL<\\e1> , and SR-121463","sentence":"However, several promising nonpeptide, vasopressin receptor antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan , and SR-121463"}
{"PMID":16843091,"re_id":6,"annotated sentence":"However, several promising nonpeptide, <e2>vasopressin receptor<\\e2> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and <e1>SR-121463<\\e1>  Prospective, randomized, placebo-controlled trials performed with these agents found that they corrected hyponatremia efficiently and safely","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"SR-121463","object":"vasopressin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, several promising nonpeptide, <e2>GENE-N<\\e2> antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and <e1>CHEMICAL<\\e1>  Prospective, randomized, placebo-controlled trials performed with these agents found that they corrected hyponatremia efficiently and safely","sentence":"However, several promising nonpeptide, vasopressin receptor antagonists have been described; these agents are VPA-985 (lixivaptan), YM-087 (conivaptan), OPC-41061 (tolvaptan), and SR-121463  Prospective, randomized, placebo-controlled trials performed with these agents found that they corrected hyponatremia efficiently and safely"}
{"PMID":1686208,"re_id":0,"annotated sentence":"Sedation and <e2>histamine H1-receptor<\\e2> antagonism: studies in man with the enantiomers of chlorpheniramine and <e1>dimethindene<\\e1>  1","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"dimethindene","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sedation and <e2>GENE-Y<\\e2> antagonism: studies in man with the enantiomers of chlorpheniramine and <e1>CHEMICAL<\\e1>  1","sentence":"Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene  1"}
{"PMID":1686208,"re_id":1,"annotated sentence":"Sedation and <e2>histamine H1-receptor<\\e2> antagonism: studies in man with the enantiomers of <e1>chlorpheniramine<\\e1> and dimethindene","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"chlorpheniramine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sedation and <e2>GENE-Y<\\e2> antagonism: studies in man with the enantiomers of <e1>CHEMICAL<\\e1> and dimethindene","sentence":"Sedation and histamine H1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene"}
{"PMID":16866189,"re_id":0,"annotated sentence":"BG also showed a protective effect in the presence of a <e2>DNA polymerase beta<\\e2> inhibitor (<e1>cytosine arabinoside-3-phosphate<\\e1>  Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cytosine arabinoside-3-phosphate","object":"DNA polymerase beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BG also showed a protective effect in the presence of a <e2>GENE-Y<\\e2> inhibitor (<e1>CHEMICAL<\\e1>  Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving GENE-Y.","sentence":"BG also showed a protective effect in the presence of a DNA polymerase beta inhibitor (cytosine arabinoside-3-phosphate  Ara-C), demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta."}
{"PMID":16866189,"re_id":1,"annotated sentence":"BG also showed a protective effect in the presence of a <e2>DNA polymerase beta<\\e2> inhibitor (cytosine arabinoside-3-phosphate, <e1>Ara-C<\\e1> , demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Ara-C","object":"DNA polymerase beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BG also showed a protective effect in the presence of a <e2>GENE-Y<\\e2> inhibitor (cytosine arabinoside-3-phosphate, <e1>CHEMICAL<\\e1> , demonstrating that BG does not act through an anti-mutagenic mechanism of action involving GENE-Y.","sentence":"BG also showed a protective effect in the presence of a DNA polymerase beta inhibitor (cytosine arabinoside-3-phosphate, Ara-C , demonstrating that BG does not act through an anti-mutagenic mechanism of action involving DNA polymerase beta."}
{"PMID":16901636,"re_id":0,"annotated sentence":"Our purpose was to test the impact of single and\/or combined treatment with the <e2>AT(1)<\\e2> receptor blocker <e1>candesartan<\\e1> and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"candesartan","object":"AT(1)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our purpose was to test the impact of single and\/or combined treatment with the <e2>GENE-N<\\e2> receptor blocker <e1>CHEMICAL<\\e1> and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats","sentence":"Our purpose was to test the impact of single and\/or combined treatment with the AT(1) receptor blocker candesartan and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats"}
{"PMID":16901636,"re_id":1,"annotated sentence":"Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the <e2>HMG-CoA reductase<\\e2> inhibitor <e1>rosuvastatin<\\e1> and their combination","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rosuvastatin","object":"HMG-CoA reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> and their combination","sentence":"Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination"}
{"PMID":16901636,"re_id":2,"annotated sentence":"Reduction of cerebral infarct size by the <e2>AT1<\\e2> receptor blocker <e1>candesartan<\\e1>  the HMG-CoA reductase inhibitor rosuvastatin and their combination","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"candesartan","object":"AT1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Reduction of cerebral infarct size by the <e2>GENE-N<\\e2> receptor blocker <e1>CHEMICAL<\\e1>  the HMG-CoA reductase inhibitor rosuvastatin and their combination","sentence":"Reduction of cerebral infarct size by the AT1 receptor blocker candesartan  the HMG-CoA reductase inhibitor rosuvastatin and their combination"}
{"PMID":16901636,"re_id":3,"annotated sentence":"Our purpose was to test the impact of single and\/or combined treatment with the AT(1)-receptor blocker candesartan and the <e2>HMG-CoA reductase<\\e2> inhibitor <e1>rosuvastatin<\\e1> on infarct size and neuroscore in transient cerebral ischemia in rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rosuvastatin","object":"HMG-CoA reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our purpose was to test the impact of single and\/or combined treatment with the AT(1)-receptor blocker candesartan and the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> on infarct size and neuroscore in transient cerebral ischemia in rats","sentence":"Our purpose was to test the impact of single and\/or combined treatment with the AT(1)-receptor blocker candesartan and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats"}
{"PMID":16905533,"re_id":15,"annotated sentence":"Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to <e1>phosphatidic acid<\\e1> by <e2>DAG kinase<\\e2> (DGK)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"phosphatidic acid","object":"DAG kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to <e1>CHEMICAL<\\e1> by <e2>GENE-N<\\e2> (DGK)","sentence":"Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (DGK)"}
{"PMID":16905533,"re_id":16,"annotated sentence":"Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to <e1>phosphatidic acid<\\e1> by DAG kinase (<e2>DGK<\\e2> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"phosphatidic acid","object":"DGK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to <e1>CHEMICAL<\\e1> by DAG kinase (<e2>GENE-N<\\e2> ","sentence":"Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (DGK "}
{"PMID":16905533,"re_id":17,"annotated sentence":"<e1>Diacylglycerol<\\e1> (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by <e2>DAG kinase<\\e2> (DGK)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Diacylglycerol","object":"DAG kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by <e2>GENE-N<\\e2> (DGK)","sentence":"Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (DGK)"}
{"PMID":16905533,"re_id":18,"annotated sentence":"<e1>Diacylglycerol<\\e1> (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (<e2>DGK<\\e2> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Diacylglycerol","object":"DGK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (<e2>GENE-N<\\e2> ","sentence":"Diacylglycerol (DAG) acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (DGK "}
{"PMID":16905533,"re_id":19,"annotated sentence":"Diacylglycerol (<e1>DAG<\\e1>  acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by <e2>DAG kinase<\\e2> (DGK)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"DAG","object":"DAG kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Diacylglycerol (<e1>CHEMICAL<\\e1>  acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by <e2>CHEMICAL kinase<\\e2> (DGK)","sentence":"Diacylglycerol (DAG  acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (DGK)"}
{"PMID":16905533,"re_id":20,"annotated sentence":"Diacylglycerol (<e1>DAG<\\e1>  acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (<e2>DGK<\\e2> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"DAG","object":"DGK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Diacylglycerol (<e1>CHEMICAL<\\e1>  acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by CHEMICAL kinase (<e2>GENE-N<\\e2> ","sentence":"Diacylglycerol (DAG  acts as an allosteric activator of protein kinase C (PKC) and is converted to phosphatidic acid by DAG kinase (DGK "}
{"PMID":1692236,"re_id":5,"annotated sentence":"Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of <e2>acetylcholinesterase<\\e2> against denaturation by heat or <e1>guanidine<\\e1> following phosphorylation by organophosphorus anticholinesterase compounds","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"guanidine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of <e2>GENE-Y<\\e2> against denaturation by heat or <e1>CHEMICAL<\\e1> following phosphorylation by organophosphorus anticholinesterase compounds","sentence":"Monoclonal antibody 25B1 appears to be directed against a conformational epitope located in close proximity to the catalytic center of the enzyme and was found to be most suitable for studying the stabilization of the active site of acetylcholinesterase against denaturation by heat or guanidine following phosphorylation by organophosphorus anticholinesterase compounds"}
{"PMID":1692236,"re_id":6,"annotated sentence":"Monoclonal antibody 25B1 generated against <e1>diisopropyl phosphorofluoridate<\\e1> inhibited fetal <e2>bovine serum acetylcholinesterase<\\e2> has been extensively characterized with respect to its anticholinesterase properties","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diisopropyl phosphorofluoridate","object":"bovine serum acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Monoclonal antibody 25B1 generated against <e1>CHEMICAL<\\e1> inhibited fetal <e2>GENE-Y<\\e2> has been extensively characterized with respect to its anticholinesterase properties","sentence":"Monoclonal antibody 25B1 generated against diisopropyl phosphorofluoridate inhibited fetal bovine serum acetylcholinesterase has been extensively characterized with respect to its anticholinesterase properties"}
{"PMID":16964330,"re_id":11,"annotated sentence":"The <e1>sordarins<\\e1> group are protein synthesis inhibitors that work by blocking the function of <e2>fungal translation elongation factor 2<\\e2>  Other protein inhibitors are zofimarin, BE31045, SCH57504, xylarin, hypoxysordarin and GR135402","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sordarins","object":"fungal translation elongation factor 2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e1>CHEMICAL<\\e1> group are protein synthesis inhibitors that work by blocking the function of <e2>GENE-N<\\e2>  Other protein inhibitors are zofimarin, BE31045, SCH57504, xylarin, hypoxysordarin and GR135402","sentence":"The sordarins group are protein synthesis inhibitors that work by blocking the function of fungal translation elongation factor 2  Other protein inhibitors are zofimarin, BE31045, SCH57504, xylarin, hypoxysordarin and GR135402"}
{"PMID":16965760,"re_id":9,"annotated sentence":"It has been known for decades that <e1>lithium chloride<\\e1> (LiCl) leads to D-myo-inositol 1-phosphate accumulation on <e2>GPCR<\\e2> activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"lithium chloride","object":"GPCR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It has been known for decades that <e1>CHEMICAL<\\e1> (LiCl) leads to D-myo-inositol 1-phosphate accumulation on <e2>GENE-N<\\e2> activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade","sentence":"It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade"}
{"PMID":16965760,"re_id":10,"annotated sentence":"It has been known for decades that lithium chloride (<e1>LiCl<\\e1>  leads to D-myo-inositol 1-phosphate accumulation on <e2>GPCR<\\e2> activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"LiCl","object":"GPCR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It has been known for decades that lithium chloride (<e1>CHEMICAL<\\e1>  leads to D-myo-inositol 1-phosphate accumulation on <e2>GENE-N<\\e2> activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade","sentence":"It has been known for decades that lithium chloride (LiCl  leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting inositol monophosphatase, the final enzyme of the IP3 metabolic cascade"}
{"PMID":16965760,"re_id":11,"annotated sentence":"It has been known for decades that <e1>lithium chloride<\\e1> (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting <e2>inositol monophosphatase<\\e2>  the final enzyme of the IP3 metabolic cascade","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lithium chloride","object":"inositol monophosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It has been known for decades that <e1>CHEMICAL<\\e1> (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting <e2>GENE-N<\\e2>  the final enzyme of the IP3 metabolic cascade","sentence":"It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting inositol monophosphatase  the final enzyme of the IP3 metabolic cascade"}
{"PMID":16965760,"re_id":12,"annotated sentence":"It has been known for decades that lithium chloride (<e1>LiCl<\\e1>  leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting <e2>inositol monophosphatase<\\e2>  the final enzyme of the IP3 metabolic cascade","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"LiCl","object":"inositol monophosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It has been known for decades that lithium chloride (<e1>CHEMICAL<\\e1>  leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting <e2>GENE-N<\\e2>  the final enzyme of the IP3 metabolic cascade","sentence":"It has been known for decades that lithium chloride (LiCl  leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting inositol monophosphatase  the final enzyme of the IP3 metabolic cascade"}
{"PMID":16965760,"re_id":16,"annotated sentence":"Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by <e1>D-myo-inositol 1,4,5-trisphosphate<\\e1> (IP3), a <e2>PLC-beta<\\e2> hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"D-myo-inositol 1,4,5-trisphosphate","object":"PLC-beta","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phospholipase C beta (GENE-N)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by <e1>CHEMICAL<\\e1> (IP3), a <e2>GENE-N<\\e2> hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays","sentence":"Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays"}
{"PMID":16965760,"re_id":17,"annotated sentence":"Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (<e1>IP3<\\e1> , a <e2>PLC-beta<\\e2> hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"IP3","object":"PLC-beta","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phospholipase C beta (GENE-N)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (<e1>CHEMICAL<\\e1> , a <e2>GENE-N<\\e2> hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays","sentence":"Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3 , a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays"}
{"PMID":16965760,"re_id":18,"annotated sentence":"Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a <e2>PLC-beta<\\e2> hydrolysis product, or by measuring the production of <e1>inositol phosphate<\\e1> using cumbersome radioactive assays","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"inositol phosphate","object":"PLC-beta","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Phospholipase C beta (GENE-N)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a <e2>GENE-N<\\e2> hydrolysis product, or by measuring the production of <e1>CHEMICAL<\\e1> using cumbersome radioactive assays","sentence":"Phospholipase C beta (PLC-beta)-coupled G protein-coupled receptor (GPCR) activities traditionally are assessed by measuring Ca2+ triggered by D-myo-inositol 1,4,5-trisphosphate (IP3), a PLC-beta hydrolysis product, or by measuring the production of inositol phosphate using cumbersome radioactive assays"}
{"PMID":16965760,"re_id":19,"annotated sentence":"It has been known for decades that lithium chloride (LiCl) leads to <e1>D-myo-inositol 1-phosphate<\\e1> accumulation on GPCR activation by inhibiting <e2>inositol monophosphatase<\\e2>  the final enzyme of the IP3 metabolic cascade","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"D-myo-inositol 1-phosphate","object":"inositol monophosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It has been known for decades that lithium chloride (LiCl) leads to <e1>CHEMICAL<\\e1> accumulation on GPCR activation by inhibiting <e2>GENE-N<\\e2>  the final enzyme of the IP3 metabolic cascade","sentence":"It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting inositol monophosphatase  the final enzyme of the IP3 metabolic cascade"}
{"PMID":16965760,"re_id":20,"annotated sentence":"It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting <e2>inositol monophosphatase<\\e2>  the final enzyme of the <e1>IP3<\\e1> metabolic cascade","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"IP3","object":"inositol monophosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting <e2>GENE-N<\\e2>  the final enzyme of the <e1>CHEMICAL<\\e1> metabolic cascade","sentence":"It has been known for decades that lithium chloride (LiCl) leads to D-myo-inositol 1-phosphate accumulation on GPCR activation by inhibiting inositol monophosphatase  the final enzyme of the IP3 metabolic cascade"}
{"PMID":16970975,"re_id":0,"annotated sentence":"Once formed, the molecule can be converted to <e1>glycine<\\e1> by <e2>alanine-glyoxylate aminotransferase<\\e2> (AGAT)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"glycine","object":"alanine-glyoxylate aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Once formed, the molecule can be converted to <e1>CHEMICAL<\\e1> by <e2>GENE-Y<\\e2> (AGAT)","sentence":"Once formed, the molecule can be converted to glycine by alanine-glyoxylate aminotransferase (AGAT)"}
{"PMID":16970975,"re_id":1,"annotated sentence":"Once formed, the molecule can be converted to <e1>glycine<\\e1> by alanine-glyoxylate aminotransferase (<e2>AGAT<\\e2> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"glycine","object":"AGAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Once formed, the molecule can be converted to <e1>CHEMICAL<\\e1> by alanine-glyoxylate aminotransferase (<e2>GENE-Y<\\e2> ","sentence":"Once formed, the molecule can be converted to glycine by alanine-glyoxylate aminotransferase (AGAT "}
{"PMID":16980198,"re_id":5,"annotated sentence":"inactivation of cortisol to cortisone) to prevent activation of the <e2>mineralocorticoid receptor<\\e2> (MR) by <e1>cortisol<\\e1>  Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which cortisol activates the MR resulting in severe hypertension and hypokalemia","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"cortisol","object":"mineralocorticoid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"inactivation of CHEMICAL to cortisone) to prevent activation of the <e2>GENE-Y<\\e2> (MR) by <e1>CHEMICAL<\\e1>  Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which CHEMICAL activates the MR resulting in severe hypertension and hypokalemia","sentence":"inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor (MR) by cortisol  Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which cortisol activates the MR resulting in severe hypertension and hypokalemia"}
{"PMID":16980198,"re_id":6,"annotated sentence":"inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor (<e2>MR<\\e2>  by <e1>cortisol<\\e1>  Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which cortisol activates the MR resulting in severe hypertension and hypokalemia","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"cortisol","object":"MR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"inactivation of CHEMICAL to cortisone) to prevent activation of the mineralocorticoid receptor (<e2>GENE-Y<\\e2>  by <e1>CHEMICAL<\\e1>  Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which CHEMICAL activates the GENE-Y resulting in severe hypertension and hypokalemia","sentence":"inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor (MR  by cortisol  Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which cortisol activates the MR resulting in severe hypertension and hypokalemia"}
{"PMID":16980198,"re_id":7,"annotated sentence":"Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which <e1>cortisol<\\e1> activates the <e2>MR<\\e2> resulting in severe hypertension and hypokalemia","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"cortisol","object":"MR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which <e1>CHEMICAL<\\e1> activates the <e2>GENE-Y<\\e2> resulting in severe hypertension and hypokalemia","sentence":"Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which cortisol activates the MR resulting in severe hypertension and hypokalemia"}
{"PMID":16980198,"re_id":8,"annotated sentence":"Ingestion of competitive inhibitors of <e2>11beta-HSD2<\\e2> such as liquorice and <e1>carbenoxolone<\\e1> result in a similar but milder clinical phenotype","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carbenoxolone","object":"11beta-HSD2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ingestion of competitive inhibitors of <e2>GENE-Y<\\e2> such as liquorice and <e1>CHEMICAL<\\e1> result in a similar but milder clinical phenotype","sentence":"Ingestion of competitive inhibitors of 11beta-HSD2 such as liquorice and carbenoxolone result in a similar but milder clinical phenotype"}
{"PMID":16980198,"re_id":9,"annotated sentence":"<e2>11Beta-HSD1<\\e2> activates cortisone to <e1>cortisol<\\e1> to facilitate glucocorticoid receptor (GR)-mediated action","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"cortisol","object":"11Beta-HSD1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> activates cortisone to <e1>CHEMICAL<\\e1> to facilitate glucocorticoid receptor (GR)-mediated action","sentence":"11Beta-HSD1 activates cortisone to cortisol to facilitate glucocorticoid receptor (GR)-mediated action"}
{"PMID":16980198,"re_id":10,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"cortisone","object":"11beta-HSD2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":16980198,"re_id":11,"annotated sentence":"<e2>11Beta-HSD1<\\e2> activates <e1>cortisone<\\e1> to cortisol to facilitate glucocorticoid receptor (GR)-mediated action","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cortisone","object":"11Beta-HSD1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> activates <e1>CHEMICAL<\\e1> to cortisol to facilitate glucocorticoid receptor (GR)-mediated action","sentence":"11Beta-HSD1 activates cortisone to cortisol to facilitate glucocorticoid receptor (GR)-mediated action"}
{"PMID":16980198,"re_id":12,"annotated sentence":"none","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cortisol","object":"11beta-HSD2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":16982809,"re_id":0,"annotated sentence":"<e1>ATRA<\\e1> regulates gene expression via the activation of the <e2>retinoic acid receptor (RAR)alpha<\\e2> in human DCs, and RARalpha acutely regulates CD1d expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ATRA","object":"retinoic acid receptor (RAR)alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> regulates gene expression via the activation of the <e2>GENE-Y<\\e2> in human DCs, and RARalpha acutely regulates CD1d expression","sentence":"ATRA regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and RARalpha acutely regulates CD1d expression"}
{"PMID":16982809,"re_id":1,"annotated sentence":"<e1>ATRA<\\e1> regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and <e2>RARalpha<\\e2> acutely regulates CD1d expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ATRA","object":"RARalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and <e2>GENE-Y<\\e2> acutely regulates CD1d expression","sentence":"ATRA regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and RARalpha acutely regulates CD1d expression"}
{"PMID":16982809,"re_id":2,"annotated sentence":"<e1>ATRA<\\e1> regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and RARalpha acutely regulates <e2>CD1d<\\e2> expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ATRA","object":"CD1d","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and RARalpha acutely regulates <e2>GENE-Y<\\e2> expression","sentence":"ATRA regulates gene expression via the activation of the retinoic acid receptor (RAR)alpha in human DCs, and RARalpha acutely regulates CD1d expression"}
{"PMID":16982809,"re_id":3,"annotated sentence":"The <e1>retinoic acid<\\e1> induced elevated expression of <e2>CD1d<\\e2> is coupled to enhanced iNKT cell activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"retinoic acid","object":"CD1d","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> induced elevated expression of <e2>GENE-Y<\\e2> is coupled to enhanced iNKT cell activation","sentence":"The retinoic acid induced elevated expression of CD1d is coupled to enhanced iNKT cell activation"}
{"PMID":16982809,"re_id":4,"annotated sentence":"Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit <e1>retinoid<\\e1> signaling leading to <e2>CD1d<\\e2> up-regulation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"retinoid","object":"CD1d","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit <e1>CHEMICAL<\\e1> signaling leading to <e2>GENE-Y<\\e2> up-regulation","sentence":"Furthermore, in vivo relevant lipids such as oxidized low-density lipoprotein can also elicit retinoid signaling leading to CD1d up-regulation"}
{"PMID":16982809,"re_id":5,"annotated sentence":"Here we demonstrate that PPARgamma, turns on <e1>retinoic acid<\\e1> synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as <e2>retinol dehydrogenase 10<\\e2> and retinaldehyde dehydrogenase type 2 (RALDH2)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"retinoic acid","object":"retinol dehydrogenase 10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we demonstrate that PPARgamma, turns on <e1>CHEMICAL<\\e1> synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as <e2>GENE-Y<\\e2> and retinaldehyde dehydrogenase type 2 (RALDH2)","sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2)"}
{"PMID":16982809,"re_id":6,"annotated sentence":"Here we demonstrate that PPARgamma, turns on <e1>retinoic acid<\\e1> synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and <e2>retinaldehyde dehydrogenase type 2<\\e2> (RALDH2)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"retinoic acid","object":"retinaldehyde dehydrogenase type 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we demonstrate that PPARgamma, turns on <e1>CHEMICAL<\\e1> synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and <e2>GENE-Y<\\e2> (RALDH2)","sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2)"}
{"PMID":16982809,"re_id":7,"annotated sentence":"Here we demonstrate that PPARgamma, turns on <e1>retinoic acid<\\e1> synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (<e2>RALDH2<\\e2> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"retinoic acid","object":"RALDH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we demonstrate that PPARgamma, turns on <e1>CHEMICAL<\\e1> synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (<e2>GENE-Y<\\e2> ","sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2 "}
{"PMID":16982809,"re_id":8,"annotated sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of <e1>retinol<\\e1> and retinal metabolizing enzymes such as <e2>retinol dehydrogenase 10<\\e2> and retinaldehyde dehydrogenase type 2 (RALDH2)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"retinol","object":"retinol dehydrogenase 10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of <e1>CHEMICAL<\\e1> and retinal metabolizing enzymes such as <e2>CHEMICAL dehydrogenase 10<\\e2> and retinaldehyde dehydrogenase type 2 (RALDH2)","sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2)"}
{"PMID":16982809,"re_id":9,"annotated sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of <e1>retinol<\\e1> and retinal metabolizing enzymes such as retinol dehydrogenase 10 and <e2>retinaldehyde dehydrogenase type 2<\\e2> (RALDH2)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"retinol","object":"retinaldehyde dehydrogenase type 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of <e1>CHEMICAL<\\e1> and retinal metabolizing enzymes such as CHEMICAL dehydrogenase 10 and <e2>GENE-Y<\\e2> (RALDH2)","sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2)"}
{"PMID":16982809,"re_id":10,"annotated sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of <e1>retinol<\\e1> and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (<e2>RALDH2<\\e2> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"retinol","object":"RALDH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of <e1>CHEMICAL<\\e1> and retinal metabolizing enzymes such as CHEMICAL dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (<e2>GENE-Y<\\e2> ","sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2 "}
{"PMID":16982809,"re_id":11,"annotated sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and <e1>retinal<\\e1> metabolizing enzymes such as <e2>retinol dehydrogenase 10<\\e2> and retinaldehyde dehydrogenase type 2 (RALDH2)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"retinal","object":"retinol dehydrogenase 10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and <e1>CHEMICAL<\\e1> metabolizing enzymes such as <e2>GENE-Y<\\e2> and CHEMICALdehyde dehydrogenase type 2 (RALDH2)","sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2)"}
{"PMID":16982809,"re_id":12,"annotated sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and <e1>retinal<\\e1> metabolizing enzymes such as retinol dehydrogenase 10 and <e2>retinaldehyde dehydrogenase type 2<\\e2> (RALDH2)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"retinal","object":"retinaldehyde dehydrogenase type 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and <e1>CHEMICAL<\\e1> metabolizing enzymes such as retinol dehydrogenase 10 and <e2>CHEMICALdehyde dehydrogenase type 2<\\e2> (RALDH2)","sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2)"}
{"PMID":16982809,"re_id":13,"annotated sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and <e1>retinal<\\e1> metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (<e2>RALDH2<\\e2> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"retinal","object":"RALDH2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and <e1>CHEMICAL<\\e1> metabolizing enzymes such as retinol dehydrogenase 10 and CHEMICALdehyde dehydrogenase type 2 (<e2>GENE-Y<\\e2> ","sentence":"Here we demonstrate that PPARgamma, turns on retinoic acid synthesis by inducing the expression of retinol and retinal metabolizing enzymes such as retinol dehydrogenase 10 and retinaldehyde dehydrogenase type 2 (RALDH2 "}
{"PMID":17015817,"re_id":0,"annotated sentence":"CONTEXT: <e1>Ramelteon<\\e1> is a novel <e2>MT1<\\e2> and MT2 melatonin receptor selective agonist recently approved for insomnia treatment","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"Ramelteon","object":"MT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONTEXT: <e1>CHEMICAL<\\e1> is a novel <e2>GENE-Y<\\e2> and MT2 melatonin receptor selective agonist recently approved for insomnia treatment","sentence":"CONTEXT: Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment"}
{"PMID":17015817,"re_id":1,"annotated sentence":"CONTEXT: <e1>Ramelteon<\\e1> is a novel MT1 and <e2>MT2 melatonin receptor<\\e2> selective agonist recently approved for insomnia treatment","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"Ramelteon","object":"MT2 melatonin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONTEXT: <e1>CHEMICAL<\\e1> is a novel MT1 and <e2>GENE-Y<\\e2> selective agonist recently approved for insomnia treatment","sentence":"CONTEXT: Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment"}
{"PMID":17016511,"re_id":0,"annotated sentence":"Late INa induced by the <e2>VGSC<\\e2> long QT mutant R1623Q was reduced by <e1>resveratrol<\\e1> and quercetin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"resveratrol","object":"VGSC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Late INa induced by the <e2>GENE-N<\\e2> long QT mutant R1623Q was reduced by <e1>CHEMICAL<\\e1> and quercetin","sentence":"Late INa induced by the VGSC long QT mutant R1623Q was reduced by resveratrol and quercetin"}
{"PMID":17016511,"re_id":1,"annotated sentence":"Late INa induced by the VGSC long QT mutant <e2>R1623Q<\\e2> was reduced by <e1>resveratrol<\\e1> and quercetin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"resveratrol","object":"R1623Q","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Late INa induced by the VGSC long QT mutant <e2>GENE-N<\\e2> was reduced by <e1>CHEMICAL<\\e1> and quercetin","sentence":"Late INa induced by the VGSC long QT mutant R1623Q was reduced by resveratrol and quercetin"}
{"PMID":17016511,"re_id":2,"annotated sentence":"Late INa induced by the <e2>VGSC<\\e2> long QT mutant R1623Q was reduced by resveratrol and <e1>quercetin<\\e1>  Resveratrol and quercetin also blocked late INa induced by the toxin, ATX II, with IC50s of 26.1 microM and 24.9 microM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"quercetin","object":"VGSC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Late INa induced by the <e2>GENE-N<\\e2> long QT mutant R1623Q was reduced by resveratrol and <e1>CHEMICAL<\\e1>  Resveratrol and CHEMICAL also blocked late INa induced by the toxin, ATX II, with IC50s of 26.1 microM and 24.9 microM, respectively","sentence":"Late INa induced by the VGSC long QT mutant R1623Q was reduced by resveratrol and quercetin  Resveratrol and quercetin also blocked late INa induced by the toxin, ATX II, with IC50s of 26.1 microM and 24.9 microM, respectively"}
{"PMID":17016511,"re_id":3,"annotated sentence":"Late INa induced by the VGSC long QT mutant <e2>R1623Q<\\e2> was reduced by resveratrol and <e1>quercetin<\\e1>  Resveratrol and quercetin also blocked late INa induced by the toxin, ATX II, with IC50s of 26.1 microM and 24.9 microM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"quercetin","object":"R1623Q","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Late INa induced by the VGSC long QT mutant <e2>GENE-N<\\e2> was reduced by resveratrol and <e1>CHEMICAL<\\e1>  Resveratrol and CHEMICAL also blocked late INa induced by the toxin, ATX II, with IC50s of 26.1 microM and 24.9 microM, respectively","sentence":"Late INa induced by the VGSC long QT mutant R1623Q was reduced by resveratrol and quercetin  Resveratrol and quercetin also blocked late INa induced by the toxin, ATX II, with IC50s of 26.1 microM and 24.9 microM, respectively"}
{"PMID":17016621,"re_id":0,"annotated sentence":"Enhancement of radiosensitivity by <e2>topoisomerase II<\\e2> inhibitor, <e1>amrubicin<\\e1> and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"amrubicin","object":"topoisomerase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Enhancement of radiosensitivity by <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1> and CHEMICALol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction","sentence":"Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction"}
{"PMID":17016621,"re_id":1,"annotated sentence":"Enhancement of radiosensitivity by <e2>topoisomerase II<\\e2> inhibitor, amrubicin and <e1>amrubicinol<\\e1>  in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"amrubicinol","object":"topoisomerase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Enhancement of radiosensitivity by <e2>GENE-Y<\\e2> inhibitor, amrubicin and <e1>CHEMICAL<\\e1>  in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction","sentence":"Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol  in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction"}
{"PMID":17016621,"re_id":2,"annotated sentence":"Similar to <e1>AMR<\\e1> and AMROH, adriamycin and etoposide (VP-16) are <e2>DNA topoisomerase II<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AMR","object":"DNA topoisomerase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to <e1>CHEMICAL<\\e1> and CHEMICALOH, adriamycin and etoposide (VP-16) are <e2>GENE-Y<\\e2> inhibitors","sentence":"Similar to AMR and AMROH, adriamycin and etoposide (VP-16) are DNA topoisomerase II inhibitors"}
{"PMID":17016621,"re_id":3,"annotated sentence":"Similar to AMR and <e1>AMROH<\\e1>  adriamycin and etoposide (VP-16) are <e2>DNA topoisomerase II<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AMROH","object":"DNA topoisomerase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to AMR and <e1>CHEMICAL<\\e1>  adriamycin and etoposide (VP-16) are <e2>GENE-Y<\\e2> inhibitors","sentence":"Similar to AMR and AMROH  adriamycin and etoposide (VP-16) are DNA topoisomerase II inhibitors"}
{"PMID":17016621,"re_id":4,"annotated sentence":"Similar to AMR and AMROH, <e1>adriamycin<\\e1> and etoposide (VP-16) are <e2>DNA topoisomerase II<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"adriamycin","object":"DNA topoisomerase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to AMR and AMROH, <e1>CHEMICAL<\\e1> and etoposide (VP-16) are <e2>GENE-Y<\\e2> inhibitors","sentence":"Similar to AMR and AMROH, adriamycin and etoposide (VP-16) are DNA topoisomerase II inhibitors"}
{"PMID":17016621,"re_id":5,"annotated sentence":"Similar to AMR and AMROH, adriamycin and <e1>etoposide<\\e1> (VP-16) are <e2>DNA topoisomerase II<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"etoposide","object":"DNA topoisomerase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to AMR and AMROH, adriamycin and <e1>CHEMICAL<\\e1> (VP-16) are <e2>GENE-Y<\\e2> inhibitors","sentence":"Similar to AMR and AMROH, adriamycin and etoposide (VP-16) are DNA topoisomerase II inhibitors"}
{"PMID":17016621,"re_id":6,"annotated sentence":"Similar to AMR and AMROH, adriamycin and etoposide (<e1>VP-16<\\e1>  are <e2>DNA topoisomerase II<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"VP-16","object":"DNA topoisomerase II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar to AMR and AMROH, adriamycin and etoposide (<e1>CHEMICAL<\\e1>  are <e2>GENE-Y<\\e2> inhibitors","sentence":"Similar to AMR and AMROH, adriamycin and etoposide (VP-16  are DNA topoisomerase II inhibitors"}
{"PMID":17033106,"re_id":1,"annotated sentence":"pylori may in fact, antagonize, <e1>aspirin<\\e1> induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from <e2>COX-2<\\e2> expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"aspirin","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"pylori may in fact, antagonize, <e1>CHEMICAL<\\e1> induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from <e2>GENE-N<\\e2> expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF","sentence":"pylori may in fact, antagonize, aspirin induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF"}
{"PMID":17033106,"re_id":2,"annotated sentence":"none","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"aspirin","object":"cyclooxygenase (COX)-2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"none","sentence":"none"}
{"PMID":17033106,"re_id":3,"annotated sentence":"pylori may in fact, antagonize, <e1>aspirin<\\e1> induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as <e2>TGF alpha<\\e2> and VEGF","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"aspirin","object":"TGF alpha","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"pylori may in fact, antagonize, <e1>CHEMICAL<\\e1> induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as <e2>GENE-N<\\e2> and VEGF","sentence":"pylori may in fact, antagonize, aspirin induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF"}
{"PMID":17033106,"re_id":4,"annotated sentence":"pylori may in fact, antagonize, <e1>aspirin<\\e1> induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and <e2>VEGF<\\e2>  The present review summarizes and further addresses the issue of the interaction between these two major ulcer risk factors determined in the stomach of humans and experimental animals.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"aspirin","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"pylori may in fact, antagonize, <e1>CHEMICAL<\\e1> induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and <e2>GENE-N<\\e2>  The present review summarizes and further addresses the issue of the interaction between these two major ulcer risk factors determined in the stomach of humans and experimental animals.","sentence":"pylori may in fact, antagonize, aspirin induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF  The present review summarizes and further addresses the issue of the interaction between these two major ulcer risk factors determined in the stomach of humans and experimental animals."}
{"PMID":17033106,"re_id":5,"annotated sentence":"pylori may in fact, antagonize, <e1>aspirin<\\e1> induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from <e2>COX-2<\\e2> expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"aspirin","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"pylori may in fact, antagonize, <e1>CHEMICAL<\\e1> induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from <e2>GENE-N<\\e2> expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF","sentence":"pylori may in fact, antagonize, aspirin induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF"}
{"PMID":17033106,"re_id":6,"annotated sentence":"pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in <e1>PGE(2)<\\e1> possibly derived from <e2>COX-2<\\e2> expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PGE(2)","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in <e1>CHEMICAL<\\e1> possibly derived from <e2>GENE-N<\\e2> expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF","sentence":"pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF"}
{"PMID":17041099,"re_id":3,"annotated sentence":"Based on selective nucleoside protection, TS was found to be the primary pemetrexed target in both cell lines with <e2>GARFT<\\e2> inhibition requiring 20- to 30-fold higher <e1>pemetrexed<\\e1> concentrations","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"pemetrexed","object":"GARFT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Based on selective nucleoside protection, TS was found to be the primary CHEMICAL target in both cell lines with <e2>GENE-Y<\\e2> inhibition requiring 20- to 30-fold higher <e1>CHEMICAL<\\e1> concentrations","sentence":"Based on selective nucleoside protection, TS was found to be the primary pemetrexed target in both cell lines with GARFT inhibition requiring 20- to 30-fold higher pemetrexed concentrations"}
{"PMID":17041099,"re_id":4,"annotated sentence":"<e2>Methylthioadenosine phosphorylase<\\e2> (MTAP) salvages purines by releasing <e1>adenine<\\e1> from methylthioadenosine and is often deleted in mesothelioma","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"adenine","object":"Methylthioadenosine phosphorylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (MTAP) salvages purines by releasing <e1>CHEMICAL<\\e1> from methylthioadenosine and is often deleted in mesothelioma","sentence":"Methylthioadenosine phosphorylase (MTAP) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma"}
{"PMID":17041099,"re_id":5,"annotated sentence":"Methylthioadenosine phosphorylase (<e2>MTAP<\\e2>  salvages purines by releasing <e1>adenine<\\e1> from methylthioadenosine and is often deleted in mesothelioma","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"adenine","object":"MTAP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methylthioadenosine phosphorylase (<e2>GENE-Y<\\e2>  salvages purines by releasing <e1>CHEMICAL<\\e1> from methylthioadenosine and is often deleted in mesothelioma","sentence":"Methylthioadenosine phosphorylase (MTAP  salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma"}
{"PMID":17041099,"re_id":6,"annotated sentence":"<e2>Methylthioadenosine phosphorylase<\\e2> (MTAP) salvages purines by releasing adenine from <e1>methylthioadenosine<\\e1> and is often deleted in mesothelioma","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"methylthioadenosine","object":"Methylthioadenosine phosphorylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (MTAP) salvages purines by releasing adenine from <e1>CHEMICAL<\\e1> and is often deleted in mesothelioma","sentence":"Methylthioadenosine phosphorylase (MTAP) salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma"}
{"PMID":17041099,"re_id":7,"annotated sentence":"Methylthioadenosine phosphorylase (<e2>MTAP<\\e2>  salvages purines by releasing adenine from <e1>methylthioadenosine<\\e1> and is often deleted in mesothelioma","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"methylthioadenosine","object":"MTAP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methylthioadenosine phosphorylase (<e2>GENE-Y<\\e2>  salvages purines by releasing adenine from <e1>CHEMICAL<\\e1> and is often deleted in mesothelioma","sentence":"Methylthioadenosine phosphorylase (MTAP  salvages purines by releasing adenine from methylthioadenosine and is often deleted in mesothelioma"}
{"PMID":17082235,"re_id":12,"annotated sentence":"The most active of these compounds, <e1>gliquidone<\\e1>  is shown to be as potent as pioglitazone at inducing <e2>PPARgamma<\\e2> target gene expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"gliquidone","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most active of these compounds, <e1>CHEMICAL<\\e1>  is shown to be as potent as pioglitazone at inducing <e2>GENE-Y<\\e2> target gene expression","sentence":"The most active of these compounds, gliquidone  is shown to be as potent as pioglitazone at inducing PPARgamma target gene expression"}
{"PMID":17082235,"re_id":13,"annotated sentence":"The most active of these compounds, gliquidone, is shown to be as potent as <e1>pioglitazone<\\e1> at inducing <e2>PPARgamma<\\e2> target gene expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"pioglitazone","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most active of these compounds, gliquidone, is shown to be as potent as <e1>CHEMICAL<\\e1> at inducing <e2>GENE-Y<\\e2> target gene expression","sentence":"The most active of these compounds, gliquidone, is shown to be as potent as pioglitazone at inducing PPARgamma target gene expression"}
{"PMID":17082235,"re_id":14,"annotated sentence":"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating <e2>insulin<\\e2> release (<e1>sulfonylureas<\\e1>  glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"sulfonylureas","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating <e2>GENE-Y<\\e2> release (<e1>CHEMICAL<\\e1>  glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving GENE-Y resistance (thiazolidinediones)","sentence":"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas  glinides), or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones)"}
{"PMID":17082235,"re_id":15,"annotated sentence":"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating <e2>insulin<\\e2> release (sulfonylureas, <e1>glinides<\\e1> , or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glinides","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating <e2>GENE-Y<\\e2> release (sulfonylureas, <e1>CHEMICAL<\\e1> , or target the peroxisome proliferator-activated receptor (PPARgamma) improving GENE-Y resistance (thiazolidinediones)","sentence":"Most drugs currently employed in the treatment of type 2 diabetes either target the sulfonylurea receptor stimulating insulin release (sulfonylureas, glinides , or target the peroxisome proliferator-activated receptor (PPARgamma) improving insulin resistance (thiazolidinediones)"}
{"PMID":17082235,"re_id":16,"annotated sentence":"Among the measured compounds, <e1>gliquidone<\\e1> and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit <e2>PPARgamma<\\e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"gliquidone","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the measured compounds, <e1>CHEMICAL<\\e1> and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit <e2>GENE-Y<\\e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment","sentence":"Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit PPARgamma agonistic activity at concentrations comparable with those reached under pharmacological treatment"}
{"PMID":17082235,"re_id":17,"annotated sentence":"Among the measured compounds, gliquidone and <e1>glipizide<\\e1> (two sulfonylureas), as well as nateglinide (a glinide), exhibit <e2>PPARgamma<\\e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"glipizide","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the measured compounds, gliquidone and <e1>CHEMICAL<\\e1> (two sulfonylureas), as well as nateglinide (a glinide), exhibit <e2>GENE-Y<\\e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment","sentence":"Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit PPARgamma agonistic activity at concentrations comparable with those reached under pharmacological treatment"}
{"PMID":17082235,"re_id":18,"annotated sentence":"Among the measured compounds, gliquidone and glipizide (two <e1>sulfonylureas<\\e1> , as well as nateglinide (a glinide), exhibit <e2>PPARgamma<\\e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"sulfonylureas","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the measured compounds, gliquidone and glipizide (two <e1>CHEMICAL<\\e1> , as well as nateglinide (a glinide), exhibit <e2>GENE-Y<\\e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment","sentence":"Among the measured compounds, gliquidone and glipizide (two sulfonylureas , as well as nateglinide (a glinide), exhibit PPARgamma agonistic activity at concentrations comparable with those reached under pharmacological treatment"}
{"PMID":17082235,"re_id":19,"annotated sentence":"Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as <e1>nateglinide<\\e1> (a glinide), exhibit <e2>PPARgamma<\\e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"nateglinide","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as <e1>CHEMICAL<\\e1> (a glinide), exhibit <e2>GENE-Y<\\e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment","sentence":"Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nateglinide (a glinide), exhibit PPARgamma agonistic activity at concentrations comparable with those reached under pharmacological treatment"}
{"PMID":17082235,"re_id":20,"annotated sentence":"Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nateglinide (a <e1>glinide<\\e1> , exhibit <e2>PPARgamma<\\e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"glinide","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nateCHEMICAL (a <e1>CHEMICAL<\\e1> , exhibit <e2>GENE-Y<\\e2> agonistic activity at concentrations comparable with those reached under pharmacological treatment","sentence":"Among the measured compounds, gliquidone and glipizide (two sulfonylureas), as well as nateglinide (a glinide , exhibit PPARgamma agonistic activity at concentrations comparable with those reached under pharmacological treatment"}
{"PMID":17082235,"re_id":21,"annotated sentence":"<e1>Glinides<\\e1>  sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new <e2>PPARgamma<\\e2> agonists","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"Glinides","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new <e2>GENE-Y<\\e2> agonists","sentence":"Glinides  sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new PPARgamma agonists"}
{"PMID":17082235,"re_id":22,"annotated sentence":"Glinides, <e1>sulfonylureas<\\e1>  and other acidified sulfonamides may be promising leads in the development of new <e2>PPARgamma<\\e2> agonists","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"sulfonylureas","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Glinides, <e1>CHEMICAL<\\e1>  and other acidified sulfonamides may be promising leads in the development of new <e2>GENE-Y<\\e2> agonists","sentence":"Glinides, sulfonylureas  and other acidified sulfonamides may be promising leads in the development of new PPARgamma agonists"}
{"PMID":17082235,"re_id":23,"annotated sentence":"Glinides, sulfonylureas, and other <e1>acidified sulfonamides<\\e1> may be promising leads in the development of new <e2>PPARgamma<\\e2> agonists","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"acidified sulfonamides","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Glinides, sulfonylureas, and other <e1>CHEMICAL<\\e1> may be promising leads in the development of new <e2>GENE-Y<\\e2> agonists","sentence":"Glinides, sulfonylureas, and other acidified sulfonamides may be promising leads in the development of new PPARgamma agonists"}
{"PMID":17082235,"re_id":24,"annotated sentence":"Our work shows that <e1>sulfonylureas<\\e1> and glinides additionally bind to PPARgamma and exhibit <e2>PPARgamma<\\e2> agonistic activity","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"sulfonylureas","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our work shows that <e1>CHEMICAL<\\e1> and glinides additionally bind to GENE-Y and exhibit <e2>GENE-Y<\\e2> agonistic activity","sentence":"Our work shows that sulfonylureas and glinides additionally bind to PPARgamma and exhibit PPARgamma agonistic activity"}
{"PMID":17082235,"re_id":25,"annotated sentence":"Our work shows that sulfonylureas and <e1>glinides<\\e1> additionally bind to PPARgamma and exhibit <e2>PPARgamma<\\e2> agonistic activity","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"glinides","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our work shows that sulfonylureas and <e1>CHEMICAL<\\e1> additionally bind to GENE-Y and exhibit <e2>GENE-Y<\\e2> agonistic activity","sentence":"Our work shows that sulfonylureas and glinides additionally bind to PPARgamma and exhibit PPARgamma agonistic activity"}
{"PMID":17088426,"re_id":4,"annotated sentence":"Such organization results in the local activation of <e2>PKA<\\e2> subsets through the generation of confined intracellular gradients of <e1>cAMP<\\e1>  but the mechanisms responsible for limiting the diffusion of cAMP largely remain to be clarified","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"cAMP","object":"PKA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Such organization results in the local activation of <e2>GENE-N<\\e2> subsets through the generation of confined intracellular gradients of <e1>CHEMICAL<\\e1>  but the mechanisms responsible for limiting the diffusion of CHEMICAL largely remain to be clarified","sentence":"Such organization results in the local activation of PKA subsets through the generation of confined intracellular gradients of cAMP  but the mechanisms responsible for limiting the diffusion of cAMP largely remain to be clarified"}
{"PMID":17088426,"re_id":5,"annotated sentence":"By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized <e2>PDE4B<\\e2> and PDE4D are responsible for selectively modulating the concentration of <e1>cAMP<\\e1> in individual subcellular compartments","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cAMP","object":"PDE4B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized <e2>GENE-Y<\\e2> and PDE4D are responsible for selectively modulating the concentration of <e1>CHEMICAL<\\e1> in individual subcellular compartments","sentence":"By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and PDE4D are responsible for selectively modulating the concentration of cAMP in individual subcellular compartments"}
{"PMID":17088426,"re_id":6,"annotated sentence":"By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and <e2>PDE4D<\\e2> are responsible for selectively modulating the concentration of <e1>cAMP<\\e1> in individual subcellular compartments","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cAMP","object":"PDE4D","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and <e2>GENE-Y<\\e2> are responsible for selectively modulating the concentration of <e1>CHEMICAL<\\e1> in individual subcellular compartments","sentence":"By using pharmacological and genetic manipulation of phosphodiesterases (PDEs), we demonstrate that compartmentalized PDE4B and PDE4D are responsible for selectively modulating the concentration of cAMP in individual subcellular compartments"}
{"PMID":17088426,"re_id":7,"annotated sentence":"We propose a model whereby compartmentalized <e2>PDEs<\\e2>  rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different <e1>cAMP<\\e1> concentrations irrespective of their distance from the site of cAMP synthesis.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cAMP","object":"PDEs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We propose a model whereby compartmentalized <e2>GENE-N<\\e2>  rather than representing an enzymatic barrier to CHEMICAL diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different <e1>CHEMICAL<\\e1> concentrations irrespective of their distance from the site of CHEMICAL synthesis.","sentence":"We propose a model whereby compartmentalized PDEs  rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different cAMP concentrations irrespective of their distance from the site of cAMP synthesis."}
{"PMID":17088426,"re_id":8,"annotated sentence":"We propose a model whereby compartmentalized <e2>PDEs<\\e2>  rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different cAMP concentrations irrespective of their distance from the site of <e1>cAMP<\\e1> synthesis.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cAMP","object":"PDEs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We propose a model whereby compartmentalized <e2>GENE-N<\\e2>  rather than representing an enzymatic barrier to CHEMICAL diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different CHEMICAL concentrations irrespective of their distance from the site of <e1>CHEMICAL<\\e1> synthesis.","sentence":"We propose a model whereby compartmentalized PDEs  rather than representing an enzymatic barrier to cAMP diffusion, act as a sink to drain the second messenger from discrete locations, resulting in multiple and simultaneous domains with different cAMP concentrations irrespective of their distance from the site of cAMP synthesis."}
{"PMID":17089011,"re_id":4,"annotated sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors <e1>doxorubicin<\\e1> and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in <e2>FAS promoter<\\e2> activity when compared with control cells growing in drug-free culture conditions","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"doxorubicin","object":"FAS promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors <e1>CHEMICAL<\\e1> and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in <e2>GENE-N<\\e2> activity when compared with control cells growing in drug-free culture conditions","sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions"}
{"PMID":17089011,"re_id":5,"annotated sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and <e1>etopoxide<\\e1> (VP-16) demonstrated a 2- to 3-fold increase in <e2>FAS promoter<\\e2> activity when compared with control cells growing in drug-free culture conditions","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"etopoxide","object":"FAS promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and <e1>CHEMICAL<\\e1> (VP-16) demonstrated a 2- to 3-fold increase in <e2>GENE-N<\\e2> activity when compared with control cells growing in drug-free culture conditions","sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions"}
{"PMID":17089011,"re_id":6,"annotated sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (<e1>VP-16<\\e1>  demonstrated a 2- to 3-fold increase in <e2>FAS promoter<\\e2> activity when compared with control cells growing in drug-free culture conditions","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"VP-16","object":"FAS promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (<e1>CHEMICAL<\\e1>  demonstrated a 2- to 3-fold increase in <e2>GENE-N<\\e2> activity when compared with control cells growing in drug-free culture conditions","sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16  demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions"}
{"PMID":17089011,"re_id":7,"annotated sentence":"SK-Br3 cells cultured in the presence of <e2>topoisomerase IIalpha<\\e2> (TOP2A) inhibitors <e1>doxorubicin<\\e1> and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"doxorubicin","object":"topoisomerase IIalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SK-Br3 cells cultured in the presence of <e2>GENE-Y<\\e2> (TOP2A) inhibitors <e1>CHEMICAL<\\e1> and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions","sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions"}
{"PMID":17089011,"re_id":8,"annotated sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (<e2>TOP2A<\\e2>  inhibitors <e1>doxorubicin<\\e1> and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"doxorubicin","object":"TOP2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (<e2>GENE-Y<\\e2>  inhibitors <e1>CHEMICAL<\\e1> and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions","sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A  inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions"}
{"PMID":17089011,"re_id":9,"annotated sentence":"SK-Br3 cells cultured in the presence of <e2>topoisomerase IIalpha<\\e2> (TOP2A) inhibitors doxorubicin and <e1>etopoxide<\\e1> (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"etopoxide","object":"topoisomerase IIalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SK-Br3 cells cultured in the presence of <e2>GENE-Y<\\e2> (TOP2A) inhibitors doxorubicin and <e1>CHEMICAL<\\e1> (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions","sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions"}
{"PMID":17089011,"re_id":10,"annotated sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (<e2>TOP2A<\\e2>  inhibitors doxorubicin and <e1>etopoxide<\\e1> (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"etopoxide","object":"TOP2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (<e2>GENE-Y<\\e2>  inhibitors doxorubicin and <e1>CHEMICAL<\\e1> (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions","sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A  inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions"}
{"PMID":17089011,"re_id":11,"annotated sentence":"SK-Br3 cells cultured in the presence of <e2>topoisomerase IIalpha<\\e2> (TOP2A) inhibitors doxorubicin and etopoxide (<e1>VP-16<\\e1>  demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"VP-16","object":"topoisomerase IIalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SK-Br3 cells cultured in the presence of <e2>GENE-Y<\\e2> (TOP2A) inhibitors doxorubicin and etopoxide (<e1>CHEMICAL<\\e1>  demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions","sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16  demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions"}
{"PMID":17089011,"re_id":12,"annotated sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (<e2>TOP2A<\\e2>  inhibitors doxorubicin and etopoxide (<e1>VP-16<\\e1>  demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"VP-16","object":"TOP2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (<e2>GENE-Y<\\e2>  inhibitors doxorubicin and etopoxide (<e1>CHEMICAL<\\e1>  demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions","sentence":"SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A  inhibitors doxorubicin and etopoxide (VP-16  demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions"}
{"PMID":17094978,"re_id":1,"annotated sentence":"RESULT(S): The expression of endometrial <e2>ERalpha<\\e2>  PRAB, PRB, and SRC-1 was increased significantly after 1 week of <e1>mifepristone<\\e1>  but the increase was no longer seen after 10 weeks","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"mifepristone","object":"ERalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULT(S): The expression of endometrial <e2>GENE-Y<\\e2>  PRAB, PRB, and SRC-1 was increased significantly after 1 week of <e1>CHEMICAL<\\e1>  but the increase was no longer seen after 10 weeks","sentence":"RESULT(S): The expression of endometrial ERalpha  PRAB, PRB, and SRC-1 was increased significantly after 1 week of mifepristone  but the increase was no longer seen after 10 weeks"}
{"PMID":17094978,"re_id":2,"annotated sentence":"RESULT(S): The expression of endometrial ERalpha, <e2>PRAB<\\e2>  PRB, and SRC-1 was increased significantly after 1 week of <e1>mifepristone<\\e1>  but the increase was no longer seen after 10 weeks","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"mifepristone","object":"PRAB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULT(S): The expression of endometrial ERalpha, <e2>GENE-N<\\e2>  PRB, and SRC-1 was increased significantly after 1 week of <e1>CHEMICAL<\\e1>  but the increase was no longer seen after 10 weeks","sentence":"RESULT(S): The expression of endometrial ERalpha, PRAB  PRB, and SRC-1 was increased significantly after 1 week of mifepristone  but the increase was no longer seen after 10 weeks"}
{"PMID":17094978,"re_id":3,"annotated sentence":"RESULT(S): The expression of endometrial ERalpha, PRAB, <e2>PRB<\\e2>  and SRC-1 was increased significantly after 1 week of <e1>mifepristone<\\e1>  but the increase was no longer seen after 10 weeks","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"mifepristone","object":"PRB","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULT(S): The expression of endometrial ERalpha, PRAB, <e2>GENE-Y<\\e2>  and SRC-1 was increased significantly after 1 week of <e1>CHEMICAL<\\e1>  but the increase was no longer seen after 10 weeks","sentence":"RESULT(S): The expression of endometrial ERalpha, PRAB, PRB  and SRC-1 was increased significantly after 1 week of mifepristone  but the increase was no longer seen after 10 weeks"}
{"PMID":17094978,"re_id":4,"annotated sentence":"RESULT(S): The expression of endometrial ERalpha, PRAB, PRB, and <e2>SRC-1<\\e2> was increased significantly after 1 week of <e1>mifepristone<\\e1>  but the increase was no longer seen after 10 weeks","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"mifepristone","object":"SRC-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULT(S): The expression of endometrial ERalpha, PRAB, PRB, and <e2>GENE-Y<\\e2> was increased significantly after 1 week of <e1>CHEMICAL<\\e1>  but the increase was no longer seen after 10 weeks","sentence":"RESULT(S): The expression of endometrial ERalpha, PRAB, PRB, and SRC-1 was increased significantly after 1 week of mifepristone  but the increase was no longer seen after 10 weeks"}
{"PMID":17094978,"re_id":5,"annotated sentence":"CONCLUSION(S): Short-term exposure of <e1>mifepristone<\\e1> in new starters of DMPA increases the expression of endometrial <e2>ERalpha<\\e2>  PRAB, PRB, and SRC-1 and promotes cell proliferation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"mifepristone","object":"ERalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION(S): Short-term exposure of <e1>CHEMICAL<\\e1> in new starters of DMPA increases the expression of endometrial <e2>GENE-Y<\\e2>  PRAB, PRB, and SRC-1 and promotes cell proliferation","sentence":"CONCLUSION(S): Short-term exposure of mifepristone in new starters of DMPA increases the expression of endometrial ERalpha  PRAB, PRB, and SRC-1 and promotes cell proliferation"}
{"PMID":17094978,"re_id":6,"annotated sentence":"CONCLUSION(S): Short-term exposure of <e1>mifepristone<\\e1> in new starters of DMPA increases the expression of endometrial ERalpha, <e2>PRAB<\\e2>  PRB, and SRC-1 and promotes cell proliferation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"mifepristone","object":"PRAB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSION(S): Short-term exposure of <e1>CHEMICAL<\\e1> in new starters of DMPA increases the expression of endometrial ERalpha, <e2>GENE-N<\\e2>  PRB, and SRC-1 and promotes cell proliferation","sentence":"CONCLUSION(S): Short-term exposure of mifepristone in new starters of DMPA increases the expression of endometrial ERalpha, PRAB  PRB, and SRC-1 and promotes cell proliferation"}
{"PMID":17094978,"re_id":7,"annotated sentence":"CONCLUSION(S): Short-term exposure of <e1>mifepristone<\\e1> in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, <e2>PRB<\\e2>  and SRC-1 and promotes cell proliferation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"mifepristone","object":"PRB","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION(S): Short-term exposure of <e1>CHEMICAL<\\e1> in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, <e2>GENE-Y<\\e2>  and SRC-1 and promotes cell proliferation","sentence":"CONCLUSION(S): Short-term exposure of mifepristone in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, PRB  and SRC-1 and promotes cell proliferation"}
{"PMID":17094978,"re_id":8,"annotated sentence":"CONCLUSION(S): Short-term exposure of <e1>mifepristone<\\e1> in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, PRB, and <e2>SRC-1<\\e2> and promotes cell proliferation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"mifepristone","object":"SRC-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION(S): Short-term exposure of <e1>CHEMICAL<\\e1> in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, PRB, and <e2>GENE-Y<\\e2> and promotes cell proliferation","sentence":"CONCLUSION(S): Short-term exposure of mifepristone in new starters of DMPA increases the expression of endometrial ERalpha, PRAB, PRB, and SRC-1 and promotes cell proliferation"}
{"PMID":17097861,"re_id":0,"annotated sentence":"The cytosolic fraction obtained from pancreatic islets obtained from <e1>GalN<\\e1> treated rats had an increased <e2>PTB<\\e2> level compared to the levels obtained from the pancreatic islets of control rats","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GalN","object":"PTB","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The cytosolic fraction obtained from pancreatic islets obtained from <e1>CHEMICAL<\\e1> treated rats had an increased <e2>GENE-Y<\\e2> level compared to the levels obtained from the pancreatic islets of control rats","sentence":"The cytosolic fraction obtained from pancreatic islets obtained from GalN treated rats had an increased PTB level compared to the levels obtained from the pancreatic islets of control rats"}
{"PMID":17097861,"re_id":1,"annotated sentence":"In the present study, <e1>glucose<\\e1> stimulated <e2>insulin<\\e2> secretion was significantly increased in GalN-treated rats compared to controls","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, <e1>CHEMICAL<\\e1> stimulated <e2>GENE-N<\\e2> secretion was significantly increased in GalN-treated rats compared to controls","sentence":"In the present study, glucose stimulated insulin secretion was significantly increased in GalN-treated rats compared to controls"}
{"PMID":17097861,"re_id":2,"annotated sentence":"In the present study, glucose-stimulated <e2>insulin<\\e2> secretion was significantly increased in <e1>GalN<\\e1> treated rats compared to controls","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GalN","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study, glucose-stimulated <e2>GENE-N<\\e2> secretion was significantly increased in <e1>CHEMICAL<\\e1> treated rats compared to controls","sentence":"In the present study, glucose-stimulated insulin secretion was significantly increased in GalN treated rats compared to controls"}
{"PMID":17097861,"re_id":3,"annotated sentence":"Levels of mRNA encoding <e2>insulin 1<\\e2>  ICA512, and PC1\/3 were increased in the pancreatic islets of <e1>GalN<\\e1> treated rats","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GalN","object":"insulin 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Levels of mRNA encoding <e2>GENE-Y<\\e2>  ICA512, and PC1\/3 were increased in the pancreatic islets of <e1>CHEMICAL<\\e1> treated rats","sentence":"Levels of mRNA encoding insulin 1  ICA512, and PC1\/3 were increased in the pancreatic islets of GalN treated rats"}
{"PMID":17097861,"re_id":4,"annotated sentence":"Levels of mRNA encoding insulin 1, <e2>ICA512<\\e2>  and PC1\/3 were increased in the pancreatic islets of <e1>GalN<\\e1> treated rats","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GalN","object":"ICA512","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Levels of mRNA encoding insulin 1, <e2>GENE-Y<\\e2>  and PC1\/3 were increased in the pancreatic islets of <e1>CHEMICAL<\\e1> treated rats","sentence":"Levels of mRNA encoding insulin 1, ICA512  and PC1\/3 were increased in the pancreatic islets of GalN treated rats"}
{"PMID":17097861,"re_id":5,"annotated sentence":"When the <e2>PTB-binding site<\\e2> in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from <e1>GalN<\\e1> treated rats compared to the level in control rats","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GalN","object":"PTB-binding site","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When the <e2>GENE-N<\\e2> in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from <e1>CHEMICAL<\\e1> treated rats compared to the level in control rats","sentence":"When the PTB-binding site in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from GalN treated rats compared to the level in control rats"}
{"PMID":17097861,"re_id":6,"annotated sentence":"When the PTB-binding site in <e2>insulin 1<\\e2> mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from <e1>GalN<\\e1> treated rats compared to the level in control rats","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GalN","object":"insulin 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When the PTB-binding site in <e2>GENE-Y<\\e2> mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from <e1>CHEMICAL<\\e1> treated rats compared to the level in control rats","sentence":"When the PTB-binding site in insulin 1 mRNA was incubated with the islet cytosolic fraction, the RNA-protein complex level was increased in the cytosolic fraction obtained from GalN treated rats compared to the level in control rats"}
{"PMID":17112405,"re_id":2,"annotated sentence":"RESULTS: In the <e1>NMDA<\\e1> injured brain, the <e2>CysLT1 receptor<\\e2> mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"NMDA","object":"CysLT1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: In the <e1>CHEMICAL<\\e1> injured brain, the <e2>GENE-Y<\\e2> mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes","sentence":"RESULTS: In the NMDA injured brain, the CysLT1 receptor mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes"}
{"PMID":17112405,"re_id":3,"annotated sentence":"CONCLUSION: <e2>CysLT1 receptor<\\e2> expression in neurons is upregulated after <e1>NMDA<\\e1> injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"NMDA","object":"CysLT1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: <e2>GENE-Y<\\e2> expression in neurons is upregulated after <e1>CHEMICAL<\\e1> injection, and CHEMICAL-induced responses are inhibited by GENE-Y antagonists, indicating that the increased GENE-Y is involved in CHEMICAL excitotoxicity.","sentence":"CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity."}
{"PMID":17112405,"re_id":4,"annotated sentence":"CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased <e2>CysLT1 receptor<\\e2> is involved in <e1>NMDA<\\e1> excitotoxicity.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"NMDA","object":"CysLT1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: GENE-Y expression in neurons is upregulated after CHEMICAL injection, and CHEMICAL-induced responses are inhibited by GENE-Y antagonists, indicating that the increased <e2>GENE-Y<\\e2> is involved in <e1>CHEMICAL<\\e1> excitotoxicity.","sentence":"CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity."}
{"PMID":17112405,"re_id":5,"annotated sentence":"Pranlukast, ketamine and edaravone decreased NMDA-induced injury; <e1>pranlukast<\\e1> (0.1 mg\/kg) and ketamine inhibited the upregulated expression of the <e2>CysLT1 receptor<\\e2>  CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"pranlukast","object":"CysLT1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pranlukast, ketamine and edaravone decreased NMDA-induced injury; <e1>CHEMICAL<\\e1> (0.1 mg\/kg) and ketamine inhibited the upregulated expression of the <e2>GENE-Y<\\e2>  CONCLUSION: GENE-Y expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by GENE-Y antagonists, indicating that the increased GENE-Y is involved in NMDA excitotoxicity.","sentence":"Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg\/kg) and ketamine inhibited the upregulated expression of the CysLT1 receptor  CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity."}
{"PMID":17112405,"re_id":6,"annotated sentence":"Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg\/kg) and <e1>ketamine<\\e1> inhibited the upregulated expression of the <e2>CysLT1 receptor<\\e2>  CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ketamine","object":"CysLT1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pranlukast, CHEMICAL and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg\/kg) and <e1>CHEMICAL<\\e1> inhibited the upregulated expression of the <e2>GENE-Y<\\e2>  CONCLUSION: GENE-Y expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by GENE-Y antagonists, indicating that the increased GENE-Y is involved in NMDA excitotoxicity.","sentence":"Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg\/kg) and ketamine inhibited the upregulated expression of the CysLT1 receptor  CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity."}
{"PMID":17112405,"re_id":7,"annotated sentence":"The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a <e2>CysLT1 receptor<\\e2> antagonist, <e1>pranlukast<\\e1> (0.01 and 0.1 mg\/kg), an NMDA receptor antagonist, ketamine (30 mg\/kg), and an antioxidant, edaravone (9 mg\/kg) were observed","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"pranlukast","object":"CysLT1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The changes in GENE-Y expression 24 h after NMDA injection and the effects of a <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1> (0.01 and 0.1 mg\/kg), an NMDA receptor antagonist, ketamine (30 mg\/kg), and an antioxidant, edaravone (9 mg\/kg) were observed","sentence":"The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg\/kg), an NMDA receptor antagonist, ketamine (30 mg\/kg), and an antioxidant, edaravone (9 mg\/kg) were observed"}
{"PMID":17112405,"re_id":8,"annotated sentence":"The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg\/kg), an <e2>NMDA receptor<\\e2> antagonist, <e1>ketamine<\\e1> (30 mg\/kg), and an antioxidant, edaravone (9 mg\/kg) were observed","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"ketamine","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg\/kg), an <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1> (30 mg\/kg), and an antioxidant, edaravone (9 mg\/kg) were observed","sentence":"The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg\/kg), an NMDA receptor antagonist, ketamine (30 mg\/kg), and an antioxidant, edaravone (9 mg\/kg) were observed"}
{"PMID":17119350,"re_id":3,"annotated sentence":"We have previously demonstrated that phosphorylation of <e2>Fas-associated death domain-containing protein<\\e2> (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/FADD plays an important role in cell growth suppression by <e1>paclitaxel<\\e1>  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"paclitaxel","object":"Fas-associated death domain-containing protein","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have previously demonstrated that phosphorylation of <e2>GENE-Y<\\e2> (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/FADD plays an important role in cell growth suppression by <e1>CHEMICAL<\\e1>  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens","sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/FADD plays an important role in cell growth suppression by paclitaxel  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens"}
{"PMID":17119350,"re_id":4,"annotated sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (<e2>FADD<\\e2>  at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/FADD plays an important role in cell growth suppression by <e1>paclitaxel<\\e1>  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"paclitaxel","object":"FADD","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (<e2>GENE-Y<\\e2>  at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/GENE-Y plays an important role in cell growth suppression by <e1>CHEMICAL<\\e1>  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated GENE-Y\/JNK (P-GENE-Y\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens","sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD  at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/FADD plays an important role in cell growth suppression by paclitaxel  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens"}
{"PMID":17119350,"re_id":5,"annotated sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through <e2>c-jun NH2-terminal kinase<\\e2> (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/FADD plays an important role in cell growth suppression by <e1>paclitaxel<\\e1>  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"paclitaxel","object":"c-jun NH2-terminal kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through <e2>GENE-N<\\e2> (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/FADD plays an important role in cell growth suppression by <e1>CHEMICAL<\\e1>  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens","sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/FADD plays an important role in cell growth suppression by paclitaxel  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens"}
{"PMID":17119350,"re_id":6,"annotated sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (<e2>JNK<\\e2>  activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/FADD plays an important role in cell growth suppression by <e1>paclitaxel<\\e1>  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"paclitaxel","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (<e2>GENE-N<\\e2>  activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of GENE-N\/FADD plays an important role in cell growth suppression by <e1>CHEMICAL<\\e1>  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/GENE-N (P-FADD\/GENE-N) was analyzed immunohistochemically using 107 human breast cancer specimens","sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK  activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/FADD plays an important role in cell growth suppression by paclitaxel  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens"}
{"PMID":17119350,"re_id":7,"annotated sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of <e2>JNK<\\e2> FADD plays an important role in cell growth suppression by <e1>paclitaxel<\\e1>  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"paclitaxel","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (GENE-N) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of <e2>GENE-N<\\e2> FADD plays an important role in cell growth suppression by <e1>CHEMICAL<\\e1>  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/GENE-N (P-FADD\/GENE-N) was analyzed immunohistochemically using 107 human breast cancer specimens","sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK FADD plays an important role in cell growth suppression by paclitaxel  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens"}
{"PMID":17119350,"re_id":8,"annotated sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/<e2>FADD<\\e2> plays an important role in cell growth suppression by <e1>paclitaxel<\\e1>  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"paclitaxel","object":"FADD","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (GENE-Y) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/<e2>GENE-Y<\\e2> plays an important role in cell growth suppression by <e1>CHEMICAL<\\e1>  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated GENE-Y\/JNK (P-GENE-Y\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens","sentence":"We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2\/M, and that Bcl-2 phosphorylation downstream of JNK\/FADD plays an important role in cell growth suppression by paclitaxel  In this study, the clinicopathological association of phosphorylated Bcl-2 (P-Bcl-2) with estrogen, progesterone, c-erbB-2 receptors, p53 expressions and phosphorylated FADD\/JNK (P-FADD\/JNK) was analyzed immunohistochemically using 107 human breast cancer specimens"}
{"PMID":1712335,"re_id":5,"annotated sentence":"Carvedilol (0.3 mg\/kg, iv) produced a significant inhibition of the <e2>beta 1 adrenoceptor<\\e2> mediated positive chronotropic response to <e1>isoproterenol<\\e1>  This same dose of carvedilol also inhibited, but to a lesser degree, the beta 2 adrenoceptor mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"isoproterenol","object":"beta 1 adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Carvedilol (0.3 mg\/kg, iv) produced a significant inhibition of the <e2>GENE-Y<\\e2> mediated positive chronotropic response to <e1>CHEMICAL<\\e1>  This same dose of carvedilol also inhibited, but to a lesser degree, the beta 2 adrenoceptor mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II","sentence":"Carvedilol (0.3 mg\/kg, iv) produced a significant inhibition of the beta 1 adrenoceptor mediated positive chronotropic response to isoproterenol  This same dose of carvedilol also inhibited, but to a lesser degree, the beta 2 adrenoceptor mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II"}
{"PMID":1712335,"re_id":6,"annotated sentence":"The vasopressor response to the <e2>calcium channel<\\e2> activator, <e1>BAY-K-8644<\\e1>  which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg\/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"BAY-K-8644","object":"calcium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The vasopressor response to the <e2>GENE-N<\\e2> activator, <e1>CHEMICAL<\\e1>  which is mediated through the opening of voltage dependent GENE-Ns and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg\/kg, iv), suggesting that carvedilol is also a GENE-N antagonist, consistent with our previous in vitro studies","sentence":"The vasopressor response to the calcium channel activator, BAY-K-8644  which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg\/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies"}
{"PMID":1712335,"re_id":7,"annotated sentence":"The vasopressor response to the calcium channel activator, <e1>BAY-K-8644<\\e1>  which is mediated through the opening of <e2>voltage dependent calcium channels<\\e2> and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg\/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"BAY-K-8644","object":"voltage dependent calcium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The vasopressor response to the calcium channel activator, <e1>CHEMICAL<\\e1>  which is mediated through the opening of <e2>GENE-N<\\e2> and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg\/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies","sentence":"The vasopressor response to the calcium channel activator, BAY-K-8644  which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg\/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies"}
{"PMID":1712335,"re_id":8,"annotated sentence":"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of <e2>voltage dependent calcium channels<\\e2> and the subsequent translocation of extracellular calcium, was significantly inhibited by <e1>carvedilol<\\e1> (1 mg\/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carvedilol","object":"voltage dependent calcium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of <e2>GENE-N<\\e2> and the subsequent translocation of extracellular calcium, was significantly inhibited by <e1>CHEMICAL<\\e1> (1 mg\/kg, iv), suggesting that CHEMICAL is also a calcium channel antagonist, consistent with our previous in vitro studies","sentence":"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg\/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies"}
{"PMID":1712335,"re_id":9,"annotated sentence":"Thus, <e1>carvedilol<\\e1> blocks both beta 1 and beta 2 adrenoceptors at antihypertensive doses, with modest selectivity being observed for the <e2>beta 1 adrenoceptor<\\e2> subtype","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carvedilol","object":"beta 1 adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, <e1>CHEMICAL<\\e1> blocks both beta 1 and beta 2 adrenoceptors at antihypertensive doses, with modest selectivity being observed for the <e2>GENE-Y<\\e2> subtype","sentence":"Thus, carvedilol blocks both beta 1 and beta 2 adrenoceptors at antihypertensive doses, with modest selectivity being observed for the beta 1 adrenoceptor subtype"}
{"PMID":1712335,"re_id":10,"annotated sentence":"<e1>Carvedilol<\\e1> (0.3 mg\/kg, iv) produced a significant inhibition of the <e2>beta 1 adrenoceptor<\\e2> mediated positive chronotropic response to isoproterenol","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Carvedilol","object":"beta 1 adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (0.3 mg\/kg, iv) produced a significant inhibition of the <e2>GENE-Y<\\e2> mediated positive chronotropic response to isoproterenol","sentence":"Carvedilol (0.3 mg\/kg, iv) produced a significant inhibition of the beta 1 adrenoceptor mediated positive chronotropic response to isoproterenol"}
{"PMID":1712335,"re_id":11,"annotated sentence":"This same dose of <e1>carvedilol<\\e1> also inhibited, but to a lesser degree, the <e2>beta 2 adrenoceptor<\\e2> mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carvedilol","object":"beta 2 adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This same dose of <e1>CHEMICAL<\\e1> also inhibited, but to a lesser degree, the <e2>GENE-Y<\\e2> mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II","sentence":"This same dose of carvedilol also inhibited, but to a lesser degree, the beta 2 adrenoceptor mediated vasodepressor response to salbutamol in pithed rats whose blood pressure was elevated by a constant intravenous infusion of angiotensin II"}
{"PMID":1712335,"re_id":12,"annotated sentence":"<e1>Carvedilol<\\e1> produced significant inhibition of the <e2>alpha 1 adrenoceptor<\\e2> mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Carvedilol","object":"alpha 1 adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> produced significant inhibition of the <e2>GENE-N<\\e2> mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an GENE-N antagonist at antihypertensive doses","sentence":"Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses"}
{"PMID":1712335,"re_id":13,"annotated sentence":"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg\/kg, iv), suggesting that <e1>carvedilol<\\e1> is also a <e2>calcium channel<\\e2> antagonist, consistent with our previous in vitro studies","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"carvedilol","object":"calcium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The vasopressor response to the GENE-N activator, BAY-K-8644, which is mediated through the opening of voltage dependent GENE-Ns and the subsequent translocation of extracellular calcium, was significantly inhibited by CHEMICAL (1 mg\/kg, iv), suggesting that <e1>CHEMICAL<\\e1> is also a <e2>GENE-N<\\e2> antagonist, consistent with our previous in vitro studies","sentence":"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium, was significantly inhibited by carvedilol (1 mg\/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies"}
{"PMID":1712335,"re_id":14,"annotated sentence":"In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the <e2>alpha 1 adrenoceptor<\\e2> antagonist, <e1>prazosin<\\e1> (1 mg\/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg\/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"prazosin","object":"alpha 1 adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1> (1 mg\/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg\/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and GENE-Ns","sentence":"In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg\/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg\/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors"}
{"PMID":1712335,"re_id":15,"annotated sentence":"In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg\/kg, iv), and the nonselective <e2>beta adrenoceptor<\\e2> antagonist, <e1>propranolol<\\e1> (3 mg\/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"propranolol","object":"beta adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg\/kg, iv), and the nonselective <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1> (3 mg\/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors","sentence":"In anesthetized spontaneously hypertensive rats, the antihypertensive activity of carvedilol was nearly abolished by combined pretreatment of the rats with high doses of the alpha 1 adrenoceptor antagonist, prazosin (1 mg\/kg, iv), and the nonselective beta adrenoceptor antagonist, propranolol (3 mg\/kg, iv), suggesting that the majority of the antihypertensive response produced by carvedilol may be accounted for by blockade of beta and alpha 1 adrenoceptors"}
{"PMID":1712335,"re_id":16,"annotated sentence":"We therefore conclude that <e1>carvedilol<\\e1>  at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of <e2>calcium channels<\\e2> in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"carvedilol","object":"calcium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We therefore conclude that <e1>CHEMICAL<\\e1>  at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of <e2>GENE-N<\\e2> in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)","sentence":"We therefore conclude that carvedilol  at antihypertensive doses, is an antagonist of beta 1, beta 2, and alpha 1 adrenoceptors, and also of calcium channels in vascular smooth muscle.(ABSTRACT TRUNCATED AT 400 WORDS)"}
{"PMID":1712335,"re_id":17,"annotated sentence":"The mechanism(s) responsible for arterial vasodilation observed following acute administration of <e1>racemic carvedilol<\\e1>  a novel vasodilator\/<e2>beta adrenoceptor<\\e2> antagonist, has been investigated in rats","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"racemic carvedilol","object":"beta adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The mechanism(s) responsible for arterial vasodilation observed following acute administration of <e1>CHEMICAL<\\e1>  a novel vasodilator\/<e2>GENE-N<\\e2> antagonist, has been investigated in rats","sentence":"The mechanism(s) responsible for arterial vasodilation observed following acute administration of racemic carvedilol  a novel vasodilator\/beta adrenoceptor antagonist, has been investigated in rats"}
{"PMID":1712335,"re_id":18,"annotated sentence":"Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that <e1>carvedilol<\\e1> is also an <e2>alpha 1 adrenoceptor<\\e2> antagonist at antihypertensive doses","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"carvedilol","object":"alpha 1 adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Carvedilol produced significant inhibition of the GENE-N mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that <e1>CHEMICAL<\\e1> is also an <e2>GENE-N<\\e2> antagonist at antihypertensive doses","sentence":"Carvedilol produced significant inhibition of the alpha 1 adrenoceptor mediated pressor response to cirazoline in the pithed rat, but had no effect on the alpha 2 adrenoceptor mediated pressor response to B-HT 933, suggesting that carvedilol is also an alpha 1 adrenoceptor antagonist at antihypertensive doses"}
{"PMID":1712335,"re_id":19,"annotated sentence":"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of <e2>voltage dependent calcium channels<\\e2> and the subsequent translocation of extracellular <e1>calcium<\\e1>  was significantly inhibited by carvedilol (1 mg\/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"calcium","object":"voltage dependent calcium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The vasopressor response to the CHEMICAL channel activator, BAY-K-8644, which is mediated through the opening of <e2>voltage dependent CHEMICAL channels<\\e2> and the subsequent translocation of extracellular <e1>CHEMICAL<\\e1>  was significantly inhibited by carvedilol (1 mg\/kg, iv), suggesting that carvedilol is also a CHEMICAL channel antagonist, consistent with our previous in vitro studies","sentence":"The vasopressor response to the calcium channel activator, BAY-K-8644, which is mediated through the opening of voltage dependent calcium channels and the subsequent translocation of extracellular calcium  was significantly inhibited by carvedilol (1 mg\/kg, iv), suggesting that carvedilol is also a calcium channel antagonist, consistent with our previous in vitro studies"}
{"PMID":17138606,"re_id":1,"annotated sentence":"<e2>5-HT3 receptor<\\e2> antagonism with <e1>alosetron<\\e1> reduced responses to 5-HT in controls but not during inflammation","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"alosetron","object":"5-HT3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> antagonism with <e1>CHEMICAL<\\e1> reduced responses to 5-HT in controls but not during inflammation","sentence":"5-HT3 receptor antagonism with alosetron reduced responses to 5-HT in controls but not during inflammation"}
{"PMID":17138644,"re_id":8,"annotated sentence":"These results highlight the importance of <e2>PR<\\e2> activation of the Src\/MAPK signaling pathway for <e1>progesterone<\\e1> induced transcription of select target genes and cell cycle progression.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"progesterone","object":"PR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results highlight the importance of <e2>GENE-Y<\\e2> activation of the Src\/MAPK signaling pathway for <e1>CHEMICAL<\\e1> induced transcription of select target genes and cell cycle progression.","sentence":"These results highlight the importance of PR activation of the Src\/MAPK signaling pathway for progesterone induced transcription of select target genes and cell cycle progression."}
{"PMID":17138644,"re_id":9,"annotated sentence":"These results highlight the importance of PR activation of the <e2>Src<\\e2> MAPK signaling pathway for <e1>progesterone<\\e1> induced transcription of select target genes and cell cycle progression.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"progesterone","object":"Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results highlight the importance of PR activation of the <e2>GENE-Y<\\e2> MAPK signaling pathway for <e1>CHEMICAL<\\e1> induced transcription of select target genes and cell cycle progression.","sentence":"These results highlight the importance of PR activation of the Src MAPK signaling pathway for progesterone induced transcription of select target genes and cell cycle progression."}
{"PMID":17138644,"re_id":10,"annotated sentence":"These results highlight the importance of PR activation of the Src\/<e2>MAPK<\\e2> signaling pathway for <e1>progesterone<\\e1> induced transcription of select target genes and cell cycle progression.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"progesterone","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results highlight the importance of PR activation of the Src\/<e2>GENE-N<\\e2> signaling pathway for <e1>CHEMICAL<\\e1> induced transcription of select target genes and cell cycle progression.","sentence":"These results highlight the importance of PR activation of the Src\/MAPK signaling pathway for progesterone induced transcription of select target genes and cell cycle progression."}
{"PMID":17138644,"re_id":11,"annotated sentence":"<e1>Progestin<\\e1> activation of <e2>Src<\\e2> MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Progestin","object":"Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> activation of <e2>GENE-Y<\\e2> MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear","sentence":"Progestin activation of Src MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear"}
{"PMID":17138644,"re_id":12,"annotated sentence":"<e1>Progestin<\\e1> activation of Src\/<e2>MAPK<\\e2> occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Progestin","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> activation of Src\/<e2>GENE-N<\\e2> occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear","sentence":"Progestin activation of Src\/MAPK occurred outside the nucleus with the B isoform of PR that was distributed between the cytoplasm and nucleus, but not with PR-A that was predominantly nuclear"}
{"PMID":17138644,"re_id":13,"annotated sentence":"<e1>Progestin<\\e1> induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on <e2>PR<\\e2> activation of the Src\/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Progestin","object":"PR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on <e2>GENE-Y<\\e2> activation of the Src\/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with GENE-Y activation of Src","sentence":"Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src\/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src"}
{"PMID":17138644,"re_id":14,"annotated sentence":"<e1>Progestin<\\e1> induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the <e2>Src<\\e2> MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Progestin","object":"Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the <e2>GENE-Y<\\e2> MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of GENE-Y","sentence":"Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src"}
{"PMID":17138644,"re_id":15,"annotated sentence":"<e1>Progestin<\\e1> induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src\/<e2>MAPK<\\e2> pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Progestin","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src\/<e2>GENE-N<\\e2> pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src","sentence":"Progestin induction of the cyclin D1 gene, which lacks a progesterone response element, was dependent on PR activation of the Src\/MAPK pathway, whereas induction of the Sgk (serum and glucocorticoid regulated kinase) gene that contains a functional progesterone response element was unaffected by mutations that interfere with PR activation of Src"}
{"PMID":17146052,"re_id":0,"annotated sentence":"injection of a subthreshold dose of <e1>picrotoxin<\\e1>  a use-dependent <e2>gamma-aminobutyric acid receptor<\\e2> antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"picrotoxin","object":"gamma-aminobutyric acid receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"injection of a subthreshold dose of <e1>CHEMICAL<\\e1>  a use-dependent <e2>GENE-N<\\e2> antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice","sentence":"injection of a subthreshold dose of picrotoxin  a use-dependent gamma-aminobutyric acid receptor antagonist, reduces cortical electroencephalogram delta power and transiently inhibits spontaneous seizure activity in ADNFLE mutant mice"}
{"PMID":17154506,"re_id":15,"annotated sentence":"MicroPET imaging in nonhuman primates with [<e1>11C<\\e1> 1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the <e2>SERT<\\e2> rich brain regions and peak uptake being achieved in about 55 min postinjection","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"11C","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"MicroPET imaging in nonhuman primates with [<e1>CHEMICAL<\\e1> 1 and [CHEMICAL]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the <e2>GENE-N<\\e2> rich brain regions and peak uptake being achieved in about 55 min postinjection","sentence":"MicroPET imaging in nonhuman primates with [11C 1 and [11C]2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the SERT rich brain regions and peak uptake being achieved in about 55 min postinjection"}
{"PMID":17154506,"re_id":16,"annotated sentence":"MicroPET imaging in nonhuman primates with [11C]1 and [<e1>11C<\\e1> 2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the <e2>SERT<\\e2> rich brain regions and peak uptake being achieved in about 55 min postinjection","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"11C","object":"SERT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"MicroPET imaging in nonhuman primates with [CHEMICAL]1 and [<e1>CHEMICAL<\\e1> 2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the <e2>GENE-N<\\e2> rich brain regions and peak uptake being achieved in about 55 min postinjection","sentence":"MicroPET imaging in nonhuman primates with [11C]1 and [11C 2 demonstrated that both tracers behave similarly in vivo with high uptake being observed in the SERT rich brain regions and peak uptake being achieved in about 55 min postinjection"}
{"PMID":17163232,"re_id":0,"annotated sentence":"This trial investigated the possibility of pharmacokinetic interactions between the <e2>AT1 receptor<\\e2> antagonist <e1>olmesartan medoxomil<\\e1> and the thiazide diuretic hydrochlorothiazide in healthy subjects","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"olmesartan medoxomil","object":"AT1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This trial investigated the possibility of pharmacokinetic interactions between the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> and the thiazide diuretic hydrochlorothiazide in healthy subjects","sentence":"This trial investigated the possibility of pharmacokinetic interactions between the AT1 receptor antagonist olmesartan medoxomil and the thiazide diuretic hydrochlorothiazide in healthy subjects"}
{"PMID":17194211,"re_id":4,"annotated sentence":"<e2>SecS<\\e2> required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate <e1>selenocysteyl<\\e1> tRNA([Ser]Sec)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"selenocysteyl","object":"SecS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate <e1>CHEMICAL<\\e1> tRNA([Ser]Sec)","sentence":"SecS required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate selenocysteyl tRNA([Ser]Sec)"}
{"PMID":17194211,"re_id":5,"annotated sentence":"In addition, we found that <e2>selenophosphate synthetase 2<\\e2> could synthesize <e1>monoselenophosphate<\\e1> in vitro but selenophosphate synthetase 1 could not","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"monoselenophosphate","object":"selenophosphate synthetase 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, we found that <e2>GENE-Y<\\e2> could synthesize <e1>CHEMICAL<\\e1> in vitro but selenophosphate synthetase 1 could not","sentence":"In addition, we found that selenophosphate synthetase 2 could synthesize monoselenophosphate in vitro but selenophosphate synthetase 1 could not"}
{"PMID":17194211,"re_id":6,"annotated sentence":"<e2>SecS<\\e2> required selenophosphate and <e1>O-phosphoseryl<\\e1> tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"O-phosphoseryl","object":"SecS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> required selenophosphate and <e1>CHEMICAL<\\e1> tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec)","sentence":"SecS required selenophosphate and O-phosphoseryl tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec)"}
{"PMID":17194211,"re_id":7,"annotated sentence":"<e2>SecS<\\e2> required <e1>selenophosphate<\\e1> and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"selenophosphate","object":"SecS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> required <e1>CHEMICAL<\\e1> and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec)","sentence":"SecS required selenophosphate and O-phosphoseryl-tRNA([Ser]Sec) as substrates to generate selenocysteyl-tRNA([Ser]Sec)"}
{"PMID":17194886,"re_id":8,"annotated sentence":"<e1>Triflusal<\\e1> (30 mg\/kg) also significantly decreased the protein levels of <e2>IL-Ibeta<\\e2> but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Triflusal","object":"IL-Ibeta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (30 mg\/kg) also significantly decreased the protein levels of <e2>GENE-Y<\\e2> but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion","sentence":"Triflusal (30 mg\/kg) also significantly decreased the protein levels of IL-Ibeta but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion"}
{"PMID":17207582,"re_id":16,"annotated sentence":"The <e2>GRIP1<\\e2> reduction was inhibited by <e1>MK-801<\\e1>  an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"MK-801","object":"GRIP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> reduction was inhibited by <e1>CHEMICAL<\\e1>  an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist","sentence":"The GRIP1 reduction was inhibited by MK-801  an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist"}
{"PMID":17207582,"re_id":17,"annotated sentence":"<e1>EGTA<\\e1> and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented <e2>GRIP1<\\e2> degradation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"EGTA","object":"GRIP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented <e2>GENE-Y<\\e2> degradation","sentence":"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented GRIP1 degradation"}
{"PMID":17207582,"re_id":18,"annotated sentence":"EGTA and <e1>1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis<\\e1> (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented <e2>GRIP1<\\e2> degradation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis","object":"GRIP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"EGTA and <e1>CHEMICAL<\\e1> (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented <e2>GENE-Y<\\e2> degradation","sentence":"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented GRIP1 degradation"}
{"PMID":17207582,"re_id":19,"annotated sentence":"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (<e1>BAPTA<\\e1> , two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented <e2>GRIP1<\\e2> degradation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"BAPTA","object":"GRIP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (<e1>CHEMICAL<\\e1> , two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented <e2>GENE-Y<\\e2> degradation","sentence":"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA , two Ca2+ chelators, but not nifedipine, an L-type Ca2+ channel blocker, prevented GRIP1 degradation"}
{"PMID":17207582,"re_id":20,"annotated sentence":"Our results suggest that <e1>glutamate<\\e1> induces <e2>GRIP1<\\e2> degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"glutamate","object":"GRIP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results suggest that <e1>CHEMICAL<\\e1> induces <e2>GENE-Y<\\e2> degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GENE-Y degradation may play an important role in regulating GluR2 surface expression.","sentence":"Our results suggest that glutamate induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression."}
{"PMID":17207582,"re_id":21,"annotated sentence":"Our results suggest that <e1>glutamate<\\e1> induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that <e2>GRIP1<\\e2> degradation may play an important role in regulating GluR2 surface expression.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"glutamate","object":"GRIP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results suggest that <e1>CHEMICAL<\\e1> induces GENE-Y degradation by proteasome through an NMDA receptor-Ca2+ pathway and that <e2>GENE-Y<\\e2> degradation may play an important role in regulating GluR2 surface expression.","sentence":"Our results suggest that glutamate induces GRIP1 degradation by proteasome through an NMDA receptor-Ca2+ pathway and that GRIP1 degradation may play an important role in regulating GluR2 surface expression."}
{"PMID":17207582,"re_id":22,"annotated sentence":"<e1>Glutamate<\\e1> stimulates <e2>glutamate receptor interacting protein 1<\\e2> degradation by ubiquitin-proteasome system to regulate surface expression of GluR2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Glutamate","object":"glutamate receptor interacting protein 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> stimulates <e2>GENE-Y<\\e2> degradation by ubiquitin-proteasome system to regulate surface expression of GluR2","sentence":"Glutamate stimulates glutamate receptor interacting protein 1 degradation by ubiquitin-proteasome system to regulate surface expression of GluR2"}
{"PMID":17207582,"re_id":23,"annotated sentence":"Down-regulation of <e2>GRIP1<\\e2> by <e1>glutamate<\\e1> was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"glutamate","object":"GRIP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Down-regulation of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin","sentence":"Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin"}
{"PMID":17207582,"re_id":24,"annotated sentence":"Furthermore, MG132 prevented <e1>glutamate<\\e1> stimulated reduction in surface amount of <e2>GluR2<\\e2>  and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"glutamate","object":"GluR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, MG132 prevented <e1>CHEMICAL<\\e1> stimulated reduction in surface amount of <e2>GENE-Y<\\e2>  and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GENE-Y in neurons","sentence":"Furthermore, MG132 prevented glutamate stimulated reduction in surface amount of GluR2  and knockdown of GRIP1 by RNAi against GRIP1 reduced surface GluR2 in neurons"}
{"PMID":17207582,"re_id":25,"annotated sentence":"Here we report that <e1>glutamate<\\e1> stimulation caused a rapid reduction in protein levels of <e2>GRIP1<\\e2>  but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"glutamate","object":"GRIP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we report that <e1>CHEMICAL<\\e1> stimulation caused a rapid reduction in protein levels of <e2>GENE-Y<\\e2>  but not that of CHEMICAL receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures","sentence":"Here we report that glutamate stimulation caused a rapid reduction in protein levels of GRIP1  but not that of glutamate receptor (GluR) 1, GluR2 and protein interacting with C kinase 1 (PICK1) in rat primary cortical neuron cultures"}
{"PMID":17207582,"re_id":26,"annotated sentence":"Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (<e1>MG132<\\e1> , a <e2>proteasome<\\e2> inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"MG132","object":"proteasome","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (<e1>CHEMICAL<\\e1> , a <e2>GENE-N<\\e2> inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin","sentence":"Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132 , a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin"}
{"PMID":17207582,"re_id":27,"annotated sentence":"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not <e1>nifedipine<\\e1>  an <e2>L-type Ca2+ channel<\\e2> blocker, prevented GRIP1 degradation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nifedipine","object":"L-type Ca2+ channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not <e1>CHEMICAL<\\e1>  an <e2>GENE-N<\\e2> blocker, prevented GRIP1 degradation","sentence":"EGTA and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetra acetic acid tetrakis (BAPTA), two Ca2+ chelators, but not nifedipine  an L-type Ca2+ channel blocker, prevented GRIP1 degradation"}
{"PMID":17207582,"re_id":28,"annotated sentence":"Down-regulation of GRIP1 by glutamate was blocked by <e1>carbobenzoxyl-leucinyl-leucinyl-leucinal<\\e1> (MG132), a <e2>proteasome<\\e2> inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carbobenzoxyl-leucinyl-leucinyl-leucinal","object":"proteasome","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Down-regulation of GRIP1 by glutamate was blocked by <e1>CHEMICAL<\\e1> (MG132), a <e2>GENE-N<\\e2> inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin","sentence":"Down-regulation of GRIP1 by glutamate was blocked by carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132), a proteasome inhibitor and by expression of K48R-ubiquitin, a dominant negative form of ubiquitin"}
{"PMID":17207582,"re_id":29,"annotated sentence":"The GRIP1 reduction was inhibited by <e1>MK-801<\\e1>  an <e2>N-methyl-d-aspartate (NMDA) receptor<\\e2> antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"MK-801","object":"N-methyl-d-aspartate (NMDA) receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The GRIP1 reduction was inhibited by <e1>CHEMICAL<\\e1>  an <e2>GENE-N<\\e2> antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist","sentence":"The GRIP1 reduction was inhibited by MK-801  an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist"}
{"PMID":17207582,"re_id":30,"annotated sentence":"The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by <e1>6-cyano-7-nitroquinoxaline-2,3-dione<\\e1> (CNQX), an <e2>AMPA receptor<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"6-cyano-7-nitroquinoxaline-2,3-dione","object":"AMPA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by <e1>CHEMICAL<\\e1> (CNQX), an <e2>GENE-N<\\e2> antagonist","sentence":"The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), an AMPA receptor antagonist"}
{"PMID":17207582,"re_id":31,"annotated sentence":"The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (<e1>CNQX<\\e1> , an <e2>AMPA receptor<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"CNQX","object":"AMPA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (<e1>CHEMICAL<\\e1> , an <e2>GENE-N<\\e2> antagonist","sentence":"The GRIP1 reduction was inhibited by MK-801, an N-methyl-d-aspartate (NMDA) receptor antagonist, but not by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX , an AMPA receptor antagonist"}
{"PMID":17223000,"re_id":3,"annotated sentence":"RESULTS: <e1>Leukotriene D(4)<\\e1> upregulated <e2>MUC2\/5AC<\\e2> gene expression and mucin secretion in a dose dependent pattern","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Leukotriene D(4)","object":"MUC2\/5AC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> upregulated <e2>GENE-N<\\e2> gene expression and mucin secretion in a dose dependent pattern","sentence":"RESULTS: Leukotriene D(4) upregulated MUC2\/5AC gene expression and mucin secretion in a dose dependent pattern"}
{"PMID":17223000,"re_id":4,"annotated sentence":"RESULTS: <e1>Leukotriene D(4)<\\e1> upregulated MUC2\/5AC gene expression and <e2>mucin<\\e2> secretion in a dose dependent pattern","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Leukotriene D(4)","object":"mucin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> upregulated MUC2\/5AC gene expression and <e2>GENE-N<\\e2> secretion in a dose dependent pattern","sentence":"RESULTS: Leukotriene D(4) upregulated MUC2\/5AC gene expression and mucin secretion in a dose dependent pattern"}
{"PMID":17223000,"re_id":5,"annotated sentence":"The inhibitory effect of the leukotriene receptor antagonist on <e1>leukotriene D4<\\e1> induced MUC2\/5AC gene expression and <e2>mucin<\\e2> secretion in human airway epithelial cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"leukotriene D4","object":"mucin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibitory effect of the leukotriene receptor antagonist on <e1>CHEMICAL<\\e1> induced MUC2\/5AC gene expression and <e2>GENE-N<\\e2> secretion in human airway epithelial cells","sentence":"The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4 induced MUC2\/5AC gene expression and mucin secretion in human airway epithelial cells"}
{"PMID":17223000,"re_id":6,"annotated sentence":"The inhibitory effect of the leukotriene receptor antagonist on <e1>leukotriene D4<\\e1> induced <e2>MUC2\/5AC<\\e2> gene expression and mucin secretion in human airway epithelial cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"leukotriene D4","object":"MUC2\/5AC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibitory effect of the leukotriene receptor antagonist on <e1>CHEMICAL<\\e1> induced <e2>GENE-N<\\e2> gene expression and mucin secretion in human airway epithelial cells","sentence":"The inhibitory effect of the leukotriene receptor antagonist on leukotriene D4 induced MUC2\/5AC gene expression and mucin secretion in human airway epithelial cells"}
{"PMID":17223000,"re_id":7,"annotated sentence":"Pranlukast hydrate (ONO-1078, 100 microM) downregulated the <e1>leukotriene D(4)<\\e1> induced <e2>MUC2\/5AC<\\e2> gene expression and mucin secretion","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"leukotriene D(4)","object":"MUC2\/5AC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pranlukast hydrate (ONO-1078, 100 microM) downregulated the <e1>CHEMICAL<\\e1> induced <e2>GENE-N<\\e2> gene expression and mucin secretion","sentence":"Pranlukast hydrate (ONO-1078, 100 microM) downregulated the leukotriene D(4) induced MUC2\/5AC gene expression and mucin secretion"}
{"PMID":17223000,"re_id":8,"annotated sentence":"Pranlukast hydrate (ONO-1078, 100 microM) downregulated the <e1>leukotriene D(4)<\\e1> induced MUC2\/5AC gene expression and <e2>mucin<\\e2> secretion","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"leukotriene D(4)","object":"mucin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pranlukast hydrate (ONO-1078, 100 microM) downregulated the <e1>CHEMICAL<\\e1> induced MUC2\/5AC gene expression and <e2>GENE-N<\\e2> secretion","sentence":"Pranlukast hydrate (ONO-1078, 100 microM) downregulated the leukotriene D(4) induced MUC2\/5AC gene expression and mucin secretion"}
{"PMID":17223000,"re_id":9,"annotated sentence":"<e1>Pranlukast hydrate<\\e1> (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced <e2>MUC2\/5AC<\\e2> gene expression and mucin secretion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Pranlukast hydrate","object":"MUC2\/5AC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced <e2>GENE-N<\\e2> gene expression and mucin secretion","sentence":"Pranlukast hydrate (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2\/5AC gene expression and mucin secretion"}
{"PMID":17223000,"re_id":10,"annotated sentence":"<e1>Pranlukast hydrate<\\e1> (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2\/5AC gene expression and <e2>mucin<\\e2> secretion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Pranlukast hydrate","object":"mucin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2\/5AC gene expression and <e2>GENE-N<\\e2> secretion","sentence":"Pranlukast hydrate (ONO-1078, 100 microM) downregulated the leukotriene D(4)-induced MUC2\/5AC gene expression and mucin secretion"}
{"PMID":17223000,"re_id":11,"annotated sentence":"Pranlukast hydrate (<e1>ONO-1078<\\e1>  100 microM) downregulated the leukotriene D(4)-induced <e2>MUC2\/5AC<\\e2> gene expression and mucin secretion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ONO-1078","object":"MUC2\/5AC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pranlukast hydrate (<e1>CHEMICAL<\\e1>  100 microM) downregulated the leukotriene D(4)-induced <e2>GENE-N<\\e2> gene expression and mucin secretion","sentence":"Pranlukast hydrate (ONO-1078  100 microM) downregulated the leukotriene D(4)-induced MUC2\/5AC gene expression and mucin secretion"}
{"PMID":17223000,"re_id":12,"annotated sentence":"Pranlukast hydrate (<e1>ONO-1078<\\e1>  100 microM) downregulated the leukotriene D(4)-induced MUC2\/5AC gene expression and <e2>mucin<\\e2> secretion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ONO-1078","object":"mucin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pranlukast hydrate (<e1>CHEMICAL<\\e1>  100 microM) downregulated the leukotriene D(4)-induced MUC2\/5AC gene expression and <e2>GENE-N<\\e2> secretion","sentence":"Pranlukast hydrate (ONO-1078  100 microM) downregulated the leukotriene D(4)-induced MUC2\/5AC gene expression and mucin secretion"}
{"PMID":17223000,"re_id":13,"annotated sentence":"METHODS: The effect of leukotriene D(4) and the <e2>leukotriene receptor<\\e2> antagonist, <e1>pranlukast hydrate<\\e1> (ONO-1078) on the regulation of MUC2\/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"pranlukast hydrate","object":"leukotriene receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"METHODS: The effect of leukotriene D(4) and the <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1> (ONO-1078) on the regulation of MUC2\/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells","sentence":"METHODS: The effect of leukotriene D(4) and the leukotriene receptor antagonist, pranlukast hydrate (ONO-1078) on the regulation of MUC2\/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells"}
{"PMID":17223000,"re_id":14,"annotated sentence":"METHODS: The effect of leukotriene D(4) and the <e2>leukotriene receptor<\\e2> antagonist, pranlukast hydrate (<e1>ONO-1078<\\e1>  on the regulation of MUC2\/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"ONO-1078","object":"leukotriene receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"METHODS: The effect of leukotriene D(4) and the <e2>GENE-N<\\e2> antagonist, pranlukast hydrate (<e1>CHEMICAL<\\e1>  on the regulation of MUC2\/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells","sentence":"METHODS: The effect of leukotriene D(4) and the leukotriene receptor antagonist, pranlukast hydrate (ONO-1078  on the regulation of MUC2\/5AC gene expression and mucin secretion were observed in human airway NCI-H292 epithelial cells"}
{"PMID":17224860,"re_id":4,"annotated sentence":"CONCLUSION: In postmenopausal women, isolated <e1>isoflavone<\\e1> treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating <e2>pre-beta high-density lipoprotein<\\e2> level, which could provide beneficial vascular effects.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"isoflavone","object":"pre-beta high-density lipoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSION: In postmenopausal women, isolated <e1>CHEMICAL<\\e1> treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating <e2>GENE-N<\\e2> level, which could provide beneficial vascular effects.","sentence":"CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect ABCA1-dependent cholesterol efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects."}
{"PMID":17224860,"re_id":5,"annotated sentence":"However, as a novel finding, <e1>isoflavone<\\e1> treatment increased a subclass of <e2>high-density lipoprotein<\\e2>  the pre-beta high-density lipoprotein levels by 18% without affecting any other serum lipid concentrations","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"isoflavone","object":"high-density lipoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, as a novel finding, <e1>CHEMICAL<\\e1> treatment increased a subclass of <e2>GENE-N<\\e2>  the pre-beta GENE-N levels by 18% without affecting any other serum lipid concentrations","sentence":"However, as a novel finding, isoflavone treatment increased a subclass of high-density lipoprotein  the pre-beta high-density lipoprotein levels by 18% without affecting any other serum lipid concentrations"}
{"PMID":17224860,"re_id":6,"annotated sentence":"However, as a novel finding, <e1>isoflavone<\\e1> treatment increased a subclass of high-density lipoprotein, the <e2>pre-beta high-density lipoprotein<\\e2> levels by 18% without affecting any other serum lipid concentrations","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"isoflavone","object":"pre-beta high-density lipoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, as a novel finding, <e1>CHEMICAL<\\e1> treatment increased a subclass of high-density lipoprotein, the <e2>GENE-N<\\e2> levels by 18% without affecting any other serum lipid concentrations","sentence":"However, as a novel finding, isoflavone treatment increased a subclass of high-density lipoprotein, the pre-beta high-density lipoprotein levels by 18% without affecting any other serum lipid concentrations"}
{"PMID":17224860,"re_id":7,"annotated sentence":"CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect <e2>ABCA1<\\e2> dependent <e1>cholesterol<\\e1> efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cholesterol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect <e2>GENE-Y<\\e2> dependent <e1>CHEMICAL<\\e1> efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects.","sentence":"CONCLUSION: In postmenopausal women, isolated isoflavone treatment does not affect ABCA1 dependent cholesterol efflux potential from macrophages but increases circulating pre-beta high-density lipoprotein level, which could provide beneficial vascular effects."}
{"PMID":17224860,"re_id":8,"annotated sentence":"We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by <e2>adenosine triphosphate-binding cassette A1<\\e2>  (ABCA1), dependent <e1>cholesterol<\\e1> efflux from macrophages","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cholesterol","object":"adenosine triphosphate-binding cassette A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse CHEMICAL transport as evaluated by <e2>GENE-Y<\\e2>  (ABCA1), dependent <e1>CHEMICAL<\\e1> efflux from macrophages","sentence":"We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1  (ABCA1), dependent cholesterol efflux from macrophages"}
{"PMID":17224860,"re_id":9,"annotated sentence":"We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- (<e2>ABCA1<\\e2> , dependent <e1>cholesterol<\\e1> efflux from macrophages","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cholesterol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse CHEMICAL transport as evaluated by adenosine triphosphate-binding cassette A1- (<e2>GENE-Y<\\e2> , dependent <e1>CHEMICAL<\\e1> efflux from macrophages","sentence":"We studied in a clinical trial whether isolated isoflavone treatment in postmenopausal women could affect reverse cholesterol transport as evaluated by adenosine triphosphate-binding cassette A1- (ABCA1 , dependent cholesterol efflux from macrophages"}
{"PMID":17224860,"re_id":10,"annotated sentence":"[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and <e2>ABCA1<\\e2> dependent <e1>cholesterol<\\e1> efflux and serum lipid and lipoprotein levels were assessed","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cholesterol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"[H]-Cholesterol-labeled J774 macrophage cells, with and without GENE-Y up-regulation, were incubated with the samples, and <e2>GENE-Y<\\e2> dependent <e1>CHEMICAL<\\e1> efflux and serum lipid and lipoprotein levels were assessed","sentence":"[H]-Cholesterol-labeled J774 macrophage cells, with and without ABCA1 up-regulation, were incubated with the samples, and ABCA1 dependent cholesterol efflux and serum lipid and lipoprotein levels were assessed"}
{"PMID":17224860,"re_id":11,"annotated sentence":"Thus, isoflavone supplementation did not affect <e2>ABCA1<\\e2> dependent <e1>cholesterol<\\e1> efflux to serum","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cholesterol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, isoflavone supplementation did not affect <e2>GENE-Y<\\e2> dependent <e1>CHEMICAL<\\e1> efflux to serum","sentence":"Thus, isoflavone supplementation did not affect ABCA1 dependent cholesterol efflux to serum"}
{"PMID":17224860,"re_id":12,"annotated sentence":"<e2>ABCA1<\\e2> facilitated <e1>cholesterol<\\e1> efflux and lipid parameters did not differ between equol-producing and non-equol-producing women","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cholesterol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> facilitated <e1>CHEMICAL<\\e1> efflux and lipid parameters did not differ between equol-producing and non-equol-producing women","sentence":"ABCA1 facilitated cholesterol efflux and lipid parameters did not differ between equol-producing and non-equol-producing women"}
{"PMID":17229632,"re_id":20,"annotated sentence":"We investigated the efficacy of <e1>sorafenib<\\e1> at inhibiting mutants of the <e2>receptor tyrosine kinases<\\e2> PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"receptor tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We investigated the efficacy of <e1>CHEMICAL<\\e1> at inhibiting mutants of the <e2>GENE-N<\\e2> PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies","sentence":"We investigated the efficacy of sorafenib at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies"}
{"PMID":17229632,"re_id":21,"annotated sentence":"We investigated the efficacy of <e1>sorafenib<\\e1> at inhibiting mutants of the receptor tyrosine kinases <e2>PDGFRbeta<\\e2>  KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"PDGFRbeta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We investigated the efficacy of <e1>CHEMICAL<\\e1> at inhibiting mutants of the receptor tyrosine kinases <e2>GENE-Y<\\e2>  KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies","sentence":"We investigated the efficacy of sorafenib at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta  KIT, and FLT3, which are implicated in the pathogenesis of myeloid malignancies"}
{"PMID":17229632,"re_id":22,"annotated sentence":"We investigated the efficacy of <e1>sorafenib<\\e1> at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, <e2>KIT<\\e2>  and FLT3, which are implicated in the pathogenesis of myeloid malignancies","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We investigated the efficacy of <e1>CHEMICAL<\\e1> at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, <e2>GENE-Y<\\e2>  and FLT3, which are implicated in the pathogenesis of myeloid malignancies","sentence":"We investigated the efficacy of sorafenib at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, KIT  and FLT3, which are implicated in the pathogenesis of myeloid malignancies"}
{"PMID":17229632,"re_id":23,"annotated sentence":"We investigated the efficacy of <e1>sorafenib<\\e1> at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, KIT, and <e2>FLT3<\\e2>  which are implicated in the pathogenesis of myeloid malignancies","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We investigated the efficacy of <e1>CHEMICAL<\\e1> at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, KIT, and <e2>GENE-Y<\\e2>  which are implicated in the pathogenesis of myeloid malignancies","sentence":"We investigated the efficacy of sorafenib at inhibiting mutants of the receptor tyrosine kinases PDGFRbeta, KIT, and FLT3  which are implicated in the pathogenesis of myeloid malignancies"}
{"PMID":17229632,"re_id":24,"annotated sentence":"The ability of <e1>sorafenib<\\e1> to inhibit oncogenic <e2>PDGFRbeta<\\e2> and FLT3 mutants and overcome resistance to other small molecule inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"PDGFRbeta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ability of <e1>CHEMICAL<\\e1> to inhibit oncogenic <e2>GENE-Y<\\e2> and FLT3 mutants and overcome resistance to other small molecule inhibitors","sentence":"The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors"}
{"PMID":17229632,"re_id":25,"annotated sentence":"The ability of <e1>sorafenib<\\e1> to inhibit oncogenic PDGFRbeta and <e2>FLT3<\\e2> mutants and overcome resistance to other small molecule inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ability of <e1>CHEMICAL<\\e1> to inhibit oncogenic PDGFRbeta and <e2>GENE-Y<\\e2> mutants and overcome resistance to other small molecule inhibitors","sentence":"The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors"}
{"PMID":17229632,"re_id":26,"annotated sentence":"RESULTS: We show that <e1>sorafenib<\\e1> is a potent inhibitor of <e2>ETV6<\\e2> PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"ETV6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: We show that <e1>CHEMICAL<\\e1> is a potent inhibitor of <e2>GENE-Y<\\e2> PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors","sentence":"RESULTS: We show that sorafenib is a potent inhibitor of ETV6 PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors"}
{"PMID":17229632,"re_id":27,"annotated sentence":"RESULTS: We show that <e1>sorafenib<\\e1> is a potent inhibitor of ETV6-<e2>PDGFRbeta<\\e2> and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"PDGFRbeta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: We show that <e1>CHEMICAL<\\e1> is a potent inhibitor of ETV6-<e2>GENE-Y<\\e2> and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors","sentence":"RESULTS: We show that sorafenib is a potent inhibitor of ETV6-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors"}
{"PMID":17229632,"re_id":28,"annotated sentence":"RESULTS: We show that <e1>sorafenib<\\e1> is a potent inhibitor of ETV6-PDGFRbeta and <e2>FLT3<\\e2> mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: We show that <e1>CHEMICAL<\\e1> is a potent inhibitor of ETV6-PDGFRbeta and <e2>GENE-Y<\\e2> mutants, including some of the mutants that confer resistance to PKC412 and other GENE-Y inhibitors","sentence":"RESULTS: We show that sorafenib is a potent inhibitor of ETV6-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors"}
{"PMID":17229632,"re_id":29,"annotated sentence":"RESULTS: We show that <e1>sorafenib<\\e1> is a potent inhibitor of ETV6-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other <e2>FLT3<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: We show that <e1>CHEMICAL<\\e1> is a potent inhibitor of ETV6-PDGFRbeta and GENE-Y mutants, including some of the mutants that confer resistance to PKC412 and other <e2>GENE-Y<\\e2> inhibitors","sentence":"RESULTS: We show that sorafenib is a potent inhibitor of ETV6-PDGFRbeta and FLT3 mutants, including some of the mutants that confer resistance to PKC412 and other FLT3 inhibitors"}
{"PMID":17229632,"re_id":30,"annotated sentence":"<e1>Sorafenib<\\e1> induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing <e2>FLT3<\\e2> with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing <e2>GENE-Y<\\e2> with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines","sentence":"Sorafenib induced a cell cycle block and apoptosis in the acute myeloid leukemia cell lines MV4-11 and MOLM-13, both expressing FLT3 with an internal tandem duplication, whereas no effect was observed on four other acute myeloid leukemia cell lines"}
{"PMID":17229632,"re_id":31,"annotated sentence":"<e1>Sorafenib<\\e1> (BAY43-9006, Nexavar) is a small molecule <e2>B-RAF<\\e2> inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sorafenib","object":"B-RAF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (BAY43-9006, Nexavar) is a small molecule <e2>GENE-Y<\\e2> inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families","sentence":"Sorafenib (BAY43-9006, Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families"}
{"PMID":17229632,"re_id":32,"annotated sentence":"INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of <e1>sorafenib<\\e1> for the treatment of myeloid malignancies expressing activated forms of <e2>PDGFRbeta<\\e2> and FLT3.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"PDGFRbeta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of <e1>CHEMICAL<\\e1> for the treatment of myeloid malignancies expressing activated forms of <e2>GENE-Y<\\e2> and FLT3.","sentence":"INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of sorafenib for the treatment of myeloid malignancies expressing activated forms of PDGFRbeta and FLT3."}
{"PMID":17229632,"re_id":33,"annotated sentence":"INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of <e1>sorafenib<\\e1> for the treatment of myeloid malignancies expressing activated forms of PDGFRbeta and <e2>FLT3<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sorafenib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of <e1>CHEMICAL<\\e1> for the treatment of myeloid malignancies expressing activated forms of PDGFRbeta and <e2>GENE-Y<\\e2> ","sentence":"INTERPRETATION AND CONCLUSIONS: These results warrant further clinical studies of sorafenib for the treatment of myeloid malignancies expressing activated forms of PDGFRbeta and FLT3 "}
{"PMID":17229632,"re_id":34,"annotated sentence":"Sorafenib (<e1>BAY43-9006<\\e1>  Nexavar) is a small molecule <e2>B-RAF<\\e2> inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"BAY43-9006","object":"B-RAF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sorafenib (<e1>CHEMICAL<\\e1>  Nexavar) is a small molecule <e2>GENE-Y<\\e2> inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families","sentence":"Sorafenib (BAY43-9006  Nexavar) is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families"}
{"PMID":17229632,"re_id":35,"annotated sentence":"Sorafenib (BAY43-9006, <e1>Nexavar<\\e1>  is a small molecule <e2>B-RAF<\\e2> inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Nexavar","object":"B-RAF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sorafenib (BAY43-9006, <e1>CHEMICAL<\\e1>  is a small molecule <e2>GENE-Y<\\e2> inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families","sentence":"Sorafenib (BAY43-9006, Nexavar  is a small molecule B-RAF inhibitor that is used for the treatment of renal cell carcinoma, and has been shown to have activity against receptor tyrosine kinases from the platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR) families"}
{"PMID":17251323,"re_id":3,"annotated sentence":"Exposure to <e1>mifepristone<\\e1> (a <e2>glucocorticoid receptor<\\e2> antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"mifepristone","object":"glucocorticoid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exposure to <e1>CHEMICAL<\\e1> (a <e2>GENE-Y<\\e2> antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA","sentence":"Exposure to mifepristone (a glucocorticoid receptor antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA"}
{"PMID":17251323,"re_id":4,"annotated sentence":"Exposure to mifepristone (a glucocorticoid receptor antagonist), but not <e1>spironolactone<\\e1> (a <e2>mineralocorticoid receptor<\\e2> antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"spironolactone","object":"mineralocorticoid receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Exposure to mifepristone (a glucocorticoid receptor antagonist), but not <e1>CHEMICAL<\\e1> (a <e2>GENE-N<\\e2> antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA","sentence":"Exposure to mifepristone (a glucocorticoid receptor antagonist), but not spironolactone (a mineralocorticoid receptor antagonist), precluded both the corticosteroid-induced elevation in amiloride-sensitive I(sc) and the induced changes in beta- and gamma-ENaC mRNA"}
{"PMID":17259377,"re_id":0,"annotated sentence":"All three <e1>salicylates<\\e1> inhibited the diabetes-induced translocation of <e2>p50<\\e2> (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"salicylates","object":"p50","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All three <e1>CHEMICAL<\\e1> inhibited the diabetes-induced translocation of <e2>GENE-Y<\\e2> (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of GENE-Y and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections","sentence":"All three salicylates inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections"}
{"PMID":17259377,"re_id":1,"annotated sentence":"All three <e1>salicylates<\\e1> inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of <e2>p50<\\e2> and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"salicylates","object":"p50","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All three <e1>CHEMICAL<\\e1> inhibited the diabetes-induced translocation of GENE-Y (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of <e2>GENE-Y<\\e2> and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections","sentence":"All three salicylates inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections"}
{"PMID":17259377,"re_id":2,"annotated sentence":"All three <e1>salicylates<\\e1> inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and <e2>p65<\\e2> into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"salicylates","object":"p65","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All three <e1>CHEMICAL<\\e1> inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and <e2>GENE-Y<\\e2> into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections","sentence":"All three salicylates inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB) into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections"}
{"PMID":17259377,"re_id":3,"annotated sentence":"Oral <e1>aspirin<\\e1> (as a representative of the salicylate family) inhibited diabetes-induced increase in <e2>NF-kappaB<\\e2> DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"aspirin","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Oral <e1>CHEMICAL<\\e1> (as a representative of the salicylate family) inhibited diabetes-induced increase in <e2>GENE-N<\\e2> DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina","sentence":"Oral aspirin (as a representative of the salicylate family) inhibited diabetes-induced increase in NF-kappaB DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina"}
{"PMID":17259377,"re_id":4,"annotated sentence":"Oral aspirin (as a representative of the <e1>salicylate<\\e1> family) inhibited diabetes-induced increase in <e2>NF-kappaB<\\e2> DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"salicylate","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Oral aspirin (as a representative of the <e1>CHEMICAL<\\e1> family) inhibited diabetes-induced increase in <e2>GENE-N<\\e2> DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina","sentence":"Oral aspirin (as a representative of the salicylate family) inhibited diabetes-induced increase in NF-kappaB DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina"}
{"PMID":17259377,"re_id":5,"annotated sentence":"All three <e1>salicylates<\\e1> inhibited the diabetes-induced translocation of p50 (a subunit of <e2>NF-kappaB<\\e2>  into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"salicylates","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"All three <e1>CHEMICAL<\\e1> inhibited the diabetes-induced translocation of p50 (a subunit of <e2>GENE-N<\\e2>  into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections","sentence":"All three salicylates inhibited the diabetes-induced translocation of p50 (a subunit of NF-kappaB  into nuclei of retinal vascular endothelial cells of the isolated retinal vasculature, as well as of p50 and p65 into nuclei of cells in the ganglion cell layer and inner nuclear layer on whole-retinal sections"}
{"PMID":17259377,"re_id":6,"annotated sentence":"<e1>Sulfasalazine<\\e1> (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by <e2>NF-kappaB<\\e2>  including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sulfasalazine","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by <e2>GENE-N<\\e2>  including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate","sentence":"Sulfasalazine (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB  including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate"}
{"PMID":17259377,"re_id":7,"annotated sentence":"<e1>Sulfasalazine<\\e1> (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, <e2>intracellular adhesion molecule-1<\\e2>  inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sulfasalazine","object":"intracellular adhesion molecule-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, <e2>GENE-Y<\\e2>  inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate","sentence":"Sulfasalazine (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1  inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate"}
{"PMID":17259377,"re_id":8,"annotated sentence":"<e1>Sulfasalazine<\\e1> (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, <e2>inducible nitric oxide synthase<\\e2>  and cyclooxygenase-2 in whole-retinal lysate","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sulfasalazine","object":"inducible nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, <e2>GENE-Y<\\e2>  and cyclooxygenase-2 in whole-retinal lysate","sentence":"Sulfasalazine (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase  and cyclooxygenase-2 in whole-retinal lysate"}
{"PMID":17259377,"re_id":9,"annotated sentence":"<e1>Sulfasalazine<\\e1> (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and <e2>cyclooxygenase-2<\\e2> in whole-retinal lysate","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sulfasalazine","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and <e2>GENE-Y<\\e2> in whole-retinal lysate","sentence":"Sulfasalazine (also as a representative of the salicylates) inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB, including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate"}
{"PMID":17259377,"re_id":10,"annotated sentence":"Sulfasalazine (also as a representative of the <e1>salicylates<\\e1>  inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by <e2>NF-kappaB<\\e2>  including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"salicylates","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Sulfasalazine (also as a representative of the <e1>CHEMICAL<\\e1>  inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by <e2>GENE-N<\\e2>  including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate","sentence":"Sulfasalazine (also as a representative of the salicylates  inhibited the diabetes-induced upregulation of several inflammatory gene products, which are regulated by NF-kappaB  including vascular cell adhesion molecule, intracellular adhesion molecule-1, inducible nitric oxide synthase, and cyclooxygenase-2 in whole-retinal lysate"}
{"PMID":17259377,"re_id":11,"annotated sentence":"<e1>Salicylates<\\e1>  in doses administrated in our experiments, inhibited <e2>NF-kappa<\\e2>  and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Salicylates","object":"NF-kappa","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  in doses administrated in our experiments, inhibited <e2>GENE-N<\\e2>  and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy.","sentence":"Salicylates  in doses administrated in our experiments, inhibited NF-kappa  and perhaps other transcription factors in the retina, were well tolerated, and offered new tools to investigate and inhibit the development of diabetic retinopathy."}
{"PMID":17289088,"re_id":2,"annotated sentence":"In addition, activation of protein kinase C and increases in intracellular <e1>cAMP<\\e1> also enhance cholinergic activity in T cells, and <e2>lymphocyte function associated antigen-1<\\e2> (LFA-1; CD11a\/CD18) is an important mediator of leukocyte migration and T cell activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"cAMP","object":"lymphocyte function associated antigen-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, activation of protein kinase C and increases in intracellular <e1>CHEMICAL<\\e1> also enhance cholinergic activity in T cells, and <e2>GENE-Y<\\e2> (LFA-1; CD11a\/CD18) is an important mediator of leukocyte migration and T cell activation","sentence":"In addition, activation of protein kinase C and increases in intracellular cAMP also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a\/CD18) is an important mediator of leukocyte migration and T cell activation"}
{"PMID":17289088,"re_id":3,"annotated sentence":"In addition, activation of protein kinase C and increases in intracellular <e1>cAMP<\\e1> also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (<e2>LFA-1<\\e2>  CD11a\/CD18) is an important mediator of leukocyte migration and T cell activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"cAMP","object":"LFA-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, activation of protein kinase C and increases in intracellular <e1>CHEMICAL<\\e1> also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (<e2>GENE-Y<\\e2>  CD11a\/CD18) is an important mediator of leukocyte migration and T cell activation","sentence":"In addition, activation of protein kinase C and increases in intracellular cAMP also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1  CD11a\/CD18) is an important mediator of leukocyte migration and T cell activation"}
{"PMID":17289088,"re_id":4,"annotated sentence":"In addition, activation of protein kinase C and increases in intracellular <e1>cAMP<\\e1> also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; <e2>CD11a<\\e2> CD18) is an important mediator of leukocyte migration and T cell activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"cAMP","object":"CD11a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, activation of protein kinase C and increases in intracellular <e1>CHEMICAL<\\e1> also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; <e2>GENE-Y<\\e2> CD18) is an important mediator of leukocyte migration and T cell activation","sentence":"In addition, activation of protein kinase C and increases in intracellular cAMP also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a CD18) is an important mediator of leukocyte migration and T cell activation"}
{"PMID":17289088,"re_id":5,"annotated sentence":"In addition, activation of protein kinase C and increases in intracellular <e1>cAMP<\\e1> also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a\/<e2>CD18<\\e2>  is an important mediator of leukocyte migration and T cell activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"cAMP","object":"CD18","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, activation of protein kinase C and increases in intracellular <e1>CHEMICAL<\\e1> also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a\/<e2>GENE-Y<\\e2>  is an important mediator of leukocyte migration and T cell activation","sentence":"In addition, activation of protein kinase C and increases in intracellular cAMP also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a\/CD18  is an important mediator of leukocyte migration and T cell activation"}
{"PMID":17289088,"re_id":6,"annotated sentence":"We found that <e1>simvastatin<\\e1> abolishes anti-<e2>CD11a<\\e2> mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"simvastatin","object":"CD11a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> abolishes anti-<e2>GENE-Y<\\e2> mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity","sentence":"We found that simvastatin abolishes anti-CD11a mAb-induced increases in lymphocytic cholinergic activity in a manner independent of its cholesterol-lowering activity"}
{"PMID":17289088,"re_id":7,"annotated sentence":"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (<e1>ACh<\\e1> ; <e2>choline acetyltransferase<\\e2> (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"ACh","object":"choline acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (<e1>CHEMICAL<\\e1> ; <e2>GENE-Y<\\e2> (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic CHEMICAL receptors (mCHEMICALRs and nCHEMICALRs, respectively)","sentence":"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh ; choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)"}
{"PMID":17289088,"re_id":8,"annotated sentence":"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (<e1>ACh<\\e1> ; choline acetyltransferase (<e2>ChAT<\\e2> , its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"ACh","object":"ChAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (<e1>CHEMICAL<\\e1> ; choline acetyltransferase (<e2>GENE-Y<\\e2> , its synthesizing enzyme; and both muscarinic and nicotinic CHEMICAL receptors (mCHEMICALRs and nCHEMICALRs, respectively)","sentence":"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh ; choline acetyltransferase (ChAT , its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)"}
{"PMID":17289088,"re_id":9,"annotated sentence":"Lymphocytes possess the essential components of a cholinergic system, including <e1>acetylcholine<\\e1> (ACh); <e2>choline acetyltransferase<\\e2> (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"acetylcholine","object":"choline acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Lymphocytes possess the essential components of a cholinergic system, including <e1>CHEMICAL<\\e1> (ACh); <e2>GENE-Y<\\e2> (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)","sentence":"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (ChAT), its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)"}
{"PMID":17289088,"re_id":10,"annotated sentence":"Lymphocytes possess the essential components of a cholinergic system, including <e1>acetylcholine<\\e1> (ACh); choline acetyltransferase (<e2>ChAT<\\e2> , its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"acetylcholine","object":"ChAT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Lymphocytes possess the essential components of a cholinergic system, including <e1>CHEMICAL<\\e1> (ACh); choline acetyltransferase (<e2>GENE-Y<\\e2> , its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)","sentence":"Lymphocytes possess the essential components of a cholinergic system, including acetylcholine (ACh); choline acetyltransferase (ChAT , its synthesizing enzyme; and both muscarinic and nicotinic ACh receptors (mAChRs and nAChRs, respectively)"}
{"PMID":17341305,"re_id":5,"annotated sentence":"<e2>PR isoform B<\\e2> levels were low in virgin control mice and increased after <e1>progestin<\\e1> treatment in both strains","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"progestin","object":"PR isoform B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> levels were low in virgin control mice and increased after <e1>CHEMICAL<\\e1> treatment in both strains","sentence":"PR isoform B levels were low in virgin control mice and increased after progestin treatment in both strains"}
{"PMID":17341305,"re_id":6,"annotated sentence":"INTRODUCTION: Medroxyprogesterone acetate (<e1>MPA<\\e1>  induces estrogen receptor (ER)-positive and progesterone receptor (<e2>PR<\\e2> -positive ductal invasive mammary carcinomas in BALB\/c mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"MPA","object":"PR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"INTRODUCTION: Medroxyprogesterone acetate (<e1>CHEMICAL<\\e1>  induces estrogen receptor (ER)-positive and progesterone receptor (<e2>GENE-Y<\\e2> -positive ductal invasive mammary carcinomas in BALB\/c mice","sentence":"INTRODUCTION: Medroxyprogesterone acetate (MPA  induces estrogen receptor (ER)-positive and progesterone receptor (PR -positive ductal invasive mammary carcinomas in BALB\/c mice"}
{"PMID":17341305,"re_id":7,"annotated sentence":"INTRODUCTION: Medroxyprogesterone acetate (<e1>MPA<\\e1>  induces <e2>estrogen receptor<\\e2> (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"MPA","object":"estrogen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"INTRODUCTION: Medroxyprogesterone acetate (<e1>CHEMICAL<\\e1>  induces <e2>GENE-Y<\\e2> (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice","sentence":"INTRODUCTION: Medroxyprogesterone acetate (MPA  induces estrogen receptor (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice"}
{"PMID":17341305,"re_id":8,"annotated sentence":"INTRODUCTION: Medroxyprogesterone acetate (<e1>MPA<\\e1>  induces estrogen receptor (<e2>ER<\\e2> -positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"MPA","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"INTRODUCTION: Medroxyprogesterone acetate (<e1>CHEMICAL<\\e1>  induces estrogen receptor (<e2>GENE-Y<\\e2> -positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice","sentence":"INTRODUCTION: Medroxyprogesterone acetate (MPA  induces estrogen receptor (ER -positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice"}
{"PMID":17341305,"re_id":9,"annotated sentence":"INTRODUCTION: <e1>Medroxyprogesterone acetate<\\e1> (MPA) induces estrogen receptor (ER)-positive and progesterone receptor (<e2>PR<\\e2> -positive ductal invasive mammary carcinomas in BALB\/c mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"Medroxyprogesterone acetate","object":"PR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"INTRODUCTION: <e1>CHEMICAL<\\e1> (MPA) induces estrogen receptor (ER)-positive and progesterone receptor (<e2>GENE-Y<\\e2> -positive ductal invasive mammary carcinomas in BALB\/c mice","sentence":"INTRODUCTION: Medroxyprogesterone acetate (MPA) induces estrogen receptor (ER)-positive and progesterone receptor (PR -positive ductal invasive mammary carcinomas in BALB\/c mice"}
{"PMID":17341305,"re_id":10,"annotated sentence":"INTRODUCTION: <e1>Medroxyprogesterone acetate<\\e1> (MPA) induces <e2>estrogen receptor<\\e2> (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"Medroxyprogesterone acetate","object":"estrogen receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"INTRODUCTION: <e1>CHEMICAL<\\e1> (MPA) induces <e2>GENE-Y<\\e2> (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice","sentence":"INTRODUCTION: Medroxyprogesterone acetate (MPA) induces estrogen receptor (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice"}
{"PMID":17341305,"re_id":11,"annotated sentence":"INTRODUCTION: <e1>Medroxyprogesterone acetate<\\e1> (MPA) induces estrogen receptor (<e2>ER<\\e2> -positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"Medroxyprogesterone acetate","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"INTRODUCTION: <e1>CHEMICAL<\\e1> (MPA) induces estrogen receptor (<e2>GENE-Y<\\e2> -positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice","sentence":"INTRODUCTION: Medroxyprogesterone acetate (MPA) induces estrogen receptor (ER -positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice"}
{"PMID":17341305,"re_id":12,"annotated sentence":"INTRODUCTION: <e1>Medroxyprogesterone acetate<\\e1> (MPA) induces estrogen receptor (ER)-positive and <e2>progesterone receptor<\\e2> (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"Medroxyprogesterone acetate","object":"progesterone receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"INTRODUCTION: <e1>CHEMICAL<\\e1> (MPA) induces estrogen receptor (ER)-positive and <e2>GENE-Y<\\e2> (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice","sentence":"INTRODUCTION: Medroxyprogesterone acetate (MPA) induces estrogen receptor (ER)-positive and progesterone receptor (PR)-positive ductal invasive mammary carcinomas in BALB\/c mice"}
{"PMID":17341305,"re_id":13,"annotated sentence":"The expression of <e2>ER-alpha<\\e2> and PR isoform A in virgin mice was surprisingly much higher in BALB\/c than in C57BL\/6 mammary glands, and both receptors were downregulated in <e1>progestin<\\e1> treated BALB\/c mice (P < 0.05)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"progestin","object":"ER-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of <e2>GENE-Y<\\e2> and PR isoform A in virgin mice was surprisingly much higher in BALB\/c than in C57BL\/6 mammary glands, and both receptors were downregulated in <e1>CHEMICAL<\\e1> treated BALB\/c mice (P < 0.05)","sentence":"The expression of ER-alpha and PR isoform A in virgin mice was surprisingly much higher in BALB\/c than in C57BL\/6 mammary glands, and both receptors were downregulated in progestin treated BALB\/c mice (P < 0.05)"}
{"PMID":17341305,"re_id":14,"annotated sentence":"The expression of ER-alpha and <e2>PR isoform A<\\e2> in virgin mice was surprisingly much higher in BALB\/c than in C57BL\/6 mammary glands, and both receptors were downregulated in <e1>progestin<\\e1> treated BALB\/c mice (P < 0.05)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"progestin","object":"PR isoform A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of ER-alpha and <e2>GENE-Y<\\e2> in virgin mice was surprisingly much higher in BALB\/c than in C57BL\/6 mammary glands, and both receptors were downregulated in <e1>CHEMICAL<\\e1> treated BALB\/c mice (P < 0.05)","sentence":"The expression of ER-alpha and PR isoform A in virgin mice was surprisingly much higher in BALB\/c than in C57BL\/6 mammary glands, and both receptors were downregulated in progestin treated BALB\/c mice (P < 0.05)"}
{"PMID":17350061,"re_id":2,"annotated sentence":"Various genes controlled by <e1>estrogen<\\e1>  including <e2>X-inactive-specific transcript<\\e2>  anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"estrogen","object":"X-inactive-specific transcript","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Various genes controlled by <e1>CHEMICAL<\\e1>  including <e2>GENE-Y<\\e2>  anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed","sentence":"Various genes controlled by estrogen  including X-inactive-specific transcript  anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed"}
{"PMID":17350061,"re_id":3,"annotated sentence":"Various genes controlled by <e1>estrogen<\\e1>  including X-inactive-specific transcript, <e2>anterior gradient-2<\\e2>  trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"estrogen","object":"anterior gradient-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Various genes controlled by <e1>CHEMICAL<\\e1>  including X-inactive-specific transcript, <e2>GENE-Y<\\e2>  trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed","sentence":"Various genes controlled by estrogen  including X-inactive-specific transcript, anterior gradient-2  trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed"}
{"PMID":17350061,"re_id":4,"annotated sentence":"Various genes controlled by <e1>estrogen<\\e1>  including X-inactive-specific transcript, anterior gradient-2, <e2>trefoil factor-1<\\e2>  CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"estrogen","object":"trefoil factor-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Various genes controlled by <e1>CHEMICAL<\\e1>  including X-inactive-specific transcript, anterior gradient-2, <e2>GENE-Y<\\e2>  CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed","sentence":"Various genes controlled by estrogen  including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1  CRP-ductin, ghrelin, and small proline-rich protein-2A, were dramatically over-expressed"}
{"PMID":17350061,"re_id":5,"annotated sentence":"Various genes controlled by <e1>estrogen<\\e1>  including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, <e2>CRP-ductin<\\e2>  ghrelin, and small proline-rich protein-2A, were dramatically over-expressed","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"estrogen","object":"CRP-ductin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Various genes controlled by <e1>CHEMICAL<\\e1>  including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, <e2>GENE-Y<\\e2>  ghrelin, and small proline-rich protein-2A, were dramatically over-expressed","sentence":"Various genes controlled by estrogen  including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin  ghrelin, and small proline-rich protein-2A, were dramatically over-expressed"}
{"PMID":17350061,"re_id":6,"annotated sentence":"Various genes controlled by <e1>estrogen<\\e1>  including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, <e2>ghrelin<\\e2>  and small proline-rich protein-2A, were dramatically over-expressed","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"estrogen","object":"ghrelin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Various genes controlled by <e1>CHEMICAL<\\e1>  including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, <e2>GENE-Y<\\e2>  and small proline-rich protein-2A, were dramatically over-expressed","sentence":"Various genes controlled by estrogen  including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin  and small proline-rich protein-2A, were dramatically over-expressed"}
{"PMID":17350061,"re_id":7,"annotated sentence":"Various genes controlled by <e1>estrogen<\\e1>  including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and <e2>small proline-rich protein-2A<\\e2>  were dramatically over-expressed","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"estrogen","object":"small proline-rich protein-2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Various genes controlled by <e1>CHEMICAL<\\e1>  including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and <e2>GENE-Y<\\e2>  were dramatically over-expressed","sentence":"Various genes controlled by estrogen  including X-inactive-specific transcript, anterior gradient-2, trefoil factor-1, CRP-ductin, ghrelin, and small proline-rich protein-2A  were dramatically over-expressed"}
{"PMID":17350061,"re_id":8,"annotated sentence":"<e1>Estrogen<\\e1> regulated genes including cytokeratin 1-19 and <e2>Cyp2a4<\\e2> were over-expressed, although Cyp3a25 was suppressed","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Estrogen","object":"Cyp2a4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> regulated genes including cytokeratin 1-19 and <e2>GENE-Y<\\e2> were over-expressed, although Cyp3a25 was suppressed","sentence":"Estrogen regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed"}
{"PMID":17350061,"re_id":9,"annotated sentence":"<e1>Estrogen<\\e1> regulated genes including <e2>cytokeratin 1-19<\\e2> and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Estrogen","object":"cytokeratin 1-19","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> regulated genes including <e2>GENE-Y<\\e2> and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed","sentence":"Estrogen regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed"}
{"PMID":17350061,"re_id":10,"annotated sentence":"<e1>Estrogen<\\e1> regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although <e2>Cyp3a25<\\e2> was suppressed","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Estrogen","object":"Cyp3a25","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although <e2>GENE-Y<\\e2> was suppressed","sentence":"Estrogen regulated genes including cytokeratin 1-19 and Cyp2a4 were over-expressed, although Cyp3a25 was suppressed"}
{"PMID":17350061,"re_id":11,"annotated sentence":"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of <e2>17beta-hydroxysteroid dehydrogenase-7<\\e2> (HSD17beta7; involved in <e1>estradiol<\\e1> production) and decreased expression of HSD17beta5 (involved in testosterone production)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"estradiol","object":"17beta-hydroxysteroid dehydrogenase-7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of <e2>GENE-Y<\\e2> (HSD17beta7; involved in <e1>CHEMICAL<\\e1> production) and decreased expression of HSD17beta5 (involved in testosterone production)","sentence":"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production)"}
{"PMID":17350061,"re_id":12,"annotated sentence":"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (<e2>HSD17beta7<\\e2>  involved in <e1>estradiol<\\e1> production) and decreased expression of HSD17beta5 (involved in testosterone production)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"estradiol","object":"HSD17beta7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (<e2>GENE-Y<\\e2>  involved in <e1>CHEMICAL<\\e1> production) and decreased expression of HSD17beta5 (involved in testosterone production)","sentence":"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7  involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production)"}
{"PMID":17350061,"re_id":13,"annotated sentence":"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of <e2>HSD17beta5<\\e2> (involved in <e1>testosterone<\\e1> production)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"testosterone","object":"HSD17beta5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of <e2>GENE-Y<\\e2> (involved in <e1>CHEMICAL<\\e1> production)","sentence":"Several genes involved with steroid metabolism also showed remarkable expression changes, including increased expression of 17beta-hydroxysteroid dehydrogenase-7 (HSD17beta7; involved in estradiol production) and decreased expression of HSD17beta5 (involved in testosterone production)"}
{"PMID":17350061,"re_id":14,"annotated sentence":"The expression of key genes important in <e1>methionine<\\e1> metabolism, such as <e2>methionine adenosyltransferase-1a<\\e2>  betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"methionine","object":"methionine adenosyltransferase-1a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of key genes important in <e1>CHEMICAL<\\e1> metabolism, such as <e2>CHEMICAL adenosyltransferase-1a<\\e2>  betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed","sentence":"The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a  betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed"}
{"PMID":17350061,"re_id":15,"annotated sentence":"The expression of key genes important in <e1>methionine<\\e1> metabolism, such as methionine adenosyltransferase-1a, <e2>betaine-homocysteine methyltransferase<\\e2> and thioether S-methyltransferase, were suppressed","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"methionine","object":"betaine-homocysteine methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of key genes important in <e1>CHEMICAL<\\e1> metabolism, such as CHEMICAL adenosyltransferase-1a, <e2>GENE-Y<\\e2> and thioether S-methyltransferase, were suppressed","sentence":"The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and thioether S-methyltransferase, were suppressed"}
{"PMID":17350061,"re_id":16,"annotated sentence":"The expression of key genes important in <e1>methionine<\\e1> metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and <e2>thioether S-methyltransferase<\\e2>  were suppressed","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"methionine","object":"thioether S-methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of key genes important in <e1>CHEMICAL<\\e1> metabolism, such as CHEMICAL adenosyltransferase-1a, betaine-homocysteine methyltransferase and <e2>GENE-Y<\\e2>  were suppressed","sentence":"The expression of key genes important in methionine metabolism, such as methionine adenosyltransferase-1a, betaine-homocysteine methyltransferase and thioether S-methyltransferase  were suppressed"}
{"PMID":17352828,"re_id":1,"annotated sentence":"<e1>Monosodium urate<\\e1> crystals stimulate monocytes and macrophages to release <e2>IL-1beta<\\e2> through the NALP3 component of the inflammasome","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Monosodium urate","object":"IL-1beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> crystals stimulate monocytes and macrophages to release <e2>GENE-Y<\\e2> through the NALP3 component of the inflammasome","sentence":"Monosodium urate crystals stimulate monocytes and macrophages to release IL-1beta through the NALP3 component of the inflammasome"}
{"PMID":17355872,"re_id":5,"annotated sentence":"We identified <e1>suramin<\\e1> as a compound that binds to human SIRT5 and showed that it inhibits <e2>SIRT5 NAD(+)-dependent deacetylase<\\e2> activity with an IC(50) value of 22 microM","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"suramin","object":"SIRT5 NAD(+)-dependent deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We identified <e1>CHEMICAL<\\e1> as a compound that binds to human SIRT5 and showed that it inhibits <e2>GENE-Y<\\e2> activity with an IC(50) value of 22 microM","sentence":"We identified suramin as a compound that binds to human SIRT5 and showed that it inhibits SIRT5 NAD(+)-dependent deacetylase activity with an IC(50) value of 22 microM"}
{"PMID":17355872,"re_id":6,"annotated sentence":"Structural basis of inhibition of the <e2>human NAD+-dependent deacetylase SIRT5<\\e2> by <e1>suramin<\\e1>  Sirtuins are NAD(+)-dependent protein deacetylases and are emerging as molecular targets for the development of pharmaceuticals to treat human metabolic and neurological diseases and cancer","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"suramin","object":"human NAD+-dependent deacetylase SIRT5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Structural basis of inhibition of the <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1>  Sirtuins are NAD(+)-dependent protein deacetylases and are emerging as molecular targets for the development of pharmaceuticals to treat human metabolic and neurological diseases and cancer","sentence":"Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin  Sirtuins are NAD(+)-dependent protein deacetylases and are emerging as molecular targets for the development of pharmaceuticals to treat human metabolic and neurological diseases and cancer"}
{"PMID":17369066,"re_id":0,"annotated sentence":"In humans, <e2>methionine synthase<\\e2> deficiency results in the accumulation of <e1>methyltetrahydrofolate<\\e1> at the expense of folate derivatives required for purine and thymidylate biosynthesis","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"methyltetrahydrofolate","object":"methionine synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In humans, <e2>GENE-Y<\\e2> deficiency results in the accumulation of <e1>CHEMICAL<\\e1> at the expense of folate derivatives required for purine and thymidylate biosynthesis","sentence":"In humans, methionine synthase deficiency results in the accumulation of methyltetrahydrofolate at the expense of folate derivatives required for purine and thymidylate biosynthesis"}
{"PMID":17369473,"re_id":0,"annotated sentence":"In summary, <e1>phenformin<\\e1> and metformin increase <e2>AMPK<\\e2> activity and phosphorylation in the isolated heart","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"phenformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In summary, <e1>CHEMICAL<\\e1> and metformin increase <e2>GENE-N<\\e2> activity and phosphorylation in the isolated heart","sentence":"In summary, phenformin and metformin increase AMPK activity and phosphorylation in the isolated heart"}
{"PMID":17369473,"re_id":1,"annotated sentence":"In summary, phenformin and <e1>metformin<\\e1> increase <e2>AMPK<\\e2> activity and phosphorylation in the isolated heart","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In summary, phenformin and <e1>CHEMICAL<\\e1> increase <e2>GENE-N<\\e2> activity and phosphorylation in the isolated heart","sentence":"In summary, phenformin and metformin increase AMPK activity and phosphorylation in the isolated heart"}
{"PMID":17369473,"re_id":2,"annotated sentence":"Cytosolic [AMP] reported metabolically active <e1>AMP<\\e1>  which triggered increased <e2>AMPK<\\e2> activity, but measures of total AMP did not.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"AMP","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cytosolic [CHEMICAL] reported metabolically active <e1>CHEMICAL<\\e1>  which triggered increased <e2>CHEMICALK<\\e2> activity, but measures of total CHEMICAL did not.","sentence":"Cytosolic [AMP] reported metabolically active AMP  which triggered increased AMPK activity, but measures of total AMP did not."}
{"PMID":17369473,"re_id":3,"annotated sentence":"<e1>Metformin<\\e1> and phenformin, which are biguanides, have been reported to increase <e2>AMPK<\\e2> activity without increasing AMP\/ATP","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and phenformin, which are biguanides, have been reported to increase <e2>GENE-N<\\e2> activity without increasing AMP\/ATP","sentence":"Metformin and phenformin, which are biguanides, have been reported to increase AMPK activity without increasing AMP\/ATP"}
{"PMID":17369473,"re_id":4,"annotated sentence":"Metformin and <e1>phenformin<\\e1>  which are biguanides, have been reported to increase <e2>AMPK<\\e2> activity without increasing AMP\/ATP","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"phenformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Metformin and <e1>CHEMICAL<\\e1>  which are biguanides, have been reported to increase <e2>GENE-N<\\e2> activity without increasing AMP\/ATP","sentence":"Metformin and phenformin  which are biguanides, have been reported to increase AMPK activity without increasing AMP\/ATP"}
{"PMID":17369473,"re_id":5,"annotated sentence":"Metformin and phenformin, which are <e1>biguanides<\\e1>  have been reported to increase <e2>AMPK<\\e2> activity without increasing AMP\/ATP","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"biguanides","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Metformin and phenformin, which are <e1>CHEMICAL<\\e1>  have been reported to increase <e2>GENE-N<\\e2> activity without increasing AMP\/ATP","sentence":"Metformin and phenformin, which are biguanides  have been reported to increase AMPK activity without increasing AMP\/ATP"}
{"PMID":17369473,"re_id":6,"annotated sentence":"In hearts treated with <e1>phenformin<\\e1> for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and <e2>AMPK<\\e2> activity was elevated at 36 min","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"phenformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In hearts treated with <e1>CHEMICAL<\\e1> for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and <e2>GENE-N<\\e2> activity was elevated at 36 min","sentence":"In hearts treated with phenformin for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and AMPK activity was elevated at 36 min"}
{"PMID":17369473,"re_id":7,"annotated sentence":"In hearts treated with <e1>metformin<\\e1>  [AMP] was increased at 50 min and <e2>AMPK<\\e2> activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In hearts treated with <e1>CHEMICAL<\\e1>  [AMP] was increased at 50 min and <e2>GENE-N<\\e2> activity, phosphorylated GENE-N, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min","sentence":"In hearts treated with metformin  [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min"}
{"PMID":17369473,"re_id":8,"annotated sentence":"In hearts treated with <e1>metformin<\\e1>  [AMP] was increased at 50 min and AMPK activity, phosphorylated <e2>AMPK<\\e2>  and phosphorylated acetyl-CoA carboxylase were elevated at 61 min","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In hearts treated with <e1>CHEMICAL<\\e1>  [AMP] was increased at 50 min and GENE-N activity, phosphorylated <e2>GENE-N<\\e2>  and phosphorylated acetyl-CoA carboxylase were elevated at 61 min","sentence":"In hearts treated with metformin  [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK  and phosphorylated acetyl-CoA carboxylase were elevated at 61 min"}
{"PMID":17369473,"re_id":9,"annotated sentence":"In hearts treated with <e1>metformin<\\e1>  [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and <e2>phosphorylated acetyl-CoA carboxylase<\\e2> were elevated at 61 min","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"metformin","object":"phosphorylated acetyl-CoA carboxylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In hearts treated with <e1>CHEMICAL<\\e1>  [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and <e2>GENE-N<\\e2> were elevated at 61 min","sentence":"In hearts treated with metformin  [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min"}
{"PMID":17369473,"re_id":10,"annotated sentence":"<e1>Metformin<\\e1> and phenformin activate <e2>AMP-activated protein kinase<\\e2> in the heart by increasing cytosolic AMP concentration","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Metformin","object":"AMP-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and phenformin activate <e2>GENE-N<\\e2> in the heart by increasing cytosolic AMP concentration","sentence":"Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration"}
{"PMID":17369473,"re_id":11,"annotated sentence":"Metformin and <e1>phenformin<\\e1> activate <e2>AMP-activated protein kinase<\\e2> in the heart by increasing cytosolic AMP concentration","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"phenformin","object":"AMP-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Metformin and <e1>CHEMICAL<\\e1> activate <e2>GENE-N<\\e2> in the heart by increasing cytosolic AMP concentration","sentence":"Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration"}
{"PMID":17382376,"re_id":2,"annotated sentence":"In the current project, we found that the selective <e2>H(1)<\\e2> antagonist pyrilamine also reversed the <e1>dizocilpine<\\e1> induced impairment in PPI of tactile startle with an auditory prepulse","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"dizocilpine","object":"H(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the current project, we found that the selective <e2>GENE-Y<\\e2> antagonist pyrilamine also reversed the <e1>CHEMICAL<\\e1> induced impairment in PPI of tactile startle with an auditory prepulse","sentence":"In the current project, we found that the selective H(1) antagonist pyrilamine also reversed the dizocilpine induced impairment in PPI of tactile startle with an auditory prepulse"}
{"PMID":17382376,"re_id":3,"annotated sentence":"In summary, the therapeutic effect of <e1>clozapine<\\e1> in reversing PPI impairment was mimicked by the <e2>H(1)<\\e2> antagonist pyrilamine, while pyrilamine had a mixed effect on cognition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"clozapine","object":"H(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In summary, the therapeutic effect of <e1>CHEMICAL<\\e1> in reversing PPI impairment was mimicked by the <e2>GENE-Y<\\e2> antagonist pyrilamine, while pyrilamine had a mixed effect on cognition","sentence":"In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the H(1) antagonist pyrilamine, while pyrilamine had a mixed effect on cognition"}
{"PMID":17382376,"re_id":4,"annotated sentence":"<e2>Histamine H(1)<\\e2> blockade is one of the more prominent actions of the multi-receptor acting antipsychotic <e1>clozapine<\\e1>  It is currently not known how much this H(1) antagonism of clozapine contributes to the therapeutic or adverse side effects of clozapine","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"clozapine","object":"Histamine H(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> blockade is one of the more prominent actions of the multi-receptor acting antipsychotic <e1>CHEMICAL<\\e1>  It is currently not known how much this H(1) antagonism of CHEMICAL contributes to the therapeutic or adverse side effects of CHEMICAL","sentence":"Histamine H(1) blockade is one of the more prominent actions of the multi-receptor acting antipsychotic clozapine  It is currently not known how much this H(1) antagonism of clozapine contributes to the therapeutic or adverse side effects of clozapine"}
{"PMID":17382376,"re_id":5,"annotated sentence":"Thus, <e2>H(1)<\\e2> antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as <e1>clozapine<\\e1> ","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"clozapine","object":"H(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, <e2>GENE-Y<\\e2> antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as <e1>CHEMICAL<\\e1> ","sentence":"Thus, H(1) antagonism seems to play a role in part of the beneficial actions of antipsychotics, such as clozapine "}
{"PMID":17382376,"re_id":6,"annotated sentence":"It is currently not known how much this <e2>H(1)<\\e2> antagonism of <e1>clozapine<\\e1> contributes to the therapeutic or adverse side effects of clozapine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"clozapine","object":"H(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It is currently not known how much this <e2>GENE-Y<\\e2> antagonism of <e1>CHEMICAL<\\e1> contributes to the therapeutic or adverse side effects of CHEMICAL","sentence":"It is currently not known how much this H(1) antagonism of clozapine contributes to the therapeutic or adverse side effects of clozapine"}
{"PMID":17382376,"re_id":7,"annotated sentence":"In the current project, we found that the selective <e2>H(1)<\\e2> antagonist <e1>pyrilamine<\\e1> also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"pyrilamine","object":"H(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the current project, we found that the selective <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse","sentence":"In the current project, we found that the selective H(1) antagonist pyrilamine also reversed the dizocilpine-induced impairment in PPI of tactile startle with an auditory prepulse"}
{"PMID":17382376,"re_id":8,"annotated sentence":"In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the <e2>H(1)<\\e2> antagonist <e1>pyrilamine<\\e1>  while pyrilamine had a mixed effect on cognition","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"pyrilamine","object":"H(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1>  while CHEMICAL had a mixed effect on cognition","sentence":"In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the H(1) antagonist pyrilamine  while pyrilamine had a mixed effect on cognition"}
{"PMID":17382376,"re_id":9,"annotated sentence":"In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the <e2>H(1)<\\e2> antagonist pyrilamine, while <e1>pyrilamine<\\e1> had a mixed effect on cognition","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"pyrilamine","object":"H(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the <e2>GENE-Y<\\e2> antagonist CHEMICAL, while <e1>CHEMICAL<\\e1> had a mixed effect on cognition","sentence":"In summary, the therapeutic effect of clozapine in reversing PPI impairment was mimicked by the H(1) antagonist pyrilamine, while pyrilamine had a mixed effect on cognition"}
{"PMID":17403374,"re_id":0,"annotated sentence":"Furthermore, the enzymatic activity of <e2>alanine aminotransferase<\\e2> (ALT), which converts the critical gluconeogenic amino acid alanine into <e1>pyruvate<\\e1>  is decreased (approximately 50%) in KLF15-\/- hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyruvate","object":"alanine aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the enzymatic activity of <e2>GENE-N<\\e2> (ALT), which converts the critical gluconeogenic amino acid alanine into <e1>CHEMICAL<\\e1>  is decreased (approximately 50%) in KLF15-\/- hepatocytes","sentence":"Furthermore, the enzymatic activity of alanine aminotransferase (ALT), which converts the critical gluconeogenic amino acid alanine into pyruvate  is decreased (approximately 50%) in KLF15-\/- hepatocytes"}
{"PMID":17403374,"re_id":1,"annotated sentence":"Furthermore, the enzymatic activity of alanine aminotransferase (<e2>ALT<\\e2> , which converts the critical gluconeogenic amino acid alanine into <e1>pyruvate<\\e1>  is decreased (approximately 50%) in KLF15-\/- hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyruvate","object":"ALT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the enzymatic activity of alanine aminotransferase (<e2>GENE-N<\\e2> , which converts the critical gluconeogenic amino acid alanine into <e1>CHEMICAL<\\e1>  is decreased (approximately 50%) in KLF15-\/- hepatocytes","sentence":"Furthermore, the enzymatic activity of alanine aminotransferase (ALT , which converts the critical gluconeogenic amino acid alanine into pyruvate  is decreased (approximately 50%) in KLF15-\/- hepatocytes"}
{"PMID":17403374,"re_id":2,"annotated sentence":"Furthermore, the enzymatic activity of <e2>alanine aminotransferase<\\e2> (ALT), which converts the critical gluconeogenic <e1>amino acid<\\e1> alanine into pyruvate, is decreased (approximately 50%) in KLF15-\/- hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"amino acid","object":"alanine aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the enzymatic activity of <e2>GENE-N<\\e2> (ALT), which converts the critical gluconeogenic <e1>CHEMICAL<\\e1> alanine into pyruvate, is decreased (approximately 50%) in KLF15-\/- hepatocytes","sentence":"Furthermore, the enzymatic activity of alanine aminotransferase (ALT), which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in KLF15-\/- hepatocytes"}
{"PMID":17403374,"re_id":3,"annotated sentence":"Furthermore, the enzymatic activity of alanine aminotransferase (<e2>ALT<\\e2> , which converts the critical gluconeogenic <e1>amino acid<\\e1> alanine into pyruvate, is decreased (approximately 50%) in KLF15-\/- hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"amino acid","object":"ALT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the enzymatic activity of alanine aminotransferase (<e2>GENE-N<\\e2> , which converts the critical gluconeogenic <e1>CHEMICAL<\\e1> alanine into pyruvate, is decreased (approximately 50%) in KLF15-\/- hepatocytes","sentence":"Furthermore, the enzymatic activity of alanine aminotransferase (ALT , which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in KLF15-\/- hepatocytes"}
{"PMID":17403374,"re_id":4,"annotated sentence":"Furthermore, the enzymatic activity of <e2>alanine aminotransferase<\\e2> (ALT), which converts the critical gluconeogenic amino acid <e1>alanine<\\e1> into pyruvate, is decreased (approximately 50%) in KLF15-\/- hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"alanine","object":"alanine aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the enzymatic activity of <e2>CHEMICAL aminotransferase<\\e2> (ALT), which converts the critical gluconeogenic amino acid <e1>CHEMICAL<\\e1> into pyruvate, is decreased (approximately 50%) in KLF15-\/- hepatocytes","sentence":"Furthermore, the enzymatic activity of alanine aminotransferase (ALT), which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in KLF15-\/- hepatocytes"}
{"PMID":17403374,"re_id":5,"annotated sentence":"Furthermore, the enzymatic activity of alanine aminotransferase (<e2>ALT<\\e2> , which converts the critical gluconeogenic amino acid <e1>alanine<\\e1> into pyruvate, is decreased (approximately 50%) in KLF15-\/- hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"alanine","object":"ALT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the enzymatic activity of CHEMICAL aminotransferase (<e2>GENE-N<\\e2> , which converts the critical gluconeogenic amino acid <e1>CHEMICAL<\\e1> into pyruvate, is decreased (approximately 50%) in KLF15-\/- hepatocytes","sentence":"Furthermore, the enzymatic activity of alanine aminotransferase (ALT , which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in KLF15-\/- hepatocytes"}
{"PMID":17427197,"re_id":5,"annotated sentence":"TGF-beta1 and high <e1>D-glucose<\\e1> increased p42\/44(mapk) and <e2>Smad2<\\e2> phosphorylation, an effect blocked by PD-98059 (MEK1\/2 inhibitor)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"D-glucose","object":"Smad2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"TGF-beta1 and high <e1>CHEMICAL<\\e1> increased p42\/44(mapk) and <e2>GENE-Y<\\e2> phosphorylation, an effect blocked by PD-98059 (MEK1\/2 inhibitor)","sentence":"TGF-beta1 and high D-glucose increased p42\/44(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1\/2 inhibitor)"}
{"PMID":17427197,"re_id":6,"annotated sentence":"<e1>D-glucose<\\e1> stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42\/44 and <e2>Smad2<\\e2> requiring functional type II TGF-beta receptors in human umbilical vein endothelium","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"D-glucose","object":"Smad2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42\/44 and <e2>GENE-Y<\\e2> requiring functional type II TGF-beta receptors in human umbilical vein endothelium","sentence":"D-glucose stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42\/44 and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium"}
{"PMID":17427197,"re_id":7,"annotated sentence":"High <e1>D-glucose<\\e1> increases L-arginine transport and eNOS expression following <e2>TbetaRII<\\e2> activation by TGF-beta1 involving p42\/44(mapk) and Smad2 in HUVEC","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"D-glucose","object":"TbetaRII","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"High <e1>CHEMICAL<\\e1> increases L-arginine transport and eNOS expression following <e2>GENE-Y<\\e2> activation by TGF-beta1 involving p42\/44(mapk) and Smad2 in HUVEC","sentence":"High D-glucose increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42\/44(mapk) and Smad2 in HUVEC"}
{"PMID":17427197,"re_id":8,"annotated sentence":"High <e1>D-glucose<\\e1> increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42\/44(mapk) and <e2>Smad2<\\e2> in HUVEC","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"D-glucose","object":"Smad2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"High <e1>CHEMICAL<\\e1> increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42\/44(mapk) and <e2>GENE-Y<\\e2> in HUVEC","sentence":"High D-glucose increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42\/44(mapk) and Smad2 in HUVEC"}
{"PMID":17427197,"re_id":9,"annotated sentence":"<e2>TGF-beta1<\\e2> release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal) <e1>D-glucose<\\e1>  TGF-beta1 increases L-arginine transport (half maximal effect approximately 1.6 ng\/ml) in normal D-glucose, but did not alter high D-glucose-increased L-arginine transport","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"D-glucose","object":"TGF-beta1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal) <e1>CHEMICAL<\\e1>  GENE-Y increases L-arginine transport (half maximal effect approximately 1.6 ng\/ml) in normal CHEMICAL, but did not alter high CHEMICAL-increased L-arginine transport","sentence":"TGF-beta1 release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal) D-glucose  TGF-beta1 increases L-arginine transport (half maximal effect approximately 1.6 ng\/ml) in normal D-glucose, but did not alter high D-glucose-increased L-arginine transport"}
{"PMID":17427197,"re_id":10,"annotated sentence":"TGF-beta1 and high <e1>D-glucose<\\e1> increased <e2>hCAT-1<\\e2> mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"D-glucose","object":"hCAT-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"TGF-beta1 and high <e1>CHEMICAL<\\e1> increased <e2>GENE-Y<\\e2> mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation","sentence":"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation"}
{"PMID":17427197,"re_id":11,"annotated sentence":"High <e1>D-glucose<\\e1> increases L-arginine transport and <e2>eNOS<\\e2> expression following TbetaRII activation by TGF-beta1 involving p42\/44(mapk) and Smad2 in HUVEC","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"D-glucose","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"High <e1>CHEMICAL<\\e1> increases L-arginine transport and <e2>GENE-Y<\\e2> expression following TbetaRII activation by TGF-beta1 involving p42\/44(mapk) and Smad2 in HUVEC","sentence":"High D-glucose increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42\/44(mapk) and Smad2 in HUVEC"}
{"PMID":17427197,"re_id":12,"annotated sentence":"Elevated extracellular <e1>D-glucose<\\e1> increases <e2>transforming growth factor beta1<\\e2> (TGF-beta1) release from human umbilical vein endothelium (HUVEC)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"D-glucose","object":"transforming growth factor beta1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Elevated extracellular <e1>CHEMICAL<\\e1> increases <e2>GENE-Y<\\e2> (TGF-beta1) release from human umbilical vein endothelium (HUVEC)","sentence":"Elevated extracellular D-glucose increases transforming growth factor beta1 (TGF-beta1) release from human umbilical vein endothelium (HUVEC)"}
{"PMID":17427197,"re_id":13,"annotated sentence":"Elevated extracellular <e1>D-glucose<\\e1> increases transforming growth factor beta1 (<e2>TGF-beta1<\\e2>  release from human umbilical vein endothelium (HUVEC)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"D-glucose","object":"TGF-beta1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Elevated extracellular <e1>CHEMICAL<\\e1> increases transforming growth factor beta1 (<e2>GENE-Y<\\e2>  release from human umbilical vein endothelium (HUVEC)","sentence":"Elevated extracellular D-glucose increases transforming growth factor beta1 (TGF-beta1  release from human umbilical vein endothelium (HUVEC)"}
{"PMID":17427197,"re_id":14,"annotated sentence":"TGF-beta1 and high D-glucose increased p42\/44(mapk) and <e2>Smad2<\\e2> phosphorylation, an effect blocked by <e1>PD-98059<\\e1> (MEK1\/2 inhibitor)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PD-98059","object":"Smad2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"TGF-beta1 and high D-glucose increased p42\/44(mapk) and <e2>GENE-Y<\\e2> phosphorylation, an effect blocked by <e1>CHEMICAL<\\e1> (MEK1\/2 inhibitor)","sentence":"TGF-beta1 and high D-glucose increased p42\/44(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1\/2 inhibitor)"}
{"PMID":17427197,"re_id":15,"annotated sentence":"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of <e1>NO<\\e1> synthesis) and <e2>endothelial NO synthase<\\e2> (eNOS) protein abundance, but did not alter eNOS phosphorylation","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"NO","object":"endothelial NO synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of <e1>CHEMICAL<\\e1> synthesis) and <e2>endothelial CHEMICAL synthase<\\e2> (eCHEMICALS) protein abundance, but did not alter eCHEMICALS phosphorylation","sentence":"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation"}
{"PMID":17427197,"re_id":16,"annotated sentence":"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of <e1>NO<\\e1> synthesis) and endothelial NO synthase (<e2>eNOS<\\e2>  protein abundance, but did not alter eNOS phosphorylation","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"NO","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of <e1>CHEMICAL<\\e1> synthesis) and endothelial CHEMICAL synthase (<e2>eCHEMICALS<\\e2>  protein abundance, but did not alter eCHEMICALS phosphorylation","sentence":"TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS  protein abundance, but did not alter eNOS phosphorylation"}
{"PMID":17459764,"re_id":8,"annotated sentence":"Moreover stimulation of <e2>COX-2 promoter<\\e2> activity was increased by those <e1>PUFAs<\\e1> or rosiglitazone","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"PUFAs","object":"COX-2 promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover stimulation of <e2>GENE-N<\\e2> activity was increased by those <e1>CHEMICAL<\\e1> or rosiglitazone","sentence":"Moreover stimulation of COX-2 promoter activity was increased by those PUFAs or rosiglitazone"}
{"PMID":17459764,"re_id":9,"annotated sentence":"Moreover stimulation of <e2>COX-2 promoter<\\e2> activity was increased by those PUFAs or <e1>rosiglitazone<\\e1>  The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"rosiglitazone","object":"COX-2 promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover stimulation of <e2>GENE-N<\\e2> activity was increased by those PUFAs or <e1>CHEMICAL<\\e1>  The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of GENE-N activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction","sentence":"Moreover stimulation of COX-2 promoter activity was increased by those PUFAs or rosiglitazone  The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction"}
{"PMID":17459764,"re_id":10,"annotated sentence":"<e1>n-3 and n-6 polyunsaturated fatty acids<\\e1> induce the expression of COX-2 via <e2>PPARgamma<\\e2> activation in human keratinocyte HaCaT cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"n-3 and n-6 polyunsaturated fatty acids","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induce the expression of COX-2 via <e2>GENE-Y<\\e2> activation in human keratinocyte HaCaT cells","sentence":"n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells"}
{"PMID":17459764,"re_id":11,"annotated sentence":"Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of <e1>AA<\\e1> metabolites in <e2>PPAR<\\e2> activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"AA","object":"PPAR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of <e1>CHEMICAL<\\e1> metabolites in <e2>GENE-N<\\e2> activation","sentence":"Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation"}
{"PMID":17459764,"re_id":12,"annotated sentence":"These findings demonstrate that <e1>n-3 and n-6 PUFA<\\e1> increased <e2>PPARgamma<\\e2> activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"n-3 and n-6 PUFA","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings demonstrate that <e1>CHEMICAL<\\e1> increased <e2>GENE-Y<\\e2> activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells","sentence":"These findings demonstrate that n-3 and n-6 PUFA increased PPARgamma activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells"}
{"PMID":17459764,"re_id":13,"annotated sentence":"These findings demonstrate that <e1>n-3 and n-6 PUFA<\\e1> increased PPARgamma activity is necessary for the <e2>COX-2<\\e2> induction in HaCaT human keratinocyte cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"n-3 and n-6 PUFA","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings demonstrate that <e1>CHEMICAL<\\e1> increased PPARgamma activity is necessary for the <e2>GENE-Y<\\e2> induction in HaCaT human keratinocyte cells","sentence":"These findings demonstrate that n-3 and n-6 PUFA increased PPARgamma activity is necessary for the COX-2 induction in HaCaT human keratinocyte cells"}
{"PMID":17459764,"re_id":14,"annotated sentence":"Given the anti-inflammatory properties of EPA, we suggest that induction of <e2>COX-2<\\e2> in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of <e1>PUFAs n-3<\\e1> or n-6.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"PUFAs n-3","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Given the anti-inflammatory properties of EPA, we suggest that induction of <e2>GENE-Y<\\e2> in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of <e1>CHEMICAL<\\e1> or n-6.","sentence":"Given the anti-inflammatory properties of EPA, we suggest that induction of COX-2 in keratinocytes may be important in the anti-inflammatory and protective mechanism of action of PUFAs n-3 or n-6."}
{"PMID":17459764,"re_id":15,"annotated sentence":"We demonstrate that only treatment of HaCaT with <e1>GLA<\\e1> and EPA or a PPARgamma ligand (roziglitazone), induced <e2>COX-2<\\e2> expression (protein and mRNA)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GLA","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We demonstrate that only treatment of HaCaT with <e1>CHEMICAL<\\e1> and EPA or a PPARgamma ligand (roziglitazone), induced <e2>GENE-Y<\\e2> expression (protein and mRNA)","sentence":"We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand (roziglitazone), induced COX-2 expression (protein and mRNA)"}
{"PMID":17459764,"re_id":16,"annotated sentence":"We demonstrate that only treatment of HaCaT with GLA and <e1>EPA<\\e1> or a PPARgamma ligand (roziglitazone), induced <e2>COX-2<\\e2> expression (protein and mRNA)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"EPA","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We demonstrate that only treatment of HaCaT with GLA and <e1>CHEMICAL<\\e1> or a PPARgamma ligand (roziglitazone), induced <e2>GENE-Y<\\e2> expression (protein and mRNA)","sentence":"We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand (roziglitazone), induced COX-2 expression (protein and mRNA)"}
{"PMID":17459764,"re_id":17,"annotated sentence":"We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand (<e1>roziglitazone<\\e1> , induced <e2>COX-2<\\e2> expression (protein and mRNA)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"roziglitazone","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand (<e1>CHEMICAL<\\e1> , induced <e2>GENE-Y<\\e2> expression (protein and mRNA)","sentence":"We demonstrate that only treatment of HaCaT with GLA and EPA or a PPARgamma ligand (roziglitazone , induced COX-2 expression (protein and mRNA)"}
{"PMID":17459764,"re_id":18,"annotated sentence":"<e1>n-3 and n-6 polyunsaturated fatty acids<\\e1> induce the expression of <e2>COX-2<\\e2> via PPARgamma activation in human keratinocyte HaCaT cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"n-3 and n-6 polyunsaturated fatty acids","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induce the expression of <e2>GENE-Y<\\e2> via PPARgamma activation in human keratinocyte HaCaT cells","sentence":"n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells"}
{"PMID":17459764,"re_id":19,"annotated sentence":"Finally, <e2>PLA2<\\e2> inhibitor methyl <e1>arachidonyl fluorophosphonate<\\e1> blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"arachidonyl fluorophosphonate","object":"PLA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, <e2>GENE-Y<\\e2> inhibitor methyl <e1>CHEMICAL<\\e1> blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation","sentence":"Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation"}
{"PMID":17459764,"re_id":20,"annotated sentence":"Finally, PLA2 inhibitor methyl <e1>arachidonyl fluorophosphonate<\\e1> blocked the PUFA effects on <e2>COX-2<\\e2> induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"arachidonyl fluorophosphonate","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, PLA2 inhibitor methyl <e1>CHEMICAL<\\e1> blocked the PUFA effects on <e2>GENE-Y<\\e2> induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation","sentence":"Finally, PLA2 inhibitor methyl arachidonyl fluorophosphonate blocked the PUFA effects on COX-2 induction, promoter activity and arachidonic acid mobilization suggesting involvement of AA metabolites in PPAR activation"}
{"PMID":17459764,"re_id":21,"annotated sentence":"The inhibitory effects of <e1>GW9662<\\e1> and T0070907 (<e2>PPARgamma<\\e2> antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"GW9662","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibitory effects of <e1>CHEMICAL<\\e1> and T0070907 (<e2>GENE-Y<\\e2> antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that GENE-Y is implicated in COX-2 induction","sentence":"The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction"}
{"PMID":17459764,"re_id":22,"annotated sentence":"The inhibitory effects of GW9662 and <e1>T0070907<\\e1> (<e2>PPARgamma<\\e2> antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"T0070907","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibitory effects of GW9662 and <e1>CHEMICAL<\\e1> (<e2>GENE-Y<\\e2> antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that GENE-Y is implicated in COX-2 induction","sentence":"The inhibitory effects of GW9662 and T0070907 (PPARgamma antagonists), on COX-2 expression and on stimulation of COX-2 promoter activity by EPA and GLA suggest that PPARgamma is implicated in COX-2 induction"}
{"PMID":17472819,"re_id":1,"annotated sentence":"OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting <e2>beta(2)-adrenergic<\\e2> agonist that is the <e1>[R,R] isomer of formoterol<\\e1>  and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"[R,R] isomer of formoterol","object":"beta(2)-adrenergic","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting <e2>GENE-Y<\\e2> agonist that is the <e1>CHEMICAL<\\e1>  and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD)","sentence":"OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting beta(2)-adrenergic agonist that is the [R,R] isomer of formoterol  and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD)"}
{"PMID":17472819,"re_id":2,"annotated sentence":"OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized <e1>arformoterol tartrate<\\e1> (a selective, long-acting <e2>beta(2)-adrenergic<\\e2> agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"arformoterol tartrate","object":"beta(2)-adrenergic","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized <e1>CHEMICAL<\\e1> (a selective, long-acting <e2>GENE-Y<\\e2> agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD)","sentence":"OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting beta(2)-adrenergic agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD)"}
{"PMID":17477831,"re_id":1,"annotated sentence":"The cytosolic <e2>ACC1<\\e2> is expressed primarily in liver and adipose tissue, and uses malonyl-coenzyme A as a key building block in <e1>fatty acid<\\e1> biosynthesis","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"fatty acid","object":"ACC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The cytosolic <e2>GENE-Y<\\e2> is expressed primarily in liver and adipose tissue, and uses malonyl-coenzyme A as a key building block in <e1>CHEMICAL<\\e1> biosynthesis","sentence":"The cytosolic ACC1 is expressed primarily in liver and adipose tissue, and uses malonyl-coenzyme A as a key building block in fatty acid biosynthesis"}
{"PMID":17477831,"re_id":2,"annotated sentence":"The mitochondrial <e2>ACC2<\\e2> is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of <e1>fatty acid<\\e1> oxidation","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"fatty acid","object":"ACC2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mitochondrial <e2>GENE-Y<\\e2> is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of <e1>CHEMICAL<\\e1> oxidation","sentence":"The mitochondrial ACC2 is primarily expressed in heart and skeletal muscle, where it is involved in the regulation of fatty acid oxidation"}
{"PMID":17477831,"re_id":3,"annotated sentence":"<e2>Acetyl-coenzyme A carboxylase<\\e2> (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in <e1>fatty acid<\\e1> biosynthesis and oxidation","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"fatty acid","object":"Acetyl-coenzyme A carboxylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in <e1>CHEMICAL<\\e1> biosynthesis and oxidation","sentence":"Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in fatty acid biosynthesis and oxidation"}
{"PMID":17477831,"re_id":4,"annotated sentence":"Acetyl-coenzyme A carboxylase (<e2>ACC<\\e2>  enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in <e1>fatty acid<\\e1> biosynthesis and oxidation","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"fatty acid","object":"ACC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Acetyl-coenzyme A carboxylase (<e2>GENE-N<\\e2>  enzymes exist as two isoforms, GENE-N1 and GENE-N2, which play critical roles in <e1>CHEMICAL<\\e1> biosynthesis and oxidation","sentence":"Acetyl-coenzyme A carboxylase (ACC  enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in fatty acid biosynthesis and oxidation"}
{"PMID":17477831,"re_id":5,"annotated sentence":"Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, <e2>ACC1<\\e2> and ACC2, which play critical roles in <e1>fatty acid<\\e1> biosynthesis and oxidation","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"fatty acid","object":"ACC1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, <e2>GENE-Y<\\e2> and ACC2, which play critical roles in <e1>CHEMICAL<\\e1> biosynthesis and oxidation","sentence":"Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and ACC2, which play critical roles in fatty acid biosynthesis and oxidation"}
{"PMID":17477831,"re_id":6,"annotated sentence":"Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and <e2>ACC2<\\e2>  which play critical roles in <e1>fatty acid<\\e1> biosynthesis and oxidation","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"fatty acid","object":"ACC2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and <e2>GENE-Y<\\e2>  which play critical roles in <e1>CHEMICAL<\\e1> biosynthesis and oxidation","sentence":"Acetyl-coenzyme A carboxylase (ACC) enzymes exist as two isoforms, ACC1 and ACC2  which play critical roles in fatty acid biosynthesis and oxidation"}
{"PMID":17486539,"re_id":0,"annotated sentence":"In contrast, the <e1>RA<\\e1> catabolising enzymes <e2>Cyp26A1<\\e2> and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"RA","object":"Cyp26A1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, the <e1>CHEMICAL<\\e1> catabolising enzymes <e2>GENE-N<\\e2> and Cyp26B1 which are known to be CHEMICAL-responsive were not expressed at all in the developing eye","sentence":"In contrast, the RA catabolising enzymes Cyp26A1 and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye"}
{"PMID":17486539,"re_id":1,"annotated sentence":"In contrast, the <e1>RA<\\e1> catabolising enzymes Cyp26A1 and <e2>Cyp26B1<\\e2> which are known to be RA-responsive were not expressed at all in the developing eye","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"RA","object":"Cyp26B1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, the <e1>CHEMICAL<\\e1> catabolising enzymes Cyp26A1 and <e2>GENE-N<\\e2> which are known to be CHEMICAL-responsive were not expressed at all in the developing eye","sentence":"In contrast, the RA catabolising enzymes Cyp26A1 and Cyp26B1 which are known to be RA-responsive were not expressed at all in the developing eye"}
{"PMID":17498508,"re_id":2,"annotated sentence":"Incretin-receptor activation leads to <e1>glucose<\\e1> dependent <e2>insulin<\\e2> secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Incretin-receptor activation leads to <e1>CHEMICAL<\\e1> dependent <e2>GENE-Y<\\e2> secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis","sentence":"Incretin-receptor activation leads to glucose dependent insulin secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis"}
{"PMID":17501690,"re_id":2,"annotated sentence":"This report reviews published and unpublished data that suggest that <e1>aripiprazole<\\e1> acts as a selective partial agonist at the <e2>dopamine D(2) receptor<\\e2> and does not affect 5-HT receptors at therapeutic doses.","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"aripiprazole","object":"dopamine D(2) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This report reviews published and unpublished data that suggest that <e1>CHEMICAL<\\e1> acts as a selective partial agonist at the <e2>GENE-Y<\\e2> and does not affect 5-HT receptors at therapeutic doses.","sentence":"This report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the dopamine D(2) receptor and does not affect 5-HT receptors at therapeutic doses."}
{"PMID":17504182,"re_id":0,"annotated sentence":"<e1>Mifepriston'e<\\e1> blocks <e2>glucocorticoid receptor<\\e2> activation without modifying cortisol synthesis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Mifepriston'e","object":"glucocorticoid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> blocks <e2>GENE-Y<\\e2> activation without modifying cortisol synthesis","sentence":"Mifepriston'e blocks glucocorticoid receptor activation without modifying cortisol synthesis"}
{"PMID":17507169,"re_id":2,"annotated sentence":"The present findings confirm that PVN CB1 receptors, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of <e2>CB1 receptors<\\e2> by <e1>SR 141716A<\\e1> increases the density of these receptors in the PVN","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SR 141716A","object":"CB1 receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present findings confirm that PVN GENE-Y, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> increases the density of these receptors in the PVN","sentence":"The present findings confirm that PVN CB1 receptors, localized mainly in GABAergic synapses that control in an inhibitory fashion excitatory synapses, exert an inhibitory control on penile erection, demonstrating for the first time that chronic blockade of CB1 receptors by SR 141716A increases the density of these receptors in the PVN"}
{"PMID":17507169,"re_id":3,"annotated sentence":"[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (<e1>SR 141716A<\\e1> , a selective <e2>cannabinoid CB1 receptor<\\e2> antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"SR 141716A","object":"cannabinoid CB1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (<e1>CHEMICAL<\\e1> , a selective <e2>GENE-Y<\\e2> antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection","sentence":"[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide] (SR 141716A , a selective cannabinoid CB1 receptor antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection"}
{"PMID":17507169,"re_id":4,"annotated sentence":"[<e1>N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide<\\e1>  (SR 141716A), a selective <e2>cannabinoid CB1 receptor<\\e2> antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide","object":"cannabinoid CB1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"[<e1>CHEMICAL<\\e1>  (SR 141716A), a selective <e2>GENE-Y<\\e2> antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection","sentence":"[N-(piperidin-1-yl)-5-(4-chlorophenyl)-4-methyl-1H-pyrazole-3-carboxyamide  (SR 141716A), a selective cannabinoid CB1 receptor antagonist, injected into the paraventricular nucleus of the hypothalamus (PVN) of male rats, induces penile erection"}
{"PMID":17510465,"re_id":1,"annotated sentence":"Modulation of the function of CD36 (CD36-\/- mice), <e2>p38<\\e2> MAPK) (<e1>SB203580<\\e1> , COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SB203580","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Modulation of the function of CD36 (CD36-\/- mice), <e2>GENE-N<\\e2> MAPK) (<e1>CHEMICAL<\\e1> , COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition","sentence":"Modulation of the function of CD36 (CD36-\/- mice), p38 MAPK) (SB203580 , COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition"}
{"PMID":17510465,"re_id":2,"annotated sentence":"Modulation of the function of CD36 (CD36-\/- mice), p38(<e2>MAPK<\\e2>  (<e1>SB203580<\\e1> , COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SB203580","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Modulation of the function of CD36 (CD36-\/- mice), p38(<e2>GENE-N<\\e2>  (<e1>CHEMICAL<\\e1> , COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition","sentence":"Modulation of the function of CD36 (CD36-\/- mice), p38(MAPK  (SB203580 , COX-1 (indomethacin), and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition"}
{"PMID":17510465,"re_id":3,"annotated sentence":"Modulation of the function of CD36 (CD36-\/- mice), p38(MAPK) (SB203580), <e2>COX-1<\\e2> (<e1>indomethacin<\\e1> , and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"indomethacin","object":"COX-1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Modulation of the function of CD36 (CD36-\/- mice), p38(MAPK) (SB203580), <e2>GENE-N<\\e2> (<e1>CHEMICAL<\\e1> , and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition","sentence":"Modulation of the function of CD36 (CD36-\/- mice), p38(MAPK) (SB203580), COX-1 (indomethacin , and glycoprotein Ib alpha (Nk-protease, 6D1 antibody) induced approximately 50% inhibition"}
{"PMID":17512723,"re_id":0,"annotated sentence":"We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that <e2>human type 12 RDH<\\e2> reduces dihydrotestosterone to <e1>androstanediol<\\e1>  and is thus also involved in steroid metabolism","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"androstanediol","object":"human type 12 RDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that <e2>GENE-Y<\\e2> reduces dihydrotestosterone to <e1>CHEMICAL<\\e1>  and is thus also involved in steroid metabolism","sentence":"We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that human type 12 RDH reduces dihydrotestosterone to androstanediol  and is thus also involved in steroid metabolism"}
{"PMID":17544870,"re_id":3,"annotated sentence":"The <e1>sibutramine<\\e1> group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial <e2>peptide YY<\\e2> compared with the placebo group","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"sibutramine","object":"peptide YY","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial <e2>GENE-Y<\\e2> compared with the placebo group","sentence":"The sibutramine group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial peptide YY compared with the placebo group"}
{"PMID":17544870,"re_id":4,"annotated sentence":"CONCLUSIONS: Weight reduction with <e1>sibutramine<\\e1> is associated with altered gastric functions and increased <e2>peptide YY<\\e2> and is significantly associated with SLC6A4 genotype","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"sibutramine","object":"peptide YY","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: Weight reduction with <e1>CHEMICAL<\\e1> is associated with altered gastric functions and increased <e2>GENE-Y<\\e2> and is significantly associated with SLC6A4 genotype","sentence":"CONCLUSIONS: Weight reduction with sibutramine is associated with altered gastric functions and increased peptide YY and is significantly associated with SLC6A4 genotype"}
{"PMID":17575572,"re_id":1,"annotated sentence":"An investigation of the absolute configuration of the potent <e2>histamine H3 receptor<\\e2> antagonist <e1>GT-2331<\\e1> using vibrational circular dichroism","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"GT-2331","object":"histamine H3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"An investigation of the absolute configuration of the potent <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> using vibrational circular dichroism","sentence":"An investigation of the absolute configuration of the potent histamine H3 receptor antagonist GT-2331 using vibrational circular dichroism"}
{"PMID":17588565,"re_id":2,"annotated sentence":"In this study the neuromuscular blocking drug <e1>vecuronium<\\e1> and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant <e2>human muscarinic M2 receptors<\\e2> K(off) values min(-1); vecuronium (125 nM), atropine 0.45+\/-0.07+blocker 0.04+\/-0.02; gallamine (21 nM), atropine 0.42+\/-0.05+blocker 0.15+\/-0.04; pancuronium(21 nM), atropine 0.36+\/-0.03+blocker 0.03+\/-0.01)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"vecuronium","object":"human muscarinic M2 receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study the neuromuscular blocking drug <e1>CHEMICAL<\\e1> and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant <e2>GENE-Y<\\e2> K(off) values min(-1); CHEMICAL (125 nM), atropine 0.45+\/-0.07+blocker 0.04+\/-0.02; gallamine (21 nM), atropine 0.42+\/-0.05+blocker 0.15+\/-0.04; pancuronium(21 nM), atropine 0.36+\/-0.03+blocker 0.03+\/-0.01)","sentence":"In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant human muscarinic M2 receptors K(off) values min(-1); vecuronium (125 nM), atropine 0.45+\/-0.07+blocker 0.04+\/-0.02; gallamine (21 nM), atropine 0.42+\/-0.05+blocker 0.15+\/-0.04; pancuronium(21 nM), atropine 0.36+\/-0.03+blocker 0.03+\/-0.01)"}
{"PMID":17588565,"re_id":3,"annotated sentence":"In this study the neuromuscular blocking drug vecuronium and the controls <e1>gallamine<\\e1> and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant <e2>human muscarinic M2 receptors<\\e2> K(off) values min(-1); vecuronium (125 nM), atropine 0.45+\/-0.07+blocker 0.04+\/-0.02; gallamine (21 nM), atropine 0.42+\/-0.05+blocker 0.15+\/-0.04; pancuronium(21 nM), atropine 0.36+\/-0.03+blocker 0.03+\/-0.01)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"gallamine","object":"human muscarinic M2 receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study the neuromuscular blocking drug vecuronium and the controls <e1>CHEMICAL<\\e1> and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant <e2>GENE-Y<\\e2> K(off) values min(-1); vecuronium (125 nM), atropine 0.45+\/-0.07+blocker 0.04+\/-0.02; CHEMICAL (21 nM), atropine 0.42+\/-0.05+blocker 0.15+\/-0.04; pancuronium(21 nM), atropine 0.36+\/-0.03+blocker 0.03+\/-0.01)","sentence":"In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant human muscarinic M2 receptors K(off) values min(-1); vecuronium (125 nM), atropine 0.45+\/-0.07+blocker 0.04+\/-0.02; gallamine (21 nM), atropine 0.42+\/-0.05+blocker 0.15+\/-0.04; pancuronium(21 nM), atropine 0.36+\/-0.03+blocker 0.03+\/-0.01)"}
{"PMID":17588565,"re_id":4,"annotated sentence":"In this study the neuromuscular blocking drug vecuronium and the controls gallamine and <e1>pancuronium<\\e1> slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant <e2>human muscarinic M2 receptors<\\e2> K(off) values min(-1); vecuronium (125 nM), atropine 0.45+\/-0.07+blocker 0.04+\/-0.02; gallamine (21 nM), atropine 0.42+\/-0.05+blocker 0.15+\/-0.04; pancuronium(21 nM), atropine 0.36+\/-0.03+blocker 0.03+\/-0.01)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"pancuronium","object":"human muscarinic M2 receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study the neuromuscular blocking drug vecuronium and the controls gallamine and <e1>CHEMICAL<\\e1> slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant <e2>GENE-Y<\\e2> K(off) values min(-1); vecuronium (125 nM), atropine 0.45+\/-0.07+blocker 0.04+\/-0.02; gallamine (21 nM), atropine 0.42+\/-0.05+blocker 0.15+\/-0.04; CHEMICAL(21 nM), atropine 0.36+\/-0.03+blocker 0.03+\/-0.01)","sentence":"In this study the neuromuscular blocking drug vecuronium and the controls gallamine and pancuronium slowed the rate of atropine induced [(3)H]N-methylscopolamine dissociation from Chinese hamster ovary cells expressing recombinant human muscarinic M2 receptors K(off) values min(-1); vecuronium (125 nM), atropine 0.45+\/-0.07+blocker 0.04+\/-0.02; gallamine (21 nM), atropine 0.42+\/-0.05+blocker 0.15+\/-0.04; pancuronium(21 nM), atropine 0.36+\/-0.03+blocker 0.03+\/-0.01)"}
{"PMID":17592724,"re_id":7,"annotated sentence":"Patients with acute vitiligo have low epidermal <e2>catalase<\\e2> expression\/activities and accumulate 10(-3) M <e1>H(2)O(2)<\\e1>  One consequence of this severe oxidative stress is an altered calcium homeostasis in epidermal keratinocytes and melanocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"H(2)O(2)","object":"catalase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Patients with acute vitiligo have low epidermal <e2>GENE-Y<\\e2> expression\/activities and accumulate 10(-3) M <e1>CHEMICAL<\\e1>  One consequence of this severe oxidative stress is an altered calcium homeostasis in epidermal keratinocytes and melanocytes","sentence":"Patients with acute vitiligo have low epidermal catalase expression\/activities and accumulate 10(-3) M H(2)O(2)  One consequence of this severe oxidative stress is an altered calcium homeostasis in epidermal keratinocytes and melanocytes"}
{"PMID":17602574,"re_id":16,"annotated sentence":"However, upon addition of NO to <e2>CDO<\\e2> in the presence of substrate <e1>l-cysteine<\\e1>  a low-spin {FeNO}7 (S = 1\/2) signal that accounts for approximately 85% of the iron within the enzyme develops","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"l-cysteine","object":"CDO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, upon addition of NO to <e2>GENE-Y<\\e2> in the presence of substrate <e1>CHEMICAL<\\e1>  a low-spin {FeNO}7 (S = 1\/2) signal that accounts for approximately 85% of the iron within the enzyme develops","sentence":"However, upon addition of NO to CDO in the presence of substrate l-cysteine  a low-spin {FeNO}7 (S = 1\/2) signal that accounts for approximately 85% of the iron within the enzyme develops"}
{"PMID":17602574,"re_id":17,"annotated sentence":"<e2>Mammalian cysteine dioxygenase<\\e2> (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative <e1>cysteine<\\e1> catabolism","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cysteine","object":"Mammalian cysteine dioxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>Mammalian CHEMICAL dioxygenase<\\e2> (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative <e1>CHEMICAL<\\e1> catabolism","sentence":"Mammalian cysteine dioxygenase (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism"}
{"PMID":17602574,"re_id":18,"annotated sentence":"Mammalian cysteine dioxygenase (<e2>CDO<\\e2>  is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative <e1>cysteine<\\e1> catabolism","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cysteine","object":"CDO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mammalian CHEMICAL dioxygenase (<e2>GENE-Y<\\e2>  is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative <e1>CHEMICAL<\\e1> catabolism","sentence":"Mammalian cysteine dioxygenase (CDO  is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism"}
{"PMID":17632107,"re_id":3,"annotated sentence":"The transcriptional activity of torafugu <e2>PPARalpha1<\\e2> was enhanced 4.5- and 11.5-fold by <e1>Wy-14643<\\e1> and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Wy-14643","object":"PPARalpha1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The transcriptional activity of torafugu <e2>GENE-Y<\\e2> was enhanced 4.5- and 11.5-fold by <e1>CHEMICAL<\\e1> and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively","sentence":"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively"}
{"PMID":17632107,"re_id":4,"annotated sentence":"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by <e1>Wy-14643<\\e1> and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of <e2>PPARalpha2<\\e2>  4.5- and 7.3-fold at the same concentration of the respective ligands, respectively","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Wy-14643","object":"PPARalpha2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by <e1>CHEMICAL<\\e1> and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of <e2>GENE-Y<\\e2>  4.5- and 7.3-fold at the same concentration of the respective ligands, respectively","sentence":"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2  4.5- and 7.3-fold at the same concentration of the respective ligands, respectively"}
{"PMID":17632107,"re_id":5,"annotated sentence":"The transcriptional activity of torafugu <e2>PPARalpha1<\\e2> was enhanced 4.5- and 11.5-fold by Wy-14643 and <e1>5,8,11,14-eicosatetraynoic acid<\\e1> (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"5,8,11,14-eicosatetraynoic acid","object":"PPARalpha1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The transcriptional activity of torafugu <e2>GENE-Y<\\e2> was enhanced 4.5- and 11.5-fold by Wy-14643 and <e1>CHEMICAL<\\e1> (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively","sentence":"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively"}
{"PMID":17632107,"re_id":6,"annotated sentence":"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and <e1>5,8,11,14-eicosatetraynoic acid<\\e1> (ETYA) each at 10 microM, respectively, whereas that of <e2>PPARalpha2<\\e2>  4.5- and 7.3-fold at the same concentration of the respective ligands, respectively","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"5,8,11,14-eicosatetraynoic acid","object":"PPARalpha2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and <e1>CHEMICAL<\\e1> (ETYA) each at 10 microM, respectively, whereas that of <e2>GENE-Y<\\e2>  4.5- and 7.3-fold at the same concentration of the respective ligands, respectively","sentence":"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (ETYA) each at 10 microM, respectively, whereas that of PPARalpha2  4.5- and 7.3-fold at the same concentration of the respective ligands, respectively"}
{"PMID":17632107,"re_id":7,"annotated sentence":"The transcriptional activity of torafugu <e2>PPARalpha1<\\e2> was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (<e1>ETYA<\\e1>  each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ETYA","object":"PPARalpha1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The transcriptional activity of torafugu <e2>GENE-Y<\\e2> was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (<e1>CHEMICAL<\\e1>  each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively","sentence":"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (ETYA  each at 10 microM, respectively, whereas that of PPARalpha2, 4.5- and 7.3-fold at the same concentration of the respective ligands, respectively"}
{"PMID":17632107,"re_id":8,"annotated sentence":"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (<e1>ETYA<\\e1>  each at 10 microM, respectively, whereas that of <e2>PPARalpha2<\\e2>  4.5- and 7.3-fold at the same concentration of the respective ligands, respectively","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ETYA","object":"PPARalpha2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (<e1>CHEMICAL<\\e1>  each at 10 microM, respectively, whereas that of <e2>GENE-Y<\\e2>  4.5- and 7.3-fold at the same concentration of the respective ligands, respectively","sentence":"The transcriptional activity of torafugu PPARalpha1 was enhanced 4.5- and 11.5-fold by Wy-14643 and 5,8,11,14-eicosatetraynoic acid (ETYA  each at 10 microM, respectively, whereas that of PPARalpha2  4.5- and 7.3-fold at the same concentration of the respective ligands, respectively"}
{"PMID":17632107,"re_id":9,"annotated sentence":"Furthermore, the activities of the two <e2>torafugu PPARalphas<\\e2> were enhanced 4.3- and 7.6-fold by <e1>arachidonic acid<\\e1>  4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"arachidonic acid","object":"torafugu PPARalphas","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the activities of the two <e2>GENE-N<\\e2> were enhanced 4.3- and 7.6-fold by <e1>CHEMICAL<\\e1>  4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively","sentence":"Furthermore, the activities of the two torafugu PPARalphas were enhanced 4.3- and 7.6-fold by arachidonic acid  4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively"}
{"PMID":17632107,"re_id":10,"annotated sentence":"Furthermore, the activities of the two <e2>torafugu PPARalphas<\\e2> were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by <e1>docosahexaenoic acid<\\e1>  and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"docosahexaenoic acid","object":"torafugu PPARalphas","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the activities of the two <e2>GENE-N<\\e2> were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by <e1>CHEMICAL<\\e1>  and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively","sentence":"Furthermore, the activities of the two torafugu PPARalphas were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by docosahexaenoic acid  and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively"}
{"PMID":17632107,"re_id":11,"annotated sentence":"Furthermore, the activities of the two <e2>torafugu PPARalphas<\\e2> were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by <e1>eicosapentaenoic acid<\\e1> each at 50 microM, respectively","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"eicosapentaenoic acid","object":"torafugu PPARalphas","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the activities of the two <e2>GENE-N<\\e2> were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by <e1>CHEMICAL<\\e1> each at 50 microM, respectively","sentence":"Furthermore, the activities of the two torafugu PPARalphas were enhanced 4.3- and 7.6-fold by arachidonic acid, 4.4- and 5.2-fold by docosahexaenoic acid, and 6.7- and 8.0-fold by eicosapentaenoic acid each at 50 microM, respectively"}
{"PMID":17643344,"re_id":0,"annotated sentence":"Combination chemotherapy with a <e2>substance P receptor<\\e2> antagonist (<e1>aprepitant<\\e1>  and melarsoprol in a mouse model of human African trypanosomiasis","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"aprepitant","object":"substance P receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Combination chemotherapy with a <e2>GENE-Y<\\e2> antagonist (<e1>CHEMICAL<\\e1>  and melarsoprol in a mouse model of human African trypanosomiasis","sentence":"Combination chemotherapy with a substance P receptor antagonist (aprepitant  and melarsoprol in a mouse model of human African trypanosomiasis"}
{"PMID":17643344,"re_id":1,"annotated sentence":"Combination chemotherapy with a <e2>substance P receptor<\\e2> antagonist (aprepitant) and <e1>melarsoprol<\\e1> in a mouse model of human African trypanosomiasis","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"melarsoprol","object":"substance P receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Combination chemotherapy with a <e2>GENE-Y<\\e2> antagonist (aprepitant) and <e1>CHEMICAL<\\e1> in a mouse model of human African trypanosomiasis","sentence":"Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis"}
{"PMID":17643344,"re_id":2,"annotated sentence":"In this study we investigated the effects of combination chemotherapy with melarsoprol and a <e2>humanised SP receptor<\\e2> antagonist <e1>aprepitant<\\e1> (EMEND) in this mouse model","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"aprepitant","object":"humanised SP receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study we investigated the effects of combination chemotherapy with melarsoprol and a <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> (EMEND) in this mouse model","sentence":"In this study we investigated the effects of combination chemotherapy with melarsoprol and a humanised SP receptor antagonist aprepitant (EMEND) in this mouse model"}
{"PMID":17643344,"re_id":3,"annotated sentence":"In this study we investigated the effects of combination chemotherapy with melarsoprol and a <e2>humanised SP receptor<\\e2> antagonist aprepitant (<e1>EMEND<\\e1>  in this mouse model","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"EMEND","object":"humanised SP receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this study we investigated the effects of combination chemotherapy with melarsoprol and a <e2>GENE-Y<\\e2> antagonist aprepitant (<e1>CHEMICAL<\\e1>  in this mouse model","sentence":"In this study we investigated the effects of combination chemotherapy with melarsoprol and a humanised SP receptor antagonist aprepitant (EMEND  in this mouse model"}
{"PMID":17652763,"re_id":1,"annotated sentence":"It is thought to play a critical role in the visual cycle by functioning as an acceptor of <e1>11-cis-retinol<\\e1> from the <e2>isomerohydrolase<\\e2> reaction","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"11-cis-retinol","object":"isomerohydrolase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It is thought to play a critical role in the visual cycle by functioning as an acceptor of <e1>CHEMICAL<\\e1> from the <e2>GENE-N<\\e2> reaction","sentence":"It is thought to play a critical role in the visual cycle by functioning as an acceptor of 11-cis-retinol from the isomerohydrolase reaction"}
{"PMID":17653133,"re_id":2,"annotated sentence":"Using this assay, we found that both <e1>superoxide<\\e1> and nitric oxide inhibit renal cortical <e2>DDAH<\\e2> activity in vitro.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"superoxide","object":"DDAH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using this assay, we found that both <e1>CHEMICAL<\\e1> and nitric oxide inhibit renal cortical <e2>GENE-Y<\\e2> activity in vitro.","sentence":"Using this assay, we found that both superoxide and nitric oxide inhibit renal cortical DDAH activity in vitro."}
{"PMID":17653133,"re_id":3,"annotated sentence":"Using this assay, we found that both superoxide and <e1>nitric oxide<\\e1> inhibit renal cortical <e2>DDAH<\\e2> activity in vitro.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nitric oxide","object":"DDAH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using this assay, we found that both superoxide and <e1>CHEMICAL<\\e1> inhibit renal cortical <e2>GENE-Y<\\e2> activity in vitro.","sentence":"Using this assay, we found that both superoxide and nitric oxide inhibit renal cortical DDAH activity in vitro."}
{"PMID":17653133,"re_id":4,"annotated sentence":"Our optimized <e1>L-citrulline<\\e1> production assay to measure <e2>DDAH<\\e2> activity correlated closely with the direct measure of the rate of asymmetric dimethylarginine consumption","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"L-citrulline","object":"DDAH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our optimized <e1>CHEMICAL<\\e1> production assay to measure <e2>GENE-Y<\\e2> activity correlated closely with the direct measure of the rate of asymmetric dimethylarginine consumption","sentence":"Our optimized L-citrulline production assay to measure DDAH activity correlated closely with the direct measure of the rate of asymmetric dimethylarginine consumption"}
{"PMID":17653133,"re_id":5,"annotated sentence":"<e2>Dimethylarginine dimethylaminohydrolase<\\e2> (DDAH) metabolizes asymmetric dimethylarginine to generate <e1>L-citrulline<\\e1> and is present in large quantities in the kidney","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"L-citrulline","object":"Dimethylarginine dimethylaminohydrolase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (DDAH) metabolizes asymmetric dimethylarginine to generate <e1>CHEMICAL<\\e1> and is present in large quantities in the kidney","sentence":"Dimethylarginine dimethylaminohydrolase (DDAH) metabolizes asymmetric dimethylarginine to generate L-citrulline and is present in large quantities in the kidney"}
{"PMID":17653133,"re_id":6,"annotated sentence":"Dimethylarginine dimethylaminohydrolase (<e2>DDAH<\\e2>  metabolizes asymmetric dimethylarginine to generate <e1>L-citrulline<\\e1> and is present in large quantities in the kidney","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"L-citrulline","object":"DDAH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dimethylarginine dimethylaminohydrolase (<e2>GENE-Y<\\e2>  metabolizes asymmetric dimethylarginine to generate <e1>CHEMICAL<\\e1> and is present in large quantities in the kidney","sentence":"Dimethylarginine dimethylaminohydrolase (DDAH  metabolizes asymmetric dimethylarginine to generate L-citrulline and is present in large quantities in the kidney"}
{"PMID":17653133,"re_id":7,"annotated sentence":"We present a new study that optimizes the Prescott-Jones colorimetric assay to measure <e2>DDAH<\\e2> dependent <e1>L-citrulline<\\e1> generation in kidney homogenates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"L-citrulline","object":"DDAH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We present a new study that optimizes the Prescott-Jones colorimetric assay to measure <e2>GENE-Y<\\e2> dependent <e1>CHEMICAL<\\e1> generation in kidney homogenates","sentence":"We present a new study that optimizes the Prescott-Jones colorimetric assay to measure DDAH dependent L-citrulline generation in kidney homogenates"}
{"PMID":17653133,"re_id":8,"annotated sentence":"Our optimized L-citrulline production assay to measure <e2>DDAH<\\e2> activity correlated closely with the direct measure of the rate of asymmetric <e1>dimethylarginine<\\e1> consumption","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dimethylarginine","object":"DDAH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our optimized L-citrulline production assay to measure <e2>GENE-Y<\\e2> activity correlated closely with the direct measure of the rate of asymmetric <e1>CHEMICAL<\\e1> consumption","sentence":"Our optimized L-citrulline production assay to measure DDAH activity correlated closely with the direct measure of the rate of asymmetric dimethylarginine consumption"}
{"PMID":17653133,"re_id":9,"annotated sentence":"We found that the removal of <e1>urea<\\e1> with <e2>urease<\\e2> is necessary since urea also produces a positive reaction","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"urea","object":"urease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We found that the removal of <e1>CHEMICAL<\\e1> with <e2>CHEMICALse<\\e2> is necessary since CHEMICAL also produces a positive reaction","sentence":"We found that the removal of urea with urease is necessary since urea also produces a positive reaction"}
{"PMID":17653133,"re_id":10,"annotated sentence":"<e2>Dimethylarginine dimethylaminohydrolase<\\e2> (DDAH) metabolizes asymmetric <e1>dimethylarginine<\\e1> to generate L-citrulline and is present in large quantities in the kidney","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dimethylarginine","object":"Dimethylarginine dimethylaminohydrolase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (DDAH) metabolizes asymmetric <e1>CHEMICAL<\\e1> to generate L-citrulline and is present in large quantities in the kidney","sentence":"Dimethylarginine dimethylaminohydrolase (DDAH) metabolizes asymmetric dimethylarginine to generate L-citrulline and is present in large quantities in the kidney"}
{"PMID":17653133,"re_id":11,"annotated sentence":"Dimethylarginine dimethylaminohydrolase (<e2>DDAH<\\e2>  metabolizes asymmetric <e1>dimethylarginine<\\e1> to generate L-citrulline and is present in large quantities in the kidney","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dimethylarginine","object":"DDAH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Dimethylarginine dimethylaminohydrolase (<e2>GENE-Y<\\e2>  metabolizes asymmetric <e1>CHEMICAL<\\e1> to generate L-citrulline and is present in large quantities in the kidney","sentence":"Dimethylarginine dimethylaminohydrolase (DDAH  metabolizes asymmetric dimethylarginine to generate L-citrulline and is present in large quantities in the kidney"}
{"PMID":17660958,"re_id":6,"annotated sentence":"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting <e2>HER2<\\e2> neu as well as the epidermal growth factor receptor (EGFR), <e1>lapatinib<\\e1>  Other trials are investigating differences in duration","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lapatinib","object":"HER2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting <e2>GENE-Y<\\e2> neu as well as the epidermal growth factor receptor (EGFR), <e1>CHEMICAL<\\e1>  Other trials are investigating differences in duration","sentence":"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2 neu as well as the epidermal growth factor receptor (EGFR), lapatinib  Other trials are investigating differences in duration"}
{"PMID":17660958,"re_id":7,"annotated sentence":"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2\/<e2>neu<\\e2> as well as the epidermal growth factor receptor (EGFR), <e1>lapatinib<\\e1>  Other trials are investigating differences in duration","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lapatinib","object":"neu","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2\/<e2>GENE-Y<\\e2> as well as the epidermal growth factor receptor (EGFR), <e1>CHEMICAL<\\e1>  Other trials are investigating differences in duration","sentence":"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2\/neu as well as the epidermal growth factor receptor (EGFR), lapatinib  Other trials are investigating differences in duration"}
{"PMID":17660958,"re_id":8,"annotated sentence":"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2\/neu as well as the <e2>epidermal growth factor receptor<\\e2> (EGFR), <e1>lapatinib<\\e1>  Other trials are investigating differences in duration","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lapatinib","object":"epidermal growth factor receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2\/neu as well as the <e2>GENE-Y<\\e2> (EGFR), <e1>CHEMICAL<\\e1>  Other trials are investigating differences in duration","sentence":"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2\/neu as well as the epidermal growth factor receptor (EGFR), lapatinib  Other trials are investigating differences in duration"}
{"PMID":17660958,"re_id":9,"annotated sentence":"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2\/neu as well as the epidermal growth factor receptor (<e2>EGFR<\\e2> , <e1>lapatinib<\\e1>  Other trials are investigating differences in duration","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lapatinib","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2\/neu as well as the epidermal growth factor receptor (<e2>GENE-Y<\\e2> , <e1>CHEMICAL<\\e1>  Other trials are investigating differences in duration","sentence":"The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2\/neu as well as the epidermal growth factor receptor (EGFR , lapatinib  Other trials are investigating differences in duration"}
{"PMID":17662248,"re_id":2,"annotated sentence":"Exposure of Jurkat cells to either <e1>(5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine<\\e1> [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective <e2>NMDA receptor<\\e2> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+\/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"(5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Exposure of Jurkat cells to either <e1>CHEMICAL<\\e1> [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective <e2>GENE-N<\\e2> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+\/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin","sentence":"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+\/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin"}
{"PMID":17662248,"re_id":3,"annotated sentence":"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [<e1>(+)-MK 801<\\e1>  or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective <e2>NMDA receptor<\\e2> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+\/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"(+)-MK 801","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [<e1>CHEMICAL<\\e1>  or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective <e2>GENE-N<\\e2> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+\/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin","sentence":"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801  or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+\/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin"}
{"PMID":17662248,"re_id":4,"annotated sentence":"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or <e1>D-(-)-2-amino-5-phosphonopentanoic acid<\\e1> (D-AP5), two selective <e2>NMDA receptor<\\e2> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+\/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"D-(-)-2-amino-5-phosphonopentanoic acid","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or <e1>CHEMICAL<\\e1> (D-AP5), two selective <e2>GENE-N<\\e2> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+\/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin","sentence":"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+\/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin"}
{"PMID":17662248,"re_id":5,"annotated sentence":"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (<e1>D-AP5<\\e1> , two selective <e2>NMDA receptor<\\e2> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+\/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"D-AP5","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (<e1>CHEMICAL<\\e1> , two selective <e2>GENE-N<\\e2> antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+\/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin","sentence":"Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5 , two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+\/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin"}
{"PMID":17673606,"re_id":5,"annotated sentence":"Using <e2>hNET<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the <e1>DVS<\\e1> analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"DVS","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using <e2>GENE-Y<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for CHEMICAL at sites labeled by [(3)H]NIS was found to distinguish CHEMICAL, the <e1>CHEMICAL<\\e1> analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other GENE-Y antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine"}
{"PMID":17673606,"re_id":6,"annotated sentence":"Using <e2>hNET<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog <e1>rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol<\\e1> (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using <e2>GENE-Y<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog <e1>CHEMICAL<\\e1> (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other GENE-Y antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine"}
{"PMID":17673606,"re_id":7,"annotated sentence":"Using <e2>hNET<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (<e1>WY-46824<\\e1> , methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"WY-46824","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using <e2>GENE-Y<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (<e1>CHEMICAL<\\e1> , methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other GENE-Y antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824 , methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine"}
{"PMID":17673606,"re_id":8,"annotated sentence":"Using <e2>hNET<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), <e1>methylphenidate<\\e1>  and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"methylphenidate","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using <e2>GENE-Y<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), <e1>CHEMICAL<\\e1>  and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other GENE-Y antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate  and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine"}
{"PMID":17673606,"re_id":9,"annotated sentence":"Using <e2>hNET<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the <e1>cocaine<\\e1> analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"cocaine","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using <e2>GENE-Y<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the <e1>CHEMICAL<\\e1> analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other GENE-Y antagonists, such as NIS, mazindol, tricyclic antidepressants, and CHEMICAL","sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine"}
{"PMID":17673606,"re_id":10,"annotated sentence":"Using <e2>hNET<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog <e1>3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester<\\e1> (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using <e2>GENE-Y<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog <e1>CHEMICAL<\\e1> (RTI-55) from other GENE-Y antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine"}
{"PMID":17673606,"re_id":11,"annotated sentence":"Using <e2>hNET<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (<e1>RTI-55<\\e1>  from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"RTI-55","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using <e2>GENE-Y<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (<e1>CHEMICAL<\\e1>  from other GENE-Y antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55  from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine"}
{"PMID":17673606,"re_id":12,"annotated sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other <e2>hNET<\\e2> antagonists, such as <e1>NIS<\\e1>  mazindol, tricyclic antidepressants, and cocaine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"NIS","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using GENE-Y in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]CHEMICAL was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other <e2>GENE-Y<\\e2> antagonists, such as <e1>CHEMICAL<\\e1>  mazindol, tricyclic antidepressants, and cocaine","sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS  mazindol, tricyclic antidepressants, and cocaine"}
{"PMID":17673606,"re_id":13,"annotated sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other <e2>hNET<\\e2> antagonists, such as NIS, <e1>mazindol<\\e1>  tricyclic antidepressants, and cocaine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"mazindol","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using GENE-Y in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other <e2>GENE-Y<\\e2> antagonists, such as NIS, <e1>CHEMICAL<\\e1>  tricyclic antidepressants, and cocaine","sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol  tricyclic antidepressants, and cocaine"}
{"PMID":17673606,"re_id":14,"annotated sentence":"<e1>Desvenlafaxine succinate<\\e1> (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (<e2>hNET<\\e2> and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Desvenlafaxine succinate","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (<e2>GENE-Y<\\e2> and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause","sentence":"Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause"}
{"PMID":17673606,"re_id":15,"annotated sentence":"<e1>Desvenlafaxine succinate<\\e1> (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and <e2>hSERT<\\e2>  respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Desvenlafaxine succinate","object":"hSERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and <e2>GENE-Y<\\e2>  respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause","sentence":"Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and hSERT  respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause"}
{"PMID":17673606,"re_id":16,"annotated sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other <e2>hNET<\\e2> antagonists, such as NIS, mazindol, <e1>tricyclic<\\e1> antidepressants, and cocaine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"tricyclic","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using GENE-Y in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other <e2>GENE-Y<\\e2> antagonists, such as NIS, mazindol, <e1>CHEMICAL<\\e1> antidepressants, and cocaine","sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine"}
{"PMID":17673606,"re_id":17,"annotated sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other <e2>hNET<\\e2> antagonists, such as NIS, mazindol, tricyclic antidepressants, and <e1>cocaine<\\e1>  These differences seem not to arise from preparation-specific perturbations of ligand intrinsic affinity or antagonist-specific surface trafficking but rather from protein conformational alterations that perturb the relationships between distinct hNET binding sites","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"cocaine","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using GENE-Y in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the CHEMICAL analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other <e2>GENE-Y<\\e2> antagonists, such as NIS, mazindol, tricyclic antidepressants, and <e1>CHEMICAL<\\e1>  These differences seem not to arise from preparation-specific perturbations of ligand intrinsic affinity or antagonist-specific surface trafficking but rather from protein conformational alterations that perturb the relationships between distinct GENE-Y binding sites","sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine  These differences seem not to arise from preparation-specific perturbations of ligand intrinsic affinity or antagonist-specific surface trafficking but rather from protein conformational alterations that perturb the relationships between distinct hNET binding sites"}
{"PMID":17673606,"re_id":18,"annotated sentence":"<e1>Desvenlafaxine succinate<\\e1> identifies novel antagonist binding determinants in the <e2>human norepinephrine transporter<\\e2>  Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Desvenlafaxine succinate","object":"human norepinephrine transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> identifies novel antagonist binding determinants in the <e2>GENE-Y<\\e2>  CHEMICAL (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause","sentence":"Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter  Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause"}
{"PMID":17673606,"re_id":19,"annotated sentence":"Desvenlafaxine succinate (<e1>DVS<\\e1>  is a recently introduced antagonist of the human norepinephrine and serotonin transporters (<e2>hNET<\\e2> and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"DVS","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Desvenlafaxine succinate (<e1>CHEMICAL<\\e1>  is a recently introduced antagonist of the human norepinephrine and serotonin transporters (<e2>GENE-Y<\\e2> and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause","sentence":"Desvenlafaxine succinate (DVS  is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause"}
{"PMID":17673606,"re_id":20,"annotated sentence":"Desvenlafaxine succinate (<e1>DVS<\\e1>  is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and <e2>hSERT<\\e2>  respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"DVS","object":"hSERT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Desvenlafaxine succinate (<e1>CHEMICAL<\\e1>  is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and <e2>GENE-Y<\\e2>  respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause","sentence":"Desvenlafaxine succinate (DVS  is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and hSERT  respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause"}
{"PMID":17673606,"re_id":21,"annotated sentence":"Using <e2>hNET<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish <e1>DVS<\\e1>  the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"DVS","object":"hNET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using <e2>GENE-Y<\\e2> in transfected human embryonic kidney-293 cells, this difference in potency for CHEMICAL at sites labeled by [(3)H]NIS was found to distinguish <e1>CHEMICAL<\\e1>  the CHEMICAL analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other GENE-Y antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine","sentence":"Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS  the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine"}
{"PMID":17935273,"re_id":0,"annotated sentence":"<e1>Sorafenib<\\e1> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (<e2>VEGFR-2<\\e2>  VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sorafenib","object":"VEGFR-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (<e2>GENE-Y<\\e2>  VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor","sentence":"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2  VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor"}
{"PMID":17935273,"re_id":1,"annotated sentence":"<e1>Sorafenib<\\e1> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, <e2>VEGFR-3<\\e2>  and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sorafenib","object":"VEGFR-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, <e2>GENE-Y<\\e2>  and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor","sentence":"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3  and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor"}
{"PMID":17935273,"re_id":2,"annotated sentence":"<e1>Sorafenib<\\e1> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and <e2>platelet-derived growth factor receptor beta<\\e2> (PDGFR-beta), while temsirolimus is an mTOR inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sorafenib","object":"platelet-derived growth factor receptor beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and <e2>GENE-Y<\\e2> (PDGFR-beta), while temsirolimus is an mTOR inhibitor","sentence":"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor"}
{"PMID":17935273,"re_id":3,"annotated sentence":"<e1>Sorafenib<\\e1> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (<e2>PDGFR-beta<\\e2> , while temsirolimus is an mTOR inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sorafenib","object":"PDGFR-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (<e2>GENE-Y<\\e2> , while temsirolimus is an mTOR inhibitor","sentence":"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta , while temsirolimus is an mTOR inhibitor"}
{"PMID":17935273,"re_id":4,"annotated sentence":"Sorafenib and <e1>sunitinib<\\e1> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (<e2>VEGFR-2<\\e2>  VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sunitinib","object":"VEGFR-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sorafenib and <e1>CHEMICAL<\\e1> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (<e2>GENE-Y<\\e2>  VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor","sentence":"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2  VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor"}
{"PMID":17935273,"re_id":5,"annotated sentence":"Sorafenib and <e1>sunitinib<\\e1> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, <e2>VEGFR-3<\\e2>  and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sunitinib","object":"VEGFR-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sorafenib and <e1>CHEMICAL<\\e1> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, <e2>GENE-Y<\\e2>  and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor","sentence":"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3  and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor"}
{"PMID":17935273,"re_id":6,"annotated sentence":"Sorafenib and <e1>sunitinib<\\e1> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and <e2>platelet-derived growth factor receptor beta<\\e2> (PDGFR-beta), while temsirolimus is an mTOR inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sunitinib","object":"platelet-derived growth factor receptor beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sorafenib and <e1>CHEMICAL<\\e1> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and <e2>GENE-Y<\\e2> (PDGFR-beta), while temsirolimus is an mTOR inhibitor","sentence":"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor"}
{"PMID":17935273,"re_id":7,"annotated sentence":"Sorafenib and <e1>sunitinib<\\e1> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (<e2>PDGFR-beta<\\e2> , while temsirolimus is an mTOR inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sunitinib","object":"PDGFR-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sorafenib and <e1>CHEMICAL<\\e1> are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (<e2>GENE-Y<\\e2> , while temsirolimus is an mTOR inhibitor","sentence":"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta , while temsirolimus is an mTOR inhibitor"}
{"PMID":17935273,"re_id":8,"annotated sentence":"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while <e1>temsirolimus<\\e1> is an <e2>mTOR<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"temsirolimus","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while <e1>CHEMICAL<\\e1> is an <e2>GENE-Y<\\e2> inhibitor","sentence":"Sorafenib and sunitinib are synthetic, orally active agents shown to directly inhibit vascular endothelial growth factor receptors -2 and -3 (VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR-beta), while temsirolimus is an mTOR inhibitor"}
{"PMID":18034539,"re_id":3,"annotated sentence":"One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas <e1>tazarotene<\\e1> preferentially binds to and activates RAR-beta and -gamma in preference to <e2>RAR-alpha<\\e2>  The other is that there is already increased formation of retinoic acid in the psoriatic lesion","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"tazarotene","object":"RAR-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, GENE-Y, -beta and -gamma, without measurable receptor binding, whereas <e1>CHEMICAL<\\e1> preferentially binds to and activates RAR-beta and -gamma in preference to <e2>GENE-Y<\\e2>  The other is that there is already increased formation of retinoic acid in the psoriatic lesion","sentence":"One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha  The other is that there is already increased formation of retinoic acid in the psoriatic lesion"}
{"PMID":18035186,"re_id":1,"annotated sentence":"Rasagiline [<e1>N-propargyl-l(R)-aminoindan<\\e1>  is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain <e2>MAO-B<\\e2> and is specifically designed for the treatment of Parkinson's disease (PD)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"N-propargyl-l(R)-aminoindan","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rasagiline [<e1>CHEMICAL<\\e1>  is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain <e2>GENE-Y<\\e2> and is specifically designed for the treatment of Parkinson's disease (PD)","sentence":"Rasagiline [N-propargyl-l(R)-aminoindan  is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain MAO-B and is specifically designed for the treatment of Parkinson's disease (PD)"}
{"PMID":18035186,"re_id":2,"annotated sentence":"Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation <e1>propargylamine<\\e1> pharmacophore that selectively and irreversibly inhibits brain <e2>MAO-B<\\e2> and is specifically designed for the treatment of Parkinson's disease (PD)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"propargylamine","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation <e1>CHEMICAL<\\e1> pharmacophore that selectively and irreversibly inhibits brain <e2>GENE-Y<\\e2> and is specifically designed for the treatment of Parkinson's disease (PD)","sentence":"Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain MAO-B and is specifically designed for the treatment of Parkinson's disease (PD)"}
{"PMID":18035186,"re_id":3,"annotated sentence":"Comprehensive review of <e1>rasagiline<\\e1>  a second-generation <e2>monoamine oxidase<\\e2> inhibitor, for the treatment of Parkinson's disease","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rasagiline","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Comprehensive review of <e1>CHEMICAL<\\e1>  a second-generation <e2>GENE-N<\\e2> inhibitor, for the treatment of Parkinson's disease","sentence":"Comprehensive review of rasagiline  a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease"}
{"PMID":18035186,"re_id":4,"annotated sentence":"Based on the results from those studies, we concluded that <e1>rasagiline<\\e1> PO QD, at the therapeutic dosage range of 0.5 to 1 rag\/d, is effective and well tolerated and completely, selectively, and specifically inhibited <e2>MAO-B<\\e2>  Pharmacologically, rasagiline was found to be < or =10-fold more potent than selegiline and was not metabolized to amphetamine derivatives","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rasagiline","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Based on the results from those studies, we concluded that <e1>CHEMICAL<\\e1> PO QD, at the therapeutic dosage range of 0.5 to 1 rag\/d, is effective and well tolerated and completely, selectively, and specifically inhibited <e2>GENE-Y<\\e2>  Pharmacologically, CHEMICAL was found to be < or =10-fold more potent than selegiline and was not metabolized to amphetamine derivatives","sentence":"Based on the results from those studies, we concluded that rasagiline PO QD, at the therapeutic dosage range of 0.5 to 1 rag\/d, is effective and well tolerated and completely, selectively, and specifically inhibited MAO-B  Pharmacologically, rasagiline was found to be < or =10-fold more potent than selegiline and was not metabolized to amphetamine derivatives"}
{"PMID":18035186,"re_id":5,"annotated sentence":"<e1>Rasagiline<\\e1> [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain <e2>MAO-B<\\e2> and is specifically designed for the treatment of Parkinson's disease (PD)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Rasagiline","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain <e2>GENE-Y<\\e2> and is specifically designed for the treatment of Parkinson's disease (PD)","sentence":"Rasagiline [N-propargyl-l(R)-aminoindan] is a second-generation propargylamine pharmacophore that selectively and irreversibly inhibits brain MAO-B and is specifically designed for the treatment of Parkinson's disease (PD)"}
{"PMID":18393142,"re_id":0,"annotated sentence":"This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to <e2>factor Xa<\\e2> (<e1>rivaroxaban<\\e1> and apixaban) and IIa (dabigatran)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivaroxaban","object":"factor Xa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to <e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1> and apixaban) and IIa (dabigatran)","sentence":"This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran)"}
{"PMID":18393142,"re_id":1,"annotated sentence":"This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to <e2>factor Xa<\\e2> (rivaroxaban and <e1>apixaban<\\e1>  and IIa (dabigatran)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"apixaban","object":"factor Xa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to <e2>GENE-Y<\\e2> (rivaroxaban and <e1>CHEMICAL<\\e1>  and IIa (dabigatran)","sentence":"This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban  and IIa (dabigatran)"}
{"PMID":18423812,"re_id":0,"annotated sentence":"INTERVENTIONS: In the 8-week run-in period, all participants received the <e2>ACE<\\e2> inhibitor <e1>cilazapril<\\e1> (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130\/80 mm Hg","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cilazapril","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"INTERVENTIONS: In the 8-week run-in period, all participants received the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130\/80 mm Hg","sentence":"INTERVENTIONS: In the 8-week run-in period, all participants received the ACE inhibitor cilazapril (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130\/80 mm Hg"}
{"PMID":18439678,"re_id":18,"annotated sentence":"Two <e1>imidazoquinoline<\\e1> molecules, imiquimod and gardiquimod, markedly activated both <e2>porcine TLR7<\\e2> and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imidazoquinoline","object":"porcine TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two <e1>CHEMICAL<\\e1> molecules, imiquimod and gardiquimod, markedly activated both <e2>GENE-Y<\\e2> and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands","sentence":"Two imidazoquinoline molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands"}
{"PMID":18439678,"re_id":19,"annotated sentence":"Two <e1>imidazoquinoline<\\e1> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and <e2>TLR8<\\e2> whereas only human TLR7, but not TLR8, was activated by the ligands","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imidazoquinoline","object":"TLR8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two <e1>CHEMICAL<\\e1> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and <e2>GENE-Y<\\e2> whereas only human TLR7, but not GENE-Y, was activated by the ligands","sentence":"Two imidazoquinoline molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands"}
{"PMID":18439678,"re_id":20,"annotated sentence":"Two <e1>imidazoquinoline<\\e1> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only <e2>human TLR7<\\e2>  but not TLR8, was activated by the ligands","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imidazoquinoline","object":"human TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two <e1>CHEMICAL<\\e1> molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only <e2>GENE-Y<\\e2>  but not TLR8, was activated by the ligands","sentence":"Two imidazoquinoline molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7  but not TLR8, was activated by the ligands"}
{"PMID":18439678,"re_id":21,"annotated sentence":"Two imidazoquinoline molecules, <e1>imiquimod<\\e1> and gardiquimod, markedly activated both <e2>porcine TLR7<\\e2> and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imiquimod","object":"porcine TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two imidazoquinoline molecules, <e1>CHEMICAL<\\e1> and gardiquimod, markedly activated both <e2>GENE-Y<\\e2> and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands","sentence":"Two imidazoquinoline molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands"}
{"PMID":18439678,"re_id":22,"annotated sentence":"Two imidazoquinoline molecules, <e1>imiquimod<\\e1> and gardiquimod, markedly activated both porcine TLR7 and <e2>TLR8<\\e2> whereas only human TLR7, but not TLR8, was activated by the ligands","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imiquimod","object":"TLR8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two imidazoquinoline molecules, <e1>CHEMICAL<\\e1> and gardiquimod, markedly activated both porcine TLR7 and <e2>GENE-Y<\\e2> whereas only human TLR7, but not GENE-Y, was activated by the ligands","sentence":"Two imidazoquinoline molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands"}
{"PMID":18439678,"re_id":23,"annotated sentence":"Two imidazoquinoline molecules, <e1>imiquimod<\\e1> and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only <e2>human TLR7<\\e2>  but not TLR8, was activated by the ligands","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imiquimod","object":"human TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two imidazoquinoline molecules, <e1>CHEMICAL<\\e1> and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only <e2>GENE-Y<\\e2>  but not TLR8, was activated by the ligands","sentence":"Two imidazoquinoline molecules, imiquimod and gardiquimod, markedly activated both porcine TLR7 and TLR8 whereas only human TLR7  but not TLR8, was activated by the ligands"}
{"PMID":18439678,"re_id":24,"annotated sentence":"Two imidazoquinoline molecules, imiquimod and <e1>gardiquimod<\\e1>  markedly activated both <e2>porcine TLR7<\\e2> and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"gardiquimod","object":"porcine TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two imidazoquinoline molecules, imiquimod and <e1>CHEMICAL<\\e1>  markedly activated both <e2>GENE-Y<\\e2> and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands","sentence":"Two imidazoquinoline molecules, imiquimod and gardiquimod  markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands"}
{"PMID":18439678,"re_id":25,"annotated sentence":"Two imidazoquinoline molecules, imiquimod and <e1>gardiquimod<\\e1>  markedly activated both porcine TLR7 and <e2>TLR8<\\e2> whereas only human TLR7, but not TLR8, was activated by the ligands","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"gardiquimod","object":"TLR8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two imidazoquinoline molecules, imiquimod and <e1>CHEMICAL<\\e1>  markedly activated both porcine TLR7 and <e2>GENE-Y<\\e2> whereas only human TLR7, but not GENE-Y, was activated by the ligands","sentence":"Two imidazoquinoline molecules, imiquimod and gardiquimod  markedly activated both porcine TLR7 and TLR8 whereas only human TLR7, but not TLR8, was activated by the ligands"}
{"PMID":18439678,"re_id":26,"annotated sentence":"Two imidazoquinoline molecules, imiquimod and <e1>gardiquimod<\\e1>  markedly activated both porcine TLR7 and TLR8 whereas only <e2>human TLR7<\\e2>  but not TLR8, was activated by the ligands","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"gardiquimod","object":"human TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Two imidazoquinoline molecules, imiquimod and <e1>CHEMICAL<\\e1>  markedly activated both porcine TLR7 and TLR8 whereas only <e2>GENE-Y<\\e2>  but not TLR8, was activated by the ligands","sentence":"Two imidazoquinoline molecules, imiquimod and gardiquimod  markedly activated both porcine TLR7 and TLR8 whereas only human TLR7  but not TLR8, was activated by the ligands"}
{"PMID":18439678,"re_id":27,"annotated sentence":"Porcine TLR8 and <e2>TLR7<\\e2> are both activated by a selective TLR7 ligand, <e1>imiquimod<\\e1>  Toll-like receptors (TLRs) are a family of highly conserved germline-encoded pattern-recognition receptors (PRR), which are utilized by the innate immune system to recognize microbial components, known as pathogen-associated molecular patterns (PAMP)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imiquimod","object":"TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Porcine TLR8 and <e2>GENE-Y<\\e2> are both activated by a selective GENE-Y ligand, <e1>CHEMICAL<\\e1>  Toll-like receptors (TLRs) are a family of highly conserved germline-encoded pattern-recognition receptors (PRR), which are utilized by the innate immune system to recognize microbial components, known as pathogen-associated molecular patterns (PAMP)","sentence":"Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod  Toll-like receptors (TLRs) are a family of highly conserved germline-encoded pattern-recognition receptors (PRR), which are utilized by the innate immune system to recognize microbial components, known as pathogen-associated molecular patterns (PAMP)"}
{"PMID":18439678,"re_id":28,"annotated sentence":"Porcine <e2>TLR8<\\e2> and TLR7 are both activated by a selective TLR7 ligand, <e1>imiquimod<\\e1>  Toll-like receptors (TLRs) are a family of highly conserved germline-encoded pattern-recognition receptors (PRR), which are utilized by the innate immune system to recognize microbial components, known as pathogen-associated molecular patterns (PAMP)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"imiquimod","object":"TLR8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Porcine <e2>GENE-Y<\\e2> and TLR7 are both activated by a selective TLR7 ligand, <e1>CHEMICAL<\\e1>  Toll-like receptors (TLRs) are a family of highly conserved germline-encoded pattern-recognition receptors (PRR), which are utilized by the innate immune system to recognize microbial components, known as pathogen-associated molecular patterns (PAMP)","sentence":"Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod  Toll-like receptors (TLRs) are a family of highly conserved germline-encoded pattern-recognition receptors (PRR), which are utilized by the innate immune system to recognize microbial components, known as pathogen-associated molecular patterns (PAMP)"}
{"PMID":18439678,"re_id":29,"annotated sentence":"Moreover, activation of transfected cells and porcine PBMC by <e2>TLR7<\\e2> ligands was inhibited by <e1>bafilomycin A(1)<\\e1> indicating the requirement of endosomal\/lysosomal acidification for activation of the receptors.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bafilomycin A(1)","object":"TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, activation of transfected cells and porcine PBMC by <e2>GENE-Y<\\e2> ligands was inhibited by <e1>CHEMICAL<\\e1> indicating the requirement of endosomal\/lysosomal acidification for activation of the receptors.","sentence":"Moreover, activation of transfected cells and porcine PBMC by TLR7 ligands was inhibited by bafilomycin A(1) indicating the requirement of endosomal\/lysosomal acidification for activation of the receptors."}
{"PMID":18574460,"re_id":5,"annotated sentence":"The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for <e1>4-chloropropofol<\\e1> in <e2>Na(V)1.2<\\e2>  Membrane depolarization inducing inactivation strongly increased the blocking potency of all compounds","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"4-chloropropofol","object":"Na(V)1.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for <e1>CHEMICAL<\\e1> in <e2>GENE-Y<\\e2>  Membrane depolarization inducing inactivation strongly increased the blocking potency of all compounds","sentence":"The IC(50) for block of resting channels at -150 mV was 2.3, 3.9 and 11.3 microM in Na(V)1.4, respectively, and 29.2 microM for 4-chloropropofol in Na(V)1.2  Membrane depolarization inducing inactivation strongly increased the blocking potency of all compounds"}
{"PMID":18574460,"re_id":6,"annotated sentence":"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for <e1>4-iodopropofol<\\e1>  4-bromopropofol and 4-chloropropofol in <e2>Na(V)1.4<\\e2>  and 450 nM for 4-chloropropofol in Na(V)1.2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"4-iodopropofol","object":"Na(V)1.4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for <e1>CHEMICAL<\\e1>  4-bromopropofol and 4-chloropropofol in <e2>GENE-Y<\\e2>  and 450 nM for 4-chloropropofol in Na(V)1.2","sentence":"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol  4-bromopropofol and 4-chloropropofol in Na(V)1.4  and 450 nM for 4-chloropropofol in Na(V)1.2"}
{"PMID":18574460,"re_id":7,"annotated sentence":"High-affinity blockade of <e2>voltage-operated skeletal muscle and neuronal sodium channels<\\e2> by <e1>halogenated propofol<\\e1> analogues","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"halogenated propofol","object":"voltage-operated skeletal muscle and neuronal sodium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"High-affinity blockade of <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1> analogues","sentence":"High-affinity blockade of voltage-operated skeletal muscle and neuronal sodium channels by halogenated propofol analogues"}
{"PMID":18574460,"re_id":8,"annotated sentence":"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, <e1>4-bromopropofol<\\e1> and 4-chloropropofol in <e2>Na(V)1.4<\\e2>  and 450 nM for 4-chloropropofol in Na(V)1.2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"4-bromopropofol","object":"Na(V)1.4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, <e1>CHEMICAL<\\e1> and 4-chloropropofol in <e2>GENE-Y<\\e2>  and 450 nM for 4-chloropropofol in Na(V)1.2","sentence":"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4  and 450 nM for 4-chloropropofol in Na(V)1.2"}
{"PMID":18574460,"re_id":9,"annotated sentence":"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and <e1>4-chloropropofol<\\e1> in <e2>Na(V)1.4<\\e2>  and 450 nM for 4-chloropropofol in Na(V)1.2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"4-chloropropofol","object":"Na(V)1.4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and <e1>CHEMICAL<\\e1> in <e2>GENE-Y<\\e2>  and 450 nM for CHEMICAL in Na(V)1.2","sentence":"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4  and 450 nM for 4-chloropropofol in Na(V)1.2"}
{"PMID":18574460,"re_id":10,"annotated sentence":"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for <e1>4-chloropropofol<\\e1> in <e2>Na(V)1.2<\\e2>  Recovery from fast inactivation was prolonged in the presence of drug leading to an accumulation of block during repetitive stimulation at high frequencies (100 Hz)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"4-chloropropofol","object":"Na(V)1.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and CHEMICAL in Na(V)1.4, and 450 nM for <e1>CHEMICAL<\\e1> in <e2>GENE-Y<\\e2>  Recovery from fast inactivation was prolonged in the presence of drug leading to an accumulation of block during repetitive stimulation at high frequencies (100 Hz)","sentence":"Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for 4-chloropropofol in Na(V)1.2  Recovery from fast inactivation was prolonged in the presence of drug leading to an accumulation of block during repetitive stimulation at high frequencies (100 Hz)"}
{"PMID":18574460,"re_id":11,"annotated sentence":"CONCLUSIONS AND IMPLICATIONS: <e1>Halogenated propofol<\\e1> analogues constitute a novel class of <e2>sodium channel<\\e2> blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Halogenated propofol","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS AND IMPLICATIONS: <e1>CHEMICAL<\\e1> analogues constitute a novel class of <e2>GENE-N<\\e2> blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine","sentence":"CONCLUSIONS AND IMPLICATIONS: Halogenated propofol analogues constitute a novel class of sodium channel blocking drugs possessing almost 100-fold higher potency compared with the local anaesthetic and anti-arrhythmic drug lidocaine"}
{"PMID":18627212,"re_id":0,"annotated sentence":"<e1>Irbesartan<\\e1> (Aprovel, Avapro, Irbetan, Karvea), an <e2>angiotensin II receptor type 1<\\e2> antagonist, is approved in many countries worldwide for the treatment of hypertension","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Irbesartan","object":"angiotensin II receptor type 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Aprovel, Avapro, Irbetan, Karvea), an <e2>GENE-Y<\\e2> antagonist, is approved in many countries worldwide for the treatment of hypertension","sentence":"Irbesartan (Aprovel, Avapro, Irbetan, Karvea), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension"}
{"PMID":18627212,"re_id":1,"annotated sentence":"Irbesartan (<e1>Aprovel<\\e1>  Avapro, Irbetan, Karvea), an <e2>angiotensin II receptor type 1<\\e2> antagonist, is approved in many countries worldwide for the treatment of hypertension","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Aprovel","object":"angiotensin II receptor type 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Irbesartan (<e1>CHEMICAL<\\e1>  Avapro, Irbetan, Karvea), an <e2>GENE-Y<\\e2> antagonist, is approved in many countries worldwide for the treatment of hypertension","sentence":"Irbesartan (Aprovel  Avapro, Irbetan, Karvea), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension"}
{"PMID":18627212,"re_id":2,"annotated sentence":"Irbesartan (Aprovel, <e1>Avapro<\\e1>  Irbetan, Karvea), an <e2>angiotensin II receptor type 1<\\e2> antagonist, is approved in many countries worldwide for the treatment of hypertension","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Avapro","object":"angiotensin II receptor type 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Irbesartan (Aprovel, <e1>CHEMICAL<\\e1>  Irbetan, Karvea), an <e2>GENE-Y<\\e2> antagonist, is approved in many countries worldwide for the treatment of hypertension","sentence":"Irbesartan (Aprovel, Avapro  Irbetan, Karvea), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension"}
{"PMID":18627212,"re_id":3,"annotated sentence":"Irbesartan (Aprovel, Avapro, <e1>Irbetan<\\e1>  Karvea), an <e2>angiotensin II receptor type 1<\\e2> antagonist, is approved in many countries worldwide for the treatment of hypertension","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Irbetan","object":"angiotensin II receptor type 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Irbesartan (Aprovel, Avapro, <e1>CHEMICAL<\\e1>  Karvea), an <e2>GENE-Y<\\e2> antagonist, is approved in many countries worldwide for the treatment of hypertension","sentence":"Irbesartan (Aprovel, Avapro, Irbetan  Karvea), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension"}
{"PMID":18627212,"re_id":4,"annotated sentence":"Irbesartan (Aprovel, Avapro, Irbetan, <e1>Karvea<\\e1> , an <e2>angiotensin II receptor type 1<\\e2> antagonist, is approved in many countries worldwide for the treatment of hypertension","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Karvea","object":"angiotensin II receptor type 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Irbesartan (Aprovel, Avapro, Irbetan, <e1>CHEMICAL<\\e1> , an <e2>GENE-Y<\\e2> antagonist, is approved in many countries worldwide for the treatment of hypertension","sentence":"Irbesartan (Aprovel, Avapro, Irbetan, Karvea , an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension"}
{"PMID":18773878,"re_id":5,"annotated sentence":"<e1>RTX<\\e1> treatment also induced foci of <e2>RAD51<\\e2>  gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"RTX","object":"RAD51","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment also induced foci of <e2>GENE-Y<\\e2>  gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied","sentence":"RTX treatment also induced foci of RAD51  gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied"}
{"PMID":18773878,"re_id":6,"annotated sentence":"<e1>RTX<\\e1> treatment also induced foci of RAD51, <e2>gamma-H2AX<\\e2>  phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"RTX","object":"gamma-H2AX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment also induced foci of RAD51, <e2>GENE-Y<\\e2>  phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied","sentence":"RTX treatment also induced foci of RAD51, gamma-H2AX  phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied"}
{"PMID":18773878,"re_id":7,"annotated sentence":"<e1>RTX<\\e1> treatment also induced foci of RAD51, gamma-H2AX, <e2>phospho-Chk1<\\e2>  and phospho-NBS1, although the extent of co-localization with RPA2 foci varied","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"RTX","object":"phospho-Chk1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment also induced foci of RAD51, gamma-H2AX, <e2>GENE-Y<\\e2>  and phospho-NBS1, although the extent of co-localization with RPA2 foci varied","sentence":"RTX treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1  and phospho-NBS1, although the extent of co-localization with RPA2 foci varied"}
{"PMID":18773878,"re_id":8,"annotated sentence":"<e1>RTX<\\e1> treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and <e2>phospho-NBS1<\\e2>  although the extent of co-localization with RPA2 foci varied","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"RTX","object":"phospho-NBS1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and <e2>GENE-Y<\\e2>  although the extent of co-localization with RPA2 foci varied","sentence":"RTX treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and phospho-NBS1  although the extent of co-localization with RPA2 foci varied"}
{"PMID":18773878,"re_id":9,"annotated sentence":"When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed (<e1>RTX<\\e1> , which specifically inhibits <e2>TS<\\e2>  To our knowledge, this is the first demonstration in mammalian cells that depletion of RAD51 causes sensitivity to thymidylate deprivation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"RTX","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed (<e1>CHEMICAL<\\e1> , which specifically inhibits <e2>GENE-Y<\\e2>  To our knowledge, this is the first demonstration in mammalian cells that depletion of RAD51 causes sensitivity to thymidylate deprivation","sentence":"When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed (RTX , which specifically inhibits TS  To our knowledge, this is the first demonstration in mammalian cells that depletion of RAD51 causes sensitivity to thymidylate deprivation"}
{"PMID":18773878,"re_id":10,"annotated sentence":"DNA damage is accepted as a consequence of <e1>thymidylate<\\e1> deprivation induced by chemotherapeutic inhibitors of <e2>thymidylate synthase<\\e2> (TS), but the types of damage and signaling responses remain incompletely understood","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"thymidylate","object":"thymidylate synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"DNA damage is accepted as a consequence of <e1>CHEMICAL<\\e1> deprivation induced by chemotherapeutic inhibitors of <e2>CHEMICAL synthase<\\e2> (TS), but the types of damage and signaling responses remain incompletely understood","sentence":"DNA damage is accepted as a consequence of thymidylate deprivation induced by chemotherapeutic inhibitors of thymidylate synthase (TS), but the types of damage and signaling responses remain incompletely understood"}
{"PMID":18773878,"re_id":11,"annotated sentence":"DNA damage is accepted as a consequence of <e1>thymidylate<\\e1> deprivation induced by chemotherapeutic inhibitors of thymidylate synthase (<e2>TS<\\e2> , but the types of damage and signaling responses remain incompletely understood","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"thymidylate","object":"TS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"DNA damage is accepted as a consequence of <e1>CHEMICAL<\\e1> deprivation induced by chemotherapeutic inhibitors of CHEMICAL synthase (<e2>GENE-Y<\\e2> , but the types of damage and signaling responses remain incompletely understood","sentence":"DNA damage is accepted as a consequence of thymidylate deprivation induced by chemotherapeutic inhibitors of thymidylate synthase (TS , but the types of damage and signaling responses remain incompletely understood"}
{"PMID":18996527,"re_id":1,"annotated sentence":"Nicotinic acid (<e1>NA<\\e1> , a widely used drug to lower elevated plasma lipid levels, induced <e2>NNMT<\\e2> enzyme activity in white adipose tissue of mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":null,"object":"NNMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nicotinic acid (<e1>NA<\\e1> , a widely used drug to lower elevated plasma lipid levels, induced <e2>GENE-Y<\\e2> enzyme activity in white adipose tissue of mice","sentence":"Nicotinic acid (NA , a widely used drug to lower elevated plasma lipid levels, induced NNMT enzyme activity in white adipose tissue of mice"}
{"PMID":18996527,"re_id":2,"annotated sentence":"<e1>Nicotinic acid<\\e1> (NA), a widely used drug to lower elevated plasma lipid levels, induced <e2>NNMT<\\e2> enzyme activity in white adipose tissue of mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Nicotinic acid","object":"NNMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (NA), a widely used drug to lower elevated plasma lipid levels, induced <e2>GENE-Y<\\e2> enzyme activity in white adipose tissue of mice","sentence":"Nicotinic acid (NA), a widely used drug to lower elevated plasma lipid levels, induced NNMT enzyme activity in white adipose tissue of mice"}
{"PMID":18996527,"re_id":3,"annotated sentence":"Homocysteine release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the <e2>NNMT<\\e2> inhibitor <e1>1-methylnicotinamide<\\e1>  Nicotinic acid (NA), a widely used drug to lower elevated plasma lipid levels, induced NNMT enzyme activity in white adipose tissue of mice","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"1-methylnicotinamide","object":"NNMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Homocysteine release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  Nicotinic acid (NA), a widely used drug to lower elevated plasma lipid levels, induced GENE-Y enzyme activity in white adipose tissue of mice","sentence":"Homocysteine release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the NNMT inhibitor 1-methylnicotinamide  Nicotinic acid (NA), a widely used drug to lower elevated plasma lipid levels, induced NNMT enzyme activity in white adipose tissue of mice"}
{"PMID":18996527,"re_id":4,"annotated sentence":"<e2>Nicotinamide N-methyltransferase<\\e2> (NNMT) catalyses the conversion of nicotinamide to <e1>1-methylnicotinamide<\\e1> and plays an important role in hepatic detoxification reactions","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"1-methylnicotinamide","object":"Nicotinamide N-methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (NNMT) catalyses the conversion of nicotinamide to <e1>CHEMICAL<\\e1> and plays an important role in hepatic detoxification reactions","sentence":"Nicotinamide N-methyltransferase (NNMT) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions"}
{"PMID":18996527,"re_id":5,"annotated sentence":"Nicotinamide N-methyltransferase (<e2>NNMT<\\e2>  catalyses the conversion of nicotinamide to <e1>1-methylnicotinamide<\\e1> and plays an important role in hepatic detoxification reactions","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"1-methylnicotinamide","object":"NNMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nicotinamide N-methyltransferase (<e2>GENE-Y<\\e2>  catalyses the conversion of nicotinamide to <e1>CHEMICAL<\\e1> and plays an important role in hepatic detoxification reactions","sentence":"Nicotinamide N-methyltransferase (NNMT  catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions"}
{"PMID":18996527,"re_id":6,"annotated sentence":"These data support the concept that adipose tissue <e2>NNMT<\\e2> contributes to the increased plasma <e1>homocysteine<\\e1> levels in patients treated with NA.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"homocysteine","object":"NNMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data support the concept that adipose tissue <e2>GENE-Y<\\e2> contributes to the increased plasma <e1>CHEMICAL<\\e1> levels in patients treated with NA.","sentence":"These data support the concept that adipose tissue NNMT contributes to the increased plasma homocysteine levels in patients treated with NA."}
{"PMID":18996527,"re_id":7,"annotated sentence":"<e1>Homocysteine<\\e1>  the atherogenic product of the <e2>NNMT<\\e2> catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"Homocysteine","object":"NNMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  the atherogenic product of the <e2>GENE-Y<\\e2> catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures","sentence":"Homocysteine  the atherogenic product of the NNMT catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures"}
{"PMID":18996527,"re_id":8,"annotated sentence":"<e2>Nicotinamide N-methyltransferase<\\e2> (NNMT) catalyses the conversion of <e1>nicotinamide<\\e1> to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"nicotinamide","object":"Nicotinamide N-methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (NNMT) catalyses the conversion of <e1>CHEMICAL<\\e1> to 1-methylCHEMICAL and plays an important role in hepatic detoxification reactions","sentence":"Nicotinamide N-methyltransferase (NNMT) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions"}
{"PMID":18996527,"re_id":9,"annotated sentence":"Nicotinamide N-methyltransferase (<e2>NNMT<\\e2>  catalyses the conversion of <e1>nicotinamide<\\e1> to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"nicotinamide","object":"NNMT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Nicotinamide N-methyltransferase (<e2>GENE-Y<\\e2>  catalyses the conversion of <e1>CHEMICAL<\\e1> to 1-methylCHEMICAL and plays an important role in hepatic detoxification reactions","sentence":"Nicotinamide N-methyltransferase (NNMT  catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions"}
{"PMID":19039322,"re_id":5,"annotated sentence":"A comparison of bosutinib with <e1>dasatinib<\\e1> across the whole <e2>kinase<\\e2> panel revealed overlapping, but distinct, inhibition profiles","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dasatinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A comparison of bosutinib with <e1>CHEMICAL<\\e1> across the whole <e2>GENE-N<\\e2> panel revealed overlapping, but distinct, inhibition profiles","sentence":"A comparison of bosutinib with dasatinib across the whole kinase panel revealed overlapping, but distinct, inhibition profiles"}
{"PMID":19039322,"re_id":6,"annotated sentence":"Global target profile of the <e2>kinase<\\e2> inhibitor <e1>bosutinib<\\e1> in primary chronic myeloid leukemia cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bosutinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Global target profile of the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> in primary chronic myeloid leukemia cells","sentence":"Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells"}
{"PMID":19039322,"re_id":7,"annotated sentence":"Finally, <e1>bosutinib<\\e1> is the first <e2>kinase<\\e2> inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bosutinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Finally, <e1>CHEMICAL<\\e1> is the first <e2>GENE-N<\\e2> inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.","sentence":"Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation."}
{"PMID":19039322,"re_id":8,"annotated sentence":"Finally, <e1>bosutinib<\\e1> is the first kinase inhibitor shown to target <e2>CAMK2G<\\e2>  recently implicated in myeloid leukemia cell proliferation.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bosutinib","object":"CAMK2G","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, <e1>CHEMICAL<\\e1> is the first kinase inhibitor shown to target <e2>GENE-Y<\\e2>  recently implicated in myeloid leukemia cell proliferation.","sentence":"Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G  recently implicated in myeloid leukemia cell proliferation."}
{"PMID":19039322,"re_id":9,"annotated sentence":"Here, we characterized the target profile of the dual <e2>SRC<\\e2> ABL inhibitor <e1>bosutinib<\\e1> employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bosutinib","object":"SRC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we characterized the target profile of the dual <e2>GENE-Y<\\e2> ABL inhibitor <e1>CHEMICAL<\\e1> employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel","sentence":"Here, we characterized the target profile of the dual SRC ABL inhibitor bosutinib employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel"}
{"PMID":19039322,"re_id":10,"annotated sentence":"Here, we characterized the target profile of the dual SRC\/<e2>ABL<\\e2> inhibitor <e1>bosutinib<\\e1> employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bosutinib","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we characterized the target profile of the dual SRC\/<e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel","sentence":"Here, we characterized the target profile of the dual SRC\/ABL inhibitor bosutinib employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel"}
{"PMID":19039322,"re_id":11,"annotated sentence":"A comparison of <e1>bosutinib<\\e1> with dasatinib across the whole <e2>kinase<\\e2> panel revealed overlapping, but distinct, inhibition profiles","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bosutinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A comparison of <e1>CHEMICAL<\\e1> with dasatinib across the whole <e2>GENE-N<\\e2> panel revealed overlapping, but distinct, inhibition profiles","sentence":"A comparison of bosutinib with dasatinib across the whole kinase panel revealed overlapping, but distinct, inhibition profiles"}
{"PMID":1911436,"re_id":7,"annotated sentence":"The affinity labeling <e1>nucleotide<\\e1> analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the <e2>dehydrogenase<\\e2> and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nucleotide","object":"dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The affinity labeling <e1>CHEMICAL<\\e1> analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the <e2>GENE-N<\\e2> and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)","sentence":"The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the dehydrogenase and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)"}
{"PMID":1911436,"re_id":8,"annotated sentence":"The affinity labeling nucleotide analog, <e1>5'-[p-(fluorosulfonyl)benzoyl]adenosine<\\e1> (FSA), inactivates the <e2>dehydrogenase<\\e2> and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"5'-[p-(fluorosulfonyl)benzoyl]adenosine","object":"dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The affinity labeling nucleotide analog, <e1>CHEMICAL<\\e1> (FSA), inactivates the <e2>GENE-N<\\e2> and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)","sentence":"The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA), inactivates the dehydrogenase and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)"}
{"PMID":1911436,"re_id":9,"annotated sentence":"The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (<e1>FSA<\\e1> , inactivates the <e2>dehydrogenase<\\e2> and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"FSA","object":"dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (<e1>CHEMICAL<\\e1> , inactivates the <e2>GENE-N<\\e2> and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)","sentence":"The affinity labeling nucleotide analog, 5'-[p-(fluorosulfonyl)benzoyl]adenosine (FSA , inactivates the dehydrogenase and isomerase activities at similar rates in an irreversible manner which follows first order kinetics with respect to both time and alkylator concentration (0.2-0.6 mM)"}
{"PMID":1911436,"re_id":10,"annotated sentence":"The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as <e2>dehydrogenase<\\e2> from inactivation by <e1>FSA<\\e1>  These observations are evidence for a single cofactor binding region which services both enzyme activities.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"FSA","object":"dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as <e2>GENE-N<\\e2> from inactivation by <e1>CHEMICAL<\\e1>  These observations are evidence for a single cofactor binding region which services both enzyme activities.","sentence":"The 3 beta-hydroxysteroid substrate, pregnenolone, protects isomerase as well as dehydrogenase from inactivation by FSA  These observations are evidence for a single cofactor binding region which services both enzyme activities."}
{"PMID":1911436,"re_id":14,"annotated sentence":"Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the <e2>dehydrogenase<\\e2> and isomerase substrate <e1>steroids<\\e1> bind at different sites on the same protein","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"steroids","object":"dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the <e2>GENE-N<\\e2> and isomerase substrate <e1>CHEMICAL<\\e1> bind at different sites on the same protein","sentence":"Affinity alkylation with 2 alpha-bromoacetoxyprogesterone suggests that the dehydrogenase and isomerase substrate steroids bind at different sites on the same protein"}
{"PMID":19149483,"re_id":0,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (<e1>SU 11248<\\e1>  Sutent) specific for <e2>VEGF receptor<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SU 11248","object":"VEGF receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (<e1>CHEMICAL<\\e1>  Sutent) specific for <e2>GENE-N<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248  Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":1,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (<e1>SU 11248<\\e1>  Sutent) specific for VEGF receptor <e2>kinase<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SU 11248","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others GENE-N inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic GENE-N, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (<e1>CHEMICAL<\\e1>  Sutent) specific for VEGF receptor <e2>GENE-N<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT GENE-N","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248  Sutent) specific for VEGF receptor kinase  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":2,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, <e1>Sutent<\\e1>  specific for <e2>VEGF receptor<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sutent","object":"VEGF receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, <e1>CHEMICAL<\\e1>  specific for <e2>GENE-N<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent  specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":3,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, <e1>Sutent<\\e1>  specific for VEGF receptor <e2>kinase<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sutent","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others GENE-N inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic GENE-N, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, <e1>CHEMICAL<\\e1>  specific for VEGF receptor <e2>GENE-N<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT GENE-N","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent  specific for VEGF receptor kinase  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":4,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, <e1>AMN107<\\e1> (Nilotinib) and INNO-406 (NS-187) specific for <e2>c-KIT<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AMN107","object":"c-KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, <e1>CHEMICAL<\\e1> (Nilotinib) and INNO-406 (NS-187) specific for <e2>GENE-Y<\\e2> kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":5,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (<e1>Nilotinib<\\e1>  and INNO-406 (NS-187) specific for <e2>c-KIT<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Nilotinib","object":"c-KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (<e1>CHEMICAL<\\e1>  and INNO-406 (NS-187) specific for <e2>GENE-Y<\\e2> kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib  and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":6,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and <e1>INNO-406<\\e1> (NS-187) specific for <e2>c-KIT<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"INNO-406","object":"c-KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and <e1>CHEMICAL<\\e1> (NS-187) specific for <e2>GENE-Y<\\e2> kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":7,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (<e1>NS-187<\\e1>  specific for <e2>c-KIT<\\e2> kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NS-187","object":"c-KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (<e1>CHEMICAL<\\e1>  specific for <e2>GENE-Y<\\e2> kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187  specific for c-KIT kinase"}
{"PMID":19149483,"re_id":8,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: <e1>Lapatinib<\\e1> (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Lapatinib","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: <e1>CHEMICAL<\\e1> (CHEMICAL ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PGENE-N787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":9,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (<e1>Lapatinib ditosylate<\\e1>  Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Lapatinib ditosylate","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (<e1>CHEMICAL<\\e1>  Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PGENE-N787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate  Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":10,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, <e1>Tykerb<\\e1>  GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Tykerb","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, <e1>CHEMICAL<\\e1>  GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PGENE-N787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb  GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":11,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, <e1>GW-572016<\\e1> , Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GW-572016","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, <e1>CHEMICAL<\\e1> , Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PGENE-N787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016 , Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":12,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), <e1>Canertinib<\\e1> (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Canertinib","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), <e1>CHEMICAL<\\e1> (CI-1033), Zactima (ZD6474), Vatalanib (PGENE-N787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":13,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (<e1>CI-1033<\\e1> , Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CI-1033","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (<e1>CHEMICAL<\\e1> , Zactima (ZD6474), Vatalanib (PGENE-N787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033 , Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":14,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), <e1>Zactima<\\e1> (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Zactima","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), <e1>CHEMICAL<\\e1> (ZD6474), Vatalanib (PGENE-N787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":15,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (<e1>ZD6474<\\e1> , Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ZD6474","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (<e1>CHEMICAL<\\e1> , Vatalanib (PGENE-N787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474 , Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":16,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), <e1>Vatalanib<\\e1> (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Vatalanib","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), <e1>CHEMICAL<\\e1> (PGENE-N787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":17,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (<e1>PTK787<\\e1> ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PTK787","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (<e1>CHEMICAL<\\e1> ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787 ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":18,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/<e1>ZK 222584<\\e1> , Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ZK 222584","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PGENE-N787\/<e1>CHEMICAL<\\e1> , Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584 , Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":19,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), <e1>Sorafenib<\\e1> (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sorafenib","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PGENE-N787\/ZK 222584), <e1>CHEMICAL<\\e1> (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":20,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (<e1>Bay 43-9006<\\e1>  Nexavar), and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Bay 43-9006","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PGENE-N787\/ZK 222584), Sorafenib (<e1>CHEMICAL<\\e1>  Nexavar), and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006  Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":21,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, <e1>Nexavar<\\e1> , and Leflunomide (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Nexavar","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PGENE-N787\/ZK 222584), Sorafenib (Bay 43-9006, <e1>CHEMICAL<\\e1> , and Leflunomide (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar , and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":22,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include <e1>Dasatinib<\\e1> (BMS-354825) specific for <e2>ABL<\\e2> non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Dasatinib","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Others kinase inhibitors used recently in cancer therapy include <e1>CHEMICAL<\\e1> (BMS-354825) specific for <e2>GENE-Y<\\e2> non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":23,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include <e1>Dasatinib<\\e1> (BMS-354825) specific for ABL <e2>non-receptor cytoplasmic kinase<\\e2>  Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Dasatinib","object":"non-receptor cytoplasmic kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others kinase inhibitors used recently in cancer therapy include <e1>CHEMICAL<\\e1> (BMS-354825) specific for ABL <e2>GENE-N<\\e2>  Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase  Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":24,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and <e1>Leflunomide<\\e1> (SU101, Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Leflunomide","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PGENE-N787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and <e1>CHEMICAL<\\e1> (SU101, Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava)"}
{"PMID":19149483,"re_id":25,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (<e1>SU101<\\e1>  Arava)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SU101","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PGENE-N787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (<e1>CHEMICAL<\\e1>  Arava)","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101  Arava)"}
{"PMID":19149483,"re_id":26,"annotated sentence":"The following <e2>TK<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, <e1>Arava<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Arava","object":"TK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The following <e2>GENE-N<\\e2> blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PGENE-N787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, <e1>CHEMICAL<\\e1> ","sentence":"The following TK blockers for treatment of various human tumors are in clinical development: Lapatinib (Lapatinib ditosylate, Tykerb, GW-572016), Canertinib (CI-1033), Zactima (ZD6474), Vatalanib (PTK787\/ZK 222584), Sorafenib (Bay 43-9006, Nexavar), and Leflunomide (SU101, Arava "}
{"PMID":19149483,"re_id":27,"annotated sentence":"The most successful example of <e2>kinase<\\e2> blockers is <e1>Imatinib<\\e1> (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The most successful example of <e2>GENE-N<\\e2> blockers is <e1>CHEMICAL<\\e1> (CHEMICAL mesylate, Gleevec, STI571), the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia"}
{"PMID":19149483,"re_id":28,"annotated sentence":"The most successful example of kinase blockers is <e1>Imatinib<\\e1> (Imatinib mesylate, Gleevec, STI571), the inhibitor of <e2>Bcr<\\e2> Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib","object":"Bcr","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most successful example of kinase blockers is <e1>CHEMICAL<\\e1> (CHEMICAL mesylate, Gleevec, STI571), the inhibitor of <e2>GENE-Y<\\e2> Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia"}
{"PMID":19149483,"re_id":29,"annotated sentence":"The most successful example of kinase blockers is <e1>Imatinib<\\e1> (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr\/<e2>Abl<\\e2> oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib","object":"Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most successful example of kinase blockers is <e1>CHEMICAL<\\e1> (CHEMICAL mesylate, Gleevec, STI571), the inhibitor of Bcr\/<e2>GENE-Y<\\e2> oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, STI571), the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia"}
{"PMID":19149483,"re_id":30,"annotated sentence":"The most successful example of <e2>kinase<\\e2> blockers is Imatinib (<e1>Imatinib mesylate<\\e1>  Gleevec, STI571), the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib mesylate","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The most successful example of <e2>GENE-N<\\e2> blockers is Imatinib (<e1>CHEMICAL<\\e1>  Gleevec, STI571), the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate  Gleevec, STI571), the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia"}
{"PMID":19149483,"re_id":31,"annotated sentence":"The most successful example of kinase blockers is Imatinib (<e1>Imatinib mesylate<\\e1>  Gleevec, STI571), the inhibitor of <e2>Bcr<\\e2> Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib mesylate","object":"Bcr","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most successful example of kinase blockers is Imatinib (<e1>CHEMICAL<\\e1>  Gleevec, STI571), the inhibitor of <e2>GENE-Y<\\e2> Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate  Gleevec, STI571), the inhibitor of Bcr Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia"}
{"PMID":19149483,"re_id":32,"annotated sentence":"The most successful example of kinase blockers is Imatinib (<e1>Imatinib mesylate<\\e1>  Gleevec, STI571), the inhibitor of Bcr\/<e2>Abl<\\e2> oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imatinib mesylate","object":"Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most successful example of kinase blockers is Imatinib (<e1>CHEMICAL<\\e1>  Gleevec, STI571), the inhibitor of Bcr\/<e2>GENE-Y<\\e2> oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate  Gleevec, STI571), the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia"}
{"PMID":19149483,"re_id":33,"annotated sentence":"The most successful example of <e2>kinase<\\e2> blockers is Imatinib (Imatinib mesylate, <e1>Gleevec<\\e1>  STI571), the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gleevec","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The most successful example of <e2>GENE-N<\\e2> blockers is Imatinib (Imatinib mesylate, <e1>CHEMICAL<\\e1>  STI571), the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec  STI571), the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia"}
{"PMID":19149483,"re_id":34,"annotated sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, <e1>Gleevec<\\e1>  STI571), the inhibitor of <e2>Bcr<\\e2> Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gleevec","object":"Bcr","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, <e1>CHEMICAL<\\e1>  STI571), the inhibitor of <e2>GENE-Y<\\e2> Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec  STI571), the inhibitor of Bcr Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia"}
{"PMID":19149483,"re_id":35,"annotated sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, <e1>Gleevec<\\e1>  STI571), the inhibitor of Bcr\/<e2>Abl<\\e2> oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gleevec","object":"Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, <e1>CHEMICAL<\\e1>  STI571), the inhibitor of Bcr\/<e2>GENE-Y<\\e2> oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec  STI571), the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia"}
{"PMID":19149483,"re_id":36,"annotated sentence":"The most successful example of <e2>kinase<\\e2> blockers is Imatinib (Imatinib mesylate, Gleevec, <e1>STI571<\\e1> , the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"STI571","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The most successful example of <e2>GENE-N<\\e2> blockers is Imatinib (Imatinib mesylate, Gleevec, <e1>CHEMICAL<\\e1> , the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, STI571 , the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia"}
{"PMID":19149483,"re_id":37,"annotated sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, <e1>STI571<\\e1> , the inhibitor of <e2>Bcr<\\e2> Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"STI571","object":"Bcr","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, <e1>CHEMICAL<\\e1> , the inhibitor of <e2>GENE-Y<\\e2> Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, STI571 , the inhibitor of Bcr Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia"}
{"PMID":19149483,"re_id":38,"annotated sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, <e1>STI571<\\e1> , the inhibitor of Bcr\/<e2>Abl<\\e2> oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"STI571","object":"Abl","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, <e1>CHEMICAL<\\e1> , the inhibitor of Bcr\/<e2>GENE-Y<\\e2> oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia","sentence":"The most successful example of kinase blockers is Imatinib (Imatinib mesylate, Gleevec, STI571 , the inhibitor of Bcr\/Abl oncoprotein, which has become a first-line therapy for chronic myelogenous leukemia"}
{"PMID":19149483,"re_id":39,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (<e1>BMS-354825<\\e1>  specific for <e2>ABL<\\e2> non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"BMS-354825","object":"ABL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (<e1>CHEMICAL<\\e1>  specific for <e2>GENE-Y<\\e2> non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825  specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":40,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, <e1>Gefitinib<\\e1> (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for <e2>VEGF receptor<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gefitinib","object":"VEGF receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, <e1>CHEMICAL<\\e1> (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for <e2>GENE-N<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":41,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, <e1>Gefitinib<\\e1> (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor <e2>kinase<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gefitinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others GENE-N inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic GENE-N, <e1>CHEMICAL<\\e1> (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor <e2>GENE-N<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT GENE-N","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":42,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (<e1>Iressa<\\e1> , Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for <e2>VEGF receptor<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Iressa","object":"VEGF receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (<e1>CHEMICAL<\\e1> , Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for <e2>GENE-N<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa , Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":43,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (<e1>Iressa<\\e1> , Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor <e2>kinase<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Iressa","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others GENE-N inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic GENE-N, Gefitinib (<e1>CHEMICAL<\\e1> , Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor <e2>GENE-N<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT GENE-N","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa , Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":44,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), <e1>Erlotinib<\\e1> (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for <e2>VEGF receptor<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Erlotinib","object":"VEGF receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), <e1>CHEMICAL<\\e1> (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for <e2>GENE-N<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":45,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), <e1>Erlotinib<\\e1> (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor <e2>kinase<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Erlotinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others GENE-N inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic GENE-N, Gefitinib (Iressa), <e1>CHEMICAL<\\e1> (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor <e2>GENE-N<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT GENE-N","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":46,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (<e1>OSI-774<\\e1>  Tarceva) and Sunitinib (SU 11248, Sutent) specific for <e2>VEGF receptor<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"OSI-774","object":"VEGF receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (<e1>CHEMICAL<\\e1>  Tarceva) and Sunitinib (SU 11248, Sutent) specific for <e2>GENE-N<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774  Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":47,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (<e1>OSI-774<\\e1>  Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor <e2>kinase<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"OSI-774","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others GENE-N inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic GENE-N, Gefitinib (Iressa), Erlotinib (<e1>CHEMICAL<\\e1>  Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor <e2>GENE-N<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT GENE-N","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774  Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":48,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, <e1>Tarceva<\\e1>  and Sunitinib (SU 11248, Sutent) specific for <e2>VEGF receptor<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Tarceva","object":"VEGF receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, <e1>CHEMICAL<\\e1>  and Sunitinib (SU 11248, Sutent) specific for <e2>GENE-N<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva  and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":49,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, <e1>Tarceva<\\e1>  and Sunitinib (SU 11248, Sutent) specific for VEGF receptor <e2>kinase<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Tarceva","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others GENE-N inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic GENE-N, Gefitinib (Iressa), Erlotinib (OSI-774, <e1>CHEMICAL<\\e1>  and Sunitinib (SU 11248, Sutent) specific for VEGF receptor <e2>GENE-N<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT GENE-N","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva  and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":50,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and <e1>Sunitinib<\\e1> (SU 11248, Sutent) specific for <e2>VEGF receptor<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sunitinib","object":"VEGF receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and <e1>CHEMICAL<\\e1> (SU 11248, Sutent) specific for <e2>GENE-N<\\e2> kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase, AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19149483,"re_id":51,"annotated sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and <e1>Sunitinib<\\e1> (SU 11248, Sutent) specific for VEGF receptor <e2>kinase<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sunitinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Others GENE-N inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic GENE-N, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and <e1>CHEMICAL<\\e1> (SU 11248, Sutent) specific for VEGF receptor <e2>GENE-N<\\e2>  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT GENE-N","sentence":"Others kinase inhibitors used recently in cancer therapy include Dasatinib (BMS-354825) specific for ABL non-receptor cytoplasmic kinase, Gefitinib (Iressa), Erlotinib (OSI-774, Tarceva) and Sunitinib (SU 11248, Sutent) specific for VEGF receptor kinase  AMN107 (Nilotinib) and INNO-406 (NS-187) specific for c-KIT kinase"}
{"PMID":19300583,"re_id":1,"annotated sentence":"Currently, the use of orally administered <e2>MAO<\\e2> inhibitor antidepressants (eg, <e1>phenelzine<\\e1>  tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the \"cheese reaction\") when combined with dietary tyramine","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"phenelzine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Currently, the use of orally administered <e2>GENE-N<\\e2> inhibitor antidepressants (eg, <e1>CHEMICAL<\\e1>  tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the \"cheese reaction\") when combined with dietary tyramine","sentence":"Currently, the use of orally administered MAO inhibitor antidepressants (eg, phenelzine  tranylcypromine) is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the \"cheese reaction\") when combined with dietary tyramine"}
{"PMID":19300583,"re_id":2,"annotated sentence":"Currently, the use of orally administered <e2>MAO<\\e2> inhibitor antidepressants (eg, phenelzine, <e1>tranylcypromine<\\e1>  is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the \"cheese reaction\") when combined with dietary tyramine","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"tranylcypromine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Currently, the use of orally administered <e2>GENE-N<\\e2> inhibitor antidepressants (eg, phenelzine, <e1>CHEMICAL<\\e1>  is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the \"cheese reaction\") when combined with dietary tyramine","sentence":"Currently, the use of orally administered MAO inhibitor antidepressants (eg, phenelzine, tranylcypromine  is limited by the risk of tyramine-provoked events (eg, acute hypertension and headache, also known as the \"cheese reaction\") when combined with dietary tyramine"}
{"PMID":19445548,"re_id":2,"annotated sentence":"<e2>CYP2D6<\\e2> inhibitors, such as <e1>paroxetine<\\e1>  are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"paroxetine","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitors, such as <e1>CHEMICAL<\\e1>  are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor GENE-Y metabolizers","sentence":"CYP2D6 inhibitors, such as paroxetine  are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers"}
{"PMID":19445548,"re_id":3,"annotated sentence":"It undergoes extensive biotransformation, which is affected by poor metabolism by <e2>cytochrome P450 (CYP) 2D6<\\e2> in a small percentage of the population; these patients have greater exposure to and slower elimination of <e1>atomoxetine<\\e1> than extensive metabolizers","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"atomoxetine","object":"cytochrome P450 (CYP) 2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It undergoes extensive biotransformation, which is affected by poor metabolism by <e2>GENE-Y<\\e2> in a small percentage of the population; these patients have greater exposure to and slower elimination of <e1>CHEMICAL<\\e1> than extensive metabolizers","sentence":"It undergoes extensive biotransformation, which is affected by poor metabolism by cytochrome P450 (CYP) 2D6 in a small percentage of the population; these patients have greater exposure to and slower elimination of atomoxetine than extensive metabolizers"}
{"PMID":19445548,"re_id":4,"annotated sentence":"CYP2D6 inhibitors, such as paroxetine, are associated with changes in <e1>atomoxetine<\\e1> pharmacokinetics similar to those observed among poor <e2>CYP2D6<\\e2> metabolizers","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"atomoxetine","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GENE-Y inhibitors, such as paroxetine, are associated with changes in <e1>CHEMICAL<\\e1> pharmacokinetics similar to those observed among poor <e2>GENE-Y<\\e2> metabolizers","sentence":"CYP2D6 inhibitors, such as paroxetine, are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers"}
{"PMID":19445548,"re_id":5,"annotated sentence":"<e1>Atomoxetine<\\e1> appeared better tolerated among extensive <e2>CYP2D6<\\e2> metabolizers than among poor metabolizers","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Atomoxetine","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> appeared better tolerated among extensive <e2>GENE-Y<\\e2> metabolizers than among poor metabolizers","sentence":"Atomoxetine appeared better tolerated among extensive CYP2D6 metabolizers than among poor metabolizers"}
{"PMID":19531491,"re_id":4,"annotated sentence":"The recently discovered hyperinsulinism\/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by <e1>GTP<\\e1> causes excessive secretion of <e2>insulin<\\e2>  Subsequent studies demonstrated that wild-type and hyperinsulinemia\/hyperammonemia forms of GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GTP","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The recently discovered hyperGENE-Yism\/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by <e1>CHEMICAL<\\e1> causes excessive secretion of <e2>GENE-Y<\\e2>  Subsequent studies demonstrated that wild-type and hyperGENE-Yemia\/hyperammonemia forms of GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate","sentence":"The recently discovered hyperinsulinism\/hyperammonemia disorder showed that the loss of allosteric inhibition of GDH by GTP causes excessive secretion of insulin  Subsequent studies demonstrated that wild-type and hyperinsulinemia\/hyperammonemia forms of GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate"}
{"PMID":19531491,"re_id":5,"annotated sentence":"Subsequent studies demonstrated that wild-type and hyperinsulinemia\/hyperammonemia forms of <e2>GDH<\\e2> are inhibited by the green tea polyphenols, <e1>epigallocatechin gallate<\\e1> and epicatechin gallate","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"epigallocatechin gallate","object":"GDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Subsequent studies demonstrated that wild-type and hyperinsulinemia\/hyperammonemia forms of <e2>GENE-Y<\\e2> are inhibited by the green tea polyphenols, <e1>CHEMICAL<\\e1> and epicatechin gallate","sentence":"Subsequent studies demonstrated that wild-type and hyperinsulinemia\/hyperammonemia forms of GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate"}
{"PMID":19531491,"re_id":6,"annotated sentence":"Subsequent studies demonstrated that wild-type and hyperinsulinemia\/hyperammonemia forms of <e2>GDH<\\e2> are inhibited by the green tea polyphenols, epigallocatechin gallate and <e1>epicatechin gallate<\\e1>  This was followed by high throughput studies that identified more stable inhibitors, including hexachlorophene, GW5074, and bithionol","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"epicatechin gallate","object":"GDH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Subsequent studies demonstrated that wild-type and hyperinsulinemia\/hyperammonemia forms of <e2>GENE-Y<\\e2> are inhibited by the green tea polyphenols, epigallocatechin gallate and <e1>CHEMICAL<\\e1>  This was followed by high throughput studies that identified more stable inhibitors, including hexachlorophene, GW5074, and bithionol","sentence":"Subsequent studies demonstrated that wild-type and hyperinsulinemia\/hyperammonemia forms of GDH are inhibited by the green tea polyphenols, epigallocatechin gallate and epicatechin gallate  This was followed by high throughput studies that identified more stable inhibitors, including hexachlorophene, GW5074, and bithionol"}
{"PMID":19531491,"re_id":8,"annotated sentence":"<e2>Mammalian glutamate dehydrogenase<\\e2> (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to <e1>2-oxoglutarate<\\e1> using NAD(P)(+) as coenzyme","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"2-oxoglutarate","object":"Mammalian glutamate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to <e1>CHEMICAL<\\e1> using NAD(P)(+) as coenzyme","sentence":"Mammalian glutamate dehydrogenase (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using NAD(P)(+) as coenzyme"}
{"PMID":19531491,"re_id":9,"annotated sentence":"Mammalian glutamate dehydrogenase (<e2>GDH<\\e2>  is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to <e1>2-oxoglutarate<\\e1> using NAD(P)(+) as coenzyme","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"2-oxoglutarate","object":"GDH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Mammalian glutamate dehydrogenase (<e2>GENE-N<\\e2>  is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to <e1>CHEMICAL<\\e1> using NAD(P)(+) as coenzyme","sentence":"Mammalian glutamate dehydrogenase (GDH  is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using NAD(P)(+) as coenzyme"}
{"PMID":19531491,"re_id":10,"annotated sentence":"<e2>Mammalian glutamate dehydrogenase<\\e2> (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of <e1>l-glutamate<\\e1> to 2-oxoglutarate using NAD(P)(+) as coenzyme","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"l-glutamate","object":"Mammalian glutamate dehydrogenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of <e1>CHEMICAL<\\e1> to 2-oxoglutarate using NAD(P)(+) as coenzyme","sentence":"Mammalian glutamate dehydrogenase (GDH) is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using NAD(P)(+) as coenzyme"}
{"PMID":19531491,"re_id":11,"annotated sentence":"Mammalian glutamate dehydrogenase (<e2>GDH<\\e2>  is a homohexameric enzyme that catalyzes the reversible oxidative deamination of <e1>l-glutamate<\\e1> to 2-oxoglutarate using NAD(P)(+) as coenzyme","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"l-glutamate","object":"GDH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Mammalian glutamate dehydrogenase (<e2>GENE-N<\\e2>  is a homohexameric enzyme that catalyzes the reversible oxidative deamination of <e1>CHEMICAL<\\e1> to 2-oxoglutarate using NAD(P)(+) as coenzyme","sentence":"Mammalian glutamate dehydrogenase (GDH  is a homohexameric enzyme that catalyzes the reversible oxidative deamination of l-glutamate to 2-oxoglutarate using NAD(P)(+) as coenzyme"}
{"PMID":19690271,"re_id":1,"annotated sentence":"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord <e2>COX-2<\\e2> (cyclooxygenase-2), with a subsequent increase in central <e1>prostaglandin E2<\\e1> (PGE2) levels associated with the development of hyperalgesia","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin E2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord <e2>GENE-Y<\\e2> (cyclooxygenase-2), with a subsequent increase in central <e1>CHEMICAL<\\e1> (PGE2) levels associated with the development of hyperalgesia","sentence":"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (cyclooxygenase-2), with a subsequent increase in central prostaglandin E2 (PGE2) levels associated with the development of hyperalgesia"}
{"PMID":19690271,"re_id":2,"annotated sentence":"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (<e2>cyclooxygenase-2<\\e2> , with a subsequent increase in central <e1>prostaglandin E2<\\e1> (PGE2) levels associated with the development of hyperalgesia","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin E2","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (<e2>GENE-Y<\\e2> , with a subsequent increase in central <e1>CHEMICAL<\\e1> (PGE2) levels associated with the development of hyperalgesia","sentence":"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (cyclooxygenase-2 , with a subsequent increase in central prostaglandin E2 (PGE2) levels associated with the development of hyperalgesia"}
{"PMID":19690271,"re_id":3,"annotated sentence":"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord <e2>COX-2<\\e2> (cyclooxygenase-2), with a subsequent increase in central prostaglandin E2 (<e1>PGE2<\\e1>  levels associated with the development of hyperalgesia","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PGE2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord <e2>GENE-Y<\\e2> (cyclooxygenase-2), with a subsequent increase in central prostaglandin E2 (<e1>CHEMICAL<\\e1>  levels associated with the development of hyperalgesia","sentence":"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (cyclooxygenase-2), with a subsequent increase in central prostaglandin E2 (PGE2  levels associated with the development of hyperalgesia"}
{"PMID":19690271,"re_id":4,"annotated sentence":"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (<e2>cyclooxygenase-2<\\e2> , with a subsequent increase in central prostaglandin E2 (<e1>PGE2<\\e1>  levels associated with the development of hyperalgesia","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PGE2","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (<e2>GENE-Y<\\e2> , with a subsequent increase in central prostaglandin E2 (<e1>CHEMICAL<\\e1>  levels associated with the development of hyperalgesia","sentence":"BACKGROUND: Peripheral inflammatory pain is associated with an upregulation of spinal cord COX-2 (cyclooxygenase-2 , with a subsequent increase in central prostaglandin E2 (PGE2  levels associated with the development of hyperalgesia"}
{"PMID":1978244,"re_id":6,"annotated sentence":"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against <e2>alpha 1a-adrenoceptor<\\e2> selective agonist <e1>methoxamine<\\e1> induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for WB4101 and 9.09 +\/- 0.05 (n = 3) for 5-methyl-urapidil","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"methoxamine","object":"alpha 1a-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against <e2>GENE-Y<\\e2> selective agonist <e1>CHEMICAL<\\e1> induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for WB4101 and 9.09 +\/- 0.05 (n = 3) for 5-methyl-urapidil","sentence":"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against alpha 1a-adrenoceptor selective agonist methoxamine induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for WB4101 and 9.09 +\/- 0.05 (n = 3) for 5-methyl-urapidil"}
{"PMID":1978244,"re_id":7,"annotated sentence":"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against <e2>alpha 1a-adrenoceptor<\\e2> selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for <e1>WB4101<\\e1> and 9.09 +\/- 0.05 (n = 3) for 5-methyl-urapidil","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"WB4101","object":"alpha 1a-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The Schild plots for the competitive antagonists CHEMICAL and 5-methyl-urapidil against <e2>GENE-Y<\\e2> selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for <e1>CHEMICAL<\\e1> and 9.09 +\/- 0.05 (n = 3) for 5-methyl-urapidil","sentence":"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against alpha 1a-adrenoceptor selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for WB4101 and 9.09 +\/- 0.05 (n = 3) for 5-methyl-urapidil"}
{"PMID":1978244,"re_id":8,"annotated sentence":"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against <e2>alpha 1a-adrenoceptor<\\e2> selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for WB4101 and 9.09 +\/- 0.05 (n = 3) for <e1>5-methyl-urapidil<\\e1>  However, the Schilod plots for these antagonists against norepinephrine were curvilinear","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"5-methyl-urapidil","object":"alpha 1a-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The Schild plots for the competitive antagonists WB4101 and CHEMICAL against <e2>GENE-Y<\\e2> selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for WB4101 and 9.09 +\/- 0.05 (n = 3) for <e1>CHEMICAL<\\e1>  However, the Schilod plots for these antagonists against norepinephrine were curvilinear","sentence":"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against alpha 1a-adrenoceptor selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for WB4101 and 9.09 +\/- 0.05 (n = 3) for 5-methyl-urapidil  However, the Schilod plots for these antagonists against norepinephrine were curvilinear"}
{"PMID":1978244,"re_id":9,"annotated sentence":"Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that <e2>alpha 1-adrenoceptor<\\e2> populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for <e1>WB4101<\\e1> and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"WB4101","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that <e2>GENE-N<\\e2> populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for <e1>CHEMICAL<\\e1> and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both CHEMICAL and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)","sentence":"Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that alpha 1-adrenoceptor populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for 5-methyl-urapidil) and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)"}
{"PMID":1978244,"re_id":10,"annotated sentence":"Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that <e2>alpha 1-adrenoceptor<\\e2> populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for <e1>5-methyl-urapidil<\\e1>  and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"5-methyl-urapidil","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that <e2>GENE-N<\\e2> populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for <e1>CHEMICAL<\\e1>  and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and CHEMICAL), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)","sentence":"Computer-assisted analysis of these curvilinear Schild plots in a two-receptor system indicated that alpha 1-adrenoceptor populations responsible for the constrictive response are predominantly (approximately 80-90%) low affinity sites for the two antagonists (pKd approximately 8.1 for WB4101 and pKd approximately 7.1 for 5-methyl-urapidil  and a small population (approximately 10-20%) are high affinity sites (pKd approximately 9.1 for both WB4101 and 5-methyl-urapidil), which was in good agreement with radioligand binding studies.(ABSTRACT TRUNCATED AT 400 WORDS)"}
{"PMID":1978244,"re_id":11,"annotated sentence":"Using the <e2>alpha 1-adrenoceptor<\\e2> subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and <e1>5-methyl-urapidil<\\e1>  we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"5-methyl-urapidil","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Using the <e2>GENE-N<\\e2> subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and <e1>CHEMICAL<\\e1>  we have examined the possible heterogeneity in the GENE-N populations in rabbit aorta","sentence":"Using the alpha 1-adrenoceptor subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and 5-methyl-urapidil  we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta"}
{"PMID":1978244,"re_id":12,"annotated sentence":"Using the <e2>alpha 1-adrenoceptor<\\e2> subtype-selective antagonists <e1>chlorethylclonidine<\\e1> (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"chlorethylclonidine","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Using the <e2>GENE-N<\\e2> subtype-selective antagonists <e1>CHEMICAL<\\e1> (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the GENE-N populations in rabbit aorta","sentence":"Using the alpha 1-adrenoceptor subtype-selective antagonists chlorethylclonidine (CEC), WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta"}
{"PMID":1978244,"re_id":13,"annotated sentence":"Radioligand binding studies with the nonselective <e2>alpha 1-adrenoceptor<\\e2> antagonist radioligand <e1>125I-BE2254<\\e1> showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"125I-BE2254","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Radioligand binding studies with the nonselective <e2>GENE-N<\\e2> antagonist radioligand <e1>CHEMICAL<\\e1> showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1)","sentence":"Radioligand binding studies with the nonselective alpha 1-adrenoceptor antagonist radioligand 125I-BE2254 showed that 73-87% of the binding sites in rabbit aorta are CEC sensitive and they are predominantly low affinity sites both for WB4101 (pKd = 8.1) and for 5-methylurapidil (pKd = 7.1)"}
{"PMID":1978244,"re_id":14,"annotated sentence":"Using the <e2>alpha 1-adrenoceptor<\\e2> subtype-selective antagonists chlorethylclonidine (<e1>CEC<\\e1> , WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"CEC","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Using the <e2>GENE-N<\\e2> subtype-selective antagonists chlorethylclonidine (<e1>CHEMICAL<\\e1> , WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the GENE-N populations in rabbit aorta","sentence":"Using the alpha 1-adrenoceptor subtype-selective antagonists chlorethylclonidine (CEC , WB4101, and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta"}
{"PMID":1978244,"re_id":15,"annotated sentence":"Using the <e2>alpha 1-adrenoceptor<\\e2> subtype-selective antagonists chlorethylclonidine (CEC), <e1>WB4101<\\e1>  and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"WB4101","object":"alpha 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Using the <e2>GENE-N<\\e2> subtype-selective antagonists chlorethylclonidine (CEC), <e1>CHEMICAL<\\e1>  and 5-methyl-urapidil, we have examined the possible heterogeneity in the GENE-N populations in rabbit aorta","sentence":"Using the alpha 1-adrenoceptor subtype-selective antagonists chlorethylclonidine (CEC), WB4101  and 5-methyl-urapidil, we have examined the possible heterogeneity in the alpha 1-adrenoceptor populations in rabbit aorta"}
{"PMID":1978244,"re_id":16,"annotated sentence":"The Schild plots for the competitive antagonists <e1>WB4101<\\e1> and 5-methyl-urapidil against <e2>alpha 1a-adrenoceptor<\\e2> selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for WB4101 and 9.09 +\/- 0.05 (n = 3) for 5-methyl-urapidil","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"WB4101","object":"alpha 1a-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The Schild plots for the competitive antagonists <e1>CHEMICAL<\\e1> and 5-methyl-urapidil against <e2>GENE-Y<\\e2> selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for CHEMICAL and 9.09 +\/- 0.05 (n = 3) for 5-methyl-urapidil","sentence":"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against alpha 1a-adrenoceptor selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for WB4101 and 9.09 +\/- 0.05 (n = 3) for 5-methyl-urapidil"}
{"PMID":1978244,"re_id":17,"annotated sentence":"The Schild plots for the competitive antagonists WB4101 and <e1>5-methyl-urapidil<\\e1> against <e2>alpha 1a-adrenoceptor<\\e2> selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for WB4101 and 9.09 +\/- 0.05 (n = 3) for 5-methyl-urapidil","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"5-methyl-urapidil","object":"alpha 1a-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The Schild plots for the competitive antagonists WB4101 and <e1>CHEMICAL<\\e1> against <e2>GENE-Y<\\e2> selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for WB4101 and 9.09 +\/- 0.05 (n = 3) for CHEMICAL","sentence":"The Schild plots for the competitive antagonists WB4101 and 5-methyl-urapidil against alpha 1a-adrenoceptor selective agonist methoxamine-induced contraction were linear and had slopes not significantly different from unity, with a pA2 of 9.07 +\/- 0.07 (n = 5) for WB4101 and 9.09 +\/- 0.05 (n = 3) for 5-methyl-urapidil"}
{"PMID":19920913,"re_id":0,"annotated sentence":"<e1>Ambrisentan<\\e1> is an <e2>endothelin receptor<\\e2> antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Ambrisentan","object":"endothelin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is an <e2>GENE-N<\\e2> antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH)","sentence":"Ambrisentan is an endothelin receptor antagonist (ERA) that was recently approved for treatment of pulmonary arterial hypertension (PAH)"}
{"PMID":19920913,"re_id":1,"annotated sentence":"<e1>Ambrisentan<\\e1> is the first <e2>ET(A)<\\e2> selective ERA approved for use in the US","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Ambrisentan","object":"ET(A)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is the first <e2>GENE-Y<\\e2> selective ERA approved for use in the US","sentence":"Ambrisentan is the first ET(A) selective ERA approved for use in the US"}
{"PMID":19962254,"re_id":0,"annotated sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, <e1>promegestone<\\e1>  nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>sulfatase<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"promegestone","object":"sulfatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, <e1>CHEMICAL<\\e1>  nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>GENE-N<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone  nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":19962254,"re_id":1,"annotated sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, <e1>promegestone<\\e1>  nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1<\\e2> activities","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"promegestone","object":"17beta-hydroxysteroid-dehydrogenase type 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, <e1>CHEMICAL<\\e1>  nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>GENE-Y<\\e2> activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone  nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":19962254,"re_id":2,"annotated sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, <e1>nomegestrol acetate<\\e1> and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>sulfatase<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nomegestrol acetate","object":"sulfatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, <e1>CHEMICAL<\\e1> and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>GENE-N<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":19962254,"re_id":3,"annotated sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, <e1>nomegestrol acetate<\\e1> and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1<\\e2> activities","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nomegestrol acetate","object":"17beta-hydroxysteroid-dehydrogenase type 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, <e1>CHEMICAL<\\e1> and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>GENE-Y<\\e2> activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":19962254,"re_id":4,"annotated sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and <e1>norelgestromin<\\e1> can reduce intratissular levels of estradiol in breast cancer by blocking <e2>sulfatase<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"norelgestromin","object":"sulfatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and <e1>CHEMICAL<\\e1> can reduce intratissular levels of estradiol in breast cancer by blocking <e2>GENE-N<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":19962254,"re_id":5,"annotated sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and <e1>norelgestromin<\\e1> can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1<\\e2> activities","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"norelgestromin","object":"17beta-hydroxysteroid-dehydrogenase type 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and <e1>CHEMICAL<\\e1> can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>GENE-Y<\\e2> activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":19962254,"re_id":6,"annotated sentence":"As discussed in this review, various <e1>progestogens<\\e1> including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>sulfatase<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"progestogens","object":"sulfatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"As discussed in this review, various <e1>CHEMICAL<\\e1> including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>GENE-N<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":19962254,"re_id":7,"annotated sentence":"As discussed in this review, various <e1>progestogens<\\e1> including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1<\\e2> activities","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"progestogens","object":"17beta-hydroxysteroid-dehydrogenase type 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As discussed in this review, various <e1>CHEMICAL<\\e1> including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>GENE-Y<\\e2> activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":19962254,"re_id":8,"annotated sentence":"As discussed in this review, various progestogens including <e1>dydrogesterone<\\e1> and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>sulfatase<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dydrogesterone","object":"sulfatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"As discussed in this review, various progestogens including <e1>CHEMICAL<\\e1> and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>GENE-N<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":19962254,"re_id":9,"annotated sentence":"As discussed in this review, various progestogens including <e1>dydrogesterone<\\e1> and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1<\\e2> activities","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dydrogesterone","object":"17beta-hydroxysteroid-dehydrogenase type 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As discussed in this review, various progestogens including <e1>CHEMICAL<\\e1> and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>GENE-Y<\\e2> activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":19962254,"re_id":10,"annotated sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, <e1>medrogestone<\\e1>  promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>sulfatase<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"medrogestone","object":"sulfatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, <e1>CHEMICAL<\\e1>  promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking <e2>GENE-N<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone  promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":19962254,"re_id":11,"annotated sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, <e1>medrogestone<\\e1>  promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1<\\e2> activities","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"medrogestone","object":"17beta-hydroxysteroid-dehydrogenase type 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, <e1>CHEMICAL<\\e1>  promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and <e2>GENE-Y<\\e2> activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone  promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":19962254,"re_id":12,"annotated sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of <e1>estradiol<\\e1> in breast cancer by blocking <e2>sulfatase<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"estradiol","object":"sulfatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of <e1>CHEMICAL<\\e1> in breast cancer by blocking <e2>GENE-N<\\e2> and 17beta-hydroxysteroid-dehydrogenase type 1 activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":19962254,"re_id":13,"annotated sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of <e1>estradiol<\\e1> in breast cancer by blocking sulfatase and <e2>17beta-hydroxysteroid-dehydrogenase type 1<\\e2> activities","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"estradiol","object":"17beta-hydroxysteroid-dehydrogenase type 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of <e1>CHEMICAL<\\e1> in breast cancer by blocking sulfatase and <e2>GENE-Y<\\e2> activities","sentence":"As discussed in this review, various progestogens including dydrogesterone and its 20alpha-dihydro-derivative, medrogestone, promegestone, nomegestrol acetate and norelgestromin can reduce intratissular levels of estradiol in breast cancer by blocking sulfatase and 17beta-hydroxysteroid-dehydrogenase type 1 activities"}
{"PMID":20025554,"re_id":2,"annotated sentence":"<e1>Mitiglinide<\\e1> reduced fasting plasma glucose and <e2>GA<\\e2> levels after 4 weeks and Hb(A1c) levels after 8 weeks","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Mitiglinide","object":"GA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced fasting plasma glucose and <e2>GENE-Y<\\e2> levels after 4 weeks and Hb(A1c) levels after 8 weeks","sentence":"Mitiglinide reduced fasting plasma glucose and GA levels after 4 weeks and Hb(A1c) levels after 8 weeks"}
{"PMID":20025554,"re_id":3,"annotated sentence":"<e1>Mitiglinide<\\e1> reduced fasting plasma glucose and GA levels after 4 weeks and <e2>Hb(A1c)<\\e2> levels after 8 weeks","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Mitiglinide","object":"Hb(A1c)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced fasting plasma glucose and GA levels after 4 weeks and <e2>GENE-Y<\\e2> levels after 8 weeks","sentence":"Mitiglinide reduced fasting plasma glucose and GA levels after 4 weeks and Hb(A1c) levels after 8 weeks"}
{"PMID":20089905,"re_id":5,"annotated sentence":"<e1>Ibuprofen<\\e1> activates <e2>PPARgamma<\\e2> in neuron-like PC12 and B104 cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Ibuprofen","object":"PPARgamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> activates <e2>GENE-Y<\\e2> in neuron-like PC12 and B104 cells","sentence":"Ibuprofen activates PPARgamma in neuron-like PC12 and B104 cells"}
{"PMID":20089905,"re_id":6,"annotated sentence":"In addition, another study suggests that <e1>ibuprofen<\\e1> reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate <e2>amyloid-beta42<\\e2> formation by direct inhibition of the gamma-secretase complex","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ibuprofen","object":"amyloid-beta42","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, another study suggests that <e1>CHEMICAL<\\e1> reduces generation of GENE-Y peptide via inactivation of RhoA signaling, although it may also regulate <e2>GENE-Y<\\e2> formation by direct inhibition of the gamma-secretase complex","sentence":"In addition, another study suggests that ibuprofen reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex"}
{"PMID":20089905,"re_id":7,"annotated sentence":"Recently, we have demonstrated that <e1>ibuprofen<\\e1> inhibits intracellular signaling of <e2>RhoA<\\e2> and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ibuprofen","object":"RhoA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Recently, we have demonstrated that <e1>CHEMICAL<\\e1> inhibits intracellular signaling of <e2>GENE-Y<\\e2> and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents","sentence":"Recently, we have demonstrated that ibuprofen inhibits intracellular signaling of RhoA and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents"}
{"PMID":20089905,"re_id":8,"annotated sentence":"In addition, another study suggests that <e1>ibuprofen<\\e1> reduces generation of <e2>amyloid-beta42<\\e2> peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ibuprofen","object":"amyloid-beta42","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, another study suggests that <e1>CHEMICAL<\\e1> reduces generation of <e2>GENE-Y<\\e2> peptide via inactivation of RhoA signaling, although it may also regulate GENE-Y formation by direct inhibition of the gamma-secretase complex","sentence":"In addition, another study suggests that ibuprofen reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex"}
{"PMID":20089905,"re_id":9,"annotated sentence":"In addition, another study suggests that <e1>ibuprofen<\\e1> reduces generation of amyloid-beta42 peptide via inactivation of <e2>RhoA<\\e2> signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ibuprofen","object":"RhoA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, another study suggests that <e1>CHEMICAL<\\e1> reduces generation of amyloid-beta42 peptide via inactivation of <e2>GENE-Y<\\e2> signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex","sentence":"In addition, another study suggests that ibuprofen reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex"}
{"PMID":20089905,"re_id":10,"annotated sentence":"The molecular mechanisms by which <e1>ibuprofen<\\e1> inhibits the <e2>RhoA<\\e2> signal in neurons, however, remain unclear","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ibuprofen","object":"RhoA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The molecular mechanisms by which <e1>CHEMICAL<\\e1> inhibits the <e2>GENE-Y<\\e2> signal in neurons, however, remain unclear","sentence":"The molecular mechanisms by which ibuprofen inhibits the RhoA signal in neurons, however, remain unclear"}
{"PMID":20089905,"re_id":11,"annotated sentence":"Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling <e1>ibuprofen<\\e1> to <e2>RhoA<\\e2> inhibition and subsequent neurite growth promotion in neurons","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ibuprofen","object":"RhoA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling <e1>CHEMICAL<\\e1> to <e2>GENE-Y<\\e2> inhibition and subsequent neurite growth promotion in neurons","sentence":"Here, we report that the transcription factor peroxisome proliferator-activated receptor gamma (PPARgamma) is essential for coupling ibuprofen to RhoA inhibition and subsequent neurite growth promotion in neurons"}
{"PMID":20089905,"re_id":12,"annotated sentence":"A molecular mechanism for <e1>ibuprofen<\\e1> mediated <e2>RhoA<\\e2> inhibition in neurons","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ibuprofen","object":"RhoA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A molecular mechanism for <e1>CHEMICAL<\\e1> mediated <e2>GENE-Y<\\e2> inhibition in neurons","sentence":"A molecular mechanism for ibuprofen mediated RhoA inhibition in neurons"}
{"PMID":20089905,"re_id":13,"annotated sentence":"<e1>Ibuprofen<\\e1> is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of <e2>cyclooxygenases<\\e2>  Recently, we have demonstrated that ibuprofen inhibits intracellular signaling of RhoA and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Ibuprofen","object":"cyclooxygenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of <e2>GENE-N<\\e2>  Recently, we have demonstrated that ibuprofen inhibits intracellular signaling of RhoA and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents","sentence":"Ibuprofen is a nonsteroidal anti-inflammatory drug widely used to relieve pain and inflammation in many disorders via inhibition of cyclooxygenases  Recently, we have demonstrated that ibuprofen inhibits intracellular signaling of RhoA and promotes significant axonal growth and functional recovery following spinal cord lesions in rodents"}
{"PMID":20089905,"re_id":14,"annotated sentence":"Activation of PPARgamma with traditional agonists mimics the <e2>RhoA<\\e2> inhibiting properties of <e1>ibuprofen<\\e1> in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ibuprofen","object":"RhoA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of PPARgamma with traditional agonists mimics the <e2>GENE-Y<\\e2> inhibiting properties of <e1>CHEMICAL<\\e1> in PC12 cells and, like CHEMICAL, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors","sentence":"Activation of PPARgamma with traditional agonists mimics the RhoA inhibiting properties of ibuprofen in PC12 cells and, like ibuprofen, promotes neurite elongation in primary cultured neurons exposed to axonal growth inhibitors"}
{"PMID":20089905,"re_id":15,"annotated sentence":"These findings support that PPARgamma plays an essential role in mediating the <e2>RhoA<\\e2> inhibiting effect of <e1>ibuprofen<\\e1>  Elucidation of the novel molecular mechanisms linking ibuprofen to RhoA inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ibuprofen","object":"RhoA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings support that PPARgamma plays an essential role in mediating the <e2>GENE-Y<\\e2> inhibiting effect of <e1>CHEMICAL<\\e1>  Elucidation of the novel molecular mechanisms linking CHEMICAL to GENE-Y inhibition may provide additional therapeutic targets to the disorders characterized by GENE-Y activation, including spinal cord injuries and Alzheimer's disease.","sentence":"These findings support that PPARgamma plays an essential role in mediating the RhoA inhibiting effect of ibuprofen  Elucidation of the novel molecular mechanisms linking ibuprofen to RhoA inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease."}
{"PMID":20089905,"re_id":16,"annotated sentence":"Elucidation of the novel molecular mechanisms linking <e1>ibuprofen<\\e1> to <e2>RhoA<\\e2> inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ibuprofen","object":"RhoA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Elucidation of the novel molecular mechanisms linking <e1>CHEMICAL<\\e1> to <e2>GENE-Y<\\e2> inhibition may provide additional therapeutic targets to the disorders characterized by GENE-Y activation, including spinal cord injuries and Alzheimer's disease.","sentence":"Elucidation of the novel molecular mechanisms linking ibuprofen to RhoA inhibition may provide additional therapeutic targets to the disorders characterized by RhoA activation, including spinal cord injuries and Alzheimer's disease."}
{"PMID":20089905,"re_id":17,"annotated sentence":"In addition, another study suggests that <e1>ibuprofen<\\e1> reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the <e2>gamma-secretase complex<\\e2>  The molecular mechanisms by which ibuprofen inhibits the RhoA signal in neurons, however, remain unclear","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ibuprofen","object":"gamma-secretase complex","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, another study suggests that <e1>CHEMICAL<\\e1> reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the <e2>GENE-N<\\e2>  The molecular mechanisms by which CHEMICAL inhibits the RhoA signal in neurons, however, remain unclear","sentence":"In addition, another study suggests that ibuprofen reduces generation of amyloid-beta42 peptide via inactivation of RhoA signaling, although it may also regulate amyloid-beta42 formation by direct inhibition of the gamma-secretase complex  The molecular mechanisms by which ibuprofen inhibits the RhoA signal in neurons, however, remain unclear"}
{"PMID":20135071,"re_id":0,"annotated sentence":"Of these, the <e2>thrombin<\\e2> inhibitor <e1>dabigatran<\\e1> and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dabigatran","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of these, the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe","sentence":"Of these, the thrombin inhibitor dabigatran and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe"}
{"PMID":20135071,"re_id":1,"annotated sentence":"Of these, the thrombin inhibitor dabigatran and <e2>factor Xa<\\e2> inhibitor <e1>rivaroxaban<\\e1> have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivaroxaban","object":"factor Xa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of these, the thrombin inhibitor dabigatran and <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe","sentence":"Of these, the thrombin inhibitor dabigatran and factor Xa inhibitor rivaroxaban have recently been licensed for thromboprophylaxis after orthopaedic surgery mainly in Europe"}
{"PMID":20135071,"re_id":2,"annotated sentence":"In addition, the <e2>factor Xa<\\e2> inhibitor <e1>apixaban<\\e1> is in late-stage clinical development","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"apixaban","object":"factor Xa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> is in late-stage clinical development","sentence":"In addition, the factor Xa inhibitor apixaban is in late-stage clinical development"}
{"PMID":20184869,"re_id":3,"annotated sentence":"We determined whether an <e2>angiotensin-converting enzyme<\\e2> (ACE) inhibitor, <e1>captopril<\\e1>  inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"captopril","object":"angiotensin-converting enzyme","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We determined whether an <e2>GENE-Y<\\e2> (ACE) inhibitor, <e1>CHEMICAL<\\e1>  inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-CHEMICAL complex","sentence":"We determined whether an angiotensin-converting enzyme (ACE) inhibitor, captopril  inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex"}
{"PMID":20184869,"re_id":4,"annotated sentence":"We determined whether an angiotensin-converting enzyme (<e2>ACE<\\e2>  inhibitor, <e1>captopril<\\e1>  inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"captopril","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We determined whether an angiotensin-converting enzyme (<e2>GENE-Y<\\e2>  inhibitor, <e1>CHEMICAL<\\e1>  inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-CHEMICAL complex","sentence":"We determined whether an angiotensin-converting enzyme (ACE  inhibitor, captopril  inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex"}
{"PMID":20184869,"re_id":5,"annotated sentence":"METHODS: The inhibitory effect of <e1>captopril<\\e1> on <e2>MMP-2<\\e2> activity was measured in peritoneal effluents from 17 patients on CAPD","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"captopril","object":"MMP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: The inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-Y<\\e2> activity was measured in peritoneal effluents from 17 patients on CAPD","sentence":"METHODS: The inhibitory effect of captopril on MMP-2 activity was measured in peritoneal effluents from 17 patients on CAPD"}
{"PMID":20184869,"re_id":6,"annotated sentence":"RESULTS: <e1>Captopril<\\e1> directly inhibited <e2>MMP-2<\\e2> activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol\/l), and that captopril binding to the MMP-2 active site could be formed in each complex model without molecular distortion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Captopril","object":"MMP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> directly inhibited <e2>GENE-Y<\\e2> activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol\/l), and that captopril binding to the GENE-Y active site could be formed in each complex model without molecular distortion","sentence":"RESULTS: Captopril directly inhibited MMP-2 activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol\/l), and that captopril binding to the MMP-2 active site could be formed in each complex model without molecular distortion"}
{"PMID":20184869,"re_id":7,"annotated sentence":"CONCLUSION: ACE inhibitors, such as <e1>captopril<\\e1>  may be applied as important compounds for <e2>MMP-2<\\e2> inhibition in inflammation caused by CAPD.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"captopril","object":"MMP-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: ACE inhibitors, such as <e1>CHEMICAL<\\e1>  may be applied as important compounds for <e2>GENE-Y<\\e2> inhibition in inflammation caused by CAPD.","sentence":"CONCLUSION: ACE inhibitors, such as captopril  may be applied as important compounds for MMP-2 inhibition in inflammation caused by CAPD."}
{"PMID":20184869,"re_id":8,"annotated sentence":"CONCLUSION: <e2>ACE<\\e2> inhibitors, such as <e1>captopril<\\e1>  may be applied as important compounds for MMP-2 inhibition in inflammation caused by CAPD.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"captopril","object":"ACE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: <e2>GENE-Y<\\e2> inhibitors, such as <e1>CHEMICAL<\\e1>  may be applied as important compounds for MMP-2 inhibition in inflammation caused by CAPD.","sentence":"CONCLUSION: ACE inhibitors, such as captopril  may be applied as important compounds for MMP-2 inhibition in inflammation caused by CAPD."}
{"PMID":20184869,"re_id":9,"annotated sentence":"<e1>Captopril<\\e1> directly inhibits <e2>matrix metalloproteinase-2<\\e2> activity in continuous ambulatory peritoneal dialysis therapy","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Captopril","object":"matrix metalloproteinase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> directly inhibits <e2>GENE-Y<\\e2> activity in continuous ambulatory peritoneal dialysis therapy","sentence":"Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy"}
{"PMID":20188727,"re_id":10,"annotated sentence":"<e1>Phenformin<\\e1> reduced the open probability of <e2>Kir6.1<\\e2> SUR2B channels by approximately 90% in inside-out patches","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Phenformin","object":"Kir6.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced the open probability of <e2>GENE-Y<\\e2> SUR2B channels by approximately 90% in inside-out patches","sentence":"Phenformin reduced the open probability of Kir6.1 SUR2B channels by approximately 90% in inside-out patches"}
{"PMID":20188727,"re_id":11,"annotated sentence":"<e1>Phenformin<\\e1> reduced the open probability of Kir6.1\/<e2>SUR2B<\\e2> channels by approximately 90% in inside-out patches","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Phenformin","object":"SUR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> reduced the open probability of Kir6.1\/<e2>GENE-Y<\\e2> channels by approximately 90% in inside-out patches","sentence":"Phenformin reduced the open probability of Kir6.1\/SUR2B channels by approximately 90% in inside-out patches"}
{"PMID":20188727,"re_id":12,"annotated sentence":"<e1>Phenformin<\\e1> but not metformin inhibits a number of variants of <e2>K(ATP)<\\e2> including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and Kir6.2\/SUR2B) and pancreatic beta-cells (Kir6.2\/SUR1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Phenformin","object":"K(ATP)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> but not metformin inhibits a number of variants of <e2>GENE-N<\\e2> including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and Kir6.2\/SUR2B) and pancreatic beta-cells (Kir6.2\/SUR1)","sentence":"Phenformin but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and Kir6.2\/SUR2B) and pancreatic beta-cells (Kir6.2\/SUR1)"}
{"PMID":20188727,"re_id":13,"annotated sentence":"<e1>Phenformin<\\e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (<e2>Kir6.1<\\e2> SUR2B and Kir6.2\/SUR2B) and pancreatic beta-cells (Kir6.2\/SUR1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Phenformin","object":"Kir6.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (<e2>GENE-Y<\\e2> SUR2B and Kir6.2\/SUR2B) and pancreatic beta-cells (Kir6.2\/SUR1)","sentence":"Phenformin but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1 SUR2B and Kir6.2\/SUR2B) and pancreatic beta-cells (Kir6.2\/SUR1)"}
{"PMID":20188727,"re_id":14,"annotated sentence":"<e1>Phenformin<\\e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/<e2>SUR2B<\\e2> and Kir6.2\/SUR2B) and pancreatic beta-cells (Kir6.2\/SUR1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Phenformin","object":"SUR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/<e2>GENE-Y<\\e2> and Kir6.2\/GENE-Y) and pancreatic beta-cells (Kir6.2\/SUR1)","sentence":"Phenformin but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and Kir6.2\/SUR2B) and pancreatic beta-cells (Kir6.2\/SUR1)"}
{"PMID":20188727,"re_id":15,"annotated sentence":"<e1>Phenformin<\\e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and <e2>Kir6.2<\\e2> SUR2B) and pancreatic beta-cells (Kir6.2\/SUR1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Phenformin","object":"Kir6.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and <e2>GENE-Y<\\e2> SUR2B) and pancreatic beta-cells (GENE-Y\/SUR1)","sentence":"Phenformin but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and Kir6.2 SUR2B) and pancreatic beta-cells (Kir6.2\/SUR1)"}
{"PMID":20188727,"re_id":16,"annotated sentence":"<e1>Phenformin<\\e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and Kir6.2\/<e2>SUR2B<\\e2>  and pancreatic beta-cells (Kir6.2\/SUR1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Phenformin","object":"SUR2B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/GENE-Y and Kir6.2\/<e2>GENE-Y<\\e2>  and pancreatic beta-cells (Kir6.2\/SUR1)","sentence":"Phenformin but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and Kir6.2\/SUR2B  and pancreatic beta-cells (Kir6.2\/SUR1)"}
{"PMID":20188727,"re_id":17,"annotated sentence":"<e1>Phenformin<\\e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and Kir6.2\/SUR2B) and pancreatic beta-cells (<e2>Kir6.2<\\e2> SUR1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Phenformin","object":"Kir6.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and GENE-Y\/SUR2B) and pancreatic beta-cells (<e2>GENE-Y<\\e2> SUR1)","sentence":"Phenformin but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and Kir6.2\/SUR2B) and pancreatic beta-cells (Kir6.2 SUR1)"}
{"PMID":20188727,"re_id":18,"annotated sentence":"<e1>Phenformin<\\e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and Kir6.2\/SUR2B) and pancreatic beta-cells (Kir6.2\/<e2>SUR1<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Phenformin","object":"SUR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and Kir6.2\/SUR2B) and pancreatic beta-cells (Kir6.2\/<e2>GENE-Y<\\e2> ","sentence":"Phenformin but not metformin inhibits a number of variants of K(ATP) including the cloned equivalents of currents present in vascular and non-vascular smooth muscle (Kir6.1\/SUR2B and Kir6.2\/SUR2B) and pancreatic beta-cells (Kir6.2\/SUR1 "}
{"PMID":20188727,"re_id":19,"annotated sentence":"<e1>Phenformin<\\e1> has a direct inhibitory effect on the <e2>ATP-sensitive potassium channel<\\e2>  The biguanides, phenformin and metformin, are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating AMPK activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Phenformin","object":"ATP-sensitive potassium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> has a direct inhibitory effect on the <e2>GENE-N<\\e2>  The biguanides, phenformin and metformin, are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating AMPK activity","sentence":"Phenformin has a direct inhibitory effect on the ATP-sensitive potassium channel  The biguanides, phenformin and metformin, are used in the treatment of type II diabetes mellitus, as well as being routinely used in studies investigating AMPK activity"}
{"PMID":20188727,"re_id":20,"annotated sentence":"The extent and rate of inhibition are similar to that seen with the known <e2>K(ATP)<\\e2> blocker <e1>PNU 37883A<\\e1>  Additionally, phenformin inhibited the current elicited through the Kir6.2DeltaC26 (functional without SUR) channel with an IC50 of 1.78 mM","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PNU 37883A","object":"K(ATP)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The extent and rate of inhibition are similar to that seen with the known <e2>GENE-N<\\e2> blocker <e1>CHEMICAL<\\e1>  Additionally, phenformin inhibited the current elicited through the Kir6.2DeltaC26 (functional without SUR) channel with an IC50 of 1.78 mM","sentence":"The extent and rate of inhibition are similar to that seen with the known K(ATP) blocker PNU 37883A  Additionally, phenformin inhibited the current elicited through the Kir6.2DeltaC26 (functional without SUR) channel with an IC50 of 1.78 mM"}
{"PMID":20188727,"re_id":21,"annotated sentence":"Additionally, <e1>phenformin<\\e1> inhibited the current elicited through the <e2>Kir6.2DeltaC26<\\e2> (functional without SUR) channel with an IC50 of 1.78 mM","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"phenformin","object":"Kir6.2DeltaC26","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> inhibited the current elicited through the <e2>GENE-Y<\\e2> (functional without SUR) channel with an IC50 of 1.78 mM","sentence":"Additionally, phenformin inhibited the current elicited through the Kir6.2DeltaC26 (functional without SUR) channel with an IC50 of 1.78 mM"}
{"PMID":20204178,"re_id":4,"annotated sentence":"In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although <e1>paricalcitol<\\e1> induced the expression of <e2>CaSR<\\e2> mRNA more effectively","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"paricalcitol","object":"CaSR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In pig parathyroid cells, CHEMICAL and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although <e1>CHEMICAL<\\e1> induced the expression of <e2>GENE-Y<\\e2> mRNA more effectively","sentence":"In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively"}
{"PMID":20204178,"re_id":5,"annotated sentence":"Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum <e1>Ca<\\e1> regulates <e2>PTH<\\e2> secretion mediated by the Ca-sensing receptor (CaSR)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Ca","object":"PTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Different VDRAs are known to have differential effects on serum calcium (CHEMICAL), which may also affect serum GENE-Y levels since serum <e1>CHEMICAL<\\e1> regulates <e2>GENE-Y<\\e2> secretion mediated by the CHEMICAL-sensing receptor (CHEMICALSR)","sentence":"Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (CaSR)"}
{"PMID":20204178,"re_id":6,"annotated sentence":"Both drugs at the tested doses (0.042-0.33 mug\/kg) suppressed PTH mRNA expression and serum <e2>PTH<\\e2> effectively in the 5\/6 NX rats, but <e1>paricalcitol<\\e1> was less potent in raising serum Ca than doxercalciferol","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"paricalcitol","object":"PTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both drugs at the tested doses (0.042-0.33 mug\/kg) suppressed GENE-Y mRNA expression and serum <e2>GENE-Y<\\e2> effectively in the 5\/6 NX rats, but <e1>CHEMICAL<\\e1> was less potent in raising serum Ca than doxercalciferol","sentence":"Both drugs at the tested doses (0.042-0.33 mug\/kg) suppressed PTH mRNA expression and serum PTH effectively in the 5\/6 NX rats, but paricalcitol was less potent in raising serum Ca than doxercalciferol"}
{"PMID":20204178,"re_id":7,"annotated sentence":"Both drugs at the tested doses (0.042-0.33 mug\/kg) suppressed PTH mRNA expression and serum <e2>PTH<\\e2> effectively in the 5\/6 NX rats, but paricalcitol was less potent in raising serum Ca than <e1>doxercalciferol<\\e1>  In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"doxercalciferol","object":"PTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both drugs at the tested doses (0.042-0.33 mug\/kg) suppressed GENE-Y mRNA expression and serum <e2>GENE-Y<\\e2> effectively in the 5\/6 NX rats, but paricalcitol was less potent in raising serum Ca than <e1>CHEMICAL<\\e1>  In pig parathyroid cells, paricalcitol and the active form of CHEMICAL induced VDR translocation from the cytoplasm into the nucleus, suppressed GENE-Y mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively","sentence":"Both drugs at the tested doses (0.042-0.33 mug\/kg) suppressed PTH mRNA expression and serum PTH effectively in the 5\/6 NX rats, but paricalcitol was less potent in raising serum Ca than doxercalciferol  In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively"}
{"PMID":20204178,"re_id":8,"annotated sentence":"Both drugs at the tested doses (0.042-0.33 mug\/kg) suppressed <e2>PTH<\\e2> mRNA expression and serum PTH effectively in the 5\/6 NX rats, but <e1>paricalcitol<\\e1> was less potent in raising serum Ca than doxercalciferol","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"paricalcitol","object":"PTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both drugs at the tested doses (0.042-0.33 mug\/kg) suppressed <e2>GENE-Y<\\e2> mRNA expression and serum GENE-Y effectively in the 5\/6 NX rats, but <e1>CHEMICAL<\\e1> was less potent in raising serum Ca than doxercalciferol","sentence":"Both drugs at the tested doses (0.042-0.33 mug\/kg) suppressed PTH mRNA expression and serum PTH effectively in the 5\/6 NX rats, but paricalcitol was less potent in raising serum Ca than doxercalciferol"}
{"PMID":20204178,"re_id":9,"annotated sentence":"Both drugs at the tested doses (0.042-0.33 mug\/kg) suppressed <e2>PTH<\\e2> mRNA expression and serum PTH effectively in the 5\/6 NX rats, but paricalcitol was less potent in raising serum Ca than <e1>doxercalciferol<\\e1>  In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"doxercalciferol","object":"PTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both drugs at the tested doses (0.042-0.33 mug\/kg) suppressed <e2>GENE-Y<\\e2> mRNA expression and serum GENE-Y effectively in the 5\/6 NX rats, but paricalcitol was less potent in raising serum Ca than <e1>CHEMICAL<\\e1>  In pig parathyroid cells, paricalcitol and the active form of CHEMICAL induced VDR translocation from the cytoplasm into the nucleus, suppressed GENE-Y mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively","sentence":"Both drugs at the tested doses (0.042-0.33 mug\/kg) suppressed PTH mRNA expression and serum PTH effectively in the 5\/6 NX rats, but paricalcitol was less potent in raising serum Ca than doxercalciferol  In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively"}
{"PMID":20204178,"re_id":10,"annotated sentence":"In pig parathyroid cells, <e1>paricalcitol<\\e1> and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed <e2>PTH<\\e2> mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"paricalcitol","object":"PTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In pig parathyroid cells, <e1>CHEMICAL<\\e1> and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed <e2>GENE-Y<\\e2> mRNA expression and inhibited cell proliferation in a similar manner, although CHEMICAL induced the expression of CaSR mRNA more effectively","sentence":"In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively"}
{"PMID":20204178,"re_id":11,"annotated sentence":"In pig parathyroid cells, paricalcitol and the active form of <e1>doxercalciferol<\\e1> induced VDR translocation from the cytoplasm into the nucleus, suppressed <e2>PTH<\\e2> mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"doxercalciferol","object":"PTH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In pig parathyroid cells, paricalcitol and the active form of <e1>CHEMICAL<\\e1> induced VDR translocation from the cytoplasm into the nucleus, suppressed <e2>GENE-Y<\\e2> mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively","sentence":"In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively"}
{"PMID":20223979,"re_id":1,"annotated sentence":"<e1>Thalidomide<\\e1> initiates its teratogenic effects by binding to CRBN and inhibiting the associated <e2>ubiquitin ligase<\\e2> activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Thalidomide","object":"ubiquitin ligase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> initiates its teratogenic effects by binding to CRBN and inhibiting the associated <e2>GENE-N<\\e2> activity","sentence":"Thalidomide initiates its teratogenic effects by binding to CRBN and inhibiting the associated ubiquitin ligase activity"}
{"PMID":20448797,"re_id":0,"annotated sentence":"<e1>Telmisartan<\\e1> is an <e2>angiotensin II receptor<\\e2> blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Telmisartan","object":"angiotensin II receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is an <e2>GENE-N<\\e2> blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure","sentence":"Telmisartan is an angiotensin II receptor blocker (ARB) displaying unique pharmacologic properties, including a longer half life than any other ARB, that result in large and sustained reductions of blood pressure"}
{"PMID":20512796,"re_id":2,"annotated sentence":"With the pentapeptide linked through the C7alpha position of <e1>estradiol<\\e1>  the resulting PROTAC shows the most effective <e2>ER<\\e2> degradation and highest affinity for the estrogen receptor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"estradiol","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"With the pentapeptide linked through the C7alpha position of <e1>CHEMICAL<\\e1>  the resulting PROTAC shows the most effective <e2>GENE-N<\\e2> degradation and highest affinity for the estrogen receptor","sentence":"With the pentapeptide linked through the C7alpha position of estradiol  the resulting PROTAC shows the most effective ER degradation and highest affinity for the estrogen receptor"}
{"PMID":20512796,"re_id":3,"annotated sentence":"Recent studies indicate that <e1>tamoxifen<\\e1> initially acts as an antagonist, but later functions as an <e2>ER<\\e2> agonist, promoting tumor growth","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"tamoxifen","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Recent studies indicate that <e1>CHEMICAL<\\e1> initially acts as an antagonist, but later functions as an <e2>GENE-N<\\e2> agonist, promoting tumor growth","sentence":"Recent studies indicate that tamoxifen initially acts as an antagonist, but later functions as an ER agonist, promoting tumor growth"}
{"PMID":20512796,"re_id":4,"annotated sentence":"Recent studies indicate that <e1>tamoxifen<\\e1> initially acts as an antagonist, but later functions as an <e2>ER<\\e2> agonist, promoting tumor growth","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"tamoxifen","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Recent studies indicate that <e1>CHEMICAL<\\e1> initially acts as an antagonist, but later functions as an <e2>GENE-N<\\e2> agonist, promoting tumor growth","sentence":"Recent studies indicate that tamoxifen initially acts as an antagonist, but later functions as an ER agonist, promoting tumor growth"}
{"PMID":20590599,"re_id":4,"annotated sentence":"<e1>salmeterol<\\e1> and formoterol, for the <e2>beta(2)-adrenoceptor<\\e2> over the beta(1) or beta(3)), while others (e.g","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"salmeterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and formoterol, for the <e2>GENE-Y<\\e2> over the beta(1) or beta(3)), while others (e.g","sentence":"salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or beta(3)), while others (e.g"}
{"PMID":20590599,"re_id":5,"annotated sentence":"<e1>salmeterol<\\e1> and formoterol, for the beta(2)-adrenoceptor over the <e2>beta(1)<\\e2> or beta(3)), while others (e.g","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"salmeterol","object":"beta(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and formoterol, for the beta(2)-adrenoceptor over the <e2>GENE-Y<\\e2> or beta(3)), while others (e.g","sentence":"salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or beta(3)), while others (e.g"}
{"PMID":20590599,"re_id":6,"annotated sentence":"salmeterol and <e1>formoterol<\\e1>  for the <e2>beta(2)-adrenoceptor<\\e2> over the beta(1) or beta(3)), while others (e.g","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"formoterol","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"salmeterol and <e1>CHEMICAL<\\e1>  for the <e2>GENE-Y<\\e2> over the beta(1) or beta(3)), while others (e.g","sentence":"salmeterol and formoterol  for the beta(2)-adrenoceptor over the beta(1) or beta(3)), while others (e.g"}
{"PMID":20590599,"re_id":7,"annotated sentence":"salmeterol and <e1>formoterol<\\e1>  for the beta(2)-adrenoceptor over the beta(1) or <e2>beta(3)<\\e2> , while others (e.g","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"formoterol","object":"beta(3)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"salmeterol and <e1>CHEMICAL<\\e1>  for the beta(2)-adrenoceptor over the beta(1) or <e2>GENE-Y<\\e2> , while others (e.g","sentence":"salmeterol and formoterol  for the beta(2)-adrenoceptor over the beta(1) or beta(3) , while others (e.g"}
{"PMID":20590599,"re_id":8,"annotated sentence":"none","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"isoprenaline","object":"beta(2)-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":20590599,"re_id":9,"annotated sentence":"none","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"isoprenaline","object":"beta(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":20590599,"re_id":10,"annotated sentence":"none","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"isoprenaline","object":"beta(3)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":20600573,"re_id":0,"annotated sentence":"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the <e1>N-propargyl<\\e1> moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating <e2>Bcl-2<\\e2> family proteins","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"N-propargyl","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the <e1>CHEMICAL<\\e1> moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating <e2>GENE-Y<\\e2> family proteins","sentence":"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins"}
{"PMID":20600573,"re_id":1,"annotated sentence":"<e1>Rasagiline<\\e1>  a novel anti-Parkinsonian <e2>monoamine oxidase-B<\\e2> inhibitor with neuroprotective activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Rasagiline","object":"monoamine oxidase-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a novel anti-Parkinsonian <e2>GENE-Y<\\e2> inhibitor with neuroprotective activity","sentence":"Rasagiline  a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity"}
{"PMID":20600573,"re_id":2,"annotated sentence":"<e1>Rasagiline<\\e1> (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible <e2>monoamine oxidase (MAO)-B<\\e2> inhibitor, anti-Parkinsonian drug","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Rasagiline","object":"monoamine oxidase (MAO)-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible <e2>GENE-Y<\\e2> inhibitor, anti-Parkinsonian drug","sentence":"Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug"}
{"PMID":20600573,"re_id":3,"annotated sentence":"Rasagiline (<e1>N-propargyl-1-(R)-aminoindan<\\e1>  is a novel, highly potent irreversible <e2>monoamine oxidase (MAO)-B<\\e2> inhibitor, anti-Parkinsonian drug","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"N-propargyl-1-(R)-aminoindan","object":"monoamine oxidase (MAO)-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rasagiline (<e1>CHEMICAL<\\e1>  is a novel, highly potent irreversible <e2>GENE-Y<\\e2> inhibitor, anti-Parkinsonian drug","sentence":"Rasagiline (N-propargyl-1-(R)-aminoindan  is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug"}
{"PMID":20600573,"re_id":4,"annotated sentence":"Its S-isomer, <e1>TVP1022<\\e1> is thousand times less potent as an <e2>MAO-B<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TVP1022","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Its S-isomer, <e1>CHEMICAL<\\e1> is thousand times less potent as an <e2>GENE-Y<\\e2> inhibitor","sentence":"Its S-isomer, TVP1022 is thousand times less potent as an MAO-B inhibitor"}
{"PMID":20600573,"re_id":5,"annotated sentence":"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of <e1>rasagiline<\\e1> does not depend on inhibition of <e2>MAO-B<\\e2>  but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rasagiline","object":"MAO-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of <e1>CHEMICAL<\\e1> does not depend on inhibition of <e2>GENE-Y<\\e2>  but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins","sentence":"However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B  but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins"}
{"PMID":20615127,"re_id":5,"annotated sentence":"Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum <e2>TSH<\\e2> level with high dose of <e1>levothyroxine<\\e1> might be optimum for normal growth.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"levothyroxine","object":"TSH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum <e2>GENE-N<\\e2> level with high dose of <e1>CHEMICAL<\\e1> might be optimum for normal growth.","sentence":"Our findings suggest that R316C causes reduced association with and impaired release of NCoR, resulting in RTH predominantly at the pituitary level, and that slightly elevated serum TSH level with high dose of levothyroxine might be optimum for normal growth."}
{"PMID":20724158,"re_id":0,"annotated sentence":"With exposure to <e1>rofecoxib<\\e1>  a selective <e2>COX-2<\\e2> inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"With exposure to <e1>CHEMICAL<\\e1>  a selective <e2>GENE-Y<\\e2> inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective GENE-Y inhibitors in breast cancer prophylaxis.","sentence":"With exposure to rofecoxib  a selective COX-2 inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis."}
{"PMID":20724158,"re_id":1,"annotated sentence":"With exposure to <e1>rofecoxib<\\e1>  a selective COX-2 inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective <e2>COX-2<\\e2> inhibitors in breast cancer prophylaxis.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rofecoxib","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"With exposure to <e1>CHEMICAL<\\e1>  a selective GENE-Y inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective <e2>GENE-Y<\\e2> inhibitors in breast cancer prophylaxis.","sentence":"With exposure to rofecoxib  a selective COX-2 inhibitor, breast cancer risk reduction was appreciable (46%), suggesting a possible role for selective COX-2 inhibitors in breast cancer prophylaxis."}
{"PMID":20724158,"re_id":2,"annotated sentence":"METHODS: We conducted a case-control study to measure the association between selective <e2>cox-2<\\e2> inhibitors, particularly <e1>celecoxib<\\e1>  rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"celecoxib","object":"cox-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: We conducted a case-control study to measure the association between selective <e2>GENE-Y<\\e2> inhibitors, particularly <e1>CHEMICAL<\\e1>  rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk","sentence":"METHODS: We conducted a case-control study to measure the association between selective cox-2 inhibitors, particularly celecoxib  rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk"}
{"PMID":20724158,"re_id":3,"annotated sentence":"METHODS: We conducted a case-control study to measure the association between selective <e2>cox-2<\\e2> inhibitors, particularly celecoxib, <e1>rofecoxib<\\e1>  valdecoxib and non-specific NSAID subgroups, and breast cancer risk","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rofecoxib","object":"cox-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: We conducted a case-control study to measure the association between selective <e2>GENE-Y<\\e2> inhibitors, particularly celecoxib, <e1>CHEMICAL<\\e1>  valdecoxib and non-specific NSAID subgroups, and breast cancer risk","sentence":"METHODS: We conducted a case-control study to measure the association between selective cox-2 inhibitors, particularly celecoxib, rofecoxib  valdecoxib and non-specific NSAID subgroups, and breast cancer risk"}
{"PMID":20724158,"re_id":4,"annotated sentence":"METHODS: We conducted a case-control study to measure the association between selective <e2>cox-2<\\e2> inhibitors, particularly celecoxib, rofecoxib, <e1>valdecoxib<\\e1> and non-specific NSAID subgroups, and breast cancer risk","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"valdecoxib","object":"cox-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: We conducted a case-control study to measure the association between selective <e2>GENE-Y<\\e2> inhibitors, particularly celecoxib, rofecoxib, <e1>CHEMICAL<\\e1> and non-specific NSAID subgroups, and breast cancer risk","sentence":"METHODS: We conducted a case-control study to measure the association between selective cox-2 inhibitors, particularly celecoxib, rofecoxib, valdecoxib and non-specific NSAID subgroups, and breast cancer risk"}
{"PMID":20724158,"re_id":5,"annotated sentence":"BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-<e1>steroidal<\\e1> anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of <e2>cyclooxygenase-2<\\e2> (COX-2)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"steroidal","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-<e1>CHEMICAL<\\e1> anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of <e2>GENE-Y<\\e2> (COX-2)","sentence":"BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 (COX-2)"}
{"PMID":20724158,"re_id":6,"annotated sentence":"BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-<e1>steroidal<\\e1> anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 (<e2>COX-2<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"steroidal","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-<e1>CHEMICAL<\\e1> anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 (<e2>GENE-Y<\\e2> ","sentence":"BACKGROUND: Recent epidemiologic and laboratory studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of breast cancer through inhibition of cyclooxygenase-2 (COX-2 "}
{"PMID":2087492,"re_id":3,"annotated sentence":"The suppressive effect of <e1>ceruletide<\\e1> on barrel rotation could be partially countered by MK-329, a selective peripheral <e2>CCK<\\e2> (CCK-A) receptor antagonist","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"ceruletide","object":"CCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The suppressive effect of <e1>CHEMICAL<\\e1> on barrel rotation could be partially countered by MK-329, a selective peripheral <e2>GENE-Y<\\e2> (GENE-Y-A) receptor antagonist","sentence":"The suppressive effect of ceruletide on barrel rotation could be partially countered by MK-329, a selective peripheral CCK (CCK-A) receptor antagonist"}
{"PMID":2087492,"re_id":4,"annotated sentence":"The suppressive effect of <e1>ceruletide<\\e1> on barrel rotation could be partially countered by MK-329, a selective peripheral CCK <e2>(CCK-A) receptor<\\e2> antagonist","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"ceruletide","object":"(CCK-A) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The suppressive effect of <e1>CHEMICAL<\\e1> on barrel rotation could be partially countered by MK-329, a selective peripheral CCK <e2>GENE-Y<\\e2> antagonist","sentence":"The suppressive effect of ceruletide on barrel rotation could be partially countered by MK-329, a selective peripheral CCK (CCK-A) receptor antagonist"}
{"PMID":2087492,"re_id":5,"annotated sentence":"These findings suggest that <e1>ceruletide<\\e1> specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through <e2>CCK-A receptor<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"ceruletide","object":"CCK-A receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings suggest that <e1>CHEMICAL<\\e1> specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through <e2>GENE-Y<\\e2> ","sentence":"These findings suggest that ceruletide specifically suppresses the barrel rotation evoked by SMS 201-995 in a long-lasting manner possibly acting through CCK-A receptor "}
{"PMID":2087492,"re_id":6,"annotated sentence":"The suppressive effect of ceruletide on barrel rotation could be partially countered by <e1>MK-329<\\e1>  a selective peripheral <e2>CCK<\\e2> (CCK-A) receptor antagonist","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"MK-329","object":"CCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The suppressive effect of ceruletide on barrel rotation could be partially countered by <e1>CHEMICAL<\\e1>  a selective peripheral <e2>GENE-Y<\\e2> (GENE-Y-A) receptor antagonist","sentence":"The suppressive effect of ceruletide on barrel rotation could be partially countered by MK-329  a selective peripheral CCK (CCK-A) receptor antagonist"}
{"PMID":2087492,"re_id":7,"annotated sentence":"The suppressive effect of ceruletide on barrel rotation could be partially countered by <e1>MK-329<\\e1>  a selective peripheral CCK <e2>(CCK-A) receptor<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"MK-329","object":"(CCK-A) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The suppressive effect of ceruletide on barrel rotation could be partially countered by <e1>CHEMICAL<\\e1>  a selective peripheral CCK <e2>GENE-Y<\\e2> antagonist","sentence":"The suppressive effect of ceruletide on barrel rotation could be partially countered by MK-329  a selective peripheral CCK (CCK-A) receptor antagonist"}
{"PMID":21058326,"re_id":7,"annotated sentence":"BACKGROUND: The effects of <e2>histamine H1<\\e2> antagonist <e1>chlorcyclizine<\\e1> on rat palate development were characterized following in utero exposure","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"chlorcyclizine","object":"histamine H1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"BACKGROUND: The effects of <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> on rat palate development were characterized following in utero exposure","sentence":"BACKGROUND: The effects of histamine H1 antagonist chlorcyclizine on rat palate development were characterized following in utero exposure"}
{"PMID":21058326,"re_id":8,"annotated sentence":"Effects of the <e2>histamine H1<\\e2> antagonist <e1>chlorcyclizine<\\e1> on rat fetal palate development","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"chlorcyclizine","object":"histamine H1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effects of the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> on rat fetal palate development","sentence":"Effects of the histamine H1 antagonist chlorcyclizine on rat fetal palate development"}
{"PMID":2120879,"re_id":3,"annotated sentence":"The smooth muscle relaxant, <e1>W-7<\\e1>  which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced <e2>PRL<\\e2> secretion in a dose-dependent manner (r = -0.991, p less than 0.01)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"W-7","object":"PRL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The smooth muscle relaxant, <e1>CHEMICAL<\\e1>  which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced <e2>GENE-Y<\\e2> secretion in a dose-dependent manner (r = -0.991, p less than 0.01)","sentence":"The smooth muscle relaxant, W-7  which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced PRL secretion in a dose-dependent manner (r = -0.991, p less than 0.01)"}
{"PMID":2120879,"re_id":4,"annotated sentence":"Removing medium Ca2+, blocking <e2>Ca2+ channels<\\e2> with 50 mumol\/l <e1>verapamil<\\e1>  or inhibiting calmodulin activation with 20 mumol\/l trifluoperazine, 10 mumol\/l chlorpromazine or 10 mumol\/l pimozide almost completely blocked hyposmolarity-induced secretion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"verapamil","object":"Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Removing medium Ca2+, blocking <e2>GENE-N<\\e2> with 50 mumol\/l <e1>CHEMICAL<\\e1>  or inhibiting calmodulin activation with 20 mumol\/l trifluoperazine, 10 mumol\/l chlorpromazine or 10 mumol\/l pimozide almost completely blocked hyposmolarity-induced secretion","sentence":"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol\/l verapamil  or inhibiting calmodulin activation with 20 mumol\/l trifluoperazine, 10 mumol\/l chlorpromazine or 10 mumol\/l pimozide almost completely blocked hyposmolarity-induced secretion"}
{"PMID":2120879,"re_id":5,"annotated sentence":"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol\/l verapamil, or inhibiting <e2>calmodulin<\\e2> activation with 20 mumol\/l <e1>trifluoperazine<\\e1>  10 mumol\/l chlorpromazine or 10 mumol\/l pimozide almost completely blocked hyposmolarity-induced secretion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"trifluoperazine","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol\/l verapamil, or inhibiting <e2>GENE-Y<\\e2> activation with 20 mumol\/l <e1>CHEMICAL<\\e1>  10 mumol\/l chlorpromazine or 10 mumol\/l pimozide almost completely blocked hyposmolarity-induced secretion","sentence":"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol\/l verapamil, or inhibiting calmodulin activation with 20 mumol\/l trifluoperazine  10 mumol\/l chlorpromazine or 10 mumol\/l pimozide almost completely blocked hyposmolarity-induced secretion"}
{"PMID":2120879,"re_id":6,"annotated sentence":"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol\/l verapamil, or inhibiting <e2>calmodulin<\\e2> activation with 20 mumol\/l trifluoperazine, 10 mumol\/l <e1>chlorpromazine<\\e1> or 10 mumol\/l pimozide almost completely blocked hyposmolarity-induced secretion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"chlorpromazine","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol\/l verapamil, or inhibiting <e2>GENE-Y<\\e2> activation with 20 mumol\/l trifluoperazine, 10 mumol\/l <e1>CHEMICAL<\\e1> or 10 mumol\/l pimozide almost completely blocked hyposmolarity-induced secretion","sentence":"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol\/l verapamil, or inhibiting calmodulin activation with 20 mumol\/l trifluoperazine, 10 mumol\/l chlorpromazine or 10 mumol\/l pimozide almost completely blocked hyposmolarity-induced secretion"}
{"PMID":2120879,"re_id":7,"annotated sentence":"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol\/l verapamil, or inhibiting <e2>calmodulin<\\e2> activation with 20 mumol\/l trifluoperazine, 10 mumol\/l chlorpromazine or 10 mumol\/l <e1>pimozide<\\e1> almost completely blocked hyposmolarity-induced secretion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"pimozide","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol\/l verapamil, or inhibiting <e2>GENE-Y<\\e2> activation with 20 mumol\/l trifluoperazine, 10 mumol\/l chlorpromazine or 10 mumol\/l <e1>CHEMICAL<\\e1> almost completely blocked hyposmolarity-induced secretion","sentence":"Removing medium Ca2+, blocking Ca2+ channels with 50 mumol\/l verapamil, or inhibiting calmodulin activation with 20 mumol\/l trifluoperazine, 10 mumol\/l chlorpromazine or 10 mumol\/l pimozide almost completely blocked hyposmolarity-induced secretion"}
{"PMID":21318872,"re_id":0,"annotated sentence":"An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement <e1>spermine<\\e1> and this can be accomplished by breeding with CAG-<e2>SMS<\\e2> mice that express SpmS from a ubiquitous promoter","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"spermine","object":"SMS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement <e1>CHEMICAL<\\e1> and this can be accomplished by breeding with CAG-<e2>GENE-Y<\\e2> mice that express SpmS from a ubiquitous promoter","sentence":"An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement spermine and this can be accomplished by breeding with CAG-SMS mice that express SpmS from a ubiquitous promoter"}
{"PMID":21318872,"re_id":1,"annotated sentence":"An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement <e1>spermine<\\e1> and this can be accomplished by breeding with CAG-SMS mice that express <e2>SpmS<\\e2> from a ubiquitous promoter","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"spermine","object":"SpmS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement <e1>CHEMICAL<\\e1> and this can be accomplished by breeding with CAG-SMS mice that express <e2>GENE-Y<\\e2> from a ubiquitous promoter","sentence":"An essential control in experiments using Gy mice is to demonstrate that the abnormal phenotypes exhibited by these mice are abolished by providing replacement spermine and this can be accomplished by breeding with CAG-SMS mice that express SpmS from a ubiquitous promoter"}
{"PMID":21926191,"re_id":1,"annotated sentence":"Importantly, treatment with <e1>cabozantinib<\\e1> did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of <e2>VEGF<\\e2> signaling that do not target MET","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"cabozantinib","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Importantly, treatment with <e1>CHEMICAL<\\e1> did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of <e2>GENE-Y<\\e2> signaling that do not target MET","sentence":"Importantly, treatment with cabozantinib did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of VEGF signaling that do not target MET"}
{"PMID":21926191,"re_id":2,"annotated sentence":"Collectively, these data suggest that <e1>cabozantinib<\\e1> is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated <e2>MET<\\e2> and VEGFR signaling.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"cabozantinib","object":"MET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Collectively, these data suggest that <e1>CHEMICAL<\\e1> is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated <e2>GENE-Y<\\e2> and VEGFR signaling.","sentence":"Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling."}
{"PMID":21926191,"re_id":3,"annotated sentence":"Collectively, these data suggest that <e1>cabozantinib<\\e1> is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and <e2>VEGFR<\\e2> signaling.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"cabozantinib","object":"VEGFR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Collectively, these data suggest that <e1>CHEMICAL<\\e1> is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and <e2>GENE-N<\\e2> signaling.","sentence":"Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling."}
{"PMID":21926191,"re_id":4,"annotated sentence":"<e1>Cabozantinib<\\e1> (XL184) is a small-molecule <e2>kinase<\\e2> inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Cabozantinib","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (XL184) is a small-molecule <e2>GENE-N<\\e2> inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine GENE-Ns that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","sentence":"Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3"}
{"PMID":21926191,"re_id":5,"annotated sentence":"<e1>Cabozantinib<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward <e2>MET<\\e2> and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Cabozantinib","object":"MET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward <e2>GENE-Y<\\e2> and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","sentence":"Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3"}
{"PMID":21926191,"re_id":6,"annotated sentence":"<e1>Cabozantinib<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and <e2>VEGF receptor 2<\\e2> (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Cabozantinib","object":"VEGF receptor 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and <e2>GENE-Y<\\e2> (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","sentence":"Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3"}
{"PMID":21926191,"re_id":7,"annotated sentence":"<e1>Cabozantinib<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (<e2>VEGFR2<\\e2> , as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Cabozantinib","object":"VEGFR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (<e2>GENE-Y<\\e2> , as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","sentence":"Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2 , as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3"}
{"PMID":21926191,"re_id":8,"annotated sentence":"<e1>Cabozantinib<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other <e2>receptor tyrosine kinases<\\e2> that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Cabozantinib","object":"receptor tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other <e2>GENE-N<\\e2> that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","sentence":"Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3"}
{"PMID":21926191,"re_id":9,"annotated sentence":"<e1>Cabozantinib<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including <e2>RET<\\e2>  KIT, AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Cabozantinib","object":"RET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including <e2>GENE-Y<\\e2>  KIT, AXL, and FLT3","sentence":"Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET  KIT, AXL, and FLT3"}
{"PMID":21926191,"re_id":10,"annotated sentence":"<e1>Cabozantinib<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, <e2>KIT<\\e2>  AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Cabozantinib","object":"KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, <e2>GENE-Y<\\e2>  AXL, and FLT3","sentence":"Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT  AXL, and FLT3"}
{"PMID":21926191,"re_id":11,"annotated sentence":"<e1>Cabozantinib<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, <e2>AXL<\\e2>  and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Cabozantinib","object":"AXL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, <e2>GENE-Y<\\e2>  and FLT3","sentence":"Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL  and FLT3"}
{"PMID":21926191,"re_id":12,"annotated sentence":"<e1>Cabozantinib<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and <e2>FLT3<\\e2>  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Cabozantinib","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and <e2>GENE-Y<\\e2>  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro","sentence":"Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro"}
{"PMID":21926191,"re_id":13,"annotated sentence":"Cabozantinib (<e1>XL184<\\e1>  is a small-molecule <e2>kinase<\\e2> inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"XL184","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cabozantinib (<e1>CHEMICAL<\\e1>  is a small-molecule <e2>GENE-N<\\e2> inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine GENE-Ns that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","sentence":"Cabozantinib (XL184  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3"}
{"PMID":21926191,"re_id":14,"annotated sentence":"Cabozantinib (<e1>XL184<\\e1>  is a small-molecule kinase inhibitor with potent activity toward <e2>MET<\\e2> and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"XL184","object":"MET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cabozantinib (<e1>CHEMICAL<\\e1>  is a small-molecule kinase inhibitor with potent activity toward <e2>GENE-Y<\\e2> and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","sentence":"Cabozantinib (XL184  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3"}
{"PMID":21926191,"re_id":15,"annotated sentence":"Cabozantinib (<e1>XL184<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and <e2>VEGF receptor 2<\\e2> (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"XL184","object":"VEGF receptor 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cabozantinib (<e1>CHEMICAL<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and <e2>GENE-Y<\\e2> (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","sentence":"Cabozantinib (XL184  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3"}
{"PMID":21926191,"re_id":16,"annotated sentence":"Cabozantinib (<e1>XL184<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (<e2>VEGFR2<\\e2> , as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"XL184","object":"VEGFR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cabozantinib (<e1>CHEMICAL<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (<e2>GENE-Y<\\e2> , as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","sentence":"Cabozantinib (XL184  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2 , as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3"}
{"PMID":21926191,"re_id":17,"annotated sentence":"Cabozantinib (<e1>XL184<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other <e2>receptor tyrosine kinases<\\e2> that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"XL184","object":"receptor tyrosine kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cabozantinib (<e1>CHEMICAL<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other <e2>GENE-N<\\e2> that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3","sentence":"Cabozantinib (XL184  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3"}
{"PMID":21926191,"re_id":18,"annotated sentence":"Cabozantinib (<e1>XL184<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including <e2>RET<\\e2>  KIT, AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"XL184","object":"RET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cabozantinib (<e1>CHEMICAL<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including <e2>GENE-Y<\\e2>  KIT, AXL, and FLT3","sentence":"Cabozantinib (XL184  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET  KIT, AXL, and FLT3"}
{"PMID":21926191,"re_id":19,"annotated sentence":"Cabozantinib (<e1>XL184<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, <e2>KIT<\\e2>  AXL, and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"XL184","object":"KIT","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cabozantinib (<e1>CHEMICAL<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, <e2>GENE-Y<\\e2>  AXL, and FLT3","sentence":"Cabozantinib (XL184  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT  AXL, and FLT3"}
{"PMID":21926191,"re_id":20,"annotated sentence":"Cabozantinib (<e1>XL184<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, <e2>AXL<\\e2>  and FLT3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"XL184","object":"AXL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cabozantinib (<e1>CHEMICAL<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, <e2>GENE-Y<\\e2>  and FLT3","sentence":"Cabozantinib (XL184  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL  and FLT3"}
{"PMID":21926191,"re_id":21,"annotated sentence":"Cabozantinib (<e1>XL184<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and <e2>FLT3<\\e2>  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"XL184","object":"FLT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cabozantinib (<e1>CHEMICAL<\\e1>  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and <e2>GENE-Y<\\e2>  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro","sentence":"Cabozantinib (XL184  is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro"}
{"PMID":21926191,"re_id":22,"annotated sentence":"Treatment with <e1>cabozantinib<\\e1> inhibited <e2>MET<\\e2> and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cabozantinib","object":"MET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro","sentence":"Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro"}
{"PMID":21926191,"re_id":23,"annotated sentence":"Treatment with <e1>cabozantinib<\\e1> inhibited MET and <e2>VEGFR2<\\e2> phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cabozantinib","object":"VEGFR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> inhibited MET and <e2>GENE-Y<\\e2> phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro","sentence":"Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro"}
{"PMID":21926191,"re_id":24,"annotated sentence":"<e1>Cabozantinib<\\e1> (XL184), a novel <e2>MET<\\e2> and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Cabozantinib","object":"MET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (XL184), a novel <e2>GENE-Y<\\e2> and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","sentence":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth"}
{"PMID":21926191,"re_id":25,"annotated sentence":"<e1>Cabozantinib<\\e1> (XL184), a novel MET and <e2>VEGFR2<\\e2> inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Cabozantinib","object":"VEGFR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (XL184), a novel MET and <e2>GENE-Y<\\e2> inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","sentence":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth"}
{"PMID":21926191,"re_id":26,"annotated sentence":"Cabozantinib (<e1>XL184<\\e1> , a novel <e2>MET<\\e2> and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"XL184","object":"MET","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cabozantinib (<e1>CHEMICAL<\\e1> , a novel <e2>GENE-Y<\\e2> and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","sentence":"Cabozantinib (XL184 , a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth"}
{"PMID":21926191,"re_id":27,"annotated sentence":"Cabozantinib (<e1>XL184<\\e1> , a novel MET and <e2>VEGFR2<\\e2> inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"XL184","object":"VEGFR2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cabozantinib (<e1>CHEMICAL<\\e1> , a novel MET and <e2>GENE-Y<\\e2> inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","sentence":"Cabozantinib (XL184 , a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth"}
{"PMID":21955206,"re_id":2,"annotated sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>colchicoside<\\e1> inhibited RANKL-induced <e2>NF-kappaB<\\e2> activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"colchicoside","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of the GENE-N pathway was responsible for this effect since the <e1>CHEMICAL<\\e1> inhibited RANKL-induced <e2>GENE-N<\\e2> activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of GENE-Nalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of GENE-N","sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the colchicoside inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB"}
{"PMID":21955206,"re_id":3,"annotated sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>colchicoside<\\e1> inhibited RANKL-induced NF-kappaB activation, activation of <e2>IkappaB kinase<\\e2> (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"colchicoside","object":"IkappaB kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>CHEMICAL<\\e1> inhibited RANKL-induced NF-kappaB activation, activation of <e2>GENE-N<\\e2> (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB","sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the colchicoside inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB"}
{"PMID":21955206,"re_id":4,"annotated sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>colchicoside<\\e1> inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (<e2>IKK<\\e2>  and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"colchicoside","object":"IKK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>CHEMICAL<\\e1> inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (<e2>GENE-N<\\e2>  and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB","sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the colchicoside inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK  and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB"}
{"PMID":21955206,"re_id":5,"annotated sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>colchicoside<\\e1> inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of <e2>NF-kappaBalpha<\\e2> (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"colchicoside","object":"NF-kappaBalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>CHEMICAL<\\e1> inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of <e2>GENE-Y<\\e2> (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB","sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the colchicoside inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB"}
{"PMID":21955206,"re_id":6,"annotated sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>colchicoside<\\e1> inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (<e2>IkappaBalpha<\\e2>  phosphorylation and degradation, an inhibitor of NF-kappaB","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"colchicoside","object":"IkappaBalpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>CHEMICAL<\\e1> inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (<e2>GENE-Y<\\e2>  phosphorylation and degradation, an inhibitor of NF-kappaB","sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the colchicoside inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha  phosphorylation and degradation, an inhibitor of NF-kappaB"}
{"PMID":21955206,"re_id":7,"annotated sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>colchicoside<\\e1> inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of <e2>NF-kappaB<\\e2>  Furthermore, an inhibitor of the IkappaBalpha kinase gamma or NF-kappaB essential modulator, the regulatory component of the IKK complex, demonstrated that the NF-kappaB signalling pathway is mandatory for osteoclastogenesis induced by RANKL","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"colchicoside","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of the GENE-N pathway was responsible for this effect since the <e1>CHEMICAL<\\e1> inhibited RANKL-induced GENE-N activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of GENE-Nalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of <e2>GENE-N<\\e2>  Furthermore, an inhibitor of the IkappaBalpha kinase gamma or GENE-N essential modulator, the regulatory component of the IKK complex, demonstrated that the GENE-N signalling pathway is mandatory for osteoclastogenesis induced by RANKL","sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the colchicoside inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB  Furthermore, an inhibitor of the IkappaBalpha kinase gamma or NF-kappaB essential modulator, the regulatory component of the IKK complex, demonstrated that the NF-kappaB signalling pathway is mandatory for osteoclastogenesis induced by RANKL"}
{"PMID":21955206,"re_id":8,"annotated sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>colchicoside<\\e1> inhibited <e2>RANKL<\\e2> induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"colchicoside","object":"RANKL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB","sentence":"Inhibition of the NF-kappaB pathway was responsible for this effect since the colchicoside inhibited RANKL induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB"}
{"PMID":21955206,"re_id":9,"annotated sentence":"CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that <e1>thiocolchicoside<\\e1> significantly suppressed osteoclastogenesis induced by <e2>RANKL<\\e2> and tumour cells via the NF-kappaB signalling pathway","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"thiocolchicoside","object":"RANKL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that <e1>CHEMICAL<\\e1> significantly suppressed osteoclastogenesis induced by <e2>GENE-Y<\\e2> and tumour cells via the NF-kappaB signalling pathway","sentence":"CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that thiocolchicoside significantly suppressed osteoclastogenesis induced by RANKL and tumour cells via the NF-kappaB signalling pathway"}
{"PMID":21955206,"re_id":10,"annotated sentence":"CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that <e1>thiocolchicoside<\\e1> significantly suppressed osteoclastogenesis induced by RANKL and tumour cells via the <e2>NF-kappaB<\\e2> signalling pathway","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"thiocolchicoside","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that <e1>CHEMICAL<\\e1> significantly suppressed osteoclastogenesis induced by RANKL and tumour cells via the <e2>GENE-N<\\e2> signalling pathway","sentence":"CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that thiocolchicoside significantly suppressed osteoclastogenesis induced by RANKL and tumour cells via the NF-kappaB signalling pathway"}
{"PMID":22064666,"re_id":3,"annotated sentence":"Although genetic polymorphisms in the endothelial nitric oxide synthase (<e2>eNOS<\\e2>  gene may impair endogenous <e1>NO<\\e1> formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"NO","object":"eNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although genetic polymorphisms in the endothelial nitric oxide synthase (<e2>eCHEMICALS<\\e2>  gene may impair endogenous <e1>CHEMICAL<\\e1> formation, there is little information about how eCHEMICALS polymorphisms and haplotypes affect the responses to sildenafil","sentence":"Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS  gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil"}
{"PMID":22064666,"re_id":4,"annotated sentence":"Although genetic polymorphisms in the <e2>endothelial nitric oxide synthase<\\e2> (eNOS) gene may impair endogenous <e1>NO<\\e1> formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"NO","object":"endothelial nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although genetic polymorphisms in the <e2>GENE-Y<\\e2> (eCHEMICALS) gene may impair endogenous <e1>CHEMICAL<\\e1> formation, there is little information about how eCHEMICALS polymorphisms and haplotypes affect the responses to sildenafil","sentence":"Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil"}
{"PMID":22080037,"re_id":0,"annotated sentence":"Here, we report biochemical evidence that <e1>mercury<\\e1> alone induces <e2>NF-\u03baB<\\e2> activation, resulting in the induced expression of COX-2 and iNOS","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"mercury","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Here, we report biochemical evidence that <e1>CHEMICAL<\\e1> alone induces <e2>GENE-N<\\e2> activation, resulting in the induced expression of COX-2 and iNOS","sentence":"Here, we report biochemical evidence that mercury alone induces NF-\u03baB activation, resulting in the induced expression of COX-2 and iNOS"}
{"PMID":22080037,"re_id":1,"annotated sentence":"Here, we report biochemical evidence that <e1>mercury<\\e1> alone induces NF-\u03baB activation, resulting in the induced expression of <e2>COX-2<\\e2> and iNOS","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"mercury","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we report biochemical evidence that <e1>CHEMICAL<\\e1> alone induces NF-\u03baB activation, resulting in the induced expression of <e2>GENE-Y<\\e2> and iNOS","sentence":"Here, we report biochemical evidence that mercury alone induces NF-\u03baB activation, resulting in the induced expression of COX-2 and iNOS"}
{"PMID":22080037,"re_id":2,"annotated sentence":"Here, we report biochemical evidence that <e1>mercury<\\e1> alone induces NF-\u03baB activation, resulting in the induced expression of COX-2 and <e2>iNOS<\\e2>  The results suggest that mercury can induce inflammatory diseases by lowering host defense.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"mercury","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we report biochemical evidence that <e1>CHEMICAL<\\e1> alone induces NF-\u03baB activation, resulting in the induced expression of COX-2 and <e2>GENE-Y<\\e2>  The results suggest that CHEMICAL can induce inflammatory diseases by lowering host defense.","sentence":"Here, we report biochemical evidence that mercury alone induces NF-\u03baB activation, resulting in the induced expression of COX-2 and iNOS  The results suggest that mercury can induce inflammatory diseases by lowering host defense."}
{"PMID":22080037,"re_id":3,"annotated sentence":"<e1>Mercury<\\e1> induces the expression of <e2>cyclooxygenase-2<\\e2> and inducible nitric oxide synthase","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Mercury","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induces the expression of <e2>GENE-Y<\\e2> and inducible nitric oxide synthase","sentence":"Mercury induces the expression of cyclooxygenase-2 and inducible nitric oxide synthase"}
{"PMID":22080037,"re_id":4,"annotated sentence":"<e1>Mercury<\\e1> induces the expression of cyclooxygenase-2 and <e2>inducible nitric oxide synthase<\\e2>  Nuclear factor-\u03baB (NF-\u03baB) is a transcription factor that mediates the inducible expression of a variety of genes involved in immune and inflammatory responses","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Mercury","object":"inducible nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induces the expression of cyclooxygenase-2 and <e2>GENE-Y<\\e2>  Nuclear factor-\u03baB (NF-\u03baB) is a transcription factor that mediates the inducible expression of a variety of genes involved in immune and inflammatory responses","sentence":"Mercury induces the expression of cyclooxygenase-2 and inducible nitric oxide synthase  Nuclear factor-\u03baB (NF-\u03baB) is a transcription factor that mediates the inducible expression of a variety of genes involved in immune and inflammatory responses"}
{"PMID":22381584,"re_id":0,"annotated sentence":"Unexpectedly, both the <e2>mGluR(5)<\\e2> pecific agonist, <e1>CHPG<\\e1>  and the group II mGluR (mGlu(2\/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current\/hyperpolarization","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"CHPG","object":"mGluR(5)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Unexpectedly, both the <e2>GENE-Y<\\e2> pecific agonist, <e1>CHEMICAL<\\e1>  and the group II mGluR (mGlu(2\/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current\/hyperpolarization","sentence":"Unexpectedly, both the mGluR(5) pecific agonist, CHPG  and the group II mGluR (mGlu(2\/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current\/hyperpolarization"}
{"PMID":22381584,"re_id":1,"annotated sentence":"Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the <e2>group II mGluR<\\e2> (mGlu(2\/3)) agonist, <e1>LY379268<\\e1> (LY), induced a TTX-insensitive outward current\/hyperpolarization","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"LY379268","object":"group II mGluR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the <e2>GENE-N<\\e2> (mGlu(2\/3)) agonist, <e1>CHEMICAL<\\e1> (LY), induced a TTX-insensitive outward current\/hyperpolarization","sentence":"Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the group II mGluR (mGlu(2\/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current\/hyperpolarization"}
{"PMID":22381584,"re_id":2,"annotated sentence":"Both outward currents were significantly reduced by the <e2>mGluR<\\e2> antagonist <e1>MCPG<\\e1> and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"MCPG","object":"mGluR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both outward currents were significantly reduced by the <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> and the CHPG-induced current was blocked by the specific GENE-N(5) antagonist MTEP","sentence":"Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP"}
{"PMID":22381584,"re_id":3,"annotated sentence":"Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific <e2>mGluR(5)<\\e2> antagonist <e1>MTEP<\\e1>  Concurrent Ca(2+)imaging revealed that while CHPG actions did include release of Ca(2+) from CPA\/thapsigargin-sensitive intracellular stores, actions of LY did not","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"MTEP","object":"mGluR(5)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1>  Concurrent Ca(2+)imaging revealed that while CHPG actions did include release of Ca(2+) from CPA\/thapsigargin-sensitive intracellular stores, actions of LY did not","sentence":"Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP  Concurrent Ca(2+)imaging revealed that while CHPG actions did include release of Ca(2+) from CPA\/thapsigargin-sensitive intracellular stores, actions of LY did not"}
{"PMID":22391562,"re_id":0,"annotated sentence":"We have examined the effectiveness of two novel <e2>Chk1<\\e2> selective inhibitors, <e1>AR323<\\e1> and AR678, in a panel of melanoma cell lines and normal cell types","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AR323","object":"Chk1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have examined the effectiveness of two novel <e2>GENE-Y<\\e2> selective inhibitors, <e1>CHEMICAL<\\e1> and AR678, in a panel of melanoma cell lines and normal cell types","sentence":"We have examined the effectiveness of two novel Chk1 selective inhibitors, AR323 and AR678, in a panel of melanoma cell lines and normal cell types"}
{"PMID":22391562,"re_id":1,"annotated sentence":"We have examined the effectiveness of two novel <e2>Chk1<\\e2> selective inhibitors, AR323 and <e1>AR678<\\e1>  in a panel of melanoma cell lines and normal cell types","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AR678","object":"Chk1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have examined the effectiveness of two novel <e2>GENE-Y<\\e2> selective inhibitors, AR323 and <e1>CHEMICAL<\\e1>  in a panel of melanoma cell lines and normal cell types","sentence":"We have examined the effectiveness of two novel Chk1 selective inhibitors, AR323 and AR678  in a panel of melanoma cell lines and normal cell types"}
{"PMID":22406476,"re_id":2,"annotated sentence":"Aspirin and <e1>metformin<\\e1> (an activator of <e2>AMPK<\\e2>  increased inhibition of mTOR and Akt, as well as autophagy in CRC cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"metformin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Aspirin and <e1>CHEMICAL<\\e1> (an activator of <e2>GENE-N<\\e2>  increased inhibition of mTOR and Akt, as well as autophagy in CRC cells","sentence":"Aspirin and metformin (an activator of AMPK  increased inhibition of mTOR and Akt, as well as autophagy in CRC cells"}
{"PMID":22406476,"re_id":3,"annotated sentence":"CONCLUSIONS: <e1>Aspirin<\\e1> is an inhibitor of mTOR and an activator of <e2>AMPK<\\e2>  targeting regulators of intracellular energy homeostasis and metabolism","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Aspirin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CONCLUSIONS: <e1>CHEMICAL<\\e1> is an inhibitor of mTOR and an activator of <e2>GENE-N<\\e2>  targeting regulators of intracellular energy homeostasis and metabolism","sentence":"CONCLUSIONS: Aspirin is an inhibitor of mTOR and an activator of AMPK  targeting regulators of intracellular energy homeostasis and metabolism"}
{"PMID":22406476,"re_id":4,"annotated sentence":"<e1>Aspirin<\\e1> inhibits mTOR signaling, activates <e2>AMP-activated protein kinase<\\e2>  and induces autophagy in colorectal cancer cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Aspirin","object":"AMP-activated protein kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits mTOR signaling, activates <e2>GENE-N<\\e2>  and induces autophagy in colorectal cancer cells","sentence":"Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase  and induces autophagy in colorectal cancer cells"}
{"PMID":22406476,"re_id":5,"annotated sentence":"<e1>Aspirin<\\e1> changed nucleotide ratios and activated <e2>AMPK<\\e2> in CRC cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Aspirin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> changed nucleotide ratios and activated <e2>GENE-N<\\e2> in CRC cells","sentence":"Aspirin changed nucleotide ratios and activated AMPK in CRC cells"}
{"PMID":22406476,"re_id":6,"annotated sentence":"<e1>Aspirin<\\e1> and metformin (an activator of <e2>AMPK<\\e2>  increased inhibition of mTOR and Akt, as well as autophagy in CRC cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Aspirin","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and metformin (an activator of <e2>GENE-N<\\e2>  increased inhibition of mTOR and Akt, as well as autophagy in CRC cells","sentence":"Aspirin and metformin (an activator of AMPK  increased inhibition of mTOR and Akt, as well as autophagy in CRC cells"}
{"PMID":22406476,"re_id":7,"annotated sentence":"RESULTS: <e1>Aspirin<\\e1> reduced <e2>mTOR<\\e2> signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Aspirin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> reduced <e2>GENE-Y<\\e2> signaling in CRC cells by inhibiting the GENE-Y effectors S6K1 and 4E-BP1","sentence":"RESULTS: Aspirin reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1"}
{"PMID":22406476,"re_id":8,"annotated sentence":"<e1>Aspirin<\\e1> inhibits <e2>mTOR<\\e2> signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Aspirin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells","sentence":"Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells"}
{"PMID":22406476,"re_id":9,"annotated sentence":"Aspirin and <e1>metformin<\\e1> (an activator of AMPK) increased inhibition of <e2>mTOR<\\e2> and Akt, as well as autophagy in CRC cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"metformin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Aspirin and <e1>CHEMICAL<\\e1> (an activator of AMPK) increased inhibition of <e2>GENE-Y<\\e2> and Akt, as well as autophagy in CRC cells","sentence":"Aspirin and metformin (an activator of AMPK) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells"}
{"PMID":22406476,"re_id":10,"annotated sentence":"Aspirin and <e1>metformin<\\e1> (an activator of AMPK) increased inhibition of mTOR and <e2>Akt<\\e2>  as well as autophagy in CRC cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"metformin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Aspirin and <e1>CHEMICAL<\\e1> (an activator of AMPK) increased inhibition of mTOR and <e2>GENE-N<\\e2>  as well as autophagy in CRC cells","sentence":"Aspirin and metformin (an activator of AMPK) increased inhibition of mTOR and Akt  as well as autophagy in CRC cells"}
{"PMID":22406476,"re_id":11,"annotated sentence":"Rectal mucosal samples from patients given <e1>aspirin<\\e1> had reduced phosphorylation of <e2>S6K1<\\e2> and S6","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"aspirin","object":"S6K1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rectal mucosal samples from patients given <e1>CHEMICAL<\\e1> had reduced phosphorylation of <e2>GENE-Y<\\e2> and S6","sentence":"Rectal mucosal samples from patients given aspirin had reduced phosphorylation of S6K1 and S6"}
{"PMID":22406476,"re_id":12,"annotated sentence":"Rectal mucosal samples from patients given <e1>aspirin<\\e1> had reduced phosphorylation of S6K1 and <e2>S6<\\e2>  CONCLUSIONS: Aspirin is an inhibitor of mTOR and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"aspirin","object":"S6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rectal mucosal samples from patients given <e1>CHEMICAL<\\e1> had reduced phosphorylation of GENE-YK1 and <e2>GENE-Y<\\e2>  CONCLUSIONS: Aspirin is an inhibitor of mTOR and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism","sentence":"Rectal mucosal samples from patients given aspirin had reduced phosphorylation of S6K1 and S6  CONCLUSIONS: Aspirin is an inhibitor of mTOR and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism"}
{"PMID":22406476,"re_id":13,"annotated sentence":"CONCLUSIONS: <e1>Aspirin<\\e1> is an inhibitor of <e2>mTOR<\\e2> and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Aspirin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: <e1>CHEMICAL<\\e1> is an inhibitor of <e2>GENE-Y<\\e2> and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism","sentence":"CONCLUSIONS: Aspirin is an inhibitor of mTOR and an activator of AMPK, targeting regulators of intracellular energy homeostasis and metabolism"}
{"PMID":22406476,"re_id":14,"annotated sentence":"RESULTS: <e1>Aspirin<\\e1> reduced mTOR signaling in CRC cells by inhibiting the <e2>mTOR<\\e2> effectors S6K1 and 4E-BP1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Aspirin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> reduced GENE-Y signaling in CRC cells by inhibiting the <e2>GENE-Y<\\e2> effectors S6K1 and 4E-BP1","sentence":"RESULTS: Aspirin reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1"}
{"PMID":22406476,"re_id":15,"annotated sentence":"RESULTS: <e1>Aspirin<\\e1> reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors <e2>S6K1<\\e2> and 4E-BP1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Aspirin","object":"S6K1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors <e2>GENE-Y<\\e2> and 4E-BP1","sentence":"RESULTS: Aspirin reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1"}
{"PMID":22406476,"re_id":16,"annotated sentence":"RESULTS: <e1>Aspirin<\\e1> reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and <e2>4E-BP1<\\e2>  Aspirin changed nucleotide ratios and activated AMPK in CRC cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Aspirin","object":"4E-BP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and <e2>GENE-Y<\\e2>  CHEMICAL changed nucleotide ratios and activated AMPK in CRC cells","sentence":"RESULTS: Aspirin reduced mTOR signaling in CRC cells by inhibiting the mTOR effectors S6K1 and 4E-BP1  Aspirin changed nucleotide ratios and activated AMPK in CRC cells"}
{"PMID":22406476,"re_id":17,"annotated sentence":"<e2>mTOR<\\e2> was still inhibited by <e1>aspirin<\\e1> in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"aspirin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> was still inhibited by <e1>CHEMICAL<\\e1> in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of CHEMICAL-induced inhibition of GENE-Y","sentence":"mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin-induced inhibition of mTOR"}
{"PMID":22406476,"re_id":18,"annotated sentence":"mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of <e1>aspirin<\\e1> induced inhibition of <e2>mTOR<\\e2>  Aspirin induced autophagy, a feature of mTOR inhibition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"aspirin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GENE-Y was still inhibited by CHEMICAL in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of <e1>CHEMICAL<\\e1> induced inhibition of <e2>GENE-Y<\\e2>  Aspirin induced autophagy, a feature of GENE-Y inhibition","sentence":"mTOR was still inhibited by aspirin in CRC cells after siRNA knockdown of AMPKalpha, indicating AMPK-dependent and AMPK-independent mechanisms of aspirin induced inhibition of mTOR  Aspirin induced autophagy, a feature of mTOR inhibition"}
{"PMID":22406476,"re_id":19,"annotated sentence":"<e1>Aspirin<\\e1> induced autophagy, a feature of <e2>mTOR<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Aspirin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced autophagy, a feature of <e2>GENE-Y<\\e2> inhibition","sentence":"Aspirin induced autophagy, a feature of mTOR inhibition"}
{"PMID":22406476,"re_id":20,"annotated sentence":"<e1>Aspirin<\\e1> and metformin (an activator of AMPK) increased inhibition of <e2>mTOR<\\e2> and Akt, as well as autophagy in CRC cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Aspirin","object":"mTOR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and metformin (an activator of AMPK) increased inhibition of <e2>GENE-Y<\\e2> and Akt, as well as autophagy in CRC cells","sentence":"Aspirin and metformin (an activator of AMPK) increased inhibition of mTOR and Akt, as well as autophagy in CRC cells"}
{"PMID":22406476,"re_id":21,"annotated sentence":"<e1>Aspirin<\\e1> and metformin (an activator of AMPK) increased inhibition of mTOR and <e2>Akt<\\e2>  as well as autophagy in CRC cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Aspirin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and metformin (an activator of AMPK) increased inhibition of mTOR and <e2>GENE-N<\\e2>  as well as autophagy in CRC cells","sentence":"Aspirin and metformin (an activator of AMPK) increased inhibition of mTOR and Akt  as well as autophagy in CRC cells"}
{"PMID":22410778,"re_id":4,"annotated sentence":"Exogenous stimulation of <e2>PKA<\\e2> activity, achieved by <e1>forskolin<\\e1> treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"forskolin","object":"PKA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Exogenous stimulation of <e2>GENE-N<\\e2> activity, achieved by <e1>CHEMICAL<\\e1> treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels","sentence":"Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels"}
{"PMID":22410778,"re_id":5,"annotated sentence":"Exogenous stimulation of PKA activity, achieved by <e1>forskolin<\\e1> treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced <e2>complex I<\\e2> activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"forskolin","object":"complex I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Exogenous stimulation of PKA activity, achieved by <e1>CHEMICAL<\\e1> treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced <e2>GENE-N<\\e2> activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels","sentence":"Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels"}
{"PMID":22410778,"re_id":6,"annotated sentence":"Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected <e2>K-ras<\\e2> transformed cells from apoptosis induced by <e1>glucose<\\e1> deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"glucose","object":"K-ras","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected <e2>GENE-Y<\\e2> transformed cells from apoptosis induced by <e1>CHEMICAL<\\e1> deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels","sentence":"Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels"}
{"PMID":22422627,"re_id":2,"annotated sentence":"<e1>SB203580<\\e1> (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of <e2>collagen type I<\\e2> and \u03b1-SMA in TGF-\u03b21-induced NPDFs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"SB203580","object":"collagen type I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of <e2>GENE-N<\\e2> and \u03b1-SMA in TGF-\u03b21-induced NPDFs","sentence":"SB203580 (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and \u03b1-SMA in TGF-\u03b21-induced NPDFs"}
{"PMID":22422627,"re_id":3,"annotated sentence":"<e1>SB203580<\\e1> (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and <e2>\u03b1-SMA<\\e2> in TGF-\u03b21-induced NPDFs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"SB203580","object":"\u03b1-SMA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and <e2>GENE-Y<\\e2> in TGF-\u03b21-induced NPDFs","sentence":"SB203580 (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and \u03b1-SMA in TGF-\u03b21-induced NPDFs"}
{"PMID":22422627,"re_id":4,"annotated sentence":"<e1>SB203580<\\e1> (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and \u03b1-SMA in <e2>TGF-\u03b21<\\e2> induced NPDFs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"SB203580","object":"TGF-\u03b21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and \u03b1-SMA in <e2>GENE-Y<\\e2> induced NPDFs","sentence":"SB203580 (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and \u03b1-SMA in TGF-\u03b21 induced NPDFs"}
{"PMID":22422627,"re_id":5,"annotated sentence":"In <e2>TGF-\u03b21<\\e2> induced NPDFs, <e1>berberine<\\e1> significantly inhibited the expression of \u03b1-SMA and collagen type I mRNA and reduced \u03b1-SMA and collagen protein levels","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"berberine","object":"TGF-\u03b21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In <e2>GENE-Y<\\e2> induced NPDFs, <e1>CHEMICAL<\\e1> significantly inhibited the expression of \u03b1-SMA and collagen type I mRNA and reduced \u03b1-SMA and collagen protein levels","sentence":"In TGF-\u03b21 induced NPDFs, berberine significantly inhibited the expression of \u03b1-SMA and collagen type I mRNA and reduced \u03b1-SMA and collagen protein levels"}
{"PMID":22422627,"re_id":6,"annotated sentence":"In TGF-\u03b21-induced NPDFs, <e1>berberine<\\e1> significantly inhibited the expression of <e2>\u03b1-SMA<\\e2> and collagen type I mRNA and reduced \u03b1-SMA and collagen protein levels","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"berberine","object":"\u03b1-SMA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In TGF-\u03b21-induced NPDFs, <e1>CHEMICAL<\\e1> significantly inhibited the expression of <e2>GENE-Y<\\e2> and collagen type I mRNA and reduced GENE-Y and collagen protein levels","sentence":"In TGF-\u03b21-induced NPDFs, berberine significantly inhibited the expression of \u03b1-SMA and collagen type I mRNA and reduced \u03b1-SMA and collagen protein levels"}
{"PMID":22422627,"re_id":7,"annotated sentence":"In TGF-\u03b21-induced NPDFs, <e1>berberine<\\e1> significantly inhibited the expression of \u03b1-SMA and <e2>collagen type I<\\e2> mRNA and reduced \u03b1-SMA and collagen protein levels","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"berberine","object":"collagen type I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In TGF-\u03b21-induced NPDFs, <e1>CHEMICAL<\\e1> significantly inhibited the expression of \u03b1-SMA and <e2>GENE-N<\\e2> mRNA and reduced \u03b1-SMA and collagen protein levels","sentence":"In TGF-\u03b21-induced NPDFs, berberine significantly inhibited the expression of \u03b1-SMA and collagen type I mRNA and reduced \u03b1-SMA and collagen protein levels"}
{"PMID":22422627,"re_id":8,"annotated sentence":"In TGF-\u03b21-induced NPDFs, <e1>berberine<\\e1> significantly inhibited the expression of \u03b1-SMA and collagen type I mRNA and reduced <e2>\u03b1-SMA<\\e2> and collagen protein levels","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"berberine","object":"\u03b1-SMA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In TGF-\u03b21-induced NPDFs, <e1>CHEMICAL<\\e1> significantly inhibited the expression of GENE-Y and collagen type I mRNA and reduced <e2>GENE-Y<\\e2> and collagen protein levels","sentence":"In TGF-\u03b21-induced NPDFs, berberine significantly inhibited the expression of \u03b1-SMA and collagen type I mRNA and reduced \u03b1-SMA and collagen protein levels"}
{"PMID":22422627,"re_id":9,"annotated sentence":"In TGF-\u03b21-induced NPDFs, <e1>berberine<\\e1> significantly inhibited the expression of \u03b1-SMA and collagen type I mRNA and reduced \u03b1-SMA and <e2>collagen<\\e2> protein levels","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"berberine","object":"collagen","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In TGF-\u03b21-induced NPDFs, <e1>CHEMICAL<\\e1> significantly inhibited the expression of \u03b1-SMA and GENE-N type I mRNA and reduced \u03b1-SMA and <e2>GENE-N<\\e2> protein levels","sentence":"In TGF-\u03b21-induced NPDFs, berberine significantly inhibited the expression of \u03b1-SMA and collagen type I mRNA and reduced \u03b1-SMA and collagen protein levels"}
{"PMID":22422627,"re_id":10,"annotated sentence":"<e1>Berberine<\\e1> only suppressed the expression of <e2>pp38<\\e2> among the evaluated signaling molecules","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Berberine","object":"pp38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> only suppressed the expression of <e2>GENE-N<\\e2> among the evaluated signaling molecules","sentence":"Berberine only suppressed the expression of pp38 among the evaluated signaling molecules"}
{"PMID":22422627,"re_id":11,"annotated sentence":"<e1>SB203580<\\e1> (a specific inhibitor of <e2>p38<\\e2> kinase) markedly suppressed the increased expression of collagen type I and \u03b1-SMA in TGF-\u03b21-induced NPDFs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SB203580","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (a specific inhibitor of <e2>GENE-N<\\e2> kinase) markedly suppressed the increased expression of collagen type I and \u03b1-SMA in TGF-\u03b21-induced NPDFs","sentence":"SB203580 (a specific inhibitor of p38 kinase) markedly suppressed the increased expression of collagen type I and \u03b1-SMA in TGF-\u03b21-induced NPDFs"}
{"PMID":22422627,"re_id":12,"annotated sentence":"<e1>SB203580<\\e1> (a specific inhibitor of p38 <e2>kinase<\\e2>  markedly suppressed the increased expression of collagen type I and \u03b1-SMA in TGF-\u03b21-induced NPDFs","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SB203580","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (a specific inhibitor of p38 <e2>GENE-N<\\e2>  markedly suppressed the increased expression of collagen type I and \u03b1-SMA in TGF-\u03b21-induced NPDFs","sentence":"SB203580 (a specific inhibitor of p38 kinase  markedly suppressed the increased expression of collagen type I and \u03b1-SMA in TGF-\u03b21-induced NPDFs"}
{"PMID":22552008,"re_id":24,"annotated sentence":"CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as <e1>lenalidomide<\\e1>  and pomalidomide-induced <e2>cytokine<\\e2> production in T cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"lenalidomide","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CRBN mediated antiproliferative activities of CHEMICAL and pomalidomide in myeloma cells, as well as <e1>CHEMICAL<\\e1>  and pomalidomide-induced <e2>GENE-N<\\e2> production in T cells","sentence":"CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide  and pomalidomide-induced cytokine production in T cells"}
{"PMID":22552008,"re_id":25,"annotated sentence":"CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and <e1>pomalidomide<\\e1> induced <e2>cytokine<\\e2> production in T cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"pomalidomide","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CRBN mediated antiproliferative activities of lenalidomide and CHEMICAL in myeloma cells, as well as lenalidomide- and <e1>CHEMICAL<\\e1> induced <e2>GENE-N<\\e2> production in T cells","sentence":"CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide induced cytokine production in T cells"}
{"PMID":22552008,"re_id":26,"annotated sentence":"Overexpression of CRBN wild-type protein, but not CRBN(YW\/AA) mutant protein, in KMS12 myeloma cells, amplified <e1>pomalidomide<\\e1> mediated reductions in c-myc and IRF4 expression and increases in p21(<e2>WAF-1<\\e2>  expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"pomalidomide","object":"WAF-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Overexpression of CRBN wild-type protein, but not CRBN(YW\/AA) mutant protein, in KMS12 myeloma cells, amplified <e1>CHEMICAL<\\e1> mediated reductions in c-myc and IRF4 expression and increases in p21(<e2>GENE-Y<\\e2>  expression","sentence":"Overexpression of CRBN wild-type protein, but not CRBN(YW\/AA) mutant protein, in KMS12 myeloma cells, amplified pomalidomide mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1  expression"}
{"PMID":22552008,"re_id":27,"annotated sentence":"Overexpression of CRBN wild-type protein, but not CRBN(YW\/AA) mutant protein, in KMS12 myeloma cells, amplified <e1>pomalidomide<\\e1> mediated reductions in c-myc and IRF4 expression and increases in <e2>p21<\\e2> WAF-1) expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"pomalidomide","object":"p21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Overexpression of CRBN wild-type protein, but not CRBN(YW\/AA) mutant protein, in KMS12 myeloma cells, amplified <e1>CHEMICAL<\\e1> mediated reductions in c-myc and IRF4 expression and increases in <e2>GENE-Y<\\e2> WAF-1) expression","sentence":"Overexpression of CRBN wild-type protein, but not CRBN(YW\/AA) mutant protein, in KMS12 myeloma cells, amplified pomalidomide mediated reductions in c-myc and IRF4 expression and increases in p21 WAF-1) expression"}
{"PMID":22552008,"re_id":28,"annotated sentence":"Overexpression of CRBN wild-type protein, but not CRBN(YW\/AA) mutant protein, in KMS12 myeloma cells, amplified <e1>pomalidomide<\\e1> mediated reductions in <e2>c-myc<\\e2> and IRF4 expression and increases in p21(WAF-1) expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"pomalidomide","object":"c-myc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Overexpression of CRBN wild-type protein, but not CRBN(YW\/AA) mutant protein, in KMS12 myeloma cells, amplified <e1>CHEMICAL<\\e1> mediated reductions in <e2>GENE-Y<\\e2> and IRF4 expression and increases in p21(WAF-1) expression","sentence":"Overexpression of CRBN wild-type protein, but not CRBN(YW\/AA) mutant protein, in KMS12 myeloma cells, amplified pomalidomide mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression"}
{"PMID":22552008,"re_id":29,"annotated sentence":"Overexpression of CRBN wild-type protein, but not CRBN(YW\/AA) mutant protein, in KMS12 myeloma cells, amplified <e1>pomalidomide<\\e1> mediated reductions in c-myc and <e2>IRF4<\\e2> expression and increases in p21(WAF-1) expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"pomalidomide","object":"IRF4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Overexpression of CRBN wild-type protein, but not CRBN(YW\/AA) mutant protein, in KMS12 myeloma cells, amplified <e1>CHEMICAL<\\e1> mediated reductions in c-myc and <e2>GENE-Y<\\e2> expression and increases in p21(WAF-1) expression","sentence":"Overexpression of CRBN wild-type protein, but not CRBN(YW\/AA) mutant protein, in KMS12 myeloma cells, amplified pomalidomide mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression"}
{"PMID":22552008,"re_id":30,"annotated sentence":"Long-term selection for <e1>lenalidomide<\\e1> resistance in H929 myeloma cell lines was accompanied by a reduction in <e2>CRBN<\\e2>  while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"lenalidomide","object":"CRBN","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Long-term selection for <e1>CHEMICAL<\\e1> resistance in H929 myeloma cell lines was accompanied by a reduction in <e2>GENE-Y<\\e2>  while in DF15R myeloma cells resistant to both pomalidomide and CHEMICAL, GENE-Y protein was undetectable","sentence":"Long-term selection for lenalidomide resistance in H929 myeloma cell lines was accompanied by a reduction in CRBN  while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable"}
{"PMID":22552008,"re_id":31,"annotated sentence":"<e1>Lenalidomide<\\e1> and pomalidomide inhibited autoubiquitination of <e2>CRBN<\\e2> in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW\/AA)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Lenalidomide","object":"CRBN","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and pomalidomide inhibited autoubiquitination of <e2>GENE-Y<\\e2> in HEK293T cells expressing thalidomide-binding competent wild-type GENE-Y, but not thalidomide-binding defective GENE-Y(YW\/AA)","sentence":"Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW\/AA)"}
{"PMID":22552008,"re_id":32,"annotated sentence":"<e1>Lenalidomide<\\e1> and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type <e2>CRBN<\\e2>  but not thalidomide-binding defective CRBN(YW\/AA)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Lenalidomide","object":"CRBN","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and pomalidomide inhibited autoubiquitination of GENE-Y in HEK293T cells expressing thalidomide-binding competent wild-type <e2>GENE-Y<\\e2>  but not thalidomide-binding defective GENE-Y(YW\/AA)","sentence":"Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN  but not thalidomide-binding defective CRBN(YW\/AA)"}
{"PMID":22552008,"re_id":33,"annotated sentence":"Lenalidomide and <e1>pomalidomide<\\e1> inhibited autoubiquitination of <e2>CRBN<\\e2> in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW\/AA)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"pomalidomide","object":"CRBN","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Lenalidomide and <e1>CHEMICAL<\\e1> inhibited autoubiquitination of <e2>GENE-Y<\\e2> in HEK293T cells expressing thalidomide-binding competent wild-type GENE-Y, but not thalidomide-binding defective GENE-Y(YW\/AA)","sentence":"Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW\/AA)"}
{"PMID":22552008,"re_id":34,"annotated sentence":"Lenalidomide and <e1>pomalidomide<\\e1> inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type <e2>CRBN<\\e2>  but not thalidomide-binding defective CRBN(YW\/AA)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"pomalidomide","object":"CRBN","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Lenalidomide and <e1>CHEMICAL<\\e1> inhibited autoubiquitination of GENE-Y in HEK293T cells expressing thalidomide-binding competent wild-type <e2>GENE-Y<\\e2>  but not thalidomide-binding defective GENE-Y(YW\/AA)","sentence":"Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN  but not thalidomide-binding defective CRBN(YW\/AA)"}
{"PMID":22566187,"re_id":0,"annotated sentence":"These <e1>polyphenols<\\e1>  but not GvEx, showed a certain level of inhibition of human-cDNA-expressed <e2>CYPs<\\e2>  In a comparison of GLT and grapefruit juice, GLT showed weaker inhibition of CYP activities and of midazolam 1'-hydroxylation than grapefruit juice","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"polyphenols","object":"CYPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These <e1>CHEMICAL<\\e1>  but not GvEx, showed a certain level of inhibition of human-cDNA-expressed <e2>GENE-N<\\e2>  In a comparison of GLT and grapefruit juice, GLT showed weaker inhibition of CYP activities and of midazolam 1'-hydroxylation than grapefruit juice","sentence":"These polyphenols  but not GvEx, showed a certain level of inhibition of human-cDNA-expressed CYPs  In a comparison of GLT and grapefruit juice, GLT showed weaker inhibition of CYP activities and of midazolam 1'-hydroxylation than grapefruit juice"}
{"PMID":22594847,"re_id":4,"annotated sentence":"<e1>Crizotinib<\\e1> is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the <e2>ALK<\\e2> fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Crizotinib","object":"ALK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the <e2>GENE-Y<\\e2> fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing GENE-Y","sentence":"Crizotinib is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK"}
{"PMID":22594847,"re_id":5,"annotated sentence":"<e1>Crizotinib<\\e1> is an oral <e2>tyrosine kinase<\\e2> inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Crizotinib","object":"tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is an oral <e2>GENE-N<\\e2> inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK","sentence":"Crizotinib is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK"}
{"PMID":2262902,"re_id":8,"annotated sentence":"<e1>Enprofylline<\\e1>  a weak adenosine antagonist but potent inhibitor of <e2>cyclic AMP phosphodiesterase<\\e2>  did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Enprofylline","object":"cyclic AMP phosphodiesterase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a weak adenosine antagonist but potent inhibitor of <e2>GENE-N<\\e2>  did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions","sentence":"Enprofylline  a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase  did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions"}
{"PMID":2262902,"re_id":9,"annotated sentence":"<e2>adenosine<\\e2> agonists, <e1>N6-(R-phenylisopropyl)adenosine<\\e1> (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"N6-(R-phenylisopropyl)adenosine","object":"adenosine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> agonists, <e1>CHEMICAL<\\e1> (R-PIA), N6-(S-phenylisopropyl)GENE-N, 5'-(N-cyclopropyl)-carboxamidoGENE-N, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","sentence":"adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod"}
{"PMID":2262902,"re_id":10,"annotated sentence":"<e2>adenosine<\\e2> agonists, N6-(R-phenylisopropyl)adenosine (<e1>R-PIA<\\e1> , N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"R-PIA","object":"adenosine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> agonists, N6-(R-phenylisopropyl)GENE-N (<e1>CHEMICAL<\\e1> , N6-(S-phenylisopropyl)GENE-N, 5'-(N-cyclopropyl)-carboxamidoGENE-N, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","sentence":"adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA , N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod"}
{"PMID":2262902,"re_id":11,"annotated sentence":"<e2>adenosine<\\e2> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), <e1>N6-(S-phenylisopropyl)adenosine<\\e1>  5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"N6-(S-phenylisopropyl)adenosine","object":"adenosine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> agonists, N6-(R-phenylisopropyl)GENE-N (R-PIA), <e1>CHEMICAL<\\e1>  5'-(N-cyclopropyl)-carboxamidoGENE-N, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","sentence":"adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine  5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod"}
{"PMID":2262902,"re_id":12,"annotated sentence":"<e2>adenosine<\\e2> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, <e1>5'-(N-cyclopropyl)-carboxamidoadenosine<\\e1>  antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"5'-(N-cyclopropyl)-carboxamidoadenosine","object":"adenosine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> agonists, N6-(R-phenylisopropyl)GENE-N (R-PIA), N6-(S-phenylisopropyl)GENE-N, <e1>CHEMICAL<\\e1>  antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","sentence":"adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine  antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod"}
{"PMID":2262902,"re_id":13,"annotated sentence":"<e2>adenosine<\\e2> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, <e1>theophylline<\\e1> and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"theophylline","object":"adenosine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> agonists, N6-(R-phenylisopropyl)GENE-N (R-PIA), N6-(S-phenylisopropyl)GENE-N, 5'-(N-cyclopropyl)-carboxamidoGENE-N, antagonists, <e1>CHEMICAL<\\e1> and 8-p-(sulfophenyl)CHEMICAL as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","sentence":"adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod"}
{"PMID":2262902,"re_id":14,"annotated sentence":"<e2>adenosine<\\e2> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and <e1>8-p-(sulfophenyl)theophylline<\\e1> as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"8-p-(sulfophenyl)theophylline","object":"adenosine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> agonists, N6-(R-phenylisopropyl)GENE-N (R-PIA), N6-(S-phenylisopropyl)GENE-N, 5'-(N-cyclopropyl)-carboxamidoGENE-N, antagonists, theophylline and <e1>CHEMICAL<\\e1> as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","sentence":"adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod"}
{"PMID":2262902,"re_id":15,"annotated sentence":"<e2>adenosine<\\e2> agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as <e1>enprofylline<\\e1> on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"enprofylline","object":"adenosine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> agonists, N6-(R-phenylisopropyl)GENE-N (R-PIA), N6-(S-phenylisopropyl)GENE-N, 5'-(N-cyclopropyl)-carboxamidoGENE-N, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as <e1>CHEMICAL<\\e1> on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod","sentence":"adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod"}
{"PMID":2262902,"re_id":16,"annotated sentence":"<e1>Enprofylline<\\e1>  a weak <e2>adenosine<\\e2> antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Enprofylline","object":"adenosine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a weak <e2>GENE-N<\\e2> antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain GENE-N receptor mechanism(s) in ethanol-GENE-N interactions","sentence":"Enprofylline  a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions"}
{"PMID":22641218,"re_id":2,"annotated sentence":"<e1>Celastrol<\\e1> also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and <e2>Annexin V<\\e2> markers of apoptosis","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Celastrol","object":"Annexin V","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and <e2>GENE-Y<\\e2> markers of apoptosis","sentence":"Celastrol also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and Annexin V markers of apoptosis"}
{"PMID":22641218,"re_id":3,"annotated sentence":"<e1>Celastrol<\\e1>  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased <e2>TGF-\u03b21<\\e2> induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Celastrol","object":"TGF-\u03b21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased <e2>GENE-Y<\\e2> induced phosphorylation of TAK1 and RELA, and suppressed basal, GENE-Y- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity","sentence":"Celastrol  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21 induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity"}
{"PMID":22641218,"re_id":4,"annotated sentence":"<e1>Celastrol<\\e1>  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, <e2>TGF-\u03b21<\\e2>  and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Celastrol","object":"TGF-\u03b21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased GENE-Y-induced phosphorylation of TAK1 and RELA, and suppressed basal, <e2>GENE-Y<\\e2>  and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity","sentence":"Celastrol  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21  and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity"}
{"PMID":22641218,"re_id":5,"annotated sentence":"<e1>Celastrol<\\e1>  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and <e2>tumor necrosis factor-alpha<\\e2> (TNF-\u03b1)-induced NF-\u03baB reporter gene activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Celastrol","object":"tumor necrosis factor-alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and <e2>GENE-Y<\\e2> (TNF-\u03b1)-induced NF-\u03baB reporter gene activity","sentence":"Celastrol  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity"}
{"PMID":22641218,"re_id":6,"annotated sentence":"<e1>Celastrol<\\e1>  a <e2>TAK1<\\e2> inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Celastrol","object":"TAK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of GENE-Y and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity","sentence":"Celastrol  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity"}
{"PMID":22641218,"re_id":7,"annotated sentence":"<e1>Celastrol<\\e1>  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of <e2>TAK1<\\e2> and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Celastrol","object":"TAK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a GENE-Y inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of <e2>GENE-Y<\\e2> and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity","sentence":"Celastrol  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity"}
{"PMID":22641218,"re_id":8,"annotated sentence":"<e1>Celastrol<\\e1>  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and <e2>RELA<\\e2>  and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Celastrol","object":"RELA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and <e2>GENE-Y<\\e2>  and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity","sentence":"Celastrol  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA  and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity"}
{"PMID":22641218,"re_id":9,"annotated sentence":"<e1>Celastrol<\\e1>  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced <e2>NF-\u03baB<\\e2> reporter gene activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Celastrol","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced <e2>GENE-N<\\e2> reporter gene activity","sentence":"Celastrol  a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-\u03b21-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-\u03b21- and tumor necrosis factor-alpha (TNF-\u03b1)-induced NF-\u03baB reporter gene activity"}
{"PMID":22641218,"re_id":10,"annotated sentence":"<e1>Celastrol<\\e1> highlights the therapeutic potential of agents targeting <e2>TAK1<\\e2> as a key node in this pro-oncogenic TGF-\u03b2-NF-\u03baB signal pathway.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Celastrol","object":"TAK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> highlights the therapeutic potential of agents targeting <e2>GENE-Y<\\e2> as a key node in this pro-oncogenic TGF-\u03b2-NF-\u03baB signal pathway.","sentence":"Celastrol highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic TGF-\u03b2-NF-\u03baB signal pathway."}
{"PMID":22708686,"re_id":8,"annotated sentence":"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of <e2>p38<\\e2> MAPK and ERK1\/2 phosphorylation by <e1>dynorphin A<\\e1>  CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"dynorphin A","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of <e2>GENE-N<\\e2> MAPK and ERK1\/2 phosphorylation by <e1>CHEMICAL<\\e1>  CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors","sentence":"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1\/2 phosphorylation by dynorphin A  CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors"}
{"PMID":22708686,"re_id":9,"annotated sentence":"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 <e2>MAPK<\\e2> and ERK1\/2 phosphorylation by <e1>dynorphin A<\\e1>  CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"dynorphin A","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 <e2>GENE-N<\\e2> and ERK1\/2 phosphorylation by <e1>CHEMICAL<\\e1>  CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors","sentence":"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1\/2 phosphorylation by dynorphin A  CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors"}
{"PMID":22708686,"re_id":10,"annotated sentence":"CONCLUSIONS AND IMPLICATIONS: In different cell systems, <e1>mianserin<\\e1> directly activates <e2>kappa-opioid receptors<\\e2>  displaying partial agonist activity at brain receptors","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"mianserin","object":"kappa-opioid receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS AND IMPLICATIONS: In different cell systems, <e1>CHEMICAL<\\e1> directly activates <e2>GENE-Y<\\e2>  displaying partial agonist activity at brain receptors","sentence":"CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors  displaying partial agonist activity at brain receptors"}
{"PMID":22708686,"re_id":11,"annotated sentence":"In [(35)S]GTPgammaS assays, <e1>mianserin<\\e1> selectively activated <e2>kappa-opioid receptors<\\e2>  The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"mianserin","object":"kappa-opioid receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In [(35)S]GTPgammaS assays, <e1>CHEMICAL<\\e1> selectively activated <e2>GENE-Y<\\e2>  The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI)","sentence":"In [(35)S]GTPgammaS assays, mianserin selectively activated kappa-opioid receptors  The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI)"}
{"PMID":22708686,"re_id":12,"annotated sentence":"The agonist activity was antagonized by the selective <e2>kappa-opioid<\\e2> blocker <e1>nor-binaltorphimine<\\e1> (nor-BNI)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nor-binaltorphimine","object":"kappa-opioid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The agonist activity was antagonized by the selective <e2>GENE-Y<\\e2> blocker <e1>CHEMICAL<\\e1> (nor-BNI)","sentence":"The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI)"}
{"PMID":22708686,"re_id":13,"annotated sentence":"The agonist activity was antagonized by the selective <e2>kappa-opioid<\\e2> blocker nor-binaltorphimine (<e1>nor-BNI<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nor-BNI","object":"kappa-opioid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The agonist activity was antagonized by the selective <e2>GENE-Y<\\e2> blocker nor-binaltorphimine (<e1>CHEMICAL<\\e1> ","sentence":"The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI "}
{"PMID":22708686,"re_id":14,"annotated sentence":"When combined, <e1>mianserin<\\e1> antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of <e2>p38<\\e2> MAPK and ERK1\/2 phosphorylation by dynorphin A","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"mianserin","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When combined, <e1>CHEMICAL<\\e1> antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of <e2>GENE-N<\\e2> MAPK and ERK1\/2 phosphorylation by dynorphin A","sentence":"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1\/2 phosphorylation by dynorphin A"}
{"PMID":22708686,"re_id":15,"annotated sentence":"When combined, <e1>mianserin<\\e1> antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 <e2>MAPK<\\e2> and ERK1\/2 phosphorylation by dynorphin A","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"mianserin","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When combined, <e1>CHEMICAL<\\e1> antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 <e2>GENE-N<\\e2> and ERK1\/2 phosphorylation by dynorphin A","sentence":"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1\/2 phosphorylation by dynorphin A"}
{"PMID":22708686,"re_id":16,"annotated sentence":"We previously reported that <e1>tricyclic<\\e1> antidepressants act as agonists at distinct <e2>opioid receptors<\\e2>  Here, we investigated the effect of the atypical antidepressant mianserin at cloned and native opioid receptors","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"tricyclic","object":"opioid receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We previously reported that <e1>CHEMICAL<\\e1> antidepressants act as agonists at distinct <e2>GENE-N<\\e2>  Here, we investigated the effect of the atypical antidepressant mianserin at cloned and native GENE-N","sentence":"We previously reported that tricyclic antidepressants act as agonists at distinct opioid receptors  Here, we investigated the effect of the atypical antidepressant mianserin at cloned and native opioid receptors"}
{"PMID":22708686,"re_id":17,"annotated sentence":"CONCLUSIONS AND IMPLICATIONS: In different cell systems, <e1>mianserin<\\e1> directly activates <e2>kappa-opioid receptors<\\e2>  displaying partial agonist activity at brain receptors","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"mianserin","object":"kappa-opioid receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS AND IMPLICATIONS: In different cell systems, <e1>CHEMICAL<\\e1> directly activates <e2>GENE-Y<\\e2>  displaying partial agonist activity at brain receptors","sentence":"CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors  displaying partial agonist activity at brain receptors"}
{"PMID":22708686,"re_id":18,"annotated sentence":"The <e1>mianserin<\\e1> analogue mirtazapine also displayed <e2>kappa-opioid<\\e2> agonist activity","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"mianserin","object":"kappa-opioid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> analogue mirtazapine also displayed <e2>GENE-Y<\\e2> agonist activity","sentence":"The mianserin analogue mirtazapine also displayed kappa-opioid agonist activity"}
{"PMID":22708686,"re_id":19,"annotated sentence":"The mianserin analogue <e1>mirtazapine<\\e1> also displayed <e2>kappa-opioid<\\e2> agonist activity","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"mirtazapine","object":"kappa-opioid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mianserin analogue <e1>CHEMICAL<\\e1> also displayed <e2>GENE-Y<\\e2> agonist activity","sentence":"The mianserin analogue mirtazapine also displayed kappa-opioid agonist activity"}
{"PMID":22708686,"re_id":20,"annotated sentence":"The atypical antidepressant <e1>mianserin<\\e1> exhibits agonist activity at <e2>kappa-opioid receptors<\\e2>  BACKGROUND AND PURPOSE: Antidepressants are known to interact with the opioid system through mechanisms not completely understood","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"mianserin","object":"kappa-opioid receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The atypical antidepressant <e1>CHEMICAL<\\e1> exhibits agonist activity at <e2>GENE-Y<\\e2>  BACKGROUND AND PURPOSE: Antidepressants are known to interact with the opioid system through mechanisms not completely understood","sentence":"The atypical antidepressant mianserin exhibits agonist activity at kappa-opioid receptors  BACKGROUND AND PURPOSE: Antidepressants are known to interact with the opioid system through mechanisms not completely understood"}
{"PMID":22708686,"re_id":21,"annotated sentence":"In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full <e2>kappa-opioid<\\e2> agonists <e1>(-)-U50,488<\\e1> and dynorphin A","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"(-)-U50,488","object":"kappa-opioid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full <e2>GENE-Y<\\e2> agonists <e1>CHEMICAL<\\e1> and dynorphin A","sentence":"In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and dynorphin A"}
{"PMID":22708686,"re_id":22,"annotated sentence":"In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full <e2>kappa-opioid<\\e2> agonists (-)-U50,488 and <e1>dynorphin A<\\e1>  When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1\/2 phosphorylation by dynorphin A","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"dynorphin A","object":"kappa-opioid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full <e2>GENE-Y<\\e2> agonists (-)-U50,488 and <e1>CHEMICAL<\\e1>  When combined, mianserin antagonized the effects of the full GENE-Y receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1\/2 phosphorylation by CHEMICAL","sentence":"In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and dynorphin A  When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1\/2 phosphorylation by dynorphin A"}
{"PMID":22708686,"re_id":23,"annotated sentence":"The agonist activity was antagonized by the selective <e2>kappa-opioid<\\e2> blocker <e1>nor-binaltorphimine<\\e1> (nor-BNI)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"nor-binaltorphimine","object":"kappa-opioid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The agonist activity was antagonized by the selective <e2>GENE-Y<\\e2> blocker <e1>CHEMICAL<\\e1> (nor-BNI)","sentence":"The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI)"}
{"PMID":22708686,"re_id":24,"annotated sentence":"The agonist activity was antagonized by the selective <e2>kappa-opioid<\\e2> blocker nor-binaltorphimine (<e1>nor-BNI<\\e1> ","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"nor-BNI","object":"kappa-opioid","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The agonist activity was antagonized by the selective <e2>GENE-Y<\\e2> blocker nor-binaltorphimine (<e1>CHEMICAL<\\e1> ","sentence":"The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI "}
{"PMID":22708686,"re_id":25,"annotated sentence":"When combined, <e1>mianserin<\\e1> antagonized the effects of the full <e2>kappa-opioid receptor<\\e2> agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1\/2 phosphorylation by dynorphin A","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"mianserin","object":"kappa-opioid receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When combined, <e1>CHEMICAL<\\e1> antagonized the effects of the full <e2>GENE-Y<\\e2> agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1\/2 phosphorylation by dynorphin A","sentence":"When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1\/2 phosphorylation by dynorphin A"}
{"PMID":22824191,"re_id":0,"annotated sentence":"In the present study we tested whether <e1>propranolol<\\e1>  a <e2>\u03b2-receptor<\\e2> antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"propranolol","object":"\u03b2-receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present study we tested whether <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8)","sentence":"In the present study we tested whether propranolol  a \u03b2-receptor antagonist commonly used as antihypertensive drug, could ameliorate the cognitive impairments and increases in AD-related markers shown by the senescence-accelerated mouse prone-8 (SAMP8)"}
{"PMID":22884520,"re_id":1,"annotated sentence":"The purpose of this review is to summarize current knowledge about <e1>oxysterol<\\e1> dependent activation by <e2>LXR<\\e2> of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of LXR-dependent genes.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"oxysterol","object":"LXR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The purpose of this review is to summarize current knowledge about <e1>CHEMICAL<\\e1> dependent activation by <e2>GENE-N<\\e2> of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of CHEMICAL generation for expression of GENE-N-dependent genes.","sentence":"The purpose of this review is to summarize current knowledge about oxysterol dependent activation by LXR of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of LXR-dependent genes."}
{"PMID":22884520,"re_id":2,"annotated sentence":"<e2>LXRs<\\e2> are thought to be activated predominantly by <e1>oxysterols<\\e1> generated enzymatically from cholesterol in different cell organelles","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"oxysterols","object":"LXRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> are thought to be activated predominantly by <e1>CHEMICAL<\\e1> generated enzymatically from cholesterol in different cell organelles","sentence":"LXRs are thought to be activated predominantly by oxysterols generated enzymatically from cholesterol in different cell organelles"}
{"PMID":22884520,"re_id":3,"annotated sentence":"Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in <e2>sterol-27-hydroxylase<\\e2> activity lead to specific blocks in <e1>oxysterol<\\e1> production and impaired LXR-dependent gene activation","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"oxysterol","object":"sterol-27-hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in <e2>GENE-Y<\\e2> activity lead to specific blocks in <e1>CHEMICAL<\\e1> production and impaired LXR-dependent gene activation","sentence":"Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in sterol-27-hydroxylase activity lead to specific blocks in oxysterol production and impaired LXR-dependent gene activation"}
{"PMID":22898212,"re_id":10,"annotated sentence":"Mass spectral analysis of <e1>CBDP<\\e1> inhibited <e2>BChE<\\e2> digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CBDP","object":"BChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mass spectral analysis of <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438","sentence":"Mass spectral analysis of CBDP inhibited BChE digested with Glu-C showed an o-hydroxybenzyl adduct (+106amu) on lysine 499, a residue far from the active site, but not on His-438"}
{"PMID":22898212,"re_id":11,"annotated sentence":"<e1>CBDP<\\e1> irreversibly inhibits <e2>butyrylcholinesterase<\\e2> (BChE) in human plasma by forming adducts on the active site serine (Ser-198)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CBDP","object":"butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> irreversibly inhibits <e2>GENE-Y<\\e2> (BChE) in human plasma by forming adducts on the active site serine (Ser-198)","sentence":"CBDP irreversibly inhibits butyrylcholinesterase (BChE) in human plasma by forming adducts on the active site serine (Ser-198)"}
{"PMID":22898212,"re_id":12,"annotated sentence":"<e1>CBDP<\\e1> irreversibly inhibits butyrylcholinesterase (<e2>BChE<\\e2>  in human plasma by forming adducts on the active site serine (Ser-198)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CBDP","object":"BChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> irreversibly inhibits butyrylcholinesterase (<e2>GENE-Y<\\e2>  in human plasma by forming adducts on the active site serine (Ser-198)","sentence":"CBDP irreversibly inhibits butyrylcholinesterase (BChE  in human plasma by forming adducts on the active site serine (Ser-198)"}
{"PMID":22902329,"re_id":0,"annotated sentence":"We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by <e1>\u03b1-tocopherol<\\e1> in the rat dentate gyrus, increasing <e2>cyclic adenosine monophosphate response element binding protein<\\e2> phosphorylation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"\u03b1-tocopherol","object":"cyclic adenosine monophosphate response element binding protein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by <e1>CHEMICAL<\\e1> in the rat dentate gyrus, increasing <e2>GENE-N<\\e2> phosphorylation","sentence":"We previously demonstrated that the somatostatinergic system, implicated in neuronal survival control, can be modulated by \u03b1-tocopherol in the rat dentate gyrus, increasing cyclic adenosine monophosphate response element binding protein phosphorylation"}
{"PMID":22931533,"re_id":8,"annotated sentence":"<e1>Galantamine<\\e1> is a reversible, competitive <e2>acetylcholinesterase<\\e2> (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Galantamine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a reversible, competitive <e2>GENE-Y<\\e2> (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids","sentence":"Galantamine is a reversible, competitive acetylcholinesterase (AChE) inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids"}
{"PMID":22931533,"re_id":9,"annotated sentence":"<e1>Galantamine<\\e1> is a reversible, competitive acetylcholinesterase (<e2>AChE<\\e2>  inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Galantamine","object":"AChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is a reversible, competitive acetylcholinesterase (<e2>GENE-Y<\\e2>  inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids","sentence":"Galantamine is a reversible, competitive acetylcholinesterase (AChE  inhibitor and allosteric potentiating ligand of nicotinic acetylcholine receptors (nAChR-APL) that shares many common structural elements with morphinan-based opioids"}
{"PMID":22967140,"re_id":1,"annotated sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective <e2>ER\u03b2<\\e2> agonist-<e1>DPN<\\e1> [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"DPN","object":"ER\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective <e2>GENE-Y<\\e2> agonist-<e1>CHEMICAL<\\e1> [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective GENE-Y antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)"}
{"PMID":22967140,"re_id":2,"annotated sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective <e2>ER\u03b2<\\e2> agonist-DPN [<e1>2,3-bis(4-hydroxyphenyl)-propionitrile<\\e1> , a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"2,3-bis(4-hydroxyphenyl)-propionitrile","object":"ER\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective <e2>GENE-Y<\\e2> agonist-DPN [<e1>CHEMICAL<\\e1> , a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective GENE-Y antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile , a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)"}
{"PMID":22967140,"re_id":3,"annotated sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective <e2>ER\u03b1<\\e2> agonist-<e1>PPT<\\e1> [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"PPT","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective <e2>GENE-Y<\\e2> agonist-<e1>CHEMICAL<\\e1> [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective GENE-Y antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)"}
{"PMID":22967140,"re_id":4,"annotated sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective <e2>ER\u03b1<\\e2> agonist-PPT [<e1>4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol<\\e1> , a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective <e2>GENE-Y<\\e2> agonist-PPT [<e1>CHEMICAL<\\e1> , a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective GENE-Y antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol , a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)"}
{"PMID":22967140,"re_id":5,"annotated sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective <e2>ER\u03b1<\\e2> antagonist-<e1>MPP<\\e1> [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"MPP","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective GENE-Y agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective <e2>GENE-Y<\\e2> antagonist-<e1>CHEMICAL<\\e1> [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)"}
{"PMID":22967140,"re_id":6,"annotated sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective <e2>ER\u03b1<\\e2> antagonist-MPP [<e1>1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol<\\e1> -1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective GENE-Y agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective <e2>GENE-Y<\\e2> antagonist-MPP [<e1>CHEMICAL<\\e1> -1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol -1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)"}
{"PMID":22967140,"re_id":7,"annotated sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective <e2>ER\u03b1<\\e2> antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-<e1>1H-pyrazole dihydrochloride<\\e1>  or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"1H-pyrazole dihydrochloride","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective GENE-Y agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective <e2>GENE-Y<\\e2> antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-<e1>CHEMICAL<\\e1>  or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride  or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)"}
{"PMID":22967140,"re_id":8,"annotated sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective <e2>ER\u03b2<\\e2> antagonist-<e1>PHTPP<\\e1> (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"PHTPP","object":"ER\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective GENE-Y agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective <e2>GENE-Y<\\e2> antagonist-<e1>CHEMICAL<\\e1> (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)","sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol)"}
{"PMID":22967140,"re_id":9,"annotated sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective <e2>ER\u03b2<\\e2> antagonist-PHTPP (<e1>4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol<\\e1> ","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol","object":"ER\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective GENE-Y agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective <e2>GENE-Y<\\e2> antagonist-PHTPP (<e1>CHEMICAL<\\e1> ","sentence":"Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ER\u03b1 agonist-PPT [4,4',4\u2033-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ER\u03b2 agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ER\u03b1 antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ER\u03b2 antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol "}
{"PMID":22967140,"re_id":10,"annotated sentence":"Modulation of the <e1>nitric oxide<\\e1> producing system (demonstrated via the <e2>NADPH-diaphorase<\\e2> histochemical reaction) by oestradiol has been established in several structures of the rat brain","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"nitric oxide","object":"NADPH-diaphorase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Modulation of the <e1>CHEMICAL<\\e1> producing system (demonstrated via the <e2>GENE-N<\\e2> histochemical reaction) by oestradiol has been established in several structures of the rat brain","sentence":"Modulation of the nitric oxide producing system (demonstrated via the NADPH-diaphorase histochemical reaction) by oestradiol has been established in several structures of the rat brain"}
{"PMID":22982206,"re_id":2,"annotated sentence":"Furthermore, <e1>salubrinal<\\e1>  a specific <e2>eIF2\u03b1<\\e2> phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"salubrinal","object":"eIF2\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1>  a specific <e2>GENE-Y<\\e2> phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA","sentence":"Furthermore, salubrinal  a specific eIF2\u03b1 phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA"}
{"PMID":22982206,"re_id":3,"annotated sentence":"Furthermore, <e1>salubrinal<\\e1>  a specific eIF2\u03b1 phosphorylation-inducing agent, increased <e2>CHOP<\\e2> and DR5 expression in the presence of VA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"salubrinal","object":"CHOP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1>  a specific eIF2\u03b1 phosphorylation-inducing agent, increased <e2>GENE-Y<\\e2> and DR5 expression in the presence of VA","sentence":"Furthermore, salubrinal  a specific eIF2\u03b1 phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA"}
{"PMID":22982206,"re_id":4,"annotated sentence":"Furthermore, <e1>salubrinal<\\e1>  a specific eIF2\u03b1 phosphorylation-inducing agent, increased CHOP and <e2>DR5<\\e2> expression in the presence of VA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"salubrinal","object":"DR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1>  a specific eIF2\u03b1 phosphorylation-inducing agent, increased CHOP and <e2>GENE-Y<\\e2> expression in the presence of VA","sentence":"Furthermore, salubrinal  a specific eIF2\u03b1 phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA"}
{"PMID":22982206,"re_id":5,"annotated sentence":"<e1>Verrucarin A<\\e1> sensitizes TRAIL-induced apoptosis via the upregulation of <e2>DR5<\\e2> in an eIF2\u03b1\/CHOP-dependent manner","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Verrucarin A","object":"DR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> sensitizes TRAIL-induced apoptosis via the upregulation of <e2>GENE-Y<\\e2> in an eIF2\u03b1\/CHOP-dependent manner","sentence":"Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2\u03b1\/CHOP-dependent manner"}
{"PMID":22982206,"re_id":6,"annotated sentence":"<e1>Verrucarin A<\\e1> sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an <e2>eIF2\u03b1<\\e2> CHOP-dependent manner","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Verrucarin A","object":"eIF2\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an <e2>GENE-Y<\\e2> CHOP-dependent manner","sentence":"Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2\u03b1 CHOP-dependent manner"}
{"PMID":22982206,"re_id":7,"annotated sentence":"<e1>Verrucarin A<\\e1> sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2\u03b1\/<e2>CHOP<\\e2> dependent manner","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Verrucarin A","object":"CHOP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2\u03b1\/<e2>GENE-Y<\\e2> dependent manner","sentence":"Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2\u03b1\/CHOP dependent manner"}
{"PMID":22996137,"re_id":1,"annotated sentence":"Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface <e2>glucose transporter isoform 4<\\e2> (GLUT4) and <e1>glucose<\\e1> uptake","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glucose","object":"glucose transporter isoform 4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface <e2>CHEMICAL transporter isoform 4<\\e2> (GLUT4) and <e1>CHEMICAL<\\e1> uptake","sentence":"Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4) and glucose uptake"}
{"PMID":22996137,"re_id":2,"annotated sentence":"Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (<e2>GLUT4<\\e2>  and <e1>glucose<\\e1> uptake","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glucose","object":"GLUT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface CHEMICAL transporter isoform 4 (<e2>GENE-Y<\\e2>  and <e1>CHEMICAL<\\e1> uptake","sentence":"Disruption of microtubule prevented insulin-induced actin remodeling and distal insulin signal transduction, with reduction in surface glucose transporter isoform 4 (GLUT4  and glucose uptake"}
{"PMID":23022398,"re_id":2,"annotated sentence":"Our data also indicate that <e2>NMDA receptor<\\e2> pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since <e1>AP7<\\e1> microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AP7","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our data also indicate that <e2>GENE-N<\\e2> pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since <e1>CHEMICAL<\\e1> microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO","sentence":"Our data also indicate that NMDA receptor pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO"}
{"PMID":23022398,"re_id":3,"annotated sentence":"Other groups received either an infusion of the selective <e2>NMDA receptor<\\e2> antagonist (<e1>AP7<\\e1>  10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"AP7","object":"NMDA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Other groups received either an infusion of the selective <e2>GENE-N<\\e2> antagonist (<e1>CHEMICAL<\\e1>  10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900)","sentence":"Other groups received either an infusion of the selective NMDA receptor antagonist (AP7  10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900)"}
{"PMID":23024204,"re_id":0,"annotated sentence":"The acetylation of <e1>TETA<\\e1> is increased in <e2>SSAT1<\\e2> overexpressing mice compared with wild-type mice","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"TETA","object":"SSAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The acetylation of <e1>CHEMICAL<\\e1> is increased in <e2>GENE-Y<\\e2> overexpressing mice compared with wild-type mice","sentence":"The acetylation of TETA is increased in SSAT1 overexpressing mice compared with wild-type mice"}
{"PMID":23024204,"re_id":1,"annotated sentence":"However, SSAT1-deficient mice metabolize <e1>TETA<\\e1> at the same rate as the wild-type mice, indicating the existence of another <e2>N-acetylase<\\e2> respons 2ible for its metabolism in mice","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"TETA","object":"N-acetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, SSAT1-deficient mice metabolize <e1>CHEMICAL<\\e1> at the same rate as the wild-type mice, indicating the existence of another <e2>GENE-N<\\e2> respons 2ible for its metabolism in mice","sentence":"However, SSAT1-deficient mice metabolize TETA at the same rate as the wild-type mice, indicating the existence of another N-acetylase respons 2ible for its metabolism in mice"}
{"PMID":23024204,"re_id":2,"annotated sentence":"Here, we show that siRNA-mediated knockdown of <e2>SSAT2<\\e2> in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of <e1>TETA<\\e1> to MAT","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"TETA","object":"SSAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we show that siRNA-mediated knockdown of <e2>GENE-Y<\\e2> in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of <e1>CHEMICAL<\\e1> to MAT","sentence":"Here, we show that siRNA-mediated knockdown of SSAT2 in HEPG2 cells and in primary hepatocytes from the SSAT1-deficient or wild-type mice reduced the metabolism of TETA to MAT"}
{"PMID":23024204,"re_id":3,"annotated sentence":"By contrast, <e1>1,12-diamino-3,6,9-triazadodecane<\\e1> SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by <e2>SSAT1<\\e2> in HEPG2 cells and in wild-type primary hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"1,12-diamino-3,6,9-triazadodecane","object":"SSAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"By contrast, <e1>CHEMICAL<\\e1> SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by <e2>GENE-Y<\\e2> in HEPG2 cells and in wild-type primary hepatocytes","sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes"}
{"PMID":23024204,"re_id":4,"annotated sentence":"By contrast, <e1>1,12-diamino-3,6,9-triazadodecane<\\e1> SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of <e2>human recombinant SSAT2<\\e2> and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"1,12-diamino-3,6,9-triazadodecane","object":"human recombinant SSAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"By contrast, <e1>CHEMICAL<\\e1> SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of <e2>GENE-Y<\\e2> and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes","sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes"}
{"PMID":23024204,"re_id":5,"annotated sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane(<e1>SpmTrien<\\e1> , a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by <e2>SSAT1<\\e2> in HEPG2 cells and in wild-type primary hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"SpmTrien","object":"SSAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane(<e1>CHEMICAL<\\e1> , a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by <e2>GENE-Y<\\e2> in HEPG2 cells and in wild-type primary hepatocytes","sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien , a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes"}
{"PMID":23024204,"re_id":6,"annotated sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane(<e1>SpmTrien<\\e1> , a charge-deficient spermine analog, was an extremely poor substrate of <e2>human recombinant SSAT2<\\e2> and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"SpmTrien","object":"human recombinant SSAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane(<e1>CHEMICAL<\\e1> , a charge-deficient spermine analog, was an extremely poor substrate of <e2>GENE-Y<\\e2> and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes","sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien , a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes"}
{"PMID":23024204,"re_id":7,"annotated sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient <e1>spermine<\\e1> analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by <e2>SSAT1<\\e2> in HEPG2 cells and in wild-type primary hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"spermine","object":"SSAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient <e1>CHEMICAL<\\e1> analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by <e2>GENE-Y<\\e2> in HEPG2 cells and in wild-type primary hepatocytes","sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes"}
{"PMID":23024204,"re_id":8,"annotated sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient <e1>spermine<\\e1> analog, was an extremely poor substrate of <e2>human recombinant SSAT2<\\e2> and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"spermine","object":"human recombinant SSAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient <e1>CHEMICAL<\\e1> analog, was an extremely poor substrate of <e2>GENE-Y<\\e2> and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes","sentence":"By contrast, 1,12-diamino-3,6,9-triazadodecane(SpmTrien), a charge-deficient spermine analog, was an extremely poor substrate of human recombinant SSAT2 and was metabolized by SSAT1 in HEPG2 cells and in wild-type primary hepatocytes"}
{"PMID":23024204,"re_id":9,"annotated sentence":"Metabolism of <e1>triethylenetetramine<\\e1> and 1,12-diamino-3,6,9-triazadodecane by the spermidine\/spermine-N(1)-acetyltransferase and <e2>thialysine acetyltransferase<\\e2>  Triethylenetetramine (TETA; Syprine; Merck Rahway, NJ), a drug for Wilson's disease, is a copper chelator and a charge-deficient analog of polyamine spermidine","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"triethylenetetramine","object":"thialysine acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Metabolism of <e1>CHEMICAL<\\e1> and 1,12-diamino-3,6,9-triazadodecane by the spermidine\/spermine-N(1)-acetyltransferase and <e2>GENE-N<\\e2>  Triethylenetetramine (TETA; Syprine; Merck Rahway, NJ), a drug for Wilson's disease, is a copper chelator and a charge-deficient analog of polyamine spermidine","sentence":"Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine\/spermine-N(1)-acetyltransferase and thialysine acetyltransferase  Triethylenetetramine (TETA; Syprine; Merck Rahway, NJ), a drug for Wilson's disease, is a copper chelator and a charge-deficient analog of polyamine spermidine"}
{"PMID":23024204,"re_id":10,"annotated sentence":"Metabolism of <e1>triethylenetetramine<\\e1> and 1,12-diamino-3,6,9-triazadodecane by the <e2>spermidine\/spermine-N(1)-acetyltransferase<\\e2> and thialysine acetyltransferase","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"triethylenetetramine","object":"spermidine\/spermine-N(1)-acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Metabolism of <e1>CHEMICAL<\\e1> and 1,12-diamino-3,6,9-triazadodecane by the <e2>GENE-Y<\\e2> and thialysine acetyltransferase","sentence":"Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine\/spermine-N(1)-acetyltransferase and thialysine acetyltransferase"}
{"PMID":23024204,"re_id":11,"annotated sentence":"Metabolism of triethylenetetramine and <e1>1,12-diamino-3,6,9-triazadodecane<\\e1> by the spermidine\/spermine-N(1)-acetyltransferase and <e2>thialysine acetyltransferase<\\e2>  Triethylenetetramine (TETA; Syprine; Merck Rahway, NJ), a drug for Wilson's disease, is a copper chelator and a charge-deficient analog of polyamine spermidine","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"1,12-diamino-3,6,9-triazadodecane","object":"thialysine acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Metabolism of triethylenetetramine and <e1>CHEMICAL<\\e1> by the spermidine\/spermine-N(1)-acetyltransferase and <e2>GENE-N<\\e2>  Triethylenetetramine (TETA; Syprine; Merck Rahway, NJ), a drug for Wilson's disease, is a copper chelator and a charge-deficient analog of polyamine spermidine","sentence":"Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine\/spermine-N(1)-acetyltransferase and thialysine acetyltransferase  Triethylenetetramine (TETA; Syprine; Merck Rahway, NJ), a drug for Wilson's disease, is a copper chelator and a charge-deficient analog of polyamine spermidine"}
{"PMID":23024204,"re_id":12,"annotated sentence":"Metabolism of triethylenetetramine and <e1>1,12-diamino-3,6,9-triazadodecane<\\e1> by the <e2>spermidine\/spermine-N(1)-acetyltransferase<\\e2> and thialysine acetyltransferase","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"1,12-diamino-3,6,9-triazadodecane","object":"spermidine\/spermine-N(1)-acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Metabolism of triethylenetetramine and <e1>CHEMICAL<\\e1> by the <e2>GENE-Y<\\e2> and thialysine acetyltransferase","sentence":"Metabolism of triethylenetetramine and 1,12-diamino-3,6,9-triazadodecane by the spermidine\/spermine-N(1)-acetyltransferase and thialysine acetyltransferase"}
{"PMID":23024204,"re_id":13,"annotated sentence":"Thus, despite the similar structures of TETA and SpmTrien, <e2>SSAT2<\\e2> is the main acetylator of <e1>TETA<\\e1>  whereas SpmTrien is primarily acetylated by SSAT1.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"TETA","object":"SSAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, despite the similar structures of CHEMICAL and SpmTrien, <e2>GENE-Y<\\e2> is the main acetylator of <e1>CHEMICAL<\\e1>  whereas SpmTrien is primarily acetylated by SSAT1.","sentence":"Thus, despite the similar structures of TETA and SpmTrien, SSAT2 is the main acetylator of TETA  whereas SpmTrien is primarily acetylated by SSAT1."}
{"PMID":23024204,"re_id":14,"annotated sentence":"Thus, despite the similar structures of TETA and SpmTrien, SSAT2 is the main acetylator of TETA, whereas <e1>SpmTrien<\\e1> is primarily acetylated by <e2>SSAT1<\\e2> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"SpmTrien","object":"SSAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, despite the similar structures of TETA and CHEMICAL, SSAT2 is the main acetylator of TETA, whereas <e1>CHEMICAL<\\e1> is primarily acetylated by <e2>GENE-Y<\\e2> ","sentence":"Thus, despite the similar structures of TETA and SpmTrien, SSAT2 is the main acetylator of TETA, whereas SpmTrien is primarily acetylated by SSAT1 "}
{"PMID":23024204,"re_id":15,"annotated sentence":"We recently showed that <e1>TETA<\\e1> is metabolized in vitro by polyamine catabolic enzyme <e2>spermidine\/spermine-N(1)-acetyltransferase<\\e2> (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"TETA","object":"spermidine\/spermine-N(1)-acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We recently showed that <e1>CHEMICAL<\\e1> is metabolized in vitro by polyamine catabolic enzyme <e2>GENE-Y<\\e2> (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)","sentence":"We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)"}
{"PMID":23024204,"re_id":16,"annotated sentence":"We recently showed that <e1>TETA<\\e1> is metabolized in vitro by polyamine catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (<e2>SSAT1<\\e2>  and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"TETA","object":"SSAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We recently showed that <e1>CHEMICAL<\\e1> is metabolized in vitro by polyamine catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (<e2>GENE-Y<\\e2>  and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)","sentence":"We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (SSAT1  and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)"}
{"PMID":23024204,"re_id":17,"annotated sentence":"We recently showed that <e1>TETA<\\e1> is metabolized in vitro by polyamine catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (SSAT1) and by <e2>thialysine acetyltransferase<\\e2> (SSAT2) to its monoacetylated derivative (MAT)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"TETA","object":"thialysine acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We recently showed that <e1>CHEMICAL<\\e1> is metabolized in vitro by polyamine catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (SSAT1) and by <e2>GENE-Y<\\e2> (SSAT2) to its monoacetylated derivative (MAT)","sentence":"We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)"}
{"PMID":23024204,"re_id":18,"annotated sentence":"We recently showed that <e1>TETA<\\e1> is metabolized in vitro by polyamine catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (<e2>SSAT2<\\e2>  to its monoacetylated derivative (MAT)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"TETA","object":"SSAT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We recently showed that <e1>CHEMICAL<\\e1> is metabolized in vitro by polyamine catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (<e2>GENE-Y<\\e2>  to its monoacetylated derivative (MAT)","sentence":"We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (SSAT2  to its monoacetylated derivative (MAT)"}
{"PMID":23024204,"re_id":19,"annotated sentence":"We recently showed that TETA is metabolized in vitro by <e1>polyamine<\\e1> catabolic enzyme <e2>spermidine\/spermine-N(1)-acetyltransferase<\\e2> (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"polyamine","object":"spermidine\/spermine-N(1)-acetyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We recently showed that TETA is metabolized in vitro by <e1>CHEMICAL<\\e1> catabolic enzyme <e2>GENE-Y<\\e2> (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)","sentence":"We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (SSAT1) and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)"}
{"PMID":23024204,"re_id":20,"annotated sentence":"We recently showed that TETA is metabolized in vitro by <e1>polyamine<\\e1> catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (<e2>SSAT1<\\e2>  and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"polyamine","object":"SSAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We recently showed that TETA is metabolized in vitro by <e1>CHEMICAL<\\e1> catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (<e2>GENE-Y<\\e2>  and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)","sentence":"We recently showed that TETA is metabolized in vitro by polyamine catabolic enzyme spermidine\/spermine-N(1)-acetyltransferase (SSAT1  and by thialysine acetyltransferase (SSAT2) to its monoacetylated derivative (MAT)"}
{"PMID":23030680,"re_id":1,"annotated sentence":"In vitro metabolism of the <e2>5-hydroxytryptamine1B<\\e2> receptor antagonist <e1>elzasonan<\\e1>  The metabolism of elzasonan has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed P450 enzymes (rCYP)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"elzasonan","object":"5-hydroxytryptamine1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In vitro metabolism of the <e2>GENE-Y<\\e2> receptor antagonist <e1>CHEMICAL<\\e1>  The metabolism of CHEMICAL has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed P450 enzymes (rCYP)","sentence":"In vitro metabolism of the 5-hydroxytryptamine1B receptor antagonist elzasonan  The metabolism of elzasonan has been examined in vitro using hepatic microsomes from human and recombinant heterologously expressed P450 enzymes (rCYP)"}
{"PMID":23030680,"re_id":2,"annotated sentence":"Cytochrome b5 has shown to be an essential component in <e2>P450 3A4<\\e2> catalyzed <e1>5-hydroxyelzasonan<\\e1> formation and provides insights on the disconnect between human liver microsomes data and that of rCYP","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"5-hydroxyelzasonan","object":"P450 3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cytochrome b5 has shown to be an essential component in <e2>GENE-Y<\\e2> catalyzed <e1>CHEMICAL<\\e1> formation and provides insights on the disconnect between human liver microsomes data and that of rCYP","sentence":"Cytochrome b5 has shown to be an essential component in P450 3A4 catalyzed 5-hydroxyelzasonan formation and provides insights on the disconnect between human liver microsomes data and that of rCYP"}
{"PMID":23030680,"re_id":3,"annotated sentence":"The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each <e2>rCYP<\\e2> in the metabolism of <e1>elzasonan<\\e1>  Results demonstrated the involvement of CYP3A4 in the pathways leading to M3a, M3, M5 and M6 and CYP2C8 in the formation of M4","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"elzasonan","object":"rCYP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The GENE-N data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each <e2>GENE-N<\\e2> in the metabolism of <e1>CHEMICAL<\\e1>  Results demonstrated the involvement of CYP3A4 in the pathways leading to M3a, M3, M5 and M6 and CYP2C8 in the formation of M4","sentence":"The rCYP data was normalized relative to the levels of each CYP form in native human liver microsomes to better assess the contribution of each rCYP in the metabolism of elzasonan  Results demonstrated the involvement of CYP3A4 in the pathways leading to M3a, M3, M5 and M6 and CYP2C8 in the formation of M4"}
{"PMID":23042728,"re_id":6,"annotated sentence":"The signaling of both <e2>Sox9<\\e2> and Runx2, key regulators of chondrogenesis, was downregulated by <e1>VPA<\\e1>  In contrast, VPD had little effect on limb morphology and no significant effect on HDAC activity or the expression of marker genes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"VPA","object":"Sox9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The signaling of both <e2>GENE-Y<\\e2> and Runx2, key regulators of chondrogenesis, was downregulated by <e1>CHEMICAL<\\e1>  In contrast, VPD had little effect on limb morphology and no significant effect on HDAC activity or the expression of marker genes","sentence":"The signaling of both Sox9 and Runx2, key regulators of chondrogenesis, was downregulated by VPA  In contrast, VPD had little effect on limb morphology and no significant effect on HDAC activity or the expression of marker genes"}
{"PMID":23042728,"re_id":7,"annotated sentence":"The signaling of both Sox9 and <e2>Runx2<\\e2>  key regulators of chondrogenesis, was downregulated by <e1>VPA<\\e1>  In contrast, VPD had little effect on limb morphology and no significant effect on HDAC activity or the expression of marker genes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"VPA","object":"Runx2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The signaling of both Sox9 and <e2>GENE-Y<\\e2>  key regulators of chondrogenesis, was downregulated by <e1>CHEMICAL<\\e1>  In contrast, VPD had little effect on limb morphology and no significant effect on HDAC activity or the expression of marker genes","sentence":"The signaling of both Sox9 and Runx2  key regulators of chondrogenesis, was downregulated by VPA  In contrast, VPD had little effect on limb morphology and no significant effect on HDAC activity or the expression of marker genes"}
{"PMID":23042728,"re_id":8,"annotated sentence":"<e1>VPA<\\e1> caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its <e2>HDAC<\\e2> inhibitory effect","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"VPA","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its <e2>GENE-N<\\e2> inhibitory effect","sentence":"VPA caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its HDAC inhibitory effect"}
{"PMID":23042728,"re_id":9,"annotated sentence":"In utero exposure to <e1>valproic acid<\\e1> (VPA), a <e2>histone deacetylase<\\e2> (HDAC) inhibitor, causes neural tube, heart, and limb defects","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"valproic acid","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In utero exposure to <e1>CHEMICAL<\\e1> (VPA), a <e2>GENE-N<\\e2> (HDAC) inhibitor, causes neural tube, heart, and limb defects","sentence":"In utero exposure to valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, causes neural tube, heart, and limb defects"}
{"PMID":23042728,"re_id":10,"annotated sentence":"In utero exposure to <e1>valproic acid<\\e1> (VPA), a histone deacetylase (<e2>HDAC<\\e2>  inhibitor, causes neural tube, heart, and limb defects","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"valproic acid","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In utero exposure to <e1>CHEMICAL<\\e1> (VPA), a histone deacetylase (<e2>GENE-N<\\e2>  inhibitor, causes neural tube, heart, and limb defects","sentence":"In utero exposure to valproic acid (VPA), a histone deacetylase (HDAC  inhibitor, causes neural tube, heart, and limb defects"}
{"PMID":23042728,"re_id":11,"annotated sentence":"In utero exposure to valproic acid (<e1>VPA<\\e1> , a <e2>histone deacetylase<\\e2> (HDAC) inhibitor, causes neural tube, heart, and limb defects","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"VPA","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In utero exposure to valproic acid (<e1>CHEMICAL<\\e1> , a <e2>GENE-N<\\e2> (HDAC) inhibitor, causes neural tube, heart, and limb defects","sentence":"In utero exposure to valproic acid (VPA , a histone deacetylase (HDAC) inhibitor, causes neural tube, heart, and limb defects"}
{"PMID":23042728,"re_id":12,"annotated sentence":"In utero exposure to valproic acid (<e1>VPA<\\e1> , a histone deacetylase (<e2>HDAC<\\e2>  inhibitor, causes neural tube, heart, and limb defects","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"VPA","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In utero exposure to valproic acid (<e1>CHEMICAL<\\e1> , a histone deacetylase (<e2>GENE-N<\\e2>  inhibitor, causes neural tube, heart, and limb defects","sentence":"In utero exposure to valproic acid (VPA , a histone deacetylase (HDAC  inhibitor, causes neural tube, heart, and limb defects"}
{"PMID":23042730,"re_id":0,"annotated sentence":"In summary, activation of <e2>caspases<\\e2> and oxidative stress were observed after <e1>AMD<\\e1> TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated AMD\/TNF-induced cytotoxicity.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"AMD","object":"caspases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In summary, activation of <e2>GENE-N<\\e2> and oxidative stress were observed after <e1>CHEMICAL<\\e1> TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated CHEMICAL\/TNF-induced cytotoxicity.","sentence":"In summary, activation of caspases and oxidative stress were observed after AMD TNF cotreatment, and caspase inhibitors and a lipid-soluble free-radical scavenger attenuated AMD\/TNF-induced cytotoxicity."}
{"PMID":23042730,"re_id":1,"annotated sentence":"<e1>\u03b1-TOCO<\\e1> plus a <e2>pancaspase<\\e2> inhibitor completely abolished AMD\/TNF-induced cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"\u03b1-TOCO","object":"pancaspase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> plus a <e2>GENE-N<\\e2> inhibitor completely abolished AMD\/TNF-induced cytotoxicity","sentence":"\u03b1-TOCO plus a pancaspase inhibitor completely abolished AMD\/TNF-induced cytotoxicity"}
{"PMID":23044488,"re_id":2,"annotated sentence":"Human serum butyrylcholinesterase (<e2>HuBChE<\\e2>  is currently the most suitable bioscavenger for the prophylaxis of highly toxic <e1>organophosphate<\\e1> (OP) nerve agents","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"organophosphate","object":"HuBChE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Human serum butyrylcholinesterase (<e2>GENE-Y<\\e2>  is currently the most suitable bioscavenger for the prophylaxis of highly toxic <e1>CHEMICAL<\\e1> (OP) nerve agents","sentence":"Human serum butyrylcholinesterase (HuBChE  is currently the most suitable bioscavenger for the prophylaxis of highly toxic organophosphate (OP) nerve agents"}
{"PMID":23044488,"re_id":3,"annotated sentence":"<e2>Human serum butyrylcholinesterase<\\e2> (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic <e1>organophosphate<\\e1> (OP) nerve agents","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"organophosphate","object":"Human serum butyrylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic <e1>CHEMICAL<\\e1> (OP) nerve agents","sentence":"Human serum butyrylcholinesterase (HuBChE) is currently the most suitable bioscavenger for the prophylaxis of highly toxic organophosphate (OP) nerve agents"}
{"PMID":23053666,"re_id":5,"annotated sentence":"Cu-dependent <e2>tyrosinase<\\e2> activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate <e1>l-DOPA<\\e1>  These results indicate that CLDN3 and CLDN4 affect sensitivity of the ovarian cancer cells to the cytotoxic effect of cDDP by regulating expression of the Cu transporter CTR1.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"l-DOPA","object":"tyrosinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cu-dependent <e2>GENE-Y<\\e2> activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate <e1>CHEMICAL<\\e1>  These results indicate that CLDN3 and CLDN4 affect sensitivity of the ovarian cancer cells to the cytotoxic effect of cDDP by regulating expression of the Cu transporter CTR1.","sentence":"Cu-dependent tyrosinase activity was also markedly reduced in both types of CLDN knockdown cells when incubated with the substrate l-DOPA  These results indicate that CLDN3 and CLDN4 affect sensitivity of the ovarian cancer cells to the cytotoxic effect of cDDP by regulating expression of the Cu transporter CTR1."}
{"PMID":23055538,"re_id":0,"annotated sentence":"Protein expression of <e2>Ugt1a6<\\e2> also decreased and corresponded with reduced in vitro glucuronidation of <e1>bisphenol A<\\e1> in S9 fractions from livers of pregnant mice","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"bisphenol A","object":"Ugt1a6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Protein expression of <e2>GENE-Y<\\e2> also decreased and corresponded with reduced in vitro glucuronidation of <e1>CHEMICAL<\\e1> in S9 fractions from livers of pregnant mice","sentence":"Protein expression of Ugt1a6 also decreased and corresponded with reduced in vitro glucuronidation of bisphenol A in S9 fractions from livers of pregnant mice"}
{"PMID":23056222,"re_id":12,"annotated sentence":"Results showed that <e1>DMF<\\e1> increased nuclear levels of <e2>Nrf2<\\e2>  and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMF","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Results showed that <e1>CHEMICAL<\\e1> increased nuclear levels of <e2>GENE-Y<\\e2>  and both CHEMICAL and adenovirus-mediated overexpression of GENE-Y (Ad-GENE-Y) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","sentence":"Results showed that DMF increased nuclear levels of Nrf2  and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)"}
{"PMID":23056222,"re_id":13,"annotated sentence":"Results showed that DMF increased nuclear levels of Nrf2, and both <e1>DMF<\\e1> and adenovirus-mediated overexpression of <e2>Nrf2<\\e2> (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMF","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Results showed that CHEMICAL increased nuclear levels of GENE-Y, and both <e1>CHEMICAL<\\e1> and adenovirus-mediated overexpression of <e2>GENE-Y<\\e2> (Ad-GENE-Y) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","sentence":"Results showed that DMF increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)"}
{"PMID":23056222,"re_id":14,"annotated sentence":"Finally, <e1>DMF<\\e1> suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of <e2>Nrf2<\\e2> and phospho-Smad3, respectively","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMF","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, <e1>CHEMICAL<\\e1> suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of <e2>GENE-Y<\\e2> and phospho-Smad3, respectively","sentence":"Finally, DMF suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively"}
{"PMID":23056222,"re_id":15,"annotated sentence":"Additionally, <e1>DMF<\\e1> and Ad-Nrf2 repressed <e2>TGF-beta<\\e2> stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"DMF","object":"TGF-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> and Ad-Nrf2 repressed <e2>GENE-Y<\\e2> stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression","sentence":"Additionally, DMF and Ad-Nrf2 repressed TGF-beta stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression"}
{"PMID":23056222,"re_id":16,"annotated sentence":"However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of <e1>DMF<\\e1> on <e2>TGF-beta<\\e2> induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"DMF","object":"TGF-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-Y<\\e2> induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of CHEMICAL","sentence":"However, downregulation of the antioxidant response element (ARE)-driven Nrf2 target genes such as NQO1, HO-1 and glutathione S-transferase (GST) did not reverse the inhibitory effect of DMF on TGF-beta induced upregulation of profibrotic genes or extracellular matrix proteins, suggesting an ARE-independent anti-fibrotic activity of DMF"}
{"PMID":23056222,"re_id":17,"annotated sentence":"Results showed that DMF increased nuclear levels of Nrf2, and both <e1>DMF<\\e1> and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased <e2>PAI-1<\\e2>  alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"DMF","object":"PAI-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Results showed that CHEMICAL increased nuclear levels of Nrf2, and both <e1>CHEMICAL<\\e1> and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased <e2>GENE-Y<\\e2>  alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","sentence":"Results showed that DMF increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1  alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)"}
{"PMID":23056222,"re_id":18,"annotated sentence":"Results showed that DMF increased nuclear levels of Nrf2, and both <e1>DMF<\\e1> and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, <e2>alpha-smooth muscle actin<\\e2> (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"DMF","object":"alpha-smooth muscle actin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Results showed that CHEMICAL increased nuclear levels of Nrf2, and both <e1>CHEMICAL<\\e1> and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, <e2>GENE-Y<\\e2> (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","sentence":"Results showed that DMF increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)"}
{"PMID":23056222,"re_id":19,"annotated sentence":"Results showed that DMF increased nuclear levels of Nrf2, and both <e1>DMF<\\e1> and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (<e2>alpha-SMA<\\e2> , fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"DMF","object":"alpha-SMA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Results showed that CHEMICAL increased nuclear levels of Nrf2, and both <e1>CHEMICAL<\\e1> and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (<e2>GENE-Y<\\e2> , fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","sentence":"Results showed that DMF increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA , fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)"}
{"PMID":23056222,"re_id":20,"annotated sentence":"Results showed that DMF increased nuclear levels of Nrf2, and both <e1>DMF<\\e1> and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), <e2>fibronectin<\\e2> and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"DMF","object":"fibronectin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Results showed that CHEMICAL increased nuclear levels of Nrf2, and both <e1>CHEMICAL<\\e1> and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), <e2>GENE-Y<\\e2> and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","sentence":"Results showed that DMF increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)"}
{"PMID":23056222,"re_id":21,"annotated sentence":"Results showed that DMF increased nuclear levels of Nrf2, and both <e1>DMF<\\e1> and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and <e2>type 1 collagen<\\e2> expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"DMF","object":"type 1 collagen","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results showed that CHEMICAL increased nuclear levels of Nrf2, and both <e1>CHEMICAL<\\e1> and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and <e2>GENE-N<\\e2> expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)","sentence":"Results showed that DMF increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F)"}
{"PMID":23056222,"re_id":22,"annotated sentence":"<e1>Dimethylfumarate<\\e1> attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta\/<e2>Smad<\\e2> signaling","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Dimethylfumarate","object":"Smad","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta\/<e2>GENE-N<\\e2> signaling","sentence":"Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta\/Smad signaling"}
{"PMID":23056222,"re_id":23,"annotated sentence":"<e1>Dimethylfumarate<\\e1> attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of <e2>transforming growth factor-beta<\\e2> Smad signaling","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Dimethylfumarate","object":"transforming growth factor-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of <e2>GENE-Y<\\e2> Smad signaling","sentence":"Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta Smad signaling"}
{"PMID":23056222,"re_id":24,"annotated sentence":"Finally, <e1>DMF<\\e1> suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and <e2>alpha-SMA<\\e2>  fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"DMF","object":"alpha-SMA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, <e1>CHEMICAL<\\e1> suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and <e2>GENE-Y<\\e2>  fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively","sentence":"Finally, DMF suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA  fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively"}
{"PMID":23056222,"re_id":25,"annotated sentence":"Finally, <e1>DMF<\\e1> suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, <e2>fibronectin<\\e2> and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"DMF","object":"fibronectin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, <e1>CHEMICAL<\\e1> suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, <e2>GENE-Y<\\e2> and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively","sentence":"Finally, DMF suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively"}
{"PMID":23056222,"re_id":26,"annotated sentence":"Finally, <e1>DMF<\\e1> suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and <e2>type 1 collagen<\\e2> expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"DMF","object":"type 1 collagen","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Finally, <e1>CHEMICAL<\\e1> suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and <e2>GENE-N<\\e2> expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively","sentence":"Finally, DMF suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively"}
{"PMID":23056222,"re_id":27,"annotated sentence":"Finally, <e1>DMF<\\e1> suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and <e2>phospho-Smad3<\\e2>  respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"DMF","object":"phospho-Smad3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, <e1>CHEMICAL<\\e1> suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and <e2>GENE-Y<\\e2>  respectively","sentence":"Finally, DMF suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3  respectively"}
{"PMID":23056222,"re_id":28,"annotated sentence":"In summary, <e1>DMF<\\e1> attenuated renal fibrosis via the Nrf2-mediated inhibition of <e2>TGF-beta<\\e2> Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"DMF","object":"TGF-beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In summary, <e1>CHEMICAL<\\e1> attenuated renal fibrosis via the Nrf2-mediated inhibition of <e2>GENE-Y<\\e2> Smad3 signaling in an ARE-independent manner, suggesting that CHEMICAL could be used to treat renal fibrosis.","sentence":"In summary, DMF attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis."}
{"PMID":23056222,"re_id":29,"annotated sentence":"In summary, <e1>DMF<\\e1> attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta\/<e2>Smad3<\\e2> signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"DMF","object":"Smad3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In summary, <e1>CHEMICAL<\\e1> attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta\/<e2>GENE-Y<\\e2> signaling in an ARE-independent manner, suggesting that CHEMICAL could be used to treat renal fibrosis.","sentence":"In summary, DMF attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta\/Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis."}
{"PMID":23056222,"re_id":30,"annotated sentence":"Additionally, <e1>DMF<\\e1> and Ad-Nrf2 repressed TGF-beta-stimulated <e2>Smad3<\\e2> activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DMF","object":"Smad3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> and Ad-Nrf2 repressed TGF-beta-stimulated <e2>GENE-Y<\\e2> activity by inhibiting GENE-Y phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression","sentence":"Additionally, DMF and Ad-Nrf2 repressed TGF-beta-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression"}
{"PMID":23056222,"re_id":31,"annotated sentence":"Additionally, <e1>DMF<\\e1> and Ad-Nrf2 repressed TGF-beta-stimulated Smad3 activity by inhibiting <e2>Smad3<\\e2> phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DMF","object":"Smad3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, <e1>CHEMICAL<\\e1> and Ad-Nrf2 repressed TGF-beta-stimulated GENE-Y activity by inhibiting <e2>GENE-Y<\\e2> phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression","sentence":"Additionally, DMF and Ad-Nrf2 repressed TGF-beta-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression"}
{"PMID":23059626,"re_id":0,"annotated sentence":"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while <e2>osteocalcin<\\e2> (OCN) was augmented in CCL3(-\/-) and <e1>Met<\\e1> RANTES-treated mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Met","object":"osteocalcin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while <e2>GENE-Y<\\e2> (OCN) was augmented in CCL3(-\/-) and <e1>CHEMICAL<\\e1> RANTES-treated mice","sentence":"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-\/-) and Met RANTES-treated mice"}
{"PMID":23059626,"re_id":1,"annotated sentence":"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (<e2>OCN<\\e2>  was augmented in CCL3(-\/-) and <e1>Met<\\e1> RANTES-treated mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Met","object":"OCN","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (<e2>GENE-Y<\\e2>  was augmented in CCL3(-\/-) and <e1>CHEMICAL<\\e1> RANTES-treated mice","sentence":"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (OCN  was augmented in CCL3(-\/-) and Met RANTES-treated mice"}
{"PMID":23059626,"re_id":2,"annotated sentence":"The expression of the osteoblast markers runt-related transcription factor 2 (<e2>RUNX2<\\e2>  and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-\/-) and <e1>Met<\\e1> RANTES-treated mice","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"RUNX2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of the osteoblast markers runt-related transcription factor 2 (<e2>GENE-Y<\\e2>  and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-\/-) and <e1>CHEMICAL<\\e1> RANTES-treated mice","sentence":"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2  and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-\/-) and Met RANTES-treated mice"}
{"PMID":23059626,"re_id":3,"annotated sentence":"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and <e2>periostin<\\e2> was decreased, while osteocalcin (OCN) was augmented in CCL3(-\/-) and <e1>Met<\\e1> RANTES-treated mice","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"periostin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and <e2>GENE-Y<\\e2> was decreased, while osteocalcin (OCN) was augmented in CCL3(-\/-) and <e1>CHEMICAL<\\e1> RANTES-treated mice","sentence":"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-\/-) and Met RANTES-treated mice"}
{"PMID":23059626,"re_id":4,"annotated sentence":"The expression of the osteoblast markers <e2>runt-related transcription factor 2<\\e2> (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-\/-) and <e1>Met<\\e1> RANTES-treated mice","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"runt-related transcription factor 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of the osteoblast markers <e2>GENE-Y<\\e2> (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-\/-) and <e1>CHEMICAL<\\e1> RANTES-treated mice","sentence":"The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-\/-) and Met RANTES-treated mice"}
{"PMID":23059626,"re_id":5,"annotated sentence":"mRNA levels of <e2>receptor activator of nuclear factor kappa-B<\\e2> (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>Met<\\e1> RANTES","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"receptor activator of nuclear factor kappa-B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"mRNA levels of <e2>GENE-Y<\\e2> (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>CHEMICAL<\\e1> RANTES","sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with Met RANTES"}
{"PMID":23059626,"re_id":6,"annotated sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (<e2>RANK<\\e2> , its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>Met<\\e1> RANTES","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"RANK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (<e2>GENE-Y<\\e2> , its ligand GENE-YL, tumor necrosis factor alpha (TNF-\u03b1) and GENE-YL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>CHEMICAL<\\e1> RANTES","sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK , its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with Met RANTES"}
{"PMID":23059626,"re_id":7,"annotated sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand <e2>RANKL<\\e2>  tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>Met<\\e1> RANTES","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"RANKL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand <e2>GENE-Y<\\e2>  tumor necrosis factor alpha (TNF-\u03b1) and GENE-Y\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>CHEMICAL<\\e1> RANTES","sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL  tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with Met RANTES"}
{"PMID":23059626,"re_id":8,"annotated sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, <e2>tumor necrosis factor alpha<\\e2> (TNF-\u03b1) and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>Met<\\e1> RANTES","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"tumor necrosis factor alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, <e2>GENE-Y<\\e2> (TNF-\u03b1) and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>CHEMICAL<\\e1> RANTES","sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with Met RANTES"}
{"PMID":23059626,"re_id":9,"annotated sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (<e2>TNF-\u03b1<\\e2>  and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>Met<\\e1> RANTES","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (<e2>GENE-Y<\\e2>  and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>CHEMICAL<\\e1> RANTES","sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1  and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with Met RANTES"}
{"PMID":23059626,"re_id":10,"annotated sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and <e2>RANKL<\\e2> osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>Met<\\e1> RANTES","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"RANKL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand GENE-Y, tumor necrosis factor alpha (TNF-\u03b1) and <e2>GENE-Y<\\e2> osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>CHEMICAL<\\e1> RANTES","sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with Met RANTES"}
{"PMID":23059626,"re_id":11,"annotated sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/<e2>osteoprotegerin<\\e2> (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>Met<\\e1> RANTES","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"osteoprotegerin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/<e2>GENE-Y<\\e2> (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>CHEMICAL<\\e1> RANTES","sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with Met RANTES"}
{"PMID":23059626,"re_id":12,"annotated sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/osteoprotegerin (<e2>OPG<\\e2>  ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>Met<\\e1> RANTES","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"OPG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/osteoprotegerin (<e2>GENE-Y<\\e2>  ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with <e1>CHEMICAL<\\e1> RANTES","sentence":"mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-\u03b1) and RANKL\/osteoprotegerin (OPG  ratio were diminished in the periodontium of CCL3(-\/-) mice and in the group treated with Met RANTES"}
{"PMID":23059626,"re_id":13,"annotated sentence":"<e1>Met<\\e1> RANTES treatment also reduced the levels of <e2>cathepsin K<\\e2> and metalloproteinase 13 (MMP13)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"cathepsin K","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> RANTES treatment also reduced the levels of <e2>GENE-Y<\\e2> and metalloproteinase 13 (MMP13)","sentence":"Met RANTES treatment also reduced the levels of cathepsin K and metalloproteinase 13 (MMP13)"}
{"PMID":23059626,"re_id":14,"annotated sentence":"<e1>Met<\\e1> RANTES treatment also reduced the levels of cathepsin K and <e2>metalloproteinase 13<\\e2> (MMP13)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"metalloproteinase 13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> RANTES treatment also reduced the levels of cathepsin K and <e2>GENE-Y<\\e2> (MMP13)","sentence":"Met RANTES treatment also reduced the levels of cathepsin K and metalloproteinase 13 (MMP13)"}
{"PMID":23059626,"re_id":15,"annotated sentence":"<e1>Met<\\e1> RANTES treatment also reduced the levels of cathepsin K and metalloproteinase 13 (<e2>MMP13<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Met","object":"MMP13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> RANTES treatment also reduced the levels of cathepsin K and metalloproteinase 13 (<e2>GENE-Y<\\e2> ","sentence":"Met RANTES treatment also reduced the levels of cathepsin K and metalloproteinase 13 (MMP13 "}
{"PMID":23059626,"re_id":16,"annotated sentence":"Our results showed that bone remodeling was significantly decreased in CCL3(-\/-) and CCR1(-\/-) mice and in animals treated with <e1>Met<\\e1> RANTES (an antagonist of <e2>CCR5<\\e2> and CCR1)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Met","object":"CCR5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results showed that bone remodeling was significantly decreased in CCL3(-\/-) and CCR1(-\/-) mice and in animals treated with <e1>CHEMICAL<\\e1> RANTES (an antagonist of <e2>GENE-Y<\\e2> and CCR1)","sentence":"Our results showed that bone remodeling was significantly decreased in CCL3(-\/-) and CCR1(-\/-) mice and in animals treated with Met RANTES (an antagonist of CCR5 and CCR1)"}
{"PMID":23059626,"re_id":17,"annotated sentence":"Our results showed that bone remodeling was significantly decreased in CCL3(-\/-) and CCR1(-\/-) mice and in animals treated with <e1>Met<\\e1> RANTES (an antagonist of CCR5 and <e2>CCR1<\\e2> ","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Met","object":"CCR1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results showed that bone remodeling was significantly decreased in CCL3(-\/-) and GENE-Y(-\/-) mice and in animals treated with <e1>CHEMICAL<\\e1> RANTES (an antagonist of CCR5 and <e2>GENE-Y<\\e2> ","sentence":"Our results showed that bone remodeling was significantly decreased in CCL3(-\/-) and CCR1(-\/-) mice and in animals treated with Met RANTES (an antagonist of CCR5 and CCR1 "}
{"PMID":23061466,"re_id":0,"annotated sentence":"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and <e1>matrine<\\e1> carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>hERG<\\e2> blocking activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"matrine","object":"hERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The quinolizidine alkaloids (natural products) such as oxyCHEMICAL, sophoridine, sophocarpine and <e1>CHEMICAL<\\e1> carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>GENE-Y<\\e2> blocking activity","sentence":"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and hERG blocking activity"}
{"PMID":23061466,"re_id":1,"annotated sentence":"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of <e1>O=C=N-C-C-C-N<\\e1> that possessed positive ionotropic effect and <e2>hERG<\\e2> blocking activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"O=C=N-C-C-C-N","object":"hERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of <e1>CHEMICAL<\\e1> that possessed positive ionotropic effect and <e2>GENE-Y<\\e2> blocking activity","sentence":"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and hERG blocking activity"}
{"PMID":23061466,"re_id":2,"annotated sentence":"The <e1>quinolizidine alkaloids<\\e1> (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>hERG<\\e2> blocking activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"quinolizidine alkaloids","object":"hERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>GENE-Y<\\e2> blocking activity","sentence":"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and hERG blocking activity"}
{"PMID":23061466,"re_id":3,"annotated sentence":"The quinolizidine alkaloids (natural products) such as <e1>oxymatrine<\\e1>  sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>hERG<\\e2> blocking activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"oxymatrine","object":"hERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The quinolizidine alkaloids (natural products) such as <e1>CHEMICAL<\\e1>  sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>GENE-Y<\\e2> blocking activity","sentence":"The quinolizidine alkaloids (natural products) such as oxymatrine  sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and hERG blocking activity"}
{"PMID":23061466,"re_id":4,"annotated sentence":"The quinolizidine alkaloids (natural products) such as oxymatrine, <e1>sophoridine<\\e1>  sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>hERG<\\e2> blocking activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sophoridine","object":"hERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The quinolizidine alkaloids (natural products) such as oxymatrine, <e1>CHEMICAL<\\e1>  sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>GENE-Y<\\e2> blocking activity","sentence":"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine  sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and hERG blocking activity"}
{"PMID":23061466,"re_id":5,"annotated sentence":"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, <e1>sophocarpine<\\e1> and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>hERG<\\e2> blocking activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sophocarpine","object":"hERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, <e1>CHEMICAL<\\e1> and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and <e2>GENE-Y<\\e2> blocking activity","sentence":"The quinolizidine alkaloids (natural products) such as oxymatrine, sophoridine, sophocarpine and matrine carry the common molecular structure of O=C=N-C-C-C-N that possessed positive ionotropic effect and hERG blocking activity"}
{"PMID":23063595,"re_id":1,"annotated sentence":"Several effects of <e1>polyphenols<\\e1> are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, <e2>AMPK<\\e2> activators, calorie-restriction mimetics or epigenetic regulators","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"polyphenols","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Several effects of <e1>CHEMICAL<\\e1> are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, <e2>GENE-Y<\\e2> activators, calorie-restriction mimetics or epigenetic regulators","sentence":"Several effects of polyphenols are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators"}
{"PMID":23063595,"re_id":2,"annotated sentence":"Several effects of <e1>polyphenols<\\e1> are useful in this scenario, including a reduction in the activities of <e2>cytokines<\\e2> and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"polyphenols","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Several effects of <e1>CHEMICAL<\\e1> are useful in this scenario, including a reduction in the activities of <e2>GENE-N<\\e2> and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators","sentence":"Several effects of polyphenols are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators"}
{"PMID":23063595,"re_id":3,"annotated sentence":"Several effects of <e1>polyphenols<\\e1> are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through <e2>histone deacetylase<\\e2> inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"polyphenols","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Several effects of <e1>CHEMICAL<\\e1> are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through <e2>GENE-N<\\e2> inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators","sentence":"Several effects of polyphenols are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators"}
{"PMID":23064031,"re_id":0,"annotated sentence":"<e1>NFD<\\e1> suppressed <e2>EGF<\\e2> mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"NFD","object":"EGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppressed <e2>GENE-Y<\\e2> mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity","sentence":"NFD suppressed EGF mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity"}
{"PMID":23064031,"re_id":1,"annotated sentence":"<e1>NFD<\\e1> abrogated <e2>EGF<\\e2> induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)\/Akt","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"NFD","object":"EGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> abrogated <e2>GENE-Y<\\e2> induced phosphorylation of GENE-Y receptor (GENE-YR) and phosphatidylinositol 3-kinase (PI3K)\/Akt","sentence":"NFD abrogated EGF induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)\/Akt"}
{"PMID":23064031,"re_id":2,"annotated sentence":"Furthermore, the EGFR inhibitor <e1>AG1478<\\e1> inhibited EGF-induced <e2>MMP-9<\\e2> expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/Akt activation occur downstream of EGFR activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"AG1478","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, the EGFR inhibitor <e1>CHEMICAL<\\e1> inhibited EGF-induced <e2>GENE-Y<\\e2> expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/Akt activation occur downstream of EGFR activation","sentence":"Furthermore, the EGFR inhibitor AG1478 inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/Akt activation occur downstream of EGFR activation"}
{"PMID":23064031,"re_id":3,"annotated sentence":"These findings suggest that <e1>NFD<\\e1> inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent <e2>PI3K<\\e2> Akt signaling, leading to the down-regulation of MMP-9 expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"NFD","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings suggest that <e1>CHEMICAL<\\e1> inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent <e2>GENE-N<\\e2> Akt signaling, leading to the down-regulation of MMP-9 expression","sentence":"These findings suggest that NFD inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K Akt signaling, leading to the down-regulation of MMP-9 expression"}
{"PMID":23064031,"re_id":4,"annotated sentence":"These findings suggest that <e1>NFD<\\e1> inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K\/<e2>Akt<\\e2> signaling, leading to the down-regulation of MMP-9 expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"NFD","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings suggest that <e1>CHEMICAL<\\e1> inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K\/<e2>GENE-N<\\e2> signaling, leading to the down-regulation of MMP-9 expression","sentence":"These findings suggest that NFD inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K\/Akt signaling, leading to the down-regulation of MMP-9 expression"}
{"PMID":23064031,"re_id":5,"annotated sentence":"These findings suggest that <e1>NFD<\\e1> inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K\/Akt signaling, leading to the down-regulation of <e2>MMP-9<\\e2> expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"NFD","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings suggest that <e1>CHEMICAL<\\e1> inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K\/Akt signaling, leading to the down-regulation of <e2>GENE-Y<\\e2> expression","sentence":"These findings suggest that NFD inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K\/Akt signaling, leading to the down-regulation of MMP-9 expression"}
{"PMID":23064031,"re_id":6,"annotated sentence":"<e1>NFD<\\e1> suppressed EGF-mediated protein levels of <e2>c-Jun<\\e2> and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"NFD","object":"c-Jun","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppressed EGF-mediated protein levels of <e2>GENE-Y<\\e2> and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity","sentence":"NFD suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity"}
{"PMID":23064031,"re_id":7,"annotated sentence":"<e1>NFD<\\e1> suppressed EGF-mediated protein levels of c-Jun and <e2>c-Fos<\\e2>  and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"NFD","object":"c-Fos","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppressed EGF-mediated protein levels of c-Jun and <e2>GENE-Y<\\e2>  and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity","sentence":"NFD suppressed EGF-mediated protein levels of c-Jun and c-Fos  and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity"}
{"PMID":23064031,"re_id":8,"annotated sentence":"<e1>NFD<\\e1> suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced <e2>MMP-9<\\e2> expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"NFD","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced <e2>GENE-Y<\\e2> expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity","sentence":"NFD suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity"}
{"PMID":23064031,"re_id":9,"annotated sentence":"Furthermore, the EGFR inhibitor <e1>AG1478<\\e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that <e2>PI3K<\\e2> Akt activation occur downstream of EGFR activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AG1478","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the EGFR inhibitor <e1>CHEMICAL<\\e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of GENE-N\/Akt, suggesting that <e2>GENE-N<\\e2> Akt activation occur downstream of EGFR activation","sentence":"Furthermore, the EGFR inhibitor AG1478 inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K Akt activation occur downstream of EGFR activation"}
{"PMID":23064031,"re_id":10,"annotated sentence":"Furthermore, the EGFR inhibitor <e1>AG1478<\\e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/<e2>Akt<\\e2> activation occur downstream of EGFR activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AG1478","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the EGFR inhibitor <e1>CHEMICAL<\\e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/GENE-N, suggesting that PI3K\/<e2>GENE-N<\\e2> activation occur downstream of EGFR activation","sentence":"Furthermore, the EGFR inhibitor AG1478 inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/Akt activation occur downstream of EGFR activation"}
{"PMID":23064031,"re_id":11,"annotated sentence":"Furthermore, the EGFR inhibitor <e1>AG1478<\\e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/Akt activation occur downstream of <e2>EGFR<\\e2> activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AG1478","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, the GENE-Y inhibitor <e1>CHEMICAL<\\e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/Akt activation occur downstream of <e2>GENE-Y<\\e2> activation","sentence":"Furthermore, the EGFR inhibitor AG1478 inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/Akt activation occur downstream of EGFR activation"}
{"PMID":23064031,"re_id":12,"annotated sentence":"Furthermore, the <e2>EGFR<\\e2> inhibitor <e1>AG1478<\\e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/Akt activation occur downstream of EGFR activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AG1478","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/Akt activation occur downstream of GENE-Y activation","sentence":"Furthermore, the EGFR inhibitor AG1478 inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/Akt activation occur downstream of EGFR activation"}
{"PMID":23064031,"re_id":13,"annotated sentence":"Furthermore, the EGFR inhibitor <e1>AG1478<\\e1> inhibited <e2>EGF<\\e2> induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/Akt activation occur downstream of EGFR activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AG1478","object":"EGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, the GENE-YR inhibitor <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/Akt activation occur downstream of GENE-YR activation","sentence":"Furthermore, the EGFR inhibitor AG1478 inhibited EGF induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt, suggesting that PI3K\/Akt activation occur downstream of EGFR activation"}
{"PMID":23064031,"re_id":14,"annotated sentence":"Furthermore, the EGFR inhibitor <e1>AG1478<\\e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of <e2>PI3K<\\e2> Akt, suggesting that PI3K\/Akt activation occur downstream of EGFR activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AG1478","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the EGFR inhibitor <e1>CHEMICAL<\\e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of <e2>GENE-N<\\e2> Akt, suggesting that GENE-N\/Akt activation occur downstream of EGFR activation","sentence":"Furthermore, the EGFR inhibitor AG1478 inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K Akt, suggesting that PI3K\/Akt activation occur downstream of EGFR activation"}
{"PMID":23064031,"re_id":15,"annotated sentence":"Furthermore, the EGFR inhibitor <e1>AG1478<\\e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/<e2>Akt<\\e2>  suggesting that PI3K\/Akt activation occur downstream of EGFR activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AG1478","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the EGFR inhibitor <e1>CHEMICAL<\\e1> inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/<e2>GENE-N<\\e2>  suggesting that PI3K\/GENE-N activation occur downstream of EGFR activation","sentence":"Furthermore, the EGFR inhibitor AG1478 inhibited EGF-induced MMP-9 expression, cell migration and invasion, as well as the activation of PI3K\/Akt  suggesting that PI3K\/Akt activation occur downstream of EGFR activation"}
{"PMID":23064031,"re_id":16,"annotated sentence":"Inhibition of <e2>EGF<\\e2> EGFR activation with <e1>naphtho[1,2-b]furan-4,5-dione<\\e1> blocks migration and invasion of MDA-MB-231 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"naphtho[1,2-b]furan-4,5-dione","object":"EGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> GENE-YR activation with <e1>CHEMICAL<\\e1> blocks migration and invasion of MDA-MB-231 cells","sentence":"Inhibition of EGF EGFR activation with naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells"}
{"PMID":23064031,"re_id":17,"annotated sentence":"Inhibition of EGF\/<e2>EGFR<\\e2> activation with <e1>naphtho[1,2-b]furan-4,5-dione<\\e1> blocks migration and invasion of MDA-MB-231 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"naphtho[1,2-b]furan-4,5-dione","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of EGF\/<e2>GENE-Y<\\e2> activation with <e1>CHEMICAL<\\e1> blocks migration and invasion of MDA-MB-231 cells","sentence":"Inhibition of EGF\/EGFR activation with naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells"}
{"PMID":23064031,"re_id":18,"annotated sentence":"These findings suggest that <e1>NFD<\\e1> inhibited the <e2>EGF<\\e2> induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K\/Akt signaling, leading to the down-regulation of MMP-9 expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NFD","object":"EGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings suggest that <e1>CHEMICAL<\\e1> inhibited the <e2>GENE-Y<\\e2> induced invasion and migration of MDA-MB-231 cells via GENE-YR-dependent PI3K\/Akt signaling, leading to the down-regulation of MMP-9 expression","sentence":"These findings suggest that NFD inhibited the EGF induced invasion and migration of MDA-MB-231 cells via EGFR-dependent PI3K\/Akt signaling, leading to the down-regulation of MMP-9 expression"}
{"PMID":23064031,"re_id":19,"annotated sentence":"These findings suggest that <e1>NFD<\\e1> inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via <e2>EGFR<\\e2> dependent PI3K\/Akt signaling, leading to the down-regulation of MMP-9 expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NFD","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings suggest that <e1>CHEMICAL<\\e1> inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via <e2>GENE-Y<\\e2> dependent PI3K\/Akt signaling, leading to the down-regulation of MMP-9 expression","sentence":"These findings suggest that NFD inhibited the EGF-induced invasion and migration of MDA-MB-231 cells via EGFR dependent PI3K\/Akt signaling, leading to the down-regulation of MMP-9 expression"}
{"PMID":23064031,"re_id":20,"annotated sentence":"<e1>NFD<\\e1> suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced <e2>MMP-9<\\e2> expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NFD","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced <e2>GENE-Y<\\e2> expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity","sentence":"NFD suppressed EGF-mediated protein levels of c-Jun and c-Fos, and reduced MMP-9 expression and activity, concomitantly with a marked inhibition on cell migration and invasion without obvious cellular cytotoxicity"}
{"PMID":23064031,"re_id":21,"annotated sentence":"<e1>NFD<\\e1> abrogated EGF-induced phosphorylation of <e2>EGF receptor<\\e2> (EGFR) and phosphatidylinositol 3-kinase (PI3K)\/Akt","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NFD","object":"EGF receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> abrogated EGF-induced phosphorylation of <e2>GENE-Y<\\e2> (EGFR) and phosphatidylinositol 3-kinase (PI3K)\/Akt","sentence":"NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)\/Akt"}
{"PMID":23064031,"re_id":22,"annotated sentence":"<e1>NFD<\\e1> abrogated EGF-induced phosphorylation of EGF receptor (<e2>EGFR<\\e2>  and phosphatidylinositol 3-kinase (PI3K)\/Akt","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NFD","object":"EGFR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> abrogated EGF-induced phosphorylation of EGF receptor (<e2>GENE-Y<\\e2>  and phosphatidylinositol 3-kinase (PI3K)\/Akt","sentence":"NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR  and phosphatidylinositol 3-kinase (PI3K)\/Akt"}
{"PMID":23064031,"re_id":23,"annotated sentence":"<e1>NFD<\\e1> abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and <e2>phosphatidylinositol 3-kinase<\\e2> (PI3K)\/Akt","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NFD","object":"phosphatidylinositol 3-kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and <e2>GENE-N<\\e2> (PI3K)\/Akt","sentence":"NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)\/Akt"}
{"PMID":23064031,"re_id":24,"annotated sentence":"<e1>NFD<\\e1> abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (<e2>PI3K<\\e2> \/Akt","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NFD","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (<e2>GENE-N<\\e2> \/Akt","sentence":"NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K \/Akt"}
{"PMID":23064031,"re_id":25,"annotated sentence":"<e1>NFD<\\e1> abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)\/<e2>Akt<\\e2>  The specific PI3K inhibitor, wortmannin, blocked significantly EGF-induced cell migration and invasion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NFD","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)\/<e2>GENE-N<\\e2>  The specific PI3K inhibitor, wortmannin, blocked significantly EGF-induced cell migration and invasion","sentence":"NFD abrogated EGF-induced phosphorylation of EGF receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K)\/Akt  The specific PI3K inhibitor, wortmannin, blocked significantly EGF-induced cell migration and invasion"}
{"PMID":23064031,"re_id":26,"annotated sentence":"The specific <e2>PI3K<\\e2> inhibitor, <e1>wortmannin<\\e1>  blocked significantly EGF-induced cell migration and invasion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"wortmannin","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The specific <e2>GENE-N<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  blocked significantly EGF-induced cell migration and invasion","sentence":"The specific PI3K inhibitor, wortmannin  blocked significantly EGF-induced cell migration and invasion"}
{"PMID":23064031,"re_id":27,"annotated sentence":"The specific PI3K inhibitor, <e1>wortmannin<\\e1>  blocked significantly <e2>EGF<\\e2> induced cell migration and invasion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"wortmannin","object":"EGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The specific PI3K inhibitor, <e1>CHEMICAL<\\e1>  blocked significantly <e2>GENE-Y<\\e2> induced cell migration and invasion","sentence":"The specific PI3K inhibitor, wortmannin  blocked significantly EGF induced cell migration and invasion"}
{"PMID":23066090,"re_id":0,"annotated sentence":"Herein, we report the identification and characterization of <e1>3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile<\\e1> (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated <e2>insulin<\\e2> secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of <e1>CHEMICAL<\\e1> (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated <e2>GENE-Y<\\e2> secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":1,"annotated sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>ESI-09<\\e1> , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated <e2>insulin<\\e2> secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ESI-09","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>CHEMICAL<\\e1> , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated <e2>GENE-Y<\\e2> secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09 , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":2,"annotated sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>nucleotide<\\e1> EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated <e2>insulin<\\e2> secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"nucleotide","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>CHEMICAL<\\e1> EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated <e2>GENE-Y<\\e2> secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":3,"annotated sentence":"Herein, we report the identification and characterization of <e1>3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile<\\e1> (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular <e2>EPAC<\\e2> mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile","object":"EPAC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of <e1>CHEMICAL<\\e1> (ESI-09), a novel noncyclic nucleotide GENE-Y antagonist that is capable of specifically blocking intracellular <e2>GENE-Y<\\e2> mediated Rap1 activation and Akt phosphorylation, as well as GENE-Y-mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":4,"annotated sentence":"Herein, we report the identification and characterization of <e1>3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile<\\e1> (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated <e2>Rap1<\\e2> activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile","object":"Rap1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of <e1>CHEMICAL<\\e1> (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated <e2>GENE-Y<\\e2> activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":5,"annotated sentence":"Herein, we report the identification and characterization of <e1>3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile<\\e1> (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and <e2>Akt<\\e2> phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein, we report the identification and characterization of <e1>CHEMICAL<\\e1> (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and <e2>GENE-N<\\e2> phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":6,"annotated sentence":"Herein, we report the identification and characterization of <e1>3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile<\\e1> (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as <e2>EPAC<\\e2> mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile","object":"EPAC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of <e1>CHEMICAL<\\e1> (ESI-09), a novel noncyclic nucleotide GENE-Y antagonist that is capable of specifically blocking intracellular GENE-Y-mediated Rap1 activation and Akt phosphorylation, as well as <e2>GENE-Y<\\e2> mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":7,"annotated sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>ESI-09<\\e1> , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular <e2>EPAC<\\e2> mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ESI-09","object":"EPAC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>CHEMICAL<\\e1> , a novel noncyclic nucleotide GENE-Y antagonist that is capable of specifically blocking intracellular <e2>GENE-Y<\\e2> mediated Rap1 activation and Akt phosphorylation, as well as GENE-Y-mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09 , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":8,"annotated sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>ESI-09<\\e1> , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated <e2>Rap1<\\e2> activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ESI-09","object":"Rap1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>CHEMICAL<\\e1> , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated <e2>GENE-Y<\\e2> activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09 , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":9,"annotated sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>ESI-09<\\e1> , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and <e2>Akt<\\e2> phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ESI-09","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>CHEMICAL<\\e1> , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and <e2>GENE-N<\\e2> phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09 , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":10,"annotated sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>ESI-09<\\e1> , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as <e2>EPAC<\\e2> mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ESI-09","object":"EPAC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>CHEMICAL<\\e1> , a novel noncyclic nucleotide GENE-Y antagonist that is capable of specifically blocking intracellular GENE-Y-mediated Rap1 activation and Akt phosphorylation, as well as <e2>GENE-Y<\\e2> mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09 , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":11,"annotated sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>nucleotide<\\e1> EPAC antagonist that is capable of specifically blocking intracellular <e2>EPAC<\\e2> mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nucleotide","object":"EPAC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>CHEMICAL<\\e1> GENE-Y antagonist that is capable of specifically blocking intracellular <e2>GENE-Y<\\e2> mediated Rap1 activation and Akt phosphorylation, as well as GENE-Y-mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":12,"annotated sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>nucleotide<\\e1> EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated <e2>Rap1<\\e2> activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nucleotide","object":"Rap1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>CHEMICAL<\\e1> EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated <e2>GENE-Y<\\e2> activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":13,"annotated sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>nucleotide<\\e1> EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and <e2>Akt<\\e2> phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nucleotide","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>CHEMICAL<\\e1> EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and <e2>GENE-N<\\e2> phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":14,"annotated sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>nucleotide<\\e1> EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as <e2>EPAC<\\e2> mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nucleotide","object":"EPAC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>CHEMICAL<\\e1> GENE-Y antagonist that is capable of specifically blocking intracellular GENE-Y-mediated Rap1 activation and Akt phosphorylation, as well as <e2>GENE-Y<\\e2> mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":15,"annotated sentence":"Herein, we report the identification and characterization of <e1>3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile<\\e1> (ESI-09), a novel noncyclic nucleotide <e2>EPAC<\\e2> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile","object":"EPAC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of <e1>CHEMICAL<\\e1> (ESI-09), a novel noncyclic nucleotide <e2>GENE-Y<\\e2> antagonist that is capable of specifically blocking intracellular GENE-Y-mediated Rap1 activation and Akt phosphorylation, as well as GENE-Y-mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":16,"annotated sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>ESI-09<\\e1> , a novel noncyclic nucleotide <e2>EPAC<\\e2> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"ESI-09","object":"EPAC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (<e1>CHEMICAL<\\e1> , a novel noncyclic nucleotide <e2>GENE-Y<\\e2> antagonist that is capable of specifically blocking intracellular GENE-Y-mediated Rap1 activation and Akt phosphorylation, as well as GENE-Y-mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09 , a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066090,"re_id":17,"annotated sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>nucleotide<\\e1> <e2>EPAC<\\e2> antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"nucleotide","object":"EPAC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic <e1>CHEMICAL<\\e1> <e2>GENE-Y<\\e2> antagonist that is capable of specifically blocking intracellular GENE-Y-mediated Rap1 activation and Akt phosphorylation, as well as GENE-Y-mediated insulin secretion in pancreatic \u03b2 cells","sentence":"Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic \u03b2 cells"}
{"PMID":23066988,"re_id":2,"annotated sentence":"Furthermore, the <e2>AMPK<\\e2> activator <e1>5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide<\\e1> (AICAR) significantly inhibited ghrelin secretion","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, the <e2>GENE-Y<\\e2> activator <e1>CHEMICAL<\\e1> (AICAR) significantly inhibited ghrelin secretion","sentence":"Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion"}
{"PMID":23066988,"re_id":3,"annotated sentence":"Furthermore, the <e2>AMPK<\\e2> activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (<e1>AICAR<\\e1>  significantly inhibited ghrelin secretion","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"AICAR","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, the <e2>GENE-Y<\\e2> activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (<e1>CHEMICAL<\\e1>  significantly inhibited ghrelin secretion","sentence":"Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR  significantly inhibited ghrelin secretion"}
{"PMID":23066988,"re_id":4,"annotated sentence":"Finally, <e1>Metformin<\\e1> treatment caused a significant increase in the level of <e2>phosphorylated (active) AMPK<\\e2>  Our results show that Metformin directly inhibits stomach ghrelin production and secretion through AMPK","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Metformin","object":"phosphorylated (active) AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, <e1>CHEMICAL<\\e1> treatment caused a significant increase in the level of <e2>GENE-Y<\\e2>  Our results show that CHEMICAL directly inhibits stomach ghrelin production and secretion through AMPK","sentence":"Finally, Metformin treatment caused a significant increase in the level of phosphorylated (active) AMPK  Our results show that Metformin directly inhibits stomach ghrelin production and secretion through AMPK"}
{"PMID":23066988,"re_id":5,"annotated sentence":"Metformin significantly reduced <e2>ghrelin<\\e2> secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor <e1>compound C<\\e1>  Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"compound C","object":"ghrelin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Metformin significantly reduced <e2>GENE-Y<\\e2> secretion and proGENE-Y mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor <e1>CHEMICAL<\\e1>  Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited GENE-Y secretion","sentence":"Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C  Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion"}
{"PMID":23066988,"re_id":6,"annotated sentence":"Metformin significantly reduced ghrelin secretion and <e2>proghrelin<\\e2> mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor <e1>compound C<\\e1>  Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"compound C","object":"proghrelin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Metformin significantly reduced ghrelin secretion and <e2>GENE-Y<\\e2> mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor <e1>CHEMICAL<\\e1>  Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion","sentence":"Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C  Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion"}
{"PMID":23066988,"re_id":7,"annotated sentence":"Our results show that <e1>Metformin<\\e1> directly inhibits stomach <e2>ghrelin<\\e2> production and secretion through AMPK","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Metformin","object":"ghrelin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our results show that <e1>CHEMICAL<\\e1> directly inhibits stomach <e2>GENE-Y<\\e2> production and secretion through AMPK","sentence":"Our results show that Metformin directly inhibits stomach ghrelin production and secretion through AMPK"}
{"PMID":23066988,"re_id":8,"annotated sentence":"<e1>Metformin<\\e1> treatment is also associated with lower circulating levels of the <e2>orexigenic hormone<\\e2> ghrelin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Metformin","object":"orexigenic hormone","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> treatment is also associated with lower circulating levels of the <e2>GENE-N<\\e2> ghrelin","sentence":"Metformin treatment is also associated with lower circulating levels of the orexigenic hormone ghrelin"}
{"PMID":23066988,"re_id":9,"annotated sentence":"<e1>Metformin<\\e1> treatment is also associated with lower circulating levels of the orexigenic hormone <e2>ghrelin<\\e2>  To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Metformin","object":"ghrelin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment is also associated with lower circulating levels of the orexigenic hormone <e2>GENE-Y<\\e2>  To test whether CHEMICAL directly affects GENE-Y cells, rat primary stomach cells were treated with CHEMICAL and the levels of GENE-Y secretion, proGENE-Y gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined","sentence":"Metformin treatment is also associated with lower circulating levels of the orexigenic hormone ghrelin  To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined"}
{"PMID":23066988,"re_id":10,"annotated sentence":"<e1>Metformin<\\e1> directly inhibits <e2>ghrelin<\\e2> secretion through AMP-activated protein kinase in rat primary gastric cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Metformin","object":"ghrelin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> directly inhibits <e2>GENE-Y<\\e2> secretion through AMP-activated protein kinase in rat primary gastric cells","sentence":"Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells"}
{"PMID":23066988,"re_id":11,"annotated sentence":"<e1>Metformin<\\e1> significantly reduced <e2>ghrelin<\\e2> secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Metformin","object":"ghrelin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> significantly reduced <e2>GENE-Y<\\e2> secretion and proGENE-Y mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C","sentence":"Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C"}
{"PMID":23066988,"re_id":12,"annotated sentence":"<e1>Metformin<\\e1> significantly reduced ghrelin secretion and <e2>proghrelin<\\e2> mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Metformin","object":"proghrelin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> significantly reduced ghrelin secretion and <e2>GENE-Y<\\e2> mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C","sentence":"Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C"}
{"PMID":23066988,"re_id":13,"annotated sentence":"Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (<e1>AICAR<\\e1>  significantly inhibited <e2>ghrelin<\\e2> secretion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"AICAR","object":"ghrelin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (<e1>CHEMICAL<\\e1>  significantly inhibited <e2>GENE-Y<\\e2> secretion","sentence":"Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR  significantly inhibited ghrelin secretion"}
{"PMID":23066988,"re_id":14,"annotated sentence":"Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the <e2>AMPK<\\e2> inhibitor <e1>compound C<\\e1>  Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"compound C","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  Furthermore, the GENE-Y activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion","sentence":"Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C  Furthermore, the AMPK activator 5-amino-1-\u03b2-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion"}
{"PMID":23081912,"re_id":6,"annotated sentence":"Induction of AhR by <e1>TCDD<\\e1> and prochloraz resulted in a time- and dose-dependent increase of <e2>ABCG2<\\e2> gene expression and transporter protein levels","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"TCDD","object":"ABCG2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Induction of AhR by <e1>CHEMICAL<\\e1> and prochloraz resulted in a time- and dose-dependent increase of <e2>GENE-Y<\\e2> gene expression and transporter protein levels","sentence":"Induction of AhR by TCDD and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels"}
{"PMID":23081912,"re_id":7,"annotated sentence":"Induction of AhR by TCDD and <e1>prochloraz<\\e1> resulted in a time- and dose-dependent increase of <e2>ABCG2<\\e2> gene expression and transporter protein levels","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"prochloraz","object":"ABCG2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Induction of AhR by TCDD and <e1>CHEMICAL<\\e1> resulted in a time- and dose-dependent increase of <e2>GENE-Y<\\e2> gene expression and transporter protein levels","sentence":"Induction of AhR by TCDD and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels"}
{"PMID":23081912,"re_id":8,"annotated sentence":"Fungicide <e1>prochloraz<\\e1> and environmental pollutant dioxin induce the <e2>ABCG2<\\e2> transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"prochloraz","object":"ABCG2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Fungicide <e1>CHEMICAL<\\e1> and environmental pollutant dioxin induce the <e2>GENE-Y<\\e2> transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway","sentence":"Fungicide prochloraz and environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway"}
{"PMID":23081912,"re_id":9,"annotated sentence":"Fungicide prochloraz and environmental pollutant <e1>dioxin<\\e1> induce the <e2>ABCG2<\\e2> transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"dioxin","object":"ABCG2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Fungicide prochloraz and environmental pollutant <e1>CHEMICAL<\\e1> induce the <e2>GENE-Y<\\e2> transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway","sentence":"Fungicide prochloraz and environmental pollutant dioxin induce the ABCG2 transporter in bovine mammary epithelial cells by the arylhydrocarbon receptor signaling pathway"}
{"PMID":23081912,"re_id":10,"annotated sentence":"Induction of <e2>AhR<\\e2> by <e1>TCDD<\\e1> and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"TCDD","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Induction of <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels","sentence":"Induction of AhR by TCDD and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels"}
{"PMID":23081912,"re_id":11,"annotated sentence":"Induction of <e2>AhR<\\e2> by TCDD and <e1>prochloraz<\\e1> resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"prochloraz","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Induction of <e2>GENE-Y<\\e2> by TCDD and <e1>CHEMICAL<\\e1> resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels","sentence":"Induction of AhR by TCDD and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels"}
{"PMID":23081912,"re_id":12,"annotated sentence":"This effect was almost completely reversed by specific <e2>ABCG2<\\e2> inhibitor <e1>Ko143<\\e1>  In further mechanistic studies, we showed that this induction was due to binding of activated AhR to DRE sequences in the ABCG2 5'-UTR","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Ko143","object":"ABCG2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This effect was almost completely reversed by specific <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  In further mechanistic studies, we showed that this induction was due to binding of activated AhR to DRE sequences in the GENE-Y 5'-UTR","sentence":"This effect was almost completely reversed by specific ABCG2 inhibitor Ko143  In further mechanistic studies, we showed that this induction was due to binding of activated AhR to DRE sequences in the ABCG2 5'-UTR"}
{"PMID":23081912,"re_id":13,"annotated sentence":"As these regulatory motifs mediate regulation of target genes by <e2>AhR<\\e2> agonists including <e1>TCDD<\\e1> and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"TCDD","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As these regulatory motifs mediate regulation of target genes by <e2>GENE-Y<\\e2> agonists including <e1>CHEMICAL<\\e1> and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells","sentence":"As these regulatory motifs mediate regulation of target genes by AhR agonists including TCDD and prochloraz, we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells"}
{"PMID":23081912,"re_id":14,"annotated sentence":"As these regulatory motifs mediate regulation of target genes by <e2>AhR<\\e2> agonists including TCDD and <e1>prochloraz<\\e1>  we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"prochloraz","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As these regulatory motifs mediate regulation of target genes by <e2>GENE-Y<\\e2> agonists including TCDD and <e1>CHEMICAL<\\e1>  we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells","sentence":"As these regulatory motifs mediate regulation of target genes by AhR agonists including TCDD and prochloraz  we have systematically investigated the effect of both contaminants on functional ABCG2 transport activity in primary bovine mammary epithelial cells"}
{"PMID":23081912,"re_id":15,"annotated sentence":"Receptor binding was significantly reduced by specific <e2>AhR<\\e2> antagonist <e1>salicyl amide<\\e1>  Induction of AhR by TCDD and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"salicyl amide","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Receptor binding was significantly reduced by specific <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1>  Induction of GENE-Y by TCDD and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels","sentence":"Receptor binding was significantly reduced by specific AhR antagonist salicyl amide  Induction of AhR by TCDD and prochloraz resulted in a time- and dose-dependent increase of ABCG2 gene expression and transporter protein levels"}
{"PMID":23081912,"re_id":16,"annotated sentence":"TCDD or prochloraz doubled <e2>ABCG2<\\e2> mediated <e1>Hoechst H33342<\\e1> secretion","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Hoechst H33342","object":"ABCG2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"TCDD or prochloraz doubled <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> secretion","sentence":"TCDD or prochloraz doubled ABCG2 mediated Hoechst H33342 secretion"}
{"PMID":23086748,"re_id":1,"annotated sentence":"We observed similar effects of <e1>Ag<\\e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of <e2>interleukin-8<\\e2> (IL-8)\/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Ag","object":"interleukin-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We observed similar effects of <e1>CHEMICAL<\\e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of <e2>GENE-Y<\\e2> (IL-8)\/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro","sentence":"We observed similar effects of Ag NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)\/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro"}
{"PMID":23086748,"re_id":2,"annotated sentence":"We observed similar effects of <e1>Ag<\\e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (<e2>IL-8<\\e2> \/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Ag","object":"IL-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We observed similar effects of <e1>CHEMICAL<\\e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (<e2>GENE-Y<\\e2> \/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased GENE-Y protein release in vitro","sentence":"We observed similar effects of Ag NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8 \/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro"}
{"PMID":23086748,"re_id":3,"annotated sentence":"We observed similar effects of <e1>Ag<\\e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)\/<e2>macrophage inflammatory protein 2<\\e2>  IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Ag","object":"macrophage inflammatory protein 2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We observed similar effects of <e1>CHEMICAL<\\e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)\/<e2>GENE-N<\\e2>  IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro","sentence":"We observed similar effects of Ag NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)\/macrophage inflammatory protein 2  IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro"}
{"PMID":23086748,"re_id":4,"annotated sentence":"We observed similar effects of <e1>Ag<\\e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)\/macrophage inflammatory protein 2, <e2>IL-1RI<\\e2>  and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Ag","object":"IL-1RI","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We observed similar effects of <e1>CHEMICAL<\\e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)\/macrophage inflammatory protein 2, <e2>GENE-Y<\\e2>  and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro","sentence":"We observed similar effects of Ag NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)\/macrophage inflammatory protein 2, IL-1RI  and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro"}
{"PMID":23086748,"re_id":5,"annotated sentence":"We observed similar effects of <e1>Ag<\\e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)\/macrophage inflammatory protein 2, IL-1RI, and <e2>tumor necrosis factor-\u03b1<\\e2> expression in both models and increased IL-8 protein release in vitro","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Ag","object":"tumor necrosis factor-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We observed similar effects of <e1>CHEMICAL<\\e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)\/macrophage inflammatory protein 2, IL-1RI, and <e2>GENE-Y<\\e2> expression in both models and increased IL-8 protein release in vitro","sentence":"We observed similar effects of Ag NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)\/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro"}
{"PMID":23086748,"re_id":6,"annotated sentence":"We observed similar effects of <e1>Ag<\\e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)\/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased <e2>IL-8<\\e2> protein release in vitro","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Ag","object":"IL-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We observed similar effects of <e1>CHEMICAL<\\e1> NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (GENE-Y)\/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased <e2>GENE-Y<\\e2> protein release in vitro","sentence":"We observed similar effects of Ag NPs on inflammatory mediator expression in vitro and in vivo with increase of interleukin-8 (IL-8)\/macrophage inflammatory protein 2, IL-1RI, and tumor necrosis factor-\u03b1 expression in both models and increased IL-8 protein release in vitro"}
{"PMID":23086748,"re_id":7,"annotated sentence":"We found that <e1>Ag<\\e1> NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 \u03bcg\/cm(2)) and affected hepatocyte homeostasis by reducing <e2>albumin<\\e2> release","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Ag","object":"albumin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 \u03bcg\/cm(2)) and affected hepatocyte homeostasis by reducing <e2>GENE-Y<\\e2> release","sentence":"We found that Ag NPs were highly cytotoxic to hepatocytes (LC(50) lactate dehydrogenase: 2.5 \u03bcg\/cm(2)) and affected hepatocyte homeostasis by reducing albumin release"}
{"PMID":23093023,"re_id":0,"annotated sentence":"Blood pressure was increased in rats exposed to IH, and treatment with the <e2>PDK-1<\\e2> inhibitor <e1>OSU-03012<\\e1> [2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide] (33 mg\/day) lowered blood pressure in IH but not sham group rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"OSU-03012","object":"PDK-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Blood pressure was increased in rats exposed to IH, and treatment with the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> [2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide] (33 mg\/day) lowered blood pressure in IH but not sham group rats","sentence":"Blood pressure was increased in rats exposed to IH, and treatment with the PDK-1 inhibitor OSU-03012 [2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide] (33 mg\/day) lowered blood pressure in IH but not sham group rats"}
{"PMID":23093023,"re_id":1,"annotated sentence":"Blood pressure was increased in rats exposed to IH, and treatment with the <e2>PDK-1<\\e2> inhibitor OSU-03012 [<e1>2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide<\\e1>  (33 mg\/day) lowered blood pressure in IH but not sham group rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide","object":"PDK-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Blood pressure was increased in rats exposed to IH, and treatment with the <e2>GENE-Y<\\e2> inhibitor OSU-03012 [<e1>CHEMICAL<\\e1>  (33 mg\/day) lowered blood pressure in IH but not sham group rats","sentence":"Blood pressure was increased in rats exposed to IH, and treatment with the PDK-1 inhibitor OSU-03012 [2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl}-acetamide  (33 mg\/day) lowered blood pressure in IH but not sham group rats"}
{"PMID":23097088,"re_id":1,"annotated sentence":"Following <e1>CdCl\u2082<\\e1> treatment, <e2>ICAM2<\\e2> was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"CdCl\u2082","object":"ICAM2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Following <e1>CHEMICAL<\\e1> treatment, <e2>GENE-Y<\\e2> was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for GENE-Y by 6-16 h","sentence":"Following CdCl\u2082 treatment, ICAM2 was found to be upregulated during restructuring of the seminiferous epithelium, with round spermatids becoming increasingly immunoreactive for ICAM2 by 6-16 h"}
{"PMID":23097088,"re_id":2,"annotated sentence":"Interestingly, there was a loss in the binding of ICAM2 to <e2>actin<\\e2> during <e1>CdCl\u2082<\\e1> induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CdCl\u2082","object":"actin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, there was a loss in the binding of ICAM2 to <e2>GENE-N<\\e2> during <e1>CHEMICAL<\\e1> induced germ cell loss, suggesting that a loss of ICAM2-GENE-N interactions might have facilitated junction restructuring","sentence":"Interestingly, there was a loss in the binding of ICAM2 to actin during CdCl\u2082 induced germ cell loss, suggesting that a loss of ICAM2-actin interactions might have facilitated junction restructuring"}
{"PMID":23098818,"re_id":0,"annotated sentence":"The reaction was inhibited by the specific <e2>CYP2D<\\e2> inhibitors <e1>quinine<\\e1> and fluoxetine","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"quinine","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The reaction was inhibited by the specific <e2>GENE-N<\\e2> inhibitors <e1>CHEMICAL<\\e1> and fluoxetine","sentence":"The reaction was inhibited by the specific CYP2D inhibitors quinine and fluoxetine"}
{"PMID":23098818,"re_id":1,"annotated sentence":"The reaction was inhibited by the specific <e2>CYP2D<\\e2> inhibitors quinine and <e1>fluoxetine<\\e1>  Human liver microsomes of the wild-type CYP2D6 metabolized 5-methoxytryptamine to serotonin more effectively than did the defective CYP2D6*4*4 ones","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"fluoxetine","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The reaction was inhibited by the specific <e2>GENE-N<\\e2> inhibitors quinine and <e1>CHEMICAL<\\e1>  Human liver microsomes of the wild-type GENE-N6 metabolized 5-methoxytryptamine to serotonin more effectively than did the defective GENE-N6*4*4 ones","sentence":"The reaction was inhibited by the specific CYP2D inhibitors quinine and fluoxetine  Human liver microsomes of the wild-type CYP2D6 metabolized 5-methoxytryptamine to serotonin more effectively than did the defective CYP2D6*4*4 ones"}
{"PMID":23098818,"re_id":2,"annotated sentence":"Of the rat CYP isoforms studied, <e2>CYP2D<\\e2> isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to <e1>serotonin<\\e1>  but they were less effective than the human isoform CYP2D6","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"serotonin","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Of the rat CYP isoforms studied, <e2>GENE-N<\\e2> isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to <e1>CHEMICAL<\\e1>  but they were less effective than the human isoform GENE-N6","sentence":"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to serotonin  but they were less effective than the human isoform CYP2D6"}
{"PMID":23098818,"re_id":3,"annotated sentence":"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to <e1>serotonin<\\e1>  but they were less effective than the <e2>human isoform CYP2D6<\\e2>  Microsomes from different brain regions were capable of metabolizing 5-methoxytryptamine to serotonin","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"serotonin","object":"human isoform CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to <e1>CHEMICAL<\\e1>  but they were less effective than the <e2>GENE-Y<\\e2>  Microsomes from different brain regions were capable of metabolizing 5-methoxytryptamine to CHEMICAL","sentence":"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to serotonin  but they were less effective than the human isoform CYP2D6  Microsomes from different brain regions were capable of metabolizing 5-methoxytryptamine to serotonin"}
{"PMID":23098818,"re_id":4,"annotated sentence":"The catalytic competence of <e2>cytochrome P450<\\e2> in the synthesis of <e1>serotonin<\\e1> from 5-methoxytryptamine in the brain: an in vitro study","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"serotonin","object":"cytochrome P450","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The catalytic competence of <e2>GENE-N<\\e2> in the synthesis of <e1>CHEMICAL<\\e1> from 5-methoxytryptamine in the brain: an in vitro study","sentence":"The catalytic competence of cytochrome P450 in the synthesis of serotonin from 5-methoxytryptamine in the brain: an in vitro study"}
{"PMID":23098818,"re_id":5,"annotated sentence":"Human liver microsomes of the wild-type <e2>CYP2D6<\\e2> metabolized 5-methoxytryptamine to <e1>serotonin<\\e1> more effectively than did the defective CYP2D6*4*4 ones","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"serotonin","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Human liver microsomes of the wild-type <e2>GENE-Y<\\e2> metabolized 5-methoxytryptamine to <e1>CHEMICAL<\\e1> more effectively than did the defective GENE-Y*4*4 ones","sentence":"Human liver microsomes of the wild-type CYP2D6 metabolized 5-methoxytryptamine to serotonin more effectively than did the defective CYP2D6*4*4 ones"}
{"PMID":23098818,"re_id":6,"annotated sentence":"Human liver microsomes of the wild-type CYP2D6 metabolized 5-methoxytryptamine to <e1>serotonin<\\e1> more effectively than did the defective <e2>CYP2D6<\\e2> 4*4 ones","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"serotonin","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Human liver microsomes of the wild-type GENE-Y metabolized 5-methoxytryptamine to <e1>CHEMICAL<\\e1> more effectively than did the defective <e2>GENE-Y<\\e2> 4*4 ones","sentence":"Human liver microsomes of the wild-type CYP2D6 metabolized 5-methoxytryptamine to serotonin more effectively than did the defective CYP2D6 4*4 ones"}
{"PMID":23098818,"re_id":7,"annotated sentence":"The obtained results indicate that <e2>rat brain CYP2D<\\e2> isoforms catalyze the formation of <e1>serotonin<\\e1> from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"serotonin","object":"rat brain CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results indicate that <e2>GENE-N<\\e2> isoforms catalyze the formation of <e1>CHEMICAL<\\e1> from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect CHEMICAL metabolism in the brain","sentence":"The obtained results indicate that rat brain CYP2D isoforms catalyze the formation of serotonin from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain"}
{"PMID":23098818,"re_id":8,"annotated sentence":"The obtained results indicate that rat brain CYP2D isoforms catalyze the formation of serotonin from 5-methoxytryptamine, and that the deficit or genetic defect of <e2>CYP2D<\\e2> may affect <e1>serotonin<\\e1> metabolism in the brain","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"serotonin","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results indicate that rat brain GENE-N isoforms catalyze the formation of CHEMICAL from 5-methoxytryptamine, and that the deficit or genetic defect of <e2>GENE-N<\\e2> may affect <e1>CHEMICAL<\\e1> metabolism in the brain","sentence":"The obtained results indicate that rat brain CYP2D isoforms catalyze the formation of serotonin from 5-methoxytryptamine, and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain"}
{"PMID":23098818,"re_id":9,"annotated sentence":"Of the rat CYP isoforms studied, <e2>CYP2D<\\e2> isoforms were the most efficient in catalyzing the <e1>O<\\e1> demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"O","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CHEMICALf the rat CYP isoforms studied, <e2>GENE-N<\\e2> isoforms were the most efficient in catalyzing the <e1>CHEMICAL<\\e1> demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform GENE-N6","sentence":"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6"}
{"PMID":23098818,"re_id":10,"annotated sentence":"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the <e1>O<\\e1> demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the <e2>human isoform CYP2D6<\\e2>  Microsomes from different brain regions were capable of metabolizing 5-methoxytryptamine to serotonin","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"O","object":"human isoform CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CHEMICALf the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the <e1>CHEMICAL<\\e1> demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the <e2>GENE-Y<\\e2>  Microsomes from different brain regions were capable of metabolizing 5-methoxytryptamine to serotonin","sentence":"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6  Microsomes from different brain regions were capable of metabolizing 5-methoxytryptamine to serotonin"}
{"PMID":23098818,"re_id":11,"annotated sentence":"Of the rat CYP isoforms studied, <e2>CYP2D<\\e2> isoforms were the most efficient in catalyzing the O-demethylation of <e1>5-methoxytryptamine<\\e1> to serotonin, but they were less effective than the human isoform CYP2D6","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"5-methoxytryptamine","object":"CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Of the rat CYP isoforms studied, <e2>GENE-N<\\e2> isoforms were the most efficient in catalyzing the O-demethylation of <e1>CHEMICAL<\\e1> to serotonin, but they were less effective than the human isoform GENE-N6","sentence":"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6"}
{"PMID":23098818,"re_id":12,"annotated sentence":"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of <e1>5-methoxytryptamine<\\e1> to serotonin, but they were less effective than the <e2>human isoform CYP2D6<\\e2>  Microsomes from different brain regions were capable of metabolizing 5-methoxytryptamine to serotonin","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"5-methoxytryptamine","object":"human isoform CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of <e1>CHEMICAL<\\e1> to serotonin, but they were less effective than the <e2>GENE-Y<\\e2>  Microsomes from different brain regions were capable of metabolizing CHEMICAL to serotonin","sentence":"Of the rat CYP isoforms studied, CYP2D isoforms were the most efficient in catalyzing the O-demethylation of 5-methoxytryptamine to serotonin, but they were less effective than the human isoform CYP2D6  Microsomes from different brain regions were capable of metabolizing 5-methoxytryptamine to serotonin"}
{"PMID":23098818,"re_id":13,"annotated sentence":"The catalytic competence of <e2>cytochrome P450<\\e2> in the synthesis of serotonin from <e1>5-methoxytryptamine<\\e1> in the brain: an in vitro study","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"5-methoxytryptamine","object":"cytochrome P450","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The catalytic competence of <e2>GENE-N<\\e2> in the synthesis of serotonin from <e1>CHEMICAL<\\e1> in the brain: an in vitro study","sentence":"The catalytic competence of cytochrome P450 in the synthesis of serotonin from 5-methoxytryptamine in the brain: an in vitro study"}
{"PMID":23098818,"re_id":14,"annotated sentence":"Human liver microsomes of the wild-type <e2>CYP2D6<\\e2> metabolized <e1>5-methoxytryptamine<\\e1> to serotonin more effectively than did the defective CYP2D6*4*4 ones","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"5-methoxytryptamine","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Human liver microsomes of the wild-type <e2>GENE-Y<\\e2> metabolized <e1>CHEMICAL<\\e1> to serotonin more effectively than did the defective GENE-Y*4*4 ones","sentence":"Human liver microsomes of the wild-type CYP2D6 metabolized 5-methoxytryptamine to serotonin more effectively than did the defective CYP2D6*4*4 ones"}
{"PMID":23098818,"re_id":15,"annotated sentence":"Human liver microsomes of the wild-type CYP2D6 metabolized <e1>5-methoxytryptamine<\\e1> to serotonin more effectively than did the defective <e2>CYP2D6<\\e2> 4*4 ones","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"5-methoxytryptamine","object":"CYP2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Human liver microsomes of the wild-type GENE-Y metabolized <e1>CHEMICAL<\\e1> to serotonin more effectively than did the defective <e2>GENE-Y<\\e2> 4*4 ones","sentence":"Human liver microsomes of the wild-type CYP2D6 metabolized 5-methoxytryptamine to serotonin more effectively than did the defective CYP2D6 4*4 ones"}
{"PMID":23098818,"re_id":16,"annotated sentence":"The obtained results indicate that <e2>rat brain CYP2D<\\e2> isoforms catalyze the formation of serotonin from <e1>5-methoxytryptamine<\\e1>  and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"5-methoxytryptamine","object":"rat brain CYP2D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The obtained results indicate that <e2>GENE-N<\\e2> isoforms catalyze the formation of serotonin from <e1>CHEMICAL<\\e1>  and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain","sentence":"The obtained results indicate that rat brain CYP2D isoforms catalyze the formation of serotonin from 5-methoxytryptamine  and that the deficit or genetic defect of CYP2D may affect serotonin metabolism in the brain"}
{"PMID":23111283,"re_id":1,"annotated sentence":"<e1>Toosendanin<\\e1> induces apoptosis through suppression of <e2>JNK<\\e2> signaling pathway in HL-60 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Toosendanin","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induces apoptosis through suppression of <e2>GENE-N<\\e2> signaling pathway in HL-60 cells","sentence":"Toosendanin induces apoptosis through suppression of JNK signaling pathway in HL-60 cells"}
{"PMID":23111283,"re_id":2,"annotated sentence":"Western blot analysis indicated that <e1>TSN<\\e1> inhibits the <e2>CDC42<\\e2> MEKK1\/JNK pathway","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TSN","object":"CDC42","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Western blot analysis indicated that <e1>CHEMICAL<\\e1> inhibits the <e2>GENE-Y<\\e2> MEKK1\/JNK pathway","sentence":"Western blot analysis indicated that TSN inhibits the CDC42 MEKK1\/JNK pathway"}
{"PMID":23111283,"re_id":3,"annotated sentence":"Western blot analysis indicated that <e1>TSN<\\e1> inhibits the CDC42\/<e2>MEKK1<\\e2> JNK pathway","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TSN","object":"MEKK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Western blot analysis indicated that <e1>CHEMICAL<\\e1> inhibits the CDC42\/<e2>GENE-Y<\\e2> JNK pathway","sentence":"Western blot analysis indicated that TSN inhibits the CDC42\/MEKK1 JNK pathway"}
{"PMID":23111283,"re_id":4,"annotated sentence":"Western blot analysis indicated that <e1>TSN<\\e1> inhibits the CDC42\/MEKK1\/<e2>JNK<\\e2> pathway","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TSN","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Western blot analysis indicated that <e1>CHEMICAL<\\e1> inhibits the CDC42\/MEKK1\/<e2>GENE-N<\\e2> pathway","sentence":"Western blot analysis indicated that TSN inhibits the CDC42\/MEKK1\/JNK pathway"}
{"PMID":23115221,"re_id":0,"annotated sentence":"Administration of low, but not high, doses of oral <e1>nicotine<\\e1> in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of <e2>tumor necrosis factor-\u03b1<\\e2>  However, the anti-inflammatory effect of nicotine was not seen after chronic s.c","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"nicotine","object":"tumor necrosis factor-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Administration of low, but not high, doses of oral <e1>CHEMICAL<\\e1> in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of <e2>GENE-Y<\\e2>  However, the anti-inflammatory effect of CHEMICAL was not seen after chronic s.c","sentence":"Administration of low, but not high, doses of oral nicotine in DSS-treated mice resulted in a significant decrease in disease severity, histologic damage scores, as well as colonic level of tumor necrosis factor-\u03b1  However, the anti-inflammatory effect of nicotine was not seen after chronic s.c"}
{"PMID":23117790,"re_id":1,"annotated sentence":"The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of <e2>orexin-A<\\e2> was reversed by the administration of <e1>SB334867<\\e1> as well as by hypothalamic BDNF knockdown","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"SB334867","object":"orexin-A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by GENE-Y, and this effect of <e2>GENE-Y<\\e2> was reversed by the administration of <e1>CHEMICAL<\\e1> as well as by hypothalamic BDNF knockdown","sentence":"The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of SB334867 as well as by hypothalamic BDNF knockdown"}
{"PMID":23117790,"re_id":2,"annotated sentence":"The MCAO-induced decrease in <e2>insulin receptor<\\e2> levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of <e1>SB334867<\\e1> as well as by hypothalamic BDNF knockdown","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"SB334867","object":"insulin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The MCAO-induced decrease in <e2>GENE-Y<\\e2> levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of <e1>CHEMICAL<\\e1> as well as by hypothalamic BDNF knockdown","sentence":"The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of SB334867 as well as by hypothalamic BDNF knockdown"}
{"PMID":23117790,"re_id":3,"annotated sentence":"Small interfering RNA directed BDNF, orexin-A, and <e1>SB334867<\\e1> [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific <e2>orexin-1 receptor<\\e2> antagonist] were administered directly into the hypothalamus","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"SB334867","object":"orexin-1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Small interfering RNA directed BDNF, orexin-A, and <e1>CHEMICAL<\\e1> [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific <e2>GENE-Y<\\e2> antagonist] were administered directly into the hypothalamus","sentence":"Small interfering RNA directed BDNF, orexin-A, and SB334867 [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus"}
{"PMID":23117790,"re_id":4,"annotated sentence":"Small interfering RNA directed BDNF, orexin-A, and SB334867 [<e1>N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea<\\e1>  a specific <e2>orexin-1 receptor<\\e2> antagonist] were administered directly into the hypothalamus","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea","object":"orexin-1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Small interfering RNA directed BDNF, orexin-A, and SB334867 [<e1>CHEMICAL<\\e1>  a specific <e2>GENE-Y<\\e2> antagonist] were administered directly into the hypothalamus","sentence":"Small interfering RNA directed BDNF, orexin-A, and SB334867 [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea  a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus"}
{"PMID":23146664,"re_id":6,"annotated sentence":"Moreover, <e1>5-ASA<\\e1> treatment restored membranous expression of adhesion molecules <e2>E-cadherin<\\e2> and \u03b2-catenin","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"5-ASA","object":"E-cadherin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> treatment restored membranous expression of adhesion molecules <e2>GENE-Y<\\e2> and \u03b2-catenin","sentence":"Moreover, 5-ASA treatment restored membranous expression of adhesion molecules E-cadherin and \u03b2-catenin"}
{"PMID":23146664,"re_id":7,"annotated sentence":"Moreover, <e1>5-ASA<\\e1> treatment restored membranous expression of adhesion molecules E-cadherin and <e2>\u03b2-catenin<\\e2>  Role of PAK1 as a mediator of mesalamine activity was validated in vitro and in vivo","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"5-ASA","object":"\u03b2-catenin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> treatment restored membranous expression of adhesion molecules E-cadherin and <e2>GENE-Y<\\e2>  Role of PAK1 as a mediator of mesalamine activity was validated in vitro and in vivo","sentence":"Moreover, 5-ASA treatment restored membranous expression of adhesion molecules E-cadherin and \u03b2-catenin  Role of PAK1 as a mediator of mesalamine activity was validated in vitro and in vivo"}
{"PMID":23146664,"re_id":8,"annotated sentence":"<e2>PAK1<\\e2> expression was elevated in APC(min) polyps and <e1>5-ASA<\\e1> treatment reduced its expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"5-ASA","object":"PAK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> expression was elevated in APC(min) polyps and <e1>CHEMICAL<\\e1> treatment reduced its expression","sentence":"PAK1 expression was elevated in APC(min) polyps and 5-ASA treatment reduced its expression"}
{"PMID":23146664,"re_id":9,"annotated sentence":"We propose that inhibition of <e2>PAK1<\\e2> expression by <e1>5-ASA<\\e1> can impede with neoplastic progression in colorectal carcinogenesis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"5-ASA","object":"PAK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We propose that inhibition of <e2>GENE-Y<\\e2> expression by <e1>CHEMICAL<\\e1> can impede with neoplastic progression in colorectal carcinogenesis","sentence":"We propose that inhibition of PAK1 expression by 5-ASA can impede with neoplastic progression in colorectal carcinogenesis"}
{"PMID":23146664,"re_id":10,"annotated sentence":"<e1>Mesalamine<\\e1> modulates intercellular adhesion through inhibition of <e2>p-21 activated kinase-1<\\e2>  Mesalamine (5-ASA) is widely used for the treatment of ulcerative colitis, a remitting condition characterized by chronic inflammation of the colon","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Mesalamine","object":"p-21 activated kinase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> modulates intercellular adhesion through inhibition of <e2>GENE-Y<\\e2>  CHEMICAL (5-ASA) is widely used for the treatment of ulcerative colitis, a remitting condition characterized by chronic inflammation of the colon","sentence":"Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1  Mesalamine (5-ASA) is widely used for the treatment of ulcerative colitis, a remitting condition characterized by chronic inflammation of the colon"}
{"PMID":23146664,"re_id":11,"annotated sentence":"The mechanism of <e2>PAK1<\\e2> inhibition and induction of membranous translocation of adhesion proteins by <e1>5-ASA<\\e1> might be independent of its known anti-inflammatory action.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"5-ASA","object":"PAK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mechanism of <e2>GENE-Y<\\e2> inhibition and induction of membranous translocation of adhesion proteins by <e1>CHEMICAL<\\e1> might be independent of its known anti-inflammatory action.","sentence":"The mechanism of PAK1 inhibition and induction of membranous translocation of adhesion proteins by 5-ASA might be independent of its known anti-inflammatory action."}
{"PMID":23146761,"re_id":0,"annotated sentence":"This study shows ability of <e1>EGCG<\\e1> to raise plasma bile acid concentrations, mainly through <e2>Cyp7a1<\\e2> upregulation, and to decrease bile production through reduction in Mrp2-mediated bile acid-independent bile flow","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"EGCG","object":"Cyp7a1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study shows ability of <e1>CHEMICAL<\\e1> to raise plasma bile acid concentrations, mainly through <e2>GENE-Y<\\e2> upregulation, and to decrease bile production through reduction in Mrp2-mediated bile acid-independent bile flow","sentence":"This study shows ability of EGCG to raise plasma bile acid concentrations, mainly through Cyp7a1 upregulation, and to decrease bile production through reduction in Mrp2-mediated bile acid-independent bile flow"}
{"PMID":23146761,"re_id":1,"annotated sentence":"In contrast, <e1>EGCG<\\e1> markedly downregulated major <e2>bile acid transporters<\\e2> (Asbt and Ost\u03b1) and regulatory molecules (Shp and Fgf15) in the ileum","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"EGCG","object":"bile acid transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, <e1>CHEMICAL<\\e1> markedly downregulated major <e2>GENE-N<\\e2> (Asbt and Ost\u03b1) and regulatory molecules (Shp and Fgf15) in the ileum","sentence":"In contrast, EGCG markedly downregulated major bile acid transporters (Asbt and Ost\u03b1) and regulatory molecules (Shp and Fgf15) in the ileum"}
{"PMID":23146761,"re_id":2,"annotated sentence":"In contrast, <e1>EGCG<\\e1> markedly downregulated major bile acid transporters (<e2>Asbt<\\e2> and Ost\u03b1) and regulatory molecules (Shp and Fgf15) in the ileum","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"EGCG","object":"Asbt","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, <e1>CHEMICAL<\\e1> markedly downregulated major bile acid transporters (<e2>GENE-Y<\\e2> and Ost\u03b1) and regulatory molecules (Shp and Fgf15) in the ileum","sentence":"In contrast, EGCG markedly downregulated major bile acid transporters (Asbt and Ost\u03b1) and regulatory molecules (Shp and Fgf15) in the ileum"}
{"PMID":23146761,"re_id":3,"annotated sentence":"In contrast, <e1>EGCG<\\e1> markedly downregulated major bile acid transporters (Asbt and <e2>Ost\u03b1<\\e2>  and regulatory molecules (Shp and Fgf15) in the ileum","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"EGCG","object":"Ost\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, <e1>CHEMICAL<\\e1> markedly downregulated major bile acid transporters (Asbt and <e2>GENE-Y<\\e2>  and regulatory molecules (Shp and Fgf15) in the ileum","sentence":"In contrast, EGCG markedly downregulated major bile acid transporters (Asbt and Ost\u03b1  and regulatory molecules (Shp and Fgf15) in the ileum"}
{"PMID":23146761,"re_id":4,"annotated sentence":"In contrast, <e1>EGCG<\\e1> markedly downregulated major bile acid transporters (Asbt and Ost\u03b1) and regulatory molecules (<e2>Shp<\\e2> and Fgf15) in the ileum","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"EGCG","object":"Shp","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, <e1>CHEMICAL<\\e1> markedly downregulated major bile acid transporters (Asbt and Ost\u03b1) and regulatory molecules (<e2>GENE-Y<\\e2> and Fgf15) in the ileum","sentence":"In contrast, EGCG markedly downregulated major bile acid transporters (Asbt and Ost\u03b1) and regulatory molecules (Shp and Fgf15) in the ileum"}
{"PMID":23146761,"re_id":5,"annotated sentence":"In contrast, <e1>EGCG<\\e1> markedly downregulated major bile acid transporters (Asbt and Ost\u03b1) and regulatory molecules (Shp and <e2>Fgf15<\\e2>  in the ileum","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"EGCG","object":"Fgf15","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, <e1>CHEMICAL<\\e1> markedly downregulated major bile acid transporters (Asbt and Ost\u03b1) and regulatory molecules (Shp and <e2>GENE-Y<\\e2>  in the ileum","sentence":"In contrast, EGCG markedly downregulated major bile acid transporters (Asbt and Ost\u03b1) and regulatory molecules (Shp and Fgf15  in the ileum"}
{"PMID":23164921,"re_id":0,"annotated sentence":"Data at transcriptional level also demonstrated that <e1>catalpol<\\e1> potently attenuated gene expressions involved in inflammation, such as <e2>iNOS<\\e2>  COX-2 and TLR4","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"catalpol","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Data at transcriptional level also demonstrated that <e1>CHEMICAL<\\e1> potently attenuated gene expressions involved in inflammation, such as <e2>GENE-Y<\\e2>  COX-2 and TLR4","sentence":"Data at transcriptional level also demonstrated that catalpol potently attenuated gene expressions involved in inflammation, such as iNOS  COX-2 and TLR4"}
{"PMID":23164921,"re_id":1,"annotated sentence":"Data at transcriptional level also demonstrated that <e1>catalpol<\\e1> potently attenuated gene expressions involved in inflammation, such as iNOS, <e2>COX-2<\\e2> and TLR4","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"catalpol","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Data at transcriptional level also demonstrated that <e1>CHEMICAL<\\e1> potently attenuated gene expressions involved in inflammation, such as iNOS, <e2>GENE-Y<\\e2> and TLR4","sentence":"Data at transcriptional level also demonstrated that catalpol potently attenuated gene expressions involved in inflammation, such as iNOS, COX-2 and TLR4"}
{"PMID":23164921,"re_id":2,"annotated sentence":"Data at transcriptional level also demonstrated that <e1>catalpol<\\e1> potently attenuated gene expressions involved in inflammation, such as iNOS, COX-2 and <e2>TLR4<\\e2>  In addition, our exploration further revealed that the suppressive action of catalpol on inflammation was mediated via inhibiting nuclear factor-\u03baB (NF-\u03baB) activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"catalpol","object":"TLR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Data at transcriptional level also demonstrated that <e1>CHEMICAL<\\e1> potently attenuated gene expressions involved in inflammation, such as iNOS, COX-2 and <e2>GENE-Y<\\e2>  In addition, our exploration further revealed that the suppressive action of CHEMICAL on inflammation was mediated via inhibiting nuclear factor-\u03baB (NF-\u03baB) activation","sentence":"Data at transcriptional level also demonstrated that catalpol potently attenuated gene expressions involved in inflammation, such as iNOS, COX-2 and TLR4  In addition, our exploration further revealed that the suppressive action of catalpol on inflammation was mediated via inhibiting nuclear factor-\u03baB (NF-\u03baB) activation"}
{"PMID":23164921,"re_id":3,"annotated sentence":"In addition, our exploration further revealed that the suppressive action of <e1>catalpol<\\e1> on inflammation was mediated via inhibiting nuclear factor-\u03baB (<e2>NF-\u03baB<\\e2>  activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"catalpol","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, our exploration further revealed that the suppressive action of <e1>CHEMICAL<\\e1> on inflammation was mediated via inhibiting nuclear factor-\u03baB (<e2>GENE-N<\\e2>  activation","sentence":"In addition, our exploration further revealed that the suppressive action of catalpol on inflammation was mediated via inhibiting nuclear factor-\u03baB (NF-\u03baB  activation"}
{"PMID":23164921,"re_id":4,"annotated sentence":"In addition, our exploration further revealed that the suppressive action of <e1>catalpol<\\e1> on inflammation was mediated via inhibiting <e2>nuclear factor-\u03baB<\\e2> (NF-\u03baB) activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"catalpol","object":"nuclear factor-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, our exploration further revealed that the suppressive action of <e1>CHEMICAL<\\e1> on inflammation was mediated via inhibiting <e2>GENE-N<\\e2> (NF-\u03baB) activation","sentence":"In addition, our exploration further revealed that the suppressive action of catalpol on inflammation was mediated via inhibiting nuclear factor-\u03baB (NF-\u03baB) activation"}
{"PMID":23164921,"re_id":5,"annotated sentence":"<e1>Catalpol<\\e1> inhibits LPS plus <e2>IFN-\u03b3<\\e2> induced inflammatory response in astrocytes primary cultures","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Catalpol","object":"IFN-\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits LPS plus <e2>GENE-Y<\\e2> induced inflammatory response in astrocytes primary cultures","sentence":"Catalpol inhibits LPS plus IFN-\u03b3 induced inflammatory response in astrocytes primary cultures"}
{"PMID":23164921,"re_id":6,"annotated sentence":"Collectively, these results suggest that <e1>catalpol<\\e1> can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of <e2>NF-\u03baB<\\e2> could be the major determinant for its anti-inflammatory mechanism","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"catalpol","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Collectively, these results suggest that <e1>CHEMICAL<\\e1> can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of <e2>GENE-N<\\e2> could be the major determinant for its anti-inflammatory mechanism","sentence":"Collectively, these results suggest that catalpol can exert inhibitory effects on the inflammatory reaction in astrocytes and that inactivation of NF-\u03baB could be the major determinant for its anti-inflammatory mechanism"}
{"PMID":23164921,"re_id":7,"annotated sentence":"Biochemical analyses showed that NO and ROS production and <e2>iNOS<\\e2> activity were significantly reduced by <e1>catalpol<\\e1>  Data at transcriptional level also demonstrated that catalpol potently attenuated gene expressions involved in inflammation, such as iNOS, COX-2 and TLR4","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"catalpol","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Biochemical analyses showed that NO and ROS production and <e2>GENE-Y<\\e2> activity were significantly reduced by <e1>CHEMICAL<\\e1>  Data at transcriptional level also demonstrated that CHEMICAL potently attenuated gene expressions involved in inflammation, such as GENE-Y, COX-2 and TLR4","sentence":"Biochemical analyses showed that NO and ROS production and iNOS activity were significantly reduced by catalpol  Data at transcriptional level also demonstrated that catalpol potently attenuated gene expressions involved in inflammation, such as iNOS, COX-2 and TLR4"}
{"PMID":23177789,"re_id":0,"annotated sentence":"<e2>Protein tyrosine phosphatase 1B<\\e2> inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum <e1>saponins<\\e1>  Protein tyrosine phosphatase 1B (PTP1B) is an important factor in non-insulin-dependent diabetes mellitus (type-2 diabetes), and a promising target for treatment of diabetes and obesity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"saponins","object":"Protein tyrosine phosphatase 1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum <e1>CHEMICAL<\\e1>  GENE-Y (PTP1B) is an important factor in non-insulin-dependent diabetes mellitus (type-2 diabetes), and a promising target for treatment of diabetes and obesity","sentence":"Protein tyrosine phosphatase 1B inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins  Protein tyrosine phosphatase 1B (PTP1B) is an important factor in non-insulin-dependent diabetes mellitus (type-2 diabetes), and a promising target for treatment of diabetes and obesity"}
{"PMID":23177789,"re_id":1,"annotated sentence":"<e2>Protein tyrosine phosphatase 1B<\\e2> inhibitory effect by <e1>dammarane<\\e1> type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dammarane","object":"Protein tyrosine phosphatase 1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitory effect by <e1>CHEMICAL<\\e1> type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins","sentence":"Protein tyrosine phosphatase 1B inhibitory effect by dammarane type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins"}
{"PMID":23177789,"re_id":2,"annotated sentence":"<e2>Protein tyrosine phosphatase 1B<\\e2> inhibitory effect by dammarane-type <e1>triterpenes<\\e1> from hydrolyzate of total Gynostemma pentaphyllum saponins","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"triterpenes","object":"Protein tyrosine phosphatase 1B","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> inhibitory effect by dammarane-type <e1>CHEMICAL<\\e1> from hydrolyzate of total Gynostemma pentaphyllum saponins","sentence":"Protein tyrosine phosphatase 1B inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins"}
{"PMID":23182946,"re_id":2,"annotated sentence":"Therefore, the present results show that the earlier cerebellar responses to <e1>(PhTe)(2)<\\e1> include disruption of cytoskeletal homeostasis that could be related with <e2>MAPK<\\e2> and PKA activation and reactive astrogliosis","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"(PhTe)(2)","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Therefore, the present results show that the earlier cerebellar responses to <e1>CHEMICAL<\\e1> include disruption of cytoskeletal homeostasis that could be related with <e2>GENE-N<\\e2> and PKA activation and reactive astrogliosis","sentence":"Therefore, the present results show that the earlier cerebellar responses to (PhTe)(2) include disruption of cytoskeletal homeostasis that could be related with MAPK and PKA activation and reactive astrogliosis"}
{"PMID":23182946,"re_id":3,"annotated sentence":"Therefore, the present results show that the earlier cerebellar responses to <e1>(PhTe)(2)<\\e1> include disruption of cytoskeletal homeostasis that could be related with MAPK and <e2>PKA<\\e2> activation and reactive astrogliosis","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"(PhTe)(2)","object":"PKA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Therefore, the present results show that the earlier cerebellar responses to <e1>CHEMICAL<\\e1> include disruption of cytoskeletal homeostasis that could be related with MAPK and <e2>GENE-N<\\e2> activation and reactive astrogliosis","sentence":"Therefore, the present results show that the earlier cerebellar responses to (PhTe)(2) include disruption of cytoskeletal homeostasis that could be related with MAPK and PKA activation and reactive astrogliosis"}
{"PMID":23182946,"re_id":4,"annotated sentence":"Also, reactive astrogliosis takes part of the early responses to the insult with <e1>(PhTe)(2)<\\e1>  evidenced by upregulated <e2>GFAP<\\e2> in Western blot, PCR and immunofluorescence analysis","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"(PhTe)(2)","object":"GFAP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Also, reactive astrogliosis takes part of the early responses to the insult with <e1>CHEMICAL<\\e1>  evidenced by upregulated <e2>GENE-Y<\\e2> in Western blot, PCR and immunofluorescence analysis","sentence":"Also, reactive astrogliosis takes part of the early responses to the insult with (PhTe)(2)  evidenced by upregulated GFAP in Western blot, PCR and immunofluorescence analysis"}
{"PMID":23182946,"re_id":5,"annotated sentence":"Six days after (PhTe)(2) injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for <e2>NeuN<\\e2>  suggesting that the in vivo exposure to <e1>(PhTe)(2)<\\e1> progressed to neuronal death","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"(PhTe)(2)","object":"NeuN","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Six days after CHEMICAL injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in GENE-Y positive population evidenced by flow cytometry and reduced immunofluorescence for <e2>GENE-Y<\\e2>  suggesting that the in vivo exposure to <e1>CHEMICAL<\\e1> progressed to neuronal death","sentence":"Six days after (PhTe)(2) injection we found persistent astrogliosis, increased propidium iodide (PI) positive cells in NeuN positive population evidenced by flow cytometry and reduced immunofluorescence for NeuN  suggesting that the in vivo exposure to (PhTe)(2) progressed to neuronal death"}
{"PMID":23182946,"re_id":6,"annotated sentence":"Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased <e2>Akt<\\e2> immunoreactivity, however phospho-GSK-3-\u03b2 (Ser9) was not altered in <e1>(PhTe)(2)<\\e1> injected rat","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"(PhTe)(2)","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased <e2>GENE-N<\\e2> immunoreactivity, however phospho-GSK-3-\u03b2 (Ser9) was not altered in <e1>CHEMICAL<\\e1> injected rat","sentence":"Neurodegeneration was related with decreased [(3)H]glutamate uptake and decreased Akt immunoreactivity, however phospho-GSK-3-\u03b2 (Ser9) was not altered in (PhTe)(2) injected rat"}
{"PMID":23198810,"re_id":0,"annotated sentence":"Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted <e1>quinone<\\e1> substrate by the cancer-associated <e2>human NAD(P)H:quinone oxidoreductase isozyme 1<\\e2> (hNQO1)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"quinone","object":"human NAD(P)H:quinone oxidoreductase isozyme 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Fluorescence of the reporter dye is turned on by rapid removal of the CHEMICAL quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted <e1>CHEMICAL<\\e1> substrate by the cancer-associated <e2>human NAD(P)H:CHEMICAL oxidoreductase isozyme 1<\\e2> (hNQO1)","sentence":"Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated human NAD(P)H:quinone oxidoreductase isozyme 1 (hNQO1)"}
{"PMID":23198810,"re_id":1,"annotated sentence":"Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted <e1>quinone<\\e1> substrate by the cancer-associated human NAD(P)H:quinone oxidoreductase isozyme 1 (<e2>hNQO1<\\e2> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"quinone","object":"hNQO1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Fluorescence of the reporter dye is turned on by rapid removal of the CHEMICAL quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted <e1>CHEMICAL<\\e1> substrate by the cancer-associated human NAD(P)H:CHEMICAL oxidoreductase isozyme 1 (<e2>GENE-Y<\\e2> ","sentence":"Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated human NAD(P)H:quinone oxidoreductase isozyme 1 (hNQO1 "}
{"PMID":23199028,"re_id":0,"annotated sentence":"Synthesis, biological evaluation, and molecular modeling of <e1>glycyrrhizin<\\e1> derivatives as potent <e2>high-mobility group box-1<\\e2> inhibitors with anti-heart-failure activity in vivo","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"glycyrrhizin","object":"high-mobility group box-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis, biological evaluation, and molecular modeling of <e1>CHEMICAL<\\e1> derivatives as potent <e2>GENE-Y<\\e2> inhibitors with anti-heart-failure activity in vivo","sentence":"Synthesis, biological evaluation, and molecular modeling of glycyrrhizin derivatives as potent high-mobility group box-1 inhibitors with anti-heart-failure activity in vivo"}
{"PMID":23200253,"re_id":0,"annotated sentence":"Within the <e1>TPBP<\\e1> scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-<e2>mAChR<\\e2> antagonism, which was demonstrated to be mediated via the orthosteric site","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"TPBP","object":"mAChR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Within the <e1>CHEMICAL<\\e1> scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-<e2>GENE-N<\\e2> antagonism, which was demonstrated to be mediated via the orthosteric site","sentence":"Within the TPBP scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-mAChR antagonism, which was demonstrated to be mediated via the orthosteric site"}
{"PMID":23200253,"re_id":1,"annotated sentence":"Within the TPBP scaffold, either electronic or steric perturbations to the central <e1>piperidine<\\e1> ring led to a loss of selective M(1) allosteric agonism and afforded pan-<e2>mAChR<\\e2> antagonism, which was demonstrated to be mediated via the orthosteric site","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"piperidine","object":"mAChR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Within the TPBP scaffold, either electronic or steric perturbations to the central <e1>CHEMICAL<\\e1> ring led to a loss of selective M(1) allosteric agonism and afforded pan-<e2>GENE-N<\\e2> antagonism, which was demonstrated to be mediated via the orthosteric site","sentence":"Within the TPBP scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-mAChR antagonism, which was demonstrated to be mediated via the orthosteric site"}
{"PMID":23200253,"re_id":2,"annotated sentence":"Additional SAR around a related M(1) allosteric agonist family (<e1>VU0357017<\\e1>  identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan-<e2>mAChR<\\e2> orthosteric antagonism","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"VU0357017","object":"mAChR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Additional SAR around a related M(1) allosteric agonist family (<e1>CHEMICAL<\\e1>  identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan-<e2>GENE-N<\\e2> orthosteric antagonism","sentence":"Additional SAR around a related M(1) allosteric agonist family (VU0357017  identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan-mAChR orthosteric antagonism"}
{"PMID":23205514,"re_id":0,"annotated sentence":"2.\u2002The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a <e2>P-gp<\\e2> substrate, <e1>risperidone<\\e1>  and its major metabolite, 9-hydroxyrisperidone, in rats","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"risperidone","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"2.\u2002The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a <e2>GENE-Y<\\e2> substrate, <e1>CHEMICAL<\\e1>  and its major metabolite, 9-hydroxyCHEMICAL, in rats","sentence":"2.\u2002The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone  and its major metabolite, 9-hydroxyrisperidone, in rats"}
{"PMID":23205514,"re_id":1,"annotated sentence":"2.\u2002The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a <e2>P-gp<\\e2> substrate, risperidone, and its major metabolite, <e1>9-hydroxyrisperidone<\\e1>  in rats","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"9-hydroxyrisperidone","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"2.\u2002The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a <e2>GENE-Y<\\e2> substrate, risperidone, and its major metabolite, <e1>CHEMICAL<\\e1>  in rats","sentence":"2.\u2002The objective of this article is to examine the effects of single and repeated administrations of silymarin on pharmacokinetics of a P-gp substrate, risperidone, and its major metabolite, 9-hydroxyrisperidone  in rats"}
{"PMID":23205571,"re_id":1,"annotated sentence":"On the other hand, peptides modified with <e1>(2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid<\\e1>  apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to <e2>arginine vasopressin<\\e2>  The results of this study provide useful information about the structure-activity relationship of arginine vasopressin analogues and can help to design compounds with desired biological properties.","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"(2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid","object":"arginine vasopressin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"On the other hand, peptides modified with <e1>CHEMICAL<\\e1>  apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to <e2>GENE-Y<\\e2>  The results of this study provide useful information about the structure-activity relationship of GENE-Y analogues and can help to design compounds with desired biological properties.","sentence":"On the other hand, peptides modified with (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid  apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to arginine vasopressin  The results of this study provide useful information about the structure-activity relationship of arginine vasopressin analogues and can help to design compounds with desired biological properties."}
{"PMID":23211426,"re_id":0,"annotated sentence":"<e2>Liver X Receptor (LXR) \u03b1<\\e2> and LXR \u03b2 are nuclear receptors activated by <e1>oxysterols<\\e1>  oxidized derivatives of cholesterol","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"oxysterols","object":"Liver X Receptor (LXR) \u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> and LXR \u03b2 are nuclear receptors activated by <e1>CHEMICAL<\\e1>  oxidized derivatives of cholesterol","sentence":"Liver X Receptor (LXR) \u03b1 and LXR \u03b2 are nuclear receptors activated by oxysterols  oxidized derivatives of cholesterol"}
{"PMID":23211426,"re_id":1,"annotated sentence":"Liver X Receptor (LXR) \u03b1 and <e2>LXR \u03b2<\\e2> are nuclear receptors activated by <e1>oxysterols<\\e1>  oxidized derivatives of cholesterol","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"oxysterols","object":"LXR \u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Liver X Receptor (LXR) \u03b1 and <e2>GENE-Y<\\e2> are nuclear receptors activated by <e1>CHEMICAL<\\e1>  oxidized derivatives of cholesterol","sentence":"Liver X Receptor (LXR) \u03b1 and LXR \u03b2 are nuclear receptors activated by oxysterols  oxidized derivatives of cholesterol"}
{"PMID":23211523,"re_id":1,"annotated sentence":"\u03b2-catenin regulates <e1>GnRH<\\e1> induced <e2>FSH\u03b2<\\e2> gene expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GnRH","object":"FSH\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"\u03b2-catenin regulates <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> gene expression","sentence":"\u03b2-catenin regulates GnRH induced FSH\u03b2 gene expression"}
{"PMID":23211523,"re_id":2,"annotated sentence":"Furthermore, knockdown of Brms1L significantly attenuated <e1>GnRH<\\e1> induced <e2>FSH\u03b2<\\e2> expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GnRH","object":"FSH\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, knockdown of Brms1L significantly attenuated <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> expression","sentence":"Furthermore, knockdown of Brms1L significantly attenuated GnRH induced FSH\u03b2 expression"}
{"PMID":23211523,"re_id":3,"annotated sentence":"Thus, our findings indicate that the expression of Brms1L depends on \u03b2-catenin activity and contributes to <e2>FSH\u03b2<\\e2> induction by <e1>GnRH<\\e1> ","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GnRH","object":"FSH\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, our findings indicate that the expression of Brms1L depends on \u03b2-catenin activity and contributes to <e2>GENE-Y<\\e2> induction by <e1>CHEMICAL<\\e1> ","sentence":"Thus, our findings indicate that the expression of Brms1L depends on \u03b2-catenin activity and contributes to FSH\u03b2 induction by GnRH "}
{"PMID":23211523,"re_id":4,"annotated sentence":"<e1>GnRH<\\e1> caused a sustained increase in nuclear <e2>\u03b2-catenin<\\e2> levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GnRH","object":"\u03b2-catenin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> caused a sustained increase in nuclear <e2>GENE-Y<\\e2> levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition","sentence":"GnRH caused a sustained increase in nuclear \u03b2-catenin levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition"}
{"PMID":23211523,"re_id":5,"annotated sentence":"Small interfering RNA-mediated knockdown of \u03b2-catenin mRNA demonstrated that induction of <e2>FSH\u03b2<\\e2> mRNA by <e1>GnRH<\\e1> depended on \u03b2-catenin and that regulation of FSH\u03b2 by \u03b2-catenin occurred independently of the JNK-c-jun pathway","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GnRH","object":"FSH\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Small interfering RNA-mediated knockdown of \u03b2-catenin mRNA demonstrated that induction of <e2>GENE-Y<\\e2> mRNA by <e1>CHEMICAL<\\e1> depended on \u03b2-catenin and that regulation of GENE-Y by \u03b2-catenin occurred independently of the JNK-c-jun pathway","sentence":"Small interfering RNA-mediated knockdown of \u03b2-catenin mRNA demonstrated that induction of FSH\u03b2 mRNA by GnRH depended on \u03b2-catenin and that regulation of FSH\u03b2 by \u03b2-catenin occurred independently of the JNK-c-jun pathway"}
{"PMID":23220037,"re_id":1,"annotated sentence":"In conclusion, in this cellular model, <e1>DOX<\\e1> effectively protects against PQ toxicity by inducing <e2>P-gp<\\e2> and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"DOX","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, in this cellular model, <e1>CHEMICAL<\\e1> effectively protects against PQ toxicity by inducing <e2>GENE-N<\\e2> and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.","sentence":"In conclusion, in this cellular model, DOX effectively protects against PQ toxicity by inducing P-gp and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications."}
{"PMID":23220037,"re_id":2,"annotated sentence":"The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether <e1>doxorubicin<\\e1> (DOX), a known <e2>P-gp<\\e2> inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"doxorubicin","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether <e1>CHEMICAL<\\e1> (DOX), a known <e2>GENE-N<\\e2> inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario","sentence":"The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (DOX), a known P-gp inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario"}
{"PMID":23220037,"re_id":3,"annotated sentence":"The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (<e1>DOX<\\e1> , a known <e2>P-gp<\\e2> inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"DOX","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (<e1>CHEMICAL<\\e1> , a known <e2>GENE-N<\\e2> inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario","sentence":"The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (DOX , a known P-gp inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario"}
{"PMID":23220037,"re_id":4,"annotated sentence":"The herbicide <e1>paraquat<\\e1> (PQ) is a <e2>P-gp<\\e2> substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"paraquat","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The herbicide <e1>CHEMICAL<\\e1> (PQ) is a <e2>GENE-N<\\e2> substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote","sentence":"The herbicide paraquat (PQ) is a P-gp substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote"}
{"PMID":23220742,"re_id":0,"annotated sentence":"<e1>P505-15<\\e1> successfully inhibited SYK-mediated <e2>B-cell receptor<\\e2> signaling and decreased cell viability in NHL and CLL","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"P505-15","object":"B-cell receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> successfully inhibited SYK-mediated <e2>GENE-N<\\e2> signaling and decreased cell viability in NHL and CLL","sentence":"P505-15 successfully inhibited SYK-mediated B-cell receptor signaling and decreased cell viability in NHL and CLL"}
{"PMID":23220742,"re_id":1,"annotated sentence":"The selective <e2>SYK<\\e2> inhibitor <e1>P505-15<\\e1> (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"P505-15","object":"SYK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia","sentence":"The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia"}
{"PMID":23220742,"re_id":2,"annotated sentence":"The selective <e2>SYK<\\e2> inhibitor P505-15 (<e1>PRT062607<\\e1>  inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PRT062607","object":"SYK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective <e2>GENE-Y<\\e2> inhibitor P505-15 (<e1>CHEMICAL<\\e1>  inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia","sentence":"The selective SYK inhibitor P505-15 (PRT062607  inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia"}
{"PMID":23220742,"re_id":3,"annotated sentence":"<e1>P505-15<\\e1> (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule <e2>SYK<\\e2> inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"P505-15","object":"SYK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule <e2>GENE-Y<\\e2> inhibitor (GENE-Y IC(50) = 1 nM) with anti-GENE-Y activity that is at least 80-fold greater than its affinity for other kinases","sentence":"P505-15 (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases"}
{"PMID":23220742,"re_id":4,"annotated sentence":"<e1>P505-15<\\e1> (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (<e2>SYK<\\e2> IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"P505-15","object":"SYK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule GENE-Y inhibitor (<e2>GENE-Y<\\e2> IC(50) = 1 nM) with anti-GENE-Y activity that is at least 80-fold greater than its affinity for other kinases","sentence":"P505-15 (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases"}
{"PMID":23220742,"re_id":5,"annotated sentence":"<e1>P505-15<\\e1> (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-<e2>SYK<\\e2> activity that is at least 80-fold greater than its affinity for other kinases","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"P505-15","object":"SYK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule GENE-Y inhibitor (GENE-Y IC(50) = 1 nM) with anti-<e2>GENE-Y<\\e2> activity that is at least 80-fold greater than its affinity for other kinases","sentence":"P505-15 (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases"}
{"PMID":23220742,"re_id":6,"annotated sentence":"P505-15 (also known as <e1>PRT062607<\\e1>  is a novel, highly selective, and orally bioavailable small molecule <e2>SYK<\\e2> inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PRT062607","object":"SYK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"P505-15 (also known as <e1>CHEMICAL<\\e1>  is a novel, highly selective, and orally bioavailable small molecule <e2>GENE-Y<\\e2> inhibitor (GENE-Y IC(50) = 1 nM) with anti-GENE-Y activity that is at least 80-fold greater than its affinity for other kinases","sentence":"P505-15 (also known as PRT062607  is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases"}
{"PMID":23220742,"re_id":7,"annotated sentence":"P505-15 (also known as <e1>PRT062607<\\e1>  is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (<e2>SYK<\\e2> IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PRT062607","object":"SYK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"P505-15 (also known as <e1>CHEMICAL<\\e1>  is a novel, highly selective, and orally bioavailable small molecule GENE-Y inhibitor (<e2>GENE-Y<\\e2> IC(50) = 1 nM) with anti-GENE-Y activity that is at least 80-fold greater than its affinity for other kinases","sentence":"P505-15 (also known as PRT062607  is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases"}
{"PMID":23220742,"re_id":8,"annotated sentence":"P505-15 (also known as <e1>PRT062607<\\e1>  is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-<e2>SYK<\\e2> activity that is at least 80-fold greater than its affinity for other kinases","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PRT062607","object":"SYK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"P505-15 (also known as <e1>CHEMICAL<\\e1>  is a novel, highly selective, and orally bioavailable small molecule GENE-Y inhibitor (GENE-Y IC(50) = 1 nM) with anti-<e2>GENE-Y<\\e2> activity that is at least 80-fold greater than its affinity for other kinases","sentence":"P505-15 (also known as PRT062607  is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases"}
{"PMID":23220742,"re_id":9,"annotated sentence":"<e1>P505-15<\\e1> successfully inhibited <e2>SYK<\\e2> mediated B-cell receptor signaling and decreased cell viability in NHL and CLL","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"P505-15","object":"SYK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> successfully inhibited <e2>GENE-Y<\\e2> mediated B-cell receptor signaling and decreased cell viability in NHL and CLL","sentence":"P505-15 successfully inhibited SYK mediated B-cell receptor signaling and decreased cell viability in NHL and CLL"}
{"PMID":23229511,"re_id":2,"annotated sentence":"Although treatment with <e1>17-AAG<\\e1> reduced <e2>AhR<\\e2> levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"17-AAG","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although treatment with <e1>CHEMICAL<\\e1> reduced <e2>GENE-Y<\\e2> levels and GENE-Y-regulated gene expression in lung AD cells, GENE-Y expression increased anticancer activity of CHEMICAL","sentence":"Although treatment with 17-AAG reduced AhR levels and AhR-regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG"}
{"PMID":23229511,"re_id":3,"annotated sentence":"Although treatment with <e1>17-AAG<\\e1> reduced AhR levels and <e2>AhR<\\e2> regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"17-AAG","object":"AhR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although treatment with <e1>CHEMICAL<\\e1> reduced GENE-Y levels and <e2>GENE-Y<\\e2> regulated gene expression in lung AD cells, GENE-Y expression increased anticancer activity of CHEMICAL","sentence":"Although treatment with 17-AAG reduced AhR levels and AhR regulated gene expression in lung AD cells, AhR expression increased anticancer activity of 17-AAG"}
{"PMID":23229511,"re_id":4,"annotated sentence":"In addition, <e1>17-AAG<\\e1> treatment reduced cell viability, <e2>CDK2<\\e2>  CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"17-AAG","object":"CDK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> treatment reduced cell viability, <e2>GENE-Y<\\e2>  CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells","sentence":"In addition, 17-AAG treatment reduced cell viability, CDK2  CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells"}
{"PMID":23229511,"re_id":5,"annotated sentence":"In addition, <e1>17-AAG<\\e1> treatment reduced cell viability, CDK2, <e2>CDK4<\\e2>  cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"17-AAG","object":"CDK4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> treatment reduced cell viability, CDK2, <e2>GENE-Y<\\e2>  cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells","sentence":"In addition, 17-AAG treatment reduced cell viability, CDK2, CDK4  cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells"}
{"PMID":23229511,"re_id":6,"annotated sentence":"In addition, <e1>17-AAG<\\e1> treatment reduced cell viability, CDK2, CDK4, <e2>cyclin E<\\e2>  cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"17-AAG","object":"cyclin E","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> treatment reduced cell viability, CDK2, CDK4, <e2>GENE-N<\\e2>  cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells","sentence":"In addition, 17-AAG treatment reduced cell viability, CDK2, CDK4, cyclin E  cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells"}
{"PMID":23229511,"re_id":7,"annotated sentence":"In addition, <e1>17-AAG<\\e1> treatment reduced cell viability, CDK2, CDK4, cyclin E, <e2>cyclin D1<\\e2>  and phosphorylated Rb levels in AhR-expressing lung AD cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"17-AAG","object":"cyclin D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> treatment reduced cell viability, CDK2, CDK4, cyclin E, <e2>GENE-Y<\\e2>  and phosphorylated Rb levels in AhR-expressing lung AD cells","sentence":"In addition, 17-AAG treatment reduced cell viability, CDK2, CDK4, cyclin E, cyclin D1  and phosphorylated Rb levels in AhR-expressing lung AD cells"}
{"PMID":23229511,"re_id":8,"annotated sentence":"In addition, <e1>17-AAG<\\e1> treatment reduced cell viability, CDK2, CDK4, cyclin E, cyclin D1, and <e2>phosphorylated Rb<\\e2> levels in AhR-expressing lung AD cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"17-AAG","object":"phosphorylated Rb","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> treatment reduced cell viability, CDK2, CDK4, cyclin E, cyclin D1, and <e2>GENE-Y<\\e2> levels in AhR-expressing lung AD cells","sentence":"In addition, 17-AAG treatment reduced cell viability, CDK2, CDK4, cyclin E, cyclin D1, and phosphorylated Rb levels in AhR-expressing lung AD cells"}
{"PMID":23229511,"re_id":9,"annotated sentence":"<e1>17-Allylamino-17-demethoxygeldanamycin<\\e1> (17-AAG), an <e2>Hsp90<\\e2> inhibitor, is currently under evaluation for its anticancer activity in clinical trials","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"17-Allylamino-17-demethoxygeldanamycin","object":"Hsp90","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (17-AAG), an <e2>GENE-N<\\e2> inhibitor, is currently under evaluation for its anticancer activity in clinical trials","sentence":"17-Allylamino-17-demethoxygeldanamycin (17-AAG), an Hsp90 inhibitor, is currently under evaluation for its anticancer activity in clinical trials"}
{"PMID":23229511,"re_id":10,"annotated sentence":"17-Allylamino-17-demethoxygeldanamycin (<e1>17-AAG<\\e1> , an <e2>Hsp90<\\e2> inhibitor, is currently under evaluation for its anticancer activity in clinical trials","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"17-AAG","object":"Hsp90","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"17-Allylamino-17-demethoxygeldanamycin (<e1>CHEMICAL<\\e1> , an <e2>GENE-N<\\e2> inhibitor, is currently under evaluation for its anticancer activity in clinical trials","sentence":"17-Allylamino-17-demethoxygeldanamycin (17-AAG , an Hsp90 inhibitor, is currently under evaluation for its anticancer activity in clinical trials"}
{"PMID":23230131,"re_id":3,"annotated sentence":"Wild-type enzymes and variants of <e2>CDA<\\e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Ara-C","object":"CDA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wild-type enzymes and variants of <e2>GENE-Y<\\e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>CHEMICAL<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":4,"annotated sentence":"Wild-type enzymes and variants of CDA (<e2>Lys27Gln<\\e2> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Ara-C","object":"Lys27Gln","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (<e2>GENE-N<\\e2> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>CHEMICAL<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":5,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and <e2>Ala70Thr<\\e2>  and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Ara-C","object":"Ala70Thr","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and <e2>GENE-N<\\e2>  and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>CHEMICAL<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr  and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":6,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <e2>DCK<\\e2> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Ara-C","object":"DCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <e2>GENE-Y<\\e2> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>CHEMICAL<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":7,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<e2>Ile24Val<\\e2>  Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Ara-C","object":"Ile24Val","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<e2>GENE-N<\\e2>  Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>CHEMICAL<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val  Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":8,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <e2>Ala119Gly<\\e2>  and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Ara-C","object":"Ala119Gly","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <e2>GENE-N<\\e2>  and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>CHEMICAL<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly  and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":9,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <e2>Pro122Ser<\\e2>  were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>Ara-C<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Ara-C","object":"Pro122Ser","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <e2>GENE-N<\\e2>  were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (<e1>CHEMICAL<\\e1> , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser  were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C , dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":10,"annotated sentence":"Wild-type enzymes and variants of <e2>CDA<\\e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>dFdC<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"CDA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wild-type enzymes and variants of <e2>GENE-Y<\\e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>CHEMICAL<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":11,"annotated sentence":"Wild-type enzymes and variants of CDA (<e2>Lys27Gln<\\e2> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>dFdC<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"Lys27Gln","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (<e2>GENE-N<\\e2> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>CHEMICAL<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":12,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and <e2>Ala70Thr<\\e2>  and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>dFdC<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"Ala70Thr","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and <e2>GENE-N<\\e2>  and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>CHEMICAL<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr  and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":13,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <e2>DCK<\\e2> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>dFdC<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"DCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <e2>GENE-Y<\\e2> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>CHEMICAL<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":14,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<e2>Ile24Val<\\e2>  Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>dFdC<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"Ile24Val","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<e2>GENE-N<\\e2>  Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>CHEMICAL<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val  Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":15,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <e2>Ala119Gly<\\e2>  and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>dFdC<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"Ala119Gly","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <e2>GENE-N<\\e2>  and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>CHEMICAL<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly  and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":16,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <e2>Pro122Ser<\\e2>  were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>dFdC<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"Pro122Ser","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <e2>GENE-N<\\e2>  were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), <e1>CHEMICAL<\\e1>  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser  were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC  and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":17,"annotated sentence":"Wild-type enzymes and variants of <e2>CDA<\\e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine<\\e1> (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2',2'-difluorodeoxyuridine","object":"CDA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wild-type enzymes and variants of <e2>GENE-Y<\\e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>CHEMICAL<\\e1> (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":18,"annotated sentence":"Wild-type enzymes and variants of CDA (<e2>Lys27Gln<\\e2> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine<\\e1> (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2',2'-difluorodeoxyuridine","object":"Lys27Gln","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (<e2>GENE-N<\\e2> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>CHEMICAL<\\e1> (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":19,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and <e2>Ala70Thr<\\e2>  and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine<\\e1> (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2',2'-difluorodeoxyuridine","object":"Ala70Thr","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and <e2>GENE-N<\\e2>  and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>CHEMICAL<\\e1> (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr  and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":20,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <e2>DCK<\\e2> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine<\\e1> (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2',2'-difluorodeoxyuridine","object":"DCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <e2>GENE-Y<\\e2> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>CHEMICAL<\\e1> (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":21,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<e2>Ile24Val<\\e2>  Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine<\\e1> (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2',2'-difluorodeoxyuridine","object":"Ile24Val","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<e2>GENE-N<\\e2>  Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>CHEMICAL<\\e1> (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val  Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":22,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <e2>Ala119Gly<\\e2>  and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine<\\e1> (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2',2'-difluorodeoxyuridine","object":"Ala119Gly","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <e2>GENE-N<\\e2>  and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>CHEMICAL<\\e1> (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly  and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":23,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <e2>Pro122Ser<\\e2>  were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>2',2'-difluorodeoxyuridine<\\e1> (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2',2'-difluorodeoxyuridine","object":"Pro122Ser","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <e2>GENE-N<\\e2>  were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite <e1>CHEMICAL<\\e1> (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser  were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":24,"annotated sentence":"Wild-type enzymes and variants of <e2>CDA<\\e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (<e1>dFdU<\\e1>  as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdU","object":"CDA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wild-type enzymes and variants of <e2>GENE-Y<\\e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (<e1>CHEMICAL<\\e1>  as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU  as substrates"}
{"PMID":23230131,"re_id":25,"annotated sentence":"All three <e2>CDA<\\e2> proteins showed similar K(m) and V(max) for <e1>Ara-C<\\e1> and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Ara-C","object":"CDA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All three <e2>GENE-Y<\\e2> proteins showed similar K(m) and V(max) for <e1>CHEMICAL<\\e1> and dFdC deamination, except for GENE-Y70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for CHEMICAL deamination","sentence":"All three CDA proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination"}
{"PMID":23230131,"re_id":26,"annotated sentence":"All three <e2>CDA<\\e2> proteins showed similar K(m) and V(max) for Ara-C and <e1>dFdC<\\e1> deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"CDA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All three <e2>GENE-Y<\\e2> proteins showed similar K(m) and V(max) for Ara-C and <e1>CHEMICAL<\\e1> deamination, except for GENE-Y70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination","sentence":"All three CDA proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for CDA70Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination"}
{"PMID":23230131,"re_id":27,"annotated sentence":"All three CDA proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for <e2>CDA<\\e2> 0Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for <e1>Ara-C<\\e1> deamination","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Ara-C","object":"CDA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All three GENE-Y proteins showed similar K(m) and V(max) for CHEMICAL and dFdC deamination, except for <e2>GENE-Y<\\e2> 0Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for <e1>CHEMICAL<\\e1> deamination","sentence":"All three CDA proteins showed similar K(m) and V(max) for Ara-C and dFdC deamination, except for CDA 0Thr, which had a 2.5-fold lower K(m) and 6-fold lower V(max) for Ara-C deamination"}
{"PMID":23230131,"re_id":28,"annotated sentence":"All four <e2>DCK<\\e2> proteins yielded comparable metabolic activity for <e1>Ara-C<\\e1> and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Ara-C","object":"DCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All four <e2>GENE-Y<\\e2> proteins yielded comparable metabolic activity for <e1>CHEMICAL<\\e1> and dFdC monophosphorylation, except for GENE-Y24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)","sentence":"All four DCK proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)"}
{"PMID":23230131,"re_id":29,"annotated sentence":"All four <e2>DCK<\\e2> proteins yielded comparable metabolic activity for Ara-C and <e1>dFdC<\\e1> monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"DCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All four <e2>GENE-Y<\\e2> proteins yielded comparable metabolic activity for Ara-C and <e1>CHEMICAL<\\e1> monophosphorylation, except for GENE-Y24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of CHEMICAL monophosphorylation due to a 40% decrease in K(m) (P < 0.05)","sentence":"All four DCK proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for DCK24Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)"}
{"PMID":23230131,"re_id":30,"annotated sentence":"<e1>Gemcitabine<\\e1> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>DCK<\\e2> , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Gemcitabine","object":"DCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>GENE-Y<\\e2> , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","sentence":"Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (DCK , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear"}
{"PMID":23230131,"re_id":31,"annotated sentence":"<e1>Gemcitabine<\\e1> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by <e2>cytidine deaminase<\\e2> (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Gemcitabine","object":"cytidine deaminase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by <e2>GENE-Y<\\e2> (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","sentence":"Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear"}
{"PMID":23230131,"re_id":32,"annotated sentence":"<e1>Gemcitabine<\\e1> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (<e2>CDA<\\e2>  and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Gemcitabine","object":"CDA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (<e2>GENE-Y<\\e2>  and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","sentence":"Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA  and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear"}
{"PMID":23230131,"re_id":33,"annotated sentence":"<e1>Gemcitabine<\\e1> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and <e2>deoxycytidine kinase<\\e2> (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Gemcitabine","object":"deoxycytidine kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and <e2>GENE-Y<\\e2> (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","sentence":"Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear"}
{"PMID":23230131,"re_id":34,"annotated sentence":"All four DCK proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for <e2>DCK<\\e2> 4Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of <e1>dFdC<\\e1> monophosphorylation due to a 40% decrease in K(m) (P < 0.05)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"DCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All four GENE-Y proteins yielded comparable metabolic activity for Ara-C and CHEMICAL monophosphorylation, except for <e2>GENE-Y<\\e2> 4Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of <e1>CHEMICAL<\\e1> monophosphorylation due to a 40% decrease in K(m) (P < 0.05)","sentence":"All four DCK proteins yielded comparable metabolic activity for Ara-C and dFdC monophosphorylation, except for DCK 4Val, which demonstrated an approximately 2-fold increase (P < 0.05) in the intrinsic clearance of dFdC monophosphorylation due to a 40% decrease in K(m) (P < 0.05)"}
{"PMID":23230131,"re_id":35,"annotated sentence":"In conclusion, the <e2>Lys27Gln<\\e2> substitution does not significantly modulate CDA activity toward <e1>dFdC<\\e1>  and therefore would not contribute to interindividual variability in response to gemcitabine","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"Lys27Gln","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, the <e2>GENE-N<\\e2> substitution does not significantly modulate CDA activity toward <e1>CHEMICAL<\\e1>  and therefore would not contribute to interindividual variability in response to gemcitabine","sentence":"In conclusion, the Lys27Gln substitution does not significantly modulate CDA activity toward dFdC  and therefore would not contribute to interindividual variability in response to gemcitabine"}
{"PMID":23230131,"re_id":36,"annotated sentence":"In conclusion, the Lys27Gln substitution does not significantly modulate <e2>CDA<\\e2> activity toward <e1>dFdC<\\e1>  and therefore would not contribute to interindividual variability in response to gemcitabine","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"CDA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, the Lys27Gln substitution does not significantly modulate <e2>GENE-Y<\\e2> activity toward <e1>CHEMICAL<\\e1>  and therefore would not contribute to interindividual variability in response to gemcitabine","sentence":"In conclusion, the Lys27Gln substitution does not significantly modulate CDA activity toward dFdC  and therefore would not contribute to interindividual variability in response to gemcitabine"}
{"PMID":23230131,"re_id":37,"annotated sentence":"Gemcitabine (<e1>dFdC<\\e1>  2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>DCK<\\e2> , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"DCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gemcitabine (<e1>CHEMICAL<\\e1>  2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>GENE-Y<\\e2> , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","sentence":"Gemcitabine (dFdC  2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (DCK , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear"}
{"PMID":23230131,"re_id":38,"annotated sentence":"Gemcitabine (<e1>dFdC<\\e1>  2',2'-difluorodeoxycytidine) is metabolized by <e2>cytidine deaminase<\\e2> (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"cytidine deaminase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gemcitabine (<e1>CHEMICAL<\\e1>  2',2'-difluorodeoxycytidine) is metabolized by <e2>GENE-Y<\\e2> (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","sentence":"Gemcitabine (dFdC  2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear"}
{"PMID":23230131,"re_id":39,"annotated sentence":"Gemcitabine (<e1>dFdC<\\e1>  2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (<e2>CDA<\\e2>  and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"CDA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gemcitabine (<e1>CHEMICAL<\\e1>  2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (<e2>GENE-Y<\\e2>  and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","sentence":"Gemcitabine (dFdC  2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA  and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear"}
{"PMID":23230131,"re_id":40,"annotated sentence":"Gemcitabine (<e1>dFdC<\\e1>  2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and <e2>deoxycytidine kinase<\\e2> (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"deoxycytidine kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gemcitabine (<e1>CHEMICAL<\\e1>  2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and <e2>GENE-Y<\\e2> (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","sentence":"Gemcitabine (dFdC  2',2'-difluorodeoxycytidine) is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear"}
{"PMID":23230131,"re_id":41,"annotated sentence":"The higher in vitro catalytic efficiency of <e2>DCK<\\e2> 4Val toward <e1>dFdC<\\e1> monophosphorylation may be relevant to dFdC clinical response","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"DCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The higher in vitro catalytic efficiency of <e2>GENE-Y<\\e2> 4Val toward <e1>CHEMICAL<\\e1> monophosphorylation may be relevant to CHEMICAL clinical response","sentence":"The higher in vitro catalytic efficiency of DCK 4Val toward dFdC monophosphorylation may be relevant to dFdC clinical response"}
{"PMID":23230131,"re_id":42,"annotated sentence":"The higher in vitro catalytic efficiency of <e2>DCK<\\e2> 4Val toward dFdC monophosphorylation may be relevant to <e1>dFdC<\\e1> clinical response","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dFdC","object":"DCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The higher in vitro catalytic efficiency of <e2>GENE-Y<\\e2> 4Val toward CHEMICAL monophosphorylation may be relevant to <e1>CHEMICAL<\\e1> clinical response","sentence":"The higher in vitro catalytic efficiency of DCK 4Val toward dFdC monophosphorylation may be relevant to dFdC clinical response"}
{"PMID":23230131,"re_id":43,"annotated sentence":"Gemcitabine (dFdC, <e1>2',2'-difluorodeoxycytidine<\\e1>  is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>DCK<\\e2> , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2',2'-difluorodeoxycytidine","object":"DCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gemcitabine (dFdC, <e1>CHEMICAL<\\e1>  is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (<e2>GENE-Y<\\e2> , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","sentence":"Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine  is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (DCK , but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear"}
{"PMID":23230131,"re_id":44,"annotated sentence":"Gemcitabine (dFdC, <e1>2',2'-difluorodeoxycytidine<\\e1>  is metabolized by <e2>cytidine deaminase<\\e2> (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2',2'-difluorodeoxycytidine","object":"cytidine deaminase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gemcitabine (dFdC, <e1>CHEMICAL<\\e1>  is metabolized by <e2>GENE-Y<\\e2> (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","sentence":"Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine  is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear"}
{"PMID":23230131,"re_id":45,"annotated sentence":"Gemcitabine (dFdC, <e1>2',2'-difluorodeoxycytidine<\\e1>  is metabolized by cytidine deaminase (<e2>CDA<\\e2>  and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2',2'-difluorodeoxycytidine","object":"CDA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gemcitabine (dFdC, <e1>CHEMICAL<\\e1>  is metabolized by cytidine deaminase (<e2>GENE-Y<\\e2>  and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","sentence":"Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine  is metabolized by cytidine deaminase (CDA  and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear"}
{"PMID":23230131,"re_id":46,"annotated sentence":"Gemcitabine (dFdC, <e1>2',2'-difluorodeoxycytidine<\\e1>  is metabolized by cytidine deaminase (CDA) and <e2>deoxycytidine kinase<\\e2> (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2',2'-difluorodeoxycytidine","object":"deoxycytidine kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gemcitabine (dFdC, <e1>CHEMICAL<\\e1>  is metabolized by cytidine deaminase (CDA) and <e2>GENE-Y<\\e2> (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear","sentence":"Gemcitabine (dFdC, 2',2'-difluorodeoxycytidine  is metabolized by cytidine deaminase (CDA) and deoxycytidine kinase (DCK), but the contribution of genetic variation in these enzymes to the variability in systemic exposure and response observed in cancer patients is unclear"}
{"PMID":23230131,"re_id":47,"annotated sentence":"Wild-type enzymes and variants of <e2>CDA<\\e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cytarabine","object":"CDA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wild-type enzymes and variants of <e2>GENE-Y<\\e2> (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>CHEMICAL<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":48,"annotated sentence":"Wild-type enzymes and variants of CDA (<e2>Lys27Gln<\\e2> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cytarabine","object":"Lys27Gln","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (<e2>GENE-N<\\e2> and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>CHEMICAL<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":49,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and <e2>Ala70Thr<\\e2>  and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cytarabine","object":"Ala70Thr","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and <e2>GENE-N<\\e2>  and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>CHEMICAL<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr  and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":50,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <e2>DCK<\\e2> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cytarabine","object":"DCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and <e2>GENE-Y<\\e2> (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>CHEMICAL<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":51,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<e2>Ile24Val<\\e2>  Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cytarabine","object":"Ile24Val","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (<e2>GENE-N<\\e2>  Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>CHEMICAL<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val  Ala119Gly, and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":52,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <e2>Ala119Gly<\\e2>  and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cytarabine","object":"Ala119Gly","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, <e2>GENE-N<\\e2>  and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>CHEMICAL<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly  and Pro122Ser) were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23230131,"re_id":53,"annotated sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <e2>Pro122Ser<\\e2>  were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>cytarabine<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cytarabine","object":"Pro122Ser","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and <e2>GENE-N<\\e2>  were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for <e1>CHEMICAL<\\e1> (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates","sentence":"Wild-type enzymes and variants of CDA (Lys27Gln and Ala70Thr) and DCK (Ile24Val, Ala119Gly, and Pro122Ser  were expressed in and purified from Escherichia coli, and enzyme kinetic parameters were estimated for cytarabine (Ara-C), dFdC, and its metabolite 2',2'-difluorodeoxyuridine (dFdU) as substrates"}
{"PMID":23232060,"re_id":0,"annotated sentence":"A series of compounds based on a <e1>4-phenyl-2-phenylaminopyridine<\\e1> scaffold that are potent and selective inhibitors of <e2>Traf2- and Nck-interacting kinase<\\e2> (TNIK) activity are described","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"4-phenyl-2-phenylaminopyridine","object":"Traf2- and Nck-interacting kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of compounds based on a <e1>CHEMICAL<\\e1> scaffold that are potent and selective inhibitors of <e2>GENE-Y<\\e2> (TNIK) activity are described","sentence":"A series of compounds based on a 4-phenyl-2-phenylaminopyridine scaffold that are potent and selective inhibitors of Traf2- and Nck-interacting kinase (TNIK) activity are described"}
{"PMID":23232060,"re_id":1,"annotated sentence":"A series of compounds based on a <e1>4-phenyl-2-phenylaminopyridine<\\e1> scaffold that are potent and selective inhibitors of Traf2- and Nck-interacting kinase (<e2>TNIK<\\e2>  activity are described","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"4-phenyl-2-phenylaminopyridine","object":"TNIK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of compounds based on a <e1>CHEMICAL<\\e1> scaffold that are potent and selective inhibitors of Traf2- and Nck-interacting kinase (<e2>GENE-Y<\\e2>  activity are described","sentence":"A series of compounds based on a 4-phenyl-2-phenylaminopyridine scaffold that are potent and selective inhibitors of Traf2- and Nck-interacting kinase (TNIK  activity are described"}
{"PMID":23232060,"re_id":2,"annotated sentence":"Discovery of <e1>4-phenyl-2-phenylaminopyridine<\\e1> based <e2>TNIK<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"4-phenyl-2-phenylaminopyridine","object":"TNIK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Discovery of <e1>CHEMICAL<\\e1> based <e2>GENE-Y<\\e2> inhibitors","sentence":"Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors"}
{"PMID":23239555,"re_id":0,"annotated sentence":"Here we present <e1>boronic<\\e1> and borinic acid derivatives as a new class of potent and nontoxic <e2>APT<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"boronic","object":"APT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Here we present <e1>CHEMICAL<\\e1> and borinic acid derivatives as a new class of potent and nontoxic <e2>GENE-N<\\e2> inhibitors","sentence":"Here we present boronic and borinic acid derivatives as a new class of potent and nontoxic APT inhibitors"}
{"PMID":23239555,"re_id":1,"annotated sentence":"Here we present boronic and <e1>borinic acid<\\e1> derivatives as a new class of potent and nontoxic <e2>APT<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"borinic acid","object":"APT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Here we present boronic and <e1>CHEMICAL<\\e1> derivatives as a new class of potent and nontoxic <e2>GENE-N<\\e2> inhibitors","sentence":"Here we present boronic and borinic acid derivatives as a new class of potent and nontoxic APT inhibitors"}
{"PMID":23239555,"re_id":2,"annotated sentence":"<e1>Boron<\\e1> based inhibitors of <e2>acyl protein thioesterases 1 and 2<\\e2>  Ras proteins are of importance in cell proliferation, and hence their mutated forms play causative roles in many kinds of cancer in different tissues","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Boron","object":"acyl protein thioesterases 1 and 2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> based inhibitors of <e2>GENE-N<\\e2>  Ras proteins are of importance in cell proliferation, and hence their mutated forms play causative roles in many kinds of cancer in different tissues","sentence":"Boron based inhibitors of acyl protein thioesterases 1 and 2  Ras proteins are of importance in cell proliferation, and hence their mutated forms play causative roles in many kinds of cancer in different tissues"}
{"PMID":23254196,"re_id":13,"annotated sentence":"Furthermore, <e2>thrombin<\\e2> diminished cAMP production in ECs, which were prevented by treatment with <e1>genistein<\\e1>  These findings demonstrated that genistein improves thrombin-induced endothelial barrier dysfunction in ECs through PKA-mediated suppression of RhoA signaling.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"genistein","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e2>GENE-Y<\\e2> diminished cAMP production in ECs, which were prevented by treatment with <e1>CHEMICAL<\\e1>  These findings demonstrated that CHEMICAL improves GENE-Y-induced endothelial barrier dysfunction in ECs through PKA-mediated suppression of RhoA signaling.","sentence":"Furthermore, thrombin diminished cAMP production in ECs, which were prevented by treatment with genistein  These findings demonstrated that genistein improves thrombin-induced endothelial barrier dysfunction in ECs through PKA-mediated suppression of RhoA signaling."}
{"PMID":23254196,"re_id":14,"annotated sentence":"Here, we report that <e1>genistein<\\e1> at physiologically relevant concentrations (0.1-10 \u03bcM) significantly inhibited <e2>thrombin<\\e2> induced increase in endothelial monolayer permeability","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"genistein","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here, we report that <e1>CHEMICAL<\\e1> at physiologically relevant concentrations (0.1-10 \u03bcM) significantly inhibited <e2>GENE-Y<\\e2> induced increase in endothelial monolayer permeability","sentence":"Here, we report that genistein at physiologically relevant concentrations (0.1-10 \u03bcM) significantly inhibited thrombin induced increase in endothelial monolayer permeability"}
{"PMID":23254196,"re_id":15,"annotated sentence":"<e1>Genistein<\\e1> also reduced the formation of stress fibers by <e2>thrombin<\\e2> and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)\/Thr(18) in endothelial cells (ECs)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Genistein","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also reduced the formation of stress fibers by <e2>GENE-Y<\\e2> and suppressed GENE-Y-induced phosphorylation of myosin light chain (MLC) on Ser(19)\/Thr(18) in endothelial cells (ECs)","sentence":"Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)\/Thr(18) in endothelial cells (ECs)"}
{"PMID":23254196,"re_id":16,"annotated sentence":"<e1>Genistein<\\e1> also reduced the formation of stress fibers by thrombin and suppressed <e2>thrombin<\\e2> induced phosphorylation of myosin light chain (MLC) on Ser(19)\/Thr(18) in endothelial cells (ECs)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Genistein","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also reduced the formation of stress fibers by GENE-Y and suppressed <e2>GENE-Y<\\e2> induced phosphorylation of myosin light chain (MLC) on Ser(19)\/Thr(18) in endothelial cells (ECs)","sentence":"Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin induced phosphorylation of myosin light chain (MLC) on Ser(19)\/Thr(18) in endothelial cells (ECs)"}
{"PMID":23254196,"re_id":17,"annotated sentence":"<e1>Genistein<\\e1> also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of <e2>myosin light chain<\\e2> (MLC) on Ser(19)\/Thr(18) in endothelial cells (ECs)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Genistein","object":"myosin light chain","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of <e2>GENE-N<\\e2> (MLC) on Ser(19)\/Thr(18) in endothelial cells (ECs)","sentence":"Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)\/Thr(18) in endothelial cells (ECs)"}
{"PMID":23254196,"re_id":18,"annotated sentence":"<e1>Genistein<\\e1> also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (<e2>MLC<\\e2>  on Ser(19)\/Thr(18) in endothelial cells (ECs)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Genistein","object":"MLC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (<e2>GENE-N<\\e2>  on Ser(19)\/Thr(18) in endothelial cells (ECs)","sentence":"Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (MLC  on Ser(19)\/Thr(18) in endothelial cells (ECs)"}
{"PMID":23256625,"re_id":1,"annotated sentence":"3.\u2002In vitro, <e1>GSK1292263<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards <e2>CYPs<\\e2> (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"CYPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"3.\u2002In vitro, <e1>CHEMICAL<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards <e2>GENE-N<\\e2> (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2","sentence":"3.\u2002In vitro, GSK1292263 demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2"}
{"PMID":23256625,"re_id":2,"annotated sentence":"3.\u2002In vitro, <e1>GSK1292263<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (<e2>CYP1A2<\\e2>  2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"CYP1A2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"3.\u2002In vitro, <e1>CHEMICAL<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (<e2>GENE-Y<\\e2>  2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2","sentence":"3.\u2002In vitro, GSK1292263 demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2  2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2"}
{"PMID":23256625,"re_id":3,"annotated sentence":"3.\u2002In vitro, <e1>GSK1292263<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, <e2>2C9<\\e2>  2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"2C9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"3.\u2002In vitro, <e1>CHEMICAL<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, <e2>GENE-Y<\\e2>  2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2","sentence":"3.\u2002In vitro, GSK1292263 demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9  2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2"}
{"PMID":23256625,"re_id":4,"annotated sentence":"3.\u2002In vitro, <e1>GSK1292263<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, <e2>2C19<\\e2>  2D6, 3A4), Pgp, OATP1B3, or OCT2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"2C19","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"3.\u2002In vitro, <e1>CHEMICAL<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, <e2>GENE-Y<\\e2>  2D6, 3A4), Pgp, OATP1B3, or OCT2","sentence":"3.\u2002In vitro, GSK1292263 demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19  2D6, 3A4), Pgp, OATP1B3, or OCT2"}
{"PMID":23256625,"re_id":5,"annotated sentence":"3.\u2002In vitro, <e1>GSK1292263<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, <e2>2D6<\\e2>  3A4), Pgp, OATP1B3, or OCT2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"2D6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"3.\u2002In vitro, <e1>CHEMICAL<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, <e2>GENE-Y<\\e2>  3A4), Pgp, OATP1B3, or OCT2","sentence":"3.\u2002In vitro, GSK1292263 demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6  3A4), Pgp, OATP1B3, or OCT2"}
{"PMID":23256625,"re_id":6,"annotated sentence":"3.\u2002In vitro, <e1>GSK1292263<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, <e2>3A4<\\e2> , Pgp, OATP1B3, or OCT2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"3.\u2002In vitro, <e1>CHEMICAL<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, <e2>GENE-Y<\\e2> , Pgp, OATP1B3, or OCT2","sentence":"3.\u2002In vitro, GSK1292263 demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4 , Pgp, OATP1B3, or OCT2"}
{"PMID":23256625,"re_id":7,"annotated sentence":"3.\u2002In vitro, <e1>GSK1292263<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), <e2>Pgp<\\e2>  OATP1B3, or OCT2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"Pgp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"3.\u2002In vitro, <e1>CHEMICAL<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), <e2>GENE-N<\\e2>  OATP1B3, or OCT2","sentence":"3.\u2002In vitro, GSK1292263 demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp  OATP1B3, or OCT2"}
{"PMID":23256625,"re_id":8,"annotated sentence":"3.\u2002In vitro, <e1>GSK1292263<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, <e2>OATP1B3<\\e2>  or OCT2","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"3.\u2002In vitro, <e1>CHEMICAL<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, <e2>GENE-Y<\\e2>  or OCT2","sentence":"3.\u2002In vitro, GSK1292263 demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3  or OCT2"}
{"PMID":23256625,"re_id":9,"annotated sentence":"3.\u2002In vitro, <e1>GSK1292263<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or <e2>OCT2<\\e2>  However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"OCT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"3.\u2002In vitro, <e1>CHEMICAL<\\e1> demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or <e2>GENE-Y<\\e2>  However, CHEMICAL inhibited BCRP and OATP1B1, which are transporters involved in statin disposition","sentence":"3.\u2002In vitro, GSK1292263 demonstrated little\/weak inhibition (IC50 values >30 \u03bcM) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2  However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition"}
{"PMID":23256625,"re_id":10,"annotated sentence":"However, <e1>GSK1292263<\\e1> inhibited <e2>BCRP<\\e2> and OATP1B1, which are transporters involved in statin disposition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"BCRP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> and OATP1B1, which are transporters involved in statin disposition","sentence":"However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition"}
{"PMID":23256625,"re_id":11,"annotated sentence":"However, <e1>GSK1292263<\\e1> inhibited BCRP and <e2>OATP1B1<\\e2>  which are transporters involved in statin disposition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, <e1>CHEMICAL<\\e1> inhibited BCRP and <e2>GENE-Y<\\e2>  which are transporters involved in statin disposition","sentence":"However, GSK1292263 inhibited BCRP and OATP1B1  which are transporters involved in statin disposition"}
{"PMID":23256625,"re_id":12,"annotated sentence":"4.\u2002In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with <e1>GSK1292263<\\e1>  which is consistent with an inhibitory effect on intestinal BCRP and <e2>CYP3A4<\\e2>  In contrast, GSK1292263 did not inhibit OATP1B1 based on the lack of changes in simvastatin acid exposure [mean AUC(0-inf) ratio (90% CI) of 1.05 (0.91, 1.21)]","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"CYP3A4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4.\u2002In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with <e1>CHEMICAL<\\e1>  which is consistent with an inhibitory effect on intestinal BCRP and <e2>GENE-Y<\\e2>  In contrast, CHEMICAL did not inhibit OATP1B1 based on the lack of changes in simvastatin acid exposure [mean AUC(0-inf) ratio (90% CI) of 1.05 (0.91, 1.21)]","sentence":"4.\u2002In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263  which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4  In contrast, GSK1292263 did not inhibit OATP1B1 based on the lack of changes in simvastatin acid exposure [mean AUC(0-inf) ratio (90% CI) of 1.05 (0.91, 1.21)]"}
{"PMID":23256625,"re_id":13,"annotated sentence":"4.\u2002In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with <e1>GSK1292263<\\e1>  which is consistent with an inhibitory effect on intestinal <e2>BCRP<\\e2> and CYP3A4","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"BCRP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"4.\u2002In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with <e1>CHEMICAL<\\e1>  which is consistent with an inhibitory effect on intestinal <e2>GENE-Y<\\e2> and CYP3A4","sentence":"4.\u2002In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263  which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4"}
{"PMID":23256625,"re_id":14,"annotated sentence":"1.\u2002This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the <e2>HMG-coA reductase<\\e2> inhibitors <e1>simvastatin<\\e1> and rosuvastatin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"simvastatin","object":"HMG-coA reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"1.\u2002This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the <e2>GENE-Y<\\e2> inhibitors <e1>CHEMICAL<\\e1> and rosuvastatin","sentence":"1.\u2002This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin"}
{"PMID":23256625,"re_id":15,"annotated sentence":"This study provides a mechanistic understanding of the in vivo inhibition of <e2>transporters<\\e2> and enzymes by <e1>GSK1292263<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study provides a mechanistic understanding of the in vivo inhibition of <e2>GENE-N<\\e2> and enzymes by <e1>CHEMICAL<\\e1> ","sentence":"This study provides a mechanistic understanding of the in vivo inhibition of transporters and enzymes by GSK1292263 "}
{"PMID":23256625,"re_id":16,"annotated sentence":"1.\u2002This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the <e2>HMG-coA reductase<\\e2> inhibitors simvastatin and <e1>rosuvastatin<\\e1>  2.\u2002In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300\u2009mg BID) on the pharmacokinetic profile of simvastatin (40\u2009mg single dose) and rosuvastatin (10\u2009mg single dose)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rosuvastatin","object":"HMG-coA reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"1.\u2002This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the <e2>GENE-Y<\\e2> inhibitors simvastatin and <e1>CHEMICAL<\\e1>  2.\u2002In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300\u2009mg BID) on the pharmacokinetic profile of simvastatin (40\u2009mg single dose) and CHEMICAL (10\u2009mg single dose)","sentence":"1.\u2002This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin  2.\u2002In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300\u2009mg BID) on the pharmacokinetic profile of simvastatin (40\u2009mg single dose) and rosuvastatin (10\u2009mg single dose)"}
{"PMID":23256625,"re_id":17,"annotated sentence":"2.\u2002In vitro experiments assessed the inhibition of <e2>transporters<\\e2> and CYP enzymes by <e1>GSK1292263<\\e1>  and a clinical drug interaction study investigated the effect of GSK1292263 (300\u2009mg BID) on the pharmacokinetic profile of simvastatin (40\u2009mg single dose) and rosuvastatin (10\u2009mg single dose)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"2.\u2002In vitro experiments assessed the inhibition of <e2>GENE-N<\\e2> and CYP enzymes by <e1>CHEMICAL<\\e1>  and a clinical drug interaction study investigated the effect of CHEMICAL (300\u2009mg BID) on the pharmacokinetic profile of simvastatin (40\u2009mg single dose) and rosuvastatin (10\u2009mg single dose)","sentence":"2.\u2002In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263  and a clinical drug interaction study investigated the effect of GSK1292263 (300\u2009mg BID) on the pharmacokinetic profile of simvastatin (40\u2009mg single dose) and rosuvastatin (10\u2009mg single dose)"}
{"PMID":23256625,"re_id":18,"annotated sentence":"2.\u2002In vitro experiments assessed the inhibition of transporters and <e2>CYP<\\e2> enzymes by <e1>GSK1292263<\\e1>  and a clinical drug interaction study investigated the effect of GSK1292263 (300\u2009mg BID) on the pharmacokinetic profile of simvastatin (40\u2009mg single dose) and rosuvastatin (10\u2009mg single dose)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GSK1292263","object":"CYP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"2.\u2002In vitro experiments assessed the inhibition of transporters and <e2>GENE-N<\\e2> enzymes by <e1>CHEMICAL<\\e1>  and a clinical drug interaction study investigated the effect of CHEMICAL (300\u2009mg BID) on the pharmacokinetic profile of simvastatin (40\u2009mg single dose) and rosuvastatin (10\u2009mg single dose)","sentence":"2.\u2002In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263  and a clinical drug interaction study investigated the effect of GSK1292263 (300\u2009mg BID) on the pharmacokinetic profile of simvastatin (40\u2009mg single dose) and rosuvastatin (10\u2009mg single dose)"}
{"PMID":23256625,"re_id":19,"annotated sentence":"1.\u2002This work investigated the drug interaction potential of <e1>GSK1292263<\\e1>  a novel <e2>GPR119<\\e2> agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"GSK1292263","object":"GPR119","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"1.\u2002This work investigated the drug interaction potential of <e1>CHEMICAL<\\e1>  a novel <e2>GENE-Y<\\e2> agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin","sentence":"1.\u2002This work investigated the drug interaction potential of GSK1292263  a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin"}
{"PMID":23256625,"re_id":20,"annotated sentence":"Evaluation of drug interactions of <e1>GSK1292263<\\e1> (a <e2>GPR119<\\e2> agonist) with statins: from in vitro data to clinical study design","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"GSK1292263","object":"GPR119","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Evaluation of drug interactions of <e1>CHEMICAL<\\e1> (a <e2>GENE-Y<\\e2> agonist) with statins: from in vitro data to clinical study design","sentence":"Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design"}
{"PMID":23257178,"re_id":2,"annotated sentence":"The presence of <e1>steroid<\\e1> hormones most probably causes the degradation of the <e2>Tat2<\\e2> permease and impairment of tryptophan import.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"steroid","object":"Tat2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The presence of <e1>CHEMICAL<\\e1> hormones most probably causes the degradation of the <e2>GENE-N<\\e2> permease and impairment of tryptophan import.","sentence":"The presence of steroid hormones most probably causes the degradation of the Tat2 permease and impairment of tryptophan import."}
{"PMID":23261528,"re_id":0,"annotated sentence":"Further study showed that <e1>icariin<\\e1> dose-dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro-inflammatory <e2>cytokine<\\e2> levels of activated T cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"icariin","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Further study showed that <e1>CHEMICAL<\\e1> dose-dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro-inflammatory <e2>GENE-N<\\e2> levels of activated T cells","sentence":"Further study showed that icariin dose-dependently inhibited the proliferation and activation of T lymphocytes, and suppressed pro-inflammatory cytokine levels of activated T cells"}
{"PMID":23261528,"re_id":1,"annotated sentence":"Inhibition of Th1\/Th17 responses via suppression of <e2>STAT1<\\e2> and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside <e1>icariin<\\e1>  Inflammatory bowel disease (IBD) is a chronic inflammatory disorder in the intestine which involves overproduction of pro-inflammatory cytokines and excessive functions of inflammatory cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"icariin","object":"STAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of Th1\/Th17 responses via suppression of <e2>GENE-Y<\\e2> and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside <e1>CHEMICAL<\\e1>  Inflammatory bowel disease (IBD) is a chronic inflammatory disorder in the intestine which involves overproduction of pro-inflammatory cytokines and excessive functions of inflammatory cells","sentence":"Inhibition of Th1\/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin  Inflammatory bowel disease (IBD) is a chronic inflammatory disorder in the intestine which involves overproduction of pro-inflammatory cytokines and excessive functions of inflammatory cells"}
{"PMID":23261528,"re_id":2,"annotated sentence":"Inhibition of Th1\/Th17 responses via suppression of STAT1 and <e2>STAT3<\\e2> activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside <e1>icariin<\\e1>  Inflammatory bowel disease (IBD) is a chronic inflammatory disorder in the intestine which involves overproduction of pro-inflammatory cytokines and excessive functions of inflammatory cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"icariin","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of Th1\/Th17 responses via suppression of STAT1 and <e2>GENE-Y<\\e2> activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside <e1>CHEMICAL<\\e1>  Inflammatory bowel disease (IBD) is a chronic inflammatory disorder in the intestine which involves overproduction of pro-inflammatory cytokines and excessive functions of inflammatory cells","sentence":"Inhibition of Th1\/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin  Inflammatory bowel disease (IBD) is a chronic inflammatory disorder in the intestine which involves overproduction of pro-inflammatory cytokines and excessive functions of inflammatory cells"}
{"PMID":23261528,"re_id":3,"annotated sentence":"Moreover, <e1>icariin<\\e1> treatment inhibited the phosphorylations of <e2>STAT1<\\e2> and STAT3 in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"icariin","object":"STAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> treatment inhibited the phosphorylations of <e2>GENE-Y<\\e2> and STAT3 in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively","sentence":"Moreover, icariin treatment inhibited the phosphorylations of STAT1 and STAT3 in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively"}
{"PMID":23261528,"re_id":4,"annotated sentence":"Moreover, <e1>icariin<\\e1> treatment inhibited the phosphorylations of STAT1 and <e2>STAT3<\\e2> in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"icariin","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> treatment inhibited the phosphorylations of STAT1 and <e2>GENE-Y<\\e2> in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively","sentence":"Moreover, icariin treatment inhibited the phosphorylations of STAT1 and STAT3 in CD4(+) T cells, which were the crucial transcription factors for Th1 and Th17 respectively"}
{"PMID":23261528,"re_id":5,"annotated sentence":"Inhibition of Th1\/Th17 responses via suppression of <e2>STAT1<\\e2> and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural <e1>flavonoid<\\e1> glucoside icariin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flavonoid","object":"STAT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of Th1\/Th17 responses via suppression of <e2>GENE-Y<\\e2> and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural <e1>CHEMICAL<\\e1> glucoside icariin","sentence":"Inhibition of Th1\/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin"}
{"PMID":23261528,"re_id":6,"annotated sentence":"Inhibition of Th1\/Th17 responses via suppression of STAT1 and <e2>STAT3<\\e2> activation contributes to the amelioration of murine experimental colitis by a natural <e1>flavonoid<\\e1> glucoside icariin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flavonoid","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of Th1\/Th17 responses via suppression of STAT1 and <e2>GENE-Y<\\e2> activation contributes to the amelioration of murine experimental colitis by a natural <e1>CHEMICAL<\\e1> glucoside icariin","sentence":"Inhibition of Th1\/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin"}
{"PMID":23261705,"re_id":0,"annotated sentence":"Pharmacological inhibition of MTORC1 with <e1>rapamycin<\\e1> abrogated the <e2>insulin<\\e2> induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"rapamycin","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacological inhibition of MTORC1 with <e1>CHEMICAL<\\e1> abrogated the <e2>GENE-Y<\\e2> induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6","sentence":"Pharmacological inhibition of MTORC1 with rapamycin abrogated the insulin induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6"}
{"PMID":23261705,"re_id":1,"annotated sentence":"Furthermore, <e2>insulin<\\e2> stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by <e1>rapamycin<\\e1>  Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"rapamycin","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e2>GENE-Y<\\e2> stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by <e1>CHEMICAL<\\e1>  Taken together, the present studies show that GENE-Y stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.","sentence":"Furthermore, insulin stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by rapamycin  Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway."}
{"PMID":23261705,"re_id":2,"annotated sentence":"Furthermore, insulin-stimulated T-I cell proliferation and the expression of <e2>cell cycle regulatory proteins<\\e2> CDK4, CCND3 and PCNA were also blocked by <e1>rapamycin<\\e1>  Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"rapamycin","object":"cell cycle regulatory proteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, insulin-stimulated T-I cell proliferation and the expression of <e2>GENE-N<\\e2> CDK4, CCND3 and PCNA were also blocked by <e1>CHEMICAL<\\e1>  Taken together, the present studies show that insulin stimulates cell proliferation and GENE-N in T-I cells via activation of the MTORC1 signaling pathway.","sentence":"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by rapamycin  Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway."}
{"PMID":23261705,"re_id":3,"annotated sentence":"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins <e2>CDK4<\\e2>  CCND3 and PCNA were also blocked by <e1>rapamycin<\\e1>  Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"rapamycin","object":"CDK4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins <e2>GENE-Y<\\e2>  CCND3 and PCNA were also blocked by <e1>CHEMICAL<\\e1>  Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.","sentence":"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4  CCND3 and PCNA were also blocked by rapamycin  Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway."}
{"PMID":23261705,"re_id":4,"annotated sentence":"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, <e2>CCND3<\\e2> and PCNA were also blocked by <e1>rapamycin<\\e1>  Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"rapamycin","object":"CCND3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, <e2>GENE-Y<\\e2> and PCNA were also blocked by <e1>CHEMICAL<\\e1>  Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.","sentence":"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by rapamycin  Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway."}
{"PMID":23261705,"re_id":5,"annotated sentence":"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and <e2>PCNA<\\e2> were also blocked by <e1>rapamycin<\\e1>  Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"rapamycin","object":"PCNA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and <e2>GENE-Y<\\e2> were also blocked by <e1>CHEMICAL<\\e1>  Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway.","sentence":"Furthermore, insulin-stimulated T-I cell proliferation and the expression of cell cycle regulatory proteins CDK4, CCND3 and PCNA were also blocked by rapamycin  Taken together, the present studies show that insulin stimulates cell proliferation and cell cycle regulatory proteins in T-I cells via activation of the MTORC1 signaling pathway."}
{"PMID":23261705,"re_id":6,"annotated sentence":"Pharmacological inhibition of <e2>MTORC1<\\e2> with <e1>rapamycin<\\e1> abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rapamycin","object":"MTORC1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pharmacological inhibition of <e2>GENE-N<\\e2> with <e1>CHEMICAL<\\e1> abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6","sentence":"Pharmacological inhibition of MTORC1 with rapamycin abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6"}
{"PMID":23261705,"re_id":7,"annotated sentence":"Pharmacological inhibition of MTORC1 with <e1>rapamycin<\\e1> abrogated the insulin-induced phosphorylation of <e2>EIF4EBP1<\\e2>  RPS6KB1 and its downstream effector, RPS6","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rapamycin","object":"EIF4EBP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacological inhibition of MTORC1 with <e1>CHEMICAL<\\e1> abrogated the insulin-induced phosphorylation of <e2>GENE-Y<\\e2>  RPS6KB1 and its downstream effector, RPS6","sentence":"Pharmacological inhibition of MTORC1 with rapamycin abrogated the insulin-induced phosphorylation of EIF4EBP1  RPS6KB1 and its downstream effector, RPS6"}
{"PMID":23261705,"re_id":8,"annotated sentence":"Pharmacological inhibition of MTORC1 with <e1>rapamycin<\\e1> abrogated the insulin-induced phosphorylation of EIF4EBP1, <e2>RPS6KB1<\\e2> and its downstream effector, RPS6","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rapamycin","object":"RPS6KB1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacological inhibition of MTORC1 with <e1>CHEMICAL<\\e1> abrogated the insulin-induced phosphorylation of EIF4EBP1, <e2>GENE-Y<\\e2> and its downstream effector, RPS6","sentence":"Pharmacological inhibition of MTORC1 with rapamycin abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6"}
{"PMID":23261705,"re_id":9,"annotated sentence":"Pharmacological inhibition of MTORC1 with <e1>rapamycin<\\e1> abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, <e2>RPS6<\\e2>  These results were further confirmed by demonstrating that knockdown of Mtor using siRNA reduced the insulin-stimulated MTORC1 signaling","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rapamycin","object":"RPS6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Pharmacological inhibition of MTORC1 with <e1>CHEMICAL<\\e1> abrogated the insulin-induced phosphorylation of EIF4EBP1, GENE-YKB1 and its downstream effector, <e2>GENE-Y<\\e2>  These results were further confirmed by demonstrating that knockdown of Mtor using siRNA reduced the insulin-stimulated MTORC1 signaling","sentence":"Pharmacological inhibition of MTORC1 with rapamycin abrogated the insulin-induced phosphorylation of EIF4EBP1, RPS6KB1 and its downstream effector, RPS6  These results were further confirmed by demonstrating that knockdown of Mtor using siRNA reduced the insulin-stimulated MTORC1 signaling"}
{"PMID":23265901,"re_id":0,"annotated sentence":"We report the discovery of novel series of highly potent <e2>TLR7<\\e2> agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various <e1>tertiary amines<\\e1> onto the N(9)-position of the adenine moiety","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"tertiary amines","object":"TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report the discovery of novel series of highly potent <e2>GENE-Y<\\e2> agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various <e1>CHEMICAL<\\e1> onto the N(9)-position of the adenine moiety","sentence":"We report the discovery of novel series of highly potent TLR7 agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety"}
{"PMID":23265901,"re_id":1,"annotated sentence":"We report the discovery of novel series of highly potent <e2>TLR7<\\e2> agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the <e1>N<\\e1> 9)-position of the adenine moiety","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"N","object":"TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report the discovery of novel series of highly potent <e2>GENE-Y<\\e2> agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the <e1>CHEMICAL<\\e1> 9)-position of the adenine moiety","sentence":"We report the discovery of novel series of highly potent TLR7 agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N 9)-position of the adenine moiety"}
{"PMID":23265901,"re_id":2,"annotated sentence":"We report the discovery of novel series of highly potent <e2>TLR7<\\e2> agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the <e1>adenine<\\e1> moiety","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"adenine","object":"TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report the discovery of novel series of highly potent <e2>GENE-Y<\\e2> agonists based on 8-oxoCHEMICALs, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the <e1>CHEMICAL<\\e1> moiety","sentence":"We report the discovery of novel series of highly potent TLR7 agonists based on 8-oxoadenines, 1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety"}
{"PMID":23265901,"re_id":3,"annotated sentence":"The introduction of the <e1>amino<\\e1> group resulted in not only improved water solubility but also enhanced <e2>TLR7<\\e2> agonistic activity","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"amino","object":"TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The introduction of the <e1>CHEMICAL<\\e1> group resulted in not only improved water solubility but also enhanced <e2>GENE-Y<\\e2> agonistic activity","sentence":"The introduction of the amino group resulted in not only improved water solubility but also enhanced TLR7 agonistic activity"}
{"PMID":23265901,"re_id":4,"annotated sentence":"We report the discovery of novel series of highly potent <e2>TLR7<\\e2> agonists based on <e1>8-oxoadenines<\\e1>  1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"8-oxoadenines","object":"TLR7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We report the discovery of novel series of highly potent <e2>GENE-Y<\\e2> agonists based on <e1>CHEMICAL<\\e1>  1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety","sentence":"We report the discovery of novel series of highly potent TLR7 agonists based on 8-oxoadenines  1 and 2 by introducing and optimizing various tertiary amines onto the N(9)-position of the adenine moiety"}
{"PMID":23265901,"re_id":5,"annotated sentence":"Synthesis and evaluation of <e1>8-oxoadenine<\\e1> derivatives as potent <e2>Toll-like receptor 7<\\e2> agonists with high water solubility","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"8-oxoadenine","object":"Toll-like receptor 7","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and evaluation of <e1>CHEMICAL<\\e1> derivatives as potent <e2>GENE-Y<\\e2> agonists with high water solubility","sentence":"Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility"}
{"PMID":23265904,"re_id":0,"annotated sentence":"Inhibitors based on a <e1>benzo-fused spirocyclic oxazepine<\\e1> scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 (<e2>SCD1<\\e2>  and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"benzo-fused spirocyclic oxazepine","object":"SCD1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibitors based on a <e1>CHEMICAL<\\e1> scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 (<e2>GENE-Y<\\e2>  and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model","sentence":"Inhibitors based on a benzo-fused spirocyclic oxazepine scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 (SCD1  and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model"}
{"PMID":23265904,"re_id":1,"annotated sentence":"Inhibitors based on a <e1>benzo-fused spirocyclic oxazepine<\\e1> scaffold were discovered for <e2>stearoyl-coenzyme A (CoA) desaturase 1<\\e2> (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"benzo-fused spirocyclic oxazepine","object":"stearoyl-coenzyme A (CoA) desaturase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibitors based on a <e1>CHEMICAL<\\e1> scaffold were discovered for <e2>GENE-Y<\\e2> (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model","sentence":"Inhibitors based on a benzo-fused spirocyclic oxazepine scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model"}
{"PMID":23267767,"re_id":0,"annotated sentence":"The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited <e2>human Hsp60<\\e2> chaperone activity (IC(50): 6.80 \u00b1 0.25 \u03bcM) and this inhibition activity was higher than that of <e1>ETB<\\e1> (IC(50): 10.9 \u00b1 0.63 \u03bcM).","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ETB","object":"human Hsp60","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited <e2>GENE-Y<\\e2> chaperone activity (IC(50): 6.80 \u00b1 0.25 \u03bcM) and this inhibition activity was higher than that of <e1>CHEMICAL<\\e1> (IC(50): 10.9 \u00b1 0.63 \u03bcM).","sentence":"The porcine heart malate dehydrogenase (MDH) refolding assay revealed that compound 1l inhibited human Hsp60 chaperone activity (IC(50): 6.80 \u00b1 0.25 \u03bcM) and this inhibition activity was higher than that of ETB (IC(50): 10.9 \u00b1 0.63 \u03bcM)."}
{"PMID":23270704,"re_id":3,"annotated sentence":"<e1>Apocynin<\\e1> and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3\u03b2-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated <e2>p66Shc<\\e2> in rat testes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Apocynin","object":"p66Shc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3\u03b2-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated <e2>GENE-Y<\\e2> in rat testes","sentence":"Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3\u03b2-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes"}
{"PMID":23270704,"re_id":4,"annotated sentence":"Apocynin and <e1>raisanberine<\\e1> alleviate intermittent hypoxia induced abnormal StAR and 3\u03b2-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated <e2>p66Shc<\\e2> in rat testes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"raisanberine","object":"p66Shc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Apocynin and <e1>CHEMICAL<\\e1> alleviate intermittent hypoxia induced abnormal StAR and 3\u03b2-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated <e2>GENE-Y<\\e2> in rat testes","sentence":"Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3\u03b2-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes"}
{"PMID":23270704,"re_id":5,"annotated sentence":"We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, <e1>APO<\\e1> (apocynin) an inhibitor of <e2>NOX<\\e2> and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"APO","object":"NOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (GENE-N), therefore, <e1>CHEMICAL<\\e1> (apocynin) an inhibitor of <e2>GENE-N<\\e2> and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis","sentence":"We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (apocynin) an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis"}
{"PMID":23270704,"re_id":6,"annotated sentence":"We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (<e1>apocynin<\\e1>  an inhibitor of <e2>NOX<\\e2> and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"apocynin","object":"NOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (GENE-N), therefore, APO (<e1>CHEMICAL<\\e1>  an inhibitor of <e2>GENE-N<\\e2> and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis","sentence":"We hypothesized that hypoxia induced testicular damage is mediated by an activated NADPH oxidase (NOX), therefore, APO (apocynin  an inhibitor of NOX and raisanberine (RS), a calcium influx inhibitor were tested if they could attenuate hypoxic toxicity to the testis"}
{"PMID":23270704,"re_id":7,"annotated sentence":"<e1>APO<\\e1> and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and <e2>p66Shc<\\e2> in testes.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"APO","object":"p66Shc","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and <e2>GENE-Y<\\e2> in testes.","sentence":"APO and RS at least partially normalize hypoxia caused male hypogonadism by suppressing ER stress, and p66Shc in testes."}
{"PMID":23270704,"re_id":8,"annotated sentence":"Apocynin and <e1>raisanberine<\\e1> alleviate intermittent hypoxia induced abnormal StAR and <e2>3\u03b2-HSD<\\e2> and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"raisanberine","object":"3\u03b2-HSD","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Apocynin and <e1>CHEMICAL<\\e1> alleviate intermittent hypoxia induced abnormal StAR and <e2>GENE-N<\\e2> and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes","sentence":"Apocynin and raisanberine alleviate intermittent hypoxia induced abnormal StAR and 3\u03b2-HSD and low testosterone by suppressing endoplasmic reticulum stress and activated p66Shc in rat testes"}
{"PMID":23271742,"re_id":6,"annotated sentence":"Furthermore, we found that <e1>arsenic trioxide<\\e1> activates the <e2>Pirh2 promoter<\\e2> and consequently induces Pirh2 expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"arsenic trioxide","object":"Pirh2 promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, we found that <e1>CHEMICAL<\\e1> activates the <e2>GENE-N<\\e2> and consequently induces Pirh2 expression","sentence":"Furthermore, we found that arsenic trioxide activates the Pirh2 promoter and consequently induces Pirh2 expression"}
{"PMID":23271742,"re_id":7,"annotated sentence":"Furthermore, we found that <e1>arsenic trioxide<\\e1> activates the Pirh2 promoter and consequently induces <e2>Pirh2<\\e2> expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"arsenic trioxide","object":"Pirh2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, we found that <e1>CHEMICAL<\\e1> activates the GENE-Y promoter and consequently induces <e2>GENE-Y<\\e2> expression","sentence":"Furthermore, we found that arsenic trioxide activates the Pirh2 promoter and consequently induces Pirh2 expression"}
{"PMID":23271742,"re_id":8,"annotated sentence":"Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances, <e1>arsenic<\\e1> induced degradation of <e2>\u0394Np63<\\e2> protein","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"arsenic","object":"\u0394Np63","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances, <e1>CHEMICAL<\\e1> induced degradation of <e2>GENE-Y<\\e2> protein","sentence":"Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances, arsenic induced degradation of \u0394Np63 protein"}
{"PMID":23271742,"re_id":9,"annotated sentence":"Together, these data suggest that <e1>arsenic<\\e1> degrades <e2>\u0394Np63<\\e2> protein at least in part via Pirh2-dependent proteolysis and that inhibition of \u0394Np63 expression facilitates tumor cells to arsenic-induced death.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"arsenic","object":"\u0394Np63","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Together, these data suggest that <e1>CHEMICAL<\\e1> degrades <e2>GENE-Y<\\e2> protein at least in part via Pirh2-dependent proteolysis and that inhibition of GENE-Y expression facilitates tumor cells to CHEMICAL-induced death.","sentence":"Together, these data suggest that arsenic degrades \u0394Np63 protein at least in part via Pirh2-dependent proteolysis and that inhibition of \u0394Np63 expression facilitates tumor cells to arsenic-induced death."}
{"PMID":23271742,"re_id":10,"annotated sentence":"Together, these data suggest that <e1>arsenic<\\e1> degrades \u0394Np63 protein at least in part via Pirh2-dependent proteolysis and that inhibition of <e2>\u0394Np63<\\e2> expression facilitates tumor cells to arsenic-induced death.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"arsenic","object":"\u0394Np63","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Together, these data suggest that <e1>CHEMICAL<\\e1> degrades GENE-Y protein at least in part via Pirh2-dependent proteolysis and that inhibition of <e2>GENE-Y<\\e2> expression facilitates tumor cells to CHEMICAL-induced death.","sentence":"Together, these data suggest that arsenic degrades \u0394Np63 protein at least in part via Pirh2-dependent proteolysis and that inhibition of \u0394Np63 expression facilitates tumor cells to arsenic-induced death."}
{"PMID":23271742,"re_id":11,"annotated sentence":"Here we found that <e1>arsenic trioxide<\\e1>  a frontline agent for acute promyelocytic leukemia, inhibits <e2>\u0394Np63<\\e2> but not TAp63 expression in time- and dose-dependent manners","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"arsenic trioxide","object":"\u0394Np63","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we found that <e1>CHEMICAL<\\e1>  a frontline agent for acute promyelocytic leukemia, inhibits <e2>GENE-Y<\\e2> but not TAp63 expression in time- and dose-dependent manners","sentence":"Here we found that arsenic trioxide  a frontline agent for acute promyelocytic leukemia, inhibits \u0394Np63 but not TAp63 expression in time- and dose-dependent manners"}
{"PMID":23271742,"re_id":12,"annotated sentence":"In addition, we found that <e1>arsenic trioxide<\\e1> decreases the stability of <e2>\u0394Np63<\\e2> protein via a proteasome-dependent pathway but has little effect on the level of \u0394Np63 transcript","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"arsenic trioxide","object":"\u0394Np63","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, we found that <e1>CHEMICAL<\\e1> decreases the stability of <e2>GENE-Y<\\e2> protein via a proteasome-dependent pathway but has little effect on the level of GENE-Y transcript","sentence":"In addition, we found that arsenic trioxide decreases the stability of \u0394Np63 protein via a proteasome-dependent pathway but has little effect on the level of \u0394Np63 transcript"}
{"PMID":23274058,"re_id":5,"annotated sentence":"Additional mechanistic studies revealed that <e1>jaceosidin<\\e1> treatment resulted in an increase in phosphorylation of <e2>Cdc25C<\\e2> and ATM-Chk1\/2","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"jaceosidin","object":"Cdc25C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additional mechanistic studies revealed that <e1>CHEMICAL<\\e1> treatment resulted in an increase in phosphorylation of <e2>GENE-Y<\\e2> and ATM-Chk1\/2","sentence":"Additional mechanistic studies revealed that jaceosidin treatment resulted in an increase in phosphorylation of Cdc25C and ATM-Chk1\/2"}
{"PMID":23274058,"re_id":6,"annotated sentence":"Additional mechanistic studies revealed that <e1>jaceosidin<\\e1> treatment resulted in an increase in phosphorylation of Cdc25C and <e2>ATM<\\e2> Chk1\/2","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"jaceosidin","object":"ATM","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additional mechanistic studies revealed that <e1>CHEMICAL<\\e1> treatment resulted in an increase in phosphorylation of Cdc25C and <e2>GENE-Y<\\e2> Chk1\/2","sentence":"Additional mechanistic studies revealed that jaceosidin treatment resulted in an increase in phosphorylation of Cdc25C and ATM Chk1\/2"}
{"PMID":23274058,"re_id":7,"annotated sentence":"<e1>Jaceosidin<\\e1>  isolated from dietary mugwort (Artemisia princeps), induces G2\/M cell cycle arrest by inactivating cdc25C-cdc2 via <e2>ATM<\\e2> Chk1\/2 activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Jaceosidin","object":"ATM","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  isolated from dietary mugwort (Artemisia princeps), induces G2\/M cell cycle arrest by inactivating cdc25C-cdc2 via <e2>GENE-Y<\\e2> Chk1\/2 activation","sentence":"Jaceosidin  isolated from dietary mugwort (Artemisia princeps), induces G2\/M cell cycle arrest by inactivating cdc25C-cdc2 via ATM Chk1\/2 activation"}
{"PMID":23274058,"re_id":8,"annotated sentence":"<e1>Jaceosidin<\\e1>  isolated from dietary mugwort (Artemisia princeps), induces G2\/M cell cycle arrest by inactivating <e2>cdc25C<\\e2> cdc2 via ATM-Chk1\/2 activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Jaceosidin","object":"cdc25C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  isolated from dietary mugwort (Artemisia princeps), induces G2\/M cell cycle arrest by inactivating <e2>GENE-Y<\\e2> cdc2 via ATM-Chk1\/2 activation","sentence":"Jaceosidin  isolated from dietary mugwort (Artemisia princeps), induces G2\/M cell cycle arrest by inactivating cdc25C cdc2 via ATM-Chk1\/2 activation"}
{"PMID":23274058,"re_id":9,"annotated sentence":"<e1>Jaceosidin<\\e1>  isolated from dietary mugwort (Artemisia princeps), induces G2\/M cell cycle arrest by inactivating cdc25C-<e2>cdc2<\\e2> via ATM-Chk1\/2 activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Jaceosidin","object":"cdc2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  isolated from dietary mugwort (Artemisia princeps), induces G2\/M cell cycle arrest by inactivating GENE-Y5C-<e2>GENE-Y<\\e2> via ATM-Chk1\/2 activation","sentence":"Jaceosidin  isolated from dietary mugwort (Artemisia princeps), induces G2\/M cell cycle arrest by inactivating cdc25C-cdc2 via ATM-Chk1\/2 activation"}
{"PMID":23274058,"re_id":10,"annotated sentence":"Moreover, jaceosidin treatment resulted in phosphorylation of ERK, and pretreatment with the <e2>ERK<\\e2> inhibitor, <e1>PD98059<\\e1>  attenuated cell growth inhibition by jaceosidin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PD98059","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, jaceosidin treatment resulted in phosphorylation of GENE-N, and pretreatment with the <e2>GENE-N<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  attenuated cell growth inhibition by jaceosidin","sentence":"Moreover, jaceosidin treatment resulted in phosphorylation of ERK, and pretreatment with the ERK inhibitor, PD98059  attenuated cell growth inhibition by jaceosidin"}
{"PMID":23274058,"re_id":11,"annotated sentence":"These data suggest that <e1>jaceosidin<\\e1>  isolated from Japanese mugwort, modulates the ERK\/ATM\/Chk1\/2 pathway, leading to inactivation of the <e2>Cdc2<\\e2> cyclin B1 complex, followed by G2\/M cell cycle arrest in endometrial cancer cells.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"jaceosidin","object":"Cdc2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data suggest that <e1>CHEMICAL<\\e1>  isolated from Japanese mugwort, modulates the ERK\/ATM\/Chk1\/2 pathway, leading to inactivation of the <e2>GENE-Y<\\e2> cyclin B1 complex, followed by G2\/M cell cycle arrest in endometrial cancer cells.","sentence":"These data suggest that jaceosidin  isolated from Japanese mugwort, modulates the ERK\/ATM\/Chk1\/2 pathway, leading to inactivation of the Cdc2 cyclin B1 complex, followed by G2\/M cell cycle arrest in endometrial cancer cells."}
{"PMID":23274058,"re_id":12,"annotated sentence":"These data suggest that <e1>jaceosidin<\\e1>  isolated from Japanese mugwort, modulates the ERK\/ATM\/Chk1\/2 pathway, leading to inactivation of the Cdc2-<e2>cyclin B1<\\e2> complex, followed by G2\/M cell cycle arrest in endometrial cancer cells.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"jaceosidin","object":"cyclin B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data suggest that <e1>CHEMICAL<\\e1>  isolated from Japanese mugwort, modulates the ERK\/ATM\/Chk1\/2 pathway, leading to inactivation of the Cdc2-<e2>GENE-Y<\\e2> complex, followed by G2\/M cell cycle arrest in endometrial cancer cells.","sentence":"These data suggest that jaceosidin  isolated from Japanese mugwort, modulates the ERK\/ATM\/Chk1\/2 pathway, leading to inactivation of the Cdc2-cyclin B1 complex, followed by G2\/M cell cycle arrest in endometrial cancer cells."}
{"PMID":23274898,"re_id":6,"annotated sentence":"Exogenous <e1>ATP<\\e1> transiently activated <e2>Akt<\\e2> and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ATP","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Exogenous <e1>CHEMICAL<\\e1> transiently activated <e2>GENE-N<\\e2> and, inhibiting phosphatidylinositol 3-kinase (PI3K) or GENE-N as well as dominant-negative GENE-N mutant, reduced CHEMICAL-dependent 2-NBDG uptake and GENE-N phosphorylation","sentence":"Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation"}
{"PMID":23274898,"re_id":7,"annotated sentence":"Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by <e2>adenosine-phosphate phosphatase<\\e2> and by purinergic receptor blockade (<e1>suramin<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"suramin","object":"adenosine-phosphate phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by <e2>GENE-N<\\e2> and by purinergic receptor blockade (<e1>CHEMICAL<\\e1> ","sentence":"Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin "}
{"PMID":23274898,"re_id":8,"annotated sentence":"Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by <e2>purinergic receptor<\\e2> blockade (<e1>suramin<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"suramin","object":"purinergic receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by <e2>GENE-N<\\e2> blockade (<e1>CHEMICAL<\\e1> ","sentence":"Electrical stimulation, ATP, and insulin each increased fluorescent 2-NBD-Glucose (2-NBDG) uptake in primary myotubes, but only electrical stimulation and ATP-dependent 2-NBDG uptake were inhibited by adenosine-phosphate phosphatase and by purinergic receptor blockade (suramin "}
{"PMID":23274898,"re_id":9,"annotated sentence":"Electrical stimulation transiently elevated extracellular ATP and caused <e2>Akt<\\e2> phosphorylation that was additive to insulin and inhibited by <e1>suramin<\\e1>  Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"suramin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Electrical stimulation transiently elevated extracellular ATP and caused <e2>GENE-N<\\e2> phosphorylation that was additive to insulin and inhibited by <e1>CHEMICAL<\\e1>  Exogenous ATP transiently activated GENE-N and, inhibiting phosphatidylinositol 3-kinase (PI3K) or GENE-N as well as dominant-negative GENE-N mutant, reduced ATP-dependent 2-NBDG uptake and GENE-N phosphorylation","sentence":"Electrical stimulation transiently elevated extracellular ATP and caused Akt phosphorylation that was additive to insulin and inhibited by suramin  Exogenous ATP transiently activated Akt and, inhibiting phosphatidylinositol 3-kinase (PI3K) or Akt as well as dominant-negative Akt mutant, reduced ATP-dependent 2-NBDG uptake and Akt phosphorylation"}
{"PMID":23274898,"re_id":10,"annotated sentence":"ATP-dependent 2-NBDG uptake was also inhibited by the G protein \u03b2\u03b3 subunit-interacting peptide \u03b2ark-ct and by the <e2>phosphatidylinositol 3-kinase-\u03b3<\\e2> (PI3K\u03b3) inhibitor <e1>AS605240<\\e1>  ATP caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160\/Rab8A reduced by dominant-negative Akt or PI3K\u03b3 kinase-dead mutants, and potentiated by myristoylated PI3K\u03b3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AS605240","object":"phosphatidylinositol 3-kinase-\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"ATP-dependent 2-NBDG uptake was also inhibited by the G protein \u03b2\u03b3 subunit-interacting peptide \u03b2ark-ct and by the <e2>GENE-Y<\\e2> (PI3K\u03b3) inhibitor <e1>CHEMICAL<\\e1>  ATP caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160\/Rab8A reduced by dominant-negative Akt or PI3K\u03b3 kinase-dead mutants, and potentiated by myristoylated PI3K\u03b3","sentence":"ATP-dependent 2-NBDG uptake was also inhibited by the G protein \u03b2\u03b3 subunit-interacting peptide \u03b2ark-ct and by the phosphatidylinositol 3-kinase-\u03b3 (PI3K\u03b3) inhibitor AS605240  ATP caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160\/Rab8A reduced by dominant-negative Akt or PI3K\u03b3 kinase-dead mutants, and potentiated by myristoylated PI3K\u03b3"}
{"PMID":23274898,"re_id":11,"annotated sentence":"ATP-dependent 2-NBDG uptake was also inhibited by the G protein \u03b2\u03b3 subunit-interacting peptide \u03b2ark-ct and by the phosphatidylinositol 3-kinase-\u03b3 (<e2>PI3K\u03b3<\\e2>  inhibitor <e1>AS605240<\\e1>  ATP caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160\/Rab8A reduced by dominant-negative Akt or PI3K\u03b3 kinase-dead mutants, and potentiated by myristoylated PI3K\u03b3","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AS605240","object":"PI3K\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"ATP-dependent 2-NBDG uptake was also inhibited by the G protein \u03b2\u03b3 subunit-interacting peptide \u03b2ark-ct and by the phosphatidylinositol 3-kinase-\u03b3 (<e2>GENE-Y<\\e2>  inhibitor <e1>CHEMICAL<\\e1>  ATP caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160\/Rab8A reduced by dominant-negative Akt or GENE-Y kinase-dead mutants, and potentiated by myristoylated GENE-Y","sentence":"ATP-dependent 2-NBDG uptake was also inhibited by the G protein \u03b2\u03b3 subunit-interacting peptide \u03b2ark-ct and by the phosphatidylinositol 3-kinase-\u03b3 (PI3K\u03b3  inhibitor AS605240  ATP caused translocation of GLUT4myc-eGFP to the cell surface, mechanistically mediated by increased exocytosis involving AS160\/Rab8A reduced by dominant-negative Akt or PI3K\u03b3 kinase-dead mutants, and potentiated by myristoylated PI3K\u03b3"}
{"PMID":23274898,"re_id":12,"annotated sentence":"Electrical Stimuli Release ATP to Increase <e2>GLUT4<\\e2> Translocation and <e1>Glucose<\\e1> Uptake via PI3K\u03b3-Akt-AS160 in Skeletal Muscle Cells","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Glucose","object":"GLUT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Electrical Stimuli Release ATP to Increase <e2>GENE-Y<\\e2> Translocation and <e1>CHEMICAL<\\e1> Uptake via PI3K\u03b3-Akt-AS160 in Skeletal Muscle Cells","sentence":"Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3K\u03b3-Akt-AS160 in Skeletal Muscle Cells"}
{"PMID":23279865,"re_id":1,"annotated sentence":"A series of <e1>anthra[1,2-d]imidazole-6,11-dione<\\e1> derivatives were synthesized and evaluated for <e2>telomerase<\\e2> inhibition, hTERT expression and suppression of cancer cell growth in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"anthra[1,2-d]imidazole-6,11-dione","object":"telomerase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> derivatives were synthesized and evaluated for <e2>GENE-Y<\\e2> inhibition, hTERT expression and suppression of cancer cell growth in vitro","sentence":"A series of anthra[1,2-d]imidazole-6,11-dione derivatives were synthesized and evaluated for telomerase inhibition, hTERT expression and suppression of cancer cell growth in vitro"}
{"PMID":23279865,"re_id":2,"annotated sentence":"Structure-based design, synthesis and evaluation of novel <e1>anthra[1,2-d]imidazole-6,11-dione<\\e1> derivatives as <e2>telomerase<\\e2> inhibitors and potential for cancer polypharmacology","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"anthra[1,2-d]imidazole-6,11-dione","object":"telomerase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Structure-based design, synthesis and evaluation of novel <e1>CHEMICAL<\\e1> derivatives as <e2>GENE-Y<\\e2> inhibitors and potential for cancer polypharmacology","sentence":"Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology"}
{"PMID":23284002,"re_id":4,"annotated sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the <e2>NF-E2-related factor 2<\\e2> antioxidant response element (Nrf2-ARE) activator <e1>sulforaphane<\\e1>  or small interfering RNA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"sulforaphane","object":"NF-E2-related factor 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the <e2>GENE-Y<\\e2> antioxidant response element (Nrf2-ARE) activator <e1>CHEMICAL<\\e1>  or small interfering RNA","sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2 antioxidant response element (Nrf2-ARE) activator sulforaphane  or small interfering RNA"}
{"PMID":23284002,"re_id":5,"annotated sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-<e2>antioxidant response element<\\e2> (Nrf2-ARE) activator <e1>sulforaphane<\\e1>  or small interfering RNA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"sulforaphane","object":"antioxidant response element","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-<e2>GENE-N<\\e2> (Nrf2-ARE) activator <e1>CHEMICAL<\\e1>  or small interfering RNA","sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane  or small interfering RNA"}
{"PMID":23284002,"re_id":6,"annotated sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (<e2>Nrf2<\\e2> ARE) activator <e1>sulforaphane<\\e1>  or small interfering RNA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"sulforaphane","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (<e2>GENE-Y<\\e2> ARE) activator <e1>CHEMICAL<\\e1>  or small interfering RNA","sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2 ARE) activator sulforaphane  or small interfering RNA"}
{"PMID":23284002,"re_id":7,"annotated sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-<e2>ARE<\\e2>  activator <e1>sulforaphane<\\e1>  or small interfering RNA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"sulforaphane","object":"ARE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-<e2>GENE-N<\\e2>  activator <e1>CHEMICAL<\\e1>  or small interfering RNA","sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE  activator sulforaphane  or small interfering RNA"}
{"PMID":23284002,"re_id":8,"annotated sentence":"In conclusion, this study provides the first evidence implicating that <e1>TSA<\\e1> inhibits TGF-\u03b2-induced ROS accumulation and myofibroblast differentiation via enhanced <e2>Nrf2<\\e2> ARE signaling.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"TSA","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, this study provides the first evidence implicating that <e1>CHEMICAL<\\e1> inhibits TGF-\u03b2-induced ROS accumulation and myofibroblast differentiation via enhanced <e2>GENE-Y<\\e2> ARE signaling.","sentence":"In conclusion, this study provides the first evidence implicating that TSA inhibits TGF-\u03b2-induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2 ARE signaling."}
{"PMID":23284002,"re_id":9,"annotated sentence":"In conclusion, this study provides the first evidence implicating that <e1>TSA<\\e1> inhibits TGF-\u03b2-induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-<e2>ARE<\\e2> signaling.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"TSA","object":"ARE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, this study provides the first evidence implicating that <e1>CHEMICAL<\\e1> inhibits TGF-\u03b2-induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-<e2>GENE-N<\\e2> signaling.","sentence":"In conclusion, this study provides the first evidence implicating that TSA inhibits TGF-\u03b2-induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-ARE signaling."}
{"PMID":23284002,"re_id":10,"annotated sentence":"<e1>Trichostatin A<\\e1> inhibits transforming growth factor-\u03b2-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced <e2>NF-E2-related factor 2<\\e2> antioxidant response element signaling","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Trichostatin A","object":"NF-E2-related factor 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits transforming growth factor-\u03b2-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced <e2>GENE-Y<\\e2> antioxidant response element signaling","sentence":"Trichostatin A inhibits transforming growth factor-\u03b2-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2 antioxidant response element signaling"}
{"PMID":23284002,"re_id":11,"annotated sentence":"<e1>Trichostatin A<\\e1> inhibits transforming growth factor-\u03b2-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-<e2>antioxidant response element<\\e2> signaling","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Trichostatin A","object":"antioxidant response element","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> inhibits transforming growth factor-\u03b2-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-<e2>GENE-N<\\e2> signaling","sentence":"Trichostatin A inhibits transforming growth factor-\u03b2-induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling"}
{"PMID":23284002,"re_id":12,"annotated sentence":"In addition, <e1>TSA<\\e1> induced Nrf2 nuclear translocation and up-regulated the expression of <e2>Nrf2<\\e2> ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"TSA","object":"Nrf2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induced GENE-Y nuclear translocation and up-regulated the expression of <e2>GENE-Y<\\e2> ARE downstream antioxidant genes, whereas GENE-Y knockdown by RNA interference blocked the inhibition of CHEMICAL on myofibroblast differentiation","sentence":"In addition, TSA induced Nrf2 nuclear translocation and up-regulated the expression of Nrf2 ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation"}
{"PMID":23284002,"re_id":13,"annotated sentence":"In addition, <e1>TSA<\\e1> induced Nrf2 nuclear translocation and up-regulated the expression of Nrf2-<e2>ARE<\\e2> downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"TSA","object":"ARE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, <e1>CHEMICAL<\\e1> induced Nrf2 nuclear translocation and up-regulated the expression of Nrf2-<e2>GENE-N<\\e2> downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of CHEMICAL on myofibroblast differentiation","sentence":"In addition, TSA induced Nrf2 nuclear translocation and up-regulated the expression of Nrf2-ARE downstream antioxidant genes, whereas Nrf2 knockdown by RNA interference blocked the inhibition of TSA on myofibroblast differentiation"}
{"PMID":23284002,"re_id":14,"annotated sentence":"In conclusion, this study provides the first evidence implicating that <e1>TSA<\\e1> inhibits <e2>TGF-\u03b2<\\e2> induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-ARE signaling.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TSA","object":"TGF-\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, this study provides the first evidence implicating that <e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-ARE signaling.","sentence":"In conclusion, this study provides the first evidence implicating that TSA inhibits TGF-\u03b2 induced ROS accumulation and myofibroblast differentiation via enhanced Nrf2-ARE signaling."}
{"PMID":23284002,"re_id":15,"annotated sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the <e2>NAD(P)H oxidase<\\e2> inhibitor <e1>diphenyleneiodonium<\\e1> (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diphenyleneiodonium","object":"NAD(P)H oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1> (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA","sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI), the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA"}
{"PMID":23284002,"re_id":16,"annotated sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the <e2>NAD(P)H oxidase<\\e2> inhibitor diphenyleneiodonium (<e1>DPI<\\e1> , the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DPI","object":"NAD(P)H oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the <e2>GENE-N<\\e2> inhibitor diphenyleneiodonium (<e1>CHEMICAL<\\e1> , the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA","sentence":"Human immortalized corneal fibroblasts were treated with TGF-\u03b2 in the presence of TSA, the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI , the antioxidant N-acetyl-cysteine (NAC), the NF-E2-related factor 2-antioxidant response element (Nrf2-ARE) activator sulforaphane, or small interfering RNA"}
{"PMID":23284002,"re_id":17,"annotated sentence":"Treatment with <e1>TSA<\\e1> and the Nrf2-ARE activator resulted in increased inhibition of the <e2>TGF-\u03b2<\\e2> induced myofibroblast differentiation as compared with treatment with DPI or NAC","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TSA","object":"TGF-\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> and the Nrf2-ARE activator resulted in increased inhibition of the <e2>GENE-Y<\\e2> induced myofibroblast differentiation as compared with treatment with DPI or NAC","sentence":"Treatment with TSA and the Nrf2-ARE activator resulted in increased inhibition of the TGF-\u03b2 induced myofibroblast differentiation as compared with treatment with DPI or NAC"}
{"PMID":23284002,"re_id":18,"annotated sentence":"<e1>Trichostatin A<\\e1> inhibits <e2>transforming growth factor-\u03b2<\\e2> induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Trichostatin A","object":"transforming growth factor-\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling","sentence":"Trichostatin A inhibits transforming growth factor-\u03b2 induced reactive oxygen species accumulation and myofibroblast differentiation via enhanced NF-E2-related factor 2-antioxidant response element signaling"}
{"PMID":23284002,"re_id":19,"annotated sentence":"Furthermore, <e1>TSA<\\e1> also decreased cellular ROS and H(2)O(2) accumulation induced by <e2>TGF-\u03b2<\\e2>  whereas it elevated intracellular GSH level and cellular total antioxidant capacity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TSA","object":"TGF-\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> also decreased cellular ROS and H(2)O(2) accumulation induced by <e2>GENE-Y<\\e2>  whereas it elevated intracellular GSH level and cellular total antioxidant capacity","sentence":"Furthermore, TSA also decreased cellular ROS and H(2)O(2) accumulation induced by TGF-\u03b2  whereas it elevated intracellular GSH level and cellular total antioxidant capacity"}
{"PMID":23287700,"re_id":3,"annotated sentence":"Results indicate that <e1>AM4054<\\e1> serves as an effective <e2>CB(1)<\\e2> discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"AM4054","object":"CB(1)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results indicate that <e1>CHEMICAL<\\e1> serves as an effective <e2>GENE-N<\\e2> discriminative stimulus, with an onset and time course of action comparable with that of the GENE-N agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the CHEMICAL dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of CHEMICAL","sentence":"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054"}
{"PMID":23287700,"re_id":4,"annotated sentence":"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel <e2>CB(1)<\\e2> full agonist <e1>AM4054<\\e1>  Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-ACTIVATOR","subject":"AM4054","object":"CB(1)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present studies, the GENE-N inverse agonist SR141716A (rimonabant) and the GENE-N neutral antagonist AM4113 were compared for their ability to modify GENE-N receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel <e2>GENE-N<\\e2> full agonist <e1>CHEMICAL<\\e1>  Results indicate that CHEMICAL serves as an effective GENE-N discriminative stimulus, with an onset and time course of action comparable with that of the GENE-N agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the CHEMICAL dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of CHEMICAL","sentence":"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054  Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054"}
{"PMID":23287700,"re_id":5,"annotated sentence":"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the <e2>CB(1)<\\e2> agonist <e1>\u0394(9)-tetrahydrocannabinol<\\e1>  and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"\u0394(9)-tetrahydrocannabinol","object":"CB(1)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results indicate that AM4054 serves as an effective GENE-N discriminative stimulus, with an onset and time course of action comparable with that of the <e2>GENE-N<\\e2> agonist <e1>CHEMICAL<\\e1>  and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054","sentence":"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist \u0394(9)-tetrahydrocannabinol  and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054"}
{"PMID":23287700,"re_id":6,"annotated sentence":"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the <e2>CB(1)<\\e2> agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the <e1>AM4054<\\e1> dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"AM4054","object":"CB(1)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results indicate that CHEMICAL serves as an effective GENE-N discriminative stimulus, with an onset and time course of action comparable with that of the <e2>GENE-N<\\e2> agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the <e1>CHEMICAL<\\e1> dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of CHEMICAL","sentence":"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054"}
{"PMID":23287700,"re_id":7,"annotated sentence":"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the <e2>CB(1)<\\e2> agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of <e1>AM4054<\\e1>  Schild analyses further show that rimonabant and AM4113 produce highly similar antagonist effects, as evident in comparable pA(2) values (6.9)","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"AM4054","object":"CB(1)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results indicate that CHEMICAL serves as an effective GENE-N discriminative stimulus, with an onset and time course of action comparable with that of the <e2>GENE-N<\\e2> agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the CHEMICAL dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of <e1>CHEMICAL<\\e1>  Schild analyses further show that rimonabant and AM4113 produce highly similar antagonist effects, as evident in comparable pA(2) values (6.9)","sentence":"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054  Schild analyses further show that rimonabant and AM4113 produce highly similar antagonist effects, as evident in comparable pA(2) values (6.9)"}
{"PMID":23287700,"re_id":8,"annotated sentence":"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the <e2>CB(1)<\\e2> agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist <e1>rimonabant<\\e1> and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-INHIBITOR","subject":"rimonabant","object":"CB(1)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results indicate that AM4054 serves as an effective GENE-N discriminative stimulus, with an onset and time course of action comparable with that of the <e2>GENE-N<\\e2> agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist <e1>CHEMICAL<\\e1> and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054","sentence":"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054"}
{"PMID":23287700,"re_id":9,"annotated sentence":"In the present studies, the <e2>CB(1)<\\e2> inverse agonist <e1>SR141716A<\\e1> (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-INHIBITOR","subject":"SR141716A","object":"CB(1)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present studies, the <e2>GENE-N<\\e2> inverse agonist <e1>CHEMICAL<\\e1> (rimonabant) and the GENE-N neutral antagonist AM4113 were compared for their ability to modify GENE-N receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel GENE-N full agonist AM4054","sentence":"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054"}
{"PMID":23287700,"re_id":10,"annotated sentence":"In the present studies, the <e2>CB(1)<\\e2> inverse agonist SR141716A (<e1>rimonabant<\\e1>  and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-INHIBITOR","subject":"rimonabant","object":"CB(1)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present studies, the <e2>GENE-N<\\e2> inverse agonist SR141716A (<e1>CHEMICAL<\\e1>  and the GENE-N neutral antagonist AM4113 were compared for their ability to modify GENE-N receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel GENE-N full agonist AM4054","sentence":"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant  and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054"}
{"PMID":23287700,"re_id":11,"annotated sentence":"<e2>Cannabinoid receptor 1<\\e2> (CB(1)) inverse agonists (e.g., <e1>rimonabant<\\e1>  have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-INHIBITOR","subject":"rimonabant","object":"Cannabinoid receptor 1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> (CB(1)) inverse agonists (e.g., <e1>CHEMICAL<\\e1>  have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications","sentence":"Cannabinoid receptor 1 (CB(1)) inverse agonists (e.g., rimonabant  have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications"}
{"PMID":23287700,"re_id":12,"annotated sentence":"Cannabinoid receptor 1 (<e2>CB(1)<\\e2>  inverse agonists (e.g., <e1>rimonabant<\\e1>  have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-INHIBITOR","subject":"rimonabant","object":"CB(1)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cannabinoid receptor 1 (<e2>GENE-N<\\e2>  inverse agonists (e.g., <e1>CHEMICAL<\\e1>  have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications","sentence":"Cannabinoid receptor 1 (CB(1)  inverse agonists (e.g., rimonabant  have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications"}
{"PMID":23287700,"re_id":13,"annotated sentence":"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the <e2>CB(1)<\\e2> neutral antagonist <e1>AM4113<\\e1> were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"AM4113","object":"CB(1)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the present studies, the GENE-N inverse agonist SR141716A (rimonabant) and the <e2>GENE-N<\\e2> neutral antagonist <e1>CHEMICAL<\\e1> were compared for their ability to modify GENE-N receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel GENE-N full agonist AM4054","sentence":"In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054"}
{"PMID":23287700,"re_id":14,"annotated sentence":"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the <e2>CB(1)<\\e2> agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist <e1>AM4113<\\e1> produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"AM4113","object":"CB(1)","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results indicate that AM4054 serves as an effective GENE-N discriminative stimulus, with an onset and time course of action comparable with that of the <e2>GENE-N<\\e2> agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist <e1>CHEMICAL<\\e1> produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054","sentence":"Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist \u0394(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054"}
{"PMID":23292752,"re_id":0,"annotated sentence":"<e1>Dabigatran<\\e1> has an advantage over the indirect <e2>thrombin<\\e2> inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Dabigatran","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has an advantage over the indirect <e2>GENE-Y<\\e2> inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound GENE-Y","sentence":"Dabigatran has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin"}
{"PMID":23292752,"re_id":1,"annotated sentence":"<e1>Dabigatran<\\e1> has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and <e2>fibrin<\\e2> bound thrombin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Dabigatran","object":"fibrin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and <e2>GENE-N<\\e2> bound thrombin","sentence":"Dabigatran has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin bound thrombin"}
{"PMID":23292752,"re_id":2,"annotated sentence":"<e1>Dabigatran<\\e1> has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound <e2>thrombin<\\e2>  The reversible binding of dabigatran may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent thrombin inhibitors, e.g","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Dabigatran","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> has an advantage over the indirect GENE-Y inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound <e2>GENE-Y<\\e2>  The reversible binding of dabigatran may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent GENE-Y inhibitors, e.g","sentence":"Dabigatran has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin  The reversible binding of dabigatran may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent thrombin inhibitors, e.g"}
{"PMID":23292752,"re_id":3,"annotated sentence":"The reversible binding of <e1>dabigatran<\\e1> may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent <e2>thrombin<\\e2> inhibitors, e.g","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dabigatran","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The reversible binding of <e1>CHEMICAL<\\e1> may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent <e2>GENE-Y<\\e2> inhibitors, e.g","sentence":"The reversible binding of dabigatran may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent thrombin inhibitors, e.g"}
{"PMID":23292752,"re_id":4,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivaroxaban","object":"FXa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23292752,"re_id":5,"annotated sentence":"<e1>rivaroxaban<\\e1> and apixaban, are potent, oral direct inhibitors of <e2>prothrombinase<\\e2> bound, clot-associated or free FXa","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivaroxaban","object":"prothrombinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and apixaban, are potent, oral direct inhibitors of <e2>GENE-N<\\e2> bound, clot-associated or free FXa","sentence":"rivaroxaban and apixaban, are potent, oral direct inhibitors of prothrombinase bound, clot-associated or free FXa"}
{"PMID":23292752,"re_id":6,"annotated sentence":"<e1>rivaroxaban<\\e1> and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free <e2>FXa<\\e2>  Both agents have a rapid onset of action, a wide therapeutic window, little or no interaction with food and other drugs, minimal inter-patient variability, and display similar pharmacokinetics in different patient populations","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivaroxaban","object":"FXa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free <e2>GENE-Y<\\e2>  Both agents have a rapid onset of action, a wide therapeutic window, little or no interaction with food and other drugs, minimal inter-patient variability, and display similar pharmacokinetics in different patient populations","sentence":"rivaroxaban and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free FXa  Both agents have a rapid onset of action, a wide therapeutic window, little or no interaction with food and other drugs, minimal inter-patient variability, and display similar pharmacokinetics in different patient populations"}
{"PMID":23292752,"re_id":7,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"apixaban","object":"FXa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23292752,"re_id":8,"annotated sentence":"rivaroxaban and <e1>apixaban<\\e1>  are potent, oral direct inhibitors of <e2>prothrombinase<\\e2> bound, clot-associated or free FXa","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"apixaban","object":"prothrombinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"rivaroxaban and <e1>CHEMICAL<\\e1>  are potent, oral direct inhibitors of <e2>GENE-N<\\e2> bound, clot-associated or free FXa","sentence":"rivaroxaban and apixaban  are potent, oral direct inhibitors of prothrombinase bound, clot-associated or free FXa"}
{"PMID":23292752,"re_id":9,"annotated sentence":"rivaroxaban and <e1>apixaban<\\e1>  are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free <e2>FXa<\\e2>  Both agents have a rapid onset of action, a wide therapeutic window, little or no interaction with food and other drugs, minimal inter-patient variability, and display similar pharmacokinetics in different patient populations","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"apixaban","object":"FXa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"rivaroxaban and <e1>CHEMICAL<\\e1>  are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free <e2>GENE-Y<\\e2>  Both agents have a rapid onset of action, a wide therapeutic window, little or no interaction with food and other drugs, minimal inter-patient variability, and display similar pharmacokinetics in different patient populations","sentence":"rivaroxaban and apixaban  are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free FXa  Both agents have a rapid onset of action, a wide therapeutic window, little or no interaction with food and other drugs, minimal inter-patient variability, and display similar pharmacokinetics in different patient populations"}
{"PMID":23292752,"re_id":10,"annotated sentence":"Although parenteral oral direct <e2>thrombin<\\e2> inhibitors (DTIs), such as <e1>argatroban<\\e1> and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"argatroban","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although parenteral oral direct <e2>GENE-Y<\\e2> inhibitors (DTIs), such as <e1>CHEMICAL<\\e1> and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic GENE-Y antagonists","sentence":"Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists"}
{"PMID":23292752,"re_id":11,"annotated sentence":"Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as <e1>dabigatran<\\e1> are novel synthetic <e2>thrombin<\\e2> antagonists","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"dabigatran","object":"thrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although parenteral oral direct GENE-Y inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as <e1>CHEMICAL<\\e1> are novel synthetic <e2>GENE-Y<\\e2> antagonists","sentence":"Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists"}
{"PMID":23295229,"re_id":8,"annotated sentence":"This shift in conformational population at higher <e1>Mg(2+)<\\e1> ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the <e2>ALDH1<\\e2> pocket","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Mg(2+)","object":"ALDH1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This shift in conformational population at higher <e1>CHEMICAL<\\e1> ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the <e2>GENE-Y<\\e2> pocket","sentence":"This shift in conformational population at higher Mg(2+) ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the ALDH1 pocket"}
{"PMID":23295229,"re_id":9,"annotated sentence":"As the <e1>Mg(2+)<\\e1> ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 \u03bcM Mg(2+)) to 0.050 s(-1) (6000 \u03bcM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the <e2>ALDH1<\\e2> NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 \u03bcM Mg(2+)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Mg(2+)","object":"ALDH1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"As the <e1>CHEMICAL<\\e1> ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 \u03bcM CHEMICAL) to 0.050 s(-1) (6000 \u03bcM CHEMICAL) and a distinct shift in steady-state conformational population from one that favors the <e2>GENE-Y<\\e2> NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the GENE-Y-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 \u03bcM CHEMICAL","sentence":"As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 \u03bcM Mg(2+)) to 0.050 s(-1) (6000 \u03bcM Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1 NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 \u03bcM Mg(2+)"}
{"PMID":23295229,"re_id":10,"annotated sentence":"Physiologic levels of <e1>Mg(2+)<\\e1> ions decrease <e2>ALDH1<\\e2> activity in part by increasing NADH binding affinity to the enzyme","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Mg(2+)","object":"ALDH1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Physiologic levels of <e1>CHEMICAL<\\e1> ions decrease <e2>GENE-Y<\\e2> activity in part by increasing NADH binding affinity to the enzyme","sentence":"Physiologic levels of Mg(2+) ions decrease ALDH1 activity in part by increasing NADH binding affinity to the enzyme"}
{"PMID":23295229,"re_id":11,"annotated sentence":"<e2>Aldehyde dehydrogenase 1<\\e2> (ALDH1A1) catalyzes the oxidation of toxic aldehydes to <e1>carboxylic acids<\\e1>  Physiologic levels of Mg(2+) ions decrease ALDH1 activity in part by increasing NADH binding affinity to the enzyme","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"carboxylic acids","object":"Aldehyde dehydrogenase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (ALDH1A1) catalyzes the oxidation of toxic aldehydes to <e1>CHEMICAL<\\e1>  Physiologic levels of Mg(2+) ions decrease ALDH1 activity in part by increasing NADH binding affinity to the enzyme","sentence":"Aldehyde dehydrogenase 1 (ALDH1A1) catalyzes the oxidation of toxic aldehydes to carboxylic acids  Physiologic levels of Mg(2+) ions decrease ALDH1 activity in part by increasing NADH binding affinity to the enzyme"}
{"PMID":23295229,"re_id":12,"annotated sentence":"Aldehyde dehydrogenase 1 (<e2>ALDH1A1<\\e2>  catalyzes the oxidation of toxic aldehydes to <e1>carboxylic acids<\\e1>  Physiologic levels of Mg(2+) ions decrease ALDH1 activity in part by increasing NADH binding affinity to the enzyme","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"carboxylic acids","object":"ALDH1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Aldehyde dehydrogenase 1 (<e2>GENE-Y<\\e2>  catalyzes the oxidation of toxic aldehydes to <e1>CHEMICAL<\\e1>  Physiologic levels of Mg(2+) ions decrease ALDH1 activity in part by increasing NADH binding affinity to the enzyme","sentence":"Aldehyde dehydrogenase 1 (ALDH1A1  catalyzes the oxidation of toxic aldehydes to carboxylic acids  Physiologic levels of Mg(2+) ions decrease ALDH1 activity in part by increasing NADH binding affinity to the enzyme"}
{"PMID":23295229,"re_id":13,"annotated sentence":"<e2>Aldehyde dehydrogenase 1<\\e2> (ALDH1A1) catalyzes the oxidation of toxic <e1>aldehydes<\\e1> to carboxylic acids","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"aldehydes","object":"Aldehyde dehydrogenase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (ALDH1A1) catalyzes the oxidation of toxic <e1>CHEMICAL<\\e1> to carboxylic acids","sentence":"Aldehyde dehydrogenase 1 (ALDH1A1) catalyzes the oxidation of toxic aldehydes to carboxylic acids"}
{"PMID":23295229,"re_id":14,"annotated sentence":"Aldehyde dehydrogenase 1 (<e2>ALDH1A1<\\e2>  catalyzes the oxidation of toxic <e1>aldehydes<\\e1> to carboxylic acids","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"aldehydes","object":"ALDH1A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Aldehyde dehydrogenase 1 (<e2>GENE-Y<\\e2>  catalyzes the oxidation of toxic <e1>CHEMICAL<\\e1> to carboxylic acids","sentence":"Aldehyde dehydrogenase 1 (ALDH1A1  catalyzes the oxidation of toxic aldehydes to carboxylic acids"}
{"PMID":23296102,"re_id":1,"annotated sentence":"Moreover, <e1>Acrolein<\\e1> resulted in activation of astrocytes, up-regulation of <e2>BACE-1<\\e2> in cortex and down-regulation of ADAM-10 in hippocampus and cortex","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Acrolein","object":"BACE-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> resulted in activation of astrocytes, up-regulation of <e2>GENE-Y<\\e2> in cortex and down-regulation of ADAM-10 in hippocampus and cortex","sentence":"Moreover, Acrolein resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of ADAM-10 in hippocampus and cortex"}
{"PMID":23296102,"re_id":2,"annotated sentence":"Interestingly, <e1>Acrolein<\\e1> increased proteins' levels of <e2>amyloid precursor protein<\\e2> (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Acrolein","object":"amyloid precursor protein","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> increased proteins' levels of <e2>GENE-Y<\\e2> (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels","sentence":"Interestingly, Acrolein increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels"}
{"PMID":23296102,"re_id":3,"annotated sentence":"Interestingly, <e1>Acrolein<\\e1> increased proteins' levels of amyloid precursor protein (APP), <e2>\u03b2-secretase<\\e2> (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Acrolein","object":"\u03b2-secretase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> increased proteins' levels of amyloid precursor protein (APP), <e2>GENE-N<\\e2> (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels","sentence":"Interestingly, Acrolein increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels"}
{"PMID":23296102,"re_id":4,"annotated sentence":"Interestingly, <e1>Acrolein<\\e1> increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (<e2>BACE-1<\\e2>  and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Acrolein","object":"BACE-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (<e2>GENE-Y<\\e2>  and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels","sentence":"Interestingly, Acrolein increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1  and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels"}
{"PMID":23296102,"re_id":5,"annotated sentence":"Interestingly, <e1>Acrolein<\\e1> increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the <e2>amyloid \u03b2-peptide transporter<\\e2> receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Acrolein","object":"amyloid \u03b2-peptide transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the <e2>GENE-Y<\\e2> receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels","sentence":"Interestingly, Acrolein increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels"}
{"PMID":23296102,"re_id":6,"annotated sentence":"Interestingly, <e1>Acrolein<\\e1> increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter <e2>receptor for advanced glycation end products<\\e2>  and decreased A-disintegrin and metalloprotease (ADAM) 10 levels","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Acrolein","object":"receptor for advanced glycation end products","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter <e2>GENE-Y<\\e2>  and decreased A-disintegrin and metalloprotease (ADAM) 10 levels","sentence":"Interestingly, Acrolein increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products  and decreased A-disintegrin and metalloprotease (ADAM) 10 levels"}
{"PMID":23296102,"re_id":7,"annotated sentence":"Moreover, <e1>Acrolein<\\e1> resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of <e2>ADAM-10<\\e2> in hippocampus and cortex","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Acrolein","object":"ADAM-10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of <e2>GENE-Y<\\e2> in hippocampus and cortex","sentence":"Moreover, Acrolein resulted in activation of astrocytes, up-regulation of BACE-1 in cortex and down-regulation of ADAM-10 in hippocampus and cortex"}
{"PMID":23296102,"re_id":8,"annotated sentence":"Interestingly, <e1>Acrolein<\\e1> increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased <e2>A-disintegrin and metalloprotease (ADAM) 10<\\e2> levels","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Acrolein","object":"A-disintegrin and metalloprotease (ADAM) 10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased <e2>GENE-Y<\\e2> levels","sentence":"Interestingly, Acrolein increased proteins' levels of amyloid precursor protein (APP), \u03b2-secretase (BACE-1) and the amyloid \u03b2-peptide transporter receptor for advanced glycation end products, and decreased A-disintegrin and metalloprotease (ADAM) 10 levels"}
{"PMID":23296142,"re_id":0,"annotated sentence":"Regulation of sexual reproduction by <e1>estradiol<\\e1> involves the activation of <e2>estrogen receptors<\\e2> (ERs) in the hypothalamus","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"estradiol","object":"estrogen receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Regulation of sexual reproduction by <e1>CHEMICAL<\\e1> involves the activation of <e2>GENE-Y<\\e2> (ERs) in the hypothalamus","sentence":"Regulation of sexual reproduction by estradiol involves the activation of estrogen receptors (ERs) in the hypothalamus"}
{"PMID":23296142,"re_id":1,"annotated sentence":"Regulation of sexual reproduction by <e1>estradiol<\\e1> involves the activation of estrogen receptors (<e2>ERs<\\e2>  in the hypothalamus","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"estradiol","object":"ERs","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Regulation of sexual reproduction by <e1>CHEMICAL<\\e1> involves the activation of estrogen receptors (<e2>GENE-Y<\\e2>  in the hypothalamus","sentence":"Regulation of sexual reproduction by estradiol involves the activation of estrogen receptors (ERs  in the hypothalamus"}
{"PMID":23296142,"re_id":2,"annotated sentence":"Using surface biotinylation, we observed that treatment of N-38 neurons with estradiol or with a membrane impermeant <e1>estradiol<\\e1> elevated plasma membrane <e2>ER\u03b1<\\e2> protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"estradiol","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using surface biotinylation, we observed that treatment of N-38 neurons with CHEMICAL or with a membrane impermeant <e1>CHEMICAL<\\e1> elevated plasma membrane <e2>GENE-Y<\\e2> protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane","sentence":"Using surface biotinylation, we observed that treatment of N-38 neurons with estradiol or with a membrane impermeant estradiol elevated plasma membrane ER\u03b1 protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane"}
{"PMID":23296142,"re_id":3,"annotated sentence":"These results indicate that membrane <e2>ER\u03b1<\\e2> levels in N-38 neurons are dynamically autoregulated by <e1>estradiol<\\e1> ","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"estradiol","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that membrane <e2>GENE-Y<\\e2> levels in N-38 neurons are dynamically autoregulated by <e1>CHEMICAL<\\e1> ","sentence":"These results indicate that membrane ER\u03b1 levels in N-38 neurons are dynamically autoregulated by estradiol "}
{"PMID":23296142,"re_id":4,"annotated sentence":"Using surface biotinylation, we observed that treatment of N-38 neurons with <e1>estradiol<\\e1> or with a membrane impermeant estradiol elevated plasma membrane <e2>ER\u03b1<\\e2> protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"estradiol","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Using surface biotinylation, we observed that treatment of N-38 neurons with <e1>CHEMICAL<\\e1> or with a membrane impermeant CHEMICAL elevated plasma membrane <e2>GENE-Y<\\e2> protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane","sentence":"Using surface biotinylation, we observed that treatment of N-38 neurons with estradiol or with a membrane impermeant estradiol elevated plasma membrane ER\u03b1 protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane"}
{"PMID":23296142,"re_id":5,"annotated sentence":"Insertion of <e2>ER\u03b1<\\e2> was blocked by the ER antagonist <e1>ICI 182,780<\\e1> or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ICI 182,780","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Insertion of <e2>GENE-Y<\\e2> was blocked by the ER antagonist <e1>CHEMICAL<\\e1> or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)","sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)"}
{"PMID":23296142,"re_id":6,"annotated sentence":"Insertion of <e2>ER\u03b1<\\e2> was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor <e1>bisindolylmaleimide<\\e1> (BIS)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bisindolylmaleimide","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Insertion of <e2>GENE-Y<\\e2> was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor <e1>CHEMICAL<\\e1> (BIS)","sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)"}
{"PMID":23296142,"re_id":7,"annotated sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the <e2>protein kinase C<\\e2> (PKC) pathway inhibitor <e1>bisindolylmaleimide<\\e1> (BIS)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bisindolylmaleimide","object":"protein kinase C","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the <e2>GENE-N<\\e2> (PKC) pathway inhibitor <e1>CHEMICAL<\\e1> (BIS)","sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)"}
{"PMID":23296142,"re_id":8,"annotated sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (<e2>PKC<\\e2>  pathway inhibitor <e1>bisindolylmaleimide<\\e1> (BIS)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bisindolylmaleimide","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (<e2>GENE-N<\\e2>  pathway inhibitor <e1>CHEMICAL<\\e1> (BIS)","sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC  pathway inhibitor bisindolylmaleimide (BIS)"}
{"PMID":23296142,"re_id":9,"annotated sentence":"Insertion of <e2>ER\u03b1<\\e2> was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (<e1>BIS<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"BIS","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Insertion of <e2>GENE-Y<\\e2> was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (<e1>CHEMICAL<\\e1> ","sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS "}
{"PMID":23296142,"re_id":10,"annotated sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the <e2>protein kinase C<\\e2> (PKC) pathway inhibitor bisindolylmaleimide (<e1>BIS<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"BIS","object":"protein kinase C","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the <e2>GENE-N<\\e2> (PKC) pathway inhibitor bisindolylmaleimide (<e1>CHEMICAL<\\e1> ","sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS "}
{"PMID":23296142,"re_id":11,"annotated sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (<e2>PKC<\\e2>  pathway inhibitor bisindolylmaleimide (<e1>BIS<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"BIS","object":"PKC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (<e2>GENE-N<\\e2>  pathway inhibitor bisindolylmaleimide (<e1>CHEMICAL<\\e1> ","sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC  pathway inhibitor bisindolylmaleimide (BIS "}
{"PMID":23296142,"re_id":12,"annotated sentence":"Insertion of ER\u03b1 was blocked by the <e2>ER<\\e2> antagonist <e1>ICI 182,780<\\e1> or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"ICI 182,780","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Insertion of GENE-Y\u03b1 was blocked by the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)","sentence":"Insertion of ER\u03b1 was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS)"}
{"PMID":23296837,"re_id":4,"annotated sentence":"Reductions in striatal dopamine and <e2>tyrosine hydroxylase<\\e2> content were also less pronounced with <e1>EHT<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"EHT","object":"tyrosine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reductions in striatal dopamine and <e2>GENE-Y<\\e2> content were also less pronounced with <e1>CHEMICAL<\\e1> treatment","sentence":"Reductions in striatal dopamine and tyrosine hydroxylase content were also less pronounced with EHT treatment"}
{"PMID":23296837,"re_id":5,"annotated sentence":"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of <e2>phosphoprotein phosphatase 2A<\\e2> (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by <e1>EHT<\\e1>  These findings indicate that the neuroprotective effect of EHT against MPTP is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of PP2A","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"EHT","object":"phosphoprotein phosphatase 2A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of <e2>GENE-N<\\e2> (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by <e1>CHEMICAL<\\e1>  These findings indicate that the neuroprotective effect of CHEMICAL against MPTP is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of PP2A","sentence":"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT  These findings indicate that the neuroprotective effect of EHT against MPTP is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of PP2A"}
{"PMID":23296837,"re_id":6,"annotated sentence":"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (<e2>PP2A<\\e2> , the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by <e1>EHT<\\e1>  These findings indicate that the neuroprotective effect of EHT against MPTP is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of PP2A","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"EHT","object":"PP2A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (<e2>GENE-N<\\e2> , the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by <e1>CHEMICAL<\\e1>  These findings indicate that the neuroprotective effect of CHEMICAL against MPTP is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of GENE-N","sentence":"Additionally, in SH-SY5Y cells, MPP(+)-induced demethylation of phosphoprotein phosphatase 2A (PP2A , the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT  These findings indicate that the neuroprotective effect of EHT against MPTP is through several mechanisms including its anti-inflammatory and antioxidant activities as well as its ability to modulate the methylation and hence activity of PP2A"}
{"PMID":23296837,"re_id":7,"annotated sentence":"Additionally, in SH-SY5Y cells, <e1>MPP(+)<\\e1> induced demethylation of <e2>phosphoprotein phosphatase 2A<\\e2> (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"MPP(+)","object":"phosphoprotein phosphatase 2A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Additionally, in SH-SY5Y cells, <e1>CHEMICAL<\\e1> induced demethylation of <e2>GENE-N<\\e2> (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT","sentence":"Additionally, in SH-SY5Y cells, MPP(+) induced demethylation of phosphoprotein phosphatase 2A (PP2A), the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT"}
{"PMID":23296837,"re_id":8,"annotated sentence":"Additionally, in SH-SY5Y cells, <e1>MPP(+)<\\e1> induced demethylation of phosphoprotein phosphatase 2A (<e2>PP2A<\\e2> , the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"MPP(+)","object":"PP2A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Additionally, in SH-SY5Y cells, <e1>CHEMICAL<\\e1> induced demethylation of phosphoprotein phosphatase 2A (<e2>GENE-N<\\e2> , the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT","sentence":"Additionally, in SH-SY5Y cells, MPP(+) induced demethylation of phosphoprotein phosphatase 2A (PP2A , the master regulator of the cellular phosphoregulatory network, and cytotoxicity were ameliorated by EHT"}
{"PMID":23296837,"re_id":9,"annotated sentence":"The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and <e2>JNK<\\e2> activation were significantly prevented with <e1>EHT<\\e1>  In cultured primary microglia and astrocytes, EHT had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NF\u03baB activation, iNOS induction, and nitric oxide production","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"EHT","object":"JNK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and <e2>GENE-N<\\e2> activation were significantly prevented with <e1>CHEMICAL<\\e1>  In cultured primary microglia and astrocytes, CHEMICAL had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NF\u03baB activation, iNOS induction, and nitric oxide production","sentence":"The neuroinflammatory response to MPTP was markedly attenuated, and indices of oxidative stress and JNK activation were significantly prevented with EHT  In cultured primary microglia and astrocytes, EHT had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NF\u03baB activation, iNOS induction, and nitric oxide production"}
{"PMID":23296837,"re_id":10,"annotated sentence":"In cultured primary microglia and astrocytes, <e1>EHT<\\e1> had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced <e2>NF\u03baB<\\e2> activation, iNOS induction, and nitric oxide production","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"EHT","object":"NF\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In cultured primary microglia and astrocytes, <e1>CHEMICAL<\\e1> had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced <e2>GENE-N<\\e2> activation, iNOS induction, and nitric oxide production","sentence":"In cultured primary microglia and astrocytes, EHT had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NF\u03baB activation, iNOS induction, and nitric oxide production"}
{"PMID":23296837,"re_id":11,"annotated sentence":"In cultured primary microglia and astrocytes, <e1>EHT<\\e1> had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NF\u03baB activation, <e2>iNOS<\\e2> induction, and nitric oxide production","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"EHT","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In cultured primary microglia and astrocytes, <e1>CHEMICAL<\\e1> had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NF\u03baB activation, <e2>GENE-Y<\\e2> induction, and nitric oxide production","sentence":"In cultured primary microglia and astrocytes, EHT had a direct anti-inflammatory effect demonstrated by repression of lipopolysaccharide-induced NF\u03baB activation, iNOS induction, and nitric oxide production"}
{"PMID":23297346,"re_id":1,"annotated sentence":"Substantial evidence shows that <e1>H(2)S<\\e1> is involved in aging by inhibiting free-radical reactions, activating <e2>SIRT1<\\e2>  and probably interacting with the age-related gene Klotho","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"H(2)S","object":"SIRT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Substantial evidence shows that <e1>CHEMICAL<\\e1> is involved in aging by inhibiting free-radical reactions, activating <e2>GENE-Y<\\e2>  and probably interacting with the age-related gene Klotho","sentence":"Substantial evidence shows that H(2)S is involved in aging by inhibiting free-radical reactions, activating SIRT1  and probably interacting with the age-related gene Klotho"}
{"PMID":23298677,"re_id":3,"annotated sentence":"Induction of <e2>HO-1<\\e2> through p38 MAPK\/Nrf2 signaling pathway by <e1>ethanol<\\e1> extract of Inula helenium L","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ethanol","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Induction of <e2>GENE-Y<\\e2> through p38 MAPK\/Nrf2 signaling pathway by <e1>CHEMICAL<\\e1> extract of Inula helenium L","sentence":"Induction of HO-1 through p38 MAPK\/Nrf2 signaling pathway by ethanol extract of Inula helenium L"}
{"PMID":23298677,"re_id":4,"annotated sentence":"Induction of HO-1 through <e2>p38<\\e2> MAPK\/Nrf2 signaling pathway by <e1>ethanol<\\e1> extract of Inula helenium L","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ethanol","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Induction of HO-1 through <e2>GENE-N<\\e2> MAPK\/Nrf2 signaling pathway by <e1>CHEMICAL<\\e1> extract of Inula helenium L","sentence":"Induction of HO-1 through p38 MAPK\/Nrf2 signaling pathway by ethanol extract of Inula helenium L"}
{"PMID":23298677,"re_id":5,"annotated sentence":"Induction of HO-1 through p38 <e2>MAPK<\\e2> Nrf2 signaling pathway by <e1>ethanol<\\e1> extract of Inula helenium L","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ethanol","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Induction of HO-1 through p38 <e2>GENE-N<\\e2> Nrf2 signaling pathway by <e1>CHEMICAL<\\e1> extract of Inula helenium L","sentence":"Induction of HO-1 through p38 MAPK Nrf2 signaling pathway by ethanol extract of Inula helenium L"}
{"PMID":23298677,"re_id":6,"annotated sentence":"The induction of <e2>HO-1<\\e2> by EIH was inhibited by <e1>SB203580<\\e1> but not by SP600125, PD98059, nor LY294002","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SB203580","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The induction of <e2>GENE-Y<\\e2> by EIH was inhibited by <e1>CHEMICAL<\\e1> but not by SP600125, PD98059, nor LY294002","sentence":"The induction of HO-1 by EIH was inhibited by SB203580 but not by SP600125, PD98059, nor LY294002"}
{"PMID":23312283,"re_id":2,"annotated sentence":"FMO3 expression is induced by dietary bile acids by a mechanism that involves the <e2>farnesoid X receptor<\\e2> (FXR), a <e1>bile acid<\\e1> activated nuclear receptor","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"bile acid","object":"farnesoid X receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"FMO3 expression is induced by dietary CHEMICALs by a mechanism that involves the <e2>GENE-Y<\\e2> (FXR), a <e1>CHEMICAL<\\e1> activated nuclear receptor","sentence":"FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR), a bile acid activated nuclear receptor"}
{"PMID":23312283,"re_id":3,"annotated sentence":"FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (<e2>FXR<\\e2> , a <e1>bile acid<\\e1> activated nuclear receptor","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"bile acid","object":"FXR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"FMO3 expression is induced by dietary CHEMICALs by a mechanism that involves the farnesoid X receptor (<e2>GENE-Y<\\e2> , a <e1>CHEMICAL<\\e1> activated nuclear receptor","sentence":"FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR , a bile acid activated nuclear receptor"}
{"PMID":23312283,"re_id":4,"annotated sentence":"<e2>FMO3<\\e2> expression is induced by dietary <e1>bile acids<\\e1> by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"bile acids","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> expression is induced by dietary <e1>CHEMICAL<\\e1> by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor","sentence":"FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor"}
{"PMID":23312283,"re_id":5,"annotated sentence":"In mice, this reduction in <e2>FMO3<\\e2> expression is due primarily to downregulation by <e1>androgens<\\e1>  FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"androgens","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In mice, this reduction in <e2>GENE-Y<\\e2> expression is due primarily to downregulation by <e1>CHEMICAL<\\e1>  GENE-Y expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor","sentence":"In mice, this reduction in FMO3 expression is due primarily to downregulation by androgens  FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor"}
{"PMID":23312283,"re_id":6,"annotated sentence":"Analysis of natural genetic variation among inbred strains of mice indicates that <e2>FMO3<\\e2> and <e1>TMAO<\\e1> are significantly correlated, and TMAO levels explain 11% of the variation in atherosclerosis.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"TMAO","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Analysis of natural genetic variation among inbred strains of mice indicates that <e2>GENE-Y<\\e2> and <e1>CHEMICAL<\\e1> are significantly correlated, and CHEMICAL levels explain 11% of the variation in atherosclerosis.","sentence":"Analysis of natural genetic variation among inbred strains of mice indicates that FMO3 and TMAO are significantly correlated, and TMAO levels explain 11% of the variation in atherosclerosis."}
{"PMID":23312283,"re_id":7,"annotated sentence":"We demonstrate that two <e2>flavin mono-oxygenase<\\e2> family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to <e1>TMAO<\\e1>  Further, we show that FMO3 exhibits 10-fold higher specific activity than FMO1","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"TMAO","object":"flavin mono-oxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We demonstrate that two <e2>GENE-N<\\e2> family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to <e1>CHEMICAL<\\e1>  Further, we show that FMO3 exhibits 10-fold higher specific activity than FMO1","sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO  Further, we show that FMO3 exhibits 10-fold higher specific activity than FMO1"}
{"PMID":23312283,"re_id":8,"annotated sentence":"We demonstrate that two flavin mono-oxygenase family members, <e2>FMO1<\\e2> and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to <e1>TMAO<\\e1>  Further, we show that FMO3 exhibits 10-fold higher specific activity than FMO1","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"TMAO","object":"FMO1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We demonstrate that two flavin mono-oxygenase family members, <e2>GENE-Y<\\e2> and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to <e1>CHEMICAL<\\e1>  Further, we show that FMO3 exhibits 10-fold higher specific activity than GENE-Y","sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO  Further, we show that FMO3 exhibits 10-fold higher specific activity than FMO1"}
{"PMID":23312283,"re_id":9,"annotated sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>FMO3<\\e2>  oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to <e1>TMAO<\\e1>  Further, we show that FMO3 exhibits 10-fold higher specific activity than FMO1","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"TMAO","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>GENE-Y<\\e2>  oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to <e1>CHEMICAL<\\e1>  Further, we show that GENE-Y exhibits 10-fold higher specific activity than FMO1","sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3  oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO  Further, we show that FMO3 exhibits 10-fold higher specific activity than FMO1"}
{"PMID":23312283,"re_id":10,"annotated sentence":"FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing <e2>FMO3<\\e2> decreases <e1>TMAO<\\e1> levels","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"TMAO","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"GENE-Y overexpression in mice significantly increases plasma CHEMICAL levels while silencing <e2>GENE-Y<\\e2> decreases <e1>CHEMICAL<\\e1> levels","sentence":"FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing FMO3 decreases TMAO levels"}
{"PMID":23312283,"re_id":11,"annotated sentence":"We demonstrate that two <e2>flavin mono-oxygenase<\\e2> family members, FMO1 and FMO3, oxidize <e1>trimethylamine<\\e1> (TMA), derived from gut flora metabolism of choline, to TMAO","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"trimethylamine","object":"flavin mono-oxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We demonstrate that two <e2>GENE-N<\\e2> family members, FMO1 and FMO3, oxidize <e1>CHEMICAL<\\e1> (TMA), derived from gut flora metabolism of choline, to TMAO","sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO"}
{"PMID":23312283,"re_id":12,"annotated sentence":"We demonstrate that two flavin mono-oxygenase family members, <e2>FMO1<\\e2> and FMO3, oxidize <e1>trimethylamine<\\e1> (TMA), derived from gut flora metabolism of choline, to TMAO","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"trimethylamine","object":"FMO1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We demonstrate that two flavin mono-oxygenase family members, <e2>GENE-Y<\\e2> and FMO3, oxidize <e1>CHEMICAL<\\e1> (TMA), derived from gut flora metabolism of choline, to TMAO","sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO"}
{"PMID":23312283,"re_id":13,"annotated sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>FMO3<\\e2>  oxidize <e1>trimethylamine<\\e1> (TMA), derived from gut flora metabolism of choline, to TMAO","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"trimethylamine","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>GENE-Y<\\e2>  oxidize <e1>CHEMICAL<\\e1> (TMA), derived from gut flora metabolism of choline, to TMAO","sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3  oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO"}
{"PMID":23312283,"re_id":14,"annotated sentence":"We demonstrate that two <e2>flavin mono-oxygenase<\\e2> family members, FMO1 and FMO3, oxidize trimethylamine (<e1>TMA<\\e1> , derived from gut flora metabolism of choline, to TMAO","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"TMA","object":"flavin mono-oxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We demonstrate that two <e2>GENE-N<\\e2> family members, FMO1 and FMO3, oxidize trimethylamine (<e1>CHEMICAL<\\e1> , derived from gut flora metabolism of choline, to CHEMICALO","sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3, oxidize trimethylamine (TMA , derived from gut flora metabolism of choline, to TMAO"}
{"PMID":23312283,"re_id":15,"annotated sentence":"We demonstrate that two flavin mono-oxygenase family members, <e2>FMO1<\\e2> and FMO3, oxidize trimethylamine (<e1>TMA<\\e1> , derived from gut flora metabolism of choline, to TMAO","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"TMA","object":"FMO1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We demonstrate that two flavin mono-oxygenase family members, <e2>GENE-Y<\\e2> and FMO3, oxidize trimethylamine (<e1>CHEMICAL<\\e1> , derived from gut flora metabolism of choline, to CHEMICALO","sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3, oxidize trimethylamine (TMA , derived from gut flora metabolism of choline, to TMAO"}
{"PMID":23312283,"re_id":16,"annotated sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>FMO3<\\e2>  oxidize trimethylamine (<e1>TMA<\\e1> , derived from gut flora metabolism of choline, to TMAO","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"TMA","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>GENE-Y<\\e2>  oxidize trimethylamine (<e1>CHEMICAL<\\e1> , derived from gut flora metabolism of choline, to CHEMICALO","sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3  oxidize trimethylamine (TMA , derived from gut flora metabolism of choline, to TMAO"}
{"PMID":23312283,"re_id":17,"annotated sentence":"We demonstrate that two <e2>flavin mono-oxygenase<\\e2> family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of <e1>choline<\\e1>  to TMAO","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"choline","object":"flavin mono-oxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We demonstrate that two <e2>GENE-N<\\e2> family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of <e1>CHEMICAL<\\e1>  to TMAO","sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline  to TMAO"}
{"PMID":23312283,"re_id":18,"annotated sentence":"We demonstrate that two flavin mono-oxygenase family members, <e2>FMO1<\\e2> and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of <e1>choline<\\e1>  to TMAO","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"choline","object":"FMO1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We demonstrate that two flavin mono-oxygenase family members, <e2>GENE-Y<\\e2> and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of <e1>CHEMICAL<\\e1>  to TMAO","sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline  to TMAO"}
{"PMID":23312283,"re_id":19,"annotated sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>FMO3<\\e2>  oxidize trimethylamine (TMA), derived from gut flora metabolism of <e1>choline<\\e1>  to TMAO","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"choline","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and <e2>GENE-Y<\\e2>  oxidize trimethylamine (TMA), derived from gut flora metabolism of <e1>CHEMICAL<\\e1>  to TMAO","sentence":"We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3  oxidize trimethylamine (TMA), derived from gut flora metabolism of choline  to TMAO"}
{"PMID":23312283,"re_id":20,"annotated sentence":"<e2>FMO3<\\e2> overexpression in mice significantly increases plasma <e1>TMAO<\\e1> levels while silencing FMO3 decreases TMAO levels","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"TMAO","object":"FMO3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> overexpression in mice significantly increases plasma <e1>CHEMICAL<\\e1> levels while silencing GENE-Y decreases CHEMICAL levels","sentence":"FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing FMO3 decreases TMAO levels"}
{"PMID":23313637,"re_id":0,"annotated sentence":"Synthesis of <e1>quinoline<\\e1> derivatives: discovery of a potent and selective <e2>phosphodiesterase 5<\\e2> inhibitor for the treatment of Alzheimer's disease","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"quinoline","object":"phosphodiesterase 5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis of <e1>CHEMICAL<\\e1> derivatives: discovery of a potent and selective <e2>GENE-Y<\\e2> inhibitor for the treatment of Alzheimer's disease","sentence":"Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease"}
{"PMID":23313637,"re_id":1,"annotated sentence":"Phosphodiesterase type 5 (<e2>PDE5<\\e2>  mediates the degradation of <e1>cGMP<\\e1> in a variety of tissues including brain","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cGMP","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Phosphodiesterase type 5 (<e2>GENE-Y<\\e2>  mediates the degradation of <e1>CHEMICAL<\\e1> in a variety of tissues including brain","sentence":"Phosphodiesterase type 5 (PDE5  mediates the degradation of cGMP in a variety of tissues including brain"}
{"PMID":23313637,"re_id":2,"annotated sentence":"<e2>Phosphodiesterase type 5<\\e2> (PDE5) mediates the degradation of <e1>cGMP<\\e1> in a variety of tissues including brain","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cGMP","object":"Phosphodiesterase type 5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (PDE5) mediates the degradation of <e1>CHEMICAL<\\e1> in a variety of tissues including brain","sentence":"Phosphodiesterase type 5 (PDE5) mediates the degradation of cGMP in a variety of tissues including brain"}
{"PMID":23314054,"re_id":1,"annotated sentence":"A novel potent compound, <e1>N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide<\\e1> (12c), which binds <e2>Mcl-1<\\e2> with an IC(50) value of 54 nM was obtained","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide","object":"Mcl-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A novel potent compound, <e1>CHEMICAL<\\e1> (12c), which binds <e2>GENE-Y<\\e2> with an IC(50) value of 54 nM was obtained","sentence":"A novel potent compound, N-benzyl-5-(4-isopropylthiophenol)-2-hydroxyl nicotinamide (12c), which binds Mcl-1 with an IC(50) value of 54 nM was obtained"}
{"PMID":23314054,"re_id":2,"annotated sentence":"We have previously reported a nanomolar inhibitor of antiapoptotic <e2>Mcl-1<\\e2> protein, <e1>3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile<\\e1> (S1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile","object":"Mcl-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have previously reported a nanomolar inhibitor of antiapoptotic <e2>GENE-Y<\\e2> protein, <e1>CHEMICAL<\\e1> (S1)","sentence":"We have previously reported a nanomolar inhibitor of antiapoptotic Mcl-1 protein, 3-thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1)"}
{"PMID":23314054,"re_id":3,"annotated sentence":"Fragment-based design, synthesis, and biological evaluation of <e1>N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide<\\e1> derivatives as novel <e2>Mcl-1<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide","object":"Mcl-1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Fragment-based design, synthesis, and biological evaluation of <e1>CHEMICAL<\\e1> derivatives as novel <e2>GENE-N<\\e2> inhibitors","sentence":"Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors"}
{"PMID":23318685,"re_id":0,"annotated sentence":"<e1>Peginesatide<\\e1>  a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the <e2>erythropoietin receptor<\\e2> dimer that governs erythropoiesis","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Peginesatide","object":"erythropoietin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1>  a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the <e2>GENE-N<\\e2> dimer that governs erythropoiesis","sentence":"Peginesatide  a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis"}
{"PMID":23318685,"re_id":1,"annotated sentence":"Peginesatide, a <e1>polyethylene glycol<\\e1> (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the <e2>erythropoietin receptor<\\e2> dimer that governs erythropoiesis","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"polyethylene glycol","object":"erythropoietin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Peginesatide, a <e1>CHEMICAL<\\e1> (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the <e2>GENE-N<\\e2> dimer that governs erythropoiesis","sentence":"Peginesatide, a polyethylene glycol (PEG)ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis"}
{"PMID":23318685,"re_id":2,"annotated sentence":"Peginesatide, a polyethylene glycol (<e1>PEG<\\e1> ylated peptide-based erythropoiesis-stimulating agent, stimulates the <e2>erythropoietin receptor<\\e2> dimer that governs erythropoiesis","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"PEG","object":"erythropoietin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Peginesatide, a polyethylene glycol (<e1>CHEMICAL<\\e1> ylated peptide-based erythropoiesis-stimulating agent, stimulates the <e2>GENE-N<\\e2> dimer that governs erythropoiesis","sentence":"Peginesatide, a polyethylene glycol (PEG ylated peptide-based erythropoiesis-stimulating agent, stimulates the erythropoietin receptor dimer that governs erythropoiesis"}
{"PMID":23322166,"re_id":3,"annotated sentence":"LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of <e1>LPA<\\e1> by driving MRTF-dependent <e2>CTGF<\\e2> expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"LPA","object":"CTGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CHEMICAL1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of <e1>CHEMICAL<\\e1> by driving MRTF-dependent <e2>GENE-Y<\\e2> expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J","sentence":"LPA1-induced cytoskeleton reorganization therefore makes a previously unrecognized but critically important contribution to the profibrotic activities of LPA by driving MRTF-dependent CTGF expression, which, in turn, drives fibroblast proliferation.-Sakai, N., Chun, J., Duffield, J"}
{"PMID":23330546,"re_id":0,"annotated sentence":"<e1>Bile acids<\\e1> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, <e2>constitutive androstane receptor<\\e2>  and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Bile acids","object":"constitutive androstane receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, <e2>GENE-Y<\\e2>  and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism","sentence":"Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor  and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism"}
{"PMID":23330546,"re_id":1,"annotated sentence":"<e1>Bile acids<\\e1> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and <e2>vitamin D receptor<\\e2>  and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Bile acids","object":"vitamin D receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and <e2>GENE-Y<\\e2>  and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism","sentence":"Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor  and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism"}
{"PMID":23330546,"re_id":2,"annotated sentence":"<e1>Bile acids<\\e1> are signaling molecules that activate <e2>nuclear receptors<\\e2>  such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Bile acids","object":"nuclear receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> are signaling molecules that activate <e2>GENE-N<\\e2>  such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism","sentence":"Bile acids are signaling molecules that activate nuclear receptors  such as farnesoid X receptor, pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism"}
{"PMID":23330546,"re_id":3,"annotated sentence":"<e1>Bile acids<\\e1> are signaling molecules that activate nuclear receptors, such as <e2>farnesoid X receptor<\\e2>  pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Bile acids","object":"farnesoid X receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> are signaling molecules that activate nuclear receptors, such as <e2>GENE-Y<\\e2>  pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism","sentence":"Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor  pregnane X receptor, constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism"}
{"PMID":23330546,"re_id":4,"annotated sentence":"<e1>Bile acids<\\e1> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, <e2>pregnane X receptor<\\e2>  constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Bile acids","object":"pregnane X receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, <e2>GENE-Y<\\e2>  constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism","sentence":"Bile acids are signaling molecules that activate nuclear receptors, such as farnesoid X receptor, pregnane X receptor  constitutive androstane receptor, and vitamin D receptor, and play a critical role in the regulation of lipid, glucose, energy, and drug metabolism"}
{"PMID":23333834,"re_id":6,"annotated sentence":"Results confirmed that <e1>YR-11<\\e1> peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of <e2>NF-\u03baB<\\e2>  The results obtained in this study substantiate the therapeutic benefit of this novel peptide in the prevention of bone loss and inflammation in rheumatoid arthritis with reduced side effects.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"YR-11","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results confirmed that <e1>CHEMICAL<\\e1> peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of <e2>GENE-N<\\e2>  The results obtained in this study substantiate the therapeutic benefit of this novel peptide in the prevention of bone loss and inflammation in rheumatoid arthritis with reduced side effects.","sentence":"Results confirmed that YR-11 peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of NF-\u03baB  The results obtained in this study substantiate the therapeutic benefit of this novel peptide in the prevention of bone loss and inflammation in rheumatoid arthritis with reduced side effects."}
{"PMID":23333834,"re_id":7,"annotated sentence":"The peptide <e1>YR-11<\\e1> (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and <e2>RANKL<\\e2> induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"YR-11","object":"RANKL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The peptide <e1>CHEMICAL<\\e1> (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-GENE-Y binding, and <e2>GENE-Y<\\e2> induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity","sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity"}
{"PMID":23333834,"re_id":8,"annotated sentence":"The peptide <e1>YR-11<\\e1> (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced <e2>TRAP<\\e2> activity and formation of multinucleated osteoclasts without any cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"YR-11","object":"TRAP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The peptide <e1>CHEMICAL<\\e1> (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced <e2>GENE-Y<\\e2> activity and formation of multinucleated osteoclasts without any cytotoxicity","sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity"}
{"PMID":23333834,"re_id":9,"annotated sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of <e1>cysteine<\\e1> with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and <e2>RANKL<\\e2> induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cysteine","object":"RANKL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of <e1>CHEMICAL<\\e1> with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-GENE-Y binding, and <e2>GENE-Y<\\e2> induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity","sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity"}
{"PMID":23333834,"re_id":10,"annotated sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of <e1>cysteine<\\e1> with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced <e2>TRAP<\\e2> activity and formation of multinucleated osteoclasts without any cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cysteine","object":"TRAP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of <e1>CHEMICAL<\\e1> with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced <e2>GENE-Y<\\e2> activity and formation of multinucleated osteoclasts without any cytotoxicity","sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity"}
{"PMID":23333834,"re_id":11,"annotated sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a <e1>serine<\\e1> residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and <e2>RANKL<\\e2> induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"serine","object":"RANKL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a <e1>CHEMICAL<\\e1> residue in the template sequence, significantly (p<0.05) inhibited RANK-GENE-Y binding, and <e2>GENE-Y<\\e2> induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity","sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity"}
{"PMID":23333834,"re_id":12,"annotated sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a <e1>serine<\\e1> residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced <e2>TRAP<\\e2> activity and formation of multinucleated osteoclasts without any cytotoxicity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"serine","object":"TRAP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a <e1>CHEMICAL<\\e1> residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced <e2>GENE-Y<\\e2> activity and formation of multinucleated osteoclasts without any cytotoxicity","sentence":"The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity"}
{"PMID":23333834,"re_id":13,"annotated sentence":"Results confirmed that <e1>YR-11<\\e1> peptide inhibited pro-inflammatory <e2>cytokines<\\e2> in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of NF-\u03baB","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"YR-11","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Results confirmed that <e1>CHEMICAL<\\e1> peptide inhibited pro-inflammatory <e2>GENE-N<\\e2> in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of NF-\u03baB","sentence":"Results confirmed that YR-11 peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of NF-\u03baB"}
{"PMID":23333834,"re_id":14,"annotated sentence":"Results confirmed that <e1>YR-11<\\e1> peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on <e2>RANKL<\\e2> induced nuclear translocation of NF-\u03baB","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"YR-11","object":"RANKL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Results confirmed that <e1>CHEMICAL<\\e1> peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on <e2>GENE-Y<\\e2> induced nuclear translocation of NF-\u03baB","sentence":"Results confirmed that YR-11 peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of NF-\u03baB"}
{"PMID":23333897,"re_id":1,"annotated sentence":"The activation of <e2>Rac1<\\e2> was induced by <e1>silica<\\e1> nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"silica","object":"Rac1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The activation of <e2>GENE-Y<\\e2> was induced by <e1>CHEMICAL<\\e1> nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation","sentence":"The activation of Rac1 was induced by silica nanoparticles as well as BCG DNA and is suggested as the critical signaling event inducing both cytoskeleton changes as well as inflammatory cell activation"}
{"PMID":23337567,"re_id":0,"annotated sentence":"Additionally, these effects of <e1>ATO<\\e1> on \u03b3-H2AX, Chk1, Chk2, p53, and p21(waf1\/cip1) were reduced by an <e2>ATM<\\e2> inhibitor","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ATO","object":"ATM","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, these effects of <e1>CHEMICAL<\\e1> on \u03b3-H2AX, Chk1, Chk2, p53, and p21(waf1\/cip1) were reduced by an <e2>GENE-Y<\\e2> inhibitor","sentence":"Additionally, these effects of ATO on \u03b3-H2AX, Chk1, Chk2, p53, and p21(waf1\/cip1) were reduced by an ATM inhibitor"}
{"PMID":23337567,"re_id":1,"annotated sentence":"Osteoblasts survive the <e1>arsenic trioxide<\\e1> treatment by activation of <e2>ATM<\\e2> mediated pathway","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"arsenic trioxide","object":"ATM","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Osteoblasts survive the <e1>CHEMICAL<\\e1> treatment by activation of <e2>GENE-Y<\\e2> mediated pathway","sentence":"Osteoblasts survive the arsenic trioxide treatment by activation of ATM mediated pathway"}
{"PMID":23337567,"re_id":2,"annotated sentence":"Additionally, these effects of <e1>ATO<\\e1> on \u03b3-H2AX, <e2>Chk1<\\e2>  Chk2, p53, and p21(waf1\/cip1) were reduced by an ATM inhibitor","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ATO","object":"Chk1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, these effects of <e1>CHEMICAL<\\e1> on \u03b3-H2AX, <e2>GENE-Y<\\e2>  Chk2, p53, and p21(waf1\/cip1) were reduced by an ATM inhibitor","sentence":"Additionally, these effects of ATO on \u03b3-H2AX, Chk1  Chk2, p53, and p21(waf1\/cip1) were reduced by an ATM inhibitor"}
{"PMID":23337567,"re_id":3,"annotated sentence":"Additionally, these effects of <e1>ATO<\\e1> on \u03b3-H2AX, Chk1, <e2>Chk2<\\e2>  p53, and p21(waf1\/cip1) were reduced by an ATM inhibitor","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ATO","object":"Chk2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, these effects of <e1>CHEMICAL<\\e1> on \u03b3-H2AX, Chk1, <e2>GENE-Y<\\e2>  p53, and p21(waf1\/cip1) were reduced by an ATM inhibitor","sentence":"Additionally, these effects of ATO on \u03b3-H2AX, Chk1, Chk2  p53, and p21(waf1\/cip1) were reduced by an ATM inhibitor"}
{"PMID":23337567,"re_id":4,"annotated sentence":"Additionally, these effects of <e1>ATO<\\e1> on \u03b3-H2AX, Chk1, Chk2, <e2>p53<\\e2>  and p21(waf1\/cip1) were reduced by an ATM inhibitor","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ATO","object":"p53","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, these effects of <e1>CHEMICAL<\\e1> on \u03b3-H2AX, Chk1, Chk2, <e2>GENE-Y<\\e2>  and p21(waf1\/cip1) were reduced by an ATM inhibitor","sentence":"Additionally, these effects of ATO on \u03b3-H2AX, Chk1, Chk2, p53  and p21(waf1\/cip1) were reduced by an ATM inhibitor"}
{"PMID":23337567,"re_id":5,"annotated sentence":"Additionally, these effects of <e1>ATO<\\e1> on \u03b3-H2AX, Chk1, Chk2, p53, and <e2>p21<\\e2> waf1\/cip1) were reduced by an ATM inhibitor","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ATO","object":"p21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, these effects of <e1>CHEMICAL<\\e1> on \u03b3-H2AX, Chk1, Chk2, p53, and <e2>GENE-Y<\\e2> waf1\/cip1) were reduced by an ATM inhibitor","sentence":"Additionally, these effects of ATO on \u03b3-H2AX, Chk1, Chk2, p53, and p21 waf1\/cip1) were reduced by an ATM inhibitor"}
{"PMID":23337567,"re_id":6,"annotated sentence":"Additionally, these effects of <e1>ATO<\\e1> on \u03b3-H2AX, Chk1, Chk2, p53, and p21(<e2>waf1<\\e2> cip1) were reduced by an ATM inhibitor","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ATO","object":"waf1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, these effects of <e1>CHEMICAL<\\e1> on \u03b3-H2AX, Chk1, Chk2, p53, and p21(<e2>GENE-Y<\\e2> cip1) were reduced by an ATM inhibitor","sentence":"Additionally, these effects of ATO on \u03b3-H2AX, Chk1, Chk2, p53, and p21(waf1 cip1) were reduced by an ATM inhibitor"}
{"PMID":23337567,"re_id":7,"annotated sentence":"Additionally, these effects of <e1>ATO<\\e1> on \u03b3-H2AX, Chk1, Chk2, p53, and p21(waf1\/<e2>cip1<\\e2>  were reduced by an ATM inhibitor","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ATO","object":"cip1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, these effects of <e1>CHEMICAL<\\e1> on \u03b3-H2AX, Chk1, Chk2, p53, and p21(waf1\/<e2>GENE-Y<\\e2>  were reduced by an ATM inhibitor","sentence":"Additionally, these effects of ATO on \u03b3-H2AX, Chk1, Chk2, p53, and p21(waf1\/cip1  were reduced by an ATM inhibitor"}
{"PMID":23337567,"re_id":8,"annotated sentence":"Additionally, these effects of <e1>ATO<\\e1> on \u03b3-<e2>H2AX<\\e2>  Chk1, Chk2, p53, and p21(waf1\/cip1) were reduced by an ATM inhibitor","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ATO","object":"H2AX","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, these effects of <e1>CHEMICAL<\\e1> on \u03b3-<e2>GENE-Y<\\e2>  Chk1, Chk2, p53, and p21(waf1\/cip1) were reduced by an ATM inhibitor","sentence":"Additionally, these effects of ATO on \u03b3-H2AX  Chk1, Chk2, p53, and p21(waf1\/cip1) were reduced by an ATM inhibitor"}
{"PMID":23348407,"re_id":0,"annotated sentence":"Furthermore, a mixture of <e1>isoflavonoid<\\e1> parent compounds, and a mixture of isoflavonoid metabolites were found to have <e2>PPAR\u03b3<\\e2> activating abilities","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"isoflavonoid","object":"PPAR\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, a mixture of <e1>CHEMICAL<\\e1> parent compounds, and a mixture of CHEMICAL metabolites were found to have <e2>GENE-Y<\\e2> activating abilities","sentence":"Furthermore, a mixture of isoflavonoid parent compounds, and a mixture of isoflavonoid metabolites were found to have PPAR\u03b3 activating abilities"}
{"PMID":23348407,"re_id":1,"annotated sentence":"Furthermore, a mixture of isoflavonoid parent compounds, and a mixture of <e1>isoflavonoid<\\e1> metabolites were found to have <e2>PPAR\u03b3<\\e2> activating abilities","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"isoflavonoid","object":"PPAR\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, a mixture of CHEMICAL parent compounds, and a mixture of <e1>CHEMICAL<\\e1> metabolites were found to have <e2>GENE-Y<\\e2> activating abilities","sentence":"Furthermore, a mixture of isoflavonoid parent compounds, and a mixture of isoflavonoid metabolites were found to have PPAR\u03b3 activating abilities"}
{"PMID":23349208,"re_id":10,"annotated sentence":"In monocytes, both <e1>EPA<\\e1> and DHA increased <e2>interleukin (IL)-10<\\e2> without affecting tumor necrosis factor (TNF)-\u03b1 and IL-6","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"EPA","object":"interleukin (IL)-10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In monocytes, both <e1>CHEMICAL<\\e1> and DHA increased <e2>GENE-Y<\\e2> without affecting tumor necrosis factor (TNF)-\u03b1 and IL-6","sentence":"In monocytes, both EPA and DHA increased interleukin (IL)-10 without affecting tumor necrosis factor (TNF)-\u03b1 and IL-6"}
{"PMID":23349208,"re_id":11,"annotated sentence":"In monocytes, both EPA and <e1>DHA<\\e1> increased <e2>interleukin (IL)-10<\\e2> without affecting tumor necrosis factor (TNF)-\u03b1 and IL-6","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"DHA","object":"interleukin (IL)-10","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In monocytes, both EPA and <e1>CHEMICAL<\\e1> increased <e2>GENE-Y<\\e2> without affecting tumor necrosis factor (TNF)-\u03b1 and IL-6","sentence":"In monocytes, both EPA and DHA increased interleukin (IL)-10 without affecting tumor necrosis factor (TNF)-\u03b1 and IL-6"}
{"PMID":23349208,"re_id":12,"annotated sentence":"Both <e1>fatty acids<\\e1>  but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of <e2>cytokine<\\e2> expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)\u03b3-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"fatty acids","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both <e1>CHEMICAL<\\e1>  but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of <e2>GENE-N<\\e2> expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)\u03b3-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells","sentence":"Both fatty acids  but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)\u03b3-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells"}
{"PMID":23349208,"re_id":13,"annotated sentence":"Both fatty acids, but <e1>DHA<\\e1> to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of <e2>cytokine<\\e2> expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)\u03b3-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"DHA","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both fatty acids, but <e1>CHEMICAL<\\e1> to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of <e2>GENE-N<\\e2> expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)\u03b3-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells","sentence":"Both fatty acids, but DHA to a lesser extent compared with EPA, selectively and dose-dependently reduced the percentage of cytokine expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)\u03b3-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells"}
{"PMID":23349208,"re_id":14,"annotated sentence":"Both fatty acids, but DHA to a lesser extent compared with <e1>EPA<\\e1>  selectively and dose-dependently reduced the percentage of <e2>cytokine<\\e2> expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)\u03b3-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"EPA","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Both fatty acids, but DHA to a lesser extent compared with <e1>CHEMICAL<\\e1>  selectively and dose-dependently reduced the percentage of <e2>GENE-N<\\e2> expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)\u03b3-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells","sentence":"Both fatty acids, but DHA to a lesser extent compared with EPA  selectively and dose-dependently reduced the percentage of cytokine expressing Th cells in a peroxisome proliferator-activated receptor (PPAR)\u03b3-dependent fashion, whereas the expression of the cell surface marker CD69 was unaltered on activated T cells"}
{"PMID":23353658,"re_id":0,"annotated sentence":"In the in vitro model we observed high permeability of <e1>imperatorin<\\e1> and isoimperatorin with the <e2>P-gp<\\e2> mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"imperatorin","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the in vitro model we observed high permeability of <e1>CHEMICAL<\\e1> and isoCHEMICAL with the <e2>GENE-N<\\e2> mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82","sentence":"In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the P-gp mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82"}
{"PMID":23353658,"re_id":1,"annotated sentence":"In the in vitro model we observed high permeability of imperatorin and <e1>isoimperatorin<\\e1> with the <e2>P-gp<\\e2> mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"isoimperatorin","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the in vitro model we observed high permeability of imperatorin and <e1>CHEMICAL<\\e1> with the <e2>GENE-N<\\e2> mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82","sentence":"In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the P-gp mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82"}
{"PMID":23353658,"re_id":2,"annotated sentence":"In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the <e2>P-gp<\\e2> mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of <e1>cnidilin<\\e1> with 0.82","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cnidilin","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the <e2>GENE-N<\\e2> mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of <e1>CHEMICAL<\\e1> with 0.82","sentence":"In the in vitro model we observed high permeability of imperatorin and isoimperatorin with the P-gp mediated efflux ratios of 0.53 and 0.06, as well as medium permeability of cnidilin with 0.82"}
{"PMID":23353701,"re_id":8,"annotated sentence":"In agreement with these data, the exogenous treatment of <e1>SAH<\\e1> or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on <e2>Src<\\e2>  the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"SAH","object":"Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In agreement with these data, the exogenous treatment of <e1>CHEMICAL<\\e1> or inhibition of CHEMICALH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on <e2>GENE-Y<\\e2>  the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and GENE-Y","sentence":"In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src  the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src"}
{"PMID":23353701,"re_id":9,"annotated sentence":"Through immunoblotting analysis, it was found that <e1>AdOx<\\e1> was capable of indirectly diminishing the phosphorylation of oncogenic <e2>Src<\\e2> and its kinase activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"AdOx","object":"Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Through immunoblotting analysis, it was found that <e1>CHEMICAL<\\e1> was capable of indirectly diminishing the phosphorylation of oncogenic <e2>GENE-Y<\\e2> and its kinase activity","sentence":"Through immunoblotting analysis, it was found that AdOx was capable of indirectly diminishing the phosphorylation of oncogenic Src and its kinase activity"}
{"PMID":23353701,"re_id":10,"annotated sentence":"Interestingly, <e1>AdOx<\\e1> disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of <e2>Src<\\e2> and p85\/PI3K, which is linked to various tumorigenic responses","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"AdOx","object":"Src","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of <e2>GENE-Y<\\e2> and p85\/PI3K, which is linked to various tumorigenic responses","sentence":"Interestingly, AdOx disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85\/PI3K, which is linked to various tumorigenic responses"}
{"PMID":23353701,"re_id":11,"annotated sentence":"Interestingly, <e1>AdOx<\\e1> disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and <e2>p85<\\e2> PI3K, which is linked to various tumorigenic responses","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"AdOx","object":"p85","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and <e2>GENE-N<\\e2> PI3K, which is linked to various tumorigenic responses","sentence":"Interestingly, AdOx disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85 PI3K, which is linked to various tumorigenic responses"}
{"PMID":23353701,"re_id":12,"annotated sentence":"Interestingly, <e1>AdOx<\\e1> disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85\/<e2>PI3K<\\e2>  which is linked to various tumorigenic responses","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"AdOx","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85\/<e2>GENE-N<\\e2>  which is linked to various tumorigenic responses","sentence":"Interestingly, AdOx disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85\/PI3K  which is linked to various tumorigenic responses"}
{"PMID":23353701,"re_id":13,"annotated sentence":"Through immunoblotting analysis, it was found that <e1>AdOx<\\e1> was capable of indirectly diminishing the phosphorylation of oncogenic Src and its <e2>kinase<\\e2> activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AdOx","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Through immunoblotting analysis, it was found that <e1>CHEMICAL<\\e1> was capable of indirectly diminishing the phosphorylation of oncogenic Src and its <e2>GENE-N<\\e2> activity","sentence":"Through immunoblotting analysis, it was found that AdOx was capable of indirectly diminishing the phosphorylation of oncogenic Src and its kinase activity"}
{"PMID":23353701,"re_id":14,"annotated sentence":"Interestingly, <e1>AdOx<\\e1> disrupted <e2>actin<\\e2> cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85\/PI3K, which is linked to various tumorigenic responses","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AdOx","object":"actin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interestingly, <e1>CHEMICAL<\\e1> disrupted <e2>GENE-N<\\e2> cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85\/PI3K, which is linked to various tumorigenic responses","sentence":"Interestingly, AdOx disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85\/PI3K, which is linked to various tumorigenic responses"}
{"PMID":23353701,"re_id":15,"annotated sentence":"In agreement with these data, the exogenous treatment of SAH or inhibition of <e2>SAHH<\\e2> by specific siRNA or another type of inhibitor, <e1>3-deazaadenosine<\\e1> (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-deazaadenosine","object":"SAHH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In agreement with these data, the exogenous treatment of SAH or inhibition of <e2>GENE-Y<\\e2> by specific siRNA or another type of inhibitor, <e1>CHEMICAL<\\e1> (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src","sentence":"In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src"}
{"PMID":23353701,"re_id":16,"annotated sentence":"In agreement with these data, the exogenous treatment of SAH or inhibition of <e2>SAHH<\\e2> by specific siRNA or another type of inhibitor, 3-deazaadenosine (<e1>DAZA<\\e1> , similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DAZA","object":"SAHH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In agreement with these data, the exogenous treatment of SAH or inhibition of <e2>GENE-Y<\\e2> by specific siRNA or another type of inhibitor, 3-deazaadenosine (<e1>CHEMICAL<\\e1> , similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src","sentence":"In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA , similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src"}
{"PMID":23353701,"re_id":17,"annotated sentence":"Treatment with <e1>adenosine dialdehyde<\\e1> (AdOx), an inhibitor of transmethylation-suppressive <e2>adenosylhomocysteine (SAH) hydrolase<\\e2> (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"adenosine dialdehyde","object":"adenosylhomocysteine (SAH) hydrolase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> (AdOx), an inhibitor of transmethylation-suppressive <e2>GENE-Y<\\e2> (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner","sentence":"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner"}
{"PMID":23353701,"re_id":18,"annotated sentence":"Treatment with <e1>adenosine dialdehyde<\\e1> (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (<e2>SAHH<\\e2> , enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"adenosine dialdehyde","object":"SAHH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (<e2>GENE-Y<\\e2> , enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner","sentence":"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (SAHH , enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner"}
{"PMID":23353701,"re_id":19,"annotated sentence":"Treatment with adenosine dialdehyde (<e1>AdOx<\\e1> , an inhibitor of transmethylation-suppressive <e2>adenosylhomocysteine (SAH) hydrolase<\\e2> (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AdOx","object":"adenosylhomocysteine (SAH) hydrolase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with adenosine dialdehyde (<e1>CHEMICAL<\\e1> , an inhibitor of transmethylation-suppressive <e2>GENE-Y<\\e2> (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner","sentence":"Treatment with adenosine dialdehyde (AdOx , an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner"}
{"PMID":23353701,"re_id":20,"annotated sentence":"Treatment with adenosine dialdehyde (<e1>AdOx<\\e1> , an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (<e2>SAHH<\\e2> , enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AdOx","object":"SAHH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with adenosine dialdehyde (<e1>CHEMICAL<\\e1> , an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (<e2>GENE-Y<\\e2> , enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner","sentence":"Treatment with adenosine dialdehyde (AdOx , an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (SAHH , enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner"}
{"PMID":23353701,"re_id":21,"annotated sentence":"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive <e2>adenosylhomocysteine (SAH) hydrolase<\\e2> (SAHH), enhanced the level of <e1>SAH<\\e1> and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"SAH","object":"adenosylhomocysteine (SAH) hydrolase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive <e2>adenosylhomocysteine (CHEMICAL) hydrolase<\\e2> (CHEMICALH), enhanced the level of <e1>CHEMICAL<\\e1> and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner","sentence":"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner"}
{"PMID":23353701,"re_id":22,"annotated sentence":"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (<e2>SAHH<\\e2> , enhanced the level of <e1>SAH<\\e1> and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"SAH","object":"SAHH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (CHEMICAL) hydrolase (<e2>CHEMICALH<\\e2> , enhanced the level of <e1>CHEMICAL<\\e1> and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner","sentence":"Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (SAHH , enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner"}
{"PMID":23353736,"re_id":0,"annotated sentence":"A series of <e2>MMP-1<\\e2> inhibitors have been identified based upon a <e1>methyl rosmarinate<\\e1> scaffold using structure-based drug design methods","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"methyl rosmarinate","object":"MMP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e2>GENE-Y<\\e2> inhibitors have been identified based upon a <e1>CHEMICAL<\\e1> scaffold using structure-based drug design methods","sentence":"A series of MMP-1 inhibitors have been identified based upon a methyl rosmarinate scaffold using structure-based drug design methods"}
{"PMID":23353736,"re_id":1,"annotated sentence":"Synthesis of derivatives of <e1>methyl rosmarinate<\\e1> and their inhibitory activities against matrix metalloproteinase-1 (<e2>MMP-1<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"methyl rosmarinate","object":"MMP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis of derivatives of <e1>CHEMICAL<\\e1> and their inhibitory activities against matrix metalloproteinase-1 (<e2>GENE-Y<\\e2> ","sentence":"Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1 "}
{"PMID":23353736,"re_id":2,"annotated sentence":"Synthesis of derivatives of <e1>methyl rosmarinate<\\e1> and their inhibitory activities against <e2>matrix metalloproteinase-1<\\e2> (MMP-1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"methyl rosmarinate","object":"matrix metalloproteinase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis of derivatives of <e1>CHEMICAL<\\e1> and their inhibitory activities against <e2>GENE-Y<\\e2> (MMP-1)","sentence":"Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1)"}
{"PMID":23353741,"re_id":0,"annotated sentence":"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as <e2>cyclooxygenase-2<\\e2> (COX-2)-derived <e1>prostaglandin E2<\\e1> (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin E2","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as <e2>GENE-Y<\\e2> (COX-2)-derived <e1>CHEMICAL<\\e1> (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line","sentence":"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (COX-2)-derived prostaglandin E2 (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line"}
{"PMID":23353741,"re_id":1,"annotated sentence":"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (<e2>COX-2<\\e2> -derived <e1>prostaglandin E2<\\e1> (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin E2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (<e2>GENE-Y<\\e2> -derived <e1>CHEMICAL<\\e1> (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line","sentence":"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (COX-2 -derived prostaglandin E2 (PGE2) inhibitory activity of murine macrophage RAW 264.7 cell line"}
{"PMID":23353741,"re_id":2,"annotated sentence":"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as <e2>cyclooxygenase-2<\\e2> (COX-2)-derived prostaglandin E2 (<e1>PGE2<\\e1>  inhibitory activity of murine macrophage RAW 264.7 cell line","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PGE2","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as <e2>GENE-Y<\\e2> (COX-2)-derived prostaglandin E2 (<e1>CHEMICAL<\\e1>  inhibitory activity of murine macrophage RAW 264.7 cell line","sentence":"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (COX-2)-derived prostaglandin E2 (PGE2  inhibitory activity of murine macrophage RAW 264.7 cell line"}
{"PMID":23353741,"re_id":3,"annotated sentence":"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (<e2>COX-2<\\e2> -derived prostaglandin E2 (<e1>PGE2<\\e1>  inhibitory activity of murine macrophage RAW 264.7 cell line","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"PGE2","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (<e2>GENE-Y<\\e2> -derived prostaglandin E2 (<e1>CHEMICAL<\\e1>  inhibitory activity of murine macrophage RAW 264.7 cell line","sentence":"All the compounds were evaluated for their anti-tumor activity against MCF-7, A549 and B16-F10 tumor cell lines as well as cyclooxygenase-2 (COX-2 -derived prostaglandin E2 (PGE2  inhibitory activity of murine macrophage RAW 264.7 cell line"}
{"PMID":23356880,"re_id":6,"annotated sentence":"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the <e2>lipoxygenase<\\e2> (LOX)-pathway (one having as precursors the <e1>polyunsaturated fatty acids<\\e1> containing a cis-cis-1,4-pentadiene system)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"polyunsaturated fatty acids","object":"lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the <e2>GENE-N<\\e2> (LOX)-pathway (one having as precursors the <e1>CHEMICAL<\\e1> containing a cis-cis-1,4-pentadiene system)","sentence":"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (LOX)-pathway (one having as precursors the polyunsaturated fatty acids containing a cis-cis-1,4-pentadiene system)"}
{"PMID":23356880,"re_id":7,"annotated sentence":"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (<e2>LOX<\\e2> -pathway (one having as precursors the <e1>polyunsaturated fatty acids<\\e1> containing a cis-cis-1,4-pentadiene system)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"polyunsaturated fatty acids","object":"LOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (<e2>GENE-N<\\e2> -pathway (one having as precursors the <e1>CHEMICAL<\\e1> containing a cis-cis-1,4-pentadiene system)","sentence":"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (LOX -pathway (one having as precursors the polyunsaturated fatty acids containing a cis-cis-1,4-pentadiene system)"}
{"PMID":23356880,"re_id":8,"annotated sentence":"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the <e2>lipoxygenase<\\e2> (LOX)-pathway (one having as precursors the polyunsaturated fatty acids containing a <e1>cis-cis-1,4-pentadiene<\\e1> system)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cis-cis-1,4-pentadiene","object":"lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the <e2>GENE-N<\\e2> (LOX)-pathway (one having as precursors the polyunsaturated fatty acids containing a <e1>CHEMICAL<\\e1> system)","sentence":"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (LOX)-pathway (one having as precursors the polyunsaturated fatty acids containing a cis-cis-1,4-pentadiene system)"}
{"PMID":23356880,"re_id":9,"annotated sentence":"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (<e2>LOX<\\e2> -pathway (one having as precursors the polyunsaturated fatty acids containing a <e1>cis-cis-1,4-pentadiene<\\e1> system)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cis-cis-1,4-pentadiene","object":"LOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (<e2>GENE-N<\\e2> -pathway (one having as precursors the polyunsaturated fatty acids containing a <e1>CHEMICAL<\\e1> system)","sentence":"Its head-space aroma displayed new volatile phytomolecules and also had higher levels of green volatiles from the lipoxygenase (LOX -pathway (one having as precursors the polyunsaturated fatty acids containing a cis-cis-1,4-pentadiene system)"}
{"PMID":23368735,"re_id":4,"annotated sentence":"In general, antiproliferative activity is greatly enhanced by low levels of the <e2>glutathione synthase<\\e2> inhibitor <e1>l-buthionine sulfoxime<\\e1>  The work illustrates how subtle changes to the design of low-spin d(6) metal complexes can lead to major changes in cellular metabolism and to potent complexes with novel mechanisms of anticancer activity.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"l-buthionine sulfoxime","object":"glutathione synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In general, antiproliferative activity is greatly enhanced by low levels of the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  The work illustrates how subtle changes to the design of low-spin d(6) metal complexes can lead to major changes in cellular metabolism and to potent complexes with novel mechanisms of anticancer activity.","sentence":"In general, antiproliferative activity is greatly enhanced by low levels of the glutathione synthase inhibitor l-buthionine sulfoxime  The work illustrates how subtle changes to the design of low-spin d(6) metal complexes can lead to major changes in cellular metabolism and to potent complexes with novel mechanisms of anticancer activity."}
{"PMID":23368743,"re_id":0,"annotated sentence":"The recent identification of <e1>zinc<\\e1> permeability of the lysosomal ion channel <e2>TRPML1<\\e2> (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in zinc transport","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"zinc","object":"TRPML1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The recent identification of <e1>CHEMICAL<\\e1> permeability of the lysosomal ion channel <e2>GENE-Y<\\e2> (transient receptor potential mucolipin 1), and the evidence of abnormal CHEMICAL levels in cells deficient in GENE-Y, suggested a role for GENE-Y\u00a0in CHEMICAL transport","sentence":"The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in zinc transport"}
{"PMID":23368743,"re_id":1,"annotated sentence":"The recent identification of <e1>zinc<\\e1> permeability of the lysosomal ion channel TRPML1 (<e2>transient receptor potential mucolipin 1<\\e2> , and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in zinc transport","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"zinc","object":"transient receptor potential mucolipin 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The recent identification of <e1>CHEMICAL<\\e1> permeability of the lysosomal ion channel TRPML1 (<e2>GENE-Y<\\e2> , and the evidence of abnormal CHEMICAL levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in CHEMICAL transport","sentence":"The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1 , and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in zinc transport"}
{"PMID":23368743,"re_id":2,"annotated sentence":"The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for <e2>TRPML1<\\e2> in <e1>zinc<\\e1> transport","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"zinc","object":"TRPML1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The recent identification of CHEMICAL permeability of the lysosomal ion channel GENE-Y (transient receptor potential mucolipin 1), and the evidence of abnormal CHEMICAL levels in cells deficient in GENE-Y, suggested a role for <e2>GENE-Y<\\e2> in <e1>CHEMICAL<\\e1> transport","sentence":"The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1 in zinc transport"}
{"PMID":23368743,"re_id":3,"annotated sentence":"Cellular <e1>zinc<\\e1> is controlled by <e2>zinc-chelating proteins<\\e2> and by zinc transporters","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"zinc","object":"zinc-chelating proteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cellular <e1>CHEMICAL<\\e1> is controlled by <e2>CHEMICAL-chelating proteins<\\e2> and by CHEMICAL transporters","sentence":"Cellular zinc is controlled by zinc-chelating proteins and by zinc transporters"}
{"PMID":23368743,"re_id":4,"annotated sentence":"Cellular <e1>zinc<\\e1> is controlled by zinc-chelating proteins and by <e2>zinc transporters<\\e2>  The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in zinc transport","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"zinc","object":"zinc transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Cellular <e1>CHEMICAL<\\e1> is controlled by CHEMICAL-chelating proteins and by <e2>CHEMICAL transporters<\\e2>  The recent identification of CHEMICAL permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal CHEMICAL levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in CHEMICAL transport","sentence":"Cellular zinc is controlled by zinc-chelating proteins and by zinc transporters  The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1\u00a0in zinc transport"}
{"PMID":23368743,"re_id":5,"annotated sentence":"These results underscore a role for <e2>TRPML1<\\e2> in <e1>zinc<\\e1> metabolism","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"zinc","object":"TRPML1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results underscore a role for <e2>GENE-Y<\\e2> in <e1>CHEMICAL<\\e1> metabolism","sentence":"These results underscore a role for TRPML1 in zinc metabolism"}
{"PMID":23368743,"re_id":6,"annotated sentence":"Furthermore, they suggest that <e2>TRPML1<\\e2> works in concert with ZnT4 to regulate <e1>zinc<\\e1> translocation between the cytoplasm and lysosomes.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"zinc","object":"TRPML1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, they suggest that <e2>GENE-Y<\\e2> works in concert with ZnT4 to regulate <e1>CHEMICAL<\\e1> translocation between the cytoplasm and lysosomes.","sentence":"Furthermore, they suggest that TRPML1 works in concert with ZnT4 to regulate zinc translocation between the cytoplasm and lysosomes."}
{"PMID":23368743,"re_id":7,"annotated sentence":"Furthermore, they suggest that TRPML1 works in concert with <e2>ZnT4<\\e2> to regulate <e1>zinc<\\e1> translocation between the cytoplasm and lysosomes.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"zinc","object":"ZnT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, they suggest that TRPML1 works in concert with <e2>GENE-Y<\\e2> to regulate <e1>CHEMICAL<\\e1> translocation between the cytoplasm and lysosomes.","sentence":"Furthermore, they suggest that TRPML1 works in concert with ZnT4 to regulate zinc translocation between the cytoplasm and lysosomes."}
{"PMID":23370008,"re_id":6,"annotated sentence":"Importantly, expression of the acute-phase reactant <e2>serum amyloid A<\\e2> (SAA) significantly increased after <e1>ritodrine<\\e1> injection, with values indicating the largest fold-change","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ritodrine","object":"serum amyloid A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Importantly, expression of the acute-phase reactant <e2>GENE-N<\\e2> (SAA) significantly increased after <e1>CHEMICAL<\\e1> injection, with values indicating the largest fold-change","sentence":"Importantly, expression of the acute-phase reactant serum amyloid A (SAA) significantly increased after ritodrine injection, with values indicating the largest fold-change"}
{"PMID":23370008,"re_id":7,"annotated sentence":"Importantly, expression of the acute-phase reactant serum amyloid A (<e2>SAA<\\e2>  significantly increased after <e1>ritodrine<\\e1> injection, with values indicating the largest fold-change","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ritodrine","object":"SAA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Importantly, expression of the acute-phase reactant serum amyloid A (<e2>GENE-N<\\e2>  significantly increased after <e1>CHEMICAL<\\e1> injection, with values indicating the largest fold-change","sentence":"Importantly, expression of the acute-phase reactant serum amyloid A (SAA  significantly increased after ritodrine injection, with values indicating the largest fold-change"}
{"PMID":23370008,"re_id":8,"annotated sentence":"<e2>Serum amyloid A<\\e2> upsurge precedes standard biomarkers of hepatotoxicity in <e1>ritodrine<\\e1> injected mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ritodrine","object":"Serum amyloid A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> upsurge precedes standard biomarkers of hepatotoxicity in <e1>CHEMICAL<\\e1> injected mice","sentence":"Serum amyloid A upsurge precedes standard biomarkers of hepatotoxicity in ritodrine injected mice"}
{"PMID":23370008,"re_id":9,"annotated sentence":"The increase in <e2>SAA<\\e2> expression is specific to <e1>ritodrine<\\e1> induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ritodrine","object":"SAA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The increase in <e2>GENE-N<\\e2> expression is specific to <e1>CHEMICAL<\\e1> induced liver damage, because GENE-N expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin","sentence":"The increase in SAA expression is specific to ritodrine induced liver damage, because SAA expression was not induced by other hepatotoxic drugs such as acetaminophen, valproic acid, or metformin"}
{"PMID":23370008,"re_id":10,"annotated sentence":"Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (cAMP) accumulation was not a primary cause of the <e1>ritodrine<\\e1> induced <e2>SAA<\\e2> increase","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ritodrine","object":"SAA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (cAMP) accumulation was not a primary cause of the <e1>CHEMICAL<\\e1> induced <e2>GENE-N<\\e2> increase","sentence":"Our in vitro studies showed that cyclic adenosine 3',5'-monophosphate (cAMP) accumulation was not a primary cause of the ritodrine induced SAA increase"}
{"PMID":23371303,"re_id":13,"annotated sentence":"Pharmacodynamic data suggest that <e1>ceftazidime<\\e1> avibactam is rapidly bactericidal versus <e2>\u03b2-lactamase<\\e2> producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ceftazidime","object":"\u03b2-lactamase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pharmacodynamic data suggest that <e1>CHEMICAL<\\e1> avibactam is rapidly bactericidal versus <e2>GENE-N<\\e2> producing Gram-negative bacilli that are not inhibited by CHEMICAL alone.Clinical trials to date have reported that CHEMICAL-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates","sentence":"Pharmacodynamic data suggest that ceftazidime avibactam is rapidly bactericidal versus \u03b2-lactamase producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates"}
{"PMID":23371303,"re_id":14,"annotated sentence":"Pharmacodynamic data suggest that ceftazidime-<e1>avibactam<\\e1> is rapidly bactericidal versus <e2>\u03b2-lactamase<\\e2> producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"avibactam","object":"\u03b2-lactamase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Pharmacodynamic data suggest that ceftazidime-<e1>CHEMICAL<\\e1> is rapidly bactericidal versus <e2>GENE-N<\\e2> producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-CHEMICAL is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates","sentence":"Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus \u03b2-lactamase producing Gram-negative bacilli that are not inhibited by ceftazidime alone.Clinical trials to date have reported that ceftazidime-avibactam is as effective as standard carbapenem therapy in complicated intra-abdominal infection and complicated urinary tract infection, including infection caused by cephalosporin-resistant Gram-negative isolates"}
{"PMID":23371303,"re_id":15,"annotated sentence":"Avibactam (formerly <e1>NXL104<\\e1>  AVE1330A) is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some <e2>Ambler class D<\\e2> enzymes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NXL104","object":"Ambler class D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Avibactam (formerly <e1>CHEMICAL<\\e1>  AVE1330A) is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some <e2>GENE-N<\\e2> enzymes","sentence":"Avibactam (formerly NXL104  AVE1330A) is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some Ambler class D enzymes"}
{"PMID":23371303,"re_id":16,"annotated sentence":"Avibactam (formerly <e1>NXL104<\\e1>  AVE1330A) is a synthetic non-\u03b2-lactam, <e2>\u03b2-lactamase<\\e2> inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some Ambler class D enzymes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NXL104","object":"\u03b2-lactamase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Avibactam (formerly <e1>CHEMICAL<\\e1>  AVE1330A) is a synthetic non-\u03b2-lactam, <e2>GENE-N<\\e2> inhibitor that inhibits the activities of Ambler class A and C GENE-Ns and some Ambler class D enzymes","sentence":"Avibactam (formerly NXL104  AVE1330A) is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some Ambler class D enzymes"}
{"PMID":23371303,"re_id":17,"annotated sentence":"<e1>Avibactam<\\e1> (formerly NXL104, AVE1330A) is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some <e2>Ambler class D<\\e2> enzymes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Avibactam","object":"Ambler class D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (formerly NXL104, AVE1330A) is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some <e2>GENE-N<\\e2> enzymes","sentence":"Avibactam (formerly NXL104, AVE1330A) is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some Ambler class D enzymes"}
{"PMID":23371303,"re_id":18,"annotated sentence":"<e1>Avibactam<\\e1> (formerly NXL104, AVE1330A) is a synthetic non-\u03b2-lactam, <e2>\u03b2-lactamase<\\e2> inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some Ambler class D enzymes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Avibactam","object":"\u03b2-lactamase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (formerly NXL104, AVE1330A) is a synthetic non-\u03b2-lactam, <e2>GENE-N<\\e2> inhibitor that inhibits the activities of Ambler class A and C GENE-Ns and some Ambler class D enzymes","sentence":"Avibactam (formerly NXL104, AVE1330A) is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some Ambler class D enzymes"}
{"PMID":23371303,"re_id":19,"annotated sentence":"Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, <e1>avibactam<\\e1> serves to broaden the spectrum of ceftazidime versus <e2>\u00df-lactamase<\\e2> producing Gram-negative bacilli","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"avibactam","object":"\u00df-lactamase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Ceftazidime-CHEMICAL appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, <e1>CHEMICAL<\\e1> serves to broaden the spectrum of ceftazidime versus <e2>GENE-N<\\e2> producing Gram-negative bacilli","sentence":"Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of ceftazidime versus \u00df-lactamase producing Gram-negative bacilli"}
{"PMID":23371303,"re_id":20,"annotated sentence":"Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of <e1>ceftazidime<\\e1> versus <e2>\u00df-lactamase<\\e2> producing Gram-negative bacilli","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ceftazidime","object":"\u00df-lactamase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of <e1>CHEMICAL<\\e1> versus <e2>GENE-N<\\e2> producing Gram-negative bacilli","sentence":"Ceftazidime-avibactam appears to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date.In conclusion, avibactam serves to broaden the spectrum of ceftazidime versus \u00df-lactamase producing Gram-negative bacilli"}
{"PMID":23371303,"re_id":21,"annotated sentence":"Avibactam (formerly NXL104, <e1>AVE1330A<\\e1>  is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some <e2>Ambler class D<\\e2> enzymes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AVE1330A","object":"Ambler class D","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Avibactam (formerly NXL104, <e1>CHEMICAL<\\e1>  is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some <e2>GENE-N<\\e2> enzymes","sentence":"Avibactam (formerly NXL104, AVE1330A  is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some Ambler class D enzymes"}
{"PMID":23371303,"re_id":22,"annotated sentence":"Avibactam (formerly NXL104, <e1>AVE1330A<\\e1>  is a synthetic non-\u03b2-lactam, <e2>\u03b2-lactamase<\\e2> inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some Ambler class D enzymes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AVE1330A","object":"\u03b2-lactamase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Avibactam (formerly NXL104, <e1>CHEMICAL<\\e1>  is a synthetic non-\u03b2-lactam, <e2>GENE-N<\\e2> inhibitor that inhibits the activities of Ambler class A and C GENE-Ns and some Ambler class D enzymes","sentence":"Avibactam (formerly NXL104, AVE1330A  is a synthetic non-\u03b2-lactam, \u03b2-lactamase inhibitor that inhibits the activities of Ambler class A and C \u03b2-lactamases and some Ambler class D enzymes"}
{"PMID":23371303,"re_id":23,"annotated sentence":"The addition of <e1>avibactam<\\e1> greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of <e2>\u03b2-lactamase<\\e2> enzyme(s)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"avibactam","object":"\u03b2-lactamase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The addition of <e1>CHEMICAL<\\e1> greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of <e2>GENE-N<\\e2> enzyme(s)","sentence":"The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of \u03b2-lactamase enzyme(s)"}
{"PMID":23371303,"re_id":24,"annotated sentence":"The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of <e1>ceftazidime<\\e1> versus most species of Enterobacteriaceae depending on the presence or absence of <e2>\u03b2-lactamase<\\e2> enzyme(s)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ceftazidime","object":"\u03b2-lactamase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of <e1>CHEMICAL<\\e1> versus most species of Enterobacteriaceae depending on the presence or absence of <e2>GENE-N<\\e2> enzyme(s)","sentence":"The addition of avibactam greatly (4-1024-fold minimum inhibitory concentration [MIC] reduction) improves the activity of ceftazidime versus most species of Enterobacteriaceae depending on the presence or absence of \u03b2-lactamase enzyme(s)"}
{"PMID":23371303,"re_id":25,"annotated sentence":"<e1>Ceftazidime<\\e1> avibactam: a novel cephalosporin\/<e2>\u03b2-lactamase<\\e2> inhibitor combination","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Ceftazidime","object":"\u03b2-lactamase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> avibactam: a novel cephalosporin\/<e2>GENE-N<\\e2> inhibitor combination","sentence":"Ceftazidime avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination"}
{"PMID":23371303,"re_id":26,"annotated sentence":"Ceftazidime-<e1>avibactam<\\e1>  a novel cephalosporin\/<e2>\u03b2-lactamase<\\e2> inhibitor combination","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"avibactam","object":"\u03b2-lactamase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Ceftazidime-<e1>CHEMICAL<\\e1>  a novel cephalosporin\/<e2>GENE-N<\\e2> inhibitor combination","sentence":"Ceftazidime-avibactam  a novel cephalosporin\/\u03b2-lactamase inhibitor combination"}
{"PMID":23378608,"re_id":0,"annotated sentence":"Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective <e2>cyclooxygenase-2<\\e2> inhibitor, <e1>celecoxib<\\e1>  improved vascular function, and also attenuated obesity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"celecoxib","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1>  improved vascular function, and also attenuated obesity","sentence":"Moreover, treatment of high-fat-diet-fed apelin-knockout mice with a selective cyclooxygenase-2 inhibitor, celecoxib  improved vascular function, and also attenuated obesity"}
{"PMID":23379481,"re_id":0,"annotated sentence":"<e1>Upamostat<\\e1> (Mesupron\u00ae) is a new small molecule <e2>serine protease<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Upamostat","object":"serine protease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (Mesupron\u00ae) is a new small molecule <e2>GENE-N<\\e2> inhibitor","sentence":"Upamostat (Mesupron\u00ae) is a new small molecule serine protease inhibitor"}
{"PMID":23379481,"re_id":1,"annotated sentence":"Upamostat (<e1>Mesupron<\\e1> ) is a new small molecule <e2>serine protease<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Mesupron","object":"serine protease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Upamostat (<e1>CHEMICAL<\\e1> ) is a new small molecule <e2>GENE-N<\\e2> inhibitor","sentence":"Upamostat (Mesupron ) is a new small molecule serine protease inhibitor"}
{"PMID":23384997,"re_id":5,"annotated sentence":"Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas <e2>GPx1b1<\\e2> and GPx1b2 were highly induced by exposure to <e1>selenium<\\e1> levels that had some toxic effects on the cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"selenium","object":"GPx1b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, GPx1a was the most sensitive to CHEMICAL availability in non stressful conditions, whereas <e2>GENE-Y<\\e2> and GPx1b2 were highly induced by exposure to <e1>CHEMICAL<\\e1> levels that had some toxic effects on the cells","sentence":"Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas GPx1b1 and GPx1b2 were highly induced by exposure to selenium levels that had some toxic effects on the cells"}
{"PMID":23384997,"re_id":6,"annotated sentence":"Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas GPx1b1 and <e2>GPx1b2<\\e2> were highly induced by exposure to <e1>selenium<\\e1> levels that had some toxic effects on the cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"selenium","object":"GPx1b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, GPx1a was the most sensitive to CHEMICAL availability in non stressful conditions, whereas GPx1b1 and <e2>GENE-Y<\\e2> were highly induced by exposure to <e1>CHEMICAL<\\e1> levels that had some toxic effects on the cells","sentence":"Interestingly, GPx1a was the most sensitive to selenium availability in non stressful conditions, whereas GPx1b1 and GPx1b2 were highly induced by exposure to selenium levels that had some toxic effects on the cells"}
{"PMID":23385959,"re_id":0,"annotated sentence":"These findings are the first to show that long-term exposure to <e1>Mn<\\e1> during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, <e2>p38<\\e2> MAPK) phosphorylation and caspase activity in the striatum","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Mn","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings are the first to show that long-term exposure to <e1>CHEMICAL<\\e1> during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, <e2>GENE-N<\\e2> MAPK) phosphorylation and caspase activity in the striatum","sentence":"These findings are the first to show that long-term exposure to Mn during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38 MAPK) phosphorylation and caspase activity in the striatum"}
{"PMID":23385959,"re_id":1,"annotated sentence":"These findings are the first to show that long-term exposure to <e1>Mn<\\e1> during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38(<e2>MAPK<\\e2>  phosphorylation and caspase activity in the striatum","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Mn","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings are the first to show that long-term exposure to <e1>CHEMICAL<\\e1> during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38(<e2>GENE-N<\\e2>  phosphorylation and caspase activity in the striatum","sentence":"These findings are the first to show that long-term exposure to Mn during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38(MAPK  phosphorylation and caspase activity in the striatum"}
{"PMID":23385959,"re_id":2,"annotated sentence":"These findings are the first to show that long-term exposure to <e1>Mn<\\e1> during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38(MAPK) phosphorylation and <e2>caspase<\\e2> activity in the striatum","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Mn","object":"caspase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings are the first to show that long-term exposure to <e1>CHEMICAL<\\e1> during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38(MAPK) phosphorylation and <e2>GENE-N<\\e2> activity in the striatum","sentence":"These findings are the first to show that long-term exposure to Mn during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38(MAPK) phosphorylation and caspase activity in the striatum"}
{"PMID":23385959,"re_id":3,"annotated sentence":"<e1>Mn<\\e1> exposure (20\u00a0mg\/kg) increased <e2>p38<\\e2> MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Mn","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> exposure (20\u00a0mg\/kg) increased <e2>GENE-N<\\e2> MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation","sentence":"Mn exposure (20\u00a0mg\/kg) increased p38 MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation"}
{"PMID":23385959,"re_id":4,"annotated sentence":"<e1>Mn<\\e1> exposure (20\u00a0mg\/kg) increased p38(<e2>MAPK<\\e2>  and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Mn","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> exposure (20\u00a0mg\/kg) increased p38(<e2>GENE-N<\\e2>  and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation","sentence":"Mn exposure (20\u00a0mg\/kg) increased p38(MAPK  and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation"}
{"PMID":23385959,"re_id":5,"annotated sentence":"<e1>Mn<\\e1> exposure (20\u00a0mg\/kg) increased p38(MAPK) and <e2>Akt<\\e2> phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Mn","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> exposure (20\u00a0mg\/kg) increased p38(MAPK) and <e2>GENE-N<\\e2> phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation","sentence":"Mn exposure (20\u00a0mg\/kg) increased p38(MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation"}
{"PMID":23385959,"re_id":6,"annotated sentence":"<e1>Mn<\\e1> (10 and 20\u00a0mg\/kg) increased <e2>caspase<\\e2> activity and F(2)-isoprostane production (a biological marker of lipid peroxidation)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Mn","object":"caspase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (10 and 20\u00a0mg\/kg) increased <e2>GENE-N<\\e2> activity and F(2)-isoprostane production (a biological marker of lipid peroxidation)","sentence":"Mn (10 and 20\u00a0mg\/kg) increased caspase activity and F(2)-isoprostane production (a biological marker of lipid peroxidation)"}
{"PMID":23385959,"re_id":7,"annotated sentence":"Notably, the antioxidant Trolox\u2122 reversed the <e1>Mn<\\e1> (20\u00a0mg\/kg)-dependent augmentation in <e2>p38<\\e2> MAPK) phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Mn","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Notably, the antioxidant Trolox\u2122 reversed the <e1>CHEMICAL<\\e1> (20\u00a0mg\/kg)-dependent augmentation in <e2>GENE-N<\\e2> MAPK) phosphorylation and reduced the CHEMICAL (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production","sentence":"Notably, the antioxidant Trolox\u2122 reversed the Mn (20\u00a0mg\/kg)-dependent augmentation in p38 MAPK) phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production"}
{"PMID":23385959,"re_id":8,"annotated sentence":"Notably, the antioxidant Trolox\u2122 reversed the <e1>Mn<\\e1> (20\u00a0mg\/kg)-dependent augmentation in p38(<e2>MAPK<\\e2>  phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Mn","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Notably, the antioxidant Trolox\u2122 reversed the <e1>CHEMICAL<\\e1> (20\u00a0mg\/kg)-dependent augmentation in p38(<e2>GENE-N<\\e2>  phosphorylation and reduced the CHEMICAL (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production","sentence":"Notably, the antioxidant Trolox\u2122 reversed the Mn (20\u00a0mg\/kg)-dependent augmentation in p38(MAPK  phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production"}
{"PMID":23385959,"re_id":9,"annotated sentence":"Notably, the antioxidant Trolox\u2122 reversed the Mn (20\u00a0mg\/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the <e1>Mn<\\e1> (20\u00a0mg\/kg)-induced <e2>caspase<\\e2> activity and F(2)-isoprostane production","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Mn","object":"caspase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Notably, the antioxidant Trolox\u2122 reversed the CHEMICAL (20\u00a0mg\/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the <e1>CHEMICAL<\\e1> (20\u00a0mg\/kg)-induced <e2>GENE-N<\\e2> activity and F(2)-isoprostane production","sentence":"Notably, the antioxidant Trolox\u2122 reversed the Mn (20\u00a0mg\/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production"}
{"PMID":23385959,"re_id":10,"annotated sentence":"<e1>Mn<\\e1> exposure (20\u00a0mg\/kg) increased p38(MAPK) and Akt phosphorylation, but decreased <e2>DARPP-32<\\e2> Thr-34 phosphorylation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Mn","object":"DARPP-32","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> exposure (20\u00a0mg\/kg) increased p38(MAPK) and Akt phosphorylation, but decreased <e2>GENE-Y<\\e2> Thr-34 phosphorylation","sentence":"Mn exposure (20\u00a0mg\/kg) increased p38(MAPK) and Akt phosphorylation, but decreased DARPP-32 Thr-34 phosphorylation"}
{"PMID":23385959,"re_id":11,"annotated sentence":"Notably, the antioxidant <e1>Trolox<\\e1>  reversed the Mn (20\u00a0mg\/kg)-dependent augmentation in <e2>p38<\\e2> MAPK) phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Trolox","object":"p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Notably, the antioxidant <e1>CHEMICAL<\\e1>  reversed the Mn (20\u00a0mg\/kg)-dependent augmentation in <e2>GENE-N<\\e2> MAPK) phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production","sentence":"Notably, the antioxidant Trolox  reversed the Mn (20\u00a0mg\/kg)-dependent augmentation in p38 MAPK) phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production"}
{"PMID":23385959,"re_id":12,"annotated sentence":"Notably, the antioxidant <e1>Trolox<\\e1>  reversed the Mn (20\u00a0mg\/kg)-dependent augmentation in p38(<e2>MAPK<\\e2>  phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Trolox","object":"MAPK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Notably, the antioxidant <e1>CHEMICAL<\\e1>  reversed the Mn (20\u00a0mg\/kg)-dependent augmentation in p38(<e2>GENE-N<\\e2>  phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production","sentence":"Notably, the antioxidant Trolox  reversed the Mn (20\u00a0mg\/kg)-dependent augmentation in p38(MAPK  phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production"}
{"PMID":23385959,"re_id":13,"annotated sentence":"Notably, the antioxidant <e1>Trolox<\\e1>  reversed the Mn (20\u00a0mg\/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced <e2>caspase<\\e2> activity and F(2)-isoprostane production","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Trolox","object":"caspase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Notably, the antioxidant <e1>CHEMICAL<\\e1>  reversed the Mn (20\u00a0mg\/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced <e2>GENE-N<\\e2> activity and F(2)-isoprostane production","sentence":"Notably, the antioxidant Trolox  reversed the Mn (20\u00a0mg\/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20\u00a0mg\/kg)-induced caspase activity and F(2)-isoprostane production"}
{"PMID":23386029,"re_id":0,"annotated sentence":"<e1>Nocapyrone H<\\e1> (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and <e2>interleukin-1\u03b2<\\e2> (IL-1\u03b2)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Nocapyrone H","object":"interleukin-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and <e2>GENE-Y<\\e2> (IL-1\u03b2)","sentence":"Nocapyrone H (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and interleukin-1\u03b2 (IL-1\u03b2)"}
{"PMID":23386029,"re_id":1,"annotated sentence":"<e1>Nocapyrone H<\\e1> (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and interleukin-1\u03b2 (<e2>IL-1\u03b2<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Nocapyrone H","object":"IL-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and interleukin-1\u03b2 (<e2>GENE-Y<\\e2> ","sentence":"Nocapyrone H (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and interleukin-1\u03b2 (IL-1\u03b2 "}
{"PMID":23386703,"re_id":0,"annotated sentence":"Investigating the enteroenteric recirculation of <e1>apixaban<\\e1>  a <e2>factor Xa<\\e2> inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"apixaban","object":"factor Xa","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Investigating the enteroenteric recirculation of <e1>CHEMICAL<\\e1>  a <e2>GENE-N<\\e2> inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats","sentence":"Investigating the enteroenteric recirculation of apixaban  a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats"}
{"PMID":23386703,"re_id":1,"annotated sentence":"The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with <e1>GF-120918<\\e1>  a dual <e2>BCRP<\\e2> and P-gp inhibitor)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GF-120918","object":"BCRP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with <e1>CHEMICAL<\\e1>  a dual <e2>GENE-Y<\\e2> and P-gp inhibitor)","sentence":"The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with GF-120918  a dual BCRP and P-gp inhibitor)"}
{"PMID":23386703,"re_id":2,"annotated sentence":"The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with <e1>GF-120918<\\e1>  a dual BCRP and <e2>P-gp<\\e2> inhibitor)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GF-120918","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with <e1>CHEMICAL<\\e1>  a dual BCRP and <e2>GENE-N<\\e2> inhibitor)","sentence":"The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with GF-120918  a dual BCRP and P-gp inhibitor)"}
{"PMID":23386703,"re_id":3,"annotated sentence":"<e2>BCRP<\\e2> appeared to play a more important role for absorption and intestinal and renal elimination of <e1>apixaban<\\e1> than P-gp in transporter-KO rats after oral and i.v","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"apixaban","object":"BCRP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> appeared to play a more important role for absorption and intestinal and renal elimination of <e1>CHEMICAL<\\e1> than P-gp in transporter-KO rats after oral and i.v","sentence":"BCRP appeared to play a more important role for absorption and intestinal and renal elimination of apixaban than P-gp in transporter-KO rats after oral and i.v"}
{"PMID":23386703,"re_id":4,"annotated sentence":"BCRP appeared to play a more important role for absorption and intestinal and renal elimination of <e1>apixaban<\\e1> than <e2>P-gp<\\e2> in transporter-KO rats after oral and i.v","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"apixaban","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"BCRP appeared to play a more important role for absorption and intestinal and renal elimination of <e1>CHEMICAL<\\e1> than <e2>GENE-N<\\e2> in transporter-KO rats after oral and i.v","sentence":"BCRP appeared to play a more important role for absorption and intestinal and renal elimination of apixaban than P-gp in transporter-KO rats after oral and i.v"}
{"PMID":23391336,"re_id":1,"annotated sentence":"A large number of <e1>aromatic\/heterocyclic sulfonamides<\\e1> and some 5-mercapto-1,3,4-thiadiazoles were investigated as <e2>TcCA<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"aromatic\/heterocyclic sulfonamides","object":"TcCA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A large number of <e1>CHEMICAL<\\e1> and some 5-mercapto-1,3,4-thiadiazoles were investigated as <e2>GENE-Y<\\e2> inhibitors","sentence":"A large number of aromatic\/heterocyclic sulfonamides and some 5-mercapto-1,3,4-thiadiazoles were investigated as TcCA inhibitors"}
{"PMID":23391336,"re_id":2,"annotated sentence":"A large number of aromatic\/heterocyclic sulfonamides and some <e1>5-mercapto-1,3,4-thiadiazoles<\\e1> were investigated as <e2>TcCA<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"5-mercapto-1,3,4-thiadiazoles","object":"TcCA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A large number of aromatic\/heterocyclic sulfonamides and some <e1>CHEMICAL<\\e1> were investigated as <e2>GENE-Y<\\e2> inhibitors","sentence":"A large number of aromatic\/heterocyclic sulfonamides and some 5-mercapto-1,3,4-thiadiazoles were investigated as TcCA inhibitors"}
{"PMID":23391336,"re_id":3,"annotated sentence":"Cloning, Characterization, and <e1>Sulfonamide<\\e1> and Thiol Inhibition Studies of an <e2>\u03b1-Carbonic Anhydrase<\\e2> from Trypanosoma cruzi, the Causative Agent of Chagas Disease","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Sulfonamide","object":"\u03b1-Carbonic Anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cloning, Characterization, and <e1>CHEMICAL<\\e1> and Thiol Inhibition Studies of an <e2>GENE-Y<\\e2> from Trypanosoma cruzi, the Causative Agent of Chagas Disease","sentence":"Cloning, Characterization, and Sulfonamide and Thiol Inhibition Studies of an \u03b1-Carbonic Anhydrase from Trypanosoma cruzi, the Causative Agent of Chagas Disease"}
{"PMID":23391336,"re_id":4,"annotated sentence":"Cloning, Characterization, and Sulfonamide and <e1>Thiol<\\e1> Inhibition Studies of an <e2>\u03b1-Carbonic Anhydrase<\\e2> from Trypanosoma cruzi, the Causative Agent of Chagas Disease","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Thiol","object":"\u03b1-Carbonic Anhydrase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cloning, Characterization, and Sulfonamide and <e1>CHEMICAL<\\e1> Inhibition Studies of an <e2>GENE-Y<\\e2> from Trypanosoma cruzi, the Causative Agent of Chagas Disease","sentence":"Cloning, Characterization, and Sulfonamide and Thiol Inhibition Studies of an \u03b1-Carbonic Anhydrase from Trypanosoma cruzi, the Causative Agent of Chagas Disease"}
{"PMID":23391336,"re_id":5,"annotated sentence":"The enzyme (TcCA) has a very high catalytic activity for the <e1>CO(2)<\\e1> hydration reaction, being similar kinetically to the human (h) isoform <e2>hCA II<\\e2>  although it is devoid of the His64 proton shuttle","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"CO(2)","object":"hCA II","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The enzyme (TcCA) has a very high catalytic activity for the <e1>CHEMICAL<\\e1> hydration reaction, being similar kinetically to the human (h) isoform <e2>GENE-Y<\\e2>  although it is devoid of the His64 proton shuttle","sentence":"The enzyme (TcCA) has a very high catalytic activity for the CO(2) hydration reaction, being similar kinetically to the human (h) isoform hCA II  although it is devoid of the His64 proton shuttle"}
{"PMID":23391336,"re_id":6,"annotated sentence":"The enzyme (<e2>TcCA<\\e2>  has a very high catalytic activity for the <e1>CO(2)<\\e1> hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"CO(2)","object":"TcCA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The enzyme (<e2>GENE-Y<\\e2>  has a very high catalytic activity for the <e1>CHEMICAL<\\e1> hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle","sentence":"The enzyme (TcCA  has a very high catalytic activity for the CO(2) hydration reaction, being similar kinetically to the human (h) isoform hCA II, although it is devoid of the His64 proton shuttle"}
{"PMID":23391632,"re_id":8,"annotated sentence":"The mRNA level for <e2>nestin<\\e2> (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-<e1>EDS<\\e1>  but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"EDS","object":"nestin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mRNA level for <e2>GENE-Y<\\e2> (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-<e1>CHEMICAL<\\e1>  but not in the DEHP treated testes, suggesting that these GENE-Y positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes","sentence":"The mRNA level for nestin (Nes, biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS  but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes"}
{"PMID":23391632,"re_id":9,"annotated sentence":"The mRNA level for nestin (<e2>Nes<\\e2>  biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-<e1>EDS<\\e1>  but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"EDS","object":"Nes","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The mRNA level for nestin (<e2>GENE-Y<\\e2>  biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-<e1>CHEMICAL<\\e1>  but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes","sentence":"The mRNA level for nestin (Nes  biomarker for stem Leydig cells) was significantly increased in the control testis on day 4 post-EDS  but not in the DEHP treated testes, suggesting that these nestin positive stem cells were differentiated into progenitor Leydig cells in the DEHP-treated testes"}
{"PMID":23393127,"re_id":4,"annotated sentence":"A dominant negative PKA (DNPKA) reduced <e1>GnRH<\\e1> stimulated <e2>pCREB<\\e2> and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"pCREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A dominant negative PKA (DNPKA) reduced <e1>CHEMICAL<\\e1> stimulated <e2>GENE-N<\\e2> and markedly decreased CHEMICAL stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","sentence":"A dominant negative PKA (DNPKA) reduced GnRH stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway"}
{"PMID":23393127,"re_id":5,"annotated sentence":"A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased <e1>GnRH<\\e1> stimulation of FSH\u03b2 mRNA and <e2>FSH\u03b2<\\e2> UC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"FSH\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A dominant negative PKA (DNPKA) reduced CHEMICAL-stimulated pCREB and markedly decreased <e1>CHEMICAL<\\e1> stimulation of GENE-Y mRNA and <e2>GENE-Y<\\e2> UC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","sentence":"A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2 UC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway"}
{"PMID":23393127,"re_id":6,"annotated sentence":"In perifusion studies, FSH\u03b2 mRNA levels and <e2>FSH\u03b2<\\e2> UC activities were increased by pulsatile <e1>GnRH<\\e1>  with significantly greater increases at low compared with high pulse frequencies","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"FSH\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In perifusion studies, GENE-Y mRNA levels and <e2>GENE-Y<\\e2> UC activities were increased by pulsatile <e1>CHEMICAL<\\e1>  with significantly greater increases at low compared with high pulse frequencies","sentence":"In perifusion studies, FSH\u03b2 mRNA levels and FSH\u03b2 UC activities were increased by pulsatile GnRH  with significantly greater increases at low compared with high pulse frequencies"}
{"PMID":23393127,"re_id":7,"annotated sentence":"<e1>GnRH<\\e1> pulse frequency-dependent stimulation of FSH\u03b2 transcription is mediated via activation of PKA and <e2>CREB<\\e2>  Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> pulse frequency-dependent stimulation of FSH\u03b2 transcription is mediated via activation of PKA and <e2>GENE-N<\\e2>  Expression of pituitary FSH and LH, under the control of pulsatile CHEMICAL, is essential for fertility","sentence":"GnRH pulse frequency-dependent stimulation of FSH\u03b2 transcription is mediated via activation of PKA and CREB  Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility"}
{"PMID":23393127,"re_id":8,"annotated sentence":"<e1>GnRH<\\e1> pulse frequency-dependent stimulation of FSH\u03b2 transcription is mediated via activation of <e2>PKA<\\e2> and CREB","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"PKA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> pulse frequency-dependent stimulation of FSH\u03b2 transcription is mediated via activation of <e2>GENE-N<\\e2> and CREB","sentence":"GnRH pulse frequency-dependent stimulation of FSH\u03b2 transcription is mediated via activation of PKA and CREB"}
{"PMID":23393127,"re_id":9,"annotated sentence":"Correlating with <e2>FSH\u03b2<\\e2> activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high <e1>GnRH<\\e1> pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"FSH\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Correlating with <e2>GENE-Y<\\e2> activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high <e1>CHEMICAL<\\e1> pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies","sentence":"Correlating with FSH\u03b2 activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies"}
{"PMID":23393127,"re_id":10,"annotated sentence":"Correlating with FSH\u03b2 activation, both <e2>PKA<\\e2> activity and levels of pCREB were increased to a greater extent by low compared with high <e1>GnRH<\\e1> pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"PKA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Correlating with FSH\u03b2 activation, both <e2>GENE-N<\\e2> activity and levels of pCREB were increased to a greater extent by low compared with high <e1>CHEMICAL<\\e1> pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNGENE-N at both low and high pulse frequencies","sentence":"Correlating with FSH\u03b2 activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies"}
{"PMID":23393127,"re_id":11,"annotated sentence":"Correlating with FSH\u03b2 activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high <e1>GnRH<\\e1> pulse frequencies, and the induction of <e2>pCREB<\\e2> was also attenuated by overexpression of DNPKA at both low and high pulse frequencies","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"pCREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Correlating with FSH\u03b2 activation, both PKA activity and levels of GENE-N were increased to a greater extent by low compared with high <e1>CHEMICAL<\\e1> pulse frequencies, and the induction of <e2>GENE-N<\\e2> was also attenuated by overexpression of DNPKA at both low and high pulse frequencies","sentence":"Correlating with FSH\u03b2 activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies"}
{"PMID":23393127,"re_id":12,"annotated sentence":"Taken together, these data indicate that a PKA-mediated signaling pathway mediates <e1>GnRH<\\e1> activation of <e2>CREB<\\e2> at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent FSH\u03b2 activation.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together, these data indicate that a PKA-mediated signaling pathway mediates <e1>CHEMICAL<\\e1> activation of <e2>GENE-N<\\e2> at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic CHEMICAL signal to result in frequency-dependent FSH\u03b2 activation.","sentence":"Taken together, these data indicate that a PKA-mediated signaling pathway mediates GnRH activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent FSH\u03b2 activation."}
{"PMID":23393127,"re_id":13,"annotated sentence":"Taken together, these data indicate that a PKA-mediated signaling pathway mediates GnRH activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic <e1>GnRH<\\e1> signal to result in frequency-dependent <e2>FSH\u03b2<\\e2> activation.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"FSH\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, these data indicate that a PKA-mediated signaling pathway mediates CHEMICAL activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic <e1>CHEMICAL<\\e1> signal to result in frequency-dependent <e2>GENE-Y<\\e2> activation.","sentence":"Taken together, these data indicate that a PKA-mediated signaling pathway mediates GnRH activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent FSH\u03b2 activation."}
{"PMID":23393127,"re_id":14,"annotated sentence":"cAMP response element-binding protein (CREB) has been implicated in the regulation of FSH\u03b2 gene expression, but the molecular mechanisms by which pulsatile <e1>GnRH<\\e1> regulates <e2>CREB<\\e2> activation remain poorly understood","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"cAMP response element-binding protein (GENE-N) has been implicated in the regulation of FSH\u03b2 gene expression, but the molecular mechanisms by which pulsatile <e1>CHEMICAL<\\e1> regulates <e2>GENE-N<\\e2> activation remain poorly understood","sentence":"cAMP response element-binding protein (CREB) has been implicated in the regulation of FSH\u03b2 gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood"}
{"PMID":23393127,"re_id":15,"annotated sentence":"We hypothesized that <e2>CREB<\\e2> is activated by a distinct signaling pathway in response to pulsatile <e1>GnRH<\\e1> in a frequency-dependent manner to dictate the FSH\u03b2 transcriptional response","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We hypothesized that <e2>GENE-N<\\e2> is activated by a distinct signaling pathway in response to pulsatile <e1>CHEMICAL<\\e1> in a frequency-dependent manner to dictate the FSH\u03b2 transcriptional response","sentence":"We hypothesized that CREB is activated by a distinct signaling pathway in response to pulsatile GnRH in a frequency-dependent manner to dictate the FSH\u03b2 transcriptional response"}
{"PMID":23393127,"re_id":16,"annotated sentence":"<e1>GnRH<\\e1> stimulation of <e2>CREB<\\e2> phosphorylation (pCREB) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> stimulation of <e2>GENE-N<\\e2> phosphorylation (pGENE-N) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89","sentence":"GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89"}
{"PMID":23393127,"re_id":17,"annotated sentence":"<e1>GnRH<\\e1> stimulation of CREB phosphorylation (<e2>pCREB<\\e2>  in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"GnRH","object":"pCREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> stimulation of CREB phosphorylation (<e2>GENE-N<\\e2>  in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89","sentence":"GnRH stimulation of CREB phosphorylation (pCREB  in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89"}
{"PMID":23393127,"re_id":18,"annotated sentence":"A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased <e1>GnRH<\\e1> stimulation of <e2>FSH\u03b2<\\e2> mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GnRH","object":"FSH\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A dominant negative PKA (DNPKA) reduced CHEMICAL-stimulated pCREB and markedly decreased <e1>CHEMICAL<\\e1> stimulation of <e2>GENE-Y<\\e2> mRNA and GENE-YLUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","sentence":"A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway"}
{"PMID":23393127,"re_id":19,"annotated sentence":"In perifusion studies, <e2>FSH\u03b2<\\e2> mRNA levels and FSH\u03b2LUC activities were increased by pulsatile <e1>GnRH<\\e1>  with significantly greater increases at low compared with high pulse frequencies","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GnRH","object":"FSH\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In perifusion studies, <e2>GENE-Y<\\e2> mRNA levels and GENE-YLUC activities were increased by pulsatile <e1>CHEMICAL<\\e1>  with significantly greater increases at low compared with high pulse frequencies","sentence":"In perifusion studies, FSH\u03b2 mRNA levels and FSH\u03b2LUC activities were increased by pulsatile GnRH  with significantly greater increases at low compared with high pulse frequencies"}
{"PMID":23393127,"re_id":20,"annotated sentence":"<e1>GnRH<\\e1> pulse frequency-dependent stimulation of <e2>FSH\u03b2<\\e2> transcription is mediated via activation of PKA and CREB","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GnRH","object":"FSH\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> pulse frequency-dependent stimulation of <e2>GENE-Y<\\e2> transcription is mediated via activation of PKA and CREB","sentence":"GnRH pulse frequency-dependent stimulation of FSH\u03b2 transcription is mediated via activation of PKA and CREB"}
{"PMID":23393127,"re_id":21,"annotated sentence":"DNPKA markedly reduced these <e1>GnRH<\\e1> stimulated <e2>FSH\u03b2<\\e2> responses at both low and high pulse frequencies","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GnRH","object":"FSH\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"DNPKA markedly reduced these <e1>CHEMICAL<\\e1> stimulated <e2>GENE-Y<\\e2> responses at both low and high pulse frequencies","sentence":"DNPKA markedly reduced these GnRH stimulated FSH\u03b2 responses at both low and high pulse frequencies"}
{"PMID":23393127,"re_id":22,"annotated sentence":"Correlating with FSH\u03b2 activation, both PKA activity and levels of <e2>pCREB<\\e2> were increased to a greater extent by low compared with high <e1>GnRH<\\e1> pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"GnRH","object":"pCREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Correlating with FSH\u03b2 activation, both PKA activity and levels of <e2>GENE-N<\\e2> were increased to a greater extent by low compared with high <e1>CHEMICAL<\\e1> pulse frequencies, and the induction of GENE-N was also attenuated by overexpression of DNPKA at both low and high pulse frequencies","sentence":"Correlating with FSH\u03b2 activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies"}
{"PMID":23393127,"re_id":23,"annotated sentence":"GnRH stimulation of <e2>CREB<\\e2> phosphorylation (pCREB) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, <e1>H89<\\e1>  A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"H89","object":"CREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"GnRH stimulation of <e2>GENE-N<\\e2> phosphorylation (pGENE-N) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, <e1>CHEMICAL<\\e1>  A dominant negative PKA (DNPKA) reduced GnRH-stimulated pGENE-N and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","sentence":"GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89  A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway"}
{"PMID":23393127,"re_id":24,"annotated sentence":"GnRH stimulation of CREB phosphorylation (<e2>pCREB<\\e2>  in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, <e1>H89<\\e1>  A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"H89","object":"pCREB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"GnRH stimulation of CREB phosphorylation (<e2>GENE-N<\\e2>  in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, <e1>CHEMICAL<\\e1>  A dominant negative PKA (DNPKA) reduced GnRH-stimulated GENE-N and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","sentence":"GnRH stimulation of CREB phosphorylation (pCREB  in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89  A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway"}
{"PMID":23393127,"re_id":25,"annotated sentence":"GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a <e2>protein kinase A<\\e2> (PKA) inhibitor, <e1>H89<\\e1>  A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"H89","object":"protein kinase A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a <e2>GENE-N<\\e2> (PKA) inhibitor, <e1>CHEMICAL<\\e1>  A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","sentence":"GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89  A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway"}
{"PMID":23393127,"re_id":26,"annotated sentence":"GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (<e2>PKA<\\e2>  inhibitor, <e1>H89<\\e1>  A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"H89","object":"PKA","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (<e2>GENE-N<\\e2>  inhibitor, <e1>CHEMICAL<\\e1>  A dominant negative GENE-N (DNGENE-N) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway","sentence":"GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived L\u03b2T2 cell line was attenuated by a protein kinase A (PKA  inhibitor, H89  A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSH\u03b2 mRNA and FSH\u03b2LUC activity, but had little effect on LH\u03b2LUC activity, indicating relative specificity of this pathway"}
{"PMID":23395669,"re_id":1,"annotated sentence":"We concluded that <e1>sophocarpine<\\e1> could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of <e2>AMPK<\\e2> ","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"sophocarpine","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We concluded that <e1>CHEMICAL<\\e1> could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of <e2>GENE-Y<\\e2> ","sentence":"We concluded that sophocarpine could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of AMPK "}
{"PMID":23395669,"re_id":2,"annotated sentence":"<e1>Sophocarpine<\\e1> alleviates hepatocyte steatosis through activating <e2>AMPK<\\e2> signaling pathway","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Sophocarpine","object":"AMPK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> alleviates hepatocyte steatosis through activating <e2>GENE-Y<\\e2> signaling pathway","sentence":"Sophocarpine alleviates hepatocyte steatosis through activating AMPK signaling pathway"}
{"PMID":23395669,"re_id":3,"annotated sentence":"Moreover, compared with the model group, <e1>sophocarpine<\\e1> could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and <e2>ACC<\\e2> (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"sophocarpine","object":"ACC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, compared with the model group, <e1>CHEMICAL<\\e1> could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and <e2>GENE-N<\\e2> (>3.27-fold) protein expressions, and reduce P-GENE-N (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression","sentence":"Moreover, compared with the model group, sophocarpine could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression"}
{"PMID":23395669,"re_id":4,"annotated sentence":"Moreover, compared with the model group, <e1>sophocarpine<\\e1> could significantly increase <e2>P-AMPK\u03b1<\\e2> (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"sophocarpine","object":"P-AMPK\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, compared with the model group, <e1>CHEMICAL<\\e1> could significantly increase <e2>GENE-N<\\e2> (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression","sentence":"Moreover, compared with the model group, sophocarpine could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression"}
{"PMID":23395669,"re_id":5,"annotated sentence":"Moreover, compared with the model group, <e1>sophocarpine<\\e1> could significantly increase P-AMPK\u03b1 (>5.82-fold), <e2>AMPK\u03b1<\\e2> (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"sophocarpine","object":"AMPK\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, compared with the model group, <e1>CHEMICAL<\\e1> could significantly increase P-GENE-N (>5.82-fold), <e2>GENE-N<\\e2> (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression","sentence":"Moreover, compared with the model group, sophocarpine could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression"}
{"PMID":23395669,"re_id":6,"annotated sentence":"While <e1>sophocarpine<\\e1> treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of <e2>adiponectin<\\e2> expression (>1.48-fold)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"sophocarpine","object":"adiponectin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While <e1>CHEMICAL<\\e1> treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of <e2>GENE-Y<\\e2> expression (>1.48-fold)","sentence":"While sophocarpine treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold)"}
{"PMID":23395669,"re_id":7,"annotated sentence":"Moreover, compared with the model group, <e1>sophocarpine<\\e1> could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce <e2>P-ACC<\\e2> (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"sophocarpine","object":"P-ACC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, compared with the model group, <e1>CHEMICAL<\\e1> could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce <e2>GENE-N<\\e2> (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression","sentence":"Moreover, compared with the model group, sophocarpine could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression"}
{"PMID":23395669,"re_id":8,"annotated sentence":"Moreover, compared with the model group, <e1>sophocarpine<\\e1> could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and <e2>HNF-4\u03b1<\\e2> (<0.20-fold) protein expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"sophocarpine","object":"HNF-4\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, compared with the model group, <e1>CHEMICAL<\\e1> could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and <e2>GENE-Y<\\e2> (<0.20-fold) protein expression","sentence":"Moreover, compared with the model group, sophocarpine could significantly increase P-AMPK\u03b1 (>5.82-fold), AMPK\u03b1 (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4\u03b1 (<0.20-fold) protein expression"}
{"PMID":23395669,"re_id":9,"annotated sentence":"While <e1>sophocarpine<\\e1> treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of <e2>leptin<\\e2> expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"sophocarpine","object":"leptin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"While <e1>CHEMICAL<\\e1> treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of <e2>GENE-Y<\\e2> expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold)","sentence":"While sophocarpine treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold)"}
{"PMID":23395914,"re_id":0,"annotated sentence":"The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of darunavir with the <e2>P-gp<\\e2> inhibitor <e1>zosuquidar<\\e1>  In presence of zosuquidar, a 2.2-, 4.2- and 5.7-fold increase in Papp values were measured for duodenum, proximal jejunum and ileum, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"zosuquidar","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The involvement of GENE-N in the absorption of darunavir was clearly shown by coperfusion of darunavir with the <e2>GENE-N<\\e2> inhibitor <e1>CHEMICAL<\\e1>  In presence of CHEMICAL, a 2.2-, 4.2- and 5.7-fold increase in Papp values were measured for duodenum, proximal jejunum and ileum, respectively","sentence":"The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar  In presence of zosuquidar, a 2.2-, 4.2- and 5.7-fold increase in Papp values were measured for duodenum, proximal jejunum and ileum, respectively"}
{"PMID":23395914,"re_id":1,"annotated sentence":"Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of <e1>ketoconazole<\\e1> on <e2>P-gp<\\e2> as the main mechanism for the increased transport of darunavir across the small intestine.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ketoconazole","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Upon studying the drug-drug interaction of darunavir with CHEMICAL, data were indicative for an inhibitory effect of <e1>CHEMICAL<\\e1> on <e2>GENE-N<\\e2> as the main mechanism for the increased transport of darunavir across the small intestine.","sentence":"Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on P-gp as the main mechanism for the increased transport of darunavir across the small intestine."}
{"PMID":23395914,"re_id":2,"annotated sentence":"The involvement of <e2>P-gp<\\e2> in the absorption of <e1>darunavir<\\e1> was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"darunavir","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The involvement of <e2>GENE-N<\\e2> in the absorption of <e1>CHEMICAL<\\e1> was clearly shown by coperfusion of CHEMICAL with the GENE-N inhibitor zosuquidar","sentence":"The involvement of P-gp in the absorption of darunavir was clearly shown by coperfusion of darunavir with the P-gp inhibitor zosuquidar"}
{"PMID":23395914,"re_id":3,"annotated sentence":"Involvement of <e2>P450<\\e2> mediated metabolism in the absorption of <e1>darunavir<\\e1> could not be demonstrated in this rat model","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"darunavir","object":"P450","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Involvement of <e2>GENE-N<\\e2> mediated metabolism in the absorption of <e1>CHEMICAL<\\e1> could not be demonstrated in this rat model","sentence":"Involvement of P450 mediated metabolism in the absorption of darunavir could not be demonstrated in this rat model"}
{"PMID":23395914,"re_id":4,"annotated sentence":"Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on <e2>P-gp<\\e2> as the main mechanism for the increased transport of <e1>darunavir<\\e1> across the small intestine.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"darunavir","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Upon studying the drug-drug interaction of CHEMICAL with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on <e2>GENE-N<\\e2> as the main mechanism for the increased transport of <e1>CHEMICAL<\\e1> across the small intestine.","sentence":"Upon studying the drug-drug interaction of darunavir with ketoconazole, data were indicative for an inhibitory effect of ketoconazole on P-gp as the main mechanism for the increased transport of darunavir across the small intestine."}
{"PMID":23395914,"re_id":5,"annotated sentence":"To evaluate to what extent the regional differences in expression of <e2>P-gp<\\e2> and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of <e1>darunavir<\\e1> across different small intestinal segments (duodenum, proximal jejunum and ileum)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"darunavir","object":"P-gp","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To evaluate to what extent the regional differences in expression of <e2>GENE-N<\\e2> and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of <e1>CHEMICAL<\\e1> across different small intestinal segments (duodenum, proximal jejunum and ileum)","sentence":"To evaluate to what extent the regional differences in expression of P-gp and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of darunavir across different small intestinal segments (duodenum, proximal jejunum and ileum)"}
{"PMID":23395914,"re_id":6,"annotated sentence":"To evaluate to what extent the regional differences in expression of P-gp and <e2>P450 enzymes<\\e2> affect the absorption of a dual substrate, we investigated the transport of <e1>darunavir<\\e1> across different small intestinal segments (duodenum, proximal jejunum and ileum)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"darunavir","object":"P450 enzymes","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To evaluate to what extent the regional differences in expression of P-gp and <e2>GENE-N<\\e2> affect the absorption of a dual substrate, we investigated the transport of <e1>CHEMICAL<\\e1> across different small intestinal segments (duodenum, proximal jejunum and ileum)","sentence":"To evaluate to what extent the regional differences in expression of P-gp and P450 enzymes affect the absorption of a dual substrate, we investigated the transport of darunavir across different small intestinal segments (duodenum, proximal jejunum and ileum)"}
{"PMID":23396144,"re_id":0,"annotated sentence":"In another experiment, topical application of CFB, CFE or <e1>CLS<\\e1> prior to UVB irradiation (200mJ\/cm(2)) on BALB\/c mice, inhibited the UVB-elevated protein levels of <e2>COX-2<\\e2>  iNOS, and TNF-\u03b1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"CLS","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In another experiment, topical application of CFB, CFE or <e1>CHEMICAL<\\e1> prior to UVB irradiation (200mJ\/cm(2)) on BALB\/c mice, inhibited the UVB-elevated protein levels of <e2>GENE-Y<\\e2>  iNOS, and TNF-\u03b1","sentence":"In another experiment, topical application of CFB, CFE or CLS prior to UVB irradiation (200mJ\/cm(2)) on BALB\/c mice, inhibited the UVB-elevated protein levels of COX-2  iNOS, and TNF-\u03b1"}
{"PMID":23396144,"re_id":1,"annotated sentence":"In another experiment, topical application of CFB, CFE or <e1>CLS<\\e1> prior to UVB irradiation (200mJ\/cm(2)) on BALB\/c mice, inhibited the UVB-elevated protein levels of COX-2, <e2>iNOS<\\e2>  and TNF-\u03b1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"CLS","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In another experiment, topical application of CFB, CFE or <e1>CHEMICAL<\\e1> prior to UVB irradiation (200mJ\/cm(2)) on BALB\/c mice, inhibited the UVB-elevated protein levels of COX-2, <e2>GENE-Y<\\e2>  and TNF-\u03b1","sentence":"In another experiment, topical application of CFB, CFE or CLS prior to UVB irradiation (200mJ\/cm(2)) on BALB\/c mice, inhibited the UVB-elevated protein levels of COX-2, iNOS  and TNF-\u03b1"}
{"PMID":23396144,"re_id":2,"annotated sentence":"In another experiment, topical application of CFB, CFE or <e1>CLS<\\e1> prior to UVB irradiation (200mJ\/cm(2)) on BALB\/c mice, inhibited the UVB-elevated protein levels of COX-2, iNOS, and <e2>TNF-\u03b1<\\e2>  Furthermore, CFB, CFE and CLS suppressed oxidative damages caused by UVB irradiation for example lipid peroxidation and\/or protein carbonylation, which seemed to be mediated by up-regulation of antioxidant defense enzymes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"CLS","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In another experiment, topical application of CFB, CFE or <e1>CHEMICAL<\\e1> prior to UVB irradiation (200mJ\/cm(2)) on BALB\/c mice, inhibited the UVB-elevated protein levels of COX-2, iNOS, and <e2>GENE-Y<\\e2>  Furthermore, CFB, CFE and CHEMICAL suppressed oxidative damages caused by UVB irradiation for example lipid peroxidation and\/or protein carbonylation, which seemed to be mediated by up-regulation of antioxidant defense enzymes","sentence":"In another experiment, topical application of CFB, CFE or CLS prior to UVB irradiation (200mJ\/cm(2)) on BALB\/c mice, inhibited the UVB-elevated protein levels of COX-2, iNOS, and TNF-\u03b1  Furthermore, CFB, CFE and CLS suppressed oxidative damages caused by UVB irradiation for example lipid peroxidation and\/or protein carbonylation, which seemed to be mediated by up-regulation of antioxidant defense enzymes"}
{"PMID":23396144,"re_id":3,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"buthanol","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":4,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"buthanol","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":5,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"buthanol","object":"inducible nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":6,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"buthanol","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":7,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"buthanol","object":"tumor necrosis factor-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":8,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"buthanol","object":"TNF- \u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":9,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ethylacetate","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":10,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ethylacetate","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":11,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ethylacetate","object":"inducible nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":12,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ethylacetate","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":13,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ethylacetate","object":"tumor necrosis factor-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":14,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ethylacetate","object":"TNF- \u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":15,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"methanol","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":16,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"methanol","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":17,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"methanol","object":"inducible nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":18,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"methanol","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":19,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"methanol","object":"tumor necrosis factor-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":20,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"methanol","object":"TNF- \u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23396144,"re_id":21,"annotated sentence":"fragile extract (CFB or CFE) and a single compound, <e1>clerosterol<\\e1> (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including <e2>cyclooxygenase-2<\\e2> (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"clerosterol","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"fragile extract (CFB or CFE) and a single compound, <e1>CHEMICAL<\\e1> (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including <e2>GENE-Y<\\e2> (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)","sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)"}
{"PMID":23396144,"re_id":22,"annotated sentence":"fragile extract (CFB or CFE) and a single compound, <e1>clerosterol<\\e1> (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (<e2>COX-2<\\e2> , inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"clerosterol","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"fragile extract (CFB or CFE) and a single compound, <e1>CHEMICAL<\\e1> (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (<e2>GENE-Y<\\e2> , inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)","sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2 , inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)"}
{"PMID":23396144,"re_id":23,"annotated sentence":"fragile extract (CFB or CFE) and a single compound, <e1>clerosterol<\\e1> (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), <e2>inducible nitric oxide synthase<\\e2> (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"clerosterol","object":"inducible nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"fragile extract (CFB or CFE) and a single compound, <e1>CHEMICAL<\\e1> (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), <e2>GENE-Y<\\e2> (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)","sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)"}
{"PMID":23396144,"re_id":24,"annotated sentence":"fragile extract (CFB or CFE) and a single compound, <e1>clerosterol<\\e1> (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (<e2>iNOS<\\e2> , and tumor necrosis factor-\u03b1 (TNF- \u03b1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"clerosterol","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"fragile extract (CFB or CFE) and a single compound, <e1>CHEMICAL<\\e1> (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (<e2>GENE-Y<\\e2> , and tumor necrosis factor-\u03b1 (TNF- \u03b1)","sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS , and tumor necrosis factor-\u03b1 (TNF- \u03b1)"}
{"PMID":23396144,"re_id":25,"annotated sentence":"fragile extract (CFB or CFE) and a single compound, <e1>clerosterol<\\e1> (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and <e2>tumor necrosis factor-\u03b1<\\e2> (TNF- \u03b1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"clerosterol","object":"tumor necrosis factor-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"fragile extract (CFB or CFE) and a single compound, <e1>CHEMICAL<\\e1> (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and <e2>GENE-Y<\\e2> (TNF- \u03b1)","sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)"}
{"PMID":23396144,"re_id":26,"annotated sentence":"fragile extract (CFB or CFE) and a single compound, <e1>clerosterol<\\e1> (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (<e2>TNF- \u03b1<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"clerosterol","object":"TNF- \u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"fragile extract (CFB or CFE) and a single compound, <e1>CHEMICAL<\\e1> (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (<e2>GENE-Y<\\e2> ","sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (CLS) isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1 "}
{"PMID":23396144,"re_id":27,"annotated sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS<\\e1>  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including <e2>cyclooxygenase-2<\\e2> (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"CLS","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CHEMICAL<\\e1>  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including <e2>GENE-Y<\\e2> (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)","sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (CLS  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)"}
{"PMID":23396144,"re_id":28,"annotated sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS<\\e1>  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (<e2>COX-2<\\e2> , inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"CLS","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CHEMICAL<\\e1>  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (<e2>GENE-Y<\\e2> , inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)","sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (CLS  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2 , inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)"}
{"PMID":23396144,"re_id":29,"annotated sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS<\\e1>  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), <e2>inducible nitric oxide synthase<\\e2> (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"CLS","object":"inducible nitric oxide synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CHEMICAL<\\e1>  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), <e2>GENE-Y<\\e2> (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)","sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (CLS  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)"}
{"PMID":23396144,"re_id":30,"annotated sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS<\\e1>  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (<e2>iNOS<\\e2> , and tumor necrosis factor-\u03b1 (TNF- \u03b1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"CLS","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CHEMICAL<\\e1>  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (<e2>GENE-Y<\\e2> , and tumor necrosis factor-\u03b1 (TNF- \u03b1)","sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (CLS  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS , and tumor necrosis factor-\u03b1 (TNF- \u03b1)"}
{"PMID":23396144,"re_id":31,"annotated sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS<\\e1>  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and <e2>tumor necrosis factor-\u03b1<\\e2> (TNF- \u03b1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"CLS","object":"tumor necrosis factor-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CHEMICAL<\\e1>  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and <e2>GENE-Y<\\e2> (TNF- \u03b1)","sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (CLS  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1)"}
{"PMID":23396144,"re_id":32,"annotated sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CLS<\\e1>  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (<e2>TNF- \u03b1<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"CLS","object":"TNF- \u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (<e1>CHEMICAL<\\e1>  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (<e2>GENE-Y<\\e2> ","sentence":"fragile extract (CFB or CFE) and a single compound, clerosterol (CLS  isolated from CFE attenuated UVB (60mJ\/cm(2))-induced cytotoxicity and reduced expression of pro-inflammatory proteins including cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and tumor necrosis factor-\u03b1 (TNF- \u03b1 "}
{"PMID":23401473,"re_id":2,"annotated sentence":"In overexpressing cell lines, <e2>OATP1B1<\\e2>  and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin <e1>flavonolignans<\\e1> investigated","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flavonolignans","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In overexpressing cell lines, <e2>GENE-Y<\\e2>  and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin <e1>CHEMICAL<\\e1> investigated","sentence":"In overexpressing cell lines, OATP1B1  and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated"}
{"PMID":23401473,"re_id":3,"annotated sentence":"In overexpressing cell lines, OATP1B1- and <e2>OATP1B3<\\e2> mediated estradiol-17\u03b2-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin <e1>flavonolignans<\\e1> investigated","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flavonolignans","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In overexpressing cell lines, OATP1B1- and <e2>GENE-Y<\\e2> mediated estradiol-17\u03b2-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin <e1>CHEMICAL<\\e1> investigated","sentence":"In overexpressing cell lines, OATP1B1- and OATP1B3 mediated estradiol-17\u03b2-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated"}
{"PMID":23401473,"re_id":4,"annotated sentence":"In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and <e2>OATP2B1<\\e2> mediated estrone-3-sulfate uptake were inhibited by most of the silymarin <e1>flavonolignans<\\e1> investigated","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flavonolignans","object":"OATP2B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and <e2>GENE-Y<\\e2> mediated estrone-3-sulfate uptake were inhibited by most of the silymarin <e1>CHEMICAL<\\e1> investigated","sentence":"In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and OATP2B1 mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated"}
{"PMID":23401473,"re_id":5,"annotated sentence":"<e2>OATP1B1<\\e2> , OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), <e1>silybin A<\\e1> (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"silybin A","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> , OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), <e1>CHEMICAL<\\e1> (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","sentence":"OATP1B1 , OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)"}
{"PMID":23401473,"re_id":6,"annotated sentence":"OATP1B1-, <e2>OATP1B3<\\e2> , and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), <e1>silybin A<\\e1> (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"silybin A","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OATP1B1-, <e2>GENE-Y<\\e2> , and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), <e1>CHEMICAL<\\e1> (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","sentence":"OATP1B1-, OATP1B3 , and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)"}
{"PMID":23401473,"re_id":7,"annotated sentence":"OATP1B1-, OATP1B3-, and <e2>OATP2B1<\\e2> mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), <e1>silybin A<\\e1> (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"silybin A","object":"OATP2B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OATP1B1-, OATP1B3-, and <e2>GENE-Y<\\e2> mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), <e1>CHEMICAL<\\e1> (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","sentence":"OATP1B1-, OATP1B3-, and OATP2B1 mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)"}
{"PMID":23401473,"re_id":8,"annotated sentence":"<e2>OATP1B1<\\e2> , OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), <e1>silybin B<\\e1> (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"silybin B","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> , OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), <e1>CHEMICAL<\\e1> (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","sentence":"OATP1B1 , OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)"}
{"PMID":23401473,"re_id":9,"annotated sentence":"OATP1B1-, <e2>OATP1B3<\\e2> , and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), <e1>silybin B<\\e1> (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"silybin B","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OATP1B1-, <e2>GENE-Y<\\e2> , and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), <e1>CHEMICAL<\\e1> (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","sentence":"OATP1B1-, OATP1B3 , and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)"}
{"PMID":23401473,"re_id":10,"annotated sentence":"OATP1B1-, OATP1B3-, and <e2>OATP2B1<\\e2> mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), <e1>silybin B<\\e1> (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"silybin B","object":"OATP2B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OATP1B1-, OATP1B3-, and <e2>GENE-Y<\\e2> mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), <e1>CHEMICAL<\\e1> (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","sentence":"OATP1B1-, OATP1B3-, and OATP2B1 mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)"}
{"PMID":23401473,"re_id":11,"annotated sentence":"<e2>OATP1B1<\\e2> , OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and <e1>silychristin<\\e1> (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"silychristin","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> , OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and <e1>CHEMICAL<\\e1> (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","sentence":"OATP1B1 , OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)"}
{"PMID":23401473,"re_id":12,"annotated sentence":"OATP1B1-, <e2>OATP1B3<\\e2> , and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and <e1>silychristin<\\e1> (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"silychristin","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OATP1B1-, <e2>GENE-Y<\\e2> , and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and <e1>CHEMICAL<\\e1> (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","sentence":"OATP1B1-, OATP1B3 , and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)"}
{"PMID":23401473,"re_id":13,"annotated sentence":"OATP1B1-, OATP1B3-, and <e2>OATP2B1<\\e2> mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and <e1>silychristin<\\e1> (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"silychristin","object":"OATP2B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"OATP1B1-, OATP1B3-, and <e2>GENE-Y<\\e2> mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and <e1>CHEMICAL<\\e1> (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)","sentence":"OATP1B1-, OATP1B3-, and OATP2B1 mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 \u00b5M, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 \u00b5M, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 \u00b5M, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 \u00b5M, respectively)"}
{"PMID":23401473,"re_id":14,"annotated sentence":"Furthermore, silymarin, <e1>silybin A<\\e1>  and silybin B (100 \u00b5M) significantly inhibited <e2>OATP<\\e2> mediated estradiol-17\u03b2-glucuronide and rosuvastatin uptake into human hepatocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"silybin A","object":"OATP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, silymarin, <e1>CHEMICAL<\\e1>  and silybin B (100 \u00b5M) significantly inhibited <e2>GENE-N<\\e2> mediated estradiol-17\u03b2-glucuronide and rosuvastatin uptake into human hepatocytes","sentence":"Furthermore, silymarin, silybin A  and silybin B (100 \u00b5M) significantly inhibited OATP mediated estradiol-17\u03b2-glucuronide and rosuvastatin uptake into human hepatocytes"}
{"PMID":23401473,"re_id":15,"annotated sentence":"Furthermore, silymarin, silybin A, and <e1>silybin B<\\e1> (100 \u00b5M) significantly inhibited <e2>OATP<\\e2> mediated estradiol-17\u03b2-glucuronide and rosuvastatin uptake into human hepatocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"silybin B","object":"OATP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, silymarin, silybin A, and <e1>CHEMICAL<\\e1> (100 \u00b5M) significantly inhibited <e2>GENE-N<\\e2> mediated estradiol-17\u03b2-glucuronide and rosuvastatin uptake into human hepatocytes","sentence":"Furthermore, silymarin, silybin A, and silybin B (100 \u00b5M) significantly inhibited OATP mediated estradiol-17\u03b2-glucuronide and rosuvastatin uptake into human hepatocytes"}
{"PMID":23401473,"re_id":16,"annotated sentence":"In overexpressing cell lines, <e2>OATP1B1<\\e2>  and OATP1B3-mediated <e1>estradiol-17\u03b2-glucuronide<\\e1> uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"estradiol-17\u03b2-glucuronide","object":"OATP1B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In overexpressing cell lines, <e2>GENE-Y<\\e2>  and OATP1B3-mediated <e1>CHEMICAL<\\e1> uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated","sentence":"In overexpressing cell lines, OATP1B1  and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated"}
{"PMID":23401473,"re_id":17,"annotated sentence":"In overexpressing cell lines, OATP1B1- and <e2>OATP1B3<\\e2> mediated <e1>estradiol-17\u03b2-glucuronide<\\e1> uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"estradiol-17\u03b2-glucuronide","object":"OATP1B3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In overexpressing cell lines, OATP1B1- and <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated","sentence":"In overexpressing cell lines, OATP1B1- and OATP1B3 mediated estradiol-17\u03b2-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated"}
{"PMID":23401473,"re_id":18,"annotated sentence":"In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and <e2>OATP2B1<\\e2> mediated <e1>estrone-3-sulfate<\\e1> uptake were inhibited by most of the silymarin flavonolignans investigated","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"estrone-3-sulfate","object":"OATP2B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and <e2>GENE-Y<\\e2> mediated <e1>CHEMICAL<\\e1> uptake were inhibited by most of the silymarin flavonolignans investigated","sentence":"In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17\u03b2-glucuronide uptake and OATP2B1 mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated"}
{"PMID":23401473,"re_id":19,"annotated sentence":"Furthermore, silymarin, silybin A, and silybin B (100 \u00b5M) significantly inhibited <e2>OATP<\\e2> mediated <e1>estradiol-17\u03b2-glucuronide<\\e1> and rosuvastatin uptake into human hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"estradiol-17\u03b2-glucuronide","object":"OATP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, silymarin, silybin A, and silybin B (100 \u00b5M) significantly inhibited <e2>GENE-N<\\e2> mediated <e1>CHEMICAL<\\e1> and rosuvastatin uptake into human hepatocytes","sentence":"Furthermore, silymarin, silybin A, and silybin B (100 \u00b5M) significantly inhibited OATP mediated estradiol-17\u03b2-glucuronide and rosuvastatin uptake into human hepatocytes"}
{"PMID":23401473,"re_id":20,"annotated sentence":"Furthermore, silymarin, silybin A, and silybin B (100 \u00b5M) significantly inhibited <e2>OATP<\\e2> mediated estradiol-17\u03b2-glucuronide and <e1>rosuvastatin<\\e1> uptake into human hepatocytes","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"rosuvastatin","object":"OATP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, silymarin, silybin A, and silybin B (100 \u00b5M) significantly inhibited <e2>GENE-N<\\e2> mediated estradiol-17\u03b2-glucuronide and <e1>CHEMICAL<\\e1> uptake into human hepatocytes","sentence":"Furthermore, silymarin, silybin A, and silybin B (100 \u00b5M) significantly inhibited OATP mediated estradiol-17\u03b2-glucuronide and rosuvastatin uptake into human hepatocytes"}
{"PMID":23403085,"re_id":0,"annotated sentence":"Further investigation demonstrated that 8k reduced <e1>H2O2<\\e1> induced activation of mitochondrial apoptosis by inhibiting the expression of <e2>Bax<\\e2> and elevating the expression of Bcl-2","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"H2O2","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Further investigation demonstrated that 8k reduced <e1>CHEMICAL<\\e1> induced activation of mitochondrial apoptosis by inhibiting the expression of <e2>GENE-N<\\e2> and elevating the expression of Bcl-2","sentence":"Further investigation demonstrated that 8k reduced H2O2 induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of Bcl-2"}
{"PMID":23403085,"re_id":1,"annotated sentence":"Further investigation demonstrated that 8k reduced <e1>H2O2<\\e1> induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of <e2>Bcl-2<\\e2>  Moreover, the molecular mechanism underlying the observed neuroprotective effects of 8k was exerted via the Akt and JNK pathways","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"H2O2","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Further investigation demonstrated that 8k reduced <e1>CHEMICAL<\\e1> induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of <e2>GENE-N<\\e2>  Moreover, the molecular mechanism underlying the observed neuroprotective effects of 8k was exerted via the Akt and JNK pathways","sentence":"Further investigation demonstrated that 8k reduced H2O2 induced activation of mitochondrial apoptosis by inhibiting the expression of Bax and elevating the expression of Bcl-2  Moreover, the molecular mechanism underlying the observed neuroprotective effects of 8k was exerted via the Akt and JNK pathways"}
{"PMID":23404443,"re_id":1,"annotated sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>insulin<\\e2> (achieved by administering insulin plus <e1>glucose<\\e1>  glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>GENE-Y<\\e2> (achieved by administering GENE-Y plus <e1>CHEMICAL<\\e1>  CHEMICAL only, CHEMICAL and GLP-1, and CHEMICAL and GLP-1 combined with arginine)","sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose  glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine)"}
{"PMID":23404443,"re_id":2,"annotated sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>insulin<\\e2> (achieved by administering insulin plus glucose, <e1>glucose<\\e1> only, glucose and GLP-1, and glucose and GLP-1 combined with arginine)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>GENE-Y<\\e2> (achieved by administering GENE-Y plus CHEMICAL, <e1>CHEMICAL<\\e1> only, CHEMICAL and GLP-1, and CHEMICAL and GLP-1 combined with arginine)","sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine)"}
{"PMID":23404443,"re_id":3,"annotated sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>insulin<\\e2> (achieved by administering insulin plus glucose, glucose only, <e1>glucose<\\e1> and GLP-1, and glucose and GLP-1 combined with arginine)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>GENE-Y<\\e2> (achieved by administering GENE-Y plus CHEMICAL, CHEMICAL only, <e1>CHEMICAL<\\e1> and GLP-1, and CHEMICAL and GLP-1 combined with arginine)","sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine)"}
{"PMID":23404443,"re_id":4,"annotated sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>insulin<\\e2> (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and <e1>glucose<\\e1> and GLP-1 combined with arginine)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>GENE-Y<\\e2> (achieved by administering GENE-Y plus CHEMICAL, CHEMICAL only, CHEMICAL and GLP-1, and <e1>CHEMICAL<\\e1> and GLP-1 combined with arginine)","sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine)"}
{"PMID":23404443,"re_id":5,"annotated sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>insulin<\\e2> (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with <e1>arginine<\\e1> ","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"arginine","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of <e2>GENE-Y<\\e2> (achieved by administering GENE-Y plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with <e1>CHEMICAL<\\e1> ","sentence":"Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine "}
{"PMID":23407783,"re_id":2,"annotated sentence":"Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10\u00a0mg\/kg\/day), and the partial <e2>N-methyl-D-aspartate (NMDA) receptor<\\e2> agonist, <e1>D-cycloserine<\\e1> (10\u00a0mg\/kg\/day), two compounds which have demonstrated clinical efficacy against PTSD","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"D-cycloserine","object":"N-methyl-D-aspartate (NMDA) receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10\u00a0mg\/kg\/day), and the partial <e2>GENE-N<\\e2> agonist, <e1>CHEMICAL<\\e1> (10\u00a0mg\/kg\/day), two compounds which have demonstrated clinical efficacy against PTSD","sentence":"Effects of SSR125543 were compared to those of the 5-HT reuptake inhibitor, paroxetine (10\u00a0mg\/kg\/day), and the partial N-methyl-D-aspartate (NMDA) receptor agonist, D-cycloserine (10\u00a0mg\/kg\/day), two compounds which have demonstrated clinical efficacy against PTSD"}
{"PMID":23407783,"re_id":3,"annotated sentence":"RATIONALE: The selective <e2>CRF(1) (corticotropin releasing factor type 1) receptor<\\e2> antagonist <e1>SSR125543<\\e1> has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"SSR125543","object":"CRF(1) (corticotropin releasing factor type 1) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RATIONALE: The selective <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure","sentence":"RATIONALE: The selective CRF(1) (corticotropin releasing factor type 1) receptor antagonist SSR125543 has been previously shown to attenuate the long-term cognitive deficit produced by traumatic stress exposure"}
{"PMID":23407783,"re_id":4,"annotated sentence":"The <e2>CRF(1) receptor<\\e2> antagonist <e1>SSR125543<\\e1> prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"SSR125543","object":"CRF(1) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine","sentence":"The CRF(1) receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: Comparison with paroxetine and D-cycloserine"}
{"PMID":23407783,"re_id":5,"annotated sentence":"CONCLUSIONS: These findings confirm that the <e2>CRF(1) receptor<\\e2> antagonist <e1>SSR125543<\\e1> is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress.","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"SSR125543","object":"CRF(1) receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: These findings confirm that the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress.","sentence":"CONCLUSIONS: These findings confirm that the CRF(1) receptor antagonist SSR125543 is able to attenuate the behavioral effects of traumatic stress exposure and indicate that these effects are associated with a normalization of hippocampal neuronal excitability impaired by stress."}
{"PMID":23409871,"re_id":1,"annotated sentence":"A series of <e1>indazole arylsulfonamides<\\e1> were synthesized and examined as <e2>human CCR4<\\e2> antagonists","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"indazole arylsulfonamides","object":"human CCR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of <e1>CHEMICAL<\\e1> were synthesized and examined as <e2>GENE-Y<\\e2> antagonists","sentence":"A series of indazole arylsulfonamides were synthesized and examined as human CCR4 antagonists"}
{"PMID":23412396,"re_id":6,"annotated sentence":"Mice given daily injections of high dose <e1>JZL184<\\e1> (\u226516 mg\/kg) for six days displayed decreased <e2>CB(1)<\\e2> receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTP\u03b3S binding assays, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"JZL184","object":"CB(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Mice given daily injections of high dose <e1>CHEMICAL<\\e1> (\u226516 mg\/kg) for six days displayed decreased <e2>GENE-Y<\\e2> receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTP\u03b3S binding assays, respectively","sentence":"Mice given daily injections of high dose JZL184 (\u226516 mg\/kg) for six days displayed decreased CB(1) receptor density and function in brain, as assessed in [(3)H]SR141716A binding and CP55,940-stimulated [(35)S]GTP\u03b3S binding assays, respectively"}
{"PMID":23412396,"re_id":7,"annotated sentence":"The monoacylglycerol lipase (<e2>MAGL<\\e2>  inhibitor <e1>JZL184<\\e1> produces antinociceptive and anti-inflammatory effects","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"JZL184","object":"MAGL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The monoacylglycerol lipase (<e2>GENE-Y<\\e2>  inhibitor <e1>CHEMICAL<\\e1> produces antinociceptive and anti-inflammatory effects","sentence":"The monoacylglycerol lipase (MAGL  inhibitor JZL184 produces antinociceptive and anti-inflammatory effects"}
{"PMID":23412396,"re_id":8,"annotated sentence":"The <e2>monoacylglycerol lipase<\\e2> (MAGL) inhibitor <e1>JZL184<\\e1> produces antinociceptive and anti-inflammatory effects","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"JZL184","object":"monoacylglycerol lipase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> (MAGL) inhibitor <e1>CHEMICAL<\\e1> produces antinociceptive and anti-inflammatory effects","sentence":"The monoacylglycerol lipase (MAGL) inhibitor JZL184 produces antinociceptive and anti-inflammatory effects"}
{"PMID":23412396,"re_id":9,"annotated sentence":"Repeated Low Dose Administration of the <e2>Monoacylglycerol Lipase<\\e2> Inhibitor <e1>JZL184<\\e1> Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"JZL184","object":"Monoacylglycerol Lipase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Repeated Low Dose Administration of the <e2>GENE-Y<\\e2> Inhibitor <e1>CHEMICAL<\\e1> Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects","sentence":"Repeated Low Dose Administration of the Monoacylglycerol Lipase Inhibitor JZL184 Retains CB1 Receptor Mediated Antinociceptive and Gastroprotective Effects"}
{"PMID":23416003,"re_id":0,"annotated sentence":"<e1>Bicyclic pyrazinone and pyrimidinone amides<\\e1> were designed and synthesized as potent TF-<e2>FVIIa<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Bicyclic pyrazinone and pyrimidinone amides","object":"FVIIa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> were designed and synthesized as potent TF-<e2>GENE-Y<\\e2> inhibitors","sentence":"Bicyclic pyrazinone and pyrimidinone amides were designed and synthesized as potent TF-FVIIa inhibitors"}
{"PMID":23416003,"re_id":1,"annotated sentence":"<e1>Bicyclic pyrazinone and pyrimidinone amides<\\e1> were designed and synthesized as potent <e2>TF<\\e2> FVIIa inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Bicyclic pyrazinone and pyrimidinone amides","object":"TF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> were designed and synthesized as potent <e2>GENE-Y<\\e2> FVIIa inhibitors","sentence":"Bicyclic pyrazinone and pyrimidinone amides were designed and synthesized as potent TF FVIIa inhibitors"}
{"PMID":23416003,"re_id":2,"annotated sentence":"Design and synthesis of <e1>bicyclic pyrazinone and pyrimidinone amides<\\e1> as potent <e2>TF<\\e2> FVIIa inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bicyclic pyrazinone and pyrimidinone amides","object":"TF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Design and synthesis of <e1>CHEMICAL<\\e1> as potent <e2>GENE-Y<\\e2> FVIIa inhibitors","sentence":"Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF FVIIa inhibitors"}
{"PMID":23416003,"re_id":3,"annotated sentence":"Design and synthesis of <e1>bicyclic pyrazinone and pyrimidinone amides<\\e1> as potent TF-<e2>FVIIa<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bicyclic pyrazinone and pyrimidinone amides","object":"FVIIa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Design and synthesis of <e1>CHEMICAL<\\e1> as potent TF-<e2>GENE-Y<\\e2> inhibitors","sentence":"Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors"}
{"PMID":23416191,"re_id":0,"annotated sentence":"The most potent compound 5 (<e1>HJC0123<\\e1>  has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved <e2>caspase-3<\\e2>  inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"HJC0123","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most potent compound 5 (<e1>CHEMICAL<\\e1>  has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved <e2>GENE-Y<\\e2>  inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values","sentence":"The most potent compound 5 (HJC0123  has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3  inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values"}
{"PMID":23416191,"re_id":1,"annotated sentence":"The most potent compound 5 (<e1>HJC0123<\\e1>  has demonstrated to inhibit <e2>STAT3 promoter<\\e2> activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"HJC0123","object":"STAT3 promoter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The most potent compound 5 (<e1>CHEMICAL<\\e1>  has demonstrated to inhibit <e2>GENE-N<\\e2> activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values","sentence":"The most potent compound 5 (HJC0123  has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values"}
{"PMID":23416191,"re_id":2,"annotated sentence":"The most potent compound 5 (<e1>HJC0123<\\e1>  has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of <e2>STAT3<\\e2>  increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"HJC0123","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The most potent compound 5 (<e1>CHEMICAL<\\e1>  has demonstrated to inhibit GENE-Y promoter activity, downregulate phosphorylation of <e2>GENE-Y<\\e2>  increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values","sentence":"The most potent compound 5 (HJC0123  has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3  increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values"}
{"PMID":23416191,"re_id":3,"annotated sentence":"Fragment-based drug design and identification of <e1>HJC0123<\\e1>  a novel orally bioavailable <e2>STAT3<\\e2> inhibitor for cancer therapy","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"HJC0123","object":"STAT3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Fragment-based drug design and identification of <e1>CHEMICAL<\\e1>  a novel orally bioavailable <e2>GENE-Y<\\e2> inhibitor for cancer therapy","sentence":"Fragment-based drug design and identification of HJC0123  a novel orally bioavailable STAT3 inhibitor for cancer therapy"}
{"PMID":23427190,"re_id":0,"annotated sentence":"Therefore, we examined whether the <e2>PDE5<\\e2> I <e1>vardenafil<\\e1> improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"vardenafil","object":"PDE5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Therefore, we examined whether the <e2>GENE-Y<\\e2> I <e1>CHEMICAL<\\e1> improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults","sentence":"Therefore, we examined whether the PDE5 I vardenafil improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults"}
{"PMID":23427190,"re_id":1,"annotated sentence":"The effects of the <e2>phosphodiesterase type 5<\\e2> inhibitor <e1>vardenafil<\\e1> on cognitive performance in healthy adults: a behavioral- electroencephalography study","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"vardenafil","object":"phosphodiesterase type 5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effects of the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> on cognitive performance in healthy adults: a behavioral- electroencephalography study","sentence":"The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral- electroencephalography study"}
{"PMID":23428346,"re_id":3,"annotated sentence":"We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased <e2>NADPH oxidase<\\e2> activity and immunoreactivity for the protein nitration marker <e1>3-nitrotyrosine<\\e1> in the cerebral cortex","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"3-nitrotyrosine","object":"NADPH oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased <e2>GENE-N<\\e2> activity and immunoreactivity for the protein nitration marker <e1>CHEMICAL<\\e1> in the cerebral cortex","sentence":"We found that atorvastatin withdrawal decreased levels of nitric oxide and mitochondrial superoxide dismutase activity, whereas increased NADPH oxidase activity and immunoreactivity for the protein nitration marker 3-nitrotyrosine in the cerebral cortex"}
{"PMID":23428346,"re_id":4,"annotated sentence":"Statins are inhibitors of the enzyme <e2>3-hydroxy-3-methylglutaryl coenzyme A reductase<\\e2>  the rate-limiting step in <e1>cholesterol<\\e1> biosynthesis","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"cholesterol","object":"3-hydroxy-3-methylglutaryl coenzyme A reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Statins are inhibitors of the enzyme <e2>GENE-Y<\\e2>  the rate-limiting step in <e1>CHEMICAL<\\e1> biosynthesis","sentence":"Statins are inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase  the rate-limiting step in cholesterol biosynthesis"}
{"PMID":23428368,"re_id":1,"annotated sentence":"Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8\u200a\u03bcg\/100\u200ag body weight (BW), i.p.) for 15 days or along with a <e2>peroxisome proliferator-activated receptor alpha<\\e2> agonist <e1>bezafibrate<\\e1> (Bzf; 30\u200a\u03bcg\/100\u200ag BW, oral) and were found to improve in the Bzf co-treated condition","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"bezafibrate","object":"peroxisome proliferator-activated receptor alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8\u200a\u03bcg\/100\u200ag body weight (BW), i.p.) for 15 days or along with a <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> (Bzf; 30\u200a\u03bcg\/100\u200ag BW, oral) and were found to improve in the Bzf co-treated condition","sentence":"Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8\u200a\u03bcg\/100\u200ag body weight (BW), i.p.) for 15 days or along with a peroxisome proliferator-activated receptor alpha agonist bezafibrate (Bzf; 30\u200a\u03bcg\/100\u200ag BW, oral) and were found to improve in the Bzf co-treated condition"}
{"PMID":23428368,"re_id":2,"annotated sentence":"Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8\u200a\u03bcg\/100\u200ag body weight (BW), i.p.) for 15 days or along with a <e2>peroxisome proliferator-activated receptor alpha<\\e2> agonist bezafibrate (<e1>Bzf<\\e1>  30\u200a\u03bcg\/100\u200ag BW, oral) and were found to improve in the Bzf co-treated condition","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"Bzf","object":"peroxisome proliferator-activated receptor alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8\u200a\u03bcg\/100\u200ag body weight (BW), i.p.) for 15 days or along with a <e2>GENE-Y<\\e2> agonist bezafibrate (<e1>CHEMICAL<\\e1>  30\u200a\u03bcg\/100\u200ag BW, oral) and were found to improve in the CHEMICAL co-treated condition","sentence":"Cardiac hypertrophy, structural remodeling, and expression of the genes associated with fatty acid metabolism were examined in rats treated with triiodothyronine (T3) alone (8\u200a\u03bcg\/100\u200ag body weight (BW), i.p.) for 15 days or along with a peroxisome proliferator-activated receptor alpha agonist bezafibrate (Bzf  30\u200a\u03bcg\/100\u200ag BW, oral) and were found to improve in the Bzf co-treated condition"}
{"PMID":23429911,"re_id":2,"annotated sentence":"Moreover, the effects of the <e2>DRD3<\\e2> agonist <e1>7-hydroxy-N,N-dipropyl-2-aminotetralin<\\e1> (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"7-hydroxy-N,N-dipropyl-2-aminotetralin","object":"DRD3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the effects of the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when GENE-Y proteins were abundant","sentence":"Moreover, the effects of the DRD3 agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant"}
{"PMID":23429911,"re_id":3,"annotated sentence":"Moreover, the effects of the DRD3 agonist <e1>7-hydroxy-N,N-dipropyl-2-aminotetralin<\\e1> (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when <e2>DRD3<\\e2> proteins were abundant","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"7-hydroxy-N,N-dipropyl-2-aminotetralin","object":"DRD3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the effects of the GENE-Y agonist <e1>CHEMICAL<\\e1> (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when <e2>GENE-Y<\\e2> proteins were abundant","sentence":"Moreover, the effects of the DRD3 agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (7-OH-DPAT)-induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant"}
{"PMID":23429911,"re_id":4,"annotated sentence":"Moreover, the effects of the <e2>DRD3<\\e2> agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (<e1>7-OH-DPAT<\\e1> -induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"7-OH-DPAT","object":"DRD3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the effects of the <e2>GENE-Y<\\e2> agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (<e1>CHEMICAL<\\e1> -induced locomotor hypoactivity were significantly increased when GENE-Y proteins were abundant","sentence":"Moreover, the effects of the DRD3 agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (7-OH-DPAT -induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant"}
{"PMID":23429911,"re_id":5,"annotated sentence":"Moreover, the effects of the DRD3 agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (<e1>7-OH-DPAT<\\e1> -induced locomotor hypoactivity were significantly increased when <e2>DRD3<\\e2> proteins were abundant","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"7-OH-DPAT","object":"DRD3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, the effects of the GENE-Y agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (<e1>CHEMICAL<\\e1> -induced locomotor hypoactivity were significantly increased when <e2>GENE-Y<\\e2> proteins were abundant","sentence":"Moreover, the effects of the DRD3 agonist 7-hydroxy-N,N-dipropyl-2-aminotetralin (7-OH-DPAT -induced locomotor hypoactivity were significantly increased when DRD3 proteins were abundant"}
{"PMID":23432124,"re_id":2,"annotated sentence":"<e1>(2R)-IKM-159<\\e1> locks the <e2>GluA2<\\e2> in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"(2R)-IKM-159","object":"GluA2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> locks the <e2>GENE-Y<\\e2> in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors.","sentence":"(2R)-IKM-159 locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors."}
{"PMID":23432124,"re_id":3,"annotated sentence":"<e1>(2R)-IKM-159<\\e1> locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of <e2>AMPA receptors<\\e2> ","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"(2R)-IKM-159","object":"AMPA receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of <e2>GENE-N<\\e2> ","sentence":"(2R)-IKM-159 locks the GluA2 in an open form, consistent with a pharmacological action as competitive antagonist of AMPA receptors "}
{"PMID":23432124,"re_id":4,"annotated sentence":"Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid <e2>(AMPA) receptor<\\e2> antagonist <e1>IKM-159<\\e1>  asymmetric synthesis, neuroactivity, and structural characterization","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"IKM-159","object":"(AMPA) receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid <e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1>  asymmetric synthesis, neuroactivity, and structural characterization","sentence":"Studies on an (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptor antagonist IKM-159  asymmetric synthesis, neuroactivity, and structural characterization"}
{"PMID":23432124,"re_id":5,"annotated sentence":"<e1>IKM-159<\\e1> was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as <e2>AMPA receptor<\\e2> selective antagonists","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"IKM-159","object":"AMPA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as <e2>GENE-N<\\e2> selective antagonists","sentence":"IKM-159 was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as AMPA receptor selective antagonists"}
{"PMID":23432124,"re_id":6,"annotated sentence":"IKM-159 was developed and identified as a member of a new class of heterotricyclic <e1>glutamate<\\e1> analogues that act as <e2>AMPA receptor<\\e2> selective antagonists","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"glutamate","object":"AMPA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"IKM-159 was developed and identified as a member of a new class of heterotricyclic <e1>CHEMICAL<\\e1> analogues that act as <e2>GENE-N<\\e2> selective antagonists","sentence":"IKM-159 was developed and identified as a member of a new class of heterotricyclic glutamate analogues that act as AMPA receptor selective antagonists"}
{"PMID":23432429,"re_id":12,"annotated sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, <e1>flavanone<\\e1>  chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flavanone","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, <e1>CHEMICAL<\\e1>  chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone  chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432429,"re_id":13,"annotated sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by <e1>2'-methoxy-5,7-dihydroxyflavone<\\e1>  2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"2'-methoxy-5,7-dihydroxyflavone","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by <e1>CHEMICAL<\\e1>  2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone  2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432429,"re_id":14,"annotated sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, <e1>2-ethynylnaphthalene<\\e1>  2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"2-ethynylnaphthalene","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, <e1>CHEMICAL<\\e1>  2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene  2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432429,"re_id":15,"annotated sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, <e1>2'-methoxyflavone<\\e1>  2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"2'-methoxyflavone","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, <e1>CHEMICAL<\\e1>  2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone  2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432429,"re_id":16,"annotated sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, <e1>2-naphththalene propargyl ether<\\e1>  acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"2-naphththalene propargyl ether","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, <e1>CHEMICAL<\\e1>  acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether  acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432429,"re_id":17,"annotated sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, <e1>acenaphthene<\\e1>  acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"acenaphthene","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, <e1>CHEMICAL<\\e1>  acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene  acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432429,"re_id":18,"annotated sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, <e1>chrysin<\\e1>  3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"chrysin","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, <e1>CHEMICAL<\\e1>  3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin  3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432429,"re_id":19,"annotated sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, <e1>acenaphthylene<\\e1>  naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"acenaphthylene","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, <e1>CHEMICAL<\\e1>  naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene  naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432429,"re_id":20,"annotated sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, <e1>naphthalene<\\e1>  1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"naphthalene","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylCHEMICAL, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, <e1>CHEMICAL<\\e1>  1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene  1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432429,"re_id":21,"annotated sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, <e1>1-acetylpyrene<\\e1>  flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"1-acetylpyrene","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, <e1>CHEMICAL<\\e1>  flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene  flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432429,"re_id":22,"annotated sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, <e1>3-ethynylphenanthrene<\\e1>  flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-ethynylphenanthrene","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, <e1>CHEMICAL<\\e1>  flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene  flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432429,"re_id":23,"annotated sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, <e1>flavone<\\e1>  and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"flavone","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyCHEMICAL, 2-ethynylnaphthalene, 2'-methoxyCHEMICAL, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, <e1>CHEMICAL<\\e1>  and 7-hydroxyCHEMICAL; these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone  and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432429,"re_id":24,"annotated sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and <e1>7-hydroxyflavone<\\e1>  these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"7-hydroxyflavone","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Coumarin 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and <e1>CHEMICAL<\\e1>  these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone  these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432429,"re_id":25,"annotated sentence":"<e1>Coumarin<\\e1> 7-hydroxylation, catalyzed by <e2>P450 2A13<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Coumarin","object":"P450 2A13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> 7-hydroxylation, catalyzed by <e2>GENE-Y<\\e2>  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values","sentence":"Coumarin 7-hydroxylation, catalyzed by P450 2A13  was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values"}
{"PMID":23432662,"re_id":0,"annotated sentence":"Full agonists to the <e2>peroxisome proliferator-activated receptor (PPAR)\u03b3<\\e2>  such as <e1>Rosiglitazone<\\e1>  have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-ACTIVATOR","subject":"Rosiglitazone","object":"peroxisome proliferator-activated receptor (PPAR)\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Full agonists to the <e2>GENE-Y<\\e2>  such as <e1>CHEMICAL<\\e1>  have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity","sentence":"Full agonists to the peroxisome proliferator-activated receptor (PPAR)\u03b3  such as Rosiglitazone  have been associated with a series of undesired side effects, such as weight gain, fluid retention, cardiac hypertrophy, and hepatotoxicity"}
{"PMID":23435615,"re_id":0,"annotated sentence":"PURPOSE: <e1>Omeprazole<\\e1> has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with <e2>cytochrome P450 (CYP) 2C19<\\e2> genotype groups","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Omeprazole","object":"cytochrome P450 (CYP) 2C19","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"PURPOSE: <e1>CHEMICAL<\\e1> has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with <e2>GENE-Y<\\e2> genotype groups","sentence":"PURPOSE: Omeprazole has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with cytochrome P450 (CYP) 2C19 genotype groups"}
{"PMID":23435615,"re_id":1,"annotated sentence":"The <e1>(R)-omeprazole<\\e1> hydroxylation index reflects <e2>CYP2C19<\\e2> activity in healthy Japanese volunteers","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"(R)-omeprazole","object":"CYP2C19","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e1>CHEMICAL<\\e1> hydroxylation index reflects <e2>GENE-Y<\\e2> activity in healthy Japanese volunteers","sentence":"The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers"}
{"PMID":23435615,"re_id":2,"annotated sentence":"Additionally, there was a significant difference in plasma concentrations of <e1>(R)-5-hydroxyomeprazole<\\e1> among <e2>CYP2C19<\\e2> genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"(R)-5-hydroxyomeprazole","object":"CYP2C19","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, there was a significant difference in plasma concentrations of <e1>CHEMICAL<\\e1> among <e2>GENE-Y<\\e2> genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole","sentence":"Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among CYP2C19 genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole"}
{"PMID":23435615,"re_id":3,"annotated sentence":"Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among <e2>CYP2C19<\\e2> genotype groups, whereas no significant differences were observed in that of <e1>(S)-5-hydroxyomeprazole<\\e1>  Similarly, (R)-omeprazole HI in hmEMs, htEMs, and PMs were 5.6, 3.1, and 0.3, respectively, which were significantly different, but no significant difference was present in the (S)-omeprazole HI","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"(S)-5-hydroxyomeprazole","object":"CYP2C19","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among <e2>GENE-Y<\\e2> genotype groups, whereas no significant differences were observed in that of <e1>CHEMICAL<\\e1>  Similarly, (R)-omeprazole HI in hmEMs, htEMs, and PMs were 5.6, 3.1, and 0.3, respectively, which were significantly different, but no significant difference was present in the (S)-omeprazole HI","sentence":"Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among CYP2C19 genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole  Similarly, (R)-omeprazole HI in hmEMs, htEMs, and PMs were 5.6, 3.1, and 0.3, respectively, which were significantly different, but no significant difference was present in the (S)-omeprazole HI"}
{"PMID":23435615,"re_id":4,"annotated sentence":"CONCLUSION: Our findings demonstrate that <e1>(R)-omeprazole<\\e1> HI correlated better with <e2>CYP2C19<\\e2> genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"(R)-omeprazole","object":"CYP2C19","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Our findings demonstrate that <e1>CHEMICAL<\\e1> HI correlated better with <e2>GENE-Y<\\e2> genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in GENE-Y genotype groups prior to omeprazole treatment.","sentence":"CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with CYP2C19 genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment."}
{"PMID":23435615,"re_id":5,"annotated sentence":"CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with <e2>CYP2C19<\\e2> genotype groups than <e1>racemic-omeprazole<\\e1> HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"racemic-omeprazole","object":"CYP2C19","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with <e2>GENE-Y<\\e2> genotype groups than <e1>CHEMICAL<\\e1> HI, and these results may be useful for classification among patients in GENE-Y genotype groups prior to omeprazole treatment.","sentence":"CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with CYP2C19 genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment."}
{"PMID":23440512,"re_id":0,"annotated sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, <e1>all-trans retinoic acid<\\e1> (atRA), which regulates the expression of a battery of target genes through several families of <e2>nuclear receptors<\\e2> (RARs, RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"all-trans retinoic acid","object":"nuclear receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, <e1>CHEMICAL<\\e1> (atRA), which regulates the expression of a battery of target genes through several families of <e2>GENE-N<\\e2> (RARs, RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators","sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators"}
{"PMID":23440512,"re_id":1,"annotated sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, <e1>all-trans retinoic acid<\\e1> (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (<e2>RARs<\\e2>  RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"all-trans retinoic acid","object":"RARs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, <e1>CHEMICAL<\\e1> (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (<e2>GENE-N<\\e2>  RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators","sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs  RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators"}
{"PMID":23440512,"re_id":2,"annotated sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, <e1>all-trans retinoic acid<\\e1> (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, <e2>RXRs<\\e2> and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"all-trans retinoic acid","object":"RXRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, <e1>CHEMICAL<\\e1> (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, <e2>GENE-N<\\e2> and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators","sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators"}
{"PMID":23440512,"re_id":3,"annotated sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, <e1>all-trans retinoic acid<\\e1> (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPAR\u03b2\/\u03b4), <e2>polymorphic retinoic acid (RA) response elements<\\e2> and multiple coregulators","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"all-trans retinoic acid","object":"polymorphic retinoic acid (RA) response elements","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, <e1>CHEMICAL<\\e1> (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPAR\u03b2\/\u03b4), <e2>GENE-N<\\e2> and multiple coregulators","sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA), which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators"}
{"PMID":23440512,"re_id":4,"annotated sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<e1>atRA<\\e1> , which regulates the expression of a battery of target genes through several families of <e2>nuclear receptors<\\e2> (RARs, RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"atRA","object":"nuclear receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<e1>CHEMICAL<\\e1> , which regulates the expression of a battery of target genes through several families of <e2>GENE-N<\\e2> (RARs, RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators","sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA , which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators"}
{"PMID":23440512,"re_id":5,"annotated sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<e1>atRA<\\e1> , which regulates the expression of a battery of target genes through several families of nuclear receptors (<e2>RARs<\\e2>  RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"atRA","object":"RARs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<e1>CHEMICAL<\\e1> , which regulates the expression of a battery of target genes through several families of nuclear receptors (<e2>GENE-N<\\e2>  RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators","sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA , which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs  RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators"}
{"PMID":23440512,"re_id":6,"annotated sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<e1>atRA<\\e1> , which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, <e2>RXRs<\\e2> and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"atRA","object":"RXRs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<e1>CHEMICAL<\\e1> , which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, <e2>GENE-N<\\e2> and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators","sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA , which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators"}
{"PMID":23440512,"re_id":7,"annotated sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<e1>atRA<\\e1> , which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPAR\u03b2\/\u03b4), <e2>polymorphic retinoic acid (RA) response elements<\\e2> and multiple coregulators","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"atRA","object":"polymorphic retinoic acid (RA) response elements","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (<e1>CHEMICAL<\\e1> , which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPAR\u03b2\/\u03b4), <e2>GENE-N<\\e2> and multiple coregulators","sentence":"The pleiotropic effects of vitamin A are exerted mainly by one active metabolite, all-trans retinoic acid (atRA , which regulates the expression of a battery of target genes through several families of nuclear receptors (RARs, RXRs and PPAR\u03b2\/\u03b4), polymorphic retinoic acid (RA) response elements and multiple coregulators"}
{"PMID":23443810,"re_id":0,"annotated sentence":"Interestingly, <e2>miR-21<\\e2> expression positively correlated with urine albumin <e1>creatine<\\e1> ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"creatine","object":"miR-21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, <e2>GENE-Y<\\e2> expression positively correlated with urine albumin <e1>CHEMICAL<\\e1> ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with CHEMICAL clearance ratio (Ccr) and MMP-9 protein","sentence":"Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein"}
{"PMID":23443810,"re_id":1,"annotated sentence":"Interestingly, <e2>miR-21<\\e2> expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with <e1>creatine<\\e1> clearance ratio (Ccr) and MMP-9 protein","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"creatine","object":"miR-21","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, <e2>GENE-Y<\\e2> expression positively correlated with urine albumin CHEMICAL ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with <e1>CHEMICAL<\\e1> clearance ratio (Ccr) and MMP-9 protein","sentence":"Interestingly, miR-21 expression positively correlated with urine albumin creatine ratio (ACR), TIMP1, collagen IV (ColIV), and fibronectin (FN); while negatively correlated with creatine clearance ratio (Ccr) and MMP-9 protein"}
{"PMID":23444386,"re_id":2,"annotated sentence":"Studies on the kinetics of the <e2>hSULT2A1<\\e2> catalyzed sulfation of <e1>dehydroepiandrosterone<\\e1> (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"dehydroepiandrosterone","object":"hSULT2A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Studies on the kinetics of the <e2>GENE-Y<\\e2> catalyzed sulfation of <e1>CHEMICAL<\\e1> (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme","sentence":"Studies on the kinetics of the hSULT2A1 catalyzed sulfation of dehydroepiandrosterone (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme"}
{"PMID":23444386,"re_id":3,"annotated sentence":"Studies on the kinetics of the <e2>hSULT2A1<\\e2> catalyzed sulfation of dehydroepiandrosterone (<e1>DHEA<\\e1>  showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"DHEA","object":"hSULT2A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Studies on the kinetics of the <e2>GENE-Y<\\e2> catalyzed sulfation of dehydroepiandrosterone (<e1>CHEMICAL<\\e1>  showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme","sentence":"Studies on the kinetics of the hSULT2A1 catalyzed sulfation of dehydroepiandrosterone (DHEA  showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme"}
{"PMID":23444386,"re_id":4,"annotated sentence":"The <e2>human cytosolic sulfotransferase hSULT2A1<\\e2> catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous <e1>hydroxysteroids<\\e1> and bile acids","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"hydroxysteroids","object":"human cytosolic sulfotransferase hSULT2A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous <e1>CHEMICAL<\\e1> and bile acids","sentence":"The human cytosolic sulfotransferase hSULT2A1 catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous hydroxysteroids and bile acids"}
{"PMID":23444386,"re_id":5,"annotated sentence":"The <e2>human cytosolic sulfotransferase hSULT2A1<\\e2> catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous hydroxysteroids and <e1>bile acids<\\e1>  Reversible modulation of the catalytic activity of this enzyme could play important roles in its physiologic functions","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"bile acids","object":"human cytosolic sulfotransferase hSULT2A1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous hydroxysteroids and <e1>CHEMICAL<\\e1>  Reversible modulation of the catalytic activity of this enzyme could play important roles in its physiologic functions","sentence":"The human cytosolic sulfotransferase hSULT2A1 catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous hydroxysteroids and bile acids  Reversible modulation of the catalytic activity of this enzyme could play important roles in its physiologic functions"}
{"PMID":23448346,"re_id":1,"annotated sentence":"Computational docking analysis was conducted to model the interaction of these antagonists with the human ER\u03b1 and showed that they could tightly bind to the ER\u03b1 in a manner similar to that of <e1>ICI-182,780<\\e1>  a pure <e2>ER<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"ICI-182,780","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Computational docking analysis was conducted to model the interaction of these antagonists with the human GENE-Y\u03b1 and showed that they could tightly bind to the GENE-Y\u03b1 in a manner similar to that of <e1>CHEMICAL<\\e1>  a pure <e2>GENE-Y<\\e2> antagonist","sentence":"Computational docking analysis was conducted to model the interaction of these antagonists with the human ER\u03b1 and showed that they could tightly bind to the ER\u03b1 in a manner similar to that of ICI-182,780  a pure ER antagonist"}
{"PMID":23448346,"re_id":2,"annotated sentence":"These results provide an example that attachment of a bulky side chain to the C-7\u03b1 position of E2 can produce ER antagonists with <e2>ER<\\e2> affinity comparable to that of <e1>ICI-182,780<\\e1> ","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"ICI-182,780","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results provide an example that attachment of a bulky side chain to the C-7\u03b1 position of E2 can produce GENE-Y antagonists with <e2>GENE-Y<\\e2> affinity comparable to that of <e1>CHEMICAL<\\e1> ","sentence":"These results provide an example that attachment of a bulky side chain to the C-7\u03b1 position of E2 can produce ER antagonists with ER affinity comparable to that of ICI-182,780 "}
{"PMID":23449197,"re_id":0,"annotated sentence":"<e1>7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole<\\e1> 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as <e2>activin receptor-like kinase 5<\\e2> or ALK5) inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole","object":"activin receptor-like kinase 5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as <e2>GENE-Y<\\e2> or ALK5) inhibitor","sentence":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitor"}
{"PMID":23449197,"re_id":1,"annotated sentence":"<e1>7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole<\\e1> 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as activin receptor-like kinase 5 or <e2>ALK5<\\e2>  inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole","object":"ALK5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as activin receptor-like kinase 5 or <e2>GENE-Y<\\e2>  inhibitor","sentence":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as activin receptor-like kinase 5 or ALK5  inhibitor"}
{"PMID":23449197,"re_id":2,"annotated sentence":"<e1>7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole<\\e1> 11 (TASP0382088) was synthesized and evaluated as <e2>transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor<\\e2> (also known as activin receptor-like kinase 5 or ALK5) inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole","object":"transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> 11 (TASP0382088) was synthesized and evaluated as <e2>GENE-Y<\\e2> (also known as activin receptor-like kinase 5 or ALK5) inhibitor","sentence":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitor"}
{"PMID":23449197,"re_id":3,"annotated sentence":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (<e1>TASP0382088<\\e1>  was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as <e2>activin receptor-like kinase 5<\\e2> or ALK5) inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TASP0382088","object":"activin receptor-like kinase 5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (<e1>CHEMICAL<\\e1>  was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as <e2>GENE-Y<\\e2> or ALK5) inhibitor","sentence":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088  was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitor"}
{"PMID":23449197,"re_id":4,"annotated sentence":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (<e1>TASP0382088<\\e1>  was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as activin receptor-like kinase 5 or <e2>ALK5<\\e2>  inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TASP0382088","object":"ALK5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (<e1>CHEMICAL<\\e1>  was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as activin receptor-like kinase 5 or <e2>GENE-Y<\\e2>  inhibitor","sentence":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088  was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as activin receptor-like kinase 5 or ALK5  inhibitor"}
{"PMID":23449197,"re_id":5,"annotated sentence":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (<e1>TASP0382088<\\e1>  was synthesized and evaluated as <e2>transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor<\\e2> (also known as activin receptor-like kinase 5 or ALK5) inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TASP0382088","object":"transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (<e1>CHEMICAL<\\e1>  was synthesized and evaluated as <e2>GENE-Y<\\e2> (also known as activin receptor-like kinase 5 or ALK5) inhibitor","sentence":"7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088  was synthesized and evaluated as transforming growth factor-\u03b2 (TGF-\u03b2) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitor"}
{"PMID":23449197,"re_id":6,"annotated sentence":"Discovery of <e1>7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole<\\e1> (TASP0382088): a potent and selective <e2>transforming growth factor-\u03b2 type I receptor<\\e2> inhibitor as a topical drug for alopecia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole","object":"transforming growth factor-\u03b2 type I receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Discovery of <e1>CHEMICAL<\\e1> (TASP0382088): a potent and selective <e2>GENE-Y<\\e2> inhibitor as a topical drug for alopecia","sentence":"Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-\u03b2 type I receptor inhibitor as a topical drug for alopecia"}
{"PMID":23449197,"re_id":7,"annotated sentence":"Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (<e1>TASP0382088<\\e1> : a potent and selective <e2>transforming growth factor-\u03b2 type I receptor<\\e2> inhibitor as a topical drug for alopecia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TASP0382088","object":"transforming growth factor-\u03b2 type I receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (<e1>CHEMICAL<\\e1> : a potent and selective <e2>GENE-Y<\\e2> inhibitor as a topical drug for alopecia","sentence":"Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088 : a potent and selective transforming growth factor-\u03b2 type I receptor inhibitor as a topical drug for alopecia"}
{"PMID":23454145,"re_id":29,"annotated sentence":"In non-pre-treated cells, <e2>HMG-CoA<\\e2> was up-regulated by both <e1>7-ketosterols<\\e1>  However, exposure to inhibitors down-regulated the expression levels, mainly in 7-ketocholesterol-incubated cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"7-ketosterols","object":"HMG-CoA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In non-pre-treated cells, <e2>GENE-Y<\\e2> was up-regulated by both <e1>CHEMICAL<\\e1>  However, exposure to inhibitors down-regulated the expression levels, mainly in 7-ketocholesterol-incubated cells","sentence":"In non-pre-treated cells, HMG-CoA was up-regulated by both 7-ketosterols  However, exposure to inhibitors down-regulated the expression levels, mainly in 7-ketocholesterol-incubated cells"}
{"PMID":23454145,"re_id":30,"annotated sentence":"In non-pre-treated cells, only <e2>efflux transporters<\\e2> were down-regulated by <e1>7-ketosterols<\\e1>  showing a greater influence upon ABCG5 expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"7-ketosterols","object":"efflux transporters","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In non-pre-treated cells, only <e2>GENE-N<\\e2> were down-regulated by <e1>CHEMICAL<\\e1>  showing a greater influence upon ABCG5 expression","sentence":"In non-pre-treated cells, only efflux transporters were down-regulated by 7-ketosterols  showing a greater influence upon ABCG5 expression"}
{"PMID":23454145,"re_id":31,"annotated sentence":"Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced <e2>NPC1L1<\\e2> expression only in <e1>7-ketocholesterol<\\e1> incubated cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"7-ketocholesterol","object":"NPC1L1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced <e2>GENE-Y<\\e2> expression only in <e1>CHEMICAL<\\e1> incubated cells","sentence":"Cell-pre-incubation with bradykinin induced changes in ABCG expression levels after 7-ketostigmasterol-incubation; however, the energetic metabolism inhibition reduced NPC1L1 expression only in 7-ketocholesterol incubated cells"}
{"PMID":23454297,"re_id":0,"annotated sentence":"In lymphocytes, the NTPDase and <e2>ADA<\\e2> activities were increased in all groups treated with <e1>caffeic acid<\\e1> when compared to control (P<0.05)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"caffeic acid","object":"ADA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In lymphocytes, the NTPDase and <e2>GENE-Y<\\e2> activities were increased in all groups treated with <e1>CHEMICAL<\\e1> when compared to control (P<0.05)","sentence":"In lymphocytes, the NTPDase and ADA activities were increased in all groups treated with caffeic acid when compared to control (P<0.05)"}
{"PMID":23454297,"re_id":1,"annotated sentence":"In lymphocytes, the <e2>NTPDase<\\e2> and ADA activities were increased in all groups treated with <e1>caffeic acid<\\e1> when compared to control (P<0.05)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"caffeic acid","object":"NTPDase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In lymphocytes, the <e2>GENE-N<\\e2> and ADA activities were increased in all groups treated with <e1>CHEMICAL<\\e1> when compared to control (P<0.05)","sentence":"In lymphocytes, the NTPDase and ADA activities were increased in all groups treated with caffeic acid when compared to control (P<0.05)"}
{"PMID":23462233,"re_id":2,"annotated sentence":"The procedure was to reduce liver <e2>AOX<\\e2> activity by providing <e1>tungsten<\\e1> or hydralazine in the drinking water or to use the AOX-deficient DBA\/2 mouse strain","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"tungsten","object":"AOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The procedure was to reduce liver <e2>GENE-N<\\e2> activity by providing <e1>CHEMICAL<\\e1> or hydralazine in the drinking water or to use the GENE-N-deficient DBA\/2 mouse strain","sentence":"The procedure was to reduce liver AOX activity by providing tungsten or hydralazine in the drinking water or to use the AOX-deficient DBA\/2 mouse strain"}
{"PMID":23462233,"re_id":3,"annotated sentence":"The procedure was to reduce liver <e2>AOX<\\e2> activity by providing tungsten or <e1>hydralazine<\\e1> in the drinking water or to use the AOX-deficient DBA\/2 mouse strain","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"hydralazine","object":"AOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The procedure was to reduce liver <e2>GENE-N<\\e2> activity by providing tungsten or <e1>CHEMICAL<\\e1> in the drinking water or to use the GENE-N-deficient DBA\/2 mouse strain","sentence":"The procedure was to reduce liver AOX activity by providing tungsten or hydralazine in the drinking water or to use the AOX-deficient DBA\/2 mouse strain"}
{"PMID":23462233,"re_id":4,"annotated sentence":"Liver <e2>AOX<\\e2> activity was reduced by 45% with <e1>tungsten<\\e1> and 61% with hydralazine and 81% in AOX-deficient mice relative to controls","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"tungsten","object":"AOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Liver <e2>GENE-N<\\e2> activity was reduced by 45% with <e1>CHEMICAL<\\e1> and 61% with hydralazine and 81% in GENE-N-deficient mice relative to controls","sentence":"Liver AOX activity was reduced by 45% with tungsten and 61% with hydralazine and 81% in AOX-deficient mice relative to controls"}
{"PMID":23462233,"re_id":5,"annotated sentence":"Liver <e2>AOX<\\e2> activity was reduced by 45% with tungsten and 61% with <e1>hydralazine<\\e1> and 81% in AOX-deficient mice relative to controls","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"hydralazine","object":"AOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Liver <e2>GENE-N<\\e2> activity was reduced by 45% with tungsten and 61% with <e1>CHEMICAL<\\e1> and 81% in GENE-N-deficient mice relative to controls","sentence":"Liver AOX activity was reduced by 45% with tungsten and 61% with hydralazine and 81% in AOX-deficient mice relative to controls"}
{"PMID":23462233,"re_id":6,"annotated sentence":"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the <e2>AOX<\\e2> generated nitrosoguanidine metabolite was decreased by 30% with <e1>tungsten<\\e1> and 56% with hydralazine and 86% in the AOX-deficient mice","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"tungsten","object":"AOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the <e2>GENE-N<\\e2> generated nitrosoguanidine metabolite was decreased by 30% with <e1>CHEMICAL<\\e1> and 56% with hydralazine and 86% in the GENE-N-deficient mice","sentence":"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice"}
{"PMID":23462233,"re_id":7,"annotated sentence":"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the <e2>AOX<\\e2> generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with <e1>hydralazine<\\e1> and 86% in the AOX-deficient mice","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"hydralazine","object":"AOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the <e2>GENE-N<\\e2> generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with <e1>CHEMICAL<\\e1> and 86% in the GENE-N-deficient mice","sentence":"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice"}
{"PMID":23462233,"re_id":8,"annotated sentence":"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the <e2>AOX<\\e2> generated <e1>nitrosoguanidine<\\e1> metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"nitrosoguanidine","object":"AOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the <e2>GENE-N<\\e2> generated <e1>CHEMICAL<\\e1> metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the GENE-N-deficient mice","sentence":"When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice"}
{"PMID":23462233,"re_id":9,"annotated sentence":"Possible <e2>AOX<\\e2> involvement in <e1>IMI<\\e1> metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"IMI","object":"AOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Possible <e2>GENE-N<\\e2> involvement in <e1>CHEMICAL<\\e1> metabolism in insects was evaluated using GENE-N-expressing and GENE-N-deficient Drosophila, but no differences were found in CHEMICAL nitroreduction or sensitivity between the two strains","sentence":"Possible AOX involvement in IMI metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains"}
{"PMID":23462233,"re_id":10,"annotated sentence":"Possible AOX involvement in <e1>IMI<\\e1> metabolism in insects was evaluated using <e2>AOX<\\e2> expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"IMI","object":"AOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Possible GENE-N involvement in <e1>CHEMICAL<\\e1> metabolism in insects was evaluated using <e2>GENE-N<\\e2> expressing and GENE-N-deficient Drosophila, but no differences were found in CHEMICAL nitroreduction or sensitivity between the two strains","sentence":"Possible AOX involvement in IMI metabolism in insects was evaluated using AOX expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains"}
{"PMID":23462233,"re_id":11,"annotated sentence":"This is the first study to establish the in vivo relevance of <e2>AOX<\\e2> in <e1>neonicotinoid<\\e1> metabolism in mammals and one of the first for xenobiotics in general.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"neonicotinoid","object":"AOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This is the first study to establish the in vivo relevance of <e2>GENE-N<\\e2> in <e1>CHEMICAL<\\e1> metabolism in mammals and one of the first for xenobiotics in general.","sentence":"This is the first study to establish the in vivo relevance of AOX in neonicotinoid metabolism in mammals and one of the first for xenobiotics in general."}
{"PMID":23462233,"re_id":12,"annotated sentence":"Currently, the most important insecticides are <e1>neonicotinoids<\\e1>  which are metabolized in vitro by <e2>AOX<\\e2> on reduction of the nitroimino group and by CYPs via oxidation reactions","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"neonicotinoids","object":"AOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Currently, the most important insecticides are <e1>CHEMICAL<\\e1>  which are metabolized in vitro by <e2>GENE-N<\\e2> on reduction of the nitroimino group and by CYPs via oxidation reactions","sentence":"Currently, the most important insecticides are neonicotinoids  which are metabolized in vitro by AOX on reduction of the nitroimino group and by CYPs via oxidation reactions"}
{"PMID":23462233,"re_id":13,"annotated sentence":"Currently, the most important insecticides are <e1>neonicotinoids<\\e1>  which are metabolized in vitro by AOX on reduction of the nitroimino group and by <e2>CYPs<\\e2> via oxidation reactions","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"neonicotinoids","object":"CYPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Currently, the most important insecticides are <e1>CHEMICAL<\\e1>  which are metabolized in vitro by AOX on reduction of the nitroimino group and by <e2>GENE-N<\\e2> via oxidation reactions","sentence":"Currently, the most important insecticides are neonicotinoids  which are metabolized in vitro by AOX on reduction of the nitroimino group and by CYPs via oxidation reactions"}
{"PMID":23462233,"re_id":14,"annotated sentence":"Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by <e2>AOX<\\e2> on reduction of the <e1>nitroimino<\\e1> group and by CYPs via oxidation reactions","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"nitroimino","object":"AOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by <e2>GENE-N<\\e2> on reduction of the <e1>CHEMICAL<\\e1> group and by CYPs via oxidation reactions","sentence":"Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by AOX on reduction of the nitroimino group and by CYPs via oxidation reactions"}
{"PMID":23462233,"re_id":15,"annotated sentence":"Thus, decreasing liver <e2>AOX<\\e2> activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of <e1>IMI<\\e1> treated mice","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"IMI","object":"AOX","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Thus, decreasing liver <e2>GENE-N<\\e2> activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of <e1>CHEMICAL<\\e1> treated mice","sentence":"Thus, decreasing liver AOX activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of IMI treated mice"}
{"PMID":23462380,"re_id":0,"annotated sentence":"none","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"neostigmine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"none","sentence":"none"}
{"PMID":23465614,"re_id":0,"annotated sentence":"Of the compounds active in the present assay system, the most potent compound 7, <e1>platyphyllonol-5-O-\u03b2-d-xylopyranoside<\\e1>  significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and <e2>CCAAT\/enhancer binding protein \u03b1<\\e2> (C\/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"platyphyllonol-5-O-\u03b2-d-xylopyranoside","object":"CCAAT\/enhancer binding protein \u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of the compounds active in the present assay system, the most potent compound 7, <e1>CHEMICAL<\\e1>  significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and <e2>GENE-Y<\\e2> (C\/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist","sentence":"Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-\u03b2-d-xylopyranoside  significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and CCAAT\/enhancer binding protein \u03b1 (C\/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist"}
{"PMID":23465614,"re_id":1,"annotated sentence":"Of the compounds active in the present assay system, the most potent compound 7, <e1>platyphyllonol-5-O-\u03b2-d-xylopyranoside<\\e1>  significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and CCAAT\/enhancer binding protein \u03b1 (<e2>C\/EBP\u03b1<\\e2>  protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"platyphyllonol-5-O-\u03b2-d-xylopyranoside","object":"C\/EBP\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of the compounds active in the present assay system, the most potent compound 7, <e1>CHEMICAL<\\e1>  significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and CCAAT\/enhancer binding protein \u03b1 (<e2>GENE-Y<\\e2>  protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist","sentence":"Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-\u03b2-d-xylopyranoside  significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and CCAAT\/enhancer binding protein \u03b1 (C\/EBP\u03b1  protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist"}
{"PMID":23465614,"re_id":2,"annotated sentence":"Of the compounds active in the present assay system, the most potent compound 7, <e1>platyphyllonol-5-O-\u03b2-d-xylopyranoside<\\e1>  significantly suppressed the induction of <e2>peroxisome proliferator activated receptor \u03b3<\\e2> (PPAR\u03b3 and CCAAT\/enhancer binding protein \u03b1 (C\/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"platyphyllonol-5-O-\u03b2-d-xylopyranoside","object":"peroxisome proliferator activated receptor \u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of the compounds active in the present assay system, the most potent compound 7, <e1>CHEMICAL<\\e1>  significantly suppressed the induction of <e2>GENE-Y<\\e2> (PPAR\u03b3 and CCAAT\/enhancer binding protein \u03b1 (C\/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist","sentence":"Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-\u03b2-d-xylopyranoside  significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and CCAAT\/enhancer binding protein \u03b1 (C\/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist"}
{"PMID":23465614,"re_id":3,"annotated sentence":"Of the compounds active in the present assay system, the most potent compound 7, <e1>platyphyllonol-5-O-\u03b2-d-xylopyranoside<\\e1>  significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (<e2>PPAR\u03b3<\\e2> and CCAAT\/enhancer binding protein \u03b1 (C\/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"platyphyllonol-5-O-\u03b2-d-xylopyranoside","object":"PPAR\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of the compounds active in the present assay system, the most potent compound 7, <e1>CHEMICAL<\\e1>  significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (<e2>GENE-Y<\\e2> and CCAAT\/enhancer binding protein \u03b1 (C\/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a GENE-Y agonist","sentence":"Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-\u03b2-d-xylopyranoside  significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and CCAAT\/enhancer binding protein \u03b1 (C\/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by troglitazone, a PPAR\u03b3 agonist"}
{"PMID":23465614,"re_id":4,"annotated sentence":"Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-\u03b2-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and CCAAT\/enhancer binding protein \u03b1 (C\/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by <e1>troglitazone<\\e1>  a <e2>PPAR\u03b3<\\e2> agonist","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"troglitazone","object":"PPAR\u03b3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-\u03b2-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (GENE-Y and CCAAT\/enhancer binding protein \u03b1 (C\/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by <e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> agonist","sentence":"Of the compounds active in the present assay system, the most potent compound 7, platyphyllonol-5-O-\u03b2-d-xylopyranoside, significantly suppressed the induction of peroxisome proliferator activated receptor \u03b3 (PPAR\u03b3 and CCAAT\/enhancer binding protein \u03b1 (C\/EBP\u03b1) protein expression, and inhibited adipocyte differentiation induced by troglitazone  a PPAR\u03b3 agonist"}
{"PMID":23468189,"re_id":0,"annotated sentence":"Based on our previously published work on CXCR4 antagonists, we have synthesized a series of <e1>aryl sulfonamides<\\e1> that inhibit the <e2>CXCR4<\\e2> CXCL12 interaction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"aryl sulfonamides","object":"CXCR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Based on our previously published work on GENE-Y antagonists, we have synthesized a series of <e1>CHEMICAL<\\e1> that inhibit the <e2>GENE-Y<\\e2> CXCL12 interaction","sentence":"Based on our previously published work on CXCR4 antagonists, we have synthesized a series of aryl sulfonamides that inhibit the CXCR4 CXCL12 interaction"}
{"PMID":23468189,"re_id":1,"annotated sentence":"Based on our previously published work on CXCR4 antagonists, we have synthesized a series of <e1>aryl sulfonamides<\\e1> that inhibit the CXCR4\/<e2>CXCL12<\\e2> interaction","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"aryl sulfonamides","object":"CXCL12","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Based on our previously published work on CXCR4 antagonists, we have synthesized a series of <e1>CHEMICAL<\\e1> that inhibit the CXCR4\/<e2>GENE-Y<\\e2> interaction","sentence":"Based on our previously published work on CXCR4 antagonists, we have synthesized a series of aryl sulfonamides that inhibit the CXCR4\/CXCL12 interaction"}
{"PMID":23468189,"re_id":2,"annotated sentence":"These data demonstrate that <e1>benzenesulfonamides<\\e1> are a unique class of <e2>CXCR4<\\e2> inhibitors with high potency.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"benzenesulfonamides","object":"CXCR4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These data demonstrate that <e1>CHEMICAL<\\e1> are a unique class of <e2>GENE-Y<\\e2> inhibitors with high potency.","sentence":"These data demonstrate that benzenesulfonamides are a unique class of CXCR4 inhibitors with high potency."}
{"PMID":23468189,"re_id":3,"annotated sentence":"<e1>Benzenesulfonamides<\\e1>  a unique class of <e2>chemokine receptor type 4<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Benzenesulfonamides","object":"chemokine receptor type 4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a unique class of <e2>GENE-Y<\\e2> inhibitors","sentence":"Benzenesulfonamides  a unique class of chemokine receptor type 4 inhibitors"}
{"PMID":23470629,"re_id":0,"annotated sentence":"Measurement of Transport Activities of <e1>3\u03b2-Hydroxy-\u0394(5)-bile Acids<\\e1> in <e2>Bile Salt Export Pump<\\e2> and Multidrug Resistance-Associated Proteins Using LC-MS\/MS","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"3\u03b2-Hydroxy-\u0394(5)-bile Acids","object":"Bile Salt Export Pump","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Measurement of Transport Activities of <e1>CHEMICAL<\\e1> in <e2>GENE-Y<\\e2> and Multidrug Resistance-Associated Proteins Using LC-MS\/MS","sentence":"Measurement of Transport Activities of 3\u03b2-Hydroxy-\u0394(5)-bile Acids in Bile Salt Export Pump and Multidrug Resistance-Associated Proteins Using LC-MS\/MS"}
{"PMID":23470629,"re_id":1,"annotated sentence":"Measurement of Transport Activities of <e1>3\u03b2-Hydroxy-\u0394(5)-bile Acids<\\e1> in Bile Salt Export Pump and <e2>Multidrug Resistance-Associated Proteins<\\e2> Using LC-MS\/MS","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"3\u03b2-Hydroxy-\u0394(5)-bile Acids","object":"Multidrug Resistance-Associated Proteins","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Measurement of Transport Activities of <e1>CHEMICAL<\\e1> in Bile Salt Export Pump and <e2>GENE-N<\\e2> Using LC-MS\/MS","sentence":"Measurement of Transport Activities of 3\u03b2-Hydroxy-\u0394(5)-bile Acids in Bile Salt Export Pump and Multidrug Resistance-Associated Proteins Using LC-MS\/MS"}
{"PMID":23470629,"re_id":2,"annotated sentence":"The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and <e2>human bile salt export pump<\\e2> expressing Sf9 cells for conjugated <e1>3\u03b2-hydroxy-\u0394(5)-bile acids<\\e1>  The present study demonstrated that human multidrug resistance-associated protein 3 vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"3\u03b2-hydroxy-\u0394(5)-bile acids","object":"human bile salt export pump","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and <e2>GENE-Y<\\e2> expressing Sf9 cells for conjugated <e1>CHEMICAL<\\e1>  The present study demonstrated that human multidrug resistance-associated protein 3 vesicles accepted conjugated CHEMICAL along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.","sentence":"The analytical method was applied to measurements of transport activities in membrane vesicles obtained from human multidrug resistance-associated protein 2-, 3-, and human bile salt export pump expressing Sf9 cells for conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids  The present study demonstrated that human multidrug resistance-associated protein 3 vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate."}
{"PMID":23470629,"re_id":3,"annotated sentence":"The present study demonstrated that <e2>human multidrug resistance-associated protein 3<\\e2> vesicles accepted conjugated <e1>3\u03b2-hydroxy-\u0394(5)-bile acids<\\e1> along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"3\u03b2-hydroxy-\u0394(5)-bile acids","object":"human multidrug resistance-associated protein 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present study demonstrated that <e2>GENE-Y<\\e2> vesicles accepted conjugated <e1>CHEMICAL<\\e1> along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate.","sentence":"The present study demonstrated that human multidrug resistance-associated protein 3 vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate."}
{"PMID":23470629,"re_id":4,"annotated sentence":"The present study demonstrated that <e2>human multidrug resistance-associated protein 3<\\e2> vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common <e1>bile acids<\\e1> such as glycocholic acid and taurolithocholic acid 3-sulfate.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"bile acids","object":"human multidrug resistance-associated protein 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present study demonstrated that <e2>GENE-Y<\\e2> vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-CHEMICAL along with common <e1>CHEMICAL<\\e1> such as glycocholic acid and taurolithocholic acid 3-sulfate.","sentence":"The present study demonstrated that human multidrug resistance-associated protein 3 vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate."}
{"PMID":23470629,"re_id":5,"annotated sentence":"The present study demonstrated that <e2>human multidrug resistance-associated protein 3<\\e2> vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as <e1>glycocholic acid<\\e1> and taurolithocholic acid 3-sulfate.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glycocholic acid","object":"human multidrug resistance-associated protein 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present study demonstrated that <e2>GENE-Y<\\e2> vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as <e1>CHEMICAL<\\e1> and taurolithocholic acid 3-sulfate.","sentence":"The present study demonstrated that human multidrug resistance-associated protein 3 vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate."}
{"PMID":23470629,"re_id":6,"annotated sentence":"The present study demonstrated that <e2>human multidrug resistance-associated protein 3<\\e2> vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as glycocholic acid and <e1>taurolithocholic acid 3-sulfate<\\e1> ","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"taurolithocholic acid 3-sulfate","object":"human multidrug resistance-associated protein 3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present study demonstrated that <e2>GENE-Y<\\e2> vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as glycocholic acid and <e1>CHEMICAL<\\e1> ","sentence":"The present study demonstrated that human multidrug resistance-associated protein 3 vesicles accepted conjugated 3\u03b2-hydroxy-\u0394(5)-bile acids along with common bile acids such as glycocholic acid and taurolithocholic acid 3-sulfate "}
{"PMID":23474389,"re_id":0,"annotated sentence":"A series of substituted <e1>3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines<\\e1> has been synthesised and tested in vitro as potential pro-apoptotic <e2>Bcl-2<\\e2> inhibitory anticancer agents","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of substituted <e1>CHEMICAL<\\e1> has been synthesised and tested in vitro as potential pro-apoptotic <e2>GENE-Y<\\e2> inhibitory anticancer agents","sentence":"A series of substituted 3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines has been synthesised and tested in vitro as potential pro-apoptotic Bcl-2 inhibitory anticancer agents"}
{"PMID":23474389,"re_id":1,"annotated sentence":"Active compounds, such as the <e1>nitrobenzyl<\\e1> analogue 6c, were found to exhibit sub-micromolar IC50 values in <e2>Bcl-2<\\e2> expressing human cancer cell lines","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nitrobenzyl","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Active compounds, such as the <e1>CHEMICAL<\\e1> analogue 6c, were found to exhibit sub-micromolar IC50 values in <e2>GENE-Y<\\e2> expressing human cancer cell lines","sentence":"Active compounds, such as the nitrobenzyl analogue 6c, were found to exhibit sub-micromolar IC50 values in Bcl-2 expressing human cancer cell lines"}
{"PMID":23474389,"re_id":2,"annotated sentence":"Synthesis and evaluation of <e1>3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines<\\e1> as <e2>Bcl-2<\\e2> inhibitory anticancer agents","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Synthesis and evaluation of <e1>CHEMICAL<\\e1> as <e2>GENE-Y<\\e2> inhibitory anticancer agents","sentence":"Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents"}
{"PMID":23475432,"re_id":2,"annotated sentence":"Upon <e1>nicotine<\\e1> pre-exposure, brain <e2>acetylcholinesterase<\\e2> increased, while monoamine oxidase (MAO) decreased","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"nicotine","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Upon <e1>CHEMICAL<\\e1> pre-exposure, brain <e2>GENE-Y<\\e2> increased, while monoamine oxidase (MAO) decreased","sentence":"Upon nicotine pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase (MAO) decreased"}
{"PMID":23475432,"re_id":3,"annotated sentence":"Upon <e1>nicotine<\\e1> pre-exposure, brain acetylcholinesterase increased, while <e2>monoamine oxidase<\\e2> (MAO) decreased","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"nicotine","object":"monoamine oxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Upon <e1>CHEMICAL<\\e1> pre-exposure, brain acetylcholinesterase increased, while <e2>GENE-N<\\e2> (MAO) decreased","sentence":"Upon nicotine pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase (MAO) decreased"}
{"PMID":23475432,"re_id":4,"annotated sentence":"Upon <e1>nicotine<\\e1> pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase (<e2>MAO<\\e2>  decreased","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"nicotine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Upon <e1>CHEMICAL<\\e1> pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase (<e2>GENE-N<\\e2>  decreased","sentence":"Upon nicotine pre-exposure, brain acetylcholinesterase increased, while monoamine oxidase (MAO  decreased"}
{"PMID":23475432,"re_id":5,"annotated sentence":"The toxic effects of <e2>MAO<\\e2> significantly attenuated with <e1>nicotine<\\e1> pre-exposure","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"nicotine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The toxic effects of <e2>GENE-N<\\e2> significantly attenuated with <e1>CHEMICAL<\\e1> pre-exposure","sentence":"The toxic effects of MAO significantly attenuated with nicotine pre-exposure"}
{"PMID":23475432,"re_id":6,"annotated sentence":"<e2>Glutathione-S-transferase<\\e2>  a phase II enzyme, was inhibited by both <e1>arsenic<\\e1> and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"arsenic","object":"Glutathione-S-transferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2>  a phase II enzyme, was inhibited by both <e1>CHEMICAL<\\e1> and nicotine but no such inhibition was noted in CHEMICAL-treated animals pre-exposed to nicotine","sentence":"Glutathione-S-transferase  a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine"}
{"PMID":23475432,"re_id":7,"annotated sentence":"<e2>Glutathione-S-transferase<\\e2>  a phase II enzyme, was inhibited by both arsenic and <e1>nicotine<\\e1> but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nicotine","object":"Glutathione-S-transferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2>  a phase II enzyme, was inhibited by both arsenic and <e1>CHEMICAL<\\e1> but no such inhibition was noted in arsenic-treated animals pre-exposed to CHEMICAL","sentence":"Glutathione-S-transferase  a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine"}
{"PMID":23475784,"re_id":1,"annotated sentence":"We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the <e2>aromatase<\\e2> inhibitor, <e1>fadrozole<\\e1> (FAD)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"fadrozole","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1> (FAD)","sentence":"We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the aromatase inhibitor, fadrozole (FAD)"}
{"PMID":23475784,"re_id":2,"annotated sentence":"We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the <e2>aromatase<\\e2> inhibitor, fadrozole (<e1>FAD<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"FAD","object":"aromatase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the <e2>GENE-Y<\\e2> inhibitor, fadrozole (<e1>CHEMICAL<\\e1> ","sentence":"We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the aromatase inhibitor, fadrozole (FAD "}
{"PMID":23478802,"re_id":16,"annotated sentence":"We found that <e1>pBQN<\\e1> activates <e2>TRPA1<\\e2> starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"pBQN","object":"TRPA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We found that <e1>CHEMICAL<\\e1> activates <e2>GENE-Y<\\e2> starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline","sentence":"We found that pBQN activates TRPA1 starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline"}
{"PMID":23478802,"re_id":17,"annotated sentence":"Interestingly, following pBQN desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist <e1>carvacrol<\\e1>  whereas the triple cysteine mutant <e2>TRPA1<\\e2> retained its full response","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-ACTIVATOR","subject":"carvacrol","object":"TRPA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, following pBQN desensitization, wild-type GENE-Y had dramatically reduced response to the nonelectrophile agonist <e1>CHEMICAL<\\e1>  whereas the triple cysteine mutant <e2>GENE-Y<\\e2> retained its full response","sentence":"Interestingly, following pBQN desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist carvacrol  whereas the triple cysteine mutant TRPA1 retained its full response"}
{"PMID":23478802,"re_id":18,"annotated sentence":"Although naturally occurring electrophilic plant compounds, such as mustard oil and <e1>cinnamaldehyde<\\e1>  are <e2>TRPA1<\\e2> agonists, it is unknown whether arthropod-produced electrophiles activate mammalian TRPA1","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"cinnamaldehyde","object":"TRPA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although naturally occurring electrophilic plant compounds, such as mustard oil and <e1>CHEMICAL<\\e1>  are <e2>GENE-Y<\\e2> agonists, it is unknown whether arthropod-produced electrophiles activate mammalian GENE-Y","sentence":"Although naturally occurring electrophilic plant compounds, such as mustard oil and cinnamaldehyde  are TRPA1 agonists, it is unknown whether arthropod-produced electrophiles activate mammalian TRPA1"}
{"PMID":23478802,"re_id":19,"annotated sentence":"Interestingly, following pBQN desensitization, wild-type <e2>TRPA1<\\e2> had dramatically reduced response to the nonelectrophile agonist <e1>carvacrol<\\e1>  whereas the triple cysteine mutant TRPA1 retained its full response","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"carvacrol","object":"TRPA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Interestingly, following pBQN desensitization, wild-type <e2>GENE-Y<\\e2> had dramatically reduced response to the nonelectrophile agonist <e1>CHEMICAL<\\e1>  whereas the triple cysteine mutant GENE-Y retained its full response","sentence":"Interestingly, following pBQN desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist carvacrol  whereas the triple cysteine mutant TRPA1 retained its full response"}
{"PMID":23479193,"re_id":0,"annotated sentence":"Synthesis and in-silico studies of some <e1>diaryltriazole<\\e1> derivatives as potential <e2>cyclooxygenase<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diaryltriazole","object":"cyclooxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Synthesis and in-silico studies of some <e1>CHEMICAL<\\e1> derivatives as potential <e2>GENE-N<\\e2> inhibitors","sentence":"Synthesis and in-silico studies of some diaryltriazole derivatives as potential cyclooxygenase inhibitors"}
{"PMID":23479738,"re_id":21,"annotated sentence":"A highly potent inhibition of the <e2>peroxidase<\\e2> catalytic reaction by <e1>NO<\\e1> SNO was seen in assays employing the coupled Prx-Trx system","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NO","object":"peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A highly potent inhibition of the <e2>GENE-N<\\e2> catalytic reaction by <e1>CHEMICAL<\\e1> SCHEMICAL was seen in assays employing the coupled Prx-Trx system","sentence":"A highly potent inhibition of the peroxidase catalytic reaction by NO SNO was seen in assays employing the coupled Prx-Trx system"}
{"PMID":23479738,"re_id":22,"annotated sentence":"A highly potent inhibition of the <e2>peroxidase<\\e2> catalytic reaction by NO\/<e1>SNO<\\e1> was seen in assays employing the coupled Prx-Trx system","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"SNO","object":"peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A highly potent inhibition of the <e2>GENE-N<\\e2> catalytic reaction by NO\/<e1>CHEMICAL<\\e1> was seen in assays employing the coupled Prx-Trx system","sentence":"A highly potent inhibition of the peroxidase catalytic reaction by NO\/SNO was seen in assays employing the coupled Prx-Trx system"}
{"PMID":23479738,"re_id":23,"annotated sentence":"In this setting, <e1>S-nitrosocysteine<\\e1> (10 \u03bcm) effectively blocked the <e2>Trx<\\e2> mediated regeneration of oxidized Prx1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"S-nitrosocysteine","object":"Trx","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this setting, <e1>CHEMICAL<\\e1> (10 \u03bcm) effectively blocked the <e2>GENE-Y<\\e2> mediated regeneration of oxidized Prx1","sentence":"In this setting, S-nitrosocysteine (10 \u03bcm) effectively blocked the Trx mediated regeneration of oxidized Prx1"}
{"PMID":23479738,"re_id":24,"annotated sentence":"In this setting, <e1>S-nitrosocysteine<\\e1> (10 \u03bcm) effectively blocked the Trx-mediated regeneration of <e2>oxidized Prx1<\\e2>  This effect appeared to be due to both competition between S-nitrosocysteine and Prx1 for the Trx system and direct modulation by S-nitrosocysteine of Trx reductase activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"S-nitrosocysteine","object":"oxidized Prx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this setting, <e1>CHEMICAL<\\e1> (10 \u03bcm) effectively blocked the Trx-mediated regeneration of <e2>GENE-Y<\\e2>  This effect appeared to be due to both competition between CHEMICAL and Prx1 for the Trx system and direct modulation by CHEMICAL of Trx reductase activity","sentence":"In this setting, S-nitrosocysteine (10 \u03bcm) effectively blocked the Trx-mediated regeneration of oxidized Prx1  This effect appeared to be due to both competition between S-nitrosocysteine and Prx1 for the Trx system and direct modulation by S-nitrosocysteine of Trx reductase activity"}
{"PMID":23485615,"re_id":1,"annotated sentence":"CK significantly inhibited <e1>DMN<\\e1> induced increases in serum <e2>alanine aminotransferase<\\e2> (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"DMN","object":"alanine aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CK significantly inhibited <e1>CHEMICAL<\\e1> induced increases in serum <e2>GENE-N<\\e2> (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content","sentence":"CK significantly inhibited DMN induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content"}
{"PMID":23485615,"re_id":2,"annotated sentence":"CK significantly inhibited <e1>DMN<\\e1> induced increases in serum alanine aminotransferase (<e2>ALT<\\e2>  and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"DMN","object":"ALT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CK significantly inhibited <e1>CHEMICAL<\\e1> induced increases in serum alanine aminotransferase (<e2>GENE-N<\\e2>  and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content","sentence":"CK significantly inhibited DMN induced increases in serum alanine aminotransferase (ALT  and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content"}
{"PMID":23485615,"re_id":3,"annotated sentence":"CK significantly inhibited <e1>DMN<\\e1> induced increases in serum alanine aminotransferase (ALT) and <e2>aspartate aminotransferase<\\e2> (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"DMN","object":"aspartate aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CK significantly inhibited <e1>CHEMICAL<\\e1> induced increases in serum alanine aminotransferase (ALT) and <e2>GENE-N<\\e2> (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content","sentence":"CK significantly inhibited DMN induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content"}
{"PMID":23485615,"re_id":4,"annotated sentence":"CK significantly inhibited <e1>DMN<\\e1> induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (<e2>AST<\\e2>  activities, fibrosis score, and hepatic malondialdehyde and collagen content","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"DMN","object":"AST","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CK significantly inhibited <e1>CHEMICAL<\\e1> induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (<e2>GENE-N<\\e2>  activities, fibrosis score, and hepatic malondialdehyde and collagen content","sentence":"CK significantly inhibited DMN induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST  activities, fibrosis score, and hepatic malondialdehyde and collagen content"}
{"PMID":23485615,"re_id":5,"annotated sentence":"<e1>DMN<\\e1> induced cyclooxygenase-2 (COX-2) expression and <e2>nuclear factor-kappa B<\\e2> (NF-\u03baB) activation was reduced by CK treatment","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"DMN","object":"nuclear factor-kappa B","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induced cyclooxygenase-2 (COX-2) expression and <e2>GENE-N<\\e2> (NF-\u03baB) activation was reduced by CK treatment","sentence":"DMN induced cyclooxygenase-2 (COX-2) expression and nuclear factor-kappa B (NF-\u03baB) activation was reduced by CK treatment"}
{"PMID":23485615,"re_id":6,"annotated sentence":"<e1>DMN<\\e1> induced cyclooxygenase-2 (COX-2) expression and nuclear factor-kappa B (<e2>NF-\u03baB<\\e2>  activation was reduced by CK treatment","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"DMN","object":"NF-\u03baB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> induced cyclooxygenase-2 (COX-2) expression and nuclear factor-kappa B (<e2>GENE-N<\\e2>  activation was reduced by CK treatment","sentence":"DMN induced cyclooxygenase-2 (COX-2) expression and nuclear factor-kappa B (NF-\u03baB  activation was reduced by CK treatment"}
{"PMID":23485615,"re_id":7,"annotated sentence":"CK significantly inhibited <e1>DMN<\\e1> induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and <e2>collagen<\\e2> content","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMN","object":"collagen","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"CK significantly inhibited <e1>CHEMICAL<\\e1> induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and <e2>GENE-N<\\e2> content","sentence":"CK significantly inhibited DMN induced increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, fibrosis score, and hepatic malondialdehyde and collagen content"}
{"PMID":23485615,"re_id":8,"annotated sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN<\\e1> induced increases in <e2>matrix metalloproteinase-13<\\e2> (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMN","object":"matrix metalloproteinase-13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>CHEMICAL<\\e1> induced increases in <e2>GENE-Y<\\e2> (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein","sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited DMN induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein"}
{"PMID":23485615,"re_id":9,"annotated sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN<\\e1> induced increases in matrix metalloproteinase-13 (<e2>MMP-13<\\e2> , tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMN","object":"MMP-13","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>CHEMICAL<\\e1> induced increases in matrix metalloproteinase-13 (<e2>GENE-Y<\\e2> , tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein","sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited DMN induced increases in matrix metalloproteinase-13 (MMP-13 , tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein"}
{"PMID":23485615,"re_id":10,"annotated sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN<\\e1> induced increases in matrix metalloproteinase-13 (MMP-13), <e2>tissue inhibitor of metalloproteinase-1<\\e2> (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMN","object":"tissue inhibitor of metalloproteinase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>CHEMICAL<\\e1> induced increases in matrix metalloproteinase-13 (MMP-13), <e2>GENE-Y<\\e2> (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein","sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited DMN induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein"}
{"PMID":23485615,"re_id":11,"annotated sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN<\\e1> induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (<e2>TIMP-1<\\e2> , and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMN","object":"TIMP-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>CHEMICAL<\\e1> induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (<e2>GENE-Y<\\e2> , and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein","sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited DMN induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1 , and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein"}
{"PMID":23485615,"re_id":12,"annotated sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN<\\e1> induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and <e2>tumor necrosis factor-\u03b1<\\e2> (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMN","object":"tumor necrosis factor-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>CHEMICAL<\\e1> induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and <e2>GENE-Y<\\e2> (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein","sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited DMN induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein"}
{"PMID":23485615,"re_id":13,"annotated sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN<\\e1> induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (<e2>TNF-\u03b1<\\e2>  mRNA, and collagen type I and \u03b1-smooth muscle actin protein","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMN","object":"TNF-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>CHEMICAL<\\e1> induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (<e2>GENE-Y<\\e2>  mRNA, and collagen type I and \u03b1-smooth muscle actin protein","sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited DMN induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1  mRNA, and collagen type I and \u03b1-smooth muscle actin protein"}
{"PMID":23485615,"re_id":14,"annotated sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN<\\e1> induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and <e2>collagen type I<\\e2> and \u03b1-smooth muscle actin protein","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMN","object":"collagen type I","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>CHEMICAL<\\e1> induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and <e2>GENE-N<\\e2> and \u03b1-smooth muscle actin protein","sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited DMN induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein"}
{"PMID":23485615,"re_id":15,"annotated sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>DMN<\\e1> induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and <e2>\u03b1-smooth muscle actin<\\e2> protein","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMN","object":"\u03b1-smooth muscle actin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited <e1>CHEMICAL<\\e1> induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and <e2>GENE-Y<\\e2> protein","sentence":"Reverse transcription polymerase chain reaction (RT-PCR) and western blot analyses revealed that CK inhibited DMN induced increases in matrix metalloproteinase-13 (MMP-13), tissue inhibitor of metalloproteinase-1 (TIMP-1), and tumor necrosis factor-\u03b1 (TNF-\u03b1) mRNA, and collagen type I and \u03b1-smooth muscle actin protein"}
{"PMID":23485615,"re_id":16,"annotated sentence":"<e1>DMN<\\e1> induced <e2>cyclooxygenase-2<\\e2> (COX-2) expression and nuclear factor-kappa B (NF-\u03baB) activation was reduced by CK treatment","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMN","object":"cyclooxygenase-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> (COX-2) expression and nuclear factor-kappa B (NF-\u03baB) activation was reduced by CK treatment","sentence":"DMN induced cyclooxygenase-2 (COX-2) expression and nuclear factor-kappa B (NF-\u03baB) activation was reduced by CK treatment"}
{"PMID":23485615,"re_id":17,"annotated sentence":"<e1>DMN<\\e1> induced cyclooxygenase-2 (<e2>COX-2<\\e2>  expression and nuclear factor-kappa B (NF-\u03baB) activation was reduced by CK treatment","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DMN","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> induced cyclooxygenase-2 (<e2>GENE-Y<\\e2>  expression and nuclear factor-kappa B (NF-\u03baB) activation was reduced by CK treatment","sentence":"DMN induced cyclooxygenase-2 (COX-2  expression and nuclear factor-kappa B (NF-\u03baB) activation was reduced by CK treatment"}
{"PMID":23485651,"re_id":3,"annotated sentence":"Extrinsic apoptotic pathway markers such as Fas levels and <e2>caspase-8<\\e2> activity increased as a result of <e1>CdTe<\\e1> QD exposure","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"CdTe","object":"caspase-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Extrinsic apoptotic pathway markers such as Fas levels and <e2>GENE-Y<\\e2> activity increased as a result of <e1>CHEMICAL<\\e1> QD exposure","sentence":"Extrinsic apoptotic pathway markers such as Fas levels and caspase-8 activity increased as a result of CdTe QD exposure"}
{"PMID":23485651,"re_id":4,"annotated sentence":"Our findings reveal that <e1>CdTe<\\e1> QDs cause oxidative stress, interfere with antioxidant defenses and activate protein <e2>kinases<\\e2>  leading to apoptosis via both extrinsic and intrinsic pathways","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"CdTe","object":"kinases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our findings reveal that <e1>CHEMICAL<\\e1> QDs cause oxidative stress, interfere with antioxidant defenses and activate protein <e2>GENE-N<\\e2>  leading to apoptosis via both extrinsic and intrinsic pathways","sentence":"Our findings reveal that CdTe QDs cause oxidative stress, interfere with antioxidant defenses and activate protein kinases  leading to apoptosis via both extrinsic and intrinsic pathways"}
{"PMID":23485651,"re_id":5,"annotated sentence":"Extrinsic apoptotic pathway markers such as <e2>Fas<\\e2> levels and caspase-8 activity increased as a result of <e1>CdTe<\\e1> QD exposure","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"CdTe","object":"Fas","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Extrinsic apoptotic pathway markers such as <e2>GENE-Y<\\e2> levels and caspase-8 activity increased as a result of <e1>CHEMICAL<\\e1> QD exposure","sentence":"Extrinsic apoptotic pathway markers such as Fas levels and caspase-8 activity increased as a result of CdTe QD exposure"}
{"PMID":23512787,"re_id":6,"annotated sentence":"<e1>Puerarin<\\e1> administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and <e2>PI3K<\\e2> Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Puerarin","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and <e2>GENE-N<\\e2> Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice","sentence":"Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice"}
{"PMID":23512787,"re_id":7,"annotated sentence":"<e1>Puerarin<\\e1> administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K\/<e2>Akt<\\e2> pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Puerarin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K\/<e2>GENE-N<\\e2> pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice","sentence":"Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K\/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice"}
{"PMID":23512787,"re_id":8,"annotated sentence":"<e1>Puerarin<\\e1> administration enhanced glutathione (GSH) activity, <e2>glial cell line-derived neurotrophic factor<\\e2> (GDNF) expression and PI3K\/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Puerarin","object":"glial cell line-derived neurotrophic factor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> administration enhanced glutathione (GSH) activity, <e2>GENE-Y<\\e2> (GDNF) expression and PI3K\/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice","sentence":"Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF) expression and PI3K\/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice"}
{"PMID":23512787,"re_id":9,"annotated sentence":"<e1>Puerarin<\\e1> administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (<e2>GDNF<\\e2>  expression and PI3K\/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Puerarin","object":"GDNF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (<e2>GENE-Y<\\e2>  expression and PI3K\/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice","sentence":"Puerarin administration enhanced glutathione (GSH) activity, glial cell line-derived neurotrophic factor (GDNF  expression and PI3K\/Akt pathway activation, which might ameliorate MPTP injection-induced progressive elevation of reactive oxygen species (ROS) formation in mice"}
{"PMID":23512787,"re_id":10,"annotated sentence":"In addition to the effect on ROS, <e1>puerarin<\\e1> ameliorated MPTP-reduced lysosome-associated membrane protein type 2A (<e2>Lamp 2A<\\e2>  expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"puerarin","object":"Lamp 2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition to the effect on ROS, <e1>CHEMICAL<\\e1> ameliorated MPTP-reduced lysosome-associated membrane protein type 2A (<e2>GENE-Y<\\e2>  expression","sentence":"In addition to the effect on ROS, puerarin ameliorated MPTP-reduced lysosome-associated membrane protein type 2A (Lamp 2A  expression"}
{"PMID":23512787,"re_id":11,"annotated sentence":"In addition to the effect on ROS, puerarin ameliorated <e1>MPTP<\\e1> reduced <e2>lysosome-associated membrane protein type 2A<\\e2> (Lamp 2A) expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"MPTP","object":"lysosome-associated membrane protein type 2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition to the effect on ROS, puerarin ameliorated <e1>CHEMICAL<\\e1> reduced <e2>GENE-Y<\\e2> (Lamp 2A) expression","sentence":"In addition to the effect on ROS, puerarin ameliorated MPTP reduced lysosome-associated membrane protein type 2A (Lamp 2A) expression"}
{"PMID":23512787,"re_id":12,"annotated sentence":"In addition to the effect on ROS, puerarin ameliorated <e1>MPTP<\\e1> reduced lysosome-associated membrane protein type 2A (<e2>Lamp 2A<\\e2>  expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"MPTP","object":"Lamp 2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In addition to the effect on ROS, puerarin ameliorated <e1>CHEMICAL<\\e1> reduced lysosome-associated membrane protein type 2A (<e2>GENE-Y<\\e2>  expression","sentence":"In addition to the effect on ROS, puerarin ameliorated MPTP reduced lysosome-associated membrane protein type 2A (Lamp 2A  expression"}
{"PMID":23512787,"re_id":13,"annotated sentence":"Taken together, our data demonstrate that <e1>puerarin<\\e1> attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K\/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of <e2>Lamp 2A<\\e2> expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"puerarin","object":"Lamp 2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, our data demonstrate that <e1>CHEMICAL<\\e1> attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K\/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of <e2>GENE-Y<\\e2> expression","sentence":"Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K\/Akt pathway and GSH activation, which subsequently ameliorate MPTP-induced ROS formation and decrease of Lamp 2A expression"}
{"PMID":23512787,"re_id":14,"annotated sentence":"Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K\/Akt pathway and GSH activation, which subsequently ameliorate <e1>MPTP<\\e1> induced ROS formation and decrease of <e2>Lamp 2A<\\e2> expression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"MPTP","object":"Lamp 2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Taken together, our data demonstrate that puerarin attenuates CHEMICAL-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K\/Akt pathway and GSH activation, which subsequently ameliorate <e1>CHEMICAL<\\e1> induced ROS formation and decrease of <e2>GENE-Y<\\e2> expression","sentence":"Taken together, our data demonstrate that puerarin attenuates MPTP-induced dopaminergic neuronal degeneration via modulating GDNF expression, PI3K\/Akt pathway and GSH activation, which subsequently ameliorate MPTP induced ROS formation and decrease of Lamp 2A expression"}
{"PMID":23524663,"re_id":1,"annotated sentence":"Instead, radiolabeled <e1>nucleosides<\\e1> resulting from <e2>nuclease<\\e2> hydrolysis were observed","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"nucleosides","object":"nuclease","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Instead, radiolabeled <e1>CHEMICAL<\\e1> resulting from <e2>GENE-N<\\e2> hydrolysis were observed","sentence":"Instead, radiolabeled nucleosides resulting from nuclease hydrolysis were observed"}
{"PMID":23527317,"re_id":5,"annotated sentence":"A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the <e2>vesicular monoamine transporter<\\e2> and for their inhibition of vesicular <e1>[(3)H]dopamine<\\e1> uptake","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"[(3)H]dopamine","object":"vesicular monoamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the <e2>GENE-N<\\e2> and for their inhibition of vesicular <e1>CHEMICAL<\\e1> uptake","sentence":"A series of N-substituted lobelane analogues was synthesized and evaluated for their [(3)H]dihydrotetrabenazine binding affinity at the vesicular monoamine transporter and for their inhibition of vesicular [(3)H]dopamine uptake"}
{"PMID":23527529,"re_id":1,"annotated sentence":"<e1>IPI-926<\\e1> is both a substrate and inhibitor (IC50\u2009=\u20091.9\u2009\u00b5M) of <e2>P-glycoprotein<\\e2>  6","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"IPI-926","object":"P-glycoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is both a substrate and inhibitor (IC50\u2009=\u20091.9\u2009\u00b5M) of <e2>GENE-N<\\e2>  6","sentence":"IPI-926 is both a substrate and inhibitor (IC50\u2009=\u20091.9\u2009\u00b5M) of P-glycoprotein  6"}
{"PMID":23527529,"re_id":2,"annotated sentence":"<e1>IPI-926<\\e1> is both a substrate and inhibitor (IC50\u2009=\u20091.9\u2009\u00b5M) of <e2>P-glycoprotein<\\e2>  6","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"IPI-926","object":"P-glycoprotein","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is both a substrate and inhibitor (IC50\u2009=\u20091.9\u2009\u00b5M) of <e2>GENE-N<\\e2>  6","sentence":"IPI-926 is both a substrate and inhibitor (IC50\u2009=\u20091.9\u2009\u00b5M) of P-glycoprotein  6"}
{"PMID":23529825,"re_id":0,"annotated sentence":"Oral <e1>lorcaserin<\\e1> (BELVIQ(\u00ae)), a selective serotonin <e2>5-HT2C<\\e2> receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"lorcaserin","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Oral <e1>CHEMICAL<\\e1> (BELVIQ(\u00ae)), a selective serotonin <e2>GENE-Y<\\e2> receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g","sentence":"Oral lorcaserin (BELVIQ(\u00ae)), a selective serotonin 5-HT2C receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g"}
{"PMID":23529825,"re_id":1,"annotated sentence":"Oral lorcaserin (<e1>BELVIQ<\\e1> \u00ae)), a selective serotonin <e2>5-HT2C<\\e2> receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"BELVIQ","object":"5-HT2C","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Oral lorcaserin (<e1>CHEMICAL<\\e1> \u00ae)), a selective serotonin <e2>GENE-Y<\\e2> receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g","sentence":"Oral lorcaserin (BELVIQ \u00ae)), a selective serotonin 5-HT2C receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g"}
{"PMID":23530834,"re_id":0,"annotated sentence":"Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (DPP-4) inhibitors, among them, the <e1>cyclopropyl-substituted phenylalanine<\\e1> derivative 11h displayed the most potent <e2>DPP-4<\\e2> inhibitory activity with an IC50 value of 0.247 \u03bcM","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cyclopropyl-substituted phenylalanine","object":"DPP-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (GENE-Y) inhibitors, among them, the <e1>CHEMICAL<\\e1> derivative 11h displayed the most potent <e2>GENE-Y<\\e2> inhibitory activity with an IC50 value of 0.247 \u03bcM","sentence":"Biological evaluation revealed that most tested compounds were potent dipeptidyl peptidase 4 (DPP-4) inhibitors, among them, the cyclopropyl-substituted phenylalanine derivative 11h displayed the most potent DPP-4 inhibitory activity with an IC50 value of 0.247 \u03bcM"}
{"PMID":23530834,"re_id":1,"annotated sentence":"Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a <e1>2-Cyanopyrrolidine<\\e1> Moiety as Potent <e2>Dipeptidyl Peptidase 4<\\e2> Inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"2-Cyanopyrrolidine","object":"Dipeptidyl Peptidase 4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a <e1>CHEMICAL<\\e1> Moiety as Potent <e2>GENE-Y<\\e2> Inhibitors","sentence":"Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a 2-Cyanopyrrolidine Moiety as Potent Dipeptidyl Peptidase 4 Inhibitors"}
{"PMID":23530834,"re_id":2,"annotated sentence":"Design, Synthesis, Biological Evaluation, and Docking Studies of <e1>(S)-Phenylalanine<\\e1> Derivatives with a 2-Cyanopyrrolidine Moiety as Potent <e2>Dipeptidyl Peptidase 4<\\e2> Inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"(S)-Phenylalanine","object":"Dipeptidyl Peptidase 4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Design, Synthesis, Biological Evaluation, and Docking Studies of <e1>CHEMICAL<\\e1> Derivatives with a 2-Cyanopyrrolidine Moiety as Potent <e2>GENE-Y<\\e2> Inhibitors","sentence":"Design, Synthesis, Biological Evaluation, and Docking Studies of (S)-Phenylalanine Derivatives with a 2-Cyanopyrrolidine Moiety as Potent Dipeptidyl Peptidase 4 Inhibitors"}
{"PMID":23532932,"re_id":9,"annotated sentence":"<e1>TCPOBOP<\\e1>  a CAR ligand, modestly induced <e2>mdr1a<\\e2> fLUC in pxr(+\/+) and pxr(-\/-) strains, consistent with CAR's minor role in mdr1a regulation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"TCPOBOP","object":"mdr1a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a CAR ligand, modestly induced <e2>GENE-Y<\\e2> fLUC in pxr(+\/+) and pxr(-\/-) strains, consistent with CAR's minor role in GENE-Y regulation","sentence":"TCPOBOP  a CAR ligand, modestly induced mdr1a fLUC in pxr(+\/+) and pxr(-\/-) strains, consistent with CAR's minor role in mdr1a regulation"}
{"PMID":23535185,"re_id":6,"annotated sentence":"Furthermore, <e1>galangin<\\e1> attenuated <e2>IgE<\\e2> mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"galangin","object":"IgE","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> attenuated <e2>GENE-N<\\e2> mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue","sentence":"Furthermore, galangin attenuated IgE mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue"}
{"PMID":23535185,"re_id":7,"annotated sentence":"<e1>Galangin<\\e1> decreased expression of pro-inflammatory <e2>cytokines<\\e2>  such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6, IL-1\u03b2, and IL-8","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Galangin","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> decreased expression of pro-inflammatory <e2>GENE-N<\\e2>  such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6, IL-1\u03b2, and IL-8","sentence":"Galangin decreased expression of pro-inflammatory cytokines  such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6, IL-1\u03b2, and IL-8"}
{"PMID":23535185,"re_id":8,"annotated sentence":"<e1>Galangin<\\e1> decreased expression of pro-inflammatory cytokines, such as <e2>tumor necrosis factor (TNF)-\u03b1<\\e2>  interleukin (IL)-6, IL-1\u03b2, and IL-8","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Galangin","object":"tumor necrosis factor (TNF)-\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> decreased expression of pro-inflammatory cytokines, such as <e2>GENE-Y<\\e2>  interleukin (IL)-6, IL-1\u03b2, and IL-8","sentence":"Galangin decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1  interleukin (IL)-6, IL-1\u03b2, and IL-8"}
{"PMID":23535185,"re_id":9,"annotated sentence":"<e1>Galangin<\\e1> decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, <e2>interleukin<\\e2> (IL)-6, IL-1\u03b2, and IL-8","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Galangin","object":"interleukin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, <e2>GENE-Y<\\e2> (IL)-6, IL-1\u03b2, and IL-8","sentence":"Galangin decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6, IL-1\u03b2, and IL-8"}
{"PMID":23535185,"re_id":10,"annotated sentence":"<e1>Galangin<\\e1> decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, interleukin <e2>(IL)-6<\\e2>  IL-1\u03b2, and IL-8","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Galangin","object":"(IL)-6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, interleukin <e2>GENE-Y<\\e2>  IL-1\u03b2, and IL-8","sentence":"Galangin decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6  IL-1\u03b2, and IL-8"}
{"PMID":23535185,"re_id":11,"annotated sentence":"<e1>Galangin<\\e1> decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6, <e2>IL-1\u03b2<\\e2>  and IL-8","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Galangin","object":"IL-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6, <e2>GENE-Y<\\e2>  and IL-8","sentence":"Galangin decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6, IL-1\u03b2  and IL-8"}
{"PMID":23535185,"re_id":12,"annotated sentence":"<e1>Galangin<\\e1> decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6, IL-1\u03b2, and <e2>IL-8<\\e2>  The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-\u03baB, and caspase-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Galangin","object":"IL-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6, IL-1\u03b2, and <e2>GENE-Y<\\e2>  The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-\u03baB, and caspase-1","sentence":"Galangin decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-6, IL-1\u03b2, and IL-8  The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-\u03baB, and caspase-1"}
{"PMID":23535185,"re_id":13,"annotated sentence":"The inhibitory effect of <e1>galangin<\\e1> on theses pro-inflammatory <e2>cytokines<\\e2> was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-\u03baB, and caspase-1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"galangin","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The inhibitory effect of <e1>CHEMICAL<\\e1> on theses pro-inflammatory <e2>GENE-N<\\e2> was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-\u03baB, and caspase-1","sentence":"The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-\u03baB, and caspase-1"}
{"PMID":23535185,"re_id":14,"annotated sentence":"Furthermore, <e1>galangin<\\e1> attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of <e2>histamine receptor 1<\\e2> at the inflamed tissue","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"galangin","object":"histamine receptor 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of <e2>GENE-Y<\\e2> at the inflamed tissue","sentence":"Furthermore, galangin attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue"}
{"PMID":23535185,"re_id":15,"annotated sentence":"Our results showed that <e1>galangin<\\e1> down-regulates mast cell-derived allergic inflammatory reactions by blocking histamine release and expression of pro-inflammatory <e2>cytokines<\\e2>  In light of in vitro and in vivo anti-allergic inflammatory effects, galangin could be a beneficial anti-allergic inflammatory agent.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"galangin","object":"cytokines","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Our results showed that <e1>CHEMICAL<\\e1> down-regulates mast cell-derived allergic inflammatory reactions by blocking histamine release and expression of pro-inflammatory <e2>GENE-N<\\e2>  In light of in vitro and in vivo anti-allergic inflammatory effects, CHEMICAL could be a beneficial anti-allergic inflammatory agent.","sentence":"Our results showed that galangin down-regulates mast cell-derived allergic inflammatory reactions by blocking histamine release and expression of pro-inflammatory cytokines  In light of in vitro and in vivo anti-allergic inflammatory effects, galangin could be a beneficial anti-allergic inflammatory agent."}
{"PMID":23537747,"re_id":1,"annotated sentence":"Next, <e1>nobiletin<\\e1> significantly decreased the levels of <e2>phospho-ERK2<\\e2> and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"nobiletin","object":"phospho-ERK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Next, <e1>CHEMICAL<\\e1> significantly decreased the levels of <e2>GENE-Y<\\e2> and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration","sentence":"Next, nobiletin significantly decreased the levels of phospho-ERK2 and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration"}
{"PMID":23537747,"re_id":2,"annotated sentence":"Next, <e1>nobiletin<\\e1> significantly decreased the levels of phospho-ERK2 and <e2>phospho-Akt<\\e2> in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"nobiletin","object":"phospho-Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Next, <e1>CHEMICAL<\\e1> significantly decreased the levels of phospho-ERK2 and <e2>GENE-N<\\e2> in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration","sentence":"Next, nobiletin significantly decreased the levels of phospho-ERK2 and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration"}
{"PMID":23537747,"re_id":3,"annotated sentence":"Next, <e1>nobiletin<\\e1> significantly decreased the levels of phospho-ERK2 and phospho-Akt in <e2>ERK2<\\e2> or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"nobiletin","object":"ERK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Next, <e1>CHEMICAL<\\e1> significantly decreased the levels of phospho-GENE-Y and phospho-Akt in <e2>GENE-Y<\\e2> or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration","sentence":"Next, nobiletin significantly decreased the levels of phospho-ERK2 and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration"}
{"PMID":23537747,"re_id":4,"annotated sentence":"Next, <e1>nobiletin<\\e1> significantly decreased the levels of phospho-ERK2 and phospho-Akt in ERK2 or <e2>Akt<\\e2> siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"nobiletin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Next, <e1>CHEMICAL<\\e1> significantly decreased the levels of phospho-ERK2 and phospho-GENE-N in ERK2 or <e2>GENE-N<\\e2> siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration","sentence":"Next, nobiletin significantly decreased the levels of phospho-ERK2 and phospho-Akt in ERK2 or Akt siRNA-transfected cells concomitantly with a marked reduction on cell invasion and migration"}
{"PMID":23537747,"re_id":5,"annotated sentence":"<e1>Nobiletin<\\e1> attenuates metastasis via both <e2>ERK<\\e2> and PI3K\/Akt pathways in HGF-treated liver cancer HepG2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Nobiletin","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> attenuates metastasis via both <e2>GENE-N<\\e2> and PI3K\/Akt pathways in HGF-treated liver cancer HepG2 cells","sentence":"Nobiletin attenuates metastasis via both ERK and PI3K\/Akt pathways in HGF-treated liver cancer HepG2 cells"}
{"PMID":23537747,"re_id":6,"annotated sentence":"<e1>Nobiletin<\\e1> attenuates metastasis via both ERK and <e2>PI3K<\\e2> Akt pathways in HGF-treated liver cancer HepG2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Nobiletin","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> attenuates metastasis via both ERK and <e2>GENE-N<\\e2> Akt pathways in HGF-treated liver cancer HepG2 cells","sentence":"Nobiletin attenuates metastasis via both ERK and PI3K Akt pathways in HGF-treated liver cancer HepG2 cells"}
{"PMID":23537747,"re_id":7,"annotated sentence":"<e1>Nobiletin<\\e1> attenuates metastasis via both ERK and PI3K\/<e2>Akt<\\e2> pathways in HGF-treated liver cancer HepG2 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Nobiletin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> attenuates metastasis via both ERK and PI3K\/<e2>GENE-N<\\e2> pathways in HGF-treated liver cancer HepG2 cells","sentence":"Nobiletin attenuates metastasis via both ERK and PI3K\/Akt pathways in HGF-treated liver cancer HepG2 cells"}
{"PMID":23537747,"re_id":8,"annotated sentence":"In conclusion, <e1>nobiletin<\\e1> attenuates <e2>HGF<\\e2> induced HepG2 cells metastasis involving both ERK and PI3K\/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nobiletin","object":"HGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> attenuates <e2>GENE-Y<\\e2> induced HepG2 cells metastasis involving both ERK and PI3K\/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.","sentence":"In conclusion, nobiletin attenuates HGF induced HepG2 cells metastasis involving both ERK and PI3K\/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma."}
{"PMID":23537747,"re_id":9,"annotated sentence":"In conclusion, <e1>nobiletin<\\e1> attenuates HGF-induced HepG2 cells metastasis involving both <e2>ERK<\\e2> and PI3K\/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nobiletin","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> attenuates HGF-induced HepG2 cells metastasis involving both <e2>GENE-N<\\e2> and PI3K\/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.","sentence":"In conclusion, nobiletin attenuates HGF-induced HepG2 cells metastasis involving both ERK and PI3K\/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma."}
{"PMID":23537747,"re_id":10,"annotated sentence":"In conclusion, <e1>nobiletin<\\e1> attenuates HGF-induced HepG2 cells metastasis involving both ERK and <e2>PI3K<\\e2> Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nobiletin","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> attenuates HGF-induced HepG2 cells metastasis involving both ERK and <e2>GENE-N<\\e2> Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.","sentence":"In conclusion, nobiletin attenuates HGF-induced HepG2 cells metastasis involving both ERK and PI3K Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma."}
{"PMID":23537747,"re_id":11,"annotated sentence":"In conclusion, <e1>nobiletin<\\e1> attenuates HGF-induced HepG2 cells metastasis involving both ERK and PI3K\/<e2>Akt<\\e2> pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nobiletin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In conclusion, <e1>CHEMICAL<\\e1> attenuates HGF-induced HepG2 cells metastasis involving both ERK and PI3K\/<e2>GENE-N<\\e2> pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma.","sentence":"In conclusion, nobiletin attenuates HGF-induced HepG2 cells metastasis involving both ERK and PI3K\/Akt pathways and are potentially useful as anti-metastatic agents for the treatment of hepatoma."}
{"PMID":23537747,"re_id":12,"annotated sentence":"Among them, <e1>nobiletin<\\e1> markedly inhibited <e2>HGF<\\e2> induced the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay and transwell-chamber invasion\/migration assay under non-cytotoxic concentrations","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nobiletin","object":"HGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among them, <e1>CHEMICAL<\\e1> markedly inhibited <e2>GENE-Y<\\e2> induced the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay and transwell-chamber invasion\/migration assay under non-cytotoxic concentrations","sentence":"Among them, nobiletin markedly inhibited HGF induced the abilities of the adhesion, invasion, and migration by cell-matrix adhesion assay and transwell-chamber invasion\/migration assay under non-cytotoxic concentrations"}
{"PMID":23537747,"re_id":13,"annotated sentence":"Data also showed <e1>nobiletin<\\e1> inhibited <e2>HGF<\\e2> induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nobiletin","object":"HGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Data also showed <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia","sentence":"Data also showed nobiletin inhibited HGF induced cell scattering and cytoskeleton changed such as filopodia and lamellipodia"}
{"PMID":23537747,"re_id":14,"annotated sentence":"Furthermore, <e1>nobiletin<\\e1> could inhibit <e2>HGF<\\e2> induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1\/2 and p38","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nobiletin","object":"HGF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> could inhibit <e2>GENE-Y<\\e2> induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1\/2 and p38","sentence":"Furthermore, nobiletin could inhibit HGF induced the membrane localization of phosphorylated c-Met, ERK2, and Akt, but not phosphorylated JNK1\/2 and p38"}
{"PMID":23537747,"re_id":15,"annotated sentence":"Furthermore, <e1>nobiletin<\\e1> could inhibit HGF-induced the membrane localization of phosphorylated <e2>c-Met<\\e2>  ERK2, and Akt, but not phosphorylated JNK1\/2 and p38","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nobiletin","object":"c-Met","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> could inhibit HGF-induced the membrane localization of phosphorylated <e2>GENE-Y<\\e2>  ERK2, and Akt, but not phosphorylated JNK1\/2 and p38","sentence":"Furthermore, nobiletin could inhibit HGF-induced the membrane localization of phosphorylated c-Met  ERK2, and Akt, but not phosphorylated JNK1\/2 and p38"}
{"PMID":23537747,"re_id":16,"annotated sentence":"Furthermore, <e1>nobiletin<\\e1> could inhibit HGF-induced the membrane localization of phosphorylated c-Met, <e2>ERK2<\\e2>  and Akt, but not phosphorylated JNK1\/2 and p38","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nobiletin","object":"ERK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> could inhibit HGF-induced the membrane localization of phosphorylated c-Met, <e2>GENE-Y<\\e2>  and Akt, but not phosphorylated JNK1\/2 and p38","sentence":"Furthermore, nobiletin could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2  and Akt, but not phosphorylated JNK1\/2 and p38"}
{"PMID":23537747,"re_id":17,"annotated sentence":"Furthermore, <e1>nobiletin<\\e1> could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and <e2>Akt<\\e2>  but not phosphorylated JNK1\/2 and p38","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nobiletin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, <e1>CHEMICAL<\\e1> could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and <e2>GENE-N<\\e2>  but not phosphorylated JNK1\/2 and p38","sentence":"Furthermore, nobiletin could inhibit HGF-induced the membrane localization of phosphorylated c-Met, ERK2, and Akt  but not phosphorylated JNK1\/2 and p38"}
{"PMID":23541982,"re_id":2,"annotated sentence":"Excess of <e1>cholesterol<\\e1> converted into 24OHC may up-regulate <e2>ApoE<\\e2> synthesis which is a scavenger for A\u03b2 and Tau","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"cholesterol","object":"ApoE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Excess of <e1>CHEMICAL<\\e1> converted into 24OHC may up-regulate <e2>GENE-Y<\\e2> synthesis which is a scavenger for A\u03b2 and Tau","sentence":"Excess of cholesterol converted into 24OHC may up-regulate ApoE synthesis which is a scavenger for A\u03b2 and Tau"}
{"PMID":23541982,"re_id":3,"annotated sentence":"Excess of cholesterol converted into <e1>24OHC<\\e1> may up-regulate <e2>ApoE<\\e2> synthesis which is a scavenger for A\u03b2 and Tau","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"24OHC","object":"ApoE","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Excess of cholesterol converted into <e1>CHEMICAL<\\e1> may up-regulate <e2>GENE-Y<\\e2> synthesis which is a scavenger for A\u03b2 and Tau","sentence":"Excess of cholesterol converted into 24OHC may up-regulate ApoE synthesis which is a scavenger for A\u03b2 and Tau"}
{"PMID":23541982,"re_id":4,"annotated sentence":"<e1>Cholesterol<\\e1> also increases <e2>Amyloid \u03b2<\\e2> (A\u03b2) deposition and tau pathology","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Cholesterol","object":"Amyloid \u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also increases <e2>GENE-Y<\\e2> (A\u03b2) deposition and tau pathology","sentence":"Cholesterol also increases Amyloid \u03b2 (A\u03b2) deposition and tau pathology"}
{"PMID":23541982,"re_id":5,"annotated sentence":"<e1>Cholesterol<\\e1> also increases Amyloid \u03b2 (<e2>A\u03b2<\\e2>  deposition and tau pathology","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Cholesterol","object":"A\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also increases Amyloid \u03b2 (<e2>GENE-Y<\\e2>  deposition and tau pathology","sentence":"Cholesterol also increases Amyloid \u03b2 (A\u03b2  deposition and tau pathology"}
{"PMID":23541982,"re_id":6,"annotated sentence":"<e1>Cholesterol<\\e1> also increases Amyloid \u03b2 (A\u03b2) deposition and <e2>tau<\\e2> pathology","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Cholesterol","object":"tau","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also increases Amyloid \u03b2 (A\u03b2) deposition and <e2>GENE-Y<\\e2> pathology","sentence":"Cholesterol also increases Amyloid \u03b2 (A\u03b2) deposition and tau pathology"}
{"PMID":23543737,"re_id":2,"annotated sentence":"In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular <e1>glutamate<\\e1> is reduced when <e2>CaMKII<\\e2> is inhibited","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glutamate","object":"CaMKII","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular <e1>CHEMICAL<\\e1> is reduced when <e2>GENE-N<\\e2> is inhibited","sentence":"In the current study, we extend these findings to show that the ability of astrocytes to buffer extracellular glutamate is reduced when CaMKII is inhibited"}
{"PMID":23547652,"re_id":1,"annotated sentence":"We have identified <e1>3-hydroxypyridin-2-thione<\\e1> (3-HPT) as a novel ZBG that is compatible with <e2>HDAC<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-hydroxypyridin-2-thione","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have identified <e1>CHEMICAL<\\e1> (3-HPT) as a novel ZBG that is compatible with <e2>GENE-N<\\e2> inhibition","sentence":"We have identified 3-hydroxypyridin-2-thione (3-HPT) as a novel ZBG that is compatible with HDAC inhibition"}
{"PMID":23547652,"re_id":2,"annotated sentence":"We have identified 3-hydroxypyridin-2-thione (<e1>3-HPT<\\e1>  as a novel ZBG that is compatible with <e2>HDAC<\\e2> inhibition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-HPT","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We have identified 3-hydroxypyridin-2-thione (<e1>CHEMICAL<\\e1>  as a novel ZBG that is compatible with <e2>GENE-N<\\e2> inhibition","sentence":"We have identified 3-hydroxypyridin-2-thione (3-HPT  as a novel ZBG that is compatible with HDAC inhibition"}
{"PMID":23547652,"re_id":3,"annotated sentence":"<e1>3-HPT<\\e1> inhibits <e2>HDAC 6<\\e2> and HDAC 8 with an IC50 of 681 and 3675 nM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-HPT","object":"HDAC 6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits <e2>GENE-Y<\\e2> and HDAC 8 with an IC50 of 681 and 3675 nM, respectively","sentence":"3-HPT inhibits HDAC 6 and HDAC 8 with an IC50 of 681 and 3675 nM, respectively"}
{"PMID":23547652,"re_id":4,"annotated sentence":"<e1>3-HPT<\\e1> inhibits HDAC 6 and <e2>HDAC 8<\\e2> with an IC50 of 681 and 3675 nM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-HPT","object":"HDAC 8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibits HDAC 6 and <e2>GENE-Y<\\e2> with an IC50 of 681 and 3675 nM, respectively","sentence":"3-HPT inhibits HDAC 6 and HDAC 8 with an IC50 of 681 and 3675 nM, respectively"}
{"PMID":23547652,"re_id":5,"annotated sentence":"Small molecules bearing hydroxamic acid as the <e1>zinc<\\e1> binding group (ZBG) have been the most effective <e2>histone deacetylase<\\e2> inhibitors (HDACi) to date","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"zinc","object":"histone deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Small molecules bearing hydroxamic acid as the <e1>CHEMICAL<\\e1> binding group (ZBG) have been the most effective <e2>GENE-N<\\e2> inhibitors (HDACi) to date","sentence":"Small molecules bearing hydroxamic acid as the zinc binding group (ZBG) have been the most effective histone deacetylase inhibitors (HDACi) to date"}
{"PMID":23547652,"re_id":6,"annotated sentence":"Small molecules bearing hydroxamic acid as the <e1>zinc<\\e1> binding group (ZBG) have been the most effective histone deacetylase inhibitors (<e2>HDAC<\\e2> ) to date","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"zinc","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Small molecules bearing hydroxamic acid as the <e1>CHEMICAL<\\e1> binding group (ZBG) have been the most effective histone deacetylase inhibitors (<e2>GENE-N<\\e2> ) to date","sentence":"Small molecules bearing hydroxamic acid as the zinc binding group (ZBG) have been the most effective histone deacetylase inhibitors (HDAC ) to date"}
{"PMID":23547652,"re_id":7,"annotated sentence":"Subsequent optimization led to several novel <e1>3HPT<\\e1> based <e2>HDAC<\\e2>  that are selective for HDAC 6 and HDAC 8","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3HPT","object":"HDAC","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Subsequent optimization led to several novel <e1>CHEMICAL<\\e1> based <e2>GENE-N<\\e2>  that are selective for GENE-N 6 and GENE-N 8","sentence":"Subsequent optimization led to several novel 3HPT based HDAC  that are selective for HDAC 6 and HDAC 8"}
{"PMID":23547652,"re_id":8,"annotated sentence":"Subsequent optimization led to several novel <e1>3HPT<\\e1> based HDACi that are selective for <e2>HDAC 6<\\e2> and HDAC 8","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3HPT","object":"HDAC 6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Subsequent optimization led to several novel <e1>CHEMICAL<\\e1> based HDACi that are selective for <e2>GENE-Y<\\e2> and HDAC 8","sentence":"Subsequent optimization led to several novel 3HPT based HDACi that are selective for HDAC 6 and HDAC 8"}
{"PMID":23547652,"re_id":9,"annotated sentence":"Subsequent optimization led to several novel <e1>3HPT<\\e1> based HDACi that are selective for HDAC 6 and <e2>HDAC 8<\\e2>  Furthermore, a subset of these inhibitors induces apoptosis in various cancer cell lines.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3HPT","object":"HDAC 8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Subsequent optimization led to several novel <e1>CHEMICAL<\\e1> based HDACi that are selective for HDAC 6 and <e2>GENE-Y<\\e2>  Furthermore, a subset of these inhibitors induces apoptosis in various cancer cell lines.","sentence":"Subsequent optimization led to several novel 3HPT based HDACi that are selective for HDAC 6 and HDAC 8  Furthermore, a subset of these inhibitors induces apoptosis in various cancer cell lines."}
{"PMID":23547652,"re_id":10,"annotated sentence":"<e1>3-Hydroxypyridin-2-thione<\\e1> as Novel Zinc Binding Group for Selective <e2>Histone Deacetylase<\\e2> Inhibition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-Hydroxypyridin-2-thione","object":"Histone Deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> as Novel Zinc Binding Group for Selective <e2>GENE-N<\\e2> Inhibition","sentence":"3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition"}
{"PMID":23547652,"re_id":11,"annotated sentence":"3-Hydroxypyridin-2-thione as Novel <e1>Zinc<\\e1> Binding Group for Selective <e2>Histone Deacetylase<\\e2> Inhibition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Zinc","object":"Histone Deacetylase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"3-Hydroxypyridin-2-thione as Novel <e1>CHEMICAL<\\e1> Binding Group for Selective <e2>GENE-N<\\e2> Inhibition","sentence":"3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition"}
{"PMID":23561088,"re_id":0,"annotated sentence":"Maqui berry (Aristotelia chilensis) and the constituent <e1>delphinidin glycoside<\\e1> inhibit <e2>photoreceptor<\\e2> cell death induced by visible light","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"delphinidin glycoside","object":"photoreceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Maqui berry (Aristotelia chilensis) and the constituent <e1>CHEMICAL<\\e1> inhibit <e2>GENE-N<\\e2> cell death induced by visible light","sentence":"Maqui berry (Aristotelia chilensis) and the constituent delphinidin glycoside inhibit photoreceptor cell death induced by visible light"}
{"PMID":23561088,"re_id":1,"annotated sentence":"These findings indicate that MBE and its <e1>anthocyanidins<\\e1> suppress the light-induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of <e2>phosphorylated-p38<\\e2> may be involved in the underlying mechanism.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"anthocyanidins","object":"phosphorylated-p38","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings indicate that MBE and its <e1>CHEMICAL<\\e1> suppress the light-induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of <e2>GENE-N<\\e2> may be involved in the underlying mechanism.","sentence":"These findings indicate that MBE and its anthocyanidins suppress the light-induced photoreceptor cell death by inhibiting ROS production, suggesting that the inhibition of phosphorylated-p38 may be involved in the underlying mechanism."}
{"PMID":23561205,"re_id":0,"annotated sentence":"Moreover, <e1>curcumin<\\e1> could also down-regulate the expression and activity of <e2>matrix metalloproteinase-9<\\e2> (MMP-9)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"curcumin","object":"matrix metalloproteinase-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> could also down-regulate the expression and activity of <e2>GENE-Y<\\e2> (MMP-9)","sentence":"Moreover, curcumin could also down-regulate the expression and activity of matrix metalloproteinase-9 (MMP-9)"}
{"PMID":23561205,"re_id":1,"annotated sentence":"Moreover, <e1>curcumin<\\e1> could also down-regulate the expression and activity of matrix metalloproteinase-9 (<e2>MMP-9<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"curcumin","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> could also down-regulate the expression and activity of matrix metalloproteinase-9 (<e2>GENE-Y<\\e2> ","sentence":"Moreover, curcumin could also down-regulate the expression and activity of matrix metalloproteinase-9 (MMP-9 "}
{"PMID":23561205,"re_id":2,"annotated sentence":"Moreover, <e1>curcumin<\\e1> could also down-regulate the expression and activity of <e2>matrix metalloproteinase-9<\\e2> (MMP-9)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"curcumin","object":"matrix metalloproteinase-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> could also down-regulate the expression and activity of <e2>GENE-Y<\\e2> (MMP-9)","sentence":"Moreover, curcumin could also down-regulate the expression and activity of matrix metalloproteinase-9 (MMP-9)"}
{"PMID":23561205,"re_id":3,"annotated sentence":"Moreover, <e1>curcumin<\\e1> could also down-regulate the expression and activity of matrix metalloproteinase-9 (<e2>MMP-9<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"curcumin","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> could also down-regulate the expression and activity of matrix metalloproteinase-9 (<e2>GENE-Y<\\e2> ","sentence":"Moreover, curcumin could also down-regulate the expression and activity of matrix metalloproteinase-9 (MMP-9 "}
{"PMID":23562365,"re_id":2,"annotated sentence":"Treatment with <e1>EVn-50<\\e1> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of <e2>Histone 3<\\e2> at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"EVn-50","object":"Histone 3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of <e2>GENE-N<\\e2> at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c","sentence":"Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c"}
{"PMID":23562365,"re_id":3,"annotated sentence":"Treatment with <e1>EVn-50<\\e1> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of <e2>Cdk1<\\e2> at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"EVn-50","object":"Cdk1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of <e2>GENE-Y<\\e2> at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c","sentence":"Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c"}
{"PMID":23562365,"re_id":4,"annotated sentence":"Treatment with EVn-50 or <e1>VB1<\\e1> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of <e2>Histone 3<\\e2> at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"VB1","object":"Histone 3","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Treatment with EVn-50 or <e1>CHEMICAL<\\e1> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of <e2>GENE-N<\\e2> at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c","sentence":"Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c"}
{"PMID":23562365,"re_id":5,"annotated sentence":"Treatment with EVn-50 or <e1>VB1<\\e1> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of <e2>Cdk1<\\e2> at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"VB1","object":"Cdk1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with EVn-50 or <e1>CHEMICAL<\\e1> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of <e2>GENE-Y<\\e2> at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c","sentence":"Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c"}
{"PMID":23562365,"re_id":6,"annotated sentence":"Treatment with <e1>EVn-50<\\e1> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of <e2>cyclin B1<\\e2>  and decreased expression of Cdc25c","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"EVn-50","object":"cyclin B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of <e2>GENE-Y<\\e2>  and decreased expression of Cdc25c","sentence":"Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1  and decreased expression of Cdc25c"}
{"PMID":23562365,"re_id":7,"annotated sentence":"Treatment with EVn-50 or <e1>VB1<\\e1> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of <e2>cyclin B1<\\e2>  and decreased expression of Cdc25c","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"VB1","object":"cyclin B1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with EVn-50 or <e1>CHEMICAL<\\e1> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of <e2>GENE-Y<\\e2>  and decreased expression of Cdc25c","sentence":"Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1  and decreased expression of Cdc25c"}
{"PMID":23562365,"re_id":8,"annotated sentence":"Treatment with <e1>EVn-50<\\e1> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of <e2>Cdc25c<\\e2>  Moreover, we found that exposure of MDA-MB-435 cells to EVn-50 or VB1 caused obvious apoptosis of MDA-MB-435 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"EVn-50","object":"Cdc25c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with <e1>CHEMICAL<\\e1> or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of <e2>GENE-Y<\\e2>  Moreover, we found that exposure of MDA-MB-435 cells to CHEMICAL or VB1 caused obvious apoptosis of MDA-MB-435 cells","sentence":"Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c  Moreover, we found that exposure of MDA-MB-435 cells to EVn-50 or VB1 caused obvious apoptosis of MDA-MB-435 cells"}
{"PMID":23562365,"re_id":9,"annotated sentence":"Treatment with EVn-50 or <e1>VB1<\\e1> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of <e2>Cdc25c<\\e2>  Moreover, we found that exposure of MDA-MB-435 cells to EVn-50 or VB1 caused obvious apoptosis of MDA-MB-435 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"VB1","object":"Cdc25c","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with EVn-50 or <e1>CHEMICAL<\\e1> resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of <e2>GENE-Y<\\e2>  Moreover, we found that exposure of MDA-MB-435 cells to EVn-50 or CHEMICAL caused obvious apoptosis of MDA-MB-435 cells","sentence":"Treatment with EVn-50 or VB1 resulted in arresting the MDA-MB-435 and SMMC-7721 cells at G2\/M phase, which was further supported by observations of increased phosphorylation of Histone 3 at Ser10, phosphorylation of Cdk1 at Tyr15, expression of cyclin B1, and decreased expression of Cdc25c  Moreover, we found that exposure of MDA-MB-435 cells to EVn-50 or VB1 caused obvious apoptosis of MDA-MB-435 cells"}
{"PMID":23562496,"re_id":1,"annotated sentence":"<e1>Xanthohumol<\\e1> and 2-hydroxychalcone induced apoptosis by <e2>Bcl-2<\\e2> downregulation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Xanthohumol","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and 2-hydroxychalcone induced apoptosis by <e2>GENE-Y<\\e2> downregulation","sentence":"Xanthohumol and 2-hydroxychalcone induced apoptosis by Bcl-2 downregulation"}
{"PMID":23562496,"re_id":2,"annotated sentence":"Xanthohumol and <e1>2-hydroxychalcone<\\e1> induced apoptosis by <e2>Bcl-2<\\e2> downregulation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"2-hydroxychalcone","object":"Bcl-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Xanthohumol and <e1>CHEMICAL<\\e1> induced apoptosis by <e2>GENE-Y<\\e2> downregulation","sentence":"Xanthohumol and 2-hydroxychalcone induced apoptosis by Bcl-2 downregulation"}
{"PMID":23562496,"re_id":3,"annotated sentence":"Importantly, <e1>2-hydroxychalcone<\\e1> and xanthohumol exerted more potent inhibitory effects on the proliferation, <e2>MMP-9<\\e2> expression and invasive phenotype of MDA-MB-231 than chalcone","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"2-hydroxychalcone","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Importantly, <e1>CHEMICAL<\\e1> and xanthohumol exerted more potent inhibitory effects on the proliferation, <e2>GENE-Y<\\e2> expression and invasive phenotype of MDA-MB-231 than chalcone","sentence":"Importantly, 2-hydroxychalcone and xanthohumol exerted more potent inhibitory effects on the proliferation, MMP-9 expression and invasive phenotype of MDA-MB-231 than chalcone"}
{"PMID":23562496,"re_id":4,"annotated sentence":"Importantly, 2-hydroxychalcone and <e1>xanthohumol<\\e1> exerted more potent inhibitory effects on the proliferation, <e2>MMP-9<\\e2> expression and invasive phenotype of MDA-MB-231 than chalcone","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"xanthohumol","object":"MMP-9","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Importantly, 2-hydroxychalcone and <e1>CHEMICAL<\\e1> exerted more potent inhibitory effects on the proliferation, <e2>GENE-Y<\\e2> expression and invasive phenotype of MDA-MB-231 than chalcone","sentence":"Importantly, 2-hydroxychalcone and xanthohumol exerted more potent inhibitory effects on the proliferation, MMP-9 expression and invasive phenotype of MDA-MB-231 than chalcone"}
{"PMID":23566269,"re_id":1,"annotated sentence":"<e1>3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one<\\e1> exhibited the predicted binding mode and demonstrated high inhibitory activity for <e2>human DAAO<\\e2> in enzyme- and cell-based assays","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one","object":"human DAAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> exhibited the predicted binding mode and demonstrated high inhibitory activity for <e2>GENE-Y<\\e2> in enzyme- and cell-based assays","sentence":"3-Hydroxy-5-(2-phenylethyl)pyridine-2(1H)-one exhibited the predicted binding mode and demonstrated high inhibitory activity for human DAAO in enzyme- and cell-based assays"}
{"PMID":23566269,"re_id":2,"annotated sentence":"<e1>4-Hydroxypyridazin-3(2H)-one<\\e1> Derivatives as Novel <e2>d-Amino Acid Oxidase<\\e2> Inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"4-Hydroxypyridazin-3(2H)-one","object":"d-Amino Acid Oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> Derivatives as Novel <e2>GENE-Y<\\e2> Inhibitors","sentence":"4-Hydroxypyridazin-3(2H)-one Derivatives as Novel d-Amino Acid Oxidase Inhibitors"}
{"PMID":23566269,"re_id":3,"annotated sentence":"We identified a series of <e1>4-hydroxypyridazin-3(2H)-one<\\e1> derivatives as novel <e2>DAAO<\\e2> inhibitors with high potency and substantial cell permeability using fragment-based drug design","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"4-hydroxypyridazin-3(2H)-one","object":"DAAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We identified a series of <e1>CHEMICAL<\\e1> derivatives as novel <e2>GENE-Y<\\e2> inhibitors with high potency and substantial cell permeability using fragment-based drug design","sentence":"We identified a series of 4-hydroxypyridazin-3(2H)-one derivatives as novel DAAO inhibitors with high potency and substantial cell permeability using fragment-based drug design"}
{"PMID":23566269,"re_id":4,"annotated sentence":"d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including <e1>d-serine<\\e1>  a coagonist of the <e2>N-methyl-d-aspartate receptor<\\e2>  We identified a series of 4-hydroxypyridazin-3(2H)-one derivatives as novel DAAO inhibitors with high potency and substantial cell permeability using fragment-based drug design","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"d-serine","object":"N-methyl-d-aspartate receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including <e1>CHEMICAL<\\e1>  a coagonist of the <e2>GENE-N<\\e2>  We identified a series of 4-hydroxypyridazin-3(2H)-one derivatives as novel DAAO inhibitors with high potency and substantial cell permeability using fragment-based drug design","sentence":"d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine  a coagonist of the N-methyl-d-aspartate receptor  We identified a series of 4-hydroxypyridazin-3(2H)-one derivatives as novel DAAO inhibitors with high potency and substantial cell permeability using fragment-based drug design"}
{"PMID":23566269,"re_id":5,"annotated sentence":"<e2>d-Amino acid oxidase<\\e2> (DAAO) catalyzes the oxidation of d-amino acids including <e1>d-serine<\\e1>  a coagonist of the N-methyl-d-aspartate receptor","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"d-serine","object":"d-Amino acid oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (DAAO) catalyzes the oxidation of d-amino acids including <e1>CHEMICAL<\\e1>  a coagonist of the N-methyl-d-aspartate receptor","sentence":"d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine  a coagonist of the N-methyl-d-aspartate receptor"}
{"PMID":23566269,"re_id":6,"annotated sentence":"d-Amino acid oxidase (<e2>DAAO<\\e2>  catalyzes the oxidation of d-amino acids including <e1>d-serine<\\e1>  a coagonist of the N-methyl-d-aspartate receptor","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"d-serine","object":"DAAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"d-Amino acid oxidase (<e2>GENE-Y<\\e2>  catalyzes the oxidation of d-amino acids including <e1>CHEMICAL<\\e1>  a coagonist of the N-methyl-d-aspartate receptor","sentence":"d-Amino acid oxidase (DAAO  catalyzes the oxidation of d-amino acids including d-serine  a coagonist of the N-methyl-d-aspartate receptor"}
{"PMID":23566269,"re_id":7,"annotated sentence":"<e2>d-Amino acid oxidase<\\e2> (DAAO) catalyzes the oxidation of <e1>d-amino acids<\\e1> including d-serine, a coagonist of the N-methyl-d-aspartate receptor","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"d-amino acids","object":"d-Amino acid oxidase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> (DAAO) catalyzes the oxidation of <e1>CHEMICAL<\\e1> including d-serine, a coagonist of the N-methyl-d-aspartate receptor","sentence":"d-Amino acid oxidase (DAAO) catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor"}
{"PMID":23566269,"re_id":8,"annotated sentence":"d-Amino acid oxidase (<e2>DAAO<\\e2>  catalyzes the oxidation of <e1>d-amino acids<\\e1> including d-serine, a coagonist of the N-methyl-d-aspartate receptor","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"d-amino acids","object":"DAAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"d-Amino acid oxidase (<e2>GENE-Y<\\e2>  catalyzes the oxidation of <e1>CHEMICAL<\\e1> including d-serine, a coagonist of the N-methyl-d-aspartate receptor","sentence":"d-Amino acid oxidase (DAAO  catalyzes the oxidation of d-amino acids including d-serine, a coagonist of the N-methyl-d-aspartate receptor"}
{"PMID":23567241,"re_id":2,"annotated sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, <e1>heptylparaben<\\e1> (C7) and pentylparaben (C5) showed the most potent <e2>ER\u03b1<\\e2> and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"heptylparaben","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, <e1>CHEMICAL<\\e1> (C7) and pentylparaben (C5) showed the most potent <e2>GENE-Y<\\e2> and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12"}
{"PMID":23567241,"re_id":3,"annotated sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, <e1>heptylparaben<\\e1> (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and <e2>ER\u03b2<\\e2> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"heptylparaben","object":"ER\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, <e1>CHEMICAL<\\e1> (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and <e2>GENE-Y<\\e2> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12"}
{"PMID":23567241,"re_id":4,"annotated sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and <e1>pentylparaben<\\e1> (C5) showed the most potent <e2>ER\u03b1<\\e2> and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"pentylparaben","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and <e1>CHEMICAL<\\e1> (C5) showed the most potent <e2>GENE-Y<\\e2> and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12"}
{"PMID":23567241,"re_id":5,"annotated sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and <e1>pentylparaben<\\e1> (C5) showed the most potent ER\u03b1 and <e2>ER\u03b2<\\e2> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"pentylparaben","object":"ER\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and <e1>CHEMICAL<\\e1> (C5) showed the most potent ER\u03b1 and <e2>GENE-Y<\\e2> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12"}
{"PMID":23567241,"re_id":6,"annotated sentence":"Most <e1>parabens<\\e1> showing estrogenic activity exhibited <e2>ER\u03b2<\\e2> agonistic activity at lower concentrations than those inducing ER\u03b1-agonistic activity","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"parabens","object":"ER\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Most <e1>CHEMICAL<\\e1> showing estrogenic activity exhibited <e2>GENE-Y<\\e2> agonistic activity at lower concentrations than those inducing ER\u03b1-agonistic activity","sentence":"Most parabens showing estrogenic activity exhibited ER\u03b2 agonistic activity at lower concentrations than those inducing ER\u03b1-agonistic activity"}
{"PMID":23567241,"re_id":7,"annotated sentence":"Most <e1>parabens<\\e1> showing estrogenic activity exhibited ER\u03b2-agonistic activity at lower concentrations than those inducing <e2>ER\u03b1<\\e2> agonistic activity","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"parabens","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Most <e1>CHEMICAL<\\e1> showing estrogenic activity exhibited ER\u03b2-agonistic activity at lower concentrations than those inducing <e2>GENE-Y<\\e2> agonistic activity","sentence":"Most parabens showing estrogenic activity exhibited ER\u03b2-agonistic activity at lower concentrations than those inducing ER\u03b1 agonistic activity"}
{"PMID":23567241,"re_id":8,"annotated sentence":"These results indicate that <e1>parabens<\\e1> are selective agonists for <e2>ER\u03b2<\\e2> over ER\u03b1; their interactions with ER\u03b1\/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"parabens","object":"ER\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that <e1>CHEMICAL<\\e1> are selective agonists for <e2>GENE-Y<\\e2> over ER\u03b1; their interactions with ER\u03b1\/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.","sentence":"These results indicate that parabens are selective agonists for ER\u03b2 over ER\u03b1; their interactions with ER\u03b1\/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity."}
{"PMID":23567241,"re_id":9,"annotated sentence":"These results indicate that <e1>parabens<\\e1> are selective agonists for ER\u03b2 over <e2>ER\u03b1<\\e2>  their interactions with ER\u03b1\/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"parabens","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that <e1>CHEMICAL<\\e1> are selective agonists for ER\u03b2 over <e2>GENE-Y<\\e2>  their interactions with GENE-Y\/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.","sentence":"These results indicate that parabens are selective agonists for ER\u03b2 over ER\u03b1  their interactions with ER\u03b1\/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity."}
{"PMID":23567241,"re_id":10,"annotated sentence":"Fourteen of 17 <e1>parabens<\\e1> exhibited <e2>hER\u03b1<\\e2> and\/or hER\u03b2 agonistic activity at concentrations of \u2a7d1\u00d710(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"parabens","object":"hER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Fourteen of 17 <e1>CHEMICAL<\\e1> exhibited <e2>GENE-Y<\\e2> and\/or hER\u03b2 agonistic activity at concentrations of \u2a7d1\u00d710(-5)M, whereas none of the 17 CHEMICAL showed AR agonistic or antagonistic activity","sentence":"Fourteen of 17 parabens exhibited hER\u03b1 and\/or hER\u03b2 agonistic activity at concentrations of \u2a7d1\u00d710(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity"}
{"PMID":23567241,"re_id":11,"annotated sentence":"Fourteen of 17 <e1>parabens<\\e1> exhibited hER\u03b1 and\/or <e2>hER\u03b2<\\e2> agonistic activity at concentrations of \u2a7d1\u00d710(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"parabens","object":"hER\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Fourteen of 17 <e1>CHEMICAL<\\e1> exhibited hER\u03b1 and\/or <e2>GENE-Y<\\e2> agonistic activity at concentrations of \u2a7d1\u00d710(-5)M, whereas none of the 17 CHEMICAL showed AR agonistic or antagonistic activity","sentence":"Fourteen of 17 parabens exhibited hER\u03b1 and\/or hER\u03b2 agonistic activity at concentrations of \u2a7d1\u00d710(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity"}
{"PMID":23567241,"re_id":12,"annotated sentence":"Among 12 <e1>parabens<\\e1> with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent <e2>ER\u03b1<\\e2> and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"parabens","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among 12 <e1>CHEMICAL<\\e1> with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent <e2>GENE-Y<\\e2> and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12"}
{"PMID":23567241,"re_id":13,"annotated sentence":"Among 12 <e1>parabens<\\e1> with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and <e2>ER\u03b2<\\e2> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"parabens","object":"ER\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among 12 <e1>CHEMICAL<\\e1> with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and <e2>GENE-Y<\\e2> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12"}
{"PMID":23567241,"re_id":14,"annotated sentence":"Among 12 parabens with linear <e1>alkyl<\\e1> chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent <e2>ER\u03b1<\\e2> and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"alkyl","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among 12 parabens with linear <e1>CHEMICAL<\\e1> chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent <e2>GENE-Y<\\e2> and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the CHEMICAL chain was shortened to C1 or lengthened to C12","sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12"}
{"PMID":23567241,"re_id":15,"annotated sentence":"Among 12 parabens with linear <e1>alkyl<\\e1> chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and <e2>ER\u03b2<\\e2> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"alkyl","object":"ER\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among 12 parabens with linear <e1>CHEMICAL<\\e1> chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and <e2>GENE-Y<\\e2> agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the CHEMICAL chain was shortened to C1 or lengthened to C12","sentence":"Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ER\u03b1 and ER\u03b2 agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12"}
{"PMID":23567241,"re_id":16,"annotated sentence":"These results indicate that <e1>parabens<\\e1> are selective agonists for ER\u03b2 over ER\u03b1; their interactions with ER\u03b1\/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by <e2>carboxylesterases<\\e2>  leading to attenuation of their estrogenic activity.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"parabens","object":"carboxylesterases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results indicate that <e1>CHEMICAL<\\e1> are selective agonists for ER\u03b2 over ER\u03b1; their interactions with ER\u03b1\/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by <e2>GENE-N<\\e2>  leading to attenuation of their estrogenic activity.","sentence":"These results indicate that parabens are selective agonists for ER\u03b2 over ER\u03b1; their interactions with ER\u03b1\/\u03b2 are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases  leading to attenuation of their estrogenic activity."}
{"PMID":23570999,"re_id":0,"annotated sentence":"Wattakaka volubilis <e1>steroidal glycoside<\\e1> mixture (WVSM) and PPG (1-50\u03bcM) significantly inhibited the <e2>COX-2<\\e2> and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"steroidal glycoside","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wattakaka volubilis <e1>CHEMICAL<\\e1> mixture (WVSM) and PPG (1-50\u03bcM) significantly inhibited the <e2>GENE-Y<\\e2> and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells","sentence":"Wattakaka volubilis steroidal glycoside mixture (WVSM) and PPG (1-50\u03bcM) significantly inhibited the COX-2 and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells"}
{"PMID":23570999,"re_id":1,"annotated sentence":"Wattakaka volubilis <e1>steroidal glycoside<\\e1> mixture (WVSM) and PPG (1-50\u03bcM) significantly inhibited the COX-2 and <e2>iNOS<\\e2> enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"steroidal glycoside","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wattakaka volubilis <e1>CHEMICAL<\\e1> mixture (WVSM) and PPG (1-50\u03bcM) significantly inhibited the COX-2 and <e2>GENE-Y<\\e2> enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells","sentence":"Wattakaka volubilis steroidal glycoside mixture (WVSM) and PPG (1-50\u03bcM) significantly inhibited the COX-2 and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells"}
{"PMID":23570999,"re_id":2,"annotated sentence":"Wattakaka volubilis steroidal glycoside mixture (WVSM) and <e1>PPG<\\e1> (1-50\u03bcM) significantly inhibited the <e2>COX-2<\\e2> and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PPG","object":"COX-2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wattakaka volubilis steroidal glycoside mixture (WVSM) and <e1>CHEMICAL<\\e1> (1-50\u03bcM) significantly inhibited the <e2>GENE-Y<\\e2> and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells","sentence":"Wattakaka volubilis steroidal glycoside mixture (WVSM) and PPG (1-50\u03bcM) significantly inhibited the COX-2 and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells"}
{"PMID":23570999,"re_id":3,"annotated sentence":"Wattakaka volubilis steroidal glycoside mixture (WVSM) and <e1>PPG<\\e1> (1-50\u03bcM) significantly inhibited the COX-2 and <e2>iNOS<\\e2> enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PPG","object":"iNOS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Wattakaka volubilis steroidal glycoside mixture (WVSM) and <e1>CHEMICAL<\\e1> (1-50\u03bcM) significantly inhibited the COX-2 and <e2>GENE-Y<\\e2> enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells","sentence":"Wattakaka volubilis steroidal glycoside mixture (WVSM) and PPG (1-50\u03bcM) significantly inhibited the COX-2 and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells"}
{"PMID":23583009,"re_id":5,"annotated sentence":"Our data showed that chronic <e1>ethanol<\\e1> over-activated <e2>CYP2E1<\\e2> but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg\/kg.bw.)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ethanol","object":"CYP2E1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our data showed that chronic <e1>CHEMICAL<\\e1> over-activated <e2>GENE-Y<\\e2> but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg\/kg.bw.)","sentence":"Our data showed that chronic ethanol over-activated CYP2E1 but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg\/kg.bw.)"}
{"PMID":23583009,"re_id":6,"annotated sentence":"<e1>Quercetin<\\e1> (100\u03bcM) induced <e2>HO-1<\\e2> and depleted heme pool when incubated to human hepatocytes","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"Quercetin","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (100\u03bcM) induced <e2>GENE-Y<\\e2> and depleted heme pool when incubated to human hepatocytes","sentence":"Quercetin (100\u03bcM) induced HO-1 and depleted heme pool when incubated to human hepatocytes"}
{"PMID":23583009,"re_id":7,"annotated sentence":"<e1>Ethanol<\\e1> stimulated (100mM) <e2>CYP2E1<\\e2> upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"Ethanol","object":"CYP2E1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> stimulated (100mM) <e2>GENE-Y<\\e2> upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation","sentence":"Ethanol stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation"}
{"PMID":23583009,"re_id":8,"annotated sentence":"CO donor dose-dependently inactivated <e2>CYP2E1<\\e2> of <e1>ethanol<\\e1> incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"ethanol","object":"CYP2E1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CO donor dose-dependently inactivated <e2>GENE-Y<\\e2> of <e1>CHEMICAL<\\e1> incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger","sentence":"CO donor dose-dependently inactivated CYP2E1 of ethanol incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger"}
{"PMID":23583009,"re_id":9,"annotated sentence":"Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by <e1>quercetin<\\e1> through <e2>HO-1<\\e2> induction","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"UPREGULATOR","subject":"quercetin","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by <e1>CHEMICAL<\\e1> through <e2>GENE-Y<\\e2> induction","sentence":"Thus, CYP2E1-mediated ethanol hepatotoxicity was alleviated by quercetin through HO-1 induction"}
{"PMID":23583009,"re_id":10,"annotated sentence":"Our data showed that chronic <e1>ethanol<\\e1> over-activated CYP2E1 but suppressed <e2>HO-1<\\e2> with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg\/kg.bw.)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"ethanol","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our data showed that chronic <e1>CHEMICAL<\\e1> over-activated CYP2E1 but suppressed <e2>GENE-Y<\\e2> with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg\/kg.bw.)","sentence":"Our data showed that chronic ethanol over-activated CYP2E1 but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg\/kg.bw.)"}
{"PMID":23583009,"re_id":11,"annotated sentence":"Ethanol-stimulated (100mM) <e2>CYP2E1<\\e2> upregulation was suppressed by <e1>quercetin<\\e1> but further enhanced by HO-1 inhibition with resultant heme accumulation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"quercetin","object":"CYP2E1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ethanol-stimulated (100mM) <e2>GENE-Y<\\e2> upregulation was suppressed by <e1>CHEMICAL<\\e1> but further enhanced by HO-1 inhibition with resultant heme accumulation","sentence":"Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation"}
{"PMID":23583009,"re_id":12,"annotated sentence":"<e1>CO<\\e1> scavenging blocked the suppression of quercetin only on <e2>CYP2E1<\\e2> activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"CO","object":"CYP2E1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> scavenging blocked the suppression of quercetin only on <e2>GENE-Y<\\e2> activity","sentence":"CO scavenging blocked the suppression of quercetin only on CYP2E1 activity"}
{"PMID":23583009,"re_id":13,"annotated sentence":"<e1>CO<\\e1> donor dose-dependently inactivated <e2>CYP2E1<\\e2> of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"CO","object":"CYP2E1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> donor dose-dependently inactivated <e2>GENE-Y<\\e2> of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CHEMICAL scavenger","sentence":"CO donor dose-dependently inactivated CYP2E1 of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger"}
{"PMID":23583009,"re_id":14,"annotated sentence":"<e1>Quercetin<\\e1> suppressed <e2>CYP2E1<\\e2> dependent ethanol hepatotoxicity via depleting heme pool and releasing CO","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Quercetin","object":"CYP2E1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> suppressed <e2>GENE-Y<\\e2> dependent ethanol hepatotoxicity via depleting heme pool and releasing CO","sentence":"Quercetin suppressed CYP2E1 dependent ethanol hepatotoxicity via depleting heme pool and releasing CO"}
{"PMID":23583009,"re_id":15,"annotated sentence":"CO donor dose-dependently inactivated <e2>CYP2E1<\\e2> of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by <e1>CO<\\e1> scavenger","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"CO","object":"CYP2E1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CHEMICAL donor dose-dependently inactivated <e2>GENE-Y<\\e2> of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by <e1>CHEMICAL<\\e1> scavenger","sentence":"CO donor dose-dependently inactivated CYP2E1 of ethanol-incubated microsome, which was mimicked by HO-1 substrate but abolished by CO scavenger"}
{"PMID":23583009,"re_id":16,"annotated sentence":"However, the precise mechanism by which <e1>quercetin<\\e1> counteracts <e2>CYP2E1<\\e2> mediated ethanol hepatotoxicity through HO-1 system is still remained unclear","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"quercetin","object":"CYP2E1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, the precise mechanism by which <e1>CHEMICAL<\\e1> counteracts <e2>GENE-Y<\\e2> mediated ethanol hepatotoxicity through HO-1 system is still remained unclear","sentence":"However, the precise mechanism by which quercetin counteracts CYP2E1 mediated ethanol hepatotoxicity through HO-1 system is still remained unclear"}
{"PMID":23583009,"re_id":17,"annotated sentence":"<e1>Ethanol<\\e1> stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by <e2>HO-1<\\e2> inhibition with resultant heme accumulation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Ethanol","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by <e2>GENE-Y<\\e2> inhibition with resultant heme accumulation","sentence":"Ethanol stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation"}
{"PMID":23583009,"re_id":18,"annotated sentence":"Depleted heme pool and <e1>CO<\\e1> releasing limited protein synthesis and inhibited enzymatic activity of <e2>CYP2E1<\\e2>  respectively.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CO","object":"CYP2E1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Depleted heme pool and <e1>CHEMICAL<\\e1> releasing limited protein synthesis and inhibited enzymatic activity of <e2>GENE-Y<\\e2>  respectively.","sentence":"Depleted heme pool and CO releasing limited protein synthesis and inhibited enzymatic activity of CYP2E1  respectively."}
{"PMID":23583009,"re_id":19,"annotated sentence":"Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by <e2>HO-1<\\e2> inhibition with resultant <e1>heme<\\e1> accumulation","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"heme","object":"HO-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by <e2>GENE-Y<\\e2> inhibition with resultant <e1>CHEMICAL<\\e1> accumulation","sentence":"Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation"}
{"PMID":23583510,"re_id":0,"annotated sentence":"Novel racemic <e1>tetrahydrocurcuminoid dihydropyrimidinone<\\e1> analogues as potent <e2>acetylcholinesterase<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"tetrahydrocurcuminoid dihydropyrimidinone","object":"acetylcholinesterase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Novel racemic <e1>CHEMICAL<\\e1> analogues as potent <e2>GENE-Y<\\e2> inhibitors","sentence":"Novel racemic tetrahydrocurcuminoid dihydropyrimidinone analogues as potent acetylcholinesterase inhibitors"}
{"PMID":23583603,"re_id":5,"annotated sentence":"Furthermore, we detected that <e1>ICI<\\e1> treatment induced <e2>glycogen synthase kinase<\\e2> (Gsk3-\u03b2) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ICI","object":"glycogen synthase kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, we detected that <e1>CHEMICAL<\\e1> treatment induced <e2>GENE-N<\\e2> (Gsk3-\u03b2) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization","sentence":"Furthermore, we detected that ICI treatment induced glycogen synthase kinase (Gsk3-\u03b2) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization"}
{"PMID":23583603,"re_id":6,"annotated sentence":"Furthermore, we detected that <e1>ICI<\\e1> treatment induced glycogen synthase kinase (<e2>Gsk3-\u03b2<\\e2>  Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ICI","object":"Gsk3-\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Furthermore, we detected that <e1>CHEMICAL<\\e1> treatment induced glycogen synthase kinase (<e2>GENE-Y<\\e2>  Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization","sentence":"Furthermore, we detected that ICI treatment induced glycogen synthase kinase (Gsk3-\u03b2  Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization"}
{"PMID":23583603,"re_id":7,"annotated sentence":"Agonistic activity of <e1>ICI 182 780<\\e1> on activation of GSK 3\u03b2\/<e2>AKT<\\e2> pathway in the rat uterus during the estrous cycle","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ICI 182 780","object":"AKT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Agonistic activity of <e1>CHEMICAL<\\e1> on activation of GSK 3\u03b2\/<e2>GENE-N<\\e2> pathway in the rat uterus during the estrous cycle","sentence":"Agonistic activity of ICI 182 780 on activation of GSK 3\u03b2\/AKT pathway in the rat uterus during the estrous cycle"}
{"PMID":23583603,"re_id":8,"annotated sentence":"The overall results indicate that <e1>ICI<\\e1> may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the <e2>Akt<\\e2> pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ICI","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The overall results indicate that <e1>CHEMICAL<\\e1> may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the <e2>GENE-N<\\e2> pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model.","sentence":"The overall results indicate that ICI may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the Akt pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model."}
{"PMID":23583603,"re_id":9,"annotated sentence":"Both <e1>ICI<\\e1> treatments, induced a significant decrease (p<0.01) in uterine <e2>estrogen receptor alpha<\\e2> (ER\u03b1) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ICI","object":"estrogen receptor alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both <e1>CHEMICAL<\\e1> treatments, induced a significant decrease (p<0.01) in uterine <e2>GENE-Y<\\e2> (ER\u03b1) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals","sentence":"Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ER\u03b1) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals"}
{"PMID":23583603,"re_id":10,"annotated sentence":"Both <e1>ICI<\\e1> treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (<e2>ER\u03b1<\\e2>  content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ICI","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Both <e1>CHEMICAL<\\e1> treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (<e2>GENE-Y<\\e2>  content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals","sentence":"Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ER\u03b1  content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals"}
{"PMID":23583603,"re_id":11,"annotated sentence":"We observed that the administration of <e1>ICI<\\e1> at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of <e2>Akt<\\e2> phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ICI","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We observed that the administration of <e1>CHEMICAL<\\e1> at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of <e2>GENE-N<\\e2> phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas CHEMICAL treatment at 00:00h on estrus day had no effect on these parameters","sentence":"We observed that the administration of ICI at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of Akt phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters"}
{"PMID":23583603,"re_id":12,"annotated sentence":"Agonistic activity of <e1>ICI 182 780<\\e1> on activation of <e2>GSK 3\u03b2<\\e2> AKT pathway in the rat uterus during the estrous cycle","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"ICI 182 780","object":"GSK 3\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Agonistic activity of <e1>CHEMICAL<\\e1> on activation of <e2>GENE-Y<\\e2> AKT pathway in the rat uterus during the estrous cycle","sentence":"Agonistic activity of ICI 182 780 on activation of GSK 3\u03b2 AKT pathway in the rat uterus during the estrous cycle"}
{"PMID":23583910,"re_id":2,"annotated sentence":"A <e1>N,N-dimethylaminopropyl<\\e1> derivative showed promising inhibition of <e2>Trypanosoma cruzi OSC<\\e2> in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"N,N-dimethylaminopropyl","object":"Trypanosoma cruzi OSC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A <e1>CHEMICAL<\\e1> derivative showed promising inhibition of <e2>GENE-Y<\\e2> in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line.","sentence":"A N,N-dimethylaminopropyl derivative showed promising inhibition of Trypanosoma cruzi OSC in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line."}
{"PMID":23583910,"re_id":3,"annotated sentence":"<e1>Aminopropylindenes<\\e1> derived from Grundmann's ketone as a novel chemotype of <e2>oxidosqualene cyclase<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Aminopropylindenes","object":"oxidosqualene cyclase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> derived from Grundmann's ketone as a novel chemotype of <e2>GENE-Y<\\e2> inhibitors","sentence":"Aminopropylindenes derived from Grundmann's ketone as a novel chemotype of oxidosqualene cyclase inhibitors"}
{"PMID":23583910,"re_id":4,"annotated sentence":"Aminopropylindenes derived from <e1>Grundmann's ketone<\\e1> as a novel chemotype of <e2>oxidosqualene cyclase<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Grundmann's ketone","object":"oxidosqualene cyclase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Aminopropylindenes derived from <e1>CHEMICAL<\\e1> as a novel chemotype of <e2>GENE-Y<\\e2> inhibitors","sentence":"Aminopropylindenes derived from Grundmann's ketone as a novel chemotype of oxidosqualene cyclase inhibitors"}
{"PMID":23583910,"re_id":5,"annotated sentence":"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (<e2>OSC<\\e2> -mediated cyclization of 2,3-oxidosqualen to <e1>lanosterol<\\e1> was prepared from Grundmann's ketone","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"lanosterol","object":"OSC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (<e2>GENE-Y<\\e2> -mediated cyclization of 2,3-oxidosqualen to <e1>CHEMICAL<\\e1> was prepared from Grundmann's ketone","sentence":"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC -mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone"}
{"PMID":23583910,"re_id":6,"annotated sentence":"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the <e2>oxidosqualene cyclase(1)<\\e2> (OSC)-mediated cyclization of 2,3-oxidosqualen to <e1>lanosterol<\\e1> was prepared from Grundmann's ketone","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"lanosterol","object":"oxidosqualene cyclase(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the <e2>GENE-Y<\\e2> (OSC)-mediated cyclization of 2,3-oxidosqualen to <e1>CHEMICAL<\\e1> was prepared from Grundmann's ketone","sentence":"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone"}
{"PMID":23583910,"re_id":7,"annotated sentence":"A N,N-dimethylaminopropyl derivative showed promising inhibition of <e2>Trypanosoma cruzi OSC<\\e2> in combination with low cytotoxicity, and showed significant reduction of <e1>cholesterol<\\e1> biosynthesis in a human cell line.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"cholesterol","object":"Trypanosoma cruzi OSC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A N,N-dimethylaminopropyl derivative showed promising inhibition of <e2>GENE-Y<\\e2> in combination with low cytotoxicity, and showed significant reduction of <e1>CHEMICAL<\\e1> biosynthesis in a human cell line.","sentence":"A N,N-dimethylaminopropyl derivative showed promising inhibition of Trypanosoma cruzi OSC in combination with low cytotoxicity, and showed significant reduction of cholesterol biosynthesis in a human cell line."}
{"PMID":23583910,"re_id":8,"annotated sentence":"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (<e2>OSC<\\e2> -mediated cyclization of <e1>2,3-oxidosqualen<\\e1> to lanosterol was prepared from Grundmann's ketone","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2,3-oxidosqualen","object":"OSC","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (<e2>GENE-Y<\\e2> -mediated cyclization of <e1>CHEMICAL<\\e1> to lanosterol was prepared from Grundmann's ketone","sentence":"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC -mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone"}
{"PMID":23583910,"re_id":9,"annotated sentence":"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the <e2>oxidosqualene cyclase(1)<\\e2> (OSC)-mediated cyclization of <e1>2,3-oxidosqualen<\\e1> to lanosterol was prepared from Grundmann's ketone","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2,3-oxidosqualen","object":"oxidosqualene cyclase(1)","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the <e2>GENE-Y<\\e2> (OSC)-mediated cyclization of <e1>CHEMICAL<\\e1> to lanosterol was prepared from Grundmann's ketone","sentence":"A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann's ketone"}
{"PMID":23583931,"re_id":4,"annotated sentence":"During repetitive stimulation of skeletal muscle, extracellular <e1>ATP<\\e1> levels raise, activating <e2>purinergic receptors<\\e2>  increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ATP","object":"purinergic receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"During repetitive stimulation of skeletal muscle, extracellular <e1>CHEMICAL<\\e1> levels raise, activating <e2>GENE-N<\\e2>  increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation","sentence":"During repetitive stimulation of skeletal muscle, extracellular ATP levels raise, activating purinergic receptors  increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation"}
{"PMID":23583931,"re_id":5,"annotated sentence":"MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles <e1>ATP<\\e1> activates <e2>P2Y1<\\e2> but not P2X receptors","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ATP","object":"P2Y1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"MRS2179, a GENE-YR blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles <e1>CHEMICAL<\\e1> activates <e2>GENE-Y<\\e2> but not P2X receptors","sentence":"MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles ATP activates P2Y1 but not P2X receptors"}
{"PMID":23583931,"re_id":6,"annotated sentence":"Consistent with two <e1>glucose<\\e1> uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or <e2>glucose transporter<\\e2> (GLUT4), and blocked by dual blockade","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glucose","object":"glucose transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Consistent with two <e1>CHEMICAL<\\e1> uptake pathways, induced uptake of 2-NBDG, a fluorescent CHEMICAL derivative, was decreased by inhibition of HCs or <e2>CHEMICAL transporter<\\e2> (GLUT4), and blocked by dual blockade","sentence":"Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (GLUT4), and blocked by dual blockade"}
{"PMID":23583931,"re_id":7,"annotated sentence":"Consistent with two <e1>glucose<\\e1> uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (<e2>GLUT4<\\e2> , and blocked by dual blockade","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glucose","object":"GLUT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Consistent with two <e1>CHEMICAL<\\e1> uptake pathways, induced uptake of 2-NBDG, a fluorescent CHEMICAL derivative, was decreased by inhibition of HCs or CHEMICAL transporter (<e2>GENE-Y<\\e2> , and blocked by dual blockade","sentence":"Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (GLUT4 , and blocked by dual blockade"}
{"PMID":23583931,"re_id":8,"annotated sentence":"Consistent with two glucose uptake pathways, induced uptake of <e1>2-NBDG<\\e1>  a fluorescent glucose derivative, was decreased by inhibition of HCs or <e2>glucose transporter<\\e2> (GLUT4), and blocked by dual blockade","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2-NBDG","object":"glucose transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Consistent with two glucose uptake pathways, induced uptake of <e1>CHEMICAL<\\e1>  a fluorescent glucose derivative, was decreased by inhibition of HCs or <e2>GENE-N<\\e2> (GLUT4), and blocked by dual blockade","sentence":"Consistent with two glucose uptake pathways, induced uptake of 2-NBDG  a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (GLUT4), and blocked by dual blockade"}
{"PMID":23583931,"re_id":9,"annotated sentence":"Consistent with two glucose uptake pathways, induced uptake of <e1>2-NBDG<\\e1>  a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (<e2>GLUT4<\\e2> , and blocked by dual blockade","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"2-NBDG","object":"GLUT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Consistent with two glucose uptake pathways, induced uptake of <e1>CHEMICAL<\\e1>  a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (<e2>GENE-Y<\\e2> , and blocked by dual blockade","sentence":"Consistent with two glucose uptake pathways, induced uptake of 2-NBDG  a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (GLUT4 , and blocked by dual blockade"}
{"PMID":23583931,"re_id":10,"annotated sentence":"The <e1>ATP<\\e1> required for potentiation of skeletal muscle contraction is released via <e2>pannexin<\\e2> hemichannels","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ATP","object":"pannexin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e1>CHEMICAL<\\e1> required for potentiation of skeletal muscle contraction is released via <e2>GENE-N<\\e2> hemichannels","sentence":"The ATP required for potentiation of skeletal muscle contraction is released via pannexin hemichannels"}
{"PMID":23583931,"re_id":11,"annotated sentence":"Opening of <e2>Panx1<\\e2> HCs during repetitive activation allows efflux of <e1>ATP<\\e1>  influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"ATP","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Opening of <e2>GENE-Y<\\e2> HCs during repetitive activation allows efflux of <e1>CHEMICAL<\\e1>  influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction","sentence":"Opening of Panx1 HCs during repetitive activation allows efflux of ATP  influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction"}
{"PMID":23583931,"re_id":12,"annotated sentence":"Opening of <e2>Panx1<\\e2> HCs during repetitive activation allows efflux of ATP, influx of <e1>glucose<\\e1> and possibly Ca(2+) too, which are required for potentiation of contraction","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glucose","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Opening of <e2>GENE-Y<\\e2> HCs during repetitive activation allows efflux of ATP, influx of <e1>CHEMICAL<\\e1> and possibly Ca(2+) too, which are required for potentiation of contraction","sentence":"Opening of Panx1 HCs during repetitive activation allows efflux of ATP, influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction"}
{"PMID":23583931,"re_id":13,"annotated sentence":"Opening of <e2>Panx1<\\e2> HCs during repetitive activation allows efflux of ATP, influx of glucose and possibly <e1>Ca(2+)<\\e1> too, which are required for potentiation of contraction","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Ca(2+)","object":"Panx1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Opening of <e2>GENE-Y<\\e2> HCs during repetitive activation allows efflux of ATP, influx of glucose and possibly <e1>CHEMICAL<\\e1> too, which are required for potentiation of contraction","sentence":"Opening of Panx1 HCs during repetitive activation allows efflux of ATP, influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction"}
{"PMID":23585332,"re_id":0,"annotated sentence":"The rate limiting enzyme of beta-oxidation (<e2>ACOX1<\\e2>  was significantly over-expressed in the liver with <e1>tBHQ<\\e1> treatment","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"tBHQ","object":"ACOX1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The rate limiting enzyme of beta-oxidation (<e2>GENE-Y<\\e2>  was significantly over-expressed in the liver with <e1>CHEMICAL<\\e1> treatment","sentence":"The rate limiting enzyme of beta-oxidation (ACOX1  was significantly over-expressed in the liver with tBHQ treatment"}
{"PMID":23585332,"re_id":1,"annotated sentence":"These results indicate that <e1>tBHQ<\\e1> suppresses body weight gain in mice, possibly at least related to the up-regulation of <e2>ACOX1<\\e2> gene expression.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"tBHQ","object":"ACOX1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that <e1>CHEMICAL<\\e1> suppresses body weight gain in mice, possibly at least related to the up-regulation of <e2>GENE-Y<\\e2> gene expression.","sentence":"These results indicate that tBHQ suppresses body weight gain in mice, possibly at least related to the up-regulation of ACOX1 gene expression."}
{"PMID":23585380,"re_id":0,"annotated sentence":"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the <e2>VEGF<\\e2> release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core <e1>PLGA<\\e1> and more than 45% with HMW core PLGA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"PLGA","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (GENE-N), are encapsulated separately in the core and shell domains, respectively, the <e2>GENE-N<\\e2> release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core <e1>CHEMICAL<\\e1> and more than 45% with HMW core CHEMICAL","sentence":"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA"}
{"PMID":23585380,"re_id":1,"annotated sentence":"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of <e2>PDGF<\\e2>  and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core <e1>PLGA<\\e1> and more than 45% with HMW core PLGA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"PLGA","object":"PDGF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When dual angiogenic growth factors (GFs), such as platelet-derived GF (GENE-N) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of <e2>GENE-N<\\e2>  and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core <e1>CHEMICAL<\\e1> and more than 45% with HMW core CHEMICAL","sentence":"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF  and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA"}
{"PMID":23585380,"re_id":2,"annotated sentence":"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the <e2>VEGF<\\e2> release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core <e1>PLGA<\\e1>  As for the angiogenic potential of MC GFs with human umbilical vein endothelial cells (HUVECs), the fluorescence signal of CD31+ suggests that the angiogenic sprout of ECs is more active in MC-mediated GF delivery than conventional GF delivery, and this difference is significant, based on the number of capillary branches in the unit area","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"PLGA","object":"VEGF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (GENE-N), are encapsulated separately in the core and shell domains, respectively, the <e2>GENE-N<\\e2> release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core CHEMICAL and more than 45% with HMW core <e1>CHEMICAL<\\e1>  As for the angiogenic potential of MC GFs with human umbilical vein endothelial cells (HUVECs), the fluorescence signal of CD31+ suggests that the angiogenic sprout of ECs is more active in MC-mediated GF delivery than conventional GF delivery, and this difference is significant, based on the number of capillary branches in the unit area","sentence":"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA  As for the angiogenic potential of MC GFs with human umbilical vein endothelial cells (HUVECs), the fluorescence signal of CD31+ suggests that the angiogenic sprout of ECs is more active in MC-mediated GF delivery than conventional GF delivery, and this difference is significant, based on the number of capillary branches in the unit area"}
{"PMID":23585380,"re_id":3,"annotated sentence":"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of <e2>PDGF<\\e2>  and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core <e1>PLGA<\\e1>  As for the angiogenic potential of MC GFs with human umbilical vein endothelial cells (HUVECs), the fluorescence signal of CD31+ suggests that the angiogenic sprout of ECs is more active in MC-mediated GF delivery than conventional GF delivery, and this difference is significant, based on the number of capillary branches in the unit area","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"PLGA","object":"PDGF","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"When dual angiogenic growth factors (GFs), such as platelet-derived GF (GENE-N) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of <e2>GENE-N<\\e2>  and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core CHEMICAL and more than 45% with HMW core <e1>CHEMICAL<\\e1>  As for the angiogenic potential of MC GFs with human umbilical vein endothelial cells (HUVECs), the fluorescence signal of CD31+ suggests that the angiogenic sprout of ECs is more active in MC-mediated GF delivery than conventional GF delivery, and this difference is significant, based on the number of capillary branches in the unit area","sentence":"When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF  and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA  As for the angiogenic potential of MC GFs with human umbilical vein endothelial cells (HUVECs), the fluorescence signal of CD31+ suggests that the angiogenic sprout of ECs is more active in MC-mediated GF delivery than conventional GF delivery, and this difference is significant, based on the number of capillary branches in the unit area"}
{"PMID":23587425,"re_id":0,"annotated sentence":"Potency switch between CHK1 and <e2>MK2<\\e2>  Discovery of <e1>imidazo[1,2-a]pyrazine<\\e1>  and imidazo[1,2-c]pyrimidine-based kinase inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"imidazo[1,2-a]pyrazine","object":"MK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Potency switch between CHK1 and <e2>GENE-Y<\\e2>  Discovery of <e1>CHEMICAL<\\e1>  and imidazo[1,2-c]pyrimidine-based kinase inhibitors","sentence":"Potency switch between CHK1 and MK2  Discovery of imidazo[1,2-a]pyrazine  and imidazo[1,2-c]pyrimidine-based kinase inhibitors"}
{"PMID":23587425,"re_id":1,"annotated sentence":"Potency switch between CHK1 and MK2: Discovery of <e1>imidazo[1,2-a]pyrazine<\\e1>  and imidazo[1,2-c]pyrimidine-based <e2>kinase<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"imidazo[1,2-a]pyrazine","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Potency switch between CHK1 and MK2: Discovery of <e1>CHEMICAL<\\e1>  and imidazo[1,2-c]pyrimidine-based <e2>GENE-N<\\e2> inhibitors","sentence":"Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine  and imidazo[1,2-c]pyrimidine-based kinase inhibitors"}
{"PMID":23587425,"re_id":2,"annotated sentence":"Potency switch between <e2>CHK1<\\e2> and MK2: Discovery of <e1>imidazo[1,2-a]pyrazine<\\e1>  and imidazo[1,2-c]pyrimidine-based kinase inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"imidazo[1,2-a]pyrazine","object":"CHK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Potency switch between <e2>GENE-Y<\\e2> and MK2: Discovery of <e1>CHEMICAL<\\e1>  and imidazo[1,2-c]pyrimidine-based kinase inhibitors","sentence":"Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine  and imidazo[1,2-c]pyrimidine-based kinase inhibitors"}
{"PMID":23587425,"re_id":3,"annotated sentence":"Potency switch between CHK1 and <e2>MK2<\\e2>  Discovery of imidazo[1,2-a]pyrazine- and <e1>imidazo[1,2-c]pyrimidine<\\e1> based kinase inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"imidazo[1,2-c]pyrimidine","object":"MK2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Potency switch between CHK1 and <e2>GENE-Y<\\e2>  Discovery of imidazo[1,2-a]pyrazine- and <e1>CHEMICAL<\\e1> based kinase inhibitors","sentence":"Potency switch between CHK1 and MK2  Discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine based kinase inhibitors"}
{"PMID":23587425,"re_id":4,"annotated sentence":"Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and <e1>imidazo[1,2-c]pyrimidine<\\e1> based <e2>kinase<\\e2> inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"imidazo[1,2-c]pyrimidine","object":"kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and <e1>CHEMICAL<\\e1> based <e2>GENE-N<\\e2> inhibitors","sentence":"Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine based kinase inhibitors"}
{"PMID":23587425,"re_id":5,"annotated sentence":"Potency switch between <e2>CHK1<\\e2> and MK2: Discovery of imidazo[1,2-a]pyrazine- and <e1>imidazo[1,2-c]pyrimidine<\\e1> based kinase inhibitors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"imidazo[1,2-c]pyrimidine","object":"CHK1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Potency switch between <e2>GENE-Y<\\e2> and MK2: Discovery of imidazo[1,2-a]pyrazine- and <e1>CHEMICAL<\\e1> based kinase inhibitors","sentence":"Potency switch between CHK1 and MK2: Discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine based kinase inhibitors"}
{"PMID":23591110,"re_id":0,"annotated sentence":"A series of structurally novel <e1>aryl ureas<\\e1> was derived from optimization of the HTS lead as selective <e2>histamine H3 receptor<\\e2> (H3R) antagonists","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"aryl ureas","object":"histamine H3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of structurally novel <e1>CHEMICAL<\\e1> was derived from optimization of the HTS lead as selective <e2>GENE-Y<\\e2> (H3R) antagonists","sentence":"A series of structurally novel aryl ureas was derived from optimization of the HTS lead as selective histamine H3 receptor (H3R) antagonists"}
{"PMID":23591110,"re_id":1,"annotated sentence":"A series of structurally novel <e1>aryl ureas<\\e1> was derived from optimization of the HTS lead as selective histamine H3 receptor (<e2>H3R<\\e2>  antagonists","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"aryl ureas","object":"H3R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"A series of structurally novel <e1>CHEMICAL<\\e1> was derived from optimization of the HTS lead as selective histamine H3 receptor (<e2>GENE-Y<\\e2>  antagonists","sentence":"A series of structurally novel aryl ureas was derived from optimization of the HTS lead as selective histamine H3 receptor (H3R  antagonists"}
{"PMID":23591110,"re_id":2,"annotated sentence":"Discovery of <e1>aryl ureas<\\e1> and aryl amides as potent and selective <e2>histamine H3 receptor<\\e2> antagonists for the treatment of obesity (Part I)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"aryl ureas","object":"histamine H3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Discovery of <e1>CHEMICAL<\\e1> and aryl amides as potent and selective <e2>GENE-Y<\\e2> antagonists for the treatment of obesity (Part I)","sentence":"Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (Part I)"}
{"PMID":23591110,"re_id":3,"annotated sentence":"Discovery of aryl ureas and <e1>aryl amides<\\e1> as potent and selective <e2>histamine H3 receptor<\\e2> antagonists for the treatment of obesity (Part I)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"aryl amides","object":"histamine H3 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Discovery of aryl ureas and <e1>CHEMICAL<\\e1> as potent and selective <e2>GENE-Y<\\e2> antagonists for the treatment of obesity (Part I)","sentence":"Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (Part I)"}
{"PMID":23597506,"re_id":0,"annotated sentence":"In terms of the mechanisms, we found that fatty acid amide hydrolase (<e2>FAAH<\\e2>  which degrades <e1>anandamide<\\e1>  was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"anandamide","object":"FAAH","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In terms of the mechanisms, we found that fatty acid amide hydrolase (<e2>GENE-N<\\e2>  which degrades <e1>CHEMICAL<\\e1>  was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences","sentence":"In terms of the mechanisms, we found that fatty acid amide hydrolase (FAAH  which degrades anandamide  was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences"}
{"PMID":23597506,"re_id":1,"annotated sentence":"In terms of the mechanisms, we found that <e2>fatty acid amide hydrolase<\\e2> (FAAH) which degrades <e1>anandamide<\\e1>  was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"anandamide","object":"fatty acid amide hydrolase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In terms of the mechanisms, we found that <e2>GENE-N<\\e2> (FAAH) which degrades <e1>CHEMICAL<\\e1>  was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences","sentence":"In terms of the mechanisms, we found that fatty acid amide hydrolase (FAAH) which degrades anandamide  was upregulated after nerve injury at both ages, so that this upregulation likely did not account for the age-dependent differences"}
{"PMID":23597506,"re_id":2,"annotated sentence":"However, enzymes contributing to oxidative metabolism of <e1>anandamide<\\e1>  namely <e2>cyclooxygenase-1<\\e2> and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"anandamide","object":"cyclooxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, enzymes contributing to oxidative metabolism of <e1>CHEMICAL<\\e1>  namely <e2>GENE-Y<\\e2> and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of CHEMICAL","sentence":"However, enzymes contributing to oxidative metabolism of anandamide  namely cyclooxygenase-1 and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide"}
{"PMID":23597506,"re_id":3,"annotated sentence":"However, enzymes contributing to oxidative metabolism of <e1>anandamide<\\e1>  namely cyclooxygenase-1 and <e2>Cyp2D6<\\e2>  were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"anandamide","object":"Cyp2D6","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, enzymes contributing to oxidative metabolism of <e1>CHEMICAL<\\e1>  namely cyclooxygenase-1 and <e2>GENE-N<\\e2>  were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of CHEMICAL","sentence":"However, enzymes contributing to oxidative metabolism of anandamide  namely cyclooxygenase-1 and Cyp2D6  were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide"}
{"PMID":23597506,"re_id":4,"annotated sentence":"However, enzymes contributing to oxidative metabolism of anandamide, namely <e2>cyclooxygenase-1<\\e2> and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of <e1>anandamide<\\e1>  This may overwhelm the capacity of R-flurbiprofen to restore anandamide homeostasis and may contribute to the heightened risk for neuropathic pain at old age.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"anandamide","object":"cyclooxygenase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, enzymes contributing to oxidative metabolism of CHEMICAL, namely <e2>GENE-Y<\\e2> and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of <e1>CHEMICAL<\\e1>  This may overwhelm the capacity of R-flurbiprofen to restore CHEMICAL homeostasis and may contribute to the heightened risk for neuropathic pain at old age.","sentence":"However, enzymes contributing to oxidative metabolism of anandamide, namely cyclooxygenase-1 and Cyp2D6, were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide  This may overwhelm the capacity of R-flurbiprofen to restore anandamide homeostasis and may contribute to the heightened risk for neuropathic pain at old age."}
{"PMID":23597506,"re_id":5,"annotated sentence":"However, enzymes contributing to oxidative metabolism of anandamide, namely cyclooxygenase-1 and <e2>Cyp2D6<\\e2>  were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of <e1>anandamide<\\e1>  This may overwhelm the capacity of R-flurbiprofen to restore anandamide homeostasis and may contribute to the heightened risk for neuropathic pain at old age.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"anandamide","object":"Cyp2D6","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, enzymes contributing to oxidative metabolism of CHEMICAL, namely cyclooxygenase-1 and <e2>GENE-N<\\e2>  were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of <e1>CHEMICAL<\\e1>  This may overwhelm the capacity of R-flurbiprofen to restore CHEMICAL homeostasis and may contribute to the heightened risk for neuropathic pain at old age.","sentence":"However, enzymes contributing to oxidative metabolism of anandamide, namely cyclooxygenase-1 and Cyp2D6  were increased in the brain of aged mice, possibly enhancing the oxidative breakdown of anandamide  This may overwhelm the capacity of R-flurbiprofen to restore anandamide homeostasis and may contribute to the heightened risk for neuropathic pain at old age."}
{"PMID":23600914,"re_id":12,"annotated sentence":"The expression of <e2>ABCA1<\\e2> and ABCG1 was induced by 24-OHC, as well as TO901317 and <e1>retinoic acid<\\e1>  which are ligands of the nuclear receptors LXR\/RXR","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"retinoic acid","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of <e2>GENE-Y<\\e2> and ABCG1 was induced by 24-OHC, as well as TO901317 and <e1>CHEMICAL<\\e1>  which are ligands of the nuclear receptors LXR\/RXR","sentence":"The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and retinoic acid  which are ligands of the nuclear receptors LXR\/RXR"}
{"PMID":23600914,"re_id":13,"annotated sentence":"The expression of ABCA1 and <e2>ABCG1<\\e2> was induced by 24-OHC, as well as TO901317 and <e1>retinoic acid<\\e1>  which are ligands of the nuclear receptors LXR\/RXR","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"retinoic acid","object":"ABCG1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of ABCA1 and <e2>GENE-Y<\\e2> was induced by 24-OHC, as well as TO901317 and <e1>CHEMICAL<\\e1>  which are ligands of the nuclear receptors LXR\/RXR","sentence":"The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and retinoic acid  which are ligands of the nuclear receptors LXR\/RXR"}
{"PMID":23600914,"re_id":14,"annotated sentence":"The expression of <e2>ABCA1<\\e2> and ABCG1 was induced by <e1>24-OHC<\\e1>  as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR\/RXR","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"24-OHC","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of <e2>GENE-Y<\\e2> and ABCG1 was induced by <e1>CHEMICAL<\\e1>  as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR\/RXR","sentence":"The expression of ABCA1 and ABCG1 was induced by 24-OHC  as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR\/RXR"}
{"PMID":23600914,"re_id":15,"annotated sentence":"The expression of ABCA1 and <e2>ABCG1<\\e2> was induced by <e1>24-OHC<\\e1>  as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR\/RXR","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"24-OHC","object":"ABCG1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of ABCA1 and <e2>GENE-Y<\\e2> was induced by <e1>CHEMICAL<\\e1>  as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR\/RXR","sentence":"The expression of ABCA1 and ABCG1 was induced by 24-OHC  as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR\/RXR"}
{"PMID":23600914,"re_id":16,"annotated sentence":"The expression of <e2>ABCA1<\\e2> and ABCG1 was induced by 24-OHC, as well as <e1>TO901317<\\e1> and retinoic acid, which are ligands of the nuclear receptors LXR\/RXR","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"TO901317","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of <e2>GENE-Y<\\e2> and ABCG1 was induced by 24-OHC, as well as <e1>CHEMICAL<\\e1> and retinoic acid, which are ligands of the nuclear receptors LXR\/RXR","sentence":"The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR\/RXR"}
{"PMID":23600914,"re_id":17,"annotated sentence":"The expression of ABCA1 and <e2>ABCG1<\\e2> was induced by 24-OHC, as well as <e1>TO901317<\\e1> and retinoic acid, which are ligands of the nuclear receptors LXR\/RXR","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"TO901317","object":"ABCG1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The expression of ABCA1 and <e2>GENE-Y<\\e2> was induced by 24-OHC, as well as <e1>CHEMICAL<\\e1> and retinoic acid, which are ligands of the nuclear receptors LXR\/RXR","sentence":"The expression of ABCA1 and ABCG1 was induced by 24-OHC, as well as TO901317 and retinoic acid, which are ligands of the nuclear receptors LXR\/RXR"}
{"PMID":23600914,"re_id":18,"annotated sentence":"Because <e1>24(S)-hydroxycholesterol<\\e1> (24-OHC), produced by <e2>24-hydroxylase<\\e2>  induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"24(S)-hydroxycholesterol","object":"24-hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Because <e1>CHEMICAL<\\e1> (24-OHC), produced by <e2>GENE-Y<\\e2>  induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells","sentence":"Because 24(S)-hydroxycholesterol (24-OHC), produced by 24-hydroxylase  induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells"}
{"PMID":23600914,"re_id":19,"annotated sentence":"Because 24(S)-hydroxycholesterol (<e1>24-OHC<\\e1> , produced by <e2>24-hydroxylase<\\e2>  induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"24-OHC","object":"24-hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Because 24(S)-hydroxycholesterol (<e1>CHEMICAL<\\e1> , produced by <e2>GENE-Y<\\e2>  induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells","sentence":"Because 24(S)-hydroxycholesterol (24-OHC , produced by 24-hydroxylase  induces apoptosis of neuronal cells, it is vital to eliminate it rapidly from cells"}
{"PMID":23600914,"re_id":20,"annotated sentence":"To confirm the role of each transporter, we analyzed HEK293 cells stably expressing <e2>human ABCA1<\\e2> or ABCG1; we clearly observed <e1>24-OHC<\\e1> efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"24-OHC","object":"human ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To confirm the role of each transporter, we analyzed HEK293 cells stably expressing <e2>GENE-Y<\\e2> or ABCG1; we clearly observed <e1>CHEMICAL<\\e1> efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal","sentence":"To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or ABCG1; we clearly observed 24-OHC efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal"}
{"PMID":23600914,"re_id":21,"annotated sentence":"To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or <e2>ABCG1<\\e2>  we clearly observed <e1>24-OHC<\\e1> efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"24-OHC","object":"ABCG1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or <e2>GENE-Y<\\e2>  we clearly observed <e1>CHEMICAL<\\e1> efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal","sentence":"To confirm the role of each transporter, we analyzed HEK293 cells stably expressing human ABCA1 or ABCG1  we clearly observed 24-OHC efflux in the presence of HDL, whereas efflux in the presence of apolipoprotein A-I was marginal"}
{"PMID":23600914,"re_id":22,"annotated sentence":"<e1>24(S)-hydroxycholesterol<\\e1> is actively eliminated from neuronal cells by <e2>ABCA1<\\e2>  High cholesterol turnover catalyzed by cholesterol 24-hydroxylase is essential for neural functions, especially learning","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"24(S)-hydroxycholesterol","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> is actively eliminated from neuronal cells by <e2>GENE-Y<\\e2>  High cholesterol turnover catalyzed by cholesterol 24-hydroxylase is essential for neural functions, especially learning","sentence":"24(S)-hydroxycholesterol is actively eliminated from neuronal cells by ABCA1  High cholesterol turnover catalyzed by cholesterol 24-hydroxylase is essential for neural functions, especially learning"}
{"PMID":23600914,"re_id":23,"annotated sentence":"These results suggest that <e2>ABCA1<\\e2> actively eliminates <e1>24-OHC<\\e1> in the presence of HDL as a lipid acceptor and protects neuronal cells","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"24-OHC","object":"ABCA1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e2>GENE-Y<\\e2> actively eliminates <e1>CHEMICAL<\\e1> in the presence of HDL as a lipid acceptor and protects neuronal cells","sentence":"These results suggest that ABCA1 actively eliminates 24-OHC in the presence of HDL as a lipid acceptor and protects neuronal cells"}
{"PMID":23600914,"re_id":24,"annotated sentence":"High <e1>cholesterol<\\e1> turnover catalyzed by <e2>cholesterol 24-hydroxylase<\\e2> is essential for neural functions, especially learning","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"cholesterol","object":"cholesterol 24-hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"High <e1>CHEMICAL<\\e1> turnover catalyzed by <e2>CHEMICAL 24-hydroxylase<\\e2> is essential for neural functions, especially learning","sentence":"High cholesterol turnover catalyzed by cholesterol 24-hydroxylase is essential for neural functions, especially learning"}
{"PMID":23602989,"re_id":8,"annotated sentence":"The selective <e2>CaMKII\u03b1<\\e2> inhibitor <e1>KN-62<\\e1> reversed the blockade produced by ionomycin and K(+)-depolarization","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"KN-62","object":"CaMKII\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> reversed the blockade produced by ionomycin and K(+)-depolarization","sentence":"The selective CaMKII\u03b1 inhibitor KN-62 reversed the blockade produced by ionomycin and K(+)-depolarization"}
{"PMID":23602989,"re_id":9,"annotated sentence":"The selective <e2>CaMKII\u03b1<\\e2> inhibitor KN-62 reversed the blockade produced by <e1>ionomycin<\\e1> and K(+)-depolarization","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ionomycin","object":"CaMKII\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective <e2>GENE-Y<\\e2> inhibitor KN-62 reversed the blockade produced by <e1>CHEMICAL<\\e1> and K(+)-depolarization","sentence":"The selective CaMKII\u03b1 inhibitor KN-62 reversed the blockade produced by ionomycin and K(+)-depolarization"}
{"PMID":23602989,"re_id":10,"annotated sentence":"In K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when <e2>CaMKII\u03b1<\\e2> was blocked with <e1>KN-62<\\e1>  In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4\u00a0nM","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"KN-62","object":"CaMKII\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when <e2>GENE-Y<\\e2> was blocked with <e1>CHEMICAL<\\e1>  In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4\u00a0nM","sentence":"In K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when CaMKII\u03b1 was blocked with KN-62  In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4\u00a0nM"}
{"PMID":23602989,"re_id":11,"annotated sentence":"In the presence of this inhibitor, the selective <e2>D3<\\e2> agonist <e1>PD 128,907<\\e1> reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4\u00a0nM","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"PD 128,907","object":"D3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the presence of this inhibitor, the selective <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4\u00a0nM","sentence":"In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4\u00a0nM"}
{"PMID":23602989,"re_id":12,"annotated sentence":"In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the <e2>D1<\\e2> agonist <e1>SKF 38393<\\e1> from 56 to 4\u00a0nM","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"SKF 38393","object":"D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> from 56 to 4\u00a0nM","sentence":"In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4\u00a0nM"}
{"PMID":23605050,"re_id":0,"annotated sentence":"Additionally, treatment with <e1>glucose<\\e1> iron showed a higher <e2>HO<\\e2> activity","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"glucose","object":"HO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Additionally, treatment with <e1>CHEMICAL<\\e1> iron showed a higher <e2>GENE-N<\\e2> activity","sentence":"Additionally, treatment with glucose iron showed a higher HO activity"}
{"PMID":23605050,"re_id":1,"annotated sentence":"Additionally, treatment with glucose\/<e1>iron<\\e1> showed a higher <e2>HO<\\e2> activity","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"iron","object":"HO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Additionally, treatment with glucose\/<e1>CHEMICAL<\\e1> showed a higher <e2>GENE-N<\\e2> activity","sentence":"Additionally, treatment with glucose\/iron showed a higher HO activity"}
{"PMID":23605050,"re_id":2,"annotated sentence":"The <e2>Bcl2<\\e2> Bax ratio increased and Mfn2 expression decreased in MIN6 cells after <e1>glucose<\\e1> stimulation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"Bcl2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> Bax ratio increased and Mfn2 expression decreased in MIN6 cells after <e1>CHEMICAL<\\e1> stimulation","sentence":"The Bcl2 Bax ratio increased and Mfn2 expression decreased in MIN6 cells after glucose stimulation"}
{"PMID":23605050,"re_id":3,"annotated sentence":"The Bcl2\/<e2>Bax<\\e2> ratio increased and Mfn2 expression decreased in MIN6 cells after <e1>glucose<\\e1> stimulation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The Bcl2\/<e2>GENE-Y<\\e2> ratio increased and Mfn2 expression decreased in MIN6 cells after <e1>CHEMICAL<\\e1> stimulation","sentence":"The Bcl2\/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after glucose stimulation"}
{"PMID":23605050,"re_id":4,"annotated sentence":"Our study revealed that high <e1>glucose<\\e1> Fe concentrations in MIN6 cells induced an increase of the <e2>Bcl2<\\e2> Bax ratio, an indicator of increased cell apoptosis.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"Bcl2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our study revealed that high <e1>CHEMICAL<\\e1> Fe concentrations in MIN6 cells induced an increase of the <e2>GENE-Y<\\e2> Bax ratio, an indicator of increased cell apoptosis.","sentence":"Our study revealed that high glucose Fe concentrations in MIN6 cells induced an increase of the Bcl2 Bax ratio, an indicator of increased cell apoptosis."}
{"PMID":23605050,"re_id":5,"annotated sentence":"Our study revealed that high <e1>glucose<\\e1> Fe concentrations in MIN6 cells induced an increase of the Bcl2\/<e2>Bax<\\e2> ratio, an indicator of increased cell apoptosis.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our study revealed that high <e1>CHEMICAL<\\e1> Fe concentrations in MIN6 cells induced an increase of the Bcl2\/<e2>GENE-Y<\\e2> ratio, an indicator of increased cell apoptosis.","sentence":"Our study revealed that high glucose Fe concentrations in MIN6 cells induced an increase of the Bcl2\/Bax ratio, an indicator of increased cell apoptosis."}
{"PMID":23605050,"re_id":6,"annotated sentence":"Our study revealed that high glucose\/<e1>Fe<\\e1> concentrations in MIN6 cells induced an increase of the <e2>Bcl2<\\e2> Bax ratio, an indicator of increased cell apoptosis.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Fe","object":"Bcl2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our study revealed that high glucose\/<e1>CHEMICAL<\\e1> concentrations in MIN6 cells induced an increase of the <e2>GENE-Y<\\e2> Bax ratio, an indicator of increased cell apoptosis.","sentence":"Our study revealed that high glucose\/Fe concentrations in MIN6 cells induced an increase of the Bcl2 Bax ratio, an indicator of increased cell apoptosis."}
{"PMID":23605050,"re_id":7,"annotated sentence":"Our study revealed that high glucose\/<e1>Fe<\\e1> concentrations in MIN6 cells induced an increase of the Bcl2\/<e2>Bax<\\e2> ratio, an indicator of increased cell apoptosis.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Fe","object":"Bax","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Our study revealed that high glucose\/<e1>CHEMICAL<\\e1> concentrations in MIN6 cells induced an increase of the Bcl2\/<e2>GENE-Y<\\e2> ratio, an indicator of increased cell apoptosis.","sentence":"Our study revealed that high glucose\/Fe concentrations in MIN6 cells induced an increase of the Bcl2\/Bax ratio, an indicator of increased cell apoptosis."}
{"PMID":23605050,"re_id":8,"annotated sentence":"The Bcl2\/Bax ratio increased and <e2>Mfn2<\\e2> expression decreased in MIN6 cells after <e1>glucose<\\e1> stimulation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"glucose","object":"Mfn2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The Bcl2\/Bax ratio increased and <e2>GENE-Y<\\e2> expression decreased in MIN6 cells after <e1>CHEMICAL<\\e1> stimulation","sentence":"The Bcl2\/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after glucose stimulation"}
{"PMID":23607523,"re_id":0,"annotated sentence":"Targeted disruption of the gene encoding the <e2>N-glycosyltransferase<\\e2>  prlH, abolished <e1>pyralomicin<\\e1> production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyralomicin","object":"N-glycosyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Targeted disruption of the gene encoding the <e2>GENE-N<\\e2>  prlH, abolished <e1>CHEMICAL<\\e1> production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.","sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase  prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety."}
{"PMID":23607523,"re_id":1,"annotated sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, <e2>prlH<\\e2>  abolished <e1>pyralomicin<\\e1> production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"pyralomicin","object":"prlH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, <e2>GENE-Y<\\e2>  abolished <e1>CHEMICAL<\\e1> production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.","sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH  abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety."}
{"PMID":23607523,"re_id":2,"annotated sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of <e2>PrlA<\\e2> confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the <e1>C7<\\e1> cyclitol moiety.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"C7","object":"PrlA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of <e2>GENE-Y<\\e2> confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the <e1>CHEMICAL<\\e1> cyclitol moiety.","sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7 cyclitol moiety."}
{"PMID":23607523,"re_id":3,"annotated sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a <e2>sugar phosphate cyclase<\\e2> involved in the formation of the <e1>C7<\\e1> cyclitol moiety.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"C7","object":"sugar phosphate cyclase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a <e2>GENE-N<\\e2> involved in the formation of the <e1>CHEMICAL<\\e1> cyclitol moiety.","sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7 cyclitol moiety."}
{"PMID":23607523,"re_id":4,"annotated sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of <e2>PrlA<\\e2> confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-<e1>cyclitol<\\e1> moiety.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"cyclitol","object":"PrlA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of <e2>GENE-Y<\\e2> confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-<e1>CHEMICAL<\\e1> moiety.","sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety."}
{"PMID":23607523,"re_id":5,"annotated sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a <e2>sugar phosphate cyclase<\\e2> involved in the formation of the C7-<e1>cyclitol<\\e1> moiety.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"cyclitol","object":"sugar phosphate cyclase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a <e2>GENE-N<\\e2> involved in the formation of the C7-<e1>CHEMICAL<\\e1> moiety.","sentence":"Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety."}
{"PMID":23607523,"re_id":6,"annotated sentence":"This includes <e2>nonribosomal peptide synthetases<\\e2> (NRPS) and polyketide synthases (PKS) required for the formation of the <e1>benzopyranopyrrole<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"benzopyranopyrrole","object":"nonribosomal peptide synthetases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This includes <e2>GENE-N<\\e2> (NRPS) and polyketide synthases (PKS) required for the formation of the <e1>CHEMICAL<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure","sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure"}
{"PMID":23607523,"re_id":7,"annotated sentence":"This includes nonribosomal peptide synthetases (<e2>NRPS<\\e2>  and polyketide synthases (PKS) required for the formation of the <e1>benzopyranopyrrole<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"benzopyranopyrrole","object":"NRPS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This includes nonribosomal peptide synthetases (<e2>GENE-N<\\e2>  and polyketide synthases (PKS) required for the formation of the <e1>CHEMICAL<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure","sentence":"This includes nonribosomal peptide synthetases (NRPS  and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure"}
{"PMID":23607523,"re_id":8,"annotated sentence":"This includes nonribosomal peptide synthetases (NRPS) and <e2>polyketide synthases<\\e2> (PKS) required for the formation of the <e1>benzopyranopyrrole<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"benzopyranopyrrole","object":"polyketide synthases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This includes nonribosomal peptide synthetases (NRPS) and <e2>GENE-N<\\e2> (PKS) required for the formation of the <e1>CHEMICAL<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure","sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure"}
{"PMID":23607523,"re_id":9,"annotated sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (<e2>PKS<\\e2>  required for the formation of the <e1>benzopyranopyrrole<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"benzopyranopyrrole","object":"PKS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (<e2>GENE-N<\\e2>  required for the formation of the <e1>CHEMICAL<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure","sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS  required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure"}
{"PMID":23607523,"re_id":10,"annotated sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the <e1>benzopyranopyrrole<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four <e2>halogenases<\\e2>  an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"benzopyranopyrrole","object":"halogenases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the <e1>CHEMICAL<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four <e2>GENE-N<\\e2>  an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure","sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases  an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure"}
{"PMID":23607523,"re_id":11,"annotated sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the <e1>benzopyranopyrrole<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an <e2>O-methyltransferase<\\e2>  and an N-glycosyltransferase) necessary for further modifications of the core structure","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"benzopyranopyrrole","object":"O-methyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the <e1>CHEMICAL<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an <e2>GENE-N<\\e2>  and an N-glycosyltransferase) necessary for further modifications of the core structure","sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase  and an N-glycosyltransferase) necessary for further modifications of the core structure"}
{"PMID":23607523,"re_id":12,"annotated sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the <e1>benzopyranopyrrole<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an <e2>N-glycosyltransferase<\\e2>  necessary for further modifications of the core structure","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"benzopyranopyrrole","object":"N-glycosyltransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the <e1>CHEMICAL<\\e1> core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an <e2>GENE-N<\\e2>  necessary for further modifications of the core structure","sentence":"This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase  necessary for further modifications of the core structure"}
{"PMID":23608737,"re_id":2,"annotated sentence":"To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the <e2>ER\u03b1<\\e2> selective agonist <e1>PPT<\\e1> or the ER\u03b2-selective agonist DPN were compared to Sham mice, and mice lacking either ER\u03b1 (\u03b1ERKO) or ER\u03b2 (\u03b2ERKO) were compared to WT littermates","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"PPT","object":"ER\u03b1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the <e2>GENE-Y<\\e2> selective agonist <e1>CHEMICAL<\\e1> or the ER\u03b2-selective agonist DPN were compared to Sham mice, and mice lacking either GENE-Y (\u03b1ERKO) or ER\u03b2 (\u03b2ERKO) were compared to WT littermates","sentence":"To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ER\u03b1 selective agonist PPT or the ER\u03b2-selective agonist DPN were compared to Sham mice, and mice lacking either ER\u03b1 (\u03b1ERKO) or ER\u03b2 (\u03b2ERKO) were compared to WT littermates"}
{"PMID":23608737,"re_id":3,"annotated sentence":"To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ER\u03b1-selective agonist PPT or the <e2>ER\u03b2<\\e2> selective agonist <e1>DPN<\\e1> were compared to Sham mice, and mice lacking either ER\u03b1 (\u03b1ERKO) or ER\u03b2 (\u03b2ERKO) were compared to WT littermates","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"DPN","object":"ER\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ER\u03b1-selective agonist PPT or the <e2>GENE-Y<\\e2> selective agonist <e1>CHEMICAL<\\e1> were compared to Sham mice, and mice lacking either ER\u03b1 (\u03b1ERKO) or GENE-Y (\u03b2ERKO) were compared to WT littermates","sentence":"To examine receptor mediation of estradiol effects, Ovx mice replaced for 2 days with either the ER\u03b1-selective agonist PPT or the ER\u03b2 selective agonist DPN were compared to Sham mice, and mice lacking either ER\u03b1 (\u03b1ERKO) or ER\u03b2 (\u03b2ERKO) were compared to WT littermates"}
{"PMID":23609438,"re_id":0,"annotated sentence":"The <e2>Intermediate-conductance Calcium-activated Potassium Channel KCa3.1<\\e2> Regulates Vascular Smooth Muscle Cell Proliferation via Controlling <e1>Calcium<\\e1> dependent Signaling","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Calcium","object":"Intermediate-conductance Calcium-activated Potassium Channel KCa3.1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>Intermediate-conductance CHEMICAL-activated Potassium Channel KCa3.1<\\e2> Regulates Vascular Smooth Muscle Cell Proliferation via Controlling <e1>CHEMICAL<\\e1> dependent Signaling","sentence":"The Intermediate-conductance Calcium-activated Potassium Channel KCa3.1 Regulates Vascular Smooth Muscle Cell Proliferation via Controlling Calcium dependent Signaling"}
{"PMID":23610086,"re_id":0,"annotated sentence":"The current study examined the bioactivation potential of <e2>ghrelin receptor<\\e2> inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and <e1>1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone<\\e1> (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-INHIBITOR","subject":"1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone","object":"ghrelin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The current study examined the bioactivation potential of <e2>GENE-Y<\\e2> inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and <e1>CHEMICAL<\\e1> (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure","sentence":"The current study examined the bioactivation potential of ghrelin receptor inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure"}
{"PMID":23610086,"re_id":1,"annotated sentence":"The current study examined the bioactivation potential of <e2>ghrelin receptor<\\e2> inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused <e1>imidazo[2,1-b]thiazole<\\e1> motif in the core structure","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-INHIBITOR","subject":"imidazo[2,1-b]thiazole","object":"ghrelin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The current study examined the bioactivation potential of <e2>GENE-Y<\\e2> inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused <e1>CHEMICAL<\\e1> motif in the core structure","sentence":"The current study examined the bioactivation potential of ghrelin receptor inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure"}
{"PMID":23610086,"re_id":2,"annotated sentence":"The current study examined the bioactivation potential of <e2>ghrelin receptor<\\e2> inverse agonists, <e1>1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone<\\e1> (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-INHIBITOR","subject":"1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone","object":"ghrelin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The current study examined the bioactivation potential of <e2>GENE-Y<\\e2> inverse agonists, <e1>CHEMICAL<\\e1> (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure","sentence":"The current study examined the bioactivation potential of ghrelin receptor inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure"}
{"PMID":23610086,"re_id":3,"annotated sentence":"Reactive Metabolite Trapping Studies on <e1>Imidazo- and 2-Methylimidazo[2,1-b]thiazole<\\e1> based Inverse Agonists of the <e2>Ghrelin Receptor<\\e2>  The current study examined the bioactivation potential of ghrelin receptor inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-INHIBITOR","subject":"Imidazo- and 2-Methylimidazo[2,1-b]thiazole","object":"Ghrelin Receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Reactive Metabolite Trapping Studies on <e1>CHEMICAL<\\e1> based Inverse Agonists of the <e2>GENE-Y<\\e2>  The current study examined the bioactivation potential of ghrelin receptor inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure","sentence":"Reactive Metabolite Trapping Studies on Imidazo- and 2-Methylimidazo[2,1-b]thiazole based Inverse Agonists of the Ghrelin Receptor  The current study examined the bioactivation potential of ghrelin receptor inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure"}
{"PMID":23619613,"re_id":10,"annotated sentence":"Processing of polysialylated NCAM was reproduced in a mouse model by <e1>bleomycin<\\e1> administration leading to an activation of the inflammasome and secretion of <e2>interleukin (IL)-1\u03b2<\\e2>  As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1\u03b2 or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"bleomycin","object":"interleukin (IL)-1\u03b2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Processing of polysialylated NCAM was reproduced in a mouse model by <e1>CHEMICAL<\\e1> administration leading to an activation of the inflammasome and secretion of <e2>GENE-Y<\\e2>  As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1\u03b2 or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM","sentence":"Processing of polysialylated NCAM was reproduced in a mouse model by bleomycin administration leading to an activation of the inflammasome and secretion of interleukin (IL)-1\u03b2  As shown in a cell culture model, polySia-NCAM-140 was kept in the late trans-Golgi apparatus of lung epithelial cells and stimulation by IL-1\u03b2 or lipopolysaccharide induced metalloprotease-mediated ectodomain shedding, resulting in the secretion of soluble polySia-NCAM"}
{"PMID":23624423,"re_id":14,"annotated sentence":"<e1>4-Hydroxytamoxifen<\\e1> stimulated processing of <e2>cyclin E<\\e2> is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"4-Hydroxytamoxifen","object":"cyclin E","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> stimulated processing of <e2>GENE-Y<\\e2> is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells","sentence":"4-Hydroxytamoxifen stimulated processing of cyclin E is mediated via G protein-coupled receptor 30 (GPR30) and accompanied by enhanced migration in MCF-7 breast cancer cells"}
{"PMID":23624423,"re_id":15,"annotated sentence":"<e1>17\u03b2-Estradiol<\\e1> (E2) has been recently shown to induce <e2>cyclin E<\\e2> processing in breast cancer cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"17\u03b2-Estradiol","object":"cyclin E","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (E2) has been recently shown to induce <e2>GENE-Y<\\e2> processing in breast cancer cells","sentence":"17\u03b2-Estradiol (E2) has been recently shown to induce cyclin E processing in breast cancer cells"}
{"PMID":23624423,"re_id":16,"annotated sentence":"Collectively, our data indicate that <e1>OHT<\\e1> contributes to the production of proteolyzed <e2>cyclin E<\\e2> via GPR30 with augmented migration in MCF-7 cells.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"OHT","object":"cyclin E","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Collectively, our data indicate that <e1>CHEMICAL<\\e1> contributes to the production of proteolyzed <e2>GENE-Y<\\e2> via GPR30 with augmented migration in MCF-7 cells.","sentence":"Collectively, our data indicate that OHT contributes to the production of proteolyzed cyclin E via GPR30 with augmented migration in MCF-7 cells."}
{"PMID":23631463,"re_id":1,"annotated sentence":"In the current study, we show that systematic modification of an <e1>aminoalkylindole<\\e1> scaffold identifies two new compounds with dual CB1R antagonist\/<e2>CB2R<\\e2> agonist activity","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"aminoalkylindole","object":"CB2R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the current study, we show that systematic modification of an <e1>CHEMICAL<\\e1> scaffold identifies two new compounds with dual CB1R antagonist\/<e2>GENE-Y<\\e2> agonist activity","sentence":"In the current study, we show that systematic modification of an aminoalkylindole scaffold identifies two new compounds with dual CB1R antagonist\/CB2R agonist activity"}
{"PMID":23631463,"re_id":2,"annotated sentence":"Collectively, these initial findings suggest that design and systematic modification of <e1>aminoalkylindoles<\\e1> such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist\/<e2>CB2R<\\e2> agonist activity with potential for use as treatments of alcohol abuse.","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"aminoalkylindoles","object":"CB2R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Collectively, these initial findings suggest that design and systematic modification of <e1>CHEMICAL<\\e1> such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist\/<e2>GENE-Y<\\e2> agonist activity with potential for use as treatments of alcohol abuse.","sentence":"Collectively, these initial findings suggest that design and systematic modification of aminoalkylindoles such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist\/CB2R agonist activity with potential for use as treatments of alcohol abuse."}
{"PMID":23631463,"re_id":3,"annotated sentence":"We have recently reported that a mono-hydroxylated metabolite of the synthetic <e1>aminoalkylindole<\\e1> cannabinoid JHW-073 (3) exhibits neutral antagonist activity at <e2>CB1Rs<\\e2> and thus may serve as a promising lead for the development of novel alcohol abuse therapies","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"aminoalkylindole","object":"CB1Rs","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have recently reported that a mono-hydroxylated metabolite of the synthetic <e1>CHEMICAL<\\e1> cannabinoid JHW-073 (3) exhibits neutral antagonist activity at <e2>GENE-Y<\\e2> and thus may serve as a promising lead for the development of novel alcohol abuse therapies","sentence":"We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid JHW-073 (3) exhibits neutral antagonist activity at CB1Rs and thus may serve as a promising lead for the development of novel alcohol abuse therapies"}
{"PMID":23631463,"re_id":4,"annotated sentence":"We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid <e1>JHW-073<\\e1> (3) exhibits neutral antagonist activity at <e2>CB1Rs<\\e2> and thus may serve as a promising lead for the development of novel alcohol abuse therapies","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"JHW-073","object":"CB1Rs","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid <e1>CHEMICAL<\\e1> (3) exhibits neutral antagonist activity at <e2>GENE-Y<\\e2> and thus may serve as a promising lead for the development of novel alcohol abuse therapies","sentence":"We have recently reported that a mono-hydroxylated metabolite of the synthetic aminoalkylindole cannabinoid JHW-073 (3) exhibits neutral antagonist activity at CB1Rs and thus may serve as a promising lead for the development of novel alcohol abuse therapies"}
{"PMID":23631463,"re_id":5,"annotated sentence":"In the current study, we show that systematic modification of an <e1>aminoalkylindole<\\e1> scaffold identifies two new compounds with dual <e2>CB1R<\\e2> antagonist\/CB2R agonist activity","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"aminoalkylindole","object":"CB1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the current study, we show that systematic modification of an <e1>CHEMICAL<\\e1> scaffold identifies two new compounds with dual <e2>GENE-Y<\\e2> antagonist\/CB2R agonist activity","sentence":"In the current study, we show that systematic modification of an aminoalkylindole scaffold identifies two new compounds with dual CB1R antagonist\/CB2R agonist activity"}
{"PMID":23631463,"re_id":6,"annotated sentence":"Collectively, these initial findings suggest that design and systematic modification of <e1>aminoalkylindoles<\\e1> such as 3 may lead to development of novel cannabinoid ligands with dual <e2>CB1R<\\e2> antagonist\/CB2R agonist activity with potential for use as treatments of alcohol abuse.","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"aminoalkylindoles","object":"CB1R","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Collectively, these initial findings suggest that design and systematic modification of <e1>CHEMICAL<\\e1> such as 3 may lead to development of novel cannabinoid ligands with dual <e2>GENE-Y<\\e2> antagonist\/CB2R agonist activity with potential for use as treatments of alcohol abuse.","sentence":"Collectively, these initial findings suggest that design and systematic modification of aminoalkylindoles such as 3 may lead to development of novel cannabinoid ligands with dual CB1R antagonist\/CB2R agonist activity with potential for use as treatments of alcohol abuse."}
{"PMID":23636640,"re_id":0,"annotated sentence":"The improved survival rates for obese mice chronically treated with <e1>vildagliptin<\\e1> suggest that chronic <e2>DPP4<\\e2> inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"vildagliptin","object":"DPP4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The improved survival rates for obese mice chronically treated with <e1>CHEMICAL<\\e1> suggest that chronic <e2>GENE-Y<\\e2> inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.","sentence":"The improved survival rates for obese mice chronically treated with vildagliptin suggest that chronic DPP4 inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy."}
{"PMID":23636640,"re_id":1,"annotated sentence":"METHODS: After 1\u00a0month of HFD alone, the mice were given the <e2>DPP4<\\e2> inhibitor <e1>vildagliptin<\\e1> for a further 11\u00a0months","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"vildagliptin","object":"DPP4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"METHODS: After 1\u00a0month of HFD alone, the mice were given the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> for a further 11\u00a0months","sentence":"METHODS: After 1\u00a0month of HFD alone, the mice were given the DPP4 inhibitor vildagliptin for a further 11\u00a0months"}
{"PMID":23636640,"re_id":2,"annotated sentence":"Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the <e2>dipeptidyl peptidase-4<\\e2> inhibitor <e1>vildagliptin<\\e1> in an advanced-aged diet-induced obesity mouse model","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"vildagliptin","object":"dipeptidyl peptidase-4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> in an advanced-aged diet-induced obesity mouse model","sentence":"Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model"}
{"PMID":23639187,"re_id":0,"annotated sentence":"Protein levels of the <e2>glucose transporter<\\e2> (GLUT4) involved in <e1>glucose<\\e1> transport via these two pathways were also increased","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glucose","object":"glucose transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Protein levels of the <e2>CHEMICAL transporter<\\e2> (GLUT4) involved in <e1>CHEMICAL<\\e1> transport via these two pathways were also increased","sentence":"Protein levels of the glucose transporter (GLUT4) involved in glucose transport via these two pathways were also increased"}
{"PMID":23639187,"re_id":1,"annotated sentence":"Protein levels of the glucose transporter (<e2>GLUT4<\\e2>  involved in <e1>glucose<\\e1> transport via these two pathways were also increased","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glucose","object":"GLUT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Protein levels of the CHEMICAL transporter (<e2>GENE-Y<\\e2>  involved in <e1>CHEMICAL<\\e1> transport via these two pathways were also increased","sentence":"Protein levels of the glucose transporter (GLUT4  involved in glucose transport via these two pathways were also increased"}
{"PMID":23639192,"re_id":8,"annotated sentence":"<e1>Puerarin<\\e1> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent <e2>MEK<\\e2> ERK and PI3K\/Akt activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Puerarin","object":"MEK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent <e2>GENE-N<\\e2> ERK and PI3K\/Akt activation","sentence":"Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK ERK and PI3K\/Akt activation"}
{"PMID":23639192,"re_id":9,"annotated sentence":"<e1>Puerarin<\\e1> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK\/<e2>ERK<\\e2> and PI3K\/Akt activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Puerarin","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK\/<e2>GENE-N<\\e2> and PI3K\/Akt activation","sentence":"Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK\/ERK and PI3K\/Akt activation"}
{"PMID":23639192,"re_id":10,"annotated sentence":"<e1>Puerarin<\\e1> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK\/ERK and <e2>PI3K<\\e2> Akt activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Puerarin","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK\/ERK and <e2>GENE-N<\\e2> Akt activation","sentence":"Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK\/ERK and PI3K Akt activation"}
{"PMID":23639192,"re_id":11,"annotated sentence":"<e1>Puerarin<\\e1> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK\/ERK and PI3K\/<e2>Akt<\\e2> activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Puerarin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK\/ERK and PI3K\/<e2>GENE-N<\\e2> activation","sentence":"Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK\/ERK and PI3K\/Akt activation"}
{"PMID":23639192,"re_id":12,"annotated sentence":"Moreover, we also demonstrate that <e1>puerarin<\\e1> functions at least partially through activation of <e2>MEK<\\e2> ERK and PI3K\/Akt signaling","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"puerarin","object":"MEK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, we also demonstrate that <e1>CHEMICAL<\\e1> functions at least partially through activation of <e2>GENE-N<\\e2> ERK and PI3K\/Akt signaling","sentence":"Moreover, we also demonstrate that puerarin functions at least partially through activation of MEK ERK and PI3K\/Akt signaling"}
{"PMID":23639192,"re_id":13,"annotated sentence":"Moreover, we also demonstrate that <e1>puerarin<\\e1> functions at least partially through activation of MEK\/<e2>ERK<\\e2> and PI3K\/Akt signaling","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"puerarin","object":"ERK","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, we also demonstrate that <e1>CHEMICAL<\\e1> functions at least partially through activation of MEK\/<e2>GENE-N<\\e2> and PI3K\/Akt signaling","sentence":"Moreover, we also demonstrate that puerarin functions at least partially through activation of MEK\/ERK and PI3K\/Akt signaling"}
{"PMID":23639192,"re_id":14,"annotated sentence":"Puerarin promotes proliferation by altering cell cycle distribution whereas <e1>puerarin<\\e1> mediated survival may be associated with up-regulation of <e2>Bcl-xL<\\e2> expression","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"puerarin","object":"Bcl-xL","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Puerarin promotes proliferation by altering cell cycle distribution whereas <e1>CHEMICAL<\\e1> mediated survival may be associated with up-regulation of <e2>GENE-Y<\\e2> expression","sentence":"Puerarin promotes proliferation by altering cell cycle distribution whereas puerarin mediated survival may be associated with up-regulation of Bcl-xL expression"}
{"PMID":23639192,"re_id":15,"annotated sentence":"Moreover, we also demonstrate that <e1>puerarin<\\e1> functions at least partially through activation of MEK\/ERK and <e2>PI3K<\\e2> Akt signaling","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"puerarin","object":"PI3K","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, we also demonstrate that <e1>CHEMICAL<\\e1> functions at least partially through activation of MEK\/ERK and <e2>GENE-N<\\e2> Akt signaling","sentence":"Moreover, we also demonstrate that puerarin functions at least partially through activation of MEK\/ERK and PI3K Akt signaling"}
{"PMID":23639192,"re_id":16,"annotated sentence":"Moreover, we also demonstrate that <e1>puerarin<\\e1> functions at least partially through activation of MEK\/ERK and PI3K\/<e2>Akt<\\e2> signaling","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"puerarin","object":"Akt","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Moreover, we also demonstrate that <e1>CHEMICAL<\\e1> functions at least partially through activation of MEK\/ERK and PI3K\/<e2>GENE-N<\\e2> signaling","sentence":"Moreover, we also demonstrate that puerarin functions at least partially through activation of MEK\/ERK and PI3K\/Akt signaling"}
{"PMID":23639192,"re_id":17,"annotated sentence":"Treatment with the <e2>ER<\\e2> antagonist <e1>ICI 182,780<\\e1> abolishes the above actions of puerarin on osteoblast-derived cells","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"ICI 182,780","object":"ER","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Treatment with the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> abolishes the above actions of puerarin on osteoblast-derived cells","sentence":"Treatment with the ER antagonist ICI 182,780 abolishes the above actions of puerarin on osteoblast-derived cells"}
{"PMID":23639572,"re_id":2,"annotated sentence":"RESULTS: Pretreatment of ucOC (30ng\/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the <e2>phosphatidylinositol 3-kinase<\\e2> (PI3-kinase) inhibitor, <e1>wortmannin<\\e1>  Treatment of ucOC (ranged from 0.3 to 30ng\/ml) significantly increased the phosphorylation of Akt and eNOS and nitric oxide secretion from endothelial cells in a PI3-kinase dependent manner","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"wortmannin","object":"phosphatidylinositol 3-kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: Pretreatment of ucOC (30ng\/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the <e2>GENE-N<\\e2> (PI3-kinase) inhibitor, <e1>CHEMICAL<\\e1>  Treatment of ucOC (ranged from 0.3 to 30ng\/ml) significantly increased the phosphorylation of Akt and eNOS and nitric oxide secretion from endothelial cells in a PI3-kinase dependent manner","sentence":"RESULTS: Pretreatment of ucOC (30ng\/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, wortmannin  Treatment of ucOC (ranged from 0.3 to 30ng\/ml) significantly increased the phosphorylation of Akt and eNOS and nitric oxide secretion from endothelial cells in a PI3-kinase dependent manner"}
{"PMID":23639572,"re_id":3,"annotated sentence":"RESULTS: Pretreatment of ucOC (30ng\/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (<e2>PI3-kinase<\\e2>  inhibitor, <e1>wortmannin<\\e1>  Treatment of ucOC (ranged from 0.3 to 30ng\/ml) significantly increased the phosphorylation of Akt and eNOS and nitric oxide secretion from endothelial cells in a PI3-kinase dependent manner","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"wortmannin","object":"PI3-kinase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"RESULTS: Pretreatment of ucOC (30ng\/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (<e2>GENE-N<\\e2>  inhibitor, <e1>CHEMICAL<\\e1>  Treatment of ucOC (ranged from 0.3 to 30ng\/ml) significantly increased the phosphorylation of Akt and eNOS and nitric oxide secretion from endothelial cells in a GENE-N dependent manner","sentence":"RESULTS: Pretreatment of ucOC (30ng\/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (PI3-kinase  inhibitor, wortmannin  Treatment of ucOC (ranged from 0.3 to 30ng\/ml) significantly increased the phosphorylation of Akt and eNOS and nitric oxide secretion from endothelial cells in a PI3-kinase dependent manner"}
{"PMID":23643725,"re_id":1,"annotated sentence":"In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150\u03bcgL(-1) <e1>oxyfluorfen<\\e1> showed a higher <e2>CAT<\\e2> activity than controls","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"oxyfluorfen","object":"CAT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150\u03bcgL(-1) <e1>CHEMICAL<\\e1> showed a higher <e2>GENE-N<\\e2> activity than controls","sentence":"In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150\u03bcgL(-1) oxyfluorfen showed a higher CAT activity than controls"}
{"PMID":23643745,"re_id":0,"annotated sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using <e2>D1<\\e2> D5 (<e1>SCH23390<\\e1> , D2\/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"SCH23390","object":"D1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using <e2>GENE-Y<\\e2> D5 (<e1>CHEMICAL<\\e1> , D2\/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice","sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1 D5 (SCH23390 , D2\/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice"}
{"PMID":23643745,"re_id":1,"annotated sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/<e2>D5<\\e2> (<e1>SCH23390<\\e1> , D2\/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"SCH23390","object":"D5","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/<e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1> , D2\/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice","sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390 , D2\/D3 (raclopride, amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice"}
{"PMID":23643745,"re_id":2,"annotated sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), <e2>D2<\\e2> D3 (<e1>raclopride<\\e1>  amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"raclopride","object":"D2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), <e2>GENE-Y<\\e2> D3 (<e1>CHEMICAL<\\e1>  amisulpride) and D3 (S33084) receptor antagonists, and by using GENE-Y receptor knockout mice","sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), D2 D3 (raclopride  amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice"}
{"PMID":23643745,"re_id":3,"annotated sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), D2\/<e2>D3<\\e2> (<e1>raclopride<\\e1>  amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"raclopride","object":"D3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), D2\/<e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1>  amisulpride) and GENE-Y (S33084) receptor antagonists, and by using D2 receptor knockout mice","sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), D2\/D3 (raclopride  amisulpride) and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice"}
{"PMID":23643745,"re_id":4,"annotated sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), <e2>D2<\\e2> D3 (raclopride, <e1>amisulpride<\\e1>  and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"amisulpride","object":"D2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), <e2>GENE-Y<\\e2> D3 (raclopride, <e1>CHEMICAL<\\e1>  and D3 (S33084) receptor antagonists, and by using GENE-Y receptor knockout mice","sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), D2 D3 (raclopride, amisulpride  and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice"}
{"PMID":23643745,"re_id":5,"annotated sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), D2\/<e2>D3<\\e2> (raclopride, <e1>amisulpride<\\e1>  and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"amisulpride","object":"D3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), D2\/<e2>GENE-Y<\\e2> (raclopride, <e1>CHEMICAL<\\e1>  and GENE-Y (S33084) receptor antagonists, and by using D2 receptor knockout mice","sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), D2\/D3 (raclopride, amisulpride  and D3 (S33084) receptor antagonists, and by using D2 receptor knockout mice"}
{"PMID":23643745,"re_id":6,"annotated sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), D2\/D3 (raclopride, amisulpride) and <e2>D3<\\e2> (<e1>S33084<\\e1>  receptor antagonists, and by using D2 receptor knockout mice","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"S33084","object":"D3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), D2\/GENE-Y (raclopride, amisulpride) and <e2>GENE-Y<\\e2> (<e1>CHEMICAL<\\e1>  receptor antagonists, and by using D2 receptor knockout mice","sentence":"The involvement of the various DA receptor subtypes in the motor effects of N\/OFQ and NOP receptor antagonists was evaluated pharmacologically, using D1\/D5 (SCH23390), D2\/D3 (raclopride, amisulpride) and D3 (S33084  receptor antagonists, and by using D2 receptor knockout mice"}
{"PMID":23643747,"re_id":8,"annotated sentence":"<e1>Haloperidol<\\e1> promotes mTORC1-dependent phosphorylation of <e2>ribosomal protein S6<\\e2> via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Haloperidol","object":"ribosomal protein S6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> promotes mTORC1-dependent phosphorylation of <e2>GENE-Y<\\e2> via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1","sentence":"Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1"}
{"PMID":23643747,"re_id":9,"annotated sentence":"These results show that <e1>haloperidol<\\e1> promotes mTORC1- and S6K1-dependent phosphorylation of <e2>rpS6<\\e2> at Ser240\/244, in a subpopulation of striatal MSNs expressing D2Rs","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"haloperidol","object":"rpS6","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results show that <e1>CHEMICAL<\\e1> promotes mTORC1- and S6K1-dependent phosphorylation of <e2>GENE-Y<\\e2> at Ser240\/244, in a subpopulation of striatal MSNs expressing D2Rs","sentence":"These results show that haloperidol promotes mTORC1- and S6K1-dependent phosphorylation of rpS6 at Ser240\/244, in a subpopulation of striatal MSNs expressing D2Rs"}
{"PMID":23643747,"re_id":10,"annotated sentence":"This effect was prevented by <e1>rapamycin<\\e1>  an inhibitor of the <e2>mammalian target of rapamycin complex 1<\\e2> (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rapamycin","object":"mammalian target of rapamycin complex 1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This effect was prevented by <e1>CHEMICAL<\\e1>  an inhibitor of the <e2>mammalian target of CHEMICAL complex 1<\\e2> (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)","sentence":"This effect was prevented by rapamycin  an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)"}
{"PMID":23643747,"re_id":11,"annotated sentence":"This effect was prevented by <e1>rapamycin<\\e1>  an inhibitor of the mammalian target of rapamycin complex 1 (<e2>mTORC1<\\e2> , or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rapamycin","object":"mTORC1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This effect was prevented by <e1>CHEMICAL<\\e1>  an inhibitor of the mammalian target of CHEMICAL complex 1 (<e2>GENE-N<\\e2> , or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)","sentence":"This effect was prevented by rapamycin  an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1 , or by PF470867, a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)"}
{"PMID":23643747,"re_id":12,"annotated sentence":"This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by <e1>PF470867<\\e1>  a selective inhibitor of the <e2>p70 ribosomal S6 kinase 1<\\e2> (S6K1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PF470867","object":"p70 ribosomal S6 kinase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by <e1>CHEMICAL<\\e1>  a selective inhibitor of the <e2>GENE-Y<\\e2> (S6K1)","sentence":"This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867  a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1)"}
{"PMID":23643747,"re_id":13,"annotated sentence":"This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by <e1>PF470867<\\e1>  a selective inhibitor of the p70 ribosomal S6 kinase 1 (<e2>S6K1<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"PF470867","object":"S6K1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by <e1>CHEMICAL<\\e1>  a selective inhibitor of the p70 ribosomal S6 kinase 1 (<e2>GENE-N<\\e2> ","sentence":"This effect was prevented by rapamycin, an inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), or by PF470867  a selective inhibitor of the p70 ribosomal S6 kinase 1 (S6K1 "}
{"PMID":23643747,"re_id":14,"annotated sentence":"In line with this observation, incubation of striatal slices with <e1>okadaic acid<\\e1> and calyculin A, two inhibitors of <e2>PP-1<\\e2>  increased Ser240\/244 phosphorylation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"okadaic acid","object":"PP-1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In line with this observation, incubation of striatal slices with <e1>CHEMICAL<\\e1> and calyculin A, two inhibitors of <e2>GENE-N<\\e2>  increased Ser240\/244 phosphorylation","sentence":"In line with this observation, incubation of striatal slices with okadaic acid and calyculin A, two inhibitors of PP-1  increased Ser240\/244 phosphorylation"}
{"PMID":23643747,"re_id":15,"annotated sentence":"<e1>Haloperidol<\\e1> promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of <e2>protein phosphatase-1<\\e2>  The ribosomal protein S6 (rpS6) is a component of the small 40S ribosomal subunit, involved in multiple physiological functions","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Haloperidol","object":"protein phosphatase-1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of <e2>GENE-N<\\e2>  The ribosomal protein S6 (rpS6) is a component of the small 40S ribosomal subunit, involved in multiple physiological functions","sentence":"Haloperidol promotes mTORC1-dependent phosphorylation of ribosomal protein S6 via dopamine- and cAMP-regulated phosphoprotein of 32 kDa and inhibition of protein phosphatase-1  The ribosomal protein S6 (rpS6) is a component of the small 40S ribosomal subunit, involved in multiple physiological functions"}
{"PMID":23643747,"re_id":16,"annotated sentence":"In line with this observation, incubation of striatal slices with okadaic acid and <e1>calyculin A<\\e1>  two inhibitors of <e2>PP-1<\\e2>  increased Ser240\/244 phosphorylation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"calyculin A","object":"PP-1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In line with this observation, incubation of striatal slices with okadaic acid and <e1>CHEMICAL<\\e1>  two inhibitors of <e2>GENE-N<\\e2>  increased Ser240\/244 phosphorylation","sentence":"In line with this observation, incubation of striatal slices with okadaic acid and calyculin A  two inhibitors of PP-1  increased Ser240\/244 phosphorylation"}
{"PMID":23644213,"re_id":1,"annotated sentence":"These compounds resulted from our efforts to merge the pharmacophores of selective <e2>factor Xa<\\e2> inhibitor <e1>rivaroxaban<\\e1> with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"rivaroxaban","object":"factor Xa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These compounds resulted from our efforts to merge the pharmacophores of selective <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1> with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity","sentence":"These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity"}
{"PMID":23644213,"re_id":2,"annotated sentence":"Resulting from this study, a structurally novel class of submicromolar fibrinogen <e2>GPIIb\/IIIa<\\e2> binding inhibitor bearing <e1>1,2,4-oxadiazol-5(4H)-one<\\e1> moiety is also described.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"1,2,4-oxadiazol-5(4H)-one","object":"GPIIb\/IIIa","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Resulting from this study, a structurally novel class of submicromolar fibrinogen <e2>GENE-Y<\\e2> binding inhibitor bearing <e1>CHEMICAL<\\e1> moiety is also described.","sentence":"Resulting from this study, a structurally novel class of submicromolar fibrinogen GPIIb\/IIIa binding inhibitor bearing 1,2,4-oxadiazol-5(4H)-one moiety is also described."}
{"PMID":23645211,"re_id":0,"annotated sentence":"The <e2>caspase-3<\\e2> immunopositivity was increased in degenerating neurons of the <e1>Cd<\\e1> group","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Cd","object":"caspase-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> immunopositivity was increased in degenerating neurons of the <e1>CHEMICAL<\\e1> group","sentence":"The caspase-3 immunopositivity was increased in degenerating neurons of the Cd group"}
{"PMID":23645211,"re_id":1,"annotated sentence":"Rats intoxicated with <e1>Cd<\\e1> for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants <e2>superoxide dismutase<\\e2>  glutathione peroxidase and catalase in the frontal cortex tissue","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Cd","object":"superoxide dismutase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Rats intoxicated with <e1>CHEMICAL<\\e1> for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants <e2>GENE-N<\\e2>  glutathione peroxidase and catalase in the frontal cortex tissue","sentence":"Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase  glutathione peroxidase and catalase in the frontal cortex tissue"}
{"PMID":23645211,"re_id":2,"annotated sentence":"Rats intoxicated with <e1>Cd<\\e1> for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, <e2>glutathione peroxidase<\\e2> and catalase in the frontal cortex tissue","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Cd","object":"glutathione peroxidase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Rats intoxicated with <e1>CHEMICAL<\\e1> for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, <e2>GENE-N<\\e2> and catalase in the frontal cortex tissue","sentence":"Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and catalase in the frontal cortex tissue"}
{"PMID":23645211,"re_id":3,"annotated sentence":"Rats intoxicated with <e1>Cd<\\e1> for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and <e2>catalase<\\e2> in the frontal cortex tissue","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Cd","object":"catalase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Rats intoxicated with <e1>CHEMICAL<\\e1> for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and <e2>GENE-Y<\\e2> in the frontal cortex tissue","sentence":"Rats intoxicated with Cd for 30 days, significantly increased tissue malondialdehyde (MDA) levels and significantly decreased enzymatic antioxidants superoxide dismutase, glutathione peroxidase and catalase in the frontal cortex tissue"}
{"PMID":23645248,"re_id":0,"annotated sentence":"In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the <e2>sodium iodide symporter<\\e2>  was significantly inhibited by <e1>17beta-oestradiol<\\e1> In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem\/progenitor cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"17beta-oestradiol","object":"sodium iodide symporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the <e2>GENE-Y<\\e2>  was significantly inhibited by <e1>CHEMICAL<\\e1> In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem\/progenitor cells","sentence":"In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the sodium iodide symporter  was significantly inhibited by 17beta-oestradiol In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem\/progenitor cells"}
{"PMID":23703578,"re_id":0,"annotated sentence":"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent <e2>CYP3A<\\e2> inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or <e1>boceprevir<\\e1>  and therefore their coadministration is contraindicated","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"boceprevir","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Simvastatin and lovastatin metabolized through GENE-N have the highest potency for drug-drug interaction with potent <e2>GENE-N<\\e2> inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or <e1>CHEMICAL<\\e1>  and therefore their coadministration is contraindicated","sentence":"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir  and therefore their coadministration is contraindicated"}
{"PMID":23703578,"re_id":1,"annotated sentence":"All HIV PIs except nelfinavir are coadministered with a low dose of <e1>ritonavir<\\e1>  a potent <e2>CYP3A<\\e2> inhibitor to improve their pharmacokinetic properties","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ritonavir","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"All HIV PIs except nelfinavir are coadministered with a low dose of <e1>CHEMICAL<\\e1>  a potent <e2>GENE-N<\\e2> inhibitor to improve their pharmacokinetic properties","sentence":"All HIV PIs except nelfinavir are coadministered with a low dose of ritonavir  a potent CYP3A inhibitor to improve their pharmacokinetic properties"}
{"PMID":23703578,"re_id":2,"annotated sentence":"The HCV-PIs <e1>boceprevir<\\e1> and telaprevir are both, to different extents, inhibitors of <e2>CYP3A<\\e2>  This review summarizes the pharmacokinetic properties of statins and PIs with emphasis on their metabolic pathways explaining clinically important drug-drug interactions","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"boceprevir","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The HCV-PIs <e1>CHEMICAL<\\e1> and telaprevir are both, to different extents, inhibitors of <e2>GENE-N<\\e2>  This review summarizes the pharmacokinetic properties of statins and PIs with emphasis on their metabolic pathways explaining clinically important drug-drug interactions","sentence":"The HCV-PIs boceprevir and telaprevir are both, to different extents, inhibitors of CYP3A  This review summarizes the pharmacokinetic properties of statins and PIs with emphasis on their metabolic pathways explaining clinically important drug-drug interactions"}
{"PMID":23703578,"re_id":3,"annotated sentence":"The HCV-PIs boceprevir and <e1>telaprevir<\\e1> are both, to different extents, inhibitors of <e2>CYP3A<\\e2>  This review summarizes the pharmacokinetic properties of statins and PIs with emphasis on their metabolic pathways explaining clinically important drug-drug interactions","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"telaprevir","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The HCV-PIs boceprevir and <e1>CHEMICAL<\\e1> are both, to different extents, inhibitors of <e2>GENE-N<\\e2>  This review summarizes the pharmacokinetic properties of statins and PIs with emphasis on their metabolic pathways explaining clinically important drug-drug interactions","sentence":"The HCV-PIs boceprevir and telaprevir are both, to different extents, inhibitors of CYP3A  This review summarizes the pharmacokinetic properties of statins and PIs with emphasis on their metabolic pathways explaining clinically important drug-drug interactions"}
{"PMID":23703578,"re_id":4,"annotated sentence":"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent <e2>CYP3A<\\e2> inhibitors such as <e1>ritonavir<\\e1>  or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ritonavir","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Simvastatin and lovastatin metabolized through GENE-N have the highest potency for drug-drug interaction with potent <e2>GENE-N<\\e2> inhibitors such as <e1>CHEMICAL<\\e1>  or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated","sentence":"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir  or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated"}
{"PMID":23703578,"re_id":5,"annotated sentence":"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent <e2>CYP3A<\\e2> inhibitors such as ritonavir- or <e1>cobicistat<\\e1> boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cobicistat","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Simvastatin and lovastatin metabolized through GENE-N have the highest potency for drug-drug interaction with potent <e2>GENE-N<\\e2> inhibitors such as ritonavir- or <e1>CHEMICAL<\\e1> boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated","sentence":"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated"}
{"PMID":23703578,"re_id":6,"annotated sentence":"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent <e2>CYP3A<\\e2> inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, <e1>telaprevir<\\e1> or boceprevir, and therefore their coadministration is contraindicated","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"telaprevir","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Simvastatin and lovastatin metabolized through GENE-N have the highest potency for drug-drug interaction with potent <e2>GENE-N<\\e2> inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, <e1>CHEMICAL<\\e1> or boceprevir, and therefore their coadministration is contraindicated","sentence":"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated"}
{"PMID":23703578,"re_id":7,"annotated sentence":"<e1>Atorvastatin<\\e1> is also a <e2>CYP3A<\\e2> substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Atorvastatin","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> is also a <e2>GENE-N<\\e2> substrate, but less potent drug-drug interactions have been reported with GENE-N inhibitors","sentence":"Atorvastatin is also a CYP3A substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors"}
{"PMID":23703578,"re_id":8,"annotated sentence":"Drug-drug interactions are dependent on statins' pharmacokinetic profile: <e1>simvastatin<\\e1>  lovastatin and atorvastatin are metabolized through <e2>cytochrome P450 (CYP) 3A<\\e2>  while the metabolism of the other statins is independent of this CYP","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"simvastatin","object":"cytochrome P450 (CYP) 3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Drug-drug interactions are dependent on statins' pharmacokinetic profile: <e1>CHEMICAL<\\e1>  lovastatin and atorvastatin are metabolized through <e2>GENE-N<\\e2>  while the metabolism of the other statins is independent of this CYP","sentence":"Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin  lovastatin and atorvastatin are metabolized through cytochrome P450 (CYP) 3A  while the metabolism of the other statins is independent of this CYP"}
{"PMID":23703578,"re_id":9,"annotated sentence":"Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, <e1>lovastatin<\\e1> and atorvastatin are metabolized through <e2>cytochrome P450 (CYP) 3A<\\e2>  while the metabolism of the other statins is independent of this CYP","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"lovastatin","object":"cytochrome P450 (CYP) 3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, <e1>CHEMICAL<\\e1> and atorvastatin are metabolized through <e2>GENE-N<\\e2>  while the metabolism of the other statins is independent of this CYP","sentence":"Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and atorvastatin are metabolized through cytochrome P450 (CYP) 3A  while the metabolism of the other statins is independent of this CYP"}
{"PMID":23703578,"re_id":10,"annotated sentence":"Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and <e1>atorvastatin<\\e1> are metabolized through <e2>cytochrome P450 (CYP) 3A<\\e2>  while the metabolism of the other statins is independent of this CYP","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"atorvastatin","object":"cytochrome P450 (CYP) 3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and <e1>CHEMICAL<\\e1> are metabolized through <e2>GENE-N<\\e2>  while the metabolism of the other statins is independent of this CYP","sentence":"Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and atorvastatin are metabolized through cytochrome P450 (CYP) 3A  while the metabolism of the other statins is independent of this CYP"}
{"PMID":23703578,"re_id":11,"annotated sentence":"<e1>Simvastatin<\\e1> and lovastatin metabolized through <e2>CYP3A<\\e2> have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"Simvastatin","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and lovastatin metabolized through <e2>GENE-N<\\e2> have the highest potency for drug-drug interaction with potent GENE-N inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated","sentence":"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated"}
{"PMID":23703578,"re_id":12,"annotated sentence":"Simvastatin and <e1>lovastatin<\\e1> metabolized through <e2>CYP3A<\\e2> have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"lovastatin","object":"CYP3A","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Simvastatin and <e1>CHEMICAL<\\e1> metabolized through <e2>GENE-N<\\e2> have the highest potency for drug-drug interaction with potent GENE-N inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated","sentence":"Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated"}
{"PMID":23742252,"re_id":0,"annotated sentence":"The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective <e2>anaplastic lymphoma kinase<\\e2> inhibitor 15b (<e1>LDK378<\\e1>  are described","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"LDK378","object":"anaplastic lymphoma kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective <e2>GENE-Y<\\e2> inhibitor 15b (<e1>CHEMICAL<\\e1>  are described","sentence":"The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378  are described"}
{"PMID":23742252,"re_id":1,"annotated sentence":"In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation <e2>ALK<\\e2> inhibitor 4 (<e1>TAE684<\\e1> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TAE684","object":"ALK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation <e2>GENE-Y<\\e2> inhibitor 4 (<e1>CHEMICAL<\\e1> ","sentence":"In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684 "}
{"PMID":2450203,"re_id":7,"annotated sentence":"These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that <e1>BDZs<\\e1> limit SRF by slowing recovery of <e2>sodium channels<\\e2> from inactivation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"BDZs","object":"sodium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These findings suggest that limitation of SRF was produced by binding of CHEMICAL, but not beta CCs, to voltage-dependent GENE-N and not to high affinity central BDZ receptors, and that <e1>CHEMICAL<\\e1> limit SRF by slowing recovery of <e2>GENE-N<\\e2> from inactivation","sentence":"These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation"}
{"PMID":2450203,"re_id":8,"annotated sentence":"Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a <e2>BDZ receptor<\\e2> weak partial agonist (<e1>Ro 15-1788<\\e1>  at micromolar concentrations","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"Ro 15-1788","object":"BDZ receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity GENE-Ns (Ro 5-4864) at high nanomolar concentrations and by a <e2>GENE-N<\\e2> weak partial agonist (<e1>CHEMICAL<\\e1>  at micromolar concentrations","sentence":"Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788  at micromolar concentrations"}
{"PMID":2450203,"re_id":9,"annotated sentence":"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the <e2>BDZ receptor<\\e2>  including <e1>Ro 15-1788<\\e1> and the beta CCs","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"Ro 15-1788","object":"BDZ receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the <e2>GENE-N<\\e2>  including <e1>CHEMICAL<\\e1> and the beta CCs","sentence":"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the BDZ receptor  including Ro 15-1788 and the beta CCs"}
{"PMID":2450203,"re_id":10,"annotated sentence":"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the <e2>BDZ receptor<\\e2>  including Ro 15-1788 and the <e1>beta CCs<\\e1>  These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"beta CCs","object":"BDZ receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the <e2>GENE-N<\\e2>  including Ro 15-1788 and the <e1>CHEMICAL<\\e1>  These findings suggest that limitation of SRF was produced by binding of BDZs, but not CHEMICAL, to voltage-dependent sodium channels and not to high affinity central GENE-Ns, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation","sentence":"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the BDZ receptor  including Ro 15-1788 and the beta CCs  These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation"}
{"PMID":2450203,"re_id":11,"annotated sentence":"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the <e2>BDZ receptor<\\e2>  including <e1>Ro 15-1788<\\e1> and the beta CCs","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-INHIBITOR","subject":"Ro 15-1788","object":"BDZ receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the <e2>GENE-N<\\e2>  including <e1>CHEMICAL<\\e1> and the beta CCs","sentence":"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the BDZ receptor  including Ro 15-1788 and the beta CCs"}
{"PMID":2450203,"re_id":12,"annotated sentence":"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the <e2>BDZ receptor<\\e2>  including Ro 15-1788 and the <e1>beta CCs<\\e1>  These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST-INHIBITOR","subject":"beta CCs","object":"BDZ receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the <e2>GENE-N<\\e2>  including Ro 15-1788 and the <e1>CHEMICAL<\\e1>  These findings suggest that limitation of SRF was produced by binding of BDZs, but not CHEMICAL, to voltage-dependent sodium channels and not to high affinity central GENE-Ns, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation","sentence":"The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the BDZ receptor  including Ro 15-1788 and the beta CCs  These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation"}
{"PMID":2521824,"re_id":4,"annotated sentence":"In addition to effects on cell proliferation, <e1>DHT<\\e1> increased the percentage of <e2>alkaline phosphatase<\\e2> (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DHT","object":"alkaline phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition to effects on cell proliferation, <e1>CHEMICAL<\\e1> increased the percentage of <e2>GENE-N<\\e2> (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens","sentence":"In addition to effects on cell proliferation, DHT increased the percentage of alkaline phosphatase (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens"}
{"PMID":2521824,"re_id":5,"annotated sentence":"In addition to effects on cell proliferation, <e1>DHT<\\e1> increased the percentage of alkaline phosphatase (<e2>ALP<\\e2>  positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"DHT","object":"ALP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In addition to effects on cell proliferation, <e1>CHEMICAL<\\e1> increased the percentage of alkaline phosphatase (<e2>GENE-N<\\e2>  positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens","sentence":"In addition to effects on cell proliferation, DHT increased the percentage of alkaline phosphatase (ALP  positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens"}
{"PMID":2521824,"re_id":6,"annotated sentence":"We conclude that <e1>androgens<\\e1> can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the <e2>osteoblast-line differentiation marker<\\e2> ALP, presumably by an androgen receptor mediated mechanism.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"androgens","object":"osteoblast-line differentiation marker","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We conclude that <e1>CHEMICAL<\\e1> can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the <e2>GENE-N<\\e2> ALP, presumably by an androgen receptor mediated mechanism.","sentence":"We conclude that androgens can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker ALP, presumably by an androgen receptor mediated mechanism."}
{"PMID":2521824,"re_id":7,"annotated sentence":"We conclude that <e1>androgens<\\e1> can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker <e2>ALP<\\e2>  presumably by an androgen receptor mediated mechanism.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"androgens","object":"ALP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We conclude that <e1>CHEMICAL<\\e1> can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker <e2>GENE-N<\\e2>  presumably by an androgen receptor mediated mechanism.","sentence":"We conclude that androgens can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker ALP  presumably by an androgen receptor mediated mechanism."}
{"PMID":2569356,"re_id":0,"annotated sentence":"The effect of <e2>histamine-H1 receptor<\\e2> antagonism with <e1>terfenadine<\\e1> on concentration-related AMP-induced bronchoconstriction in asthma","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"terfenadine","object":"histamine-H1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The effect of <e2>GENE-Y<\\e2> antagonism with <e1>CHEMICAL<\\e1> on concentration-related AMP-induced bronchoconstriction in asthma","sentence":"The effect of histamine-H1 receptor antagonism with terfenadine on concentration-related AMP-induced bronchoconstriction in asthma"}
{"PMID":25802231,"re_id":2,"annotated sentence":"<e1>Ibrutinib<\\e1> (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits <e2>B-cell antigen receptor<\\e2> signalling downstream of BTK","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Ibrutinib","object":"B-cell antigen receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits <e2>GENE-N<\\e2> signalling downstream of BTK","sentence":"Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK"}
{"PMID":25802231,"re_id":3,"annotated sentence":"Ibrutinib (<e1>Imbruvica(R)<\\e1>  is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits <e2>B-cell antigen receptor<\\e2> signalling downstream of BTK","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Imbruvica(R)","object":"B-cell antigen receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Ibrutinib (<e1>CHEMICAL<\\e1>  is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits <e2>GENE-N<\\e2> signalling downstream of BTK","sentence":"Ibrutinib (Imbruvica(R)  is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK"}
{"PMID":25802231,"re_id":4,"annotated sentence":"<e1>Ibrutinib<\\e1> (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (<e2>BTK<\\e2>  that inhibits B-cell antigen receptor signalling downstream of BTK","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Ibrutinib","object":"BTK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (<e2>GENE-Y<\\e2>  that inhibits B-cell antigen receptor signalling downstream of GENE-Y","sentence":"Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK  that inhibits B-cell antigen receptor signalling downstream of BTK"}
{"PMID":25802231,"re_id":5,"annotated sentence":"<e1>Ibrutinib<\\e1> (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of <e2>BTK<\\e2>  Oral ibrutinib is indicated for the treatment of patients with relapsed\/refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or TP53 mutation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Ibrutinib","object":"BTK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (GENE-Y) that inhibits B-cell antigen receptor signalling downstream of <e2>GENE-Y<\\e2>  Oral ibrutinib is indicated for the treatment of patients with relapsed\/refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or TP53 mutation","sentence":"Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK  Oral ibrutinib is indicated for the treatment of patients with relapsed\/refractory mantle cell lymphoma (MCL) or chronic lymphocytic leukaemia (CLL) and for the treatment of patients with CLL and a chromosome 17 deletion (del 17p) or TP53 mutation"}
{"PMID":25802231,"re_id":6,"annotated sentence":"<e1>Ibrutinib<\\e1> (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of <e2>Bruton's tyrosine kinase<\\e2> (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Ibrutinib","object":"Bruton's tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of <e2>GENE-Y<\\e2> (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK","sentence":"Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK"}
{"PMID":25802231,"re_id":7,"annotated sentence":"Ibrutinib (<e1>Imbruvica(R)<\\e1>  is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (<e2>BTK<\\e2>  that inhibits B-cell antigen receptor signalling downstream of BTK","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imbruvica(R)","object":"BTK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ibrutinib (<e1>CHEMICAL<\\e1>  is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (<e2>GENE-Y<\\e2>  that inhibits B-cell antigen receptor signalling downstream of GENE-Y","sentence":"Ibrutinib (Imbruvica(R)  is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK  that inhibits B-cell antigen receptor signalling downstream of BTK"}
{"PMID":25802231,"re_id":8,"annotated sentence":"Ibrutinib (<e1>Imbruvica(R)<\\e1>  is a first-in-class, potent, orally administered, covalent inhibitor of <e2>Bruton's tyrosine kinase<\\e2> (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Imbruvica(R)","object":"Bruton's tyrosine kinase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ibrutinib (<e1>CHEMICAL<\\e1>  is a first-in-class, potent, orally administered, covalent inhibitor of <e2>GENE-Y<\\e2> (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK","sentence":"Ibrutinib (Imbruvica(R)  is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK"}
{"PMID":2859531,"re_id":2,"annotated sentence":"<e1>Propranolol<\\e1> treatment (4 X 40 mg\/day) increased the density of <e2>beta 2-adrenoceptors<\\e2> by 25% after 2 days; concomitantly PRA and heart rate were reduced","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Propranolol","object":"beta 2-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment (4 X 40 mg\/day) increased the density of <e2>GENE-Y<\\e2> by 25% after 2 days; concomitantly PRA and heart rate were reduced","sentence":"Propranolol treatment (4 X 40 mg\/day) increased the density of beta 2-adrenoceptors by 25% after 2 days; concomitantly PRA and heart rate were reduced"}
{"PMID":2859531,"re_id":3,"annotated sentence":"<e1>Mepindolol<\\e1> treatment (2 X 5 mg\/day) caused a 30% decrease of <e2>beta 2-adrenoceptor<\\e2> density and PRA after 2 days; both parameters remained reduced during treatment","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Mepindolol","object":"beta 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> treatment (2 X 5 mg\/day) caused a 30% decrease of <e2>GENE-Y<\\e2> density and PRA after 2 days; both parameters remained reduced during treatment","sentence":"Mepindolol treatment (2 X 5 mg\/day) caused a 30% decrease of beta 2-adrenoceptor density and PRA after 2 days; both parameters remained reduced during treatment"}
{"PMID":2859531,"re_id":4,"annotated sentence":"To study the mechanism underlying this phenomenon, the effects of the nonselective <e2>beta-adrenoceptor<\\e2> antagonists <e1>propranolol<\\e1> [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+\/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"propranolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To study the mechanism underlying this phenomenon, the effects of the nonselective <e2>GENE-N<\\e2> antagonists <e1>CHEMICAL<\\e1> [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+\/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years","sentence":"To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+\/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years"}
{"PMID":2859531,"re_id":5,"annotated sentence":"To study the mechanism underlying this phenomenon, the effects of the nonselective <e2>beta-adrenoceptor<\\e2> antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], <e1>alprenolol<\\e1> (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+\/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"alprenolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To study the mechanism underlying this phenomenon, the effects of the nonselective <e2>GENE-N<\\e2> antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], <e1>CHEMICAL<\\e1> (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+\/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years","sentence":"To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+\/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years"}
{"PMID":2859531,"re_id":6,"annotated sentence":"To study the mechanism underlying this phenomenon, the effects of the nonselective <e2>beta-adrenoceptor<\\e2> antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and <e1>mepindolol<\\e1> (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+\/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"mepindolol","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"To study the mechanism underlying this phenomenon, the effects of the nonselective <e2>GENE-N<\\e2> antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and <e1>CHEMICAL<\\e1> (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+\/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years","sentence":"To study the mechanism underlying this phenomenon, the effects of the nonselective beta-adrenoceptor antagonists propranolol [no intrinsic sympathomimetic activity (ISA)], alprenolol (weak ISA) and mepindolol (strong ISA) on lymphocyte beta 2-adrenoceptor density--assessed by (+\/-)-[125I]-iodocyanopindolol (ICYP) binding--and plasma renin activity (PRA) were investigated in male healthy volunteers aged 23-35 years"}
{"PMID":2882965,"re_id":0,"annotated sentence":"Inhibition of <e2>5-lipoxygenase<\\e2> pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and <e1>5-aminosalicylic acid<\\e1>  The possible effect of sulfasalazine, 5-aminosalicylic acid, and acetyl-5-aminosalicylic acid on endogenous arachidonic acid release and metabolism was studied in human polymorphonuclear leukocytes (PMNs)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"5-aminosalicylic acid","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and <e1>CHEMICAL<\\e1>  The possible effect of sulfasalazine, CHEMICAL, and acetyl-CHEMICAL on endogenous arachidonic acid release and metabolism was studied in human polymorphonuclear leukocytes (PMNs)","sentence":"Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid  The possible effect of sulfasalazine, 5-aminosalicylic acid, and acetyl-5-aminosalicylic acid on endogenous arachidonic acid release and metabolism was studied in human polymorphonuclear leukocytes (PMNs)"}
{"PMID":2882965,"re_id":1,"annotated sentence":"Inhibition of <e2>5-lipoxygenase<\\e2> pathway of arachidonic acid metabolism in human neutrophils by <e1>sulfasalazine<\\e1> and 5-aminosalicylic acid","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"sulfasalazine","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> pathway of arachidonic acid metabolism in human neutrophils by <e1>CHEMICAL<\\e1> and 5-aminosalicylic acid","sentence":"Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid"}
{"PMID":2882965,"re_id":2,"annotated sentence":"Interference with <e2>lipoxygenase<\\e2> enzymes, rather than a <e1>steroid<\\e1> like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"steroid","object":"lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interference with <e2>GENE-N<\\e2> enzymes, rather than a <e1>CHEMICAL<\\e1> like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action.","sentence":"Interference with lipoxygenase enzymes, rather than a steroid like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action."}
{"PMID":2882965,"re_id":3,"annotated sentence":"Inhibition of <e2>5-lipoxygenase<\\e2> pathway of <e1>arachidonic acid<\\e1> metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"arachidonic acid","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of <e2>GENE-Y<\\e2> pathway of <e1>CHEMICAL<\\e1> metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid","sentence":"Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid"}
{"PMID":2882965,"re_id":4,"annotated sentence":"Interference with <e2>lipoxygenase<\\e2> enzymes, rather than a steroid-like inhibition of <e1>arachidonic acid<\\e1> release from intracellular phospholipids, seems to be the mode of action.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"arachidonic acid","object":"lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Interference with <e2>GENE-N<\\e2> enzymes, rather than a steroid-like inhibition of <e1>CHEMICAL<\\e1> release from intracellular phospholipids, seems to be the mode of action.","sentence":"Interference with lipoxygenase enzymes, rather than a steroid-like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action."}
{"PMID":2888789,"re_id":1,"annotated sentence":"It is suggested that all the additional actions of <e1>bevantolol<\\e1> can be attributed to a partial agonist action on <e2>alpha-adrenoceptors<\\e2> ","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"bevantolol","object":"alpha-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"It is suggested that all the additional actions of <e1>CHEMICAL<\\e1> can be attributed to a partial agonist action on <e2>GENE-N<\\e2> ","sentence":"It is suggested that all the additional actions of bevantolol can be attributed to a partial agonist action on alpha-adrenoceptors "}
{"PMID":2888789,"re_id":2,"annotated sentence":"UNLABELLED: <e1>Bevantolol<\\e1> is a <e2>beta-1 adrenoceptor<\\e2> antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Bevantolol","object":"beta-1 adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"UNLABELLED: <e1>CHEMICAL<\\e1> is a <e2>GENE-Y<\\e2> antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension","sentence":"UNLABELLED: Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension"}
{"PMID":2888789,"re_id":3,"annotated sentence":"<e1>Bevantolol<\\e1>  a <e2>beta-1 adrenoceptor<\\e2> antagonist with unique additional actions","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Bevantolol","object":"beta-1 adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> antagonist with unique additional actions","sentence":"Bevantolol  a beta-1 adrenoceptor antagonist with unique additional actions"}
{"PMID":2889803,"re_id":4,"annotated sentence":"The apparent affinity of <e2>benzodiazepine receptors<\\e2> for clonazepam in mice receiving alprazolam (0.05 mg\/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of <e1>alprazolam<\\e1> increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"alprazolam","object":"benzodiazepine receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The apparent affinity of <e2>GENE-N<\\e2> for clonazepam in mice receiving CHEMICAL (0.05 mg\/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of <e1>CHEMICAL<\\e1> increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)","sentence":"The apparent affinity of benzodiazepine receptors for clonazepam in mice receiving alprazolam (0.05 mg\/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.(ABSTRACT TRUNCATED AT 250 WORDS)"}
{"PMID":2922761,"re_id":7,"annotated sentence":"In contrast, serum <e2>alkaline phosphatase<\\e2> was elevated in animals dosed with <e1>13cisRA<\\e1> or 4HPR but not in those dose with ROAc","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"13cisRA","object":"alkaline phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, serum <e2>GENE-N<\\e2> was elevated in animals dosed with <e1>CHEMICAL<\\e1> or 4HPR but not in those dose with ROAc","sentence":"In contrast, serum alkaline phosphatase was elevated in animals dosed with 13cisRA or 4HPR but not in those dose with ROAc"}
{"PMID":2922761,"re_id":8,"annotated sentence":"In contrast, serum <e2>alkaline phosphatase<\\e2> was elevated in animals dosed with 13cisRA or <e1>4HPR<\\e1> but not in those dose with ROAc","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"4HPR","object":"alkaline phosphatase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast, serum <e2>GENE-N<\\e2> was elevated in animals dosed with 13cisRA or <e1>CHEMICAL<\\e1> but not in those dose with ROAc","sentence":"In contrast, serum alkaline phosphatase was elevated in animals dosed with 13cisRA or 4HPR but not in those dose with ROAc"}
{"PMID":2922761,"re_id":9,"annotated sentence":"When menadione was omitted from the diet, however, <e1>4HPR<\\e1> dosed animals had elevated <e2>prothrombin<\\e2> times","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"4HPR","object":"prothrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"When menadione was omitted from the diet, however, <e1>CHEMICAL<\\e1> dosed animals had elevated <e2>GENE-Y<\\e2> times","sentence":"When menadione was omitted from the diet, however, 4HPR dosed animals had elevated prothrombin times"}
{"PMID":2922761,"re_id":10,"annotated sentence":"In the high-dose <e1>ROAc<\\e1> group, there was a twofold increase in <e2>prothrombin<\\e2> times but only after prolonged dosing","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ROAc","object":"prothrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In the high-dose <e1>CHEMICAL<\\e1> group, there was a twofold increase in <e2>GENE-Y<\\e2> times but only after prolonged dosing","sentence":"In the high-dose ROAc group, there was a twofold increase in prothrombin times but only after prolonged dosing"}
{"PMID":2922761,"re_id":11,"annotated sentence":"The order of effect was <e1>4HPR<\\e1> greater than ROAc greater than 13cisRA, with increases in <e2>prothrombin<\\e2> times correlating with increases in hemorrhagic deaths","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"4HPR","object":"prothrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The order of effect was <e1>CHEMICAL<\\e1> greater than ROAc greater than 13cisRA, with increases in <e2>GENE-Y<\\e2> times correlating with increases in hemorrhagic deaths","sentence":"The order of effect was 4HPR greater than ROAc greater than 13cisRA, with increases in prothrombin times correlating with increases in hemorrhagic deaths"}
{"PMID":2922761,"re_id":12,"annotated sentence":"The order of effect was 4HPR greater than <e1>ROAc<\\e1> greater than 13cisRA, with increases in <e2>prothrombin<\\e2> times correlating with increases in hemorrhagic deaths","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ROAc","object":"prothrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The order of effect was 4HPR greater than <e1>CHEMICAL<\\e1> greater than 13cisRA, with increases in <e2>GENE-Y<\\e2> times correlating with increases in hemorrhagic deaths","sentence":"The order of effect was 4HPR greater than ROAc greater than 13cisRA, with increases in prothrombin times correlating with increases in hemorrhagic deaths"}
{"PMID":2922761,"re_id":13,"annotated sentence":"The order of effect was 4HPR greater than ROAc greater than <e1>13cisRA<\\e1>  with increases in <e2>prothrombin<\\e2> times correlating with increases in hemorrhagic deaths","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"13cisRA","object":"prothrombin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The order of effect was 4HPR greater than ROAc greater than <e1>CHEMICAL<\\e1>  with increases in <e2>GENE-Y<\\e2> times correlating with increases in hemorrhagic deaths","sentence":"The order of effect was 4HPR greater than ROAc greater than 13cisRA  with increases in prothrombin times correlating with increases in hemorrhagic deaths"}
{"PMID":2922761,"re_id":14,"annotated sentence":"<e1>13cisRA<\\e1> and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma <e2>osteocalcin<\\e2>  an effect that correlated with retinoid-induced bone effects","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"13cisRA","object":"osteocalcin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma <e2>GENE-Y<\\e2>  an effect that correlated with retinoid-induced bone effects","sentence":"13cisRA and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma osteocalcin  an effect that correlated with retinoid-induced bone effects"}
{"PMID":2922761,"re_id":15,"annotated sentence":"13cisRA and <e1>ROAc<\\e1>  but not 4HPR, caused a dose-dependent reduction in plasma <e2>osteocalcin<\\e2>  an effect that correlated with retinoid-induced bone effects","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"ROAc","object":"osteocalcin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"13cisRA and <e1>CHEMICAL<\\e1>  but not 4HPR, caused a dose-dependent reduction in plasma <e2>GENE-Y<\\e2>  an effect that correlated with retinoid-induced bone effects","sentence":"13cisRA and ROAc  but not 4HPR, caused a dose-dependent reduction in plasma osteocalcin  an effect that correlated with retinoid-induced bone effects"}
{"PMID":2922761,"re_id":16,"annotated sentence":"13cisRA and ROAc, but not <e1>4HPR<\\e1>  caused a dose-dependent reduction in plasma <e2>osteocalcin<\\e2>  an effect that correlated with retinoid-induced bone effects","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"4HPR","object":"osteocalcin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"13cisRA and ROAc, but not <e1>CHEMICAL<\\e1>  caused a dose-dependent reduction in plasma <e2>GENE-Y<\\e2>  an effect that correlated with retinoid-induced bone effects","sentence":"13cisRA and ROAc, but not 4HPR  caused a dose-dependent reduction in plasma osteocalcin  an effect that correlated with retinoid-induced bone effects"}
{"PMID":2982865,"re_id":2,"annotated sentence":"However, in the presence of 100 mM <e1>Na+<\\e1>  which is required for opiate inhibition of <e2>adenylate cyclase<\\e2> activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +\/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +\/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +\/- 110 nM","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Na+","object":"adenylate cyclase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"However, in the presence of 100 mM <e1>CHEMICAL<\\e1>  which is required for opiate inhibition of <e2>GENE-N<\\e2> activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +\/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +\/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +\/- 110 nM","sentence":"However, in the presence of 100 mM Na+  which is required for opiate inhibition of adenylate cyclase activity, analysis of competition binding data revealed three sites: the first, consisting of 17.5% of total receptor population has a Kd = 0.38 +\/- 0.18 nM; the second, 50.6% of the population, has a Kd = 6.8 +\/- 2.2 nM; and the third, 31.9% of the population, has a Kd of 410 +\/- 110 nM"}
{"PMID":3004501,"re_id":4,"annotated sentence":"Kinetic analysis revealed that the inhibition of the <e2>leukotriene C synthetase<\\e2> reaction by <e1>diethylcarbamazine<\\e1> was competitive with respect to LTA4","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diethylcarbamazine","object":"leukotriene C synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Kinetic analysis revealed that the inhibition of the <e2>GENE-Y<\\e2> reaction by <e1>CHEMICAL<\\e1> was competitive with respect to LTA4","sentence":"Kinetic analysis revealed that the inhibition of the leukotriene C synthetase reaction by diethylcarbamazine was competitive with respect to LTA4"}
{"PMID":3004501,"re_id":5,"annotated sentence":"In contrast to <e1>diethylcarbamazine<\\e1>  piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the <e2>5-lipoxygenase<\\e2> step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diethylcarbamazine","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast to <e1>CHEMICAL<\\e1>  piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the <e2>GENE-Y<\\e2> step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells","sentence":"In contrast to diethylcarbamazine  piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells"}
{"PMID":3004501,"re_id":6,"annotated sentence":"In contrast to <e1>diethylcarbamazine<\\e1>  piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the <e2>leukotriene synthetase<\\e2> of these cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diethylcarbamazine","object":"leukotriene synthetase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"In contrast to <e1>CHEMICAL<\\e1>  piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the <e2>GENE-N<\\e2> of these cells","sentence":"In contrast to diethylcarbamazine  piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells"}
{"PMID":3004501,"re_id":7,"annotated sentence":"In contrast to diethylcarbamazine, <e1>piriprost<\\e1> (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the <e2>5-lipoxygenase<\\e2> step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"piriprost","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast to diethylcarbamazine, <e1>CHEMICAL<\\e1> (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the <e2>GENE-Y<\\e2> step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells","sentence":"In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells"}
{"PMID":3004501,"re_id":8,"annotated sentence":"In contrast to diethylcarbamazine, piriprost (<e1>U-60,257<\\e1>  6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the <e2>5-lipoxygenase<\\e2> step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"U-60,257","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast to diethylcarbamazine, piriprost (<e1>CHEMICAL<\\e1>  6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the <e2>GENE-Y<\\e2> step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells","sentence":"In contrast to diethylcarbamazine, piriprost (U-60,257  6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells"}
{"PMID":3004501,"re_id":9,"annotated sentence":"In contrast to diethylcarbamazine, piriprost (U-60,257; <e1>6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1<\\e1> , which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the <e2>5-lipoxygenase<\\e2> step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast to diethylcarbamazine, piriprost (U-60,257; <e1>CHEMICAL<\\e1> , which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the <e2>GENE-Y<\\e2> step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells","sentence":"In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1 , which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells"}
{"PMID":3004501,"re_id":10,"annotated sentence":"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between <e1>diethylcarbamazine<\\e1> and piriprost, a <e2>5-lipoxygenase<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diethylcarbamazine","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by CHEMICAL, and synergism between <e1>CHEMICAL<\\e1> and piriprost, a <e2>GENE-Y<\\e2> inhibitor","sentence":"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor"}
{"PMID":3004501,"re_id":11,"annotated sentence":"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and <e1>piriprost<\\e1>  a <e2>5-lipoxygenase<\\e2> inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"piriprost","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and <e1>CHEMICAL<\\e1>  a <e2>GENE-Y<\\e2> inhibitor","sentence":"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost  a 5-lipoxygenase inhibitor"}
{"PMID":3004501,"re_id":12,"annotated sentence":"Inhibition of the <e2>leukotriene synthetase<\\e2> of rat basophil leukemia cells by <e1>diethylcarbamazine<\\e1>  and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diethylcarbamazine","object":"leukotriene synthetase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of the <e2>GENE-N<\\e2> of rat basophil leukemia cells by <e1>CHEMICAL<\\e1>  and synergism between CHEMICAL and piriprost, a 5-lipoxygenase inhibitor","sentence":"Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine  and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor"}
{"PMID":3004501,"re_id":13,"annotated sentence":"Similar concentrations also inhibited the formation of <e1>leukotriene C4<\\e1> (LTC4) by <e2>LTC synthetase<\\e2>  a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"leukotriene C4","object":"LTC synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar concentrations also inhibited the formation of <e1>CHEMICAL<\\e1> (LTC4) by <e2>GENE-Y<\\e2>  a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione","sentence":"Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by LTC synthetase  a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione"}
{"PMID":3004501,"re_id":14,"annotated sentence":"Similar concentrations also inhibited the formation of leukotriene C4 (<e1>LTC4<\\e1>  by <e2>LTC synthetase<\\e2>  a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"LTC4","object":"LTC synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar concentrations also inhibited the formation of leukotriene C4 (<e1>CHEMICAL<\\e1>  by <e2>GENE-Y<\\e2>  a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione","sentence":"Similar concentrations also inhibited the formation of leukotriene C4 (LTC4  by LTC synthetase  a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione"}
{"PMID":3004501,"re_id":15,"annotated sentence":"In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of <e1>sulfidopeptide leuktrienes<\\e1> in RBL cells at the <e2>5-lipoxygenase<\\e2> step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"sulfidopeptide leuktrienes","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of <e1>CHEMICAL<\\e1> in RBL cells at the <e2>GENE-Y<\\e2> step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells","sentence":"In contrast to diethylcarbamazine, piriprost (U-60,257; 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin I1), which inhibits the formation of sulfidopeptide leuktrienes in RBL cells at the 5-lipoxygenase step (EC50 5 microM), did not inhibit the leukotriene synthetase of these cells"}
{"PMID":3004501,"re_id":16,"annotated sentence":"These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of <e1>LTA4<\\e1> in the <e2>leukotriene C synthetase<\\e2> reaction.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"LTA4","object":"leukotriene C synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of <e1>CHEMICAL<\\e1> in the <e2>GENE-Y<\\e2> reaction.","sentence":"These results are consistent with the interpretation that both piriprost and diethylcarbamazine inhibit leukotriene formation but that they act on sequential steps in the biosynthetic pathway in such a manner as to synergistically interfere with the availability or utilization of LTA4 in the leukotriene C synthetase reaction."}
{"PMID":3004501,"re_id":17,"annotated sentence":"Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by <e2>LTC synthetase<\\e2>  a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling <e1>LTA4<\\e1> to glutathione","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"LTA4","object":"LTC synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by <e2>GENE-Y<\\e2>  a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling <e1>CHEMICAL<\\e1> to glutathione","sentence":"Similar concentrations also inhibited the formation of leukotriene C4 (LTC4) by LTC synthetase  a detergent-solubilized cell free particulate enzyme from RBL cells which is capable of coupling LTA4 to glutathione"}
{"PMID":3004501,"re_id":18,"annotated sentence":"The EC50 for inhibition of the <e2>leukotriene C synthetase<\\e2> of RBL cells was directly proportional to the <e1>LTA4<\\e1> concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"LTA4","object":"leukotriene C synthetase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The EC50 for inhibition of the <e2>GENE-Y<\\e2> of RBL cells was directly proportional to the <e1>CHEMICAL<\\e1> concentration in the incubations, ranging from 1.5 mM at 10 microM CHEMICAL to over 40 mM at 500 microM CHEMICAL","sentence":"The EC50 for inhibition of the leukotriene C synthetase of RBL cells was directly proportional to the LTA4 concentration in the incubations, ranging from 1.5 mM at 10 microM LTA4 to over 40 mM at 500 microM LTA4"}
{"PMID":3089818,"re_id":0,"annotated sentence":"The test procedure was verified with respect to intestinal <e1>lactose<\\e1> hydrolysis by demonstrating a linear relationship between lactose\/lactulose excretion and log jejunal mucosal <e2>lactase<\\e2> activity by in vitro assay (R2 = 0.95) in a further group of subjects","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"lactose","object":"lactase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The test procedure was verified with respect to intestinal <e1>CHEMICAL<\\e1> hydrolysis by demonstrating a linear relationship between CHEMICAL\/lactulose excretion and log jejunal mucosal <e2>GENE-Y<\\e2> activity by in vitro assay (R2 = 0.95) in a further group of subjects","sentence":"The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose\/lactulose excretion and log jejunal mucosal lactase activity by in vitro assay (R2 = 0.95) in a further group of subjects"}
{"PMID":3089818,"re_id":1,"annotated sentence":"The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between <e1>lactose<\\e1> lactulose excretion and log jejunal mucosal <e2>lactase<\\e2> activity by in vitro assay (R2 = 0.95) in a further group of subjects","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"lactose","object":"lactase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The test procedure was verified with respect to intestinal CHEMICAL hydrolysis by demonstrating a linear relationship between <e1>CHEMICAL<\\e1> lactulose excretion and log jejunal mucosal <e2>GENE-Y<\\e2> activity by in vitro assay (R2 = 0.95) in a further group of subjects","sentence":"The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose lactulose excretion and log jejunal mucosal lactase activity by in vitro assay (R2 = 0.95) in a further group of subjects"}
{"PMID":3089818,"re_id":2,"annotated sentence":"The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose\/<e1>lactulose<\\e1> excretion and log jejunal mucosal <e2>lactase<\\e2> activity by in vitro assay (R2 = 0.95) in a further group of subjects","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"lactulose","object":"lactase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose\/<e1>CHEMICAL<\\e1> excretion and log jejunal mucosal <e2>GENE-Y<\\e2> activity by in vitro assay (R2 = 0.95) in a further group of subjects","sentence":"The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose\/lactulose excretion and log jejunal mucosal lactase activity by in vitro assay (R2 = 0.95) in a further group of subjects"}
{"PMID":3089818,"re_id":3,"annotated sentence":"Differential <e1>lactose<\\e1> lactulose\/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal <e2>lactase<\\e2> deficiency.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"lactose","object":"lactase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Differential <e1>CHEMICAL<\\e1> lactulose\/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal <e2>GENE-Y<\\e2> deficiency.","sentence":"Differential lactose lactulose\/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal lactase deficiency."}
{"PMID":3089818,"re_id":4,"annotated sentence":"Differential lactose\/<e1>lactulose<\\e1> L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal <e2>lactase<\\e2> deficiency.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"lactulose","object":"lactase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Differential lactose\/<e1>CHEMICAL<\\e1> L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal <e2>GENE-Y<\\e2> deficiency.","sentence":"Differential lactose\/lactulose L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal lactase deficiency."}
{"PMID":3089818,"re_id":5,"annotated sentence":"Differential lactose\/lactulose\/<e1>L-rhamnose<\\e1> absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal <e2>lactase<\\e2> deficiency.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-rhamnose","object":"lactase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Differential lactose\/lactulose\/<e1>CHEMICAL<\\e1> absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal <e2>GENE-Y<\\e2> deficiency.","sentence":"Differential lactose\/lactulose\/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal lactase deficiency."}
{"PMID":3134891,"re_id":25,"annotated sentence":"The irreversible complex between <e1>phenoxybenzamine<\\e1> and calmodulin may be useful for inhibiting certain <e2>calmodulin<\\e2> dependent reactions and for studying the various biological functions of calmodulin.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"phenoxybenzamine","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The irreversible complex between <e1>CHEMICAL<\\e1> and GENE-N may be useful for inhibiting certain <e2>GENE-N<\\e2> dependent reactions and for studying the various biological functions of GENE-N.","sentence":"The irreversible complex between phenoxybenzamine and calmodulin may be useful for inhibiting certain calmodulin dependent reactions and for studying the various biological functions of calmodulin."}
{"PMID":3588607,"re_id":18,"annotated sentence":"<e1>Xanthines<\\e1> are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of <e2>adenosine receptors<\\e2>  Caffeine and theophylline are virtually non-selective for A2 and A2 receptors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Xanthines","object":"adenosine receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> are classical antagonists for GENE-N for many of their pharmacological actions may be due to blockade of <e2>GENE-N<\\e2>  Caffeine and theophylline are virtually non-selective for A2 and A2 receptors","sentence":"Xanthines are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of adenosine receptors  Caffeine and theophylline are virtually non-selective for A2 and A2 receptors"}
{"PMID":3588607,"re_id":19,"annotated sentence":"<e1>Xanthines<\\e1> are classical antagonists for <e2>adenosine receptors<\\e2> for many of their pharmacological actions may be due to blockade of adenosine receptors","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Xanthines","object":"adenosine receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> are classical antagonists for <e2>GENE-N<\\e2> for many of their pharmacological actions may be due to blockade of GENE-N","sentence":"Xanthines are classical antagonists for adenosine receptors for many of their pharmacological actions may be due to blockade of adenosine receptors"}
{"PMID":3735252,"re_id":3,"annotated sentence":"Inhibition of testicular <e2>LDH-X<\\e2> from laboratory animals and man by <e1>gossypol<\\e1> and its isomers","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"gossypol","object":"LDH-X","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of testicular <e2>GENE-N<\\e2> from laboratory animals and man by <e1>CHEMICAL<\\e1> and its isomers","sentence":"Inhibition of testicular LDH-X from laboratory animals and man by gossypol and its isomers"}
{"PMID":3735252,"re_id":4,"annotated sentence":"<e1>Gossypol acetic acid<\\e1> (0-100 mumol\/l) inhibited <e2>LDH-X<\\e2> prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gossypol acetic acid","object":"LDH-X","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (0-100 mumol\/l) inhibited <e2>GENE-N<\\e2> prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster","sentence":"Gossypol acetic acid (0-100 mumol\/l) inhibited LDH-X prepared from the testes of the mouse greater than rabbit greater than human greater than rat greater than hamster"}
{"PMID":3735252,"re_id":5,"annotated sentence":"The inhibitory effect of <e1>(+)-, (-)-, (+\/-)-gossypol<\\e1> and (+\/-)-gossypol acetic acid upon testicular cytosolic <e2>LDH-X<\\e2> was measured in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"(+)-, (-)-, (+\/-)-gossypol","object":"LDH-X","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibitory effect of <e1>CHEMICAL<\\e1> and (+\/-)-gossypol acetic acid upon testicular cytosolic <e2>GENE-Y<\\e2> was measured in vitro","sentence":"The inhibitory effect of (+)-, (-)-, (+\/-)-gossypol and (+\/-)-gossypol acetic acid upon testicular cytosolic LDH-X was measured in vitro"}
{"PMID":3735252,"re_id":6,"annotated sentence":"<e1>Gossypol<\\e1> and its isomers were non-competitive inhibitors of <e2>human and hamster LDH-X<\\e2> with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Gossypol","object":"human and hamster LDH-X","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> and its isomers were non-competitive inhibitors of <e2>GENE-N<\\e2> with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate","sentence":"Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate"}
{"PMID":3735252,"re_id":7,"annotated sentence":"The inhibitory effect of (+)-, (-)-, (+\/-)-gossypol and <e1>(+\/-)-gossypol acetic acid<\\e1> upon testicular cytosolic <e2>LDH-X<\\e2> was measured in vitro","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"(+\/-)-gossypol acetic acid","object":"LDH-X","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The inhibitory effect of (+)-, (-)-, (+\/-)-gossypol and <e1>CHEMICAL<\\e1> upon testicular cytosolic <e2>GENE-Y<\\e2> was measured in vitro","sentence":"The inhibitory effect of (+)-, (-)-, (+\/-)-gossypol and (+\/-)-gossypol acetic acid upon testicular cytosolic LDH-X was measured in vitro"}
{"PMID":3735252,"re_id":8,"annotated sentence":"Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme <e1>NADH<\\e1>  competitive inhibitors of <e2>human LDH-X<\\e2> and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"NADH","object":"human LDH-X","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme <e1>CHEMICAL<\\e1>  competitive inhibitors of <e2>GENE-Y<\\e2> and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate","sentence":"Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH  competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate"}
{"PMID":3735252,"re_id":9,"annotated sentence":"Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of <e2>hamster LDH-X<\\e2> with respect to the substrate <e1>alpha-ketobutyrate<\\e1>  Co-incubation with human serum albumin or poly-L-lysine but not lysine protected human and hamster LDH-X from gossypol.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"alpha-ketobutyrate","object":"hamster LDH-X","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Gossypol and its isomers were non-competitive inhibitors of human and GENE-Y with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of <e2>GENE-Y<\\e2> with respect to the substrate <e1>CHEMICAL<\\e1>  Co-incubation with human serum albumin or poly-L-lysine but not lysine protected human and GENE-Y from gossypol.","sentence":"Gossypol and its isomers were non-competitive inhibitors of human and hamster LDH-X with respect to the coenzyme NADH, competitive inhibitors of human LDH-X and noncompetitive-competitive inhibitors of hamster LDH-X with respect to the substrate alpha-ketobutyrate  Co-incubation with human serum albumin or poly-L-lysine but not lysine protected human and hamster LDH-X from gossypol."}
{"PMID":3917545,"re_id":0,"annotated sentence":"Most reducing cofactors for the peroxidase protect <e2>PHS<\\e2> and prostacyclin synthase from inactivation by <e1>hydroperoxides<\\e1>  PB, however, does not protect these enzymes, but rather augments their hydroperoxide-dependent inactivation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"hydroperoxides","object":"PHS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Most reducing cofactors for the peroxidase protect <e2>GENE-N<\\e2> and prostacyclin synthase from inactivation by <e1>CHEMICAL<\\e1>  PB, however, does not protect these enzymes, but rather augments their hydroperoxide-dependent inactivation","sentence":"Most reducing cofactors for the peroxidase protect PHS and prostacyclin synthase from inactivation by hydroperoxides  PB, however, does not protect these enzymes, but rather augments their hydroperoxide-dependent inactivation"}
{"PMID":3917545,"re_id":1,"annotated sentence":"Most reducing cofactors for the peroxidase protect PHS and <e2>prostacyclin synthase<\\e2> from inactivation by <e1>hydroperoxides<\\e1>  PB, however, does not protect these enzymes, but rather augments their hydroperoxide-dependent inactivation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"hydroperoxides","object":"prostacyclin synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Most reducing cofactors for the peroxidase protect PHS and <e2>GENE-Y<\\e2> from inactivation by <e1>CHEMICAL<\\e1>  PB, however, does not protect these enzymes, but rather augments their hydroperoxide-dependent inactivation","sentence":"Most reducing cofactors for the peroxidase protect PHS and prostacyclin synthase from inactivation by hydroperoxides  PB, however, does not protect these enzymes, but rather augments their hydroperoxide-dependent inactivation"}
{"PMID":3917545,"re_id":2,"annotated sentence":"Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of <e2>PHS<\\e2> is markedly increased in the presence of 100 microM <e1>H2O2<\\e1>  This inactivation is a linear function of PB concentration between 10 and 250 microM, with a half-maximal effect in this range at about 100 microM PB","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"H2O2","object":"PHS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of <e2>GENE-N<\\e2> is markedly increased in the presence of 100 microM <e1>CHEMICAL<\\e1>  This inactivation is a linear function of PB concentration between 10 and 250 microM, with a half-maximal effect in this range at about 100 microM PB","sentence":"Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of PHS is markedly increased in the presence of 100 microM H2O2  This inactivation is a linear function of PB concentration between 10 and 250 microM, with a half-maximal effect in this range at about 100 microM PB"}
{"PMID":3917545,"re_id":3,"annotated sentence":"Inactivation of <e2>prostaglandin H synthase<\\e2> and prostacyclin synthase by <e1>phenylbutazone<\\e1>  Requirement for peroxidative metabolism","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"phenylbutazone","object":"prostaglandin H synthase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inactivation of <e2>GENE-N<\\e2> and prostacyclin synthase by <e1>CHEMICAL<\\e1>  Requirement for peroxidative metabolism","sentence":"Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone  Requirement for peroxidative metabolism"}
{"PMID":3917545,"re_id":4,"annotated sentence":"Inactivation of prostaglandin H synthase and <e2>prostacyclin synthase<\\e2> by <e1>phenylbutazone<\\e1>  Requirement for peroxidative metabolism","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"phenylbutazone","object":"prostacyclin synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inactivation of prostaglandin H synthase and <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1>  Requirement for peroxidative metabolism","sentence":"Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone  Requirement for peroxidative metabolism"}
{"PMID":3917545,"re_id":10,"annotated sentence":"Chromatographic analysis of the metabolism of <e1>14C-labeled arachidonic acid<\\e1> in this system revealed that PB-dependent inactivation of <e2>PHS<\\e2> is markedly increased in the presence of 100 microM H2O2","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"14C-labeled arachidonic acid","object":"PHS","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Chromatographic analysis of the metabolism of <e1>CHEMICAL<\\e1> in this system revealed that PB-dependent inactivation of <e2>GENE-N<\\e2> is markedly increased in the presence of 100 microM H2O2","sentence":"Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of PHS is markedly increased in the presence of 100 microM H2O2"}
{"PMID":6150080,"re_id":3,"annotated sentence":"In plasma membranes prepared from these isolated brown fat cells by <e1>borate<\\e1> extraction there was a similar enrichment of activity of <e2>SSAO<\\e2> and of the plasma membrane marker enzyme, phosphodiesterase I","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"borate","object":"SSAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In plasma membranes prepared from these isolated brown fat cells by <e1>CHEMICAL<\\e1> extraction there was a similar enrichment of activity of <e2>GENE-Y<\\e2> and of the plasma membrane marker enzyme, phosphodiesterase I","sentence":"In plasma membranes prepared from these isolated brown fat cells by borate extraction there was a similar enrichment of activity of SSAO and of the plasma membrane marker enzyme, phosphodiesterase I"}
{"PMID":6150080,"re_id":4,"annotated sentence":"Staining was largely absent when substrate was omitted or after pretreatment with the irreversible <e2>SSAO<\\e2> inhibitor, <e1>hydralazine<\\e1> and the slowly reversible inhibitor, semicarbazide","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"hydralazine","object":"SSAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Staining was largely absent when substrate was omitted or after pretreatment with the irreversible <e2>GENE-Y<\\e2> inhibitor, <e1>CHEMICAL<\\e1> and the slowly reversible inhibitor, semicarbazide","sentence":"Staining was largely absent when substrate was omitted or after pretreatment with the irreversible SSAO inhibitor, hydralazine and the slowly reversible inhibitor, semicarbazide"}
{"PMID":6150080,"re_id":5,"annotated sentence":"Staining was largely absent when substrate was omitted or after pretreatment with the irreversible <e2>SSAO<\\e2> inhibitor, hydralazine and the slowly reversible inhibitor, <e1>semicarbazide<\\e1>  It is not definitely proven that this staining represents sites of enzyme activity but the results are consistent with evidence from other studies indicating that SSAO in brown adipose tissue of the rat may be found predominantly at the fat cell surface.(ABSTRACT TRUNCATED AT 250 WORDS)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"semicarbazide","object":"SSAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Staining was largely absent when substrate was omitted or after pretreatment with the irreversible <e2>GENE-Y<\\e2> inhibitor, hydralazine and the slowly reversible inhibitor, <e1>CHEMICAL<\\e1>  It is not definitely proven that this staining represents sites of enzyme activity but the results are consistent with evidence from other studies indicating that GENE-Y in brown adipose tissue of the rat may be found predominantly at the fat cell surface.(ABSTRACT TRUNCATED AT 250 WORDS)","sentence":"Staining was largely absent when substrate was omitted or after pretreatment with the irreversible SSAO inhibitor, hydralazine and the slowly reversible inhibitor, semicarbazide  It is not definitely proven that this staining represents sites of enzyme activity but the results are consistent with evidence from other studies indicating that SSAO in brown adipose tissue of the rat may be found predominantly at the fat cell surface.(ABSTRACT TRUNCATED AT 250 WORDS)"}
{"PMID":6150080,"re_id":6,"annotated sentence":"Positive staining of mitochondria was achieved in the presence of the <e2>MAO<\\e2> substrate, <e1>tryptamine<\\e1>  Staining around the edges of the brown fat cells was observed with the SSAO substrates, tyramine and benzylamine","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"tryptamine","object":"MAO","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Positive staining of mitochondria was achieved in the presence of the <e2>GENE-N<\\e2> substrate, <e1>CHEMICAL<\\e1>  Staining around the edges of the brown fat cells was observed with the SSAO substrates, tyramine and benzylamine","sentence":"Positive staining of mitochondria was achieved in the presence of the MAO substrate, tryptamine  Staining around the edges of the brown fat cells was observed with the SSAO substrates, tyramine and benzylamine"}
{"PMID":6150080,"re_id":7,"annotated sentence":"Staining around the edges of the brown fat cells was observed with the <e2>SSAO<\\e2> substrates, <e1>tyramine<\\e1> and benzylamine","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"tyramine","object":"SSAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Staining around the edges of the brown fat cells was observed with the <e2>GENE-Y<\\e2> substrates, <e1>CHEMICAL<\\e1> and benzylamine","sentence":"Staining around the edges of the brown fat cells was observed with the SSAO substrates, tyramine and benzylamine"}
{"PMID":6150080,"re_id":8,"annotated sentence":"Staining around the edges of the brown fat cells was observed with the <e2>SSAO<\\e2> substrates, tyramine and <e1>benzylamine<\\e1>  Staining was largely absent when substrate was omitted or after pretreatment with the irreversible SSAO inhibitor, hydralazine and the slowly reversible inhibitor, semicarbazide","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"benzylamine","object":"SSAO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Staining around the edges of the brown fat cells was observed with the <e2>GENE-Y<\\e2> substrates, tyramine and <e1>CHEMICAL<\\e1>  Staining was largely absent when substrate was omitted or after pretreatment with the irreversible GENE-Y inhibitor, hydralazine and the slowly reversible inhibitor, semicarbazide","sentence":"Staining around the edges of the brown fat cells was observed with the SSAO substrates, tyramine and benzylamine  Staining was largely absent when substrate was omitted or after pretreatment with the irreversible SSAO inhibitor, hydralazine and the slowly reversible inhibitor, semicarbazide"}
{"PMID":6311012,"re_id":7,"annotated sentence":"This agent acts synergistically with many <e1>penicillins<\\e1>  such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan<\\e2> of the bacterial cell wall","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"penicillins","object":"peptidoglycan","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This agent acts synergistically with many <e1>CHEMICAL<\\e1>  such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>GENE-N<\\e2> of the bacterial cell wall","sentence":"This agent acts synergistically with many penicillins  such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the peptidoglycan of the bacterial cell wall"}
{"PMID":6311012,"re_id":8,"annotated sentence":"This agent acts synergistically with many penicillins, such as <e1>ampicillin<\\e1>  carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan<\\e2> of the bacterial cell wall","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ampicillin","object":"peptidoglycan","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This agent acts synergistically with many penicillins, such as <e1>CHEMICAL<\\e1>  carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>GENE-N<\\e2> of the bacterial cell wall","sentence":"This agent acts synergistically with many penicillins, such as ampicillin  carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the peptidoglycan of the bacterial cell wall"}
{"PMID":6311012,"re_id":9,"annotated sentence":"This agent acts synergistically with many penicillins, such as ampicillin, <e1>carbenicillin<\\e1>  and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan<\\e2> of the bacterial cell wall","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"carbenicillin","object":"peptidoglycan","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This agent acts synergistically with many penicillins, such as ampicillin, <e1>CHEMICAL<\\e1>  and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>GENE-N<\\e2> of the bacterial cell wall","sentence":"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin  and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the peptidoglycan of the bacterial cell wall"}
{"PMID":6311012,"re_id":10,"annotated sentence":"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with <e1>cephalosporins<\\e1>  cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan<\\e2> of the bacterial cell wall","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"cephalosporins","object":"peptidoglycan","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with <e1>CHEMICAL<\\e1>  cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>GENE-N<\\e2> of the bacterial cell wall","sentence":"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins  cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the peptidoglycan of the bacterial cell wall"}
{"PMID":6311012,"re_id":11,"annotated sentence":"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, <e1>cefazolin<\\e1>  cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan<\\e2> of the bacterial cell wall","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"cefazolin","object":"peptidoglycan","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, <e1>CHEMICAL<\\e1>  cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>GENE-N<\\e2> of the bacterial cell wall","sentence":"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin  cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the peptidoglycan of the bacterial cell wall"}
{"PMID":6311012,"re_id":12,"annotated sentence":"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, <e1>cefamandole<\\e1>  or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan<\\e2> of the bacterial cell wall","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"cefamandole","object":"peptidoglycan","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, <e1>CHEMICAL<\\e1>  or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>GENE-N<\\e2> of the bacterial cell wall","sentence":"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole  or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the peptidoglycan of the bacterial cell wall"}
{"PMID":6311012,"re_id":13,"annotated sentence":"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or <e1>cefoxitin<\\e1> to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>peptidoglycan<\\e2> of the bacterial cell wall","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"cefoxitin","object":"peptidoglycan","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or <e1>CHEMICAL<\\e1> to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the <e2>GENE-N<\\e2> of the bacterial cell wall","sentence":"This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the peptidoglycan of the bacterial cell wall"}
{"PMID":6319437,"re_id":26,"annotated sentence":"Since both <e1>TFP<\\e1> and W-7 are potent inhibitors of <e2>calmodulin<\\e2>  we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TFP","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Since both <e1>CHEMICAL<\\e1> and W-7 are potent inhibitors of <e2>GENE-N<\\e2>  we investigated the possibility that inhibition of GENE-N was responsible for the loss of receptors","sentence":"Since both TFP and W-7 are potent inhibitors of calmodulin  we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors"}
{"PMID":6319437,"re_id":27,"annotated sentence":"Since both TFP and <e1>W-7<\\e1> are potent inhibitors of <e2>calmodulin<\\e2>  we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"W-7","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Since both TFP and <e1>CHEMICAL<\\e1> are potent inhibitors of <e2>GENE-N<\\e2>  we investigated the possibility that inhibition of GENE-N was responsible for the loss of receptors","sentence":"Since both TFP and W-7 are potent inhibitors of calmodulin  we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors"}
{"PMID":6319437,"re_id":28,"annotated sentence":"Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) <e1>Promethazine<\\e1>  a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several <e2>calmodulin<\\e2> functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg\/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Promethazine","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Three lines of evidence suggest that GENE-N inhibition is not responsible for the inhibition of binding and endocytosis: 1) <e1>CHEMICAL<\\e1>  a phenothiazine that is a poor inhibitor of GENE-N, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several <e2>GENE-N<\\e2> functions, did not cause a loss of binding; 2) the microinjection of GENE-N into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of GENE-N over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a GENE-N-binding protein, into cells (1-3 pg\/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin","sentence":"Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine  a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg\/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin"}
{"PMID":6319437,"re_id":29,"annotated sentence":"Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a <e1>phenothiazine<\\e1> that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several <e2>calmodulin<\\e2> functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg\/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"phenothiazine","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Three lines of evidence suggest that GENE-N inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a <e1>CHEMICAL<\\e1> that is a poor inhibitor of GENE-N, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several <e2>GENE-N<\\e2> functions, did not cause a loss of binding; 2) the microinjection of GENE-N into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of GENE-N over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a GENE-N-binding protein, into cells (1-3 pg\/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin","sentence":"Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg\/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin"}
{"PMID":6319437,"re_id":30,"annotated sentence":"Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as <e1>TFP<\\e1> at inhibiting endocytosis; calmidazolium, a potent inhibitor of several <e2>calmodulin<\\e2> functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg\/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"TFP","object":"calmodulin","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Three lines of evidence suggest that GENE-N inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of GENE-N, is nearly as effective as <e1>CHEMICAL<\\e1> at inhibiting endocytosis; calmidazolium, a potent inhibitor of several <e2>GENE-N<\\e2> functions, did not cause a loss of binding; 2) the microinjection of GENE-N into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of GENE-N over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a GENE-N-binding protein, into cells (1-3 pg\/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin","sentence":"Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg\/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin"}
{"PMID":6621777,"re_id":1,"annotated sentence":"From these results, it is proposed that <e2>tyrosine hydroxylase<\\e2> activity determines p-HPAA concentrations by regulating <e1>p-tyrosine<\\e1> availability","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"p-tyrosine","object":"tyrosine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"From these results, it is proposed that <e2>GENE-Y<\\e2> activity determines p-HPAA concentrations by regulating <e1>CHEMICAL<\\e1> availability","sentence":"From these results, it is proposed that tyrosine hydroxylase activity determines p-HPAA concentrations by regulating p-tyrosine availability"}
{"PMID":6701456,"re_id":0,"annotated sentence":"The binding of <e2>FHA<\\e2> HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists <e1>diphenhydramine<\\e1> and clemastine","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diphenhydramine","object":"FHA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The binding of <e2>GENE-Y<\\e2> HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists <e1>CHEMICAL<\\e1> and clemastine","sentence":"The binding of FHA HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and clemastine"}
{"PMID":6701456,"re_id":1,"annotated sentence":"The binding of <e2>FHA<\\e2> HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and <e1>clemastine<\\e1>  The histamine H2 receptor antagonist cimetidine blocked the FHA-HIS binding on 14-37% of the platelets","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"clemastine","object":"FHA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The binding of <e2>GENE-Y<\\e2> HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and <e1>CHEMICAL<\\e1>  The histamine H2 receptor antagonist cimetidine blocked the GENE-Y-HIS binding on 14-37% of the platelets","sentence":"The binding of FHA HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and clemastine  The histamine H2 receptor antagonist cimetidine blocked the FHA-HIS binding on 14-37% of the platelets"}
{"PMID":6701456,"re_id":2,"annotated sentence":"The histamine H2 receptor antagonist <e1>cimetidine<\\e1> blocked the <e2>FHA<\\e2> HIS binding on 14-37% of the platelets","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cimetidine","object":"FHA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The histamine H2 receptor antagonist <e1>CHEMICAL<\\e1> blocked the <e2>GENE-Y<\\e2> HIS binding on 14-37% of the platelets","sentence":"The histamine H2 receptor antagonist cimetidine blocked the FHA HIS binding on 14-37% of the platelets"}
{"PMID":6701456,"re_id":3,"annotated sentence":"The binding of FHA-HIS was inhibited on 35-79% of the platelets by the <e2>histamine H1 receptor<\\e2> antagonists <e1>diphenhydramine<\\e1> and clemastine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"diphenhydramine","object":"histamine H1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The binding of FHA-HIS was inhibited on 35-79% of the platelets by the <e2>GENE-Y<\\e2> antagonists <e1>CHEMICAL<\\e1> and clemastine","sentence":"The binding of FHA-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and clemastine"}
{"PMID":6701456,"re_id":4,"annotated sentence":"The binding of FHA-HIS was inhibited on 35-79% of the platelets by the <e2>histamine H1 receptor<\\e2> antagonists diphenhydramine and <e1>clemastine<\\e1>  The histamine H2 receptor antagonist cimetidine blocked the FHA-HIS binding on 14-37% of the platelets","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"clemastine","object":"histamine H1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The binding of FHA-HIS was inhibited on 35-79% of the platelets by the <e2>GENE-Y<\\e2> antagonists diphenhydramine and <e1>CHEMICAL<\\e1>  The histamine H2 receptor antagonist cimetidine blocked the FHA-HIS binding on 14-37% of the platelets","sentence":"The binding of FHA-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and clemastine  The histamine H2 receptor antagonist cimetidine blocked the FHA-HIS binding on 14-37% of the platelets"}
{"PMID":6701456,"re_id":5,"annotated sentence":"The <e2>histamine H2 receptor<\\e2> antagonist <e1>cimetidine<\\e1> blocked the FHA-HIS binding on 14-37% of the platelets","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"cimetidine","object":"histamine H2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> blocked the FHA-HIS binding on 14-37% of the platelets","sentence":"The histamine H2 receptor antagonist cimetidine blocked the FHA-HIS binding on 14-37% of the platelets"}
{"PMID":6703688,"re_id":0,"annotated sentence":"<e2>Alanine:glyoxylate aminotransferase<\\e2> (AGT) in the liver catalyzes most of the <e1>glyoxylate<\\e1> transamination in mammalian tissues (E","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glyoxylate","object":"Alanine:glyoxylate aminotransferase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>Alanine:CHEMICAL aminotransferase<\\e2> (AGT) in the liver catalyzes most of the <e1>CHEMICAL<\\e1> transamination in mammalian tissues (E","sentence":"Alanine:glyoxylate aminotransferase (AGT) in the liver catalyzes most of the glyoxylate transamination in mammalian tissues (E"}
{"PMID":6703688,"re_id":1,"annotated sentence":"Alanine:glyoxylate aminotransferase (<e2>AGT<\\e2>  in the liver catalyzes most of the <e1>glyoxylate<\\e1> transamination in mammalian tissues (E","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glyoxylate","object":"AGT","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Alanine:CHEMICAL aminotransferase (<e2>GENE-N<\\e2>  in the liver catalyzes most of the <e1>CHEMICAL<\\e1> transamination in mammalian tissues (E","sentence":"Alanine:glyoxylate aminotransferase (AGT  in the liver catalyzes most of the glyoxylate transamination in mammalian tissues (E"}
{"PMID":6703688,"re_id":2,"annotated sentence":"The holo activity of combined peroxisomal and mitochondrial <e2>AGT 1<\\e2> with a low Km for <e1>L-alanine<\\e1> rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-alanine","object":"AGT 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The holo activity of combined peroxisomal and mitochondrial <e2>GENE-Y<\\e2> with a low Km for <e1>CHEMICAL<\\e1> rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days)","sentence":"The holo activity of combined peroxisomal and mitochondrial AGT 1 with a low Km for L-alanine rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days)"}
{"PMID":6703688,"re_id":3,"annotated sentence":"The holo activity of AGT 2 with a high Km for <e1>L-alanine<\\e1> decreased more slowly than <e2>AGT 1<\\e2> (by 33% in 14 days, by 60% in 28 days)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-alanine","object":"AGT 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The holo activity of AGT 2 with a high Km for <e1>CHEMICAL<\\e1> decreased more slowly than <e2>GENE-Y<\\e2> (by 33% in 14 days, by 60% in 28 days)","sentence":"The holo activity of AGT 2 with a high Km for L-alanine decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days)"}
{"PMID":6703688,"re_id":4,"annotated sentence":"The holo activity of <e2>AGT 2<\\e2> with a high Km for <e1>L-alanine<\\e1> decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days)","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-alanine","object":"AGT 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The holo activity of <e2>GENE-Y<\\e2> with a high Km for <e1>CHEMICAL<\\e1> decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days)","sentence":"The holo activity of AGT 2 with a high Km for L-alanine decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days)"}
{"PMID":7560228,"re_id":0,"annotated sentence":"<e1>Triclosan<\\e1> inhibited both <e2>cyclooxygenase 1<\\e2> and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Triclosan","object":"cyclooxygenase 1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited both <e2>GENE-Y<\\e2> and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively","sentence":"Triclosan inhibited both cyclooxygenase 1 and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively"}
{"PMID":7560228,"re_id":1,"annotated sentence":"<e1>Triclosan<\\e1> inhibited both cyclooxygenase 1 and <e2>cyclo-oxygenase 2<\\e2> with IC-50 values of 43 microM and 227 microM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Triclosan","object":"cyclo-oxygenase 2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited both cyclooxygenase 1 and <e2>GENE-Y<\\e2> with IC-50 values of 43 microM and 227 microM, respectively","sentence":"Triclosan inhibited both cyclooxygenase 1 and cyclo-oxygenase 2 with IC-50 values of 43 microM and 227 microM, respectively"}
{"PMID":7560228,"re_id":2,"annotated sentence":"<e1>Triclosan<\\e1> also inhibited <e2>5-lipoxygenase<\\e2> with an IC-50 of 43 microM","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Triclosan","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> also inhibited <e2>GENE-Y<\\e2> with an IC-50 of 43 microM","sentence":"Triclosan also inhibited 5-lipoxygenase with an IC-50 of 43 microM"}
{"PMID":7560228,"re_id":3,"annotated sentence":"The <e2>15-lipoxygenase<\\e2> was similarly inhibited by <e1>triclosan<\\e1> with an IC-50 of 61 microM","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"triclosan","object":"15-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The <e2>GENE-Y<\\e2> was similarly inhibited by <e1>CHEMICAL<\\e1> with an IC-50 of 61 microM","sentence":"The 15-lipoxygenase was similarly inhibited by triclosan with an IC-50 of 61 microM"}
{"PMID":7560228,"re_id":4,"annotated sentence":"Hence, <e1>triclosan<\\e1> has the ability to inhibit both the <e2>cyclo-oxygenase<\\e2> and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"triclosan","object":"cyclo-oxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Hence, <e1>CHEMICAL<\\e1> has the ability to inhibit both the <e2>GENE-N<\\e2> and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy","sentence":"Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy"}
{"PMID":7560228,"re_id":5,"annotated sentence":"Hence, <e1>triclosan<\\e1> has the ability to inhibit both the cyclo-oxygenase and <e2>lipoxygenase<\\e2> pathways of arachidonic acid metabolism with similar efficacy","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"triclosan","object":"lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Hence, <e1>CHEMICAL<\\e1> has the ability to inhibit both the cyclo-oxygenase and <e2>GENE-N<\\e2> pathways of arachidonic acid metabolism with similar efficacy","sentence":"Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy"}
{"PMID":7560228,"re_id":6,"annotated sentence":"In cell culture experiments, it was found that <e1>triclosan<\\e1> inhibited <e2>IL-1 beta<\\e2> induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"triclosan","object":"IL-1 beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In cell culture experiments, it was found that <e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations","sentence":"In cell culture experiments, it was found that triclosan inhibited IL-1 beta induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations"}
{"PMID":7560228,"re_id":7,"annotated sentence":"In cell culture experiments, it was found that triclosan inhibited <e2>IL-1 beta<\\e2> induced <e1>prostaglandin E2<\\e1> production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin E2","object":"IL-1 beta","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In cell culture experiments, it was found that triclosan inhibited <e2>GENE-Y<\\e2> induced <e1>CHEMICAL<\\e1> production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations","sentence":"In cell culture experiments, it was found that triclosan inhibited IL-1 beta induced prostaglandin E2 production by human gingival fibroblasts in a concentration dependent manner, and at relatively low concentrations"}
{"PMID":7560228,"re_id":8,"annotated sentence":"Hence, triclosan has the ability to inhibit both the <e2>cyclo-oxygenase<\\e2> and lipoxygenase pathways of <e1>arachidonic acid<\\e1> metabolism with similar efficacy","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"arachidonic acid","object":"cyclo-oxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Hence, triclosan has the ability to inhibit both the <e2>GENE-N<\\e2> and lipoxygenase pathways of <e1>CHEMICAL<\\e1> metabolism with similar efficacy","sentence":"Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy"}
{"PMID":7560228,"re_id":9,"annotated sentence":"Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and <e2>lipoxygenase<\\e2> pathways of <e1>arachidonic acid<\\e1> metabolism with similar efficacy","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"arachidonic acid","object":"lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and <e2>GENE-N<\\e2> pathways of <e1>CHEMICAL<\\e1> metabolism with similar efficacy","sentence":"Hence, triclosan has the ability to inhibit both the cyclo-oxygenase and lipoxygenase pathways of arachidonic acid metabolism with similar efficacy"}
{"PMID":7599160,"re_id":10,"annotated sentence":"Cells propagated in medium containing <e1>N5-methyltetrahydrofolate<\\e1> and homocysteine showed a substantial increase in <e2>MS<\\e2> activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"N5-methyltetrahydrofolate","object":"MS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cells propagated in medium containing <e1>CHEMICAL<\\e1> and homocysteine showed a substantial increase in <e2>GENE-Y<\\e2> activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.","sentence":"Cells propagated in medium containing N5-methyltetrahydrofolate and homocysteine showed a substantial increase in MS activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme."}
{"PMID":7599160,"re_id":11,"annotated sentence":"Cells propagated in medium containing N5-methyltetrahydrofolate and <e1>homocysteine<\\e1> showed a substantial increase in <e2>MS<\\e2> activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"homocysteine","object":"MS","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Cells propagated in medium containing N5-methyltetrahydrofolate and <e1>CHEMICAL<\\e1> showed a substantial increase in <e2>GENE-Y<\\e2> activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme.","sentence":"Cells propagated in medium containing N5-methyltetrahydrofolate and homocysteine showed a substantial increase in MS activity which paralleled the increase in the intracellular concentration of Me-Cbl and the Cbl bound to the enzyme."}
{"PMID":7665369,"re_id":7,"annotated sentence":"<e1>Ergovaline<\\e1> binding and activation of <e2>D2 dopamine receptors<\\e2> in GH4ZR7 cells","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Ergovaline","object":"D2 dopamine receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> binding and activation of <e2>GENE-Y<\\e2> in GH4ZR7 cells","sentence":"Ergovaline binding and activation of D2 dopamine receptors in GH4ZR7 cells"}
{"PMID":7665369,"re_id":8,"annotated sentence":"These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several <e1>ergot alkaloids<\\e1> including ergovaline, may be due to <e2>D2 dopamine receptor<\\e2> activation.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ergot alkaloids","object":"D2 dopamine receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several <e1>CHEMICAL<\\e1> including ergovaline, may be due to <e2>GENE-Y<\\e2> activation.","sentence":"These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several ergot alkaloids including ergovaline, may be due to D2 dopamine receptor activation."}
{"PMID":7665369,"re_id":9,"annotated sentence":"These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several ergot alkaloids including <e1>ergovaline<\\e1>  may be due to <e2>D2 dopamine receptor<\\e2> activation.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"ergovaline","object":"D2 dopamine receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several ergot alkaloids including <e1>CHEMICAL<\\e1>  may be due to <e2>GENE-Y<\\e2> activation.","sentence":"These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several ergot alkaloids including ergovaline  may be due to D2 dopamine receptor activation."}
{"PMID":7665369,"re_id":10,"annotated sentence":"<e1>Ergot alkaloids<\\e1> were also effective in inhibiting <e2>VIP<\\e2> stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Ergot alkaloids","object":"VIP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> were also effective in inhibiting <e2>GENE-Y<\\e2> stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","sentence":"Ergot alkaloids were also effective in inhibiting VIP stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively"}
{"PMID":7665369,"re_id":11,"annotated sentence":"Ergot alkaloids were also effective in inhibiting <e2>VIP<\\e2> stimulated cyclic AMP production, with EC50 values for <e1>ergovaline<\\e1>  ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ergovaline","object":"VIP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ergot alkaloids were also effective in inhibiting <e2>GENE-Y<\\e2> stimulated cyclic AMP production, with EC50 values for <e1>CHEMICAL<\\e1>  ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","sentence":"Ergot alkaloids were also effective in inhibiting VIP stimulated cyclic AMP production, with EC50 values for ergovaline  ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively"}
{"PMID":7665369,"re_id":12,"annotated sentence":"Ergot alkaloids were also effective in inhibiting <e2>VIP<\\e2> stimulated cyclic AMP production, with EC50 values for ergovaline, <e1>ergonovine<\\e1>  alpha-ergocryptine, ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ergonovine","object":"VIP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ergot alkaloids were also effective in inhibiting <e2>GENE-Y<\\e2> stimulated cyclic AMP production, with EC50 values for ergovaline, <e1>CHEMICAL<\\e1>  alpha-ergocryptine, ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","sentence":"Ergot alkaloids were also effective in inhibiting VIP stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine  alpha-ergocryptine, ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively"}
{"PMID":7665369,"re_id":13,"annotated sentence":"Ergot alkaloids were also effective in inhibiting <e2>VIP<\\e2> stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, <e1>alpha-ergocryptine<\\e1>  ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"alpha-ergocryptine","object":"VIP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ergot alkaloids were also effective in inhibiting <e2>GENE-Y<\\e2> stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, <e1>CHEMICAL<\\e1>  ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","sentence":"Ergot alkaloids were also effective in inhibiting VIP stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine  ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively"}
{"PMID":7665369,"re_id":14,"annotated sentence":"Ergot alkaloids were also effective in inhibiting <e2>VIP<\\e2> stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, <e1>ergotamine<\\e1>  and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ergotamine","object":"VIP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ergot alkaloids were also effective in inhibiting <e2>GENE-Y<\\e2> stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, <e1>CHEMICAL<\\e1>  and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","sentence":"Ergot alkaloids were also effective in inhibiting VIP stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine  and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively"}
{"PMID":7665369,"re_id":15,"annotated sentence":"Ergot alkaloids were also effective in inhibiting <e2>VIP<\\e2> stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and <e1>dopamine<\\e1> of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dopamine","object":"VIP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ergot alkaloids were also effective in inhibiting <e2>GENE-Y<\\e2> stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and <e1>CHEMICAL<\\e1> of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","sentence":"Ergot alkaloids were also effective in inhibiting VIP stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively"}
{"PMID":7665369,"re_id":16,"annotated sentence":"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and <e1>ergot alkaloid<\\e1> inhibition of <e2>vasoactive intestinal peptide<\\e2> (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ergot alkaloid","object":"vasoactive intestinal peptide","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and <e1>CHEMICAL<\\e1> inhibition of <e2>GENE-Y<\\e2> (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated","sentence":"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated"}
{"PMID":7665369,"re_id":17,"annotated sentence":"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and <e1>ergot alkaloid<\\e1> inhibition of vasoactive intestinal peptide (<e2>VIP<\\e2> -stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"ergot alkaloid","object":"VIP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and <e1>CHEMICAL<\\e1> inhibition of vasoactive intestinal peptide (<e2>GENE-Y<\\e2> -stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated","sentence":"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP -stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated"}
{"PMID":7665369,"re_id":18,"annotated sentence":"Inhibition of cyclic AMP production by ergovaline was blocked by the <e2>dopamine receptor<\\e2> antagonist, <e1>(-)-sulpiride<\\e1> (IC50, 300 +\/- 150 nM)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"(-)-sulpiride","object":"dopamine receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of cyclic AMP production by ergovaline was blocked by the <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1> (IC50, 300 +\/- 150 nM)","sentence":"Inhibition of cyclic AMP production by ergovaline was blocked by the dopamine receptor antagonist, (-)-sulpiride (IC50, 300 +\/- 150 nM)"}
{"PMID":7665369,"re_id":19,"annotated sentence":"Ergot alkaloids were also effective in inhibiting <e2>VIP<\\e2> stimulated <e1>cyclic AMP<\\e1> production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"cyclic AMP","object":"VIP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ergot alkaloids were also effective in inhibiting <e2>GENE-Y<\\e2> stimulated <e1>CHEMICAL<\\e1> production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively","sentence":"Ergot alkaloids were also effective in inhibiting VIP stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +\/- 2, 47 +\/- 2, 28 +\/- 2, 2 +\/- 1, and 8 +\/- 1 nM, respectively"}
{"PMID":7665369,"re_id":20,"annotated sentence":"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of <e2>vasoactive intestinal peptide<\\e2> (VIP)-stimulated <e1>cyclic AMP<\\e1> production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"cyclic AMP","object":"vasoactive intestinal peptide","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of <e2>GENE-Y<\\e2> (VIP)-stimulated <e1>CHEMICAL<\\e1> production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated","sentence":"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated"}
{"PMID":7665369,"re_id":21,"annotated sentence":"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (<e2>VIP<\\e2> -stimulated <e1>cyclic AMP<\\e1> production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"cyclic AMP","object":"VIP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (<e2>GENE-Y<\\e2> -stimulated <e1>CHEMICAL<\\e1> production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated","sentence":"Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP -stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated"}
{"PMID":7773533,"re_id":6,"annotated sentence":"Incubation of rat aortic membranes with the irreversible <e2>alpha 1B-adrenoceptor<\\e2> antagonist, <e1>chloroethylclonidine<\\e1> (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"chloroethylclonidine","object":"alpha 1B-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Incubation of rat aortic membranes with the irreversible <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1> (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax)","sentence":"Incubation of rat aortic membranes with the irreversible alpha 1B-adrenoceptor antagonist, chloroethylclonidine (CEC: 10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax)"}
{"PMID":7773533,"re_id":7,"annotated sentence":"Incubation of rat aortic membranes with the irreversible <e2>alpha 1B-adrenoceptor<\\e2> antagonist, chloroethylclonidine (<e1>CEC<\\e1>  10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"CEC","object":"alpha 1B-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Incubation of rat aortic membranes with the irreversible <e2>GENE-Y<\\e2> antagonist, chloroethylclonidine (<e1>CHEMICAL<\\e1>  10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax)","sentence":"Incubation of rat aortic membranes with the irreversible alpha 1B-adrenoceptor antagonist, chloroethylclonidine (CEC  10 microM) did not change the KD of [3H]-prazosin binding in comparison to untreated membranes, but reduced by 88% the total number of binding sites (Bmax)"}
{"PMID":7816863,"re_id":2,"annotated sentence":"Moreover, <e1>clenbuterol HCl<\\e1> (0.1-0.5 mg\/kg, IP), a lipophilic <e2>beta 2-adrenoceptor<\\e2> agonist, significantly increased the duration of basal aggressive behavior","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"clenbuterol HCl","object":"beta 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Moreover, <e1>CHEMICAL<\\e1> (0.1-0.5 mg\/kg, IP), a lipophilic <e2>GENE-Y<\\e2> agonist, significantly increased the duration of basal aggressive behavior","sentence":"Moreover, clenbuterol HCl (0.1-0.5 mg\/kg, IP), a lipophilic beta 2-adrenoceptor agonist, significantly increased the duration of basal aggressive behavior"}
{"PMID":7816863,"re_id":3,"annotated sentence":"Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by <e1>yohimbine<\\e1>  an <e2>alpha 2-adrenoceptor<\\e2> antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"yohimbine","object":"alpha 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by <e1>CHEMICAL<\\e1>  an <e2>GENE-N<\\e2> antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.","sentence":"Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by yohimbine  an alpha 2-adrenoceptor antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice."}
{"PMID":7816863,"re_id":4,"annotated sentence":"Intraperitoneal administration of <e1>(+\/- )propranolol HCl<\\e1> (2.5-10 mg\/kg), a nonselective <e2>beta-adrenoceptor<\\e2> antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"(+\/- )propranolol HCl","object":"beta-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Intraperitoneal administration of <e1>CHEMICAL<\\e1> (2.5-10 mg\/kg), a nonselective <e2>GENE-N<\\e2> antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses","sentence":"Intraperitoneal administration of (+\/- )propranolol HCl (2.5-10 mg\/kg), a nonselective beta-adrenoceptor antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses"}
{"PMID":7816863,"re_id":5,"annotated sentence":"<e1>ICI118,551 HCl<\\e1> (1.25-5 mg\/kg, IP), a selective <e2>beta 2-adrenoceptor<\\e2> antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg\/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"ICI118,551 HCl","object":"beta 2-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (1.25-5 mg\/kg, IP), a selective <e2>GENE-Y<\\e2> antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg\/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it","sentence":"ICI118,551 HCl (1.25-5 mg\/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg\/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it"}
{"PMID":7816863,"re_id":6,"annotated sentence":"ICI118,551 HCl (1.25-5 mg\/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas <e1>metoprolol tartrate<\\e1> (5-20 mg\/kg, IP), a selective <e2>beta 1-adrenoceptor<\\e2> antagonist, did not affect it","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"metoprolol tartrate","object":"beta 1-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"ICI118,551 HCl (1.25-5 mg\/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas <e1>CHEMICAL<\\e1> (5-20 mg\/kg, IP), a selective <e2>GENE-Y<\\e2> antagonist, did not affect it","sentence":"ICI118,551 HCl (1.25-5 mg\/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg\/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it"}
{"PMID":7875228,"re_id":0,"annotated sentence":"Furthermore, the phosphorylation of <e2>myosin light chain<\\e2> produced by <e1>norepinephrine<\\e1> was greater than that produced by clonidine","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"norepinephrine","object":"myosin light chain","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the phosphorylation of <e2>GENE-N<\\e2> produced by <e1>CHEMICAL<\\e1> was greater than that produced by clonidine","sentence":"Furthermore, the phosphorylation of myosin light chain produced by norepinephrine was greater than that produced by clonidine"}
{"PMID":7875228,"re_id":1,"annotated sentence":"Furthermore, the phosphorylation of <e2>myosin light chain<\\e2> produced by norepinephrine was greater than that produced by <e1>clonidine<\\e1>  These results suggest that both alpha 1-adrenoceptor subtypes (alpha 1A and alpha 1B) increase the Ca2+ sensitivity of contractile elements, and that the Ca2+ sensitization produced by alpha 1A-subtype receptors is mediated through G-protein and protein kinase C, and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"clonidine","object":"myosin light chain","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Furthermore, the phosphorylation of <e2>GENE-N<\\e2> produced by norepinephrine was greater than that produced by <e1>CHEMICAL<\\e1>  These results suggest that both alpha 1-adrenoceptor subtypes (alpha 1A and alpha 1B) increase the Ca2+ sensitivity of contractile elements, and that the Ca2+ sensitization produced by alpha 1A-subtype receptors is mediated through G-protein and protein kinase C, and plays an important role in contraction of smooth muscle of rabbit thoracic aorta.","sentence":"Furthermore, the phosphorylation of myosin light chain produced by norepinephrine was greater than that produced by clonidine  These results suggest that both alpha 1-adrenoceptor subtypes (alpha 1A and alpha 1B) increase the Ca2+ sensitivity of contractile elements, and that the Ca2+ sensitization produced by alpha 1A-subtype receptors is mediated through G-protein and protein kinase C, and plays an important role in contraction of smooth muscle of rabbit thoracic aorta."}
{"PMID":7875228,"re_id":2,"annotated sentence":"In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective <e2>alpha 1A-adrenoceptor<\\e2> antagonist <e1>WB 4101<\\e1> (100 nM)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"WB 4101","object":"alpha 1A-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> (100 nM)","sentence":"In beta-escin-skinned strips of chloroethylclonidine-pretreated smooth muscle, the enhancement of Ca2+ contraction produced by norepinephrine was significantly decreased, whereas the amplitude was the same as that produced by methoxamine or clonidine; this enhancement was inhibited by the selective alpha 1A-adrenoceptor antagonist WB 4101 (100 nM)"}
{"PMID":7926307,"re_id":1,"annotated sentence":"The drug had a potent cytotoxic effect on RIN cells expressing <e2>GLUT2<\\e2>  but had no effect on cells lacking GLUT2 expression, as indicated by histological analysis and measurement of the blood <e1>glucose<\\e1> levels of treated animals","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"glucose","object":"GLUT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The drug had a potent cytotoxic effect on RIN cells expressing <e2>GENE-Y<\\e2>  but had no effect on cells lacking GENE-Y expression, as indicated by histological analysis and measurement of the blood <e1>CHEMICAL<\\e1> levels of treated animals","sentence":"The drug had a potent cytotoxic effect on RIN cells expressing GLUT2  but had no effect on cells lacking GLUT2 expression, as indicated by histological analysis and measurement of the blood glucose levels of treated animals"}
{"PMID":7926307,"re_id":2,"annotated sentence":"Consistent with these data, only <e2>GLUT2<\\e2> expressing RIN or AtT-20ins cells transported <e1>STZ<\\e1> efficiently","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"STZ","object":"GLUT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Consistent with these data, only <e2>GENE-Y<\\e2> expressing RIN or AtT-20ins cells transported <e1>CHEMICAL<\\e1> efficiently","sentence":"Consistent with these data, only GLUT2 expressing RIN or AtT-20ins cells transported STZ efficiently"}
{"PMID":7926307,"re_id":3,"annotated sentence":"We conclude that expression of <e2>GLUT2<\\e2> is required for efficient killing of neuroendocrine cells by <e1>STZ<\\e1>  and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"STZ","object":"GLUT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that expression of <e2>GENE-Y<\\e2> is required for efficient killing of neuroendocrine cells by <e1>CHEMICAL<\\e1>  and this effect is related to specific recognition of the drug as a transported substrate by GENE-Y but not GLUT1.","sentence":"We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by STZ  and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1."}
{"PMID":7926307,"re_id":4,"annotated sentence":"We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by <e1>STZ<\\e1>  and this effect is related to specific recognition of the drug as a transported substrate by <e2>GLUT2<\\e2> but not GLUT1.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"STZ","object":"GLUT2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that expression of GENE-Y is required for efficient killing of neuroendocrine cells by <e1>CHEMICAL<\\e1>  and this effect is related to specific recognition of the drug as a transported substrate by <e2>GENE-Y<\\e2> but not GLUT1.","sentence":"We conclude that expression of GLUT2 is required for efficient killing of neuroendocrine cells by STZ  and this effect is related to specific recognition of the drug as a transported substrate by GLUT2 but not GLUT1."}
{"PMID":8073394,"re_id":1,"annotated sentence":"The data suggest that <e1>lysine<\\e1> analogues, even at low concentrations, reduce the rate of <e2>t-PA<\\e2> induced whole blood clot lysis by several mechanisms.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"lysine","object":"t-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The data suggest that <e1>CHEMICAL<\\e1> analogues, even at low concentrations, reduce the rate of <e2>GENE-Y<\\e2> induced whole blood clot lysis by several mechanisms.","sentence":"The data suggest that lysine analogues, even at low concentrations, reduce the rate of t-PA induced whole blood clot lysis by several mechanisms."}
{"PMID":8073394,"re_id":2,"annotated sentence":"<e1>AMCA<\\e1> (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous <e2>t-PA<\\e2> or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AMCA","object":"t-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous <e2>GENE-Y<\\e2> or if (2) whole blood clots were formed in the presence of exogenous GENE-Y and a lysine analogue","sentence":"AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue"}
{"PMID":8073394,"re_id":3,"annotated sentence":"<e1>AMCA<\\e1> (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous <e2>t-PA<\\e2> and a lysine analogue","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"AMCA","object":"t-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous GENE-Y or if (2) whole blood clots were formed in the presence of exogenous <e2>GENE-Y<\\e2> and a lysine analogue","sentence":"AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue"}
{"PMID":8073394,"re_id":4,"annotated sentence":"AMCA (0.06 mM) and <e1>EACA<\\e1> (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous <e2>t-PA<\\e2> or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"EACA","object":"t-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"AMCA (0.06 mM) and <e1>CHEMICAL<\\e1> (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous <e2>GENE-Y<\\e2> or if (2) whole blood clots were formed in the presence of exogenous GENE-Y and a lysine analogue","sentence":"AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue"}
{"PMID":8073394,"re_id":5,"annotated sentence":"AMCA (0.06 mM) and <e1>EACA<\\e1> (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous <e2>t-PA<\\e2> and a lysine analogue","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"EACA","object":"t-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"AMCA (0.06 mM) and <e1>CHEMICAL<\\e1> (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous GENE-Y or if (2) whole blood clots were formed in the presence of exogenous <e2>GENE-Y<\\e2> and a lysine analogue","sentence":"AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue"}
{"PMID":8073394,"re_id":6,"annotated sentence":"Inhibitory effects of <e1>lysine<\\e1> analogues on <e2>t-PA<\\e2> induced whole blood clot lysis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lysine","object":"t-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Inhibitory effects of <e1>CHEMICAL<\\e1> analogues on <e2>GENE-Y<\\e2> induced whole blood clot lysis","sentence":"Inhibitory effects of lysine analogues on t-PA induced whole blood clot lysis"}
{"PMID":8073394,"re_id":7,"annotated sentence":"However, their inhibitory effect was markedly reduced if clots were formed in the presence of <e2>t-PA<\\e2> and then exposed to either of the <e1>lysine<\\e1> analogues","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lysine","object":"t-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, their inhibitory effect was markedly reduced if clots were formed in the presence of <e2>GENE-Y<\\e2> and then exposed to either of the <e1>CHEMICAL<\\e1> analogues","sentence":"However, their inhibitory effect was markedly reduced if clots were formed in the presence of t-PA and then exposed to either of the lysine analogues"}
{"PMID":8073394,"re_id":8,"annotated sentence":"The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of <e1>lysine<\\e1> analogues required for inhibition of clot lysis induced by exogenous <e2>t-PA<\\e2>  AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"lysine","object":"t-PA","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of <e1>CHEMICAL<\\e1> analogues required for inhibition of clot lysis induced by exogenous <e2>GENE-Y<\\e2>  AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a CHEMICAL analogue and exogenous GENE-Y or if (2) whole blood clots were formed in the presence of exogenous GENE-Y and a CHEMICAL analogue","sentence":"The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA  AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue"}
{"PMID":8098142,"re_id":0,"annotated sentence":"<e1>Histamine<\\e1> enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via <e2>H1-receptor<\\e2> activation","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"Histamine","object":"H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via <e2>GENE-Y<\\e2> activation","sentence":"Histamine enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via H1-receptor activation"}
{"PMID":8098142,"re_id":1,"annotated sentence":"In summary, these results show that the excitatory effect of <e1>histamine<\\e1> on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the <e2>H1-receptor<\\e2> mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"histamine","object":"H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In summary, these results show that the excitatory effect of <e1>CHEMICAL<\\e1> on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the <e2>GENE-Y<\\e2> mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.","sentence":"In summary, these results show that the excitatory effect of histamine on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the H1-receptor mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential."}
{"PMID":8098142,"re_id":2,"annotated sentence":"The enhancement of the depolarizing afterpotential by histamine was mimicked by the <e2>histamine H1-receptor<\\e2> agonist <e1>2-thiazolylethylamine<\\e1> and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"2-thiazolylethylamine","object":"histamine H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The enhancement of the depolarizing afterpotential by histamine was mimicked by the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine","sentence":"The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine"}
{"PMID":8098142,"re_id":3,"annotated sentence":"The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the <e2>H1-receptor<\\e2> antagonist <e1>promethazine<\\e1>  but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"promethazine","object":"H1-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine GENE-Y agonist 2-thiazolylethylamine and was reduced or blocked by the <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1>  but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine","sentence":"The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine  but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine"}
{"PMID":8098142,"re_id":4,"annotated sentence":"The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the <e2>histamine H2-receptor<\\e2> antagonist, <e1>cimetidine<\\e1>  In summary, these results show that the excitatory effect of histamine on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the H1-receptor-mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"cimetidine","object":"histamine H2-receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1>  In summary, these results show that the excitatory effect of histamine on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the H1-receptor-mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential.","sentence":"The enhancement of the depolarizing afterpotential by histamine was mimicked by the histamine H1-receptor agonist 2-thiazolylethylamine and was reduced or blocked by the H1-receptor antagonist promethazine, but was not blocked or reduced in the presence of the histamine H2-receptor antagonist, cimetidine  In summary, these results show that the excitatory effect of histamine on immunohistochemically identified vasopressin neurons in the supraoptic nucleus is due in part to the H1-receptor-mediated enhancement of the depolarizing afterpotential independent of any change in the afterhyperpolarizing potential or membrane potential."}
{"PMID":8319997,"re_id":0,"annotated sentence":"Finally, the three drugs were compared with the <e2>angiotensin converting enzyme<\\e2> inhibitor <e1>cilazapril<\\e1>  The effects of the three drugs on the plasma components of the renin-angiotensin system (plasma renin activity, immunoreactive renin, and immunoreactive angiotensin II concentrations) were also measured","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cilazapril","object":"angiotensin converting enzyme","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Finally, the three drugs were compared with the <e2>GENE-Y<\\e2> inhibitor <e1>CHEMICAL<\\e1>  The effects of the three drugs on the plasma components of the renin-angiotensin system (plasma renin activity, immunoreactive renin, and immunoreactive angiotensin II concentrations) were also measured","sentence":"Finally, the three drugs were compared with the angiotensin converting enzyme inhibitor cilazapril  The effects of the three drugs on the plasma components of the renin-angiotensin system (plasma renin activity, immunoreactive renin, and immunoreactive angiotensin II concentrations) were also measured"}
{"PMID":8319997,"re_id":1,"annotated sentence":"The goal of the present study was to compare the effects of three potent reference <e2>renin<\\e2> inhibitors (<e1>remikiren<\\e1>  CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"remikiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The goal of the present study was to compare the effects of three potent reference <e2>GENE-Y<\\e2> inhibitors (<e1>CHEMICAL<\\e1>  CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys","sentence":"The goal of the present study was to compare the effects of three potent reference renin inhibitors (remikiren  CGP 38560A, and enalkiren) in sodium-depleted normotensive squirrel monkeys"}
{"PMID":8319997,"re_id":2,"annotated sentence":"The goal of the present study was to compare the effects of three potent reference <e2>renin<\\e2> inhibitors (remikiren, <e1>CGP 38560A<\\e1>  and enalkiren) in sodium-depleted normotensive squirrel monkeys","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CGP 38560A","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The goal of the present study was to compare the effects of three potent reference <e2>GENE-Y<\\e2> inhibitors (remikiren, <e1>CHEMICAL<\\e1>  and enalkiren) in sodium-depleted normotensive squirrel monkeys","sentence":"The goal of the present study was to compare the effects of three potent reference renin inhibitors (remikiren, CGP 38560A  and enalkiren) in sodium-depleted normotensive squirrel monkeys"}
{"PMID":8319997,"re_id":3,"annotated sentence":"The goal of the present study was to compare the effects of three potent reference <e2>renin<\\e2> inhibitors (remikiren, CGP 38560A, and <e1>enalkiren<\\e1>  in sodium-depleted normotensive squirrel monkeys","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"enalkiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The goal of the present study was to compare the effects of three potent reference <e2>GENE-Y<\\e2> inhibitors (remikiren, CGP 38560A, and <e1>CHEMICAL<\\e1>  in sodium-depleted normotensive squirrel monkeys","sentence":"The goal of the present study was to compare the effects of three potent reference renin inhibitors (remikiren, CGP 38560A, and enalkiren  in sodium-depleted normotensive squirrel monkeys"}
{"PMID":8319997,"re_id":4,"annotated sentence":"One possible explanation is that, in our model, <e1>remikiren<\\e1> in contrast to CGP 38560A and enalkiren is able to inhibit <e2>renin<\\e2> in a functionally important extraplasmatic compartment.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"remikiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One possible explanation is that, in our model, <e1>CHEMICAL<\\e1> in contrast to CGP 38560A and enalkiren is able to inhibit <e2>GENE-Y<\\e2> in a functionally important extraplasmatic compartment.","sentence":"One possible explanation is that, in our model, remikiren in contrast to CGP 38560A and enalkiren is able to inhibit renin in a functionally important extraplasmatic compartment."}
{"PMID":8319997,"re_id":5,"annotated sentence":"One possible explanation is that, in our model, remikiren in contrast to <e1>CGP 38560A<\\e1> and enalkiren is able to inhibit <e2>renin<\\e2> in a functionally important extraplasmatic compartment.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"CGP 38560A","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One possible explanation is that, in our model, remikiren in contrast to <e1>CHEMICAL<\\e1> and enalkiren is able to inhibit <e2>GENE-Y<\\e2> in a functionally important extraplasmatic compartment.","sentence":"One possible explanation is that, in our model, remikiren in contrast to CGP 38560A and enalkiren is able to inhibit renin in a functionally important extraplasmatic compartment."}
{"PMID":8319997,"re_id":6,"annotated sentence":"One possible explanation is that, in our model, remikiren in contrast to CGP 38560A and <e1>enalkiren<\\e1> is able to inhibit <e2>renin<\\e2> in a functionally important extraplasmatic compartment.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"enalkiren","object":"renin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One possible explanation is that, in our model, remikiren in contrast to CGP 38560A and <e1>CHEMICAL<\\e1> is able to inhibit <e2>GENE-Y<\\e2> in a functionally important extraplasmatic compartment.","sentence":"One possible explanation is that, in our model, remikiren in contrast to CGP 38560A and enalkiren is able to inhibit renin in a functionally important extraplasmatic compartment."}
{"PMID":8384226,"re_id":0,"annotated sentence":"RESULTS: <e1>Nedocromil sodium<\\e1> inhibited the chemotactic response toward FMLP and NAF\/IL-8 of <e2>GM-CSF<\\e2> primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol\/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol\/L)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Nedocromil sodium","object":"GM-CSF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> inhibited the chemotactic response toward FMLP and NAF\/IL-8 of <e2>GENE-Y<\\e2> primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol\/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol\/L)","sentence":"RESULTS: Nedocromil sodium inhibited the chemotactic response toward FMLP and NAF\/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol\/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol\/L)"}
{"PMID":8384226,"re_id":1,"annotated sentence":"Inhibition of <e2>cytokine<\\e2> primed eosinophil chemotaxis by <e1>nedocromil sodium<\\e1>  BACKGROUND: Eosinophil influx into the lung tissue is considered to be relevant for the pathogenesis of asthma","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nedocromil sodium","object":"cytokine","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Inhibition of <e2>GENE-N<\\e2> primed eosinophil chemotaxis by <e1>CHEMICAL<\\e1>  BACKGROUND: Eosinophil influx into the lung tissue is considered to be relevant for the pathogenesis of asthma","sentence":"Inhibition of cytokine primed eosinophil chemotaxis by nedocromil sodium  BACKGROUND: Eosinophil influx into the lung tissue is considered to be relevant for the pathogenesis of asthma"}
{"PMID":8384226,"re_id":2,"annotated sentence":"CONCLUSIONS: The chemotactic responses toward <e2>C5a<\\e2> were inhibited by <e1>nedocromil sodium<\\e1> at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol\/L)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nedocromil sodium","object":"C5a","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"CONCLUSIONS: The chemotactic responses toward <e2>GENE-Y<\\e2> were inhibited by <e1>CHEMICAL<\\e1> at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol\/L)","sentence":"CONCLUSIONS: The chemotactic responses toward C5a were inhibited by nedocromil sodium at higher concentrations than were required in the priming studies (IC50 approximately 10 to 100 nmol\/L)"}
{"PMID":8384226,"re_id":3,"annotated sentence":"RESULTS: <e1>Nedocromil sodium<\\e1> inhibited the chemotactic response toward FMLP and NAF\/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol\/L), whereas these responses of <e2>IL-3<\\e2> primed eosinophils was completely inhibited (IC50 approximately 1 nmol\/L)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Nedocromil sodium","object":"IL-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> inhibited the chemotactic response toward FMLP and NAF\/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol\/L), whereas these responses of <e2>GENE-Y<\\e2> primed eosinophils was completely inhibited (IC50 approximately 1 nmol\/L)","sentence":"RESULTS: Nedocromil sodium inhibited the chemotactic response toward FMLP and NAF\/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol\/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol\/L)"}
{"PMID":8384226,"re_id":4,"annotated sentence":"RESULTS: <e1>Nedocromil sodium<\\e1> inhibited the chemotactic response toward FMLP and <e2>NAF<\\e2> IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol\/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol\/L)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Nedocromil sodium","object":"NAF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> inhibited the chemotactic response toward FMLP and <e2>GENE-Y<\\e2> IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol\/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol\/L)","sentence":"RESULTS: Nedocromil sodium inhibited the chemotactic response toward FMLP and NAF IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol\/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol\/L)"}
{"PMID":8384226,"re_id":5,"annotated sentence":"RESULTS: <e1>Nedocromil sodium<\\e1> inhibited the chemotactic response toward FMLP and NAF\/<e2>IL-8<\\e2> of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol\/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol\/L)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Nedocromil sodium","object":"IL-8","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"RESULTS: <e1>CHEMICAL<\\e1> inhibited the chemotactic response toward FMLP and NAF\/<e2>GENE-Y<\\e2> of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol\/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol\/L)","sentence":"RESULTS: Nedocromil sodium inhibited the chemotactic response toward FMLP and NAF\/IL-8 of GM-CSF primed eosinophils approximately 60% (inhibitory concentration of 50% [IC50] approximately 1 to 10 nmol\/L), whereas these responses of IL-3 primed eosinophils was completely inhibited (IC50 approximately 1 nmol\/L)"}
{"PMID":8415655,"re_id":4,"annotated sentence":"Glutathione-independent prostaglandin D synthase [<e2>prostaglandin-H2 D-isomerase<\\e2>  (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of <e1>prostaglandin D2<\\e1> in the central nervous system","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin D2","object":"prostaglandin-H2 D-isomerase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Glutathione-independent prostaglandin D synthase [<e2>GENE-Y<\\e2>  (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of <e1>CHEMICAL<\\e1> in the central nervous system","sentence":"Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase  (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system"}
{"PMID":8415655,"re_id":5,"annotated sentence":"Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; <e2>(5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase<\\e2>  EC 5.3.99.2] is an enzyme responsible for biosynthesis of <e1>prostaglandin D2<\\e1> in the central nervous system","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin D2","object":"(5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; <e2>GENE-Y<\\e2>  EC 5.3.99.2] is an enzyme responsible for biosynthesis of <e1>CHEMICAL<\\e1> in the central nervous system","sentence":"Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase  EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system"}
{"PMID":8415655,"re_id":6,"annotated sentence":"Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, <e2>EC 5.3.99.2<\\e2>  is an enzyme responsible for biosynthesis of <e1>prostaglandin D2<\\e1> in the central nervous system","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin D2","object":"EC 5.3.99.2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, <e2>GENE-Y<\\e2>  is an enzyme responsible for biosynthesis of <e1>CHEMICAL<\\e1> in the central nervous system","sentence":"Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2  is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system"}
{"PMID":8415655,"re_id":7,"annotated sentence":"Glutathione-independent <e2>prostaglandin D synthase<\\e2> [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of <e1>prostaglandin D2<\\e1> in the central nervous system","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"prostaglandin D2","object":"prostaglandin D synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Glutathione-independent <e2>GENE-Y<\\e2> [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of <e1>CHEMICAL<\\e1> in the central nervous system","sentence":"Glutathione-independent prostaglandin D synthase [prostaglandin-H2 D-isomerase; (5Z,13E)-(15S)-9 alpha,11 alpha-epidioxy-15-hydroxyprosta-5,13-dienoate D-isomerase, EC 5.3.99.2] is an enzyme responsible for biosynthesis of prostaglandin D2 in the central nervous system"}
{"PMID":8589992,"re_id":21,"annotated sentence":"Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-<e2>N-methyl-D-aspartate (NMDA) receptor<\\e2> antagonist <e1>CNQX<\\e1> (6-cyano-7-nitro-quinoxalinedione)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"CNQX","object":"N-methyl-D-aspartate (NMDA) receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-<e2>GENE-N<\\e2> antagonist <e1>CHEMICAL<\\e1> (6-cyano-7-nitro-quinoxalinedione)","sentence":"Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione)"}
{"PMID":8589992,"re_id":22,"annotated sentence":"Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-<e2>N-methyl-D-aspartate (NMDA) receptor<\\e2> antagonist CNQX (<e1>6-cyano-7-nitro-quinoxalinedione<\\e1> ","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"6-cyano-7-nitro-quinoxalinedione","object":"N-methyl-D-aspartate (NMDA) receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-<e2>GENE-N<\\e2> antagonist CNQX (<e1>CHEMICAL<\\e1> ","sentence":"Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione "}
{"PMID":8606397,"re_id":0,"annotated sentence":"Although <e1>DEC<\\e1> exerts local antioxidant activity with beneficial effects on lung tissue, this <e2>5-LO<\\e2> inhibitor intensifies the blast overpressure caused hemodynamic insufficiency.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DEC","object":"5-LO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although <e1>CHEMICAL<\\e1> exerts local antioxidant activity with beneficial effects on lung tissue, this <e2>GENE-Y<\\e2> inhibitor intensifies the blast overpressure caused hemodynamic insufficiency.","sentence":"Although DEC exerts local antioxidant activity with beneficial effects on lung tissue, this 5-LO inhibitor intensifies the blast overpressure caused hemodynamic insufficiency."}
{"PMID":8606397,"re_id":1,"annotated sentence":"One group of experimental animals was treated with <e2>5-lipoxygenase<\\e2> (5-LO) inhibitor, <e1>diethylcarbamazine<\\e1> (DEC, Sigma, St","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diethylcarbamazine","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One group of experimental animals was treated with <e2>GENE-Y<\\e2> (5-LO) inhibitor, <e1>CHEMICAL<\\e1> (DEC, Sigma, St","sentence":"One group of experimental animals was treated with 5-lipoxygenase (5-LO) inhibitor, diethylcarbamazine (DEC, Sigma, St"}
{"PMID":8606397,"re_id":2,"annotated sentence":"One group of experimental animals was treated with 5-lipoxygenase (<e2>5-LO<\\e2>  inhibitor, <e1>diethylcarbamazine<\\e1> (DEC, Sigma, St","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"diethylcarbamazine","object":"5-LO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One group of experimental animals was treated with 5-lipoxygenase (<e2>GENE-Y<\\e2>  inhibitor, <e1>CHEMICAL<\\e1> (DEC, Sigma, St","sentence":"One group of experimental animals was treated with 5-lipoxygenase (5-LO  inhibitor, diethylcarbamazine (DEC, Sigma, St"}
{"PMID":8606397,"re_id":3,"annotated sentence":"One group of experimental animals was treated with <e2>5-lipoxygenase<\\e2> (5-LO) inhibitor, diethylcarbamazine (<e1>DEC<\\e1>  Sigma, St","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DEC","object":"5-lipoxygenase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One group of experimental animals was treated with <e2>GENE-Y<\\e2> (5-LO) inhibitor, diethylcarbamazine (<e1>CHEMICAL<\\e1>  Sigma, St","sentence":"One group of experimental animals was treated with 5-lipoxygenase (5-LO) inhibitor, diethylcarbamazine (DEC  Sigma, St"}
{"PMID":8606397,"re_id":4,"annotated sentence":"One group of experimental animals was treated with 5-lipoxygenase (<e2>5-LO<\\e2>  inhibitor, diethylcarbamazine (<e1>DEC<\\e1>  Sigma, St","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DEC","object":"5-LO","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"One group of experimental animals was treated with 5-lipoxygenase (<e2>GENE-Y<\\e2>  inhibitor, diethylcarbamazine (<e1>CHEMICAL<\\e1>  Sigma, St","sentence":"One group of experimental animals was treated with 5-lipoxygenase (5-LO  inhibitor, diethylcarbamazine (DEC  Sigma, St"}
{"PMID":8647141,"re_id":0,"annotated sentence":"<e1>Tamsulosin<\\e1>  the first prostate-selective <e2>alpha 1A-adrenoceptor<\\e2> antagonist","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"Tamsulosin","object":"alpha 1A-adrenoceptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  the first prostate-selective <e2>GENE-Y<\\e2> antagonist","sentence":"Tamsulosin  the first prostate-selective alpha 1A-adrenoceptor antagonist"}
{"PMID":8666140,"re_id":8,"annotated sentence":"Expressions of <e2>insulin<\\e2> and PC3, but not PC2, are coordinately regulated by <e1>glucose<\\e1>  consistent with the important role of PC3 in regulating proinsulin processing","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Expressions of <e2>GENE-Y<\\e2> and PC3, but not PC2, are coordinately regulated by <e1>CHEMICAL<\\e1>  consistent with the important role of PC3 in regulating proGENE-Y processing","sentence":"Expressions of insulin and PC3, but not PC2, are coordinately regulated by glucose  consistent with the important role of PC3 in regulating proinsulin processing"}
{"PMID":8666140,"re_id":9,"annotated sentence":"Expressions of insulin and <e2>PC3<\\e2>  but not PC2, are coordinately regulated by <e1>glucose<\\e1>  consistent with the important role of PC3 in regulating proinsulin processing","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"PC3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Expressions of insulin and <e2>GENE-Y<\\e2>  but not PC2, are coordinately regulated by <e1>CHEMICAL<\\e1>  consistent with the important role of GENE-Y in regulating proinsulin processing","sentence":"Expressions of insulin and PC3  but not PC2, are coordinately regulated by glucose  consistent with the important role of PC3 in regulating proinsulin processing"}
{"PMID":8730743,"re_id":3,"annotated sentence":"The present results suggest that the action of <e1>DMI<\\e1> in this animal model is unlikely to be directly related to a reduction in <e2>beta-adrenoceptors<\\e2> but may be related to a reduction in frontal cortical 5-HT2A receptors.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"DMI","object":"beta-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present results suggest that the action of <e1>CHEMICAL<\\e1> in this animal model is unlikely to be directly related to a reduction in <e2>GENE-N<\\e2> but may be related to a reduction in frontal cortical 5-HT2A receptors.","sentence":"The present results suggest that the action of DMI in this animal model is unlikely to be directly related to a reduction in beta-adrenoceptors but may be related to a reduction in frontal cortical 5-HT2A receptors."}
{"PMID":8730743,"re_id":4,"annotated sentence":"After 7 days of <e1>DMI<\\e1> administration the number of <e2>beta-adrenoceptors<\\e2> was lower in frontal and occipital cortex and hippocampus","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DMI","object":"beta-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"After 7 days of <e1>CHEMICAL<\\e1> administration the number of <e2>GENE-N<\\e2> was lower in frontal and occipital cortex and hippocampus","sentence":"After 7 days of DMI administration the number of beta-adrenoceptors was lower in frontal and occipital cortex and hippocampus"}
{"PMID":8730743,"re_id":5,"annotated sentence":"The <e1>DMI<\\e1> induced reduction in <e2>beta-adrenoceptors<\\e2> did not differ in OB and sham-operated control rats","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DMI","object":"beta-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e1>CHEMICAL<\\e1> induced reduction in <e2>GENE-N<\\e2> did not differ in OB and sham-operated control rats","sentence":"The DMI induced reduction in beta-adrenoceptors did not differ in OB and sham-operated control rats"}
{"PMID":8730743,"re_id":6,"annotated sentence":"<e1>DMI<\\e1> administration for up to 21 days produced a progressive reduction in the number of <e2>5-HT2A<\\e2> receptors in frontal cortex, without significant alterations in occipital cortex","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DMI","object":"5-HT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> administration for up to 21 days produced a progressive reduction in the number of <e2>GENE-Y<\\e2> receptors in frontal cortex, without significant alterations in occipital cortex","sentence":"DMI administration for up to 21 days produced a progressive reduction in the number of 5-HT2A receptors in frontal cortex, without significant alterations in occipital cortex"}
{"PMID":8730743,"re_id":7,"annotated sentence":"The time course of the reduction in the number of <e2>5-HT2A<\\e2> receptors was similar to that of the <e1>DMI<\\e1> induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DMI","object":"5-HT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The time course of the reduction in the number of <e2>GENE-Y<\\e2> receptors was similar to that of the <e1>CHEMICAL<\\e1> induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different","sentence":"The time course of the reduction in the number of 5-HT2A receptors was similar to that of the DMI induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different"}
{"PMID":8730743,"re_id":8,"annotated sentence":"The time course of the reduction in the number of 5-HT2A receptors was similar to that of the <e1>DMI<\\e1> induced behavioural changes whereas that for the reduction in <e2>beta-adrenoceptors<\\e2> was clearly different","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DMI","object":"beta-adrenoceptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The time course of the reduction in the number of 5-HT2A receptors was similar to that of the <e1>CHEMICAL<\\e1> induced behavioural changes whereas that for the reduction in <e2>GENE-N<\\e2> was clearly different","sentence":"The time course of the reduction in the number of 5-HT2A receptors was similar to that of the DMI induced behavioural changes whereas that for the reduction in beta-adrenoceptors was clearly different"}
{"PMID":8730743,"re_id":9,"annotated sentence":"The present results suggest that the action of <e1>DMI<\\e1> in this animal model is unlikely to be directly related to a reduction in beta-adrenoceptors but may be related to a reduction in frontal cortical <e2>5-HT2A<\\e2> receptors.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DMI","object":"5-HT2A","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The present results suggest that the action of <e1>CHEMICAL<\\e1> in this animal model is unlikely to be directly related to a reduction in beta-adrenoceptors but may be related to a reduction in frontal cortical <e2>GENE-Y<\\e2> receptors.","sentence":"The present results suggest that the action of DMI in this animal model is unlikely to be directly related to a reduction in beta-adrenoceptors but may be related to a reduction in frontal cortical 5-HT2A receptors."}
{"PMID":8755512,"re_id":3,"annotated sentence":"We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both <e1>thalidomide<\\e1> and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of <e2>tumor necrosis factor alpha<\\e2> from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"thalidomide","object":"tumor necrosis factor alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We show that the binding of CHEMICAL photoaffinity label to authentic human AGP is competed with both <e1>CHEMICAL<\\e1> and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of <e2>GENE-Y<\\e2> from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of CHEMICAL.","sentence":"We show that the binding of thalidomide photoaffinity label to authentic human AGP is competed with both thalidomide and the nonradioactive photoaffinity label at concentrations comparable to those required for inhibition of production of tumor necrosis factor alpha from human monocytes, suggesting that AGP may be involved in the immunomodulatory activity of thalidomide."}
{"PMID":8755512,"re_id":4,"annotated sentence":"Binding of <e1>thalidomide<\\e1> to alpha1-acid glycoprotein may be involved in its inhibition of <e2>tumor necrosis factor alpha<\\e2> production","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"thalidomide","object":"tumor necrosis factor alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Binding of <e1>CHEMICAL<\\e1> to alpha1-acid glycoprotein may be involved in its inhibition of <e2>GENE-Y<\\e2> production","sentence":"Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production"}
{"PMID":8755512,"re_id":5,"annotated sentence":"The immunomodulatory activity of <e1>thalidomide<\\e1> has been ascribed to the selective inhibition of <e2>tumor necrosis factor alpha<\\e2> from monocytes","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"thalidomide","object":"tumor necrosis factor alpha","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The immunomodulatory activity of <e1>CHEMICAL<\\e1> has been ascribed to the selective inhibition of <e2>GENE-Y<\\e2> from monocytes","sentence":"The immunomodulatory activity of thalidomide has been ascribed to the selective inhibition of tumor necrosis factor alpha from monocytes"}
{"PMID":8797532,"re_id":1,"annotated sentence":"In conclusion, our data suggest that chronic <e1>cocaine<\\e1> use is associated with modestly reduced levels of striatal DA and the <e2>DA transporter<\\e2> in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"cocaine","object":"DA transporter","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, our data suggest that chronic <e1>CHEMICAL<\\e1> use is associated with modestly reduced levels of striatal DA and the <e2>GENE-Y<\\e2> in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug.","sentence":"In conclusion, our data suggest that chronic cocaine use is associated with modestly reduced levels of striatal DA and the DA transporter in some subjects and that these changes might contribute to the neurological and psychiatric effects of the drug."}
{"PMID":8863950,"re_id":1,"annotated sentence":"It appears likely that the <e2>histamine H2 receptor<\\e2> blocked by <e1>cimetidine<\\e1> obviated the pulmonary vasodilator effect of tolazoline therapy.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cimetidine","object":"histamine H2 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"It appears likely that the <e2>GENE-Y<\\e2> blocked by <e1>CHEMICAL<\\e1> obviated the pulmonary vasodilator effect of tolazoline therapy.","sentence":"It appears likely that the histamine H2 receptor blocked by cimetidine obviated the pulmonary vasodilator effect of tolazoline therapy."}
{"PMID":8882618,"re_id":10,"annotated sentence":"<e1>GYKI 52466<\\e1> decreased the peak amplitude of hippocampal area CA1 <e2>AMPA receptor<\\e2> mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +\/- 0.8 microM) with no apparent effect on response kinetics","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"GYKI 52466","object":"AMPA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> decreased the peak amplitude of hippocampal area CA1 <e2>GENE-N<\\e2> mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +\/- 0.8 microM) with no apparent effect on response kinetics","sentence":"GYKI 52466 decreased the peak amplitude of hippocampal area CA1 AMPA receptor mediated excitatory postsynaptic currents (e.p.s.cs) (IC50 10.8 +\/- 0.8 microM) with no apparent effect on response kinetics"}
{"PMID":8882618,"re_id":11,"annotated sentence":"<e1>Cyclothiazide<\\e1> prolonged the decay time constant of <e2>AMPA receptor<\\e2> mediated e.p.s.cs (EC50 35.7 +\/- 6.5 microM) with less pronounced effects in slowing e.p.s.c","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"Cyclothiazide","object":"AMPA receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> prolonged the decay time constant of <e2>GENE-N<\\e2> mediated e.p.s.cs (EC50 35.7 +\/- 6.5 microM) with less pronounced effects in slowing e.p.s.c","sentence":"Cyclothiazide prolonged the decay time constant of AMPA receptor mediated e.p.s.cs (EC50 35.7 +\/- 6.5 microM) with less pronounced effects in slowing e.p.s.c"}
{"PMID":9008235,"re_id":0,"annotated sentence":"Activation of cytoprotective <e2>prostaglandin synthase-1<\\e2> by <e1>minoxidil<\\e1> as a possible explanation for its hair growth-stimulating effect","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"minoxidil","object":"prostaglandin synthase-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Activation of cytoprotective <e2>GENE-Y<\\e2> by <e1>CHEMICAL<\\e1> as a possible explanation for its hair growth-stimulating effect","sentence":"Activation of cytoprotective prostaglandin synthase-1 by minoxidil as a possible explanation for its hair growth-stimulating effect"}
{"PMID":9008235,"re_id":1,"annotated sentence":"We thus speculated that activation of <e2>PGHS-1<\\e2> might be a mechanism by which <e1>minoxidil<\\e1> (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"minoxidil","object":"PGHS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We thus speculated that activation of <e2>GENE-Y<\\e2> might be a mechanism by which <e1>CHEMICAL<\\e1> (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo","sentence":"We thus speculated that activation of PGHS-1 might be a mechanism by which minoxidil (2,4-diamino-6-piperidinopyrimidine-3-oxyde) stimulates hair growth in vivo"}
{"PMID":9008235,"re_id":2,"annotated sentence":"We thus speculated that activation of <e2>PGHS-1<\\e2> might be a mechanism by which minoxidil (<e1>2,4-diamino-6-piperidinopyrimidine-3-oxyde<\\e1>  stimulates hair growth in vivo","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"2,4-diamino-6-piperidinopyrimidine-3-oxyde","object":"PGHS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We thus speculated that activation of <e2>GENE-Y<\\e2> might be a mechanism by which minoxidil (<e1>CHEMICAL<\\e1>  stimulates hair growth in vivo","sentence":"We thus speculated that activation of PGHS-1 might be a mechanism by which minoxidil (2,4-diamino-6-piperidinopyrimidine-3-oxyde  stimulates hair growth in vivo"}
{"PMID":9008235,"re_id":3,"annotated sentence":"We demonstrate here that <e1>minoxidil<\\e1> is a potent activator of purified <e2>PGHS-1<\\e2> (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"ACTIVATOR","subject":"minoxidil","object":"PGHS-1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We demonstrate here that <e1>CHEMICAL<\\e1> is a potent activator of purified <e2>GENE-Y<\\e2> (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production","sentence":"We demonstrate here that minoxidil is a potent activator of purified PGHS-1 (AC50 = 80 microM), as assayed by oxygen consumption and PGE2 production"}
{"PMID":9211565,"re_id":4,"annotated sentence":"This study was designed to determine the gastroprotective properties of <e1>cinitapride<\\e1> (CNT), a novel prokinetic benzamide derivative agonist of <e2>5-HT4<\\e2> and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"cinitapride","object":"5-HT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study was designed to determine the gastroprotective properties of <e1>CHEMICAL<\\e1> (CNT), a novel prokinetic benzamide derivative agonist of <e2>GENE-Y<\\e2> and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol","sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol"}
{"PMID":9211565,"re_id":5,"annotated sentence":"This study was designed to determine the gastroprotective properties of <e1>cinitapride<\\e1> (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and <e2>5-HT1<\\e2> receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"cinitapride","object":"5-HT1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study was designed to determine the gastroprotective properties of <e1>CHEMICAL<\\e1> (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and <e2>GENE-N<\\e2> receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol","sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol"}
{"PMID":9211565,"re_id":6,"annotated sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic <e1>benzamide<\\e1> derivative agonist of <e2>5-HT4<\\e2> and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"benzamide","object":"5-HT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic <e1>CHEMICAL<\\e1> derivative agonist of <e2>GENE-Y<\\e2> and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol","sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol"}
{"PMID":9211565,"re_id":7,"annotated sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic <e1>benzamide<\\e1> derivative agonist of 5-HT4 and <e2>5-HT1<\\e2> receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"benzamide","object":"5-HT1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic <e1>CHEMICAL<\\e1> derivative agonist of 5-HT4 and <e2>GENE-N<\\e2> receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol","sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol"}
{"PMID":9211565,"re_id":8,"annotated sentence":"This study was designed to determine the gastroprotective properties of cinitapride (<e1>CNT<\\e1> , a novel prokinetic benzamide derivative agonist of <e2>5-HT4<\\e2> and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"CNT","object":"5-HT4","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"This study was designed to determine the gastroprotective properties of cinitapride (<e1>CHEMICAL<\\e1> , a novel prokinetic benzamide derivative agonist of <e2>GENE-Y<\\e2> and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol","sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT , a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol"}
{"PMID":9211565,"re_id":9,"annotated sentence":"This study was designed to determine the gastroprotective properties of cinitapride (<e1>CNT<\\e1> , a novel prokinetic benzamide derivative agonist of 5-HT4 and <e2>5-HT1<\\e2> receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"CNT","object":"5-HT1","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study was designed to determine the gastroprotective properties of cinitapride (<e1>CHEMICAL<\\e1> , a novel prokinetic benzamide derivative agonist of 5-HT4 and <e2>GENE-N<\\e2> receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol","sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT , a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol"}
{"PMID":9211565,"re_id":10,"annotated sentence":"This study was designed to determine the gastroprotective properties of <e1>cinitapride<\\e1> (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and <e2>5-HT2<\\e2> antagonist, on mucosal injury produced by 50% (v\/v) ethanol","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"cinitapride","object":"5-HT2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study was designed to determine the gastroprotective properties of <e1>CHEMICAL<\\e1> (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and <e2>GENE-N<\\e2> antagonist, on mucosal injury produced by 50% (v\/v) ethanol","sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol"}
{"PMID":9211565,"re_id":11,"annotated sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic <e1>benzamide<\\e1> derivative agonist of 5-HT4 and 5-HT1 receptors and <e2>5-HT2<\\e2> antagonist, on mucosal injury produced by 50% (v\/v) ethanol","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"benzamide","object":"5-HT2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic <e1>CHEMICAL<\\e1> derivative agonist of 5-HT4 and 5-HT1 receptors and <e2>GENE-N<\\e2> antagonist, on mucosal injury produced by 50% (v\/v) ethanol","sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT), a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol"}
{"PMID":9211565,"re_id":12,"annotated sentence":"This study was designed to determine the gastroprotective properties of cinitapride (<e1>CNT<\\e1> , a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and <e2>5-HT2<\\e2> antagonist, on mucosal injury produced by 50% (v\/v) ethanol","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"CNT","object":"5-HT2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"This study was designed to determine the gastroprotective properties of cinitapride (<e1>CHEMICAL<\\e1> , a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and <e2>GENE-N<\\e2> antagonist, on mucosal injury produced by 50% (v\/v) ethanol","sentence":"This study was designed to determine the gastroprotective properties of cinitapride (CNT , a novel prokinetic benzamide derivative agonist of 5-HT4 and 5-HT1 receptors and 5-HT2 antagonist, on mucosal injury produced by 50% (v\/v) ethanol"}
{"PMID":9299436,"re_id":0,"annotated sentence":"We have identified <e2>adenosine deaminase<\\e2>  an enzyme involved in <e1>purine<\\e1> metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"purine","object":"adenosine deaminase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We have identified <e2>GENE-Y<\\e2>  an enzyme involved in <e1>CHEMICAL<\\e1> metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2","sentence":"We have identified adenosine deaminase  an enzyme involved in purine metabolism whose deficiency is associated with severe combined immunodeficiency, as a Grb3-3 binding protein that is not able to bind to Grb2"}
{"PMID":9310349,"re_id":8,"annotated sentence":"Here we report that <e1>alendronate<\\e1> is a potent inhibitor of the <e2>protein-tyrosine-phosphatase-meg1<\\e2> (PTPmeg1)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"alendronate","object":"protein-tyrosine-phosphatase-meg1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we report that <e1>CHEMICAL<\\e1> is a potent inhibitor of the <e2>GENE-Y<\\e2> (PTPmeg1)","sentence":"Here we report that alendronate is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (PTPmeg1)"}
{"PMID":9310349,"re_id":9,"annotated sentence":"Here we report that <e1>alendronate<\\e1> is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (<e2>PTPmeg1<\\e2> ","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"alendronate","object":"PTPmeg1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we report that <e1>CHEMICAL<\\e1> is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (<e2>GENE-Y<\\e2> ","sentence":"Here we report that alendronate is a potent inhibitor of the protein-tyrosine-phosphatase-meg1 (PTPmeg1 "}
{"PMID":9310349,"re_id":10,"annotated sentence":"With either substrate, <e1>alendronate<\\e1> was a slow binding inhibitor of <e2>PTPmeg1<\\e2>  Among the other bisphosphonates studied, alendronate was more potent and selective for PTPmeg1","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"alendronate","object":"PTPmeg1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"With either substrate, <e1>CHEMICAL<\\e1> was a slow binding inhibitor of <e2>GENE-Y<\\e2>  Among the other bisphosphonates studied, CHEMICAL was more potent and selective for GENE-Y","sentence":"With either substrate, alendronate was a slow binding inhibitor of PTPmeg1  Among the other bisphosphonates studied, alendronate was more potent and selective for PTPmeg1"}
{"PMID":9310349,"re_id":11,"annotated sentence":"Among the other <e1>bisphosphonates<\\e1> studied, alendronate was more potent and selective for <e2>PTPmeg1<\\e2>  The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"bisphosphonates","object":"PTPmeg1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the other <e1>CHEMICAL<\\e1> studied, alendronate was more potent and selective for <e2>GENE-Y<\\e2>  The hydrolysis of fluorescein diphosphate by PTP epsilon and GENE-Y was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate","sentence":"Among the other bisphosphonates studied, alendronate was more potent and selective for PTPmeg1  The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate"}
{"PMID":9310349,"re_id":12,"annotated sentence":"Among the other bisphosphonates studied, <e1>alendronate<\\e1> was more potent and selective for <e2>PTPmeg1<\\e2>  The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"alendronate","object":"PTPmeg1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Among the other bisphosphonates studied, <e1>CHEMICAL<\\e1> was more potent and selective for <e2>GENE-Y<\\e2>  The hydrolysis of fluorescein diphosphate by PTP epsilon and GENE-Y was sensitive to CHEMICAL, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM CHEMICAL","sentence":"Among the other bisphosphonates studied, alendronate was more potent and selective for PTPmeg1  The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate"}
{"PMID":9310349,"re_id":13,"annotated sentence":"The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; <e2>PTPsigma<\\e2>  however, under the same conditions, was inhibited by only 50% with 141 microM <e1>alendronate<\\e1>  Similarly, with the src-pY527 substrate, alendronate inhibition was also PTP dependent","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"alendronate","object":"PTPsigma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to CHEMICAL, with IC50 values of less than 1 microM; <e2>GENE-Y<\\e2>  however, under the same conditions, was inhibited by only 50% with 141 microM <e1>CHEMICAL<\\e1>  Similarly, with the src-pY527 substrate, CHEMICAL inhibition was also PTP dependent","sentence":"The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma  however, under the same conditions, was inhibited by only 50% with 141 microM alendronate  Similarly, with the src-pY527 substrate, alendronate inhibition was also PTP dependent"}
{"PMID":9310349,"re_id":14,"annotated sentence":"<e1>Alendronate<\\e1> inhibited <e2>PTPmeg1<\\e2> with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Alendronate","object":"PTPmeg1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited <e2>GENE-Y<\\e2> with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM","sentence":"Alendronate inhibited PTPmeg1 with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM"}
{"PMID":9310349,"re_id":15,"annotated sentence":"<e1>Alendronate<\\e1> inhibited PTPmeg1 with an IC50 value of 23 microM, <e2>PTPsigma<\\e2> with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Alendronate","object":"PTPsigma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibited PTPmeg1 with an IC50 value of 23 microM, <e2>GENE-Y<\\e2> with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM","sentence":"Alendronate inhibited PTPmeg1 with an IC50 value of 23 microM, PTPsigma with an IC50 value of 2 microM, and did not inhibit PTP epsilon at concentrations up to 1 mM"}
{"PMID":9310349,"re_id":16,"annotated sentence":"<e1>Alendronate<\\e1> inhibition of <e2>protein-tyrosine-phosphatase-meg1<\\e2>  Alendronate (4-amino-1-hydroxybutylidene-1,1-bisphosphonate) is a potent bisphosphonate that inhibits osteoclastic bone resorption and has proven effective for the treatment of osteoporosis","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Alendronate","object":"protein-tyrosine-phosphatase-meg1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> inhibition of <e2>GENE-Y<\\e2>  CHEMICAL (4-amino-1-hydroxybutylidene-1,1-bisphosphonate) is a potent bisphosphonate that inhibits osteoclastic bone resorption and has proven effective for the treatment of osteoporosis","sentence":"Alendronate inhibition of protein-tyrosine-phosphatase-meg1  Alendronate (4-amino-1-hydroxybutylidene-1,1-bisphosphonate) is a potent bisphosphonate that inhibits osteoclastic bone resorption and has proven effective for the treatment of osteoporosis"}
{"PMID":9310349,"re_id":17,"annotated sentence":"The <e1>alendronate<\\e1> inhibition of these three <e2>PTPs<\\e2> and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"alendronate","object":"PTPs","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e1>CHEMICAL<\\e1> inhibition of these three <e2>GENE-N<\\e2> and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor","sentence":"The alendronate inhibition of these three PTPs and two substrates is consistent with the formation of a ternary complex comprised of enzyme, substrate, and inhibitor"}
{"PMID":9310349,"re_id":18,"annotated sentence":"<e2>PTP<\\e2> inhibition by <e1>hisphosphonates<\\e1> or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"hisphosphonates","object":"PTP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> inhibition by <e1>CHEMICAL<\\e1> or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition","sentence":"PTP inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition"}
{"PMID":9310349,"re_id":19,"annotated sentence":"<e2>PTP<\\e2> inhibition by hisphosphonates or <e1>vanadate<\\e1> was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"vanadate","object":"PTP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> inhibition by hisphosphonates or <e1>CHEMICAL<\\e1> was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition","sentence":"PTP inhibition by hisphosphonates or vanadate was diminished by the metal chelating agent EDTA, or by the reducing agent dithiothreitol, suggesting that a metal ion and the oxidation of a cysteine residue are required for full inhibition"}
{"PMID":9310349,"re_id":20,"annotated sentence":"These observations show substrate- and enzyme-specific <e2>PTP<\\e2> inhibition by <e1>alendronate<\\e1> and support the possibility that a certain PTP(s) may be the molecular target for alendronate action.","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"alendronate","object":"PTP","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These observations show substrate- and enzyme-specific <e2>GENE-N<\\e2> inhibition by <e1>CHEMICAL<\\e1> and support the possibility that a certain GENE-N(s) may be the molecular target for CHEMICAL action.","sentence":"These observations show substrate- and enzyme-specific PTP inhibition by alendronate and support the possibility that a certain PTP(s) may be the molecular target for alendronate action."}
{"PMID":9310349,"re_id":21,"annotated sentence":"The hydrolysis of fluorescein <e1>diphosphate<\\e1> by <e2>PTP epsilon<\\e2> and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"diphosphate","object":"PTP epsilon","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The hydrolysis of fluorescein <e1>CHEMICAL<\\e1> by <e2>GENE-Y<\\e2> and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate","sentence":"The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate"}
{"PMID":9310349,"re_id":22,"annotated sentence":"The hydrolysis of fluorescein <e1>diphosphate<\\e1> by PTP epsilon and <e2>PTPmeg1<\\e2> was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"diphosphate","object":"PTPmeg1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The hydrolysis of fluorescein <e1>CHEMICAL<\\e1> by PTP epsilon and <e2>GENE-Y<\\e2> was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate","sentence":"The hydrolysis of fluorescein diphosphate by PTP epsilon and PTPmeg1 was sensitive to alendronate, with IC50 values of less than 1 microM; PTPsigma, however, under the same conditions, was inhibited by only 50% with 141 microM alendronate"}
{"PMID":9313928,"re_id":44,"annotated sentence":"<e1>M&B-28767<\\e1>  a putative <e2>EP3<\\e2> agonist, and misoprostol, a putative EP2\/EP3 agonist, also bound to this receptor with Ki values of 120 nM","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"M&B-28767","object":"EP3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1>  a putative <e2>GENE-Y<\\e2> agonist, and misoprostol, a putative EP2\/GENE-Y agonist, also bound to this receptor with Ki values of 120 nM","sentence":"M&B-28767  a putative EP3 agonist, and misoprostol, a putative EP2\/EP3 agonist, also bound to this receptor with Ki values of 120 nM"}
{"PMID":9313928,"re_id":45,"annotated sentence":"M&B-28767, a putative EP3 agonist, and <e1>misoprostol<\\e1>  a putative <e2>EP2<\\e2> EP3 agonist, also bound to this receptor with Ki values of 120 nM","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"misoprostol","object":"EP2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"M&B-28767, a putative EP3 agonist, and <e1>CHEMICAL<\\e1>  a putative <e2>GENE-Y<\\e2> EP3 agonist, also bound to this receptor with Ki values of 120 nM","sentence":"M&B-28767, a putative EP3 agonist, and misoprostol  a putative EP2 EP3 agonist, also bound to this receptor with Ki values of 120 nM"}
{"PMID":9313928,"re_id":46,"annotated sentence":"M&B-28767, a putative EP3 agonist, and <e1>misoprostol<\\e1>  a putative EP2\/<e2>EP3<\\e2> agonist, also bound to this receptor with Ki values of 120 nM","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"misoprostol","object":"EP3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"M&B-28767, a putative GENE-Y agonist, and <e1>CHEMICAL<\\e1>  a putative EP2\/<e2>GENE-Y<\\e2> agonist, also bound to this receptor with Ki values of 120 nM","sentence":"M&B-28767, a putative EP3 agonist, and misoprostol  a putative EP2\/EP3 agonist, also bound to this receptor with Ki values of 120 nM"}
{"PMID":9313928,"re_id":47,"annotated sentence":"16,16-dimethyl-PGE2 and two putative <e2>EP1<\\e2> antagonists, <e1>AH6809<\\e1> and SC-19220, did not show any significant binding to this receptor","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"AH6809","object":"EP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"16,16-dimethyl-PGE2 and two putative <e2>GENE-Y<\\e2> antagonists, <e1>CHEMICAL<\\e1> and SC-19220, did not show any significant binding to this receptor","sentence":"16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor"}
{"PMID":9313928,"re_id":48,"annotated sentence":"16,16-dimethyl-PGE2 and two putative <e2>EP1<\\e2> antagonists, AH6809 and <e1>SC-19220<\\e1>  did not show any significant binding to this receptor","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"SC-19220","object":"EP1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"16,16-dimethyl-PGE2 and two putative <e2>GENE-Y<\\e2> antagonists, AH6809 and <e1>CHEMICAL<\\e1>  did not show any significant binding to this receptor","sentence":"16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and SC-19220  did not show any significant binding to this receptor"}
{"PMID":9374794,"re_id":2,"annotated sentence":"At -20 mV, 10 nM <e1>cisapride<\\e1> reduced <e2>HERG<\\e2> tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"cisapride","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"At -20 mV, 10 nM <e1>CHEMICAL<\\e1> reduced <e2>GENE-Y<\\e2> tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells)","sentence":"At -20 mV, 10 nM cisapride reduced HERG tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells)"}
{"PMID":9374794,"re_id":3,"annotated sentence":"Block of <e2>HERG<\\e2> with <e1>cisapride<\\e1> after channel activation was voltage dependent","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cisapride","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Block of <e2>GENE-Y<\\e2> with <e1>CHEMICAL<\\e1> after channel activation was voltage dependent","sentence":"Block of HERG with cisapride after channel activation was voltage dependent"}
{"PMID":9374794,"re_id":4,"annotated sentence":"Blockage of the <e2>HERG human cardiac K+ channel<\\e2> by the gastrointestinal prokinetic agent <e1>cisapride<\\e1>  Cisapride, a gastrointestinal prokinetic agent, is known to cause long Q-T syndrome and ventricular arrhythmias","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cisapride","object":"HERG human cardiac K+ channel","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Blockage of the <e2>GENE-Y<\\e2> by the gastrointestinal prokinetic agent <e1>CHEMICAL<\\e1>  Cisapride, a gastrointestinal prokinetic agent, is known to cause long Q-T syndrome and ventricular arrhythmias","sentence":"Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride  Cisapride, a gastrointestinal prokinetic agent, is known to cause long Q-T syndrome and ventricular arrhythmias"}
{"PMID":9374794,"re_id":5,"annotated sentence":"We conclude that <e1>cisapride<\\e1> is a potent blocker of <e2>HERG<\\e2> channels expressed in HEK293 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cisapride","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We conclude that <e1>CHEMICAL<\\e1> is a potent blocker of <e2>GENE-Y<\\e2> channels expressed in HEK293 cells","sentence":"We conclude that cisapride is a potent blocker of HERG channels expressed in HEK293 cells"}
{"PMID":9374794,"re_id":6,"annotated sentence":"We tested the hypothesis that <e1>cisapride<\\e1> blocks <e2>HERG<\\e2>  The whole cell patch-clamp recording technique was used to study HERG channels stably expressed heterologously in HEK293 cells","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cisapride","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We tested the hypothesis that <e1>CHEMICAL<\\e1> blocks <e2>GENE-Y<\\e2>  The whole cell patch-clamp recording technique was used to study GENE-Y channels stably expressed heterologously in HEK293 cells","sentence":"We tested the hypothesis that cisapride blocks HERG  The whole cell patch-clamp recording technique was used to study HERG channels stably expressed heterologously in HEK293 cells"}
{"PMID":9374794,"re_id":7,"annotated sentence":"Under voltage-clamp conditions, <e1>cisapride<\\e1> block of <e2>HERG<\\e2> is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cisapride","object":"HERG","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Under voltage-clamp conditions, <e1>CHEMICAL<\\e1> block of <e2>GENE-Y<\\e2> is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells)","sentence":"Under voltage-clamp conditions, cisapride block of HERG is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells)"}
{"PMID":9476974,"re_id":2,"annotated sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>monoamine transporter<\\e2> selectivities (<e1>BTCP<\\e1>  indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"BTCP","object":"monoamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>GENE-N<\\e2> selectivities (<e1>CHEMICAL<\\e1>  indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response","sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse monoamine transporter selectivities (BTCP  indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response"}
{"PMID":9476974,"re_id":3,"annotated sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>monoamine transporter<\\e2> selectivities (BTCP, <e1>indatraline<\\e1>  GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"indatraline","object":"monoamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>GENE-N<\\e2> selectivities (BTCP, <e1>CHEMICAL<\\e1>  GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response","sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse monoamine transporter selectivities (BTCP, indatraline  GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response"}
{"PMID":9476974,"re_id":4,"annotated sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>monoamine transporter<\\e2> selectivities (BTCP, indatraline, <e1>GBR 12935<\\e1>  mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"GBR 12935","object":"monoamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>GENE-N<\\e2> selectivities (BTCP, indatraline, <e1>CHEMICAL<\\e1>  mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response","sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse monoamine transporter selectivities (BTCP, indatraline, GBR 12935  mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response"}
{"PMID":9476974,"re_id":5,"annotated sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>monoamine transporter<\\e2> selectivities (BTCP, indatraline, GBR 12935, <e1>mazindol<\\e1>  nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"mazindol","object":"monoamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>GENE-N<\\e2> selectivities (BTCP, indatraline, GBR 12935, <e1>CHEMICAL<\\e1>  nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response","sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse monoamine transporter selectivities (BTCP, indatraline, GBR 12935, mazindol  nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response"}
{"PMID":9476974,"re_id":6,"annotated sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>monoamine transporter<\\e2> selectivities (BTCP, indatraline, GBR 12935, mazindol, <e1>nomifensine<\\e1>  and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nomifensine","object":"monoamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>GENE-N<\\e2> selectivities (BTCP, indatraline, GBR 12935, mazindol, <e1>CHEMICAL<\\e1>  and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response","sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse monoamine transporter selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine  and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response"}
{"PMID":9476974,"re_id":7,"annotated sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>monoamine transporter<\\e2> selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and <e1>zimeldine<\\e1>  either did not produce a rapid pressor response or produced only a small pressor response","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"zimeldine","object":"monoamine transporter","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse <e2>GENE-N<\\e2> selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and <e1>CHEMICAL<\\e1>  either did not produce a rapid pressor response or produced only a small pressor response","sentence":"Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse monoamine transporter selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine  either did not produce a rapid pressor response or produced only a small pressor response"}
{"PMID":9476974,"re_id":8,"annotated sentence":"At nonconvulsant doses, the <e2>sodium channel<\\e2> blockers <e1>acetylprocainamide<\\e1>  dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"acetylprocainamide","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"At nonconvulsant doses, the <e2>GENE-N<\\e2> blockers <e1>CHEMICAL<\\e1>  dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP","sentence":"At nonconvulsant doses, the sodium channel blockers acetylprocainamide  dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP"}
{"PMID":9476974,"re_id":9,"annotated sentence":"At nonconvulsant doses, the <e2>sodium channel<\\e2> blockers acetylprocainamide, <e1>dibucaine<\\e1>  dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dibucaine","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"At nonconvulsant doses, the <e2>GENE-N<\\e2> blockers acetylprocainamide, <e1>CHEMICAL<\\e1>  dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP","sentence":"At nonconvulsant doses, the sodium channel blockers acetylprocainamide, dibucaine  dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP"}
{"PMID":9476974,"re_id":10,"annotated sentence":"At nonconvulsant doses, the <e2>sodium channel<\\e2> blockers acetylprocainamide, dibucaine, <e1>dyclonine<\\e1>  prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dyclonine","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"At nonconvulsant doses, the <e2>GENE-N<\\e2> blockers acetylprocainamide, dibucaine, <e1>CHEMICAL<\\e1>  prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP","sentence":"At nonconvulsant doses, the sodium channel blockers acetylprocainamide, dibucaine, dyclonine  prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP"}
{"PMID":9476974,"re_id":11,"annotated sentence":"At nonconvulsant doses, the <e2>sodium channel<\\e2> blockers acetylprocainamide, dibucaine, dyclonine, <e1>prilocaine<\\e1>  proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"prilocaine","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"At nonconvulsant doses, the <e2>GENE-N<\\e2> blockers acetylprocainamide, dibucaine, dyclonine, <e1>CHEMICAL<\\e1>  proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP","sentence":"At nonconvulsant doses, the sodium channel blockers acetylprocainamide, dibucaine, dyclonine, prilocaine  proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP"}
{"PMID":9476974,"re_id":12,"annotated sentence":"At nonconvulsant doses, the <e2>sodium channel<\\e2> blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, <e1>proparacaine<\\e1>  quinidine, and tetracaine produced a small pressor response or no increase in BP","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"proparacaine","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"At nonconvulsant doses, the <e2>GENE-N<\\e2> blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, <e1>CHEMICAL<\\e1>  quinidine, and tetracaine produced a small pressor response or no increase in BP","sentence":"At nonconvulsant doses, the sodium channel blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine  quinidine, and tetracaine produced a small pressor response or no increase in BP"}
{"PMID":9476974,"re_id":13,"annotated sentence":"At nonconvulsant doses, the <e2>sodium channel<\\e2> blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, <e1>quinidine<\\e1>  and tetracaine produced a small pressor response or no increase in BP","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"quinidine","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"At nonconvulsant doses, the <e2>GENE-N<\\e2> blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, <e1>CHEMICAL<\\e1>  and tetracaine produced a small pressor response or no increase in BP","sentence":"At nonconvulsant doses, the sodium channel blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine  and tetracaine produced a small pressor response or no increase in BP"}
{"PMID":9476974,"re_id":14,"annotated sentence":"At nonconvulsant doses, the <e2>sodium channel<\\e2> blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and <e1>tetracaine<\\e1> produced a small pressor response or no increase in BP","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"tetracaine","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"At nonconvulsant doses, the <e2>GENE-N<\\e2> blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and <e1>CHEMICAL<\\e1> produced a small pressor response or no increase in BP","sentence":"At nonconvulsant doses, the sodium channel blockers acetylprocainamide, dibucaine, dyclonine, prilocaine, proparacaine, quinidine, and tetracaine produced a small pressor response or no increase in BP"}
{"PMID":9476974,"re_id":15,"annotated sentence":"The <e2>sodium channel<\\e2> blocking action of <e1>cocaine<\\e1> per se does not appear to be involved in the rapid pressor response to cocaine","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"cocaine","object":"sodium channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> blocking action of <e1>CHEMICAL<\\e1> per se does not appear to be involved in the rapid pressor response to CHEMICAL","sentence":"The sodium channel blocking action of cocaine per se does not appear to be involved in the rapid pressor response to cocaine"}
{"PMID":9476974,"re_id":16,"annotated sentence":"Intravenous (I.V.) cocaine (0.03-3 mg\/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the <e2>dopamine receptor<\\e2> antagonist, <e1>SCH 23390<\\e1>  Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse monoamine transporter selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"SCH 23390","object":"dopamine receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Intravenous (I.V.) cocaine (0.03-3 mg\/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1>  Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse monoamine transporter selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response","sentence":"Intravenous (I.V.) cocaine (0.03-3 mg\/kg) produced dose-dependent, rapid, and brief increases in blood pressure (BP) in conscious rats pretreated with the dopamine receptor antagonist, SCH 23390  Monoamine uptake inhibitors structurally analogous to cocaine (cocaethylene, CFT, betaCIT, CPT, (+)-cocaine, norcocaine, and benztropine) also produced this rapid pressor response, whereas structurally unrelated uptake inhibitors with diverse monoamine transporter selectivities (BTCP, indatraline, GBR 12935, mazindol, nomifensine, and zimeldine) either did not produce a rapid pressor response or produced only a small pressor response"}
{"PMID":9551716,"re_id":7,"annotated sentence":"In conclusion, these findings indicate that <e1>[3H]SR 142948A<\\e1> is a new potent antagonist radioligand which recognizes with high affinity both <e2>neurotensin NT1<\\e2> and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"[3H]SR 142948A","object":"neurotensin NT1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, these findings indicate that <e1>CHEMICAL<\\e1> is a new potent antagonist radioligand which recognizes with high affinity both <e2>GENE-Y<\\e2> and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain.","sentence":"In conclusion, these findings indicate that [3H]SR 142948A is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain."}
{"PMID":9551716,"re_id":8,"annotated sentence":"In conclusion, these findings indicate that <e1>[3H]SR 142948A<\\e1> is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and <e2>NT2 receptors<\\e2> and represents thus an excellent tool to study neurotensin receptors in the rat brain.","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"[3H]SR 142948A","object":"NT2 receptors","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"In conclusion, these findings indicate that <e1>CHEMICAL<\\e1> is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and <e2>GENE-Y<\\e2> and represents thus an excellent tool to study neurotensin receptors in the rat brain.","sentence":"In conclusion, these findings indicate that [3H]SR 142948A is a new potent antagonist radioligand which recognizes with high affinity both neurotensin NT1 and NT2 receptors and represents thus an excellent tool to study neurotensin receptors in the rat brain."}
{"PMID":9551716,"re_id":9,"annotated sentence":"The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of <e2>neurotensin receptors<\\e2>  <e1>[3H]SR 142948A<\\e1> (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"[3H]SR 142948A","object":"neurotensin receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of <e2>GENE-N<\\e2>  <e1>CHEMICAL<\\e1> (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain","sentence":"The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of neurotensin receptors  [3H]SR 142948A (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride), in the rat brain"}
{"PMID":9551716,"re_id":10,"annotated sentence":"The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of <e2>neurotensin receptors<\\e2>  [3H]SR 142948A (<e1>2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride<\\e1> , in the rat brain","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride","object":"neurotensin receptors","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of <e2>GENE-N<\\e2>  [3H]SR 142948A (<e1>CHEMICAL<\\e1> , in the rat brain","sentence":"The present study describes the characterization of the binding properties and autoradiographic distribution of a new nonpeptide antagonist of neurotensin receptors  [3H]SR 142948A (2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methyl carbamoyl)-2-isopropylphenyl)-1H-pyrazole-3-carbonyl]-amino]-ad amantane-2-carboxylic acid, hydrochloride , in the rat brain"}
{"PMID":9551716,"re_id":11,"annotated sentence":"Characterization of binding sites of a new <e2>neurotensin receptor<\\e2> antagonist, <e1>[3H]SR 142948A<\\e1>  in the rat brain","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"[3H]SR 142948A","object":"neurotensin receptor","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Characterization of binding sites of a new <e2>GENE-N<\\e2> antagonist, <e1>CHEMICAL<\\e1>  in the rat brain","sentence":"Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A  in the rat brain"}
{"PMID":9551716,"re_id":12,"annotated sentence":"Saturation and competition studies in the presence or absence of the <e2>histamine H1 receptor<\\e2> antagonist, <e1>levocabastine<\\e1>  revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"levocabastine","object":"histamine H1 receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Saturation and competition studies in the presence or absence of the <e2>GENE-Y<\\e2> antagonist, <e1>CHEMICAL<\\e1>  revealed that [3H]SR 142948A bound with similar affinities to both the CHEMICAL-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned CHEMICAL-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)","sentence":"Saturation and competition studies in the presence or absence of the histamine H1 receptor antagonist, levocabastine  revealed that [3H]SR 142948A bound with similar affinities to both the levocabastine-insensitive neurotensin NT1 receptors (20% of the total binding population) and the recently cloned levocabastine-sensitive neurotensin NT2 receptors (80% of the receptors) (Kd = 6.8 and 4.8 nM, respectively)"}
{"PMID":9584217,"re_id":2,"annotated sentence":"Isoform-specific inhibition of <e2>L-type calcium channels<\\e2> by <e1>dihydropyridines<\\e1> is independent of isoform-specific gating properties","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"dihydropyridines","object":"L-type calcium channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Isoform-specific inhibition of <e2>GENE-N<\\e2> by <e1>CHEMICAL<\\e1> is independent of isoform-specific gating properties","sentence":"Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties"}
{"PMID":9584217,"re_id":3,"annotated sentence":"<e1>Dihydropyridines<\\e1> (DHPs) block <e2>L-type Ca2+ channels<\\e2> more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Dihydropyridines","object":"L-type Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (DHPs) block <e2>GENE-N<\\e2> more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state","sentence":"Dihydropyridines (DHPs) block L-type Ca2+ channels more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state"}
{"PMID":9584217,"re_id":4,"annotated sentence":"We thus conclude that the more potent <e1>nisoldipine<\\e1> inhibition of smooth muscle versus <e2>cardiac L-type Ca2+ channels<\\e2> is not attributable to differences in channel inactivation or activation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"nisoldipine","object":"cardiac L-type Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"We thus conclude that the more potent <e1>CHEMICAL<\\e1> inhibition of smooth muscle versus <e2>GENE-N<\\e2> is not attributable to differences in channel inactivation or activation","sentence":"We thus conclude that the more potent nisoldipine inhibition of smooth muscle versus cardiac L-type Ca2+ channels is not attributable to differences in channel inactivation or activation"}
{"PMID":9584217,"re_id":5,"annotated sentence":"<e1>Nisoldipine<\\e1> (a DHP antagonist) blocks the <e2>smooth muscle channel<\\e2> more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"Nisoldipine","object":"smooth muscle channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e1>CHEMICAL<\\e1> (a DHP antagonist) blocks the <e2>GENE-N<\\e2> more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels","sentence":"Nisoldipine (a DHP antagonist) blocks the smooth muscle channel more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels"}
{"PMID":9584217,"re_id":6,"annotated sentence":"Nisoldipine (a <e1>DHP<\\e1> antagonist) blocks the <e2>smooth muscle channel<\\e2> more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DHP","object":"smooth muscle channel","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Nisoldipine (a <e1>CHEMICAL<\\e1> antagonist) blocks the <e2>GENE-N<\\e2> more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels","sentence":"Nisoldipine (a DHP antagonist) blocks the smooth muscle channel more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels"}
{"PMID":9584217,"re_id":7,"annotated sentence":"Dihydropyridines (<e1>DHPs<\\e1>  block <e2>L-type Ca2+ channels<\\e2> more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"DHPs","object":"L-type Ca2+ channels","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Dihydropyridines (<e1>CHEMICAL<\\e1>  block <e2>GENE-N<\\e2> more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state","sentence":"Dihydropyridines (DHPs  block L-type Ca2+ channels more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state"}
{"PMID":9587031,"re_id":0,"annotated sentence":"<e2>Methylenetetrahydrofolate reductase<\\e2> deficiency impairs <e1>methyltetrahydrofolate<\\e1> synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC\/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE\/G) are associated with defective methyl cobalamin synthesis","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"methyltetrahydrofolate","object":"Methylenetetrahydrofolate reductase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e2>GENE-Y<\\e2> deficiency impairs <e1>CHEMICAL<\\e1> synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC\/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE\/G) are associated with defective methyl cobalamin synthesis","sentence":"Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC\/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE\/G) are associated with defective methyl cobalamin synthesis"}
{"PMID":9587031,"re_id":1,"annotated sentence":"Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC\/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of <e2>methionine synthase<\\e2> (CblE\/G) are associated with defective <e1>methyl cobalamin<\\e1> synthesis","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"PRODUCT-OF","subject":"methyl cobalamin","object":"methionine synthase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC\/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of <e2>GENE-Y<\\e2> (CblE\/G) are associated with defective <e1>CHEMICAL<\\e1> synthesis","sentence":"Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC\/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE\/G) are associated with defective methyl cobalamin synthesis"}
{"PMID":9614060,"re_id":0,"annotated sentence":"These results suggest that <e2>Cat3<\\e2> compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity <e1>arginine<\\e1> transport.","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"arginine","object":"Cat3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results suggest that <e2>GENE-Y<\\e2> compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity <e1>CHEMICAL<\\e1> transport.","sentence":"These results suggest that Cat3 compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity arginine transport."}
{"PMID":9614060,"re_id":1,"annotated sentence":"The majority of <e1>L-Arg<\\e1> transport is mediated by <e2>System y+<\\e2>  although several other carriers have been kinetically defined","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"L-Arg","object":"System y+","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The majority of <e1>CHEMICAL<\\e1> transport is mediated by <e2>GENE-N<\\e2>  although several other carriers have been kinetically defined","sentence":"The majority of L-Arg transport is mediated by System y+  although several other carriers have been kinetically defined"}
{"PMID":9614060,"re_id":2,"annotated sentence":"<e2>System y+<\\e2> cationic <e1>amino acid<\\e1> transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"amino acid","object":"System y+","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"<e2>GENE-N<\\e2> cationic <e1>CHEMICAL<\\e1> transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3","sentence":"System y+ cationic amino acid transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3"}
{"PMID":9614060,"re_id":3,"annotated sentence":"System y+ cationic <e1>amino acid<\\e1> transport is mediated by proteins encoded by a family of genes, <e2>Cat1<\\e2>  Cat2, and Cat3","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"amino acid","object":"Cat1","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"System y+ cationic <e1>CHEMICAL<\\e1> transport is mediated by proteins encoded by a family of genes, <e2>GENE-Y<\\e2>  Cat2, and Cat3","sentence":"System y+ cationic amino acid transport is mediated by proteins encoded by a family of genes, Cat1  Cat2, and Cat3"}
{"PMID":9614060,"re_id":4,"annotated sentence":"System y+ cationic <e1>amino acid<\\e1> transport is mediated by proteins encoded by a family of genes, Cat1, <e2>Cat2<\\e2>  and Cat3","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"amino acid","object":"Cat2","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"System y+ cationic <e1>CHEMICAL<\\e1> transport is mediated by proteins encoded by a family of genes, Cat1, <e2>GENE-Y<\\e2>  and Cat3","sentence":"System y+ cationic amino acid transport is mediated by proteins encoded by a family of genes, Cat1, Cat2  and Cat3"}
{"PMID":9614060,"re_id":5,"annotated sentence":"System y+ cationic <e1>amino acid<\\e1> transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and <e2>Cat3<\\e2>  High affinity L-arginine transport was investigated in embryonic fibroblast cells derived from Cat1 knockout mice that lack functional Cat1","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"amino acid","object":"Cat3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"System y+ cationic <e1>CHEMICAL<\\e1> transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and <e2>GENE-Y<\\e2>  High affinity L-arginine transport was investigated in embryonic fibroblast cells derived from Cat1 knockout mice that lack functional Cat1","sentence":"System y+ cationic amino acid transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3  High affinity L-arginine transport was investigated in embryonic fibroblast cells derived from Cat1 knockout mice that lack functional Cat1"}
{"PMID":9614060,"re_id":6,"annotated sentence":"However, the apparent affinity for <e1>lysine<\\e1> transport was 2.4 times lower in Cat1(-\/-) cells when compared with wild type cells, a property characteristic of <e2>Cat3<\\e2> mediated transport","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"lysine","object":"Cat3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"However, the apparent affinity for <e1>CHEMICAL<\\e1> transport was 2.4 times lower in Cat1(-\/-) cells when compared with wild type cells, a property characteristic of <e2>GENE-Y<\\e2> mediated transport","sentence":"However, the apparent affinity for lysine transport was 2.4 times lower in Cat1(-\/-) cells when compared with wild type cells, a property characteristic of Cat3 mediated transport"}
{"PMID":9614060,"re_id":7,"annotated sentence":"Increased <e2>Cat3<\\e2> mediated cationic <e1>amino acid<\\e1> transport functionally compensates in Cat1 knockout cell lines","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"amino acid","object":"Cat3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Increased <e2>GENE-Y<\\e2> mediated cationic <e1>CHEMICAL<\\e1> transport functionally compensates in Cat1 knockout cell lines","sentence":"Increased Cat3 mediated cationic amino acid transport functionally compensates in Cat1 knockout cell lines"}
{"PMID":9712175,"re_id":0,"annotated sentence":"<e1>Lintitript<\\e1> markedly increased postprandial plasma <e2>CCK<\\e2> release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"Lintitript","object":"CCK","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> markedly increased postprandial plasma <e2>GENE-Y<\\e2> release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo","sentence":"Lintitript markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo"}
{"PMID":9712175,"re_id":1,"annotated sentence":"<e1>Lintitript<\\e1> markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial <e2>PP<\\e2> levels (P<0.01) as compared to placebo","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"Lintitript","object":"PP","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"<e1>CHEMICAL<\\e1> markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial <e2>GENE-Y<\\e2> levels (P<0.01) as compared to placebo","sentence":"Lintitript markedly increased postprandial plasma CCK release (P<0.001) while distinctly reducing postprandial PP levels (P<0.01) as compared to placebo"}
{"PMID":9712175,"re_id":2,"annotated sentence":"The study demonstrates for the first time the marked gastrokinetic properties of the new <e2>CCK-A receptor<\\e2> antagonist <e1>lintitript<\\e1> in humans.","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"lintitript","object":"CCK-A receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The study demonstrates for the first time the marked gastrokinetic properties of the new <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> in humans.","sentence":"The study demonstrates for the first time the marked gastrokinetic properties of the new CCK-A receptor antagonist lintitript in humans."}
{"PMID":9712175,"re_id":3,"annotated sentence":"We studied the role of endogenous CCK in the emptying of a solid\/liquid meal administering the new, highly specific and potent <e2>CCK-A receptor<\\e2> antagonist <e1>lintitript<\\e1>  Gastric emptying was assessed in nine healthy male volunteers using a randomized, double blind, two-period crossover design with oral lintitript (15 mg 1 h prior to meal intake) or placebo on two different days","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"lintitript","object":"CCK-A receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"We studied the role of endogenous CCK in the emptying of a solid\/liquid meal administering the new, highly specific and potent <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1>  Gastric emptying was assessed in nine healthy male volunteers using a randomized, double blind, two-period crossover design with oral CHEMICAL (15 mg 1 h prior to meal intake) or placebo on two different days","sentence":"We studied the role of endogenous CCK in the emptying of a solid\/liquid meal administering the new, highly specific and potent CCK-A receptor antagonist lintitript  Gastric emptying was assessed in nine healthy male volunteers using a randomized, double blind, two-period crossover design with oral lintitript (15 mg 1 h prior to meal intake) or placebo on two different days"}
{"PMID":9712175,"re_id":4,"annotated sentence":"Effect of <e1>lintitript<\\e1>  a new <e2>CCK-A receptor<\\e2> antagonist, on gastric emptying of a solid-liquid meal in humans","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"lintitript","object":"CCK-A receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Effect of <e1>CHEMICAL<\\e1>  a new <e2>GENE-Y<\\e2> antagonist, on gastric emptying of a solid-liquid meal in humans","sentence":"Effect of lintitript  a new CCK-A receptor antagonist, on gastric emptying of a solid-liquid meal in humans"}
{"PMID":9730867,"re_id":14,"annotated sentence":"The observed inhibition on <e2>IFN-gamma<\\e2>  GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist <e1>ICI 118,551<\\e1> (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ICI 118,551","object":"IFN-gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The observed inhibition on <e2>GENE-Y<\\e2>  GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist <e1>CHEMICAL<\\e1> (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist","sentence":"The observed inhibition on IFN-gamma  GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist"}
{"PMID":9730867,"re_id":15,"annotated sentence":"The observed inhibition on IFN-gamma, <e2>GM-CSF<\\e2>  and IL-3 mRNA was blocked by the selective beta2AR antagonist <e1>ICI 118,551<\\e1> (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ICI 118,551","object":"GM-CSF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The observed inhibition on IFN-gamma, <e2>GENE-Y<\\e2>  and IL-3 mRNA was blocked by the selective beta2AR antagonist <e1>CHEMICAL<\\e1> (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist","sentence":"The observed inhibition on IFN-gamma, GM-CSF  and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist"}
{"PMID":9730867,"re_id":16,"annotated sentence":"The observed inhibition on IFN-gamma, GM-CSF, and <e2>IL-3<\\e2> mRNA was blocked by the selective beta2AR antagonist <e1>ICI 118,551<\\e1> (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"ICI 118,551","object":"IL-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The observed inhibition on IFN-gamma, GM-CSF, and <e2>GENE-Y<\\e2> mRNA was blocked by the selective beta2AR antagonist <e1>CHEMICAL<\\e1> (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist","sentence":"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist"}
{"PMID":9730867,"re_id":17,"annotated sentence":"The observed inhibition on <e2>IFN-gamma<\\e2>  GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by <e1>timolol<\\e1> (10(-6) M), a nonselective antagonist","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"timolol","object":"IFN-gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The observed inhibition on <e2>GENE-Y<\\e2>  GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by <e1>CHEMICAL<\\e1> (10(-6) M), a nonselective antagonist","sentence":"The observed inhibition on IFN-gamma  GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist"}
{"PMID":9730867,"re_id":18,"annotated sentence":"The observed inhibition on IFN-gamma, <e2>GM-CSF<\\e2>  and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by <e1>timolol<\\e1> (10(-6) M), a nonselective antagonist","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"timolol","object":"GM-CSF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The observed inhibition on IFN-gamma, <e2>GENE-Y<\\e2>  and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by <e1>CHEMICAL<\\e1> (10(-6) M), a nonselective antagonist","sentence":"The observed inhibition on IFN-gamma, GM-CSF  and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist"}
{"PMID":9730867,"re_id":19,"annotated sentence":"The observed inhibition on IFN-gamma, GM-CSF, and <e2>IL-3<\\e2> mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by <e1>timolol<\\e1> (10(-6) M), a nonselective antagonist","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"timolol","object":"IL-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The observed inhibition on IFN-gamma, GM-CSF, and <e2>GENE-Y<\\e2> mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by <e1>CHEMICAL<\\e1> (10(-6) M), a nonselective antagonist","sentence":"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist"}
{"PMID":9730867,"re_id":20,"annotated sentence":"Secretion of <e2>GM-CSF<\\e2> protein in the presence of increasing concentrations of <e1>isoproterenol<\\e1> followed a similar pattern as observed for GM-CSF mRNA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"isoproterenol","object":"GM-CSF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Secretion of <e2>GENE-Y<\\e2> protein in the presence of increasing concentrations of <e1>CHEMICAL<\\e1> followed a similar pattern as observed for GENE-Y mRNA","sentence":"Secretion of GM-CSF protein in the presence of increasing concentrations of isoproterenol followed a similar pattern as observed for GM-CSF mRNA"}
{"PMID":9730867,"re_id":21,"annotated sentence":"Secretion of GM-CSF protein in the presence of increasing concentrations of <e1>isoproterenol<\\e1> followed a similar pattern as observed for <e2>GM-CSF<\\e2> mRNA","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"isoproterenol","object":"GM-CSF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Secretion of GENE-Y protein in the presence of increasing concentrations of <e1>CHEMICAL<\\e1> followed a similar pattern as observed for <e2>GENE-Y<\\e2> mRNA","sentence":"Secretion of GM-CSF protein in the presence of increasing concentrations of isoproterenol followed a similar pattern as observed for GM-CSF mRNA"}
{"PMID":9730867,"re_id":22,"annotated sentence":"Concanavalin A (Con A)-induced <e2>IFN-gamma<\\e2>  GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist <e1>isoproterenol<\\e1> and by the selective beta2AR agonist fenoterol","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"isoproterenol","object":"IFN-gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Concanavalin A (Con A)-induced <e2>GENE-Y<\\e2>  GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist <e1>CHEMICAL<\\e1> and by the selective beta2AR agonist fenoterol","sentence":"Concanavalin A (Con A)-induced IFN-gamma  GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol"}
{"PMID":9730867,"re_id":23,"annotated sentence":"Concanavalin A (Con A)-induced IFN-gamma, <e2>GM-CSF<\\e2>  and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist <e1>isoproterenol<\\e1> and by the selective beta2AR agonist fenoterol","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"isoproterenol","object":"GM-CSF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Concanavalin A (Con A)-induced IFN-gamma, <e2>GENE-Y<\\e2>  and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist <e1>CHEMICAL<\\e1> and by the selective beta2AR agonist fenoterol","sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF  and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol"}
{"PMID":9730867,"re_id":24,"annotated sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and <e2>IL-3<\\e2> mRNAs are dose-dependently inhibited by the nonselective betaAR agonist <e1>isoproterenol<\\e1> and by the selective beta2AR agonist fenoterol","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"isoproterenol","object":"IL-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and <e2>GENE-Y<\\e2> mRNAs are dose-dependently inhibited by the nonselective betaAR agonist <e1>CHEMICAL<\\e1> and by the selective beta2AR agonist fenoterol","sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol"}
{"PMID":9730867,"re_id":25,"annotated sentence":"Concanavalin A (Con A)-induced <e2>IFN-gamma<\\e2>  GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist <e1>fenoterol<\\e1>  IL-4 mRNA accumulation was not susceptible to betaAR stimulation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"fenoterol","object":"IFN-gamma","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Concanavalin A (Con A)-induced <e2>GENE-Y<\\e2>  GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist <e1>CHEMICAL<\\e1>  IL-4 mRNA accumulation was not susceptible to betaAR stimulation","sentence":"Concanavalin A (Con A)-induced IFN-gamma  GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol  IL-4 mRNA accumulation was not susceptible to betaAR stimulation"}
{"PMID":9730867,"re_id":26,"annotated sentence":"Concanavalin A (Con A)-induced IFN-gamma, <e2>GM-CSF<\\e2>  and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist <e1>fenoterol<\\e1>  IL-4 mRNA accumulation was not susceptible to betaAR stimulation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"fenoterol","object":"GM-CSF","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Concanavalin A (Con A)-induced IFN-gamma, <e2>GENE-Y<\\e2>  and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist <e1>CHEMICAL<\\e1>  IL-4 mRNA accumulation was not susceptible to betaAR stimulation","sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF  and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol  IL-4 mRNA accumulation was not susceptible to betaAR stimulation"}
{"PMID":9730867,"re_id":27,"annotated sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and <e2>IL-3<\\e2> mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist <e1>fenoterol<\\e1>  IL-4 mRNA accumulation was not susceptible to betaAR stimulation","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INDIRECT-DOWNREGULATOR","subject":"fenoterol","object":"IL-3","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and <e2>GENE-Y<\\e2> mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist <e1>CHEMICAL<\\e1>  IL-4 mRNA accumulation was not susceptible to betaAR stimulation","sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol  IL-4 mRNA accumulation was not susceptible to betaAR stimulation"}
{"PMID":9730867,"re_id":28,"annotated sentence":"Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the <e2>beta3AR<\\e2> agonist <e1>BRL 37344<\\e1> had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"BRL 37344","object":"beta3AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Although GENE-Y mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1> had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels","sentence":"Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the beta3AR agonist BRL 37344 had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels"}
{"PMID":9730867,"re_id":29,"annotated sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective <e2>betaAR<\\e2> agonist <e1>isoproterenol<\\e1> and by the selective beta2AR agonist fenoterol","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"isoproterenol","object":"betaAR","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective <e2>GENE-N<\\e2> agonist <e1>CHEMICAL<\\e1> and by the selective beta2AR agonist fenoterol","sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol"}
{"PMID":9730867,"re_id":30,"annotated sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective <e2>beta2AR<\\e2> agonist <e1>fenoterol<\\e1>  IL-4 mRNA accumulation was not susceptible to betaAR stimulation","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"fenoterol","object":"beta2AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective <e2>GENE-Y<\\e2> agonist <e1>CHEMICAL<\\e1>  IL-4 mRNA accumulation was not susceptible to betaAR stimulation","sentence":"Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol  IL-4 mRNA accumulation was not susceptible to betaAR stimulation"}
{"PMID":9730867,"re_id":31,"annotated sentence":"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective <e2>beta2AR<\\e2> antagonist <e1>ICI 118,551<\\e1> (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"ICI 118,551","object":"beta2AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist","sentence":"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist"}
{"PMID":9730867,"re_id":32,"annotated sentence":"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective <e2>beta2AR<\\e2> antagonist ICI 118,551 (10(-6) M) and by <e1>timolol<\\e1> (10(-6) M), a nonselective antagonist","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"timolol","object":"beta2AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective <e2>GENE-Y<\\e2> antagonist ICI 118,551 (10(-6) M) and by <e1>CHEMICAL<\\e1> (10(-6) M), a nonselective antagonist","sentence":"The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist"}
{"PMID":9730867,"re_id":33,"annotated sentence":"The selective <e2>beta1AR<\\e2> antagonist <e1>atenolol<\\e1> (0.3 x 10(-6) M) did not have any effect","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"atenolol","object":"beta1AR","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The selective <e2>GENE-Y<\\e2> antagonist <e1>CHEMICAL<\\e1> (0.3 x 10(-6) M) did not have any effect","sentence":"The selective beta1AR antagonist atenolol (0.3 x 10(-6) M) did not have any effect"}
{"PMID":9760035,"re_id":6,"annotated sentence":"All three compounds displayed antagonistic properties against <e2>oxytocin<\\e2> in vitro, with <e1>carbetocin<\\e1> being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carbetocin","object":"oxytocin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All three compounds displayed antagonistic properties against <e2>GENE-Y<\\e2> in vitro, with <e1>CHEMICAL<\\e1> being the strongest inhibitor (pA2 = 8.21) and CHEMICAL metabolite II (pA2 = 8.01) being stronger than CHEMICAL metabolite I (pA2 = 7.81)","sentence":"All three compounds displayed antagonistic properties against oxytocin in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81)"}
{"PMID":9760035,"re_id":7,"annotated sentence":"All three compounds displayed antagonistic properties against <e2>oxytocin<\\e2> in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and <e1>carbetocin<\\e1> metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carbetocin","object":"oxytocin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All three compounds displayed antagonistic properties against <e2>GENE-Y<\\e2> in vitro, with CHEMICAL being the strongest inhibitor (pA2 = 8.21) and <e1>CHEMICAL<\\e1> metabolite II (pA2 = 8.01) being stronger than CHEMICAL metabolite I (pA2 = 7.81)","sentence":"All three compounds displayed antagonistic properties against oxytocin in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81)"}
{"PMID":9760035,"re_id":8,"annotated sentence":"All three compounds displayed antagonistic properties against <e2>oxytocin<\\e2> in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than <e1>carbetocin<\\e1> metabolite I (pA2 = 7.81)","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"carbetocin","object":"oxytocin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"All three compounds displayed antagonistic properties against <e2>GENE-Y<\\e2> in vitro, with CHEMICAL being the strongest inhibitor (pA2 = 8.21) and CHEMICAL metabolite II (pA2 = 8.01) being stronger than <e1>CHEMICAL<\\e1> metabolite I (pA2 = 7.81)","sentence":"All three compounds displayed antagonistic properties against oxytocin in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81)"}
{"PMID":9760035,"re_id":9,"annotated sentence":"These results indicate that <e1>carbetocin<\\e1> is a partial agonist\/antagonist to the <e2>oxytocin receptor<\\e2> while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists","re_type_id":"CPR:5","lable_positive":"Y ","re_type":"AGONIST","subject":"carbetocin","object":"oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that <e1>CHEMICAL<\\e1> is a partial agonist\/antagonist to the <e2>GENE-Y<\\e2> while the two metabolites CHEMICAL metabolite I and CHEMICAL metabolite II are pure antagonists","sentence":"These results indicate that carbetocin is a partial agonist\/antagonist to the oxytocin receptor while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists"}
{"PMID":9760035,"re_id":10,"annotated sentence":"These results indicate that <e1>carbetocin<\\e1> is a partial agonist\/antagonist to the <e2>oxytocin receptor<\\e2> while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"carbetocin","object":"oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that <e1>CHEMICAL<\\e1> is a partial agonist\/antagonist to the <e2>GENE-Y<\\e2> while the two metabolites CHEMICAL metabolite I and CHEMICAL metabolite II are pure antagonists","sentence":"These results indicate that carbetocin is a partial agonist\/antagonist to the oxytocin receptor while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists"}
{"PMID":9760035,"re_id":11,"annotated sentence":"These results indicate that carbetocin is a partial agonist\/antagonist to the <e2>oxytocin receptor<\\e2> while the two metabolites <e1>carbetocin<\\e1> metabolite I and carbetocin metabolite II are pure antagonists","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"carbetocin","object":"oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that CHEMICAL is a partial agonist\/antagonist to the <e2>GENE-Y<\\e2> while the two metabolites <e1>CHEMICAL<\\e1> metabolite I and CHEMICAL metabolite II are pure antagonists","sentence":"These results indicate that carbetocin is a partial agonist\/antagonist to the oxytocin receptor while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists"}
{"PMID":9760035,"re_id":12,"annotated sentence":"These results indicate that carbetocin is a partial agonist\/antagonist to the <e2>oxytocin receptor<\\e2> while the two metabolites carbetocin metabolite I and <e1>carbetocin<\\e1> metabolite II are pure antagonists","re_type_id":"CPR:6","lable_positive":"Y ","re_type":"ANTAGONIST","subject":"carbetocin","object":"oxytocin receptor","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"These results indicate that CHEMICAL is a partial agonist\/antagonist to the <e2>GENE-Y<\\e2> while the two metabolites CHEMICAL metabolite I and <e1>CHEMICAL<\\e1> metabolite II are pure antagonists","sentence":"These results indicate that carbetocin is a partial agonist\/antagonist to the oxytocin receptor while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists"}
{"PMID":9843368,"re_id":2,"annotated sentence":"Crystallographic analysis of the <e2>human phenylalanine hydroxylase catalytic domain<\\e2> with bound <e1>catechol<\\e1> inhibitors at 2.0 A resolution","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"catechol","object":"human phenylalanine hydroxylase catalytic domain","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"Crystallographic analysis of the <e2>GENE-N<\\e2> with bound <e1>CHEMICAL<\\e1> inhibitors at 2.0 A resolution","sentence":"Crystallographic analysis of the human phenylalanine hydroxylase catalytic domain with bound catechol inhibitors at 2.0 A resolution"}
{"PMID":9843368,"re_id":3,"annotated sentence":"The <e2>aromatic amino acid hydroxylases<\\e2> represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by <e1>catechol<\\e1> derivatives","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"catechol","object":"aromatic amino acid hydroxylases","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"The <e2>GENE-N<\\e2> represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by <e1>CHEMICAL<\\e1> derivatives","sentence":"The aromatic amino acid hydroxylases represent a superfamily of structurally and functionally closely related enzymes, one of those functions being reversible inhibition by catechol derivatives"}
{"PMID":9843368,"re_id":4,"annotated sentence":"Crystallographic comparison with the structurally related <e2>rat tyrosine hydroxylase<\\e2> binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the <e1>catechols<\\e1> versus BH4","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"catechols","object":"rat tyrosine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Crystallographic comparison with the structurally related <e2>GENE-Y<\\e2> binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the CHEMICAL and the cofactor, compatible with a competitive type of inhibition of the <e1>CHEMICAL<\\e1> versus BH4","sentence":"Crystallographic comparison with the structurally related rat tyrosine hydroxylase binary complex with the oxidized cofactor 7,8-dihydrobiopterin revealed overlapping binding sites for the catechols and the cofactor, compatible with a competitive type of inhibition of the catechols versus BH4"}
{"PMID":9843368,"re_id":5,"annotated sentence":"Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of <e2>human phenylalanine hydroxylase<\\e2> (hPheOH), cocrystallized with various potent and well-known <e1>catechol<\\e1> inhibitors and refined at a resolution of 2.0 A","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"catechol","object":"human phenylalanine hydroxylase","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of <e2>GENE-Y<\\e2> (hPheOH), cocrystallized with various potent and well-known <e1>CHEMICAL<\\e1> inhibitors and refined at a resolution of 2.0 A","sentence":"Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human phenylalanine hydroxylase (hPheOH), cocrystallized with various potent and well-known catechol inhibitors and refined at a resolution of 2.0 A"}
{"PMID":9843368,"re_id":6,"annotated sentence":"Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human phenylalanine hydroxylase (<e2>hPheOH<\\e2> , cocrystallized with various potent and well-known <e1>catechol<\\e1> inhibitors and refined at a resolution of 2.0 A","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"INHIBITOR","subject":"catechol","object":"hPheOH","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human phenylalanine hydroxylase (<e2>GENE-Y<\\e2> , cocrystallized with various potent and well-known <e1>CHEMICAL<\\e1> inhibitors and refined at a resolution of 2.0 A","sentence":"Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human phenylalanine hydroxylase (hPheOH , cocrystallized with various potent and well-known catechol inhibitors and refined at a resolution of 2.0 A"}
{"PMID":9891987,"re_id":1,"annotated sentence":"All GCs including the antagonistic compound <e1>RU486<\\e1> efficiently reduced <e2>NF-kappaB<\\e2> mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression","re_type_id":"CPR:4","lable_positive":"Y ","re_type":"DOWNREGULATOR","subject":"RU486","object":"NF-kappaB","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"All GCs including the antagonistic compound <e1>CHEMICAL<\\e1> efficiently reduced <e2>GENE-N<\\e2> mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression","sentence":"All GCs including the antagonistic compound RU486 efficiently reduced NF-kappaB mediated transactivation to comparable extents, suggesting that ligand-induced nuclear localization of the GR is sufficient for transrepression"}
{"PMID":9990013,"re_id":32,"annotated sentence":"The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of <e1>glucose<\\e1> induced <e2>insulin<\\e2> secretion","re_type_id":"CPR:3","lable_positive":"Y ","re_type":"INDIRECT-UPREGULATOR","subject":"glucose","object":"insulin","sub_type":"CHEMICAL","obj_type":"GENE-Y","marked sentence":"The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of <e1>CHEMICAL<\\e1> induced <e2>GENE-Y<\\e2> secretion","sentence":"The ATP-sensitive potassium (KATP) channels in pancreatic beta cells are critical in the regulation of glucose induced insulin secretion"}
{"PMID":9990013,"re_id":33,"annotated sentence":"These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound <e1>MgATP<\\e1> at <e2>NBF2<\\e2>  stabilizes prebound 8-azido-ATP binding at NBF1","re_type_id":"CPR:9","lable_positive":"Y ","re_type":"SUBSTRATE","subject":"MgATP","object":"NBF2","sub_type":"CHEMICAL","obj_type":"GENE-N","marked sentence":"These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to GENE-N or by hydrolysis of bound <e1>CHEMICAL<\\e1> at <e2>GENE-N<\\e2>  stabilizes prebound 8-azido-ATP binding at NBF1","sentence":"These results suggest that SUR1 binds 8-azido-ATP strongly at NBF1 and that MgADP, either by direct binding to NBF2 or by hydrolysis of bound MgATP at NBF2  stabilizes prebound 8-azido-ATP binding at NBF1"}